"drug_name"	"drugbank_id"	"ind_name"	"ind_id"	"nct"	"status"	"phase"	"detailedstatus"	"drug_obo_id"	"drug_rxnorm_id"	"ind_obo_id"	"ind_meddra_pt"	"ind_snomed_id"
ephedrine	DB01364	Influenza-like symptoms	C0392171		Approved			CHEBI_15407	"3966"			
enoxacin	DB00467	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_157175	"3925"	MONDO_0001080		"20943002"
alatrofloxacin	DB09335	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_135829	"141440"			"70036007"
alatrofloxacin	DB09335	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_135829	"141440"	MONDO_0001080		"20943002"
alatrofloxacin	DB09335	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_135829	"141440"			"186435004"
ephedrine	DB01364	Headache Disorders	C0393735		Approved			CHEBI_15407	"3966"			"230461009"
ephedrine	DB01364	Common Cold	C0009443		Approved			CHEBI_15407	"3966"	MONDO_0005709		"82272006"
	DB14483	Primary Myelofibrosis	C0001815	NCT01014546	Terminated	Phase 1	low accrual		"1307765|142407"	MONDO_0009692	"10077161"	"128843003"
	DB14482	Primary Myelofibrosis	C0001815	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_113451	"267366"	MONDO_0009692	"10077161"	"128843003"
	DB00126	Primary Myelofibrosis	C0001815	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_29073	"1151|1370460"	MONDO_0009692	"10077161"	"128843003"
arsenic trioxide	DB01169	Primary Myelofibrosis	C0001815	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_49900	"18330"	MONDO_0009692	"10077161"	"128843003"
enalapril	DB00584	Asymptomatic left ventricular systolic dysfunction	C3698411		Approved			CHEBI_4784	"3827"			"698592004"
enalapril	DB09477	Asymptomatic left ventricular systolic dysfunction	C3698411		Approved			CHEBI_4786	"1545989|3829"			"698592004"
enalaprilat	DB09477	Asymptomatic left ventricular systolic dysfunction	C3698411		Approved			CHEBI_4786	"1545989|3829"			"698592004"
alatrofloxacin	DB09335	Female genital tract infection	C1263758		Approved			CHEBI_135829	"141440"			"125585007"
alatrofloxacin	DB09335	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_135829	"141440"			"195722003"
enoxacin	DB00467	Gonorrhea of pharynx	C0149966		Approved			CHEBI_157175	"3925"			"74372003"
alatrofloxacin	DB09335	Acute bacterial bronchitis	C0339933		Approved			CHEBI_135829	"141440"			"233598009"
alatrofloxacin	DB09335	Postoperative infection	C0392618		Approved			CHEBI_135829	"141440"			"33910007"
alatrofloxacin	DB09335	Acute gonococcal endometritis	C0153196		Approved			CHEBI_135829	"141440"	MONDO_0004264		"65295003"
enoxacin	DB00467	Acute gonococcal urethritis	C0275652		Approved			CHEBI_157175	"3925"			"29864006"
alatrofloxacin	DB09335	Acute gonococcal urethritis	C0275652		Approved			CHEBI_135829	"141440"			"29864006"
octreotide	DB00104	Acromegaly	C0001206		Approved			CHEBI_7726	"7617"	MONDO_0019933	"10000599"	"74107003"
	DB00909	Alcoholic Intoxication, Chronic	C0001973	NCT00862563	Terminated	Phase 2	Recruitment goals could not be met before ending of funding for this project.	CHEBI_10127	"39998"	HP:0030955	"10001639"	"7200002"
vigabatrin	DB01080	Alcoholic Intoxication, Chronic	C0001973	NCT01335867	Terminated	Phase 2	interim analysis of efficacy completed and termination recommended	CHEBI_63638	"14851"	HP:0030955	"10001639"	"7200002"
alatrofloxacin	DB09335	Acute bacterial sinusitis	C0275556		Approved			CHEBI_135829	"141440"			"75498004"
epinephrine	DB00668	Asthma attack	C0347950		Approved			CHEBI_28918	"3992"			
epoprostenol	DB01240	Common Cold	C0009443		Approved			CHEBI_15552	"8814"	MONDO_0005709		"82272006"
erdosteine	DB05057	Accidental poisoning by lead and its compounds and fumes	C0261486		Approved			CHEBI_135014	"24305"			
ertapenem	DB00303	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_404903	"325642"			"70036007"
ertapenem	DB00303	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_404903	"325642"			"301011002"
erythromycin	DB00199	Infective otitis media	C0729586		Approved			CHEBI_42355	"4053"			"312218008"
erythromycin	DB00199	Staphylococcus aureus infection	C1318973		Approved			CHEBI_42355	"4053"			"406602003"
erythromycin	DB00199	Group A Streptococcal Infections	C0554628		Approved			CHEBI_42355	"4053"			"302809008"
erythromycin	DB00199	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_42355	"4053"	MONDO_0001080		"20943002"
erythromycin	DB00199	Acne Vulgaris	C0001144		Approved			CHEBI_42355	"4053"			"88616000"
epirubicin	DB00445	Breast Carcinoma	C0678222		Approved			CHEBI_47898	"3995"	MONDO_0004989|MONDO_0015870		"254838004"
albendazole	DB00518	Echinococcus granulosus infection	C0152068		Approved			CHEBI_16664	"430"	MONDO_0044346		"75006000"
erythromycin	DB00199	non-gonococcal urethritis (NGU)	C1112709		Approved			CHEBI_42355	"4053"			"84619001"
ertapenem	DB00303	Female genital tract infection	C1263758		Approved			CHEBI_404903	"325642"			"125585007"
albendazole	DB00518	Echinococcus granulosus infection of liver	C0153289		Approved			CHEBI_16664	"430"			"20790006"
erythromycin	DB00199	Pneumococcal pharyngitis	C0275761		Approved			CHEBI_42355	"4053"			"76651006"
ertapenem	DB00303	Community acquired pneumonia	C0694549		Approved			CHEBI_404903	"325642"			"385093006"
ertapenem	DB00303	Miscarriage with sepsis	C0269398		Approved			CHEBI_404903	"325642"			"67465009"
erythromycin	DB00199	Acute gonococcal endometritis	C0153196		Approved			CHEBI_42355	"4053"	MONDO_0004264		"65295003"
ertapenem	DB00303	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_404903	"325642"			"369001000119100"
erythromycin	DB00199	Acute gonococcal urethritis	C0275652		Approved			CHEBI_42355	"4053"			"29864006"
albendazole	DB00518	Echinococcus granulosus infection of lung	C0153290		Approved			CHEBI_16664	"430"			"75388006"
disulfiram	DB00822	Alcoholic Intoxication, Chronic	C0001973		Approved			CHEBI_4659	"3554"	HP:0030955	"10001639"	"7200002"
ondansetron	DB00904	Alcoholic Intoxication, Chronic	C0001973	NCT01591291	Withdrawn	Phase 2/Phase 3	Grant was transferred to University of Maryland and results were reported under NCT02354703.	CHEBI_7773	"26225"	HP:0030955	"10001639"	"7200002"
ethanol	DB00898	Alcoholic Intoxication, Chronic	C0001973	NCT01375556	Terminated	Phase 1		CHEBI_16236	"1310469|448|216449"	HP:0030955	"10001639"	"7200002"
baclofen	DB00181	Alcoholic Intoxication, Chronic	C0001973	NCT01937364	Terminated	Phase 2	The enrollment in the study was too limited for meaningful data analysis.	CHEBI_2972	"1292"	HP:0030955	"10001639"	"7200002"
acamprosate	DB00659	Alcoholic Intoxication, Chronic	C0001973		Approved			CHEBI_51041	"82819"	HP:0030955	"10001639"	"7200002"
salbutamol	DB01001	Asthma attack	C0347950		Approved			CHEBI_2549	"435"			
esomeprazole	DB00736	Peptic Esophagitis	C0014869		Approved			CHEBI_50275	"283742"	MONDO_0006896		
esomeprazole	DB00338	Peptic Esophagitis	C0014869		Approved			CHEBI_77260	"7646"	MONDO_0006896		
estradiol	DB00783	Acne Vulgaris	C0001144		Approved			CHEBI_16469	"4083"			"88616000"
ethinylestradiol	DB00977	Acne Vulgaris	C0001144		Approved			CHEBI_4903	"4124"			"88616000"
estradiol	DB00783	Atrophic Vaginitis	C0221392		Approved			CHEBI_16469	"4083"			"52441000"
ethinylestradiol	DB00977	Atrophic Vaginitis	C0221392		Approved			CHEBI_4903	"4124"			"52441000"
prednisolone	DB00860	Extrinsic allergic alveolitis	C0002390		Approved			CHEBI_8378	"8638"	HP:0006516	"10081988"	"37471005"
erythromycin ethyl succinate	DB00199	Arthropathy associated with infection	C0157749		Approved			CHEBI_42355	"4053"			"363162000"
epinephrine	DB00668	anaphylaxis	C0002792		Approved			CHEBI_28918	"3992"	HP:0100845	"10002198"	"39579001"
esmolol	DB00187	Perioperative hypertension	C3661921		Approved			CHEBI_88206	"49737"			"434711000124103"
mycophenolate mofetil	DB01024	Aplastic Anemia	C0002874	NCT00354419	Terminated	Phase 1	Low accrual	CHEBI_168396	"7145|265323"	HP:0001915	"10002967"	"304132006"
romiplostim	DB05332	Aplastic Anemia	C0002874		Approved				"805452"	HP:0001915	"10002967"	"304132006"
	DB01008	Aplastic Anemia	C0002874	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_28901	"1828"	HP:0001915	"10002967"	"304132006"
enocitabine	DB00773	Aplastic Anemia	C0002874	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_4911	"4179"	HP:0001915	"10002967"	"304132006"
oxymetholone	DB06412	Aplastic Anemia	C0002874		Approved			CHEBI_7864	"7813"	HP:0001915	"10002967"	"304132006"
	DB00531	Aplastic Anemia	C0002874	NCT00578903	Terminated	Phase 2		CHEBI_4027	"1545988|3002"	HP:0001915	"10002967"	"304132006"
	DB01042	Aplastic Anemia	C0002874	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_28876	"6718"	HP:0001915	"10002967"	"304132006"
alefacept	DB00092	Aplastic Anemia	C0002874	NCT01267643	Terminated	Phase 1	Study drug not available at this time		"299635"	HP:0001915	"10002967"	"304132006"
	DB00987	Aplastic Anemia	C0002874	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_28680	"3041|968804"	HP:0001915	"10002967"	"304132006"
	DB00864	Aplastic Anemia	C0002874	NCT00578903	Terminated	Phase 2		CHEBI_61049	"42316|235991"	HP:0001915	"10002967"	"304132006"
	DB00631	Aplastic Anemia	C0002874	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_681569	"44151"	HP:0001915	"10002967"	"304132006"
	DB13144	Aplastic Anemia	C0002874	NCT00354419	Terminated	Phase 1	Low accrual		"70167"	HP:0001915	"10002967"	"304132006"
ethambutol	DB00330	Acute tuberculosis	C0275959		Approved			CHEBI_4877	"4110"			"25629007"
ethionamide	DB00609	Acute tuberculosis	C0275959		Approved			CHEBI_4885	"4127"			"25629007"
estradiol	DB00783	Atrophy of vulva	C0156393		Approved			CHEBI_16469	"4083"	MONDO_0001932		"248861000"
ethotoin	DB00754	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_4888	"4136"	MONDO_0005754		
ethotoin	DB00754	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_4888	"4136"			
famotidine	DB00927	Peptic Esophagitis	C0014869		Approved			CHEBI_4975	"4278"	MONDO_0006896		
ethyl loflazepate	DB01545	Depressive disorder	C0011581		Approved			CHEBI_31573	"24524"	MONDO_0002050		"35489007"
everolimus	DB01590	Breast Carcinoma	C0678222		Approved			CHEBI_68478	"141704"	MONDO_0004989|MONDO_0015870		"254838004"
methotrexate	DB00563	Aplastic Anemia	C0002874	NCT00578903	Terminated	Phase 2		CHEBI_44185	"6851"	HP:0001915	"10002967"	"304132006"
	DB00262	Aplastic Anemia	C0002874	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_3423	"2105"	HP:0001915	"10002967"	"304132006"
	DB00091	Aplastic Anemia	C0002874	NCT00354419	Terminated	Phase 1	Low accrual	CHEBI_4031	"3008"	HP:0001915	"10002967"	"304132006"
heparin	DB01109	Aplastic Anemia	C0002874	NCT01343680	Terminated	Phase 3	Poor patient accrual	CHEBI_28304	"5224"	HP:0001915	"10002967"	"304132006"
daclizumab	DB00111	Aplastic Anemia	C0002874	NCT00001962	Terminated	Phase 2	DSMB recommended closing the study and publishing the results		"190353"	HP:0001915	"10002967"	"304132006"
	DB00087	Aplastic Anemia	C0002874	NCT00578903	Terminated	Phase 2			"117055"	HP:0001915	"10002967"	"304132006"
everolimus	DB01590	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_68478	"141704"			"417181009"
	DB00531	Aplastic Anemia	C0002874	NCT00354419	Terminated	Phase 1	Low accrual	CHEBI_4027	"1545988|3002"	HP:0001915	"10002967"	"304132006"
exemestane	DB00990	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_4953	"258494"			"417181009"
imolamine	DB09284	Angina Pectoris	C0002962		Approved			CHEBI_135072		HP:0001681	"10002383"	"225566008"
mibefradil	DB01388	Angina Pectoris	C0002962		Approved			CHEBI_6920	"83213"	HP:0001681	"10002383"	"225566008"
diltiazem	DB00343	Angina Pectoris	C0002962		Approved			CHEBI_101278	"3443"	HP:0001681	"10002383"	"225566008"
metoprolol	DB00264	Angina Pectoris	C0002962		Approved			CHEBI_6904	"6918"	HP:0001681	"10002383"	"225566008"
molsidomine	DB09282	Angina Pectoris	C0002962		Approved			CHEBI_92623	"7023"	HP:0001681	"10002383"	"225566008"
oxprenolol	DB01580	Angina Pectoris	C0002962		Approved			CHEBI_91704	"7801"	HP:0001681	"10002383"	"225566008"
atenolol	DB00335	Angina Pectoris	C0002962		Approved			CHEBI_2904	"1202"	HP:0001681	"10002383"	"225566008"
atorvastatin	DB01076	Angina Pectoris	C0002962		Approved			CHEBI_39548	"83367"	HP:0001681	"10002383"	"225566008"
propranolol	DB00571	Angina Pectoris	C0002962		Approved			CHEBI_8499	"8787"	HP:0001681	"10002383"	"225566008"
ethionamide	DB00609	Pulmonary Mycobacterium avium complex infection	C2733595		Approved			CHEBI_4885	"4127"			"186342000"
everolimus	DB01590	Angiomyolipoma of kidney	C0241961		Approved			CHEBI_68478	"141704"	MONDO_0004555		"254921004"
ezetimibe	DB00973	Homozygous Familial Hypercholesterolemia	C0342881		Approved			CHEBI_49040	"341248"			"238078005"
ezetimibe	DB00973	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_49040	"341248"			"238079002"
famotidine	DB00927	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_4975	"4278"	MONDO_0019610		"53132006"
fluconazole	DB00196	Septicemia candida	C0349009		Approved			CHEBI_46081	"202813|4450"			
fluocinolone acetonide	DB00591	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_31623	"4461"			"53891004"
fluocinolone acetonide	DB00591	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_31623	"4461"			"200965009"
fluocinolone acetonide	DB00591	Psoriasis of scalp	C0406326		Approved			CHEBI_31623	"4461"			"238608008"
fluconazole	DB00196	Candidemia	C0877445		Approved			CHEBI_46081	"202813|4450"	MONDO_0044070		"432261003"
alizapride	DB01425	Postoperative Nausea and Vomiting	C0520909		Approved			CHEBI_94316	"17311"			"1488000"
fludrocortisone acetate	DB00687	Addison Disease	C0001403		Approved			CHEBI_50885	"4452"	MONDO_0015129	"10001130"	"373662000"
flecainide	DB01195	Paroxysmal atrial flutter	C0741292		Approved			CHEBI_75984	"4441"			"427665004"
tenitramine	DB13637	Angina Pectoris	C0002962		Approved			CHEBI_81292		HP:0001681	"10002383"	"225566008"
bepridil	DB01244	Angina Pectoris	C0002962		Approved			CHEBI_3061	"1436"	HP:0001681	"10002383"	"225566008"
glyceryl trinitrate	DB00727	Angina Pectoris	C0002962		Approved			CHEBI_28787	"4917"	HP:0001681	"10002383"	"225566008"
trimetazidine	DB09069	Angina Pectoris	C0002962		Approved			CHEBI_94789	"10826"	HP:0001681	"10002383"	"225566008"
nifedipine	DB01115	Angina Pectoris	C0002962		Approved			CHEBI_7565	"7417"	HP:0001681	"10002383"	"225566008"
clopidogrel	DB00758	Angina Pectoris	C0002962	NCT00944333	Terminated	Phase 3	STOP due to recent data in literature questioning the need to continue DAP beyond six months in patients with stable coronary artery stenting with DES.	CHEBI_37941	"32968"	HP:0001681	"10002383"	"225566008"
nicorandil	DB09220	Angina Pectoris	C0002962		Approved			CHEBI_31905	"31748"	HP:0001681	"10002383"	"225566008"
nicardipine	DB00622	Angina Pectoris	C0002962		Approved			CHEBI_180905	"7396"	HP:0001681	"10002383"	"225566008"
ranolazine	DB00243	Angina Pectoris	C0002962		Approved			CHEBI_87690	"35829"	HP:0001681	"10002383"	"225566008"
isosorbide dinitrate	DB00883	Angina Pectoris	C0002962		Approved			CHEBI_6061	"6058"	HP:0001681	"10002383"	"225566008"
nadolol	DB01203	Angina Pectoris	C0002962		Approved			CHEBI_7444	"7226"	HP:0001681	"10002383"	"225566008"
isosorbide mononitrate	DB01020	Angina Pectoris	C0002962		Approved			CHEBI_6062	"28004"	HP:0001681	"10002383"	"225566008"
verapamil	DB00661	Angina Pectoris	C0002962		Approved			CHEBI_77733	"11170"	HP:0001681	"10002383"	"225566008"
celiprolol	DB04846	Angina Pectoris	C0002962		Approved			CHEBI_94461	"20498"	HP:0001681	"10002383"	"225566008"
floctafenine	DB08976	Acute onset pain	C0184567		Approved			CHEBI_31612	"4444"			"274663001"
fentanyl	DB00813	Breakthrough cancer pain	C2721580		Approved			CHEBI_119915	"4337"			"879973007"
fludrocortisone acetate	DB00687	Adrenogenital disorder	C0701163		Approved			CHEBI_50885	"4452"			"267395000"
fenoldopam	DB00800	Malignant essential hypertension	C0024588		Approved			CHEBI_5002	"24853"	MONDO_0001133		"78975002"
fentanyl	DB00813	Postoperative Pain, Acute	C2215257		Approved			CHEBI_119915	"4337"			"107401000119105"
fenofibrate	DB01039	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_5001	"8703"			"238079002"
fluocinolone acetonide	DB12553	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_5108	"25126"			"53891004"
fluocinolone acetonide	DB12553	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_5108	"25126"			"200965009"
fluocinolone acetonide	DB12553	Psoriasis of scalp	C0406326		Approved			CHEBI_5108	"25126"			"238608008"
fluocinonide	DB01047	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_5109	"4462"			"53891004"
fluocinonide	DB01047	Psoriasis of scalp	C0406326		Approved			CHEBI_5109	"4462"			"238608008"
fluocinonide	DB01047	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_5109	"4462"			"200965009"
fluocinonide	DB12553	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_5108	"25126"			"53891004"
fluocinonide	DB12553	Psoriasis of scalp	C0406326		Approved			CHEBI_5108	"25126"			"238608008"
fluocinonide	DB12553	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_5108	"25126"			"200965009"
fluoxetine	DB00472	Depressive disorder	C0011581		Approved			CHEBI_86990	"4493"	MONDO_0002050		"35489007"
fluocinonide	DB01047	Inflammatory dermatosis	C3875321		Approved			CHEBI_5109	"4462"	MONDO_0002406		"703938007"
fluocinonide	DB12553	Inflammatory dermatosis	C3875321		Approved			CHEBI_5108	"25126"	MONDO_0002406		"703938007"
fluorometholone	DB00324	Punctate keratopathy	C0423234		Approved			CHEBI_31625	"4491"			"246936005"
ofloxacin	DB01165	Anthrax disease	C0003175		Approved			CHEBI_7731	"7623"	MONDO_0005119	"10002713"	"409498004"
amlodipine	DB00381	Angina Pectoris	C0002962		Approved			CHEBI_2668	"17767"	HP:0001681	"10002383"	"225566008"
fluoxymesterone	DB01185	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_5120	"4494"			"417181009"
fluorometholone	DB00324	Corneal Ulcer	C0010043		Approved			CHEBI_31625	"4491"	MONDO_0004577		"91514001"
fluoxetine	DB00472	Depression, Bipolar	C0005587		Approved			CHEBI_86990	"4493"			"191627008"
fluocinolone acetonide	DB00591	Scurfiness of scalp	C0423775		Approved			CHEBI_31623	"4461"			"200767005"
hydrocortisone	DB00741	Angioedema	C0002994		Approved			CHEBI_17650	"5492"	HP:0100665	"10002424"	"846575004"
betamethasone acetate	DB00443	Angioedema	C0002994		Approved			CHEBI_3077	"1514"	HP:0100665	"10002424"	"846575004"
alimemazine	DB01246	Angioedema	C0002994		Approved			CHEBI_9725	"10825"	HP:0100665	"10002424"	"846575004"
fluocinolone acetonide	DB12553	Scurfiness of scalp	C0423775		Approved			CHEBI_5108	"25126"			"200767005"
dexamethasone	DB01234	Angioedema	C0002994		Approved			CHEBI_41879	"3264"	HP:0100665	"10002424"	"846575004"
hydrocortisone succinate	DB14545	Angioedema	C0002994		Approved			CHEBI_31677	"21651"	HP:0100665	"10002424"	"846575004"
triamcinolone	DB00620	Angioedema	C0002994		Approved			CHEBI_9667	"10759"	HP:0100665	"10002424"	"846575004"
cortisone acetate	DB01380	Angioedema	C0002994		Approved			CHEBI_3897	"21655"	HP:0100665	"10002424"	"846575004"
promazine	DB00420	Angioedema	C0002994		Approved			CHEBI_8459	"8742"	HP:0100665	"10002424"	"846575004"
hydrocortisone succinate	DB00741	Angioedema	C0002994		Approved			CHEBI_17650	"5492"	HP:0100665	"10002424"	"846575004"
betamethasone	DB00443	Angioedema	C0002994		Approved			CHEBI_3077	"1514"	HP:0100665	"10002424"	"846575004"
fludroxycortide	DB00846	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_5127	"4500"			"200965009"
fludroxycortide	DB00846	Psoriasis of scalp	C0406326		Approved			CHEBI_5127	"4500"			"238608008"
fludroxycortide	DB00846	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_5127	"4500"			"53891004"
fluticasone propionate	DB00588	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_31441	"50121"			"200965009"
fluticasone propionate	DB00588	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_31441	"50121"			"53891004"
fluticasone propionate	DB00588	Psoriasis of scalp	C0406326		Approved			CHEBI_31441	"50121"			"238608008"
fluticasone propionate	DB13867	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_5134	"41126"			"200965009"
fluticasone propionate	DB13867	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_5134	"41126"			"53891004"
fluticasone propionate	DB13867	Psoriasis of scalp	C0406326		Approved			CHEBI_5134	"41126"			"238608008"
alprazolam	DB00404	Anxiety	C0003467		Approved			CHEBI_2611	"596"	HP:0000739	"10002855"	"48694002"
midazolam	DB00683	Anxiety	C0003467		Approved			CHEBI_6931	"6960"	HP:0000739	"10002855"	"48694002"
methylphenobarbital	DB00849	Anxiety	C0003467		Approved			CHEBI_6758	"6758"	HP:0000739	"10002855"	"48694002"
midazolam	DB00683	Anxiety	C0003467	NCT00942539	Terminated	Phase 2		CHEBI_6931	"6960"	HP:0000739	"10002855"	"48694002"
diazepam	DB00829	Anxiety	C0003467		Approved			CHEBI_49575	"3322"	HP:0000739	"10002855"	"48694002"
ketamine	DB01221	Anxiety	C0003467	NCT01680172	Terminated	Phase 2	Slow enrollment	CHEBI_6121	"6130"	HP:0000739	"10002855"	"48694002"
chlordiazepoxide	DB00475	Anxiety	C0003467		Approved			CHEBI_3611	"2356"	HP:0000739	"10002855"	"48694002"
oxprenolol	DB01580	Anxiety	C0003467		Approved			CHEBI_91704	"7801"	HP:0000739	"10002855"	"48694002"
trifluoperazine	DB00831	Anxiety	C0003467		Approved			CHEBI_45951	"10800"	HP:0000739	"10002855"	"48694002"
lorazepam	DB00186	Anxiety	C0003467		Approved			CHEBI_6539	"6470"	HP:0000739	"10002855"	"48694002"
chlormezanone	DB01178	Anxiety	C0003467		Approved			CHEBI_3619	"2373"	HP:0000739	"10002855"	"48694002"
cannabidiol	DB09061	Anxiety	C0003467	NCT04267679	Withdrawn	Phase 2	Stopped due to COVID-19 pandemic.	CHEBI_69478	"2045371"	HP:0000739	"10002855"	"48694002"
clorazepate	DB00628	Anxiety	C0003467		Approved			CHEBI_3761	"2353|235408"	HP:0000739	"10002855"	"48694002"
adinazolam	DB00546	Anxiety	C0003467		Approved			CHEBI_251412		HP:0000739	"10002855"	"48694002"
fosphenytoin	DB01320	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_5165	"72236"			
fusidic acid	DB02703	Furunculosis	C0016867		Approved			CHEBI_29013	"4608|113608"			
fusidic acid	DB02703	Escherichia coli septicemia	C0276088		Approved			CHEBI_29013	"4608|113608"			
leucovorin	DB00650	Anemia, Megaloblastic	C0002888		Approved			CHEBI_15640	"6313"	MONDO_0001700	"10002065"	"53165003"
allopurinol	DB00437	Calcium renal calculus	C1959799		Approved			CHEBI_40279	"519"			"427649000"
fosfomycin	DB00828	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_28915	"4550"			"301011002"
allopurinol	DB00437	Uric acid renal calculus	C0558595		Approved			CHEBI_40279	"519"			"274401005"
fomepizole	DB01213	Accidental poisoning by methyl alcohol	C0261439		Approved			CHEBI_5141	"15226"			"216640006"
ajmaline	DB01426	Cardiac Arrhythmia	C0003811		Approved			CHEBI_28462	"423"	HP:0011675	"10003119"	"698247007"
fusidic acid	DB02703	non-gonococcal urethritis (NGU)	C1112709		Approved			CHEBI_29013	"4608|113608"			"84619001"
formestane	DB08905	Malignant epithelial neoplasm of female breast	C3163805		Approved			CHEBI_75172	"15070"			"447782002"
fusidic acid	DB02703	Actinomycosis	C0001261		Approved			CHEBI_29013	"4608|113608"	MONDO_0005631	"10000620"	"11817007"
fusidic acid	DB02703	Anthrax disease	C0003175		Approved			CHEBI_29013	"4608|113608"	MONDO_0005119	"10002713"	"409498004"
fusidic acid	DB02703	Keratoconjunctivitis	C0022573		Approved			CHEBI_29013	"4608|113608"	MONDO_0004768		"88151007"
folic acid	DB00158	Breastfeeding (mother)	C1623040		Approved			CHEBI_27470	"62356|4511|202634"			"413712001"
fluvastatin	DB01095	Arteriosclerosis	C0003850		Approved			CHEBI_38562	"41127"	MONDO_0002277	"10003210"	"72092001"
prazepam	DB01588	Anxiety	C0003467		Approved			CHEBI_8362	"8627"	HP:0000739	"10002855"	"48694002"
formoterol	DB00983	Intrinsic asthma	C0155880		Approved			CHEBI_63082	"25255"	MONDO_0004765		"266361008"
halazepam	DB00801	Anxiety	C0003467		Approved			CHEBI_5603	"26412"	HP:0000739	"10002855"	"48694002"
formoterol	DB00983	Severe chronic obstructive pulmonary disease	C0730607		Approved			CHEBI_63082	"25255"			"313299006"
meprobamate	DB00371	Anxiety	C0003467		Approved			CHEBI_6761	"6760"	HP:0000739	"10002855"	"48694002"
mebicar	DB13522	Anxiety	C0003467		Approved			CHEBI_136038		HP:0000739	"10002855"	"48694002"
fusidic acid	DB02703	Acute gonococcal endometritis	C0153196		Approved			CHEBI_29013	"4608|113608"	MONDO_0004264		"65295003"
fusidic acid	DB02703	Acute gonococcal urethritis	C0275652		Approved			CHEBI_29013	"4608|113608"			"29864006"
formoterol	DB00983	Allergic asthma	C0155877		Approved			CHEBI_63082	"25255"	MONDO_0004784		"389145006"
fusidic acid	DB02703	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_29013	"4608|113608"			"448813005"
furosemide	DB00695	Decompensated cardiac failure	C0581377		Approved			CHEBI_47426	"4603"			"195111005"
fusidic acid	DB02703	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_29013	"4608|113608"			"428783003"
acetylsalicylic acid	DB00945	Arthralgia	C0003862		Approved			CHEBI_15365	"91101|1191"	HP:0002829	"10003239"	"57676002"
salicylamide	DB08797	Arthralgia	C0003862		Approved			CHEBI_32114	"9518"	HP:0002829	"10003239"	"57676002"
methyl nicotinate	DB13882	Arthralgia	C0003862		Approved			CHEBI_134761	"29900"	HP:0002829	"10003239"	"57676002"
fusidic acid	DB02703	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_29013	"4608|113608"			"186435004"
fusidic acid	DB02703	Acne Vulgaris	C0001144		Approved			CHEBI_29013	"4608|113608"			"88616000"
fusidic acid	DB02703	Infective otitis media	C0729586		Approved			CHEBI_29013	"4608|113608"			"312218008"
fusidic acid	DB02703	Escherichia coli Infections	C0014836		Approved			CHEBI_29013	"4608|113608"	MONDO_0020920		"71057007"
fusidic acid	DB02703	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_29013	"4608|113608"	MONDO_0001080		"20943002"
fusidic acid	DB02703	Cutaneous anthrax	C0003177		Approved			CHEBI_29013	"4608|113608"	MONDO_0004215	"10011660"	"84980006"
fusidic acid	DB02703	Acute gonococcal epididymo-orchitis	C0153193		Approved			CHEBI_29013	"4608|113608"	MONDO_0001125		"30168008"
fusidic acid	DB02703	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_29013	"4608|113608"	MONDO_0040732		"11218009"
fusidic acid	DB02703	Blepharoconjunctivitis	C0005743		Approved			CHEBI_29013	"4608|113608"	MONDO_0002307		"68659002"
fusidic acid	DB02703	Arthropathy associated with infection	C0157749		Approved			CHEBI_29013	"4608|113608"			"363162000"
fusidic acid	DB02703	Anterior uveitis	C0042165		Approved			CHEBI_29013	"4608|113608"	MONDO_0006651		"410692006"
fusidic acid	DB02703	Gonorrhea of pharynx	C0149966		Approved			CHEBI_29013	"4608|113608"			"74372003"
fusidic acid	DB02703	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_29013	"4608|113608"			"369001000119100"
fusidic acid	DB02703	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_29013	"4608|113608"			"128945009"
paracetamol	DB00316	Arthralgia	C0003862		Approved			CHEBI_46195	"161"	HP:0002829	"10003239"	"57676002"
caffeine	DB00201	Arthralgia	C0003862		Approved			CHEBI_27732	"1886"	HP:0002829	"10003239"	"57676002"
fusidic acid	DB02703	Acute bacterial sinusitis	C0275556		Approved			CHEBI_29013	"4608|113608"			"75498004"
fusidic acid	DB02703	Sepsis caused by Gram negative bacteria	C3163829		Approved			CHEBI_29013	"4608|113608"			"449082003"
fusidic acid	DB02703	Proteus septicemia	C0577690		Approved			CHEBI_29013	"4608|113608"			
fusidic acid	DB02703	Staphylococcus aureus infection	C1318973		Approved			CHEBI_29013	"4608|113608"			"406602003"
fusidic acid	DB02703	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_29013	"4608|113608"			"301011002"
galantamine	DB00674	Alzheimer's Disease	C0002395		Approved			CHEBI_42944	"4637"	MONDO_0004975	"10012271"	"26929004"
gatifloxacin	DB01044	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_5280	"228476|1546025"			"301011002"
gatifloxacin	DB01044	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_5280	"228476|1546025"			"70036007"
gatifloxacin	DB01044	Staphylococcus aureus infection	C1318973		Approved			CHEBI_5280	"228476|1546025"			"406602003"
gatifloxacin	DB01044	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_5280	"228476|1546025"	MONDO_0001080		"20943002"
gemifloxacin	DB01155	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_101853	"138099"			"70036007"
gefitinib	DB00317	Epidermal growth factor receptor positive non-small cell lung cancer	C1960925		Approved			CHEBI_49668	"328134"			"426964009"
ganciclovir	DB01004	Keratitis, Dendritic	C0022570		Approved			CHEBI_465284	"4678"			"29943008"
alfacalcidol	DB01436	Renal Osteodystrophy	C0035086		Approved			CHEBI_31186	"12062"	MONDO_0006946		"16726004"
alosetron	DB00969	Irritable bowel syndrome with diarrhea	C0348898		Approved			CHEBI_253342	"85248"			"197125005"
fusidic acid	DB02703	Infective blepharitis	C0729587		Approved			CHEBI_29013	"4608|113608"			"312219000"
gatifloxacin	DB01044	Proteus urinary tract infection	C0577709		Approved			CHEBI_5280	"228476|1546025"			"301012009"
gemifloxacin	DB01155	Acute bacterial bronchitis	C0339933		Approved			CHEBI_101853	"138099"			"233598009"
fusidic acid	DB02703	Hospital acquired pneumonia	C0949083		Approved			CHEBI_29013	"4608|113608"			"425464007"
ganciclovir	DB01004	Cytomegalovirus Retinitis	C0206178		Approved			CHEBI_465284	"4678"			"22455005"
gatifloxacin	DB01044	Acute gonococcal urethritis	C0275652		Approved			CHEBI_5280	"228476|1546025"			"29864006"
gatifloxacin	DB01044	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_5280	"228476|1546025"			"369001000119100"
gatifloxacin	DB01044	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_5280	"228476|1546025"			"425748003"
gemifloxacin	DB01155	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_101853	"138099"			"425748003"
naproxen	DB00788	Arthralgia	C0003862		Approved			CHEBI_7476	"7258"	HP:0002829	"10003239"	"57676002"
methyl nicotinate	DB00627	Arthralgia	C0003862		Approved			CHEBI_15940	"7393"	HP:0002829	"10003239"	"57676002"
magnesium salicylate	DB01397	Arthralgia	C0003862		Approved			CHEBI_6640		HP:0002829	"10003239"	"57676002"
gatifloxacin	DB01044	Acute bacterial sinusitis	C0275556		Approved			CHEBI_5280	"228476|1546025"			"75498004"
oxycodone	DB00497	Arthralgia	C0003862	NCT01094262	Terminated	Phase 2	Logistic reasons associated with the FDA-imposed clinical hold.	CHEBI_7852	"7804"	HP:0002829	"10003239"	"57676002"
fusidic acid	DB02703	Chlamydia trachomatis infection of genital structure	C1997322		Approved			CHEBI_29013	"4608|113608"			"428015005"
guaifenesin	DB00874	Influenza-like symptoms	C0392171		Approved			CHEBI_5551	"5032"			
glycine	DB00145	Common Cold	C0009443		Approved			CHEBI_15428	"4919"	MONDO_0005709		"82272006"
grepafloxacin	DB00365	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_5543	"83719"	MONDO_0001080		"20943002"
grepafloxacin	DB00365	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_5543	"83719"			"70036007"
guaiacol	DB11359	Common Cold	C0009443		Approved			CHEBI_28591	"5031"	MONDO_0005709		"82272006"
guaifenesin	DB00874	Headache Disorders	C0393735		Approved			CHEBI_5551	"5032"			"230461009"
guaifenesin	DB00874	Common Cold	C0009443		Approved			CHEBI_5551	"5032"	MONDO_0005709		"82272006"
ulobetasol propionate	DB00596	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_135782	"41208"			"53891004"
ulobetasol propionate	DB00596	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_135782	"41208"			"200965009"
ulobetasol propionate	DB00596	Psoriasis of scalp	C0406326		Approved			CHEBI_135782	"41208"			"238608008"
hydrocortisone acetate	DB14539	Arthritis, Gouty	C0003868		Approved			CHEBI_17609	"27197"	HP:0001997	"10018634"	"190828008"
betamethasone acetate	DB00443	Arthritis, Gouty	C0003868		Approved			CHEBI_3077	"1514"	HP:0001997	"10018634"	"190828008"
hydrocortisone succinate	DB14545	Arthritis, Gouty	C0003868		Approved			CHEBI_31677	"21651"	HP:0001997	"10018634"	"190828008"
triamcinolone diacetate	DB00620	Arthritis, Gouty	C0003868		Approved			CHEBI_9667	"10759"	HP:0001997	"10018634"	"190828008"
canakinumab	DB06168	Arthritis, Gouty	C0003868		Approved				"853491"	HP:0001997	"10018634"	"190828008"
cortisone acetate	DB01380	Arthritis, Gouty	C0003868		Approved			CHEBI_3897	"21655"	HP:0001997	"10018634"	"190828008"
triamcinolone acetonide	DB00620	Arthritis, Gouty	C0003868		Approved			CHEBI_9667	"10759"	HP:0001997	"10018634"	"190828008"
dexamethasone	DB01234	Arthritis, Gouty	C0003868		Approved			CHEBI_41879	"3264"	HP:0001997	"10018634"	"190828008"
triamcinolone	DB00620	Arthritis, Gouty	C0003868		Approved			CHEBI_9667	"10759"	HP:0001997	"10018634"	"190828008"
prednisone	DB00635	Arthritis, Gouty	C0003868		Approved			CHEBI_8382	"8640"	HP:0001997	"10018634"	"190828008"
prednisolone	DB00860	Arthritis, Gouty	C0003868		Approved			CHEBI_8378	"8638"	HP:0001997	"10018634"	"190828008"
sulindac	DB00605	Arthritis, Gouty	C0003868		Approved			CHEBI_9352	"10237"	HP:0001997	"10018634"	"190828008"
methylprednisolone	DB00959	Arthritis, Gouty	C0003868		Approved			CHEBI_6888	"6902"	HP:0001997	"10018634"	"190828008"
grepafloxacin	DB00365	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_5543	"83719"			"195722003"
goserelin	DB00014	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_5523	"50610"			"417181009"
grepafloxacin	DB00365	Acute bacterial bronchitis	C0339933		Approved			CHEBI_5543	"83719"			"233598009"
sodium citrate	DB09154	Arthritis	C0003864	NCT01421160	Withdrawn	Phase 1	PI left the institution prior to any data being collected	CHEBI_53258	"253204|56466|1310549"	MONDO_0005578	"10003246"	"3723001"
guanidine	DB00536	Lambert-Eaton Myasthenic Syndrome	C0022972		Approved			CHEBI_42820	"50675"	MONDO_0018556		"56989000"
granisetron	DB00889	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_5537	"26237"			"18846006"
alprostadil	DB00770	Aortic coarctation	C0003492		Approved			CHEBI_15544	"598"	MONDO_0007345	"10009807"	"7305005"
rituximab	DB00073	Rheumatoid Arthritis	C0003873		Approved				"2273510|2472325|121191|2105824"	MONDO_0008383	"10039073"	"69896004"
infliximab	DB00065	Rheumatoid Arthritis	C0003873		Approved				"1790539|1927283|191831|2266523|2103476"	MONDO_0008383	"10039073"	"69896004"
flunoxaprofen	DB13317	Rheumatoid Arthritis	C0003873		Approved			CHEBI_76154		MONDO_0008383	"10039073"	"69896004"
	DB00005	Rheumatoid Arthritis	C0003873	NCT01764997	Terminated	Phase 3	Due to small number of participants entering randomization. Not a safety issue.		"214555|2103480|2462511"	MONDO_0008383	"10039073"	"69896004"
alclofenac	DB13167	Rheumatoid Arthritis	C0003873		Approved			CHEBI_31183		MONDO_0008383	"10039073"	"69896004"
etodolac	DB00749	Rheumatoid Arthritis	C0003873		Approved			CHEBI_4909	"24605"	MONDO_0008383	"10039073"	"69896004"
	DB00005	Rheumatoid Arthritis	C0003873	NCT00298272	Terminated	Phase 2	Sponsor decided to end long term extension phase for business reasons unrelated to safety.		"214555|2103480|2462511"	MONDO_0008383	"10039073"	"69896004"
	DB00073	Rheumatoid Arthritis	C0003873	NCT00298272	Terminated	Phase 2	Sponsor decided to end long term extension phase for business reasons unrelated to safety.		"2273510|2472325|121191|2105824"	MONDO_0008383	"10039073"	"69896004"
hydrocodone	DB00956	Common Cold	C0009443		Approved			CHEBI_5779	"5489"	MONDO_0005709		"82272006"
hydrocortisone	DB00741	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_17650	"5492"			"53891004"
sarecycline	DB12035	Acne Vulgaris	C0001144		Approved				"2059018"			"88616000"
hydrocortisone acetate	DB00741	Arthritis, Gouty	C0003868		Approved			CHEBI_17650	"5492"	HP:0001997	"10018634"	"190828008"
betamethasone	DB00443	Arthritis, Gouty	C0003868		Approved			CHEBI_3077	"1514"	HP:0001997	"10018634"	"190828008"
allopurinol	DB00437	Arthritis, Gouty	C0003868		Approved			CHEBI_40279	"519"	HP:0001997	"10018634"	"190828008"
probenecid	DB01032	Arthritis, Gouty	C0003868		Approved			CHEBI_8426	"8698"	HP:0001997	"10018634"	"190828008"
hydrocortisone	DB00741	Arthritis, Gouty	C0003868		Approved			CHEBI_17650	"5492"	HP:0001997	"10018634"	"190828008"
hydrocortisone succinate	DB00741	Arthritis, Gouty	C0003868		Approved			CHEBI_17650	"5492"	HP:0001997	"10018634"	"190828008"
heparin	DB01109	Peripheral arterial embolism	C0564750		Approved			CHEBI_28304	"5224"			"286959000"
homatropine	DB11181	Incomplete passage of stool	C0426639		Approved			CHEBI_5747	"27084"			"249515001"
haloperidol	DB00502	Chronic schizophrenia	C0221765		Approved			CHEBI_5613	"5093"			"83746006"
hydrocortisone	DB00741	Blepharoconjunctivitis	C0005743		Approved			CHEBI_17650	"5492"	MONDO_0002307		"68659002"
heparin	DB01109	Non-Q wave myocardial infarction	C0542269		Approved			CHEBI_28304	"5224"			"314207007"
hydrocortisone	DB00741	Corneal Abrasions	C0010032		Approved			CHEBI_17650	"5492"		"10010984"	"85848002"
halofantrine	DB01218	Malaria, Vivax	C0024537		Approved			CHEBI_94392	"50749"	MONDO_0005921		"27052006"
halofantrine	DB01218	Malaria, Falciparum	C0024535		Approved			CHEBI_94392	"50749"	MONDO_0005920		"248441000"
	DB00051	Rheumatoid Arthritis	C0003873	NCT00298272	Terminated	Phase 2	Sponsor decided to end long term extension phase for business reasons unrelated to safety.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
	DB00959	Rheumatoid Arthritis	C0003873	NCT00298272	Terminated	Phase 2	Sponsor decided to end long term extension phase for business reasons unrelated to safety.	CHEBI_6888	"6902"	MONDO_0008383	"10039073"	"69896004"
hydrocortisone	DB00741	Acne Vulgaris	C0001144		Approved			CHEBI_17650	"5492"			"88616000"
hydrocortisone	DB00741	Rheumatoid Arthritis	C0003873		Approved			CHEBI_17650	"5492"	MONDO_0008383	"10039073"	"69896004"
hydrocortisone	DB00741	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_17650	"5492"			"200965009"
hydrocortisone	DB00741	Psoriasis of scalp	C0406326		Approved			CHEBI_17650	"5492"			"238608008"
hydrocortisone	DB00741	Transplanted organ rejection	C0345468		Approved			CHEBI_17650	"5492"			"213148006"
hydrocortisone	DB00741	Addison Disease	C0001403		Approved			CHEBI_17650	"5492"	MONDO_0015129	"10001130"	"373662000"
hydrocortisone	DB00741	Inflammatory dermatosis	C3875321		Approved			CHEBI_17650	"5492"	MONDO_0002406		"703938007"
hydrocortisone	DB00741	Arthritis, Psoriatic	C0003872		Approved			CHEBI_17650	"5492"	MONDO_0011849	"10037162"	"156370009"
hydrocortisone	DB00741	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_17650	"5492"	MONDO_0015253		"88854002"
hydrocortisone	DB00741	Acquired thrombocytopenia	C0154301		Approved			CHEBI_17650	"5492"	MONDO_0001198		"154826009"
hydrocortisone	DB00741	Mycosis Fungoides	C0026948		Approved			CHEBI_17650	"5492"	MONDO_0009691		"118618005"
hydrocortisone	DB00741	Infective blepharitis	C0729587		Approved			CHEBI_17650	"5492"			"312219000"
hydrocortisone	DB00741	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			CHEBI_17650	"5492"	MONDO_0041095		"232230009"
hydrocortisone	DB00741	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_17650	"5492"	MONDO_0000004		"386584007"
hydrocortisone	DB00741	Adrenogenital disorder	C0701163		Approved			CHEBI_17650	"5492"			"267395000"
hydrocortisone	DB00741	Infective otitis externa	C0021355		Approved			CHEBI_17650	"5492"			"86981007"
hydrocortisone	DB00741	Corneal Ulcer	C0010043		Approved			CHEBI_17650	"5492"	MONDO_0004577		"91514001"
hydrocortisone	DB00741	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_17650	"5492"			"699262001"
hydrocortisone	DB00741	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_17650	"5492"	MONDO_0018479		"237751000"
hydroxycarbamide	DB01005	Myeloid Leukemia, Chronic	C0023473		Approved			CHEBI_44423	"151871|5552"	MONDO_0011996		
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00298272	Terminated	Phase 2	Sponsor decided to end long term extension phase for business reasons unrelated to safety.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
hydromorphone	DB00327	Common Cold	C0009443		Approved			CHEBI_5790	"3423"	MONDO_0005709		"82272006"
	DB00244	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_6775	"52582"	MONDO_0008383	"10039073"	"69896004"
ibuprofen	DB01050	Influenza-like symptoms	C0392171		Approved			CHEBI_5855	"5640"			
	DB00795	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_9334	"9524"	MONDO_0008383	"10039073"	"69896004"
	DB00860	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_8378	"8638"	MONDO_0008383	"10039073"	"69896004"
	DB00563	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
	DB08880	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_68540	"1310520"	MONDO_0008383	"10039073"	"69896004"
ibuprofen	DB01050	Rheumatoid Arthritis	C0003873		Approved			CHEBI_5855	"5640"	MONDO_0008383	"10039073"	"69896004"
hydroxychloroquine	DB01611	Rheumatoid Arthritis	C0003873		Approved			CHEBI_5801	"5521"	MONDO_0008383	"10039073"	"69896004"
epoetin alfa	DB00016	Rheumatoid Arthritis	C0003873	NCT00236678	Terminated	Phase 2	This study was terminated due to slow enrollment, despite protocol amendments to change the entrance criteria.		"2047589|105695|105694"	MONDO_0008383	"10039073"	"69896004"
fenoprofen	DB00573	Rheumatoid Arthritis	C0003873		Approved			CHEBI_5004	"4331"	MONDO_0008383	"10039073"	"69896004"
ibuprofen	DB01050	Headache Disorders	C0393735		Approved			CHEBI_5855	"5640"			"230461009"
hydroxycarbamide	DB01005	Anemia, Sickle Cell	C0002895		Approved			CHEBI_44423	"151871|5552"	MONDO_0011382	"10040641"	"127040003"
hydromorphone	DB00327	Severe pain	C0278140		Approved			CHEBI_5790	"3423"			"76948002"
ibuprofen	DB01050	Severe pain	C0278140		Approved			CHEBI_5855	"5640"			"76948002"
hydrocortisone	DB00741	Punctate keratopathy	C0423234		Approved			CHEBI_17650	"5492"			"246936005"
hydroxychloroquine	DB01611	Quartan malaria	C0024536		Approved			CHEBI_5801	"5521"	MONDO_0001943		"27618009"
hydroxychloroquine	DB01611	Ovale malaria	C0152072		Approved			CHEBI_5801	"5521"	MONDO_0001601		"19341001"
hydroxychloroquine	DB01611	Malaria, Vivax	C0024537		Approved			CHEBI_5801	"5521"	MONDO_0005921		"27052006"
hydroxychloroquine	DB01611	Malaria, Falciparum	C0024535		Approved			CHEBI_5801	"5521"	MONDO_0005920		"248441000"
hydromorphone	DB00327	Postoperative Pain, Acute	C2215257		Approved			CHEBI_5790	"3423"			"107401000119105"
ibuprofen	DB01050	Postoperative Pain, Acute	C2215257		Approved			CHEBI_5855	"5640"			"107401000119105"
hydrocortisone	DB00741	Chronic ulcerative proctitis	C2937222		Approved			CHEBI_17650	"5492"			"52231000"
hydrocortisone	DB00741	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_17650	"5492"	MONDO_0020108	"10073785"	"413603009"
imiquimod	DB00724	wartlike skin lesion	C0043037		Approved			CHEBI_36704	"59943"			
imipenem	DB01598	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_471744	"5690|1545986"			"186435004"
indomethacin	DB00328	Rheumatoid Arthritis	C0003873		Approved			CHEBI_49662	"5781"	MONDO_0008383	"10039073"	"69896004"
	DB00795	Rheumatoid Arthritis	C0003873	NCT00521924	Terminated	Phase 3	Slow Enrollment	CHEBI_9334	"9524"	MONDO_0008383	"10039073"	"69896004"
imipenem	DB01598	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_471744	"5690|1545986"			"70036007"
	DB00244	Rheumatoid Arthritis	C0003873	NCT00521924	Terminated	Phase 3	Slow Enrollment	CHEBI_6775	"52582"	MONDO_0008383	"10039073"	"69896004"
imipramine	DB00458	Depressive disorder	C0011581		Approved			CHEBI_47499	"5691"	MONDO_0002050		"35489007"
	DB00065	Rheumatoid Arthritis	C0003873	NCT00521924	Terminated	Phase 3	Slow Enrollment		"1790539|1927283|191831|2266523|2103476"	MONDO_0008383	"10039073"	"69896004"
	DB00608	Rheumatoid Arthritis	C0003873	NCT00521924	Terminated	Phase 3	Slow Enrollment	CHEBI_3638	"2393"	MONDO_0008383	"10039073"	"69896004"
	DB00091	Rheumatoid Arthritis	C0003873	NCT00521924	Terminated	Phase 3	Slow Enrollment	CHEBI_4031	"3008"	MONDO_0008383	"10039073"	"69896004"
flurbiprofen	DB00712	Rheumatoid Arthritis	C0003873		Approved			CHEBI_5130	"4502"	MONDO_0008383	"10039073"	"69896004"
	DB00563	Rheumatoid Arthritis	C0003873	NCT01390441	Terminated	Phase 1	The study was terminated early by the Sponsor for business reasons.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
imipenem	DB01598	Pneumonia, Bacterial	C0004626		Approved			CHEBI_471744	"5690|1545986"	MONDO_0004652	"10060946"	"53084003"
idebenone	DB09081	Optic Atrophy, Hereditary, Leber	C0917796		Approved			CHEBI_31687	"51296"	MONDO_0010788		"58610003"
imipenem	DB01598	Arthropathy associated with infection	C0157749		Approved			CHEBI_471744	"5690|1545986"			"363162000"
imatinib	DB00619	Myeloid and/or lymphoid neoplasm associated with platelet derived growth factor receptor alpha rearrangement	C4545381		Approved			CHEBI_45783	"282388"	MONDO_0015689		"738527001"
imipenem	DB01598	Female genital tract infection	C1263758		Approved			CHEBI_471744	"5690|1545986"			"125585007"
inositol	DB13178	Pellagra	C0030783		Approved			CHEBI_17268	"5833"	MONDO_0019975		"418186002"
imatinib	DB00619	Leukemia, Myeloid, Chronic-Phase	C0023474		Approved			CHEBI_45783	"282388"			"413847001"
imipenem	DB01598	Acinetobacter Infections	C0001139		Approved			CHEBI_471744	"5690|1545986"	MONDO_0006635	"10051894"	"840588006"
imipenem	DB01598	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_471744	"5690|1545986"			"425748003"
imiquimod	DB00724	Superficial basal cell carcinoma	C0862889		Approved			CHEBI_36704	"59943"			"403914000"
indomethacin	DB00328	shoulder bursitis	C0262399		Approved			CHEBI_49662	"5781"			"239961006"
imatinib	DB00619	Idiopathic Hypereosinophilic Syndrome	C0206141		Approved			CHEBI_45783	"282388"	MONDO_0011895		"423294001"
imipenem	DB01598	Infection due to enterococcus	C1320183		Approved			CHEBI_471744	"5690|1545986"			"406574007"
amantadine	DB00915	Influenza due to Influenza A virus	C2711180		Approved			CHEBI_2618	"620"			"442438000"
amantadine	DB00915	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_2618	"620"	MONDO_0001945		"19972008"
irinotecan	DB00762	metastasis from malignant neoplasm of colon	C1282500		Approved			CHEBI_80630	"51499"	MONDO_0041448		
loratadine	DB00455	Rheumatoid Arthritis	C0003873	NCT01390441	Terminated	Phase 1	The study was terminated early by the Sponsor for business reasons.	CHEBI_6538	"28889"	MONDO_0008383	"10039073"	"69896004"
	DB00650	Rheumatoid Arthritis	C0003873	NCT01217814	Terminated	Phase 2	Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns	CHEBI_15640	"6313"	MONDO_0008383	"10039073"	"69896004"
folic acid	DB00158	Rheumatoid Arthritis	C0003873	NCT01217814	Terminated	Phase 2	Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns	CHEBI_27470	"62356|4511|202634"	MONDO_0008383	"10039073"	"69896004"
natalizumab	DB00108	Rheumatoid Arthritis	C0003873	NCT00831649	Terminated	Phase 2	The biological effect seen with natalizumab was not sufficient to warrant further development in RA.		"354770"	MONDO_0008383	"10039073"	"69896004"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT01862224	Terminated	Phase 2	The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
itraconazole	DB01167	onychomycosis of fingernail	C1274469		Approved			CHEBI_6076	"28031"			
iproclozide	DB09247	Depressive disorder	C0011581		Approved			CHEBI_134988		MONDO_0002050		"35489007"
iproniazid	DB04818	Depressive disorder	C0011581		Approved			CHEBI_5958	"5981"	MONDO_0002050		"35489007"
isoprenaline	DB01064	Common Cold	C0009443		Approved			CHEBI_64317	"6054"	MONDO_0005709		"82272006"
amcinonide	DB00288	Psoriasis of scalp	C0406326		Approved			CHEBI_31199	"17652"			"238608008"
amcinonide	DB00288	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_31199	"17652"			"53891004"
amcinonide	DB00288	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_31199	"17652"			"200965009"
itraconazole	DB01167	Candidemia	C0877445		Approved			CHEBI_6076	"28031"	MONDO_0044070		"432261003"
ixabepilone	DB04845	Breast Carcinoma	C0678222		Approved			CHEBI_63605	"337523"	MONDO_0004989|MONDO_0015870		"254838004"
levamisole	DB00848	Ascariasis	C0003950		Approved			CHEBI_6432	"6371"	MONDO_0005654	"10003442"	"2435008"
levamisole	DB16561	Ascariasis	C0003950		Approved			CHEBI_77278		MONDO_0005654	"10003442"	"2435008"
itraconazole	DB01167	Onychomycosis of toenails	C1274470		Approved			CHEBI_6076	"28031"			"403059006"
isoniazid	DB00951	Acute tuberculosis	C0275959		Approved			CHEBI_6030	"6038"			"25629007"
isoxsuprine	DB08941	Raynaud Disease	C0034734		Approved				"6066"	MONDO_0008364		"195295006"
diiodohydroxyquinoline	DB09115	Amebiasis	C0002438		Approved			CHEBI_5950	"3435"	MONDO_0005644	"10001980"	"111910009"
sunitinib	DB01268	Ascites	C0003962	NCT00796861	Terminated	Phase 2	Phycisican decided to terminate study due to slow patient accrual.	CHEBI_38940	"357977"	HP:0001541	"10003445"	"389026000"
inositol nicotinate	DB08949	Pellagra	C0030783		Approved			CHEBI_31699	"27604"	MONDO_0019975		"418186002"
inositol nicotinate	DB00627	Pellagra	C0030783		Approved			CHEBI_15940	"7393"	MONDO_0019975		"418186002"
lamotrigine	DB00555	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_6367	"28439"			
ketoprofen	DB01009	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6128	"6142"	MONDO_0008383	"10039073"	"69896004"
lafutidine	DB12770	Gastro-esophageal reflux disease with esophagitis	C0677659		Approved			CHEBI_31759				"266433003"
ketorolac	DB00465	Severe pain	C0278140		Approved			CHEBI_76223	"35827"			"76948002"
kanamycin	DB01172	Arthropathy associated with infection	C0157749		Approved			CHEBI_17630	"6099|1727573"			"363162000"
ketoconazole	DB01026	Adrenal Gland Hyperfunction	C0001622		Approved			CHEBI_48339	"6135"	MONDO_0006640|MONDO_0018912	"10020564"	"47270006"
lanreotide	DB06791	Hypersomatotropic gigantism	C0001207		Approved			CHEBI_135901	"68092"			"86073008"
lamotrigine	DB00555	Bipolar disorder in remission	C0270425		Approved			CHEBI_6367	"28439"			"85248005"
spironolactone	DB00421	Ascites	C0003962		Approved			CHEBI_9241	"9997"	HP:0001541	"10003445"	"389026000"
	DB00438	Ascites	C0003962	NCT01455246	Terminated	Phase 2/Phase 3	Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.	CHEBI_3508	"2191|1545984"	HP:0001541	"10003445"	"389026000"
	DB00080	Ascites	C0003962	NCT01455246	Terminated	Phase 2/Phase 3	Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.	CHEBI_600103	"22299"	HP:0001541	"10003445"	"389026000"
eplerenone	DB00700	Ascites	C0003962	NCT01801228	Withdrawn	Phase 2	difficulties to include patients	CHEBI_31547	"298869"	HP:0001541	"10003445"	"389026000"
ketorolac	DB00465	Postoperative Pain, Acute	C2215257		Approved			CHEBI_76223	"35827"			"107401000119105"
lanreotide	DB06791	Acromegaly	C0001206		Approved			CHEBI_135901	"68092"	MONDO_0019933	"10000599"	"74107003"
lactitol	DB12942	Chronic idiopathic constipation	C0267509		Approved			CHEBI_75323	"28395"			"82934008"
landiolol	DB12212	Tachyarrhythmia	C0080203		Approved			CHEBI_135809			"10049447"	"6285003"
lansoprazole	DB00448	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_6375	"17128"	MONDO_0019610		"53132006"
ketoconazole	DB01026	Scurfiness of scalp	C0423775		Approved			CHEBI_48339	"6135"			"200767005"
levetiracetam	DB01202	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_6437	"114477"			
amikacin	DB00479	Proteus septicemia	C0577690		Approved			CHEBI_2637	"641"			
amikacin	DB00479	Escherichia coli septicemia	C0276088		Approved			CHEBI_2637	"641"			
leflunomide	DB08880	Rheumatoid Arthritis	C0003873		Approved			CHEBI_68540	"1310520"	MONDO_0008383	"10039073"	"69896004"
leflunomide	DB01097	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6402	"27169"	MONDO_0008383	"10039073"	"69896004"
levofloxacin	DB01137	Staphylococcus aureus infection	C1318973		Approved			CHEBI_63598	"1546009|82122"			"406602003"
levofloxacin	DB01137	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_63598	"1546009|82122"			"301011002"
levofloxacin	DB01137	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_63598	"1546009|82122"			"186435004"
levofloxacin	DB01137	Group A Streptococcal Infections	C0554628		Approved			CHEBI_63598	"1546009|82122"			"302809008"
levofloxacin	DB01137	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_63598	"1546009|82122"			"70036007"
amikacin	DB00479	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_2637	"641"			"186435004"
amikacin	DB00479	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_2637	"641"	MONDO_0040732		"11218009"
amikacin	DB00479	Arthropathy associated with infection	C0157749		Approved			CHEBI_2637	"641"			"363162000"
leflunomide	DB08880	Arthritis, Psoriatic	C0003872		Approved			CHEBI_68540	"1310520"	MONDO_0011849	"10037162"	"156370009"
leflunomide	DB01097	Arthritis, Psoriatic	C0003872		Approved			CHEBI_6402	"27169"	MONDO_0011849	"10037162"	"156370009"
levofloxacin	DB01137	Anthrax disease	C0003175		Approved			CHEBI_63598	"1546009|82122"	MONDO_0005119	"10002713"	"409498004"
levofloxacin	DB01137	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_63598	"1546009|82122"			"195722003"
amikacin	DB00479	Diverticulitis of gastrointestinal tract	C0349774		Approved			CHEBI_2637	"641"			"271366000"
letrozole	DB01006	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_6413	"72965"			"417181009"
levofloxacin	DB01137	Acute bacterial bronchitis	C0339933		Approved			CHEBI_63598	"1546009|82122"			"233598009"
levofloxacin	DB01137	Proteus urinary tract infection	C0577709		Approved			CHEBI_63598	"1546009|82122"			"301012009"
amikacin	DB00479	Hospital acquired pneumonia	C0949083		Approved			CHEBI_2637	"641"			"425464007"
levofloxacin	DB01137	Acute maxillary sinusitis	C0155804		Approved			CHEBI_63598	"1546009|82122"	MONDO_0002186		"68272006"
amikacin	DB00479	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_2637	"641"			"128945009"
levamisole	DB00848	Ancylostomiasis	C0002831		Approved			CHEBI_6432	"6371"	MONDO_0005645		"63479002"
levamisole	DB16561	Ancylostomiasis	C0002831		Approved			CHEBI_77278		MONDO_0005645		"63479002"
levofloxacin	DB01137	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_63598	"1546009|82122"			"425748003"
levofloxacin	DB01137	Acute bacterial sinusitis	C0275556		Approved			CHEBI_63598	"1546009|82122"			"75498004"
levodopa	DB01235	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_15765	"6375"	MONDO_0001945		"19972008"
levosalbutamol	DB13139	Asthma attack	C0347950		Approved			CHEBI_8746	"237159"			
amikacin	DB00479	Escherichia coli Infections	C0014836		Approved			CHEBI_2637	"641"	MONDO_0020920		"71057007"
amikacin	DB00479	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_2637	"641"			"301011002"
dobutamine	DB00841	Asthma	C0004096	NCT00763035	Terminated	Early Phase 1	Potential participants with COPD/asthma unwilling to participate.	CHEBI_4670	"3616"	MONDO_0004979	"10003553"	"195967001"
linezolid	DB00601	Group A Streptococcal Infections	C0554628		Approved			CHEBI_63607	"190376"			"302809008"
linezolid	DB00601	Staphylococcus aureus infection	C1318973		Approved			CHEBI_63607	"190376"			"406602003"
amikacin	DB00479	Meningitis caused by Klebsiella aerogenes	C1719906		Approved			CHEBI_2637	"641"			"420585007"
amikacin	DB00479	Proteus meningitis	C0338396		Approved			CHEBI_2637	"641"			"302877009"
amikacin	DB00479	Non-tuberculous mycobacterial pneumonia	C0349650		Approved			CHEBI_2637	"641"			"277869007"
lidocaine	DB00281	Scabies <infestation>	C0036262		Approved			CHEBI_6456	"6387"	MONDO_0004525		"128869009"
lindane	DB00431	Scabies <infestation>	C0036262		Approved			CHEBI_32888	"1388"	MONDO_0004525		"128869009"
amikacin	DB00479	Meningitis, Escherichia coli	C0338395		Approved			CHEBI_2637	"641"	MONDO_0006753		"192655005"
ascorbic acid	DB14483	Ascorbic Acid Deficiency	C0003969		Approved			CHEBI_29073	"1307765|142407"	HP:0100510	"10047623"	"76169001"
zinc gluconate	DB11248	Ascorbic Acid Deficiency	C0003969		Approved			CHEBI_29708	"58300"	HP:0100510	"10047623"	"76169001"
ascorbic acid	DB00126	Ascorbic Acid Deficiency	C0003969		Approved			CHEBI_29073	"1151|1370460"	HP:0100510	"10047623"	"76169001"
ascorbic acid	DB14482	Ascorbic Acid Deficiency	C0003969		Approved			CHEBI_29073	"267366"	HP:0100510	"10047623"	"76169001"
rutoside	DB01698	Ascorbic Acid Deficiency	C0003969		Approved			CHEBI_28527	"9500"	HP:0100510	"10047623"	"76169001"
calcium pantothenate	DB01783	Ascorbic Acid Deficiency	C0003969		Approved			CHEBI_46905	"7891|62400"	HP:0100510	"10047623"	"76169001"
amikacin	DB00479	Bacterial meningitis due to Gram-negative bacteria	C0854215		Approved			CHEBI_2637	"641"	MONDO_0041825		"425887005"
amphotericin B	DB00681	Aspergillosis	C0004030		Approved			CHEBI_2682	"236594|732"	MONDO_0005657	"10074171"	"65553006"
isavuconazonium	DB11633	Aspergillosis	C0004030		Approved			CHEBI_85979	"1720882"	MONDO_0005657	"10074171"	"65553006"
isavuconazonium	DB06636	Aspergillosis	C0004030		Approved			CHEBI_85978	"1608322"	MONDO_0005657	"10074171"	"65553006"
itraconazole	DB01167	Aspergillosis	C0004030		Approved			CHEBI_6076	"28031"	MONDO_0005657	"10074171"	"65553006"
lofepramine	DB13411	Depressive disorder	C0011581		Approved			CHEBI_47782		MONDO_0002050		"35489007"
lomefloxacin	DB00978	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_116278	"28872"			"301011002"
	DB11124	Asthma	C0004096	NCT01737892	Terminated	Phase 1/Phase 2	unable to validate analytical method		"66887"	MONDO_0004979	"10003553"	"195967001"
epinephrine	DB00668	Asthma	C0004096	NCT01737892	Terminated	Phase 1/Phase 2	unable to validate analytical method	CHEBI_28918	"3992"	MONDO_0004979	"10003553"	"195967001"
ibudilast	DB05266	Asthma	C0004096		Approved			CHEBI_31684		MONDO_0004979	"10003553"	"195967001"
lansoprazole	DB00448	Asthma	C0004096	NCT00361972	Terminated	Phase 2/Phase 3	limited recruitment	CHEBI_6375	"17128"	MONDO_0004979	"10003553"	"195967001"
mometasone furoate	DB14512	Asthma	C0004096	NCT04206761	Withdrawn	Phase 3	issues related to Covid-19 restrictions/shutdowns	CHEBI_47564	"30145"	MONDO_0004979	"10003553"	"195967001"
	DB00764	Asthma	C0004096	NCT04206761	Withdrawn	Phase 3	issues related to Covid-19 restrictions/shutdowns	CHEBI_6970		MONDO_0004979	"10003553"	"195967001"
loracarbef	DB00447	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_47544	"28981"			"70036007"
loracarbef	DB00447	Group A Streptococcal Infections	C0554628		Approved			CHEBI_47544	"28981"			"302809008"
loracarbef	DB00447	Infective otitis media	C0729586		Approved			CHEBI_47544	"28981"			"312218008"
	DB00986	Asthma	C0004096	NCT04206761	Withdrawn	Phase 3	issues related to Covid-19 restrictions/shutdowns	CHEBI_94449	"1546438|4955"	MONDO_0004979	"10003553"	"195967001"
	DB05351	Asthma	C0004096	NCT00361972	Terminated	Phase 2/Phase 3	limited recruitment	CHEBI_135931	"816346"	MONDO_0004979	"10003553"	"195967001"
loracarbef	DB00447	Bronchitis	C0006277		Approved			CHEBI_47544	"28981"	MONDO_0003781	"10006451"	"32398004"
loratadine	DB00455	Common Cold	C0009443		Approved			CHEBI_6538	"28889"	MONDO_0005709		"82272006"
amineptine	DB04836	Depressive disorder	C0011581		Approved			CHEBI_32499	"17698"	MONDO_0002050		"35489007"
loteprednol etabonate	DB14596	Herpes zoster keratoconjunctivitis	C0153027		Approved			CHEBI_31784	"52177"			"42448002"
loteprednol etabonate	DB14596	Anterior uveitis	C0042165		Approved			CHEBI_31784	"52177"	MONDO_0006651		"410692006"
lomefloxacin	DB00978	Acute bacterial bronchitis	C0339933		Approved			CHEBI_116278	"28872"			"233598009"
loracarbef	DB00447	Acute bacterial bronchitis	C0339933		Approved			CHEBI_47544	"28981"			"233598009"
lisuride	DB00589	Amenorrhea	C0002453		Approved			CHEBI_51164	"6446"	MONDO_0001836	"10001928"	"14302001"
lomefloxacin	DB00978	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_116278	"28872"			"369001000119100"
loracarbef	DB00447	Acute maxillary sinusitis	C0155804		Approved			CHEBI_47544	"28981"	MONDO_0002186		"68272006"
lisuride	DB00589	Acromegaly	C0001206		Approved			CHEBI_51164	"6446"	MONDO_0019933	"10000599"	"74107003"
lofexidine	DB04948	Opioid withdrawal	C0029104		Approved			CHEBI_51368	"28863"			"87132004"
lomefloxacin	DB00978	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_116278	"28872"			"425748003"
loperamide	DB00836	Traveler's diarrhea	C0277528		Approved			CHEBI_6532	"6468"			"11840006"
mechlorethamine	DB00888	Myeloid Leukemia, Chronic	C0023473		Approved			CHEBI_28925	"6674"	MONDO_0011996		
loxoprofen	DB09212	Rheumatoid Arthritis	C0003873		Approved			CHEBI_76172	"28908"	MONDO_0008383	"10039073"	"69896004"
meclofenamic acid	DB00939	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6710	"6678|588003"	MONDO_0008383	"10039073"	"69896004"
colecalciferol	DB00169	Asthma	C0004096	NCT02687815	Terminated	Phase 2	Futility of vitamin D supplementation based on protocol threshold: <30% conditional power to detect pre-specified effect- 16% reduction in severe exacerbations.	CHEBI_28940	"2418"	MONDO_0004979	"10003553"	"195967001"
maprotiline	DB00934	Depressive disorder	C0011581		Approved			CHEBI_6690	"6646"	MONDO_0002050		"35489007"
	DB00332	Asthma	C0004096	NCT02182700	Terminated	Phase 3		CHEBI_46659	"1546373|203212|7213"	MONDO_0004979	"10003553"	"195967001"
omalizumab	DB00043	Asthma	C0004096		Approved				"302379"	MONDO_0004979	"10003553"	"195967001"
flunisolide	DB00180	Asthma	C0004096		Approved			CHEBI_5106	"1546428|25120"	MONDO_0004979	"10003553"	"195967001"
	DB00986	Asthma	C0004096	NCT02127697	Withdrawn	Phase 3		CHEBI_94449	"1546438|4955"	MONDO_0004979	"10003553"	"195967001"
	DB00986	Asthma	C0004096	NCT03795350	Terminated	Phase 1	In light of the cessation of non-essential clinical activities at CPU due to the COVID-19 pandemic, the sponsor has determined to terminate the study early.	CHEBI_94449	"1546438|4955"	MONDO_0004979	"10003553"	"195967001"
epinephrine	DB00668	Asthma	C0004096	NCT01025648	Terminated	Phase 1/Phase 2	Optimization of protocol	CHEBI_28918	"3992"	MONDO_0004979	"10003553"	"195967001"
hydrocortisone	DB00741	Asthma	C0004096		Approved			CHEBI_17650	"5492"	MONDO_0004979	"10003553"	"195967001"
medroxyprogesterone	DB00603	Atrophic Vaginitis	C0221392		Approved			CHEBI_6716	"1000112"			"52441000"
loteprednol etabonate	DB00873	Herpes zoster keratoconjunctivitis	C0153027		Approved			CHEBI_50848	"237027"			"42448002"
loteprednol etabonate	DB00873	Anterior uveitis	C0042165		Approved			CHEBI_50848	"237027"	MONDO_0006651		"410692006"
malathion	DB00772	Pediculus capitis infestation	C0030757		Approved			CHEBI_141474	"6606"	MONDO_0003471		"81000006"
mechlorethamine	DB00888	Mycosis Fungoides	C0026948		Approved			CHEBI_28925	"6674"	MONDO_0009691		"118618005"
mebendazole	DB00643	Ascariasis	C0003950		Approved			CHEBI_6704	"6672"	MONDO_0005654	"10003442"	"2435008"
lovastatin	DB00227	Arteriosclerosis	C0003850		Approved			CHEBI_40303	"6472"	MONDO_0002277	"10003210"	"72092001"
mebendazole	DB00643	Infection by Trichuris trichiura	C0040954		Approved			CHEBI_6704	"6672"			"60570001"
lumefantrine	DB06708	Malaria, Falciparum	C0024535		Approved			CHEBI_156095	"847728"	MONDO_0005920		"248441000"
lovastatin	DB00227	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_40303	"6472"			"238079002"
aminoglutethimide	DB00357	Secondary malignant neoplasm of female breast	C0346993		Approved			CHEBI_2654	"677"			"94297009"
mephenytoin	DB00532	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_6757	"6757"			
methylphenobarbital	DB00849	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_6758	"6758"	MONDO_0005754		
meloxicam	DB00814	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6741	"41493"	MONDO_0008383	"10039073"	"69896004"
	DB11124	Asthma	C0004096	NCT01025648	Terminated	Phase 1/Phase 2	Optimization of protocol		"66887"	MONDO_0004979	"10003553"	"195967001"
formoterol	DB00983	Asthma	C0004096	NCT03795350	Terminated	Phase 1	In light of the cessation of non-essential clinical activities at CPU due to the COVID-19 pandemic, the sponsor has determined to terminate the study early.	CHEBI_63082	"25255"	MONDO_0004979	"10003553"	"195967001"
flecainide	DB01195	Atrial Fibrillation	C0004238		Approved			CHEBI_75984	"4441"	MONDO_0004981	"10003658"	"49436004"
	DB00661	Atrial Fibrillation	C0004238	NCT00589303	Terminated	Phase 3	Lack of funding	CHEBI_77733	"11170"	MONDO_0004981	"10003658"	"49436004"
	DB00264	Atrial Fibrillation	C0004238	NCT00589303	Terminated	Phase 3	Lack of funding	CHEBI_6904	"6918"	MONDO_0004981	"10003658"	"49436004"
amiodarone	DB01118	Atrial Fibrillation	C0004238	NCT00589303	Terminated	Phase 3	Lack of funding	CHEBI_2663	"703"	MONDO_0004981	"10003658"	"49436004"
esmolol	DB00187	Atrial Fibrillation	C0004238		Approved			CHEBI_88206	"49737"	MONDO_0004981	"10003658"	"49436004"
landiolol	DB12212	Atrial Fibrillation	C0004238		Approved			CHEBI_135809		MONDO_0004981	"10003658"	"49436004"
warfarin	DB00682	Atrial Fibrillation	C0004238	NCT02450682	Withdrawn	Phase 2		CHEBI_87732	"11289"	MONDO_0004981	"10003658"	"49436004"
mephenytoin	DB00532	Motor cortex epilepsy	C0234978		Approved			CHEBI_6757	"6757"	MONDO_0041284		"267592003"
melatonin	DB01065	Atrial Fibrillation	C0004238	NCT02099331	Withdrawn	Phase 2	Lack of faculty staffing	CHEBI_16796	"6711"	MONDO_0004981	"10003658"	"49436004"
	DB01118	Atrial Fibrillation	C0004238	NCT00392106	Suspended	Phase 3	voluntarily by Sponsor to investigate an anticipated SAE	CHEBI_2663	"703"	MONDO_0004981	"10003658"	"49436004"
	DB01182	Atrial Fibrillation	C0004238	NCT00392106	Suspended	Phase 3	voluntarily by Sponsor to investigate an anticipated SAE	CHEBI_63619	"8754"	MONDO_0004981	"10003658"	"49436004"
pethidine	DB00454	Severe pain	C0278140		Approved			CHEBI_6754	"6754"			"76948002"
meptazinol	DB13478	Moderate pain	C0278139		Approved			CHEBI_91484				"50415004"
medrysone	DB00253	Punctate keratopathy	C0423234		Approved			CHEBI_34829	"29439"			"246936005"
meropenem	DB00760	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_43968	"1546029|29561"	MONDO_0040732		"11218009"
mesalazine	DB00244	Ulcerative colitis in remission	C3697010		Approved			CHEBI_6775	"52582"			"697969008"
mesalazine	DB00244	Chronic ulcerative rectosigmoiditis	C0267390		Approved			CHEBI_6775	"52582"			"52506002"
megestrol acetate	DB00351	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_6723	"29451"			"417181009"
orciprenaline	DB00816	Asthma attack	C0347950		Approved			CHEBI_83329	"7688"			
metharbital	DB00463	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_31827	"6825"	MONDO_0005754		
methotrexate	DB00563	Rheumatoid Arthritis	C0003873		Approved			CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
orciprenaline	DB00816	Asthma	C0004096		Approved			CHEBI_83329	"7688"	MONDO_0004979	"10003553"	"195967001"
ascorbic acid	DB00126	Atrial Fibrillation	C0004238	NCT01580683	Withdrawn	Phase 3	No funding obtained to support patient recruitment	CHEBI_29073	"1151|1370460"	MONDO_0004981	"10003658"	"49436004"
metacycline	DB00931	Bacterial enteritis	C0152516		Approved			CHEBI_6805	"6812"			"75375008"
	DB14482	Atrial Fibrillation	C0004238	NCT01580683	Withdrawn	Phase 3	No funding obtained to support patient recruitment	CHEBI_113451	"267366"	MONDO_0004981	"10003658"	"49436004"
	DB14483	Atrial Fibrillation	C0004238	NCT01580683	Withdrawn	Phase 3	No funding obtained to support patient recruitment		"1307765|142407"	MONDO_0004981	"10003658"	"49436004"
methotrexate	DB00563	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_44185	"6851"			"200965009"
methscopolamine	DB11315	Common Cold	C0009443		Approved			CHEBI_135361	"89785"	MONDO_0005709		"82272006"
methadone	DB00333	Severe pain	C0278140		Approved			CHEBI_167309	"6813"			"76948002"
	DB14208	Atrial Flutter	C0004239	NCT00736294	Terminated	Phase 3	Difficulty to include patients	CHEBI_77363		HP:0004749	"10003662"	"5370000"
landiolol	DB12212	Atrial Flutter	C0004239		Approved			CHEBI_135809		HP:0004749	"10003662"	"5370000"
ramipril	DB00178	Atrial Flutter	C0004239	NCT00736294	Terminated	Phase 3	Difficulty to include patients	CHEBI_8774	"35296"	HP:0004749	"10003662"	"5370000"
isoprenaline	DB01064	Atrioventricular Block	C0004245		Approved			CHEBI_64317	"6054"	MONDO_0000465	"10003671"	"233917008"
methotrexate	DB00563	Malignant epithelial neoplasm of female breast	C3163805		Approved			CHEBI_44185	"6851"			"447782002"
methotrexate	DB00563	Mycosis Fungoides	C0026948		Approved			CHEBI_44185	"6851"	MONDO_0009691		"118618005"
methazolamide	DB00703	Secondary glaucoma	C0149893		Approved			CHEBI_6822	"6826"			"95717004"
methotrexate	DB00563	Osteosarcoma of bone	C0585442		Approved			CHEBI_44185	"6851"			"307576001"
methadone	DB00333	Opioid withdrawal	C0029104		Approved			CHEBI_167309	"6813"			"87132004"
hydrocortisone	DB00741	Autoimmune Diseases	C0004364		Approved			CHEBI_17650	"5492"	MONDO_0007179	"10061664"	"85828009"
acetylsalicylic acid	DB00945	Back Pain	C0004604		Approved			CHEBI_15365	"91101|1191"	HP:0003418	"10003988"	"161891005"
salicylamide	DB08797	Back Pain	C0004604		Approved			CHEBI_32114	"9518"	HP:0003418	"10003988"	"161891005"
camphor	DB14156	Back Pain	C0004604		Approved			CHEBI_36773	"1952|1371994"	HP:0003418	"10003988"	"161891005"
paracetamol	DB00316	Back Pain	C0004604		Approved			CHEBI_46195	"161"	HP:0003418	"10003988"	"161891005"
methscopolamine	DB00462	Common Cold	C0009443		Approved			CHEBI_61276	"56092"	MONDO_0005709		"82272006"
methylprednisolone	DB00959	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6888	"6902"	MONDO_0008383	"10039073"	"69896004"
methylprednisolone	DB00959	Asthma	C0004096		Approved			CHEBI_6888	"6902"	MONDO_0004979	"10003553"	"195967001"
gemifloxacin	DB01155	Pneumonia, Bacterial	C0004626		Approved			CHEBI_101853	"138099"	MONDO_0004652	"10060946"	"53084003"
gatifloxacin	DB01044	Pneumonia, Bacterial	C0004626		Approved			CHEBI_5280	"228476|1546025"	MONDO_0004652	"10060946"	"53084003"
cefditoren pivoxil	DB01066	Pneumonia, Bacterial	C0004626		Approved			CHEBI_59343	"83682"	MONDO_0004652	"10060946"	"53084003"
levofloxacin	DB01137	Pneumonia, Bacterial	C0004626		Approved			CHEBI_63598	"1546009|82122"	MONDO_0004652	"10060946"	"53084003"
fusidic acid	DB02703	Pneumonia, Bacterial	C0004626		Approved			CHEBI_29013	"4608|113608"	MONDO_0004652	"10060946"	"53084003"
amikacin	DB00479	Pneumonia, Bacterial	C0004626		Approved			CHEBI_2637	"641"	MONDO_0004652	"10060946"	"53084003"
methylprednisolone	DB00959	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_6888	"6902"			"53891004"
ampicillin	DB00415	Pneumonia, Bacterial	C0004626		Approved			CHEBI_28971	"733|221058"	MONDO_0004652	"10060946"	"53084003"
methylprednisolone	DB00959	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_6888	"6902"			"200965009"
ertapenem	DB00303	Pneumonia, Bacterial	C0004626		Approved			CHEBI_404903	"325642"	MONDO_0004652	"10060946"	"53084003"
cefepime	DB01413	Pneumonia, Bacterial	C0004626		Approved			CHEBI_478164	"20481"	MONDO_0004652	"10060946"	"53084003"
methylprednisolone	DB00959	Psoriasis of scalp	C0406326		Approved			CHEBI_6888	"6902"			"238608008"
naltrexone	DB00704	Severe pain	C0278140		Approved			CHEBI_7465	"7243"			"76948002"
methylprednisolone	DB00959	Addison Disease	C0001403		Approved			CHEBI_6888	"6902"	MONDO_0015129	"10001130"	"373662000"
methylprednisolone	DB00959	Arthritis, Psoriatic	C0003872		Approved			CHEBI_6888	"6902"	MONDO_0011849	"10037162"	"156370009"
naltrexone	DB00704	Therapeutic opioid induced constipation	C3874358		Approved			CHEBI_7465	"7243"			"136801000119102"
methylprednisolone	DB00959	Mycosis Fungoides	C0026948		Approved			CHEBI_6888	"6902"	MONDO_0009691		"118618005"
methylprednisolone	DB00959	Adrenogenital disorder	C0701163		Approved			CHEBI_6888	"6902"			"267395000"
methylprednisolone	DB00959	Berylliosis	C0005138		Approved			CHEBI_6888	"6902"		"10004485"	"8247009"
methylprednisolone	DB00959	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_6888	"6902"			"699262001"
methylprednisolone	DB00959	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_6888	"6902"	MONDO_0020108	"10073785"	"413603009"
methylprednisolone	DB00959	Exacerbation of asthma	C0349790		Approved			CHEBI_6888	"6902"			"281239006"
methylprednisolone	DB00959	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_6888	"6902"	MONDO_0018479		"237751000"
kanamycin	DB01172	Pneumonia, Bacterial	C0004626		Approved			CHEBI_17630	"6099|1727573"	MONDO_0004652	"10060946"	"53084003"
erythromycin ethyl succinate	DB00199	Pneumonia, Bacterial	C0004626		Approved			CHEBI_42355	"4053"	MONDO_0004652	"10060946"	"53084003"
erythromycin	DB00199	Pneumonia, Bacterial	C0004626		Approved			CHEBI_42355	"4053"	MONDO_0004652	"10060946"	"53084003"
metronidazole	DB00916	Infection due to anaerobic bacteria	C0854328		Approved			CHEBI_6909	"6922"	MONDO_0024389		"423451008"
amisulpride	DB06288	Postoperative Nausea and Vomiting	C0520909		Approved			CHEBI_64045	"46303"			"1488000"
methylprednisolone	DB00959	Transplanted organ rejection	C0345468		Approved			CHEBI_6888	"6902"			"213148006"
methylprednisolone	DB00959	Tuberculosis, Miliary	C0041321		Approved			CHEBI_6888	"6902"	MONDO_0005848		"47604008"
amisulpride	DB06288	Chronic schizophrenia	C0221765		Approved			CHEBI_64045	"46303"			"83746006"
methylprednisolone	DB00959	Acquired thrombocytopenia	C0154301		Approved			CHEBI_6888	"6902"	MONDO_0001198		"154826009"
methylprednisolone	DB00959	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_6888	"6902"	MONDO_0015253		"88854002"
fusidic acid	DB02703	Bartonella Infections	C0004771		Approved			CHEBI_29013	"4608|113608"	MONDO_0005664	"10004145"	"266123003"
methylprednisolone acetate	DB00959	Mycosis Fungoides	C0026948		Approved			CHEBI_6888	"6902"	MONDO_0009691		"118618005"
methylprednisolone	DB00959	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_6888	"6902"	MONDO_0000004		"386584007"
methylprednisolone acetate	DB00959	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_6888	"6902"	MONDO_0000004		"386584007"
infliximab	DB00065	Behcet Syndrome	C0004943		Approved				"1790539|1927283|191831|2266523|2103476"	MONDO_0007191	"10004213"	"310701003"
methylprednisolone acetate	DB00959	Rhinitis, Allergic, Perennial	C0035457		Approved			CHEBI_6888	"6902"	MONDO_0024332		"446096008"
hydrocortisone	DB00741	Berylliosis	C0005138		Approved			CHEBI_17650	"5492"		"10004485"	"8247009"
hydrocortisone succinate	DB14545	Berylliosis	C0005138		Approved			CHEBI_31677	"21651"		"10004485"	"8247009"
methylprednisolone	DB00959	Autoimmune Diseases	C0004364		Approved			CHEBI_6888	"6902"	MONDO_0007179	"10061664"	"85828009"
metronidazole	DB00916	Acute amebiasis	C0152499		Approved			CHEBI_6909	"6922"			"39224005"
methylprednisolone acetate	DB00959	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_6888	"6902"	MONDO_0018479		"237751000"
metoclopramide	DB01233	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_107736	"6915"			"18846006"
ketamine	DB01221	Bipolar Disorder	C0005586	NCT02882711	Terminated	Phase 2	Increasing off-label practice of IV ketamine administration for treatment-resistant depression.	CHEBI_6121	"6130"	MONDO_0004985	"10057667"	"13746004"
riluzole	DB00740	Bipolar Disorder	C0005586	NCT00054704	Terminated	Phase 2	Placebo was better than active drug.	CHEBI_8863	"35623"	MONDO_0004985	"10057667"	"13746004"
	DB06690	Bipolar Disorder	C0005586	NCT02351869	Terminated	Phase 2	This study was terminated due to COVID-19 pandemic-related halting of recruitment in the context of an upcoming replacement of the study MRI scanner.	CHEBI_17045	"7486"	MONDO_0004985	"10057667"	"13746004"
loxapine	DB00408	Bipolar Disorder	C0005586		Approved			CHEBI_50841	"6475"	MONDO_0004985	"10057667"	"13746004"
midazolam	DB00683	Bipolar Disorder	C0005586	NCT02351869	Terminated	Phase 2	This study was terminated due to COVID-19 pandemic-related halting of recruitment in the context of an upcoming replacement of the study MRI scanner.	CHEBI_6931	"6960"	MONDO_0004985	"10057667"	"13746004"
mezlocillin	DB00948	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_6919	"6927"			"70036007"
micafungin	DB01141	Septicemia candida	C0349009		Approved			CHEBI_600520	"325887"			
mezlocillin	DB00948	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_6919	"6927"	MONDO_0001080		"20943002"
mezlocillin	DB00948	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_6919	"6927"			"186435004"
amitriptyline	DB00321	Depressive disorder	C0011581		Approved			CHEBI_2666	"704"	MONDO_0002050		"35489007"
metronidazole	DB15759	Infection due to anaerobic bacteria	C0854328		Approved			CHEBI_50688		MONDO_0024389		"423451008"
micafungin	DB01141	Candidemia	C0877445		Approved			CHEBI_600520	"325887"	MONDO_0044070		"432261003"
metronidazole	DB00916	Sepsis caused by Bacteroides	C0276064		Approved			CHEBI_6909	"6922"			"1201760007"
metronidazole	DB15759	Sepsis caused by Bacteroides	C0276064		Approved			CHEBI_50688				"1201760007"
metronidazole	DB00916	Arthropathy associated with infection	C0157749		Approved			CHEBI_6909	"6922"			"363162000"
metronidazole	DB15759	Arthropathy associated with infection	C0157749		Approved			CHEBI_50688				"363162000"
imatinib	DB00619	Blast Phase	C0005699		Approved			CHEBI_45783	"282388"	MONDO_0006115	"10053747"	"413656006"
metronidazole	DB00916	Female genital tract infection	C1263758		Approved			CHEBI_6909	"6922"			"125585007"
metronidazole	DB15759	Female genital tract infection	C1263758		Approved			CHEBI_50688				"125585007"
dehydrocholic acid	DB11622	Biliary Tract Diseases	C0005424		Approved			CHEBI_31459	"42625|3141"	HP:0001080	"10061008"	"105997008"
cholic acid	DB02659	Biliary Tract Diseases	C0005424		Approved			CHEBI_16359	"1440856"	HP:0001080	"10061008"	"105997008"
homatropine	DB11181	Biliary Tract Diseases	C0005424		Approved			CHEBI_5747	"27084"	HP:0001080	"10061008"	"105997008"
mezlocillin	DB00948	Acute gonococcal endometritis	C0153196		Approved			CHEBI_6919	"6927"	MONDO_0004264		"65295003"
mezlocillin	DB00948	Acute gonococcal urethritis	C0275652		Approved			CHEBI_6919	"6927"			"29864006"
metronidazole	DB15759	Acute amebiasis	C0152499		Approved			CHEBI_50688				"39224005"
minocycline	DB01017	Fusospirochetal pharyngitis	C1318559		Approved			CHEBI_50694	"6980"			
minocycline	DB01017	Acne Vulgaris	C0001144		Approved			CHEBI_50694	"6980"			"88616000"
minocycline	DB01017	Infective otitis media	C0729586		Approved			CHEBI_50694	"6980"			"312218008"
minocycline	DB01017	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_50694	"6980"	MONDO_0001080		"20943002"
minocycline	DB01017	Bartonella Infections	C0004771		Approved			CHEBI_50694	"6980"	MONDO_0005664	"10004145"	"266123003"
minocycline	DB01017	Actinomycosis	C0001261		Approved			CHEBI_50694	"6980"	MONDO_0005631	"10000620"	"11817007"
minocycline	DB01017	Anthrax disease	C0003175		Approved			CHEBI_50694	"6980"	MONDO_0005119	"10002713"	"409498004"
minocycline	DB01017	Gonorrhea of pharynx	C0149966		Approved			CHEBI_50694	"6980"			"74372003"
minocycline	DB01017	Acute gonococcal endometritis	C0153196		Approved			CHEBI_50694	"6980"	MONDO_0004264		"65295003"
minocycline	DB01017	Acute gonococcal urethritis	C0275652		Approved			CHEBI_50694	"6980"			"29864006"
minocycline	DB01017	Infection by Campylobacter fetus	C0275979		Approved			CHEBI_50694	"6980"	MONDO_0040728		"111835002"
milrinone	DB00235	Decompensated cardiac failure	C0581377		Approved			CHEBI_50693	"52769"			"195111005"
miconazole	DB01110	Decompensated cirrhosis of liver	C1619727		Approved			CHEBI_82892	"6932"			"716203000"
minoxidil	DB00350	Alopecia	C0002170		Approved			CHEBI_6942	"6984"	MONDO_0004907	"10001760"	"278040002"
minocycline	DB01017	Meningococcus carrier	C0421162		Approved			CHEBI_50694	"6980"			"170486006"
miglustat	DB00419	Niemann-Pick Disease, Type C	C0220756		Approved			CHEBI_50381	"402316"			"66751000"
minocycline	DB01017	Chlamydia trachomatis infection of genital structure	C1997322		Approved			CHEBI_50694	"6980"			"428015005"
moclobemide	DB01171	Depressive disorder	C0011581		Approved			CHEBI_83531	"30121"	MONDO_0002050		"35489007"
mometasone furoate	DB00764	Asthma	C0004096		Approved			CHEBI_6970		MONDO_0004979	"10003553"	"195967001"
mometasone furoate	DB14512	Asthma	C0004096		Approved			CHEBI_47564	"30145"	MONDO_0004979	"10003553"	"195967001"
mometasone furoate	DB14512	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_47564	"30145"			"53891004"
mometasone furoate	DB14512	Psoriasis of scalp	C0406326		Approved			CHEBI_47564	"30145"			"238608008"
mometasone furoate	DB14512	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_47564	"30145"			"200965009"
mometasone furoate	DB00764	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_6970				"53891004"
mometasone furoate	DB00764	Psoriasis of scalp	C0406326		Approved			CHEBI_6970				"238608008"
mometasone furoate	DB00764	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_6970				"200965009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT02120417	Terminated	Phase 2	The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00356681	Terminated	Phase 2	Sponsor decision to close study		"253337|2046138"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00977379	Terminated	Phase 2	Due to an insufficient number of participants enrolled.	CHEBI_31348	"194000"		"10006187"	"254837009"
fusidic acid	DB02703	Boutonneuse Fever	C0006060		Approved			CHEBI_29013	"4608|113608"	MONDO_0024472	"10006045"	"186774005"
morphine	DB00295	Severe pain	C0278140		Approved			CHEBI_17303	"7052|32926"			"76948002"
amlodipine	DB00381	Angina Pectoris, Variant	C0002963		Approved			CHEBI_2668	"17767"	MONDO_0006021	"10036759"	"87343002"
mometasone furoate	DB14512	Intrinsic asthma	C0155880		Approved			CHEBI_47564	"30145"	MONDO_0004765		"266361008"
mometasone furoate	DB00764	Intrinsic asthma	C0155880		Approved			CHEBI_6970		MONDO_0004765		"266361008"
montelukast	DB00471	Intrinsic asthma	C0155880		Approved			CHEBI_50730	"88249"	MONDO_0004765		"266361008"
mitotane	DB00648	Carcinoma in situ of adrenal cortex	C0686510		Approved			CHEBI_6954	"7004"			"92526009"
morphine	DB00295	Postoperative Pain, Acute	C2215257		Approved			CHEBI_17303	"7052|32926"			"107401000119105"
mometasone furoate	DB14512	Allergic asthma	C0155877		Approved			CHEBI_47564	"30145"	MONDO_0004784		"389145006"
mometasone furoate	DB00764	Allergic asthma	C0155877		Approved			CHEBI_6970		MONDO_0004784		"389145006"
monoxerutin	DB13764	Venous Insufficiency	C0042485		Approved			CHEBI_134704		MONDO_0000945		"20696009"
montelukast	DB00471	Allergic asthma	C0155877		Approved			CHEBI_50730	"88249"	MONDO_0004784		"389145006"
amobarbital	DB01351	Severe anxiety (panic)	C0231403		Approved			CHEBI_2673	"719"			"80583007"
nalmefene	DB06230	Opioid toxicity	C0412850		Approved			CHEBI_7457	"31479"			
naloxone	DB01183	Opioid toxicity	C0412850		Approved			CHEBI_7459	"7242"			
motretinide	DB13368	Acne Vulgaris	C0001144		Approved			CHEBI_135490				"88616000"
moxifloxacin	DB00218	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_63611	"139462"			"186435004"
moxifloxacin	DB00218	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_63611	"139462"			"70036007"
moxifloxacin	DB00218	Staphylococcus aureus infection	C1318973		Approved			CHEBI_63611	"139462"			"406602003"
moxifloxacin	DB00218	Group A Streptococcal Infections	C0554628		Approved			CHEBI_63611	"139462"			"302809008"
nabumetone	DB00461	Rheumatoid Arthritis	C0003873		Approved			CHEBI_7443	"31448"	MONDO_0008383	"10039073"	"69896004"
naproxen	DB00788	Rheumatoid Arthritis	C0003873		Approved			CHEBI_7476	"7258"	MONDO_0008383	"10039073"	"69896004"
nadifloxacin	DB12447	Acne Vulgaris	C0001144		Approved			CHEBI_31889				"88616000"
moxifloxacin	DB00218	Pneumonia, Bacterial	C0004626		Approved			CHEBI_63611	"139462"	MONDO_0004652	"10060946"	"53084003"
colecalciferol	DB00169	Malignant neoplasm of breast	C0006142	NCT01472445	Terminated	Phase 2	Slow accrual	CHEBI_28940	"2418"		"10006187"	"254837009"
nafcillin	DB00607	Staphylococcus aureus infection	C1318973		Approved			CHEBI_7447	"7233"			"406602003"
hydroxychloroquine	DB01611	Malignant neoplasm of breast	C0006142	NCT00765765	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_5801	"5521"		"10006187"	"254837009"
gefitinib	DB00317	Malignant neoplasm of breast	C0006142	NCT00252811	Withdrawn	Phase 2		CHEBI_49668	"328134"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT00827567	Terminated	Phase 2	Slow accrual	CHEBI_68478	"141704"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00006126	Withdrawn	Phase 1	Unable to accrue subjects.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
naproxen	DB00788	Headache Disorders	C0393735		Approved			CHEBI_7476	"7258"			"230461009"
moxisylyte	DB09205	Raynaud Disease	C0034734		Approved			CHEBI_94754	"10561"	MONDO_0008364		"195295006"
nafcillin	DB00607	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_7447	"7233"			"448417001"
nandrolone decanoate	DB08804	Anemia in chronic kidney disease	C1561828		Approved			CHEBI_7467	"31494"			"707323002"
nandrolone decanoate	DB13169	Anemia in chronic kidney disease	C1561828		Approved			CHEBI_7466	"7244"			"707323002"
moxifloxacin	DB00218	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_63611	"139462"			"128945009"
nandrolone	DB13169	Anemia of chronic renal failure	C0271932		Approved			CHEBI_7466	"7244"			"49708008"
moxifloxacin	DB00218	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_63611	"139462"			"425748003"
nafcillin	DB00607	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_7447	"7233"			"428783003"
naftopidil	DB12092	Prostatic Hypertrophy	C1739363		Approved			CHEBI_31891				"266569009"
moxifloxacin	DB00218	Acute bacterial sinusitis	C0275556		Approved			CHEBI_63611	"139462"			"75498004"
nafcillin	DB00607	Acute bacterial sinusitis	C0275556		Approved			CHEBI_7447	"7233"			"75498004"
nedocromil	DB00716	Asthma	C0004096		Approved			CHEBI_7492	"31563"	MONDO_0004979	"10003553"	"195967001"
amoxicillin	DB01060	Pneumonia, Bacterial	C0004626		Approved			CHEBI_2676	"1297882|723"	MONDO_0004652	"10060946"	"53084003"
	DB01008	Malignant neoplasm of breast	C0006142	NCT00006126	Withdrawn	Phase 1	Unable to accrue subjects.	CHEBI_28901	"1828"		"10006187"	"254837009"
etoposide	DB00773	Malignant neoplasm of breast	C0006142	NCT00006126	Withdrawn	Phase 1	Unable to accrue subjects.	CHEBI_4911	"4179"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT02215876	Withdrawn	Phase 2	No patients recruited.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT05191004	Withdrawn	Phase 1/Phase 2	Sponsor decision	CHEBI_31638	"282357"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00524459	Terminated	Phase 2	Terminated by sponsor due to lack of funding	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
nicotinamide	DB02701	Acne Vulgaris	C0001144		Approved			CHEBI_17154	"7405"			"88616000"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00524459	Terminated	Phase 2	Terminated by sponsor due to lack of funding	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
amoxapine	DB00543	Depressive disorder	C0011581		Approved			CHEBI_2675	"722"	MONDO_0002050		"35489007"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00657137	Terminated	Phase 2	Slow accrual	CHEBI_31348	"194000"		"10006187"	"254837009"
amoxicillin	DB01060	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_2676	"1297882|723"			"70036007"
amoxicillin	DB01060	Group A Streptococcal Infections	C0554628		Approved			CHEBI_2676	"1297882|723"			"302809008"
amoxicillin	DB01060	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_2676	"1297882|723"			"301011002"
amoxicillin	DB01060	Staphylococcus aureus infection	C1318973		Approved			CHEBI_2676	"1297882|723"			"406602003"
amoxicillin	DB01060	Escherichia coli Infections	C0014836		Approved			CHEBI_2676	"1297882|723"	MONDO_0020920		"71057007"
amoxicillin	DB01060	Infective otitis media	C0729586		Approved			CHEBI_2676	"1297882|723"			"312218008"
nesiritide	DB04899	Decompensated chronic heart failure	C1827266		Approved			CHEBI_135919	"19666"			"424404003"
nelarabine	DB01280	Precursor T-cell lymphoblastic lymphoma	C1292758		Approved			CHEBI_63612	"274771"			"421246008"
nifedipine	DB01115	Angina Pectoris, Variant	C0002963		Approved			CHEBI_7565	"7417"	MONDO_0006021	"10036759"	"87343002"
amoxicillin	DB01060	Pneumonia due to Staphylococcus aureus	C2349530		Approved			CHEBI_2676	"1297882|723"			"441658007"
amoxicillin	DB01060	Staphylococcal tonsillitis	C0275793		Approved			CHEBI_2676	"1297882|723"			"11461005"
nicotinamide	DB02701	Pellagra	C0030783		Approved			CHEBI_17154	"7405"	MONDO_0019975		"418186002"
nicotine	DB00184	Pellagra	C0030783		Approved			CHEBI_17688	"7407|31765"	MONDO_0019975		"418186002"
nicotinyl alcohol	DB04145	Pellagra	C0030783		Approved			CHEBI_45213		MONDO_0019975		"418186002"
nesiritide	DB04899	Decompensated cardiac failure	C0581377		Approved			CHEBI_135919	"19666"			"195111005"
nizatidine	DB00585	Peptic Esophagitis	C0014869		Approved			CHEBI_7601	"42319"	MONDO_0006896		
norepinephrine	DB00368	Asthma attack	C0347950		Approved			CHEBI_18357	"7512"			
norepinephrine	DB00368	Asthma	C0004096		Approved			CHEBI_18357	"7512"	MONDO_0004979	"10003553"	"195967001"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT00657137	Terminated	Phase 2	Slow accrual	CHEBI_49603	"480167"		"10006187"	"254837009"
nitrofurantoin	DB00698	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_71415	"235559|7454"			"301011002"
	DB00361	Malignant neoplasm of breast	C0006142	NCT02730091	Terminated	Phase 3		CHEBI_480999	"39541"		"10006187"	"254837009"
nitrofurazone	DB00336	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_44368	"7455"			"301011002"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00473005	Terminated	Phase 1	Principal Investigator (Dr. Guardino) left Stanford	CHEBI_31348	"194000"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT00473005	Terminated	Phase 1	Principal Investigator (Dr. Guardino) left Stanford	CHEBI_68478	"141704"		"10006187"	"254837009"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT00429403	Terminated	Phase 3	Study stopped due to low accrual.	CHEBI_5523	"50610"		"10006187"	"254837009"
toremifene	DB00539	Malignant neoplasm of breast	C0006142	NCT00010322	Terminated	Phase 3	Withdrawn due to change in standard of care - new protocol required	CHEBI_9635	"38409"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00960544	Withdrawn	Phase 2	Principal Investigator departed from institution	CHEBI_31348	"194000"		"10006187"	"254837009"
panobinostat	DB06603	Malignant neoplasm of breast	C0006142	NCT00993642	Withdrawn	Early Phase 1	Lack of accrual	CHEBI_85990	"1603350"		"10006187"	"254837009"
erlotinib	DB00530	Malignant neoplasm of breast	C0006142	NCT00611715	Terminated	Phase 2	low accrual	CHEBI_114785	"337525"		"10006187"	"254837009"
	DB01006	Malignant neoplasm of breast	C0006142	NCT00611715	Terminated	Phase 2	low accrual	CHEBI_6413	"72965"		"10006187"	"254837009"
tamoxifen	DB00675	Malignant neoplasm of breast	C0006142	NCT04504331	Terminated	Phase 1	Drug manufacturer decision to terminate development.	CHEBI_41774	"10324"		"10006187"	"254837009"
melphalan	DB01042	Malignant neoplasm of breast	C0006142	NCT00523809	Terminated	Phase 2	Slow accrual.	CHEBI_28876	"6718"		"10006187"	"254837009"
norethisterone	DB00717	Acne Vulgaris	C0001144		Approved			CHEBI_7627	"7514"			"88616000"
norethindrone acetate	DB00717	Acne Vulgaris	C0001144		Approved			CHEBI_7627	"7514"			"88616000"
norfloxacin	DB01059	Group A Streptococcal Infections	C0554628		Approved			CHEBI_100246	"7517"			"302809008"
norfloxacin	DB01059	Escherichia coli septicemia	C0276088		Approved			CHEBI_100246	"7517"			
norfloxacin	DB01059	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_100246	"7517"			"301011002"
norfloxacin	DB01059	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_100246	"7517"			"70036007"
norfloxacin	DB01059	Infective otitis media	C0729586		Approved			CHEBI_100246	"7517"			"312218008"
norfloxacin	DB01059	Pneumonia, Bacterial	C0004626		Approved			CHEBI_100246	"7517"	MONDO_0004652	"10060946"	"53084003"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00523809	Terminated	Phase 2	Slow accrual.		"253337|2046138"		"10006187"	"254837009"
norfloxacin	DB01059	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_100246	"7517"	MONDO_0001080		"20943002"
norfloxacin	DB01059	Bronchitis	C0006277		Approved			CHEBI_100246	"7517"	MONDO_0003781	"10006451"	"32398004"
norfloxacin	DB01059	Staphylococcus aureus infection	C1318973		Approved			CHEBI_100246	"7517"			"406602003"
norfloxacin	DB01059	Escherichia coli Infections	C0014836		Approved			CHEBI_100246	"7517"	MONDO_0020920		"71057007"
norfloxacin	DB01059	Infective cystitis	C0600041		Approved			CHEBI_100246	"7517"			"236620008"
norgestimate	DB00957	Acne Vulgaris	C0001144		Approved			CHEBI_50815	"31994"			"88616000"
norgestimate	DB00957	Atrophic Vaginitis	C0221392		Approved			CHEBI_50815	"31994"			"52441000"
norfloxacin	DB01059	Arthropathy associated with infection	C0157749		Approved			CHEBI_100246	"7517"			"363162000"
norfloxacin	DB01059	non-gonococcal urethritis (NGU)	C1112709		Approved			CHEBI_100246	"7517"			"84619001"
norfloxacin	DB01059	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_100246	"7517"	MONDO_0040732		"11218009"
norfloxacin	DB01059	Chronic tubotympanic suppurative otitis media	C0155440		Approved			CHEBI_100246	"7517"	MONDO_0001964		"87665008"
norfloxacin	DB01059	Anthrax disease	C0003175		Approved			CHEBI_100246	"7517"	MONDO_0005119	"10002713"	"409498004"
norfloxacin	DB01059	Female genital tract infection	C1263758		Approved			CHEBI_100246	"7517"			"125585007"
norfloxacin	DB01059	Endomyometritis	C0269050		Approved			CHEBI_100246	"7517"			"88027004"
norfloxacin	DB01059	Postnatal infection	C1278797		Approved			CHEBI_100246	"7517"			"178280004"
norfloxacin	DB01059	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			CHEBI_100246	"7517"	MONDO_0041095		"232230009"
norfloxacin	DB01059	Proteus urinary tract infection	C0577709		Approved			CHEBI_100246	"7517"			"301012009"
norfloxacin	DB01059	Postoperative infection	C0392618		Approved			CHEBI_100246	"7517"			"33910007"
norgestimate	DB00957	Atrophy of vulva	C0156393		Approved			CHEBI_50815	"31994"	MONDO_0001932		"248861000"
norfloxacin	DB01059	Acute gonococcal endometritis	C0153196		Approved			CHEBI_100246	"7517"	MONDO_0004264		"65295003"
norfloxacin	DB01059	Infective otitis externa	C0021355		Approved			CHEBI_100246	"7517"			"86981007"
amphotericin B	DB00681	Septicemia candida	C0349009		Approved			CHEBI_2682	"236594|732"			
amphotericin B	DB00681	Fungal septicemia	C2960008		Approved			CHEBI_2682	"236594|732"			
amphotericin B	DB00681	Infective otitis media	C0729586		Approved			CHEBI_2682	"236594|732"			"312218008"
ampicillin	DB00415	Escherichia coli septicemia	C0276088		Approved			CHEBI_28971	"733|221058"			
amphotericin B	DB00681	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_2682	"236594|732"	MONDO_0001080		"20943002"
amphotericin B	DB00681	Acne Vulgaris	C0001144		Approved			CHEBI_2682	"236594|732"			"88616000"
nortriptyline	DB00540	Depressive disorder	C0011581		Approved			CHEBI_7640	"7531"	MONDO_0002050		"35489007"
amphotericin B	DB00681	Candidemia	C0877445		Approved			CHEBI_2682	"236594|732"	MONDO_0044070		"432261003"
amphotericin B	DB00681	Actinomycosis	C0001261		Approved			CHEBI_2682	"236594|732"	MONDO_0005631	"10000620"	"11817007"
amphotericin B	DB00681	Anthrax disease	C0003175		Approved			CHEBI_2682	"236594|732"	MONDO_0005119	"10002713"	"409498004"
ampicillin	DB00415	Acute bacterial epiglottitis	C0275555		Approved			CHEBI_28971	"733|221058"			"21060003"
amphotericin B	DB00681	Gonorrhea of pharynx	C0149966		Approved			CHEBI_2682	"236594|732"			"74372003"
amphotericin B	DB00681	Fungal infection of lung	C0151874		Approved			CHEBI_2682	"236594|732"			"63741006"
amphotericin B	DB00681	Acute gonococcal urethritis	C0275652		Approved			CHEBI_2682	"236594|732"			"29864006"
amphotericin B	DB00681	Chlamydia trachomatis infection of genital structure	C1997322		Approved			CHEBI_2682	"236594|732"			"428015005"
ampicillin	DB00415	Septicemia due to enterococcus	C0588233		Approved			CHEBI_28971	"733|221058"			
ampicillin	DB00415	Proteus septicemia	C0577690		Approved			CHEBI_28971	"733|221058"			
ofloxacin	DB01165	Escherichia coli septicemia	C0276088		Approved			CHEBI_7731	"7623"			
ampicillin	DB00415	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_28971	"733|221058"	MONDO_0001080		"20943002"
ampicillin	DB00415	Staphylococcus aureus infection	C1318973		Approved			CHEBI_28971	"733|221058"			"406602003"
ampicillin	DB00415	Infective otitis media	C0729586		Approved			CHEBI_28971	"733|221058"			"312218008"
ampicillin	DB00415	Escherichia coli Infections	C0014836		Approved			CHEBI_28971	"733|221058"	MONDO_0020920		"71057007"
ampicillin	DB00415	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_28971	"733|221058"			"70036007"
ofloxacin	DB01165	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_7731	"7623"			"301011002"
ofloxacin	DB01165	Infective cystitis	C0600041		Approved			CHEBI_7731	"7623"			"236620008"
ofloxacin	DB01165	Group A Streptococcal Infections	C0554628		Approved			CHEBI_7731	"7623"			"302809008"
ofloxacin	DB01165	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_7731	"7623"			"70036007"
ampicillin	DB00415	Meningitis, Escherichia coli	C0338395		Approved			CHEBI_28971	"733|221058"	MONDO_0006753		"192655005"
ofloxacin	DB01165	Chronic tubotympanic suppurative otitis media	C0155440		Approved			CHEBI_7731	"7623"	MONDO_0001964		"87665008"
ampicillin	DB00415	Female genital tract infection	C1263758		Approved			CHEBI_28971	"733|221058"			"125585007"
ampicillin	DB00415	Pneumococcal pharyngitis	C0275761		Approved			CHEBI_28971	"733|221058"			"76651006"
ampicillin	DB00415	Proteus urinary tract infection	C0577709		Approved			CHEBI_28971	"733|221058"			"301012009"
octreotide	DB00104	Congenital Hyperinsulinism	C3888018		Approved			CHEBI_7726	"7617"			"360339005"
ofloxacin	DB01165	Proteus urinary tract infection	C0577709		Approved			CHEBI_7731	"7623"			"301012009"
ampicillin	DB00415	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_28971	"733|221058"			"448417001"
ampicillin	DB00415	Acute gonococcal endometritis	C0153196		Approved			CHEBI_28971	"733|221058"	MONDO_0004264		"65295003"
ofloxacin	DB01165	Infective otitis externa	C0021355		Approved			CHEBI_7731	"7623"			"86981007"
ampicillin	DB00415	Acute epiglottitis	C0155814		Approved			CHEBI_28971	"733|221058"			"29608009"
ampicillin	DB00415	Acute gonococcal urethritis	C0275652		Approved			CHEBI_28971	"733|221058"			"29864006"
ampicillin	DB00415	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_28971	"733|221058"			"128945009"
ofloxacin	DB01165	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_7731	"7623"			"369001000119100"
ofloxacin	DB01165	Proteus pneumonia	C1260917		Approved			CHEBI_7731	"7623"		"10079867"	"195888009"
ampicillin	DB00415	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_28971	"733|221058"			"425748003"
ampicillin	DB00415	Acute bacterial sinusitis	C0275556		Approved			CHEBI_28971	"733|221058"			"75498004"
ofloxacin	DB01165	Acute bacterial sinusitis	C0275556		Approved			CHEBI_7731	"7623"			"75498004"
ofloxacin	DB01165	Acute bacterial peritonitis	C0275550		Approved			CHEBI_7731	"7623"			"31860008"
ofloxacin	DB01165	Escherichia coli Infections	C0014836		Approved			CHEBI_7731	"7623"	MONDO_0020920		"71057007"
omeprazole	DB00338	Peptic Esophagitis	C0014869		Approved			CHEBI_77260	"7646"	MONDO_0006896		
ofloxacin	DB01165	Pneumonia, Bacterial	C0004626		Approved			CHEBI_7731	"7623"	MONDO_0004652	"10060946"	"53084003"
ofloxacin	DB01165	Staphylococcus aureus infection	C1318973		Approved			CHEBI_7731	"7623"			"406602003"
ofloxacin	DB01165	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_7731	"7623"	MONDO_0001080		"20943002"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT01613482	Terminated	Phase 3	Lack of enrollment		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
ofloxacin	DB01165	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_7731	"7623"			"186435004"
triptorelin	DB06825	Malignant neoplasm of breast	C0006142	NCT02113553	Terminated	Phase 2	target population not reached	CHEBI_63633	"38782"		"10006187"	"254837009"
ofloxacin	DB01165	Infective otitis media	C0729586		Approved			CHEBI_7731	"7623"			"312218008"
ofloxacin	DB01165	Bronchitis	C0006277		Approved			CHEBI_7731	"7623"	MONDO_0003781	"10006451"	"32398004"
ofloxacin	DB01165	non-gonococcal urethritis (NGU)	C1112709		Approved			CHEBI_7731	"7623"			"84619001"
ofloxacin	DB01165	Arthropathy associated with infection	C0157749		Approved			CHEBI_7731	"7623"			"363162000"
ofloxacin	DB01165	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_7731	"7623"	MONDO_0040732		"11218009"
olsalazine	DB01250	Ulcerative colitis in remission	C3697010		Approved			CHEBI_7770	"32385"			"697969008"
olsalazine	DB00244	Ulcerative colitis in remission	C3697010		Approved			CHEBI_7770	"52582"			"697969008"
ofloxacin	DB01165	Female genital tract infection	C1263758		Approved			CHEBI_7731	"7623"			"125585007"
ofloxacin	DB01165	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_7731	"7623"			"195722003"
olanzapine	DB00334	Bipolar disorder in remission	C0270425		Approved			CHEBI_7735	"61381"			"85248005"
olanzapine	DB00334	Mixed bipolar I disorder	C0236780		Approved			CHEBI_7735	"61381"			"16506000"
ofloxacin	DB01165	Acute bacterial bronchitis	C0339933		Approved			CHEBI_7731	"7623"			"233598009"
ofloxacin	DB01165	Postoperative infection	C0392618		Approved			CHEBI_7731	"7623"			"33910007"
ofloxacin	DB01165	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			CHEBI_7731	"7623"	MONDO_0041095		"232230009"
ofloxacin	DB01165	Acute gonococcal endometritis	C0153196		Approved			CHEBI_7731	"7623"	MONDO_0004264		"65295003"
ofloxacin	DB01165	Hospital acquired pneumonia	C0949083		Approved			CHEBI_7731	"7623"			"425464007"
olanzapine	DB00334	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_7735	"61381"			"191618007"
ofloxacin	DB01165	Acute maxillary sinusitis	C0155804		Approved			CHEBI_7731	"7623"	MONDO_0002186		"68272006"
ofloxacin	DB01165	Acute gonococcal urethritis	C0275652		Approved			CHEBI_7731	"7623"			"29864006"
ofloxacin	DB01165	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_7731	"7623"			"128945009"
oxcarbazepine	DB00776	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_7824	"32624"			
opipramol	DB12930	Depressive disorder	C0011581		Approved			CHEBI_94614	"7674"	MONDO_0002050		"35489007"
oxaprozin	DB00991	Rheumatoid Arthritis	C0003873		Approved			CHEBI_7822	"32613"	MONDO_0008383	"10039073"	"69896004"
oxybutynin	DB01062	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_7856	"32675"			
	DB01006	Malignant neoplasm of breast	C0006142	NCT04478266	Terminated	Phase 3	The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed.	CHEBI_6413	"72965"		"10006187"	"254837009"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT04478266	Terminated	Phase 3	The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed.	CHEBI_5523	"50610"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00722072	Terminated	Phase 2	Sponsor pulled funding and low accrual	CHEBI_31638	"282357"		"10006187"	"254837009"
oxacillin	DB00713	Staphylococcus aureus infection	C1318973		Approved			CHEBI_7809	"7773"			"406602003"
	DB00398	Malignant neoplasm of breast	C0006142	NCT00722072	Terminated	Phase 2	Sponsor pulled funding and low accrual	CHEBI_50924	"495881"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00305643	Terminated	Phase 3	Terminated due to low accrual. No data analyzed.	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB00482	Malignant neoplasm of breast	C0006142	NCT00305643	Terminated	Phase 3	Terminated due to low accrual. No data analyzed.	CHEBI_41423	"140587"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00288444	Terminated	Phase 1		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT01185509	Terminated	Phase 2	Not enough confirmed responses to continue treatment.	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT01185509	Terminated	Phase 2	Not enough confirmed responses to continue treatment.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00434941	Terminated	Phase 2	Due to the slow rate of recruitment the study was stopped.	CHEBI_31348	"194000"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT04220476	Withdrawn	Phase 2	Initiating a new study with revised Statistics.	CHEBI_6413	"72965"		"10006187"	"254837009"
oxycodone	DB00497	Severe pain	C0278140		Approved			CHEBI_7852	"7804"			"76948002"
oxytetracycline	DB00595	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_133011	"7821|1545999"	MONDO_0001080		"20943002"
oxytetracycline	DB00595	Infective otitis media	C0729586		Approved			CHEBI_133011	"7821|1545999"			"312218008"
oxytocin	DB00107	Incomplete spontaneous abortion	C0000810		Approved			CHEBI_7872	"7824"		"10061617"	"156072005"
ozagrel	DB12017	Asthma	C0004096		Approved			CHEBI_134938		MONDO_0004979	"10003553"	"195967001"
	DB00072	Malignant neoplasm of breast	C0006142	NCT01702558	Terminated	Phase 2	The sponsor decided to terminate study after 70% of participants had experienced a progression-free survival event.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
oxytetracycline	DB00595	Acute gonococcal epididymo-orchitis	C0153193		Approved			CHEBI_133011	"7821|1545999"	MONDO_0001125		"30168008"
paclitaxel	DB01229	Breast Carcinoma	C0678222		Approved			CHEBI_45863	"56946"	MONDO_0004989|MONDO_0015870		"254838004"
oxytetracycline	DB00595	Actinomycosis	C0001261		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005631	"10000620"	"11817007"
oxytetracycline	DB00595	Anthrax disease	C0003175		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005119	"10002713"	"409498004"
aminosalicylic acid	DB00233	Acute tuberculosis	C0275959		Approved			CHEBI_27565	"7833"			"25629007"
oxytetracycline	DB00595	Gonorrhea of pharynx	C0149966		Approved			CHEBI_133011	"7821|1545999"			"74372003"
amyl nitrite	DB01612	Toxic effect of cyanide	C0238080		Approved			CHEBI_55344	"742"			"66207005"
oxytetracycline	DB00595	Acute gonococcal endometritis	C0153196		Approved			CHEBI_133011	"7821|1545999"	MONDO_0004264		"65295003"
oxytetracycline	DB00595	Acute gonococcal urethritis	C0275652		Approved			CHEBI_133011	"7821|1545999"			"29864006"
pantoprazole	DB00213	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_7915	"40790"	MONDO_0019610		"53132006"
ozagrel	DB12017	Cerebral Vasospasm	C0265110		Approved			CHEBI_134938				"73173006"
oxytetracycline	DB00595	Chlamydia trachomatis infection of genital structure	C1997322		Approved			CHEBI_133011	"7821|1545999"			"428015005"
palonosetron	DB00377	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_85161	"70561"			"18846006"
benzylpenicillin	DB01053	Septicemia due to enterococcus	C0588233		Approved			CHEBI_18208	"7980"			
paroxetine	DB00715	Depressive disorder	C0011581		Approved			CHEBI_7936	"32937"	MONDO_0002050		"35489007"
penicillamine	DB00859	Rheumatoid Arthritis	C0003873		Approved			CHEBI_7959	"7975"	MONDO_0008383	"10039073"	"69896004"
pemirolast	DB00885	Asthma	C0004096		Approved			CHEBI_134936	"19551"	MONDO_0004979	"10003553"	"195967001"
benzylpenicillin	DB01053	Listerial endocarditis	C0348868		Approved			CHEBI_18208	"7980"			"186318004"
benzylpenicillin	DB01053	Cutaneous anthrax	C0003177		Approved			CHEBI_18208	"7980"	MONDO_0004215	"10011660"	"84980006"
benzylpenicillin	DB01053	Infection by Pasteurella multocida	C1260911		Approved			CHEBI_18208	"7980"	MONDO_0040998		"197718007"
benzylpenicillin	DB01053	Late latent syphilis	C1260915		Approved			CHEBI_18208	"7980"	MONDO_0040923		"186903006"
benzylpenicillin	DB01053	Anthrax disease	C0003175		Approved			CHEBI_18208	"7980"	MONDO_0005119	"10002713"	"409498004"
pazufloxacin	DB11774	Sepsis caused by Streptococcus pneumoniae	C2887084		Approved			CHEBI_94700				"448421008"
benzylpenicillin	DB01053	Abdominal actinomycosis	C0001263		Approved			CHEBI_18208	"7980"		"10000621"	"43894001"
parecoxib	DB08439	Postoperative Pain, Acute	C2215257		Approved			CHEBI_73038	"279950"			"107401000119105"
benzylpenicillin	DB01053	Botulism	C0006057		Approved			CHEBI_18208	"7980"	MONDO_0005498	"10006041"	"398565003"
benzylpenicillin	DB01053	Rat-Bite Fever	C0034686		Approved			CHEBI_18208	"7980"	MONDO_0006941		"1685005"
penciclovir	DB00299	Herpes Labialis	C0019345		Approved			CHEBI_7956	"59839"	MONDO_0043653		"1475003"
paromomycin	DB01421	Acute amebiasis	C0152499		Approved			CHEBI_7934	"7934"			"39224005"
benzylpenicillin	DB01053	Latent yaws	C0153240		Approved			CHEBI_18208	"7980"	MONDO_0040925		"186973005"
benzylpenicillin	DB01053	Fusospirochetal pharyngitis	C1318559		Approved			CHEBI_18208	"7980"			
phenoxymethylpenicillin	DB00417	Fusospirochetal pharyngitis	C1318559		Approved			CHEBI_27446	"7984"			
benzylpenicillin	DB01053	Infective otitis media	C0729586		Approved			CHEBI_18208	"7980"			"312218008"
benzylpenicillin	DB01053	Group A Streptococcal Infections	C0554628		Approved			CHEBI_18208	"7980"			"302809008"
benzylpenicillin	DB01053	Staphylococcus aureus infection	C1318973		Approved			CHEBI_18208	"7980"			"406602003"
phenoxymethylpenicillin	DB00417	Staphylococcus aureus infection	C1318973		Approved			CHEBI_27446	"7984"			"406602003"
phenoxymethylpenicillin	DB00417	Group A Streptococcal Infections	C0554628		Approved			CHEBI_27446	"7984"			"302809008"
phenoxymethylpenicillin	DB00417	Infective otitis media	C0729586		Approved			CHEBI_27446	"7984"			"312218008"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT01702558	Terminated	Phase 2	The sponsor decided to terminate study after 70% of participants had experienced a progression-free survival event.	CHEBI_31348	"194000"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00010153	Terminated	Phase 3	low accrual	CHEBI_31638	"282357"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00206414	Terminated	Phase 2	Difficulty accruing subjects the study accrual was closed	CHEBI_31638	"282357"		"10006187"	"254837009"
	DB00317	Malignant neoplasm of breast	C0006142	NCT00206414	Terminated	Phase 2	Difficulty accruing subjects the study accrual was closed	CHEBI_49668	"328134"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00206414	Terminated	Phase 2	Difficulty accruing subjects the study accrual was closed	CHEBI_2704	"84857"		"10006187"	"254837009"
	DB00331	Malignant neoplasm of breast	C0006142	NCT01627067	Terminated	Phase 2	Komen Foundation Funding Terminated	CHEBI_6801	"6809"		"10006187"	"254837009"
benzylpenicillin	DB01053	Actinomycosis	C0001261		Approved			CHEBI_18208	"7980"	MONDO_0005631	"10000620"	"11817007"
benzylpenicillin	DB01053	Tertiary lesion of yaws	C0343833		Approved			CHEBI_18208	"7980"	MONDO_0042452		"88037009"
benzylpenicillin	DB01053	Early latent syphilis, positive serology, negative cerebrospinal fluid, less than 2 years after infection	C0275842		Approved			CHEBI_18208	"7980"	MONDO_0040922		"31137003"
perazine	DB12710	Ascariasis	C0003950		Approved			CHEBI_59118	"8042"	MONDO_0005654	"10003442"	"2435008"
anastrozole	DB01217	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_2704	"84857"			"417181009"
penthienate	DB13695	Gastric spasm (disorder)	C0581358		Approved			CHEBI_135447				"196754001"
pentobarbital	DB00312	Severe anxiety (panic)	C0231403		Approved			CHEBI_7983	"8004"			"80583007"
benzylpenicillin	DB01053	Bejel	C0004945		Approved			CHEBI_18208	"7980"	MONDO_0001714		"240686008"
benzylpenicillin	DB01053	Cervicofacial actinomycosis	C0001264		Approved			CHEBI_18208	"7980"	MONDO_0005699		"23014006"
benzylpenicillin	DB01053	Gas gangrene caused by clostridium perfringens	C0343500		Approved			CHEBI_18208	"7980"			"266093005"
perazine	DB12710	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_59118	"8042"			"18846006"
phenacemide	DB01121	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_8049	"33253"			
pheniramine	DB01620	Influenza-like symptoms	C0392171		Approved			CHEBI_91591	"8132"			
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT01627067	Terminated	Phase 2	Komen Foundation Funding Terminated	CHEBI_68478	"141704"		"10006187"	"254837009"
methotrexate	DB00563	Malignant neoplasm of breast	C0006142	NCT00616122	Terminated	Phase 1/Phase 2	Risk to benefit ratio not acceptable	CHEBI_44185	"6851"		"10006187"	"254837009"
	DB01268	Malignant neoplasm of breast	C0006142	NCT00616122	Terminated	Phase 1/Phase 2	Risk to benefit ratio not acceptable	CHEBI_38940	"357977"		"10006187"	"254837009"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00570908	Terminated	Phase 2	Due to poor accrual this study is being closed to accrual	CHEBI_31348	"194000"		"10006187"	"254837009"
phenelzine	DB00780	Depressive disorder	C0011581		Approved			CHEBI_8060	"8123"	MONDO_0002050		"35489007"
phenobarbital	DB01174	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_8069	"8134"	MONDO_0005754		
phenobarbital	DB01174	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_8069	"8134"			
zoledronic acid	DB00399	Malignant neoplasm of breast	C0006142	NCT02347163	Terminated	Phase 2	The study stopped prematurely due to the low accrual rate	CHEBI_46557	"1546014|77655"		"10006187"	"254837009"
carboplatin	DB00958	Malignant neoplasm of breast	C0006142	NCT00118053	Terminated	Phase 2	slow accrual	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00118053	Terminated	Phase 2	slow accrual		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00118053	Terminated	Phase 2	slow accrual	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT00925548	Terminated	Phase 3	See termination reason in the below Purpose statement	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT02936206	Terminated	Phase 1	low accrual rate	CHEBI_31638	"282357"		"10006187"	"254837009"
	DB00675	Malignant neoplasm of breast	C0006142	NCT02936206	Terminated	Phase 1	low accrual rate	CHEBI_41774	"10324"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00543127	Terminated	Phase 3	Unjustified decision of company that funded the trial.	CHEBI_31638	"282357"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00511576	Terminated	Phase 1	Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00028483	Terminated	Phase 2		CHEBI_28748	"142433|3639"		"10006187"	"254837009"
phenylephrine	DB00388	Influenza-like symptoms	C0392171		Approved			CHEBI_8093	"8163"			
phenylpropanolamine	DB00397	Influenza-like symptoms	C0392171		Approved			CHEBI_80680	"8175"			
phenyltoloxamine	DB11160	Influenza-like symptoms	C0392171		Approved			CHEBI_135047	"33408"			
	DB01248	Malignant neoplasm of breast	C0006142	NCT01301040	Terminated	Phase 2	Slow recruitment	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT01301040	Terminated	Phase 2	Slow recruitment	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
phenytoin	DB00252	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_8107	"8183"	MONDO_0005754		
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT01301040	Terminated	Phase 2	Slow recruitment	CHEBI_47898	"3995"		"10006187"	"254837009"
phenylephrine	DB00388	Common Cold	C0009443		Approved			CHEBI_8093	"8163"	MONDO_0005709		"82272006"
phenytoin	DB00252	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_8107	"8183"			
	DB00997	Malignant neoplasm of breast	C0006142	NCT02472353	Terminated	Phase 2	did not meet target accrual	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
metformin	DB00331	Malignant neoplasm of breast	C0006142	NCT02472353	Terminated	Phase 2	did not meet target accrual	CHEBI_6801	"6809"		"10006187"	"254837009"
piperacillin	DB00319	Proteus septicemia	C0577690		Approved			CHEBI_8232	"1546000|8339"			
piperacillin	DB00319	Escherichia coli septicemia	C0276088		Approved			CHEBI_8232	"1546000|8339"			
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00193024	Terminated	Phase 2		CHEBI_47898	"3995"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00193024	Terminated	Phase 2		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
phenylpropanolamine	DB00397	Common Cold	C0009443		Approved			CHEBI_80680	"8175"	MONDO_0005709		"82272006"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT04191382	Terminated	Phase 2	early discontinuation based on strategic sponsor decision not driven by any safety concerns	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT02658084	Terminated	Phase 1/Phase 2	Terminated due to low accrual and toxicity concerns.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT02658084	Terminated	Phase 1/Phase 2	Terminated due to low accrual and toxicity concerns.	CHEBI_480999	"39541"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT00376805	Terminated	Phase 2	Withdrawn due to toxicity	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
phenytoin	DB00252	Motor cortex epilepsy	C0234978		Approved			CHEBI_8107	"8183"	MONDO_0041284		"267592003"
piperacillin	DB00319	Staphylococcus aureus infection	C1318973		Approved			CHEBI_8232	"1546000|8339"			"406602003"
piperacillin	DB00319	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_8232	"1546000|8339"	MONDO_0001080		"20943002"
piperacillin	DB00319	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_8232	"1546000|8339"			"186435004"
piperacillin	DB00319	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_8232	"1546000|8339"	MONDO_0040732		"11218009"
phenytoin	DB00252	Bipolar disorder in remission	C0270425		Approved			CHEBI_8107	"8183"			"85248005"
piperacillin	DB00319	Septicemia due to enterococcus	C0588233		Approved			CHEBI_8232	"1546000|8339"			
pirbuterol	DB01291	Asthma attack	C0347950		Approved			CHEBI_8245	"33767"			
piperacillin	DB00319	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_8232	"1546000|8339"			"301011002"
piperacillin	DB00319	Escherichia coli Infections	C0014836		Approved			CHEBI_8232	"1546000|8339"	MONDO_0020920		"71057007"
piroxicam	DB00554	Rheumatoid Arthritis	C0003873		Approved			CHEBI_8249	"8356|68115"	MONDO_0008383	"10039073"	"69896004"
piperacillin	DB00319	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_8232	"1546000|8339"			"70036007"
pirbuterol	DB01291	Asthma	C0004096		Approved			CHEBI_8245	"33767"	MONDO_0004979	"10003553"	"195967001"
pranlukast	DB01411	Asthma	C0004096		Approved			CHEBI_94810		MONDO_0004979	"10003553"	"195967001"
piperacillin	DB00319	Pneumonia, Bacterial	C0004626		Approved			CHEBI_8232	"1546000|8339"	MONDO_0004652	"10060946"	"53084003"
doxorubicin	DB00997	Malignant neoplasm of breast	C0006142	NCT02833766	Terminated	Phase 2	the trial was prematurely terminated as per SAKK board decision from 14th of November 2020. The trial is to be terminated after primary endpoint is reached.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00431795	Terminated	Phase 2	Due to poor accrual	CHEBI_47898	"3995"		"10006187"	"254837009"
pirlindole	DB09244	Depressive disorder	C0011581		Approved			CHEBI_91755		MONDO_0002050		"35489007"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00431795	Terminated	Phase 2	Due to poor accrual	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
carboplatin	DB00958	Malignant neoplasm of breast	C0006142	NCT02561832	Terminated	Phase 1	This decision was based upon strategic considerations impacting the clinical development of olaparib in this indication.	CHEBI_31355	"40048"		"10006187"	"254837009"
polysorbate 80	DB11063	Dry Eye Syndromes	C0013238		Approved			CHEBI_53426	"8560"	MONDO_0006733		"46152009"
piperacillin	DB00319	Sepsis caused by Bacteroides	C0276064		Approved			CHEBI_8232	"1546000|8339"			"1201760007"
piperacillin	DB00319	Arthropathy associated with infection	C0157749		Approved			CHEBI_8232	"1546000|8339"			"363162000"
piperacillin	DB00319	Female genital tract infection	C1263758		Approved			CHEBI_8232	"1546000|8339"			"125585007"
piperazine	DB00592	Ascariasis	C0003950		Approved			CHEBI_28568	"8340"	MONDO_0005654	"10003442"	"2435008"
piperacillin	DB00319	Appendicitis	C0003615		Approved			CHEBI_8232	"1546000|8339"	MONDO_0005649	"10003011"	"74400008"
piperacillin	DB00319	Postoperative infection	C0392618		Approved			CHEBI_8232	"1546000|8339"			"33910007"
pralidoxime	DB00733	Organophosphate poisoning	C0700359		Approved			CHEBI_8354	"34345"			"8260003"
piperacillin	DB00319	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_8232	"1546000|8339"			"128945009"
piperacillin	DB00319	Acute gonococcal urethritis	C0275652		Approved			CHEBI_8232	"1546000|8339"			"29864006"
piperacillin	DB00319	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_8232	"1546000|8339"			"369001000119100"
piperacillin	DB00319	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_8232	"1546000|8339"			"448813005"
	DB00531	Malignant neoplasm of breast	C0006142	NCT02561832	Terminated	Phase 1	This decision was based upon strategic considerations impacting the clinical development of olaparib in this indication.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
atorvastatin	DB01076	Malignant neoplasm of breast	C0006142	NCT02674204	Terminated	Phase 2	Closed due to low accrual	CHEBI_39548	"83367"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT02569801	Terminated	Phase 2	The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns.	CHEBI_31638	"282357"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT04298918	Terminated	Phase 1/Phase 2	Decision to discontinue the study based on broader development and strategic prioritisation. The Sponsor concludes there is no benefit-risk impact on the CO41863 study.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT04630210	Withdrawn	Early Phase 1	Insufficient resources	CHEBI_6413	"72965"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00054470	Withdrawn	Phase 2			"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
thalidomide	DB01041	Malignant neoplasm of breast	C0006142	NCT00193102	Terminated	Phase 2		CHEBI_74947	"10432"		"10006187"	"254837009"
prednicarbate	DB01130	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_135791	"34369"			"53891004"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00476827	Terminated	Phase 2	Slow accrual		"253337|2046138"		"10006187"	"254837009"
antazoline	DB08799	Allergic Conjunctivitis	C0009766		Approved			CHEBI_84115	"865"	MONDO_0005642	"10010744"	"231854006"
prednicarbate	DB01130	Psoriasis of scalp	C0406326		Approved			CHEBI_135791	"34369"			"238608008"
prednicarbate	DB01130	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_135791	"34369"			"200965009"
prednicarbate	DB00860	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_8378	"8638"			"53891004"
prednicarbate	DB00860	Psoriasis of scalp	C0406326		Approved			CHEBI_8378	"8638"			"238608008"
prednicarbate	DB00860	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_8378	"8638"			"200965009"
prednisolone	DB00860	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_8378	"8638"			"53891004"
prednisolone	DB00860	Addison Disease	C0001403		Approved			CHEBI_8378	"8638"	MONDO_0015129	"10001130"	"373662000"
prednisolone	DB00860	Arthritis, Psoriatic	C0003872		Approved			CHEBI_8378	"8638"	MONDO_0011849	"10037162"	"156370009"
prednisolone	DB00860	Mycosis Fungoides	C0026948		Approved			CHEBI_8378	"8638"	MONDO_0009691		"118618005"
pravastatin	DB00175	Arteriosclerosis	C0003850		Approved			CHEBI_63618	"42463"	MONDO_0002277	"10003210"	"72092001"
prednisolone	DB00860	Exacerbation of asthma	C0349790		Approved			CHEBI_8378	"8638"			"281239006"
prednisolone	DB00860	Rheumatoid Arthritis	C0003873		Approved			CHEBI_8378	"8638"	MONDO_0008383	"10039073"	"69896004"
prednisolone	DB00860	Psoriasis of scalp	C0406326		Approved			CHEBI_8378	"8638"			"238608008"
prednisolone	DB00860	Asthma	C0004096		Approved			CHEBI_8378	"8638"	MONDO_0004979	"10003553"	"195967001"
prednisolone	DB00860	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_8378	"8638"			"200965009"
prednisolone	DB00860	Punctate keratopathy	C0423234		Approved			CHEBI_8378	"8638"			"246936005"
prednisolone	DB00860	Transplanted organ rejection	C0345468		Approved			CHEBI_8378	"8638"			"213148006"
prednisolone	DB00860	Blepharoconjunctivitis	C0005743		Approved			CHEBI_8378	"8638"	MONDO_0002307		"68659002"
prednisolone	DB00860	Tuberculosis, Miliary	C0041321		Approved			CHEBI_8378	"8638"	MONDO_0005848		"47604008"
prednisolone	DB00860	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_8378	"8638"	MONDO_0015253		"88854002"
prednisolone	DB00860	Acquired thrombocytopenia	C0154301		Approved			CHEBI_8378	"8638"	MONDO_0001198		"154826009"
prednisolone	DB00860	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_8378	"8638"	MONDO_0000004		"386584007"
prednisolone	DB00860	Infective blepharitis	C0729587		Approved			CHEBI_8378	"8638"			"312219000"
prednisolone	DB00860	Adrenogenital disorder	C0701163		Approved			CHEBI_8378	"8638"			"267395000"
prednisolone	DB00860	Aspergillosis, Allergic Bronchopulmonary	C0004031		Approved			CHEBI_8378	"8638"		"10006474"	"37981002"
prednisolone	DB00860	Corneal Ulcer	C0010043		Approved			CHEBI_8378	"8638"	MONDO_0004577		"91514001"
prednisolone	DB00860	Berylliosis	C0005138		Approved			CHEBI_8378	"8638"		"10004485"	"8247009"
prednisolone	DB00860	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_8378	"8638"			"699262001"
prednisolone	DB00860	Autoimmune Diseases	C0004364		Approved			CHEBI_8378	"8638"	MONDO_0007179	"10061664"	"85828009"
prednisolone	DB00860	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_8378	"8638"	MONDO_0020108	"10073785"	"413603009"
prednisolone	DB00860	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_8378	"8638"	MONDO_0018479		"237751000"
prednisone	DB00635	Rheumatoid Arthritis	C0003873		Approved			CHEBI_8382	"8640"	MONDO_0008383	"10039073"	"69896004"
prednisone	DB00635	Asthma	C0004096		Approved			CHEBI_8382	"8640"	MONDO_0004979	"10003553"	"195967001"
bupivacaine	DB00297	Malignant neoplasm of breast	C0006142	NCT03393117	Withdrawn	Phase 2	No accrual	CHEBI_77431	"1815"		"10006187"	"254837009"
prednisone	DB00635	Addison Disease	C0001403		Approved			CHEBI_8382	"8640"	MONDO_0015129	"10001130"	"373662000"
prednisolone acetate	DB15566	Blepharoconjunctivitis	C0005743		Approved			CHEBI_8380	"34372"	MONDO_0002307		"68659002"
prednisolone acetate	DB00860	Blepharoconjunctivitis	C0005743		Approved			CHEBI_8378	"8638"	MONDO_0002307		"68659002"
prednisone	DB00635	Transplanted organ rejection	C0345468		Approved			CHEBI_8382	"8640"			"213148006"
prednisone	DB00635	Arthritis, Psoriatic	C0003872		Approved			CHEBI_8382	"8640"	MONDO_0011849	"10037162"	"156370009"
prednisone	DB00635	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_8382	"8640"	MONDO_0015253		"88854002"
prednisone	DB00635	Acquired thrombocytopenia	C0154301		Approved			CHEBI_8382	"8640"	MONDO_0001198		"154826009"
pregabalin	DB00230	Diabetic peripheral neuropathy	C0740447		Approved			CHEBI_64356	"187832"			"424736006"
prednisone	DB00635	Mycosis Fungoides	C0026948		Approved			CHEBI_8382	"8640"	MONDO_0009691		"118618005"
primaquine	DB01087	Malaria, Vivax	C0024537		Approved			CHEBI_8405	"8687"	MONDO_0005921		"27052006"
prednisolone acetate	DB15566	Infective blepharitis	C0729587		Approved			CHEBI_8380	"34372"			"312219000"
prednisolone acetate	DB00860	Infective blepharitis	C0729587		Approved			CHEBI_8378	"8638"			"312219000"
prednisone	DB00635	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_8382	"8640"	MONDO_0000004		"386584007"
prednisone	DB00635	Adrenogenital disorder	C0701163		Approved			CHEBI_8382	"8640"			"267395000"
prednisone	DB00635	Berylliosis	C0005138		Approved			CHEBI_8382	"8640"		"10004485"	"8247009"
prednisone	DB00635	Autoimmune Diseases	C0004364		Approved			CHEBI_8382	"8640"	MONDO_0007179	"10061664"	"85828009"
prednisone	DB00635	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_8382	"8640"	MONDO_0020108	"10073785"	"413603009"
prednisone	DB00635	Exacerbation of asthma	C0349790		Approved			CHEBI_8382	"8640"			"281239006"
prednisone	DB00635	Pemphigus	C0030807		Approved			CHEBI_8382	"8640"	MONDO_0006594	"10034280"	"65172003"
primidone	DB00794	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_8412	"8691"			
primidone	DB00794	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_8412	"8691"	MONDO_0005754		
proglumetacin	DB13527	Rheumatoid Arthritis	C0003873		Approved			CHEBI_76263		MONDO_0008383	"10039073"	"69896004"
propafenone	DB01182	Atrial Fibrillation	C0004238		Approved			CHEBI_63619	"8754"	MONDO_0004981	"10003658"	"49436004"
propranolol	DB00571	Atrial Fibrillation	C0004238		Approved			CHEBI_8499	"8787"	MONDO_0004981	"10003658"	"49436004"
doxorubicin	DB00997	Malignant neoplasm of breast	C0006142	NCT01131364	Terminated	Phase 1/Phase 2		CHEBI_28748	"142433|3639"		"10006187"	"254837009"
rosuvastatin	DB01098	Malignant neoplasm of breast	C0006142	NCT02483871	Withdrawn	Phase 1	Enrollment did not meet anticipated goals. Eligibility was a challenge.	CHEBI_38545	"301542"		"10006187"	"254837009"
colecalciferol	DB00169	Malignant neoplasm of breast	C0006142	NCT02856503	Withdrawn	Phase 1/Phase 2	Lack of Funding	CHEBI_28940	"2418"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02824575	Terminated	Phase 1	Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.	CHEBI_45863	"56946"		"10006187"	"254837009"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT00130507	Terminated	Phase 2	A new alternative treatment caused the decrease in the rhythm of recruitment.	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT01147016	Terminated	Phase 2	Primary co-investigator leaving the institution & funding transfer.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT02137837	Terminated	Phase 3	lack of accrual	CHEBI_2704	"84857"		"10006187"	"254837009"
propranolol	DB00571	Idiopathic hypertrophic subaortic stenosis	C0700053		Approved			CHEBI_8499	"8787"			
	DB00947	Malignant neoplasm of breast	C0006142	NCT02137837	Terminated	Phase 3	lack of accrual	CHEBI_31638	"282357"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT02137837	Terminated	Phase 3	lack of accrual	CHEBI_68478	"141704"		"10006187"	"254837009"
sorafenib	DB00398	Malignant neoplasm of breast	C0006142	NCT00525161	Terminated	Phase 2	Slow accrual and loss of funding	CHEBI_50924	"495881"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00796107	Terminated	Phase 2	Due to the discontinuation of compound development, this study has been terminated.	CHEBI_6413	"72965"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00025493	Terminated	Phase 2	poor accrual	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
pseudoephedrine	DB00852	Influenza-like symptoms	C0392171		Approved			CHEBI_51209	"8896"			
mepyramine	DB06691	Influenza-like symptoms	C0392171		Approved			CHEBI_6762	"9009"			
quinidine	DB00908	Atrial Fibrillation	C0004238		Approved			CHEBI_28593	"9068"	MONDO_0004981	"10003658"	"49436004"
quetiapine	DB01224	Bipolar Disorder	C0005586		Approved			CHEBI_8707	"51272"	MONDO_0004985	"10057667"	"13746004"
methotrexate	DB00563	Malignant neoplasm of breast	C0006142	NCT00002696	Suspended	Phase 3		CHEBI_44185	"6851"		"10006187"	"254837009"
pyrimethamine	DB00205	Toxoplasmosis associated with acquired immunodeficiency syndrome	C1720498		Approved			CHEBI_8673	"9010"			
protriptyline	DB00344	Depressive disorder	C0011581		Approved			CHEBI_8597	"8886"	MONDO_0002050		"35489007"
pseudoephedrine	DB00852	Headache Disorders	C0393735		Approved			CHEBI_51209	"8896"			"230461009"
valproic acid	DB00313	Malignant neoplasm of breast	C0006142	NCT01900730	Terminated	Phase 2	Due to low accrual	CHEBI_39867	"11118|40254"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT02384746	Terminated	Phase 1	Low accrual	CHEBI_31638	"282357"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT01690325	Terminated	Phase 2	Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
pseudoephedrine	DB00852	Common Cold	C0009443		Approved			CHEBI_51209	"8896"	MONDO_0005709		"82272006"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT03134638	Terminated	Phase 1	Business Decision	CHEBI_31638	"282357"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT01690325	Terminated	Phase 2	Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance		"253337|2046138"		"10006187"	"254837009"
mepyramine	DB06691	Common Cold	C0009443		Approved			CHEBI_6762	"9009"	MONDO_0005709		"82272006"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT01690325	Terminated	Phase 2	Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance	CHEBI_47898	"3995"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT03134638	Terminated	Phase 1	Business Decision	CHEBI_31355	"40048"		"10006187"	"254837009"
quinupristin	DB01369	Group A Streptococcal Infections	C0554628		Approved			CHEBI_8732	"229367"			"302809008"
quinestrol	DB04575	Atrophic Vaginitis	C0221392		Approved			CHEBI_8716	"9066"			"52441000"
prulifloxacin	DB11892	Lower urinary tract infectious disease	C0268821		Approved			CHEBI_32071				"4009004"
quetiapine	DB01224	Bipolar disorder in remission	C0270425		Approved			CHEBI_8707	"51272"			"85248005"
quinidine	DB00908	Pseudobulbar affect	C2316460		Approved			CHEBI_28593	"9068"			"432776007"
pyrazinamide	DB00339	Acute tuberculosis	C0275959		Approved			CHEBI_45285	"8987"			"25629007"
rivastigmine	DB00989	Alzheimer's Disease	C0002395		Approved			CHEBI_8874	"183379"	MONDO_0004975	"10012271"	"26929004"
rofecoxib	DB00533	Rheumatoid Arthritis	C0003873		Approved			CHEBI_8887	"232158"	MONDO_0008383	"10039073"	"69896004"
reproterol	DB12846	Asthma	C0004096		Approved			CHEBI_135612	"35373"	MONDO_0004979	"10003553"	"195967001"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00912444	Terminated	Phase 3	TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB01006	Malignant neoplasm of breast	C0006142	NCT00498901	Terminated	Phase 2		CHEBI_6413	"72965"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00912444	Terminated	Phase 3	TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT00498901	Terminated	Phase 2		CHEBI_5523	"50610"		"10006187"	"254837009"
	DB00864	Crohn Disease	C0010346	NCT04154735	Withdrawn	Phase 2	Discontinued by Investigator	CHEBI_61049	"42316|235991"	MONDO_0005011	"10011401"	"34000006"
ribavirin	DB00811	Early cirrhosis	C1299579		Approved			CHEBI_63580	"9344"			"371139006"
retapamulin	DB01256	Superficial bacterial infection of skin	C0342985		Approved			CHEBI_166679	"642274"			"275441009"
risperidone	DB00734	Bipolar disorder in remission	C0270425		Approved			CHEBI_8871	"35636"			"85248005"
rivastigmine	DB00989	Dementia associated with Parkinson's Disease	C1828079		Approved			CHEBI_8874	"183379"			"425390006"
risperidone	DB00734	Mixed bipolar I disorder	C0236780		Approved			CHEBI_8871	"35636"			"16506000"
ramosetron	DB09290	Irritable bowel syndrome with diarrhea	C0348898		Approved			CHEBI_135156				"197125005"
rifabutin	DB00615	Pulmonary Mycobacterium avium complex infection	C2733595		Approved			CHEBI_45367	"55672"			"186342000"
rifampicin	DB01045	Acute tuberculosis	C0275959		Approved			CHEBI_71365	"9384"			"25629007"
rifaximin	DB01220	Irritable bowel syndrome with diarrhea	C0348898		Approved			CHEBI_75246	"35619"			"197125005"
riluzole	DB00740	Amyotrophic Lateral Sclerosis	C0002736		Approved			CHEBI_8863	"35623"	MONDO_0004976	"10002026"	"86044005"
risperidone	DB00734	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_8871	"35636"			"191618007"
remifentanil	DB00899	Postoperative Pain, Acute	C2215257		Approved			CHEBI_8802	"73032"			"107401000119105"
ramipril	DB00178	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_8774	"35296"			"429589006"
ramipril	DB14208	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_77363				"429589006"
ranitidine	DB00863	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_92246	"9143"	MONDO_0019610		"53132006"
rifampicin	DB01045	Meningococcus carrier	C0421162		Approved			CHEBI_71365	"9384"			"170486006"
rimantadine	DB00478	Influenza due to Influenza A virus	C2711180		Approved			CHEBI_94440	"9386"			"442438000"
salicylic acid	DB14006	Rheumatoid Arthritis	C0003873		Approved			CHEBI_16914	"20974"	MONDO_0008383	"10039073"	"69896004"
salicylic acid	DB00936	Rheumatoid Arthritis	C0003873		Approved			CHEBI_16914	"9525"	MONDO_0008383	"10039073"	"69896004"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00912444	Terminated	Phase 3	TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00925652	Terminated	Phase 2	The study was terminated early due to slow accrual.		"253337|2046138"		"10006187"	"254837009"
methotrexate	DB00563	Malignant neoplasm of breast	C0006142	NCT00925652	Terminated	Phase 2	The study was terminated early due to slow accrual.	CHEBI_44185	"6851"		"10006187"	"254837009"
	DB14123	Malignant neoplasm of breast	C0006142	NCT01855607	Terminated	Phase 2	Lack of feasibility	CHEBI_25187	"6750|1430390"		"10006187"	"254837009"
salicylamide	DB08797	Headache Disorders	C0393735		Approved			CHEBI_32114	"9518"			"230461009"
levomenthol	DB00825	Malignant neoplasm of breast	C0006142	NCT01855607	Terminated	Phase 2	Lack of feasibility	CHEBI_15409	"236388|6750"		"10006187"	"254837009"
estradiol	DB00783	Malignant neoplasm of breast	C0006142	NCT00661531	Terminated	Phase 2	Poor accrual	CHEBI_16469	"4083"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00845910	Terminated	Phase 2	To be confirmed	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00845910	Terminated	Phase 2	To be confirmed		"253337|2046138"		"10006187"	"254837009"
salicylic acid	DB00936	Common Cold	C0009443		Approved			CHEBI_16914	"9525"	MONDO_0005709		"82272006"
salicylic acid	DB00936	Acne Vulgaris	C0001144		Approved			CHEBI_16914	"9525"			"88616000"
salicylic acid	DB14006	Common Cold	C0009443		Approved			CHEBI_16914	"20974"	MONDO_0005709		"82272006"
salicylic acid	DB14006	Acne Vulgaris	C0001144		Approved			CHEBI_16914	"20974"			"88616000"
rosuvastatin	DB01098	Arteriosclerosis	C0003850		Approved			CHEBI_38545	"301542"	MONDO_0002277	"10003210"	"72092001"
salicylic acid	DB00936	Greasy skin	C0234925		Approved			CHEBI_16914	"9525"			"42273000"
salicylic acid	DB14006	Greasy skin	C0234925		Approved			CHEBI_16914	"20974"			"42273000"
phenylbutanoic acid	DB06819	Amyotrophic Lateral Sclerosis	C0002736		Approved			CHEBI_41500	"1546447|81647"	MONDO_0004976	"10002026"	"86044005"
rosuvastatin	DB01098	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_38545	"301542"			"238079002"
rosuvastatin	DB01098	Homozygous Familial Hypercholesterolemia	C0342881		Approved			CHEBI_38545	"301542"			"238078005"
roxatidine acetate	DB08806	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_94758		MONDO_0019610		"53132006"
salicylic acid	DB00936	Plantar wart	C0042548		Approved			CHEBI_16914	"9525"	MONDO_0001795		"63440008"
salicylic acid	DB00936	Disorder of keratinization	C0475811		Approved			CHEBI_16914	"9525"	MONDO_0045011		"277905003"
salsalate	DB00936	Rheumatoid Arthritis	C0003873		Approved			CHEBI_16914	"9525"	MONDO_0008383	"10039073"	"69896004"
salicylic acid	DB13860	Rheumatoid Arthritis	C0003873		Approved			CHEBI_16914		MONDO_0008383	"10039073"	"69896004"
salicylic acid	DB13860	Common Cold	C0009443		Approved			CHEBI_16914		MONDO_0005709		"82272006"
salicylic acid	DB13860	Acne Vulgaris	C0001144		Approved			CHEBI_16914				"88616000"
salsalate	DB01399	Rheumatoid Arthritis	C0003873		Approved			CHEBI_9014	"36108"	MONDO_0008383	"10039073"	"69896004"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00845910	Terminated	Phase 2	To be confirmed	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB00675	Malignant neoplasm of breast	C0006142	NCT00738777	Suspended	Phase 2	in preparation for an amendment	CHEBI_41774	"10324"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00738777	Suspended	Phase 2	in preparation for an amendment	CHEBI_2704	"84857"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00738777	Suspended	Phase 2	in preparation for an amendment	CHEBI_31638	"282357"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01169870	Withdrawn	Phase 2	withdrawn studies	CHEBI_45863	"56946"		"10006187"	"254837009"
cisplatin	DB00515	Malignant neoplasm of breast	C0006142	NCT00603408	Terminated	Phase 2	Study was discontinued due to lack of accrual.	CHEBI_27899	"2555"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00377780	Terminated	Phase 2	wothdrawal of sponsor	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
scopolamine	DB00747	Common Cold	C0009443		Approved			CHEBI_16794	"9601|9603"	MONDO_0005709		"82272006"
sertraline	DB01104	Depressive disorder	C0011581		Approved			CHEBI_9123	"36437"	MONDO_0002050		"35489007"
setiptiline	DB09304	Depressive disorder	C0011581		Approved			CHEBI_135076		MONDO_0002050		"35489007"
aripiprazole	DB01238	Bipolar disorder in remission	C0270425		Approved			CHEBI_31236	"89013"			"85248005"
aripiprazole	DB01238	Mixed bipolar I disorder	C0236780		Approved			CHEBI_31236	"89013"			"16506000"
salicylic acid	DB13860	Greasy skin	C0234925		Approved			CHEBI_16914				"42273000"
salmeterol	DB00938	Intrinsic asthma	C0155880		Approved			CHEBI_64064	"36117"	MONDO_0004765		"266361008"
aripiprazole	DB01238	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_31236	"89013"			"191618007"
salmeterol	DB00938	Allergic asthma	C0155877		Approved			CHEBI_64064	"36117"	MONDO_0004784		"389145006"
salicylic acid	DB13860	Plantar wart	C0042548		Approved			CHEBI_16914		MONDO_0001795		"63440008"
salicylic acid	DB13860	Disorder of keratinization	C0475811		Approved			CHEBI_16914		MONDO_0045011		"277905003"
sermorelin	DB00010	Pituitary dwarfism	C0013338		Approved			CHEBI_9118	"56188"	MONDO_0000050|MONDO_0006909		"367460001"
salicylic acid	DB13860	Scurfiness of scalp	C0423775		Approved			CHEBI_16914				"200767005"
secobarbital	DB00418	Severe anxiety (panic)	C0231403		Approved			CHEBI_9073	"9624"			"80583007"
solifenacin	DB01591	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_135530	"322167"			
sotalol	DB00489	Atrial Fibrillation	C0004238		Approved			CHEBI_63622	"9947"	MONDO_0004981	"10003658"	"49436004"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00377780	Terminated	Phase 2	wothdrawal of sponsor	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
dasatinib	DB01254	Malignant neoplasm of breast	C0006142	NCT00780676	Terminated	Phase 2	Closed early for futility.	CHEBI_49375	"475342|1546019"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00377780	Terminated	Phase 2	wothdrawal of sponsor		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
doxorubicin	DB00997	Malignant neoplasm of breast	C0006142	NCT00465673	Terminated	Phase 2	Low recruitment	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT01498588	Terminated	Phase 2	Slow accrual	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT01498588	Terminated	Phase 2	Slow accrual	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT01225172	Terminated	Phase 2	Business objectives have changed.	CHEBI_6413	"72965"		"10006187"	"254837009"
sparfloxacin	DB01208	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_9212	"18469"			"70036007"
sparfloxacin	DB01208	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_9212	"18469"			"186435004"
spectinomycin	DB00919	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_9215	"270"	MONDO_0001080		"20943002"
streptomycin	DB01082	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_17076	"10109"			"301011002"
streptomycin	DB01082	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_17076	"10109"			"70036007"
sorafenib	DB00398	Malignant epithelial neoplasm of thyroid	C3163939		Approved			CHEBI_50924	"495881"			"448216007"
sparfloxacin	DB01208	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_9212	"18469"			"195722003"
sirolimus	DB00877	Pulmonary lymphangioleiomyomatosis	C0349649		Approved			CHEBI_9168	"35302"			"277844007"
sirolimus	DB00877	Lymphangiomatosis	C0334102		Approved			CHEBI_9168	"35302"			"403546006"
simvastatin	DB00641	Arteriosclerosis	C0003850		Approved			CHEBI_9150	"36567"	MONDO_0002277	"10003210"	"72092001"
artesunate	DB09274	Malaria, Vivax	C0024537		Approved			CHEBI_63918	"18346"	MONDO_0005921		"27052006"
streptomycin	DB01082	Acute tuberculosis	C0275959		Approved			CHEBI_17076	"10109"			"25629007"
sparfloxacin	DB01208	Acute bacterial bronchitis	C0339933		Approved			CHEBI_9212	"18469"			"233598009"
artesunate	DB09274	Malaria, Falciparum	C0024535		Approved			CHEBI_63918	"18346"	MONDO_0005920		"248441000"
streptomycin	DB01082	Proteus urinary tract infection	C0577709		Approved			CHEBI_17076	"10109"			"301012009"
spectinomycin	DB00919	Acute gonococcal urethritis	C0275652		Approved			CHEBI_9215	"270"			"29864006"
simvastatin	DB00641	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_9150	"36567"			"238079002"
simvastatin	DB00641	Homozygous Familial Hypercholesterolemia	C0342881		Approved			CHEBI_9150	"36567"			"238078005"
succimer	DB00566	Accidental poisoning by lead and its compounds and fumes	C0261486		Approved			CHEBI_63623	"3446"			
sulfadiazine	DB00359	Toxoplasmosis associated with acquired immunodeficiency syndrome	C1720498		Approved			CHEBI_9328	"10171"			
sulbactam	DB09324	Staphylococcus aureus infection	C1318973		Approved			CHEBI_9321	"10167"			"406602003"
sulbactam	DB09324	Escherichia coli Infections	C0014836		Approved			CHEBI_9321	"10167"	MONDO_0020920		"71057007"
sulfacetamide	DB00634	Acne Vulgaris	C0001144		Approved			CHEBI_63845	"10169"			"88616000"
sulfasalazine	DB00795	Rheumatoid Arthritis	C0003873		Approved			CHEBI_9334	"9524"	MONDO_0008383	"10039073"	"69896004"
sulfamethizole	DB00576	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_9331	"10179"			"301011002"
sulfamethizole	DB00576	Infective otitis media	C0729586		Approved			CHEBI_9331	"10179"			"312218008"
	DB00515	Malignant neoplasm of breast	C0006142	NCT01194869	Terminated	Phase 2	Slow accrual, availability of other clinical options	CHEBI_27899	"2555"		"10006187"	"254837009"
sulfamethoxazole	DB01015	Infective otitis media	C0729586		Approved			CHEBI_9332	"10180"			"312218008"
sulfamethoxazole	DB01015	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_9332	"10180"			"301011002"
sufentanil	DB00708	Pain, Postoperative	C0030201		Approved			CHEBI_9316	"56795"			"213299007"
sulfacetamide	DB00634	Blepharoconjunctivitis	C0005743		Approved			CHEBI_63845	"10169"	MONDO_0002307		"68659002"
sulbactam	DB09324	Female genital tract infection	C1263758		Approved			CHEBI_9321	"10167"			"125585007"
sulfacetamide	DB00634	Infective blepharitis	C0729587		Approved			CHEBI_63845	"10169"			"312219000"
sulfamethizole	DB00576	Proteus urinary tract infection	C0577709		Approved			CHEBI_9331	"10179"			"301012009"
sulfamethoxazole	DB01015	Proteus urinary tract infection	C0577709		Approved			CHEBI_9332	"10180"			"301012009"
sulfacetamide	DB00634	Amebiasis	C0002438		Approved			CHEBI_63845	"10169"	MONDO_0005644	"10001980"	"111910009"
sulbactam	DB09324	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_9321	"10167"			"128945009"
sulfamethoxazole	DB01015	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_9332	"10180"			"425748003"
sulfacetamide	DB00634	Scurfiness of scalp	C0423775		Approved			CHEBI_63845	"10169"			"200767005"
tacrine	DB00382	Alzheimer's Disease	C0002395		Approved			CHEBI_45980	"10318"	MONDO_0004975	"10012271"	"26929004"
sulfafurazole	DB00263	Infective otitis media	C0729586		Approved			CHEBI_102484	"10207"			"312218008"
sulfasalazine	DB00244	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6775	"52582"	MONDO_0008383	"10039073"	"69896004"
sulindac	DB00605	Rheumatoid Arthritis	C0003873		Approved			CHEBI_9352	"10237"	MONDO_0008383	"10039073"	"69896004"
tazobactam	DB01606	Pneumonia, Bacterial	C0004626		Approved			CHEBI_9421	"37617"	MONDO_0004652	"10060946"	"53084003"
	DB00398	Malignant neoplasm of breast	C0006142	NCT01194869	Terminated	Phase 2	Slow accrual, availability of other clinical options	CHEBI_50924	"495881"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01194869	Terminated	Phase 2	Slow accrual, availability of other clinical options	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00003086	Terminated	Phase 1/Phase 2	no participants enrolled in a three year period	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
irinotecan	DB00762	Malignant neoplasm of breast	C0006142	NCT00476827	Terminated	Phase 2	Slow accrual	CHEBI_80630	"51499"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT00476827	Terminated	Phase 2	Slow accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00361	Malignant neoplasm of breast	C0006142	NCT00476827	Terminated	Phase 2	Slow accrual	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00397501	Withdrawn	Phase 1/Phase 2	after original approval, IRB closed enrollment; major revisions required to re-open.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
tazarotene	DB00799	Acne Vulgaris	C0001144		Approved			CHEBI_32184	"83947"			"88616000"
tacrolimus	DB00864	Transplanted organ rejection	C0345468		Approved			CHEBI_61049	"42316|235991"			"213148006"
tamoxifen	DB00675	Malignant epithelial neoplasm of female breast	C3163805		Approved			CHEBI_41774	"10324"			"447782002"
sulfinpyrazone	DB01138	Chronic gouty arthritis	C0268108		Approved			CHEBI_9342	"10205"			"68451005"
atorvastatin	DB01076	Angina Pectoris, Variant	C0002963		Approved			CHEBI_39548	"83367"	MONDO_0006021	"10036759"	"87343002"
tazobactam	DB01606	Appendicitis	C0003615		Approved			CHEBI_9421	"37617"	MONDO_0005649	"10003011"	"74400008"
atorvastatin	DB01076	Arteriosclerosis	C0003850		Approved			CHEBI_39548	"83367"	MONDO_0002277	"10003210"	"72092001"
sulfafurazole	DB00263	Malaria, Falciparum	C0024535		Approved			CHEBI_102484	"10207"	MONDO_0005920		"248441000"
talaporfin	DB11812	Primary malignant neoplasm of brain	C0750979		Approved			CHEBI_135875				"93727008"
tazobactam	DB01606	Hospital acquired pneumonia	C0949083		Approved			CHEBI_9421	"37617"			"425464007"
atorvastatin	DB01076	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_39548	"83367"			"238079002"
atorvastatin	DB01076	Homozygous Familial Hypercholesterolemia	C0342881		Approved			CHEBI_39548	"83367"			"238078005"
tadalafil	DB00820	Prostatic Hypertrophy	C1739363		Approved			CHEBI_71940	"358263"			"266569009"
tamsulosin	DB00706	Prostatic Hypertrophy	C1739363		Approved			CHEBI_9398	"77492"			"266569009"
terbinafine	DB00857	onychomycosis of fingernail	C1274469		Approved			CHEBI_9448	"37801"			
terbutaline	DB00871	Asthma attack	C0347950		Approved			CHEBI_9449	"10368"			
fluorouracil	DB00544	metastasis from malignant neoplasm of colon	C1282500		Approved			CHEBI_46345	"4492"	MONDO_0041448		
tazobactam	DB01606	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_9421	"37617"			"70036007"
tazobactam	DB01606	Staphylococcus aureus infection	C1318973		Approved			CHEBI_9421	"37617"			"406602003"
tazobactam	DB01606	Sepsis caused by Serratia	C2887097		Approved			CHEBI_9421	"37617"			"449084002"
terbutaline	DB00871	Asthma	C0004096		Approved			CHEBI_9449	"10368"	MONDO_0004979	"10003553"	"195967001"
telithromycin	DB00976	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_29688	"274786"			"70036007"
telithromycin	DB00976	Group A Streptococcal Infections	C0554628		Approved			CHEBI_29688	"274786"			"302809008"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00397501	Withdrawn	Phase 1/Phase 2	after original approval, IRB closed enrollment; major revisions required to re-open.	CHEBI_31355	"40048"		"10006187"	"254837009"
methotrexate	DB00563	Malignant neoplasm of breast	C0006142	NCT00397501	Withdrawn	Phase 1/Phase 2	after original approval, IRB closed enrollment; major revisions required to re-open.	CHEBI_44185	"6851"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT02569489	Withdrawn	Phase 1	Reconsideration of Study Design; plan for alternative protocol		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02569489	Withdrawn	Phase 1	Reconsideration of Study Design; plan for alternative protocol	CHEBI_45863	"56946"		"10006187"	"254837009"
risedronic acid	DB00884	Malignant neoplasm of breast	C0006142	NCT00324714	Withdrawn	Phase 3		CHEBI_8869	"73056|55685"		"10006187"	"254837009"
terbutaline	DB00871	Dry Eye Syndromes	C0013238		Approved			CHEBI_9449	"10368"	MONDO_0006733		"46152009"
terfenadine	DB00342	Common Cold	C0009443		Approved			CHEBI_9453	"42330"	MONDO_0005709		"82272006"
terbinafine	DB00857	Tinea Capitis	C0040250		Approved			CHEBI_9448	"37801"		"10043866"	"5441008"
tazobactam	DB01606	Acute pyelonephritis caused by bacterium	C2062473		Approved			CHEBI_9421	"37617"			"838353009"
tegaserod	DB01079	Irritable bowel syndrome characterized by constipation	C1868889		Approved			CHEBI_51043	"139778"			"440630006"
temozolomide	DB00853	Brain Glioblastoma	C0349543		Approved			CHEBI_72564	"37776"	MONDO_0002501		"276828006"
tazobactam	DB01606	Sepsis caused by Haemophilus influenzae	C2887091		Approved			CHEBI_9421	"37617"			"447685007"
terbinafine	DB00857	Onychomycosis of toenails	C1274470		Approved			CHEBI_9448	"37801"			"403059006"
atovaquone	DB01117	Malaria, Falciparum	C0024535		Approved			CHEBI_575568	"60212"	MONDO_0005920		"248441000"
temoporfin	DB11630	Head and Neck Neoplasms	C0018671		Approved			CHEBI_9437	"115243"	MONDO_0005586|MONDO_0017371		"255055008"
tenoxicam	DB00469	Arthritis	C0003864		Approved			CHEBI_32192	"37790"	MONDO_0005578	"10003246"	"3723001"
tegaserod	DB01079	Chronic idiopathic constipation	C0267509		Approved			CHEBI_51043	"139778"			"82934008"
fluorouracil	DB00544	Superficial basal cell carcinoma	C0862889		Approved			CHEBI_46345	"4492"			"403914000"
fluorouracil	DB00544	Malignant tumor of small intestine	C0153425		Approved			CHEBI_46345	"4492"	MONDO_0000956		"363509000"
tamoxifen	DB00675	Malignant neoplasm of breast	C0006142	NCT00290654	Terminated	Phase 2	Unable to recruit further patients.	CHEBI_41774	"10324"		"10006187"	"254837009"
bevacizumab	DB00112	Malignant neoplasm of breast	C0006142	NCT05431582	Withdrawn	Phase 1	No participants enrolled		"253337|2046138"		"10006187"	"254837009"
	DB01006	Malignant neoplasm of breast	C0006142	NCT00499681	Terminated	Phase 2	slow accrual	CHEBI_6413	"72965"		"10006187"	"254837009"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT00499681	Terminated	Phase 2	slow accrual	CHEBI_49603	"480167"		"10006187"	"254837009"
tetracycline	DB00759	Infective otitis media	C0729586		Approved			CHEBI_27902	"10395"			"312218008"
tetracycline	DB00759	Acne Vulgaris	C0001144		Approved			CHEBI_27902	"10395"			"88616000"
tetracycline	DB00759	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_27902	"10395"	MONDO_0001080		"20943002"
tetracycline	DB00759	Acute gonococcal epididymo-orchitis	C0153193		Approved			CHEBI_27902	"10395"	MONDO_0001125		"30168008"
testolactone	DB00894	Malignant epithelial neoplasm of female breast	C3163805		Approved			CHEBI_9460	"10378"			"447782002"
tetracycline	DB09550	Actinomycosis	C0001261		Approved			CHEBI_27902	"2105975"	MONDO_0005631	"10000620"	"11817007"
tetracycline	DB00759	Actinomycosis	C0001261		Approved			CHEBI_27902	"10395"	MONDO_0005631	"10000620"	"11817007"
tetracycline	DB00759	Anthrax disease	C0003175		Approved			CHEBI_27902	"10395"	MONDO_0005119	"10002713"	"409498004"
tetracycline	DB09550	Anthrax disease	C0003175		Approved			CHEBI_27902	"2105975"	MONDO_0005119	"10002713"	"409498004"
testosterone	DB00624	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_17347	"10379"			"417181009"
tetracycline	DB00759	Gonorrhea of pharynx	C0149966		Approved			CHEBI_27902	"10395"			"74372003"
tetracycline	DB09550	Gonorrhea of pharynx	C0149966		Approved			CHEBI_27902	"2105975"			"74372003"
tetracycline	DB00759	Acute gonococcal endometritis	C0153196		Approved			CHEBI_27902	"10395"	MONDO_0004264		"65295003"
tetracycline	DB00759	Acute gonococcal urethritis	C0275652		Approved			CHEBI_27902	"10395"			"29864006"
tetracycline	DB09550	Acute gonococcal urethritis	C0275652		Approved			CHEBI_27902	"2105975"			"29864006"
terguride	DB13399	Chronic thromboembolic pulmonary hypertension	C2363973		Approved			CHEBI_32193				"233947005"
tetracycline	DB00759	Chlamydia trachomatis infection of genital structure	C1997322		Approved			CHEBI_27902	"10395"			"428015005"
thalidomide	DB01041	Erythema nodosum leprosum	C0343467		Approved			CHEBI_74947	"10432"			
theophylline	DB00277	Asthma attack	C0347950		Approved			CHEBI_28177	"10438|91178"			
theophylline	DB01223	Asthma attack	C0347950		Approved			CHEBI_2659	"689"			
tetracycline	DB09550	Infective otitis media	C0729586		Approved			CHEBI_27902	"2105975"			"312218008"
tetracycline	DB09550	Acne Vulgaris	C0001144		Approved			CHEBI_27902	"2105975"			"88616000"
tetracycline	DB09550	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_27902	"2105975"	MONDO_0001080		"20943002"
theophylline	DB01223	Asthma	C0004096		Approved			CHEBI_2659	"689"	MONDO_0004979	"10003553"	"195967001"
theophylline	DB00277	Asthma night-time symptoms	C1273489		Approved			CHEBI_28177	"10438|91178"			"395022009"
theophylline	DB00277	Asthma	C0004096		Approved			CHEBI_28177	"10438|91178"	MONDO_0004979	"10003553"	"195967001"
	DB01248	Malignant neoplasm of breast	C0006142	NCT02897050	Suspended	Phase 2		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
theophylline	DB01223	Asthma night-time symptoms	C1273489		Approved			CHEBI_2659	"689"			"395022009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT02897050	Suspended	Phase 2		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB01101	Malignant neoplasm of breast	C0006142	NCT02897050	Suspended	Phase 2		CHEBI_31348	"194000"		"10006187"	"254837009"
	DB00544	Malignant neoplasm of breast	C0006142	NCT02897050	Suspended	Phase 2		CHEBI_46345	"4492"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT02897050	Suspended	Phase 2		CHEBI_47898	"3995"		"10006187"	"254837009"
	DB00482	Malignant neoplasm of breast	C0006142	NCT00075673	Terminated	Phase 1		CHEBI_41423	"140587"		"10006187"	"254837009"
tetracycline	DB09550	Acute gonococcal epididymo-orchitis	C0153193		Approved			CHEBI_27902	"2105975"	MONDO_0001125		"30168008"
thiotepa	DB04572	Malignant epithelial neoplasm of female breast	C3163805		Approved			CHEBI_9570	"10473"			"447782002"
thiabendazole	DB00730	Ascariasis	C0003950		Approved			CHEBI_45979	"10450"	MONDO_0005654	"10003442"	"2435008"
sapropterin	DB00360	Classical phenylketonuria	C0751434		Approved			CHEBI_59560	"753340"	MONDO_0019259		"7573000"
thiabendazole	DB00730	Infection by Trichuris trichiura	C0040954		Approved			CHEBI_45979	"10450"			"60570001"
tetracycline	DB09550	Acute gonococcal endometritis	C0153196		Approved			CHEBI_27902	"2105975"	MONDO_0004264		"65295003"
thiabendazole	DB00730	Infection by Uncinaria	C0041648		Approved			CHEBI_45979	"10450"			"414490001"
thiotepa	DB04572	Malignant neoplasm of urinary bladder	C0005684		Approved			CHEBI_9570	"10473"	MONDO_0001187	"10005003"	"399326009"
tetracycline	DB09550	Chlamydia trachomatis infection of genital structure	C1997322		Approved			CHEBI_27902	"2105975"			"428015005"
tiagabine	DB00906	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_9586	"31914"			
azapropazone	DB07402	Rheumatoid Arthritis	C0003873		Approved			CHEBI_38010	"1029"	MONDO_0008383	"10039073"	"69896004"
ticarcillin	DB01607	Escherichia coli septicemia	C0276088		Approved			CHEBI_9587	"10591"			
ticarcillin	DB01607	Proteus septicemia	C0577690		Approved			CHEBI_9587	"10591"			
tiaprofenic acid	DB01600	Rheumatoid Arthritis	C0003873		Approved			CHEBI_32221	"38253"	MONDO_0008383	"10039073"	"69896004"
ticarcillin	DB01607	Pneumonia, Bacterial	C0004626		Approved			CHEBI_9587	"10591"	MONDO_0004652	"10060946"	"53084003"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT00075673	Terminated	Phase 1		CHEBI_480999	"39541"		"10006187"	"254837009"
bupivacaine	DB00297	Malignant neoplasm of breast	C0006142	NCT03388814	Withdrawn	Early Phase 1	Lack of Funding	CHEBI_77431	"1815"		"10006187"	"254837009"
ticarcillin	DB01607	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_9587	"10591"			"301011002"
ticarcillin	DB01607	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_9587	"10591"			"70036007"
ticarcillin	DB01607	Escherichia coli Infections	C0014836		Approved			CHEBI_9587	"10591"	MONDO_0020920		"71057007"
ticarcillin	DB01607	Staphylococcus aureus infection	C1318973		Approved			CHEBI_9587	"10591"			"406602003"
ticarcillin	DB01607	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_9587	"10591"			"186435004"
tigecycline	DB00560	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_149836	"384455"			"70036007"
levothyroxine	DB00451	Hashimoto Disease	C0677607		Approved			CHEBI_58448	"10582"	MONDO_0007699		"21983002"
ticarcillin	DB01607	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_9587	"10591"			"448417001"
ticarcillin	DB01607	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_9587	"10591"			"128945009"
ticarcillin	DB01607	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_9587	"10591"			"448813005"
ticarcillin	DB01607	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_9587	"10591"			"428783003"
tinidazole	DB00911	Acute amebiasis	C0152499		Approved			CHEBI_63627	"10612"			"39224005"
ticarcillin	DB01607	Sepsis caused by Gram negative bacteria	C3163829		Approved			CHEBI_9587	"10591"			"449082003"
tobramycin	DB00684	Escherichia coli septicemia	C0276088		Approved			CHEBI_28864	"10627"			
azathioprine	DB00993	Rheumatoid Arthritis	C0003873		Approved			CHEBI_2948	"1256"	MONDO_0008383	"10039073"	"69896004"
tiotropium bromide	DB01409	Asthma	C0004096		Approved			CHEBI_90960	"69120"	MONDO_0004979	"10003553"	"195967001"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00622466	Terminated	Phase 2	Study sponsor requested that the study be permanently closed by letter.	CHEBI_45863	"56946"		"10006187"	"254837009"
azatadine	DB00719	Common Cold	C0009443		Approved			CHEBI_2946	"18600"	MONDO_0005709		"82272006"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00448266	Terminated	Phase 2/Phase 3	Activation of a similar multicenter study for same population	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00448266	Terminated	Phase 2/Phase 3	Activation of a similar multicenter study for same population	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT00674414	Terminated	Phase 2	IDMC decision due to accrual issue (82 pts accrued / 120 expected)	CHEBI_68478	"141704"		"10006187"	"254837009"
azathioprine	DB00993	Ulcerative Colitis	C0009324		Approved			CHEBI_2948	"1256"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
tobramycin	DB00684	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_28864	"10627"			"186435004"
tobramycin	DB00684	Staphylococcus aureus infection	C1318973		Approved			CHEBI_28864	"10627"			"406602003"
tobramycin	DB00684	Escherichia coli Infections	C0014836		Approved			CHEBI_28864	"10627"	MONDO_0020920		"71057007"
tobramycin	DB00684	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_28864	"10627"			"301011002"
tobramycin	DB00684	Blepharoconjunctivitis	C0005743		Approved			CHEBI_28864	"10627"	MONDO_0002307		"68659002"
tirofiban	DB00775	Non-Q wave myocardial infarction	C0542269		Approved			CHEBI_9605	"73137"			"314207007"
tobramycin	DB00684	Anterior uveitis	C0042165		Approved			CHEBI_28864	"10627"	MONDO_0006651		"410692006"
tobramycin	DB00684	Keratoconjunctivitis	C0022573		Approved			CHEBI_28864	"10627"	MONDO_0004768		"88151007"
tobramycin	DB00684	Infective blepharitis	C0729587		Approved			CHEBI_28864	"10627"			"312219000"
tobramycin	DB00684	Hospital acquired pneumonia	C0949083		Approved			CHEBI_28864	"10627"			"425464007"
azathioprine	DB00993	Multiple Sclerosis, Acute Relapsing	C0393664		Approved			CHEBI_2948	"1256"			"230372003"
azathioprine	DB00993	Pemphigus Vulgaris	C0030809		Approved			CHEBI_2948	"1256"	MONDO_0008219		"49420001"
tobramycin	DB00684	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_28864	"10627"			"369001000119100"
tobramycin	DB00684	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_28864	"10627"			"128945009"
azathioprine	DB00993	Behcet Syndrome	C0004943		Approved			CHEBI_2948	"1256"	MONDO_0007191	"10004213"	"310701003"
tobramycin	DB00684	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_28864	"10627"			"448813005"
tizanidine	DB00697	Muscle spasticity of spinal origin	C1562430		Approved			CHEBI_63629	"57258"			"416830008"
tobramycin	DB00684	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_28864	"10627"			"428783003"
tolterodine	DB01036	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_9622	"119565"			
topiramate	DB00273	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_63631	"38404"	MONDO_0005754		
topiramate	DB00273	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_63631	"38404"			
tolmetin	DB00500	Rheumatoid Arthritis	C0003873		Approved			CHEBI_71941	"10636"	MONDO_0008383	"10039073"	"69896004"
azelaic acid	DB00548	Acne Vulgaris	C0001144		Approved			CHEBI_48131	"18602"			"88616000"
toloxatone	DB09245	Depressive disorder	C0011581		Approved			CHEBI_134870		MONDO_0002050		"35489007"
tranilast	DB07615	Asthma	C0004096		Approved			CHEBI_77572	"57330"	MONDO_0004979	"10003553"	"195967001"
triamcinolone	DB00620	Asthma	C0004096		Approved			CHEBI_9667	"10759"	MONDO_0004979	"10003553"	"195967001"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00674414	Terminated	Phase 2	IDMC decision due to accrual issue (82 pts accrued / 120 expected)		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT04102618	Terminated	Early Phase 1	Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT04102618	Terminated	Early Phase 1	Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT02725541	Withdrawn	Phase 2	loss of funding support		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
oxytocin	DB00107	Malignant neoplasm of breast	C0006142	NCT02127073	Suspended	Phase 2	Need funding and scientific collaborator	CHEBI_7872	"7824"		"10006187"	"254837009"
pregabalin	DB00230	Malignant neoplasm of breast	C0006142	NCT03407430	Terminated	Phase 2	Low patient accrual	CHEBI_64356	"187832"		"10006187"	"254837009"
	DB00399	Malignant neoplasm of breast	C0006142	NCT00301886	Withdrawn	Phase 3	withdrawn support for study	CHEBI_46557	"1546014|77655"		"10006187"	"254837009"
ibandronic acid	DB00710	Malignant neoplasm of breast	C0006142	NCT00301886	Withdrawn	Phase 3	withdrawn support for study		"115265|115264"		"10006187"	"254837009"
tretinoin	DB00755	Acne Vulgaris	C0001144		Approved			CHEBI_15367	"10753"			"88616000"
topotecan	DB01030	Malignant tumor of cervix	C0007847		Approved			CHEBI_63632	"57308"			"363354003"
torsemide	DB00214	Decompensated cardiac failure	C0581377		Approved			CHEBI_9637	"38413"			"195111005"
trandolapril	DB00519	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_9649	"38454"			"429589006"
trandolapril	DB14209	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_141521				"429589006"
azathioprine	DB00993	Chronic idiopathic thrombocytopenic purpura	C0272293		Approved			CHEBI_2948	"1256"			"13172003"
triamcinolone	DB00620	Autoimmune Diseases	C0004364		Approved			CHEBI_9667	"10759"	MONDO_0007179	"10061664"	"85828009"
triamcinolone	DB00620	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_9667	"10759"			"53891004"
triamcinolone	DB00620	Psoriasis of scalp	C0406326		Approved			CHEBI_9667	"10759"			"238608008"
triamcinolone	DB00620	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_9667	"10759"			"200965009"
triamcinolone	DB00620	Rheumatoid Arthritis	C0003873		Approved			CHEBI_9667	"10759"	MONDO_0008383	"10039073"	"69896004"
ropivacaine	DB00296	Malignant neoplasm of breast	C0006142	NCT02525211	Terminated	Phase 3	Recruitment defect	CHEBI_8890	"35780"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT03326674	Terminated	Phase 3	The Sponsor has discontinued the development of tesetaxel	CHEBI_31348	"194000"		"10006187"	"254837009"
triamcinolone	DB00620	Addison Disease	C0001403		Approved			CHEBI_9667	"10759"	MONDO_0015129	"10001130"	"373662000"
triamcinolone	DB00620	Tuberculosis, Miliary	C0041321		Approved			CHEBI_9667	"10759"	MONDO_0005848		"47604008"
triamcinolone	DB00620	Transplanted organ rejection	C0345468		Approved			CHEBI_9667	"10759"			"213148006"
triamcinolone	DB00620	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_9667	"10759"	MONDO_0015253		"88854002"
triamcinolone	DB00620	Arthritis, Psoriatic	C0003872		Approved			CHEBI_9667	"10759"	MONDO_0011849	"10037162"	"156370009"
triamcinolone	DB00620	Acquired thrombocytopenia	C0154301		Approved			CHEBI_9667	"10759"	MONDO_0001198		"154826009"
triamcinolone	DB00620	Mycosis Fungoides	C0026948		Approved			CHEBI_9667	"10759"	MONDO_0009691		"118618005"
triamcinolone	DB00620	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_9667	"10759"	MONDO_0000004		"386584007"
triamcinolone	DB00620	Adrenogenital disorder	C0701163		Approved			CHEBI_9667	"10759"			"267395000"
triamcinolone	DB00620	Berylliosis	C0005138		Approved			CHEBI_9667	"10759"		"10004485"	"8247009"
triamcinolone	DB00620	Subacute bursitis	C1290159		Approved			CHEBI_9667	"10759"	MONDO_0040698		"109298000"
triamcinolone	DB00620	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_9667	"10759"			"699262001"
triamcinolone	DB00620	Cerebral Edema	C0006114		Approved			CHEBI_9667	"10759"	HP:0002181		"2032001"
triamcinolone	DB00620	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_9667	"10759"	MONDO_0020108	"10073785"	"413603009"
triamcinolone	DB00620	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_9667	"10759"	MONDO_0018479		"237751000"
triamcinolone	DB00620	Alopecia Areata	C0002171		Approved			CHEBI_9667	"10759"	MONDO_0005340	"10001761"	"68225006"
triamcinolone acetonide	DB00620	Psoriasis of scalp	C0406326		Approved			CHEBI_9667	"10759"			"238608008"
triamcinolone acetonide	DB00620	Rheumatoid Arthritis	C0003873		Approved			CHEBI_9667	"10759"	MONDO_0008383	"10039073"	"69896004"
triamcinolone acetonide	DB00620	Asthma	C0004096		Approved			CHEBI_9667	"10759"	MONDO_0004979	"10003553"	"195967001"
triamcinolone acetonide	DB00620	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_9667	"10759"			"53891004"
triamcinolone acetonide	DB00620	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_9667	"10759"			"200965009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00074139	Withdrawn	Phase 1	No patients were enrolled	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00074139	Withdrawn	Phase 1	No patients were enrolled	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT00074139	Withdrawn	Phase 1	No patients were enrolled	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
triamcinolone acetonide	DB00620	Transplanted organ rejection	C0345468		Approved			CHEBI_9667	"10759"			"213148006"
triamcinolone acetonide	DB00620	Arthritis, Psoriatic	C0003872		Approved			CHEBI_9667	"10759"	MONDO_0011849	"10037162"	"156370009"
triamcinolone acetonide	DB00620	Acquired thrombocytopenia	C0154301		Approved			CHEBI_9667	"10759"	MONDO_0001198		"154826009"
triamcinolone acetonide	DB00620	Mycosis Fungoides	C0026948		Approved			CHEBI_9667	"10759"	MONDO_0009691		"118618005"
triamcinolone acetonide	DB00620	Adrenogenital disorder	C0701163		Approved			CHEBI_9667	"10759"			"267395000"
triamcinolone acetonide	DB00620	Berylliosis	C0005138		Approved			CHEBI_9667	"10759"		"10004485"	"8247009"
triamcinolone acetonide	DB00620	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_9667	"10759"			"699262001"
triamcinolone acetonide	DB00620	Autoimmune Diseases	C0004364		Approved			CHEBI_9667	"10759"	MONDO_0007179	"10061664"	"85828009"
triamcinolone acetonide	DB00620	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_9667	"10759"	MONDO_0020108	"10073785"	"413603009"
triamcinolone acetonide	DB00620	Alopecia Areata	C0002171		Approved			CHEBI_9667	"10759"	MONDO_0005340	"10001761"	"68225006"
triamcinolone diacetate	DB00620	Asthma	C0004096		Approved			CHEBI_9667	"10759"	MONDO_0004979	"10003553"	"195967001"
triamcinolone diacetate	DB00620	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_9667	"10759"			"200965009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00002772	Terminated	Phase 3	poor accrual	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00002772	Terminated	Phase 3	poor accrual	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00262	Malignant neoplasm of breast	C0006142	NCT00002772	Terminated	Phase 3	poor accrual	CHEBI_3423	"2105"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00002772	Terminated	Phase 3	poor accrual	CHEBI_31355	"40048"		"10006187"	"254837009"
triamcinolone diacetate	DB00620	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_9667	"10759"			"53891004"
triamcinolone diacetate	DB00620	Addison Disease	C0001403		Approved			CHEBI_9667	"10759"	MONDO_0015129	"10001130"	"373662000"
triamcinolone diacetate	DB00620	Tuberculosis, Miliary	C0041321		Approved			CHEBI_9667	"10759"	MONDO_0005848		"47604008"
triamcinolone diacetate	DB00620	Transplanted organ rejection	C0345468		Approved			CHEBI_9667	"10759"			"213148006"
triamcinolone diacetate	DB00620	Acquired thrombocytopenia	C0154301		Approved			CHEBI_9667	"10759"	MONDO_0001198		"154826009"
triamcinolone diacetate	DB00620	Arthritis, Psoriatic	C0003872		Approved			CHEBI_9667	"10759"	MONDO_0011849	"10037162"	"156370009"
triamcinolone diacetate	DB00620	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_9667	"10759"	MONDO_0015253		"88854002"
triamcinolone acetonide	DB00620	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_9667	"10759"	MONDO_0000004		"386584007"
triamcinolone diacetate	DB00620	Adrenogenital disorder	C0701163		Approved			CHEBI_9667	"10759"			"267395000"
triamcinolone diacetate	DB00620	Berylliosis	C0005138		Approved			CHEBI_9667	"10759"		"10004485"	"8247009"
triamcinolone acetonide	DB00620	Subacute bursitis	C1290159		Approved			CHEBI_9667	"10759"	MONDO_0040698		"109298000"
triamcinolone diacetate	DB00620	Autoimmune Diseases	C0004364		Approved			CHEBI_9667	"10759"	MONDO_0007179	"10061664"	"85828009"
triamcinolone diacetate	DB00620	Subacute bursitis	C1290159		Approved			CHEBI_9667	"10759"	MONDO_0040698		"109298000"
triamcinolone diacetate	DB00620	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_9667	"10759"			"699262001"
triamcinolone diacetate	DB00620	Alopecia Areata	C0002171		Approved			CHEBI_9667	"10759"	MONDO_0005340	"10001761"	"68225006"
triamcinolone diacetate	DB00620	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_9667	"10759"	MONDO_0018479		"237751000"
triamcinolone diacetate	DB00620	Rheumatoid Arthritis	C0003873		Approved			CHEBI_9667	"10759"	MONDO_0008383	"10039073"	"69896004"
	DB04572	Malignant neoplasm of breast	C0006142	NCT00002772	Terminated	Phase 3	poor accrual	CHEBI_9570	"10473"		"10006187"	"254837009"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT01005641	Withdrawn	Phase 2	Study not started for administrative reasons	CHEBI_49603	"480167"		"10006187"	"254837009"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00397761	Withdrawn	Phase 2/Phase 3		CHEBI_31348	"194000"		"10006187"	"254837009"
trientine	DB06824	Psoriasis of scalp	C0406326		Approved			CHEBI_39501	"10798"			"238608008"
trientine	DB06824	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_39501	"10798"			"200965009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00397761	Withdrawn	Phase 2/Phase 3		CHEBI_45863	"56946"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00852332	Terminated	Phase 2	The trial was stopped for futility in view of the results of the anticipated analysis	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB01269	Malignant neoplasm of breast	C0006142	NCT01009983	Terminated	Phase 2	Slow accrual		"263034"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT01009983	Terminated	Phase 2	Slow accrual	CHEBI_31355	"40048"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01009983	Terminated	Phase 2	Slow accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00101062	Terminated	Phase 2	study drug unavailable	CHEBI_6413	"72965"		"10006187"	"254837009"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT02213744	Terminated	Phase 2/Phase 3	Felt not to show benefit over control per DMC and confirmed via futility analysis	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB01101	Malignant neoplasm of breast	C0006142	NCT02213744	Terminated	Phase 2/Phase 3	Felt not to show benefit over control per DMC and confirmed via futility analysis	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT02213744	Terminated	Phase 2/Phase 3	Felt not to show benefit over control per DMC and confirmed via futility analysis		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00824733	Terminated	Phase 2	Inaccurate patient accrual for trial		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
trimethoprim	DB00440	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_45924	"10829"			"301011002"
trifluridine	DB00432	Herpes simplex keratoconjunctivitis	C0276228		Approved			CHEBI_75179	"10803"			"72321008"
trilostane	DB01108	Adrenal Gland Hyperfunction	C0001622		Approved			CHEBI_32260	"38668"	MONDO_0006640|MONDO_0018912	"10020564"	"47270006"
trimethoprim	DB00440	Blepharoconjunctivitis	C0005743		Approved			CHEBI_45924	"10829"	MONDO_0002307		"68659002"
triamcinolone diacetate	DB00620	Mycosis Fungoides	C0026948		Approved			CHEBI_9667	"10759"	MONDO_0009691		"118618005"
trimethoprim	DB00440	Infective otitis media	C0729586		Approved			CHEBI_45924	"10829"			"312218008"
azithromycin	DB00207	Pneumonia, Bacterial	C0004626		Approved			CHEBI_2955	"18631"	MONDO_0004652	"10060946"	"53084003"
trimipramine	DB00726	Depressive disorder	C0011581		Approved			CHEBI_9738	"10834"	MONDO_0002050		"35489007"
azithromycin	DB00207	Infective otitis media	C0729586		Approved			CHEBI_2955	"18631"			"312218008"
azithromycin	DB00207	Group A Streptococcal Infections	C0554628		Approved			CHEBI_2955	"18631"			"302809008"
azithromycin	DB00207	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_2955	"18631"	MONDO_0001080		"20943002"
azithromycin	DB00207	Staphylococcus aureus infection	C1318973		Approved			CHEBI_2955	"18631"			"406602003"
azithromycin	DB00207	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_2955	"18631"			"70036007"
tamoxifen	DB00675	Malignant neoplasm of breast	C0006142	NCT05128773	Terminated	Phase 3	Sponsor decision to prematurely stop the study, not linked to any safety concern	CHEBI_41774	"10324"		"10006187"	"254837009"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT00217659	Withdrawn	Phase 2	poor accrual	CHEBI_5523	"50610"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00589238	Terminated	Phase 2		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00589238	Terminated	Phase 2		CHEBI_28748	"142433|3639"		"10006187"	"254837009"
bevacizumab	DB00112	Malignant neoplasm of breast	C0006142	NCT05359874	Withdrawn	Phase 2	application has been withdrawn		"253337|2046138"		"10006187"	"254837009"
dexamethasone phosphate	DB00531	Malignant neoplasm of breast	C0006142	NCT00832338	Terminated	Phase 2	Funding withdrawn	CHEBI_68637	"1545988|3002"		"10006187"	"254837009"
	DB01234	Malignant neoplasm of breast	C0006142	NCT00832338	Terminated	Phase 2	Funding withdrawn	CHEBI_41879	"3264"		"10006187"	"254837009"
triprolidine	DB00427	Common Cold	C0009443		Approved			CHEBI_84116	"10849"	MONDO_0005709		"82272006"
azlocillin	DB01061	Bacterial sepsis	C0684256		Approved			CHEBI_2956	"1266"		"10053840"	"10001005"
azlocillin	DB01061	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_2956	"1266"			"70036007"
azlocillin	DB01061	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_2956	"1266"			"186435004"
azithromycin	DB00207	Blepharitis	C0005741		Approved			CHEBI_2955	"18631"	MONDO_0004785	"10005148"	"1231722004"
azlocillin	DB01061	Arthropathy associated with infection	C0157749		Approved			CHEBI_2956	"1266"			"363162000"
azithromycin	DB00207	Pelvic inflammatory disease due to Mycoplasma hominis	C1261256		Approved			CHEBI_2955	"18631"			"270550006"
azithromycin	DB00207	Pulmonary Mycobacterium avium complex infection	C2733595		Approved			CHEBI_2955	"18631"			"186342000"
azithromycin	DB00207	Pneumonia due to Staphylococcus aureus	C2349530		Approved			CHEBI_2955	"18631"			"441658007"
azithromycin	DB00207	Acute bacterial bronchitis	C0339933		Approved			CHEBI_2955	"18631"			"233598009"
trospium	DB00209	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_145791	"236778"			
tulobuterol	DB12248	Asthma	C0004096		Approved			CHEBI_93856	"38967"	MONDO_0004979	"10003553"	"195967001"
aztreonam	DB00355	Escherichia coli septicemia	C0276088		Approved			CHEBI_161680	"1272"			
aztreonam	DB00355	Proteus septicemia	C0577690		Approved			CHEBI_161680	"1272"			
trovafloxacin	DB00685	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_9763	"115552"			"70036007"
uracil mustard	DB00791	Myeloid Leukemia, Chronic	C0023473		Approved			CHEBI_9884	"10996"	MONDO_0011996		
trovafloxacin	DB00685	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_9763	"115552"			"186435004"
trovafloxacin	DB00685	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_9763	"115552"	MONDO_0001080		"20943002"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00832338	Terminated	Phase 2	Funding withdrawn	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00004935	Terminated	Phase 3	Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
aztreonam	DB00355	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_161680	"1272"			"186435004"
aztreonam	DB00355	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_161680	"1272"			"70036007"
aztreonam	DB00355	Escherichia coli Infections	C0014836		Approved			CHEBI_161680	"1272"	MONDO_0020920		"71057007"
aztreonam	DB00355	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_161680	"1272"			"301011002"
trovafloxacin	DB00685	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_9763	"115552"	MONDO_0040732		"11218009"
aztreonam	DB00355	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_161680	"1272"	MONDO_0040732		"11218009"
trovafloxacin	DB00685	Female genital tract infection	C1263758		Approved			CHEBI_9763	"115552"			"125585007"
trovafloxacin	DB00685	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_9763	"115552"			"195722003"
aztreonam	DB00355	Female genital tract infection	C1263758		Approved			CHEBI_161680	"1272"			"125585007"
trovafloxacin	DB00685	Endomyometritis	C0269050		Approved			CHEBI_9763	"115552"			"88027004"
trovafloxacin	DB00685	Postnatal infection	C1278797		Approved			CHEBI_9763	"115552"			"178280004"
trovafloxacin	DB00685	Postoperative infection	C0392618		Approved			CHEBI_9763	"115552"			"33910007"
trovafloxacin	DB00685	Acute bacterial bronchitis	C0339933		Approved			CHEBI_9763	"115552"			"233598009"
aztreonam	DB00355	Proteus urinary tract infection	C0577709		Approved			CHEBI_161680	"1272"			"301012009"
trovafloxacin	DB00685	Miscarriage with sepsis	C0269398		Approved			CHEBI_9763	"115552"			"67465009"
trovafloxacin	DB00685	Acute gonococcal endometritis	C0153196		Approved			CHEBI_9763	"115552"	MONDO_0004264		"65295003"
trovafloxacin	DB00685	Acute gonococcal urethritis	C0275652		Approved			CHEBI_9763	"115552"			"29864006"
valproic acid	DB00313	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_39867	"11118|40254"			
vancomycin	DB00512	Enterocolitis, Pseudomembranous	C0014358		Approved			CHEBI_28001	"11124"			
bacampicillin	DB01602	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_2968	"18687"			"70036007"
bacampicillin	DB01602	Infective otitis media	C0729586		Approved			CHEBI_2968	"18687"			"312218008"
vigabatrin	DB01080	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_63638	"14851"			
verapamil	DB00661	Atrial Fibrillation	C0004238		Approved			CHEBI_77733	"11170"	MONDO_0004981	"10003658"	"49436004"
etoposide	DB00773	Malignant neoplasm of breast	C0006142	NCT00006032	Terminated	Phase 2	low accrual	CHEBI_4911	"4179"		"10006187"	"254837009"
vancomycin	DB00512	Staphylococcus aureus infection	C1318973		Approved			CHEBI_28001	"11124"			"406602003"
	DB01181	Malignant neoplasm of breast	C0006142	NCT00006032	Terminated	Phase 2	low accrual	CHEBI_5864	"5657"		"10006187"	"254837009"
	DB01030	Malignant neoplasm of breast	C0006142	NCT00006032	Terminated	Phase 2	low accrual	CHEBI_63632	"57308"		"10006187"	"254837009"
vancomycin	DB00512	Arthropathy associated with infection	C0157749		Approved			CHEBI_28001	"11124"			"363162000"
bacitracin	DB00626	Blepharoconjunctivitis	C0005743		Approved			CHEBI_184381	"1291|1986366"	MONDO_0002307		"68659002"
valaciclovir	DB00577	Chickenpox	C0008049		Approved			CHEBI_35854	"73645"	MONDO_0005700	"10046980"	"38907003"
vasopressin	DB00067	Hemophilia A	C0019069		Approved			CHEBI_9937	"11149"	MONDO_0010602		"28293008"
vidarabine	DB00194	Keratitis, Dendritic	C0022570		Approved			CHEBI_45327	"11194"			"29943008"
verapamil	DB00661	Angina Pectoris, Variant	C0002963		Approved			CHEBI_77733	"11170"	MONDO_0006021	"10036759"	"87343002"
bacitracin	DB00626	Infective blepharitis	C0729587		Approved			CHEBI_184381	"1291|1986366"			"312219000"
verteporfin	DB00460	Ocular histoplasmosis syndrome	C1562543		Approved			CHEBI_32293	"118886"			"416770009"
valproic acid	DB00313	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_39867	"11118|40254"			"191618007"
valdecoxib	DB00580	Postoperative Pain, Acute	C2215257		Approved			CHEBI_63634	"278567"			"107401000119105"
valrubicin	DB00385	Malignant neoplasm of urinary bladder	C0005684		Approved			CHEBI_135876	"31435"	MONDO_0001187	"10005003"	"399326009"
valsartan	DB00177	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_9927	"69749"			"429589006"
valaciclovir	DB00577	Herpes Labialis	C0019345		Approved			CHEBI_35854	"73645"	MONDO_0043653		"1475003"
vancomycin	DB00512	Staphylococcal enterocolitis	C0038157		Approved			CHEBI_28001	"11124"			"32527003"
vancomycin	DB00512	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_28001	"11124"			"428783003"
verteporfin	DB00460	Choroidal retinal neovascularization	C0271066		Approved			CHEBI_32293	"118886"			"75971007"
vindesine	DB00309	Myeloid Leukemia, Chronic	C0023473		Approved			CHEBI_36373	"11204"	MONDO_0011996		
	DB00531	Malignant neoplasm of breast	C0006142	NCT03285607	Withdrawn	Phase 1	Drug provider decided not to move forward with the study.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT03285607	Withdrawn	Phase 1	Drug provider decided not to move forward with the study.	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00253318	Terminated	Phase 1	Toxicity and Lack of Efficacy	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB01234	Malignant neoplasm of breast	C0006142	NCT00253318	Terminated	Phase 1	Toxicity and Lack of Efficacy	CHEBI_41879	"3264"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT00253318	Terminated	Phase 1	Toxicity and Lack of Efficacy	CHEBI_68478	"141704"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT04762901	Withdrawn	Phase 1	Funding was terminated.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT04762901	Withdrawn	Phase 1	Funding was terminated.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT04762901	Withdrawn	Phase 1	Funding was terminated.	CHEBI_31355	"40048"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT04762901	Withdrawn	Phase 1	Funding was terminated.	CHEBI_45863	"56946"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT02340221	Terminated	Phase 3	The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.	CHEBI_31638	"282357"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT02236572	Terminated	Phase 2	Phase 2 of recruitment was contingent on 5 of 15 patients responding, which did not occur.	CHEBI_68478	"141704"		"10006187"	"254837009"
ergocalciferol	DB00153	Vitamin D-Resistant Rickets, X-Linked	C3536984		Approved			CHEBI_28934	"4018"			"82236004"
ergocalciferol	DB11094	Vitamin D-Resistant Rickets, X-Linked	C3536984		Approved			CHEBI_28934	"11253"			"82236004"
viloxazine	DB09185	Narcolepsy-Cataplexy Syndrome	C0751362		Approved			CHEBI_94405	"11196"			"193042000"
vinblastine	DB00570	Malignant epithelial neoplasm of female breast	C3163805		Approved			CHEBI_27375	"11198"			"447782002"
vinblastine	DB00570	Mycosis Fungoides	C0026948		Approved			CHEBI_27375	"11198"	MONDO_0009691		"118618005"
thiamine	DB00152	Anemia, Pernicious	C0002892		Approved			CHEBI_18385	"10454"	MONDO_0008228	"10034695"	"84027009"
vinblastine	DB00570	Letterer-Siwe Disease	C0023381		Approved			CHEBI_27375	"11198"	MONDO_0009519		"118614007"
pyridoxine	DB00165	Breastfeeding (mother)	C1623040		Approved			CHEBI_16709	"42954|684879"			"413712001"
nicotinic acid	DB00627	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_15940	"7393"			"238079002"
baclofen	DB00181	Muscle spasticity of spinal origin	C1562430		Approved			CHEBI_2972	"1292"			"416830008"
zafirlukast	DB00549	Asthma	C0004096		Approved			CHEBI_10100	"114970"	MONDO_0004979	"10003553"	"195967001"
beclometasone dipropionate	DB00394	Asthma	C0004096		Approved			CHEBI_3002	"1348"	MONDO_0004979	"10003553"	"195967001"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00684216	Terminated	Phase 2/Phase 3	acrual too slow	CHEBI_2704	"84857"		"10006187"	"254837009"
	DB00675	Malignant neoplasm of breast	C0006142	NCT00684216	Terminated	Phase 2/Phase 3	acrual too slow	CHEBI_41774	"10324"		"10006187"	"254837009"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00684216	Terminated	Phase 2/Phase 3	acrual too slow	CHEBI_31348	"194000"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00461773	Terminated	Phase 2	Lack of recrual	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT03058939	Withdrawn	Phase 2	Study never activated to enrollment.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00461773	Terminated	Phase 2	Lack of recrual		"253337|2046138"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00532285	Terminated	Phase 2	terminated	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT01254136	Terminated	Phase 1/Phase 2	Incyte has suspended development of the compound.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00651976	Terminated	Early Phase 1	funding unavailable	CHEBI_6413	"72965"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00138125	Terminated	Phase 2	Due to low accrual	CHEBI_31638	"282357"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00138125	Terminated	Phase 2	Due to low accrual		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02929576	Withdrawn	Phase 3	Further understanding about the role of androgen signaling in TNBC was required	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00935558	Withdrawn	Phase 2	no patients enrolled	CHEBI_2704	"84857"		"10006187"	"254837009"
voriconazole	DB00582	Candidemia	C0877445		Approved			CHEBI_10023	"121243"	MONDO_0044070		"432261003"
ziconotide	DB06283	Severe pain	C0278140		Approved			CHEBI_142406	"68503"			"76948002"
ziprasidone	DB00246	Bipolar disorder in remission	C0270425		Approved			CHEBI_10119	"115698"			"85248005"
zaleplon	DB00962	Sleep Initiation and Maintenance Disorders	C0021603		Approved			CHEBI_10102	"74667"			"194437008"
ziprasidone	DB00246	Mixed bipolar I disorder	C0236780		Approved			CHEBI_10119	"115698"			"16506000"
zileuton	DB00744	Intrinsic asthma	C0155880		Approved			CHEBI_10112	"40575"	MONDO_0004765		"266361008"
gonadorelin	DB00644	Amenorrhea	C0002453		Approved			CHEBI_5520	"6384"	MONDO_0001836	"10001928"	"14302001"
ziprasidone	DB00246	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_10119	"115698"			"191618007"
zileuton	DB00744	Allergic asthma	C0155877		Approved			CHEBI_10112	"40575"	MONDO_0004784		"389145006"
butacaine	DB11502	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_94820	"1829"			
benoxaprofen	DB04812	Rheumatoid Arthritis	C0003873		Approved			CHEBI_76114		MONDO_0008383	"10039073"	"69896004"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00935558	Withdrawn	Phase 2	no patients enrolled	CHEBI_6413	"72965"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00162812	Terminated	Phase 2	Low accrual rate	CHEBI_47898	"3995"		"10006187"	"254837009"
naltrexone	DB00704	Malignant neoplasm of breast	C0006142	NCT00379197	Terminated	Phase 2	slow accrual	CHEBI_7465	"7243"		"10006187"	"254837009"
bevacizumab	DB00112	Malignant neoplasm of breast	C0006142	NCT01200212	Terminated	Phase 3	A planed interim analysis shows no benefits, but higher adverse event rates for the experimental arm.		"253337|2046138"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02685306	Withdrawn	Phase 2		CHEBI_45863	"56946"		"10006187"	"254837009"
desonide	DB01260	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_204734	"3254"			"200965009"
caspofungin	DB00520	Candidemia	C0877445		Approved			CHEBI_474180	"140108"	MONDO_0044070		"432261003"
cholic acid	DB02659	Incomplete passage of stool	C0426639		Approved			CHEBI_16359	"1440856"			"249515001"
deferasirox	DB01609	beta Thalassemia	C0005283		Approved			CHEBI_49005	"614373"		"10043391"	"65959000"
fusidic acid	DB02703	Brill-Zinsser Disease	C0006181		Approved			CHEBI_29013	"4608|113608"	MONDO_0005680	"10038017"	"47761007"
pyrantel	DB11156	Ascariasis	C0003950		Approved			CHEBI_8654	"8984"	MONDO_0005654	"10003442"	"2435008"
glucagon	DB00040	Hypoglycemia due to diabetes mellitus	C0342313		Approved			CHEBI_5391	"4832|261716"			"237633009"
capreomycin	DB00314	Acute tuberculosis	C0275959		Approved			CHEBI_3371	"78903"			"25629007"
cholic acid	DB02659	Xanthomatosis, Cerebrotendinous	C0238052		Approved			CHEBI_16359	"1440856"	MONDO_0008948		"63246000"
butacaine	DB11502	Neurogenic Urinary Bladder	C0005697		Approved			CHEBI_94820	"1829"	MONDO_0001445	"10029279"	"398064005"
benfluorex	DB09022	Type 2 diabetes mellitus in obese	C0271638		Approved			CHEBI_93826	"18880"			"81531005"
mifamurtide	DB13615	Osteosarcoma of bone	C0585442		Approved			CHEBI_135906				"307576001"
pyrantel	DB11156	Mixed intestinal helminthiasis	C0153303		Approved			CHEBI_8654	"8984"			"90679001"
levosalbutamol	DB13139	Bronchospasm	C0006266		Approved			CHEBI_8746	"237159"	HP:0025428	"10006482"	"4386001"
carbarsone	DB11382	Acute amebiasis	C0152499		Approved			CHEBI_94806				"39224005"
dimercaprol	DB06782	Accidental poisoning by lead and its compounds and fumes	C0261486		Approved			CHEBI_64198	"3445"			
desonide	DB01260	Asthma	C0004096		Approved			CHEBI_204734	"3254"	MONDO_0004979	"10003553"	"195967001"
desonide	DB01260	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_204734	"3254"			"53891004"
desonide	DB01260	Psoriasis of scalp	C0406326		Approved			CHEBI_204734	"3254"			"238608008"
estrone	DB00655	Acne Vulgaris	C0001144		Approved			CHEBI_17263	"4103"			"88616000"
norepinephrine	DB00368	Bronchiectasis	C0006267		Approved			CHEBI_18357	"7512"	MONDO_0004822	"10006445"	"12295008"
formoterol	DB00983	Bronchiectasis	C0006267	NCT03846570	Terminated	Phase 3	Insufficient inclusion rate (due to COVID-19 pandemic)	CHEBI_63082	"25255"	MONDO_0004822	"10006445"	"12295008"
benzoyl peroxide	DB09096	Acne Vulgaris	C0001144		Approved			CHEBI_82405	"1418"			"88616000"
epinephrine	DB00668	Bronchiectasis	C0006267		Approved			CHEBI_28918	"3992"	MONDO_0004822	"10006445"	"12295008"
azithromycin	DB00207	Bronchiectasis	C0006267	NCT00524095	Terminated	Phase 2	we decided not to go on treatment phase	CHEBI_2955	"18631"	MONDO_0004822	"10006445"	"12295008"
pirbuterol	DB01291	Bronchiectasis	C0006267		Approved			CHEBI_8245	"33767"	MONDO_0004822	"10006445"	"12295008"
benzquinamide	DB00767	Postoperative Nausea and Vomiting	C0520909		Approved			CHEBI_27662	"19041"			"1488000"
dimercaprol	DB06782	Arsenic Poisoning	C0311375		Approved			CHEBI_64198	"3445"			"767146004"
hexamidine	DB03808	Acanthamoeba Keratitis	C0000880		Approved			CHEBI_87184	"26849"	MONDO_0005629	"10069408"	"231896005"
eicosapentaenoic acid	DB00159	Breastfeeding (mother)	C1623040		Approved			CHEBI_28364	"90"			"413712001"
hematoporphyrin	DB16183	Malignant neoplasm of esophagus	C0546837		Approved			CHEBI_36162	"5164"			"363402007"
ephedrine	DB01364	Bronchospasm	C0006266		Approved			CHEBI_15407	"3966"	HP:0025428	"10006482"	"4386001"
salbutamol	DB01001	Bronchospasm	C0006266		Approved			CHEBI_2549	"435"	HP:0025428	"10006482"	"4386001"
ipratropium	DB00332	Bronchospasm	C0006266		Approved			CHEBI_46659	"1546373|203212|7213"	HP:0025428	"10006482"	"4386001"
theophylline	DB00277	Bronchospasm	C0006266		Approved			CHEBI_28177	"10438|91178"	HP:0025428	"10006482"	"4386001"
theophylline	DB01223	Bronchospasm	C0006266		Approved			CHEBI_2659	"689"	HP:0025428	"10006482"	"4386001"
salbutamol	DB01001	Bronchospasm	C0006266	NCT00634829	Terminated	Phase 3	IND voluntarily withdrawn, without prejudice	CHEBI_2549	"435"	HP:0025428	"10006482"	"4386001"
diprophylline	DB00651	Bronchospasm	C0006266		Approved			CHEBI_4728	"3714"	HP:0025428	"10006482"	"4386001"
lodoxamide	DB06794	Conjunctivitis, Vernal	C0009773		Approved			CHEBI_135333	"52151"	MONDO_0002313		"318316003"
desonide	DB01260	Crohn's disease in remission	C1960764		Approved			CHEBI_204734	"3254"			"426549001"
estrone	DB00655	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_17263	"4103"			"18846006"
benzatropine	DB00245	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_3048	"1424"	MONDO_0001945		"19972008"
meclocycline	DB13092	Acne Vulgaris	C0001144		Approved			CHEBI_135772	"29418"			"88616000"
meclocycline	DB13092	Staphylococcus aureus infection	C1318973		Approved			CHEBI_135772	"29418"			"406602003"
meclocycline	DB13092	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_135772	"29418"	MONDO_0001080		"20943002"
meclocycline	DB13092	Infective otitis media	C0729586		Approved			CHEBI_135772	"29418"			"312218008"
pirbuterol	DB01291	Bronchitis	C0006277		Approved			CHEBI_8245	"33767"	MONDO_0003781	"10006451"	"32398004"
tetracycline	DB00759	Bronchitis	C0006277		Approved			CHEBI_27902	"10395"	MONDO_0003781	"10006451"	"32398004"
theophylline	DB01223	Bronchitis	C0006277		Approved			CHEBI_2659	"689"	MONDO_0003781	"10006451"	"32398004"
epinephrine	DB00668	Bronchitis	C0006277		Approved			CHEBI_28918	"3992"	MONDO_0003781	"10006451"	"32398004"
amphotericin B	DB00681	Bronchitis	C0006277		Approved			CHEBI_2682	"236594|732"	MONDO_0003781	"10006451"	"32398004"
tetracycline	DB09550	Bronchitis	C0006277		Approved			CHEBI_27902	"2105975"	MONDO_0003781	"10006451"	"32398004"
oxytetracycline	DB00595	Bronchitis	C0006277		Approved			CHEBI_133011	"7821|1545999"	MONDO_0003781	"10006451"	"32398004"
theophylline	DB00277	Bronchitis	C0006277		Approved			CHEBI_28177	"10438|91178"	MONDO_0003781	"10006451"	"32398004"
noxytiolin	DB13838	Infective cystitis	C0600041		Approved			CHEBI_134756	"7543"			"236620008"
betaine	DB06756	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_17750	"350374|1512"			"301011002"
betaine	DB06756	Infective cystitis	C0600041		Approved			CHEBI_17750	"350374|1512"			"236620008"
meclocycline	DB13092	Actinomycosis	C0001261		Approved			CHEBI_135772	"29418"	MONDO_0005631	"10000620"	"11817007"
meclocycline	DB13092	Anthrax disease	C0003175		Approved			CHEBI_135772	"29418"	MONDO_0005119	"10002713"	"409498004"
methyltestosterone	DB06710	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_27436	"6904"			"417181009"
meclocycline	DB13092	Gonorrhea of pharynx	C0149966		Approved			CHEBI_135772	"29418"			"74372003"
meclocycline	DB13092	Acute gonococcal endometritis	C0153196		Approved			CHEBI_135772	"29418"	MONDO_0004264		"65295003"
meclocycline	DB13092	Acute gonococcal urethritis	C0275652		Approved			CHEBI_135772	"29418"			"29864006"
betaine	DB06756	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_17750	"350374|1512"			"369001000119100"
meclocycline	DB13092	Acute bacterial sinusitis	C0275556		Approved			CHEBI_135772	"29418"			"75498004"
betamethasone	DB00443	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_3077	"1514"			"200965009"
betamethasone	DB00443	Rheumatoid Arthritis	C0003873		Approved			CHEBI_3077	"1514"	MONDO_0008383	"10039073"	"69896004"
betamethasone	DB00443	Asthma	C0004096		Approved			CHEBI_3077	"1514"	MONDO_0004979	"10003553"	"195967001"
lomefloxacin	DB00978	Bronchitis	C0006277		Approved			CHEBI_116278	"28872"	MONDO_0003781	"10006451"	"32398004"
betamethasone	DB00443	Psoriasis of scalp	C0406326		Approved			CHEBI_3077	"1514"			"238608008"
betamethasone	DB00443	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_3077	"1514"			"53891004"
ephedrine	DB01364	Bronchitis	C0006277		Approved			CHEBI_15407	"3966"	MONDO_0003781	"10006451"	"32398004"
orciprenaline	DB00816	Bronchitis	C0006277		Approved			CHEBI_83329	"7688"	MONDO_0003781	"10006451"	"32398004"
betamethasone	DB00443	Transplanted organ rejection	C0345468		Approved			CHEBI_3077	"1514"			"213148006"
betamethasone	DB00443	Addison Disease	C0001403		Approved			CHEBI_3077	"1514"	MONDO_0015129	"10001130"	"373662000"
betamethasone	DB00443	Tuberculosis, Miliary	C0041321		Approved			CHEBI_3077	"1514"	MONDO_0005848		"47604008"
betamethasone	DB00443	Arthritis, Psoriatic	C0003872		Approved			CHEBI_3077	"1514"	MONDO_0011849	"10037162"	"156370009"
betamethasone	DB00443	Acquired thrombocytopenia	C0154301		Approved			CHEBI_3077	"1514"	MONDO_0001198		"154826009"
betamethasone	DB00443	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_3077	"1514"	MONDO_0015253		"88854002"
betamethasone	DB00443	Mycosis Fungoides	C0026948		Approved			CHEBI_3077	"1514"	MONDO_0009691		"118618005"
betamethasone	DB00443	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_3077	"1514"	MONDO_0000004		"386584007"
betamethasone	DB00443	Adrenogenital disorder	C0701163		Approved			CHEBI_3077	"1514"			"267395000"
betamethasone	DB00443	Scalp Dermatoses	C0036271		Approved			CHEBI_3077	"1514"	MONDO_0006605		"402694007"
betamethasone	DB00443	Berylliosis	C0005138		Approved			CHEBI_3077	"1514"		"10004485"	"8247009"
betamethasone	DB00443	Autoimmune Diseases	C0004364		Approved			CHEBI_3077	"1514"	MONDO_0007179	"10061664"	"85828009"
betamethasone	DB00443	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_3077	"1514"			"699262001"
betamethasone	DB00443	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_3077	"1514"	MONDO_0020108	"10073785"	"413603009"
betamethasone	DB00443	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_3077	"1514"	MONDO_0018479		"237751000"
betamethasone acetate	DB00443	Rheumatoid Arthritis	C0003873		Approved			CHEBI_3077	"1514"	MONDO_0008383	"10039073"	"69896004"
betamethasone acetate	DB00443	Asthma	C0004096		Approved			CHEBI_3077	"1514"	MONDO_0004979	"10003553"	"195967001"
sulfogaiacol	DB15992	Common Cold	C0009443		Approved			CHEBI_85537		MONDO_0005709		"82272006"
fusidic acid	DB02703	Bronchitis	C0006277		Approved			CHEBI_29013	"4608|113608"	MONDO_0003781	"10006451"	"32398004"
norepinephrine	DB00368	Bronchitis	C0006277		Approved			CHEBI_18357	"7512"	MONDO_0003781	"10006451"	"32398004"
meclocycline	DB13092	Bronchitis	C0006277		Approved			CHEBI_135772	"29418"	MONDO_0003781	"10006451"	"32398004"
sulfogaiacol	DB13735	Common Cold	C0009443		Approved			CHEBI_85537		MONDO_0005709		"82272006"
terbutaline	DB00871	Bronchitis	C0006277		Approved			CHEBI_9449	"10368"	MONDO_0003781	"10006451"	"32398004"
pramocaine	DB09345	Arthropod bite wound	C1444173		Approved			CHEBI_8357	"34347"			"409985002"
ipratropium	DB00332	Bronchitis	C0006277		Approved			CHEBI_46659	"1546373|203212|7213"	MONDO_0003781	"10006451"	"32398004"
minocycline	DB01017	Bronchitis	C0006277		Approved			CHEBI_50694	"6980"	MONDO_0003781	"10006451"	"32398004"
posaconazole	DB01263	Aspergillosis	C0004030		Approved			CHEBI_64355	"282446"	MONDO_0005657	"10074171"	"65553006"
pramocaine	DB09345	Inflammatory dermatosis	C3875321		Approved			CHEBI_8357	"34347"	MONDO_0002406		"703938007"
betamethasone acetate	DB00443	Arthritis, Psoriatic	C0003872		Approved			CHEBI_3077	"1514"	MONDO_0011849	"10037162"	"156370009"
posaconazole	DB01263	Mycetoma	C0024449		Approved			CHEBI_64355	"282446"	MONDO_0005757|MONDO_0016823		"410039003"
betamethasone acetate	DB00443	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_3077	"1514"	MONDO_0000004		"386584007"
betamethasone acetate	DB00443	Adrenogenital disorder	C0701163		Approved			CHEBI_3077	"1514"			"267395000"
pramocaine	DB09345	Burn injury	C0006434		Approved			CHEBI_8357	"34347"			"125666000"
betamethasone acetate	DB00443	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_3077	"1514"	MONDO_0020108	"10073785"	"413603009"
meclocycline	DB13092	Brucellosis	C0006309		Approved			CHEBI_135772	"29418"	MONDO_0005683	"10006500"	"75702008"
amphotericin B	DB00681	Brucellosis	C0006309		Approved			CHEBI_2682	"236594|732"	MONDO_0005683	"10006500"	"75702008"
streptomycin	DB01082	Brucellosis	C0006309		Approved			CHEBI_17076	"10109"	MONDO_0005683	"10006500"	"75702008"
fusidic acid	DB02703	Brucellosis	C0006309		Approved			CHEBI_29013	"4608|113608"	MONDO_0005683	"10006500"	"75702008"
tetracycline	DB09550	Brucellosis	C0006309		Approved			CHEBI_27902	"2105975"	MONDO_0005683	"10006500"	"75702008"
oxytetracycline	DB00595	Brucellosis	C0006309		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005683	"10006500"	"75702008"
pyrithione	DB06815	Common Cold	C0009443		Approved			CHEBI_36584	"35100"	MONDO_0005709		"82272006"
betamethasone benzoate	DB00443	Psoriasis of scalp	C0406326		Approved			CHEBI_3077	"1514"			"238608008"
betamethasone benzoate	DB00443	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_3077	"1514"			"53891004"
betamethasone benzoate	DB00443	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_3077	"1514"			"200965009"
resorcinol	DB11085	Acne Vulgaris	C0001144		Approved			CHEBI_27810	"35382"			"88616000"
betamethasone dipropionate	DB00443	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_3077	"1514"			"200965009"
betamethasone dipropionate	DB00443	Psoriasis of scalp	C0406326		Approved			CHEBI_3077	"1514"			"238608008"
betamethasone dipropionate	DB00443	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_3077	"1514"			"53891004"
revaprazan	DB16308	Gastro-esophageal reflux disease with esophagitis	C0677659		Approved			CHEBI_135529				"266433003"
betamethasone acetate	DB00443	Transplanted organ rejection	C0345468		Approved			CHEBI_3077	"1514"			"213148006"
betamethasone acetate	DB00443	Acquired thrombocytopenia	C0154301		Approved			CHEBI_3077	"1514"	MONDO_0001198		"154826009"
betamethasone acetate	DB00443	Mycosis Fungoides	C0026948		Approved			CHEBI_3077	"1514"	MONDO_0009691		"118618005"
triamcinolone	DB00620	Bursitis	C0006444		Approved			CHEBI_9667	"10759"	MONDO_0002471	"10006811"	"84017003"
sulindac	DB00605	Bursitis	C0006444		Approved			CHEBI_9352	"10237"	MONDO_0002471	"10006811"	"84017003"
abarelix	DB00106	Ischemic priapism	C2711256		Approved			CHEBI_337298	"301739"			"441575009"
resorcinol	DB11085	Acneiform Eruptions	C0175167		Approved			CHEBI_27810	"35382"			"402644006"
betamethasone acetate	DB00443	Berylliosis	C0005138		Approved			CHEBI_3077	"1514"		"10004485"	"8247009"
betamethasone acetate	DB00443	Autoimmune Diseases	C0004364		Approved			CHEBI_3077	"1514"	MONDO_0007179	"10061664"	"85828009"
betamethasone acetate	DB00443	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_3077	"1514"			"699262001"
pyrithione	DB06815	Scurfiness of scalp	C0423775		Approved			CHEBI_36584	"35100"			"200767005"
tetracycline	DB00759	Brucellosis	C0006309		Approved			CHEBI_27902	"10395"	MONDO_0005683	"10006500"	"75702008"
minocycline	DB01017	Brucellosis	C0006309		Approved			CHEBI_50694	"6980"	MONDO_0005683	"10006500"	"75702008"
enocitabine	DB00773	Burkitt Lymphoma	C0006413	NCT00776373	Terminated	Phase 1/Phase 2		CHEBI_4911	"4179"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
vincristine	DB00541	Burkitt Lymphoma	C0006413		Approved			CHEBI_28445	"11202"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
	DB00987	Burkitt Lymphoma	C0006413	NCT00776373	Terminated	Phase 1/Phase 2		CHEBI_28680	"3041|968804"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
methotrexate	DB00563	Burkitt Lymphoma	C0006413		Approved			CHEBI_44185	"6851"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
	DB00877	Burkitt Lymphoma	C0006413	NCT00776373	Terminated	Phase 1/Phase 2		CHEBI_9168	"35302"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
roflumilast	DB01656	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_47657	"1091836"			"200965009"
betamethasone valerate	DB00443	Psoriasis of scalp	C0406326		Approved			CHEBI_3077	"1514"			"238608008"
betamethasone valerate	DB00443	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_3077	"1514"			"53891004"
betamethasone valerate	DB00443	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_3077	"1514"			"200965009"
tramazoline	DB13064	Common Cold	C0009443		Approved			CHEBI_134893	"38453"	MONDO_0005709		"82272006"
caroxazone	DB09254	Depressive disorder	C0011581		Approved			CHEBI_134867		MONDO_0002050		"35489007"
betamethasone acetate	DB00443	Bursitis	C0006444		Approved			CHEBI_3077	"1514"	MONDO_0002471	"10006811"	"84017003"
hydrocortisone succinate	DB14545	Bursitis	C0006444		Approved			CHEBI_31677	"21651"	MONDO_0002471	"10006811"	"84017003"
triamcinolone acetonide	DB00620	Bursitis	C0006444		Approved			CHEBI_9667	"10759"	MONDO_0002471	"10006811"	"84017003"
ketoprofen	DB01009	Bursitis	C0006444	NCT00426985	Terminated	Phase 3	Sufficient number of subjects accrued to conduct analysis	CHEBI_6128	"6142"	MONDO_0002471	"10006811"	"84017003"
triamcinolone diacetate	DB00620	Bursitis	C0006444		Approved			CHEBI_9667	"10759"	MONDO_0002471	"10006811"	"84017003"
naproxen	DB00788	Bursitis	C0006444		Approved			CHEBI_7476	"7258"	MONDO_0002471	"10006811"	"84017003"
hydrocortisone	DB00741	Bursitis	C0006444		Approved			CHEBI_17650	"5492"	MONDO_0002471	"10006811"	"84017003"
methylprednisolone	DB00959	Bursitis	C0006444		Approved			CHEBI_6888	"6902"	MONDO_0002471	"10006811"	"84017003"
indomethacin	DB00328	Bursitis	C0006444		Approved			CHEBI_49662	"5781"	MONDO_0002471	"10006811"	"84017003"
prednisolone	DB00860	Bursitis	C0006444		Approved			CHEBI_8378	"8638"	MONDO_0002471	"10006811"	"84017003"
betamethasone	DB00443	Bursitis	C0006444		Approved			CHEBI_3077	"1514"	MONDO_0002471	"10006811"	"84017003"
caspofungin	DB00520	Candidiasis	C0006840	NCT00095316	Terminated	Phase 3		CHEBI_474180	"140108"	MONDO_0002026	"10074170"	"78048006"
	DB00362	Candidiasis	C0006840	NCT00806351	Terminated	Phase 3	The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not terminate due to any safety issues or concerns.	CHEBI_55346	"341018"	MONDO_0002026	"10074170"	"78048006"
roflumilast	DB01656	Severe chronic obstructive pulmonary disease	C0730607		Approved			CHEBI_47657	"1091836"			"313299006"
betamethasone valerate	DB00443	Scalp Dermatoses	C0036271		Approved			CHEBI_3077	"1514"	MONDO_0006605		"402694007"
terazosin	DB01162	Prostatic Hypertrophy	C1739363		Approved			CHEBI_9445	"37798"			"266569009"
bitolterol	DB00901	Asthma attack	C0347950		Approved			CHEBI_3133	"19499"			
dexibuprofen	DB09213	Rheumatoid Arthritis	C0003873		Approved			CHEBI_43415		MONDO_0008383	"10039073"	"69896004"
bitolterol	DB00901	Asthma	C0004096		Approved			CHEBI_3133	"19499"	MONDO_0004979	"10003553"	"195967001"
clindamycin phosphate	DB01190	Septicemia due to anaerobes	C0152967		Approved			CHEBI_3745	"2582"			
bisoprolol	DB00612	Atrial Fibrillation	C0004238		Approved			CHEBI_3127	"19484"	MONDO_0004981	"10003658"	"49436004"
bitolterol	DB00901	Bronchiectasis	C0006267		Approved			CHEBI_3133	"19499"	MONDO_0004822	"10006445"	"12295008"
bitolterol	DB00901	Bronchitis	C0006277		Approved			CHEBI_3133	"19499"	MONDO_0003781	"10006451"	"32398004"
dexibuprofen	DB09213	Headache Disorders	C0393735		Approved			CHEBI_43415				"230461009"
clindamycin phosphate	DB01190	Acne Vulgaris	C0001144		Approved			CHEBI_3745	"2582"			"88616000"
clindamycin phosphate	DB01190	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3745	"2582"			"302809008"
clindamycin phosphate	DB01190	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3745	"2582"			"406602003"
clindamycin phosphate	DB01190	Infection due to anaerobic bacteria	C0854328		Approved			CHEBI_3745	"2582"	MONDO_0024389		"423451008"
bimatoprost	DB00905	Hypertrichosis of eyelid	C0155213		Approved			CHEBI_51230	"283810"	MONDO_0001334		"79830009"
bisacodyl	DB09020	Incomplete passage of stool	C0426639		Approved			CHEBI_3125	"1596"			"249515001"
clindamycin phosphate	DB01190	Arthropathy associated with infection	C0157749		Approved			CHEBI_3745	"2582"			"363162000"
caspofungin	DB00520	Candidiasis	C0006840	NCT00806351	Terminated	Phase 3	The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not terminate due to any safety issues or concerns.	CHEBI_474180	"140108"	MONDO_0002026	"10074170"	"78048006"
micafungin	DB01141	Candidiasis	C0006840	NCT00815516	Terminated	Phase 3	It was decided to discontinue the study due to insufficient recruitment.	CHEBI_600520	"325887"	MONDO_0002026	"10074170"	"78048006"
	DB00681	Candidiasis	C0006840	NCT00815516	Terminated	Phase 3	It was decided to discontinue the study due to insufficient recruitment.	CHEBI_2682	"236594|732"	MONDO_0002026	"10074170"	"78048006"
amphotericin B	DB00681	Candidiasis	C0006840		Approved			CHEBI_2682	"236594|732"	MONDO_0002026	"10074170"	"78048006"
	DB03619	Candidiasis	C0006840	NCT00815516	Terminated	Phase 3	It was decided to discontinue the study due to insufficient recruitment.	CHEBI_28834	"42627|3194"	MONDO_0002026	"10074170"	"78048006"
	DB05780	Candidiasis	C0006840	NCT00815516	Terminated	Phase 3	It was decided to discontinue the study due to insufficient recruitment.			MONDO_0002026	"10074170"	"78048006"
artemisinin	DB13132	Malaria, Falciparum	C0024535		Approved			CHEBI_223316	"2367409"	MONDO_0005920		"248441000"
androstanolone	DB02901	Anemia of chronic renal failure	C0271932		Approved			CHEBI_16330				"49708008"
clindamycin phosphate	DB01190	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3745	"2582"			"428783003"
biotin	DB00121	Biotin deficiency disease	C2937225		Approved			CHEBI_15956	"314583|1588"			"49607006"
biperiden	DB00810	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_3112	"1589"	MONDO_0001945		"19972008"
brompheniramine	DB00835	Influenza-like symptoms	C0392171		Approved			CHEBI_3183	"1767"			
dronedarone	DB04855	Atrial Fibrillation	C0004238		Approved			CHEBI_50659	"233698"	MONDO_0004981	"10003658"	"49436004"
propylene glycol	DB01839	Dry Eye Syndromes	C0013238		Approved			CHEBI_16997	"34693"	MONDO_0006733		"46152009"
garenoxacin	DB06160	Pneumonia, Bacterial	C0004626		Approved			CHEBI_131716		MONDO_0004652	"10060946"	"53084003"
telavancin	DB06402	Pneumonia, Bacterial	C0004626		Approved			CHEBI_71229	"473837"	MONDO_0004652	"10060946"	"53084003"
bromazine	DB01237	Common Cold	C0009443		Approved			CHEBI_59177	"19759"	MONDO_0005709		"82272006"
garenoxacin	DB06160	Infective otitis media	C0729586		Approved			CHEBI_131716				"312218008"
amphotericin B	DB00681	Cutaneous Candidiasis	C0006846		Approved			CHEBI_2682	"236594|732"	MONDO_0000879	"10054152"	"49883006"
miconazole	DB01110	Cutaneous Candidiasis	C0006846		Approved			CHEBI_82892	"6932"	MONDO_0000879	"10054152"	"49883006"
nystatin	DB00646	Cutaneous Candidiasis	C0006846		Approved			CHEBI_473992	"7597"	MONDO_0000879	"10054152"	"49883006"
ketoconazole	DB01026	Cutaneous Candidiasis	C0006846		Approved			CHEBI_48339	"6135"	MONDO_0000879	"10054152"	"49883006"
triamcinolone acetonide	DB00620	Cutaneous Candidiasis	C0006846		Approved			CHEBI_9667	"10759"	MONDO_0000879	"10054152"	"49883006"
triamcinolone	DB00620	Cutaneous Candidiasis	C0006846		Approved			CHEBI_9667	"10759"	MONDO_0000879	"10054152"	"49883006"
garenoxacin	DB06160	Infective laryngitis	C0729772		Approved			CHEBI_131716				"312423006"
tolvaptan	DB06212	Polycystic Kidney, Autosomal Dominant	C0085413		Approved			CHEBI_32246	"358257"	MONDO_0004691		"765330003"
nystatin	DB00646	Oral candidiasis	C0006849		Approved			CHEBI_473992	"7597"	MONDO_0005886	"10030963"	"79740000"
asenapine	DB06216	Mixed bipolar I disorder	C0236780		Approved			CHEBI_71255	"784649"			"16506000"
porfimer	DB00707	Malignant neoplasm of esophagus	C0546837		Approved			CHEBI_60652	"333848"			"363402007"
posaconazole	DB01263	Candidiasis	C0006840		Approved			CHEBI_64355	"282446"	MONDO_0002026	"10074170"	"78048006"
voriconazole	DB00582	Candidiasis	C0006840	NCT01092832	Terminated	Phase 3	This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any safety issues or concerns.	CHEBI_10023	"121243"	MONDO_0002026	"10074170"	"78048006"
ascorbic acid	DB00126	Breastfeeding (mother)	C1623040		Approved			CHEBI_29073	"1151|1370460"			"413712001"
ascorbic acid	DB14482	Breastfeeding (mother)	C1623040		Approved			CHEBI_29073	"267366"			"413712001"
ascorbic acid	DB14483	Breastfeeding (mother)	C1623040		Approved			CHEBI_29073	"1307765|142407"			"413712001"
telavancin	DB06402	Pneumonia due to Staphylococcus aureus	C2349530		Approved			CHEBI_71229	"473837"			"441658007"
asenapine	DB06216	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_71255	"784649"			"191618007"
nystatin	DB00646	Mucocutaneous candidiasis	C0006848		Approved			CHEBI_473992	"7597"		"10028080"	"29147005"
fluconazole	DB00196	Mucocutaneous candidiasis	C0006848		Approved			CHEBI_46081	"202813|4450"		"10028080"	"29147005"
epicriptine	DB11275	Alzheimer's Disease	C0002395		Approved			CHEBI_135927	"91171|1546422"	MONDO_0004975	"10012271"	"26929004"
serine	DB00133	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_17115	"9671"			"301011002"
auranofin	DB00995	Rheumatoid Arthritis	C0003873		Approved			CHEBI_2922	"1227"	MONDO_0008383	"10039073"	"69896004"
carboplatin	DB00958	Malignant neoplasm of breast	C0006142		Approved			CHEBI_31355	"40048"		"10006187"	"254837009"
lutein	DB00137	Dry Eye Syndromes	C0013238		Approved			CHEBI_28838	"11359"	MONDO_0006733		"46152009"
cetuximab	DB00002	Malignant tumor of colon	C0007102		Approved				"318341"	MONDO_0021063	"10009944"	"363406005"
trifluridine	DB00432	Malignant tumor of colon	C0007102		Approved			CHEBI_75179	"10803"	MONDO_0021063	"10009944"	"363406005"
fluorouracil	DB00544	Malignant tumor of colon	C0007102		Approved			CHEBI_46345	"4492"	MONDO_0021063	"10009944"	"363406005"
permethrin	DB04930	Scabies <infestation>	C0036262		Approved			CHEBI_34911	"33199"	MONDO_0004525		"128869009"
liothyronine	DB00279	Malignant neoplasm of thyroid	C0007115		Approved			CHEBI_533015	"10814"	MONDO_0002108	"10066474"	"363478007"
levothyroxine	DB00451	Malignant neoplasm of thyroid	C0007115		Approved			CHEBI_58448	"10582"	MONDO_0002108	"10066474"	"363478007"
lubiprostone	DB01046	Irritable bowel syndrome characterized by constipation	C1868889		Approved			CHEBI_34945	"623033"			"440630006"
amphotericin B	DB00681	Oral candidiasis	C0006849		Approved			CHEBI_2682	"236594|732"	MONDO_0005886	"10030963"	"79740000"
miconazole	DB01110	Oral candidiasis	C0006849		Approved			CHEBI_82892	"6932"	MONDO_0005886	"10030963"	"79740000"
ketoconazole	DB01026	Oral candidiasis	C0006849		Approved			CHEBI_48339	"6135"	MONDO_0005886	"10030963"	"79740000"
fluconazole	DB00196	Oral candidiasis	C0006849		Approved			CHEBI_46081	"202813|4450"	MONDO_0005886	"10030963"	"79740000"
permethrin	DB04930	Pediculus capitis infestation	C0030757		Approved			CHEBI_34911	"33199"	MONDO_0003471		"81000006"
permethrin	DB04930	Infestation by Phthirus pubis	C0030759		Approved			CHEBI_34911	"33199"	MONDO_0001794		"71011005"
testosterone propionate	DB01420	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_9466	"10382"			"417181009"
testosterone propionate	DB00624	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_17347	"10379"			"417181009"
serine	DB00133	Acute tuberculosis	C0275959		Approved			CHEBI_17115	"9671"			"25629007"
permethrin	DB04930	Body louse infestation	C0030758		Approved			CHEBI_34911	"33199"	MONDO_0003482		"25188002"
	DB01101	Merkel cell carcinoma	C0007129	NCT03167164	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_31348	"194000"	MONDO_0019210	"10029266"	"5052009"
temozolomide	DB00853	Merkel cell carcinoma	C0007129	NCT02831179	Withdrawn	Phase 1	Loss of funding support	CHEBI_72564	"37776"	MONDO_0019210	"10029266"	"5052009"
tesamorelin	DB08869	Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy	C3854116		Approved			CHEBI_63626	"1044584"			
fidaxomicin	DB08874	Enterocolitis, Pseudomembranous	C0014358		Approved			CHEBI_68590	"1111103"			
fesoterodine	DB06702	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_135920	"797195"			
fesoterodine	DB15578	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_135920				
ceftaroline fosamil	DB06590	Group A Streptococcal Infections	C0554628		Approved			CHEBI_70718	"1040005|1040004"			"302809008"
ceftaroline fosamil	DB06590	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_70718	"1040005|1040004"			"186435004"
ceftaroline fosamil	DB06590	Escherichia coli Infections	C0014836		Approved			CHEBI_70718	"1040005|1040004"	MONDO_0020920		"71057007"
ceftaroline fosamil	DB06590	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_70718	"1040005|1040004"			"70036007"
ceftaroline fosamil	DB06590	Staphylococcus aureus infection	C1318973		Approved			CHEBI_70718	"1040005|1040004"			"406602003"
budesonide	DB01222	Asthma	C0004096		Approved			CHEBI_3207	"19831"	MONDO_0004979	"10003553"	"195967001"
indacaterol	DB05039	Asthma	C0004096		Approved			CHEBI_68575	"1114326"	MONDO_0004979	"10003553"	"195967001"
vandetanib	DB05294	Malignant epithelial neoplasm of thyroid	C3163939		Approved			CHEBI_49960	"1098413"			"448216007"
budesonide	DB01222	Primary immunoglobulin A nephropathy (disorder)	C3161650		Approved			CHEBI_3207	"19831"			"68779003"
deferiprone	DB08826	beta Thalassemia	C0005283		Approved			CHEBI_68554	"11645"		"10043391"	"65959000"
ceftaroline fosamil	DB06590	Pneumonia due to Staphylococcus aureus	C2349530		Approved			CHEBI_70718	"1040005|1040004"			"441658007"
tafamidis	DB05352	Amyloidosis	C0002726		Approved			CHEBI_78538		MONDO_0019065	"10002022"	"17602002"
rivaroxaban	DB06228	Thromboembolism of vein	C1997614		Approved			CHEBI_68579	"1114195"			"429098002"
tafamidis	DB11644	Amyloidosis	C0002726		Approved			CHEBI_78538	"1545063"	MONDO_0019065	"10002022"	"17602002"
budesonide	DB01222	Severe chronic obstructive pulmonary disease	C0730607		Approved			CHEBI_3207	"19831"			"313299006"
	DB00112	Merkel cell carcinoma	C0007129	NCT03167164	Withdrawn	Phase 1/Phase 2	Trial not initiated		"253337|2046138"	MONDO_0019210	"10029266"	"5052009"
nivolumab	DB09035	Merkel cell carcinoma	C0007129	NCT03435640	Terminated	Phase 1/Phase 2	Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.		"1597876"	MONDO_0019210	"10029266"	"5052009"
tafamidis	DB11644	Transthyretin related familial amyloid cardiomyopathy	C4275067		Approved			CHEBI_78538	"1545063"			"715655000"
tafamidis	DB05352	Transthyretin related familial amyloid cardiomyopathy	C4275067		Approved			CHEBI_78538				"715655000"
vemurafenib	DB08881	Malignant melanoma with BRAF V600E mutation	C5394779		Approved			CHEBI_63637	"1147220"			"830150003"
budesonide	DB01222	Crohn's disease in remission	C1960764		Approved			CHEBI_3207	"19831"			"426549001"
oxaliplatin	DB00526	metastasis from malignant neoplasm of colon	C1282500		Approved			CHEBI_31941	"32592"	MONDO_0041448		
hydrocortisone acetate	DB14539	Rheumatoid Arthritis	C0003873		Approved			CHEBI_17609	"27197"	MONDO_0008383	"10039073"	"69896004"
lithium carbonate	DB14509	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6504	"42351"	MONDO_0008383	"10039073"	"69896004"
lithium carbonate	DB14509	Bipolar Disorder	C0005586		Approved			CHEBI_6504	"42351"	MONDO_0004985	"10057667"	"13746004"
lithium carbonate	DB14509	Headache Disorders	C0393735		Approved			CHEBI_6504	"42351"			"230461009"
theophylline	DB00277	Non-Small Cell Lung Carcinoma	C0007131	NCT01799161	Withdrawn	Phase 1	Insufficient funding	CHEBI_28177	"10438|91178"	MONDO_0005233	"10061873"	"254637007"
	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated		"1597876"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT00794417	Terminated	Phase 1/Phase 2		CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00291850	Terminated	Phase 2	no patient recruitment	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
potassium chloride	DB00761	Incomplete passage of stool	C0426639		Approved			CHEBI_32588	"8591"			"249515001"
sodium sulfate	DB09472	Incomplete passage of stool	C0426639		Approved			CHEBI_32149	"1299926|36721"			"249515001"
hydrocortisone acetate	DB14539	Blepharoconjunctivitis	C0005743		Approved			CHEBI_17609	"27197"	MONDO_0002307		"68659002"
hydrocortisone acetate	DB14539	Inflammatory dermatosis	C3875321		Approved			CHEBI_17609	"27197"	MONDO_0002406		"703938007"
hydrocortisone acetate	DB14539	Arthritis, Psoriatic	C0003872		Approved			CHEBI_17609	"27197"	MONDO_0011849	"10037162"	"156370009"
lithium carbonate	DB14509	Bipolar disorder in remission	C0270425		Approved			CHEBI_6504	"42351"			"85248005"
hydrocortisone acetate	DB14539	Mycosis Fungoides	C0026948		Approved			CHEBI_17609	"27197"	MONDO_0009691		"118618005"
cyanocobalamin	DB00115	Anemia, Pernicious	C0002892		Approved			CHEBI_17439	"11248"	MONDO_0008228	"10034695"	"84027009"
hydrocortisone acetate	DB14539	Bursitis	C0006444		Approved			CHEBI_17609	"27197"	MONDO_0002471	"10006811"	"84017003"
paclitaxel	DB01229	Merkel cell carcinoma	C0007129	NCT02054884	Terminated	Phase 2	Lack of enrollment	CHEBI_45863	"56946"	MONDO_0019210	"10029266"	"5052009"
	DB01229	Merkel cell carcinoma	C0007129	NCT03167164	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_45863	"56946"	MONDO_0019210	"10029266"	"5052009"
	DB00544	Merkel cell carcinoma	C0007129	NCT03167164	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_46345	"4492"	MONDO_0019210	"10029266"	"5052009"
hydrocortisone acetate	DB14539	Infective blepharitis	C0729587		Approved			CHEBI_17609	"27197"			"312219000"
lithium carbonate	DB14509	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_6504	"42351"			"191618007"
hydrocortisone acetate	DB14539	Berylliosis	C0005138		Approved			CHEBI_17609	"27197"		"10004485"	"8247009"
oxaliplatin	DB00526	Malignant tumor of small intestine	C0153425		Approved			CHEBI_31941	"32592"	MONDO_0000956		"363509000"
hydrocortisone acetate	DB00741	Rheumatoid Arthritis	C0003873		Approved			CHEBI_17650	"5492"	MONDO_0008383	"10039073"	"69896004"
hydrocortisone acetate	DB14539	Asthma	C0004096		Approved			CHEBI_17609	"27197"	MONDO_0004979	"10003553"	"195967001"
	DB00515	Non-Small Cell Lung Carcinoma	C0007131	NCT00291850	Terminated	Phase 2	no patient recruitment	CHEBI_27899	"2555"	MONDO_0005233	"10061873"	"254637007"
hydrocortisone acetate	DB14539	Transplanted organ rejection	C0345468		Approved			CHEBI_17609	"27197"			"213148006"
hydrocortisone acetate	DB00741	Blepharoconjunctivitis	C0005743		Approved			CHEBI_17650	"5492"	MONDO_0002307		"68659002"
hydrocortisone acetate	DB00741	Inflammatory dermatosis	C3875321		Approved			CHEBI_17650	"5492"	MONDO_0002406		"703938007"
hydrocortisone acetate	DB00741	Arthritis, Psoriatic	C0003872		Approved			CHEBI_17650	"5492"	MONDO_0011849	"10037162"	"156370009"
hydrocortisone acetate	DB14539	Acquired thrombocytopenia	C0154301		Approved			CHEBI_17609	"27197"	MONDO_0001198		"154826009"
hydrocortisone acetate	DB00741	Mycosis Fungoides	C0026948		Approved			CHEBI_17650	"5492"	MONDO_0009691		"118618005"
hydrocortisone acetate	DB00741	Bursitis	C0006444		Approved			CHEBI_17650	"5492"	MONDO_0002471	"10006811"	"84017003"
hydrocortisone acetate	DB14539	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_17609	"27197"	MONDO_0000004		"386584007"
hydrocortisone acetate	DB00741	Infective blepharitis	C0729587		Approved			CHEBI_17650	"5492"			"312219000"
hydrocortisone acetate	DB14539	Adrenogenital disorder	C0701163		Approved			CHEBI_17609	"27197"			"267395000"
hydrocortisone acetate	DB00741	Berylliosis	C0005138		Approved			CHEBI_17650	"5492"		"10004485"	"8247009"
hydrocortisone acetate	DB14539	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_17609	"27197"			"699262001"
hydrocortisone acetate	DB14539	Autoimmune Diseases	C0004364		Approved			CHEBI_17609	"27197"	MONDO_0007179	"10061664"	"85828009"
hydrocortisone acetate	DB00741	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_17650	"5492"			"699262001"
hydrocortisone acetate	DB14539	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_17609	"27197"	MONDO_0020108	"10073785"	"413603009"
hydrocortisone acetate	DB00741	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_17650	"5492"	MONDO_0020108	"10073785"	"413603009"
hydrocortisone acetate	DB00741	Asthma	C0004096		Approved			CHEBI_17650	"5492"	MONDO_0004979	"10003553"	"195967001"
carboplatin	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT02409355	Terminated	Phase 3	The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342.	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
	DB01101	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_31348	"194000"	MONDO_0005233	"10061873"	"254637007"
	DB00526	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_31941	"32592"	MONDO_0005233	"10061873"	"254637007"
	DB00544	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_46345	"4492"	MONDO_0005233	"10061873"	"254637007"
	DB00947	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_31638	"282357"	MONDO_0005233	"10061873"	"254637007"
leucovorin	DB00650	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_15640	"6313"	MONDO_0005233	"10061873"	"254637007"
ramucirumab	DB05578	Non-Small Cell Lung Carcinoma	C0007131		Approved				"1535922"	MONDO_0005233	"10061873"	"254637007"
zinc oxide	DB09321	Arthropod bite wound	C1444173		Approved			CHEBI_36560	"11423"			"409985002"
zinc oxide	DB09321	Cutaneous Candidiasis	C0006846		Approved			CHEBI_36560	"11423"	MONDO_0000879	"10054152"	"49883006"
magnesium hydroxide	DB09104	Incomplete passage of stool	C0426639		Approved			CHEBI_6637	"6581|243353"			"249515001"
hydrocortisone acetate	DB00741	Transplanted organ rejection	C0345468		Approved			CHEBI_17650	"5492"			"213148006"
Polymyxin B	DB00781	Blepharoconjunctivitis	C0005743		Approved				"8536"	MONDO_0002307		"68659002"
hydrocortisone acetate	DB00741	Acquired thrombocytopenia	C0154301		Approved			CHEBI_17650	"5492"	MONDO_0001198		"154826009"
vismodegib	DB08828	Basal cell carcinoma	C0007117		Approved			CHEBI_66903	"1242987"	MONDO_0020804		"1338007"
hydrocortisone acetate	DB00741	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_17650	"5492"	MONDO_0000004		"386584007"
Polymyxin B	DB00781	Infective blepharitis	C0729587		Approved				"8536"			"312219000"
hydrocortisone acetate	DB00741	Adrenogenital disorder	C0701163		Approved			CHEBI_17650	"5492"			"267395000"
peginesatide	DB08894	Anemia in chronic kidney disease	C1561828		Approved			CHEBI_66895	"1248798"			"707323002"
hydrocortisone acetate	DB00741	Autoimmune Diseases	C0004364		Approved			CHEBI_17650	"5492"	MONDO_0007179	"10061664"	"85828009"
zinc oxide	DB09321	Burn injury	C0006434		Approved			CHEBI_36560	"11423"			"125666000"
gentamicin	DB00798	Pneumonia, Bacterial	C0004626		Approved			CHEBI_17833	"1596450"	MONDO_0004652	"10060946"	"53084003"
enoxaparin sodium	DB01225	Non-Small Cell Lung Carcinoma	C0007131	NCT01058759	Terminated	Phase 3	The external funding (pharmaceutical company) was stopped and could not be substituded by internal funding.		"67108"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT01728181	Withdrawn	Phase 1/Phase 2	Stopped before approval due to ineffective drug	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
cyclophosphamide	DB00531	Non-Small Cell Lung Carcinoma	C0007131	NCT04596033	Terminated	Phase 1	Business reasons	CHEBI_4027	"1545988|3002"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT00273507	Terminated	Phase 3		CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
macrogol	DB09287	Dry Eye Syndromes	C0013238		Approved			CHEBI_46793	"8516|1314384|221147|1310594"	MONDO_0006733		"46152009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00273507	Terminated	Phase 3		CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
gentamicin	DB00798	Escherichia coli septicemia	C0276088		Approved			CHEBI_17833	"1596450"			
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT02393209	Terminated	Phase 1/Phase 2	Lack of efficacy in combination.	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
macrogol	DB11077	Dry Eye Syndromes	C0013238		Approved			CHEBI_46793	"8514"	MONDO_0006733		"46152009"
cyclophosphamide	DB00531	Non-Small Cell Lung Carcinoma	C0007131	NCT04025216	Terminated	Phase 1	The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.	CHEBI_4027	"1545988|3002"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
macrogol	DB11161	Dry Eye Syndromes	C0013238		Approved			CHEBI_46793	"8513"	MONDO_0006733		"46152009"
ferrous fumarate	DB14491	Acne Vulgaris	C0001144		Approved			CHEBI_31607	"24941"			"88616000"
macrogol	DB09287	Incomplete passage of stool	C0426639		Approved			CHEBI_46793	"8516|1314384|221147|1310594"			"249515001"
macrogol	DB11077	Incomplete passage of stool	C0426639		Approved			CHEBI_46793	"8514"			"249515001"
macrogol	DB11161	Incomplete passage of stool	C0426639		Approved			CHEBI_46793	"8513"			"249515001"
neomycin	DB00994	Blepharoconjunctivitis	C0005743		Approved			CHEBI_7507	"7299"	MONDO_0002307		"68659002"
gentamicin	DB00798	Blepharoconjunctivitis	C0005743		Approved			CHEBI_17833	"1596450"	MONDO_0002307		"68659002"
ferrous fumarate	DB14491	Breastfeeding (mother)	C1623040		Approved			CHEBI_31607	"24941"			"413712001"
neomycin	DB00994	Infective blepharitis	C0729587		Approved			CHEBI_7507	"7299"			"312219000"
ferrous fumarate	DB14491	Anemia of prematurity	C0158996		Approved			CHEBI_31607	"24941"	MONDO_0001239		"47100003"
gentamicin	DB00798	Cholangitis	C0008311		Approved			CHEBI_17833	"1596450"	MONDO_0004789	"10008604"	"82403002"
carbamide	DB03904	Scurfiness of scalp	C0423775		Approved			CHEBI_16199	"11002"			"200767005"
gentamicin	DB00798	Sepsis caused by Gram negative bacteria	C3163829		Approved			CHEBI_17833	"1596450"			"449082003"
gentamicin	DB00798	Proteus septicemia	C0577690		Approved			CHEBI_17833	"1596450"			
gentamicin	DB00798	Furunculosis	C0016867		Approved			CHEBI_17833	"1596450"			
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02318368	Terminated	Phase 2	Sponsor's decision	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT02322281	Terminated	Phase 3	Sponsor discontinued development of CO-1686 for NSCLC	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
gentamicin	DB00798	Escherichia coli Infections	C0014836		Approved			CHEBI_17833	"1596450"	MONDO_0020920		"71057007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT02322281	Terminated	Phase 3	Sponsor discontinued development of CO-1686 for NSCLC	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
gentamicin	DB00798	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_17833	"1596450"			"186435004"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT02322281	Terminated	Phase 3	Sponsor discontinued development of CO-1686 for NSCLC	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT04430933	Withdrawn	Phase 1/Phase 2	Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT04430933	Withdrawn	Phase 1/Phase 2	Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
zinc acetate	DB14487	Arthropod bite wound	C1444173		Approved			CHEBI_62984	"1299637|58295"			"409985002"
sodium phosphate, monobasic	DB09449	Calcium renal calculus	C1959799		Approved			CHEBI_37585	"36709|235496|314838|349753"			"427649000"
crospovidone	DB11061	Dry Eye Syndromes	C0013238		Approved				"8610"	MONDO_0006733		"46152009"
polyvinyl alcohol	DB11060	Dry Eye Syndromes	C0013238		Approved			CHEBI_17246	"8570"	MONDO_0006733		"46152009"
sodium phosphate, monobasic	DB09449	Incomplete passage of stool	C0426639		Approved			CHEBI_37585	"36709|235496|314838|349753"			"249515001"
gentamicin	DB00798	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_17833	"1596450"	MONDO_0040732		"11218009"
gentamicin	DB00798	Arthropathy associated with infection	C0157749		Approved			CHEBI_17833	"1596450"			"363162000"
piperonyl butoxide	DB09350	Pediculus capitis infestation	C0030757		Approved			CHEBI_32687	"8345"	MONDO_0003471		"81000006"
piperonyl butoxide	DB09350	Infestation by Phthirus pubis	C0030759		Approved			CHEBI_32687	"8345"	MONDO_0001794		"71011005"
piperonyl butoxide	DB09350	Body louse infestation	C0030758		Approved			CHEBI_32687	"8345"	MONDO_0003482		"25188002"
gentamicin	DB00798	Infective blepharitis	C0729587		Approved			CHEBI_17833	"1596450"			"312219000"
tocofersolan	DB11635	Cholestasis	C0008370		Approved				"159151"	MONDO_0001751	"10008635"	"33688009"
gentamicin	DB00798	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_17833	"1596450"			"128945009"
gentamicin	DB00798	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_17833	"1596450"			"448813005"
aceclofenac	DB06736	Rheumatoid Arthritis	C0003873		Approved			CHEBI_31159	"16689"	MONDO_0008383	"10039073"	"69896004"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT04430933	Withdrawn	Phase 1/Phase 2	Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02186301	Terminated	Phase 2/Phase 3	Sponsor discontinued development of CO-1686 for NSCLC	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT04430933	Withdrawn	Phase 1/Phase 2	Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00932152	Terminated	Phase 2	Poor enrollment/suspended to accrual; will close per AstraZeneca request		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
etoposide	DB00773	Non-Small Cell Lung Carcinoma	C0007131	NCT02768558	Terminated	Phase 3	Another treatment found efficacious	CHEBI_4911	"4179"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT04165031	Terminated	Phase 1/Phase 2	The study was terminated due to an unexpected toxicity finding.	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
	DB00002	Non-Small Cell Lung Carcinoma	C0007131	NCT04165031	Terminated	Phase 1/Phase 2	The study was terminated due to an unexpected toxicity finding.		"318341"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT02093962	Terminated	Phase 2	At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT04165031	Terminated	Phase 1/Phase 2	The study was terminated due to an unexpected toxicity finding.	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
gemcitabine	DB00441	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_175901	"12574"	MONDO_0005233	"10061873"	"254637007"
gefitinib	DB00317	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_49668	"328134"	MONDO_0005233	"10061873"	"254637007"
potassium iodide	DB06715	Common Cold	C0009443		Approved			CHEBI_8346	"8597"	MONDO_0005709		"82272006"
aurothioglucose	DB09121	Rheumatoid Arthritis	C0003873		Approved			CHEBI_2930	"4980"	MONDO_0008383	"10039073"	"69896004"
vernakalant	DB06217	Atrial Fibrillation	C0004238		Approved			CHEBI_135956		MONDO_0004981	"10003658"	"49436004"
cyclophosphamide	DB00531	Non-Small Cell Lung Carcinoma	C0007131	NCT02419170	Withdrawn	Early Phase 1	Investigator who manufactured the vaccine left the university.	CHEBI_4027	"1545988|3002"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT01268059	Terminated	Phase 1/Phase 2	In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to safety concerns.	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT01268059	Terminated	Phase 1/Phase 2	In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to safety concerns.	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
panitumumab	DB01269	Non-Small Cell Lung Carcinoma	C0007131	NCT00352950	Withdrawn	Phase 1			"263034"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT03064854	Terminated	Phase 1	Recruitment halted prematurely due to competitive landscape for lung cancer therapies	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00998166	Terminated	Phase 2	Poor enrollment		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT03064854	Terminated	Phase 1	Recruitment halted prematurely due to competitive landscape for lung cancer therapies	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
benzathine benzylpenicillin	DB01053	Group A Streptococcal Infections	C0554628		Approved			CHEBI_18208	"7980"			"302809008"
bupropion	DB01156	Depressive disorder	C0011581		Approved			CHEBI_3219	"42347"	MONDO_0002050		"35489007"
ammonium chloride	DB06767	Common Cold	C0009443		Approved			CHEBI_31206	"712"	MONDO_0005709		"82272006"
anidulafungin	DB00362	Candidemia	C0877445		Approved			CHEBI_55346	"341018"	MONDO_0044070		"432261003"
afatinib	DB08916	Epidermal growth factor receptor positive non-small cell lung cancer	C1960925		Approved			CHEBI_61390	"1430438"			"426964009"
buprenorphine	DB00921	Severe pain	C0278140		Approved			CHEBI_3216	"1819"			"76948002"
pasireotide	DB06663	Adrenal Gland Hyperfunction	C0001622		Approved			CHEBI_72312	"1364105"	MONDO_0006640|MONDO_0018912	"10020564"	"47270006"
bosutinib	DB06616	Blast Phase	C0005699		Approved			CHEBI_39112	"1307619"	MONDO_0006115	"10053747"	"413656006"
pyronaridine	DB12975	Malaria, Vivax	C0024537		Approved			CHEBI_135951		MONDO_0005921		"27052006"
pyronaridine	DB12975	Malaria, Falciparum	C0024535		Approved			CHEBI_135951		MONDO_0005920		"248441000"
amifampridine	DB11640	Lambert-Eaton Myasthenic Syndrome	C0022972		Approved			CHEBI_135948	"2106338"	MONDO_0018556		"56989000"
buprenorphine	DB00921	Postoperative Pain, Acute	C2215257		Approved			CHEBI_3216	"1819"			"107401000119105"
mirabegron	DB08893	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_65349	"1300786"			
levofolinic acid	DB11596	Anemia, Megaloblastic	C0002888		Approved			CHEBI_63606	"877015"	MONDO_0001700	"10002065"	"53165003"
etoposide	DB00773	Non-Small Cell Lung Carcinoma	C0007131	NCT01565772	Terminated	Phase 1	Slow accrual	CHEBI_4911	"4179"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT03064854	Terminated	Phase 1	Recruitment halted prematurely due to competitive landscape for lung cancer therapies	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
thymalfasin	DB04900	Non-Small Cell Lung Carcinoma	C0007131	NCT02542930	Withdrawn	Phase 2	No recruitment.	CHEBI_135915	"38221"	MONDO_0005233	"10061873"	"254637007"
finasteride	DB01216	Non-Small Cell Lung Carcinoma	C0007131	NCT02055170	Terminated	Phase 2	Unable to improve on poor accrual to study.	CHEBI_5062	"25025"	MONDO_0005233	"10061873"	"254637007"
sirolimus	DB00877	Non-Small Cell Lung Carcinoma	C0007131	NCT00818675	Terminated	Phase 2		CHEBI_9168	"35302"	MONDO_0005233	"10061873"	"254637007"
crizotinib	DB08865	Non-Small Cell Lung Carcinoma	C0007131	NCT01500824	Withdrawn	Phase 2		CHEBI_64310	"1148495"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02134015	Terminated	Phase 3	Pre-defined criteria for continuation were not reached	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
crizotinib	DB08865	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_64310	"1148495"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT04203511	Withdrawn	Phase 3	Sponsor Strategic/Business Decision	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT04203511	Withdrawn	Phase 3	Sponsor Strategic/Business Decision	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT04203511	Withdrawn	Phase 3	Sponsor Strategic/Business Decision	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
etoposide	DB00773	Non-Small Cell Lung Carcinoma	C0007131	NCT04203511	Withdrawn	Phase 3	Sponsor Strategic/Business Decision	CHEBI_4911	"4179"	MONDO_0005233	"10061873"	"254637007"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00434226	Terminated	Phase 2	Based on data collected, the combination appeared to be poorly tolearated.		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
	DB01217	Non-Small Cell Lung Carcinoma	C0007131	NCT00932152	Terminated	Phase 2	Poor enrollment/suspended to accrual; will close per AstraZeneca request	CHEBI_2704	"84857"	MONDO_0005233	"10061873"	"254637007"
hydrocortisone succinate	DB14545	Rheumatoid Arthritis	C0003873		Approved			CHEBI_31677	"21651"	MONDO_0008383	"10039073"	"69896004"
etoposide	DB00773	Non-Small Cell Lung Carcinoma	C0007131	NCT03840902	Terminated	Phase 2	Based on recommendations by an external IDMC, Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.	CHEBI_4911	"4179"	MONDO_0005233	"10061873"	"254637007"
clobetasol propionate	DB01013	Psoriasis of scalp	C0406326		Approved			CHEBI_31414	"21245"			"238608008"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT03138889	Terminated	Phase 1/Phase 2	Sponsor decision	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
clobetasol propionate	DB01013	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_31414	"21245"			"200965009"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT03138889	Terminated	Phase 1/Phase 2	Sponsor decision	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
clobetasol propionate	DB11750	Psoriasis of scalp	C0406326		Approved			CHEBI_205919	"2590"			"238608008"
metformin	DB00331	Non-Small Cell Lung Carcinoma	C0007131	NCT01997775	Terminated	Phase 2	Difficult enrollment	CHEBI_6801	"6809"	MONDO_0005233	"10061873"	"254637007"
clobetasol propionate	DB11750	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_205919	"2590"			"200965009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT03138889	Terminated	Phase 1/Phase 2	Sponsor decision	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT03840902	Terminated	Phase 2	Based on recommendations by an external IDMC, Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT03840902	Terminated	Phase 2	Based on recommendations by an external IDMC, Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT02157116	Terminated	Phase 2	Insufficient accrual to meet analysis goals	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
prednisolone sodium phosphate	DB14631	Blepharoconjunctivitis	C0005743		Approved			CHEBI_145705	"34374"	MONDO_0002307		"68659002"
prednisolone sodium phosphate	DB00860	Blepharoconjunctivitis	C0005743		Approved			CHEBI_8378	"8638"	MONDO_0002307		"68659002"
clobetasol propionate	DB01013	Inflammatory dermatosis	C3875321		Approved			CHEBI_31414	"21245"	MONDO_0002406		"703938007"
hydrocortisone succinate	DB00741	Rheumatoid Arthritis	C0003873		Approved			CHEBI_17650	"5492"	MONDO_0008383	"10039073"	"69896004"
hydrocortisone succinate	DB14545	Asthma	C0004096		Approved			CHEBI_31677	"21651"	MONDO_0004979	"10003553"	"195967001"
hydrocortisone succinate	DB00741	Asthma	C0004096		Approved			CHEBI_17650	"5492"	MONDO_0004979	"10003553"	"195967001"
hydrocortisone succinate	DB14545	Addison Disease	C0001403		Approved			CHEBI_31677	"21651"	MONDO_0015129	"10001130"	"373662000"
hydrocortisone succinate	DB14545	Transplanted organ rejection	C0345468		Approved			CHEBI_31677	"21651"			"213148006"
hydrocortisone succinate	DB00741	Addison Disease	C0001403		Approved			CHEBI_17650	"5492"	MONDO_0015129	"10001130"	"373662000"
hydrocortisone succinate	DB00741	Transplanted organ rejection	C0345468		Approved			CHEBI_17650	"5492"			"213148006"
hydrocortisone succinate	DB00741	Arthritis, Psoriatic	C0003872		Approved			CHEBI_17650	"5492"	MONDO_0011849	"10037162"	"156370009"
hydrocortisone succinate	DB14545	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_31677	"21651"	MONDO_0015253		"88854002"
hydrocortisone succinate	DB00741	Acquired thrombocytopenia	C0154301		Approved			CHEBI_17650	"5492"	MONDO_0001198		"154826009"
hydrocortisone succinate	DB14545	Mycosis Fungoides	C0026948		Approved			CHEBI_31677	"21651"	MONDO_0009691		"118618005"
hydrocortisone succinate	DB00741	Mycosis Fungoides	C0026948		Approved			CHEBI_17650	"5492"	MONDO_0009691		"118618005"
hydrocortisone succinate	DB14545	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_31677	"21651"	MONDO_0000004		"386584007"
hydrocortisone succinate	DB14545	Adrenogenital disorder	C0701163		Approved			CHEBI_31677	"21651"			"267395000"
hydrocortisone succinate	DB14545	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_31677	"21651"			"699262001"
hydrocortisone succinate	DB00741	Autoimmune Diseases	C0004364		Approved			CHEBI_17650	"5492"	MONDO_0007179	"10061664"	"85828009"
hydrocortisone succinate	DB14545	Autoimmune Diseases	C0004364		Approved			CHEBI_31677	"21651"	MONDO_0007179	"10061664"	"85828009"
hydrocortisone succinate	DB14545	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_31677	"21651"	MONDO_0020108	"10073785"	"413603009"
hydrocortisone succinate	DB00741	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_17650	"5492"	MONDO_0020108	"10073785"	"413603009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT02382406	Terminated	Phase 1/Phase 2	The study was completed. It was fully accrued.	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
procaine benzylpenicillin	DB09320	Fusospirochetal pharyngitis	C1318559		Approved			CHEBI_52154	"7983"			
mercaptopurine	DB01033	Crohn Disease	C0010346	NCT01094613	Terminated	Phase 1/Phase 2	Sponsor withdrew support of study due to reorganization and project prioritization	CHEBI_50667	"103|1546028"	MONDO_0005011	"10011401"	"34000006"
procaine benzylpenicillin	DB09320	Group A Streptococcal Infections	C0554628		Approved			CHEBI_52154	"7983"			"302809008"
procaine benzylpenicillin	DB09320	Staphylococcus aureus infection	C1318973		Approved			CHEBI_52154	"7983"			"406602003"
procaine benzylpenicillin	DB01053	Group A Streptococcal Infections	C0554628		Approved			CHEBI_18208	"7980"			"302809008"
hydrocortisone succinate	DB00741	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_17650	"5492"	MONDO_0015253		"88854002"
procaine benzylpenicillin	DB09320	Anthrax disease	C0003175		Approved			CHEBI_52154	"7983"	MONDO_0005119	"10002713"	"409498004"
hydrocortisone succinate	DB00741	Bursitis	C0006444		Approved			CHEBI_17650	"5492"	MONDO_0002471	"10006811"	"84017003"
hydrocortisone succinate	DB00741	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_17650	"5492"	MONDO_0000004		"386584007"
hydrocortisone succinate	DB00741	Adrenogenital disorder	C0701163		Approved			CHEBI_17650	"5492"			"267395000"
procaine benzylpenicillin	DB09320	Rat-Bite Fever	C0034686		Approved			CHEBI_52154	"7983"	MONDO_0006941		"1685005"
hydrocortisone succinate	DB00741	Berylliosis	C0005138		Approved			CHEBI_17650	"5492"		"10004485"	"8247009"
hydrocortisone succinate	DB00741	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_17650	"5492"			"699262001"
procaine benzylpenicillin	DB09320	Bejel	C0004945		Approved			CHEBI_52154	"7983"	MONDO_0001714		"240686008"
procaine benzylpenicillin	DB01053	Fusospirochetal pharyngitis	C1318559		Approved			CHEBI_18208	"7980"			
procaine benzylpenicillin	DB01053	Staphylococcus aureus infection	C1318973		Approved			CHEBI_18208	"7980"			"406602003"
esketamine	DB11823	Depressive disorder	C0011581		Approved			CHEBI_60799	"2119365"	MONDO_0002050		"35489007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT03840902	Terminated	Phase 2	Based on recommendations by an external IDMC, Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
	DB02546	Non-Small Cell Lung Carcinoma	C0007131	NCT00503971	Terminated	Phase 1/Phase 2		CHEBI_45716	"194337"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT00503971	Terminated	Phase 1/Phase 2		CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
porfimer	DB00707	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_60652	"333848"	MONDO_0005233	"10061873"	"254637007"
sodium citrate	DB09154	Common Cold	C0009443		Approved			CHEBI_53258	"253204|56466|1310549"	MONDO_0005709		"82272006"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT04758949	Withdrawn	Phase 2	Sponsor Decision		"1597876"	MONDO_0005233	"10061873"	"254637007"
fulvestrant	DB00947	Non-Small Cell Lung Carcinoma	C0007131	NCT00932152	Terminated	Phase 2	Poor enrollment/suspended to accrual; will close per AstraZeneca request	CHEBI_31638	"282357"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT00203931	Terminated	Phase 2	Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed after first-line therapy	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00887315	Terminated	Phase 2	Slow accrual and loss of sponsor	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
betamethasone	DB00443	Crohn Disease	C0010346		Approved			CHEBI_3077	"1514"	MONDO_0005011	"10011401"	"34000006"
diflorasone diacetate	DB00223	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_59750	"91311"			"200965009"
diflorasone diacetate	DB00223	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_59750	"91311"			"53891004"
diflorasone diacetate	DB00223	Psoriasis of scalp	C0406326		Approved			CHEBI_59750	"91311"			"238608008"
procaine benzylpenicillin	DB01053	Anthrax disease	C0003175		Approved			CHEBI_18208	"7980"	MONDO_0005119	"10002713"	"409498004"
procaine benzylpenicillin	DB01053	Rat-Bite Fever	C0034686		Approved			CHEBI_18208	"7980"	MONDO_0006941		"1685005"
carfilzomib	DB08889	Relapse multiple myeloma	C2349261		Approved			CHEBI_65347	"1302966"			"452291000124109"
butobarbital	DB01353	Severe anxiety (panic)	C0231403		Approved			CHEBI_134884	"19874"			"80583007"
procaine benzylpenicillin	DB01053	Bejel	C0004945		Approved			CHEBI_18208	"7980"	MONDO_0001714		"240686008"
fosaprepitant	DB06717	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_64321	"1731071"			"18846006"
magnesium salicylate	DB01397	Rheumatoid Arthritis	C0003873		Approved			CHEBI_6640		MONDO_0008383	"10039073"	"69896004"
lithium citrate	DB14507	Bipolar Disorder	C0005586		Approved			CHEBI_64735	"52105"	MONDO_0004985	"10057667"	"13746004"
alclometasone dipropionate	DB00240	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_53776	"108088"			"200965009"
alclometasone dipropionate	DB00240	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_53776	"108088"			"53891004"
lithium citrate	DB14509	Bipolar Disorder	C0005586		Approved			CHEBI_6504	"42351"	MONDO_0004985	"10057667"	"13746004"
alclometasone dipropionate	DB00240	Psoriasis of scalp	C0406326		Approved			CHEBI_53776	"108088"			"238608008"
cisplatin	DB00515	Non-Small Cell Lung Carcinoma	C0007131	NCT00887315	Terminated	Phase 2	Slow accrual and loss of sponsor	CHEBI_27899	"2555"	MONDO_0005233	"10061873"	"254637007"
	DB02546	Non-Small Cell Lung Carcinoma	C0007131	NCT00702572	Terminated	Phase 1	Low Enrollment	CHEBI_45716	"194337"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT00702572	Terminated	Phase 1	Low Enrollment	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00702572	Terminated	Phase 1	Low Enrollment		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT02162537	Terminated	Phase 3	Slow inclusions due in part to a change in practices. The first chemotherapy become a standard for patients with NSCL with asymptomatic brain metastases.	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
halcinonide	DB06786	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_31663	"5084"			"53891004"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT02162537	Terminated	Phase 3	Slow inclusions due in part to a change in practices. The first chemotherapy become a standard for patients with NSCL with asymptomatic brain metastases.		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT02387216	Terminated	Phase 2	Based on the preliminary results seen during interim analysis, which were confirmed in the final analysis, the Sponsor terminated the study	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
halcinonide	DB06786	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_31663	"5084"			"200965009"
halcinonide	DB06786	Psoriasis of scalp	C0406326		Approved			CHEBI_31663	"5084"			"238608008"
magnesium salicylate	DB01397	Headache Disorders	C0393735		Approved			CHEBI_6640				"230461009"
estradiol acetate	DB13952	Atrophic Vaginitis	C0221392		Approved			CHEBI_135981	"405416"			"52441000"
estradiol acetate	DB00783	Atrophic Vaginitis	C0221392		Approved			CHEBI_16469	"4083"			"52441000"
haloperidol decanoate	DB00502	Chronic schizophrenia	C0221765		Approved			CHEBI_5613	"5093"			"83746006"
fluticasone furoate	DB13867	Asthma	C0004096		Approved			CHEBI_5134	"41126"	MONDO_0004979	"10003553"	"195967001"
fluticasone furoate	DB08906	Asthma	C0004096		Approved			CHEBI_74899	"705022"	MONDO_0004979	"10003553"	"195967001"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT02382406	Terminated	Phase 1/Phase 2	The study was completed. It was fully accrued.	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
irinotecan	DB00762	Non-Small Cell Lung Carcinoma	C0007131	NCT00264134	Terminated	Phase 1/Phase 2		CHEBI_80630	"51499"	MONDO_0005233	"10061873"	"254637007"
	DB00398	Non-Small Cell Lung Carcinoma	C0007131	NCT00417248	Terminated	Phase 1/Phase 2	Negative sorafenib results from ESCAPE trial and safety concerns of regimen	CHEBI_50924	"495881"	MONDO_0005233	"10061873"	"254637007"
etoposide	DB00773	Non-Small Cell Lung Carcinoma	C0007131	NCT00417248	Terminated	Phase 1/Phase 2	Negative sorafenib results from ESCAPE trial and safety concerns of regimen	CHEBI_4911	"4179"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT00264134	Terminated	Phase 1/Phase 2		CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
potassium citrate	DB09125	Calcium renal calculus	C1959799		Approved			CHEBI_64733	"54993|1374802"			"427649000"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00264134	Terminated	Phase 1/Phase 2		CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
indigo carmine	DB11577	diagnostic cystoscopy revealed bullous edema of both ureteral orifices	C2957169		Approved			CHEBI_90117	"227312|325514|1426889|1546441"			
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03509584	Terminated	Phase 1	SAFETY		"1597876"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02342353	Terminated	Phase 1	Drug shortage	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
	DB00515	Non-Small Cell Lung Carcinoma	C0007131	NCT03317496	Terminated	Phase 2	The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).	CHEBI_27899	"2555"	MONDO_0005233	"10061873"	"254637007"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03425331	Suspended	Phase 2	Slow accrual, competing studies, and lack of efficacy		"1597876"	MONDO_0005233	"10061873"	"254637007"
flumetasone	DB00663	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_34764	"4458"			"200965009"
flumetasone	DB00663	Psoriasis of scalp	C0406326		Approved			CHEBI_34764	"4458"			"238608008"
flumetasone	DB00663	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_34764	"4458"			"53891004"
butriptyline	DB09016	Depressive disorder	C0011581		Approved			CHEBI_135227	"19895"	MONDO_0002050		"35489007"
potassium citrate	DB09125	Uric acid renal calculus	C0558595		Approved			CHEBI_64733	"54993|1374802"			"274401005"
magnesium gluconate	DB13749	Incomplete passage of stool	C0426639		Approved				"52358"			"249515001"
	DB06186	Non-Small Cell Lung Carcinoma	C0007131	NCT03425331	Suspended	Phase 2	Slow accrual, competing studies, and lack of efficacy		"1094833"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT03317496	Terminated	Phase 2	The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
clocortolone pivalate	DB00838	Psoriasis of scalp	C0406326		Approved			CHEBI_59582	"21249"			"238608008"
enzalutamide	DB08899	Metastasis from malignant tumor of prostate	C1282496		Approved			CHEBI_68534	"1307298"			
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT03317496	Terminated	Phase 2	The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
clocortolone pivalate	DB00838	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_59582	"21249"			"53891004"
clocortolone pivalate	DB00838	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_59582	"21249"			"200965009"
hematoporphyrin	DB16183	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_36162	"5164"	MONDO_0005233	"10061873"	"254637007"
caffeine	DB00201	Influenza-like symptoms	C0392171		Approved			CHEBI_27732	"1886"			
	DB06186	Non-Small Cell Lung Carcinoma	C0007131	NCT03509584	Terminated	Phase 1	SAFETY		"1094833"	MONDO_0005233	"10061873"	"254637007"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT02469701	Terminated	Phase 2	Lack of accrual		"1597876"	MONDO_0005233	"10061873"	"254637007"
lenograstim	DB13144	Non-Small Cell Lung Carcinoma	C0007131	NCT00862134	Terminated	Phase 2	Interim analysis indicated low probability of clinically significant result		"70167"	MONDO_0005233	"10061873"	"254637007"
etoposide	DB00773	Non-Small Cell Lung Carcinoma	C0007131	NCT01222572	Terminated	Phase 1/Phase 2	Slow accrual due to restrictive eligibility criteria	CHEBI_4911	"4179"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00862134	Terminated	Phase 2	Interim analysis indicated low probability of clinically significant result	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT01774578	Terminated	Phase 2/Phase 3		CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
regorafenib	DB08896	metastasis from malignant neoplasm of colon	C1282500		Approved			CHEBI_68647	"1312397"	MONDO_0041448		
choline magnesium trisalicylate	DB01401	Rheumatoid Arthritis	C0003873		Approved				"215799"	MONDO_0008383	"10039073"	"69896004"
choline magnesium trisalicylate	DB00122	Rheumatoid Arthritis	C0003873		Approved			CHEBI_15354	"2449"	MONDO_0008383	"10039073"	"69896004"
choline magnesium trisalicylate	DB00936	Rheumatoid Arthritis	C0003873		Approved			CHEBI_16914	"9525"	MONDO_0008383	"10039073"	"69896004"
	DB06186	Non-Small Cell Lung Carcinoma	C0007131	NCT03048136	Withdrawn	Phase 3	Business objective has changed		"1094833"	MONDO_0005233	"10061873"	"254637007"
calcipotriene	DB02300	Psoriasis of scalp	C0406326		Approved			CHEBI_50749	"29365"			"238608008"
calcipotriene	DB02300	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_50749	"29365"			"200965009"
methylprednisolone	DB00959	Non-Small Cell Lung Carcinoma	C0007131	NCT03661567	Terminated	Phase 2	slow enrollment	CHEBI_6888	"6902"	MONDO_0005233	"10061873"	"254637007"
calcitriol	DB00136	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_17823	"1894"			"200965009"
	DB14644	Non-Small Cell Lung Carcinoma	C0007131	NCT03661567	Terminated	Phase 2	slow enrollment	CHEBI_135765		MONDO_0005233	"10061873"	"254637007"
	DB00860	Non-Small Cell Lung Carcinoma	C0007131	NCT03661567	Terminated	Phase 2	slow enrollment	CHEBI_8378	"8638"	MONDO_0005233	"10061873"	"254637007"
belotecan	DB12459	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_135702		MONDO_0005233	"10061873"	"254637007"
gefitinib	DB00317	Non-Small Cell Lung Carcinoma	C0007131	NCT00268255	Withdrawn	Phase 1/Phase 2	Study never moved forward with accrual.	CHEBI_49668	"328134"	MONDO_0005233	"10061873"	"254637007"
	DB01254	Non-Small Cell Lung Carcinoma	C0007131	NCT00787852	Terminated	Phase 1	for efficacy and safety reasons	CHEBI_49375	"475342|1546019"	MONDO_0005233	"10061873"	"254637007"
fluorometholone acetate	DB00324	Allergic Conjunctivitis	C0009766		Approved			CHEBI_31625	"4491"	MONDO_0005642	"10010744"	"231854006"
fluorometholone acetate	DB00324	Punctate keratopathy	C0423234		Approved			CHEBI_31625	"4491"			"246936005"
benzoin	DB14020	Laryngeal papillomatosis	C0396072		Approved			CHEBI_17682	"1406"	MONDO_0023597		"232457008"
nitroprusside	DB00325	Acute exacerbation of chronic congestive heart failure	C3697063		Approved			CHEBI_7596	"7476"			"698296002"
calcifediol	DB00146	Renal Osteodystrophy	C0035086		Approved			CHEBI_17933	"1855064|1889"	MONDO_0006946		"16726004"
calcitriol	DB00136	Renal Osteodystrophy	C0035086		Approved			CHEBI_17823	"1894"	MONDO_0006946		"16726004"
caffeine	DB00201	Apnea in newborn	C0232058		Approved			CHEBI_27732	"1886"			"13094009"
nitroprusside	DB00325	Malignant essential hypertension	C0024588		Approved			CHEBI_7596	"7476"	MONDO_0001133		"78975002"
fluorometholone acetate	DB00324	Corneal Ulcer	C0010043		Approved			CHEBI_31625	"4491"	MONDO_0004577		"91514001"
nitroprusside	DB00325	Decompensated cardiac failure	C0581377		Approved			CHEBI_7596	"7476"			"195111005"
benzoin	DB14020	Disorder of keratinization	C0475811		Approved			CHEBI_17682	"1406"	MONDO_0045011		"277905003"
omacetaxine mepesuccinate	DB04865	Myeloid Leukemia, Chronic	C0023473		Approved			CHEBI_71019	"27100"	MONDO_0011996		
cabozantinib	DB08875	Metastatic Renal Cell Cancer	C0278678		Approved			CHEBI_72317	"1363268"			
sodium aurothiomalate	DB09276	Rheumatoid Arthritis	C0003873		Approved			CHEBI_35864	"4981"	MONDO_0008383	"10039073"	"69896004"
ponatinib	DB08901	Myeloid Leukemia, Chronic	C0023473		Approved			CHEBI_78543	"1364347"	MONDO_0011996		
tofacitinib	DB08895	Rheumatoid Arthritis	C0003873		Approved			CHEBI_71200	"1357536"	MONDO_0008383	"10039073"	"69896004"
tenidap	DB13481	Rheumatoid Arthritis	C0003873		Approved			CHEBI_35847		MONDO_0008383	"10039073"	"69896004"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT02737709	Terminated	Phase 2	The study have difficulty in recruiting subjectes	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00787852	Terminated	Phase 1	for efficacy and safety reasons	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
flucytosine	DB01099	Non-Small Cell Lung Carcinoma	C0007131	NCT02576665	Terminated	Phase 1	Sponsor decision	CHEBI_5100	"4451"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT02920450	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT02920450	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
tacalcitol	DB13689	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_32176	"291204"			"200965009"
crofelemer	DB04941	Non-infective diarrhea	C0267436		Approved				"1364449"	MONDO_0045030		"69980003"
phenothrin	DB13717	Scabies <infestation>	C0036262		Approved			CHEBI_34916		MONDO_0004525		"128869009"
camostat	DB13729	Gastro-esophageal reflux disease with esophagitis	C0677659		Approved			CHEBI_135632				"266433003"
thioctic acid	DB00166	Diabetic peripheral neuropathy	C0740447		Approved			CHEBI_30314	"6417"			"424736006"
pyrethrins	DB11087	Infestation by Phthirus pubis	C0030759		Approved			CHEBI_39098	"8991|2102029|1232405"	MONDO_0001794		"71011005"
pyrethrins	DB11087	Pediculus capitis infestation	C0030757		Approved			CHEBI_39098	"8991|2102029|1232405"	MONDO_0003471		"81000006"
tetramethrin	DB13752	Pediculus capitis infestation	C0030757		Approved			CHEBI_39397		MONDO_0003471		"81000006"
tetramethrin	DB13752	Infestation by Phthirus pubis	C0030759		Approved			CHEBI_39397		MONDO_0001794		"71011005"
pyrethrins	DB11087	Body louse infestation	C0030758		Approved			CHEBI_39098	"8991|2102029|1232405"	MONDO_0003482		"25188002"
obidoxime	DB13750	Organophosphate poisoning	C0700359		Approved							"8260003"
acemetacin	DB13783	Rheumatism	C0035435		Approved			CHEBI_31162	"16695"			"396332003"
oritavancin	DB04911	Streptococcal infection of skin	C1274355		Approved			CHEBI_82699	"1547611"			"402937004"
bleomycin	DB00290	FIGO stage finding for vulvar carcinoma	C1272826		Approved			CHEBI_22907	"1622"			"385370007"
lomitapide	DB08827	Homozygous Familial Hypercholesterolemia	C0342881		Approved			CHEBI_72297	"1364479"			"238078005"
bleomycin	DB00290	Malignant tumor of cervix	C0007847		Approved			CHEBI_22907	"1622"			"363354003"
mipomersen	DB05528	Homozygous Familial Hypercholesterolemia	C0342881		Approved				"1367839"			"238078005"
capecitabine	DB01101	metastasis from malignant neoplasm of colon	C1282500		Approved			CHEBI_31348	"194000"	MONDO_0041448		
ipidacrine	DB13668	Alzheimer's Disease	C0002395		Approved			CHEBI_125612		MONDO_0004975	"10012271"	"26929004"
vilanterol	DB09082	Asthma	C0004096		Approved			CHEBI_75037	"1424884"	MONDO_0004979	"10003553"	"195967001"
dimethyl fumarate	DB08908	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_76004	"1373478"			"200965009"
umeclidinium	DB09076	Asthma	C0004096		Approved			CHEBI_79041	"1487514"	MONDO_0004979	"10003553"	"195967001"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT02252796	Terminated	Phase 1	Investigator left institution	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03656627	Terminated	Phase 1	low accrual		"1597876"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT02252796	Terminated	Phase 1	Investigator left institution	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
vinorelbine	DB00361	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_480999	"39541"	MONDO_0005233	"10061873"	"254637007"
gramicidin	DB00027	Blepharoconjunctivitis	C0005743		Approved			CHEBI_5530	"5011"	MONDO_0002307		"68659002"
sofosbuvir	DB08934	Early cirrhosis	C1299579		Approved			CHEBI_85083	"1484911"			"371139006"
palifermin	DB00039	Drug-induced mucositis	C1274988		Approved				"196319"			"403666006"
tasimelteon	DB09071	Non-24 hour sleep-wake cycle	C0393772		Approved			CHEBI_79042	"1490468"			"230496009"
hachimycin	DB13302	Candidiasis	C0006840		Approved			CHEBI_35022		MONDO_0002026	"10074170"	"78048006"
gramicidin	DB00027	Infective blepharitis	C0729587		Approved			CHEBI_5530	"5011"			"312219000"
canagliflozin	DB08907	Chronic kidney disease due to type 2 diabetes mellitus	C3662038		Approved			CHEBI_73274	"1373458|1546031"			"771000119108"
fomivirsen	DB06759	Cytomegalovirus Retinitis	C0206178		Approved				"85763"			"22455005"
dabrafenib	DB08912	Malignant melanoma with BRAF V600E mutation	C5394779		Approved			CHEBI_75045	"1424911"			"830150003"
trametinib	DB08911	Malignant melanoma with BRAF V600E mutation	C5394779		Approved			CHEBI_75998	"1425099"			"830150003"
riociguat	DB08931	Chronic thromboembolic pulmonary hypertension	C2363973		Approved			CHEBI_76018	"1439816"			"233947005"
delamanid	DB11637	Tuberculosis, Drug-Resistant	C0206525		Approved			CHEBI_134742				"423709000"
sinecatechins	DB01266	Perianal warts	C0343730		Approved				"753346"			"266114001"
rifamycin	DB11753	Traveler's diarrhea	C0277528		Approved			CHEBI_29673	"35616"			"11840006"
apremilast	DB05676	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_78540	"1492727"			"200965009"
	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT04069936	Terminated	Phase 2	Resourcing		"1597876"	MONDO_0005233	"10061873"	"254637007"
dexrabeprazole	DB13762	Peptic Esophagitis	C0014869		Approved			CHEBI_134729		MONDO_0006896		
tadalafil	DB00820	Non-Small Cell Lung Carcinoma	C0007131	NCT04069936	Terminated	Phase 2	Resourcing	CHEBI_71940	"358263"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT01026844	Terminated	Phase 1	slow enrollment	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
	DB01611	Non-Small Cell Lung Carcinoma	C0007131	NCT01026844	Terminated	Phase 1	slow enrollment	CHEBI_5801	"5521"	MONDO_0005233	"10061873"	"254637007"
levofolinic acid	DB11596	Non-Small Cell Lung Carcinoma	C0007131	NCT01820091	Withdrawn	Phase 1		CHEBI_63606	"877015"	MONDO_0005233	"10061873"	"254637007"
suramin	DB04786	Non-Small Cell Lung Carcinoma	C0007131	NCT01038752	Terminated	Phase 2		CHEBI_45906	"10256"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT01038752	Terminated	Phase 2		CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
trastuzumab	DB00072	Non-Small Cell Lung Carcinoma	C0007131	NCT00758134	Terminated	Phase 2	Insufficient accrual		"2289225|2103478|2174802|2280730|2107051|224905"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT01038752	Terminated	Phase 2		CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
lucanthone	DB04967	Non-Small Cell Lung Carcinoma	C0007131	NCT02014545	Withdrawn	Phase 2	Pending resolution of study drug issues	CHEBI_51052		MONDO_0005233	"10061873"	"254637007"
irinotecan	DB00762	Non-Small Cell Lung Carcinoma	C0007131	NCT01607554	Terminated	Phase 1/Phase 2	Inadequate enrollment (2 subjects in 4 years)	CHEBI_80630	"51499"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02277457	Withdrawn	Early Phase 1		CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
mebanazine	DB09248	Depressive disorder	C0011581		Approved			CHEBI_134728		MONDO_0002050		"35489007"
estrone sulphate	DB04574	Atrophic Vaginitis	C0221392		Approved			CHEBI_17474				"52441000"
estrone sulphate	DB00655	Atrophic Vaginitis	C0221392		Approved			CHEBI_17263	"4103"			"52441000"
captodiame	DB09014	Anxiety Disorders	C0003469		Approved			CHEBI_135521			"10057666"	"197480006"
afamelanotide	DB04931	Erythropoietic Protoporphyria	C0162568		Approved			CHEBI_136034	"2262250"			"51022005"
apremilast	DB05676	Arthritis, Psoriatic	C0003872		Approved			CHEBI_78540	"1492727"	MONDO_0011849	"10037162"	"156370009"
vintafolide	DB05168	Malignant epithelial tumor of ovary	C0346161		Approved			CHEBI_134736				"254849005"
naloxegol	DB09049	Therapeutic opioid induced constipation	C3874358		Approved			CHEBI_82975	"1551777"			"136801000119102"
carbamazepine	DB00564	Epilepsy characterized by intractable complex partial seizures	C2711653		Approved			CHEBI_3387	"2002"			
carbamazepine	DB00564	Tonic-Clonic Epilepsy	C0014549		Approved			CHEBI_3387	"2002"	MONDO_0005754		
iguratimod	DB12233	Rheumatoid Arthritis	C0003873		Approved			CHEBI_31689		MONDO_0008383	"10039073"	"69896004"
acefylline	DB13573	Asthma	C0004096		Approved			CHEBI_94615		MONDO_0004979	"10003553"	"195967001"
acefylline	DB13573	Bronchitis	C0006277		Approved			CHEBI_94615		MONDO_0003781	"10006451"	"32398004"
imidafenacin	DB09262	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_134720				
tipiracil	DB09343	Malignant tumor of colon	C0007102		Approved			CHEBI_90879	"1670304"	MONDO_0021063	"10009944"	"363406005"
	DB08865	Non-Small Cell Lung Carcinoma	C0007131	NCT02277457	Withdrawn	Early Phase 1		CHEBI_64310	"1148495"	MONDO_0005233	"10061873"	"254637007"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00378404	Terminated	Phase 1	Slow accrual	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT00460317	Terminated	Phase 3	Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
diquafosol	DB15919	Dry Eye Syndromes	C0013238		Approved			CHEBI_27791		MONDO_0006733		"46152009"
efinaconazole	DB09040	Onychomycosis due to Trichophyton mentagrophytes	C0276755		Approved			CHEBI_82718	"1539753"			"23549005"
tavaborole	DB09041	Onychomycosis due to Trichophyton mentagrophytes	C0276755		Approved			CHEBI_77942	"1543173"			"23549005"
favipiravir	DB12466	Influenza caused by pandemic influenza virus	C4304383		Approved			CHEBI_134722				"719865001"
tavaborole	DB09041	Onychomycosis due to Trichophyton rubrum	C0276754		Approved			CHEBI_77942	"1543173"			"56922006"
carbamazepine	DB00564	Bipolar disorder in remission	C0270425		Approved			CHEBI_3387	"2002"			"85248005"
efinaconazole	DB09040	Onychomycosis of toenails	C1274470		Approved			CHEBI_82718	"1539753"			"403059006"
tavaborole	DB09041	Onychomycosis of toenails	C1274470		Approved			CHEBI_77942	"1543173"			"403059006"
carbamazepine	DB00564	Mixed bipolar I disorder	C0236780		Approved			CHEBI_3387	"2002"			"16506000"
carbamazepine	DB00564	Epilepsies, Partial	C0014547		Approved			CHEBI_3387	"2002"	MONDO_0005384		"230381009"
carbamazepine	DB00564	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_3387	"2002"			"191618007"
tedizolid phosphate	DB09042	Streptococcal infection of skin	C1274355		Approved			CHEBI_83326	"1540824"			"402937004"
tedizolid phosphate	DB14569	Streptococcal infection of skin	C1274355		Approved			CHEBI_82717	"1540825"			"402937004"
acefylline	DB13573	Cardiovascular Diseases	C0007222		Approved			CHEBI_94615		MONDO_0004995	"10007649"	"49601007"
netupitant	DB09048	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_85155	"1552337"			"18846006"
aflibercept	DB08885	metastasis from malignant neoplasm of colon	C1282500		Approved				"1304475|1232150"	MONDO_0041448		
adalimumab	DB00051	Chronic small plaque psoriasis	C0406317		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"			"200965009"
adalimumab	DB00051	Rheumatoid Arthritis	C0003873		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
nivolumab	DB09035	Metastatic Renal Cell Cancer	C0278678		Approved				"1597876"			
nintedanib	DB09079	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_85164	"1592737"	MONDO_0005233	"10061873"	"254637007"
carbenicillin	DB00578	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3393	"2015"			"301011002"
ceftolozane	DB09050	Sepsis caused by Serratia	C2887097		Approved			CHEBI_134719	"1597609"			"449084002"
ceftolozane	DB09050	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_134719	"1597609"			"70036007"
ceftolozane	DB09050	Acute pyelonephritis caused by bacterium	C2062473		Approved			CHEBI_134719	"1597609"			"838353009"
adalimumab	DB00051	Arthritis, Psoriatic	C0003872		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0011849	"10037162"	"156370009"
ramucirumab	DB05578	Malignant neoplasm of colon and/or rectum	C4722085		Approved				"1535922"			"781382000"
ceftolozane	DB09050	Sepsis caused by Haemophilus influenzae	C2887091		Approved			CHEBI_134719	"1597609"			"447685007"
olaparib	DB09074	Epithelial tumor of ovary	C0341823		Approved			CHEBI_83766	"1597582"	MONDO_0002229		"237057005"
aflibercept	DB08885	Central retinal vein occlusion with macular edema	C0339498		Approved				"1304475|1232150"			"232039004"
finafloxacin	DB09047	Acute otitis externa	C0149948		Approved			CHEBI_85176	"1598641"	MONDO_0001051		"30250000"
carbenicillin	DB00578	Proteus urinary tract infection	C0577709		Approved			CHEBI_3393	"2015"			"301012009"
olaparib	DB09074	Germline BRCA-mutated, HER2-negative metastatic breast cancer	C4708088		Approved			CHEBI_83766	"1597582"			"767444009"
aflibercept	DB08885	Branch retinal vein occlusion with macular edema	C0339507		Approved				"1304475|1232150"			"232048009"
nintedanib	DB09079	Interstitial lung fibrosis	C3887486		Approved			CHEBI_85164	"1592737"			"125565008"
adalimumab	DB00051	Non-infectious anterior uveitis	C0339317		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0017634		"267619000"
adalimumab	DB00051	Behcet Syndrome	C0004943		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0007191	"10004213"	"310701003"
olaparib	DB09074	Human epidermal growth factor 2 negative carcinoma of breast	C2316304		Approved			CHEBI_83766	"1597582"			"431396003"
adalimumab	DB00051	Hidradenitis Suppurativa	C0162836		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0006559		"59393003"
acotiamide	DB12482	Nonulcer dyspepsia	C0267167		Approved			CHEBI_34523				"3696007"
aflibercept	DB08885	Macular edema due to diabetes mellitus	C0730285		Approved				"1304475|1232150"	MONDO_0004728		"312912001"
aflibercept	DB08885	Glaucoma, Neovascular	C0017609		Approved				"1304475|1232150"	MONDO_0019783		"232086000"
pembrolizumab	DB09037	Metastatic Renal Cell Cancer	C0278678		Approved				"1547545"			
tocilizumab	DB06273	Still's disease with juvenile onset and/or adult onset	C1456792		Approved				"612865"			
tocilizumab	DB06273	Rheumatoid Arthritis	C0003873		Approved				"612865"	MONDO_0008383	"10039073"	"69896004"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131		Approved				"1597876"	MONDO_0005233	"10061873"	"254637007"
pembrolizumab	DB09037	Non-Small Cell Lung Carcinoma	C0007131		Approved				"1547545"	MONDO_0005233	"10061873"	"254637007"
secukinumab	DB09029	Chronic small plaque psoriasis	C0406317		Approved				"1599788"			"200965009"
alectinib	DB11363	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_90936	"1727455"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00460317	Terminated	Phase 3	Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
pentoxyverine	DB11186	Common Cold	C0009443		Approved			CHEBI_94484	"20217"	MONDO_0005709		"82272006"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT01714037	Terminated	Phase 1		CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT01714037	Terminated	Phase 1		CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
lenvatinib	DB09078	Primary thymic carcinoma	C4302369		Approved			CHEBI_85994	"1603296"			"722670005"
alectinib	DB11363	Anaplastic lymphoma kinase positive anaplastic large cell lymphoma	C4518436		Approved			CHEBI_90936	"1727455"			"738770003"
secukinumab	DB09029	Non-Radiographic Axial Spondyloarthritis	C3889038		Approved				"1599788"			"713777005"
arformoterol	DB01274	Bronchitis, Chronic	C0008677		Approved			CHEBI_408174	"304962"	MONDO_0005607	"10006458"	"63480004"
palbociclib	DB09073	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_85993	"1601374"			"417181009"
nivolumab	DB09035	Malignant neoplasm of esophagus	C0546837		Approved				"1597876"			"363402007"
becaplermin	DB00102	Neuropathic ulcer of foot due to diabetes mellitus	C0406526		Approved				"115238"			"201251005"
nivolumab	DB09035	Microsatellite instability-high colorectal cancer	C4544822		Approved				"1597876"			"737058005"
pembrolizumab	DB09037	Microsatellite instability-high colorectal cancer	C4544822		Approved				"1547545"			"737058005"
nivolumab	DB09035	Classical Hodgkin's Lymphoma	C1333064		Approved				"1597876"			"762690000"
nivolumab	DB09035	Late gastric cancer	C0349531		Approved				"1597876"			"276810009"
pembrolizumab	DB09037	Classical Hodgkin's Lymphoma	C1333064		Approved				"1547545"			"762690000"
palbociclib	DB09073	Human epidermal growth factor 2 negative carcinoma of breast	C2316304		Approved			CHEBI_85993	"1601374"			"431396003"
corticotropin	DB01285	Exacerbation of multiple sclerosis	C0581392		Approved			CHEBI_3892	"376"			"192929006"
bevacizumab	DB00112	Metastatic Renal Cell Cancer	C0278678		Approved				"253337|2046138"			
certolizumab pegol	DB08904	Rheumatoid Arthritis	C0003873		Approved				"709271"	MONDO_0008383	"10039073"	"69896004"
golimumab	DB06674	Rheumatoid Arthritis	C0003873		Approved				"819300"	MONDO_0008383	"10039073"	"69896004"
efalizumab	DB00095	Chronic small plaque psoriasis	C0406317		Approved				"356988"			"200965009"
ustekinumab	DB05679	Psoriasis	C0033860		Approved				"847083"	MONDO_0005083	"10037153"	"9014002"
certolizumab pegol	DB08904	Arthritis, Psoriatic	C0003872		Approved				"709271"	MONDO_0011849	"10037162"	"156370009"
golimumab	DB06674	Arthritis, Psoriatic	C0003872		Approved				"819300"	MONDO_0011849	"10037162"	"156370009"
cetuximab	DB00002	Malignant Rectal Neoplasm	C0949022		Approved				"318341"			"363351006"
ustekinumab	DB05679	Arthritis, Psoriatic	C0003872		Approved				"847083"	MONDO_0011849	"10037162"	"156370009"
bevacizumab	DB00112	Malignant epithelial tumor of ovary	C0346161		Approved				"253337|2046138"			"254849005"
bevacizumab	DB00112	Malignant neoplasm of colon and/or rectum	C4722085		Approved				"253337|2046138"			"781382000"
canakinumab	DB06168	Systemic onset juvenile chronic arthritis	C1384600		Approved				"853491"			"201796004"
denosumab	DB06643	Drug-induced osteoporosis	C0264115		Approved				"993449"			"14651005"
panitumumab	DB01269	Metastatic malignant neoplasm to colon	C0346974		Approved				"263034"	MONDO_0041447		"94260004"
bevacizumab	DB00112	Metastatic malignant neoplasm to colon	C0346974		Approved				"253337|2046138"	MONDO_0041447		"94260004"
ofatumumab	DB06650	Multiple Sclerosis, Acute Relapsing	C0393664		Approved				"712566"			"230372003"
brentuximab vedotin	DB08870	Anaplastic large T-cell systemic malignant lymphoma	C1275317		Approved				"1147320"			"404134006"
ipilimumab	DB06186	Microsatellite instability-high colorectal cancer	C4544822		Approved				"1094833"			"737058005"
bevacizumab	DB00112	Non-small cell lung cancer with mutation in epidermal growth factor receptor	C3840002		Approved				"253337|2046138"			"703228009"
cetuximab	DB00002	Squamous cell carcinoma of nose	C3163899		Approved				"318341"			"448930008"
bevacizumab	DB00112	Nonsquamous nonsmall cell neoplasm of lung	C2585890		Approved				"253337|2046138"			"440173001"
bevacizumab	DB00112	Malignant neoplasm of fallopian tube	C0153579		Approved				"253337|2046138"			"363444001"
carbidopa	DB00190	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_39585	"2019|1545982"	MONDO_0001945		"19972008"
certolizumab pegol	DB08904	Chronic small plaque psoriasis	C0406317		Approved				"709271"			"200965009"
infliximab	DB00065	Chronic small plaque psoriasis	C0406317		Approved				"1790539|1927283|191831|2266523|2103476"			"200965009"
etanercept	DB00005	Rheumatoid Arthritis	C0003873		Approved			CHEBI_4875	"214555|2103480|2462511"	MONDO_0008383	"10039073"	"69896004"
triamcinolone hexacetonide	DB00620	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_9667	"10759"			"53891004"
etanercept	DB00005	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_4875	"214555|2103480|2462511"			"200965009"
trastuzumab	DB00072	Peritonsillar cellulitis	C0553656		Approved				"2289225|2103478|2174802|2280730|2107051|224905"			"102453009"
etanercept	DB00005	Arthritis, Psoriatic	C0003872		Approved			CHEBI_4875	"214555|2103480|2462511"	MONDO_0011849	"10037162"	"156370009"
infliximab	DB00065	Arthritis, Psoriatic	C0003872		Approved				"1790539|1927283|191831|2266523|2103476"	MONDO_0011849	"10037162"	"156370009"
eculizumab	DB01257	Congenital hemolytic uremic syndrome	C2919522		Approved				"591781"			"444976001"
ranibizumab	DB01270	Central retinal vein occlusion with macular edema	C0339498		Approved				"595060"			"232039004"
trastuzumab	DB00072	Metastatic malignant neoplasm to stomach	C0686068		Approved				"2289225|2103478|2174802|2280730|2107051|224905"			"94606003"
ranibizumab	DB01270	Branch retinal vein occlusion with macular edema	C0339507		Approved				"595060"			"232048009"
rituximab	DB00073	Pemphigus Vulgaris	C0030809		Approved				"2273510|2472325|121191|2105824"	MONDO_0008219		"49420001"
trastuzumab	DB00072	Secondary malignant neoplasm of female breast	C0346993		Approved				"2289225|2103478|2174802|2280730|2107051|224905"			"94297009"
rituximab	DB00073	Pemphigus Foliaceus	C0263313		Approved				"2273510|2472325|121191|2105824"	MONDO_0019324		"35154004"
triamcinolone hexacetonide	DB00620	Alopecia Areata	C0002171		Approved			CHEBI_9667	"10759"	MONDO_0005340	"10001761"	"68225006"
ranibizumab	DB01270	Macular edema due to diabetes mellitus	C0730285		Approved				"595060"	MONDO_0004728		"312912001"
ranibizumab	DB01270	Choroidal retinal neovascularization	C0271066		Approved				"595060"			"75971007"
pegfilgrastim	DB00019	Chemotherapy induced neutropenia	C1827687		Approved				"2469333|2102692|338036|2048018|2260702"			
filgrastim	DB00099	Chemotherapy induced neutropenia	C1827687		Approved				"1605064|1433764|2057198|68442"			
lipegfilgrastim	DB13200	Chemotherapy induced neutropenia	C1827687		Approved				"1440046"			
epoetin alfa	DB00016	Anemia due to chemotherapy	C1998329		Approved				"2047589|105695|105694"			
tryptophan	DB00150	Non-Small Cell Lung Carcinoma	C0007131	NCT02460367	Terminated	Phase 1	Lack of enrollment and changing landscape of standard of care.	CHEBI_16828	"10898"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT02460367	Terminated	Phase 1	Lack of enrollment and changing landscape of standard of care.	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT00179699	Terminated	Phase 1		CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB00480	Non-Small Cell Lung Carcinoma	C0007131	NCT00179699	Terminated	Phase 1		CHEBI_63791	"342369"	MONDO_0005233	"10061873"	"254637007"
carbinoxamine	DB00748	Common Cold	C0009443		Approved			CHEBI_3398	"20220"	MONDO_0005709		"82272006"
epoetin theta	DB00016	Anemia due to chemotherapy	C1998329		Approved				"2047589|105695|105694"			
aldesleukin	DB00041	Metastatic Renal Cell Cancer	C0278678		Approved				"70223"			
decitabine	DB01262	Non-Small Cell Lung Carcinoma	C0007131	NCT03233724	Terminated	Phase 1/Phase 2	Study terminated due to drug supply issues.	CHEBI_50131	"15657"	MONDO_0005233	"10061873"	"254637007"
folic acid	DB00158	Non-Small Cell Lung Carcinoma	C0007131	NCT04265534	Terminated	Phase 2	Lack of Clinical Benefit	CHEBI_27470	"62356|4511|202634"	MONDO_0005233	"10061873"	"254637007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT04265534	Terminated	Phase 2	Lack of Clinical Benefit	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT04265534	Terminated	Phase 2	Lack of Clinical Benefit	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
	DB01234	Non-Small Cell Lung Carcinoma	C0007131	NCT04265534	Terminated	Phase 2	Lack of Clinical Benefit	CHEBI_41879	"3264"	MONDO_0005233	"10061873"	"254637007"
vonoprazan	DB11739	Gastro-esophageal reflux disease with esophagitis	C0677659		Approved			CHEBI_136048	"2604577"			"266433003"
elosulfase alfa	DB09051	Mucopolysaccharidosis, MPS-IV-A	C0086651		Approved				"1489914"			"130197005"
sonidegib	DB09143	Basal cell carcinoma	C0007117		Approved			CHEBI_90863	"1659191"	MONDO_0020804		"1338007"
eluxadoline	DB09272	Irritable bowel syndrome with diarrhea	C0348898		Approved			CHEBI_85980	"1653781"			"197125005"
filgrastim	DB00099	Congenital neutropenia	C0340970		Approved				"1605064|1433764|2057198|68442"			"89655007"
filgrastim	DB00099	Chronic idiopathic neutropenia	C2267231		Approved				"1605064|1433764|2057198|68442"			"248693006"
epoetin alfa	DB00016	Anemia in chronic kidney disease	C1561828		Approved				"2047589|105695|105694"			"707323002"
filgrastim	DB00099	Relapsing acute myeloid leukemia	C2349276		Approved				"1605064|1433764|2057198|68442"			"12281000132104"
evolocumab	DB09303	Familial hypercholesterolemia - heterozygous	C0342882		Approved				"1665684"			"238079002"
evolocumab	DB09303	Homozygous Familial Hypercholesterolemia	C0342881		Approved				"1665684"			"238078005"
sargramostim	DB00020	Chemotherapy induced neutropenia	C1827687		Approved				"69634"			
alglucosidase alfa	DB01272	Generalized glycogen storage disease of infants	C0342751		Approved				"2475360|629565|2475361"			
anakinra	DB00026	Rheumatoid Arthritis	C0003873		Approved				"72435"	MONDO_0008383	"10039073"	"69896004"
collagenase	DB00048	Dupuytren's disease of finger, with contracture	C0410065		Approved				"898492|2475861|58939"			
imatinib	DB00619	Non-Small Cell Lung Carcinoma	C0007131	NCT02127372	Terminated	Phase 1/Phase 2	The study was closed due to poor accrual	CHEBI_45783	"282388"	MONDO_0005233	"10061873"	"254637007"
	DB00515	Non-Small Cell Lung Carcinoma	C0007131	NCT02127372	Terminated	Phase 1/Phase 2	The study was closed due to poor accrual	CHEBI_27899	"2555"	MONDO_0005233	"10061873"	"254637007"
bevacizumab	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00378573	Terminated	Phase 2	Incidence of GI Perforation		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT02127372	Terminated	Phase 1/Phase 2	The study was closed due to poor accrual	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
prednisolone	DB00860	Crohn Disease	C0010346		Approved			CHEBI_8378	"8638"	MONDO_0005011	"10011401"	"34000006"
uridine triacetate	DB09144	Hereditary orotic aciduria	C0220987		Approved			CHEBI_90914	"1665222"			"16242007"
uridine triacetate	DB02745	Hereditary orotic aciduria	C0220987		Approved			CHEBI_16704	"11017"			"16242007"
sebelipase alfa	DB11563	Wolman Disease	C0043208		Approved				"1726975"	MONDO_0019148		"82500001"
mogamulizumab	DB12498	Mycosis Fungoides	C0026948		Approved				"2054077|2054068"	MONDO_0009691		"118618005"
turoctocog alfa	DB09109	Hemophilia A	C0019069		Approved				"1737557"	MONDO_0010602		"28293008"
cariprazine	DB06016	Mixed bipolar I disorder	C0236780		Approved			CHEBI_90933	"1667655"			"16506000"
protamine sulfate	DB09141	Heparin overdose	C0573789		Approved				"8825"			"296926001"
protamine sulfate	DB13700	Heparin overdose	C0573789		Approved				"8826"			"296926001"
cariprazine	DB06016	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_90933	"1667655"			"191618007"
agalsidase beta	DB00103	Fabry Disease	C0002986		Approved				"338817"	MONDO_0010526	"10016016"	"16652001"
agalsidase alfa	DB15874	Fabry Disease	C0002986		Approved				"259351"	MONDO_0010526	"10016016"	"16652001"
flibanserin	DB04908	Hypoactive Sexual Desire Disorder	C0020594		Approved			CHEBI_90865	"1665509"			"270903007"
saroglitazar	DB13115	Dyslipidemia due to type 2 diabetes mellitus	C3661933		Approved			CHEBI_134708				"761000119102"
idarucizumab	DB09264	Drug-induced coagulation inhibitor disorder	C0272373		Approved				"1716191"			"16773005"
pegvisomant	DB00082	Acromegaly	C0001206		Approved				"278739"	MONDO_0019933	"10000599"	"74107003"
alirocumab	DB09302	Familial hypercholesterolemia - heterozygous	C0342882		Approved				"1659152"			"238079002"
uridine triacetate	DB09144	Antimetabolite overdose	C0572583		Approved			CHEBI_90914	"1665222"			"295696001"
uridine triacetate	DB02745	Antimetabolite overdose	C0572583		Approved			CHEBI_16704	"11017"			"295696001"
somatrem	DB09098	Pituitary dwarfism	C0013338		Approved				"56570"	MONDO_0000050|MONDO_0006909		"367460001"
alirocumab	DB09302	Complex dyslipidemia	C3875286		Approved				"1659152"			"109041000119107"
ozenoxacin	DB12924	Acne Vulgaris	C0001144		Approved			CHEBI_136050	"1994739"			"88616000"
abatacept	DB01281	Rheumatoid Arthritis	C0003873		Approved				"614391"	MONDO_0008383	"10039073"	"69896004"
ixekizumab	DB11569	Chronic small plaque psoriasis	C0406317		Approved				"1745099"			"200965009"
mepolizumab	DB06612	Asthma	C0004096		Approved				"1720597"	MONDO_0004979	"10003553"	"195967001"
alefacept	DB00092	Chronic small plaque psoriasis	C0406317		Approved				"299635"			"200965009"
carmofur	DB09010	Malignant tumor of colon	C0007102		Approved			CHEBI_31360		MONDO_0021063	"10009944"	"363406005"
necitumumab	DB09559	Non-Small Cell Lung Carcinoma	C0007131		Approved				"1723738"	MONDO_0005233	"10061873"	"254637007"
osimertinib	DB09330	Epidermal growth factor receptor positive non-small cell lung cancer	C1960925		Approved			CHEBI_90943	"1721560"			"426964009"
eftrenonacog alfa	DB11608	Hemophilia B	C0008533		Approved				"1535944"	MONDO_0010604	"10016077"	"41788008"
ixekizumab	DB11569	Non-Radiographic Axial Spondyloarthritis	C3889038		Approved				"1745099"			"713777005"
carmustine	DB00262	Brain Glioblastoma	C0349543		Approved			CHEBI_3423	"2105"	MONDO_0002501		"276828006"
ozenoxacin	DB12924	Superficial bacterial infection of skin	C0342985		Approved			CHEBI_136050	"1994739"			"275441009"
necitumumab	DB09559	Squamous non-small cell lung cancer	C4509816		Approved				"1723738"			"723301009"
octocog alfa	DB00025	Hemophilia A	C0019069		Approved				"1300486"	MONDO_0010602		"28293008"
nemonoxacin	DB06600	Community acquired pneumonia	C0694549		Approved			CHEBI_136053				"385093006"
migalastat	DB05018	Fabry Disease	C0002986		Approved			CHEBI_135923	"2054252"	MONDO_0010526	"10016016"	"16652001"
elotuzumab	DB06317	Relapse multiple myeloma	C2349261		Approved				"1726104"			"452291000124109"
lenograstim	DB13144	Chemotherapy induced neutropenia	C1827687		Approved				"70167"			
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT00732303	Terminated	Phase 2	Study terminated due to withdrawal of pharmaceutical funding	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB01223	Non-Small Cell Lung Carcinoma	C0007131	NCT02080078	Terminated	Phase 1	REB decision	CHEBI_2659	"689"	MONDO_0005233	"10061873"	"254637007"
radotinib	DB12323	Myeloid Leukemia, Chronic	C0023473		Approved					MONDO_0011996		
	DB00277	Non-Small Cell Lung Carcinoma	C0007131	NCT02080078	Terminated	Phase 1	REB decision	CHEBI_28177	"10438|91178"	MONDO_0005233	"10061873"	"254637007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT02947113	Withdrawn	Phase 2	New studies available with immunotherapy so recruitment is no longer acceptable.	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
lifitegrast	DB11611	Dry Eye Syndromes	C0013238		Approved			CHEBI_133023	"1801820"	MONDO_0006733		"46152009"
brodalumab	DB11776	Chronic small plaque psoriasis	C0406317		Approved				"1872251"			"200965009"
pancrelipase	DB00085	Exocrine pancreatic insufficiency	C0267963		Approved				"1427034|235379|7880"	MONDO_0001684		"47367009"
velpatasvir	DB11613	Early cirrhosis	C1299579		Approved			CHEBI_133009	"1799206"			"371139006"
carfenazine	DB01038	Chronic schizophrenia	C0221765		Approved			CHEBI_51235				"83746006"
brodalumab	DB11776	Non-Radiographic Axial Spondyloarthritis	C3889038		Approved				"1872251"			"713777005"
obeticholic acid	DB05990	Primary cholangitis	C0267919		Approved			CHEBI_43602	"1798288"			"17266006"
darbepoetin alfa	DB00012	Anemia due to and following chemotherapy	C4708167		Approved				"283838"			"767657005"
eptacog alfa (activated)	DB00036	Hemophilia A	C0019069		Approved				"4256|253149|2386863"	MONDO_0010602		"28293008"
moroctocog alfa	DB13999	Hemophilia A	C0019069		Approved				"1300485"	MONDO_0010602		"28293008"
efmoroctocog alfa	DB11607	Hemophilia A	C0019069		Approved				"1543095"	MONDO_0010602		"28293008"
epoetin beta	DB00016	Anemia in chronic kidney disease	C1561828		Approved				"2047589|105695|105694"			"707323002"
methoxy polyethylene glycol-epoetin beta	DB09107	Anemia in chronic kidney disease	C1561828		Approved				"729596"			"707323002"
epoetin zeta	DB00016	Anemia in chronic kidney disease	C1561828		Approved				"2047589|105695|105694"			"707323002"
atezolizumab	DB11595	Carcinoma, Transitional Cell	C0007138		Approved				"1792776"	MONDO_0006474	"10044412"	"27090000"
alipogene tiparvovec	DB13521	Hyperlipoproteinemia Type I	C0023817		Approved							"275598004"
lenograstim	DB13144	Relapsing acute myeloid leukemia	C2349276		Approved				"70167"			"12281000132104"
conestat alfa	DB09228	Hereditary C1 esterase inhibitor deficiency - deficient factor	C0398775		Approved				"1599831"			"234619000"
talc	DB09511	Secondary spontaneous pneumothorax	C3161098		Approved			CHEBI_32178	"10323"			"328571000119101"
gluconolactone	DB04564	Urinary Bladder Calculi (disorder)	C0005683		Approved			CHEBI_16217	"25842"	MONDO_0006678	"10006987"	"70650003"
atezolizumab	DB11595	Extensive stage primary small cell carcinoma of lung	C4303663		Approved				"1792776"			"683991000119103"
paracetamol	DB00316	Influenza-like symptoms	C0392171		Approved			CHEBI_46195	"161"			
paracetamol	DB00316	Headache Disorders	C0393735		Approved			CHEBI_46195	"161"			"230461009"
baricitinib	DB11817	Rheumatoid Arthritis	C0003873		Approved			CHEBI_95341	"2047232"	MONDO_0008383	"10039073"	"69896004"
paracetamol	DB00316	Common Cold	C0009443		Approved			CHEBI_46195	"161"	MONDO_0005709		"82272006"
dupilumab	DB12159	Asthma	C0004096		Approved				"1876376"	MONDO_0004979	"10003553"	"195967001"
icotinib	DB11737	Non-Small Cell Lung Carcinoma	C0007131		Approved					MONDO_0005233	"10061873"	"254637007"
olmutinib	DB13164	Non-Small Cell Lung Carcinoma	C0007131		Approved					MONDO_0005233	"10061873"	"254637007"
etoposide	DB00773	Non-Small Cell Lung Carcinoma	C0007131	NCT02947113	Withdrawn	Phase 2	New studies available with immunotherapy so recruitment is no longer acceptable.	CHEBI_4911	"4179"	MONDO_0005233	"10061873"	"254637007"
ceritinib	DB09063	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_78432	"1535457"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02080078	Terminated	Phase 1	REB decision	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT02737709	Terminated	Phase 2	The study have difficulty in recruiting subjectes	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
azacitidine	DB00928	Non-Small Cell Lung Carcinoma	C0007131	NCT00901537	Terminated	Phase 1	Sponsor terminated due to no enrollments within last 4 months.	CHEBI_2038	"1251"	MONDO_0005233	"10061873"	"254637007"
niraparib	DB11793	Malignant epithelial tumor of ovary	C0346161		Approved			CHEBI_176844	"1918231"			"254849005"
naldemedine	DB11691	Therapeutic opioid induced constipation	C3874358		Approved				"1876597"			"136801000119102"
ribociclib	DB11730	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved				"1873916"			"417181009"
simoctocog alfa	DB09108	Hemophilia A	C0019069		Approved				"1729084"	MONDO_0010602		"28293008"
apatinib	DB14765	Metastatic malignant neoplasm to stomach	C0686068		Approved							"94606003"
benzoic acid	DB03793	Scleroderma	C0011644		Approved			CHEBI_30746	"18989"	HP:0100324	"10039710"	"267874003"
avelumab	DB11945	Merkel cell carcinoma	C0007129		Approved				"1875534"	MONDO_0019210	"10029266"	"5052009"
cerliponase alfa	DB13173	Late-Infantile Neuronal Ceroid Lipfuscinosis	C0022340		Approved				"1922436"			"14637005"
trafermin	DB14131	Alveolar Bone Loss	C0002382		Approved					HP:0006308	"10074846"	"109706009"
plecanatide	DB13170	Chronic idiopathic constipation	C0267509		Approved				"1873752"			"82934008"
carvedilol	DB01136	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_3441	"20352"			"429589006"
niraparib	DB11793	Carcinoma in situ of fallopian tube	C0347176		Approved			CHEBI_176844	"1918231"			"92591008"
baricitinib	DB11817	Alopecia Areata	C0002171		Approved			CHEBI_95341	"2047232"	MONDO_0005340	"10001761"	"68225006"
pegademase	DB00061	Adenosine deaminase deficiency	C0268124		Approved				"59768"			"44940001"
sarilumab	DB11767	Rheumatoid Arthritis	C0003873		Approved				"1923319"	MONDO_0008383	"10039073"	"69896004"
brigatinib	DB12267	Non-Small Cell Lung Carcinoma	C0007131		Approved				"1921217"	MONDO_0005233	"10061873"	"254637007"
guselkumab	DB11834	Chronic small plaque psoriasis	C0406317		Approved				"1928588"			"200965009"
durvalumab	DB11714	Non-Small Cell Lung Carcinoma	C0007131		Approved				"1919503"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00048087	Withdrawn	Phase 2	Slow accrual.	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
gefitinib	DB00317	Non-Small Cell Lung Carcinoma	C0007131	NCT00048087	Withdrawn	Phase 2	Slow accrual.	CHEBI_49668	"328134"	MONDO_0005233	"10061873"	"254637007"
cefaclor	DB00833	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3478	"1450910|2176"			"70036007"
cefaclor	DB00833	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3478	"1450910|2176"			"302809008"
cefaclor	DB00833	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3478	"1450910|2176"			"406602003"
cefaclor	DB00833	Infective otitis media	C0729586		Approved			CHEBI_3478	"1450910|2176"			"312218008"
vaborbactam	DB12107	Urinary tract infection caused by Escherichia coli	C0577708		Approved				"1945213"			"301011002"
cefadroxil	DB01140	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3479	"1545975|2177"			"302809008"
cefadroxil	DB01140	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3479	"1545975|2177"			"301011002"
cefadroxil	DB01140	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3479	"1545975|2177"			"406602003"
betrixaban	DB12364	At risk of venous thromboembolus	C1960639		Approved			CHEBI_140421	"1927851"			"427631000"
glecaprevir	DB13879	Early cirrhosis	C1299579		Approved				"1940635"			"371139006"
pibrentasvir	DB13878	Early cirrhosis	C1299579		Approved				"1940636"			"371139006"
cefaclor	DB00833	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_3478	"1450910|2176"			"195722003"
abemaciclib	DB12001	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved				"1946825"			"417181009"
lonoctocog alfa	DB13998	Hemophilia A	C0019069		Approved				"1796377"	MONDO_0010602		"28293008"
cefaclor	DB00833	Acute bacterial bronchitis	C0339933		Approved			CHEBI_3478	"1450910|2176"			"233598009"
cefadroxil	DB01140	Proteus urinary tract infection	C0577709		Approved			CHEBI_3479	"1545975|2177"			"301012009"
abaloparatide	DB05084	At risk of osteoporotic fracture	C1272017		Approved				"1921069"			"391040000"
zabofloxacin	DB12479	Acute infective exacerbation of chronic obstructive airways disease	C0563269		Approved							"285381006"
durvalumab	DB11714	Carcinoma, Transitional Cell	C0007138		Approved				"1919503"	MONDO_0006474	"10044412"	"27090000"
vaborbactam	DB12107	Urinary tract infection caused by Klebsiella	C4076057		Approved				"1945213"			"369001000119100"
midostaurin	DB06595	Aggressive Systemic Mastocytosis	C1112486		Approved			CHEBI_63452	"1919083"	MONDO_0020333		"397008008"
abemaciclib	DB12001	Human epidermal growth factor 2 negative carcinoma of breast	C2316304		Approved				"1946825"			"431396003"
cefamandole	DB01326	Escherichia coli septicemia	C0276088		Approved			CHEBI_3480	"2178"			
cefamandole	DB01326	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_3480	"2178"			"186435004"
apalutamide	DB11901	Metastasis from malignant tumor of prostate	C1282496		Approved				"1999574"			
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03091491	Terminated	Phase 2	Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative therapy and clinician's choice to put patient on immunotherapy outside of trial setting.		"1597876"	MONDO_0005233	"10061873"	"254637007"
folic acid	DB00158	Renal Cell Carcinoma	C0007134	NCT00485563	Terminated	Phase 2	Changes in treatment paradigm resulted in a lower than expected rate of accrual.	CHEBI_27470	"62356|4511|202634"	HP:0005584	"10067946"	"41607009"
cefamandole	DB01326	Escherichia coli Infections	C0014836		Approved			CHEBI_3480	"2178"	MONDO_0020920		"71057007"
decitabine	DB01262	Renal Cell Carcinoma	C0007134	NCT00561912	Terminated	Phase 2	Low accrual.	CHEBI_50131	"15657"	HP:0005584	"10067946"	"41607009"
cefamandole	DB01326	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3480	"2178"			"406602003"
cefamandole	DB01326	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3480	"2178"			"70036007"
cefamandole	DB01326	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3480	"2178"			"302809008"
cefamandole	DB01326	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3480	"2178"			"301011002"
tildrakizumab	DB14004	Chronic small plaque psoriasis	C0406317		Approved				"2053436|2053449"			"200965009"
dacomitinib	DB11963	Epidermal growth factor receptor positive non-small cell lung cancer	C1960925		Approved			CHEBI_132268	"2058848|2058849"			"426964009"
cefamandole	DB01326	Arthropathy associated with infection	C0157749		Approved			CHEBI_3480	"2178"			"363162000"
padeliporfin	DB15575	Adenocarcinoma of prostate	C0007112		Approved					MONDO_0005082		"399490008"
burosumab	DB14012	Vitamin D-Resistant Rickets, X-Linked	C3536984		Approved				"2043854|2043855"			"82236004"
emicizumab	DB13923	Hemophilia A	C0019069		Approved				"1989795|1989794"	MONDO_0010602		"28293008"
cefamandole	DB01326	Proteus urinary tract infection	C0577709		Approved			CHEBI_3480	"2178"			"301012009"
fostamatinib	DB12010	Thrombocytopenia due to platelet alloimmunization	C0272286		Approved				"2044896"			"2897005"
fostamatinib	DB07159	Thrombocytopenia due to platelet alloimmunization	C0272286		Approved			CHEBI_91348				"2897005"
cefamandole	DB01326	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_3480	"2178"			"128945009"
cefamandole	DB01326	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3480	"2178"			"428783003"
fosnetupitant	DB14019	Chemotherapy-induced nausea and vomiting	C0401160		Approved				"2044417"			"18846006"
larotrectinib	DB14723	Malignant Neoplasm (Morphology)	C1288351		Approved				"2105628"			
vibegron	DB14895	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_142418	"2472254"			
cefazolin	DB01327	Pneumonia, Bacterial	C0004626		Approved			CHEBI_474053	"2180"	MONDO_0004652	"10060946"	"53084003"
calaspargase pegol	DB14730	Acute lymphoblastic leukemia - category	C1531702		Approved				"2121417|2121416"			
omadacycline	DB12455	Pneumonia, Bacterial	C0004626		Approved			CHEBI_177758	"2059269"	MONDO_0004652	"10060946"	"53084003"
lorlatinib	DB12130	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_143117	"2103164"	MONDO_0005233	"10061873"	"254637007"
mepacrine	DB01103	Renal Cell Carcinoma	C0007134	NCT00574483	Withdrawn	Phase 2	reevaluation of compound development	CHEBI_8711	"9061"	HP:0005584	"10067946"	"41607009"
cefdinir	DB00535	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3485	"25037"			"302809008"
cefdinir	DB00535	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3485	"25037"			"70036007"
cefdinir	DB00535	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3485	"25037"			"406602003"
cefdinir	DB00535	Infective otitis media	C0729586		Approved			CHEBI_3485	"25037"			"312218008"
tagraxofusp	DB14731	Blastic plasmacytoid dendritic cell neoplasm	C1301363		Approved				"2109055|2109054"	MONDO_0019467		"445105005"
cefazolin	DB01327	Arthropathy associated with infection	C0157749		Approved			CHEBI_474053	"2180"			"363162000"
patisiran	DB14582	Amyloid Neuropathies	C0206247		Approved				"2053490"			"193187004"
inotersen	DB14713	Amyloid Neuropathies	C0206247		Approved				"2099289"			"193187004"
cefdinir	DB00535	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_3485	"25037"			"195722003"
andexanet alfa	DB14562	Direct acting anticoagulant adverse reaction	C0570328		Approved				"2045114"			"293332005"
baloxavir marboxil	DB13997	Influenza	C0021400		Approved				"2099995"		"10022000"	"6142004"
brexanolone	DB11859	Depression, Postpartum	C0221074		Approved			CHEBI_50169	"2121777"			"58703003"
erdafitinib	DB12147	Metastatic urothelial carcinoma	C4288754		Approved				"2123125"			"458321000124102"
volanesorsen	DB15067	Chylomicronemia syndrome	C1274228		Approved				"2637345"			"402786009"
condoliase	DB12793	Disorder of lumbar disc	C2733598		Approved				"1546420"			"443700006"
lorlatinib	DB12130	Anaplastic lymphoma kinase fusion oncogene positive non-small cell lung cancer	C5394780		Approved			CHEBI_143117	"2103164"			"830151004"
evocalcet	DB12388	Hypercalcemia due to hyperthyroidism	C0271852		Approved							"2243000"
larotrectinib	DB14723	Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion	C5192106		Approved				"2105628"			"786710002"
bremelanotide	DB11653	Hypoactive Sexual Desire Disorder	C0020594		Approved			CHEBI_177849	"2176312"			"270903007"
elapegademase	DB14712	SCID due to absent adenosine deaminase	C0272230		Approved				"2059218|2059219"			"36980009"
selinexor	DB11942	Relapse multiple myeloma	C2349261		Approved				"2178390"			"452291000124109"
solriamfetol	DB14754	Excessive daytime sleepiness - normal night sleep	C0393764		Approved				"2121751"			"230489007"
cefdinir	DB00535	Acute bacterial sinusitis	C0275556		Approved			CHEBI_3485	"25037"			"75498004"
elapegademase	DB14712	Adenosine deaminase deficiency	C0268124		Approved				"2059218|2059219"			"44940001"
quizartinib	DB12874	Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation	C4543165		Approved			CHEBI_90217	"2643048"			
risankizumab	DB14762	Chronic small plaque psoriasis	C0406317		Approved				"2166132|2166040"			"200965009"
cefditoren pivoxil	DB01066	Group A Streptococcal Infections	C0554628		Approved			CHEBI_59343	"83682"			"302809008"
cefditoren pivoxil	DB01066	Staphylococcus aureus infection	C1318973		Approved			CHEBI_59343	"83682"			"406602003"
cefditoren pivoxil	DB01066	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_59343	"83682"			"70036007"
relebactam	DB12377	Urinary tract infection caused by Escherichia coli	C0577708		Approved				"2184137|2268500"			"301011002"
relebactam	DB12377	Intestinal infection due to Pseudomonas	C0152515		Approved				"2184137|2268500"			"82930004"
upadacitinib	DB15091	Rheumatoid Arthritis	C0003873		Approved				"2196092"	MONDO_0008383	"10039073"	"69896004"
fedratinib	DB12500	Post-essential thrombocythemia myelofibrosis	C3805233		Approved			CHEBI_91408	"2197490"			"871541008"
lefamulin	DB12825	Haemophilus influenzae pneumonia	C0276026		Approved				"2198944"			"70036007"
cefepime	DB01413	Staphylococcus aureus infection	C1318973		Approved			CHEBI_478164	"20481"			"406602003"
cefepime	DB01413	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_478164	"20481"			"301011002"
cefepime	DB01413	Group A Streptococcal Infections	C0554628		Approved			CHEBI_478164	"20481"			"302809008"
cefepime	DB01413	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_478164	"20481"			"186435004"
trifarotene	DB12808	Acne Vulgaris	C0001144		Approved				"2205637"			"88616000"
lefamulin	DB12825	Pneumonia, Bacterial	C0004626		Approved				"2198944"	MONDO_0004652	"10060946"	"53084003"
cefepime	DB01413	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_478164	"20481"	MONDO_0040732		"11218009"
fedratinib	DB12500	Primary Myelofibrosis	C0001815		Approved			CHEBI_91408	"2197490"	MONDO_0009692	"10077161"	"128843003"
tenapanor	DB11761	Irritable bowel syndrome characterized by constipation	C1868889		Approved				"2199674"			"440630006"
relebactam	DB12377	Gastrointestinal infection caused by Klebsiella aerogenes	C1720135		Approved				"2184137|2268500"			"421429008"
entrectinib	DB11986	Reactive oxygen species 1 positive non-small cell lung cancer	C4302554		Approved			CHEBI_195558	"2197862"			"722425009"
pegvaliase	DB12839	Classical phenylketonuria	C0751434		Approved				"2046361|2046360"	MONDO_0019259		"7573000"
relebactam	DB12377	Intestinal infection due to E. coli	C0341558		Approved				"2184137|2268500"			"111839008"
relebactam	DB12377	Pseudomonas gastrointestinal tract infection	C0343337		Approved				"2184137|2268500"			"266078006"
cefiderocol	DB14879	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_140376	"2265702"			"301011002"
cefixime	DB00671	Bronchitis	C0006277		Approved			CHEBI_472657	"25033|1546021"	MONDO_0003781	"10006451"	"32398004"
temsirolimus	DB00877	Renal Cell Carcinoma	C0007134		Approved			CHEBI_9168	"35302"	HP:0005584	"10067946"	"41607009"
pemetrexed	DB00642	Renal Cell Carcinoma	C0007134	NCT00491075	Terminated	Phase 2	Closed early for poor accrual.	CHEBI_63616	"68446"	HP:0005584	"10067946"	"41607009"
axitinib	DB06626	Renal Cell Carcinoma	C0007134	NCT01806064	Terminated	Phase 1/Phase 2	The study did not meet endpoint.	CHEBI_66910	"1242999"	HP:0005584	"10067946"	"41607009"
methylprednisolone	DB00959	Crohn Disease	C0010346		Approved			CHEBI_6888	"6902"	MONDO_0005011	"10011401"	"34000006"
cefixime	DB00671	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_472657	"25033|1546021"	MONDO_0001080		"20943002"
cefixime	DB00671	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_472657	"25033|1546021"			"301011002"
cefixime	DB00671	Infective otitis media	C0729586		Approved			CHEBI_472657	"25033|1546021"			"312218008"
cefixime	DB00671	Group A Streptococcal Infections	C0554628		Approved			CHEBI_472657	"25033|1546021"			"302809008"
crizanlizumab	DB15271	Vaso-occlusive pain episode in sickle cell disease	C4708695		Approved				"2262279|2262421"			"769167005"
teprotumumab	DB06343	Endocrine exophthalmos	C0155264		Approved				"2274802|2274803"	MONDO_0001509		"276177000"
givosiran	DB15066	Porphyrias, Hepatic	C0162533		Approved				"2265712"	MONDO_0002520		"55056006"
osilodrostat	DB11837	Adrenal Gland Hyperfunction	C0001622		Approved				"2286252"	MONDO_0006640|MONDO_0018912	"10020564"	"47270006"
luspatercept	DB12281	beta Thalassemia	C0005283		Approved				"2262543|2262544"		"10043391"	"65959000"
selumetinib	DB11689	Neurofibromatosis 1	C0027831		Approved			CHEBI_90227	"2289380"	MONDO_0008077|MONDO_0018975		"92824003"
enfortumab vedotin	DB13007	Metastatic urothelial carcinoma	C4288754		Approved				"2277607|2268306"			"458321000124102"
turoctocog alfa pegol	DB14738	Hemophilia A	C0019069		Approved					MONDO_0010602		"28293008"
cefiderocol	DB14879	Proteus urinary tract infection	C0577709		Approved			CHEBI_140376	"2265702"			"301012009"
cefixime	DB00671	Proteus urinary tract infection	C0577709		Approved			CHEBI_472657	"25033|1546021"			"301012009"
cefixime	DB00671	Acute bacterial bronchitis	C0339933		Approved			CHEBI_472657	"25033|1546021"			"233598009"
botulinum toxin type A	DB00083	Neurogenic Urinary Bladder	C0005697		Approved				"1712|860168|1000104|860189"	MONDO_0001445	"10029279"	"398064005"
pemigatinib	DB15102	Malignant neoplasm of common bile duct (& [carcinoma])	C1541061		Approved				"2359268"			
selpercatinib	DB15685	metastasis from malignant neoplasm of thyroid	C1282509		Approved				"2370147"			
cefonicid	DB01328	Escherichia coli septicemia	C0276088		Approved			CHEBI_3491	"2183"			
cefmetazole	DB00274	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3489	"2182"			"70036007"
filgotinib	DB14845	Rheumatoid Arthritis	C0003873		Approved					MONDO_0008383	"10039073"	"69896004"
clascoterone	DB12499	Acne Vulgaris	C0001144		Approved				"2474340"			"88616000"
cefonicid	DB01328	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3491	"2183"			"406602003"
cefonicid	DB01328	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_3491	"2183"			"186435004"
pralsetinib	DB15822	Non-Small Cell Lung Carcinoma	C0007131		Approved				"2394936"	MONDO_0005233	"10061873"	"254637007"
cefonicid	DB01328	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3491	"2183"			"70036007"
cefonicid	DB01328	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3491	"2183"			"301011002"
cefonicid	DB01328	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3491	"2183"			"302809008"
cefonicid	DB01328	Infection of bone	C2242472		Approved			CHEBI_3491	"2183"	HP:0002754		"111253001"
oliceridine	DB14881	Severe pain	C0278140		Approved				"2392230"			"76948002"
oliceridine	DB14881	Moderate pain	C0278139		Approved				"2392230"			"50415004"
triheptanoin	DB11677	Disorder of fatty acid metabolism	C0268634		Approved				"1313234"			"39929009"
cefonicid	DB01328	Arthropathy associated with infection	C0157749		Approved			CHEBI_3491	"2183"			"363162000"
lumasiran	DB15935	Primary hyperoxaluria, type I	C0268164		Approved				"2467140"	MONDO_0009823		"65520001"
abametapir	DB11932	Pediculus capitis infestation	C0030757		Approved			CHEBI_192617	"2475532"	MONDO_0003471		"81000006"
fostemsavir	DB11796	Human immunodeficiency virus I infection	C0276500		Approved				"2380373"			"40780007"
somapacitan	DB15093	Adult growth hormone deficiency	C1720505		Approved				"2557394|2557373"			"421684006"
setmelanotide	DB11700	Obesity due to leptin receptor gene deficiency	C5191640		Approved				"2469247"			"785722006"
cefonicid	DB01328	Proteus urinary tract infection	C0577709		Approved			CHEBI_3491	"2183"			"301012009"
vadadustat	DB12255	Anemia in chronic kidney disease	C1561828		Approved							"707323002"
bulevirtide	DB15248	Chronic viral hepatitis B with hepatitis D	C0400918		Approved							"235869004"
bulevirtide	DB14853	Chronic viral hepatitis B with hepatitis D	C0400918		Approved							"235869004"
triheptanoin	DB11677	Long-chain fatty acid transport deficiency	C1960675		Approved				"1313234"			"426387005"
belantamab mafodotin	DB15719	Relapse multiple myeloma	C2349261		Approved				"2387834|2387833"			"452291000124109"
cefonicid	DB01328	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3491	"2183"			"428783003"
pemigatinib	DB15102	Biliary Tract Cancer	C0750952		Approved				"2359268"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
cefotaxime	DB00493	Pneumonia, Bacterial	C0004626		Approved			CHEBI_204928	"2186"	MONDO_0004652	"10060946"	"53084003"
tepotinib	DB15133	Non-Small Cell Lung Carcinoma	C0007131		Approved				"2477103"	MONDO_0005233	"10061873"	"254637007"
cefotaxime	DB00493	Escherichia coli septicemia	C0276088		Approved			CHEBI_204928	"2186"			
metformin	DB00331	Renal Cell Carcinoma	C0007134	NCT02495103	Terminated	Phase 1/Phase 2	Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All subjects are off-study.	CHEBI_6801	"6809"	HP:0005584	"10067946"	"41607009"
relugolix	DB11853	Abnormal uterine bleeding due to uterine fibroid	C5190725		Approved				"2472778"			"16754891000119106"
avelumab	DB11945	Renal Cell Carcinoma	C0007134		Approved				"1875534"	HP:0005584	"10067946"	"41607009"
	DB01590	Renal Cell Carcinoma	C0007134	NCT01115803	Terminated	Phase 1	Primary objective has been met; safety and pharmacokinetics have been characterized.	CHEBI_68478	"141704"	HP:0005584	"10067946"	"41607009"
everolimus	DB01590	Renal Cell Carcinoma	C0007134	NCT01677390	Terminated	Phase 1		CHEBI_68478	"141704"	HP:0005584	"10067946"	"41607009"
infliximab	DB00065	Crohn Disease	C0010346		Approved				"1790539|1927283|191831|2266523|2103476"	MONDO_0005011	"10011401"	"34000006"
cefotaxime	DB00493	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_204928	"2186"			"70036007"
cefotaxime	DB00493	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_204928	"2186"			"186435004"
cefotaxime	DB00493	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_204928	"2186"			"301011002"
cefotaxime	DB00493	Meningitis caused by Klebsiella aerogenes	C1719906		Approved			CHEBI_204928	"2186"			"420585007"
cefotaxime	DB00493	Meningitis, Escherichia coli	C0338395		Approved			CHEBI_204928	"2186"	MONDO_0006753		"192655005"
cefotaxime	DB00493	Female genital tract infection	C1263758		Approved			CHEBI_204928	"2186"			"125585007"
cabotegravir	DB11751	Human immunodeficiency virus I infection	C0276500		Approved			CHEBI_172944	"2475077"			"40780007"
cefotaxime	DB00493	Proteus urinary tract infection	C0577709		Approved			CHEBI_204928	"2186"			"301012009"
daprodustat	DB11682	Anemia in chronic kidney disease	C1561828		Approved			CHEBI_229223	"2628210"			"707323002"
enarodustat	DB14985	Anemia in chronic kidney disease	C1561828		Approved							"707323002"
cefotaxime	DB00493	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_204928	"2186"			"448417001"
trilaciclib	DB15442	Myelosuppression	C0854467		Approved				"2479690"			"370569000"
margetuximab	DB14967	Metastatic human epidermal growth factor 2 positive carcinoma of breast	C4721209		Approved				"2473851|2473850"			"459391000124109"
aducanumab	DB12274	Alzheimer's Disease	C0002395		Approved				"2557217|2557218"	MONDO_0004975	"10012271"	"26929004"
ibrexafungerp	DB12471	Candidiasis of vagina	C0006852		Approved				"2560213"			"72934000"
cefotetan	DB01330	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3499	"2187"			"70036007"
cefotetan	DB01330	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_3499	"2187"			"186435004"
cefotetan	DB01330	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3499	"2187"			"406602003"
cefotetan	DB01330	Escherichia coli Infections	C0014836		Approved			CHEBI_3499	"2187"	MONDO_0020920		"71057007"
cefotetan	DB01330	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3499	"2187"			"301011002"
cefotetan	DB01330	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3499	"2187"			"302809008"
bimekizumab	DB12917	Chronic small plaque psoriasis	C0406317		Approved				"2668041"			"200965009"
peficitinib	DB11708	Rheumatoid Arthritis	C0003873		Approved					MONDO_0008383	"10039073"	"69896004"
cefotetan	DB01330	Pneumonia, Bacterial	C0004626		Approved			CHEBI_3499	"2187"	MONDO_0004652	"10060946"	"53084003"
avalglucosidase alfa	DB16099	Glycogen storage disease type II late onset	C0342753		Approved				"2565814|2565813"	MONDO_0018485		"722343009"
mirogabalin	DB11825	Diabetic peripheral neuropathy	C0740447		Approved							"424736006"
cefotetan	DB01330	Female genital tract infection	C1263758		Approved			CHEBI_3499	"2187"			"125585007"
cefoxitin	DB01331	Female genital tract infection	C1263758		Approved			CHEBI_209807	"2189"			"125585007"
cefotetan	DB01330	Proteus urinary tract infection	C0577709		Approved			CHEBI_3499	"2187"			"301012009"
efgartigimod alfa	DB15270	Thrombocytopenia due to platelet alloimmunization	C0272286		Approved				"2587717"			"2897005"
cefoxitin	DB01331	Postoperative infection	C0392618		Approved			CHEBI_209807	"2189"			"33910007"
finerenone	DB16165	Chronic kidney disease due to type 2 diabetes mellitus	C3662038		Approved				"2562811"			"771000119108"
acetarsol	DB13268	Amebiasis	C0002438		Approved			CHEBI_135135		MONDO_0005644	"10001980"	"111910009"
cefotetan	DB01330	Acute gonococcal endometritis	C0153196		Approved			CHEBI_3499	"2187"	MONDO_0004264		"65295003"
vosoritide	DB11928	Achondroplasia	C0001080		Approved				"2586354"	MONDO_0007037		"86268005"
mirogabalin	DB11825	Peripheral neuropathic pain	C0458960		Approved							"279981003"
cefoxitin	DB01331	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_209807	"2189"			"448417001"
cefoxitin	DB01331	Acute gonococcal endometritis	C0153196		Approved			CHEBI_209807	"2189"	MONDO_0004264		"65295003"
inclisiran	DB14901	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_176399	"2588243"			"238079002"
cefotetan	DB01330	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3499	"2187"			"428783003"
cefoxitin	DB01331	Escherichia coli septicemia	C0276088		Approved			CHEBI_209807	"2189"			
tebentafusp	DB15283	Unresectable Uveal Melanoma	C5419539		Approved				"2590743"			
tebentafusp	DB15283	Metastatic Uveal Melanoma	C4725091		Approved				"2590743"			
cefoxitin	DB01331	Group A Streptococcal Infections	C0554628		Approved			CHEBI_209807	"2189"			"302809008"
cefoxitin	DB01331	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_209807	"2189"			"186435004"
cefoxitin	DB01331	Staphylococcus aureus infection	C1318973		Approved			CHEBI_209807	"2189"			"406602003"
cefoxitin	DB01331	Escherichia coli Infections	C0014836		Approved			CHEBI_209807	"2189"	MONDO_0020920		"71057007"
cefpodoxime proxetil	DB01416	Pneumonia, Bacterial	C0004626		Approved			CHEBI_3504	"20489"	MONDO_0004652	"10060946"	"53084003"
cefoxitin	DB01331	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_209807	"2189"	MONDO_0001080		"20943002"
cefoxitin	DB01331	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_209807	"2189"			"70036007"
cefoxitin	DB01331	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_209807	"2189"			"301011002"
cefoxitin	DB01331	Pneumonia, Bacterial	C0004626		Approved			CHEBI_209807	"2189"	MONDO_0004652	"10060946"	"53084003"
bevacizumab	DB00112	Renal Cell Carcinoma	C0007134	NCT03693573	Withdrawn	Phase 3	In the context of the ongoing evaluation of our data, we have determined that there is no need to generate additional safety data at this time in the 1L mRCC pa		"253337|2046138"	HP:0005584	"10067946"	"41607009"
mitapivat	DB16236	Deficiency of pyruvate kinase	C0340968		Approved				"2594468"	MONDO_0009950		"124331002"
sotrovimab	DB16355	COVID19 (disease)	C5203670		Approved				"2550731"		"10084268"	"840539006"
tapinarof	DB06083	Chronic small plaque psoriasis	C0406317		Approved				"2602286"			"200965009"
cefpodoxime proxetil	DB01416	Infective otitis media	C0729586		Approved			CHEBI_3504	"20489"			"312218008"
cefpodoxime proxetil	DB01416	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_3504	"20489"	MONDO_0001080		"20943002"
cefpodoxime proxetil	DB01416	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3504	"20489"			"70036007"
cefpodoxime proxetil	DB01416	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3504	"20489"			"301011002"
cefpodoxime proxetil	DB01416	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3504	"20489"			"302809008"
ceftazidime	DB00438	Escherichia coli septicemia	C0276088		Approved			CHEBI_3508	"2191|1545984"			
cefprozil	DB01150	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3506	"1546020|19552"			"302809008"
cefprozil	DB01150	Infective otitis media	C0729586		Approved			CHEBI_3506	"1546020|19552"			"312218008"
cefprozil	DB01150	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3506	"1546020|19552"			"406602003"
ceftazidime	DB00438	Pneumonia, Bacterial	C0004626		Approved			CHEBI_3508	"2191|1545984"	MONDO_0004652	"10060946"	"53084003"
ceftazidime	DB00438	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3508	"2191|1545984"			"301011002"
ceftazidime	DB00438	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_3508	"2191|1545984"			"186435004"
ceftazidime	DB00438	Escherichia coli Infections	C0014836		Approved			CHEBI_3508	"2191|1545984"	MONDO_0020920		"71057007"
cefprozil	DB01150	Bronchitis	C0006277		Approved			CHEBI_3506	"1546020|19552"	MONDO_0003781	"10006451"	"32398004"
ceftazidime	DB00438	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3508	"2191|1545984"			"406602003"
ceftazidime	DB00438	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3508	"2191|1545984"			"70036007"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT00975806	Terminated	Phase 1/Phase 2	MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
ceftazidime	DB00438	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3508	"2191|1545984"			"302809008"
everolimus	DB01590	Renal Cell Carcinoma	C0007134		Approved			CHEBI_68478	"141704"	HP:0005584	"10067946"	"41607009"
ceftibuten	DB01415	Infective otitis media	C0729586		Approved			CHEBI_3510	"20492"			"312218008"
ceftibuten	DB01415	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3510	"20492"			"302809008"
ceftizoxime	DB01332	Group A Streptococcal Infections	C0554628		Approved			CHEBI_553473	"2192"			"302809008"
ceftazidime	DB00438	Arthropathy associated with infection	C0157749		Approved			CHEBI_3508	"2191|1545984"			"363162000"
ceftazidime	DB00438	Ecthyma gangrenosum	C0276085		Approved			CHEBI_3508	"2191|1545984"			"17732003"
cefprozil	DB01150	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_3506	"1546020|19552"			"195722003"
acetazolamide	DB00819	Secondary glaucoma	C0149893		Approved			CHEBI_27690	"167"			"95717004"
ceftazidime	DB00438	Proteus urinary tract infection	C0577709		Approved			CHEBI_3508	"2191|1545984"			"301012009"
ceftibuten	DB01415	Acute bacterial bronchitis	C0339933		Approved			CHEBI_3510	"20492"			"233598009"
ceftizoxime	DB01332	Proteus urinary tract infection	C0577709		Approved			CHEBI_553473	"2192"			"301012009"
ceftazidime	DB00438	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_3508	"2191|1545984"			"448417001"
ceftizoxime	DB01332	Escherichia coli septicemia	C0276088		Approved			CHEBI_553473	"2192"			
ceftriaxone	DB01212	Escherichia coli septicemia	C0276088		Approved			CHEBI_29007	"2193"			
ceftizoxime	DB01332	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_553473	"2192"			"301011002"
ceftizoxime	DB01332	Escherichia coli Infections	C0014836		Approved			CHEBI_553473	"2192"	MONDO_0020920		"71057007"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT02626754	Terminated	Phase 2	In most sites had difficult to recruitting subjects.	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
ceftizoxime	DB01332	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_553473	"2192"	MONDO_0001080		"20943002"
pazopanib	DB06589	Renal Cell Carcinoma	C0007134		Approved			CHEBI_71219	"714438"	HP:0005584	"10067946"	"41607009"
ceftizoxime	DB01332	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_553473	"2192"			"186435004"
	DB01268	Renal Cell Carcinoma	C0007134	NCT03323710	Withdrawn	Phase 2	Poor patient recruitment.	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
ceftizoxime	DB01332	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_553473	"2192"			"70036007"
ceftizoxime	DB01332	Staphylococcus aureus infection	C1318973		Approved			CHEBI_553473	"2192"			"406602003"
ceftriaxone	DB01212	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_29007	"2193"	MONDO_0001080		"20943002"
ceftriaxone	DB01212	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_29007	"2193"			"301011002"
ceftriaxone	DB01212	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_29007	"2193"			"70036007"
ceftriaxone	DB01212	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_29007	"2193"			"186435004"
ceftriaxone	DB01212	Meningitis caused by Klebsiella aerogenes	C1719906		Approved			CHEBI_29007	"2193"			"420585007"
ceftizoxime	DB01332	Sepsis caused by Bacteroides	C0276064		Approved			CHEBI_553473	"2192"			"1201760007"
ceftriaxone	DB01212	Meningitis, Escherichia coli	C0338395		Approved			CHEBI_29007	"2193"	MONDO_0006753		"192655005"
ceftizoxime	DB01332	Arthropathy associated with infection	C0157749		Approved			CHEBI_553473	"2192"			"363162000"
ceftriaxone	DB01212	Arthropathy associated with infection	C0157749		Approved			CHEBI_29007	"2193"			"363162000"
ceftriaxone	DB01212	Gonorrhea of pharynx	C0149966		Approved			CHEBI_29007	"2193"			"74372003"
ceftizoxime	DB01332	Acute gonococcal endometritis	C0153196		Approved			CHEBI_553473	"2192"	MONDO_0004264		"65295003"
ceftizoxime	DB01332	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_553473	"2192"			"448417001"
ceftizoxime	DB01332	Acute gonococcal urethritis	C0275652		Approved			CHEBI_553473	"2192"			"29864006"
ceftizoxime	DB01332	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_553473	"2192"			"128945009"
ceftizoxime	DB01332	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_553473	"2192"			"428783003"
cefuroxime	DB01112	Escherichia coli septicemia	C0276088		Approved			CHEBI_3515	"2194"			
ceftriaxone	DB01212	Group A Streptococcal Infections	C0554628		Approved			CHEBI_29007	"2193"			"302809008"
ceftriaxone	DB01212	Escherichia coli Infections	C0014836		Approved			CHEBI_29007	"2193"	MONDO_0020920		"71057007"
ceftriaxone	DB01212	Pneumonia, Bacterial	C0004626		Approved			CHEBI_29007	"2193"	MONDO_0004652	"10060946"	"53084003"
ceftriaxone	DB01212	Infective otitis media	C0729586		Approved			CHEBI_29007	"2193"			"312218008"
cefuroxime	DB01112	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3515	"2194"			"70036007"
cefuroxime	DB01112	Escherichia coli Infections	C0014836		Approved			CHEBI_3515	"2194"	MONDO_0020920		"71057007"
cefuroxime	DB01112	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3515	"2194"			"406602003"
cefuroxime	DB01112	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3515	"2194"			"302809008"
cefuroxime	DB01112	Pneumonia, Bacterial	C0004626		Approved			CHEBI_3515	"2194"	MONDO_0004652	"10060946"	"53084003"
cefuroxime axetil	DB01112	Pneumonia, Bacterial	C0004626		Approved			CHEBI_3515	"2194"	MONDO_0004652	"10060946"	"53084003"
cefuroxime	DB01112	Infective otitis media	C0729586		Approved			CHEBI_3515	"2194"			"312218008"
ipilimumab	DB06186	Renal Cell Carcinoma	C0007134		Approved				"1094833"	HP:0005584	"10067946"	"41607009"
cefuroxime	DB01112	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_3515	"2194"			"186435004"
cefuroxime	DB01112	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3515	"2194"			"301011002"
cefuroxime	DB01112	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_3515	"2194"	MONDO_0001080		"20943002"
cefuroxime axetil	DB01112	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3515	"2194"			"302809008"
cefuroxime axetil	DB01112	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3515	"2194"			"406602003"
cefuroxime axetil	DB01112	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3515	"2194"			"301011002"
cefuroxime	DB01112	Arthropathy associated with infection	C0157749		Approved			CHEBI_3515	"2194"			"363162000"
ceftriaxone	DB01212	Female genital tract infection	C1263758		Approved			CHEBI_29007	"2193"			"125585007"
ceftriaxone	DB01212	Proteus urinary tract infection	C0577709		Approved			CHEBI_29007	"2193"			"301012009"
cefuroxime	DB01112	Gonorrhea of pharynx	C0149966		Approved			CHEBI_3515	"2194"			"74372003"
ceftriaxone	DB01212	Acute gonococcal endometritis	C0153196		Approved			CHEBI_29007	"2193"	MONDO_0004264		"65295003"
cefuroxime	DB01112	Acute gonococcal endometritis	C0153196		Approved			CHEBI_3515	"2194"	MONDO_0004264		"65295003"
ceftriaxone	DB01212	Acute gonococcal urethritis	C0275652		Approved			CHEBI_29007	"2193"			"29864006"
cefuroxime	DB01112	Acute bacterial sinusitis	C0275556		Approved			CHEBI_3515	"2194"			"75498004"
cefuroxime axetil	DB01112	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3515	"2194"			"70036007"
cefuroxime axetil	DB01112	Infective otitis media	C0729586		Approved			CHEBI_3515	"2194"			"312218008"
cefuroxime axetil	DB01112	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_3515	"2194"	MONDO_0001080		"20943002"
deucravacitinib	DB16650	Chronic small plaque psoriasis	C0406317		Approved				"2612087"			"200965009"
celecoxib	DB00482	Rheumatoid Arthritis	C0003873		Approved			CHEBI_41423	"140587"	MONDO_0008383	"10039073"	"69896004"
nivolumab	DB09035	Renal Cell Carcinoma	C0007134	NCT03435640	Terminated	Phase 1/Phase 2	Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.		"1597876"	HP:0005584	"10067946"	"41607009"
hydroxychloroquine	DB01611	Renal Cell Carcinoma	C0007134	NCT01144169	Terminated	Phase 1	barriers to accrual: delay until surgery and additional pre-operative visits	CHEBI_5801	"5521"	HP:0005584	"10067946"	"41607009"
erlotinib	DB00530	Renal Cell Carcinoma	C0007134	NCT01115803	Terminated	Phase 1	Primary objective has been met; safety and pharmacokinetics have been characterized.	CHEBI_114785	"337525"	HP:0005584	"10067946"	"41607009"
valoctocogene roxaparvovec	DB15561	Severe hereditary factor VIII deficiency disease	C0272322		Approved				"2641610"			"16872008"
cefalexin	DB00567	Infective otitis media	C0729586		Approved			CHEBI_3534	"2231|1299782"			"312218008"
cefalexin	DB00567	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3534	"2231|1299782"			"302809008"
cefalexin	DB00567	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3534	"2231|1299782"			"301011002"
cefalexin	DB00567	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3534	"2231|1299782"			"406602003"
cefalotin	DB00456	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_124991	"2236"			"70036007"
cefalotin	DB00456	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_124991	"2236"			"186435004"
tremelimumab	DB11771	Anaplastic lymphoma kinase fusion oncogene negative non-small cell lung cancer	C5394854		Approved				"2619313"			"830055006"
spesolimab	DB15626	Generalized pustular psoriasis	C0343055		Approved				"2610417"	MONDO_0100491		"238612002"
futibatinib	DB15149	Intrahepatic Cholangiocarcinoma	C0345905		Approved				"2628190"	MONDO_0003210		"109842005"
olipudase alfa	DB12835	Niemann-Pick Disease, Type A	C0268242		Approved				"2610407"	MONDO_0009756		"52165006"
olipudase alfa	DB12835	Niemann-Pick Disease, Type B	C0268243		Approved				"2610407"	MONDO_0011871		"39390005"
cefapirin	DB01139	Escherichia coli septicemia	C0276088		Approved			CHEBI_554446	"2238"			
cefapirin	DB01139	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_554446	"2238"			"186435004"
cefapirin	DB01139	Group A Streptococcal Infections	C0554628		Approved			CHEBI_554446	"2238"			"302809008"
cefapirin	DB01139	Staphylococcus aureus infection	C1318973		Approved			CHEBI_554446	"2238"			"406602003"
cefapirin	DB01139	Escherichia coli Infections	C0014836		Approved			CHEBI_554446	"2238"	MONDO_0020920		"71057007"
cefapirin	DB01139	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_554446	"2238"			"70036007"
	DB00860	Renal Cell Carcinoma	C0007134	NCT02763761	Withdrawn	Phase 2	Insufficient enrollment	CHEBI_8378	"8638"	HP:0005584	"10067946"	"41607009"
paclitaxel	DB01229	Renal Cell Carcinoma	C0007134	NCT04060342	Terminated	Phase 1	No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab.	CHEBI_45863	"56946"	HP:0005584	"10067946"	"41607009"
cefapirin	DB01139	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_554446	"2238"			"301011002"
	DB01268	Renal Cell Carcinoma	C0007134	NCT00417677	Terminated	Phase 1/Phase 2	Decision was made not to attempt a lower dose	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
cefradine	DB01333	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3547	"2239"			"70036007"
cefradine	DB01333	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_3547	"2239"			"301011002"
cefradine	DB01333	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3547	"2239"			"302809008"
cefradine	DB01333	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_3547	"2239"			"186435004"
cefradine	DB01333	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3547	"2239"			"406602003"
cefradine	DB01333	Infective otitis media	C0729586		Approved			CHEBI_3547	"2239"			"312218008"
trientine	DB06824	Renal Cell Carcinoma	C0007134		Approved			CHEBI_39501	"10798"	HP:0005584	"10067946"	"41607009"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT01070186	Withdrawn	Phase 2	No participants were enrolled.	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134		Approved			CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT03729245	Terminated	Phase 3	Sponsor decision	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
cyclophosphamide	DB00531	Renal Cell Carcinoma	C0007134	NCT04596033	Terminated	Phase 1	Business reasons	CHEBI_4027	"1545988|3002"	HP:0005584	"10067946"	"41607009"
lenvatinib	DB09078	Renal Cell Carcinoma	C0007134		Approved			CHEBI_85994	"1603296"	HP:0005584	"10067946"	"41607009"
cetirizine	DB00341	Common Cold	C0009443		Approved			CHEBI_3561	"20610"	MONDO_0005709		"82272006"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT00556205	Withdrawn	Phase 2	Toxicity of combination from other trials	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
chloroquine	DB00608	Rheumatoid Arthritis	C0003873		Approved			CHEBI_3638	"2393"	MONDO_0008383	"10039073"	"69896004"
chlorcyclizine	DB08936	Common Cold	C0009443		Approved			CHEBI_94402	"2354"	MONDO_0005709		"82272006"
sorafenib	DB00398	Renal Cell Carcinoma	C0007134		Approved			CHEBI_50924	"495881"	HP:0005584	"10067946"	"41607009"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT00330564	Terminated	Phase 2	Slow accrual.	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
sirolimus	DB00877	Renal Cell Carcinoma	C0007134	NCT00417677	Terminated	Phase 1/Phase 2	Decision was made not to attempt a lower dose	CHEBI_9168	"35302"	HP:0005584	"10067946"	"41607009"
chlorphenamine	DB01114	Influenza-like symptoms	C0392171		Approved			CHEBI_52010	"221074|2400"			
bevacizumab	DB00112	Renal Cell Carcinoma	C0007134	NCT00684996	Terminated	Phase 1/Phase 2			"253337|2046138"	HP:0005584	"10067946"	"41607009"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT01582672	Terminated	Phase 3	Lack of efficacy	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
azacitidine	DB00928	Renal Cell Carcinoma	C0007134	NCT00934440	Terminated	Phase 1/Phase 2		CHEBI_2038	"1251"	HP:0005584	"10067946"	"41607009"
propranolol	DB00571	Renal Cell Carcinoma	C0007134	NCT03323710	Withdrawn	Phase 2	Poor patient recruitment.	CHEBI_8499	"8787"	HP:0005584	"10067946"	"41607009"
	DB00635	Renal Cell Carcinoma	C0007134	NCT02763761	Withdrawn	Phase 2	Insufficient enrollment	CHEBI_8382	"8640"	HP:0005584	"10067946"	"41607009"
	DB09035	Renal Cell Carcinoma	C0007134	NCT03729245	Terminated	Phase 3	Sponsor decision		"1597876"	HP:0005584	"10067946"	"41607009"
	DB00112	Renal Cell Carcinoma	C0007134	NCT00556205	Withdrawn	Phase 2	Toxicity of combination from other trials		"253337|2046138"	HP:0005584	"10067946"	"41607009"
docetaxel	DB01248	Renal Cell Carcinoma	C0007134	NCT04260360	Withdrawn	Phase 1	Not initiated	CHEBI_4672	"72962|1299922"	HP:0005584	"10067946"	"41607009"
methylprednisolone	DB00959	Renal Cell Carcinoma	C0007134	NCT02763761	Withdrawn	Phase 2	Insufficient enrollment	CHEBI_6888	"6902"	HP:0005584	"10067946"	"41607009"
	DB00065	Renal Cell Carcinoma	C0007134	NCT02763761	Withdrawn	Phase 2	Insufficient enrollment		"1790539|1927283|191831|2266523|2103476"	HP:0005584	"10067946"	"41607009"
axitinib	DB06626	Renal Cell Carcinoma	C0007134	NCT01649180	Terminated	Phase 2	Closed due to prolonged enrollment timelines	CHEBI_66910	"1242999"	HP:0005584	"10067946"	"41607009"
chlorphenamine	DB01114	Common Cold	C0009443		Approved			CHEBI_52010	"221074|2400"	MONDO_0005709		"82272006"
chloramphenicol	DB00446	Boutonneuse Fever	C0006060		Approved			CHEBI_17698	"2348"	MONDO_0024472	"10006045"	"186774005"
chloroquine	DB00608	Quartan malaria	C0024536		Approved			CHEBI_3638	"2393"	MONDO_0001943		"27618009"
chloroquine	DB00608	Ovale malaria	C0152072		Approved			CHEBI_3638	"2393"	MONDO_0001601		"19341001"
chloroquine	DB00608	Malaria, Vivax	C0024537		Approved			CHEBI_3638	"2393"	MONDO_0005921		"27052006"
chloroquine	DB00608	Malaria, Falciparum	C0024535		Approved			CHEBI_3638	"2393"	MONDO_0005920		"248441000"
chlordiazepoxide	DB00475	Alcohol Withdrawal Delirium	C0001957		Approved			CHEBI_3611	"2356"		"10012225"	"8635005"
acetylcarnitine	DB08842	Alzheimer's Disease	C0002395		Approved			CHEBI_57589	"193"	MONDO_0004975	"10012271"	"26929004"
acetylcarnitine	DB00583	Alzheimer's Disease	C0002395		Approved			CHEBI_16347	"42955"	MONDO_0004975	"10012271"	"26929004"
ciclesonide	DB01410	Asthma	C0004096		Approved			CHEBI_31397	"274964"	MONDO_0004979	"10003553"	"195967001"
cilastatin	DB01597	Pneumonia, Bacterial	C0004626		Approved			CHEBI_3697	"2540"	MONDO_0004652	"10060946"	"53084003"
cyclacillin	DB01000	Bronchitis	C0006277		Approved			CHEBI_31444	"2968"	MONDO_0003781	"10006451"	"32398004"
cyclacillin	DB01000	Infective otitis media	C0729586		Approved			CHEBI_31444	"2968"			"312218008"
nivolumab	DB09035	Renal Cell Carcinoma	C0007134	NCT03655613	Terminated	Phase 1/Phase 2	Study terminated due to administrative reasons.		"1597876"	HP:0005584	"10067946"	"41607009"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT00480935	Terminated	Phase 2	poor recruitment	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
cilastatin	DB01597	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3697	"2540"			"70036007"
cilastatin	DB01597	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_3697	"2540"			"186435004"
dexamethasone phosphate	DB01234	Renal Cell Carcinoma	C0007134	NCT00176280	Withdrawn	Phase 2	Slow accrual	CHEBI_68637	"3264"	HP:0005584	"10067946"	"41607009"
ciclopirox	DB01188	Cutaneous Candidiasis	C0006846		Approved			CHEBI_453011	"21090"	MONDO_0000879	"10054152"	"49883006"
cilastatin	DB01597	Arthropathy associated with infection	C0157749		Approved			CHEBI_3697	"2540"			"363162000"
chlorpromazine	DB00477	Disruptive Behavior Disorder	C0012734		Approved			CHEBI_3647	"2403"			"54319003"
cilastatin	DB01597	Female genital tract infection	C1263758		Approved			CHEBI_3697	"2540"			"125585007"
chlorpromazine	DB00477	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_3647	"2403"			"191618007"
cimetidine	DB00501	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_3699	"2541"	MONDO_0019610		"53132006"
cilastatin	DB01597	Acinetobacter Infections	C0001139		Approved			CHEBI_3697	"2540"	MONDO_0006635	"10051894"	"840588006"
cilastatin	DB01597	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_3697	"2540"			"425748003"
ciclopirox	DB01188	Scurfiness of scalp	C0423775		Approved			CHEBI_453011	"21090"			"200767005"
cilastatin	DB01597	Infection due to enterococcus	C1320183		Approved			CHEBI_3697	"2540"			"406574007"
ciprofloxacin	DB00537	Escherichia coli septicemia	C0276088		Approved			CHEBI_192484	"2551"			
ciprofloxacin	DB00537	Group A Streptococcal Infections	C0554628		Approved			CHEBI_192484	"2551"			"302809008"
ciprofloxacin	DB00537	Staphylococcus aureus infection	C1318973		Approved			CHEBI_192484	"2551"			"406602003"
ciprofloxacin	DB00537	Infective cystitis	C0600041		Approved			CHEBI_192484	"2551"			"236620008"
ciprofloxacin	DB00537	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_192484	"2551"	MONDO_0001080		"20943002"
ciprofloxacin	DB00537	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_192484	"2551"			"70036007"
ciprofloxacin	DB00537	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_192484	"2551"			"301011002"
ciprofloxacin	DB00537	Pneumonia, Bacterial	C0004626		Approved			CHEBI_192484	"2551"	MONDO_0004652	"10060946"	"53084003"
ciprofloxacin	DB00537	Escherichia coli Infections	C0014836		Approved			CHEBI_192484	"2551"	MONDO_0020920		"71057007"
acetylcysteine	DB06151	Bronchiectasis	C0006267		Approved			CHEBI_28939	"197"	MONDO_0004822	"10006445"	"12295008"
ciprofloxacin	DB00537	Infective otitis media	C0729586		Approved			CHEBI_192484	"2551"			"312218008"
ciprofloxacin	DB00537	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_192484	"2551"			"186435004"
citalopram	DB00215	Depressive disorder	C0011581		Approved			CHEBI_77397	"2556"	MONDO_0002050		"35489007"
acetylcysteine	DB06151	Bronchitis	C0006277		Approved			CHEBI_28939	"197"	MONDO_0003781	"10006451"	"32398004"
citric acid	DB04272	Headache Disorders	C0393735		Approved			CHEBI_30769	"21183|221946"			"230461009"
ciprofloxacin	DB00537	Infection due to Pseudomonas aeruginosa	C0276075		Approved			CHEBI_192484	"2551"	MONDO_0040732		"11218009"
ciprofloxacin	DB00537	Arthropathy associated with infection	C0157749		Approved			CHEBI_192484	"2551"			"363162000"
ciprofloxacin	DB00537	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_192484	"2551"			"195722003"
ciprofloxacin	DB00537	Anthrax disease	C0003175		Approved			CHEBI_192484	"2551"	MONDO_0005119	"10002713"	"409498004"
acetylcysteine	DB06151	Amyloidosis	C0002726		Approved			CHEBI_28939	"197"	MONDO_0019065	"10002022"	"17602002"
ciprofloxacin	DB00537	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			CHEBI_192484	"2551"	MONDO_0041095		"232230009"
ciprofloxacin	DB00537	Proteus urinary tract infection	C0577709		Approved			CHEBI_192484	"2551"			"301012009"
ciprofloxacin	DB00537	Acute bacterial bronchitis	C0339933		Approved			CHEBI_192484	"2551"			"233598009"
ciprofloxacin	DB00537	Infective otitis externa	C0021355		Approved			CHEBI_192484	"2551"			"86981007"
ciprofloxacin	DB00537	Hospital acquired pneumonia	C0949083		Approved			CHEBI_192484	"2551"			"425464007"
ciprofloxacin	DB00537	Acute gonococcal urethritis	C0275652		Approved			CHEBI_192484	"2551"			"29864006"
ciprofloxacin	DB00537	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_192484	"2551"			"128945009"
clavulanic acid	DB00766	Escherichia coli septicemia	C0276088		Approved			CHEBI_48947	"48203|21216"			
clarithromycin	DB01211	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3732	"21212"			"406602003"
clarithromycin	DB01211	Infective otitis media	C0729586		Approved			CHEBI_3732	"21212"			"312218008"
clarithromycin	DB01211	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3732	"21212"			"302809008"
acetyldigitoxin	DB00511	Atrial Fibrillation	C0004238		Approved			CHEBI_53773	"132871"	MONDO_0004981	"10003658"	"49436004"
clarithromycin	DB01211	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_3732	"21212"			"70036007"
clarithromycin	DB01211	Pneumonia, Bacterial	C0004626		Approved			CHEBI_3732	"21212"	MONDO_0004652	"10060946"	"53084003"
clavulanic acid	DB00766	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_48947	"48203|21216"			"301011002"
clavulanic acid	DB00766	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_48947	"48203|21216"			"186435004"
clavulanic acid	DB00766	Infective otitis media	C0729586		Approved			CHEBI_48947	"48203|21216"			"312218008"
clavulanic acid	DB00766	Escherichia coli Infections	C0014836		Approved			CHEBI_48947	"48203|21216"	MONDO_0020920		"71057007"
clavulanic acid	DB00766	Haemophilus influenzae pneumonia	C0276026		Approved			CHEBI_48947	"48203|21216"			"70036007"
clavulanic acid	DB00766	Staphylococcus aureus infection	C1318973		Approved			CHEBI_48947	"48203|21216"			"406602003"
clavulanic acid	DB00766	Pneumonia, Bacterial	C0004626		Approved			CHEBI_48947	"48203|21216"	MONDO_0004652	"10060946"	"53084003"
tivozanib	DB11800	Renal Cell Carcinoma	C0007134		Approved			CHEBI_91327	"2534233"	HP:0005584	"10067946"	"41607009"
	DB14644	Renal Cell Carcinoma	C0007134	NCT02763761	Withdrawn	Phase 2	Insufficient enrollment	CHEBI_135765		HP:0005584	"10067946"	"41607009"
clindamycin	DB01190	Infection due to anaerobic bacteria	C0854328		Approved			CHEBI_3745	"2582"	MONDO_0024389		"423451008"
clindamycin	DB01190	Arthropathy associated with infection	C0157749		Approved			CHEBI_3745	"2582"			"363162000"
clarithromycin	DB01211	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_3732	"21212"			"195722003"
clarithromycin	DB01211	Pulmonary Mycobacterium avium complex infection	C2733595		Approved			CHEBI_3732	"21212"			"186342000"
clavulanic acid	DB00766	Pneumonia due to Staphylococcus aureus	C2349530		Approved			CHEBI_48947	"48203|21216"			"441658007"
clarithromycin	DB01211	Acute bacterial bronchitis	C0339933		Approved			CHEBI_3732	"21212"			"233598009"
clavulanic acid	DB00766	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_48947	"48203|21216"			"448417001"
clarithromycin	DB01211	Acute maxillary sinusitis	C0155804		Approved			CHEBI_3732	"21212"	MONDO_0002186		"68272006"
clavulanic acid	DB00766	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_48947	"48203|21216"			"448813005"
clarithromycin	DB01211	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_3732	"21212"			"425748003"
clindamycin	DB01190	Septicemia due to anaerobes	C0152967		Approved			CHEBI_3745	"2582"			
clofazimine	DB00845	Erythema nodosum leprosum	C0343467		Approved			CHEBI_3749	"2592"			
clindamycin	DB01190	Group A Streptococcal Infections	C0554628		Approved			CHEBI_3745	"2582"			"302809008"
clindamycin	DB01190	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3745	"2582"			"406602003"
clortermine	DB01527	Anorexia Nervosa	C0003125		Approved			CHEBI_134826			"10002649"	"56882008"
clindamycin	DB01190	Acne Vulgaris	C0001144		Approved			CHEBI_3745	"2582"			"88616000"
sunitinib	DB01268	Renal Cell Carcinoma	C0007134	NCT00491738	Terminated	Phase 2	Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated.	CHEBI_38940	"357977"	HP:0005584	"10067946"	"41607009"
codeine	DB00318	Influenza-like symptoms	C0392171		Approved			CHEBI_16714	"2670|1545976|235412"			
sorafenib	DB00398	Renal Cell Carcinoma	C0007134	NCT00557830	Terminated	Phase 2	The study was closed to enrollment when it became clear that enrollment was too slow to complete the full enrollment target within the time frame allowed.	CHEBI_50924	"495881"	HP:0005584	"10067946"	"41607009"
	DB00112	Renal Cell Carcinoma	C0007134	NCT00491738	Terminated	Phase 2	Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated.		"253337|2046138"	HP:0005584	"10067946"	"41607009"
axitinib	DB06626	Renal Cell Carcinoma	C0007134		Approved			CHEBI_66910	"1242999"	HP:0005584	"10067946"	"41607009"
temsirolimus	DB06287	Renal Cell Carcinoma	C0007134		Approved			CHEBI_79699	"657797"	HP:0005584	"10067946"	"41607009"
	DB00480	Renal Cell Carcinoma	C0007134	NCT00975806	Terminated	Phase 1/Phase 2	MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.	CHEBI_63791	"342369"	HP:0005584	"10067946"	"41607009"
cloxacillin	DB01147	Staphylococcus aureus infection	C1318973		Approved			CHEBI_49566	"2625"			"406602003"
	DB00112	Renal Cell Carcinoma	C0007134	NCT00934440	Terminated	Phase 1/Phase 2			"253337|2046138"	HP:0005584	"10067946"	"41607009"
sirolimus	DB00877	Renal Cell Carcinoma	C0007134		Approved			CHEBI_9168	"35302"	HP:0005584	"10067946"	"41607009"
codeine	DB00318	Common Cold	C0009443		Approved			CHEBI_16714	"2670|1545976|235412"	MONDO_0005709		"82272006"
codeine	DB00318	Headache Disorders	C0393735		Approved			CHEBI_16714	"2670|1545976|235412"			"230461009"
clotrimazole	DB00257	Cutaneous Candidiasis	C0006846		Approved			CHEBI_3764	"2623"	MONDO_0000879	"10054152"	"49883006"
clofazimine	DB00845	Dapsone resistant mycobacterium leprae disease	C1563054		Approved			CHEBI_3749	"2592"			"416597004"
clonidine	DB00575	Severe pain	C0278140		Approved			CHEBI_46632	"2599"			"76948002"
clopidogrel	DB00758	Acute ST segment elevation myocardial infarction (disorder)	C1303258		Approved			CHEBI_37941	"32968"			"401303003"
clopidogrel	DB00758	Non-Q wave myocardial infarction	C0542269		Approved			CHEBI_37941	"32968"			"314207007"
clotrimazole	DB00257	Oral candidiasis	C0006849		Approved			CHEBI_3764	"2623"	MONDO_0005886	"10030963"	"79740000"
clofazimine	DB00845	Leprosy, Multibacillary	C1562585		Approved			CHEBI_3749	"2592"			"416257001"
cloxacillin	DB01147	Acute bacterial sinusitis	C0275556		Approved			CHEBI_49566	"2625"			"75498004"
colistimethate sodium	DB01111	Escherichia coli Infections	C0014836		Approved			CHEBI_59662	"2708"	MONDO_0020920		"71057007"
cortisone acetate	DB01380	Asthma	C0004096		Approved			CHEBI_3897	"21655"	MONDO_0004979	"10003553"	"195967001"
cabozantinib	DB08875	Renal Cell Carcinoma	C0007134		Approved			CHEBI_72317	"1363268"	HP:0005584	"10067946"	"41607009"
cortisone acetate	DB01380	Psoriasis of scalp	C0406326		Approved			CHEBI_3897	"21655"			"238608008"
cemiplimab	DB14707	Squamous cell carcinoma	C0007137		Approved				"2058825|2058826"	MONDO_0005096	"10041823"	"402815007"
	DB09035	Squamous cell carcinoma	C0007137	NCT03652233	Withdrawn	Phase 1	Low accrual		"1597876"	MONDO_0005096	"10041823"	"402815007"
azacitidine	DB00928	Squamous cell carcinoma	C0007137	NCT00443261	Terminated	Phase 1	Accrual problems	CHEBI_2038	"1251"	MONDO_0005096	"10041823"	"402815007"
paclitaxel	DB01229	Squamous cell carcinoma	C0007137	NCT00573131	Terminated	Phase 2	OncoGel did not show any impact on overall tumor response	CHEBI_45863	"56946"	MONDO_0005096	"10041823"	"402815007"
cortisone acetate	DB01380	Addison Disease	C0001403		Approved			CHEBI_3897	"21655"	MONDO_0015129	"10001130"	"373662000"
cortisone acetate	DB01380	Punctate keratopathy	C0423234		Approved			CHEBI_3897	"21655"			"246936005"
cortisone acetate	DB01380	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_3897	"21655"	MONDO_0015253		"88854002"
cortisone acetate	DB01380	Mycosis Fungoides	C0026948		Approved			CHEBI_3897	"21655"	MONDO_0009691		"118618005"
colchicine	DB01394	Chronic gouty arthritis	C0268108		Approved			CHEBI_27882	"2683"			"68451005"
cortisone acetate	DB01380	Bursitis	C0006444		Approved			CHEBI_3897	"21655"	MONDO_0002471	"10006811"	"84017003"
cortisone acetate	DB01380	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			CHEBI_3897	"21655"	MONDO_0041095		"232230009"
cortisone acetate	DB01380	Corneal Ulcer	C0010043		Approved			CHEBI_3897	"21655"	MONDO_0004577		"91514001"
cortisone acetate	DB01380	Post traumatic osteoarthritis	C2894027		Approved			CHEBI_3897	"21655"			"699262001"
cortisone acetate	DB01380	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_3897	"21655"	MONDO_0020108	"10073785"	"413603009"
cortisone acetate	DB01380	Congenital adrenal hyperplasia	C0001627		Approved			CHEBI_3897	"21655"	MONDO_0018479		"237751000"
acetylsalicylic acid	DB00945	Influenza-like symptoms	C0392171		Approved			CHEBI_15365	"91101|1191"			
cortisone acetate	DB01380	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_3897	"21655"			"53891004"
acetylsalicylic acid	DB00945	Rheumatoid Arthritis	C0003873		Approved			CHEBI_15365	"91101|1191"	MONDO_0008383	"10039073"	"69896004"
cortisone acetate	DB01380	Rheumatoid Arthritis	C0003873		Approved			CHEBI_3897	"21655"	MONDO_0008383	"10039073"	"69896004"
cortisone acetate	DB01380	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_3897	"21655"			"200965009"
cortisone acetate	DB01380	Acne Vulgaris	C0001144		Approved			CHEBI_3897	"21655"			"88616000"
cromoglicic acid	DB01003	Asthma	C0004096		Approved			CHEBI_59773	"2921|42612"	MONDO_0004979	"10003553"	"195967001"
acetylsalicylic acid	DB00945	Headache Disorders	C0393735		Approved			CHEBI_15365	"91101|1191"			"230461009"
acetylsalicylic acid	DB00945	Common Cold	C0009443		Approved			CHEBI_15365	"91101|1191"	MONDO_0005709		"82272006"
cetuximab	DB00002	Squamous cell carcinoma	C0007137	NCT02298595	Withdrawn	Phase 1/Phase 2			"318341"	MONDO_0005096	"10041823"	"402815007"
benzoic acid	DB03793	Squamous cell carcinoma	C0007137	NCT03875859	Terminated	Phase 2	The available study medication reached expiry (logistics).	CHEBI_30746	"18989"	MONDO_0005096	"10041823"	"402815007"
cortisone acetate	DB01380	Transplanted organ rejection	C0345468		Approved			CHEBI_3897	"21655"			"213148006"
cortisone acetate	DB01380	Blepharoconjunctivitis	C0005743		Approved			CHEBI_3897	"21655"	MONDO_0002307		"68659002"
cortisone acetate	DB01380	Tuberculosis, Miliary	C0041321		Approved			CHEBI_3897	"21655"	MONDO_0005848		"47604008"
cortisone acetate	DB01380	Inflammatory dermatosis	C3875321		Approved			CHEBI_3897	"21655"	MONDO_0002406		"703938007"
cortisone acetate	DB01380	Arthritis, Psoriatic	C0003872		Approved			CHEBI_3897	"21655"	MONDO_0011849	"10037162"	"156370009"
cortisone acetate	DB01380	Acquired thrombocytopenia	C0154301		Approved			CHEBI_3897	"21655"	MONDO_0001198		"154826009"
cortisone acetate	DB01380	Infective blepharitis	C0729587		Approved			CHEBI_3897	"21655"			"312219000"
cortisone acetate	DB01380	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_3897	"21655"	MONDO_0000004		"386584007"
cortisone acetate	DB01380	Adrenogenital disorder	C0701163		Approved			CHEBI_3897	"21655"			"267395000"
cortisone acetate	DB01380	Infective otitis externa	C0021355		Approved			CHEBI_3897	"21655"			"86981007"
cortisone acetate	DB01380	Berylliosis	C0005138		Approved			CHEBI_3897	"21655"		"10004485"	"8247009"
cortisone acetate	DB01380	Autoimmune Diseases	C0004364		Approved			CHEBI_3897	"21655"	MONDO_0007179	"10061664"	"85828009"
cortisone acetate	DB01380	Chronic ulcerative proctitis	C2937222		Approved			CHEBI_3897	"21655"			"52231000"
cromoglicic acid	DB01003	Conjunctivitis, Vernal	C0009773		Approved			CHEBI_59773	"2921|42612"	MONDO_0002313		"318316003"
ciclosporin	DB00091	Rheumatoid Arthritis	C0003873		Approved			CHEBI_4031	"3008"	MONDO_0008383	"10039073"	"69896004"
cysteine	DB00151	Bronchiectasis	C0006267		Approved			CHEBI_17561	"3024"	MONDO_0004822	"10006445"	"12295008"
cysteine	DB00151	Bronchitis	C0006277		Approved			CHEBI_17561	"3024"	MONDO_0003781	"10006451"	"32398004"
cyclizine	DB01176	Common Cold	C0009443		Approved			CHEBI_3994	"2977"	MONDO_0005709		"82272006"
cycloserine	DB00260	Urinary tract infection caused by Escherichia coli	C0577708		Approved			CHEBI_40009	"3007"			"301011002"
ciclosporin	DB00091	Dry Eye Syndromes	C0013238		Approved			CHEBI_4031	"3008"	MONDO_0006733		"46152009"
cytarabine	DB00987	Metastatic Malignant Neoplasm to the Leptomeninges	C1704231		Approved			CHEBI_28680	"3041|968804"			"426128009"
dalfopristin	DB01764	Group A Streptococcal Infections	C0554628		Approved			CHEBI_4309	"229369"			"302809008"
dapsone	DB00250	Acne Vulgaris	C0001144		Approved			CHEBI_4325	"3108"			"88616000"
crotamiton	DB00265	Scabies <infestation>	C0036262		Approved			CHEBI_31439	"21766"	MONDO_0004525		"128869009"
cetuximab	DB00002	Squamous cell carcinoma	C0007137	NCT01794845	Terminated	Phase 2	Early termination due to lack of efficacy (overall response)		"318341"	MONDO_0005096	"10041823"	"402815007"
	DB01248	Squamous cell carcinoma	C0007137	NCT01794845	Terminated	Phase 2	Early termination due to lack of efficacy (overall response)	CHEBI_4672	"72962|1299922"	MONDO_0005096	"10041823"	"402815007"
	DB01248	Squamous cell carcinoma	C0007137	NCT00400205	Terminated	Phase 2	Safety reasons	CHEBI_4672	"72962|1299922"	MONDO_0005096	"10041823"	"402815007"
bleomycin	DB00290	Squamous cell carcinoma	C0007137		Approved			CHEBI_22907	"1622"	MONDO_0005096	"10041823"	"402815007"
fluorouracil	DB00544	Squamous cell carcinoma	C0007137	NCT00400205	Terminated	Phase 2	Safety reasons	CHEBI_46345	"4492"	MONDO_0005096	"10041823"	"402815007"
lapatinib	DB01259	Squamous cell carcinoma	C0007137	NCT01666431	Terminated	Phase 2		CHEBI_49603	"480167"	MONDO_0005096	"10041823"	"402815007"
cisplatin	DB00515	Squamous cell carcinoma	C0007137	NCT00427102	Terminated	Phase 1	No subjects enrolled and PI went to another facility	CHEBI_27899	"2555"	MONDO_0005096	"10041823"	"402815007"
	DB00958	Squamous cell carcinoma	C0007137	NCT03802058	Terminated	Phase 2	The study was halted because enrollment was too slow	CHEBI_31355	"40048"	MONDO_0005096	"10041823"	"402815007"
cyclophosphamide	DB00531	Breast Carcinoma	C0678222		Approved			CHEBI_4027	"1545988|3002"	MONDO_0004989|MONDO_0015870		"254838004"
acipimox	DB09055	Hyperlipoproteinemias	C0020476		Approved			CHEBI_94688	"16817"	MONDO_0037748		"3744001"
ciclosporin	DB00091	Keratoconjunctivitis Sicca	C0022575		Approved			CHEBI_4031	"3008"	MONDO_0000948		"302896008"
cyclophosphamide	DB00531	Mycosis Fungoides	C0026948		Approved			CHEBI_4027	"1545988|3002"	MONDO_0009691		"118618005"
cysteine	DB00151	Amyloidosis	C0002726		Approved			CHEBI_17561	"3024"	MONDO_0019065	"10002022"	"17602002"
cycloserine	DB00260	Acute tuberculosis	C0275959		Approved			CHEBI_40009	"3007"			"25629007"
darifenacin	DB00496	Bladder muscle dysfunction - overactive	C0403643		Approved			CHEBI_391960	"136198"			
demeclocycline	DB00618	Bronchitis	C0006277		Approved			CHEBI_4392	"3154"	MONDO_0003781	"10006451"	"32398004"
demeclocycline	DB00618	Infective otitis media	C0729586		Approved			CHEBI_4392	"3154"			"312218008"
demeclocycline	DB00618	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_4392	"3154"	MONDO_0001080		"20943002"
demeclocycline	DB00618	Staphylococcus aureus infection	C1318973		Approved			CHEBI_4392	"3154"			"406602003"
demexiptiline	DB08998	Depressive disorder	C0011581		Approved			CHEBI_135152		MONDO_0002050		"35489007"
desipramine	DB01151	Depressive disorder	C0011581		Approved			CHEBI_47781	"3247"	MONDO_0002050		"35489007"
paclitaxel	DB01229	Squamous cell carcinoma	C0007137	NCT03802058	Terminated	Phase 2	The study was halted because enrollment was too slow	CHEBI_45863	"56946"	MONDO_0005096	"10041823"	"402815007"
temoporfin	DB11630	Squamous cell carcinoma	C0007137		Approved			CHEBI_9437	"115243"	MONDO_0005096	"10041823"	"402815007"
	DB00515	Squamous cell carcinoma	C0007137	NCT00573131	Terminated	Phase 2	OncoGel did not show any impact on overall tumor response	CHEBI_27899	"2555"	MONDO_0005096	"10041823"	"402815007"
dehydrocholic acid	DB11622	Incomplete passage of stool	C0426639		Approved			CHEBI_31459	"42625|3141"			"249515001"
dasatinib	DB01254	Blast Phase	C0005699		Approved			CHEBI_49375	"475342|1546019"	MONDO_0006115	"10053747"	"413656006"
daptomycin	DB00080	Methicillin resistant Staphylococcus aureus skin infection	C5567802		Approved			CHEBI_600103	"22299"			"1176997000"
demeclocycline	DB00618	Actinomycosis	C0001261		Approved			CHEBI_4392	"3154"	MONDO_0005631	"10000620"	"11817007"
demeclocycline	DB00618	Anthrax disease	C0003175		Approved			CHEBI_4392	"3154"	MONDO_0005119	"10002713"	"409498004"
demeclocycline	DB00618	Gonorrhea of pharynx	C0149966		Approved			CHEBI_4392	"3154"			"74372003"
daptomycin	DB00080	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_600103	"22299"			"448417001"
demeclocycline	DB00618	Acute gonococcal endometritis	C0153196		Approved			CHEBI_4392	"3154"	MONDO_0004264		"65295003"
daptomycin	DB00080	Right-sided Staphylococcus aureus endocarditis	C1960924		Approved			CHEBI_600103	"22299"			"426087004"
demeclocycline	DB00618	Acute gonococcal urethritis	C0275652		Approved			CHEBI_4392	"3154"			"29864006"
daptomycin	DB00080	MRSA infection of postoperative wound	C0585966		Approved			CHEBI_600103	"22299"			"308155002"
dasatinib	DB01254	Leukemia, Myeloid, Chronic-Phase	C0023474		Approved			CHEBI_49375	"475342|1546019"			"413847001"
daptomycin	DB00080	Sepsis caused by methicillin resistant Staphylococcus aureus	C3164390		Approved			CHEBI_600103	"22299"			"448812000"
deferoxamine	DB00746	Poisoning by iron AND/OR its compounds	C0412842		Approved			CHEBI_4356	"3131"			"55381001"
demeclocycline	DB00618	Acute bacterial sinusitis	C0275556		Approved			CHEBI_4392	"3154"			"75498004"
demeclocycline	DB00618	Brucellosis	C0006309		Approved			CHEBI_4392	"3154"	MONDO_0005683	"10006500"	"75702008"
dexamethasone	DB01234	Asthma	C0004096		Approved			CHEBI_41879	"3264"	MONDO_0004979	"10003553"	"195967001"
desloratadine	DB00967	Common Cold	C0009443		Approved			CHEBI_291342	"275635"	MONDO_0005709		"82272006"
desoximetasone	DB00547	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_691037	"3255"			"200965009"
desoximetasone	DB00547	Psoriasis of scalp	C0406326		Approved			CHEBI_691037	"3255"			"238608008"
desoximetasone	DB00547	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_691037	"3255"			"53891004"
propranolol	DB00571	Hypertrophic Cardiomyopathy	C0007194		Approved			CHEBI_8499	"8787"	MONDO_0005045	"10020871"	"233873004"
perhexiline	DB01074	Hypertrophic Cardiomyopathy	C0007194	NCT02431221	Withdrawn	Phase 3	Lack of efficacy in a preceding study.	CHEBI_35553	"8050"	MONDO_0005045	"10020871"	"233873004"
acrivastine	DB09488	Common Cold	C0009443		Approved			CHEBI_83168	"19959"	MONDO_0005709		"82272006"
dexamethasone	DB01234	Infective otitis media	C0729586		Approved			CHEBI_41879	"3264"			"312218008"
dexamethasone	DB01234	Psoriasis of scalp	C0406326		Approved			CHEBI_41879	"3264"			"238608008"
dexamethasone	DB01234	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_41879	"3264"			"53891004"
afatinib	DB08916	Squamous cell carcinoma	C0007137	NCT03652233	Withdrawn	Phase 1	Low accrual	CHEBI_61390	"1430438"	MONDO_0005096	"10041823"	"402815007"
	DB01229	Squamous cell carcinoma	C0007137	NCT01333852	Terminated	Phase 2	Low accrual	CHEBI_45863	"56946"	MONDO_0005096	"10041823"	"402815007"
metformin	DB00331	Squamous cell carcinoma	C0007137	NCT01333852	Terminated	Phase 2	Low accrual	CHEBI_6801	"6809"	MONDO_0005096	"10041823"	"402815007"
dexamethasone	DB01234	Blepharoconjunctivitis	C0005743		Approved			CHEBI_41879	"3264"	MONDO_0002307		"68659002"
dexamethasone	DB01234	Transplanted organ rejection	C0345468		Approved			CHEBI_41879	"3264"			"213148006"
dexamethasone	DB01234	Acquired thrombocytopenia	C0154301		Approved			CHEBI_41879	"3264"	MONDO_0001198		"154826009"
dexamethasone	DB01234	Mycosis Fungoides	C0026948		Approved			CHEBI_41879	"3264"	MONDO_0009691		"118618005"
desmopressin	DB00035	Hemophilia A	C0019069		Approved			CHEBI_4450	"203658|3251"	MONDO_0010602		"28293008"
desloratadine	DB00967	Allergic urticaria	C0149526		Approved			CHEBI_291342	"275635"	MONDO_0006526		"40178009"
dexamethasone	DB01234	Branch retinal vein occlusion with macular edema	C0339507		Approved			CHEBI_41879	"3264"			"232048009"
vinflunine	DB11641	Carcinoma, Transitional Cell	C0007138		Approved			CHEBI_90241		MONDO_0006474	"10044412"	"27090000"
paclitaxel	DB01229	Carcinoma, Transitional Cell	C0007138	NCT02887248	Terminated	Phase 2	Enrollment issues	CHEBI_45863	"56946"	MONDO_0006474	"10044412"	"27090000"
	DB01229	Carcinoma, Transitional Cell	C0007138	NCT01215136	Terminated	Phase 2	Lack of Accrual	CHEBI_45863	"56946"	MONDO_0006474	"10044412"	"27090000"
mitomycin	DB00305	Carcinoma, Transitional Cell	C0007138	NCT04006691	Withdrawn	Phase 3	Due to projected low enrollment, it has decided not to move forward with the study.	CHEBI_27504	"632"	MONDO_0006474	"10044412"	"27090000"
dexamethasone	DB01234	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_41879	"3264"	MONDO_0020108	"10073785"	"413603009"
dexamethasone	DB01234	Exacerbation of asthma	C0349790		Approved			CHEBI_41879	"3264"			"281239006"
dexbrompheniramine	DB00405	Influenza-like symptoms	C0392171		Approved			CHEBI_59269	"22696|1767"			
dexamethasone	DB01234	Chronic small plaque psoriasis	C0406317		Approved			CHEBI_41879	"3264"			"200965009"
dexamethasone	DB01234	Rheumatoid Arthritis	C0003873		Approved			CHEBI_41879	"3264"	MONDO_0008383	"10039073"	"69896004"
dexamethasone	DB01234	Addison Disease	C0001403		Approved			CHEBI_41879	"3264"	MONDO_0015129	"10001130"	"373662000"
dexamethasone	DB01234	Tuberculosis, Miliary	C0041321		Approved			CHEBI_41879	"3264"	MONDO_0005848		"47604008"
dexamethasone	DB01234	Punctate keratopathy	C0423234		Approved			CHEBI_41879	"3264"			"246936005"
tolazoline	DB00797	Cerebrovascular Disorders	C0007820		Approved			CHEBI_28502	"10634"	MONDO_0011057	"10008196"	"62914000"
bifemelane	DB13550	Cerebrovascular Disorders	C0007820		Approved			CHEBI_92338		MONDO_0011057	"10008196"	"62914000"
naftidrofuryl	DB13588	Cerebrovascular Disorders	C0007820		Approved			CHEBI_91817		MONDO_0011057	"10008196"	"62914000"
dexamethasone	DB01234	Arthritis, Psoriatic	C0003872		Approved			CHEBI_41879	"3264"	MONDO_0011849	"10037162"	"156370009"
dexamethasone	DB01234	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_41879	"3264"	MONDO_0015253		"88854002"
dexamethasone	DB01234	Anterior uveitis	C0042165		Approved			CHEBI_41879	"3264"	MONDO_0006651		"410692006"
dexamethasone	DB01234	Bursitis	C0006444		Approved			CHEBI_41879	"3264"	MONDO_0002471	"10006811"	"84017003"
dexamethasone	DB01234	Central retinal vein occlusion with macular edema	C0339498		Approved			CHEBI_41879	"3264"			"232039004"
dexamethasone	DB01234	Infective blepharitis	C0729587		Approved			CHEBI_41879	"3264"			"312219000"
clopidogrel	DB00758	Cerebral Embolism	C0007780		Approved			CHEBI_37941	"32968"		"10008088"	"75543006"
warfarin	DB00682	Cerebral Embolism	C0007780		Approved			CHEBI_87732	"11289"		"10008088"	"75543006"
dexamethasone	DB01234	Malignant otitis externa due to Pseudomonas aeruginosa	C0395818		Approved			CHEBI_41879	"3264"	MONDO_0041095		"232230009"
dexamethasone	DB01234	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_41879	"3264"	MONDO_0000004		"386584007"
dexamethasone	DB01234	Adrenogenital disorder	C0701163		Approved			CHEBI_41879	"3264"			"267395000"
dexamethasone	DB01234	Corneal Ulcer	C0010043		Approved			CHEBI_41879	"3264"	MONDO_0004577		"91514001"
dexamethasone	DB01234	Berylliosis	C0005138		Approved			CHEBI_41879	"3264"		"10004485"	"8247009"
dexamethasone	DB01234	Burkitt Lymphoma	C0006413		Approved			CHEBI_41879	"3264"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
dextromethorphan	DB00514	Influenza-like symptoms	C0392171		Approved			CHEBI_4470	"3289"			
diclofenac	DB00586	Rheumatoid Arthritis	C0003873		Approved			CHEBI_47381	"3355"	MONDO_0008383	"10039073"	"69896004"
dexpanthenol	DB09357	Arthropod bite wound	C1444173		Approved			CHEBI_27373	"22701"			"409985002"
dichloroacetic acid	DB08809	wartlike skin lesion	C0043037		Approved			CHEBI_36386	"155021|3347"			
dextromethorphan	DB00514	Headache Disorders	C0393735		Approved			CHEBI_4470	"3289"			"230461009"
dextromethorphan	DB00514	Common Cold	C0009443		Approved			CHEBI_4470	"3289"	MONDO_0005709		"82272006"
phenazone	DB01435	Infective otitis media	C0729586		Approved			CHEBI_31225	"1001"			"312218008"
streptomycin	DB01082	Chancroids	C0007947		Approved			CHEBI_17076	"10109"	MONDO_0001797	"10008392"	"266143009"
ofloxacin	DB01165	Chancroids	C0007947		Approved			CHEBI_7731	"7623"	MONDO_0001797	"10008392"	"266143009"
meclocycline	DB13092	Chancroids	C0007947		Approved			CHEBI_135772	"29418"	MONDO_0001797	"10008392"	"266143009"
minocycline	DB01017	Chancroids	C0007947		Approved			CHEBI_50694	"6980"	MONDO_0001797	"10008392"	"266143009"
fusidic acid	DB02703	Chancroids	C0007947		Approved			CHEBI_29013	"4608|113608"	MONDO_0001797	"10008392"	"266143009"
dextromoramide	DB01529	Severe pain	C0278140		Approved			CHEBI_74274	"3290"			"76948002"
sulfafurazole	DB00263	Chancroids	C0007947		Approved			CHEBI_102484	"10207"	MONDO_0001797	"10008392"	"266143009"
demeclocycline	DB00618	Chancroids	C0007947		Approved			CHEBI_4392	"3154"	MONDO_0001797	"10008392"	"266143009"
norfloxacin	DB01059	Chancroids	C0007947		Approved			CHEBI_100246	"7517"	MONDO_0001797	"10008392"	"266143009"
azithromycin	DB00207	Chancroids	C0007947		Approved			CHEBI_2955	"18631"	MONDO_0001797	"10008392"	"266143009"
ceftriaxone	DB01212	Chancroids	C0007947		Approved			CHEBI_29007	"2193"	MONDO_0001797	"10008392"	"266143009"
ciprofloxacin	DB00537	Chancroids	C0007947		Approved			CHEBI_192484	"2551"	MONDO_0001797	"10008392"	"266143009"
dexpanthenol	DB09357	Contact dermatitis caused by urushiol from Pacific poison oak	C0263283		Approved			CHEBI_27373	"22701"	MONDO_0041008		"409784006"
bencyclane	DB13488	Cerebrovascular Disorders	C0007820		Approved			CHEBI_135205		MONDO_0011057	"10008196"	"62914000"
isoxsuprine	DB08941	Cerebrovascular Disorders	C0007820		Approved				"6066"	MONDO_0011057	"10008196"	"62914000"
dexetimide	DB08997	Neuroleptic-induced parkinsonism	C0236830		Approved			CHEBI_135531	"3267"			"72820004"
fusidic acid	DB02703	Chlamydia Infections	C0008149		Approved			CHEBI_29013	"4608|113608"		"10061041"	"105629000"
dextromethorphan	DB00514	Pseudobulbar affect	C2316460		Approved			CHEBI_4470	"3289"			"432776007"
acyclovir	DB00787	Chickenpox	C0008049		Approved			CHEBI_2453	"281"	MONDO_0005700	"10046980"	"38907003"
dichlorophen	DB11396	Secondary glaucoma	C0149893		Approved			CHEBI_34689				"95717004"
dichlorphenamide	DB01144	Secondary glaucoma	C0149893		Approved			CHEBI_101085	"3353"			"95717004"
diazepam	DB00829	Alcohol Withdrawal Delirium	C0001957		Approved			CHEBI_49575	"3322"		"10012225"	"8635005"
dexpanthenol	DB09357	Diaper Rash	C0011974		Approved			CHEBI_27373	"22701"		"10012444"	"91487003"
dinoprost	DB12789	Incomplete spontaneous abortion	C0000810		Approved			CHEBI_15553	"3477"		"10061617"	"156072005"
dinoprost	DB01160	Incomplete spontaneous abortion	C0000810		Approved			CHEBI_31502	"23321"		"10061617"	"156072005"
dicloxacillin	DB00485	Staphylococcus aureus infection	C1318973		Approved			CHEBI_4511	"3356"			"406602003"
adapalene	DB00210	Acne Vulgaris	C0001144		Approved			CHEBI_31174	"60223"			"88616000"
diflunisal	DB00861	Rheumatoid Arthritis	C0003873		Approved			CHEBI_39669	"3393"	MONDO_0008383	"10039073"	"69896004"
diltiazem	DB00343	Atrial Fibrillation	C0004238		Approved			CHEBI_101278	"3443"	MONDO_0004981	"10003658"	"49436004"
digoxin	DB00390	Atrial Fibrillation	C0004238		Approved			CHEBI_4551	"3407"	MONDO_0004981	"10003658"	"49436004"
dihydrocodeine	DB01551	Common Cold	C0009443		Approved			CHEBI_135276	"23088"	MONDO_0005709		"82272006"
dienestrol	DB00890	Atrophic Vaginitis	C0221392		Approved			CHEBI_4518	"3368"			"52441000"
diclofenac	DB00586	Periarthritis of shoulder	C1306835		Approved			CHEBI_47381	"3355"			"399114005"
diltiazem	DB00343	Angina Pectoris, Variant	C0002963		Approved			CHEBI_101278	"3443"	MONDO_0006021	"10036759"	"87343002"
dienestrol	DB00890	Atrophy of vulva	C0156393		Approved			CHEBI_4518	"3368"	MONDO_0001932		"248861000"
dicoumarol	DB00266	Cerebral Embolism	C0007780		Approved			CHEBI_4513	"1598"		"10008088"	"75543006"
diloxanide furoate	DB14638	Amebiasis	C0002438		Approved			CHEBI_4601	"23203"	MONDO_0005644	"10001980"	"111910009"
budesonide	DB01222	Primary Biliary Cholangitis	C0008312	NCT00746486	Terminated	Phase 3	Study stopped based on the recommendation of the IDMC after a planned Interim Analysis	CHEBI_3207	"19831"	MONDO_0005388	"10080429"	"31712002"
ursodiol	DB01586	Primary Biliary Cholangitis	C0008312		Approved			CHEBI_9907	"62427|11065"	MONDO_0005388	"10080429"	"31712002"
diethylcarbamazine	DB00711	Loiasis	C0023968		Approved			CHEBI_4527	"3384"	MONDO_0016566		"44250009"
dimethyl sulfoxide	DB01093	Chronic interstitial cystitis	C0600040		Approved			CHEBI_28262	"3455"			"197834003"
dicloxacillin	DB00485	Acute bacterial sinusitis	C0275556		Approved			CHEBI_4511	"3356"			"75498004"
digoxin	DB00390	Poisoning caused by Digitalis glycoside	C0274726		Approved			CHEBI_4551	"3407"			"12876009"
	DB00818	Cholangitis	C0008311	NCT02618668	Terminated	Phase 2		CHEBI_44915	"8782"	MONDO_0004789	"10008604"	"82403002"
kanamycin	DB01172	Cholangitis	C0008311		Approved			CHEBI_17630	"6099|1727573"	MONDO_0004789	"10008604"	"82403002"
ketamine	DB01221	Cholangitis	C0008311	NCT02618668	Terminated	Phase 2		CHEBI_6121	"6130"	MONDO_0004789	"10008604"	"82403002"
cefazolin	DB01327	Cholangitis	C0008311		Approved			CHEBI_474053	"2180"	MONDO_0004789	"10008604"	"82403002"
sulbactam	DB09324	Cholangitis	C0008311		Approved			CHEBI_9321	"10167"	MONDO_0004789	"10008604"	"82403002"
ampicillin	DB00415	Cholangitis	C0008311		Approved			CHEBI_28971	"733|221058"	MONDO_0004789	"10008604"	"82403002"
erythromycin ethyl succinate	DB00199	Cholangitis	C0008311		Approved			CHEBI_42355	"4053"	MONDO_0004789	"10008604"	"82403002"
fusidic acid	DB02703	Cholangitis	C0008311		Approved			CHEBI_29013	"4608|113608"	MONDO_0004789	"10008604"	"82403002"
dinoprostone	DB00917	Incomplete spontaneous abortion	C0000810		Approved			CHEBI_15551	"3478"		"10061617"	"156072005"
dipyridamole	DB00975	Atrial Fibrillation	C0004238		Approved			CHEBI_4653	"3521"	MONDO_0004981	"10003658"	"49436004"
dirithromycin	DB00954	Bronchitis	C0006277		Approved			CHEBI_474014		MONDO_0003781	"10006451"	"32398004"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
dirithromycin	DB00954	Staphylococcus aureus infection	C1318973		Approved			CHEBI_474014				"406602003"
dirithromycin	DB00954	Group A Streptococcal Infections	C0554628		Approved			CHEBI_474014				"302809008"
fusidic acid	DB02703	Cholera	C0008354		Approved			CHEBI_29013	"4608|113608"	MONDO_0015766	"10008631"	"63650001"
minocycline	DB01017	Cholera	C0008354		Approved			CHEBI_50694	"6980"	MONDO_0015766	"10008631"	"63650001"
tazobactam	DB01606	Cholecystitis	C0008325		Approved			CHEBI_9421	"37617"	HP:0001082	"10008612"	"76581006"
ceftolozane	DB09050	Cholecystitis	C0008325		Approved			CHEBI_134719	"1597609"	HP:0001082	"10008612"	"76581006"
doripenem	DB06211	Cholecystitis	C0008325		Approved			CHEBI_135928	"119771"	HP:0001082	"10008612"	"76581006"
chenodiol	DB06777	Cholelithiasis	C0008350		Approved			CHEBI_16755	"2323|42588"	MONDO_0012672	"10008629"	"266474003"
ursodiol	DB01586	Cholelithiasis	C0008350		Approved			CHEBI_9907	"62427|11065"	MONDO_0012672	"10008629"	"266474003"
cholic acid	DB02659	Cholelithiasis	C0008350		Approved			CHEBI_16359	"1440856"	MONDO_0012672	"10008629"	"266474003"
docetaxel	DB01248	Breast Carcinoma	C0678222		Approved			CHEBI_4672	"72962|1299922"	MONDO_0004989|MONDO_0015870		"254838004"
dirithromycin	DB00954	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_474014				"195722003"
dirithromycin	DB00954	Acute bacterial bronchitis	C0339933		Approved			CHEBI_474014				"233598009"
tocofersolan	DB00163	Cholestasis	C0008370		Approved			CHEBI_18145	"11256|237099"	MONDO_0001751	"10008635"	"33688009"
sulfadiazine	DB00359	Chorioretinitis	C0008513		Approved			CHEBI_9328	"10171"	MONDO_0004674	"10008769"	"46627006"
fenofibrate	DB01039	Primary Biliary Cholangitis	C0008312	NCT02965911	Withdrawn	Phase 1/Phase 2	No participants enrolled	CHEBI_5001	"8703"	MONDO_0005388	"10080429"	"31712002"
distigmine	DB13694	Acute cystitis	C0149523		Approved			CHEBI_80756		MONDO_0001650		"68226007"
levomenthol	DB00825	Diaper Rash	C0011974		Approved			CHEBI_15409	"236388|6750"		"10012444"	"91487003"
dobutamine	DB00841	Decompensated cardiac failure	C0581377		Approved			CHEBI_4670	"3616"			"195111005"
docosanol	DB00632	Herpes Labialis	C0019345		Approved			CHEBI_31000	"594680"	MONDO_0043653		"1475003"
levomenthol	DB00825	Scurfiness of scalp	C0423775		Approved			CHEBI_15409	"236388|6750"			"200767005"
levomenthol	DB14123	Scurfiness of scalp	C0423775		Approved			CHEBI_25187	"6750|1430390"			"200767005"
donepezil	DB00843	Alzheimer's Disease	C0002395		Approved			CHEBI_145499	"135447"	MONDO_0004975	"10012271"	"26929004"
dofetilide	DB00204	Atrial Fibrillation	C0004238		Approved			CHEBI_4681	"49247"	MONDO_0004981	"10003658"	"49436004"
doxepin	DB01142	Depressive disorder	C0011581		Approved			CHEBI_4710	"3638"	MONDO_0002050		"35489007"
doxepin	DB01142	Lichen Simplex Chronicus	C0149922		Approved			CHEBI_4710	"3638"			"53891004"
doxycycline	DB00254	Acne Vulgaris	C0001144		Approved			CHEBI_50845	"1545992|3640"			"88616000"
doxycycline	DB00254	Acute gonococcal cervicitis	C0153195		Approved			CHEBI_50845	"1545992|3640"	MONDO_0001080		"20943002"
doxycycline	DB00254	Cutaneous anthrax	C0003177		Approved			CHEBI_50845	"1545992|3640"	MONDO_0004215	"10011660"	"84980006"
doxycycline	DB00254	Cholera	C0008354		Approved			CHEBI_50845	"1545992|3640"	MONDO_0015766	"10008631"	"63650001"
doxycycline	DB00254	Chancroids	C0007947		Approved			CHEBI_50845	"1545992|3640"	MONDO_0001797	"10008392"	"266143009"
doxorubicin	DB00997	Breast Carcinoma	C0678222		Approved			CHEBI_28748	"142433|3639"	MONDO_0004989|MONDO_0015870		"254838004"
doxorubicin	DB00997	Malignant neoplasm of thyroid	C0007115		Approved			CHEBI_28748	"142433|3639"	MONDO_0002108	"10066474"	"363478007"
doxycycline	DB00254	non-gonococcal urethritis (NGU)	C1112709		Approved			CHEBI_50845	"1545992|3640"			"84619001"
doxorubicin	DB00997	Malignant epithelial neoplasm of female breast	C3163805		Approved			CHEBI_28748	"142433|3639"			"447782002"
doxycycline	DB00254	Actinomycosis	C0001261		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005631	"10000620"	"11817007"
doxycycline	DB00254	Anthrax disease	C0003175		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005119	"10002713"	"409498004"
docusate sodium	DB11089	Breastfeeding (mother)	C1623040		Approved			CHEBI_534	"82003"			"413712001"
doxepin	DB01142	Severe major depression with psychotic features	C0270458		Approved			CHEBI_4710	"3638"			"73867007"
doxycycline	DB00254	Acute gonococcal urethritis	C0275652		Approved			CHEBI_50845	"1545992|3640"			"29864006"
doxorubicin	DB00997	Osteosarcoma of bone	C0585442		Approved			CHEBI_28748	"142433|3639"			"307576001"
dopamine	DB00988	Decompensated cardiac failure	C0581377		Approved			CHEBI_18243	"3628"			"195111005"
doxifluridine	DB12947	Primary malignant neoplasm of gastrointestinal tract	C1306632		Approved			CHEBI_31521				"363745004"
doxazosin	DB00590	Prostatic Hypertrophy	C1739363		Approved			CHEBI_4708	"49276"			"266569009"
doxepin	DB01142	Depression, Bipolar	C0005587		Approved			CHEBI_4710	"3638"			"191627008"
doxycycline	DB00254	Acute bacterial sinusitis	C0275556		Approved			CHEBI_50845	"1545992|3640"			"75498004"
doxycycline	DB00254	Brucellosis	C0006309		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005683	"10006500"	"75702008"
doxorubicin	DB00997	Burkitt Lymphoma	C0006413		Approved			CHEBI_28748	"142433|3639"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
doxycycline	DB00254	Chlamydia trachomatis infection of genital structure	C1997322		Approved			CHEBI_50845	"1545992|3640"			"428015005"
doxylamine	DB00366	Influenza-like symptoms	C0392171		Approved			CHEBI_51380	"3642"			
diprophylline	DB00651	Asthma	C0004096		Approved			CHEBI_4728	"3714"	MONDO_0004979	"10003553"	"195967001"
doxylamine	DB00366	Common Cold	C0009443		Approved			CHEBI_51380	"3642"	MONDO_0005709		"82272006"
doxycycline	DB00254	Pneumonia, Bacterial	C0004626		Approved			CHEBI_50845	"1545992|3640"	MONDO_0004652	"10060946"	"53084003"
doxycycline	DB00254	Bronchitis	C0006277		Approved			CHEBI_50845	"1545992|3640"	MONDO_0003781	"10006451"	"32398004"
drospirenone	DB01395	Acne Vulgaris	C0001144		Approved			CHEBI_50838	"11636"			"88616000"
diprophylline	DB00651	Asthma night-time symptoms	C1273489		Approved			CHEBI_4728	"3714"			"395022009"
doxycycline	DB00254	Acute gonococcal epididymo-orchitis	C0153193		Approved			CHEBI_50845	"1545992|3640"	MONDO_0001125		"30168008"
doxycycline	DB00254	Boutonneuse Fever	C0006060		Approved			CHEBI_50845	"1545992|3640"	MONDO_0024472	"10006045"	"186774005"
drospirenone	DB01395	Atrophic Vaginitis	C0221392		Approved			CHEBI_50838	"11636"			"52441000"
fluocinolone acetonide	DB00591	Choroiditis	C0008526		Approved			CHEBI_31623	"4461"	MONDO_0001280	"10008792"	"16553002"
fluocinolone acetonide	DB12553	Choroiditis	C0008526		Approved			CHEBI_5108	"25126"	MONDO_0001280	"10008792"	"16553002"
albutrepenonacog alfa	DB13884	Hemophilia B	C0008533		Approved				"1743992"	MONDO_0010604	"10016077"	"41788008"
eptacog alfa (activated)	DB00036	Hemophilia B	C0008533		Approved				"4256|253149|2386863"	MONDO_0010604	"10016077"	"41788008"
doxycycline	DB00254	Bartonella Infections	C0004771		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005664	"10004145"	"266123003"
doxycycline	DB00254	Brill-Zinsser Disease	C0006181		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005680	"10038017"	"47761007"
duloxetine	DB00476	Diabetic peripheral neuropathy	C0740447		Approved			CHEBI_36795	"72625"			"424736006"
doxycycline	DB00254	Chlamydia Infections	C0008149		Approved			CHEBI_50845	"1545992|3640"		"10061041"	"105629000"
doxycycline	DB00254	Gonorrhea of pharynx	C0149966		Approved			CHEBI_50845	"1545992|3640"			"74372003"
drospirenone	DB01395	Atrophy of vulva	C0156393		Approved			CHEBI_50838	"11636"	MONDO_0001932		"248861000"
doxycycline	DB00254	Acute gonococcal endometritis	C0153196		Approved			CHEBI_50845	"1545992|3640"	MONDO_0004264		"65295003"
duloxetine	DB00476	Female stress incontinence	C0038437		Approved			CHEBI_36795	"72625"	MONDO_0004160		"60241006"
dutasteride	DB01126	Prostatic Hypertrophy	C1739363		Approved			CHEBI_521033	"228790"			"266569009"
edetic acid	DB00974	Accidental poisoning by lead and its compounds and fumes	C0261486		Approved			CHEBI_42191	"1370600|3755"			
vincristine	DB00541	Acute lymphoblastic leukemia - category	C1531702	NCT02404220	Terminated	Phase 1/Phase 2		CHEBI_28445	"11202"			
	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT02404220	Terminated	Phase 1/Phase 2		CHEBI_41879	"3264"			
posaconazole	DB01263	Chromoblastomycosis	C0008582		Approved			CHEBI_64355	"282446"		"10008803"	
ketoconazole	DB01026	Chromoblastomycosis	C0008582		Approved			CHEBI_48339	"6135"		"10008803"	
	DB14208	Atrial Fibrillation	C0004238	NCT00736294	Terminated	Phase 3	Difficulty to include patients	CHEBI_77363		MONDO_0004981	"10003658"	"49436004"
ramipril	DB00178	Atrial Fibrillation	C0004238	NCT00736294	Terminated	Phase 3	Difficulty to include patients	CHEBI_8774	"35296"	MONDO_0004981	"10003658"	"49436004"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT00707252	Terminated	Phase 1	Phase II not initiated due to cancellation of supply of Poly E by collaborator.	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
econazole	DB01127	Cutaneous Candidiasis	C0006846		Approved			CHEBI_82873	"3743"	MONDO_0000879	"10054152"	"49883006"
nonacog alfa	DB00100	Hemophilia B	C0008533		Approved				"1300488"	MONDO_0010604	"10016077"	"41788008"
umeclidinium	DB09076	Bronchitis, Chronic	C0008677		Approved			CHEBI_79041	"1487514"	MONDO_0005607	"10006458"	"63480004"
fluticasone furoate	DB13867	Bronchitis, Chronic	C0008677		Approved			CHEBI_5134	"41126"	MONDO_0005607	"10006458"	"63480004"
naloxone	DB01183	Mycosis Fungoides	C0026948	NCT02811783	Terminated	Phase 3	Sponsor decision	CHEBI_7459	"7242"	MONDO_0009691		"118618005"
echothiophate	DB01057	Esotropia	C0014877		Approved			CHEBI_4753	"89778"	MONDO_0004896		"16596007"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00964704	Withdrawn	Phase 2	No patients have been recruited therefore study has been cancelled		"253337|2046138"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00437294	Terminated	Phase 2	Lack of efficacy	CHEBI_31348	"194000"		"10006187"	"254837009"
cycloserine	DB00260	Malignant neoplasm of breast	C0006142	NCT00301080	Terminated	Phase 3	Funding for the study fell through.	CHEBI_40009	"3007"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT00934895	Terminated	Phase 1/Phase 2	Closed early due to slow accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT00934895	Terminated	Phase 1/Phase 2	Closed early due to slow accrual	CHEBI_68478	"141704"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00817362	Terminated	Phase 2	Limited efficacy response observed during interim analysis.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03417037	Withdrawn	Phase 3	Business objectives have changed.		"1597876"	MONDO_0005233	"10061873"	"254637007"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT02346370	Terminated	Phase 1	Changing standard of care therapy regimen	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
mifepristone	DB00834	Depressive disorder	C0011581	NCT00725270	Terminated	Phase 2/Phase 3	Lack of funding.	CHEBI_50692	"6964"	MONDO_0002050		"35489007"
fluticasone furoate	DB08906	Bronchitis, Chronic	C0008677		Approved			CHEBI_74899	"705022"	MONDO_0005607	"10006458"	"63480004"
tiotropium bromide	DB01409	Bronchitis, Chronic	C0008677		Approved			CHEBI_90960	"69120"	MONDO_0005607	"10006458"	"63480004"
azithromycin	DB00207	Bronchitis, Chronic	C0008677	NCT00524095	Terminated	Phase 2	we decided not to go on treatment phase	CHEBI_2955	"18631"	MONDO_0005607	"10006458"	"63480004"
ciclosporin	DB00091	Thrombocytopenia due to platelet alloimmunization	C0272286	NCT02203422	Withdrawn	Phase 3	No eligible patient was enrolled.	CHEBI_4031	"3008"			"2897005"
imatinib	DB00619	Acute lymphoblastic leukemia - category	C1531702	NCT01312818	Terminated	Phase 2	Slow accrual	CHEBI_45783	"282388"			
	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT01312818	Terminated	Phase 2	Slow accrual	CHEBI_44185	"6851"			
	DB00188	Acute lymphoblastic leukemia - category	C1531702	NCT01312818	Terminated	Phase 2	Slow accrual	CHEBI_52717	"358258"			
	DB02546	Acute lymphoblastic leukemia - category	C1531702	NCT01312818	Terminated	Phase 2	Slow accrual	CHEBI_45716	"194337"			
	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT01312818	Terminated	Phase 2	Slow accrual	CHEBI_41879	"3264"			
amphotericin B	DB00681	Acute lymphoblastic leukemia - category	C1531702	NCT03187691	Withdrawn	Phase 2	Protocol redundancy	CHEBI_2682	"236594|732"			
mifepristone	DB00834	Alzheimer's Disease	C0002395	NCT00105105	Terminated	Phase 2		CHEBI_50692	"6964"	MONDO_0004975	"10012271"	"26929004"
rituximab	DB00073	Rheumatoid Arthritis	C0003873	NCT03061838	Terminated	Phase 1	Sponsor's decision		"2273510|2472325|121191|2105824"	MONDO_0008383	"10039073"	"69896004"
clopidogrel	DB00758	Atrial Fibrillation	C0004238	NCT00243178	Terminated	Phase 3		CHEBI_37941	"32968"	MONDO_0004981	"10003658"	"49436004"
ceftriaxone	DB01212	Bipolar Disorder	C0005586	NCT00512616	Withdrawn	Phase 2		CHEBI_29007	"2193"	MONDO_0004985	"10057667"	"13746004"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00964704	Withdrawn	Phase 2	No patients have been recruited therefore study has been cancelled	CHEBI_31348	"194000"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02322814	Terminated	Phase 2	Sponsor's decision	CHEBI_45863	"56946"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT04296942	Terminated	Phase 1	One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00217659	Withdrawn	Phase 2	poor accrual	CHEBI_2704	"84857"		"10006187"	"254837009"
celecoxib	DB00482	Primary thymic carcinoma	C4302369	NCT01143545	Terminated	Phase 1	Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.	CHEBI_41423	"140587"			"722670005"
	DB00531	Primary thymic carcinoma	C4302369	NCT01143545	Terminated	Phase 1	Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.	CHEBI_4027	"1545988|3002"			"722670005"
neltenexine	DB13239	Bronchitis, Chronic	C0008677		Approved			CHEBI_135789		MONDO_0005607	"10006458"	"63480004"
dapsone	DB00250	Pemphigus Vulgaris	C0030809	NCT00429533	Terminated	Phase 2		CHEBI_4325	"3108"	MONDO_0008219		"49420001"
leucovorin	DB00650	Biliary Tract Cancer	C0750952	NCT00090025	Terminated	Phase 3	Futility reasons after Independent Data Monitoring Committee interim analysis	CHEBI_15640	"6313"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
	DB00544	Biliary Tract Cancer	C0750952	NCT00090025	Terminated	Phase 3	Futility reasons after Independent Data Monitoring Committee interim analysis	CHEBI_46345	"4492"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
oxytocin	DB00107	Bipolar Disorder	C0005586	NCT02149823	Terminated	Phase 1	All study proceedings stopped prematurely due to Covid-19 restrictions for intranasal formulations	CHEBI_7872	"7824"	MONDO_0004985	"10057667"	"13746004"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00022230	Withdrawn	Phase 1/Phase 2	PI left Institution	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00022230	Withdrawn	Phase 1/Phase 2	PI left Institution	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00022230	Withdrawn	Phase 1/Phase 2	PI left Institution	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00186	Malignant neoplasm of breast	C0006142	NCT01067144	Terminated	Phase 3	Trial met futility stopping point	CHEBI_6539	"6470"		"10006187"	"254837009"
gabapentin	DB00996	Malignant neoplasm of breast	C0006142	NCT01067144	Terminated	Phase 3	Trial met futility stopping point	CHEBI_42797	"25480"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00964704	Withdrawn	Phase 2	No patients have been recruited therefore study has been cancelled	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00964704	Withdrawn	Phase 2	No patients have been recruited therefore study has been cancelled		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT02768558	Terminated	Phase 3	Another treatment found efficacious		"1597876"	MONDO_0005233	"10061873"	"254637007"
etoricoxib	DB01628	Pain, Postoperative	C0030201	NCT00746720	Terminated	Phase 2	Patient recruitment difficulties	CHEBI_6339	"307296"			"213299007"
diprophylline	DB00651	Bronchitis, Chronic	C0008677		Approved			CHEBI_4728	"3714"	MONDO_0005607	"10006458"	"63480004"
dasatinib	DB01254	Myeloid Leukemia, Chronic	C0023473	NCT00895297	Terminated	Phase 2	Slow recruitment. No safety concerns during this study.	CHEBI_49375	"475342|1546019"	MONDO_0011996		
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT03429101	Terminated	Phase 1	Dose limiting toxicity		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
celecoxib	DB00482	Malignant neoplasm of breast	C0006142	NCT00045591	Terminated	Phase 2		CHEBI_41423	"140587"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00880009	Terminated	Phase 2	See termination reason in detailed description.	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00877	Primary Myelofibrosis	C0001815	NCT02728700	Terminated	Phase 1	Accrual factor	CHEBI_9168	"35302"	MONDO_0009692	"10077161"	"128843003"
mycophenolate mofetil	DB01024	Primary Myelofibrosis	C0001815	NCT02728700	Terminated	Phase 1	Accrual factor	CHEBI_168396	"7145|265323"	MONDO_0009692	"10077161"	"128843003"
natalizumab	DB00108	Multiple Sclerosis, Acute Relapsing	C0393664	NCT02142192	Terminated	Phase 2	Sponsor's decision.		"354770"			"230372003"
finasteride	DB01216	Prostatic Hypertrophy	C1739363	NCT01534351	Terminated	Phase 3	Business Reasons	CHEBI_5062	"25025"			"266569009"
	DB00706	Prostatic Hypertrophy	C1739363	NCT01534351	Terminated	Phase 3	Business Reasons	CHEBI_9398	"77492"			"266569009"
ascorbic acid	DB00126	Atrial Fibrillation	C0004238	NCT02762331	Terminated	Phase 1	Therapy shown effective by larger studies	CHEBI_29073	"1151|1370460"	MONDO_0004981	"10003658"	"49436004"
	DB14482	Atrial Fibrillation	C0004238	NCT02762331	Terminated	Phase 1	Therapy shown effective by larger studies	CHEBI_113451	"267366"	MONDO_0004981	"10003658"	"49436004"
	DB14483	Atrial Fibrillation	C0004238	NCT02762331	Terminated	Phase 1	Therapy shown effective by larger studies		"1307765|142407"	MONDO_0004981	"10003658"	"49436004"
aripiprazole	DB01238	Bipolar Disorder	C0005586	NCT01520350	Terminated	Phase 3	recruitment issues	CHEBI_31236	"89013"	MONDO_0004985	"10057667"	"13746004"
	DB00361	Malignant neoplasm of breast	C0006142	NCT02585388	Terminated	Phase 2	Treatment toxicity	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT02585388	Terminated	Phase 2	Treatment toxicity	CHEBI_2704	"84857"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT02585388	Terminated	Phase 2	Treatment toxicity	CHEBI_6413	"72965"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00403182	Withdrawn	Phase 3	study halted prematurely, prior to enrollment of first participant	CHEBI_6413	"72965"		"10006187"	"254837009"
azithromycin	DB00207	Blepharoconjunctivitis	C0005743	NCT00754949	Withdrawn	Phase 3		CHEBI_2955	"18631"	MONDO_0002307		"68659002"
	DB01234	Blepharoconjunctivitis	C0005743	NCT00754949	Withdrawn	Phase 3		CHEBI_41879	"3264"	MONDO_0002307		"68659002"
paclitaxel	DB01229	Metastatic urothelial carcinoma	C4288754	NCT04579224	Suspended	Phase 3	Other - New treatment available, eliminating Arm 2	CHEBI_45863	"56946"			"458321000124102"
	DB01248	Metastatic urothelial carcinoma	C4288754	NCT04579224	Suspended	Phase 3	Other - New treatment available, eliminating Arm 2	CHEBI_4672	"72962|1299922"			"458321000124102"
norepinephrine	DB00368	Alopecia	C0002170	NCT01367990	Terminated	Phase 1	Study site has terminated the study due to the complexity of the study	CHEBI_18357	"7512"	MONDO_0004907	"10001760"	"278040002"
ranibizumab	DB01270	Glaucoma, Neovascular	C0017609	NCT00727038	Withdrawn	Phase 1/Phase 2	Company withdrew funding/sponsorship		"595060"	MONDO_0019783		"232086000"
isotretinoin	DB00982	Alzheimer's Disease	C0002395	NCT01560585	Terminated	Phase 1/Phase 2	Adverse events in 2/3 participants; study was halted but not restarted after this due to insufficnet funds as well	CHEBI_6067	"6064"	MONDO_0004975	"10012271"	"26929004"
	DB00005	Rheumatoid Arthritis	C0003873	NCT05379322	Withdrawn	Phase 3	Decision of the local healthcare authority		"214555|2103480|2462511"	MONDO_0008383	"10039073"	"69896004"
adalimumab	DB00051	Rheumatoid Arthritis	C0003873	NCT05379322	Withdrawn	Phase 3	Decision of the local healthcare authority		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT02153905	Terminated	Phase 1/Phase 2	Slow, insufficient accrual.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB06186	Non-Small Cell Lung Carcinoma	C0007131	NCT05005273	Terminated	Phase 2	The Study has been terminated due to safety reasons, adverse change in the risk/benefit.		"1094833"	MONDO_0005233	"10061873"	"254637007"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT05005273	Terminated	Phase 2	The Study has been terminated due to safety reasons, adverse change in the risk/benefit.		"1597876"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT00940875	Terminated	Phase 2	Study was stopped due to slower than expected recruitment.	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
	DB08916	Non-Small Cell Lung Carcinoma	C0007131	NCT01836341	Withdrawn	Phase 1		CHEBI_61390	"1430438"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT01836341	Withdrawn	Phase 1		CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT01836341	Withdrawn	Phase 1		CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
sobrerol	DB13315	Bronchitis, Chronic	C0008677		Approved			CHEBI_134802		MONDO_0005607	"10006458"	"63480004"
mycophenolate mofetil	DB01024	Thrombocytopenia due to platelet alloimmunization	C0272286	NCT02649504	Withdrawn	Phase 3		CHEBI_168396	"7145|265323"			"2897005"
	DB00073	Thrombocytopenia due to platelet alloimmunization	C0272286	NCT02649504	Withdrawn	Phase 3			"2273510|2472325|121191|2105824"			"2897005"
	DB01234	Thrombocytopenia due to platelet alloimmunization	C0272286	NCT02649504	Withdrawn	Phase 3		CHEBI_41879	"3264"			"2897005"
tamsulosin	DB00706	Prostatic Hypertrophy	C1739363	NCT01830829	Terminated	Phase 3	Difficulty in enrolling particpants	CHEBI_9398	"77492"			"266569009"
	DB01126	Prostatic Hypertrophy	C1739363	NCT01830829	Terminated	Phase 3	Difficulty in enrolling particpants	CHEBI_521033	"228790"			"266569009"
melphalan	DB01042	Acute lymphoblastic leukemia - category	C1531702	NCT00961142	Terminated	Phase 2	slow recruitment	CHEBI_28876	"6718"			
	DB04572	Acute lymphoblastic leukemia - category	C1531702	NCT00961142	Terminated	Phase 2	slow recruitment	CHEBI_9570	"10473"			
salbutamol	DB01001	Asthma	C0004096	NCT01252758	Withdrawn	Phase 2		CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
flecainide	DB01195	Atrial Fibrillation	C0004238	NCT00392106	Suspended	Phase 3	voluntarily by Sponsor to investigate an anticipated SAE	CHEBI_75984	"4441"	MONDO_0004981	"10003658"	"49436004"
rituximab	DB00073	Rheumatoid Arthritis	C0003873	NCT00396812	Terminated	Phase 1/Phase 2	The perceived risk-benefit ratio for individuals with early active RA		"2273510|2472325|121191|2105824"	MONDO_0008383	"10039073"	"69896004"
adalimumab	DB00051	Rheumatoid Arthritis	C0003873	NCT02092961	Terminated	Phase 2	AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
adalimumab	DB00051	Rheumatoid Arthritis	C0003873	NCT02150473	Terminated	Phase 3			"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
lamotrigine	DB00555	Bipolar Disorder	C0005586	NCT00063362	Terminated	Phase 3	Funding Expiration	CHEBI_6367	"28439"	MONDO_0004985	"10057667"	"13746004"
	DB00313	Bipolar Disorder	C0005586	NCT00063362	Terminated	Phase 3	Funding Expiration	CHEBI_39867	"11118|40254"	MONDO_0004985	"10057667"	"13746004"
	DB14509	Bipolar Disorder	C0005586	NCT00063362	Terminated	Phase 3	Funding Expiration	CHEBI_6504	"42351"	MONDO_0004985	"10057667"	"13746004"
	DB00977	Malignant neoplasm of breast	C0006142	NCT00193726	Terminated	Phase 3	The accrual was very slow and there were many competing studies ongoing/initiated .	CHEBI_4903	"4124"		"10006187"	"254837009"
estradiol	DB00783	Malignant neoplasm of breast	C0006142	NCT00193726	Terminated	Phase 3	The accrual was very slow and there were many competing studies ongoing/initiated .	CHEBI_16469	"4083"		"10006187"	"254837009"
doxorubicin	DB00997	Malignant neoplasm of breast	C0006142	NCT00346229	Terminated	Phase 1	Funding	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
celecoxib	DB00482	Endocrine exophthalmos	C0155264	NCT02845336	Terminated	Phase 2	Poor enrollment	CHEBI_41423	"140587"	MONDO_0001509		"276177000"
enocitabine	DB00987	Relapsing acute myeloid leukemia	C2349276	NCT02109627	Terminated	Phase 1	Low Accrual	CHEBI_28680	"3041|968804"			"12281000132104"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00227656	Terminated	Phase 2	Study slow to accrue.	CHEBI_31348	"194000"		"10006187"	"254837009"
adapalene	DB00210	Acne Vulgaris	C0001144	NCT04329403	Withdrawn	Phase 3	Market reasons	CHEBI_31174	"60223"			"88616000"
	DB01101	Malignant neoplasm of breast	C0006142	NCT01349088	Withdrawn	Phase 1/Phase 2		CHEBI_31348	"194000"		"10006187"	"254837009"
nicotinamide	DB02701	Malignant neoplasm of breast	C0006142	NCT01349088	Withdrawn	Phase 1/Phase 2		CHEBI_17154	"7405"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT01227408	Withdrawn	Phase 2	Sponsor withdrew due to funding issues	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT01227408	Withdrawn	Phase 2	Sponsor withdrew due to funding issues	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB01101	Malignant neoplasm of breast	C0006142	NCT01227408	Withdrawn	Phase 2	Sponsor withdrew due to funding issues	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT01227408	Withdrawn	Phase 2	Sponsor withdrew due to funding issues	CHEBI_45863	"56946"		"10006187"	"254837009"
methotrexate	DB00563	Malignant neoplasm of breast	C0006142	NCT01227408	Withdrawn	Phase 2	Sponsor withdrew due to funding issues	CHEBI_44185	"6851"		"10006187"	"254837009"
dexrazoxane	DB00380	Malignant neoplasm of breast	C0006142	NCT00955890	Terminated	Phase 2	Enrolled too slow	CHEBI_50223	"42736"		"10006187"	"254837009"
enocitabine	DB00741	Acute lymphoblastic leukemia - category	C1531702	NCT02535806	Terminated	Phase 2	Funding source discontinued	CHEBI_17650	"5492"			
	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT02535806	Terminated	Phase 2	Funding source discontinued	CHEBI_44185	"6851"			
	DB01204	Acute lymphoblastic leukemia - category	C1531702	NCT02535806	Terminated	Phase 2	Funding source discontinued	CHEBI_50729	"7005"			
	DB00541	Acute lymphoblastic leukemia - category	C1531702	NCT02535806	Terminated	Phase 2	Funding source discontinued	CHEBI_28445	"11202"			
	DB00188	Acute lymphoblastic leukemia - category	C1531702	NCT02535806	Terminated	Phase 2	Funding source discontinued	CHEBI_52717	"358258"			
	DB00987	Acute lymphoblastic leukemia - category	C1531702	NCT02535806	Terminated	Phase 2	Funding source discontinued	CHEBI_28680	"3041|968804"			
	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT02535806	Terminated	Phase 2	Funding source discontinued	CHEBI_41879	"3264"			
isradipine	DB00270	Bipolar Disorder	C0005586	NCT01784666	Terminated	Phase 2	Lack of Enrollment	CHEBI_6073	"33910"	MONDO_0004985	"10057667"	"13746004"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00080626	Terminated	Phase 2	low accrual	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT02053597	Withdrawn	Phase 2	due to evolving scientific knowledge in the field that would make the questions being addressed in the trial less relevant	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02053597	Withdrawn	Phase 2	due to evolving scientific knowledge in the field that would make the questions being addressed in the trial less relevant	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00002	Non-Small Cell Lung Carcinoma	C0007131	NCT00203931	Terminated	Phase 2	Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed after first-line therapy		"318341"	MONDO_0005233	"10061873"	"254637007"
everolimus	DB01590	Carcinoma, Transitional Cell	C0007138	NCT01215136	Terminated	Phase 2	Lack of Accrual	CHEBI_68478	"141704"	MONDO_0006474	"10044412"	"27090000"
cannabidiol	DB09061	Autoimmune Chronic Hepatitis	C0241910	NCT04129489	Terminated	Phase 2	low recruitment	CHEBI_69478	"2045371"			"16098491000119109"
bevacizumab	DB00112	Metastatic Renal Cell Cancer	C0278678	NCT00913913	Terminated	Phase 2	low accrual not allowing site to meeting statistical endpoints		"253337|2046138"			
magnesium sulfate	DB00653	Asthma	C0004096	NCT01522040	Withdrawn	Phase 2/Phase 3		CHEBI_32599	"6585|1311625"	MONDO_0004979	"10003553"	"195967001"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00003086	Terminated	Phase 1/Phase 2	no participants enrolled in a three year period	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00003086	Terminated	Phase 1/Phase 2	no participants enrolled in a three year period	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB04572	Malignant neoplasm of breast	C0006142	NCT00003086	Terminated	Phase 1/Phase 2	no participants enrolled in a three year period	CHEBI_9570	"10473"		"10006187"	"254837009"
	DB00544	Malignant neoplasm of breast	C0006142	NCT00003086	Terminated	Phase 1/Phase 2	no participants enrolled in a three year period	CHEBI_46345	"4492"		"10006187"	"254837009"
	DB01042	Malignant neoplasm of breast	C0006142	NCT00003086	Terminated	Phase 1/Phase 2	no participants enrolled in a three year period	CHEBI_28876	"6718"		"10006187"	"254837009"
ifosfamide	DB01181	Malignant neoplasm of breast	C0006142	NCT00003086	Terminated	Phase 1/Phase 2	no participants enrolled in a three year period	CHEBI_5864	"5657"		"10006187"	"254837009"
benzoyl peroxide	DB09096	Acne Vulgaris	C0001144	NCT02716090	Withdrawn	Phase 3	Due to budget limitations, the company decided to withdraw this study.	CHEBI_82405	"1418"			"88616000"
	DB00210	Acne Vulgaris	C0001144	NCT02716090	Withdrawn	Phase 3	Due to budget limitations, the company decided to withdraw this study.	CHEBI_31174	"60223"			"88616000"
estradiol	DB00783	Atrophic Vaginitis	C0221392	NCT00816556	Terminated	Phase 3	Funding	CHEBI_16469	"4083"			"52441000"
mepolizumab	DB06612	Eosinophilic granulomatosis with polyangiitis	C0008728		Approved				"1720597"	MONDO_0015943	"10078117"	"82275008"
vilanterol	DB09082	Bronchitis, Chronic	C0008677		Approved			CHEBI_75037	"1424884"	MONDO_0005607	"10006458"	"63480004"
caffeine	DB00201	Cluster Headache	C0009088		Approved			CHEBI_27732	"1886"	HP:0012199	"10059133"	"193031009"
phenobarbital	DB01174	Cluster Headache	C0009088		Approved			CHEBI_8069	"8134"	HP:0012199	"10059133"	"193031009"
sumatriptan	DB00669	Cluster Headache	C0009088		Approved			CHEBI_10650	"37418"	HP:0012199	"10059133"	"193031009"
docetaxel	DB01248	Squamous non-small cell lung cancer	C4509816	NCT01911325	Terminated	Phase 1	Review of safety and preliminary efficacy data showed marginal anti-tumor activity.	CHEBI_4672	"72962|1299922"			"723301009"
	DB00362	Candidiasis	C0006840	NCT00805740	Terminated	Phase 3	The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not terminated due to any safety issues or concerns.	CHEBI_55346	"341018"	MONDO_0002026	"10074170"	"78048006"
caspofungin	DB00520	Candidiasis	C0006840	NCT00805740	Terminated	Phase 3	The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not terminated due to any safety issues or concerns.	CHEBI_474180	"140108"	MONDO_0002026	"10074170"	"78048006"
glycine	DB00145	Herpes Labialis	C0019345	NCT00913692	Terminated	Phase 2	Terminated due to slow recruitment.	CHEBI_15428	"4919"	MONDO_0043653		"1475003"
natalizumab	DB00108	Rheumatoid Arthritis	C0003873	NCT00083759	Terminated	Phase 2	The biological effect seen with natalizumab was not sufficient to warrant further development in RA.		"354770"	MONDO_0008383	"10039073"	"69896004"
ranolazine	DB00243	Atrial Fibrillation	C0004238	NCT01887353	Terminated	Phase 2	Difficultly in enrolling	CHEBI_87690	"35829"	MONDO_0004981	"10003658"	"49436004"
dasatinib	DB01254	Malignant neoplasm of breast	C0006142	NCT01410708	Withdrawn	Phase 2		CHEBI_49375	"475342|1546019"		"10006187"	"254837009"
prednisone	DB00635	Autoimmune Chronic Hepatitis	C0241910	NCT00608894	Terminated	Phase 2	Study was discontinued due to slow enrollment	CHEBI_8382	"8640"			"16098491000119109"
	DB00864	Autoimmune Chronic Hepatitis	C0241910	NCT00608894	Terminated	Phase 2	Study was discontinued due to slow enrollment	CHEBI_61049	"42316|235991"			"16098491000119109"
	DB00993	Autoimmune Chronic Hepatitis	C0241910	NCT00608894	Terminated	Phase 2	Study was discontinued due to slow enrollment	CHEBI_2948	"1256"			"16098491000119109"
finasteride	DB01216	Prostatic Hypertrophy	C1739363	NCT00064649	Terminated	Phase 3	Inability to recruit required sample size.	CHEBI_5062	"25025"			"266569009"
mesalazine	DB00563	Rheumatoid Arthritis	C0003873	NCT00521924	Terminated	Phase 3	Slow Enrollment	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
carboplatin	DB00958	Intrahepatic Cholangiocarcinoma	C0345905	NCT03081039	Withdrawn	Phase 3	Competing study	CHEBI_31355	"40048"	MONDO_0003210		"109842005"
lidocaine	DB00281	Pain, Postoperative	C0030201	NCT01155986	Terminated	Phase 2	Trial was stopped due to difficult enrolment	CHEBI_6456	"6387"			"213299007"
	DB04272	Arthritis	C0003864	NCT01421160	Withdrawn	Phase 1	PI left the institution prior to any data being collected	CHEBI_30769	"21183|221946"	MONDO_0005578	"10003246"	"3723001"
cyclophosphamide	DB00531	Relapsing acute myeloid leukemia	C2349276	NCT04893915	Withdrawn	Phase 2	No funding support	CHEBI_4027	"1545988|3002"			"12281000132104"
octreotide	DB00104	Acromegaly	C0001206	NCT00642421	Terminated	Phase 3	Commercial reasons	CHEBI_7726	"7617"	MONDO_0019933	"10000599"	"74107003"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00779220	Terminated	Phase 2		CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00053911	Terminated	Phase 3		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00053911	Terminated	Phase 3		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00544	Malignant neoplasm of breast	C0006142	NCT00053911	Terminated	Phase 3		CHEBI_46345	"4492"		"10006187"	"254837009"
	DB00675	Malignant neoplasm of breast	C0006142	NCT00053911	Terminated	Phase 3		CHEBI_41774	"10324"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00053911	Terminated	Phase 3		CHEBI_2704	"84857"		"10006187"	"254837009"
	DB00014	Malignant neoplasm of breast	C0006142	NCT00053911	Terminated	Phase 3		CHEBI_5523	"50610"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00053911	Terminated	Phase 3		CHEBI_47898	"3995"		"10006187"	"254837009"
cyclophosphamide	DB00531	Non-Small Cell Lung Carcinoma	C0007131	NCT01015443	Terminated	Phase 3	The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.	CHEBI_4027	"1545988|3002"	MONDO_0005233	"10061873"	"254637007"
ketoconazole	DB01026	Coccidioidomycosis	C0009186		Approved			CHEBI_48339	"6135"	MONDO_0005706	"10009825"	"60826002"
dihydroergotamine	DB00320	Cluster Headache	C0009088		Approved			CHEBI_4562	"3418"	HP:0012199	"10059133"	"193031009"
ergotamine	DB00696	Cluster Headache	C0009088		Approved			CHEBI_64318	"4025"	HP:0012199	"10059133"	"193031009"
lamotrigine	DB00555	Neurofibromatosis 1	C0027831	NCT02256124	Terminated	Phase 2/Phase 3	Due to our experience, the small number of new inclusions, and the uncertainty regarding the COVID-19 outbreak, we have decided to discontinue the study.	CHEBI_6367	"28439"	MONDO_0008077|MONDO_0018975		"92824003"
thalidomide	DB01041	Thrombocytopenia due to platelet alloimmunization	C0272286	NCT01976195	Withdrawn	Phase 2	No eligible patient was enrolled.	CHEBI_74947	"10432"			"2897005"
	DB01234	Thrombocytopenia due to platelet alloimmunization	C0272286	NCT01976195	Withdrawn	Phase 2	No eligible patient was enrolled.	CHEBI_41879	"3264"			"2897005"
donepezil	DB00843	Alzheimer's Disease	C0002395	NCT00874939	Terminated	Phase 1		CHEBI_145499	"135447"	MONDO_0004975	"10012271"	"26929004"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT02270632	Terminated	Phase 2	Approvals of new agents for the same indication have significantly slowed down the recruitment in this trial making the prosecution of the present investigation extremely difficult.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
	DB06228	Atrial Fibrillation	C0004238	NCT03926156	Terminated	Phase 3	COVID-19 has impacted our study recruitment	CHEBI_68579	"1114195"	MONDO_0004981	"10003658"	"49436004"
warfarin	DB00682	Atrial Fibrillation	C0004238	NCT03926156	Terminated	Phase 3	COVID-19 has impacted our study recruitment	CHEBI_87732	"11289"	MONDO_0004981	"10003658"	"49436004"
quetiapine	DB01224	Bipolar Disorder	C0005586	NCT00771134	Terminated	Phase 2	Study was previously suspended and is now terminated	CHEBI_8707	"51272"	MONDO_0004985	"10057667"	"13746004"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00925652	Terminated	Phase 2	The study was terminated early due to slow accrual.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00661531	Terminated	Phase 2	Poor accrual	CHEBI_2704	"84857"		"10006187"	"254837009"
hydromorphone	DB00327	Acute onset pain	C0184567	NCT02062879	Terminated	Phase 3	Withdrawals from study due to anticipated effects from study drugs	CHEBI_5790	"3423"			"274663001"
	DB01221	Acute onset pain	C0184567	NCT02062879	Terminated	Phase 3	Withdrawals from study due to anticipated effects from study drugs	CHEBI_6121	"6130"			"274663001"
asparaginase	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT01910428	Terminated	Phase 1	Sponsor decision based off site/PI feedback about		"1156"			
adalimumab	DB00051	Asthma	C0004096	NCT00512863	Withdrawn	Phase 2			"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0004979	"10003553"	"195967001"
	DB00243	Atrial Fibrillation	C0004238	NCT03162120	Withdrawn	Phase 2/Phase 3	new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)	CHEBI_87690	"35829"	MONDO_0004981	"10003658"	"49436004"
	DB00264	Atrial Fibrillation	C0004238	NCT03162120	Withdrawn	Phase 2/Phase 3	new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)	CHEBI_6904	"6918"	MONDO_0004981	"10003658"	"49436004"
flecainide	DB01195	Atrial Fibrillation	C0004238	NCT03162120	Withdrawn	Phase 2/Phase 3	new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)	CHEBI_75984	"4441"	MONDO_0004981	"10003658"	"49436004"
olanzapine	DB00334	Bipolar Disorder	C0005586	NCT00194064	Terminated	Phase 3	Slow enrollment	CHEBI_7735	"61381"	MONDO_0004985	"10057667"	"13746004"
tamoxifen	DB00675	Malignant neoplasm of breast	C0006142	NCT00532454	Terminated	Phase 2	planned to design a prospective study	CHEBI_41774	"10324"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT03874325	Terminated	Phase 2	lost funding	CHEBI_2704	"84857"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT03874325	Terminated	Phase 2	lost funding	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00007	Malignant neoplasm of breast	C0006142	NCT00498901	Terminated	Phase 2		CHEBI_6427	"42375"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT04274933	Terminated	Phase 1	Company Decision	CHEBI_31348	"194000"		"10006187"	"254837009"
sertraline	DB01104	Coccidioidomycosis	C0009186	NCT02908334	Withdrawn	Phase 2	failure to enroll	CHEBI_9123	"36437"	MONDO_0005706	"10009825"	"60826002"
amphotericin B	DB00681	Coccidioidomycosis	C0009186		Approved			CHEBI_2682	"236594|732"	MONDO_0005706	"10009825"	"60826002"
itraconazole	DB01167	Coccidioidomycosis	C0009186	NCT04809649	Withdrawn	Phase 2	Sponsor is not proceeding with study due to budget cuts as a result of COVID-19.	CHEBI_6076	"28031"	MONDO_0005706	"10009825"	"60826002"
posaconazole	DB01263	Coccidioidomycosis	C0009186		Approved			CHEBI_64355	"282446"	MONDO_0005706	"10009825"	"60826002"
carotegrast methyl	DB16119	Ulcerative Colitis	C0009324		Approved					MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB00233	Ulcerative Colitis	C0009324	NCT01004185	Terminated	Phase 3	Pediatric enrollment very slow.	CHEBI_27565	"7833"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
hydrocortisone	DB00741	Ulcerative Colitis	C0009324		Approved			CHEBI_17650	"5492"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
azathioprine	DB00993	Ulcerative Colitis	C0009324	NCT00537316	Terminated	Phase 3	Infusion reactions during re-induction cycles after a period of no treatment in another study [P04563, NCT0358670]	CHEBI_2948	"1256"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB00257	Ulcerative Colitis	C0009324	NCT00061282	Terminated	Phase 1/Phase 2	Funding Horizon	CHEBI_3764	"2623"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
ketamine	DB01221	Depressive disorder	C0011581	NCT01809340	Terminated	Phase 2	study team decision because of IP supply issue and necessary amendment to protocol	CHEBI_6121	"6130"	MONDO_0002050		"35489007"
	DB01017	Depressive disorder	C0011581	NCT01809340	Terminated	Phase 2	study team decision because of IP supply issue and necessary amendment to protocol	CHEBI_50694	"6980"	MONDO_0002050		"35489007"
tacrolimus	DB00864	Ulcerative Colitis	C0009324	NCT02954159	Terminated	Phase 3	insufficient enrollment	CHEBI_61049	"42316|235991"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
pramipexole	DB00413	Amyotrophic Lateral Sclerosis	C0002736	NCT01622088	Terminated	Phase 3	The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.	CHEBI_8356	"746741"	MONDO_0004976	"10002026"	"86044005"
irinotecan	DB00762	Biliary Tract Cancer	C0750952	NCT02720601	Withdrawn	Phase 2	Study was never submitted to the IRB & never opened. PI is leaving institution.	CHEBI_80630	"51499"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
	DB01101	Biliary Tract Cancer	C0750952	NCT02720601	Withdrawn	Phase 2	Study was never submitted to the IRB & never opened. PI is leaving institution.	CHEBI_31348	"194000"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
paclitaxel	DB01229	Primary thymic carcinoma	C4302369	NCT00818090	Terminated	Phase 2	marginal statistical significance	CHEBI_45863	"56946"			"722670005"
	DB00515	Primary thymic carcinoma	C4302369	NCT00818090	Terminated	Phase 2	marginal statistical significance	CHEBI_27899	"2555"			"722670005"
axitinib	DB06626	Metastatic Renal Cell Cancer	C0278678	NCT01441414	Terminated	Phase 2	See termination reason in detailed description.	CHEBI_66910	"1242999"			
enocitabine	DB01033	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.	CHEBI_50667	"103|1546028"			
	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.	CHEBI_44185	"6851"			
	DB00352	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.	CHEBI_9555	"1546005|10485"			
	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.		"1156"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.	CHEBI_4027	"1545988|3002"			
	DB00987	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.	CHEBI_28680	"3041|968804"			
	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.	CHEBI_41879	"3264"			
	DB00997	Acute lymphoblastic leukemia - category	C1531702	NCT00439296	Terminated	Phase 1/Phase 2	The study was stopped due to poor accrual and lack of funding.	CHEBI_28748	"142433|3639"			
denosumab	DB06643	Rheumatoid Arthritis	C0003873	NCT01294397	Terminated	Phase 1	Lack of enrollment.		"993449"	MONDO_0008383	"10039073"	"69896004"
	DB00005	Rheumatoid Arthritis	C0003873	NCT01294397	Terminated	Phase 1	Lack of enrollment.		"214555|2103480|2462511"	MONDO_0008383	"10039073"	"69896004"
hydroxychloroquine	DB01611	Malignant neoplasm of breast	C0006142	NCT03400254	Withdrawn	Phase 1/Phase 2	due to business decision regarding the study drug.	CHEBI_5801	"5521"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00216047	Terminated	Phase 1/Phase 2	Low patient enrollment; toxicities		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT01690325	Terminated	Phase 2	Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT01690325	Terminated	Phase 2	Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
oxymetazoline	DB00935	Common Cold	C0009443	NCT03339726	Terminated	Phase 2	did not enroll enough subjects in the 2017/2018 cold season, so the study was terminated	CHEBI_7862	"7812"	MONDO_0005709		"82272006"
	DB00388	Common Cold	C0009443	NCT03339726	Terminated	Phase 2	did not enroll enough subjects in the 2017/2018 cold season, so the study was terminated	CHEBI_8093	"8163"	MONDO_0005709		"82272006"
budesonide	DB01222	Asthma	C0004096	NCT02853578	Suspended	Phase 3	The viability of the study is being analyzed	CHEBI_3207	"19831"	MONDO_0004979	"10003553"	"195967001"
	DB01101	Malignant neoplasm of breast	C0006142	NCT02297230	Terminated	Phase 1/Phase 2	PI Left Institution prior to reaching accrual goal and analyzing data.	CHEBI_31348	"194000"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02297230	Terminated	Phase 1/Phase 2	PI Left Institution prior to reaching accrual goal and analyzing data.	CHEBI_45863	"56946"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT03430466	Terminated	Phase 2	Recruiting was not possible	CHEBI_31638	"282357"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00041171	Withdrawn	Phase 3	The study was not activated.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT01120158	Terminated	Phase 2	Due to poor accrual		"253337|2046138"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01120158	Terminated	Phase 2	Due to poor accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
everolimus	DB01590	Non-Small Cell Lung Carcinoma	C0007131	NCT01063478	Terminated	Phase 1	Poor accrual	CHEBI_68478	"141704"	MONDO_0005233	"10061873"	"254637007"
filgotinib	DB14845	Ulcerative Colitis	C0009324		Approved					MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
bupivacaine	DB00297	Pain, Postoperative	C0030201	NCT03043027	Withdrawn	Phase 3	cost of medicine too expensive to continue without funding	CHEBI_77431	"1815"			"213299007"
zoledronic acid	DB00399	Acute lymphoblastic leukemia - category	C1531702	NCT02632903	Withdrawn	Phase 2	While the clinical need for and the scientific merit remain valid, this regulated drug trial was not feasible logistically due to limited funds.	CHEBI_46557	"1546014|77655"			
warfarin	DB00682	Atrial Fibrillation	C0004238	NCT03839355	Terminated	Phase 3	Study terminated due to slower than anticipated enrollment.	CHEBI_87732	"11289"	MONDO_0004981	"10003658"	"49436004"
	DB00091	Malignant neoplasm of breast	C0006142	NCT00074269	Terminated	Phase 2	Terminated early due to poor enrollment	CHEBI_4031	"3008"		"10006187"	"254837009"
	DB00563	Malignant neoplasm of breast	C0006142	NCT00074269	Terminated	Phase 2	Terminated early due to poor enrollment	CHEBI_44185	"6851"		"10006187"	"254837009"
melphalan	DB01042	Malignant neoplasm of breast	C0006142	NCT00074269	Terminated	Phase 2	Terminated early due to poor enrollment	CHEBI_28876	"6718"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00434031	Withdrawn	Phase 2	lack of enrollment	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00434031	Withdrawn	Phase 2	lack of enrollment	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00434031	Withdrawn	Phase 2	lack of enrollment	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00434031	Withdrawn	Phase 2	lack of enrollment		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT02393248	Terminated	Phase 1/Phase 2		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT02393248	Terminated	Phase 1/Phase 2			"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT03050398	Terminated	Phase 3	GCP issues.	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT02297230	Terminated	Phase 1/Phase 2	PI Left Institution prior to reaching accrual goal and analyzing data.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
testosterone cypionate	DB00624	Cryptorchidism	C0010417		Approved			CHEBI_17347	"10379"	HP:0000028	"10011498"	"204878001"
ondansetron	DB00904	Chemotherapy-induced nausea and vomiting	C0401160	NCT00891761	Withdrawn	Phase 3	This study has been cancelled prior to enrollment.	CHEBI_7773	"26225"			"18846006"
	DB01234	Chemotherapy-induced nausea and vomiting	C0401160	NCT00891761	Withdrawn	Phase 3	This study has been cancelled prior to enrollment.	CHEBI_41879	"3264"			"18846006"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01980277	Terminated	Phase 1/Phase 2	Drug development stopped	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00331	Malignant neoplasm of breast	C0006142	NCT04899349	Terminated	Phase 2	Study was early terminated due to slow recruitment and emerging data showing that prophylactic use of metformin may prevent or reduce the incidence of all-grades alpelisib-related hyperglycemia. The decision was not driven by safety concerns	CHEBI_6801	"6809"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT04899349	Terminated	Phase 2	Study was early terminated due to slow recruitment and emerging data showing that prophylactic use of metformin may prevent or reduce the incidence of all-grades alpelisib-related hyperglycemia. The decision was not driven by safety concerns	CHEBI_31638	"282357"		"10006187"	"254837009"
dexamethasone phosphate	DB01234	Amyloidosis	C0002726	NCT04984330	Withdrawn	Early Phase 1	Funding withdrawn	CHEBI_68637	"3264"	MONDO_0019065	"10002022"	"17602002"
	DB00121	Atrial Fibrillation	C0004238	NCT00580216	Terminated	Phase 3	early discontinuation based on strategic sponsor decision not driven by any safety concern	CHEBI_15956	"314583|1588"	MONDO_0004981	"10003658"	"49436004"
warfarin	DB00682	Atrial Fibrillation	C0004238	NCT00580216	Terminated	Phase 3	early discontinuation based on strategic sponsor decision not driven by any safety concern	CHEBI_87732	"11289"	MONDO_0004981	"10003658"	"49436004"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00088985	Terminated	Phase 2	Funding unavailable		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT00088985	Terminated	Phase 2	Funding unavailable	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB00398	Malignant neoplasm of breast	C0006142	NCT00573755	Terminated	Phase 2	lack of participant accrual	CHEBI_50924	"495881"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00573755	Terminated	Phase 2	lack of participant accrual	CHEBI_2704	"84857"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00573755	Terminated	Phase 2	lack of participant accrual	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00462865	Terminated	Phase 2	DSMB determined toxicity of regimen more than originally thought. Slow accrual.		"253337|2046138"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00462865	Terminated	Phase 2	DSMB determined toxicity of regimen more than originally thought. Slow accrual.	CHEBI_31348	"194000"		"10006187"	"254837009"
cyclophosphamide	DB00531	Merkel cell carcinoma	C0007129	NCT04596033	Terminated	Phase 1	Business reasons	CHEBI_4027	"1545988|3002"	MONDO_0019210	"10029266"	"5052009"
finasteride	DB01216	Prostatic Hypertrophy	C1739363	NCT00564460	Withdrawn	Phase 3	Change of practice pattern. Green light laser	CHEBI_5062	"25025"			"266569009"
mifepristone	DB00834	Depressive disorder	C0011581	NCT00867360	Terminated	Phase 3	Insufficient recruitment.	CHEBI_50692	"6964"	MONDO_0002050		"35489007"
simvastatin	DB00641	Bipolar Disorder	C0005586	NCT01665950	Terminated	Phase 2	Lack of enrollment	CHEBI_9150	"36567"	MONDO_0004985	"10057667"	"13746004"
	DB01248	Malignant neoplasm of breast	C0006142	NCT01229605	Withdrawn	Phase 2	Study was not a good fit for the patient population seen at this hospital.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT01229605	Withdrawn	Phase 2	Study was not a good fit for the patient population seen at this hospital.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT03858972	Terminated	Phase 2	The Sponsor has discontinued the development of tesetaxel	CHEBI_31348	"194000"		"10006187"	"254837009"
tryptophan	DB00150	Malignant neoplasm of breast	C0006142	NCT00739609	Terminated	Phase 1	Lack of enrollment.	CHEBI_16828	"10898"		"10006187"	"254837009"
	DB00531	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_4027	"1545988|3002"	MONDO_0005233	"10061873"	"254637007"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT03169738	Withdrawn	Phase 1/Phase 2	Trial not initiated		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
fentanyl	DB00813	Acute onset pain	C0184567	NCT02137525	Withdrawn	Phase 2	Study was never initiated	CHEBI_119915	"4337"			"274663001"
	DB00295	Acute onset pain	C0184567	NCT02137525	Withdrawn	Phase 2	Study was never initiated	CHEBI_17303	"7052|32926"			"274663001"
fenoterol	DB01288	Asthma	C0004096	NCT02177370	Terminated	Phase 3		CHEBI_149226	"4333"	MONDO_0004979	"10003553"	"195967001"
	DB00764	Asthma	C0004096	NCT01026870	Withdrawn	Phase 3		CHEBI_6970		MONDO_0004979	"10003553"	"195967001"
mometasone furoate	DB14512	Asthma	C0004096	NCT01026870	Withdrawn	Phase 3		CHEBI_47564	"30145"	MONDO_0004979	"10003553"	"195967001"
dimethyl fumarate	DB08908	Chronic small plaque psoriasis	C0406317	NCT01815723	Withdrawn	Phase 3		CHEBI_76004	"1373478"			"200965009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00104624	Terminated	Phase 2	Toxicity issues	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
prasterone sulfate	DB01708	Malignant neoplasm of breast	C0006142	NCT00972023	Terminated	Phase 1		CHEBI_28689	"3143"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT01290718	Terminated	Phase 2	Slow recruitment		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT01290718	Terminated	Phase 2	Slow recruitment	CHEBI_31348	"194000"		"10006187"	"254837009"
denosumab	DB06643	Malignant neoplasm of breast	C0006142	NCT01952054	Terminated	Phase 2			"993449"		"10006187"	"254837009"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT00907179	Terminated	Phase 1	Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB06603	Non-Small Cell Lung Carcinoma	C0007131	NCT00907179	Terminated	Phase 1	Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..	CHEBI_85990	"1603350"	MONDO_0005233	"10061873"	"254637007"
esomeprazole	DB00338	Crohn Disease	C0010346	NCT02272868	Terminated	Phase 1/Phase 2		CHEBI_77260	"7646"	MONDO_0005011	"10011401"	"34000006"
ibuprofen	DB01050	Pain, Postoperative	C0030201	NCT02254525	Terminated	Phase 3	Sample not reached in traumathology arm	CHEBI_5855	"5640"			"213299007"
triamcinolone	DB00620	Arthritis	C0003864	NCT05005000	Terminated	Phase 2	Difficulties getting subjects recruited and enrolled.	CHEBI_9667	"10759"	MONDO_0005578	"10003246"	"3723001"
thalidomide	DB01041	Rheumatoid Arthritis	C0003873	NCT01285310	Terminated	Phase 2	Study is terminated due to lack of efficacy	CHEBI_74947	"10432"	MONDO_0008383	"10039073"	"69896004"
adalimumab	DB00051	Rheumatoid Arthritis	C0003873	NCT01264770	Terminated	Phase 2	AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
	DB01234	Asthma	C0004096	NCT03133897	Terminated	Phase 3	it was felt by the sponsoring institution that the current standard of oversight expected by the Health Canada regulations, would not be possible to achieve	CHEBI_41879	"3264"	MONDO_0004979	"10003553"	"195967001"
prednisone	DB00635	Asthma	C0004096	NCT03133897	Terminated	Phase 3	it was felt by the sponsoring institution that the current standard of oversight expected by the Health Canada regulations, would not be possible to achieve	CHEBI_8382	"8640"	MONDO_0004979	"10003553"	"195967001"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00752986	Terminated	Phase 2		CHEBI_31638	"282357"		"10006187"	"254837009"
fentanyl	DB00813	Pain, Postoperative	C0030201	NCT00807209	Terminated	Phase 2	Sponsor decision unrelated to safety	CHEBI_119915	"4337"			"213299007"
	DB00297	Pain, Postoperative	C0030201	NCT00807209	Terminated	Phase 2	Sponsor decision unrelated to safety	CHEBI_77431	"1815"			"213299007"
dexamethasone phosphate	DB01234	Anterior uveitis	C0042165	NCT00333996	Terminated	Phase 2/Phase 3		CHEBI_68637	"3264"	MONDO_0006651		"410692006"
cisplatin	DB00515	Human epidermal growth factor 2 negative carcinoma of breast	C2316304	NCT01918306	Terminated	Phase 1/Phase 2	company stopped production of study drug due to excessive toxicities, lack of efficacy	CHEBI_27899	"2555"			"431396003"
lovastatin	DB00227	Rheumatoid Arthritis	C0003873	NCT00302952	Terminated	Phase 2	Slow enrollment &Study Drug Expiration (Target: 40 randomized participants /arm)	CHEBI_40303	"6472"	MONDO_0008383	"10039073"	"69896004"
colchicine	DB01394	Atrial Fibrillation	C0004238	NCT02582190	Withdrawn	Phase 3	Investigational Medicinal Product Supplies	CHEBI_27882	"2683"	MONDO_0004981	"10003658"	"49436004"
	DB00673	Malignant neoplasm of breast	C0006142	NCT01649258	Terminated	Phase 1	Lack of Efficacy	CHEBI_499361	"358255"		"10006187"	"254837009"
granisetron	DB00889	Malignant neoplasm of breast	C0006142	NCT01649258	Terminated	Phase 1	Lack of Efficacy	CHEBI_5537	"26237"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00130507	Terminated	Phase 2	A new alternative treatment caused the decrease in the rhythm of recruitment.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00130507	Terminated	Phase 2	A new alternative treatment caused the decrease in the rhythm of recruitment.	CHEBI_31348	"194000"		"10006187"	"254837009"
metformin	DB00331	Malignant neoplasm of breast	C0006142	NCT02360059	Terminated	Phase 2	Low Accrual	CHEBI_6801	"6809"		"10006187"	"254837009"
melphalan	DB01042	Intrahepatic Cholangiocarcinoma	C0345905	NCT02415036	Terminated	Phase 2	Limited enrollment	CHEBI_28876	"6718"	MONDO_0003210		"109842005"
sunitinib	DB01268	Metastatic Renal Cell Cancer	C0278678	NCT01582672	Terminated	Phase 3	Lack of efficacy	CHEBI_38940	"357977"			
imatinib	DB00619	Myeloid Leukemia, Chronic	C0023473	NCT01650805	Terminated	Phase 3	Study terminated based on evaluation of safety data.	CHEBI_45783	"282388"	MONDO_0011996		
methotrexate	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT04095858	Terminated	Phase 3	Business Reasons	CHEBI_44185	"6851"			
	DB00864	Acute lymphoblastic leukemia - category	C1531702	NCT04095858	Terminated	Phase 3	Business Reasons	CHEBI_61049	"42316|235991"			
	DB01097	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_6402	"27169"	MONDO_0008383	"10039073"	"69896004"
	DB01611	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_5801	"5521"	MONDO_0008383	"10039073"	"69896004"
folic acid	DB00158	Rheumatoid Arthritis	C0003873	NCT02930343	Terminated	Phase 3	Due to time constraints, the study was halted prematurely	CHEBI_27470	"62356|4511|202634"	MONDO_0008383	"10039073"	"69896004"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT03001219	Terminated	Phase 2	The trial was prematurely terminated due to a lack of efficacy of the investigational drug.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
insulin glargine	DB00030	Asthma	C0004096	NCT00332826	Terminated	Phase 3	Non-safety related business decision to combine special population protocols	CHEBI_5931	"253182|631657"	MONDO_0004979	"10003553"	"195967001"
salbutamol	DB01001	Asthma	C0004096	NCT03707678	Withdrawn	Phase 2	After careful review of new data on GSK2245035, GlaxoSmithKline has decided to cancel this study.	CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00193102	Terminated	Phase 2		CHEBI_31348	"194000"		"10006187"	"254837009"
rituximab	DB00073	Thrombocytopenia due to platelet alloimmunization	C0272286	NCT02137681	Withdrawn	Phase 3	No eligible patient was enrolled.		"2273510|2472325|121191|2105824"			"2897005"
dexamethasone phosphate	DB01234	Relapse multiple myeloma	C2349261	NCT04355039	Withdrawn	Phase 1	Terminated for lack of funding.	CHEBI_68637	"3264"			"452291000124109"
etoposide	DB00773	Acute lymphoblastic leukemia - category	C1531702	NCT01677949	Withdrawn	Phase 2	Slow accrual	CHEBI_4911	"4179"			
	DB00631	Acute lymphoblastic leukemia - category	C1531702	NCT01677949	Withdrawn	Phase 2	Slow accrual	CHEBI_681569	"44151"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT01677949	Withdrawn	Phase 2	Slow accrual	CHEBI_4027	"1545988|3002"			
infliximab	DB00065	Rheumatoid Arthritis	C0003873	NCT00394589	Terminated	Phase 3	Study enrollment was stopped due to insufficient subject accrual.		"1790539|1927283|191831|2266523|2103476"	MONDO_0008383	"10039073"	"69896004"
pemetrexed	DB00642	Metastatic urothelial carcinoma	C4288754	NCT02693717	Terminated	Phase 2	The trial was closed due to the changing efficacy of treatments for metastatic urothelial cancer.	CHEBI_63616	"68446"			"458321000124102"
ciprofloxacin	DB00537	Shigella Infections	C0013371		Approved			CHEBI_192484	"2551"		"10054178"	"36188001"
itraconazole	DB01167	Alzheimer's Disease	C0002395	NCT02130661	Withdrawn	Phase 1		CHEBI_6076	"28031"	MONDO_0004975	"10012271"	"26929004"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT01651936	Terminated	Phase 2		CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
ofloxacin	DB01165	Shigella Infections	C0013371		Approved			CHEBI_7731	"7623"		"10054178"	"36188001"
sorafenib	DB00398	Biliary Tract Cancer	C0750952	NCT00955721	Terminated	Phase 1/Phase 2	Lack of Funding	CHEBI_50924	"495881"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
	DB00526	Biliary Tract Cancer	C0750952	NCT00955721	Terminated	Phase 1/Phase 2	Lack of Funding	CHEBI_31941	"32592"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
temozolomide	DB00853	Metastatic Renal Cell Cancer	C0278678	NCT04603365	Withdrawn	Phase 2	enrollment	CHEBI_72564	"37776"			
propafenone	DB01182	Atrial Fibrillation	C0004238	NCT02710669	Terminated	Phase 1/Phase 2	Study halted/terminated prematurely due to COVID.	CHEBI_63619	"8754"	MONDO_0004981	"10003658"	"49436004"
triptorelin	DB06825	Malignant neoplasm of breast	C0006142	NCT00090844	Terminated	Phase 2	Early closure due to low accrual	CHEBI_63633	"38782"		"10006187"	"254837009"
asparaginase	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT03668392	Terminated	Phase 2	low enrollment rate		"1156"			
loperamide	DB00836	Malignant neoplasm of breast	C0006142	NCT04172597	Terminated	Phase 2	Strategic business decision (unrelated to safety)	CHEBI_6532	"6468"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT00543127	Terminated	Phase 3	Unjustified decision of company that funded the trial.	CHEBI_2704	"84857"		"10006187"	"254837009"
enocitabine	DB00987	Relapsing acute myeloid leukemia	C2349276	NCT04354025	Withdrawn	Phase 2	Principal investigator decided not to move forward with the study.	CHEBI_28680	"3041|968804"			"12281000132104"
palonosetron	DB00377	Malignant tumor of small intestine	C0153425	NCT00903396	Terminated	Phase 2	Slow accrual	CHEBI_85161	"70561"	MONDO_0000956		"363509000"
mycophenolate mofetil	DB01024	Acute lymphoblastic leukemia - category	C1531702	NCT01532635	Terminated	Phase 2	Slow accrual	CHEBI_168396	"7145|265323"			
	DB00864	Acute lymphoblastic leukemia - category	C1531702	NCT01532635	Terminated	Phase 2	Slow accrual	CHEBI_61049	"42316|235991"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT01532635	Terminated	Phase 2	Slow accrual	CHEBI_4027	"1545988|3002"			
riluzole	DB00740	Bipolar Disorder	C0005586	NCT00805493	Terminated	Phase 2	Insufficient recruitment of participants	CHEBI_8863	"35623"	MONDO_0004985	"10057667"	"13746004"
	DB00398	Malignant neoplasm of breast	C0006142	NCT00607438	Terminated	Phase 2	Low accrual	CHEBI_50924	"495881"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00607438	Terminated	Phase 2	Low accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00963547	Terminated	Phase 1			"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT00963547	Terminated	Phase 1		CHEBI_49603	"480167"		"10006187"	"254837009"
busulfan	DB01008	Wolman Disease	C0043208	NCT00668564	Terminated	Phase 2	Replaced by another study	CHEBI_28901	"1828"	MONDO_0019148		"82500001"
	DB00087	Wolman Disease	C0043208	NCT00668564	Terminated	Phase 2	Replaced by another study		"117055"	MONDO_0019148		"82500001"
	DB00531	Wolman Disease	C0043208	NCT00668564	Terminated	Phase 2	Replaced by another study	CHEBI_4027	"1545988|3002"	MONDO_0019148		"82500001"
doxycycline	DB00254	Mycosis Fungoides	C0026948	NCT02341209	Terminated	Phase 2	Low enrollment	CHEBI_50845	"1545992|3640"	MONDO_0009691		"118618005"
busulfan	DB01008	Niemann-Pick Disease, Type C	C0220756	NCT00668564	Terminated	Phase 2	Replaced by another study	CHEBI_28901	"1828"			"66751000"
	DB00087	Niemann-Pick Disease, Type C	C0220756	NCT00668564	Terminated	Phase 2	Replaced by another study		"117055"			"66751000"
	DB00531	Niemann-Pick Disease, Type C	C0220756	NCT00668564	Terminated	Phase 2	Replaced by another study	CHEBI_4027	"1545988|3002"			"66751000"
lithium carbonate	DB14509	Bipolar Disorder	C0005586	NCT01928446	Terminated	Phase 2/Phase 3	terminated early due to non-safety related DMC recommendations	CHEBI_6504	"42351"	MONDO_0004985	"10057667"	"13746004"
	DB00997	Malignant neoplasm of breast	C0006142	NCT04038489	Withdrawn	Phase 2	Lack of accrual	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT04038489	Withdrawn	Phase 2	Lack of accrual	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00945	Malignant neoplasm of breast	C0006142	NCT04038489	Withdrawn	Phase 2	Lack of accrual	CHEBI_15365	"91101|1191"		"10006187"	"254837009"
	DB00675	Malignant neoplasm of breast	C0006142	NCT04038489	Withdrawn	Phase 2	Lack of accrual	CHEBI_41774	"10324"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT04038489	Withdrawn	Phase 2	Lack of accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
carboplatin	DB00958	Malignant neoplasm of breast	C0006142	NCT00470249	Terminated	Phase 2	Due to difficulty in recruitment	CHEBI_31355	"40048"		"10006187"	"254837009"
lithium carbonate	DB14509	Depressive disorder	C0011581	NCT01928446	Terminated	Phase 2/Phase 3	terminated early due to non-safety related DMC recommendations	CHEBI_6504	"42351"	MONDO_0002050		"35489007"
panobinostat	DB06603	Malignant neoplasm of breast	C0006142	NCT00777335	Terminated	Phase 2	Very low recruitement rate.	CHEBI_85990	"1603350"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00450515	Withdrawn	Phase 2	Study was dropped prior to opening.	CHEBI_31348	"194000"		"10006187"	"254837009"
sunitinib	DB01268	Metastatic Renal Cell Cancer	C0278678	NCT01673386	Terminated	Phase 2	Sponsor	CHEBI_38940	"357977"			
colecalciferol	DB00169	Malignant neoplasm of breast	C0006142	NCT01809171	Terminated	Phase 2/Phase 3	Inclusion problems	CHEBI_28940	"2418"		"10006187"	"254837009"
sunitinib	DB01268	Malignant neoplasm of breast	C0006142	NCT00824538	Terminated	Phase 2	Closed prematurely due to emerging data on toxicity and competing trials.	CHEBI_38940	"357977"		"10006187"	"254837009"
niclosamide	DB06803	Ulcerative Colitis	C0009324	NCT03521232	Terminated	Phase 1/Phase 2	Covid-19	CHEBI_7553	"7402"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB01022	Ulcerative Colitis	C0009324	NCT03358706	Suspended	Phase 1	unavailability of probe substrate	CHEBI_18067	"11258|8308"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB00338	Ulcerative Colitis	C0009324	NCT03358706	Suspended	Phase 1	unavailability of probe substrate	CHEBI_77260	"7646"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
basiliximab	DB00074	Ulcerative Colitis	C0009324	NCT01061996	Terminated	Phase 2	lack of efficacy		"196102"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
nitrous oxide	DB06690	Bipolar Disorder	C0005586	NCT02757521	Terminated	Early Phase 1	Study sponsor ended trial due to low recruitment	CHEBI_17045	"7486"	MONDO_0004985	"10057667"	"13746004"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00049660	Terminated	Phase 2/Phase 3	low accrual	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00625898	Terminated	Phase 3		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00625898	Terminated	Phase 3		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00625898	Terminated	Phase 3			"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00625898	Terminated	Phase 3			"253337|2046138"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00625898	Terminated	Phase 3		CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00544	Malignant neoplasm of breast	C0006142	NCT00625898	Terminated	Phase 3		CHEBI_46345	"4492"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00625898	Terminated	Phase 3		CHEBI_47898	"3995"		"10006187"	"254837009"
levocabastine	DB01106	Allergic Conjunctivitis	C0009766		Approved			CHEBI_135679	"28627"	MONDO_0005642	"10010744"	"231854006"
brompheniramine	DB00835	Allergic Conjunctivitis	C0009766		Approved			CHEBI_3183	"1767"	MONDO_0005642	"10010744"	"231854006"
chlorcyclizine	DB08936	Allergic Conjunctivitis	C0009766		Approved			CHEBI_94402	"2354"	MONDO_0005642	"10010744"	"231854006"
promethazine	DB01069	Allergic Conjunctivitis	C0009766		Approved			CHEBI_8461	"8745"	MONDO_0005642	"10010744"	"231854006"
bepotastine	DB04890	Allergic Conjunctivitis	C0009766		Approved			CHEBI_71204	"863035"	MONDO_0005642	"10010744"	"231854006"
phenylpropanolamine	DB00397	Allergic Conjunctivitis	C0009766		Approved			CHEBI_80680	"8175"	MONDO_0005642	"10010744"	"231854006"
prednisolone	DB00860	Allergic Conjunctivitis	C0009766		Approved			CHEBI_8378	"8638"	MONDO_0005642	"10010744"	"231854006"
astemizole	DB00637	Allergic Conjunctivitis	C0009766		Approved			CHEBI_2896	"42328"	MONDO_0005642	"10010744"	"231854006"
carbinoxamine	DB00748	Allergic Conjunctivitis	C0009766		Approved			CHEBI_3398	"20220"	MONDO_0005642	"10010744"	"231854006"
hydrocortamate	DB00741	Allergic Conjunctivitis	C0009766	NCT01860664	Terminated	Phase 2	The Sponsor has stopped responding to calls and emails	CHEBI_17650	"5492"	MONDO_0005642	"10010744"	"231854006"
phenindamine	DB01619	Allergic Conjunctivitis	C0009766		Approved			CHEBI_8065	"33283"	MONDO_0005642	"10010744"	"231854006"
acrivastine	DB09488	Allergic Conjunctivitis	C0009766		Approved			CHEBI_83168	"19959"	MONDO_0005642	"10010744"	"231854006"
hydrocortisone	DB00741	Allergic Conjunctivitis	C0009766		Approved			CHEBI_17650	"5492"	MONDO_0005642	"10010744"	"231854006"
norfloxacin	DB01059	Shigella Infections	C0013371		Approved			CHEBI_100246	"7517"		"10054178"	"36188001"
lacosamide	DB06218	Rheumatoid Arthritis	C0003873	NCT02342977	Withdrawn	Phase 2	We were unable to enroll any patients into the study.	CHEBI_135939	"623400"	MONDO_0008383	"10039073"	"69896004"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT00049660	Terminated	Phase 2/Phase 3	low accrual	CHEBI_480999	"39541"		"10006187"	"254837009"
oxaliplatin	DB00526	Malignant neoplasm of breast	C0006142	NCT00674206	Terminated	Phase 2	Sponsor funding stopped	CHEBI_31941	"32592"		"10006187"	"254837009"
lenograstim	DB13144	Malignant neoplasm of breast	C0006142	NCT02685111	Terminated	Phase 2			"70167"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT02907918	Terminated	Phase 2	Futility		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01006	Malignant neoplasm of breast	C0006142	NCT02907918	Terminated	Phase 2	Futility	CHEBI_6413	"72965"		"10006187"	"254837009"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT02907918	Terminated	Phase 2	Futility	CHEBI_5523	"50610"		"10006187"	"254837009"
dexbrompheniramine	DB00405	Allergic Conjunctivitis	C0009766		Approved			CHEBI_59269	"22696|1767"	MONDO_0005642	"10010744"	"231854006"
clemastine	DB00283	Allergic Conjunctivitis	C0009766		Approved			CHEBI_3738	"2578"	MONDO_0005642	"10010744"	"231854006"
pemirolast	DB00885	Allergic Conjunctivitis	C0009766		Approved			CHEBI_134936	"19551"	MONDO_0005642	"10010744"	"231854006"
loteprednol etabonate	DB14596	Allergic Conjunctivitis	C0009766		Approved			CHEBI_31784	"52177"	MONDO_0005642	"10010744"	"231854006"
fexofenadine	DB00950	Allergic Conjunctivitis	C0009766		Approved			CHEBI_5050	"87636"	MONDO_0005642	"10010744"	"231854006"
azelastine	DB00972	Allergic Conjunctivitis	C0009766		Approved			CHEBI_2950	"18603"	MONDO_0005642	"10010744"	"231854006"
dexamethasone phosphate	DB01234	Allergic Conjunctivitis	C0009766	NCT00881673	Withdrawn	Phase 2	Management decision	CHEBI_68637	"3264"	MONDO_0005642	"10010744"	"231854006"
octreotide	DB00104	Acromegaly	C0001206	NCT01086982	Suspended	Phase 1		CHEBI_7726	"7617"	MONDO_0019933	"10000599"	"74107003"
bimatoprost	DB00905	Alopecia	C0002170	NCT02676310	Terminated	Phase 1		CHEBI_51230	"283810"	MONDO_0004907	"10001760"	"278040002"
moxifloxacin	DB00218	Asthma	C0004096	NCT01721135	Withdrawn	Phase 1	Study was terminated due to toxicology findings after screening started but before first subject first dose.	CHEBI_63611	"139462"	MONDO_0004979	"10003553"	"195967001"
dronedarone	DB04855	Atrial Fibrillation	C0004238	NCT01151137	Terminated	Phase 3	The study was stopped because of safety concerns	CHEBI_50659	"233698"	MONDO_0004981	"10003658"	"49436004"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00020722	Terminated	Phase 2	Lack of funding to continue study.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00020722	Terminated	Phase 2	Lack of funding to continue study.	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB04572	Malignant neoplasm of breast	C0006142	NCT00020722	Terminated	Phase 2	Lack of funding to continue study.	CHEBI_9570	"10473"		"10006187"	"254837009"
	DB01181	Malignant neoplasm of breast	C0006142	NCT00020722	Terminated	Phase 2	Lack of funding to continue study.	CHEBI_5864	"5657"		"10006187"	"254837009"
etoposide	DB00773	Malignant neoplasm of breast	C0006142	NCT00020722	Terminated	Phase 2	Lack of funding to continue study.	CHEBI_4911	"4179"		"10006187"	"254837009"
	DB00642	Malignant neoplasm of breast	C0006142	NCT00470548	Terminated	Phase 1/Phase 2	Practice patterns with pemetrexed have evolved.	CHEBI_63616	"68446"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00470548	Terminated	Phase 1/Phase 2	Practice patterns with pemetrexed have evolved.	CHEBI_45863	"56946"		"10006187"	"254837009"
axitinib	DB06626	Non-Small Cell Lung Carcinoma	C0007131	NCT03472560	Terminated	Phase 2	The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)	CHEBI_66910	"1242999"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT04470674	Withdrawn	Phase 2	Lack of Accrual	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT04470674	Withdrawn	Phase 2	Lack of Accrual	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
ephedrine	DB01364	Allergic Conjunctivitis	C0009766		Approved			CHEBI_15407	"3966"	MONDO_0005642	"10010744"	"231854006"
ibuprofen	DB01050	Common Cold	C0009443	NCT01938144	Withdrawn	Phase 3		CHEBI_5855	"5640"	MONDO_0005709		"82272006"
	DB00316	Common Cold	C0009443	NCT01938144	Withdrawn	Phase 3		CHEBI_46195	"161"	MONDO_0005709		"82272006"
buprenorphine	DB00921	Pain, Postoperative	C0030201	NCT00403234	Terminated	Phase 2	due to administrative reasons not related to efficacy or safety.	CHEBI_3216	"1819"			"213299007"
tocofibrate	DB00163	Burn injury	C0006434	NCT01413620	Withdrawn	Phase 1		CHEBI_18145	"11256|237099"			"125666000"
	DB11635	Burn injury	C0006434	NCT01413620	Withdrawn	Phase 1			"159151"			"125666000"
everolimus	DB01590	Malignant Neoplasm (Morphology)	C1288351	NCT03839940	Terminated	Phase 3	Severe lack of accrual	CHEBI_68478	"141704"			
	DB01234	Malignant Neoplasm (Morphology)	C1288351	NCT03839940	Terminated	Phase 3	Severe lack of accrual	CHEBI_41879	"3264"			
quetiapine	DB01224	Anorexia Nervosa	C0003125	NCT00584688	Terminated	Phase 2	Lack of Enrollment	CHEBI_8707	"51272"		"10002649"	"56882008"
	DB00975	Rheumatoid Arthritis	C0003873	NCT01612377	Terminated	Phase 2	missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg	CHEBI_4653	"3521"	MONDO_0008383	"10039073"	"69896004"
	DB00635	Rheumatoid Arthritis	C0003873	NCT01612377	Terminated	Phase 2	missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg	CHEBI_8382	"8640"	MONDO_0008383	"10039073"	"69896004"
prednicarbate	DB00860	Rheumatoid Arthritis	C0003873	NCT01612377	Terminated	Phase 2	missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg	CHEBI_8378	"8638"	MONDO_0008383	"10039073"	"69896004"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT01212887	Terminated	Phase 1	due to safety concerns and lack of efficacy	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
dapsone	DB00250	Acne Vulgaris	C0001144	NCT01785836	Withdrawn	Phase 1	Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.	CHEBI_4325	"3108"			"88616000"
bupivacaine	DB00297	Postoperative Nausea and Vomiting	C0520909	NCT02331563	Withdrawn	Phase 3	patients should have assurance to attend this study, money is the main problem	CHEBI_77431	"1815"			"1488000"
	DB00633	Postoperative Nausea and Vomiting	C0520909	NCT02331563	Withdrawn	Phase 3	patients should have assurance to attend this study, money is the main problem	CHEBI_4466	"48937"			"1488000"
linezolid	DB00601	Community acquired pneumonia	C0694549	NCT02269644	Withdrawn	Phase 3		CHEBI_63607	"190376"			"385093006"
	DB00207	Community acquired pneumonia	C0694549	NCT02269644	Withdrawn	Phase 3		CHEBI_2955	"18631"			"385093006"
hydrocortamate	DB00741	Congenital adrenal hyperplasia	C0001627	NCT03548246	Withdrawn	Phase 2	This study plan has halted and was withdrawn from the IRB.	CHEBI_17650	"5492"	MONDO_0018479		"237751000"
	DB05812	Congenital adrenal hyperplasia	C0001627	NCT03548246	Withdrawn	Phase 2	This study plan has halted and was withdrawn from the IRB.	CHEBI_68642	"1100072"	MONDO_0018479		"237751000"
salmeterol	DB00938	Asthma	C0004096	NCT02218762	Withdrawn	Phase 1	It was decided that data from this study are no longer required and therefore it is not necessary to expose patients to the study medication	CHEBI_64064	"36117"	MONDO_0004979	"10003553"	"195967001"
bosentan	DB00559	Asthma	C0004096	NCT00815347	Terminated	Phase 2	Difficulty in recruitment.	CHEBI_51450	"75207|1468845"	MONDO_0004979	"10003553"	"195967001"
erlotinib	DB00530	Malignant neoplasm of breast	C0006142	NCT00739063	Terminated	Phase 2	Poor Accrual	CHEBI_114785	"337525"		"10006187"	"254837009"
	DB01006	Malignant neoplasm of breast	C0006142	NCT01013506	Withdrawn	Phase 2	Study was abandoned before opening to accrual. Replaced by another study.	CHEBI_6413	"72965"		"10006187"	"254837009"
	DB00014	Malignant neoplasm of breast	C0006142	NCT01013506	Withdrawn	Phase 2	Study was abandoned before opening to accrual. Replaced by another study.	CHEBI_5523	"50610"		"10006187"	"254837009"
erlotinib	DB00530	Malignant neoplasm of breast	C0006142	NCT01013506	Withdrawn	Phase 2	Study was abandoned before opening to accrual. Replaced by another study.	CHEBI_114785	"337525"		"10006187"	"254837009"
cetirizine	DB00341	Allergic Conjunctivitis	C0009766		Approved			CHEBI_3561	"20610"	MONDO_0005642	"10010744"	"231854006"
cortisone acetate	DB01380	Allergic Conjunctivitis	C0009766		Approved			CHEBI_3897	"21655"	MONDO_0005642	"10010744"	"231854006"
loratadine	DB00455	Allergic Conjunctivitis	C0009766		Approved			CHEBI_6538	"28889"	MONDO_0005642	"10010744"	"231854006"
dasatinib	DB01254	Acute lymphoblastic leukemia - category	C1531702	NCT00349518	Withdrawn	Phase 2/Phase 3		CHEBI_49375	"475342|1546019"			
dasatinib	DB01254	Myeloid Leukemia, Chronic	C0023473	NCT00349518	Withdrawn	Phase 2/Phase 3		CHEBI_49375	"475342|1546019"	MONDO_0011996		
pioglitazone	DB01132	Asthma	C0004096	NCT00787644	Terminated	Phase 2	new safety concerns which emerged about pioglitazone during the trial	CHEBI_8228	"33738"	MONDO_0004979	"10003553"	"195967001"
sotalol	DB00489	Atrial Fibrillation	C0004238	NCT02153437	Terminated	Phase 1	Insufficient enrollment	CHEBI_63622	"9947"	MONDO_0004981	"10003658"	"49436004"
estramustine	DB01196	Malignant neoplasm of breast	C0006142	NCT02853071	Withdrawn	Phase 2	withdrawal industrial	CHEBI_4868	"4089"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT01479179	Withdrawn	Phase 1/Phase 2	Drug sponsor decision to discontinue study.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
colecalciferol	DB00169	Malignant neoplasm of breast	C0006142	NCT02936999	Terminated	Early Phase 1	Terminated for lack of patient samples and funding	CHEBI_28940	"2418"		"10006187"	"254837009"
gefitinib	DB00317	Malignant neoplasm of breast	C0006142	NCT00082667	Terminated	Phase 2	PI left VICC	CHEBI_49668	"328134"		"10006187"	"254837009"
doxylamine	DB00366	Allergic Conjunctivitis	C0009766		Approved			CHEBI_51380	"3642"	MONDO_0005642	"10010744"	"231854006"
decitabine	DB01262	Primary Myelofibrosis	C0001815	NCT04283526	Withdrawn	Phase 1	This study was cancelled before enrolling any patients for business related reasons.	CHEBI_50131	"15657"	MONDO_0009692	"10077161"	"128843003"
sunitinib	DB01268	Primary Myelofibrosis	C0001815	NCT00387426	Terminated	Phase 2		CHEBI_38940	"357977"	MONDO_0009692	"10077161"	"128843003"
everolimus	DB01590	Metastatic Renal Cell Cancer	C0278678	NCT01784978	Terminated	Phase 2	Lack of recruitment	CHEBI_68478	"141704"			
	DB01268	Metastatic Renal Cell Cancer	C0278678	NCT01784978	Terminated	Phase 2	Lack of recruitment	CHEBI_38940	"357977"			
	DB11596	Rheumatoid Arthritis	C0003873	NCT01217814	Terminated	Phase 2	Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns	CHEBI_63606	"877015"	MONDO_0008383	"10039073"	"69896004"
	DB00563	Rheumatoid Arthritis	C0003873	NCT01217814	Terminated	Phase 2	Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
heparin	DB01109	Burn injury	C0006434	NCT01773083	Terminated	Phase 3	insufficient recruitment of patients and high costs associated with the purchase and blinding of study medication	CHEBI_28304	"5224"			"125666000"
pemetrexed	DB00642	Nonsquamous nonsmall cell neoplasm of lung	C2585890	NCT01373463	Terminated	Phase 1	Investigator left site	CHEBI_63616	"68446"			"440173001"
	DB00958	Nonsquamous nonsmall cell neoplasm of lung	C2585890	NCT01373463	Terminated	Phase 1	Investigator left site	CHEBI_31355	"40048"			"440173001"
mycophenolate mofetil	DB01024	Acute lymphoblastic leukemia - category	C1531702	NCT03128034	Suspended	Phase 1/Phase 2	Administrative - FDA Comments	CHEBI_168396	"7145|265323"			
	DB00091	Acute lymphoblastic leukemia - category	C1531702	NCT03128034	Suspended	Phase 1/Phase 2	Administrative - FDA Comments	CHEBI_4031	"3008"			
risperidone	DB00734	Alzheimer's Disease	C0002395	NCT00287742	Terminated	Phase 3	A decision was made to discontinue the study due to a change in the strategic direction of the company.	CHEBI_8871	"35636"	MONDO_0004975	"10012271"	"26929004"
colchicine	DB01394	Atrial Fibrillation	C0004238	NCT03015831	Terminated	Phase 3	Statistical analysis of interim data showed no advantage of colchicine	CHEBI_27882	"2683"	MONDO_0004981	"10003658"	"49436004"
ranolazine	DB00243	Atrial Fibrillation	C0004238	NCT01349491	Terminated	Phase 3	low recruitement rates	CHEBI_87690	"35829"	MONDO_0004981	"10003658"	"49436004"
	DB00997	Malignant neoplasm of breast	C0006142	NCT02215876	Withdrawn	Phase 2	No patients recruited.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
bevacizumab	DB00112	Biliary Tract Cancer	C0750952	NCT00881504	Terminated	Phase 2	It was not possible to get insurance companies to cover bevacizumab.		"253337|2046138"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
formoterol	DB00983	Alzheimer's Disease	C0002395	NCT02500784	Withdrawn	Phase 2	Funding ran out before study started, prior PI left institution.	CHEBI_63082	"25255"	MONDO_0004975	"10012271"	"26929004"
	DB00316	Rheumatoid Arthritis	C0003873	NCT01390441	Terminated	Phase 1	The study was terminated early by the Sponsor for business reasons.	CHEBI_46195	"161"	MONDO_0008383	"10039073"	"69896004"
	DB00073	Rheumatoid Arthritis	C0003873	NCT01390441	Terminated	Phase 1	The study was terminated early by the Sponsor for business reasons.		"2273510|2472325|121191|2105824"	MONDO_0008383	"10039073"	"69896004"
	DB00959	Rheumatoid Arthritis	C0003873	NCT01390441	Terminated	Phase 1	The study was terminated early by the Sponsor for business reasons.	CHEBI_6888	"6902"	MONDO_0008383	"10039073"	"69896004"
sorafenib	DB00398	Metastatic Renal Cell Cancer	C0278678	NCT01342627	Terminated	Phase 2	low enrollment rate	CHEBI_50924	"495881"			
	DB00072	Malignant neoplasm of breast	C0006142	NCT00567879	Terminated	Phase 1/Phase 2	The study was terminated early due to insufficient evidence of clinical benefit.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
panobinostat	DB06603	Malignant neoplasm of breast	C0006142	NCT00567879	Terminated	Phase 1/Phase 2	The study was terminated early due to insufficient evidence of clinical benefit.	CHEBI_85990	"1603350"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT02318901	Terminated	Phase 1/Phase 2	PI no longer at sight. Results not collected		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
cetuximab	DB00002	Malignant neoplasm of breast	C0006142	NCT02318901	Terminated	Phase 1/Phase 2	PI no longer at sight. Results not collected		"318341"		"10006187"	"254837009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT03770299	Withdrawn	Phase 2	Business objectives have changed	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT03770299	Withdrawn	Phase 2	Business objectives have changed	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB00361	Non-Small Cell Lung Carcinoma	C0007131	NCT03770299	Withdrawn	Phase 2	Business objectives have changed	CHEBI_480999	"39541"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT03770299	Withdrawn	Phase 2	Business objectives have changed	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03770299	Withdrawn	Phase 2	Business objectives have changed		"1597876"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT03770299	Withdrawn	Phase 2	Business objectives have changed	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
nicotine	DB00184	Postoperative Nausea and Vomiting	C0520909	NCT00553709	Terminated	Phase 2	Unexpected difficult recruitment. Study drug expired	CHEBI_17688	"7407|31765"			"1488000"
lorazepam	DB00186	Acute onset pain	C0184567	NCT03756038	Terminated	Phase 2	It was not feasible to enroll Emergency Department patients into this protocol	CHEBI_6539	"6470"			"274663001"
cyclophosphamide	DB00531	Pemphigus Vulgaris	C0030809	NCT00483119	Terminated	Phase 2	Study was terminated due to the death of the PI.	CHEBI_4027	"1545988|3002"	MONDO_0008219		"49420001"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00808210	Terminated	Phase 2	Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
	DB00959	Rheumatoid Arthritis	C0003873	NCT00808210	Terminated	Phase 2	Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.	CHEBI_6888	"6902"	MONDO_0008383	"10039073"	"69896004"
	DB00065	Rheumatoid Arthritis	C0003873	NCT00808210	Terminated	Phase 2	Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.		"1790539|1927283|191831|2266523|2103476"	MONDO_0008383	"10039073"	"69896004"
	DB01101	Malignant neoplasm of breast	C0006142	NCT00496366	Terminated	Phase 2		CHEBI_31348	"194000"		"10006187"	"254837009"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT00496366	Terminated	Phase 2		CHEBI_49603	"480167"		"10006187"	"254837009"
tamoxifen	DB00675	Malignant neoplasm of breast	C0006142	NCT00206492	Terminated	Phase 2	halted by the PI only 3 of 45 subjects were accrued.	CHEBI_41774	"10324"		"10006187"	"254837009"
gefitinib	DB00317	Non-Small Cell Lung Carcinoma	C0007131	NCT01871480	Terminated	Phase 2		CHEBI_49668	"328134"	MONDO_0005233	"10061873"	"254637007"
pseudoephedrine	DB00852	Allergic Conjunctivitis	C0009766		Approved			CHEBI_51209	"8896"	MONDO_0005642	"10010744"	"231854006"
chlorphenamine	DB01114	Allergic Conjunctivitis	C0009766		Approved			CHEBI_52010	"221074|2400"	MONDO_0005642	"10010744"	"231854006"
levofloxacin	DB01137	Bacterial conjunctivitis	C0009768		Approved			CHEBI_63598	"1546009|82122"	MONDO_0006668	"10061784"	"243321006"
trimethoprim	DB00440	Bacterial conjunctivitis	C0009768		Approved			CHEBI_45924	"10829"	MONDO_0006668	"10061784"	"243321006"
ofloxacin	DB01165	Bacterial conjunctivitis	C0009768		Approved			CHEBI_7731	"7623"	MONDO_0006668	"10061784"	"243321006"
gentamicin	DB00798	Bacterial conjunctivitis	C0009768		Approved			CHEBI_17833	"1596450"	MONDO_0006668	"10061784"	"243321006"
prednisolone	DB00860	Bacterial conjunctivitis	C0009768		Approved			CHEBI_8378	"8638"	MONDO_0006668	"10061784"	"243321006"
ciprofloxacin	DB00537	Bacterial conjunctivitis	C0009768		Approved			CHEBI_192484	"2551"	MONDO_0006668	"10061784"	"243321006"
prednisolone sodium phosphate	DB14631	Bacterial conjunctivitis	C0009768		Approved			CHEBI_145705	"34374"	MONDO_0006668	"10061784"	"243321006"
tobramycin	DB00684	Bacterial conjunctivitis	C0009768		Approved			CHEBI_28864	"10627"	MONDO_0006668	"10061784"	"243321006"
sulfamethizole	DB00576	Shigella Infections	C0013371		Approved			CHEBI_9331	"10179"		"10054178"	"36188001"
galantamine	DB00674	Alzheimer's Disease	C0002395	NCT00679627	Terminated	Phase 3	Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early termination of the trial	CHEBI_42944	"4637"	MONDO_0004975	"10012271"	"26929004"
methylprednisolone	DB00959	Endocrine exophthalmos	C0155264	NCT02422368	Withdrawn	Phase 2/Phase 3	Do not access to the drug	CHEBI_6888	"6902"	MONDO_0001509		"276177000"
	DB14644	Endocrine exophthalmos	C0155264	NCT02422368	Withdrawn	Phase 2/Phase 3	Do not access to the drug	CHEBI_135765		MONDO_0001509		"276177000"
	DB00860	Endocrine exophthalmos	C0155264	NCT02422368	Withdrawn	Phase 2/Phase 3	Do not access to the drug	CHEBI_8378	"8638"	MONDO_0001509		"276177000"
levodopa	DB01235	Acute onset pain	C0184567	NCT02116790	Withdrawn	Phase 2		CHEBI_15765	"6375"			"274663001"
	DB00988	Acute onset pain	C0184567	NCT02116790	Withdrawn	Phase 2		CHEBI_18243	"3628"			"274663001"
	DB00788	Acute onset pain	C0184567	NCT02116790	Withdrawn	Phase 2		CHEBI_7476	"7258"			"274663001"
	DB00190	Acute onset pain	C0184567	NCT02116790	Withdrawn	Phase 2		CHEBI_39585	"2019|1545982"			"274663001"
nivolumab	DB09035	Metastatic Renal Cell Cancer	C0278678	NCT03115801	Terminated	Phase 2	Lack of accrual		"1597876"			
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT02862574	Terminated	Phase 2	Study was terminated by sponsor and decision was not due to any safety signals.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00066807	Terminated	Phase 3	Poor accrual, patients were followed until completion of 5 yrs treatment	CHEBI_47898	"3995"		"10006187"	"254837009"
	DB00675	Malignant neoplasm of breast	C0006142	NCT00066807	Terminated	Phase 3	Poor accrual, patients were followed until completion of 5 yrs treatment	CHEBI_41774	"10324"		"10006187"	"254837009"
	DB06825	Malignant neoplasm of breast	C0006142	NCT00066807	Terminated	Phase 3	Poor accrual, patients were followed until completion of 5 yrs treatment	CHEBI_63633	"38782"		"10006187"	"254837009"
pemetrexed	DB00642	Malignant neoplasm of breast	C0006142	NCT02624700	Terminated	Phase 2		CHEBI_63616	"68446"		"10006187"	"254837009"
	DB00398	Malignant neoplasm of breast	C0006142	NCT02624700	Terminated	Phase 2		CHEBI_50924	"495881"		"10006187"	"254837009"
melatonin	DB01065	Malignant neoplasm of breast	C0006142	NCT00506064	Terminated	Phase 1	Terminated due to low accrual.	CHEBI_16796	"6711"		"10006187"	"254837009"
carboplatin	DB00958	Malignant neoplasm of breast	C0006142	NCT01333137	Terminated	Phase 1		CHEBI_31355	"40048"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT04335006	Terminated	Phase 3	Sponsor R & D Strategy Adjustment	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00006261	Withdrawn	Phase 2		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00006261	Withdrawn	Phase 2		CHEBI_28748	"142433|3639"		"10006187"	"254837009"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT01356368	Terminated	Phase 2	slow accrual rate	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
morphine	DB00295	Pain, Postoperative	C0030201	NCT02511483	Terminated	Phase 2	Difficulty with recruitment	CHEBI_17303	"7052|32926"			"213299007"
	DB00571	Pain, Postoperative	C0030201	NCT02511483	Terminated	Phase 2	Difficulty with recruitment	CHEBI_8499	"8787"			"213299007"
nivolumab	DB09035	Metastatic urothelial carcinoma	C4288754	NCT03115801	Terminated	Phase 2	Lack of accrual		"1597876"			"458321000124102"
cromoglicic acid	DB01003	Amyotrophic Lateral Sclerosis	C0002736	NCT04428775	Terminated	Phase 2	Low enrollment	CHEBI_59773	"2921|42612"	MONDO_0004976	"10002026"	"86044005"
donepezil	DB00843	Alzheimer's Disease	C0002395	NCT00693004	Terminated	Phase 2		CHEBI_145499	"135447"	MONDO_0004975	"10012271"	"26929004"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT01679951	Terminated	Phase 2	The decision was made to prematurely discontinue this trial due to lack of efficacy.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT00006261	Withdrawn	Phase 2		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
arsenic trioxide	DB01169	Malignant neoplasm of breast	C0006142	NCT00075413	Withdrawn	Phase 2	Unable to identify qualified subjects willing to participate in this study	CHEBI_49900	"18330"		"10006187"	"254837009"
nicotinamide	DB02701	Malignant neoplasm of breast	C0006142	NCT00356681	Terminated	Phase 2	Sponsor decision to close study	CHEBI_17154	"7405"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT00356681	Terminated	Phase 2	Sponsor decision to close study	CHEBI_45863	"56946"		"10006187"	"254837009"
sulfamethoxazole	DB01015	Shigella Infections	C0013371		Approved			CHEBI_9332	"10180"		"10054178"	"36188001"
melphalan	DB01042	Acute lymphoblastic leukemia - category	C1531702	NCT04282174	Withdrawn	Phase 2	Study was split into two new studies before the first participant was enrolled.	CHEBI_28876	"6718"			
	DB04572	Acute lymphoblastic leukemia - category	C1531702	NCT04282174	Withdrawn	Phase 2	Study was split into two new studies before the first participant was enrolled.	CHEBI_9570	"10473"			
	DB01008	Acute lymphoblastic leukemia - category	C1531702	NCT04282174	Withdrawn	Phase 2	Study was split into two new studies before the first participant was enrolled.	CHEBI_28901	"1828"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT04282174	Withdrawn	Phase 2	Study was split into two new studies before the first participant was enrolled.	CHEBI_4027	"1545988|3002"			
sunitinib	DB01268	Metastatic Renal Cell Cancer	C0278678	NCT03729245	Terminated	Phase 3	Sponsor decision	CHEBI_38940	"357977"			
	DB09035	Metastatic Renal Cell Cancer	C0278678	NCT03729245	Terminated	Phase 3	Sponsor decision		"1597876"			
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00406419	Terminated	Phase 3	Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
pioglitazone	DB01132	Asthma	C0004096	NCT00604578	Withdrawn	Phase 2		CHEBI_8228	"33738"	MONDO_0004979	"10003553"	"195967001"
metformin	DB00331	Atrial Fibrillation	C0004238	NCT02931253	Terminated	Phase 2	Recruitment issue: Enrollment expectation not met	CHEBI_6801	"6809"	MONDO_0004981	"10003658"	"49436004"
	DB00512	Pneumonia, Bacterial	C0004626	NCT01570192	Terminated	Phase 2	NIAID terminated the study due to low subject enrollment	CHEBI_28001	"11124"	MONDO_0004652	"10060946"	"53084003"
	DB00684	Pneumonia, Bacterial	C0004626	NCT01570192	Terminated	Phase 2	NIAID terminated the study due to low subject enrollment	CHEBI_28864	"10627"	MONDO_0004652	"10060946"	"53084003"
	DB00760	Pneumonia, Bacterial	C0004626	NCT01570192	Terminated	Phase 2	NIAID terminated the study due to low subject enrollment	CHEBI_43968	"1546029|29561"	MONDO_0004652	"10060946"	"53084003"
	DB00601	Pneumonia, Bacterial	C0004626	NCT01570192	Terminated	Phase 2	NIAID terminated the study due to low subject enrollment	CHEBI_63607	"190376"	MONDO_0004652	"10060946"	"53084003"
amikacin	DB00479	Pneumonia, Bacterial	C0004626	NCT01570192	Terminated	Phase 2	NIAID terminated the study due to low subject enrollment	CHEBI_2637	"641"	MONDO_0004652	"10060946"	"53084003"
vorinostat	DB02546	Malignant neoplasm of breast	C0006142	NCT00126451	Terminated	Phase 2		CHEBI_45716	"194337"		"10006187"	"254837009"
buspirone	DB00490	Anxiety Disorders	C0003469	NCT01496612	Terminated	Phase 2		CHEBI_3223	"1827"		"10057666"	"197480006"
azithromycin	DB00207	Asthma	C0004096	NCT00181272	Terminated	Phase 2	Principal Investigator moved institutions	CHEBI_2955	"18631"	MONDO_0004979	"10003553"	"195967001"
quetiapine	DB01224	Bipolar Disorder	C0005586	NCT00486798	Terminated	Phase 3	study was not ethically acceptable to continue and therefore it was finally stopped	CHEBI_8707	"51272"	MONDO_0004985	"10057667"	"13746004"
lamotrigine	DB00555	Bipolar Disorder	C0005586	NCT00907985	Terminated	Phase 1	Slow recruitment; trial unlikely to reach completion	CHEBI_6367	"28439"	MONDO_0004985	"10057667"	"13746004"
bevacizumab	DB00112	Malignant neoplasm of breast	C0006142	NCT00576901	Terminated	Phase 2	The sample for statistical analysis of results could not be recruited within the specified timeframe upon retirement of the original principal investigator.		"253337|2046138"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00576901	Terminated	Phase 2	The sample for statistical analysis of results could not be recruited within the specified timeframe upon retirement of the original principal investigator.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
bevacizumab	DB00112	Malignant neoplasm of breast	C0006142	NCT02250118	Terminated	Phase 1	Insufficient Recruitment		"253337|2046138"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT02730091	Terminated	Phase 3		CHEBI_6413	"72965"		"10006187"	"254837009"
	DB01217	Malignant neoplasm of breast	C0006142	NCT02730091	Terminated	Phase 3		CHEBI_2704	"84857"		"10006187"	"254837009"
cyclophosphamide	DB00531	Metastatic urothelial carcinoma	C4288754	NCT04639245	Terminated	Phase 1/Phase 2	Terminated due to slow accrual.	CHEBI_4027	"1545988|3002"			"458321000124102"
metformin	DB00331	Nonsquamous nonsmall cell neoplasm of lung	C2585890	NCT02019979	Terminated	Phase 2	PI left the institution	CHEBI_6801	"6809"			"440173001"
nivolumab	DB09035	Metastatic Renal Cell Cancer	C0278678	NCT03149159	Withdrawn	Phase 2	This study is withdrawn due to feasibility issues.		"1597876"			
	DB06186	Metastatic Renal Cell Cancer	C0278678	NCT03149159	Withdrawn	Phase 2	This study is withdrawn due to feasibility issues.		"1094833"			
tacrolimus	DB00864	Acute lymphoblastic leukemia - category	C1531702	NCT00579111	Terminated	Phase 1/Phase 2	slow accrual	CHEBI_61049	"42316|235991"			
	DB01008	Acute lymphoblastic leukemia - category	C1531702	NCT00579111	Terminated	Phase 1/Phase 2	slow accrual	CHEBI_28901	"1828"			
	DB00087	Acute lymphoblastic leukemia - category	C1531702	NCT00579111	Terminated	Phase 1/Phase 2	slow accrual		"117055"			
doxorubicin	DB00997	Malignant neoplasm of breast	C0006142	NCT01333423	Withdrawn	Phase 1		CHEBI_28748	"142433|3639"		"10006187"	"254837009"
anastrozole	DB01217	Malignant neoplasm of breast	C0006142	NCT01151215	Terminated	Phase 2	Futility	CHEBI_2704	"84857"		"10006187"	"254837009"
eplerenone	DB00700	Malignant neoplasm of breast	C0006142	NCT01708798	Terminated	Phase 2/Phase 3	Futility	CHEBI_31547	"298869"		"10006187"	"254837009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT02376699	Terminated	Phase 1	Study closed due to portfolio prioritization	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT01179269	Withdrawn	Phase 2	The study was stopped because the research team was unable to enroll any participants	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Squamous cell carcinoma	C0007137	NCT02376699	Terminated	Phase 1	Study closed due to portfolio prioritization	CHEBI_45863	"56946"	MONDO_0005096	"10041823"	"402815007"
dexamethasone phosphate	DB00537	Acute otitis externa	C0149948	NCT00945802	Terminated	Phase 3		CHEBI_68637	"2551"	MONDO_0001051		"30250000"
	DB01234	Acute otitis externa	C0149948	NCT00945802	Terminated	Phase 3		CHEBI_41879	"3264"	MONDO_0001051		"30250000"
oxytetracycline	DB00595	Bacterial conjunctivitis	C0009768		Approved			CHEBI_133011	"7821|1545999"	MONDO_0006668	"10061784"	"243321006"
gramicidin	DB00027	Bacterial conjunctivitis	C0009768		Approved			CHEBI_5530	"5011"	MONDO_0006668	"10061784"	"243321006"
gatifloxacin	DB01044	Bacterial conjunctivitis	C0009768	NCT01330355	Terminated	Phase 3	Lack of enrollment	CHEBI_5280	"228476|1546025"	MONDO_0006668	"10061784"	"243321006"
tetracycline	DB09550	Bacterial conjunctivitis	C0009768		Approved			CHEBI_27902	"2105975"	MONDO_0006668	"10061784"	"243321006"
besifloxacin	DB06771	Bacterial conjunctivitis	C0009768		Approved			CHEBI_135622	"819911"	MONDO_0006668	"10061784"	"243321006"
Polymyxin B	DB00781	Bacterial conjunctivitis	C0009768		Approved				"8536"	MONDO_0006668	"10061784"	"243321006"
gatifloxacin	DB01044	Bacterial conjunctivitis	C0009768		Approved			CHEBI_5280	"228476|1546025"	MONDO_0006668	"10061784"	"243321006"
fusidic acid	DB02703	Bacterial conjunctivitis	C0009768		Approved			CHEBI_29013	"4608|113608"	MONDO_0006668	"10061784"	"243321006"
ampicillin	DB00415	Shigella Infections	C0013371		Approved			CHEBI_28971	"733|221058"		"10054178"	"36188001"
donepezil	DB00843	Alzheimer's Disease	C0002395	NCT00602680	Terminated	Phase 2	Insufficient expected benefit risk	CHEBI_145499	"135447"	MONDO_0004975	"10012271"	"26929004"
salbutamol	DB01001	Asthma	C0004096	NCT02127697	Withdrawn	Phase 3		CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT02336984	Withdrawn	Phase 1/Phase 2	PI left Abramson Cancer Center and study never opened at Moffitt Cancer Center.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
metformin	DB00331	Malignant neoplasm of breast	C0006142	NCT01302002	Withdrawn	Early Phase 1		CHEBI_6801	"6809"		"10006187"	"254837009"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT00694200	Terminated	Phase 2	Not reached the statistical hypothesis at the interim analysis	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00694200	Terminated	Phase 2	Not reached the statistical hypothesis at the interim analysis		"253337|2046138"		"10006187"	"254837009"
tamoxifen	DB00675	Malignant neoplasm of breast	C0006142	NCT01194908	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_41774	"10324"		"10006187"	"254837009"
	DB06603	Malignant neoplasm of breast	C0006142	NCT01194908	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_85990	"1603350"		"10006187"	"254837009"
	DB01262	Malignant neoplasm of breast	C0006142	NCT01194908	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_50131	"15657"		"10006187"	"254837009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00434226	Terminated	Phase 2	Based on data collected, the combination appeared to be poorly tolearated.	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB01268	Non-Small Cell Lung Carcinoma	C0007131	NCT00434226	Terminated	Phase 2	Based on data collected, the combination appeared to be poorly tolearated.	CHEBI_38940	"357977"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT00434226	Terminated	Phase 2	Based on data collected, the combination appeared to be poorly tolearated.	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
prednisolone acetate	DB00860	Bacterial conjunctivitis	C0009768		Approved			CHEBI_8378	"8638"	MONDO_0006668	"10061784"	"243321006"
ondansetron	DB00904	Chemotherapy-induced nausea and vomiting	C0401160	NCT00818259	Terminated	Phase 1	Study terminated early prior to completing targeted enrollment of participants <6 months of age due to recruitment challenges.	CHEBI_7773	"26225"			"18846006"
	DB00673	Chemotherapy-induced nausea and vomiting	C0401160	NCT00818259	Terminated	Phase 1	Study terminated early prior to completing targeted enrollment of participants <6 months of age due to recruitment challenges.	CHEBI_499361	"358255"			"18846006"
	DB01234	Chemotherapy-induced nausea and vomiting	C0401160	NCT00818259	Terminated	Phase 1	Study terminated early prior to completing targeted enrollment of participants <6 months of age due to recruitment challenges.	CHEBI_41879	"3264"			"18846006"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT01764997	Terminated	Phase 3	Due to small number of participants entering randomization. Not a safety issue.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
	DB00051	Rheumatoid Arthritis	C0003873	NCT01764997	Terminated	Phase 3	Due to small number of participants entering randomization. Not a safety issue.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
ustekinumab	DB05679	Chronic small plaque psoriasis	C0406317	NCT01708629	Terminated	Phase 3	Sponsor decision		"847083"			"200965009"
	DB06211	Appendicitis	C0003615	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_135928	"119771"	MONDO_0005649	"10003011"	"74400008"
	DB00766	Appendicitis	C0003615	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_48947	"48203|21216"	MONDO_0005649	"10003011"	"74400008"
	DB01060	Appendicitis	C0003615	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_2676	"1297882|723"	MONDO_0005649	"10003011"	"74400008"
meropenem	DB00760	Appendicitis	C0003615	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_43968	"1546029|29561"	MONDO_0005649	"10003011"	"74400008"
moxifloxacin	DB00218	Bacterial conjunctivitis	C0009768		Approved			CHEBI_63611	"139462"	MONDO_0006668	"10061784"	"243321006"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT01198002	Terminated	Phase 3	Terminated not based on safety concerns, but due to insufficient efficacy.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT02619669	Withdrawn	Phase 1	The study was withdrawn, because no participants were enrolled in two years.	CHEBI_6413	"72965"		"10006187"	"254837009"
leucovorin	DB00650	Malignant neoplasm of breast	C0006142	NCT00005608	Terminated	Phase 2	Drug was pulled from the market.	CHEBI_15640	"6313"		"10006187"	"254837009"
	DB11596	Malignant neoplasm of breast	C0006142	NCT00005608	Terminated	Phase 2	Drug was pulled from the market.	CHEBI_63606	"877015"		"10006187"	"254837009"
	DB09256	Malignant neoplasm of breast	C0006142	NCT00005608	Terminated	Phase 2	Drug was pulled from the market.	CHEBI_32188	"4582"		"10006187"	"254837009"
nicotine	DB00184	Malignant neoplasm of breast	C0006142	NCT00751101	Terminated	Phase 2	Low Accrual	CHEBI_17688	"7407|31765"		"10006187"	"254837009"
darbepoetin alfa	DB00012	Non-Small Cell Lung Carcinoma	C0007131	NCT00858364	Terminated	Phase 3			"283838"	MONDO_0005233	"10061873"	"254637007"
oxytocin	DB00107	Pain, Postoperative	C0030201	NCT03011307	Terminated	Phase 2	Cessation of funding period prior to completion, due to slow recruitment during the pandemic.	CHEBI_7872	"7824"			"213299007"
	DB00531	Merkel cell carcinoma	C0007129	NCT03167164	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_4027	"1545988|3002"	MONDO_0019210	"10029266"	"5052009"
morphine	DB00295	Opioid withdrawal	C0029104	NCT03678792	Withdrawn	Phase 3	Infeasible to conduct at this time.	CHEBI_17303	"7052|32926"			"87132004"
	DB01183	Opioid withdrawal	C0029104	NCT03678792	Withdrawn	Phase 3	Infeasible to conduct at this time.	CHEBI_7459	"7242"			"87132004"
	DB00193	Opioid withdrawal	C0029104	NCT03678792	Withdrawn	Phase 3	Infeasible to conduct at this time.	CHEBI_75722	"10689"			"87132004"
	DB00921	Opioid withdrawal	C0029104	NCT03678792	Withdrawn	Phase 3	Infeasible to conduct at this time.	CHEBI_3216	"1819"			"87132004"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00960297	Terminated	Phase 2	Study was terminated due to slow accrual	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT00960297	Terminated	Phase 2	Study was terminated due to slow accrual	CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00960297	Terminated	Phase 2	Study was terminated due to slow accrual		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT00773383	Terminated	Phase 2		CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
ropivacaine	DB00296	Postoperative Nausea and Vomiting	C0520909	NCT02161705	Terminated	Phase 3	Poor accrual due to change in standard of care procedure.	CHEBI_8890	"35780"			"1488000"
ropivacaine	DB00296	Pain, Postoperative	C0030201	NCT02161705	Terminated	Phase 3	Poor accrual due to change in standard of care procedure.	CHEBI_8890	"35780"			"213299007"
paclitaxel	DB01229	Squamous non-small cell lung cancer	C4509816	NCT02204345	Terminated	Phase 1/Phase 2		CHEBI_45863	"56946"			"723301009"
	DB00958	Squamous non-small cell lung cancer	C4509816	NCT02204345	Terminated	Phase 1/Phase 2		CHEBI_31355	"40048"			"723301009"
tetracycline	DB00759	Bacterial conjunctivitis	C0009768		Approved			CHEBI_27902	"10395"	MONDO_0006668	"10061784"	"243321006"
prednisolone acetate	DB15566	Bacterial conjunctivitis	C0009768		Approved			CHEBI_8380	"34372"	MONDO_0006668	"10061784"	"243321006"
paclitaxel	DB01229	Biliary Tract Cancer	C0750952	NCT03818997	Withdrawn	Phase 2	Company decision	CHEBI_45863	"56946"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
leflunomide	DB01097	Rheumatoid Arthritis	C0003873	NCT00476996	Terminated	Phase 3	Recruitment was fully completed for this study; however, the study was terminated during conduct after the primary endpoint analysis was completed.	CHEBI_6402	"27169"	MONDO_0008383	"10039073"	"69896004"
	DB08880	Rheumatoid Arthritis	C0003873	NCT00476996	Terminated	Phase 3	Recruitment was fully completed for this study; however, the study was terminated during conduct after the primary endpoint analysis was completed.	CHEBI_68540	"1310520"	MONDO_0008383	"10039073"	"69896004"
	DB00563	Rheumatoid Arthritis	C0003873	NCT00476996	Terminated	Phase 3	Recruitment was fully completed for this study; however, the study was terminated during conduct after the primary endpoint analysis was completed.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
mycophenolate mofetil	DB01024	Rheumatoid Arthritis	C0003873	NCT00282412	Terminated	Phase 1	No participant enrolled for three years. No plan to continue study.	CHEBI_168396	"7145|265323"	MONDO_0008383	"10039073"	"69896004"
	DB00087	Rheumatoid Arthritis	C0003873	NCT00282412	Terminated	Phase 1	No participant enrolled for three years. No plan to continue study.		"117055"	MONDO_0008383	"10039073"	"69896004"
	DB00531	Rheumatoid Arthritis	C0003873	NCT00282412	Terminated	Phase 1	No participant enrolled for three years. No plan to continue study.	CHEBI_4027	"1545988|3002"	MONDO_0008383	"10039073"	"69896004"
oxaliplatin	DB00526	Malignant neoplasm of breast	C0006142	NCT00006121	Terminated	Phase 2	low accrual	CHEBI_31941	"32592"		"10006187"	"254837009"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT01118975	Terminated	Phase 1/Phase 2	Lost sponsorship for study drug	CHEBI_49603	"480167"		"10006187"	"254837009"
	DB02546	Malignant neoplasm of breast	C0006142	NCT01118975	Terminated	Phase 1/Phase 2	Lost sponsorship for study drug	CHEBI_45716	"194337"		"10006187"	"254837009"
estradiol	DB00783	Depression, Postpartum	C0221074	NCT00059228	Terminated	Phase 2		CHEBI_16469	"4083"			"58703003"
mycophenolate mofetil	DB01024	Malignant Neoplasm (Morphology)	C1288351	NCT01871441	Terminated	Phase 2	Trial was closed due to poor accrual.	CHEBI_168396	"7145|265323"			
	DB00864	Malignant Neoplasm (Morphology)	C1288351	NCT01871441	Terminated	Phase 2	Trial was closed due to poor accrual.	CHEBI_61049	"42316|235991"			
	DB00531	Malignant Neoplasm (Morphology)	C1288351	NCT01871441	Terminated	Phase 2	Trial was closed due to poor accrual.	CHEBI_4027	"1545988|3002"			
rosiglitazone	DB00412	Alzheimer's Disease	C0002395	NCT00550420	Terminated	Phase 3	Based on preliminary parent study results	CHEBI_50122	"84108"	MONDO_0004975	"10012271"	"26929004"
	DB00091	Rheumatoid Arthritis	C0003873	NCT00282412	Terminated	Phase 1	No participant enrolled for three years. No plan to continue study.	CHEBI_4031	"3008"	MONDO_0008383	"10039073"	"69896004"
salbutamol	DB01001	Asthma	C0004096	NCT00635505	Terminated	Phase 3	IND voluntarily withdrawn, without prejudice	CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00343512	Terminated	Phase 2	closed due to competing neoadjuvant studies for a small patient population	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT02115594	Withdrawn	Phase 2	Internal decision	CHEBI_31638	"282357"		"10006187"	"254837009"
imatinib	DB00619	Malignant neoplasm of breast	C0006142	NCT00323063	Terminated	Phase 2	Slow accrual	CHEBI_45783	"282388"		"10006187"	"254837009"
sunitinib	DB01268	Malignant neoplasm of breast	C0006142	NCT02074878	Terminated	Phase 1	Poor accrual so the study was halted on May 16, 2017.	CHEBI_38940	"357977"		"10006187"	"254837009"
	DB08865	Malignant neoplasm of breast	C0006142	NCT02074878	Terminated	Phase 1	Poor accrual so the study was halted on May 16, 2017.	CHEBI_64310	"1148495"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00665457	Terminated	Phase 2	study drug was removed from the market and low enrollment.	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB00482	Malignant neoplasm of breast	C0006142	NCT00665457	Terminated	Phase 2	study drug was removed from the market and low enrollment.	CHEBI_41423	"140587"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00665457	Terminated	Phase 2	study drug was removed from the market and low enrollment.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00665457	Terminated	Phase 2	study drug was removed from the market and low enrollment.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00665457	Terminated	Phase 2	study drug was removed from the market and low enrollment.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
azithromycin	DB00207	Bacterial conjunctivitis	C0009768		Approved			CHEBI_2955	"18631"	MONDO_0006668	"10061784"	"243321006"
cyclophosphamide	DB00531	Metastatic Renal Cell Cancer	C0278678	NCT02867332	Withdrawn	Phase 1	No funding	CHEBI_4027	"1545988|3002"			
exenatide	DB01276	Alzheimer's Disease	C0002395	NCT01255163	Terminated	Phase 2	AstraZeneca withdrew support for the study.	CHEBI_64073	"60548"	MONDO_0004975	"10012271"	"26929004"
denosumab	DB06643	Anorexia Nervosa	C0003125	NCT02567279	Terminated	Phase 3	Great difficulties were encountered during recruitment, for fear Denozumab. Only 2 patients have been included since the study start.		"993449"		"10002649"	"56882008"
cannabidiol	DB09061	Bipolar Disorder	C0005586	NCT03310593	Terminated	Phase 2/Phase 3	It was interrupted due to the coronavirus pandemic outbreak.	CHEBI_69478	"2045371"	MONDO_0004985	"10057667"	"13746004"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00702572	Terminated	Phase 1	Low Enrollment	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
ipilimumab	DB06186	Metastatic urothelial carcinoma	C4288754	NCT05154994	Suspended	Phase 1	Data Safety Monitoring Committee Requirement		"1094833"			"458321000124102"
zoledronic acid	DB00399	Metastatic Renal Cell Cancer	C0278678	NCT03408652	Terminated	Phase 3	lack of recruitment	CHEBI_46557	"1546014|77655"			
	DB06643	Metastatic Renal Cell Cancer	C0278678	NCT03408652	Terminated	Phase 3	lack of recruitment		"993449"			
sunitinib	DB01268	Metastatic Renal Cell Cancer	C0278678	NCT02071641	Terminated	Phase 2		CHEBI_38940	"357977"			
adalimumab	DB00051	Rheumatoid Arthritis	C0003873	NCT02097264	Withdrawn	Phase 2			"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
irinotecan	DB00762	Malignant neoplasm of breast	C0006142	NCT02331251	Terminated	Phase 1/Phase 2	PI not longer at site.	CHEBI_80630	"51499"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT02331251	Terminated	Phase 1/Phase 2	PI not longer at site.	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00361	Malignant neoplasm of breast	C0006142	NCT02331251	Terminated	Phase 1/Phase 2	PI not longer at site.	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT02331251	Terminated	Phase 1/Phase 2	PI not longer at site.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT02331251	Terminated	Phase 1/Phase 2	PI not longer at site.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
carboplatin	DB00958	Malignant neoplasm of breast	C0006142	NCT02978716	Terminated	Phase 2	Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns	CHEBI_31355	"40048"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01929941	Terminated	Phase 1	Business decision.	CHEBI_45863	"56946"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00678626	Withdrawn	Phase 2		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
ropivacaine	DB00296	Postoperative Nausea and Vomiting	C0520909	NCT02506855	Withdrawn	Phase 3	The investigator decided not to continue the study.	CHEBI_8890	"35780"			"1488000"
ropivacaine	DB00296	Pain, Postoperative	C0030201	NCT02506855	Withdrawn	Phase 3	The investigator decided not to continue the study.	CHEBI_8890	"35780"			"213299007"
norfloxacin	DB01059	Bacterial conjunctivitis	C0009768		Approved			CHEBI_100246	"7517"	MONDO_0006668	"10061784"	"243321006"
thiotepa	DB04572	Acute lymphoblastic leukemia - category	C1531702	NCT04151706	Suspended	Phase 2	Interim analysis	CHEBI_9570	"10473"			
	DB01008	Acute lymphoblastic leukemia - category	C1531702	NCT04151706	Suspended	Phase 2	Interim analysis	CHEBI_28901	"1828"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT04151706	Suspended	Phase 2	Interim analysis	CHEBI_4027	"1545988|3002"			
thiotepa	DB04572	Myeloid Leukemia, Chronic	C0023473	NCT04151706	Suspended	Phase 2	Interim analysis	CHEBI_9570	"10473"	MONDO_0011996		
	DB01008	Myeloid Leukemia, Chronic	C0023473	NCT04151706	Suspended	Phase 2	Interim analysis	CHEBI_28901	"1828"	MONDO_0011996		
	DB00531	Myeloid Leukemia, Chronic	C0023473	NCT04151706	Suspended	Phase 2	Interim analysis	CHEBI_4027	"1545988|3002"	MONDO_0011996		
folic acid	DB00158	Rheumatoid Arthritis	C0003873	NCT02393378	Terminated	Phase 2	Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.	CHEBI_27470	"62356|4511|202634"	MONDO_0008383	"10039073"	"69896004"
	DB00563	Rheumatoid Arthritis	C0003873	NCT02393378	Terminated	Phase 2	Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
	DB00051	Rheumatoid Arthritis	C0003873	NCT02393378	Terminated	Phase 2	Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0008383	"10039073"	"69896004"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT00754702	Terminated	Phase 2	Poor accrual	CHEBI_49603	"480167"		"10006187"	"254837009"
	DB00361	Malignant neoplasm of breast	C0006142	NCT00754702	Terminated	Phase 2	Poor accrual	CHEBI_480999	"39541"		"10006187"	"254837009"
lovastatin	DB00227	Malignant neoplasm of breast	C0006142	NCT00902668	Terminated	Phase 2	Slow accrual	CHEBI_40303	"6472"		"10006187"	"254837009"
cromoglicic acid	DB01003	Conjunctivitis, Giant Papillary	C0009769		Approved			CHEBI_59773	"2921|42612"	MONDO_0002308	"10018258"	"231857004"
oxymorphone	DB01192	Acute onset pain	C0184567	NCT02687451	Terminated	Phase 3	Released from PMR	CHEBI_7865	"7814"			"274663001"
ipilimumab	DB06186	Merkel cell carcinoma	C0007129	NCT01913691	Withdrawn	Phase 2			"1094833"	MONDO_0019210	"10029266"	"5052009"
cyclophosphamide	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT02999854	Terminated	Phase 3	Insufficient efficacy, terminated by Sponsor	CHEBI_4027	"1545988|3002"			
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT00351039	Terminated	Phase 1/Phase 2	slow accrual	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT00351039	Terminated	Phase 1/Phase 2	slow accrual	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00351039	Terminated	Phase 1/Phase 2	slow accrual		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Squamous cell carcinoma	C0007137	NCT01009203	Terminated	Phase 2	High patient withdrawal rate	CHEBI_114785	"337525"	MONDO_0005096	"10041823"	"402815007"
	DB00877	Squamous cell carcinoma	C0007137	NCT01009203	Terminated	Phase 2	High patient withdrawal rate	CHEBI_9168	"35302"	MONDO_0005096	"10041823"	"402815007"
sulfamethoxazole	DB01015	Inclusion conjunctivitis	C0009770		Approved			CHEBI_9332	"10180"		"10021629"	"231861005"
interferon beta-1b	DB00068	Multiple Sclerosis, Acute Relapsing	C0393664	NCT04079088	Withdrawn	Phase 2	Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase 2 clinical studies. This was not related to safety concerns.	CHEBI_5938	"72257|72258"			"230372003"
tocofibrate	DB00163	Hospital acquired pneumonia	C0949083	NCT01897792	Terminated	Phase 2	Inability to recruit patients that meet inclusion criteria.	CHEBI_18145	"11256|237099"			"425464007"
	DB00126	Hospital acquired pneumonia	C0949083	NCT01897792	Terminated	Phase 2	Inability to recruit patients that meet inclusion criteria.	CHEBI_29073	"1151|1370460"			"425464007"
	DB14482	Hospital acquired pneumonia	C0949083	NCT01897792	Terminated	Phase 2	Inability to recruit patients that meet inclusion criteria.	CHEBI_113451	"267366"			"425464007"
anastrozole	DB01217	Human epidermal growth factor 2 negative carcinoma of breast	C2316304	NCT01394211	Terminated	Phase 2	Slow accrual	CHEBI_2704	"84857"			"431396003"
sorafenib	DB00398	Metastatic Renal Cell Cancer	C0278678	NCT02122003	Terminated	Phase 2	availability of new and more promising therapeutic agents than expected in the experimentation in question	CHEBI_50924	"495881"			
imatinib	DB00619	Myeloid Leukemia, Chronic	C0023473	NCT00511121	Terminated	Phase 2		CHEBI_45783	"282388"	MONDO_0011996		
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01163929	Withdrawn	Phase 2	Study closed by Protocol Review Monitoring Committee because of lack of accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00542191	Terminated	Phase 2	Enrollment Completed	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00542191	Terminated	Phase 2	Enrollment Completed	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00542191	Terminated	Phase 2	Enrollment Completed	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00542191	Terminated	Phase 2	Enrollment Completed	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
potassium chloride	DB00761	Constipation	C0009806		Approved			CHEBI_32588	"8591"	HP:0002019	"10010774"	"14760008"
magnesium citrate	DB11110	Constipation	C0009806		Approved			CHEBI_131391	"52356"	HP:0002019	"10010774"	"14760008"
methadone	DB00333	Pain, Postoperative	C0030201	NCT03908944	Withdrawn	Phase 2	PI- Dr. Jellish passed away. The study was terminated with the IRB	CHEBI_167309	"6813"			"213299007"
ascorbic acid	DB00126	Diabetic peripheral neuropathy	C0740447	NCT05281562	Terminated	Phase 2/Phase 3	There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.	CHEBI_29073	"1151|1370460"			"424736006"
	DB14482	Diabetic peripheral neuropathy	C0740447	NCT05281562	Terminated	Phase 2/Phase 3	There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.	CHEBI_113451	"267366"			"424736006"
	DB14483	Diabetic peripheral neuropathy	C0740447	NCT05281562	Terminated	Phase 2/Phase 3	There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.		"1307765|142407"			"424736006"
levomenthol	DB00825	Acute onset pain	C0184567	NCT04484428	Terminated	Phase 2	Internal business decision	CHEBI_15409	"236388|6750"			"274663001"
	DB14123	Acute onset pain	C0184567	NCT04484428	Terminated	Phase 2	Internal business decision	CHEBI_25187	"6750|1430390"			"274663001"
	DB14483	Hospital acquired pneumonia	C0949083	NCT01897792	Terminated	Phase 2	Inability to recruit patients that meet inclusion criteria.		"1307765|142407"			"425464007"
	DB11635	Hospital acquired pneumonia	C0949083	NCT01897792	Terminated	Phase 2	Inability to recruit patients that meet inclusion criteria.		"159151"			"425464007"
sulfacetamide	DB00634	Inclusion conjunctivitis	C0009770		Approved			CHEBI_63845	"10169"		"10021629"	"231861005"
sulfafurazole	DB00263	Inclusion conjunctivitis	C0009770		Approved			CHEBI_102484	"10207"		"10021629"	"231861005"
erythromycin	DB00199	Inclusion conjunctivitis	C0009770		Approved			CHEBI_42355	"4053"		"10021629"	"231861005"
fenofibrate	DB01039	Primary Biliary Cholangitis	C0008312	NCT01141296	Withdrawn	Phase 2	Lack of funding	CHEBI_5001	"8703"	MONDO_0005388	"10080429"	"31712002"
thiotepa	DB04572	Acute lymphoblastic leukemia - category	C1531702	NCT00593554	Terminated	Phase 2	Slow accrual	CHEBI_9570	"10473"			
thiotepa	DB04572	Myeloid Leukemia, Chronic	C0023473	NCT00593554	Terminated	Phase 2	Slow accrual	CHEBI_9570	"10473"	MONDO_0011996		
methotrexate	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT01483690	Terminated	Phase 1/Phase 2	Toxicity	CHEBI_44185	"6851"			
	DB01204	Acute lymphoblastic leukemia - category	C1531702	NCT01483690	Terminated	Phase 1/Phase 2	Toxicity	CHEBI_50729	"7005"			
	DB00541	Acute lymphoblastic leukemia - category	C1531702	NCT01483690	Terminated	Phase 1/Phase 2	Toxicity	CHEBI_28445	"11202"			
	DB02546	Acute lymphoblastic leukemia - category	C1531702	NCT01483690	Terminated	Phase 1/Phase 2	Toxicity	CHEBI_45716	"194337"			
	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT01483690	Terminated	Phase 1/Phase 2	Toxicity		"1156"			
	DB01262	Acute lymphoblastic leukemia - category	C1531702	NCT01483690	Terminated	Phase 1/Phase 2	Toxicity	CHEBI_50131	"15657"			
	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT01483690	Terminated	Phase 1/Phase 2	Toxicity	CHEBI_41879	"3264"			
insulin glargine	DB00030	Asthma	C0004096	NCT00642616	Terminated	Phase 3	Terminated upon recommendation of the Data Safety Monitoring Board (DSMB)	CHEBI_5931	"253182|631657"	MONDO_0004979	"10003553"	"195967001"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00206453	Terminated	Phase 2	accrual too difficult to meet	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB01223	Non-Small Cell Lung Carcinoma	C0007131	NCT01799161	Withdrawn	Phase 1	Insufficient funding	CHEBI_2659	"689"	MONDO_0005233	"10061873"	"254637007"
fluconazole	DB00196	Candidemia	C0877445	NCT01176058	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_46081	"202813|4450"	MONDO_0044070		"432261003"
	DB00362	Candidemia	C0877445	NCT01176058	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_55346	"341018"	MONDO_0044070		"432261003"
ketamine	DB01221	Acute onset pain	C0184567	NCT03436121	Withdrawn	Phase 2/Phase 3	Ketamine shortage during the funding period of the trial	CHEBI_6121	"6130"			"274663001"
	DB00683	Acute onset pain	C0184567	NCT03436121	Withdrawn	Phase 2/Phase 3	Ketamine shortage during the funding period of the trial	CHEBI_6931	"6960"			"274663001"
infliximab	DB00065	Berylliosis	C0005138	NCT00111917	Terminated	Phase 1/Phase 2	Not enough patients meeting criteria to enroll in the time period		"1790539|1927283|191831|2266523|2103476"		"10004485"	"8247009"
mirtazapine	DB00370	Vomiting of pregnancy	C0269661	NCT03785691	Terminated	Phase 2	Recruiting difficulties	CHEBI_6950	"15996"			"90325002"
	DB00904	Vomiting of pregnancy	C0269661	NCT03785691	Terminated	Phase 2	Recruiting difficulties	CHEBI_7773	"26225"			"90325002"
abatacept	DB01281	Autoimmune Chronic Hepatitis	C0241910	NCT04203875	Terminated	Phase 1	Lack of eligible study participants.		"614391"			"16098491000119109"
triamcinolone diacetate	DB00620	Angioedema	C0002994		Approved			CHEBI_9667	"10759"	HP:0100665	"10002424"	"846575004"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00485589	Terminated	Phase 3	Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT02532400	Terminated	Phase 3	Hard to enroll expected number of eligible patients.	CHEBI_5523	"50610"		"10006187"	"254837009"
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT00903006	Terminated	Phase 1/Phase 2	Low Accrual	CHEBI_31638	"282357"		"10006187"	"254837009"
betamethasone	DB00443	Chronic small plaque psoriasis	C0406317	NCT02527421	Terminated	Phase 3	Not able to recruit patients with the current enrollment criteria.	CHEBI_3077	"1514"			"200965009"
	DB01254	Malignant neoplasm of breast	C0006142	NCT00903006	Terminated	Phase 1/Phase 2	Low Accrual	CHEBI_49375	"475342|1546019"		"10006187"	"254837009"
doxepin	DB01142	Primary thymic carcinoma	C4302369	NCT02062632	Terminated	Phase 2	Poor accrual	CHEBI_4710	"3638"			"722670005"
aprepitant	DB00673	Chemotherapy-induced nausea and vomiting	C0401160	NCT01874119	Terminated	Phase 2	Enrollment issues	CHEBI_499361	"358255"			"18846006"
inositol	DB13178	Alzheimer's Disease	C0002395	NCT01766336	Terminated	Phase 2		CHEBI_17268	"5833"	MONDO_0004975	"10012271"	"26929004"
nivolumab	DB09035	Rheumatoid Arthritis	C0003873	NCT03656627	Terminated	Phase 1	low accrual		"1597876"	MONDO_0008383	"10039073"	"69896004"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00616122	Terminated	Phase 1/Phase 2	Risk to benefit ratio not acceptable	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
sunitinib	DB01268	Malignant neoplasm of breast	C0006142	NCT00570908	Terminated	Phase 2	Due to poor accrual this study is being closed to accrual	CHEBI_38940	"357977"		"10006187"	"254837009"
octreotide	DB00104	Acromegaly	C0001206	NCT01295060	Terminated	Phase 3	Program was terminated for business reasons	CHEBI_7726	"7617"	MONDO_0019933	"10000599"	"74107003"
ketoprofen	DB01009	Dysmenorrhea	C0013390		Approved			CHEBI_6128	"6142"	HP:0100607	"10013935"	"431416001"
enocitabine	DB00773	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_4911	"4179"			
	DB00741	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_17650	"5492"			
	DB01033	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_50667	"103|1546028"			
	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_44185	"6851"			
	DB01204	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_50729	"7005"			
	DB00541	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_28445	"11202"			
	DB00188	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_52717	"358258"			
	DB06603	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_85990	"1603350"			
	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual		"1156"			
	DB00631	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_681569	"44151"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_4027	"1545988|3002"			
	DB00987	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_28680	"3041|968804"			
	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT02518750	Terminated	Phase 2	Due to slow accrual	CHEBI_41879	"3264"			
aripiprazole	DB01238	Bipolar Disorder	C0005586	NCT00338273	Withdrawn	Phase 3		CHEBI_31236	"89013"	MONDO_0004985	"10057667"	"13746004"
plicamycin	DB06810	Malignant neoplasm of breast	C0006142	NCT01624090	Terminated	Phase 2	Study closed due to low accrual.	CHEBI_31856	"6995"		"10006187"	"254837009"
mechlorethamine	DB00888	Mycosis Fungoides	C0026948	NCT03288818	Withdrawn	Phase 2	Funding discontinued	CHEBI_28925	"6674"	MONDO_0009691		"118618005"
dutasteride	DB01126	Prostatic Hypertrophy	C1739363	NCT00431626	Terminated	Phase 3	Low enrollment	CHEBI_521033	"228790"			"266569009"
methylprednisolone	DB00959	Angioedema	C0002994		Approved			CHEBI_6888	"6902"	HP:0100665	"10002424"	"846575004"
memantine	DB01043	Alzheimer's Disease	C0002395	NCT00857233	Terminated	Phase 3	Please see explanation in the Detailed Description field.	CHEBI_64312	"6719"	MONDO_0004975	"10012271"	"26929004"
minocycline	DB01017	Acne Vulgaris	C0001144	NCT00392223	Terminated	Phase 3	See Detailed Description	CHEBI_50694	"6980"			"88616000"
	DB00207	Acne Vulgaris	C0001144	NCT00392223	Terminated	Phase 3	See Detailed Description	CHEBI_2955	"18631"			"88616000"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT00830245	Terminated	Phase 2	low accrual rate	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
sodium phosphate, monobasic	DB09449	Constipation	C0009806		Approved			CHEBI_37585	"36709|235496|314838|349753"	HP:0002019	"10010774"	"14760008"
docusate sodium	DB11089	Constipation	C0009806		Approved			CHEBI_534	"82003"	HP:0002019	"10010774"	"14760008"
glycerol	DB09462	Constipation	C0009806		Approved			CHEBI_17754	"4910"	HP:0002019	"10010774"	"14760008"
dehydrocholic acid	DB11622	Constipation	C0009806		Approved			CHEBI_31459	"42625|3141"	HP:0002019	"10010774"	"14760008"
bisacodyl	DB09020	Constipation	C0009806	NCT02609607	Terminated	Phase 2	Poor enrollment; funding ending Dec 31, 2018.	CHEBI_3125	"1596"	HP:0002019	"10010774"	"14760008"
oxyphenisatine	DB04823	Constipation	C0009806		Approved			CHEBI_135358	"8136"	HP:0002019	"10010774"	"14760008"
oxyphenisatine acetate	DB04823	Constipation	C0009806		Approved			CHEBI_135358	"8136"	HP:0002019	"10010774"	"14760008"
oxyphenisatine acetate	DB14627	Constipation	C0009806		Approved			CHEBI_135638		HP:0002019	"10010774"	"14760008"
macrogol	DB11161	Constipation	C0009806		Approved			CHEBI_46793	"8513"	HP:0002019	"10010774"	"14760008"
	DB00497	Constipation	C0009806	NCT01014559	Terminated	Phase 3	Lack of recruitment	CHEBI_7852	"7804"	HP:0002019	"10010774"	"14760008"
magnesium gluconate	DB13749	Constipation	C0009806		Approved				"52358"	HP:0002019	"10010774"	"14760008"
carboplatin	DB00958	Metastatic urothelial carcinoma	C4288754	NCT04003610	Terminated	Phase 2	The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.	CHEBI_31355	"40048"			"458321000124102"
riluzole	DB00740	Amyotrophic Lateral Sclerosis	C0002736	NCT03679975	Terminated	Phase 2	The study is no longer required	CHEBI_8863	"35623"	MONDO_0004976	"10002026"	"86044005"
enocitabine	DB01204	Relapsing acute myeloid leukemia	C2349276	NCT04797767	Suspended	Phase 1	Pending protocol amendment	CHEBI_50729	"7005"			"12281000132104"
	DB13144	Relapsing acute myeloid leukemia	C2349276	NCT04797767	Suspended	Phase 1	Pending protocol amendment		"70167"			"12281000132104"
	DB00242	Relapsing acute myeloid leukemia	C2349276	NCT04797767	Suspended	Phase 1	Pending protocol amendment	CHEBI_567361	"44157"			"12281000132104"
	DB00987	Relapsing acute myeloid leukemia	C2349276	NCT04797767	Suspended	Phase 1	Pending protocol amendment	CHEBI_28680	"3041|968804"			"12281000132104"
lenograstim	DB13144	Chemotherapy induced neutropenia	C1827687	NCT03559387	Terminated	Phase 2	Study redesign		"70167"			
dronabinol	DB00470	Bipolar Disorder	C0005586	NCT03206463	Terminated	Phase 1	Feasibility pilot was completed	CHEBI_66964	"10402"	MONDO_0004985	"10057667"	"13746004"
busulfan	DB01008	Myeloid Leukemia, Chronic	C0023473	NCT00531310	Terminated	Phase 2	Poor accrual	CHEBI_28901	"1828"	MONDO_0011996		
citalopram	DB00215	Malignant neoplasm of breast	C0006142	NCT05063604	Terminated	Phase 2	The CAMAD clinical trial has been terminated due to difficulties in recruiting patients.	CHEBI_77397	"2556"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00539968	Terminated	Phase 1/Phase 2		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00536939	Terminated	Phase 2	Study has been terminated due to slow enrollment	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00112	Malignant neoplasm of breast	C0006142	NCT00536939	Terminated	Phase 2	Study has been terminated due to slow enrollment		"253337|2046138"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00864175	Terminated	Phase 1/Phase 2	Incyte suspended development of the compound.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00864175	Terminated	Phase 1/Phase 2	Incyte suspended development of the compound.	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
sirolimus	DB00877	Acute lymphoblastic leukemia - category	C1531702	NCT00957320	Withdrawn	Phase 1	no patients enrolled, decided not to pursue study	CHEBI_9168	"35302"			
	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT00957320	Withdrawn	Phase 1	no patients enrolled, decided not to pursue study		"1156"			
enocitabine	DB01024	Acute lymphoblastic leukemia - category	C1531702	NCT01621477	Terminated	Phase 2	Study was terminated in August 2016 due to replacement by a new study.	CHEBI_168396	"7145|265323"			
	DB00864	Acute lymphoblastic leukemia - category	C1531702	NCT01621477	Terminated	Phase 2	Study was terminated in August 2016 due to replacement by a new study.	CHEBI_61049	"42316|235991"			
	DB01008	Acute lymphoblastic leukemia - category	C1531702	NCT01621477	Terminated	Phase 2	Study was terminated in August 2016 due to replacement by a new study.	CHEBI_28901	"1828"			
	DB00631	Acute lymphoblastic leukemia - category	C1531702	NCT01621477	Terminated	Phase 2	Study was terminated in August 2016 due to replacement by a new study.	CHEBI_681569	"44151"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT01621477	Terminated	Phase 2	Study was terminated in August 2016 due to replacement by a new study.	CHEBI_4027	"1545988|3002"			
	DB00987	Acute lymphoblastic leukemia - category	C1531702	NCT01621477	Terminated	Phase 2	Study was terminated in August 2016 due to replacement by a new study.	CHEBI_28680	"3041|968804"			
memantine	DB01043	Alzheimer's Disease	C0002395	NCT00857649	Terminated	Phase 3		CHEBI_64312	"6719"	MONDO_0004975	"10012271"	"26929004"
etanercept	DB00005	Rheumatoid Arthritis	C0003873	NCT01394913	Withdrawn	Phase 3	Sponsor decision	CHEBI_4875	"214555|2103480|2462511"	MONDO_0008383	"10039073"	"69896004"
prednicarbate	DB00860	Asthma	C0004096	NCT00327197	Terminated	Phase 1	The study was truncated due to the long period of enrollment and the collection of a sufficient amount of data that allowed the scientific objectives to be met	CHEBI_8378	"8638"	MONDO_0004979	"10003553"	"195967001"
atorvastatin	DB01076	Asthma	C0004096	NCT00292201	Terminated	Phase 2	Lack of funding to complete subject recruitment and testing	CHEBI_39548	"83367"	MONDO_0004979	"10003553"	"195967001"
	DB00635	Asthma	C0004096	NCT01615874	Withdrawn	Phase 2		CHEBI_8382	"8640"	MONDO_0004979	"10003553"	"195967001"
prednicarbate	DB00860	Asthma	C0004096	NCT01615874	Withdrawn	Phase 2		CHEBI_8378	"8638"	MONDO_0004979	"10003553"	"195967001"
mitoxantrone	DB01204	Multiple Sclerosis, Acute Relapsing	C0393664	NCT05496894	Withdrawn	Phase 2	Due to the company's project adjustment, decided to stop this study	CHEBI_50729	"7005"			"230372003"
	DB01234	Amyloidosis	C0002726	NCT03130348	Withdrawn	Phase 2	Study was dropped at site before participation	CHEBI_41879	"3264"	MONDO_0019065	"10002022"	"17602002"
bortezomib	DB00188	Amyloidosis	C0002726	NCT03130348	Withdrawn	Phase 2	Study was dropped at site before participation	CHEBI_52717	"358258"	MONDO_0019065	"10002022"	"17602002"
sorafenib	DB00398	Metastatic Renal Cell Cancer	C0278678	NCT01100242	Terminated	Phase 2	Low accrual	CHEBI_50924	"495881"			
	DB00188	Metastatic Renal Cell Cancer	C0278678	NCT01100242	Terminated	Phase 2	Low accrual	CHEBI_52717	"358258"			
nivolumab	DB09035	Metastatic Renal Cell Cancer	C0278678	NCT03927248	Withdrawn	Phase 1/Phase 2	funding issues		"1597876"			
epinephrine	DB00668	Pain, Postoperative	C0030201	NCT03268278	Terminated	Phase 1	Loss of interest	CHEBI_28918	"3992"			"213299007"
	DB00281	Pain, Postoperative	C0030201	NCT03268278	Terminated	Phase 1	Loss of interest	CHEBI_6456	"6387"			"213299007"
	DB00921	Pain, Postoperative	C0030201	NCT03268278	Terminated	Phase 1	Loss of interest	CHEBI_3216	"1819"			"213299007"
mifepristone	DB00834	Severe major depression with psychotic features	C0270458	NCT00637494	Terminated	Phase 3	DRC recommended stopping study as it had missed its primary endpoint	CHEBI_50692	"6964"			"73867007"
ondansetron	DB00904	Chemotherapy-induced nausea and vomiting	C0401160	NCT02519842	Terminated	Phase 3	Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings	CHEBI_7773	"26225"			"18846006"
	DB00673	Chemotherapy-induced nausea and vomiting	C0401160	NCT02519842	Terminated	Phase 3	Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings	CHEBI_499361	"358255"			"18846006"
	DB01234	Chemotherapy-induced nausea and vomiting	C0401160	NCT02519842	Terminated	Phase 3	Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings	CHEBI_41879	"3264"			"18846006"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT00888082	Withdrawn	Phase 3		CHEBI_5523	"50610"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT01272141	Terminated	Phase 2	Slow accrual, Funding stopped	CHEBI_68478	"141704"		"10006187"	"254837009"
	DB01259	Malignant neoplasm of breast	C0006142	NCT01272141	Terminated	Phase 2	Slow accrual, Funding stopped	CHEBI_49603	"480167"		"10006187"	"254837009"
lansoprazole	DB00448	Malignant neoplasm of breast	C0006142	NCT03794596	Withdrawn	Phase 2	IP breach	CHEBI_6375	"17128"		"10006187"	"254837009"
	DB05351	Malignant neoplasm of breast	C0006142	NCT03794596	Withdrawn	Phase 2	IP breach	CHEBI_135931	"816346"		"10006187"	"254837009"
	DB00945	Malignant neoplasm of breast	C0006142	NCT03794596	Withdrawn	Phase 2	IP breach	CHEBI_15365	"91101|1191"		"10006187"	"254837009"
everolimus	DB01590	Malignant neoplasm of breast	C0006142	NCT00855114	Withdrawn	Phase 2	Withdrawn due to no accrual	CHEBI_68478	"141704"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT01147016	Terminated	Phase 2	Primary co-investigator leaving the institution & funding transfer.	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT01147016	Terminated	Phase 2	Primary co-investigator leaving the institution & funding transfer.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
macrogol	DB11077	Constipation	C0009806		Approved			CHEBI_46793	"8514"	HP:0002019	"10010774"	"14760008"
panobinostat	DB06603	Primary Myelofibrosis	C0001815	NCT00931762	Terminated	Phase 2		CHEBI_85990	"1603350"	MONDO_0009692	"10077161"	"128843003"
paclitaxel	DB01229	Human epidermal growth factor 2 negative carcinoma of breast	C2316304	NCT02824575	Terminated	Phase 1	Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.	CHEBI_45863	"56946"			"431396003"
granisetron	DB00889	Chemotherapy-induced nausea and vomiting	C0401160	NCT04085393	Withdrawn	Phase 2	sponsor withdrew study	CHEBI_5537	"26237"			"18846006"
salbutamol	DB01001	Asthma	C0004096	NCT00634829	Terminated	Phase 3	IND voluntarily withdrawn, without prejudice	CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
hydrocortamate	DB00741	Atrial Fibrillation	C0004238	NCT03682393	Withdrawn	Phase 2/Phase 3	the study never started	CHEBI_17650	"5492"	MONDO_0004981	"10003658"	"49436004"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00756470	Terminated	Phase 2	Slow accrual.	CHEBI_47898	"3995"		"10006187"	"254837009"
	DB01259	Malignant neoplasm of breast	C0006142	NCT00756470	Terminated	Phase 2	Slow accrual.	CHEBI_49603	"480167"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT00756470	Terminated	Phase 2	Slow accrual.	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00544	Malignant neoplasm of breast	C0006142	NCT00756470	Terminated	Phase 2	Slow accrual.	CHEBI_46345	"4492"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00756470	Terminated	Phase 2	Slow accrual.	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
doxorubicin	DB00997	Malignant neoplasm of breast	C0006142	NCT02850419	Withdrawn	Phase 2	Administrative	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00937417	Withdrawn	Phase 1	Withdrawn because SWOG no longer pursuing this study at this time	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB06186	Non-Small Cell Lung Carcinoma	C0007131	NCT03091491	Terminated	Phase 2	Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative therapy and clinician's choice to put patient on immunotherapy outside of trial setting.		"1094833"	MONDO_0005233	"10061873"	"254637007"
donepezil	DB00843	Alzheimer's Disease	C0002395	NCT00713765	Terminated	Phase 1	Ended prematurely - The trial never commenced.	CHEBI_145499	"135447"	MONDO_0004975	"10012271"	"26929004"
rosiglitazone	DB00412	Alzheimer's Disease	C0002395	NCT00490568	Terminated	Phase 3	Based on preliminary parent study results	CHEBI_50122	"84108"	MONDO_0004975	"10012271"	"26929004"
riluzole	DB00740	Malignant neoplasm of breast	C0006142	NCT00903214	Withdrawn	Phase 1	Funding ended	CHEBI_8863	"35623"		"10006187"	"254837009"
ketorolac	DB00465	Pain, Postoperative	C0030201	NCT02400645	Terminated	Phase 1	It was determined that one member of the team had falsified data.	CHEBI_76223	"35827"			"213299007"
	DB00297	Pain, Postoperative	C0030201	NCT02400645	Terminated	Phase 1	It was determined that one member of the team had falsified data.	CHEBI_77431	"1815"			"213299007"
deferasirox	DB01609	Primary Myelofibrosis	C0001815	NCT01159067	Terminated	Phase 2	Low enrollment	CHEBI_49005	"614373"	MONDO_0009692	"10077161"	"128843003"
lumefantrine	DB06708	Malaria, Vivax	C0024537	NCT02696928	Withdrawn	Phase 2	Lack of ethical approval in Ethiopia	CHEBI_156095	"847728"	MONDO_0005921		"27052006"
	DB01087	Malaria, Vivax	C0024537	NCT02696928	Withdrawn	Phase 2	Lack of ethical approval in Ethiopia	CHEBI_8405	"8687"	MONDO_0005921		"27052006"
methyltestosterone	DB06710	Prostatic Hypertrophy	C1739363	NCT03297398	Terminated	Phase 2	study terminated by sponsor decision	CHEBI_27436	"6904"			"266569009"
	DB00126	Prostatic Hypertrophy	C1739363	NCT03297398	Terminated	Phase 2	study terminated by sponsor decision	CHEBI_29073	"1151|1370460"			"266569009"
	DB14482	Prostatic Hypertrophy	C1739363	NCT03297398	Terminated	Phase 2	study terminated by sponsor decision	CHEBI_113451	"267366"			"266569009"
	DB14483	Prostatic Hypertrophy	C1739363	NCT03297398	Terminated	Phase 2	study terminated by sponsor decision		"1307765|142407"			"266569009"
hydrocortisone acetate	DB00741	Angioedema	C0002994		Approved			CHEBI_17650	"5492"	HP:0100665	"10002424"	"846575004"
	DB00563	Rheumatoid Arthritis	C0003873	NCT02795299	Withdrawn	Phase 2	Study not started due to Sponsor decision to not move forward with compound.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
folic acid	DB00158	Rheumatoid Arthritis	C0003873	NCT02795299	Withdrawn	Phase 2	Study not started due to Sponsor decision to not move forward with compound.	CHEBI_27470	"62356|4511|202634"	MONDO_0008383	"10039073"	"69896004"
insulin glargine	DB01306	Asthma	C0004096	NCT00523042	Terminated	Phase 3	See termination reason in detailed description		"51428|352385"	MONDO_0004979	"10003553"	"195967001"
	DB00030	Asthma	C0004096	NCT00523042	Terminated	Phase 3	See termination reason in detailed description	CHEBI_5931	"253182|631657"	MONDO_0004979	"10003553"	"195967001"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00912444	Terminated	Phase 3	TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.	CHEBI_47898	"3995"		"10006187"	"254837009"
deferasirox	DB01609	Malignant neoplasm of breast	C0006142	NCT00602446	Terminated	Phase 2	Due to slow accrual of patients	CHEBI_49005	"614373"		"10006187"	"254837009"
triamcinolone acetonide	DB00620	Angioedema	C0002994		Approved			CHEBI_9667	"10759"	HP:0100665	"10002424"	"846575004"
enocitabine	DB00773	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_4911	"4179"			
	DB01177	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_42068	"5650"			
	DB01033	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_50667	"103|1546028"			
	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_44185	"6851"			
	DB00635	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_8382	"8640"			
	DB00541	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_28445	"11202"			
	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity		"1156"			
	DB00531	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_4027	"1545988|3002"			
	DB00987	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_28680	"3041|968804"			
	DB00694	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_41977	"214468|3109"			
	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT00187005	Terminated	Phase 3	Toxicity	CHEBI_41879	"3264"			
enocitabine	DB00563	Acute lymphoblastic leukemia - category	C1531702	NCT01187810	Terminated	Phase 1	drug supply	CHEBI_44185	"6851"			
	DB00987	Acute lymphoblastic leukemia - category	C1531702	NCT01187810	Terminated	Phase 1	drug supply	CHEBI_28680	"3041|968804"			
	DB01248	Malignant neoplasm of breast	C0006142	NCT00476827	Terminated	Phase 2	Slow accrual	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
thiotepa	DB04572	Malignant neoplasm of breast	C0006142	NCT00448266	Terminated	Phase 2/Phase 3	Activation of a similar multicenter study for same population	CHEBI_9570	"10473"		"10006187"	"254837009"
macrogol	DB09287	Constipation	C0009806		Approved			CHEBI_46793	"8516|1314384|221147|1310594"	HP:0002019	"10010774"	"14760008"
abatacept	DB01281	Alopecia Areata	C0002171	NCT01917058	Withdrawn	Phase 2	Unfortunately we did not receive funding and therefore were not able to begin the trial.		"614391"	MONDO_0005340	"10001761"	"68225006"
hydrocortamate	DB00741	Congenital adrenal hyperplasia	C0001627	NCT03532022	Withdrawn	Phase 3	Protocol re-design required following EU Phase III results	CHEBI_17650	"5492"	MONDO_0018479		"237751000"
	DB00860	Congenital adrenal hyperplasia	C0001627	NCT03532022	Withdrawn	Phase 3	Protocol re-design required following EU Phase III results	CHEBI_8378	"8638"	MONDO_0018479		"237751000"
	DB00635	Congenital adrenal hyperplasia	C0001627	NCT03532022	Withdrawn	Phase 3	Protocol re-design required following EU Phase III results	CHEBI_8382	"8640"	MONDO_0018479		"237751000"
	DB01234	Congenital adrenal hyperplasia	C0001627	NCT03532022	Withdrawn	Phase 3	Protocol re-design required following EU Phase III results	CHEBI_41879	"3264"	MONDO_0018479		"237751000"
abatacept	DB01281	Rheumatoid Arthritis	C0003873	NCT01221636	Withdrawn	Phase 1			"614391"	MONDO_0008383	"10039073"	"69896004"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT00343759	Withdrawn	Phase 2		CHEBI_49603	"480167"		"10006187"	"254837009"
	DB00297	Appendicitis	C0003615	NCT01575028	Terminated	Phase 2	The study was allowed to expire due to changes in standard care for the patient population within the NCH institution.	CHEBI_77431	"1815"	MONDO_0005649	"10003011"	"74400008"
ropivacaine	DB00296	Appendicitis	C0003615	NCT01575028	Terminated	Phase 2	The study was allowed to expire due to changes in standard care for the patient population within the NCH institution.	CHEBI_8890	"35780"	MONDO_0005649	"10003011"	"74400008"
everolimus	DB01590	Myeloid Leukemia, Chronic	C0023473	NCT01188889	Withdrawn	Phase 1/Phase 2	Unable to obtain sufficient funding.	CHEBI_68478	"141704"	MONDO_0011996		
	DB00619	Myeloid Leukemia, Chronic	C0023473	NCT01188889	Withdrawn	Phase 1/Phase 2	Unable to obtain sufficient funding.	CHEBI_45783	"282388"	MONDO_0011996		
epoetin alfa	DB00016	Rheumatoid Arthritis	C0003873	NCT00123149	Withdrawn	Phase 2			"2047589|105695|105694"	MONDO_0008383	"10039073"	"69896004"
bupropion	DB01156	Depressive disorder	C0011581	NCT01046214	Terminated	Phase 1	Recruitment issues	CHEBI_3219	"42347"	MONDO_0002050		"35489007"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00549822	Terminated	Phase 2	Slow Accrual	CHEBI_6413	"72965"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00041470	Terminated	Phase 1/Phase 2	Sponsor withdrew the study	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00361	Malignant neoplasm of breast	C0006142	NCT00041470	Terminated	Phase 1/Phase 2	Sponsor withdrew the study	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00041470	Terminated	Phase 1/Phase 2	Sponsor withdrew the study		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
vancomycin	DB00512	Ulcerative Colitis	C0009324	NCT03759041	Terminated	Phase 2	Due to the lack of a clinical efficacy signal in the induction treatment phase, Seres closed the dosing phases of open label and maintenance portions of the study. Patients who had received prior doses were followed for safety data.	CHEBI_28001	"11124"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
prucalopride	DB06480	Constipation	C0009806		Approved			CHEBI_135552	"2107310"	HP:0002019	"10010774"	"14760008"
dasatinib	DB01254	Mycosis Fungoides	C0026948	NCT01609816	Terminated	Phase 1	Low accrual. No Analyses were performed	CHEBI_49375	"475342|1546019"	MONDO_0009691		"118618005"
lidocaine	DB00281	Bursitis	C0006444	NCT01807962	Terminated	Phase 3	Slower than planned recruitement	CHEBI_6456	"6387"	MONDO_0002471	"10006811"	"84017003"
bendamustine	DB06769	Amyloidosis	C0002726	NCT04943302	Withdrawn	Phase 2	PI left institution. Study not moving forward in her absence.	CHEBI_135515	"134547"	MONDO_0019065	"10002022"	"17602002"
ondansetron	DB00904	Chemotherapy-induced nausea and vomiting	C0401160	NCT03237611	Suspended	Phase 2	Expired IRB approval on 2/11/21	CHEBI_7773	"26225"			"18846006"
	DB00673	Chemotherapy-induced nausea and vomiting	C0401160	NCT03237611	Suspended	Phase 2	Expired IRB approval on 2/11/21	CHEBI_499361	"358255"			"18846006"
	DB01234	Chemotherapy-induced nausea and vomiting	C0401160	NCT03237611	Suspended	Phase 2	Expired IRB approval on 2/11/21	CHEBI_41879	"3264"			"18846006"
bendamustine	DB06769	Acute lymphoblastic leukemia - category	C1531702	NCT00790855	Terminated	Phase 1/Phase 2	Lack of Response	CHEBI_135515	"134547"			
bendamustine	DB06769	Myeloid Leukemia, Chronic	C0023473	NCT00790855	Terminated	Phase 1/Phase 2	Lack of Response	CHEBI_135515	"134547"	MONDO_0011996		
salbutamol	DB01001	Asthma	C0004096	NCT02182700	Terminated	Phase 3		CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
omalizumab	DB00043	Asthma	C0004096	NCT00162773	Terminated	Phase 2	PI left institution		"302379"	MONDO_0004979	"10003553"	"195967001"
lactulose	DB00581	Constipation	C0009806		Approved			CHEBI_6359	"6218"	HP:0002019	"10010774"	"14760008"
memantine	DB01043	Chronic schizophrenia	C0221765	NCT00148616	Terminated	Phase 3		CHEBI_64312	"6719"			"83746006"
doxycycline	DB00254	Anthrax disease	C0003175	NCT00964834	Terminated	Phase 1	Sister trial has SAE investigation underway - sponsor elected to withdraw as study expected to be repeated later	CHEBI_50845	"1545992|3640"	MONDO_0005119	"10002713"	"409498004"
estradiol	DB00783	Anorexia Nervosa	C0003125	NCT03172533	Terminated	Phase 2	Difficulties in recruitment	CHEBI_16469	"4083"		"10002649"	"56882008"
	DB00977	Anorexia Nervosa	C0003125	NCT03172533	Terminated	Phase 2	Difficulties in recruitment	CHEBI_4903	"4124"		"10002649"	"56882008"
mometasone furoate	DB14512	Chronic small plaque psoriasis	C0406317	NCT01228656	Suspended	Phase 2		CHEBI_47564	"30145"			"200965009"
	DB00764	Chronic small plaque psoriasis	C0406317	NCT01228656	Suspended	Phase 2		CHEBI_6970				"200965009"
	DB00936	Chronic small plaque psoriasis	C0406317	NCT01228656	Suspended	Phase 2		CHEBI_16914	"9525"			"200965009"
	DB14006	Chronic small plaque psoriasis	C0406317	NCT01228656	Suspended	Phase 2		CHEBI_3668	"20974"			"200965009"
	DB13860	Chronic small plaque psoriasis	C0406317	NCT01228656	Suspended	Phase 2						"200965009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT04066790	Terminated	Phase 2	We terminated this trial and initiated a new one including pertuzumab.	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT04066790	Terminated	Phase 2	We terminated this trial and initiated a new one including pertuzumab.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
colchicine	DB01394	Atrial Fibrillation	C0004238	NCT02177266	Terminated	Phase 3	Difficulty in recruiting patients	CHEBI_27882	"2683"	MONDO_0004981	"10003658"	"49436004"
cyclophosphamide	DB00531	Metastatic Uveal Melanoma	C4725091	NCT01814046	Terminated	Phase 2	Investigator left the National Institutes of Health (NIH)	CHEBI_4027	"1545988|3002"			
omacetaxine mepesuccinate	DB04865	Myeloid Leukemia, Chronic	C0023473	NCT02078960	Terminated	Phase 1/Phase 2	Inability to accrue additional sites and enroll an adequate number of subjects.	CHEBI_71019	"27100"	MONDO_0011996		
fluoxetine	DB00472	Bipolar Disorder	C0005586	NCT00005015	Terminated	Phase 3		CHEBI_86990	"4493"	MONDO_0004985	"10057667"	"13746004"
tamoxifen	DB00675	Malignant neoplasm of breast	C0006142	NCT00096369	Terminated	Phase 2	accrual goal not met	CHEBI_41774	"10324"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00057993	Withdrawn	Phase 2	Unable to accrue subjects to the study after 2 years - closed per request by Data Monitoring Committee.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
duloxetine	DB00476	Depressive disorder	C0011581	NCT03395353	Terminated	Phase 3	Business decision	CHEBI_36795	"72625"	MONDO_0002050		"35489007"
lithium carbonate	DB14509	Dysmenorrhea	C0013390		Approved			CHEBI_6504	"42351"	HP:0100607	"10013935"	"431416001"
magnesium sulfate	DB00653	Asthma	C0004096	NCT00522444	Withdrawn	Phase 3	lack of funding	CHEBI_32599	"6585|1311625"	MONDO_0004979	"10003553"	"195967001"
ketamine	DB01221	Bipolar Disorder	C0005586	NCT01504659	Terminated	Phase 2/Phase 3	Administrative issues	CHEBI_6121	"6130"	MONDO_0004985	"10057667"	"13746004"
dasatinib	DB01254	Malignant neoplasm of breast	C0006142	NCT00817531	Terminated	Phase 2	terminated due to futility after interim analysis	CHEBI_49375	"475342|1546019"		"10006187"	"254837009"
lovastatin	DB00227	Malignant neoplasm of breast	C0006142	NCT00285857	Terminated	Phase 2	Slow accrual	CHEBI_40303	"6472"		"10006187"	"254837009"
nivolumab	DB09035	Malignant neoplasm of breast	C0006142	NCT03952325	Terminated	Phase 2	The Sponsor has discontinued the development of tesetaxel		"1597876"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00589238	Terminated	Phase 2		CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00589238	Terminated	Phase 2		CHEBI_31355	"40048"		"10006187"	"254837009"
levofloxacin	DB01137	Community acquired pneumonia	C0694549	NCT01081964	Terminated	Phase 2	Financial considerations	CHEBI_63598	"1546009|82122"			"385093006"
adalimumab	DB00051	Hidradenitis Suppurativa	C0162836	NCT04988308	Terminated	Phase 2	Study has been prematurely terminated as the Interim Analysis 1 efficacy results met the prespecified futility criteria related to the primary endpoint.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0006559		"59393003"
levonorgestrel	DB00367	Dysmenorrhea	C0013390		Approved			CHEBI_6443	"6373"	HP:0100607	"10013935"	"431416001"
eplerenone	DB00700	Atrial Fibrillation	C0004238	NCT00647192	Terminated	Phase 2	Inclusion rate too low. Recruitment of further study centers too costly.	CHEBI_31547	"298869"	MONDO_0004981	"10003658"	"49436004"
aripiprazole	DB01238	Bipolar Disorder	C0005586	NCT00288353	Terminated	Phase 3	unable to secure additional funding	CHEBI_31236	"89013"	MONDO_0004985	"10057667"	"13746004"
melatonin	DB01065	Malignant neoplasm of breast	C0006142	NCT01355523	Terminated	Phase 2/Phase 3	Inclusion rate not as expected. Not financially possible to involve other centres.	CHEBI_16796	"6711"		"10006187"	"254837009"
dapsone	DB00250	Acne Vulgaris	C0001144	NCT01425320	Withdrawn	Phase 1	Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.	CHEBI_4325	"3108"			"88616000"
	DB00582	Aspergillosis	C0004030	NCT01207128	Withdrawn	Phase 2	None enrolled	CHEBI_10023	"121243"	MONDO_0005657	"10074171"	"65553006"
micafungin	DB01141	Aspergillosis	C0004030	NCT01207128	Withdrawn	Phase 2	None enrolled	CHEBI_600520	"325887"	MONDO_0005657	"10074171"	"65553006"
riluzole	DB00740	Amyotrophic Lateral Sclerosis	C0002736	NCT04326283	Terminated	Phase 1/Phase 2	Terminated as it is considered that necessary data have been collected	CHEBI_8863	"35623"	MONDO_0004976	"10002026"	"86044005"
celecoxib	DB00482	Dysmenorrhea	C0013390		Approved			CHEBI_41423	"140587"	HP:0100607	"10013935"	"431416001"
	DB00210	Acne Vulgaris	C0001144	NCT01425320	Withdrawn	Phase 1	Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.	CHEBI_31174	"60223"			"88616000"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT02598310	Terminated	Phase 2		CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT02598310	Terminated	Phase 2			"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT01199367	Terminated	Phase 1	The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2.	CHEBI_49603	"480167"		"10006187"	"254837009"
	DB01006	Malignant neoplasm of breast	C0006142	NCT01199367	Terminated	Phase 1	The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2.	CHEBI_6413	"72965"		"10006187"	"254837009"
cisplatin	DB00515	Non-Small Cell Lung Carcinoma	C0007131	NCT02537561	Withdrawn	Phase 1	The pharmaceutical company did not want to follow through with support for the study.	CHEBI_27899	"2555"	MONDO_0005233	"10061873"	"254637007"
afatinib	DB08916	Non-Small Cell Lung Carcinoma	C0007131	NCT03711422	Terminated	Phase 1	Decision to close the trial made due to low recruitment.	CHEBI_61390	"1430438"	MONDO_0005233	"10061873"	"254637007"
crizotinib	DB08865	Non-Small Cell Lung Carcinoma	C0007131	NCT02584634	Terminated	Phase 1/Phase 2	The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)	CHEBI_64310	"1148495"	MONDO_0005233	"10061873"	"254637007"
naloxone	DB01183	Constipation	C0009806	NCT01014559	Terminated	Phase 3	Lack of recruitment	CHEBI_7459	"7242"	HP:0002019	"10010774"	"14760008"
magnesium aspartate	DB13359	Constipation	C0009806		Approved					HP:0002019	"10010774"	"14760008"
dexamethasone phosphate	DB01234	Postoperative Nausea and Vomiting	C0520909	NCT01975727	Terminated	Phase 2	Study was halted prematurely for futility after an intermediate analysis	CHEBI_68637	"3264"			"1488000"
gabapentin	DB00996	Pain, Postoperative	C0030201	NCT03750773	Withdrawn	Phase 1/Phase 2	Lack of funding	CHEBI_42797	"25480"			"213299007"
prednisone	DB00635	Angioedema	C0002994		Approved			CHEBI_8382	"8640"	HP:0100665	"10002424"	"846575004"
asparaginase	DB00023	Acute lymphoblastic leukemia - category	C1531702	NCT00165087	Terminated	Phase 3	Terminated by IRB for continuing review		"1156"			
	DB00380	Acute lymphoblastic leukemia - category	C1531702	NCT00165087	Terminated	Phase 3	Terminated by IRB for continuing review	CHEBI_50223	"42736"			
	DB00997	Acute lymphoblastic leukemia - category	C1531702	NCT00165087	Terminated	Phase 3	Terminated by IRB for continuing review	CHEBI_28748	"142433|3639"			
imatinib	DB00619	Myeloid Leukemia, Chronic	C0023473	NCT02709083	Terminated	Phase 2	Original principal investigator left institution	CHEBI_45783	"282388"	MONDO_0011996		
	DB01254	Myeloid Leukemia, Chronic	C0023473	NCT02709083	Terminated	Phase 2	Original principal investigator left institution	CHEBI_49375	"475342|1546019"	MONDO_0011996		
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT00095862	Terminated	Phase 1/Phase 2		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00133796	Terminated	Phase 2	Closed to accrual 4/19/2006 / Study doesn't qualify for reporting.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT01985841	Terminated	Phase 2	Due to poor accrual	CHEBI_47898	"3995"		"10006187"	"254837009"
	DB00544	Malignant neoplasm of breast	C0006142	NCT01985841	Terminated	Phase 2	Due to poor accrual	CHEBI_46345	"4492"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT01985841	Terminated	Phase 2	Due to poor accrual	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT01985841	Terminated	Phase 2	Due to poor accrual	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT02405910	Withdrawn	Phase 2	PI Left Institution	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
sodium phosphate	DB14502	Constipation	C0009806		Approved			CHEBI_34683	"236719|314838"	HP:0002019	"10010774"	"14760008"
	DB00362	Aspergillosis	C0004030	NCT01188759	Withdrawn	Phase 3		CHEBI_55346	"341018"	MONDO_0005657	"10074171"	"65553006"
voriconazole	DB00582	Aspergillosis	C0004030	NCT01188759	Withdrawn	Phase 3		CHEBI_10023	"121243"	MONDO_0005657	"10074171"	"65553006"
busulfan	DB01008	Primary Myelofibrosis	C0001815	NCT03303950	Terminated	Phase 2	Slow accrual	CHEBI_28901	"1828"	MONDO_0009692	"10077161"	"128843003"
	DB00531	Primary Myelofibrosis	C0001815	NCT03303950	Terminated	Phase 2	Slow accrual	CHEBI_4027	"1545988|3002"	MONDO_0009692	"10077161"	"128843003"
nivolumab	DB09035	Squamous non-small cell lung cancer	C4509816	NCT02924233	Withdrawn	Phase 1/Phase 2	Symphogen made a business decision to no longer perform the clinical study		"1597876"			"723301009"
denosumab	DB06643	Renal Osteodystrophy	C0035086	NCT03960554	Terminated	Phase 2	Study lost funding		"993449"	MONDO_0006946		"16726004"
alemtuzumab	DB00087	Acute lymphoblastic leukemia - category	C1531702	NCT00983528	Terminated	Phase 1/Phase 2	Support withdrawn due to slow accrual		"117055"			
	DB00631	Acute lymphoblastic leukemia - category	C1531702	NCT00983528	Terminated	Phase 1/Phase 2	Support withdrawn due to slow accrual	CHEBI_681569	"44151"			
estradiol	DB00783	Anorexia Nervosa	C0003125	NCT02792153	Withdrawn	Phase 1	The study was withdrawn after 18 months due to lack of recruitment.	CHEBI_16469	"4083"		"10002649"	"56882008"
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00920608	Withdrawn	Phase 1		CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT00453635	Terminated	Phase 2	Due to poor accrual	CHEBI_480999	"39541"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00453635	Terminated	Phase 2	Due to poor accrual	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00453635	Terminated	Phase 2	Due to poor accrual		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00453635	Terminated	Phase 2	Due to poor accrual	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
sodium phosphate	DB09449	Constipation	C0009806		Approved			CHEBI_37585	"36709|235496|314838|349753"	HP:0002019	"10010774"	"14760008"
cholic acid	DB02659	Constipation	C0009806		Approved			CHEBI_16359	"1440856"	HP:0002019	"10010774"	"14760008"
dantron	DB04816	Constipation	C0009806		Approved			CHEBI_3682	"22293"	HP:0002019	"10010774"	"14760008"
magnesium lactate	DB14515	Constipation	C0009806		Approved				"214688"	HP:0002019	"10010774"	"14760008"
magnesium oxide	DB01377	Constipation	C0009806		Approved			CHEBI_31794	"6582"	HP:0002019	"10010774"	"14760008"
sennosides	DB11365	Constipation	C0009806		Approved			CHEBI_9112		HP:0002019	"10010774"	"14760008"
magnesium sulfate	DB00653	Constipation	C0009806		Approved			CHEBI_32599	"6585|1311625"	HP:0002019	"10010774"	"14760008"
homatropine	DB11181	Constipation	C0009806		Approved			CHEBI_5747	"27084"	HP:0002019	"10010774"	"14760008"
magnesium carbonate	DB09481	Constipation	C0009806		Approved			CHEBI_31793	"29155"	HP:0002019	"10010774"	"14760008"
magnesium hydroxide	DB09104	Constipation	C0009806		Approved			CHEBI_6637	"6581|243353"	HP:0002019	"10010774"	"14760008"
bisacodyl	DB09020	Constipation	C0009806		Approved			CHEBI_3125	"1596"	HP:0002019	"10010774"	"14760008"
micafungin	DB01141	Aspergillosis	C0004030	NCT00047827	Terminated	Phase 2	Inadequate enrollment	CHEBI_600520	"325887"	MONDO_0005657	"10074171"	"65553006"
	DB00681	Aspergillosis	C0004030	NCT00047827	Terminated	Phase 2	Inadequate enrollment	CHEBI_2682	"236594|732"	MONDO_0005657	"10074171"	"65553006"
fluorometholone	DB00324	Corneal Abrasions	C0010032		Approved			CHEBI_31625	"4491"		"10010984"	"85848002"
prednisolone	DB00860	Corneal Abrasions	C0010032		Approved			CHEBI_8378	"8638"		"10010984"	"85848002"
bortezomib	DB00188	Rheumatoid Arthritis	C0003873	NCT02102594	Terminated	Phase 2	recruitment difficulties	CHEBI_52717	"358258"	MONDO_0008383	"10039073"	"69896004"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00684216	Terminated	Phase 2/Phase 3	acrual too slow	CHEBI_6413	"72965"		"10006187"	"254837009"
methotrexate	DB00563	Malignant tumor of small intestine	C0153425	NCT00621036	Withdrawn	Phase 2	MyVax did not meet its primary endpoints	CHEBI_44185	"6851"	MONDO_0000956		"363509000"
	DB04572	Malignant tumor of small intestine	C0153425	NCT00621036	Withdrawn	Phase 2	MyVax did not meet its primary endpoints	CHEBI_9570	"10473"	MONDO_0000956		"363509000"
enocitabine	DB00959	Acute lymphoblastic leukemia - category	C1531702	NCT00991744	Suspended	Phase 3	Sterility problems in DepoCyte production	CHEBI_6888	"6902"			
	DB14644	Acute lymphoblastic leukemia - category	C1531702	NCT00991744	Suspended	Phase 3	Sterility problems in DepoCyte production	CHEBI_135765				
	DB00860	Acute lymphoblastic leukemia - category	C1531702	NCT00991744	Suspended	Phase 3	Sterility problems in DepoCyte production	CHEBI_8378	"8638"			
	DB00987	Acute lymphoblastic leukemia - category	C1531702	NCT00991744	Suspended	Phase 3	Sterility problems in DepoCyte production	CHEBI_28680	"3041|968804"			
rosiglitazone	DB00412	Alzheimer's Disease	C0002395	NCT00334568	Terminated	Phase 2	Slow recruitment	CHEBI_50122	"84108"	MONDO_0004975	"10012271"	"26929004"
estradiol	DB00783	Anorexia Nervosa	C0003125	NCT04021017	Withdrawn	Phase 1	PI Workload	CHEBI_16469	"4083"		"10002649"	"56882008"
denosumab	DB06643	Malignant neoplasm of breast	C0006142	NCT01077154	Terminated	Phase 3	Terminated: Amgen decision following Primary Analysis. Not due to safety reason		"993449"		"10006187"	"254837009"
vinorelbine	DB00361	Malignant neoplasm of breast	C0006142	NCT01254136	Terminated	Phase 1/Phase 2	Incyte has suspended development of the compound.	CHEBI_480999	"39541"		"10006187"	"254837009"
voriconazole	DB00582	Aspergillosis	C0004030	NCT01887457	Suspended	Phase 2	Transfer of management of study	CHEBI_10023	"121243"	MONDO_0005657	"10074171"	"65553006"
loteprednol etabonate	DB00873	Corneal Abrasions	C0010032		Approved			CHEBI_50848	"237027"		"10010984"	"85848002"
	DB00958	Malignant neoplasm of breast	C0006142	NCT00006123	Withdrawn	Phase 1/Phase 2	Never started	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00006123	Withdrawn	Phase 1/Phase 2	Never started		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB00262	Malignant neoplasm of breast	C0006142	NCT00006123	Withdrawn	Phase 1/Phase 2	Never started	CHEBI_3423	"2105"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00006123	Withdrawn	Phase 1/Phase 2	Never started	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
metoprolol	DB00264	Malignant neoplasm of breast	C0006142	NCT02269696	Withdrawn	Phase 3	Withdrawn	CHEBI_6904	"6918"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT01022138	Terminated	Phase 2		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
thiotepa	DB04572	Malignant neoplasm of breast	C0006142	NCT00006123	Withdrawn	Phase 1/Phase 2	Never started	CHEBI_9570	"10473"		"10006187"	"254837009"
celecoxib	DB00482	Non-Small Cell Lung Carcinoma	C0007131	NCT00211952	Suspended	Phase 3		CHEBI_41423	"140587"	MONDO_0005233	"10061873"	"254637007"
hydrocortisone acetate	DB00741	Corneal Abrasions	C0010032		Approved			CHEBI_17650	"5492"		"10010984"	"85848002"
hydrocortisone acetate	DB14539	Corneal Abrasions	C0010032		Approved			CHEBI_17609	"27197"		"10010984"	"85848002"
loteprednol etabonate	DB14596	Corneal Abrasions	C0010032		Approved			CHEBI_31784	"52177"		"10010984"	"85848002"
dexamethasone	DB01234	Corneal Abrasions	C0010032		Approved			CHEBI_41879	"3264"		"10010984"	"85848002"
tobramycin	DB00684	Corneal Abrasions	C0010032		Approved			CHEBI_28864	"10627"		"10010984"	"85848002"
medrysone	DB00253	Corneal Abrasions	C0010032		Approved			CHEBI_34829	"29439"		"10010984"	"85848002"
bacitracin	DB00626	Corneal Abrasions	C0010032		Approved			CHEBI_184381	"1291|1986366"		"10010984"	"85848002"
cortisone acetate	DB01380	Corneal Abrasions	C0010032		Approved			CHEBI_3897	"21655"		"10010984"	"85848002"
fluorometholone acetate	DB00324	Corneal Abrasions	C0010032		Approved			CHEBI_31625	"4491"		"10010984"	"85848002"
fusidic acid	DB02703	Corneal Abrasions	C0010032		Approved			CHEBI_29013	"4608|113608"		"10010984"	"85848002"
neomycin	DB00994	Corneal Abrasions	C0010032		Approved			CHEBI_7507	"7299"		"10010984"	"85848002"
octreotide	DB00104	Acromegaly	C0001206	NCT00765323	Terminated	Phase 3		CHEBI_7726	"7617"	MONDO_0019933	"10000599"	"74107003"
	DB09099	Acromegaly	C0001206	NCT00765323	Terminated	Phase 3		CHEBI_64628	"9939"	MONDO_0019933	"10000599"	"74107003"
simvastatin	DB00641	Severe asthma	C0581126	NCT02433535	Withdrawn	Phase 2		CHEBI_9150	"36567"			"370221004"
salbutamol	DB01001	Asthma	C0004096	NCT00634517	Terminated	Phase 3	IND voluntarily withdrawn, without prejudice	CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT01928615	Terminated	Phase 2	Problems with drug supply		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT04512261	Withdrawn	Phase 1/Phase 2	Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT00584012	Terminated	Phase 1	Funding issues	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
lovastatin	DB00227	Malignant neoplasm of breast	C0006142	NCT00584012	Terminated	Phase 1	Funding issues	CHEBI_40303	"6472"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00427427	Terminated	Phase 2	lack of accrual		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
bortezomib	DB00188	Non-Small Cell Lung Carcinoma	C0007131	NCT00200382	Terminated	Phase 2	The study did not achieve the statistical success to continue.	CHEBI_52717	"358258"	MONDO_0005233	"10061873"	"254637007"
	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00378573	Terminated	Phase 2	Incidence of GI Perforation	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
mechlorethamine	DB00888	Primary Myelofibrosis	C0001815	NCT02528877	Withdrawn	Phase 1	The study design was revised so a new protocol will be opened.	CHEBI_28925	"6674"	MONDO_0009692	"10077161"	"128843003"
	DB00877	Primary Myelofibrosis	C0001815	NCT02528877	Withdrawn	Phase 1	The study design was revised so a new protocol will be opened.	CHEBI_9168	"35302"	MONDO_0009692	"10077161"	"128843003"
	DB00864	Primary Myelofibrosis	C0001815	NCT02528877	Withdrawn	Phase 1	The study design was revised so a new protocol will be opened.	CHEBI_61049	"42316|235991"	MONDO_0009692	"10077161"	"128843003"
	DB01042	Primary Myelofibrosis	C0001815	NCT02528877	Withdrawn	Phase 1	The study design was revised so a new protocol will be opened.	CHEBI_28876	"6718"	MONDO_0009692	"10077161"	"128843003"
cyclophosphamide	DB00531	Burkitt Lymphoma	C0006413	NCT01163201	Withdrawn	Phase 1/Phase 2	Replaced by a new study	CHEBI_4027	"1545988|3002"	MONDO_0007243|MONDO_0020511	"10006595"	"397400006"
zoledronic acid	DB00399	Malignant neoplasm of breast	C0006142	NCT00130494	Terminated	Phase 3	Low recruitment	CHEBI_46557	"1546014|77655"		"10006187"	"254837009"
celecoxib	DB00482	Malignant neoplasm of breast	C0006142	NCT00088972	Terminated	Phase 2	Study closed due to poor accrual.	CHEBI_41423	"140587"		"10006187"	"254837009"
Vitamin E	DB00163	Ulcerative Colitis	C0009324	NCT00152841	Terminated	Phase 2	Lack of patients	CHEBI_18145	"11256|237099"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
tetracaine	DB09085	Corneal Abrasions	C0010032	NCT02483897	Withdrawn	Phase 3	inabililty to recruit at required rate	CHEBI_9468	"91189|10391"		"10010984"	"85848002"
Polymyxin B	DB00781	Corneal Abrasions	C0010032		Approved				"8536"		"10010984"	"85848002"
valaciclovir	DB00577	Metastatic Uveal Melanoma	C4725091	NCT02831933	Terminated	Phase 2	Lack of funding	CHEBI_35854	"73645"			
	DB09035	Metastatic Uveal Melanoma	C4725091	NCT02831933	Terminated	Phase 2	Lack of funding		"1597876"			
moxifloxacin	DB00218	Alzheimer's Disease	C0002395	NCT00884533	Withdrawn	Phase 1	The whole project was terminated	CHEBI_63611	"139462"	MONDO_0004975	"10012271"	"26929004"
enocitabine	DB00619	Myeloid Leukemia, Chronic	C0023473	NCT00219765	Terminated	Phase 1/Phase 2		CHEBI_45783	"282388"	MONDO_0011996		
	DB00987	Myeloid Leukemia, Chronic	C0023473	NCT00219765	Terminated	Phase 1/Phase 2		CHEBI_28680	"3041|968804"	MONDO_0011996		
	DB00694	Myeloid Leukemia, Chronic	C0023473	NCT00219765	Terminated	Phase 1/Phase 2		CHEBI_41977	"214468|3109"	MONDO_0011996		
salmeterol	DB00938	Asthma	C0004096	NCT02496715	Withdrawn	Phase 3	Development terminated.	CHEBI_64064	"36117"	MONDO_0004979	"10003553"	"195967001"
	DB00958	Malignant neoplasm of breast	C0006142	NCT03058939	Withdrawn	Phase 2	Study never activated to enrollment.	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00675	Malignant neoplasm of breast	C0006142	NCT03058939	Withdrawn	Phase 2	Study never activated to enrollment.	CHEBI_41774	"10324"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT03058939	Withdrawn	Phase 2	Study never activated to enrollment.	CHEBI_45863	"56946"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT03058939	Withdrawn	Phase 2	Study never activated to enrollment.	CHEBI_6413	"72965"		"10006187"	"254837009"
benzonatate	DB00868	Coughing	C0010200		Approved			CHEBI_3032	"18993"	HP:0012735	"10011224"	"263731006"
ciprofloxacin	DB00537	Anthrax disease	C0003175	NCT00964561	Suspended	Phase 1	On partial hold for clinical investigation into AE and SAE reported.	CHEBI_192484	"2551"	MONDO_0005119	"10002713"	"409498004"
valaciclovir	DB00577	Nonsquamous nonsmall cell neoplasm of lung	C2585890	NCT02831933	Terminated	Phase 2	Lack of funding	CHEBI_35854	"73645"			"440173001"
	DB09035	Nonsquamous nonsmall cell neoplasm of lung	C2585890	NCT02831933	Terminated	Phase 2	Lack of funding		"1597876"			"440173001"
prednisolone	DB00860	Angioedema	C0002994		Approved			CHEBI_8378	"8638"	HP:0100665	"10002424"	"846575004"
abatacept	DB01281	Rheumatoid Arthritis	C0003873	NCT02027298	Withdrawn	Phase 2	No Enrollment		"614391"	MONDO_0008383	"10039073"	"69896004"
salbutamol	DB01001	Asthma	C0004096	NCT00000577	Withdrawn	Phase 3	Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.	CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
	DB01394	Asthma	C0004096	NCT00000577	Withdrawn	Phase 3	Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.	CHEBI_27882	"2683"	MONDO_0004979	"10003553"	"195967001"
salbutamol	DB01001	Asthma	C0004096	NCT02150499	Terminated	Phase 3		CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
salbutamol	DB01001	Asthma	C0004096	NCT01218009	Terminated	Phase 3	Change to study required.	CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
	DB00997	Malignant neoplasm of breast	C0006142	NCT03285607	Withdrawn	Phase 1	Drug provider decided not to move forward with the study.	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
terpin	DB13163	Coughing	C0010200		Approved			CHEBI_134806	"89916"	HP:0012735	"10011224"	"263731006"
memantine	DB01043	Alzheimer's Disease	C0002395	NCT03316898	Withdrawn	Phase 1	Business decision to stop the study.	CHEBI_64312	"6719"	MONDO_0004975	"10012271"	"26929004"
	DB00843	Alzheimer's Disease	C0002395	NCT03316898	Withdrawn	Phase 1	Business decision to stop the study.	CHEBI_145499	"135447"	MONDO_0004975	"10012271"	"26929004"
goserelin	DB00014	Malignant neoplasm of breast	C0006142	NCT03658213	Withdrawn	Phase 3	CTP of LARES has been out of the expire date, we are trying RWS pathway for the indication expend	CHEBI_5523	"50610"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00088829	Terminated	Phase 2	Investigator left institution	CHEBI_45863	"56946"		"10006187"	"254837009"
dexamethasone phosphate	DB01234	Non-Small Cell Lung Carcinoma	C0007131	NCT02410382	Terminated	Phase 2	IRB suspension, did not resume	CHEBI_68637	"3264"	MONDO_0005233	"10061873"	"254637007"
chlorcyclizine	DB08936	Coughing	C0010200		Approved			CHEBI_94402	"2354"	HP:0012735	"10011224"	"263731006"
	DB00863	Coughing	C0010200	NCT00668317	Terminated	Phase 3	Primary care physicians began prescribing antacid therapy for chronic cough	CHEBI_92246	"9143"	HP:0012735	"10011224"	"263731006"
	DB00852	Coughing	C0010200	NCT01177852	Withdrawn	Phase 3		CHEBI_51209	"8896"	HP:0012735	"10011224"	"263731006"
cyclophosphamide	DB00531	Primary thymic carcinoma	C4302369	NCT01100944	Terminated	Phase 1/Phase 2	Principal investigator left the National Institutes of Health (NIH).	CHEBI_4027	"1545988|3002"			"722670005"
	DB00997	Primary thymic carcinoma	C4302369	NCT01100944	Terminated	Phase 1/Phase 2	Principal investigator left the National Institutes of Health (NIH).	CHEBI_28748	"142433|3639"			"722670005"
epoprostenol	DB01240	Coughing	C0010200		Approved			CHEBI_15552	"8814"	HP:0012735	"10011224"	"263731006"
cyclizine	DB01176	Coughing	C0010200		Approved			CHEBI_3994	"2977"	HP:0012735	"10011224"	"263731006"
codeine	DB00318	Coughing	C0010200		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0012735	"10011224"	"263731006"
piperidione	DB13224	Coughing	C0010200		Approved			CHEBI_81302		HP:0012735	"10011224"	"263731006"
guaiacol	DB11359	Coughing	C0010200		Approved			CHEBI_28591	"5031"	HP:0012735	"10011224"	"263731006"
benproperine	DB13309	Coughing	C0010200		Approved			CHEBI_94380		HP:0012735	"10011224"	"263731006"
clofedanol	DB04837	Coughing	C0010200		Approved			CHEBI_135207	"21254"	HP:0012735	"10011224"	"263731006"
hydrocortisone acetate	DB14539	Angioedema	C0002994		Approved			CHEBI_17609	"27197"	HP:0100665	"10002424"	"846575004"
methotrexate	DB00563	Myeloid Leukemia, Chronic	C0023473	NCT01749111	Terminated	Phase 3	Lack of accrual	CHEBI_44185	"6851"	MONDO_0011996		
	DB00531	Myeloid Leukemia, Chronic	C0023473	NCT01749111	Terminated	Phase 3	Lack of accrual	CHEBI_4027	"1545988|3002"	MONDO_0011996		
dexamethasone phosphate	DB01234	Acute lymphoblastic leukemia - category	C1531702	NCT03705507	Terminated	Phase 1/Phase 2	Poor recruitment, due to a change in the standard of care for this patient population with the use of CAR-T cells	CHEBI_68637	"3264"			
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00422942	Terminated	Phase 2	Study was terminated after enrollment of 3 participants due to recruitment difficulties.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
	DB00073	Rheumatoid Arthritis	C0003873	NCT00422942	Terminated	Phase 2	Study was terminated after enrollment of 3 participants due to recruitment difficulties.		"2273510|2472325|121191|2105824"	MONDO_0008383	"10039073"	"69896004"
amiodarone	DB01118	Atrial Fibrillation	C0004238	NCT00300495	Terminated	Phase 3	Unable to accrual total number of participants during study period.	CHEBI_2663	"703"	MONDO_0004981	"10003658"	"49436004"
	DB00072	Malignant neoplasm of breast	C0006142	NCT00440622	Terminated	Phase 3	Due to poor accrual		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00440622	Terminated	Phase 3	Due to poor accrual	CHEBI_31348	"194000"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00296010	Terminated	Phase 3	Accrual rate was too low	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00296010	Terminated	Phase 3	Accrual rate was too low	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
methotrexate	DB00563	Malignant neoplasm of breast	C0006142	NCT00296010	Terminated	Phase 3	Accrual rate was too low	CHEBI_44185	"6851"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT03846583	Withdrawn	Phase 1	Study halted prematurely, prior to enrollment of first participant.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
bevacizumab	DB00112	Non-Small Cell Lung Carcinoma	C0007131	NCT00404703	Terminated	Phase 2	Primary (safety) endpoint reached		"253337|2046138"	MONDO_0005233	"10061873"	"254637007"
cetuximab	DB00002	Non-Small Cell Lung Carcinoma	C0007131	NCT00694603	Terminated	Phase 2	Slow accrual		"318341"	MONDO_0005233	"10061873"	"254637007"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00354562	Terminated	Phase 1/Phase 2		CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
octreotide	DB00104	Acromegaly	C0001206	NCT03571594	Terminated	Phase 1	The study met a pre-defined protocol study stopping criteria	CHEBI_7726	"7617"	MONDO_0019933	"10000599"	"74107003"
prednisone	DB00635	Acute lymphoblastic leukemia - category	C1531702	NCT02815059	Withdrawn	Phase 1	Termination of Investigator Initiated Studies using Ibrutinib	CHEBI_8382	"8640"			
	DB01254	Acute lymphoblastic leukemia - category	C1531702	NCT02815059	Withdrawn	Phase 1	Termination of Investigator Initiated Studies using Ibrutinib	CHEBI_49375	"475342|1546019"			
methotrexate	DB00563	Rheumatoid Arthritis	C0003873	NCT00673920	Terminated	Phase 3	Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.	CHEBI_44185	"6851"	MONDO_0008383	"10039073"	"69896004"
celecoxib	DB00482	Bipolar Disorder	C0005586	NCT02726659	Terminated	Phase 3	Difficulty recruiting participants because principal investigator noticed that the participants in the population were responding well to low doses of mood stabilizers and therefor would not be recruited into the study.	CHEBI_41423	"140587"	MONDO_0004985	"10057667"	"13746004"
	DB00675	Malignant neoplasm of breast	C0006142	NCT00002772	Terminated	Phase 3	poor accrual	CHEBI_41774	"10324"		"10006187"	"254837009"
anastrozole	DB01217	Malignant neoplasm of breast	C0006142	NCT00555477	Terminated	Phase 2	The study was stopped after 69 subjects were enrolled because of poor accrual.	CHEBI_2704	"84857"		"10006187"	"254837009"
	DB00361	Malignant neoplasm of breast	C0006142	NCT00176488	Terminated	Phase 2	Competing studies	CHEBI_480999	"39541"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT00176488	Terminated	Phase 2	Competing studies	CHEBI_47898	"3995"		"10006187"	"254837009"
lapatinib	DB01259	Malignant neoplasm of breast	C0006142	NCT01589861	Suspended	Phase 1/Phase 2	Data analysis	CHEBI_49603	"480167"		"10006187"	"254837009"
hydrocodone	DB00956	Coughing	C0010200		Approved			CHEBI_5779	"5489"	HP:0012735	"10011224"	"263731006"
ropivacaine	DB00296	Pain, Postoperative	C0030201	NCT01432496	Terminated	Phase 3	There was insuficient recruitment in two centers	CHEBI_8890	"35780"			"213299007"
celecoxib	DB00482	Depression, Postpartum	C0221074	NCT02726659	Terminated	Phase 3	Difficulty recruiting participants because principal investigator noticed that the participants in the population were responding well to low doses of mood stabilizers and therefor would not be recruited into the study.	CHEBI_41423	"140587"			"58703003"
pioglitazone	DB01132	Amyotrophic Lateral Sclerosis	C0002736	NCT00690118	Terminated	Phase 2	The interim analysis showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.	CHEBI_8228	"33738"	MONDO_0004976	"10002026"	"86044005"
imatinib	DB00619	Myeloid Leukemia, Chronic	C0023473	NCT02174445	Terminated	Phase 3	very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements	CHEBI_45783	"282388"	MONDO_0011996		
sunitinib	DB01268	Metastatic Renal Cell Cancer	C0278678	NCT02959554	Terminated	Phase 2		CHEBI_38940	"357977"			
	DB09035	Metastatic Renal Cell Cancer	C0278678	NCT02959554	Terminated	Phase 2			"1597876"			
salbutamol	DB01001	Asthma	C0004096	NCT03376932	Withdrawn	Phase 3	withdrawn due to internal reasons	CHEBI_2549	"435"	MONDO_0004979	"10003553"	"195967001"
	DB01409	Asthma	C0004096	NCT03376932	Withdrawn	Phase 3	withdrawn due to internal reasons	CHEBI_90960	"69120"	MONDO_0004979	"10003553"	"195967001"
atorvastatin	DB01076	Atrial Fibrillation	C0004238	NCT00252967	Terminated	Phase 3	Insufficient power to show therapy difference at interim analysis.	CHEBI_39548	"83367"	MONDO_0004981	"10003658"	"49436004"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT00002772	Terminated	Phase 3	poor accrual	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00482	Malignant neoplasm of breast	C0006142	NCT00101062	Terminated	Phase 2	study drug unavailable	CHEBI_41423	"140587"		"10006187"	"254837009"
rituximab	DB00073	Rheumatoid Arthritis	C0003873	NCT00845832	Terminated	Phase 2	The study was terminated early because of a related decision to stop the development of ocrelizumab in rheumatoid arthritis.		"2273510|2472325|121191|2105824"	MONDO_0008383	"10039073"	"69896004"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT00726180	Terminated	Phase 1/Phase 2	Due to low enrollment		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
hydralazine	DB01275	Malignant neoplasm of breast	C0006142	NCT00575978	Withdrawn	Phase 1/Phase 2	IRB request	CHEBI_5775	"5470"		"10006187"	"254837009"
propranolol	DB00571	Malignant neoplasm of breast	C0006142	NCT02596867	Terminated	Phase 2	poor accrual	CHEBI_8499	"8787"		"10006187"	"254837009"
colecalciferol	DB00169	Malignant neoplasm of breast	C0006142	NCT01988090	Terminated	Phase 2	An interim analysis demonstrated no benefit of high dose vitamin D when compared to standard dose vitamin D in the reduction or prevention of arthralgia	CHEBI_28940	"2418"		"10006187"	"254837009"
ivabradine	DB09083	Angina Pectoris	C0002962		Approved			CHEBI_85966	"1649480"	HP:0001681	"10002383"	"225566008"
	DB00997	Malignant neoplasm of breast	C0006142	NCT01120171	Terminated	Phase 2	Due to poor accrual	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
cyclophosphamide	DB00531	Malignant neoplasm of breast	C0006142	NCT01120171	Terminated	Phase 2	Due to poor accrual	CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
anastrozole	DB01217	Malignant neoplasm of breast	C0006142	NCT00481845	Terminated	Phase 2	Low accrual	CHEBI_2704	"84857"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT01679743	Withdrawn	Phase 2			"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT04060342	Terminated	Phase 1	No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab.	CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT03228186	Terminated	Phase 2	Pharmaceutical company discontinued the study drug.	CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
sodium citrate	DB09154	Coughing	C0010200		Approved			CHEBI_53258	"253204|56466|1310549"	HP:0012735	"10011224"	"263731006"
sulfogaiacol	DB13735	Coughing	C0010200		Approved			CHEBI_85537		HP:0012735	"10011224"	"263731006"
methylhomatropine	DB00725	Coughing	C0010200		Approved			CHEBI_50373	"1546413|27085"	HP:0012735	"10011224"	"263731006"
dihydrocodeine	DB01551	Coughing	C0010200		Approved			CHEBI_135276	"23088"	HP:0012735	"10011224"	"263731006"
	DB00835	Coughing	C0010200	NCT01177852	Withdrawn	Phase 3		CHEBI_3183	"1767"	HP:0012735	"10011224"	"263731006"
guaifenesin	DB00874	Coughing	C0010200		Approved			CHEBI_5551	"5032"	HP:0012735	"10011224"	"263731006"
pheniramine	DB01620	Coughing	C0010200		Approved			CHEBI_91591	"8132"	HP:0012735	"10011224"	"263731006"
pentoxyverine	DB11186	Coughing	C0010200		Approved			CHEBI_94484	"20217"	HP:0012735	"10011224"	"263731006"
phenylephrine	DB00388	Coughing	C0010200		Approved			CHEBI_8093	"8163"	HP:0012735	"10011224"	"263731006"
ursodiol	DB01586	Cholangitis	C0008311	NCT03678480	Withdrawn	Phase 2	Corporate decision	CHEBI_9907	"62427|11065"	MONDO_0004789	"10008604"	"82403002"
leucovorin	DB00650	Biliary Tract Cancer	C0750952	NCT03110510	Withdrawn	Phase 2	institution problem	CHEBI_15640	"6313"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
	DB00762	Biliary Tract Cancer	C0750952	NCT03110510	Withdrawn	Phase 2	institution problem	CHEBI_80630	"51499"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
	DB00544	Biliary Tract Cancer	C0750952	NCT03110510	Withdrawn	Phase 2	institution problem	CHEBI_46345	"4492"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
	DB11596	Biliary Tract Cancer	C0750952	NCT03110510	Withdrawn	Phase 2	institution problem	CHEBI_63606	"877015"	MONDO_0003060|MONDO_0015116|MONDO_0017631		"363415003"
vidarabine	DB00194	Acute lymphoblastic leukemia - category	C1531702	NCT03326921	Suspended	Phase 1	Pause in funding	CHEBI_45327	"11194"			
vidarabine	DB00194	Myeloid Leukemia, Chronic	C0023473	NCT03326921	Suspended	Phase 1	Pause in funding	CHEBI_45327	"11194"	MONDO_0011996		
fulvestrant	DB00947	Malignant neoplasm of breast	C0006142	NCT03289039	Terminated	Phase 2	Slow accrual	CHEBI_31638	"282357"		"10006187"	"254837009"
	DB01248	Malignant neoplasm of breast	C0006142	NCT02067416	Withdrawn	Phase 2	Funding agent withdrew funding	CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
	DB01229	Malignant neoplasm of breast	C0006142	NCT02067416	Withdrawn	Phase 2	Funding agent withdrew funding	CHEBI_45863	"56946"		"10006187"	"254837009"
epirubicin	DB00445	Malignant neoplasm of breast	C0006142	NCT02067416	Withdrawn	Phase 2	Funding agent withdrew funding	CHEBI_47898	"3995"		"10006187"	"254837009"
	DB03128	Malignant neoplasm of breast	C0006142	NCT03953326	Terminated	Phase 1/Phase 2	Futility in recruitment	CHEBI_15355	"194"		"10006187"	"254837009"
nitroprusside	DB00325	Malignant neoplasm of breast	C0006142	NCT03953326	Terminated	Phase 1/Phase 2	Futility in recruitment	CHEBI_7596	"7476"		"10006187"	"254837009"
methylphenidate	DB00422	Malignant neoplasm of breast	C0006142	NCT00516269	Terminated	Phase 3	Slow Accrual	CHEBI_84276	"6901"		"10006187"	"254837009"
carboplatin	DB00958	Malignant neoplasm of breast	C0006142	NCT03147040	Terminated	Phase 2	At interim analysis insufficient benefit was observed to continu the study	CHEBI_31355	"40048"		"10006187"	"254837009"
	DB00958	Malignant neoplasm of breast	C0006142	NCT03872505	Withdrawn	Phase 2	lack of funding	CHEBI_31355	"40048"		"10006187"	"254837009"
paclitaxel	DB01229	Malignant neoplasm of breast	C0006142	NCT03872505	Withdrawn	Phase 2	lack of funding	CHEBI_45863	"56946"		"10006187"	"254837009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT01698281	Terminated	Phase 2	Poor recruitment	CHEBI_28748	"142433|3639"		"10006187"	"254837009"
dexamethasone phosphate	DB01234	Malignant neoplasm of breast	C0006142	NCT01698281	Terminated	Phase 2	Poor recruitment	CHEBI_68637	"3264"		"10006187"	"254837009"
letrozole	DB01006	Malignant neoplasm of breast	C0006142	NCT00516542	Terminated	Phase 1	Study was terminated due to lack of accrual	CHEBI_6413	"72965"		"10006187"	"254837009"
zonisamide	DB00909	Bipolar Disorder	C0005586	NCT01566370	Terminated	Phase 2	recruitment infeasible	CHEBI_10127	"39998"	MONDO_0004985	"10057667"	"13746004"
	DB00398	Malignant neoplasm of breast	C0006142	NCT00622466	Terminated	Phase 2	Study sponsor requested that the study be permanently closed by letter.	CHEBI_50924	"495881"		"10006187"	"254837009"
ondansetron	DB00904	Alcoholic Intoxication, Chronic	C0001973	NCT00890149	Terminated	Phase 2	Difficulty recruiting target sample	CHEBI_7773	"26225"	HP:0030955	"10001639"	"7200002"
varenicline	DB01273	Alcoholic Intoxication, Chronic	C0001973	NCT01169610	Terminated	Phase 3		CHEBI_84500	"591622"	HP:0030955	"10001639"	"7200002"
naltrexone	DB00704	Alcoholic Intoxication, Chronic	C0001973	NCT00156936	Terminated	Phase 3	Business decision	CHEBI_7465	"7243"	HP:0030955	"10001639"	"7200002"
levetiracetam	DB01202	Alcoholic Intoxication, Chronic	C0001973	NCT00862563	Terminated	Phase 2	Recruitment goals could not be met before ending of funding for this project.	CHEBI_6437	"114477"	HP:0030955	"10001639"	"7200002"
sertraline	DB01104	Alcoholic Intoxication, Chronic	C0001973	NCT00249431	Terminated	Phase 2	Inability to recruit patients.	CHEBI_9123	"36437"	HP:0030955	"10001639"	"7200002"
pioglitazone	DB01132	Alcoholic Intoxication, Chronic	C0001973	NCT03060772	Terminated	Phase 2	Study was suspended in 2020 due to COVID-19 pandemic as a result of recruitment challenges and the inability to conduct all study procedures (e.g., bronchoscopy) per protocol. In late 2021 the decision was made to not re-open the study.	CHEBI_8228	"33738"	HP:0030955	"10001639"	"7200002"
	DB00273	Alcoholic Intoxication, Chronic	C0001973	NCT00862563	Terminated	Phase 2	Recruitment goals could not be met before ending of funding for this project.	CHEBI_63631	"38404"	HP:0030955	"10001639"	"7200002"
methdilazine	DB00902	Angioedema	C0002994		Approved			CHEBI_6823	"29648"	HP:0100665	"10002424"	"846575004"
	DB00627	Atherosclerosis	C0004153	NCT00120289	Terminated	Phase 3	AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.	CHEBI_15940	"7393"	HP:0002621		"38716007"
sildenafil	DB00203	Atherosclerosis	C0004153	NCT02908490	Terminated	Phase 2	Slow recruitment, lack of continued funding	CHEBI_9139	"136411"	HP:0002621		"38716007"
ezetimibe	DB00973	Atherosclerosis	C0004153	NCT00651391	Terminated	Phase 3	Slow enrollment	CHEBI_49040	"341248"	HP:0002621		"38716007"
	DB00877	Atherosclerosis	C0004153	NCT00311311	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_9168	"35302"	HP:0002621		"38716007"
	DB00864	Atherosclerosis	C0004153	NCT00311311	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_61049	"42316|235991"	HP:0002621		"38716007"
etofibrate	DB00641	Atherosclerosis	C0004153	NCT00120289	Terminated	Phase 3	AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.	CHEBI_9150	"36567"	HP:0002621		"38716007"
alirocumab	DB09302	Atherosclerosis	C0004153		Approved				"1659152"	HP:0002621		"38716007"
mycophenolate mofetil	DB01024	Atherosclerosis	C0004153	NCT00311311	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_168396	"7145|265323"	HP:0002621		"38716007"
Vitamin E	DB00163	Atherosclerosis	C0004153	NCT00000600	Terminated	Phase 2		CHEBI_18145	"11256|237099"	HP:0002621		"38716007"
clopidogrel	DB00758	Atherosclerosis	C0004153	NCT00385138	Terminated	Phase 3	Insufficient evidence of the clinical effectiveness of cangrelor	CHEBI_37941	"32968"	HP:0002621		"38716007"
	DB00635	Atherosclerosis	C0004153	NCT00311311	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_8382	"8640"	HP:0002621		"38716007"
	DB00641	Atherosclerosis	C0004153	NCT00651391	Terminated	Phase 3	Slow enrollment	CHEBI_9150	"36567"	HP:0002621		"38716007"
	DB00945	Atherosclerosis	C0004153	NCT00004728	Terminated	Phase 3		CHEBI_15365	"91101|1191"	HP:0002621		"38716007"
warfarin	DB00682	Atherosclerosis	C0004153	NCT00004728	Terminated	Phase 3		CHEBI_87732	"11289"	HP:0002621		"38716007"
risperidone	DB00734	Autistic Disorder	C0004352		Approved			CHEBI_8871	"35636"	HP:0000717		"43614003"
aripiprazole	DB01238	Autistic Disorder	C0004352		Approved			CHEBI_31236	"89013"	HP:0000717		"43614003"
hydrocortisone acetate	DB00741	Cerebral Edema	C0006114		Approved			CHEBI_17650	"5492"	HP:0002181		"2032001"
betamethasone	DB00443	Cerebral Edema	C0006114		Approved			CHEBI_3077	"1514"	HP:0002181		"2032001"
methylprednisolone	DB00959	Cerebral Edema	C0006114		Approved			CHEBI_6888	"6902"	HP:0002181		"2032001"
betamethasone acetate	DB00443	Cerebral Edema	C0006114		Approved			CHEBI_3077	"1514"	HP:0002181		"2032001"
dexamethasone	DB01234	Cerebral Edema	C0006114		Approved			CHEBI_41879	"3264"	HP:0002181		"2032001"
prednisolone	DB00860	Cerebral Edema	C0006114		Approved			CHEBI_8378	"8638"	HP:0002181		"2032001"
camphor	DB11288	Back Pain	C0004604		Approved			CHEBI_28093		HP:0003418	"10003988"	"161891005"
tandospirone	DB12833	Bruxism	C0006325		Approved			CHEBI_145673		HP:0003763	"10006514"	"90207007"
cortisone acetate	DB01380	Cerebral Edema	C0006114		Approved			CHEBI_3897	"21655"	HP:0002181		"2032001"
triamcinolone diacetate	DB00620	Cerebral Edema	C0006114		Approved			CHEBI_9667	"10759"	HP:0002181		"2032001"
triamcinolone acetonide	DB00620	Cerebral Edema	C0006114		Approved			CHEBI_9667	"10759"	HP:0002181		"2032001"
mannitol	DB00742	Cerebral Edema	C0006114	NCT01954290	Withdrawn	Phase 2	Investigator is leaving the institution.	CHEBI_16899	"6628"	HP:0002181		"2032001"
mannitol	DB00742	Cerebral Edema	C0006114	NCT01605357	Withdrawn	Phase 1/Phase 2	Never started.	CHEBI_16899	"6628"	HP:0002181		"2032001"
hydrocortisone succinate	DB00741	Cerebral Edema	C0006114		Approved			CHEBI_17650	"5492"	HP:0002181		"2032001"
mannitol	DB00742	Cerebral Edema	C0006114		Approved			CHEBI_16899	"6628"	HP:0002181		"2032001"
hydroxocobalamin	DB00200	Cerebral Edema	C0006114	NCT00243022	Terminated	Phase 2	Slow accrual	CHEBI_27786	"5514"	HP:0002181		"2032001"
hydrocortisone succinate	DB14545	Cerebral Edema	C0006114		Approved			CHEBI_31677	"21651"	HP:0002181		"2032001"
hydrocortisone	DB00741	Cerebral Edema	C0006114		Approved			CHEBI_17650	"5492"	HP:0002181		"2032001"
hydrocortisone acetate	DB14539	Cerebral Edema	C0006114		Approved			CHEBI_17609	"27197"	HP:0002181		"2032001"
glibenclamide	DB01016	Cerebral Edema	C0006114	NCT02460874	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_5441	"4815"	HP:0002181		"2032001"
	DB00316	Patent ductus arteriosus	C0013274	NCT03701074	Terminated	Phase 2	very slow enrollment. Only one patient enrolled. Termination by PI	CHEBI_46195	"161"	HP:0001643		"83330001"
ibuprofen	DB01050	Patent ductus arteriosus	C0013274	NCT03701074	Terminated	Phase 2	very slow enrollment. Only one patient enrolled. Termination by PI	CHEBI_5855	"5640"	HP:0001643		"83330001"
indomethacin	DB00328	Patent ductus arteriosus	C0013274	NCT00750581	Terminated	Phase 2/Phase 3	Study medication was no longer available for study	CHEBI_49662	"5781"	HP:0001643		"83330001"
ibuprofen	DB01050	Patent ductus arteriosus	C0013274		Approved			CHEBI_5855	"5640"	HP:0001643		"83330001"
indomethacin	DB00328	Patent ductus arteriosus	C0013274		Approved			CHEBI_49662	"5781"	HP:0001643		"83330001"
	DB00316	Patent ductus arteriosus	C0013274	NCT04026464	Withdrawn	Phase 2	Unable to obtain funding to support this project	CHEBI_46195	"161"	HP:0001643		"83330001"
ibuprofen	DB01050	Patent ductus arteriosus	C0013274	NCT04026464	Withdrawn	Phase 2	Unable to obtain funding to support this project	CHEBI_5855	"5640"	HP:0001643		"83330001"
	DB00316	Patent ductus arteriosus	C0013274	NCT03537144	Terminated	Phase 3	Difficulty enrolling patients	CHEBI_46195	"161"	HP:0001643		"83330001"
indomethacin	DB00328	Patent ductus arteriosus	C0013274	NCT03537144	Terminated	Phase 3	Difficulty enrolling patients	CHEBI_49662	"5781"	HP:0001643		"83330001"
	DB00328	Patent ductus arteriosus	C0013274	NCT01070745	Withdrawn	Phase 2	Changes in approach to PDA therapy	CHEBI_49662	"5781"	HP:0001643		"83330001"
ibuprofen	DB01050	Patent ductus arteriosus	C0013274	NCT01070745	Withdrawn	Phase 2	Changes in approach to PDA therapy	CHEBI_5855	"5640"	HP:0001643		"83330001"
flumetasone	DB00663	Exanthema	C0015230		Approved			CHEBI_34764	"4458"	HP:4000054		
clindamycin	DB01190	Empyema, Pleural	C0014013		Approved			CHEBI_3745	"2582"	HP:0011919		"405951008"
clindamycin phosphate	DB01190	Empyema, Pleural	C0014013		Approved			CHEBI_3745	"2582"	HP:0011919		"405951008"
ticarcillin	DB01607	Empyema, Pleural	C0014013		Approved			CHEBI_9587	"10591"	HP:0011919		"405951008"
fluticasone propionate	DB00588	Exanthema	C0015230		Approved			CHEBI_31441	"50121"	HP:4000054		
triamcinolone diacetate	DB00620	Exanthema	C0015230		Approved			CHEBI_9667	"10759"	HP:4000054		
prednisolone	DB00860	Exanthema	C0015230		Approved			CHEBI_8378	"8638"	HP:4000054		
hydrocortisone acetate	DB00741	Exanthema	C0015230		Approved			CHEBI_17650	"5492"	HP:4000054		
amcinonide	DB00288	Exanthema	C0015230		Approved			CHEBI_31199	"17652"	HP:4000054		
zinc oxide	DB09321	Exanthema	C0015230		Approved			CHEBI_36560	"11423"	HP:4000054		
cortisone acetate	DB01380	Exanthema	C0015230		Approved			CHEBI_3897	"21655"	HP:4000054		
halcinonide	DB06786	Exanthema	C0015230		Approved			CHEBI_31663	"5084"	HP:4000054		
alclometasone dipropionate	DB00240	Exanthema	C0015230		Approved			CHEBI_53776	"108088"	HP:4000054		
carbamide	DB03904	Exanthema	C0015230		Approved			CHEBI_16199	"11002"	HP:4000054		
triamcinolone acetonide	DB00620	Exanthema	C0015230		Approved			CHEBI_9667	"10759"	HP:4000054		
zinc acetate	DB14487	Exanthema	C0015230		Approved			CHEBI_62984	"1299637|58295"	HP:4000054		
prednicarbate	DB00860	Exanthema	C0015230		Approved			CHEBI_8378	"8638"	HP:4000054		
fluocinonide	DB12553	Exanthema	C0015230		Approved			CHEBI_5108	"25126"	HP:4000054		
diflorasone diacetate	DB00223	Exanthema	C0015230		Approved			CHEBI_59750	"91311"	HP:4000054		
triamcinolone	DB00620	Exanthema	C0015230		Approved			CHEBI_9667	"10759"	HP:4000054		
hydrocortisone	DB00741	Exanthema	C0015230		Approved			CHEBI_17650	"5492"	HP:4000054		
ammonium lactate	DB06768	Exanthema	C0015230		Approved				"215247"	HP:4000054		
ulobetasol propionate	DB00596	Exanthema	C0015230		Approved			CHEBI_135782	"41208"	HP:4000054		
clocortolone pivalate	DB00838	Exanthema	C0015230		Approved			CHEBI_59582	"21249"	HP:4000054		
fluticasone propionate	DB13867	Exanthema	C0015230		Approved			CHEBI_5134	"41126"	HP:4000054		
ferric oxide	DB11576	Exanthema	C0015230		Approved			CHEBI_50819		HP:4000054		
hydrocortisone succinate	DB14545	Exanthema	C0015230		Approved			CHEBI_31677	"21651"	HP:4000054		
prednicarbate	DB01130	Exanthema	C0015230		Approved			CHEBI_135791	"34369"	HP:4000054		
hydrocortisone succinate	DB00741	Exanthema	C0015230		Approved			CHEBI_17650	"5492"	HP:4000054		
fluocinolone acetonide	DB00591	Exanthema	C0015230		Approved			CHEBI_31623	"4461"	HP:4000054		
methylprednisolone	DB00959	Exanthema	C0015230		Approved			CHEBI_6888	"6902"	HP:4000054		
desoximetasone	DB00547	Exanthema	C0015230		Approved			CHEBI_691037	"3255"	HP:4000054		
betamethasone valerate	DB00443	Exanthema	C0015230		Approved			CHEBI_3077	"1514"	HP:4000054		
betamethasone dipropionate	DB00443	Exanthema	C0015230		Approved			CHEBI_3077	"1514"	HP:4000054		
fludroxycortide	DB00846	Exanthema	C0015230		Approved			CHEBI_5127	"4500"	HP:4000054		
betamethasone benzoate	DB00443	Exanthema	C0015230		Approved			CHEBI_3077	"1514"	HP:4000054		
mometasone furoate	DB00764	Exanthema	C0015230		Approved			CHEBI_6970		HP:4000054		
mometasone furoate	DB14512	Exanthema	C0015230		Approved			CHEBI_47564	"30145"	HP:4000054		
fluocinolone acetonide	DB12553	Exanthema	C0015230		Approved			CHEBI_5108	"25126"	HP:4000054		
betamethasone acetate	DB00443	Exanthema	C0015230		Approved			CHEBI_3077	"1514"	HP:4000054		
dexamethasone	DB01234	Exanthema	C0015230		Approved			CHEBI_41879	"3264"	HP:4000054		
pramocaine	DB09345	Exanthema	C0015230		Approved			CHEBI_8357	"34347"	HP:4000054		
desonide	DB01260	Exanthema	C0015230		Approved			CHEBI_204734	"3254"	HP:4000054		
betamethasone	DB00443	Exanthema	C0015230		Approved			CHEBI_3077	"1514"	HP:4000054		
fluocinonide	DB01047	Exanthema	C0015230		Approved			CHEBI_5109	"4462"	HP:4000054		
benzoyl peroxide	DB09096	Exanthema	C0015230		Approved			CHEBI_82405	"1418"	HP:4000054		
hydrocortisone acetate	DB14539	Exanthema	C0015230		Approved			CHEBI_17609	"27197"	HP:4000054		
algeldrate	DB06723	Heartburn	C0018834		Approved			CHEBI_33130	"612|81948"	HP:0002020		"16331000"
magnesium carbonate	DB09481	Heartburn	C0018834		Approved			CHEBI_31793	"29155"	HP:0002020		"16331000"
sodium citrate	DB09154	Heartburn	C0018834		Approved			CHEBI_53258	"253204|56466|1310549"	HP:0002020		"16331000"
magnesium hydroxide	DB09104	Heartburn	C0018834		Approved			CHEBI_6637	"6581|243353"	HP:0002020		"16331000"
silicon dioxide	DB11132	Heartburn	C0018834		Approved			CHEBI_30563	"314826|1362874|9771"	HP:0002020		"16331000"
famotidine	DB00927	Heartburn	C0018834		Approved			CHEBI_4975	"4278"	HP:0002020		"16331000"
nizatidine	DB00585	Heartburn	C0018834		Approved			CHEBI_7601	"42319"	HP:0002020		"16331000"
almasilate	DB13595	Heartburn	C0018834		Approved				"17614"	HP:0002020		"16331000"
ranitidine	DB00863	Heartburn	C0018834		Approved			CHEBI_92246	"9143"	HP:0002020		"16331000"
magnesium silicate	DB09281	Heartburn	C0018834		Approved				"29170"	HP:0002020		"16331000"
potassium hydrogencarbonate	DB11098	Heartburn	C0018834		Approved			CHEBI_81862	"34296"	HP:0002020		"16331000"
carbaldrate	DB15825	Heartburn	C0018834		Approved					HP:0002020		"16331000"
alum	DB09087	Heartburn	C0018834		Approved			CHEBI_86463	"221456|54989"	HP:0002020		"16331000"
magnesium silicate	DB13249	Heartburn	C0018834		Approved				"1310566"	HP:0002020		"16331000"
cimetidine	DB00501	Heartburn	C0018834		Approved			CHEBI_3699	"2541"	HP:0002020		"16331000"
diclofenac	DB00586	Low Back Pain	C0024031		Approved			CHEBI_47381	"3355"	HP:0003419		"279039007"
ondansetron	DB00904	Nausea and vomiting	C0027498	NCT00891761	Withdrawn	Phase 3	This study has been cancelled prior to enrollment.	CHEBI_7773	"26225"	HP:0002017		"16932000"
chlorpromazine	DB00477	Nausea and vomiting	C0027498		Approved			CHEBI_3647	"2403"	HP:0002017		"16932000"
promazine	DB00420	Nausea and vomiting	C0027498		Approved			CHEBI_8459	"8742"	HP:0002017		"16932000"
	DB01234	Nausea and vomiting	C0027498	NCT00895245	Terminated	Phase 2	Study stopped due to lack of efficacy in first 6 patients	CHEBI_41879	"3264"	HP:0002017		"16932000"
perphenazine	DB00850	Nausea and vomiting	C0027498		Approved			CHEBI_8028	"8076"	HP:0002017		"16932000"
	DB00673	Nausea and vomiting	C0027498	NCT00895245	Terminated	Phase 2	Study stopped due to lack of efficacy in first 6 patients	CHEBI_499361	"358255"	HP:0002017		"16932000"
palonosetron	DB00377	Nausea and vomiting	C0027498	NCT00895245	Terminated	Phase 2	Study stopped due to lack of efficacy in first 6 patients	CHEBI_85161	"70561"	HP:0002017		"16932000"
trimethobenzamide	DB00662	Nausea and vomiting	C0027498		Approved			CHEBI_27796	"38685"	HP:0002017		"16932000"
triflupromazine	DB00508	Nausea and vomiting	C0027498		Approved			CHEBI_9711	"10805"	HP:0002017		"16932000"
perazine	DB12710	Nausea and vomiting	C0027498		Approved			CHEBI_59118	"8042"	HP:0002017		"16932000"
alizapride	DB01425	Nausea and vomiting	C0027498		Approved			CHEBI_94316	"17311"	HP:0002017		"16932000"
prochlorperazine	DB00433	Nausea and vomiting	C0027498		Approved			CHEBI_8435	"8704"	HP:0002017		"16932000"
thiethylperazine	DB00372	Nausea and vomiting	C0027498		Approved			CHEBI_9544	"10471"	HP:0002017		"16932000"
palonosetron	DB00377	Nausea and vomiting	C0027498	NCT00903396	Terminated	Phase 2	Slow accrual	CHEBI_85161	"70561"	HP:0002017		"16932000"
methadone	DB00333	Nausea and vomiting	C0027498	NCT00930332	Terminated	Phase 1	Poor accrual	CHEBI_167309	"6813"	HP:0002017		"16932000"
domperidone	DB01184	Nausea and vomiting	C0027498		Approved			CHEBI_31515	"3626"	HP:0002017		"16932000"
dimenhydrinate	DB00985	Nausea and vomiting	C0027498		Approved			CHEBI_94848	"3444"	HP:0002017		"16932000"
	DB01234	Nausea and vomiting	C0027498	NCT00891761	Withdrawn	Phase 3	This study has been cancelled prior to enrollment.	CHEBI_41879	"3264"	HP:0002017		"16932000"
promethazine	DB01069	Nausea and vomiting	C0027498		Approved			CHEBI_8461	"8745"	HP:0002017		"16932000"
etidronic acid	DB01077	Heterotopic Ossification	C0029396		Approved			CHEBI_4907	"42682|1356715"	HP:0011986		"128491006"
diltiazem	DB00343	Paroxysmal supraventricular tachycardia	C0030590		Approved			CHEBI_101278	"3443"	HP:0004763		"67198005"
methoxamine	DB00723	Paroxysmal supraventricular tachycardia	C0030590		Approved			CHEBI_6839	"6853"	HP:0004763		"67198005"
adenosine	DB00640	Paroxysmal supraventricular tachycardia	C0030590		Approved			CHEBI_16335	"296"	HP:0004763		"67198005"
verapamil	DB00661	Paroxysmal supraventricular tachycardia	C0030590		Approved			CHEBI_77733	"11170"	HP:0004763		"67198005"
propafenone	DB01182	Paroxysmal supraventricular tachycardia	C0030590		Approved			CHEBI_63619	"8754"	HP:0004763		"67198005"
ganciclovir	DB01004	Paroxysmal supraventricular tachycardia	C0030590		Approved			CHEBI_465284	"4678"	HP:0004763		"67198005"
phenoxybenzamine	DB00925	Pheochromocytoma	C0031511		Approved			CHEBI_8077	"8149"	HP:0002666		
metirosine	DB00765	Pheochromocytoma	C0031511		Approved			CHEBI_6912	"266604"	HP:0002666		
octreotide	DB00104	Pheochromocytoma	C0031511	NCT00466856	Terminated	Phase 2	due to slow accrual	CHEBI_7726	"7617"	HP:0002666		
azacitidine	DB00928	Pheochromocytoma	C0031511	NCT03165721	Terminated	Phase 2	Study closed to enrollment due to low accrual.	CHEBI_2038	"1251"	HP:0002666		
phentolamine	DB00692	Pheochromocytoma	C0031511		Approved			CHEBI_8081	"8153"	HP:0002666		
dicoumarol	DB00266	Thromboembolism	C0040038		Approved			CHEBI_4513	"1598"	HP:0001907		"371039008"
warfarin	DB00682	Thromboembolism	C0040038		Approved			CHEBI_87732	"11289"	HP:0001907		"371039008"
phenprocoumon	DB00946	Thromboembolism	C0040038		Approved			CHEBI_50438	"8150"	HP:0001907		"371039008"
cloricromen	DB13367	Thromboembolism	C0040038		Approved			CHEBI_135628		HP:0001907		"371039008"
minocycline	DB01017	Gingivostomatitis	C0149704		Approved			CHEBI_50694	"6980"	HP:0010280		"20607006"
meclocycline	DB13092	Gingivostomatitis	C0149704		Approved			CHEBI_135772	"29418"	HP:0010280		"20607006"
tetracycline	DB09550	Gingivostomatitis	C0149704		Approved			CHEBI_27902	"2105975"	HP:0010280		"20607006"
demeclocycline	DB00618	Gingivostomatitis	C0149704		Approved			CHEBI_4392	"3154"	HP:0010280		"20607006"
amphotericin B	DB00681	Gingivostomatitis	C0149704		Approved			CHEBI_2682	"236594|732"	HP:0010280		"20607006"
benzylpenicillin	DB01053	Gingivostomatitis	C0149704		Approved			CHEBI_18208	"7980"	HP:0010280		"20607006"
tetracycline	DB00759	Gingivostomatitis	C0149704		Approved			CHEBI_27902	"10395"	HP:0010280		"20607006"
phenoxymethylpenicillin	DB00417	Gingivostomatitis	C0149704		Approved			CHEBI_27446	"7984"	HP:0010280		"20607006"
procaine benzylpenicillin	DB09320	Gingivostomatitis	C0149704		Approved			CHEBI_52154	"7983"	HP:0010280		"20607006"
fusidic acid	DB02703	Gingivostomatitis	C0149704		Approved			CHEBI_29013	"4608|113608"	HP:0010280		"20607006"
procaine benzylpenicillin	DB01053	Gingivostomatitis	C0149704		Approved			CHEBI_18208	"7980"	HP:0010280		"20607006"
oxytetracycline	DB00595	Gingivostomatitis	C0149704		Approved			CHEBI_133011	"7821|1545999"	HP:0010280		"20607006"
gabapentin	DB00996	Chronic pain	C0150055	NCT01675960	Terminated	Phase 2	unable to enroll	CHEBI_42797	"25480"	HP:0012532		"82423001"
tapentadol	DB06204	Chronic pain	C0150055	NCT00986258	Terminated	Phase 3	This clinical trial was terminated early, due to slow recruitment and study drug shortages.	CHEBI_135935	"787390"	HP:0012532		"82423001"
fentanyl	DB00813	Chronic pain	C0150055	NCT02138409	Withdrawn	Phase 3	Sponsor elected not to continue with study.	CHEBI_119915	"4337"	HP:0012532		"82423001"
morphine	DB00295	Chronic pain	C0150055		Approved			CHEBI_17303	"7052|32926"	HP:0012532		"82423001"
dronabinol	DB00470	Chronic pain	C0150055	NCT02683018	Withdrawn	Phase 1	funding	CHEBI_66964	"10402"	HP:0012532		"82423001"
buprenorphine	DB00921	Chronic pain	C0150055		Approved			CHEBI_3216	"1819"	HP:0012532		"82423001"
gabapentin	DB00996	Chronic pain	C0150055	NCT02722603	Terminated	Phase 3	The study was early terminated due to insufficient recruitment	CHEBI_42797	"25480"	HP:0012532		"82423001"
lidocaine	DB00281	Chronic pain	C0150055	NCT02219321	Terminated	Phase 3	Lack of Funding	CHEBI_6456	"6387"	HP:0012532		"82423001"
hydromorphone	DB00327	Chronic pain	C0150055	NCT02321319	Terminated	Phase 3	Business decision - product discontinued	CHEBI_5790	"3423"	HP:0012532		"82423001"
oxymorphone	DB01192	Chronic pain	C0150055	NCT00765856	Terminated	Phase 3	Terminated new protocol developed which incorporated Pharmacokinetics	CHEBI_7865	"7814"	HP:0012532		"82423001"
pregabalin	DB00230	Chronic pain	C0150055	NCT01821430	Terminated	Phase 2	poor recruitment	CHEBI_64356	"187832"	HP:0012532		"82423001"
scopolamine	DB00747	Posterior synechiae	C0152253		Approved			CHEBI_16794	"9601|9603"	HP:0011484		"111512005"
medroxyprogesterone	DB00603	Secondary physiologic amenorrhea	C0232940		Approved			CHEBI_6716	"1000112"	HP:0000869		"86030004"
progesterone	DB00396	Secondary physiologic amenorrhea	C0232940		Approved			CHEBI_17026	"8727"	HP:0000869		"86030004"
norethisterone	DB00717	Secondary physiologic amenorrhea	C0232940		Approved			CHEBI_7627	"7514"	HP:0000869		"86030004"
norethindrone acetate	DB00717	Secondary physiologic amenorrhea	C0232940		Approved			CHEBI_7627	"7514"	HP:0000869		"86030004"
calcium glycerylphosphate	DB11264	Hypocalcemic tetany	C0151940		Approved			CHEBI_31336	"1909"	HP:0003472		"190869004"
calcium glucoheptonate	DB00326	Hypocalcemic tetany	C0151940		Approved			CHEBI_3314	"47618"	HP:0003472		"190869004"
calcium lactate	DB13231	Hypocalcemic tetany	C0151940		Approved				"47622"	HP:0003472		"190869004"
calcium chloride	DB01164	Hypocalcemic tetany	C0151940		Approved			CHEBI_3312	"1901|1667640"	HP:0003472		"190869004"
calcium gluconate	DB11126	Hypocalcemic tetany	C0151940		Approved			CHEBI_3309	"1908"	HP:0003472		"190869004"
calcium acetate	DB00258	Hypocalcemic tetany	C0151940		Approved			CHEBI_3310	"214342"	HP:0003472		"190869004"
lenvatinib	DB09078	Follicular thyroid carcinoma	C0206682		Approved			CHEBI_85994	"1603296"	HP:0006731		"255028004"
mazaticol	DB13448	Extrapyramidal sign	C0234133		Approved			CHEBI_135656		HP:0002071		"43378000"
macrogol	DB11077	Redness of eye	C0235267		Approved			CHEBI_46793	"8514"	HP:0025337		"703630003"
phenylephrine	DB00388	Redness of eye	C0235267		Approved			CHEBI_8093	"8163"	HP:0025337		"703630003"
tetryzoline	DB06764	Redness of eye	C0235267		Approved			CHEBI_28674	"37935"	HP:0025337		"703630003"
oxymetazoline	DB00935	Redness of eye	C0235267		Approved			CHEBI_7862	"7812"	HP:0025337		"703630003"
macrogol	DB11161	Redness of eye	C0235267		Approved			CHEBI_46793	"8513"	HP:0025337		"703630003"
pheniramine	DB01620	Redness of eye	C0235267		Approved			CHEBI_91591	"8132"	HP:0025337		"703630003"
naphazoline	DB06711	Redness of eye	C0235267		Approved			CHEBI_93363	"7247"	HP:0025337		"703630003"
antazoline	DB08799	Redness of eye	C0235267		Approved			CHEBI_84115	"865"	HP:0025337		"703630003"
crospovidone	DB11061	Redness of eye	C0235267		Approved				"8610"	HP:0025337		"703630003"
macrogol	DB09287	Redness of eye	C0235267		Approved			CHEBI_46793	"8516|1314384|221147|1310594"	HP:0025337		"703630003"
polyvinyl alcohol	DB11060	Redness of eye	C0235267		Approved			CHEBI_17246	"8570"	HP:0025337		"703630003"
zinc sulfate	DB09322	Redness of eye	C0235267		Approved			CHEBI_35176	"1299928|39954"	HP:0025337		"703630003"
dronedarone	DB04855	Paroxysmal atrial fibrillation	C0235480		Approved			CHEBI_50659	"233698"	HP:0004757		"282825002"
flecainide	DB01195	Paroxysmal atrial fibrillation	C0235480		Approved			CHEBI_75984	"4441"	HP:0004757		"282825002"
propafenone	DB01182	Paroxysmal atrial fibrillation	C0235480		Approved			CHEBI_63619	"8754"	HP:0004757		"282825002"
vasopressin	DB00067	Bedwetting	C0270327		Approved			CHEBI_9937	"11149"	HP:0010677		"8009008"
imipramine	DB00458	Bedwetting	C0270327		Approved			CHEBI_47499	"5691"	HP:0010677		"8009008"
desmopressin	DB00035	Bedwetting	C0270327		Approved			CHEBI_4450	"203658|3251"	HP:0010677		"8009008"
pheniramine	DB01620	Sore Throat	C0242429		Approved			CHEBI_91591	"8132"	HP:0033050		"267102003"
ambroxol	DB06742	Sore Throat	C0242429		Approved			CHEBI_135590	"625"	HP:0033050		"267102003"
dextromethorphan	DB00514	Sore Throat	C0242429		Approved			CHEBI_4470	"3289"	HP:0033050		"267102003"
codeine	DB00318	Sore Throat	C0242429		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0033050		"267102003"
benzocaine	DB01086	Sore Throat	C0242429		Approved			CHEBI_116735	"1399"	HP:0033050		"267102003"
tirabrutinib hydrochloride	DB15227	Microglioma	C0280803		Approved					HP:0030069	"10007953"	"307649006"
	DB00362	Invasive Pulmonary Aspergillosis	C0276653	NCT01188759	Withdrawn	Phase 3		CHEBI_55346	"341018"	HP:0020103		"3214003"
voriconazole	DB00582	Invasive Pulmonary Aspergillosis	C0276653		Approved			CHEBI_10023	"121243"	HP:0020103		"3214003"
	DB00582	Invasive Pulmonary Aspergillosis	C0276653	NCT03327727	Terminated	Phase 2	Business decision	CHEBI_10023	"121243"	HP:0020103		"3214003"
voriconazole	DB00582	Invasive Pulmonary Aspergillosis	C0276653	NCT01188759	Withdrawn	Phase 3		CHEBI_10023	"121243"	HP:0020103		"3214003"
amphotericin B	DB00681	Invasive Pulmonary Aspergillosis	C0276653		Approved			CHEBI_2682	"236594|732"	HP:0020103		"3214003"
amphotericin B	DB00681	Invasive Pulmonary Aspergillosis	C0276653	NCT03327727	Terminated	Phase 2	Business decision	CHEBI_2682	"236594|732"	HP:0020103		"3214003"
itraconazole	DB01167	Invasive Pulmonary Aspergillosis	C0276653		Approved			CHEBI_6076	"28031"	HP:0020103		"3214003"
fenofibrate	DB01039	Hypoalphalipoproteinemias	C0473527		Approved			CHEBI_5001	"8703"	HP:0003233		"190785000"
inositol	DB13178	Hypoalphalipoproteinemias	C0473527		Approved			CHEBI_17268	"5833"	HP:0003233		"190785000"
lovastatin	DB00227	Hypoalphalipoproteinemias	C0473527		Approved			CHEBI_40303	"6472"	HP:0003233		"190785000"
simvastatin	DB00641	Hypoalphalipoproteinemias	C0473527		Approved			CHEBI_9150	"36567"	HP:0003233		"190785000"
choline fenofibrate	DB13873	Hypoalphalipoproteinemias	C0473527		Approved			CHEBI_83469	"24852"	HP:0003233		"190785000"
elobixibat	DB12486	Chronic constipation	C0401149		Approved					HP:0012450		"236069009"
diphenylpyraline	DB01146	Dermatographic urticaria	C0343065		Approved			CHEBI_59788	"23386"	HP:0011971		"402410006"
promazine	DB00420	Dermatographic urticaria	C0343065		Approved			CHEBI_8459	"8742"	HP:0011971		"402410006"
carbinoxamine	DB00748	Dermatographic urticaria	C0343065		Approved			CHEBI_3398	"20220"	HP:0011971		"402410006"
pheniramine	DB01620	Dermatographic urticaria	C0343065		Approved			CHEBI_91591	"8132"	HP:0011971		"402410006"
doxylamine	DB00366	Dermatographic urticaria	C0343065		Approved			CHEBI_51380	"3642"	HP:0011971		"402410006"
cyproheptadine	DB00434	Dermatographic urticaria	C0343065		Approved			CHEBI_4046	"3013"	HP:0011971		"402410006"
phenyltoloxamine	DB11160	Dermatographic urticaria	C0343065		Approved			CHEBI_135047	"33408"	HP:0011971		"402410006"
brompheniramine	DB00835	Dermatographic urticaria	C0343065		Approved			CHEBI_3183	"1767"	HP:0011971		"402410006"
clemastine	DB00283	Dermatographic urticaria	C0343065		Approved			CHEBI_3738	"2578"	HP:0011971		"402410006"
tripelennamine	DB00792	Dermatographic urticaria	C0343065		Approved			CHEBI_9741	"10847"	HP:0011971		"402410006"
dexchlorpheniramine	DB13679	Dermatographic urticaria	C0343065		Approved			CHEBI_4464	"22697"	HP:0011971		"402410006"
alimemazine	DB01246	Dermatographic urticaria	C0343065		Approved			CHEBI_9725	"10825"	HP:0011971		"402410006"
methapyrilene	DB04819	Dermatographic urticaria	C0343065		Approved			CHEBI_6820	"6822"	HP:0011971		"402410006"
methdilazine	DB00902	Dermatographic urticaria	C0343065		Approved			CHEBI_6823	"29648"	HP:0011971		"402410006"
dexbrompheniramine	DB00405	Dermatographic urticaria	C0343065		Approved			CHEBI_59269	"22696|1767"	HP:0011971		"402410006"
hydroxyzine	DB00557	Dermatographic urticaria	C0343065		Approved			CHEBI_5818	"5553"	HP:0011971		"402410006"
azatadine	DB00719	Dermatographic urticaria	C0343065		Approved			CHEBI_2946	"18600"	HP:0011971		"402410006"
dexchlorpheniramine	DB09555	Dermatographic urticaria	C0343065		Approved			CHEBI_4465	"54828"	HP:0011971		"402410006"
triprolidine	DB00427	Dermatographic urticaria	C0343065		Approved			CHEBI_84116	"10849"	HP:0011971		"402410006"
naloxone	DB01183	Opiate Addiction	C0524662	NCT01713803	Withdrawn	Phase 3	FDA did not require a clinical trial for indication.	CHEBI_7459	"7242"	HP:0033515		"75544000"
methylprednisolone	DB00959	Opiate Addiction	C0524662	NCT02935101	Terminated	Phase 2	difficulties in recruiting study participants	CHEBI_6888	"6902"	HP:0033515		"75544000"
	DB14644	Opiate Addiction	C0524662	NCT02935101	Terminated	Phase 2	difficulties in recruiting study participants	CHEBI_135765		HP:0033515		"75544000"
	DB00860	Opiate Addiction	C0524662	NCT02935101	Terminated	Phase 2	difficulties in recruiting study participants	CHEBI_8378	"8638"	HP:0033515		"75544000"
levomethadone	DB13515	Opiate Addiction	C0524662		Approved			CHEBI_136003		HP:0033515		"75544000"
	DB00921	Opiate Addiction	C0524662	NCT01713803	Withdrawn	Phase 3	FDA did not require a clinical trial for indication.	CHEBI_3216	"1819"	HP:0033515		"75544000"
buprenorphine	DB00921	Opiate Addiction	C0524662		Approved			CHEBI_3216	"1819"	HP:0033515		"75544000"
naloxone	DB01183	Opiate Addiction	C0524662		Approved			CHEBI_7459	"7242"	HP:0033515		"75544000"
acetylmethadol	DB01433	Opiate Addiction	C0524662		Approved			CHEBI_135491	"6814"	HP:0033515		"75544000"
oxycodone	DB00497	Opiate Addiction	C0524662	NCT03837860	Terminated	Early Phase 1	PI leaving institution	CHEBI_7852	"7804"	HP:0033515		"75544000"
	DB00734	Opiate Addiction	C0524662	NCT03837860	Terminated	Early Phase 1	PI leaving institution	CHEBI_8871	"35636"	HP:0033515		"75544000"
levomethadyl acetate	DB01227	Opiate Addiction	C0524662		Approved			CHEBI_6441	"237005"	HP:0033515		"75544000"
buprenorphine	DB00921	Opiate Addiction	C0524662	NCT02516436	Withdrawn	Phase 3	FDA did not require a clinical trial for indication.	CHEBI_3216	"1819"	HP:0033515		"75544000"
buprenorphine	DB00921	Opiate Addiction	C0524662	NCT00768482	Terminated	Phase 3	This study was terminated for reasons not related to efficacy or safety	CHEBI_3216	"1819"	HP:0033515		"75544000"
warfarin	DB00682	Pulmonary Thromboembolisms	C0524702		Approved			CHEBI_87732	"11289"	HP:0034192		"233935004"
heparin	DB01109	Pulmonary Thromboembolisms	C0524702		Approved			CHEBI_28304	"5224"	HP:0034192		"233935004"
fondaparinux	DB00569	Pulmonary Thromboembolisms	C0524702		Approved			CHEBI_61033	"321208"	HP:0034192		"233935004"
clarithromycin	DB01211	Infection caused by Helicobacter pylori	C0850666		Approved			CHEBI_3732	"21212"	HP:0005202		"721730009"
vonoprazan	DB11739	Infection caused by Helicobacter pylori	C0850666		Approved			CHEBI_136048	"2604577"	HP:0005202		"721730009"
amoxicillin	DB01060	Infection caused by Helicobacter pylori	C0850666		Approved			CHEBI_2676	"1297882|723"	HP:0005202		"721730009"
oxeladin	DB04822	Dry cough	C0850149		Approved			CHEBI_135424	"32626"	HP:0031246		"11833005"
dropropizine	DB13785	Dry cough	C0850149		Approved			CHEBI_93837		HP:0031246		"11833005"
nepinalone	DB13445	Dry cough	C0850149		Approved			CHEBI_135121		HP:0031246		"11833005"
clobutinol	DB09004	Dry cough	C0850149		Approved			CHEBI_94381	"21247"	HP:0031246		"11833005"
methscopolamine	DB11315	Coughing	C0010200		Approved			CHEBI_135361	"89785"	HP:0012735	"10011224"	"263731006"
botulinum toxin type A	DB00083	Lower limb spasticity	C1271100		Approved				"1712|860168|1000104|860189"	HP:0002061		"394679006"
acyclovir	DB00787	Recurrent herpes simplex labialis	C1274321		Approved			CHEBI_2453	"281"	HP:0410028		"402892009"
famciclovir	DB00426	Recurrent herpes simplex labialis	C1274321		Approved			CHEBI_4974	"68099"	HP:0410028		"402892009"
hydrocortisone	DB00741	Recurrent herpes simplex labialis	C1274321		Approved			CHEBI_17650	"5492"	HP:0410028		"402892009"
cortisone acetate	DB01380	Recurrent herpes simplex labialis	C1274321		Approved			CHEBI_3897	"21655"	HP:0410028		"402892009"
famciclovir	DB00426	Recurrent genital herpes simplex	C1274323		Approved			CHEBI_4974	"68099"	HP:0032157		"402894005"
valaciclovir	DB00577	Recurrent genital herpes simplex	C1274323		Approved			CHEBI_35854	"73645"	HP:0032157		"402894005"
acyclovir	DB00787	Recurrent genital herpes simplex	C1274323		Approved			CHEBI_2453	"281"	HP:0032157		"402894005"
botulinum toxin type A	DB00083	Upper limb spasticity	C1273957		Approved				"1712|860168|1000104|860189"	HP:0006986		"394680009"
calcium glucoheptonate	DB00326	Disorder of electrolytes	C1704431		Approved			CHEBI_3314	"47618"	HP:0003111		"237840007"
calcium glycerylphosphate	DB11264	Disorder of electrolytes	C1704431		Approved			CHEBI_31336	"1909"	HP:0003111		"237840007"
calcium acetate	DB00258	Disorder of electrolytes	C1704431		Approved			CHEBI_3310	"214342"	HP:0003111		"237840007"
calcium lactate	DB13231	Disorder of electrolytes	C1704431		Approved				"47622"	HP:0003111		"237840007"
calcium chloride	DB01164	Disorder of electrolytes	C1704431		Approved			CHEBI_3312	"1901|1667640"	HP:0003111		"237840007"
ofloxacin	DB01165	Infection of bone	C2242472		Approved			CHEBI_7731	"7623"	HP:0002754		"111253001"
gentamicin	DB00798	Infection of bone	C2242472		Approved			CHEBI_17833	"1596450"	HP:0002754		"111253001"
cefapirin	DB01139	Infection of bone	C2242472		Approved			CHEBI_554446	"2238"	HP:0002754		"111253001"
oxacillin	DB00713	Infection of bone	C2242472		Approved			CHEBI_7809	"7773"	HP:0002754		"111253001"
cefazolin	DB01327	Infection of bone	C2242472		Approved			CHEBI_474053	"2180"	HP:0002754		"111253001"
cefalotin	DB00456	Infection of bone	C2242472		Approved			CHEBI_124991	"2236"	HP:0002754		"111253001"
metronidazole	DB00916	Infection of bone	C2242472		Approved			CHEBI_6909	"6922"	HP:0002754		"111253001"
kanamycin	DB01172	Infection of bone	C2242472		Approved			CHEBI_17630	"6099|1727573"	HP:0002754		"111253001"
ciprofloxacin	DB00537	Infection of bone	C2242472		Approved			CHEBI_192484	"2551"	HP:0002754		"111253001"
ceftizoxime	DB01332	Infection of bone	C2242472		Approved			CHEBI_553473	"2192"	HP:0002754		"111253001"
nafcillin	DB00607	Infection of bone	C2242472		Approved			CHEBI_7447	"7233"	HP:0002754		"111253001"
cefotaxime	DB00493	Infection of bone	C2242472		Approved			CHEBI_204928	"2186"	HP:0002754		"111253001"
metronidazole	DB15759	Infection of bone	C2242472		Approved			CHEBI_50688		HP:0002754		"111253001"
ceftriaxone	DB01212	Infection of bone	C2242472		Approved			CHEBI_29007	"2193"	HP:0002754		"111253001"
cilastatin	DB01597	Infection of bone	C2242472		Approved			CHEBI_3697	"2540"	HP:0002754		"111253001"
cefalexin	DB00567	Infection of bone	C2242472		Approved			CHEBI_3534	"2231|1299782"	HP:0002754		"111253001"
clindamycin	DB01190	Infection of bone	C2242472		Approved			CHEBI_3745	"2582"	HP:0002754		"111253001"
norfloxacin	DB01059	Infection of bone	C2242472		Approved			CHEBI_100246	"7517"	HP:0002754		"111253001"
clindamycin phosphate	DB01190	Infection of bone	C2242472		Approved			CHEBI_3745	"2582"	HP:0002754		"111253001"
cefamandole	DB01326	Infection of bone	C2242472		Approved			CHEBI_3480	"2178"	HP:0002754		"111253001"
ceftazidime	DB00438	Infection of bone	C2242472		Approved			CHEBI_3508	"2191|1545984"	HP:0002754		"111253001"
vancomycin	DB00512	Infection of bone	C2242472		Approved			CHEBI_28001	"11124"	HP:0002754		"111253001"
cefradine	DB01333	Infection of bone	C2242472		Approved			CHEBI_3547	"2239"	HP:0002754		"111253001"
tobramycin	DB00684	Infection of bone	C2242472		Approved			CHEBI_28864	"10627"	HP:0002754		"111253001"
piperacillin	DB00319	Infection of bone	C2242472		Approved			CHEBI_8232	"1546000|8339"	HP:0002754		"111253001"
amikacin	DB00479	Infection of bone	C2242472		Approved			CHEBI_2637	"641"	HP:0002754		"111253001"
azlocillin	DB01061	Infection of bone	C2242472		Approved			CHEBI_2956	"1266"	HP:0002754		"111253001"
cefuroxime	DB01112	Infection of bone	C2242472		Approved			CHEBI_3515	"2194"	HP:0002754		"111253001"
erythromycin ethyl succinate	DB00199	Infection of bone	C2242472		Approved			CHEBI_42355	"4053"	HP:0002754		"111253001"
atorvastatin	DB01076	Peripheral arterial stenosis	C4025272	NCT00491751	Terminated	Phase 1	Insufficient enrollment	CHEBI_39548	"83367"	HP:0004950		
ticagrelor	DB08816	Peripheral arterial stenosis	C4025272	NCT02230527	Terminated	Phase 2/Phase 3	Lack of enrollment	CHEBI_68558	"1116632"	HP:0004950		
	DB00758	Peripheral arterial stenosis	C4025272	NCT02230527	Terminated	Phase 2/Phase 3	Lack of enrollment	CHEBI_37941	"32968"	HP:0004950		
rivaroxaban	DB06228	Peripheral arterial stenosis	C4025272		Approved			CHEBI_68579	"1114195"	HP:0004950		
	DB14483	Peripheral arterial stenosis	C4025272	NCT00491751	Terminated	Phase 1	Insufficient enrollment		"1307765|142407"	HP:0004950		
	DB14482	Peripheral arterial stenosis	C4025272	NCT00491751	Terminated	Phase 1	Insufficient enrollment	CHEBI_113451	"267366"	HP:0004950		
	DB00126	Peripheral arterial stenosis	C4025272	NCT00491751	Terminated	Phase 1	Insufficient enrollment	CHEBI_29073	"1151|1370460"	HP:0004950		
	DB00945	Peripheral arterial stenosis	C4025272	NCT02433587	Withdrawn	Phase 3	Never recruited any patients.	CHEBI_15365	"91101|1191"	HP:0004950		
clopidogrel	DB00758	Peripheral arterial stenosis	C4025272	NCT02433587	Withdrawn	Phase 3	Never recruited any patients.	CHEBI_37941	"32968"	HP:0004950		
sulfogaiacol	DB15992	Coughing	C0010200		Approved			CHEBI_85537		HP:0012735	"10011224"	"263731006"
zipeprol	DB13564	Coughing	C0010200		Approved			CHEBI_135602		HP:0012735	"10011224"	"263731006"
bromazine	DB01237	Coughing	C0010200		Approved			CHEBI_59177	"19759"	HP:0012735	"10011224"	"263731006"
dextromethorphan	DB00514	Coughing	C0010200		Approved			CHEBI_4470	"3289"	HP:0012735	"10011224"	"263731006"
pyrithione	DB06815	Coughing	C0010200		Approved			CHEBI_36584	"35100"	HP:0012735	"10011224"	"263731006"
phenylpropanolamine	DB00397	Coughing	C0010200		Approved			CHEBI_80680	"8175"	HP:0012735	"10011224"	"263731006"
procaine benzylpenicillin	DB01053	Diphtheria	C0012546		Approved			CHEBI_18208	"7980"	MONDO_0005504	"10013023"	
procaine benzylpenicillin	DB09320	Diphtheria	C0012546		Approved			CHEBI_52154	"7983"	MONDO_0005504	"10013023"	
erythromycin	DB00199	Diphtheria	C0012546		Approved			CHEBI_42355	"4053"	MONDO_0005504	"10013023"	
benzylpenicillin	DB01053	Diphtheria	C0012546		Approved			CHEBI_18208	"7980"	MONDO_0005504	"10013023"	
stiripentol	DB09118	Myoclonic Epilepsy	C0014550		Approved			CHEBI_228488	"2054968"		"10054859"	
lorazepam	DB00186	Myoclonic Epilepsy	C0014550		Approved			CHEBI_6539	"6470"		"10054859"	
clonazepam	DB01068	Myoclonic Epilepsy	C0014550		Approved			CHEBI_3756	"2598"		"10054859"	
nitrazepam	DB01595	Myoclonic Epilepsy	C0014550		Approved			CHEBI_7581	"7440"		"10054859"	
ethadione	DB13799	Absence Epilepsy	C0014553		Approved			CHEBI_81296			"10034759"	"79631006"
minocycline	DB01017	Relapsing Fever	C0035021		Approved			CHEBI_50694	"6980"	MONDO_0019633	"10038300"	
demeclocycline	DB00618	Relapsing Fever	C0035021		Approved			CHEBI_4392	"3154"	MONDO_0019633	"10038300"	
amphotericin B	DB00681	Relapsing Fever	C0035021		Approved			CHEBI_2682	"236594|732"	MONDO_0019633	"10038300"	
oxytetracycline	DB00595	Relapsing Fever	C0035021		Approved			CHEBI_133011	"7821|1545999"	MONDO_0019633	"10038300"	
tetracycline	DB09550	Relapsing Fever	C0035021		Approved			CHEBI_27902	"2105975"	MONDO_0019633	"10038300"	
doxycycline	DB00254	Relapsing Fever	C0035021		Approved			CHEBI_50845	"1545992|3640"	MONDO_0019633	"10038300"	
fusidic acid	DB02703	Relapsing Fever	C0035021		Approved			CHEBI_29013	"4608|113608"	MONDO_0019633	"10038300"	
meclocycline	DB13092	Relapsing Fever	C0035021		Approved			CHEBI_135772	"29418"	MONDO_0019633	"10038300"	
tetracycline	DB00759	Relapsing Fever	C0035021		Approved			CHEBI_27902	"10395"	MONDO_0019633	"10038300"	
upadacitinib	DB15091	Ankylosing spondylitis	C0038013		Approved				"2196092"		"10002556"	"9631008"
ammonium lactate	DB06768	Dry skin	C0151908		Approved				"215247"	HP:0000958	"10013786"	
pramocaine	DB09345	Dry skin	C0151908		Approved			CHEBI_8357	"34347"	HP:0000958	"10013786"	
ampicillin	DB00415	Salmonella sepsis	C0152486		Approved			CHEBI_28971	"733|221058"		"10058878"	
ceftriaxone	DB01212	Salmonella sepsis	C0152486		Approved			CHEBI_29007	"2193"		"10058878"	
benzylpenicillin	DB01053	Anthrax sepsis	C0152946		Approved			CHEBI_18208	"7980"		"10058873"	
cefuroxime	DB01112	Streptococcal sepsis	C0152964		Approved			CHEBI_3515	"2194"		"10048960"	
cefonicid	DB01328	Streptococcal sepsis	C0152964		Approved			CHEBI_3491	"2183"		"10048960"	
ceftriaxone	DB01212	Streptococcal sepsis	C0152964		Approved			CHEBI_29007	"2193"		"10048960"	
clindamycin	DB01190	Streptococcal sepsis	C0152964		Approved			CHEBI_3745	"2582"		"10048960"	
clindamycin phosphate	DB01190	Streptococcal sepsis	C0152964		Approved			CHEBI_3745	"2582"		"10048960"	
cefotaxime	DB00493	Streptococcal sepsis	C0152964		Approved			CHEBI_204928	"2186"		"10048960"	
ampicillin	DB00415	Streptococcal sepsis	C0152964		Approved			CHEBI_28971	"733|221058"		"10048960"	
cefamandole	DB01326	Streptococcal sepsis	C0152964		Approved			CHEBI_3480	"2178"		"10048960"	
cefapirin	DB01139	Streptococcal sepsis	C0152964		Approved			CHEBI_554446	"2238"		"10048960"	
ceftazidime	DB00438	Streptococcal sepsis	C0152964		Approved			CHEBI_3508	"2191|1545984"		"10048960"	
cefoxitin	DB01331	Streptococcal sepsis	C0152964		Approved			CHEBI_209807	"2189"		"10048960"	
piperacillin	DB00319	Streptococcal sepsis	C0152964		Approved			CHEBI_8232	"1546000|8339"		"10048960"	
ceftizoxime	DB01332	Streptococcal sepsis	C0152964		Approved			CHEBI_553473	"2192"		"10048960"	
cefamandole	DB01326	Staphylococcal sepsis	C0152965		Approved			CHEBI_3480	"2178"		"10051017"	
cefapirin	DB01139	Staphylococcal sepsis	C0152965		Approved			CHEBI_554446	"2238"		"10051017"	
clindamycin phosphate	DB01190	Staphylococcal sepsis	C0152965		Approved			CHEBI_3745	"2582"		"10051017"	
cloxacillin	DB01147	Staphylococcal sepsis	C0152965		Approved			CHEBI_49566	"2625"		"10051017"	
vancomycin	DB00512	Staphylococcal sepsis	C0152965		Approved			CHEBI_28001	"11124"		"10051017"	
amikacin	DB00479	Staphylococcal sepsis	C0152965		Approved			CHEBI_2637	"641"		"10051017"	
clindamycin	DB01190	Staphylococcal sepsis	C0152965		Approved			CHEBI_3745	"2582"		"10051017"	
oxacillin	DB00713	Staphylococcal sepsis	C0152965		Approved			CHEBI_7809	"7773"		"10051017"	
ceftriaxone	DB01212	Staphylococcal sepsis	C0152965		Approved			CHEBI_29007	"2193"		"10051017"	
cefuroxime	DB01112	Staphylococcal sepsis	C0152965		Approved			CHEBI_3515	"2194"		"10051017"	
gentamicin	DB00798	Serratia sepsis	C0152973		Approved			CHEBI_17833	"1596450"		"10058879"	
aztreonam	DB00355	Serratia sepsis	C0152973		Approved			CHEBI_161680	"1272"		"10058879"	
ceftazidime	DB00438	Serratia sepsis	C0152973		Approved			CHEBI_3508	"2191|1545984"		"10058879"	
cefotaxime	DB00493	Serratia sepsis	C0152973		Approved			CHEBI_204928	"2186"		"10058879"	
piperacillin	DB00319	Serratia sepsis	C0152973		Approved			CHEBI_8232	"1546000|8339"		"10058879"	
amikacin	DB00479	Serratia sepsis	C0152973		Approved			CHEBI_2637	"641"		"10058879"	
ceftizoxime	DB01332	Serratia sepsis	C0152973		Approved			CHEBI_553473	"2192"		"10058879"	
fusidic acid	DB02703	Serratia sepsis	C0152973		Approved			CHEBI_29013	"4608|113608"		"10058879"	
lorazepam	DB00186	Atonic seizure	C0270846		Approved			CHEBI_6539	"6470"	HP:0010819	"10003628"	
clonazepam	DB01068	Atonic seizure	C0270846		Approved			CHEBI_3756	"2598"	HP:0010819	"10003628"	
	DB00147	Tardive Dyskinesia	C0686347	NCT00917293	Terminated	Phase 2	modified formulation under investigation	CHEBI_17310	"9002"	MONDO_0010096	"10043118"	
valbenazine	DB11915	Tardive Dyskinesia	C0686347		Approved				"1918219"	MONDO_0010096	"10043118"	
deutetrabenazine	DB12161	Tardive Dyskinesia	C0686347		Approved				"1876905"	MONDO_0010096	"10043118"	
propranolol	DB00571	Tardive Dyskinesia	C0686347	NCT03254186	Withdrawn	Phase 2/Phase 3	No participants	CHEBI_8499	"8787"	MONDO_0010096	"10043118"	
pyridoxine	DB00165	Tardive Dyskinesia	C0686347	NCT01908452	Withdrawn	Phase 3	Not funded	CHEBI_16709	"42954|684879"	MONDO_0010096	"10043118"	
pyridoxal phosphate	DB00114	Tardive Dyskinesia	C0686347	NCT00917293	Terminated	Phase 2	modified formulation under investigation	CHEBI_18405	"9004|1599827"	MONDO_0010096	"10043118"	
tafasitamab	DB15044	Diffuse large B-cell lymphoma refractory	C0855112		Approved				"2387211|2387334"		"10012822"	
bendamustine	DB06769	Diffuse large B-cell lymphoma refractory	C0855112	NCT02594163	Terminated	Phase 2	Sponsor decision based on portfolio prioritization	CHEBI_135515	"134547"		"10012822"	
polatuzumab vedotin	DB12240	Diffuse large B-cell lymphoma refractory	C0855112		Approved				"2174090|2174091"		"10012822"	
	DB00073	Diffuse large B-cell lymphoma refractory	C0855112	NCT02594163	Terminated	Phase 2	Sponsor decision based on portfolio prioritization		"2273510|2472325|121191|2105824"		"10012822"	
bendamustine	DB06769	Diffuse large B-cell lymphoma refractory	C0855112		Approved			CHEBI_135515	"134547"		"10012822"	
norfloxacin	DB01059	Bacterial infection due to Klebsiella pneumoniae	C0343402		Approved			CHEBI_100246	"7517"			"186435004"
dexamethasone phosphate	DB01234	Malignant neoplasm of breast	C0006142	NCT00215748	Terminated	Phase 2	slow accrual	CHEBI_68637	"3264"		"10006187"	"254837009"
trastuzumab	DB00072	Malignant neoplasm of breast	C0006142	NCT01363986	Terminated	Phase 2	Study was prematurely terminated due to difficulties experienced in recruiting patients in a reasonable timeframe.		"2289225|2103478|2174802|2280730|2107051|224905"		"10006187"	"254837009"
pheniramine	DB01620	Headache Disorders	C0393735		Approved			CHEBI_91591	"8132"			"230461009"
pheniramine	DB01620	Common Cold	C0009443		Approved			CHEBI_91591	"8132"	MONDO_0005709		"82272006"
docetaxel	DB01248	Malignant neoplasm of breast	C0006142	NCT00028483	Terminated	Phase 2		CHEBI_4672	"72962|1299922"		"10006187"	"254837009"
capecitabine	DB01101	Malignant neoplasm of breast	C0006142	NCT00347438	Terminated	Phase 2	a result of slow accrual	CHEBI_31348	"194000"		"10006187"	"254837009"
moxifloxacin	DB00218	Malignant neoplasm of breast	C0006142	NCT00324324	Terminated	Phase 3		CHEBI_63611	"139462"		"10006187"	"254837009"
phenylephrine	DB00388	Headache Disorders	C0393735		Approved			CHEBI_8093	"8163"			"230461009"
	DB00997	Malignant neoplasm of breast	C0006142	NCT00002696	Suspended	Phase 3		CHEBI_28748	"142433|3639"		"10006187"	"254837009"
	DB00531	Malignant neoplasm of breast	C0006142	NCT00002696	Suspended	Phase 3		CHEBI_4027	"1545988|3002"		"10006187"	"254837009"
	DB00544	Malignant neoplasm of breast	C0006142	NCT00002696	Suspended	Phase 3		CHEBI_46345	"4492"		"10006187"	"254837009"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02770014	Terminated	Phase 2	Terminated due to Osimertinib approval	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
erlotinib	DB00530	Non-Small Cell Lung Carcinoma	C0007131	NCT02468661	Terminated	Phase 1	Major challenge for enrollment of participants.	CHEBI_114785	"337525"	MONDO_0005233	"10061873"	"254637007"
docetaxel	DB01248	Non-Small Cell Lung Carcinoma	C0007131	NCT00738387	Terminated	Phase 3		CHEBI_4672	"72962|1299922"	MONDO_0005233	"10061873"	"254637007"
azathioprine	DB00993	Crohn Disease	C0010346	NCT00113503	Terminated	Phase 2	Insufficient enrollment	CHEBI_2948	"1256"	MONDO_0005011	"10011401"	"34000006"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131		Approved			CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT00998166	Terminated	Phase 2	Poor enrollment	CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
paclitaxel	DB01229	Non-Small Cell Lung Carcinoma	C0007131	NCT00662597	Terminated	Phase 3		CHEBI_45863	"56946"	MONDO_0005233	"10061873"	"254637007"
	DB00958	Non-Small Cell Lung Carcinoma	C0007131	NCT00662597	Terminated	Phase 3		CHEBI_31355	"40048"	MONDO_0005233	"10061873"	"254637007"
candicidin	DB01152	Candidiasis of vagina	C0006852		Approved			CHEBI_3349				"72934000"
colistin	DB00803	Escherichia coli Infections	C0014836		Approved			CHEBI_37943	"2709"	MONDO_0020920		"71057007"
ferric oxide	DB11576	Arthropod bite wound	C1444173		Approved			CHEBI_50819				"409985002"
nivolumab	DB09035	Non-Small Cell Lung Carcinoma	C0007131	NCT03048136	Withdrawn	Phase 3	Business objective has changed		"1597876"	MONDO_0005233	"10061873"	"254637007"
pemetrexed	DB00642	Non-Small Cell Lung Carcinoma	C0007131	NCT01774578	Terminated	Phase 2/Phase 3		CHEBI_63616	"68446"	MONDO_0005233	"10061873"	"254637007"
levomefolic acid	DB11256	Acne Vulgaris	C0001144		Approved			CHEBI_136009	"1592257|1025342"			"88616000"
ammonia	DB11118	Acne Vulgaris	C0001144		Approved			CHEBI_16134	"1299884"			"88616000"
caffeine	DB00201	Headache Disorders	C0393735		Approved			CHEBI_27732	"1886"			"230461009"
caffeine	DB00201	Common Cold	C0009443		Approved			CHEBI_27732	"1886"	MONDO_0005709		"82272006"
cefpodoxime proxetil	DB01416	Staphylococcus aureus infection	C1318973		Approved			CHEBI_3504	"20489"			"406602003"
clofedanol	DB04837	Common Cold	C0009443		Approved			CHEBI_135207	"21254"	MONDO_0005709		"82272006"
	DB00682	Ulcerative Colitis	C0009324	NCT03358706	Suspended	Phase 1	unavailability of probe substrate	CHEBI_87732	"11289"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB00065	Ulcerative Colitis	C0009324	NCT00537316	Terminated	Phase 3	Infusion reactions during re-induction cycles after a period of no treatment in another study [P04563, NCT0358670]		"1790539|1927283|191831|2266523|2103476"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
vedolizumab	DB09033	Ulcerative Colitis	C0009324		Approved				"1538097"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB00201	Ulcerative Colitis	C0009324	NCT03358706	Suspended	Phase 1	unavailability of probe substrate	CHEBI_27732	"1886"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
esomeprazole	DB00683	Ulcerative Colitis	C0009324	NCT03358706	Suspended	Phase 1	unavailability of probe substrate	CHEBI_6931	"6960"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
golimumab	DB06674	Ulcerative Colitis	C0009324		Approved				"819300"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB15759	Ulcerative Colitis	C0009324	NCT03986996	Terminated	Phase 2	There is no feasibility to conduct the study	CHEBI_50688		MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
infliximab	DB00065	Ulcerative Colitis	C0009324		Approved				"1790539|1927283|191831|2266523|2103476"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
naltrexone	DB00704	Ulcerative Colitis	C0009324	NCT01810185	Withdrawn	Phase 2	Low patient enrollment	CHEBI_7465	"7243"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB05679	Ulcerative Colitis	C0009324	NCT03358706	Suspended	Phase 1	unavailability of probe substrate		"847083"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
mesalazine	DB00244	Ulcerative Colitis	C0009324	NCT00254618	Terminated	Phase 1	Slow enrollment.	CHEBI_6775	"52582"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
mesalazine	DB00244	Ulcerative Colitis	C0009324		Approved			CHEBI_6775	"52582"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
sulfasalazine	DB00795	Ulcerative Colitis	C0009324		Approved			CHEBI_9334	"9524"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
tofacitinib	DB08895	Ulcerative Colitis	C0009324		Approved			CHEBI_71200	"1357536"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB01060	Ulcerative Colitis	C0009324	NCT03986996	Terminated	Phase 2	There is no feasibility to conduct the study	CHEBI_2676	"1297882|723"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB01222	Ulcerative Colitis	C0009324	NCT00805285	Terminated	Phase 2	Study terminated due to insufficient enrollment	CHEBI_3207	"19831"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
prednisolone	DB00860	Ulcerative Colitis	C0009324		Approved			CHEBI_8378	"8638"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
hydrocortamate	DB00741	Ulcerative Colitis	C0009324	NCT00805285	Terminated	Phase 2	Study terminated due to insufficient enrollment	CHEBI_17650	"5492"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
miconazole	DB01110	Ulcerative Colitis	C0009324	NCT00061282	Terminated	Phase 1/Phase 2	Funding Horizon	CHEBI_82892	"6932"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
ustekinumab	DB05679	Ulcerative Colitis	C0009324		Approved				"847083"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
nivolumab	DB09035	Ulcerative Colitis	C0009324	NCT03656627	Terminated	Phase 1	low accrual		"1597876"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB00514	Ulcerative Colitis	C0009324	NCT03358706	Suspended	Phase 1	unavailability of probe substrate	CHEBI_4470	"3289"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
cortisone acetate	DB01380	Ulcerative Colitis	C0009324		Approved			CHEBI_3897	"21655"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
balsalazide	DB01014	Ulcerative Colitis	C0009324		Approved			CHEBI_267413	"18747"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
balsalazide	DB00244	Ulcerative Colitis	C0009324		Approved			CHEBI_6775	"52582"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
sulfasalazine	DB00244	Ulcerative Colitis	C0009324		Approved			CHEBI_6775	"52582"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
	DB00254	Ulcerative Colitis	C0009324	NCT03986996	Terminated	Phase 2	There is no feasibility to conduct the study	CHEBI_50845	"1545992|3640"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
mesalazine	DB00244	Ulcerative Colitis	C0009324	NCT01004185	Terminated	Phase 3	Pediatric enrollment very slow.	CHEBI_6775	"52582"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
loperamide	DB00836	Ulcerative Colitis	C0009324	NCT02266849	Terminated	Phase 3	Insuficcient recruiting	CHEBI_6532	"6468"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
certolizumab pegol	DB08904	Crohn Disease	C0010346	NCT00899678	Terminated	Phase 2	higher than projected discontinuation rate during Maintenance Phase		"709271"	MONDO_0005011	"10011401"	"34000006"
colecalciferol	DB00169	Ulcerative Colitis	C0009324	NCT01846026	Withdrawn	Phase 1/Phase 2	At the planned study start new treatment guidelines for this disease with new drugs were implemented in clinical practice.	CHEBI_28940	"2418"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
melatonin	DB01065	Ulcerative Colitis	C0009324	NCT00790478	Terminated	Phase 2		CHEBI_16796	"6711"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
sulfadiazine	DB00359	Ulcerative Colitis	C0009324		Approved			CHEBI_9328	"10171"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
adalimumab	DB00051	Ulcerative Colitis	C0009324		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
adalimumab	DB00051	Ulcerative Colitis	C0009324	NCT01716039	Terminated	Phase 2	Unable to achieve recruitment target.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
metronidazole	DB00916	Ulcerative Colitis	C0009324	NCT03986996	Terminated	Phase 2	There is no feasibility to conduct the study	CHEBI_6909	"6922"	MONDO_0005101|MONDO_0009960	"10009900"	"64766004"
ketotifen	DB00920	Allergic Conjunctivitis	C0009766		Approved			CHEBI_92511	"6146"	MONDO_0005642	"10010744"	"231854006"
diphenhydramine	DB01075	Allergic Conjunctivitis	C0009766		Approved			CHEBI_4636	"3498"	MONDO_0005642	"10010744"	"231854006"
diphenylpyraline	DB01146	Allergic Conjunctivitis	C0009766		Approved			CHEBI_59788	"23386"	MONDO_0005642	"10010744"	"231854006"
triprolidine	DB00427	Allergic Conjunctivitis	C0009766		Approved			CHEBI_84116	"10849"	MONDO_0005642	"10010744"	"231854006"
tripelennamine	DB00792	Allergic Conjunctivitis	C0009766		Approved			CHEBI_9741	"10847"	MONDO_0005642	"10010744"	"231854006"
dexamethasone	DB01234	Allergic Conjunctivitis	C0009766		Approved			CHEBI_41879	"3264"	MONDO_0005642	"10010744"	"231854006"
olopatadine	DB00768	Allergic Conjunctivitis	C0009766	NCT01657240	Withdrawn	Phase 3	Formula Reformulation	CHEBI_7769	"135391"	MONDO_0005642	"10010744"	"231854006"
tramazoline	DB13064	Allergic Conjunctivitis	C0009766		Approved			CHEBI_134893	"38453"	MONDO_0005642	"10010744"	"231854006"
loteprednol etabonate	DB00873	Allergic Conjunctivitis	C0009766		Approved			CHEBI_50848	"237027"	MONDO_0005642	"10010744"	"231854006"
fluorometholone	DB00324	Allergic Conjunctivitis	C0009766		Approved			CHEBI_31625	"4491"	MONDO_0005642	"10010744"	"231854006"
epinastine	DB00751	Allergic Conjunctivitis	C0009766		Approved			CHEBI_51032	"39684"	MONDO_0005642	"10010744"	"231854006"
azatadine	DB00719	Allergic Conjunctivitis	C0009766		Approved			CHEBI_2946	"18600"	MONDO_0005642	"10010744"	"231854006"
alimemazine	DB01246	Allergic Conjunctivitis	C0009766		Approved			CHEBI_9725	"10825"	MONDO_0005642	"10010744"	"231854006"
methapyrilene	DB04819	Allergic Conjunctivitis	C0009766		Approved			CHEBI_6820	"6822"	MONDO_0005642	"10010744"	"231854006"
mepyramine	DB06691	Allergic Conjunctivitis	C0009766		Approved			CHEBI_6762	"9009"	MONDO_0005642	"10010744"	"231854006"
trometamol	DB03754	Allergic Conjunctivitis	C0009766		Approved			CHEBI_9754	"10865"	MONDO_0005642	"10010744"	"231854006"
alcaftadine	DB06766	Allergic Conjunctivitis	C0009766		Approved			CHEBI_71023	"1000082"	MONDO_0005642	"10010744"	"231854006"
phenyltoloxamine	DB11160	Allergic Conjunctivitis	C0009766		Approved			CHEBI_135047	"33408"	MONDO_0005642	"10010744"	"231854006"
dexchlorpheniramine	DB09555	Allergic Conjunctivitis	C0009766		Approved			CHEBI_4465	"54828"	MONDO_0005642	"10010744"	"231854006"
tobramycin	DB00684	Allergic Conjunctivitis	C0009766		Approved			CHEBI_28864	"10627"	MONDO_0005642	"10010744"	"231854006"
methdilazine	DB00902	Allergic Conjunctivitis	C0009766		Approved			CHEBI_6823	"29648"	MONDO_0005642	"10010744"	"231854006"
olopatadine	DB00768	Allergic Conjunctivitis	C0009766		Approved			CHEBI_7769	"135391"	MONDO_0005642	"10010744"	"231854006"
emedastine	DB01084	Allergic Conjunctivitis	C0009766		Approved			CHEBI_4779	"28144"	MONDO_0005642	"10010744"	"231854006"
quifenadine	DB13713	Allergic Conjunctivitis	C0009766		Approved			CHEBI_134746		MONDO_0005642	"10010744"	"231854006"
fusidic acid	DB02703	Allergic Conjunctivitis	C0009766		Approved			CHEBI_29013	"4608|113608"	MONDO_0005642	"10010744"	"231854006"
dexchlorpheniramine	DB13679	Allergic Conjunctivitis	C0009766		Approved			CHEBI_4464	"22697"	MONDO_0005642	"10010744"	"231854006"
cyclizine	DB01176	Allergic Conjunctivitis	C0009766		Approved			CHEBI_3994	"2977"	MONDO_0005642	"10010744"	"231854006"
medrysone	DB00253	Allergic Conjunctivitis	C0009766		Approved			CHEBI_34829	"29439"	MONDO_0005642	"10010744"	"231854006"
nedocromil	DB00716	Allergic Conjunctivitis	C0009766		Approved			CHEBI_7492	"31563"	MONDO_0005642	"10010744"	"231854006"
cyproheptadine	DB00434	Allergic Conjunctivitis	C0009766		Approved			CHEBI_4046	"3013"	MONDO_0005642	"10010744"	"231854006"
desloratadine	DB00967	Allergic Conjunctivitis	C0009766		Approved			CHEBI_291342	"275635"	MONDO_0005642	"10010744"	"231854006"
hydroxyzine	DB00557	Allergic Conjunctivitis	C0009766		Approved			CHEBI_5818	"5553"	MONDO_0005642	"10010744"	"231854006"
phenylephrine	DB00388	Allergic Conjunctivitis	C0009766		Approved			CHEBI_8093	"8163"	MONDO_0005642	"10010744"	"231854006"
terfenadine	DB00342	Allergic Conjunctivitis	C0009766		Approved			CHEBI_9453	"42330"	MONDO_0005642	"10010744"	"231854006"
cromoglicic acid	DB01003	Allergic Conjunctivitis	C0009766		Approved			CHEBI_59773	"2921|42612"	MONDO_0005642	"10010744"	"231854006"
ketotifen	DB00920	Allergic Conjunctivitis	C0009766	NCT00375596	Withdrawn	Phase 2	Study withdrawn without starting or enrolling subjects due to a business decision to not proceed with the project.	CHEBI_92511	"6146"	MONDO_0005642	"10010744"	"231854006"
promazine	DB00420	Allergic Conjunctivitis	C0009766		Approved			CHEBI_8459	"8742"	MONDO_0005642	"10010744"	"231854006"
ketorolac	DB00465	Allergic Conjunctivitis	C0009766		Approved			CHEBI_76223	"35827"	MONDO_0005642	"10010744"	"231854006"
pheniramine	DB01620	Allergic Conjunctivitis	C0009766		Approved			CHEBI_91591	"8132"	MONDO_0005642	"10010744"	"231854006"
	DB00193	Chronic pain	C0150055	NCT02722603	Terminated	Phase 3	The study was early terminated due to insufficient recruitment	CHEBI_75722	"10689"	HP:0012532		"82423001"
oxymorphone	DB01192	Chronic pain	C0150055		Approved			CHEBI_7865	"7814"	HP:0012532		"82423001"
morphine	DB00295	Chronic pain	C0150055	NCT00943566	Withdrawn	Phase 2	funding for project discontinued	CHEBI_17303	"7052|32926"	HP:0012532		"82423001"
	DB00708	Chronic pain	C0150055	NCT00943566	Withdrawn	Phase 2	funding for project discontinued	CHEBI_9316	"56795"	HP:0012532		"82423001"
fentanyl	DB00813	Chronic pain	C0150055	NCT00387010	Terminated	Phase 3	The sponsor felt enough information was available for the exploratory assessment of the effect of treatment with FBT on pain anxiety	CHEBI_119915	"4337"	HP:0012532		"82423001"
morphine	DB00295	Chronic pain	C0150055	NCT01964378	Terminated	Phase 3	low accrual made the study no longer feasible/decision not related to safety and efficacy	CHEBI_17303	"7052|32926"	HP:0012532		"82423001"
	DB00295	Chronic pain	C0150055	NCT03275012	Withdrawn	Phase 2	Study not started	CHEBI_17303	"7052|32926"	HP:0012532		"82423001"
tapentadol	DB06204	Chronic pain	C0150055	NCT01264887	Terminated	Phase 3	Administrative reasons	CHEBI_135935	"787390"	HP:0012532		"82423001"
ketamine	DB01221	Chronic pain	C0150055	NCT02940509	Terminated	Phase 1	Change in practice of medicine. There were no longer sufficient patients to enroll in the study that met criteria.	CHEBI_6121	"6130"	HP:0012532		"82423001"
	DB00653	Chronic pain	C0150055	NCT02940509	Terminated	Phase 1	Change in practice of medicine. There were no longer sufficient patients to enroll in the study that met criteria.	CHEBI_32599	"6585|1311625"	HP:0012532		"82423001"
pregabalin	DB00230	Chronic pain	C0150055	NCT00998816	Withdrawn	Phase 3	No funding	CHEBI_64356	"187832"	HP:0012532		"82423001"
ketamine	DB01221	Chronic pain	C0150055	NCT01755169	Terminated	Phase 2	Inability to enroll sufficient patients	CHEBI_6121	"6130"	HP:0012532		"82423001"
tramadol	DB00193	Chronic pain	C0150055		Approved			CHEBI_75722	"10689"	HP:0012532		"82423001"
bupivacaine	DB00297	Chronic pain	C0150055	NCT01584947	Terminated	Phase 2	Because of a very slow patient recruitment.	CHEBI_77431	"1815"	HP:0012532		"82423001"
lidocaine	DB00281	Chronic pain	C0150055	NCT01155986	Terminated	Phase 2	Trial was stopped due to difficult enrolment	CHEBI_6456	"6387"	HP:0012532		"82423001"
oxymorphone	DB01192	Chronic pain	C0150055	NCT01206907	Withdrawn	Phase 3	The study is no longer required for the PREA for this product.	CHEBI_7865	"7814"	HP:0012532		"82423001"
naltrexone	DB00704	Chronic pain	C0150055		Approved			CHEBI_7465	"7243"	HP:0012532		"82423001"
	DB00819	Chronic pain	C0150055	NCT02276989	Withdrawn	Phase 2	poor recruitment	CHEBI_27690	"167"	HP:0012532		"82423001"
	DB00468	Chronic pain	C0150055	NCT02276989	Withdrawn	Phase 2	poor recruitment	CHEBI_15854	"9071"	HP:0012532		"82423001"
oxymorphone	DB01192	Chronic pain	C0150055	NCT04681027	Suspended	Phase 3	Study Suspended 06Feb2020 per FDA Request	CHEBI_7865	"7814"	HP:0012532		"82423001"
riboflavin	DB00140	Chronic pain	C0150055	NCT02276989	Withdrawn	Phase 2	poor recruitment	CHEBI_17015	"9346"	HP:0012532		"82423001"
ziconotide	DB06283	Chronic pain	C0150055		Approved			CHEBI_142406	"68503"	HP:0012532		"82423001"
diflunisal	DB00861	Chronic pain	C0150055		Approved			CHEBI_39669	"3393"	HP:0012532		"82423001"
gabapentin	DB00996	Chronic pain	C0150055	NCT03275012	Withdrawn	Phase 2	Study not started	CHEBI_42797	"25480"	HP:0012532		"82423001"
tapentadol	DB06204	Chronic pain	C0150055	NCT00982280	Terminated	Phase 3	Slow Recruitment and supply of Investigational Medicinal Product Issues	CHEBI_135935	"787390"	HP:0012532		"82423001"
rimegepant	DB12457	Migraine Disorders	C0149931		Approved				"2282307"	HP:0002076	"10027599"	"37796009"
cefoxitin	DB01331	Infection of bone	C2242472		Approved			CHEBI_209807	"2189"	HP:0002754		"111253001"
fusidic acid	DB02703	Infection of bone	C2242472		Approved			CHEBI_29013	"4608|113608"	HP:0002754		"111253001"
imipenem	DB01598	Infection of bone	C2242472		Approved			CHEBI_471744	"5690|1545986"	HP:0002754		"111253001"
methscopolamine	DB00462	Coughing	C0010200		Approved			CHEBI_61276	"56092"	HP:0012735	"10011224"	"263731006"
scopolamine	DB00747	Coughing	C0010200		Approved			CHEBI_16794	"9601|9603"	HP:0012735	"10011224"	"263731006"
hydromorphone	DB00327	Coughing	C0010200		Approved			CHEBI_5790	"3423"	HP:0012735	"10011224"	"263731006"
ephedrine	DB01364	Coughing	C0010200	NCT01177852	Withdrawn	Phase 3		CHEBI_15407	"3966"	HP:0012735	"10011224"	"263731006"
benzocaine	DB01086	Coughing	C0010200		Approved			CHEBI_116735	"1399"	HP:0012735	"10011224"	"263731006"
	DB01069	Coughing	C0010200	NCT01177852	Withdrawn	Phase 3		CHEBI_8461	"8745"	HP:0012735	"10011224"	"263731006"
glycine	DB00145	Coughing	C0010200		Approved			CHEBI_15428	"4919"	HP:0012735	"10011224"	"263731006"
potassium iodide	DB06715	Coughing	C0010200		Approved			CHEBI_8346	"8597"	HP:0012735	"10011224"	"263731006"
ammonium chloride	DB06767	Coughing	C0010200		Approved			CHEBI_31206	"712"	HP:0012735	"10011224"	"263731006"
	DB01075	Coughing	C0010200	NCT01177852	Withdrawn	Phase 3		CHEBI_4636	"3498"	HP:0012735	"10011224"	"263731006"
homatropine	DB11181	Coughing	C0010200		Approved			CHEBI_5747	"27084"	HP:0012735	"10011224"	"263731006"
esomeprazole	DB00338	Coughing	C0010200	NCT00668317	Terminated	Phase 3	Primary care physicians began prescribing antacid therapy for chronic cough	CHEBI_77260	"7646"	HP:0012735	"10011224"	"263731006"
liothyronine	DB00279	Congenital Hypothyroidism	C0010308		Approved			CHEBI_533015	"10814"	MONDO_0018612	"10010510"	"190268003"
levothyroxine	DB00451	Congenital Hypothyroidism	C0010308		Approved			CHEBI_58448	"10582"	MONDO_0018612	"10010510"	"190268003"
cortisone acetate	DB01380	Crohn Disease	C0010346		Approved			CHEBI_3897	"21655"	MONDO_0005011	"10011401"	"34000006"
ustekinumab	DB05679	Crohn Disease	C0010346		Approved				"847083"	MONDO_0005011	"10011401"	"34000006"
adalimumab	DB00051	Crohn Disease	C0010346	NCT01674413	Withdrawn	Phase 3	Unable to recruit; all patients interested simply wanted to stop medication		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005011	"10011401"	"34000006"
metronidazole	DB00916	Crohn Disease	C0010346	NCT00257699	Terminated	Phase 2	Inadequate recruitment to meet completion date	CHEBI_6909	"6922"	MONDO_0005011	"10011401"	"34000006"
	DB15759	Crohn Disease	C0010346	NCT00257699	Terminated	Phase 2	Inadequate recruitment to meet completion date	CHEBI_50688		MONDO_0005011	"10011401"	"34000006"
	DB00537	Crohn Disease	C0010346	NCT00257699	Terminated	Phase 2	Inadequate recruitment to meet completion date	CHEBI_192484	"2551"	MONDO_0005011	"10011401"	"34000006"
certolizumab pegol	DB08904	Crohn Disease	C0010346		Approved				"709271"	MONDO_0005011	"10011401"	"34000006"
natalizumab	DB00108	Crohn Disease	C0010346		Approved				"354770"	MONDO_0005011	"10011401"	"34000006"
hydrocortisone acetate	DB14539	Crohn Disease	C0010346		Approved			CHEBI_17609	"27197"	MONDO_0005011	"10011401"	"34000006"
adalimumab	DB00051	Crohn Disease	C0010346	NCT04643483	Withdrawn	Phase 3	Sponsor decision		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005011	"10011401"	"34000006"
rifaximin	DB01220	Crohn Disease	C0010346	NCT04154735	Withdrawn	Phase 2	Discontinued by Investigator	CHEBI_75246	"35619"	MONDO_0005011	"10011401"	"34000006"
hydrocortisone	DB00741	Crohn Disease	C0010346		Approved			CHEBI_17650	"5492"	MONDO_0005011	"10011401"	"34000006"
adalimumab	DB00051	Crohn Disease	C0010346		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005011	"10011401"	"34000006"
adalimumab	DB00051	Crohn Disease	C0010346	NCT01562951	Terminated	Phase 3	Not enough patient population according to selection criteria to complete the study		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005011	"10011401"	"34000006"
azathioprine	DB00993	Crohn Disease	C0010346		Approved			CHEBI_2948	"1256"	MONDO_0005011	"10011401"	"34000006"
Vitamin E	DB00163	Crohn Disease	C0010346	NCT00152841	Terminated	Phase 2	Lack of patients	CHEBI_18145	"11256|237099"	MONDO_0005011	"10011401"	"34000006"
	DB01220	Crohn Disease	C0010346	NCT02272868	Terminated	Phase 1/Phase 2		CHEBI_75246	"35619"	MONDO_0005011	"10011401"	"34000006"
colecalciferol	DB00169	Crohn Disease	C0010346	NCT01046773	Terminated	Phase 1	Low enrollment	CHEBI_28940	"2418"	MONDO_0005011	"10011401"	"34000006"
budesonide	DB01222	Crohn Disease	C0010346		Approved			CHEBI_3207	"19831"	MONDO_0005011	"10011401"	"34000006"
triamcinolone	DB00620	Crohn Disease	C0010346		Approved			CHEBI_9667	"10759"	MONDO_0005011	"10011401"	"34000006"
	DB00140	Crohn Disease	C0010346	NCT02769494	Withdrawn	Phase 3	Lack of funds	CHEBI_17015	"9346"	MONDO_0005011	"10011401"	"34000006"
	DB03247	Crohn Disease	C0010346	NCT02769494	Withdrawn	Phase 3	Lack of funds	CHEBI_17621	"1925821"	MONDO_0005011	"10011401"	"34000006"
mesalazine	DB00244	Crohn Disease	C0010346	NCT00245505	Terminated	Phase 3	Study terminated due to lack of eligible patients	CHEBI_6775	"52582"	MONDO_0005011	"10011401"	"34000006"
mesalazine	DB00244	Crohn Disease	C0010346	NCT02769494	Withdrawn	Phase 3	Lack of funds	CHEBI_6775	"52582"	MONDO_0005011	"10011401"	"34000006"
abatacept	DB01281	Crohn Disease	C0010346	NCT00406653	Terminated	Phase 3	Sponsor Decision		"614391"	MONDO_0005011	"10011401"	"34000006"
naltrexone	DB00704	Crohn Disease	C0010346	NCT01810185	Withdrawn	Phase 2	Low patient enrollment	CHEBI_7465	"7243"	MONDO_0005011	"10011401"	"34000006"
	DB00531	Crohn Disease	C0010346	NCT04154735	Withdrawn	Phase 2	Discontinued by Investigator	CHEBI_4027	"1545988|3002"	MONDO_0005011	"10011401"	"34000006"
rifaximin	DB01220	Crohn Disease	C0010346	NCT02240121	Terminated	Phase 3	The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.	CHEBI_75246	"35619"	MONDO_0005011	"10011401"	"34000006"
aminosalicylic acid	DB00233	Crohn Disease	C0010346	NCT00495521	Terminated	Phase 2	Efforts at recruitment have halted as recruitment was poor	CHEBI_27565	"7833"	MONDO_0005011	"10011401"	"34000006"
dexamethasone phosphate	DB01234	Crohn Disease	C0010346	NCT01277289	Terminated	Phase 3	due to the big difficulty to enrol suitable patients	CHEBI_68637	"3264"	MONDO_0005011	"10011401"	"34000006"
infliximab	DB00065	Crohn Disease	C0010346	NCT01190839	Terminated	Phase 3	Study is terminated as per Sponsor's Decision.		"1790539|1927283|191831|2266523|2103476"	MONDO_0005011	"10011401"	"34000006"
interferon beta-1a	DB00060	Crohn Disease	C0010346	NCT00304252	Terminated	Phase 2	Lack of Efficacy		"75917"	MONDO_0005011	"10011401"	"34000006"
dexamethasone	DB01234	Crohn Disease	C0010346		Approved			CHEBI_41879	"3264"	MONDO_0005011	"10011401"	"34000006"
certolizumab pegol	DB08904	Crohn Disease	C0010346	NCT00358683	Withdrawn	Phase 3			"709271"	MONDO_0005011	"10011401"	"34000006"
hydrocortisone acetate	DB00741	Crohn Disease	C0010346		Approved			CHEBI_17650	"5492"	MONDO_0005011	"10011401"	"34000006"
aminosalicylic acid	DB00233	Crohn Disease	C0010346	NCT00417690	Terminated	Phase 2	Efforts at recruitment have halted as recruitment was poor.	CHEBI_27565	"7833"	MONDO_0005011	"10011401"	"34000006"
betamethasone acetate	DB00443	Crohn Disease	C0010346		Approved			CHEBI_3077	"1514"	MONDO_0005011	"10011401"	"34000006"
vedolizumab	DB09033	Crohn Disease	C0010346		Approved				"1538097"	MONDO_0005011	"10011401"	"34000006"
triamcinolone acetonide	DB00620	Crohn Disease	C0010346		Approved			CHEBI_9667	"10759"	MONDO_0005011	"10011401"	"34000006"
rifaximin	DB01220	Crohn Disease	C0010346	NCT02240108	Terminated	Phase 3	The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.	CHEBI_75246	"35619"	MONDO_0005011	"10011401"	"34000006"
	DB00087	Crohn Disease	C0010346	NCT04154735	Withdrawn	Phase 2	Discontinued by Investigator		"117055"	MONDO_0005011	"10011401"	"34000006"
cyclophosphamide	DB00531	Crohn Disease	C0010346	NCT02676622	Withdrawn	Phase 2	PI moved to a different institution.	CHEBI_4027	"1545988|3002"	MONDO_0005011	"10011401"	"34000006"
muromonab-CD3	DB00075	Crohn Disease	C0010346	NCT05028946	Withdrawn	Phase 1	For business reasons		"42405"	MONDO_0005011	"10011401"	"34000006"
cyclophosphamide	DB00531	Crohn Disease	C0010346	NCT01836289	Withdrawn	Phase 1/Phase 2	Too difficult to recruit given new Crohn's medications approved	CHEBI_4027	"1545988|3002"	MONDO_0005011	"10011401"	"34000006"
hydrocortisone succinate	DB14545	Crohn Disease	C0010346		Approved			CHEBI_31677	"21651"	MONDO_0005011	"10011401"	"34000006"
desonide	DB01260	Crohn Disease	C0010346		Approved			CHEBI_204734	"3254"	MONDO_0005011	"10011401"	"34000006"
prednisone	DB00635	Crohn Disease	C0010346		Approved			CHEBI_8382	"8640"	MONDO_0005011	"10011401"	"34000006"
	DB08904	Crohn Disease	C0010346	NCT04643483	Withdrawn	Phase 3	Sponsor decision		"709271"	MONDO_0005011	"10011401"	"34000006"
azathioprine	DB00993	Crohn Disease	C0010346	NCT00098111	Terminated	Phase 3	Lack of recruitment	CHEBI_2948	"1256"	MONDO_0005011	"10011401"	"34000006"
	DB00065	Crohn Disease	C0010346	NCT00796250	Terminated	Phase 3	Due to poor patient recruitment, a decision was made to terminate this trial.		"1790539|1927283|191831|2266523|2103476"	MONDO_0005011	"10011401"	"34000006"
triamcinolone diacetate	DB00620	Crohn Disease	C0010346		Approved			CHEBI_9667	"10759"	MONDO_0005011	"10011401"	"34000006"
	DB00993	Crohn Disease	C0010346	NCT00796250	Terminated	Phase 3	Due to poor patient recruitment, a decision was made to terminate this trial.	CHEBI_2948	"1256"	MONDO_0005011	"10011401"	"34000006"
	DB00860	Crohn Disease	C0010346	NCT00796250	Terminated	Phase 3	Due to poor patient recruitment, a decision was made to terminate this trial.	CHEBI_8378	"8638"	MONDO_0005011	"10011401"	"34000006"
	DB14644	Crohn Disease	C0010346	NCT00796250	Terminated	Phase 3	Due to poor patient recruitment, a decision was made to terminate this trial.	CHEBI_135765		MONDO_0005011	"10011401"	"34000006"
methylprednisolone	DB00959	Crohn Disease	C0010346	NCT00796250	Terminated	Phase 3	Due to poor patient recruitment, a decision was made to terminate this trial.	CHEBI_6888	"6902"	MONDO_0005011	"10011401"	"34000006"
adalimumab	DB00051	Crohn Disease	C0010346	NCT01986127	Terminated	Phase 3	slow recruitment		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005011	"10011401"	"34000006"
hydrocortisone succinate	DB00741	Crohn Disease	C0010346		Approved			CHEBI_17650	"5492"	MONDO_0005011	"10011401"	"34000006"
cortisone acetate	DB01380	Exfoliative dermatitis	C0011606		Approved			CHEBI_3897	"21655"	MONDO_0043233	"10012455"	"399992009"
betamethasone	DB00443	Exfoliative dermatitis	C0011606		Approved			CHEBI_3077	"1514"	MONDO_0043233	"10012455"	"399992009"
methylprednisolone	DB00959	Exfoliative dermatitis	C0011606		Approved			CHEBI_6888	"6902"	MONDO_0043233	"10012455"	"399992009"
prednisone	DB00635	Exfoliative dermatitis	C0011606		Approved			CHEBI_8382	"8640"	MONDO_0043233	"10012455"	"399992009"
triamcinolone acetonide	DB00620	Exfoliative dermatitis	C0011606		Approved			CHEBI_9667	"10759"	MONDO_0043233	"10012455"	"399992009"
betamethasone acetate	DB00443	Exfoliative dermatitis	C0011606		Approved			CHEBI_3077	"1514"	MONDO_0043233	"10012455"	"399992009"
triamcinolone	DB00620	Exfoliative dermatitis	C0011606		Approved			CHEBI_9667	"10759"	MONDO_0043233	"10012455"	"399992009"
hydrocortisone	DB00741	Exfoliative dermatitis	C0011606		Approved			CHEBI_17650	"5492"	MONDO_0043233	"10012455"	"399992009"
hydrocortisone acetate	DB00741	Exfoliative dermatitis	C0011606		Approved			CHEBI_17650	"5492"	MONDO_0043233	"10012455"	"399992009"
dexamethasone	DB01234	Exfoliative dermatitis	C0011606		Approved			CHEBI_41879	"3264"	MONDO_0043233	"10012455"	"399992009"
hydrocortisone acetate	DB14539	Exfoliative dermatitis	C0011606		Approved			CHEBI_17609	"27197"	MONDO_0043233	"10012455"	"399992009"
hydrocortisone succinate	DB00741	Exfoliative dermatitis	C0011606		Approved			CHEBI_17650	"5492"	MONDO_0043233	"10012455"	"399992009"
prednisolone	DB00860	Exfoliative dermatitis	C0011606		Approved			CHEBI_8378	"8638"	MONDO_0043233	"10012455"	"399992009"
hydrocortisone succinate	DB14545	Exfoliative dermatitis	C0011606		Approved			CHEBI_31677	"21651"	MONDO_0043233	"10012455"	"399992009"
triamcinolone diacetate	DB00620	Exfoliative dermatitis	C0011606		Approved			CHEBI_9667	"10759"	MONDO_0043233	"10012455"	"399992009"
prednisolone	DB00860	Dermatitis, Atopic	C0011615		Approved			CHEBI_8378	"8638"	HP:0001047	"10012438"	"200775004"
pimecrolimus	DB00337	Dermatitis, Atopic	C0011615		Approved			CHEBI_135888	"321952"	HP:0001047	"10012438"	"200775004"
hydrocortisone acetate	DB00741	Dermatitis, Atopic	C0011615		Approved			CHEBI_17650	"5492"	HP:0001047	"10012438"	"200775004"
	DB01069	Dermatitis, Atopic	C0011615	NCT03688464	Withdrawn	Early Phase 1	Study never started	CHEBI_8461	"8745"	HP:0001047	"10012438"	"200775004"
desoximetasone	DB00547	Dermatitis, Atopic	C0011615		Approved			CHEBI_691037	"3255"	HP:0001047	"10012438"	"200775004"
naltrexone	DB00704	Dermatitis, Atopic	C0011615	NCT04154033	Withdrawn	Phase 2	Funding	CHEBI_7465	"7243"	HP:0001047	"10012438"	"200775004"
methylprednisolone acetate	DB00959	Dermatitis, Atopic	C0011615		Approved			CHEBI_6888	"6902"	HP:0001047	"10012438"	"200775004"
fluocinolone acetonide	DB12553	Dermatitis, Atopic	C0011615		Approved			CHEBI_5108	"25126"	HP:0001047	"10012438"	"200775004"
melatonin	DB01065	Dermatitis, Atopic	C0011615	NCT03688464	Withdrawn	Early Phase 1	Study never started	CHEBI_16796	"6711"	HP:0001047	"10012438"	"200775004"
amcinonide	DB00288	Dermatitis, Atopic	C0011615		Approved			CHEBI_31199	"17652"	HP:0001047	"10012438"	"200775004"
triamcinolone diacetate	DB00620	Dermatitis, Atopic	C0011615		Approved			CHEBI_9667	"10759"	HP:0001047	"10012438"	"200775004"
methylprednisolone	DB00959	Dermatitis, Atopic	C0011615		Approved			CHEBI_6888	"6902"	HP:0001047	"10012438"	"200775004"
betamethasone benzoate	DB00443	Dermatitis, Atopic	C0011615		Approved			CHEBI_3077	"1514"	HP:0001047	"10012438"	"200775004"
halcinonide	DB06786	Dermatitis, Atopic	C0011615		Approved			CHEBI_31663	"5084"	HP:0001047	"10012438"	"200775004"
triamcinolone acetonide	DB00620	Dermatitis, Atopic	C0011615		Approved			CHEBI_9667	"10759"	HP:0001047	"10012438"	"200775004"
	DB01075	Dermatitis, Atopic	C0011615	NCT03688464	Withdrawn	Early Phase 1	Study never started	CHEBI_4636	"3498"	HP:0001047	"10012438"	"200775004"
alclometasone dipropionate	DB00240	Dermatitis, Atopic	C0011615		Approved			CHEBI_53776	"108088"	HP:0001047	"10012438"	"200775004"
diflorasone diacetate	DB00223	Dermatitis, Atopic	C0011615		Approved			CHEBI_59750	"91311"	HP:0001047	"10012438"	"200775004"
fluticasone propionate	DB00588	Dermatitis, Atopic	C0011615		Approved			CHEBI_31441	"50121"	HP:0001047	"10012438"	"200775004"
carbamide	DB03904	Dermatitis, Atopic	C0011615		Approved			CHEBI_16199	"11002"	HP:0001047	"10012438"	"200775004"
hydroxyzine	DB00557	Dermatitis, Atopic	C0011615		Approved			CHEBI_5818	"5553"	HP:0001047	"10012438"	"200775004"
dupilumab	DB12159	Dermatitis, Atopic	C0011615		Approved				"1876376"	HP:0001047	"10012438"	"200775004"
hydrocortisone succinate	DB14545	Dermatitis, Atopic	C0011615		Approved			CHEBI_31677	"21651"	HP:0001047	"10012438"	"200775004"
cortisone acetate	DB01380	Dermatitis, Atopic	C0011615		Approved			CHEBI_3897	"21655"	HP:0001047	"10012438"	"200775004"
flumetasone	DB00663	Dermatitis, Atopic	C0011615		Approved			CHEBI_34764	"4458"	HP:0001047	"10012438"	"200775004"
crisaborole	DB05219	Dermatitis, Atopic	C0011615		Approved			CHEBI_134677	"1865953"	HP:0001047	"10012438"	"200775004"
triamcinolone	DB00620	Dermatitis, Atopic	C0011615		Approved			CHEBI_9667	"10759"	HP:0001047	"10012438"	"200775004"
hydrocortisone	DB00741	Dermatitis, Atopic	C0011615		Approved			CHEBI_17650	"5492"	HP:0001047	"10012438"	"200775004"
ivermectin	DB00602	Dermatitis, Atopic	C0011615	NCT03553615	Withdrawn	Phase 2	Limited clinical capacity	CHEBI_6078	"6069"	HP:0001047	"10012438"	"200775004"
naltrexone	DB00704	Dermatitis, Atopic	C0011615	NCT04325802	Withdrawn	Phase 2	Covid-19 pandemic	CHEBI_7465	"7243"	HP:0001047	"10012438"	"200775004"
betamethasone valerate	DB00443	Dermatitis, Atopic	C0011615		Approved			CHEBI_3077	"1514"	HP:0001047	"10012438"	"200775004"
fluocinonide	DB12553	Dermatitis, Atopic	C0011615		Approved			CHEBI_5108	"25126"	HP:0001047	"10012438"	"200775004"
ammonium lactate	DB06768	Dermatitis, Atopic	C0011615		Approved				"215247"	HP:0001047	"10012438"	"200775004"
mometasone furoate	DB00764	Dermatitis, Atopic	C0011615		Approved			CHEBI_6970		HP:0001047	"10012438"	"200775004"
betamethasone acetate	DB00443	Dermatitis, Atopic	C0011615		Approved			CHEBI_3077	"1514"	HP:0001047	"10012438"	"200775004"
fluticasone propionate	DB13867	Dermatitis, Atopic	C0011615		Approved			CHEBI_5134	"41126"	HP:0001047	"10012438"	"200775004"
fludroxycortide	DB00846	Dermatitis, Atopic	C0011615		Approved			CHEBI_5127	"4500"	HP:0001047	"10012438"	"200775004"
clocortolone pivalate	DB00838	Dermatitis, Atopic	C0011615		Approved			CHEBI_59582	"21249"	HP:0001047	"10012438"	"200775004"
prednisone	DB00635	Dermatitis, Atopic	C0011615		Approved			CHEBI_8382	"8640"	HP:0001047	"10012438"	"200775004"
ulobetasol propionate	DB00596	Dermatitis, Atopic	C0011615		Approved			CHEBI_135782	"41208"	HP:0001047	"10012438"	"200775004"
hydrocortisone succinate	DB00741	Dermatitis, Atopic	C0011615		Approved			CHEBI_17650	"5492"	HP:0001047	"10012438"	"200775004"
tranilast	DB07615	Dermatitis, Atopic	C0011615		Approved			CHEBI_77572	"57330"	HP:0001047	"10012438"	"200775004"
doxepin	DB01142	Dermatitis, Atopic	C0011615		Approved			CHEBI_4710	"3638"	HP:0001047	"10012438"	"200775004"
clobetasol propionate	DB01013	Dermatitis, Atopic	C0011615		Approved			CHEBI_31414	"21245"	HP:0001047	"10012438"	"200775004"
difamilast	DB14987	Dermatitis, Atopic	C0011615		Approved					HP:0001047	"10012438"	"200775004"
delgocitinib	DB16133	Dermatitis, Atopic	C0011615		Approved			CHEBI_167600		HP:0001047	"10012438"	"200775004"
abrocitinib	DB14973	Dermatitis, Atopic	C0011615		Approved				"2591476"	HP:0001047	"10012438"	"200775004"
hydrocortisone acetate	DB14539	Dermatitis, Atopic	C0011615		Approved			CHEBI_17609	"27197"	HP:0001047	"10012438"	"200775004"
prednicarbate	DB01130	Dermatitis, Atopic	C0011615		Approved			CHEBI_135791	"34369"	HP:0001047	"10012438"	"200775004"
fluocinolone acetonide	DB00591	Dermatitis, Atopic	C0011615		Approved			CHEBI_31623	"4461"	HP:0001047	"10012438"	"200775004"
tacrolimus	DB00864	Dermatitis, Atopic	C0011615		Approved			CHEBI_61049	"42316|235991"	HP:0001047	"10012438"	"200775004"
upadacitinib	DB15091	Dermatitis, Atopic	C0011615		Approved				"2196092"	HP:0001047	"10012438"	"200775004"
baricitinib	DB11817	Dermatitis, Atopic	C0011615		Approved			CHEBI_95341	"2047232"	HP:0001047	"10012438"	"200775004"
betamethasone	DB00443	Dermatitis, Atopic	C0011615		Approved			CHEBI_3077	"1514"	HP:0001047	"10012438"	"200775004"
clobetasol propionate	DB11750	Dermatitis, Atopic	C0011615		Approved			CHEBI_205919	"2590"	HP:0001047	"10012438"	"200775004"
benzoyl peroxide	DB09096	Dermatitis, Atopic	C0011615		Approved			CHEBI_82405	"1418"	HP:0001047	"10012438"	"200775004"
clobetasone butyrate	DB13158	Dermatitis, Atopic	C0011615		Approved			CHEBI_31415	"108074"	HP:0001047	"10012438"	"200775004"
fluocinonide	DB01047	Dermatitis, Atopic	C0011615		Approved			CHEBI_5109	"4462"	HP:0001047	"10012438"	"200775004"
prednicarbate	DB00860	Dermatitis, Atopic	C0011615		Approved			CHEBI_8378	"8638"	HP:0001047	"10012438"	"200775004"
betamethasone dipropionate	DB00443	Dermatitis, Atopic	C0011615		Approved			CHEBI_3077	"1514"	HP:0001047	"10012438"	"200775004"
desonide	DB01260	Dermatitis, Atopic	C0011615		Approved			CHEBI_204734	"3254"	HP:0001047	"10012438"	"200775004"
dexamethasone	DB01234	Dermatitis, Atopic	C0011615		Approved			CHEBI_41879	"3264"	HP:0001047	"10012438"	"200775004"
mometasone furoate	DB14512	Dermatitis, Atopic	C0011615		Approved			CHEBI_47564	"30145"	HP:0001047	"10012438"	"200775004"
fluocinonide	DB01047	Contact Dermatitis	C0011616		Approved			CHEBI_5109	"4462"	MONDO_0005480	"10012442"	"40275004"
triamcinolone	DB00620	Contact Dermatitis	C0011616		Approved			CHEBI_9667	"10759"	MONDO_0005480	"10012442"	"40275004"
hydrocortisone	DB00741	Contact Dermatitis	C0011616		Approved			CHEBI_17650	"5492"	MONDO_0005480	"10012442"	"40275004"
fluocinolone acetonide	DB00591	Contact Dermatitis	C0011616		Approved			CHEBI_31623	"4461"	MONDO_0005480	"10012442"	"40275004"
ammonium lactate	DB06768	Contact Dermatitis	C0011616		Approved				"215247"	MONDO_0005480	"10012442"	"40275004"
prednicarbate	DB00860	Contact Dermatitis	C0011616		Approved			CHEBI_8378	"8638"	MONDO_0005480	"10012442"	"40275004"
halcinonide	DB06786	Contact Dermatitis	C0011616		Approved			CHEBI_31663	"5084"	MONDO_0005480	"10012442"	"40275004"
fluticasone propionate	DB13867	Contact Dermatitis	C0011616		Approved			CHEBI_5134	"41126"	MONDO_0005480	"10012442"	"40275004"
mometasone furoate	DB14512	Contact Dermatitis	C0011616		Approved			CHEBI_47564	"30145"	MONDO_0005480	"10012442"	"40275004"
hydrocortisone acetate	DB14539	Contact Dermatitis	C0011616		Approved			CHEBI_17609	"27197"	MONDO_0005480	"10012442"	"40275004"
methylprednisolone acetate	DB00959	Contact Dermatitis	C0011616		Approved			CHEBI_6888	"6902"	MONDO_0005480	"10012442"	"40275004"
betamethasone	DB00443	Contact Dermatitis	C0011616		Approved			CHEBI_3077	"1514"	MONDO_0005480	"10012442"	"40275004"
betamethasone benzoate	DB00443	Contact Dermatitis	C0011616		Approved			CHEBI_3077	"1514"	MONDO_0005480	"10012442"	"40275004"
fluocinolone acetonide	DB12553	Contact Dermatitis	C0011616		Approved			CHEBI_5108	"25126"	MONDO_0005480	"10012442"	"40275004"
amcinonide	DB00288	Contact Dermatitis	C0011616		Approved			CHEBI_31199	"17652"	MONDO_0005480	"10012442"	"40275004"
clocortolone pivalate	DB00838	Contact Dermatitis	C0011616		Approved			CHEBI_59582	"21249"	MONDO_0005480	"10012442"	"40275004"
cortisone acetate	DB01380	Contact Dermatitis	C0011616		Approved			CHEBI_3897	"21655"	MONDO_0005480	"10012442"	"40275004"
hydrocortisone succinate	DB00741	Contact Dermatitis	C0011616		Approved			CHEBI_17650	"5492"	MONDO_0005480	"10012442"	"40275004"
betamethasone valerate	DB00443	Contact Dermatitis	C0011616		Approved			CHEBI_3077	"1514"	MONDO_0005480	"10012442"	"40275004"
betamethasone acetate	DB00443	Contact Dermatitis	C0011616		Approved			CHEBI_3077	"1514"	MONDO_0005480	"10012442"	"40275004"
fluticasone propionate	DB00588	Contact Dermatitis	C0011616		Approved			CHEBI_31441	"50121"	MONDO_0005480	"10012442"	"40275004"
clobetasol propionate	DB01013	Contact Dermatitis	C0011616		Approved			CHEBI_31414	"21245"	MONDO_0005480	"10012442"	"40275004"
prednicarbate	DB01130	Contact Dermatitis	C0011616		Approved			CHEBI_135791	"34369"	MONDO_0005480	"10012442"	"40275004"
prednisone	DB00635	Contact Dermatitis	C0011616		Approved			CHEBI_8382	"8640"	MONDO_0005480	"10012442"	"40275004"
clobetasol propionate	DB11750	Contact Dermatitis	C0011616		Approved			CHEBI_205919	"2590"	MONDO_0005480	"10012442"	"40275004"
dexamethasone	DB01234	Contact Dermatitis	C0011616		Approved			CHEBI_41879	"3264"	MONDO_0005480	"10012442"	"40275004"
methylprednisolone	DB00959	Contact Dermatitis	C0011616		Approved			CHEBI_6888	"6902"	MONDO_0005480	"10012442"	"40275004"
flumetasone	DB00663	Contact Dermatitis	C0011616		Approved			CHEBI_34764	"4458"	MONDO_0005480	"10012442"	"40275004"
diflorasone diacetate	DB00223	Contact Dermatitis	C0011616		Approved			CHEBI_59750	"91311"	MONDO_0005480	"10012442"	"40275004"
triamcinolone acetonide	DB00620	Contact Dermatitis	C0011616		Approved			CHEBI_9667	"10759"	MONDO_0005480	"10012442"	"40275004"
mometasone furoate	DB00764	Contact Dermatitis	C0011616		Approved			CHEBI_6970		MONDO_0005480	"10012442"	"40275004"
hydrocortisone succinate	DB14545	Contact Dermatitis	C0011616		Approved			CHEBI_31677	"21651"	MONDO_0005480	"10012442"	"40275004"
ulobetasol propionate	DB00596	Contact Dermatitis	C0011616		Approved			CHEBI_135782	"41208"	MONDO_0005480	"10012442"	"40275004"
desoximetasone	DB00547	Contact Dermatitis	C0011616		Approved			CHEBI_691037	"3255"	MONDO_0005480	"10012442"	"40275004"
triamcinolone diacetate	DB00620	Contact Dermatitis	C0011616		Approved			CHEBI_9667	"10759"	MONDO_0005480	"10012442"	"40275004"
fluocinonide	DB12553	Contact Dermatitis	C0011616		Approved			CHEBI_5108	"25126"	MONDO_0005480	"10012442"	"40275004"
benzoyl peroxide	DB09096	Contact Dermatitis	C0011616		Approved			CHEBI_82405	"1418"	MONDO_0005480	"10012442"	"40275004"
desonide	DB01260	Contact Dermatitis	C0011616		Approved			CHEBI_204734	"3254"	MONDO_0005480	"10012442"	"40275004"
fludroxycortide	DB00846	Contact Dermatitis	C0011616		Approved			CHEBI_5127	"4500"	MONDO_0005480	"10012442"	"40275004"
alclometasone dipropionate	DB00240	Contact Dermatitis	C0011616		Approved			CHEBI_53776	"108088"	MONDO_0005480	"10012442"	"40275004"
carbamide	DB03904	Contact Dermatitis	C0011616		Approved			CHEBI_16199	"11002"	MONDO_0005480	"10012442"	"40275004"
betamethasone dipropionate	DB00443	Contact Dermatitis	C0011616		Approved			CHEBI_3077	"1514"	MONDO_0005480	"10012442"	"40275004"
prednisolone	DB00860	Contact Dermatitis	C0011616		Approved			CHEBI_8378	"8638"	MONDO_0005480	"10012442"	"40275004"
hydrocortisone acetate	DB00741	Contact Dermatitis	C0011616		Approved			CHEBI_17650	"5492"	MONDO_0005480	"10012442"	"40275004"
insulin degludec	DB00030	Diabetes Mellitus	C0011849		Approved			CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
capsaicin	DB06774	Diabetes Mellitus	C0011849	NCT00089557	Terminated	Phase 2		CHEBI_3374	"1992"	MONDO_0005015	"10012601"	"73211009"
liraglutide	DB06655	Diabetes Mellitus	C0011849	NCT02231658	Terminated	Phase 1	Too challenging to recruit appropriate participants at an acceptable speed.	CHEBI_71193	"475968"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00030	Diabetes Mellitus	C0011849	NCT00136916	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
exenatide	DB01276	Diabetes Mellitus	C0011849	NCT00701935	Terminated	Phase 2	Enrollment was much slower than anticipated, leading to a decision to terminate the study early for enrollment futility.	CHEBI_64073	"60548"	MONDO_0005015	"10012601"	"73211009"
pioglitazone	DB01132	Diabetes Mellitus	C0011849	NCT00722917	Terminated	Phase 2	Animal Toxicity Findings	CHEBI_8228	"33738"	MONDO_0005015	"10012601"	"73211009"
metformin	DB00331	Diabetes Mellitus	C0011849	NCT00762957	Terminated	Phase 3	Hepatic Safety Signal Identified.	CHEBI_6801	"6809"	MONDO_0005015	"10012601"	"73211009"
metformin	DB00331	Diabetes Mellitus	C0011849	NCT02484209	Withdrawn	Phase 3	Inclusion criteria too strict making it difficult to recruit in primary care	CHEBI_6801	"6809"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00046	Diabetes Mellitus	C0011849	NCT02446028	Suspended	Phase 2	IND Withdrawn		"314684|2376838|86009"	MONDO_0005015	"10012601"	"73211009"
	DB00030	Diabetes Mellitus	C0011849	NCT02446028	Suspended	Phase 2	IND Withdrawn	CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00030	Diabetes Mellitus	C0011849	NCT00762190	Terminated	Phase 3	Hepatic safety signal identified.	CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
rosiglitazone	DB00412	Diabetes Mellitus	C0011849	NCT00203632	Terminated	Phase 3	Terminated at 50% enrollment due to recent concerns about rosiglitazone	CHEBI_50122	"84108"	MONDO_0005015	"10012601"	"73211009"
insulin glulisine	DB00030	Diabetes Mellitus	C0011849		Approved			CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
insulin glulisine	DB01309	Diabetes Mellitus	C0011849		Approved				"400008"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00030	Diabetes Mellitus	C0011849	NCT00138671	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
ezetimibe	DB00973	Diabetes Mellitus	C0011849	NCT00395603	Terminated	Phase 3	This study was terminated early due to poor recruitment.	CHEBI_49040	"341248"	MONDO_0005015	"10012601"	"73211009"
	DB00641	Diabetes Mellitus	C0011849	NCT00395603	Terminated	Phase 3	This study was terminated early due to poor recruitment.	CHEBI_9150	"36567"	MONDO_0005015	"10012601"	"73211009"
	DB01076	Diabetes Mellitus	C0011849	NCT00395603	Terminated	Phase 3	This study was terminated early due to poor recruitment.	CHEBI_39548	"83367"	MONDO_0005015	"10012601"	"73211009"
insulin detemir	DB00030	Diabetes Mellitus	C0011849		Approved			CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
insulin detemir	DB01307	Diabetes Mellitus	C0011849		Approved				"139825"	MONDO_0005015	"10012601"	"73211009"
insulin aspart	DB00030	Diabetes Mellitus	C0011849		Approved			CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
insulin aspart	DB01306	Diabetes Mellitus	C0011849		Approved				"51428|352385"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00030	Diabetes Mellitus	C0011849	NCT00990444	Suspended	Phase 1/Phase 2		CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
insulin degludec	DB09564	Diabetes Mellitus	C0011849		Approved				"1670007"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00046	Diabetes Mellitus	C0011849	NCT01067118	Withdrawn	Phase 2	The study was suspended due to lack of study drug		"314684|2376838|86009"	MONDO_0005015	"10012601"	"73211009"
	DB00030	Diabetes Mellitus	C0011849	NCT01067118	Withdrawn	Phase 2	The study was suspended due to lack of study drug	CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
atorvastatin	DB01076	Diabetes Mellitus	C0011849	NCT00134264	Terminated	Phase 3		CHEBI_39548	"83367"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00030	Diabetes Mellitus	C0011849	NCT00287066	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
insulin glargine	DB00030	Diabetes Mellitus	C0011849	NCT00143247	Terminated	Phase 2	See termination reason in detailed description.	CHEBI_5931	"253182|631657"	MONDO_0005015	"10012601"	"73211009"
ticagrelor	DB08816	Diabetes Mellitus	C0011849	NCT04069234	Withdrawn	Phase 3	Sponsor decided to stop the study due to commercial reasons.	CHEBI_68558	"1116632"	MONDO_0005015	"10012601"	"73211009"
	DB00758	Diabetes Mellitus	C0011849	NCT04069234	Withdrawn	Phase 3	Sponsor decided to stop the study due to commercial reasons.	CHEBI_37941	"32968"	MONDO_0005015	"10012601"	"73211009"
ascorbic acid	DB00126	Diabetes Mellitus	C0011849	NCT05281562	Terminated	Phase 2/Phase 3	There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.	CHEBI_29073	"1151|1370460"	MONDO_0005015	"10012601"	"73211009"
	DB14482	Diabetes Mellitus	C0011849	NCT05281562	Terminated	Phase 2/Phase 3	There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.	CHEBI_113451	"267366"	MONDO_0005015	"10012601"	"73211009"
	DB14483	Diabetes Mellitus	C0011849	NCT05281562	Terminated	Phase 2/Phase 3	There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.		"1307765|142407"	MONDO_0005015	"10012601"	"73211009"
colecalciferol	DB00169	Diabetes Mellitus	C0011849	NCT01170442	Terminated	Phase 3	In adequate enrollment	CHEBI_28940	"2418"	MONDO_0005015	"10012601"	"73211009"
glibenclamide	DB01016	Diabetes Mellitus	C0011849	NCT00521820	Terminated	Phase 3	Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects.	CHEBI_5441	"4815"	MONDO_0005015	"10012601"	"73211009"
acarbose	DB00284	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_2376	"16681"	MONDO_0005148	"10067585"	"44054006"
	DB01132	Diabetes Mellitus	C0011849	NCT00521820	Terminated	Phase 3	Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects.	CHEBI_8228	"33738"	MONDO_0005015	"10012601"	"73211009"
glibenclamide	DB01016	Diabetes Mellitus	C0011849	NCT00759720	Terminated	Phase 3	Potential hepatic safety signal	CHEBI_5441	"4815"	MONDO_0005015	"10012601"	"73211009"
linagliptin	DB08882	Diabetes Mellitus	C0011849	NCT04371978	Terminated	Phase 3	End of COVID-19 outbreak in Israel	CHEBI_68610	"1100699"	MONDO_0005015	"10012601"	"73211009"
gliclazide	DB01120	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_31654	"4816"	MONDO_0005148	"10067585"	"44054006"
saxagliptin	DB06335	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_71272	"857974|1546030"	MONDO_0005148	"10067585"	"44054006"
insulin glargine	DB00030	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT00282971	Terminated	Phase 3	Terminated as marketing of this product will be discontinued	CHEBI_5931	"253182|631657"	MONDO_0005148	"10067585"	"44054006"
albiglutide	DB09043	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_78425	"1534763"	MONDO_0005148	"10067585"	"44054006"
vildagliptin	DB04876	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_135285	"596554"	MONDO_0005148	"10067585"	"44054006"
chlorpropamide	DB00672	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_3650	"2404"	MONDO_0005148	"10067585"	"44054006"
glipizide	DB01067	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_5384	"4821"	MONDO_0005148	"10067585"	"44054006"
liraglutide	DB06655	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT01516476	Terminated	Phase 2		CHEBI_71193	"475968"	MONDO_0005148	"10067585"	"44054006"
tirzepatide	DB15171	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_194186	"2601723"	MONDO_0005148	"10067585"	"44054006"
gliquidone	DB01251	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_93416	"25793"	MONDO_0005148	"10067585"	"44054006"
canagliflozin	DB08907	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_73274	"1373458|1546031"	MONDO_0005148	"10067585"	"44054006"
evogliptin	DB12625	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved					MONDO_0005148	"10067585"	"44054006"
nateglinide	DB00731	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_31897	"274332"	MONDO_0005148	"10067585"	"44054006"
miglitol	DB00491	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_6935	"30009"	MONDO_0005148	"10067585"	"44054006"
gemigliptin	DB12412	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_134731		MONDO_0005148	"10067585"	"44054006"
metformin	DB00331	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_6801	"6809"	MONDO_0005148	"10067585"	"44054006"
sitagliptin	DB01261	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_40237	"593411"	MONDO_0005148	"10067585"	"44054006"
alogliptin	DB06203	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_72323	"1368001"	MONDO_0005148	"10067585"	"44054006"
empagliflozin	DB09038	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_82720	"1545653"	MONDO_0005148	"10067585"	"44054006"
linagliptin	DB08882	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_68610	"1100699"	MONDO_0005148	"10067585"	"44054006"
rimonabant	DB06155	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT00478972	Terminated	Phase 3	Company decision taken in light of demands by certain national health authorities	CHEBI_34967		MONDO_0005148	"10067585"	"44054006"
rimonabant	DB06155	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT00478595	Terminated	Phase 3	Company decision taken in light of demands by certain national health authorities	CHEBI_34967		MONDO_0005148	"10067585"	"44054006"
teneligliptin	DB11950	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_136042		MONDO_0005148	"10067585"	"44054006"
tofogliflozin	DB11824	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_136041		MONDO_0005148	"10067585"	"44054006"
luseogliflozin	DB12214	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_134725		MONDO_0005148	"10067585"	"44054006"
carbutamide	DB13406	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_135118		MONDO_0005148	"10067585"	"44054006"
ipragliflozin	DB11698	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_134724		MONDO_0005148	"10067585"	"44054006"
omarigliptin	DB11992	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_134735		MONDO_0005148	"10067585"	"44054006"
metformin	DB00331	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT01051011	Terminated	Phase 3	high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation plan to address hypersensitivity reactions	CHEBI_6801	"6809"	MONDO_0005148	"10067585"	"44054006"
acetohexamide	DB00414	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_28052	"173"	MONDO_0005148	"10067585"	"44054006"
repaglinide	DB00912	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_8805	"73044"	MONDO_0005148	"10067585"	"44054006"
semaglutide	DB13928	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_167574	"1991302"	MONDO_0005148	"10067585"	"44054006"
tolazamide	DB00839	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_9613	"10633"	MONDO_0005148	"10067585"	"44054006"
pioglitazone	DB01132	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT00543959	Terminated	Phase 2	This study is being discontinued based on data suggesting that none of the doses tested demonstrated both glycemic & body fluid benefits vs. the comparitor	CHEBI_8228	"33738"	MONDO_0005148	"10067585"	"44054006"
dulaglutide	DB09045	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved				"1551291"	MONDO_0005148	"10067585"	"44054006"
tolbutamide	DB01124	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_27999	"10635"	MONDO_0005148	"10067585"	"44054006"
voglibose	DB04878	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_32300		MONDO_0005148	"10067585"	"44054006"
lobeglitazone	DB09198	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_136052		MONDO_0005148	"10067585"	"44054006"
dapagliflozin	DB06292	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_85078	"1488564"	MONDO_0005148	"10067585"	"44054006"
mitiglinide	DB01252	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_135349		MONDO_0005148	"10067585"	"44054006"
secobarbital	DB00418	Epilepsy	C0014544		Approved			CHEBI_9073	"9624"	HP:0001250	"10015037"	"84757009"
imeglimin	DB12509	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved					MONDO_0005148	"10067585"	"44054006"
troglitazone	DB00197	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_9753	"72610"	MONDO_0005148	"10067585"	"44054006"
ertugliflozin	DB11827	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_188719	"1992672"	MONDO_0005148	"10067585"	"44054006"
glibornuride	DB08962	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_135545	"102846"	MONDO_0005148	"10067585"	"44054006"
glymidine	DB01382	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_146188	"102848"	MONDO_0005148	"10067585"	"44054006"
insulin lispro	DB00046	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved				"314684|2376838|86009"	MONDO_0005148	"10067585"	"44054006"
insulin lispro	DB00030	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_5931	"253182|631657"	MONDO_0005148	"10067585"	"44054006"
insulin human	DB00030	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_5931	"253182|631657"	MONDO_0005148	"10067585"	"44054006"
trelagliptin	DB15323	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_134715		MONDO_0005148	"10067585"	"44054006"
	DB00047	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT01051011	Terminated	Phase 3	high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation plan to address hypersensitivity reactions		"2563969|274783"	MONDO_0005148	"10067585"	"44054006"
lixisenatide	DB09265	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_85662	"1440051"	MONDO_0005148	"10067585"	"44054006"
buformin	DB04830	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_3209		MONDO_0005148	"10067585"	"44054006"
glibenclamide	DB01016	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_5441	"4815"	MONDO_0005148	"10067585"	"44054006"
glimepiride	DB00222	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_5383	"25789"	MONDO_0005148	"10067585"	"44054006"
insulin glargine	DB00030	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_5931	"253182|631657"	MONDO_0005148	"10067585"	"44054006"
glisoxepide	DB01289	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_135731		MONDO_0005148	"10067585"	"44054006"
insulin glargine	DB00047	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved				"2563969|274783"	MONDO_0005148	"10067585"	"44054006"
liraglutide	DB06655	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_71193	"475968"	MONDO_0005148	"10067585"	"44054006"
pioglitazone	DB01132	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_8228	"33738"	MONDO_0005148	"10067585"	"44054006"
	DB00030	Diabetes Mellitus, Non-Insulin-Dependent	C0011860	NCT01051011	Terminated	Phase 3	high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation plan to address hypersensitivity reactions	CHEBI_5931	"253182|631657"	MONDO_0005148	"10067585"	"44054006"
anagliptin	DB12417	Diabetes Mellitus, Non-Insulin-Dependent	C0011860		Approved			CHEBI_136043		MONDO_0005148	"10067585"	"44054006"
famotidine	DB00927	Duodenal Ulcer	C0013295		Approved			CHEBI_4975	"4278"	HP:0002588	"10013836"	"51868009"
vonoprazan	DB11739	Duodenal Ulcer	C0013295		Approved			CHEBI_136048	"2604577"	HP:0002588	"10013836"	"51868009"
omeprazole	DB00338	Duodenal Ulcer	C0013295		Approved			CHEBI_77260	"7646"	HP:0002588	"10013836"	"51868009"
revaprazan	DB16308	Duodenal Ulcer	C0013295		Approved			CHEBI_135529		HP:0002588	"10013836"	"51868009"
nizatidine	DB00585	Duodenal Ulcer	C0013295		Approved			CHEBI_7601	"42319"	HP:0002588	"10013836"	"51868009"
algeldrate	DB06723	Duodenal Ulcer	C0013295		Approved			CHEBI_33130	"612|81948"	HP:0002588	"10013836"	"51868009"
cimetidine	DB00501	Duodenal Ulcer	C0013295		Approved			CHEBI_3699	"2541"	HP:0002588	"10013836"	"51868009"
rabeprazole	DB01129	Duodenal Ulcer	C0013295		Approved			CHEBI_8768	"183877|114979"	HP:0002588	"10013836"	"51868009"
ranitidine	DB00863	Duodenal Ulcer	C0013295		Approved			CHEBI_92246	"9143"	HP:0002588	"10013836"	"51868009"
lansoprazole	DB00448	Duodenal Ulcer	C0013295		Approved			CHEBI_6375	"17128"	HP:0002588	"10013836"	"51868009"
dexrabeprazole	DB13762	Duodenal Ulcer	C0013295		Approved			CHEBI_134729		HP:0002588	"10013836"	"51868009"
sucralfate	DB00364	Duodenal Ulcer	C0013295		Approved			CHEBI_9313	"10156"	HP:0002588	"10013836"	"51868009"
methylclothiazide	DB00232	Edema	C0013604		Approved			CHEBI_6847	"6860"	HP:0000969	"10030095"	"267038008"
indapamide	DB00808	Edema	C0013604		Approved			CHEBI_5893	"5764"	HP:0000969	"10030095"	"267038008"
acetazolamide	DB00819	Edema	C0013604		Approved			CHEBI_27690	"167"	HP:0000969	"10030095"	"267038008"
furosemide	DB00695	Edema	C0013604		Approved			CHEBI_47426	"4603"	HP:0000969	"10030095"	"267038008"
spironolactone	DB00421	Edema	C0013604		Approved			CHEBI_9241	"9997"	HP:0000969	"10030095"	"267038008"
piretanide	DB02925	Edema	C0013604		Approved			CHEBI_32015	"33770"	HP:0000969	"10030095"	"267038008"
amiloride	DB00594	Edema	C0013604		Approved			CHEBI_2639	"644"	HP:0000969	"10030095"	"267038008"
torsemide	DB00214	Edema	C0013604		Approved			CHEBI_9637	"38413"	HP:0000969	"10030095"	"267038008"
mannitol	DB00742	Edema	C0013604		Approved			CHEBI_16899	"6628"	HP:0000969	"10030095"	"267038008"
bumetanide	DB00887	Edema	C0013604		Approved			CHEBI_3213	"1808"	HP:0000969	"10030095"	"267038008"
chlortalidone	DB00310	Edema	C0013604		Approved			CHEBI_3654	"2409"	HP:0000969	"10030095"	"267038008"
chlorothiazide	DB00880	Edema	C0013604		Approved			CHEBI_3640	"2396"	HP:0000969	"10030095"	"267038008"
hydroflumethiazide	DB00774	Edema	C0013604		Approved			CHEBI_5784	"5495"	HP:0000969	"10030095"	"267038008"
xipamide	DB13803	Edema	C0013604		Approved			CHEBI_135499		HP:0000969	"10030095"	"267038008"
ethacrynic acid	DB00903	Edema	C0013604		Approved			CHEBI_4876	"4109|62349"	HP:0000969	"10030095"	"267038008"
hydrochlorothiazide	DB00999	Edema	C0013604		Approved			CHEBI_5778	"5487"	HP:0000969	"10030095"	"267038008"
triamterene	DB00384	Edema	C0013604		Approved			CHEBI_9671	"10763"	HP:0000969	"10030095"	"267038008"
valproic acid	DB00313	Epilepsy	C0014544		Approved			CHEBI_39867	"11118|40254"	HP:0001250	"10015037"	"84757009"
phenytoin	DB00252	Epilepsy	C0014544		Approved			CHEBI_8107	"8183"	HP:0001250	"10015037"	"84757009"
ketamine	DB01221	Epilepsy	C0014544	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_6121	"6130"	HP:0001250	"10015037"	"84757009"
metharbital	DB00463	Epilepsy	C0014544		Approved			CHEBI_31827	"6825"	HP:0001250	"10015037"	"84757009"
levetiracetam	DB01202	Epilepsy	C0014544	NCT00376766	Terminated	Phase 3	recruitment recruitment recruitment recruitment difficulties	CHEBI_6437	"114477"	HP:0001250	"10015037"	"84757009"
phensuximide	DB00832	Epilepsy	C0014544		Approved			CHEBI_8079	"33309"	HP:0001250	"10015037"	"84757009"
fosphenytoin	DB01320	Epilepsy	C0014544		Approved			CHEBI_5165	"72236"	HP:0001250	"10015037"	"84757009"
phenytoin	DB00252	Epilepsy	C0014544	NCT01878578	Terminated	Phase 1	prematurely terminated due to impossibility of recruiting the planned number of patients by the study centre.	CHEBI_8107	"8183"	HP:0001250	"10015037"	"84757009"
methsuximide	DB05246	Epilepsy	C0014544		Approved			CHEBI_6846	"47858"	HP:0001250	"10015037"	"84757009"
paramethadione	DB00617	Epilepsy	C0014544		Approved			CHEBI_7921	"32894"	HP:0001250	"10015037"	"84757009"
phenobarbital	DB01174	Epilepsy	C0014544		Approved			CHEBI_8069	"8134"	HP:0001250	"10015037"	"84757009"
midazolam	DB00683	Epilepsy	C0014544	NCT02161185	Terminated	Phase 3	Study terminated due to slow enrollment. There were no safety concerns.	CHEBI_6931	"6960"	HP:0001250	"10015037"	"84757009"
zonisamide	DB00909	Epilepsy	C0014544	NCT00692003	Terminated	Phase 3	Sponsor's decision	CHEBI_10127	"39998"	HP:0001250	"10015037"	"84757009"
	DB01202	Epilepsy	C0014544	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_6437	"114477"	HP:0001250	"10015037"	"84757009"
phenytoin	DB00252	Epilepsy	C0014544	NCT00598923	Terminated	Early Phase 1	End of funding and low enrollment	CHEBI_8107	"8183"	HP:0001250	"10015037"	"84757009"
lamotrigine	DB00555	Epilepsy	C0014544	NCT00266149	Terminated	Phase 3		CHEBI_6367	"28439"	HP:0001250	"10015037"	"84757009"
zonisamide	DB00909	Epilepsy	C0014544	NCT00693017	Terminated	Phase 3	Sponsor's decision	CHEBI_10127	"39998"	HP:0001250	"10015037"	"84757009"
lamotrigine	DB00555	Epilepsy	C0014544		Approved			CHEBI_6367	"28439"	HP:0001250	"10015037"	"84757009"
phenacemide	DB01121	Epilepsy	C0014544		Approved			CHEBI_8049	"33253"	HP:0001250	"10015037"	"84757009"
midazolam	DB00683	Epilepsy	C0014544	NCT01316445	Terminated	Phase 1	Funding agency no longer provide support.	CHEBI_6931	"6960"	HP:0001250	"10015037"	"84757009"
ethadione	DB13799	Epilepsy	C0014544		Approved			CHEBI_81296		HP:0001250	"10015037"	"84757009"
buspirone	DB00490	Epilepsy	C0014544	NCT01496612	Terminated	Phase 2		CHEBI_3223	"1827"	HP:0001250	"10015037"	"84757009"
trimethadione	DB00347	Epilepsy	C0014544		Approved			CHEBI_9727	"10827"	HP:0001250	"10015037"	"84757009"
	DB06218	Epilepsy	C0014544	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_135939	"623400"	HP:0001250	"10015037"	"84757009"
pentobarbital	DB00312	Epilepsy	C0014544		Approved			CHEBI_7983	"8004"	HP:0001250	"10015037"	"84757009"
diazepam	DB00829	Epilepsy	C0014544		Approved			CHEBI_49575	"3322"	HP:0001250	"10015037"	"84757009"
pregabalin	DB00230	Epilepsy	C0014544	NCT00372528	Terminated	Phase 3	This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug. No efficacy or safety concerns factored into this decision.	CHEBI_64356	"187832"	HP:0001250	"10015037"	"84757009"
amobarbital	DB01351	Epilepsy	C0014544		Approved			CHEBI_2673	"719"	HP:0001250	"10015037"	"84757009"
	DB00273	Epilepsy	C0014544	NCT00598923	Terminated	Early Phase 1	End of funding and low enrollment	CHEBI_63631	"38404"	HP:0001250	"10015037"	"84757009"
carvedilol	DB01136	Epilepsy	C0014544	NCT00524134	Terminated	Phase 2/Phase 3	PI left the institution.	CHEBI_3441	"20352"	HP:0001250	"10015037"	"84757009"
	DB01174	Epilepsy	C0014544	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_8069	"8134"	HP:0001250	"10015037"	"84757009"
	DB00273	Epilepsy	C0014544	NCT00563459	Terminated	Phase 3	Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this indication were terminated.	CHEBI_63631	"38404"	HP:0001250	"10015037"	"84757009"
felbamate	DB00949	Epilepsy	C0014544		Approved			CHEBI_4995	"24812"	HP:0001250	"10015037"	"84757009"
amino(diphenylhydantoin) valeric acid	DB13396	Epilepsy	C0014544		Approved			CHEBI_134734		HP:0001250	"10015037"	"84757009"
aminohydroxybutyric acid	DB15985	Epilepsy	C0014544		Approved			CHEBI_16080		HP:0001250	"10015037"	"84757009"
mephenytoin	DB00532	Epilepsy	C0014544		Approved			CHEBI_6757	"6757"	HP:0001250	"10015037"	"84757009"
carbamazepine	DB00564	Epilepsy	C0014544		Approved			CHEBI_3387	"2002"	HP:0001250	"10015037"	"84757009"
midazolam	DB00683	Epilepsy	C0014544	NCT01390220	Terminated	Phase 3		CHEBI_6931	"6960"	HP:0001250	"10015037"	"84757009"
diazepam	DB00829	Epilepsy	C0014544	NCT02316847	Terminated	Phase 2		CHEBI_49575	"3322"	HP:0001250	"10015037"	"84757009"
primidone	DB00794	Epilepsy	C0014544		Approved			CHEBI_8412	"8691"	HP:0001250	"10015037"	"84757009"
	DB00349	Epilepsy	C0014544	NCT02134366	Terminated	Phase 3	Recruitment Issues - Lack of target population	CHEBI_31413	"21241"	HP:0001250	"10015037"	"84757009"
	DB01068	Epilepsy	C0014544	NCT02134366	Terminated	Phase 3	Recruitment Issues - Lack of target population	CHEBI_3756	"2598"	HP:0001250	"10015037"	"84757009"
levetiracetam	DB01202	Epilepsy	C0014544	NCT00563459	Terminated	Phase 3	Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this indication were terminated.	CHEBI_6437	"114477"	HP:0001250	"10015037"	"84757009"
lorazepam	DB00186	Epilepsy	C0014544	NCT02134366	Terminated	Phase 3	Recruitment Issues - Lack of target population	CHEBI_6539	"6470"	HP:0001250	"10015037"	"84757009"
methylphenobarbital	DB00849	Epilepsy	C0014544		Approved			CHEBI_6758	"6758"	HP:0001250	"10015037"	"84757009"
thiopental	DB00599	Epilepsy	C0014544		Approved			CHEBI_102166	"10493"	HP:0001250	"10015037"	"84757009"
cimetidine	DB00501	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_3699	"2541"	MONDO_0007186	"10017885"	"235595009"
magnesium silicate	DB13249	Gastroesophageal reflux disease	C0017168		Approved				"1310566"	MONDO_0007186	"10017885"	"235595009"
magnesium silicate	DB09281	Gastroesophageal reflux disease	C0017168		Approved				"29170"	MONDO_0007186	"10017885"	"235595009"
dexrabeprazole	DB13762	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_134729		MONDO_0007186	"10017885"	"235595009"
cisapride	DB00604	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_3720	"35255"	MONDO_0007186	"10017885"	"235595009"
dichlorophen	DB11396	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_34689		MONDO_0005338	"10035015"	"84494001"
lansoprazole	DB00448	Gastroesophageal reflux disease	C0017168	NCT01479231	Withdrawn	Phase 1/Phase 2	Souces of funding have been terminated	CHEBI_6375	"17128"	MONDO_0007186	"10017885"	"235595009"
carbaldrate	DB15825	Gastroesophageal reflux disease	C0017168		Approved					MONDO_0007186	"10017885"	"235595009"
	DB05351	Gastroesophageal reflux disease	C0017168	NCT01479231	Withdrawn	Phase 1/Phase 2	Souces of funding have been terminated	CHEBI_135931	"816346"	MONDO_0007186	"10017885"	"235595009"
potassium hydrogencarbonate	DB11098	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_81862	"34296"	MONDO_0007186	"10017885"	"235595009"
	DB00338	Gastroesophageal reflux disease	C0017168	NCT01471925	Withdrawn	Phase 3	Change company strategy	CHEBI_77260	"7646"	MONDO_0007186	"10017885"	"235595009"
rabeprazole	DB01129	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_8768	"183877|114979"	MONDO_0007186	"10017885"	"235595009"
esomeprazole	DB00736	Gastroesophageal reflux disease	C0017168	NCT01471925	Withdrawn	Phase 3	Change company strategy	CHEBI_50275	"283742"	MONDO_0007186	"10017885"	"235595009"
pantoprazole	DB00213	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_7915	"40790"	MONDO_0007186	"10017885"	"235595009"
alum	DB09087	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_86463	"221456|54989"	MONDO_0007186	"10017885"	"235595009"
ilaprazole	DB11964	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_135544		MONDO_0007186	"10017885"	"235595009"
algeldrate	DB06723	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_33130	"612|81948"	MONDO_0007186	"10017885"	"235595009"
rabeprazole	DB01129	Gastroesophageal reflux disease	C0017168	NCT01391715	Withdrawn	Phase 3	patients could not be recuited within study duration	CHEBI_8768	"183877|114979"	MONDO_0007186	"10017885"	"235595009"
esomeprazole	DB00338	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_77260	"7646"	MONDO_0007186	"10017885"	"235595009"
magnesium hydroxide	DB09104	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_6637	"6581|243353"	MONDO_0007186	"10017885"	"235595009"
esomeprazole	DB00736	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_50275	"283742"	MONDO_0007186	"10017885"	"235595009"
roxatidine acetate	DB08806	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_94758		MONDO_0007186	"10017885"	"235595009"
famotidine	DB00927	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_4975	"4278"	MONDO_0007186	"10017885"	"235595009"
	DB01184	Gastroesophageal reflux disease	C0017168	NCT01710462	Withdrawn	Phase 3	Change of company's strategy	CHEBI_31515	"3626"	MONDO_0007186	"10017885"	"235595009"
pantoprazole	DB00213	Gastroesophageal reflux disease	C0017168	NCT01710462	Withdrawn	Phase 3	Change of company's strategy	CHEBI_7915	"40790"	MONDO_0007186	"10017885"	"235595009"
almasilate	DB13595	Gastroesophageal reflux disease	C0017168		Approved				"17614"	MONDO_0007186	"10017885"	"235595009"
	DB00338	Gastroesophageal reflux disease	C0017168	NCT00730665	Terminated	Phase 2	This study has been placed on clinical hold by the sponsor due to operational reasons.	CHEBI_77260	"7646"	MONDO_0007186	"10017885"	"235595009"
esomeprazole	DB00736	Gastroesophageal reflux disease	C0017168	NCT00730665	Terminated	Phase 2	This study has been placed on clinical hold by the sponsor due to operational reasons.	CHEBI_50275	"283742"	MONDO_0007186	"10017885"	"235595009"
lansoprazole	DB00448	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_6375	"17128"	MONDO_0007186	"10017885"	"235595009"
dexlansoprazole	DB05351	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_135931	"816346"	MONDO_0007186	"10017885"	"235595009"
omeprazole	DB00338	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_77260	"7646"	MONDO_0007186	"10017885"	"235595009"
melatonin	DB01065	Gastroesophageal reflux disease	C0017168	NCT00915616	Withdrawn	Phase 3		CHEBI_16796	"6711"	MONDO_0007186	"10017885"	"235595009"
ranitidine	DB00863	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_92246	"9143"	MONDO_0007186	"10017885"	"235595009"
magnesium carbonate	DB09481	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_31793	"29155"	MONDO_0007186	"10017885"	"235595009"
nizatidine	DB00585	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_7601	"42319"	MONDO_0007186	"10017885"	"235595009"
metoclopramide	DB01233	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_107736	"6915"	MONDO_0007186	"10017885"	"235595009"
silicon dioxide	DB11132	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_30563	"314826|1362874|9771"	MONDO_0007186	"10017885"	"235595009"
sodium citrate	DB09154	Gastroesophageal reflux disease	C0017168		Approved			CHEBI_53258	"253204|56466|1310549"	MONDO_0007186	"10017885"	"235595009"
clonidine	DB00575	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_46632	"2599"	MONDO_0005338	"10035015"	"84494001"
echothiophate	DB01057	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_4753	"89778"	MONDO_0005338	"10035015"	"84494001"
timolol	DB00373	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_9599	"1546004|10600"	MONDO_0005338	"10035015"	"84494001"
serine	DB00133	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_17115	"9671"	MONDO_0005338	"10035015"	"84494001"
befunolol	DB09013	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_135212		MONDO_0005338	"10035015"	"84494001"
brinzolamide	DB01194	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_3176	"194881"	MONDO_0005338	"10035015"	"84494001"
brimonidine	DB00484	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_3175	"134615"	MONDO_0005338	"10035015"	"84494001"
dorzolamide	DB00869	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_4702	"60207"	MONDO_0005338	"10035015"	"84494001"
dipivefrine	DB00668	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_28918	"3992"	MONDO_0005338	"10035015"	"84494001"
dipivefrine	DB00449	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_4646	"23410"	MONDO_0005338	"10035015"	"84494001"
netarsudil	DB13931	Glaucoma, Open-Angle	C0017612		Approved				"1992864"	MONDO_0005338	"10035015"	"84494001"
latanoprost	DB00654	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_6384	"43611"	MONDO_0005338	"10035015"	"84494001"
apraclonidine	DB00964	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_2788	"14845"	MONDO_0005338	"10035015"	"84494001"
latanoprostene bunod	DB11660	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_177703	"1988390"	MONDO_0005338	"10035015"	"84494001"
methazolamide	DB00703	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_6822	"6826"	MONDO_0005338	"10035015"	"84494001"
dichlorphenamide	DB01144	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_101085	"3353"	MONDO_0005338	"10035015"	"84494001"
	DB11507	Glaucoma, Open-Angle	C0017612	NCT00862472	Withdrawn	Phase 3	Management decision not to conduct an additional efficacy study.			MONDO_0005338	"10035015"	"84494001"
carteolol	DB00521	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_3437	"2116"	MONDO_0005338	"10035015"	"84494001"
timolol	DB00373	Glaucoma, Open-Angle	C0017612	NCT00862472	Withdrawn	Phase 3	Management decision not to conduct an additional efficacy study.	CHEBI_9599	"1546004|10600"	MONDO_0005338	"10035015"	"84494001"
tafluprost	DB08819	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_66899	"1244607"	MONDO_0005338	"10035015"	"84494001"
bimatoprost	DB00905	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_51230	"283810"	MONDO_0005338	"10035015"	"84494001"
acetazolamide	DB00819	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_27690	"167"	MONDO_0005338	"10035015"	"84494001"
carbachol	DB00411	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_3385	"1546387|1999"	MONDO_0005338	"10035015"	"84494001"
paclitaxel	DB01229	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_45863	"56946"	MONDO_0005338	"10035015"	"84494001"
levobetaxolol	DB09351	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_59254	"353497"	MONDO_0005338	"10035015"	"84494001"
betaxolol	DB00195	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_3082	"1520"	MONDO_0005338	"10035015"	"84494001"
metipranolol	DB01214	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_6897	"10824"	MONDO_0005338	"10035015"	"84494001"
epinephrine	DB00668	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_28918	"3992"	MONDO_0005338	"10035015"	"84494001"
hydrocortamate	DB00741	Glaucoma, Open-Angle	C0017612	NCT00705770	Withdrawn	Phase 2/Phase 3	Change in study design	CHEBI_17650	"5492"	MONDO_0005338	"10035015"	"84494001"
hydrocortamate	DB00741	Glaucoma, Open-Angle	C0017612	NCT00788541	Terminated	Phase 2	Project cancellation	CHEBI_17650	"5492"	MONDO_0005338	"10035015"	"84494001"
pilocarpine	DB01085	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_8207	"8328"	MONDO_0005338	"10035015"	"84494001"
physostigmine	DB00981	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_27953	"8299"	MONDO_0005338	"10035015"	"84494001"
travoprost	DB00287	Glaucoma, Open-Angle	C0017612	NCT01312454	Terminated	Phase 2	Management decision	CHEBI_746859	"283809"	MONDO_0005338	"10035015"	"84494001"
levobunolol	DB01210	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_6438	"1813"	MONDO_0005338	"10035015"	"84494001"
travoprost	DB00287	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_746859	"283809"	MONDO_0005338	"10035015"	"84494001"
brimonidine	DB00484	Glaucoma, Open-Angle	C0017612	NCT00961649	Terminated	Phase 2		CHEBI_3175	"134615"	MONDO_0005338	"10035015"	"84494001"
aceclidine	DB13262	Glaucoma, Open-Angle	C0017612		Approved			CHEBI_93847		MONDO_0005338	"10035015"	"84494001"
liothyronine	DB00279	Goiter	C0018021		Approved			CHEBI_533015	"10814"	HP:0000853	"10018498"	"3716002"
levothyroxine	DB00451	Goiter	C0018021		Approved			CHEBI_58448	"10582"	HP:0000853	"10018498"	"3716002"
loratadine	DB00455	Hay fever	C0018621		Approved			CHEBI_6538	"28889"	HP:0012395	"10048908"	"21719001"
cyclizine	DB01176	Hay fever	C0018621		Approved			CHEBI_3994	"2977"	HP:0012395	"10048908"	"21719001"
desloratadine	DB00967	Hay fever	C0018621		Approved			CHEBI_291342	"275635"	HP:0012395	"10048908"	"21719001"
acrivastine	DB09488	Hay fever	C0018621		Approved			CHEBI_83168	"19959"	HP:0012395	"10048908"	"21719001"
chlorphenamine	DB01114	Hay fever	C0018621		Approved			CHEBI_52010	"221074|2400"	HP:0012395	"10048908"	"21719001"
dexbrompheniramine	DB00405	Hay fever	C0018621		Approved			CHEBI_59269	"22696|1767"	HP:0012395	"10048908"	"21719001"
chlorcyclizine	DB08936	Hay fever	C0018621		Approved			CHEBI_94402	"2354"	HP:0012395	"10048908"	"21719001"
cetirizine	DB00341	Hay fever	C0018621		Approved			CHEBI_3561	"20610"	HP:0012395	"10048908"	"21719001"
quifenadine	DB13713	Hay fever	C0018621		Approved			CHEBI_134746		HP:0012395	"10048908"	"21719001"
diphenhydramine	DB01075	Hay fever	C0018621		Approved			CHEBI_4636	"3498"	HP:0012395	"10048908"	"21719001"
doxylamine	DB00366	Hay fever	C0018621		Approved			CHEBI_51380	"3642"	HP:0012395	"10048908"	"21719001"
dexchlorpheniramine	DB09555	Hay fever	C0018621		Approved			CHEBI_4465	"54828"	HP:0012395	"10048908"	"21719001"
dexchlorpheniramine	DB13679	Hay fever	C0018621		Approved			CHEBI_4464	"22697"	HP:0012395	"10048908"	"21719001"
brompheniramine	DB00835	Hay fever	C0018621		Approved			CHEBI_3183	"1767"	HP:0012395	"10048908"	"21719001"
tramazoline	DB13064	Hay fever	C0018621		Approved			CHEBI_134893	"38453"	HP:0012395	"10048908"	"21719001"
triprolidine	DB00427	Hay fever	C0018621		Approved			CHEBI_84116	"10849"	HP:0012395	"10048908"	"21719001"
triamcinolone acetonide	DB00620	Hay fever	C0018621		Approved			CHEBI_9667	"10759"	HP:0012395	"10048908"	"21719001"
azelastine	DB00972	Hay fever	C0018621		Approved			CHEBI_2950	"18603"	HP:0012395	"10048908"	"21719001"
azatadine	DB00719	Hay fever	C0018621		Approved			CHEBI_2946	"18600"	HP:0012395	"10048908"	"21719001"
mepyramine	DB06691	Hay fever	C0018621		Approved			CHEBI_6762	"9009"	HP:0012395	"10048908"	"21719001"
pseudoephedrine	DB00852	Hay fever	C0018621		Approved			CHEBI_51209	"8896"	HP:0012395	"10048908"	"21719001"
promethazine	DB01069	Hay fever	C0018621		Approved			CHEBI_8461	"8745"	HP:0012395	"10048908"	"21719001"
phenyltoloxamine	DB11160	Hay fever	C0018621		Approved			CHEBI_135047	"33408"	HP:0012395	"10048908"	"21719001"
phenylpropanolamine	DB00397	Hay fever	C0018621		Approved			CHEBI_80680	"8175"	HP:0012395	"10048908"	"21719001"
phenylephrine	DB00388	Hay fever	C0018621		Approved			CHEBI_8093	"8163"	HP:0012395	"10048908"	"21719001"
pheniramine	DB01620	Hay fever	C0018621		Approved			CHEBI_91591	"8132"	HP:0012395	"10048908"	"21719001"
olopatadine	DB00768	Hay fever	C0018621		Approved			CHEBI_7769	"135391"	HP:0012395	"10048908"	"21719001"
methylprednisolone acetate	DB00959	Hay fever	C0018621		Approved			CHEBI_6888	"6902"	HP:0012395	"10048908"	"21719001"
omalizumab	DB00043	Hay fever	C0018621		Approved				"302379"	HP:0012395	"10048908"	"21719001"
levocetirizine	DB06282	Hay fever	C0018621		Approved			CHEBI_94559	"356887"	HP:0012395	"10048908"	"21719001"
fexofenadine	DB00950	Hay fever	C0018621		Approved			CHEBI_5050	"87636"	HP:0012395	"10048908"	"21719001"
ephedrine	DB01364	Hay fever	C0018621		Approved			CHEBI_15407	"3966"	HP:0012395	"10048908"	"21719001"
terfenadine	DB00342	Hay fever	C0018621		Approved			CHEBI_9453	"42330"	HP:0012395	"10048908"	"21719001"
carbinoxamine	DB00748	Hay fever	C0018621		Approved			CHEBI_3398	"20220"	HP:0012395	"10048908"	"21719001"
ciclesonide	DB01410	Hay fever	C0018621		Approved			CHEBI_31397	"274964"	HP:0012395	"10048908"	"21719001"
	DB01220	Hepatic Encephalopathy	C0019151	NCT02086825	Withdrawn	Phase 3		CHEBI_75246	"35619"	MONDO_0001711	"10019660"	"13920009"
rifaximin	DB01220	Hepatic Encephalopathy	C0019151		Approved			CHEBI_75246	"35619"	MONDO_0001711	"10019660"	"13920009"
neomycin	DB00994	Hepatic Encephalopathy	C0019151		Approved			CHEBI_7507	"7299"	MONDO_0001711	"10019660"	"13920009"
lactulose	DB00581	Hepatic Encephalopathy	C0019151	NCT00364689	Terminated	Phase 3	Difficult to recruit participants	CHEBI_6359	"6218"	MONDO_0001711	"10019660"	"13920009"
	DB01220	Hepatic Encephalopathy	C0019151	NCT00364689	Terminated	Phase 3	Difficult to recruit participants	CHEBI_75246	"35619"	MONDO_0001711	"10019660"	"13920009"
lactulose	DB00581	Hepatic Encephalopathy	C0019151		Approved			CHEBI_6359	"6218"	MONDO_0001711	"10019660"	"13920009"
lactulose	DB00581	Hepatic Encephalopathy	C0019151	NCT02086825	Withdrawn	Phase 3		CHEBI_6359	"6218"	MONDO_0001711	"10019660"	"13920009"
flumazenil	DB01205	Hepatic Encephalopathy	C0019151	NCT02048969	Withdrawn	Phase 1/Phase 2	No subjects were able to be recruited for the study.	CHEBI_5103	"4457"	MONDO_0001711	"10019660"	"13920009"
icatibant	DB06196	Angioedemas, Hereditary	C0019243		Approved			CHEBI_68556	"1148138"	MONDO_0019623	"10019860"	"82966003"
lanadelumab	DB14597	Angioedemas, Hereditary	C0019243		Approved				"2055641|2055640"	MONDO_0019623	"10019860"	"82966003"
stanozolol	DB06718	Angioedemas, Hereditary	C0019243		Approved			CHEBI_9249	"10032"	MONDO_0019623	"10019860"	"82966003"
ecallantide	DB05311	Angioedemas, Hereditary	C0019243		Approved				"658708"	MONDO_0019623	"10019860"	"82966003"
berotralstat	DB15982	Angioedemas, Hereditary	C0019243		Approved				"2467540"	MONDO_0019623	"10019860"	"82966003"
tenofovir disoproxil	DB14126	HIV Infections	C0019693		Approved			CHEBI_63625	"1546017|117466"	MONDO_0005109	"10020161"	"86406008"
elvitegravir	DB09101	HIV Infections	C0019693		Approved			CHEBI_72289	"1306286"	MONDO_0005109	"10020161"	"86406008"
tenofovir disoproxil	DB00300	HIV Infections	C0019693		Approved			CHEBI_63717	"300195"	MONDO_0005109	"10020161"	"86406008"
stavudine	DB00649	HIV Infections	C0019693		Approved			CHEBI_63581	"59763"	MONDO_0005109	"10020161"	"86406008"
delavirdine	DB00705	HIV Infections	C0019693		Approved			CHEBI_119573	"83816"	MONDO_0005109	"10020161"	"86406008"
raltegravir	DB06817	HIV Infections	C0019693		Approved			CHEBI_82960	"719872"	MONDO_0005109	"10020161"	"86406008"
tenofovir	DB14126	HIV Infections	C0019693		Approved			CHEBI_63625	"1546017|117466"	MONDO_0005109	"10020161"	"86406008"
nelfinavir	DB00220	HIV Infections	C0019693		Approved			CHEBI_7496	"134527"	MONDO_0005109	"10020161"	"86406008"
fosamprenavir	DB01319	HIV Infections	C0019693		Approved			CHEBI_82941	"358262"	MONDO_0005109	"10020161"	"86406008"
dolutegravir	DB08930	HIV Infections	C0019693		Approved			CHEBI_76010	"1433868"	MONDO_0005109	"10020161"	"86406008"
amprenavir	DB00701	HIV Infections	C0019693		Approved			CHEBI_40050	"228656"	MONDO_0005109	"10020161"	"86406008"
darunavir	DB01264	HIV Infections	C0019693		Approved			CHEBI_367163	"460132"	MONDO_0005109	"10020161"	"86406008"
saquinavir	DB01232	HIV Infections	C0019693		Approved			CHEBI_63621	"83395"	MONDO_0005109	"10020161"	"86406008"
fosamprenavir	DB00701	HIV Infections	C0019693		Approved			CHEBI_40050	"228656"	MONDO_0005109	"10020161"	"86406008"
abacavir	DB01048	HIV Infections	C0019693		Approved			CHEBI_421707	"190521"	MONDO_0005109	"10020161"	"86406008"
tenofovir alafenamide	DB14126	HIV Infections	C0019693		Approved			CHEBI_63625	"1546017|117466"	MONDO_0005109	"10020161"	"86406008"
indinavir	DB00224	HIV Infections	C0019693		Approved			CHEBI_44032	"114289|1546024"	MONDO_0005109	"10020161"	"86406008"
tipranavir	DB00932	HIV Infections	C0019693		Approved			CHEBI_63628	"190548"	MONDO_0005109	"10020161"	"86406008"
emtricitabine	DB00879	HIV Infections	C0019693		Approved			CHEBI_31536	"276237"	MONDO_0005109	"10020161"	"86406008"
zalcitabine	DB00943	HIV Infections	C0019693		Approved			CHEBI_10101	"3363"	MONDO_0005109	"10020161"	"86406008"
efavirenz	DB00625	HIV Infections	C0019693		Approved			CHEBI_119486	"195085"	MONDO_0005109	"10020161"	"86406008"
etravirine	DB06414	HIV Infections	C0019693		Approved			CHEBI_63589	"475969"	MONDO_0005109	"10020161"	"86406008"
zidovudine	DB00495	HIV Infections	C0019693		Approved			CHEBI_10110	"11413"	MONDO_0005109	"10020161"	"86406008"
didanosine	DB00900	HIV Infections	C0019693		Approved			CHEBI_490877	"3364"	MONDO_0005109	"10020161"	"86406008"
lopinavir	DB01601	HIV Infections	C0019693		Approved			CHEBI_31781	"195088"	MONDO_0005109	"10020161"	"86406008"
atazanavir	DB01072	HIV Infections	C0019693		Approved			CHEBI_37924	"343047"	MONDO_0005109	"10020161"	"86406008"
cobicistat	DB09065	HIV Infections	C0019693		Approved			CHEBI_72291	"1306284"	MONDO_0005109	"10020161"	"86406008"
bictegravir	DB11799	HIV Infections	C0019693		Approved			CHEBI_172943	"1999660"	MONDO_0005109	"10020161"	"86406008"
ibalizumab	DB12698	HIV Infections	C0019693		Approved				"2043313|2043283"	MONDO_0005109	"10020161"	"86406008"
lamivudine	DB00709	HIV Infections	C0019693		Approved			CHEBI_63577	"68244"	MONDO_0005109	"10020161"	"86406008"
tenofovir alafenamide	DB09299	HIV Infections	C0019693		Approved			CHEBI_90926	"1721603"	MONDO_0005109	"10020161"	"86406008"
ritonavir	DB00503	HIV Infections	C0019693		Approved			CHEBI_45409	"85762"	MONDO_0005109	"10020161"	"86406008"
doravirine	DB12301	HIV Infections	C0019693		Approved				"2055755"	MONDO_0005109	"10020161"	"86406008"
nevirapine	DB00238	HIV Infections	C0019693		Approved			CHEBI_63613	"53654"	MONDO_0005109	"10020161"	"86406008"
rilpivirine	DB08864	HIV Infections	C0019693		Approved			CHEBI_68606	"1102270"	MONDO_0005109	"10020161"	"86406008"
tenofovir	DB14126	HIV Infections	C0019693	NCT01737359	Terminated	Phase 2		CHEBI_63625	"1546017|117466"	MONDO_0005109	"10020161"	"86406008"
enfuvirtide	DB00109	HIV Infections	C0019693		Approved			CHEBI_608828	"139896"	MONDO_0005109	"10020161"	"86406008"
thalidomide	DB01041	Hodgkin Disease	C0019829	NCT00209014	Terminated	Phase 2	Celgene unable to continue funds.	CHEBI_74947	"10432"	MONDO_0009348	"10020206"	"118602004"
hydrocortisone	DB00741	Hodgkin Disease	C0019829		Approved			CHEBI_17650	"5492"	MONDO_0009348	"10020206"	"118602004"
brentuximab vedotin	DB08870	Hodgkin Disease	C0019829		Approved				"1147320"	MONDO_0009348	"10020206"	"118602004"
betamethasone acetate	DB00443	Hodgkin Disease	C0019829		Approved			CHEBI_3077	"1514"	MONDO_0009348	"10020206"	"118602004"
thiotepa	DB04572	Hodgkin Disease	C0019829		Approved			CHEBI_9570	"10473"	MONDO_0009348	"10020206"	"118602004"
triamcinolone	DB00620	Hodgkin Disease	C0019829		Approved			CHEBI_9667	"10759"	MONDO_0009348	"10020206"	"118602004"
betamethasone	DB00443	Hodgkin Disease	C0019829		Approved			CHEBI_3077	"1514"	MONDO_0009348	"10020206"	"118602004"
carmustine	DB00262	Hodgkin Disease	C0019829		Approved			CHEBI_3423	"2105"	MONDO_0009348	"10020206"	"118602004"
lomustine	DB01206	Hodgkin Disease	C0019829		Approved			CHEBI_6520	"6466"	MONDO_0009348	"10020206"	"118602004"
bleomycin	DB00290	Hodgkin Disease	C0019829		Approved			CHEBI_22907	"1622"	MONDO_0009348	"10020206"	"118602004"
hydrocortisone succinate	DB14545	Hodgkin Disease	C0019829		Approved			CHEBI_31677	"21651"	MONDO_0009348	"10020206"	"118602004"
chlorambucil	DB00291	Hodgkin Disease	C0019829		Approved			CHEBI_28830	"2346"	MONDO_0009348	"10020206"	"118602004"
prednisolone	DB00860	Hodgkin Disease	C0019829		Approved			CHEBI_8378	"8638"	MONDO_0009348	"10020206"	"118602004"
triamcinolone acetonide	DB00620	Hodgkin Disease	C0019829		Approved			CHEBI_9667	"10759"	MONDO_0009348	"10020206"	"118602004"
alemtuzumab	DB00087	Hodgkin Disease	C0019829	NCT00129753	Withdrawn	Phase 2	Terminated due to slow accrual.		"117055"	MONDO_0009348	"10020206"	"118602004"
methylprednisolone	DB00959	Hodgkin Disease	C0019829		Approved			CHEBI_6888	"6902"	MONDO_0009348	"10020206"	"118602004"
triamcinolone diacetate	DB00620	Hodgkin Disease	C0019829		Approved			CHEBI_9667	"10759"	MONDO_0009348	"10020206"	"118602004"
prednisone	DB00635	Hodgkin Disease	C0019829		Approved			CHEBI_8382	"8640"	MONDO_0009348	"10020206"	"118602004"
hydrocortisone succinate	DB00741	Hodgkin Disease	C0019829		Approved			CHEBI_17650	"5492"	MONDO_0009348	"10020206"	"118602004"
hydrocortisone acetate	DB14539	Hodgkin Disease	C0019829		Approved			CHEBI_17609	"27197"	MONDO_0009348	"10020206"	"118602004"
procarbazine	DB01168	Hodgkin Disease	C0019829		Approved			CHEBI_71417	"8702"	MONDO_0009348	"10020206"	"118602004"
doxorubicin	DB00997	Hodgkin Disease	C0019829		Approved			CHEBI_28748	"142433|3639"	MONDO_0009348	"10020206"	"118602004"
dexamethasone	DB01234	Hodgkin Disease	C0019829		Approved			CHEBI_41879	"3264"	MONDO_0009348	"10020206"	"118602004"
hydrocortisone acetate	DB00741	Hodgkin Disease	C0019829		Approved			CHEBI_17650	"5492"	MONDO_0009348	"10020206"	"118602004"
dacarbazine	DB00851	Hodgkin Disease	C0019829		Approved			CHEBI_4305	"3098"	MONDO_0009348	"10020206"	"118602004"
vincristine	DB00541	Hodgkin Disease	C0019829		Approved			CHEBI_28445	"11202"	MONDO_0009348	"10020206"	"118602004"
vinblastine	DB00570	Hodgkin Disease	C0019829		Approved			CHEBI_27375	"11198"	MONDO_0009348	"10020206"	"118602004"
cortisone acetate	DB01380	Hodgkin Disease	C0019829		Approved			CHEBI_3897	"21655"	MONDO_0009348	"10020206"	"118602004"
mechlorethamine	DB00888	Hodgkin Disease	C0019829		Approved			CHEBI_28925	"6674"	MONDO_0009348	"10020206"	"118602004"
pentostatin	DB00552	Hodgkin Disease	C0019829	NCT00698685	Terminated	Phase 2	Pentostatin/alemtuzumab regimen had greater risk of graft failure.	CHEBI_27834	"8011"	MONDO_0009348	"10020206"	"118602004"
	DB00087	Hodgkin Disease	C0019829	NCT00698685	Terminated	Phase 2	Pentostatin/alemtuzumab regimen had greater risk of graft failure.		"117055"	MONDO_0009348	"10020206"	"118602004"
fenofibrate	DB01039	Hypercholesterolemia	C0020443		Approved			CHEBI_5001	"8703"	HP:0003124	"10020603"	"13644009"
cholestyramine	DB01432	Hypercholesterolemia	C0020443		Approved				"2447"	HP:0003124	"10020603"	"13644009"
simvastatin	DB00641	Hypercholesterolemia	C0020443		Approved			CHEBI_9150	"36567"	HP:0003124	"10020603"	"13644009"
rosuvastatin	DB01098	Hypercholesterolemia	C0020443		Approved			CHEBI_38545	"301542"	HP:0003124	"10020603"	"13644009"
atorvastatin	DB01076	Hypercholesterolemia	C0020443	NCT00437892	Terminated	Phase 2	Competitive trials and slow recruitment rate	CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
ezetimibe	DB00973	Hypercholesterolemia	C0020443	NCT00664469	Terminated	Phase 3	Poor enrollment	CHEBI_49040	"341248"	HP:0003124	"10020603"	"13644009"
	DB00641	Hypercholesterolemia	C0020443	NCT00664469	Terminated	Phase 3	Poor enrollment	CHEBI_9150	"36567"	HP:0003124	"10020603"	"13644009"
atorvastatin	DB01076	Hypercholesterolemia	C0020443		Approved			CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
betahistine	DB06698	Hypercholesterolemia	C0020443	NCT00466869	Terminated	Phase 2	Sponsor decision	CHEBI_35677	"1511"	HP:0003124	"10020603"	"13644009"
cerivastatin	DB00439	Hypercholesterolemia	C0020443		Approved			CHEBI_3558	"596723"	HP:0003124	"10020603"	"13644009"
pitavastatin	DB08860	Hypercholesterolemia	C0020443		Approved			CHEBI_32020	"861634"	HP:0003124	"10020603"	"13644009"
pravastatin	DB00175	Hypercholesterolemia	C0020443		Approved			CHEBI_63618	"42463"	HP:0003124	"10020603"	"13644009"
	DB01076	Hypercholesterolemia	C0020443	NCT00664469	Terminated	Phase 3	Poor enrollment	CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
evolocumab	DB09303	Hypercholesterolemia	C0020443		Approved				"1665684"	HP:0003124	"10020603"	"13644009"
colesevelam	DB00930	Hypercholesterolemia	C0020443		Approved			CHEBI_59594	"141626"	HP:0003124	"10020603"	"13644009"
fluvastatin	DB01095	Hypercholesterolemia	C0020443		Approved			CHEBI_38562	"41127"	HP:0003124	"10020603"	"13644009"
	DB00641	Hypercholesterolemia	C0020443	NCT00249899	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_9150	"36567"	HP:0003124	"10020603"	"13644009"
	DB01098	Hypercholesterolemia	C0020443	NCT00532311	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_38545	"301542"	HP:0003124	"10020603"	"13644009"
nicotinic acid	DB00627	Hypercholesterolemia	C0020443		Approved			CHEBI_15940	"7393"	HP:0003124	"10020603"	"13644009"
atorvastatin	DB01076	Hypercholesterolemia	C0020443	NCT00741715	Terminated	Phase 3	AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy	CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
	DB01076	Hypercholesterolemia	C0020443	NCT02260648	Terminated	Phase 3	Study termination due to insufficient efficacy.	CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
lovastatin	DB00227	Hypercholesterolemia	C0020443	NCT00532311	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_40303	"6472"	HP:0003124	"10020603"	"13644009"
	DB01098	Hypercholesterolemia	C0020443	NCT00664469	Terminated	Phase 3	Poor enrollment	CHEBI_38545	"301542"	HP:0003124	"10020603"	"13644009"
	DB01076	Hypercholesterolemia	C0020443	NCT00249899	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
choline fenofibrate	DB13873	Hypercholesterolemia	C0020443		Approved			CHEBI_83469	"24852"	HP:0003124	"10020603"	"13644009"
rosuvastatin	DB01098	Hypercholesterolemia	C0020443	NCT00249899	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_38545	"301542"	HP:0003124	"10020603"	"13644009"
colestipol	DB00375	Hypercholesterolemia	C0020443		Approved			CHEBI_3814	"2685"	HP:0003124	"10020603"	"13644009"
alirocumab	DB09302	Hypercholesterolemia	C0020443		Approved				"1659152"	HP:0003124	"10020603"	"13644009"
tyramine	DB08841	Hypercholesterolemia	C0020443		Approved			CHEBI_15760	"10958"	HP:0003124	"10020603"	"13644009"
	DB00641	Hypercholesterolemia	C0020443	NCT00651391	Terminated	Phase 3	Slow enrollment	CHEBI_9150	"36567"	HP:0003124	"10020603"	"13644009"
ezetimibe	DB00973	Hypercholesterolemia	C0020443	NCT00651391	Terminated	Phase 3	Slow enrollment	CHEBI_49040	"341248"	HP:0003124	"10020603"	"13644009"
ezetimibe	DB00973	Hypercholesterolemia	C0020443	NCT02260648	Terminated	Phase 3	Study termination due to insufficient efficacy.	CHEBI_49040	"341248"	HP:0003124	"10020603"	"13644009"
ezetimibe	DB00973	Hypercholesterolemia	C0020443		Approved			CHEBI_49040	"341248"	HP:0003124	"10020603"	"13644009"
	DB01076	Hypercholesterolemia	C0020443	NCT00267280	Terminated	Phase 3		CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
bezafibrate	DB01393	Hypercholesterolemia	C0020443		Approved			CHEBI_47612	"1525"	HP:0003124	"10020603"	"13644009"
simvastatin	DB00641	Hypercholesterolemia	C0020443	NCT00267280	Terminated	Phase 3		CHEBI_9150	"36567"	HP:0003124	"10020603"	"13644009"
	DB00175	Hypercholesterolemia	C0020443	NCT00532311	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_63618	"42463"	HP:0003124	"10020603"	"13644009"
Vitamin E	DB00163	Hypercholesterolemia	C0020443	NCT02634606	Terminated	Phase 3	Unable to obtain supplement for this study. Unable to recruit.	CHEBI_18145	"11256|237099"	HP:0003124	"10020603"	"13644009"
lovastatin	DB00227	Hypercholesterolemia	C0020443		Approved			CHEBI_40303	"6472"	HP:0003124	"10020603"	"13644009"
	DB00641	Hypercholesterolemia	C0020443	NCT00532311	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_9150	"36567"	HP:0003124	"10020603"	"13644009"
inositol	DB13178	Hypercholesterolemia	C0020443		Approved			CHEBI_17268	"5833"	HP:0003124	"10020603"	"13644009"
probucol	DB01599	Hypercholesterolemia	C0020443		Approved			CHEBI_8427	"8699"	HP:0003124	"10020603"	"13644009"
	DB01076	Hypercholesterolemia	C0020443	NCT00532311	Terminated	Phase 3	Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents	CHEBI_39548	"83367"	HP:0003124	"10020603"	"13644009"
bezafibrate	DB01393	Hyperlipidemia	C0020473		Approved			CHEBI_47612	"1525"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB00966	Hyperlipidemia	C0020473	NCT02608242	Terminated	Phase 1	sponsor decision	CHEBI_9434	"73494"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
colestipol	DB00375	Hyperlipidemia	C0020473		Approved			CHEBI_3814	"2685"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
atorvastatin	DB01076	Hyperlipidemia	C0020473	NCT00663234	Terminated	Phase 1/Phase 2	The study was prematurely discontinued due to administrative reasons.	CHEBI_39548	"83367"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
cholestyramine	DB01432	Hyperlipidemia	C0020473		Approved				"2447"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
tyramine	DB08841	Hyperlipidemia	C0020473		Approved			CHEBI_15760	"10958"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
etofibrate	DB00627	Hyperlipidemia	C0020473	NCT00108485	Terminated	Phase 3	Unable to recruit sufficient study subjects	CHEBI_15940	"7393"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
nicotinic acid	DB00627	Hyperlipidemia	C0020473		Approved			CHEBI_15940	"7393"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
lovastatin	DB00227	Hyperlipidemia	C0020473		Approved			CHEBI_40303	"6472"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
icosapent ethyl	DB08887	Hyperlipidemia	C0020473		Approved			CHEBI_84883	"1304974"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
colestilan	DB11634	Hyperlipidemia	C0020473		Approved			CHEBI_31428		MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
choline fenofibrate	DB13873	Hyperlipidemia	C0020473		Approved			CHEBI_83469	"24852"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
nicotinyl alcohol	DB04145	Hyperlipidemia	C0020473		Approved			CHEBI_45213		MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB00641	Hyperlipidemia	C0020473	NCT00267267	Terminated	Phase 3		CHEBI_9150	"36567"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB01076	Hyperlipidemia	C0020473	NCT00267267	Terminated	Phase 3		CHEBI_39548	"83367"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
amlodipine	DB00381	Hyperlipidemia	C0020473	NCT02608242	Terminated	Phase 1	sponsor decision	CHEBI_2668	"17767"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
dextrothyroxine	DB00509	Hyperlipidemia	C0020473		Approved			CHEBI_30659	"3292"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB01098	Hyperlipidemia	C0020473	NCT02608242	Terminated	Phase 1	sponsor decision	CHEBI_38545	"301542"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
clofibrate	DB00636	Hyperlipidemia	C0020473		Approved			CHEBI_3750	"2594"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
topiramate	DB00273	Hyperlipidemia	C0020473	NCT00231621	Terminated	Phase 3	The study was terminated prior to completion to focus on the development of a controlled release formulation.	CHEBI_63631	"38404"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB03128	Hyperlipidemia	C0020473	NCT00166166	Terminated	Phase 2	Limited clinical staff	CHEBI_15355	"194"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB00325	Hyperlipidemia	C0020473	NCT00166166	Terminated	Phase 2	Limited clinical staff	CHEBI_7596	"7476"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
fluconazole	DB00196	Hyperlipidemia	C0020473	NCT00166166	Terminated	Phase 2	Limited clinical staff	CHEBI_46081	"202813|4450"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
levothyroxine	DB00451	Hyperlipidemia	C0020473		Approved			CHEBI_58448	"10582"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
atorvastatin	DB01076	Hyperlipidemia	C0020473	NCT00004466	Terminated	Phase 2	Very poor enrollment	CHEBI_39548	"83367"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
fenofibrate	DB01039	Hyperlipidemia	C0020473		Approved			CHEBI_5001	"8703"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
ezetimibe	DB00973	Hyperlipidemia	C0020473		Approved			CHEBI_49040	"341248"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
simvastatin	DB00641	Hyperlipidemia	C0020473	NCT00267280	Terminated	Phase 3		CHEBI_9150	"36567"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB01076	Hyperlipidemia	C0020473	NCT00267280	Terminated	Phase 3		CHEBI_39548	"83367"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
ezetimibe	DB00973	Hyperlipidemia	C0020473	NCT02227784	Terminated	Phase 3	Study termination due to program termination.	CHEBI_49040	"341248"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
	DB01076	Hyperlipidemia	C0020473	NCT02227784	Terminated	Phase 3	Study termination due to program termination.	CHEBI_39548	"83367"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
probucol	DB01599	Hyperlipidemia	C0020473		Approved			CHEBI_8427	"8699"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
ezetimibe	DB00973	Hyperlipidemia	C0020473	NCT00267267	Terminated	Phase 3		CHEBI_49040	"341248"	MONDO_0001336|MONDO_0013577|MONDO_0015901|MONDO_0021187	"10062060"	"55822004"
zofenopril	DB13166	Hypertensive disease	C0020538		Approved			CHEBI_78539	"39990"	MONDO_0005044	"10020772"	"38341003"
benazepril	DB14125	Hypertensive disease	C0020538		Approved			CHEBI_88200		MONDO_0005044	"10020772"	"38341003"
furosemide	DB00695	Hypertensive disease	C0020538		Approved			CHEBI_47426	"4603"	MONDO_0005044	"10020772"	"38341003"
enalaprilat	DB09477	Hypertensive disease	C0020538		Approved			CHEBI_4786	"1545989|3829"	MONDO_0005044	"10020772"	"38341003"
chlortalidone	DB00310	Hypertensive disease	C0020538		Approved			CHEBI_3654	"2409"	MONDO_0005044	"10020772"	"38341003"
endralazine	DB13435	Hypertensive disease	C0020538		Approved			CHEBI_135105		MONDO_0005044	"10020772"	"38341003"
xipamide	DB13803	Hypertensive disease	C0020538		Approved			CHEBI_135499		MONDO_0005044	"10020772"	"38341003"
cilazapril	DB01340	Hypertensive disease	C0020538		Approved			CHEBI_3698	"21102"	MONDO_0005044	"10020772"	"38341003"
cilazapril	DB15565	Hypertensive disease	C0020538		Approved			CHEBI_81005		MONDO_0005044	"10020772"	"38341003"
prazosin	DB00457	Hypertensive disease	C0020538		Approved			CHEBI_8364	"8629"	MONDO_0005044	"10020772"	"38341003"
perindopril	DB14213	Hypertensive disease	C0020538		Approved			CHEBI_132041		MONDO_0005044	"10020772"	"38341003"
benazepril	DB00542	Hypertensive disease	C0020538		Approved			CHEBI_3011	"18867"	MONDO_0005044	"10020772"	"38341003"
fosinopril	DB14207	Hypertensive disease	C0020538		Approved			CHEBI_116962		MONDO_0005044	"10020772"	"38341003"
fosinopril	DB00492	Hypertensive disease	C0020538		Approved			CHEBI_5163	"50166"	MONDO_0005044	"10020772"	"38341003"
clevidipine	DB04920	Hypertensive disease	C0020538		Approved			CHEBI_135738	"233603|977863"	MONDO_0005044	"10020772"	"38341003"
mecamylamine	DB00657	Hypertensive disease	C0020538		Approved			CHEBI_6706	"6673"	MONDO_0005044	"10020772"	"38341003"
perindopril	DB00790	Hypertensive disease	C0020538		Approved			CHEBI_8024	"54552"	MONDO_0005044	"10020772"	"38341003"
carteolol	DB00521	Hypertensive disease	C0020538		Approved			CHEBI_3437	"2116"	MONDO_0005044	"10020772"	"38341003"
rilmenidine	DB11738	Hypertensive disease	C0020538		Approved			CHEBI_8862	"55679"	MONDO_0005044	"10020772"	"38341003"
clonidine	DB00575	Hypertensive disease	C0020538		Approved			CHEBI_46632	"2599"	MONDO_0005044	"10020772"	"38341003"
labetalol	DB00598	Hypertensive disease	C0020538		Approved			CHEBI_167638	"6185"	MONDO_0005044	"10020772"	"38341003"
verapamil	DB00661	Hypertensive disease	C0020538		Approved			CHEBI_77733	"11170"	MONDO_0005044	"10020772"	"38341003"
celiprolol	DB04846	Hypertensive disease	C0020538		Approved			CHEBI_94461	"20498"	MONDO_0005044	"10020772"	"38341003"
ketanserin	DB12465	Hypertensive disease	C0020538		Approved			CHEBI_6123	"6131"	MONDO_0005044	"10020772"	"38341003"
reserpine	DB00206	Hypertensive disease	C0020538		Approved			CHEBI_28487	"9260"	MONDO_0005044	"10020772"	"38341003"
valsartan	DB00177	Hypertensive disease	C0020538		Approved			CHEBI_9927	"69749"	MONDO_0005044	"10020772"	"38341003"
nadolol	DB01203	Hypertensive disease	C0020538		Approved			CHEBI_7444	"7226"	MONDO_0005044	"10020772"	"38341003"
isradipine	DB00270	Hypertensive disease	C0020538		Approved			CHEBI_6073	"33910"	MONDO_0005044	"10020772"	"38341003"
isotretinoin	DB00982	Hypertensive disease	C0020538		Approved			CHEBI_6067	"6064"	MONDO_0005044	"10020772"	"38341003"
carvedilol	DB01136	Hypertensive disease	C0020538		Approved			CHEBI_3441	"20352"	MONDO_0005044	"10020772"	"38341003"
sacubitril	DB09292	Hypertensive disease	C0020538		Approved			CHEBI_134714	"1656328"	MONDO_0005044	"10020772"	"38341003"
pargyline	DB01626	Hypertensive disease	C0020538		Approved			CHEBI_7930	"7930"	MONDO_0005044	"10020772"	"38341003"
doxazosin	DB00590	Hypertensive disease	C0020538		Approved			CHEBI_4708	"49276"	MONDO_0005044	"10020772"	"38341003"
diltiazem	DB00343	Hypertensive disease	C0020538		Approved			CHEBI_101278	"3443"	MONDO_0005044	"10020772"	"38341003"
betaxolol	DB00195	Hypertensive disease	C0020538		Approved			CHEBI_3082	"1520"	MONDO_0005044	"10020772"	"38341003"
moexipril	DB00691	Hypertensive disease	C0020538		Approved			CHEBI_6960	"30131"	MONDO_0005044	"10020772"	"38341003"
zofenopril	DB08766	Hypertensive disease	C0020538		Approved			CHEBI_82602		MONDO_0005044	"10020772"	"38341003"
chlorothiazide	DB00880	Hypertensive disease	C0020538		Approved			CHEBI_3640	"2396"	MONDO_0005044	"10020772"	"38341003"
bendroflumethiazide	DB00436	Hypertensive disease	C0020538		Approved			CHEBI_3013	"1369"	MONDO_0005044	"10020772"	"38341003"
minoxidil	DB00350	Hypertensive disease	C0020538		Approved			CHEBI_6942	"6984"	MONDO_0005044	"10020772"	"38341003"
enalapril	DB09477	Hypertensive disease	C0020538		Approved			CHEBI_4786	"1545989|3829"	MONDO_0005044	"10020772"	"38341003"
hydralazine	DB01275	Hypertensive disease	C0020538		Approved			CHEBI_5775	"5470"	MONDO_0005044	"10020772"	"38341003"
acebutolol	DB01193	Hypertensive disease	C0020538		Approved			CHEBI_2379	"149"	MONDO_0005044	"10020772"	"38341003"
trandolapril	DB00519	Hypertensive disease	C0020538		Approved			CHEBI_9649	"38454"	MONDO_0005044	"10020772"	"38341003"
bupranolol	DB08808	Hypertensive disease	C0020538		Approved			CHEBI_135123		MONDO_0005044	"10020772"	"38341003"
temocapril	DB08836	Hypertensive disease	C0020538		Approved			CHEBI_135771		MONDO_0005044	"10020772"	"38341003"
delapril	DB13312	Hypertensive disease	C0020538		Approved			CHEBI_135735		MONDO_0005044	"10020772"	"38341003"
guanabenz	DB00629	Hypertensive disease	C0020538		Approved			CHEBI_5553	"5033"	MONDO_0005044	"10020772"	"38341003"
trandolapril	DB14209	Hypertensive disease	C0020538		Approved			CHEBI_141521		MONDO_0005044	"10020772"	"38341003"
telmisartan	DB00966	Hypertensive disease	C0020538		Approved			CHEBI_9434	"73494"	MONDO_0005044	"10020772"	"38341003"
quinapril	DB14217	Hypertensive disease	C0020538		Approved			CHEBI_140296		MONDO_0005044	"10020772"	"38341003"
azilsartan medoxomil	DB08822	Hypertensive disease	C0020538		Approved			CHEBI_68845	"1091643|1091642"	MONDO_0005044	"10020772"	"38341003"
quinapril	DB00881	Hypertensive disease	C0020538		Approved			CHEBI_8713	"35208"	MONDO_0005044	"10020772"	"38341003"
aranidipine	DB09229	Hypertensive disease	C0020538		Approved			CHEBI_31232		MONDO_0005044	"10020772"	"38341003"
aliskiren	DB09026	Hypertensive disease	C0020538		Approved			CHEBI_601027	"325646"	MONDO_0005044	"10020772"	"38341003"
guanadrel	DB00226	Hypertensive disease	C0020538		Approved			CHEBI_5555	"26296"	MONDO_0005044	"10020772"	"38341003"
guanethidine	DB01170	Hypertensive disease	C0020538		Approved			CHEBI_5557	"5036"	MONDO_0005044	"10020772"	"38341003"
guanfacine	DB01018	Hypertensive disease	C0020538		Approved			CHEBI_5558	"40114"	MONDO_0005044	"10020772"	"38341003"
amiloride	DB00594	Hypertensive disease	C0020538		Approved			CHEBI_2639	"644"	MONDO_0005044	"10020772"	"38341003"
spirapril	DB01348	Hypertensive disease	C0020538		Approved			CHEBI_135756	"36908"	MONDO_0005044	"10020772"	"38341003"
spironolactone	DB00421	Hypertensive disease	C0020538		Approved			CHEBI_9241	"9997"	MONDO_0005044	"10020772"	"38341003"
oxprenolol	DB01580	Hypertensive disease	C0020538		Approved			CHEBI_91704	"7801"	MONDO_0005044	"10020772"	"38341003"
metoprolol	DB00264	Hypertensive disease	C0020538		Approved			CHEBI_6904	"6918"	MONDO_0005044	"10020772"	"38341003"
pindolol	DB00960	Hypertensive disease	C0020538		Approved			CHEBI_8214	"8332"	MONDO_0005044	"10020772"	"38341003"
azelnidipine	DB09230	Hypertensive disease	C0020538		Approved			CHEBI_31247		MONDO_0005044	"10020772"	"38341003"
metolazone	DB00524	Hypertensive disease	C0020538		Approved			CHEBI_64354	"6916"	MONDO_0005044	"10020772"	"38341003"
felodipine	DB01023	Hypertensive disease	C0020538		Approved			CHEBI_585948	"4316"	MONDO_0005044	"10020772"	"38341003"
tasosartan	DB01349	Hypertensive disease	C0020538		Approved			CHEBI_135666		MONDO_0005044	"10020772"	"38341003"
candesartan cilexetil	DB00796	Hypertensive disease	C0020538		Approved			CHEBI_3348	"135481"	MONDO_0005044	"10020772"	"38341003"
bisoprolol	DB00612	Hypertensive disease	C0020538		Approved			CHEBI_3127	"19484"	MONDO_0005044	"10020772"	"38341003"
candesartan cilexetil	DB13919	Hypertensive disease	C0020538		Approved			CHEBI_3347		MONDO_0005044	"10020772"	"38341003"
talinolol	DB11770	Hypertensive disease	C0020538		Approved			CHEBI_135533	"37546"	MONDO_0005044	"10020772"	"38341003"
penbutolol	DB01359	Hypertensive disease	C0020538		Approved			CHEBI_7954	"7973"	MONDO_0005044	"10020772"	"38341003"
atenolol	DB00335	Hypertensive disease	C0020538		Approved			CHEBI_2904	"1202"	MONDO_0005044	"10020772"	"38341003"
meticrane	DB13284	Hypertensive disease	C0020538		Approved			CHEBI_31839		MONDO_0005044	"10020772"	"38341003"
paclitaxel	DB01229	Hypertensive disease	C0020538		Approved			CHEBI_45863	"56946"	MONDO_0005044	"10020772"	"38341003"
terazosin	DB01162	Hypertensive disease	C0020538		Approved			CHEBI_9445	"37798"	MONDO_0005044	"10020772"	"38341003"
lisinopril	DB00722	Hypertensive disease	C0020538		Approved			CHEBI_43755	"1546022|29046"	MONDO_0005044	"10020772"	"38341003"
pinacidil	DB06762	Hypertensive disease	C0020538		Approved			CHEBI_91706	"33717"	MONDO_0005044	"10020772"	"38341003"
hydroflumethiazide	DB00774	Hypertensive disease	C0020538		Approved			CHEBI_5784	"5495"	MONDO_0005044	"10020772"	"38341003"
efonidipine	DB09235	Hypertensive disease	C0020538		Approved			CHEBI_135859		MONDO_0005044	"10020772"	"38341003"
propranolol	DB00571	Hypertensive disease	C0020538		Approved			CHEBI_8499	"8787"	MONDO_0005044	"10020772"	"38341003"
nebivolol	DB04861	Hypertensive disease	C0020538		Approved			CHEBI_64019	"31555"	MONDO_0005044	"10020772"	"38341003"
enalapril	DB00584	Hypertensive disease	C0020538		Approved			CHEBI_4784	"3827"	MONDO_0005044	"10020772"	"38341003"
nicardipine	DB00622	Hypertensive disease	C0020538		Approved			CHEBI_180905	"7396"	MONDO_0005044	"10020772"	"38341003"
irbesartan	DB01029	Hypertensive disease	C0020538		Approved			CHEBI_5959	"83818"	MONDO_0005044	"10020772"	"38341003"
polythiazide	DB01324	Hypertensive disease	C0020538		Approved			CHEBI_8327	"8565"	MONDO_0005044	"10020772"	"38341003"
amlodipine	DB00381	Hypertensive disease	C0020538		Approved			CHEBI_2668	"17767"	MONDO_0005044	"10020772"	"38341003"
trimazosin	DB09206	Hypertensive disease	C0020538		Approved			CHEBI_135710		MONDO_0005044	"10020772"	"38341003"
piretanide	DB02925	Hypertensive disease	C0020538		Approved			CHEBI_32015	"33770"	MONDO_0005044	"10020772"	"38341003"
nifedipine	DB01115	Hypertensive disease	C0020538		Approved			CHEBI_7565	"7417"	MONDO_0005044	"10020772"	"38341003"
nisoldipine	DB00401	Hypertensive disease	C0020538		Approved			CHEBI_76917	"7435"	MONDO_0005044	"10020772"	"38341003"
trichlormethiazide	DB01021	Hypertensive disease	C0020538		Approved			CHEBI_9683	"10772"	MONDO_0005044	"10020772"	"38341003"
triamterene	DB00384	Hypertensive disease	C0020538		Approved			CHEBI_9671	"10763"	MONDO_0005044	"10020772"	"38341003"
epitizide	DB13989	Hypertensive disease	C0020538		Approved			CHEBI_135688		MONDO_0005044	"10020772"	"38341003"
indapamide	DB00808	Hypertensive disease	C0020538		Approved			CHEBI_5893	"5764"	MONDO_0005044	"10020772"	"38341003"
eplerenone	DB00700	Hypertensive disease	C0020538		Approved			CHEBI_31547	"298869"	MONDO_0005044	"10020772"	"38341003"
nitroprusside	DB00325	Hypertensive disease	C0020538		Approved			CHEBI_7596	"7476"	MONDO_0005044	"10020772"	"38341003"
ramipril	DB14208	Hypertensive disease	C0020538		Approved			CHEBI_77363		MONDO_0005044	"10020772"	"38341003"
lercanidipine	DB00528	Hypertensive disease	C0020538		Approved			CHEBI_135930	"135056"	MONDO_0005044	"10020772"	"38341003"
mibefradil	DB01388	Hypertensive disease	C0020538		Approved			CHEBI_6920	"83213"	MONDO_0005044	"10020772"	"38341003"
eprosartan	DB00876	Hypertensive disease	C0020538		Approved			CHEBI_4814	"83515"	MONDO_0005044	"10020772"	"38341003"
imidapril	DB11783	Hypertensive disease	C0020538		Approved			CHEBI_135654	"60245"	MONDO_0005044	"10020772"	"38341003"
methylclothiazide	DB00232	Hypertensive disease	C0020538		Approved			CHEBI_6847	"6860"	MONDO_0005044	"10020772"	"38341003"
methyldopa	DB00968	Hypertensive disease	C0020538		Approved			CHEBI_61058	"1545996|6876"	MONDO_0005044	"10020772"	"38341003"
ramipril	DB00178	Hypertensive disease	C0020538		Approved			CHEBI_8774	"35296"	MONDO_0005044	"10020772"	"38341003"
fimasartan	DB09279	Hypertensive disease	C0020538		Approved			CHEBI_136044		MONDO_0005044	"10020772"	"38341003"
moexipril	DB14210	Hypertensive disease	C0020538		Approved			CHEBI_6960		MONDO_0005044	"10020772"	"38341003"
hydrochlorothiazide	DB00999	Hypertensive disease	C0020538		Approved			CHEBI_5778	"5487"	MONDO_0005044	"10020772"	"38341003"
torsemide	DB00214	Hypertensive disease	C0020538		Approved			CHEBI_9637	"38413"	MONDO_0005044	"10020772"	"38341003"
tienilic acid	DB04831	Hypertensive disease	C0020538		Approved			CHEBI_9590		MONDO_0005044	"10020772"	"38341003"
olmesartan medoxomil	DB00275	Hypertensive disease	C0020538		Approved			CHEBI_48416	"321064"	MONDO_0005044	"10020772"	"38341003"
losartan	DB00678	Hypertensive disease	C0020538		Approved			CHEBI_6541	"52175"	MONDO_0005044	"10020772"	"38341003"
timolol	DB00373	Hypertensive disease	C0020538		Approved			CHEBI_9599	"1546004|10600"	MONDO_0005044	"10020772"	"38341003"
captopril	DB01197	Hypertensive disease	C0020538		Approved			CHEBI_3380	"1998"	MONDO_0005044	"10020772"	"38341003"
iloprost	DB01088	Pulmonary Hypertension	C0020542	NCT01437878	Terminated	Phase 2	low recruitment	CHEBI_63916	"40138"		"10037400"	"70995007"
sildenafil	DB00203	Pulmonary Hypertension	C0020542	NCT00145938	Terminated	Phase 2	Unable to complete study	CHEBI_9139	"136411"		"10037400"	"70995007"
alprostadil	DB00770	Pulmonary Hypertension	C0020542	NCT00598429	Withdrawn	Phase 2	Withdrawn due to lack of recruitment	CHEBI_15544	"598"		"10037400"	"70995007"
epoprostenol	DB01240	Pulmonary Hypertension	C0020542	NCT01370096	Terminated	Phase 2	Difficulty with patient recruitment	CHEBI_15552	"8814"		"10037400"	"70995007"
iloprost	DB01088	Pulmonary Hypertension	C0020542	NCT00467896	Terminated	Phase 2	Sponsor's decision	CHEBI_63916	"40138"		"10037400"	"70995007"
iloprost	DB01088	Pulmonary Hypertension	C0020542	NCT02482402	Withdrawn	Phase 2	Delay in recruitment	CHEBI_63916	"40138"		"10037400"	"70995007"
	DB01136	Pulmonary Hypertension	C0020542	NCT01568645	Withdrawn	Phase 1		CHEBI_3441	"20352"		"10037400"	"70995007"
warfarin	DB00682	Pulmonary Hypertension	C0020542	NCT01036802	Terminated	Phase 2	Difficulty in accruing subjects	CHEBI_87732	"11289"		"10037400"	"70995007"
bosentan	DB00559	Pulmonary Hypertension	C0020542	NCT00377455	Terminated	Phase 2	Study was terminated due to inadequate enrolment	CHEBI_51450	"75207|1468845"		"10037400"	"70995007"
sildenafil	DB00203	Pulmonary Hypertension	C0020542	NCT00796666	Terminated	Phase 3	Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.	CHEBI_9139	"136411"		"10037400"	"70995007"
iloprost	DB01088	Pulmonary Hypertension	C0020542	NCT00981591	Withdrawn	Phase 1/Phase 2	No patients recruited	CHEBI_63916	"40138"		"10037400"	"70995007"
tadalafil	DB00820	Pulmonary Hypertension	C0020542	NCT01910389	Terminated	Phase 3	terminated by funding agency	CHEBI_71940	"358263"		"10037400"	"70995007"
imatinib	DB00619	Pulmonary Hypertension	C0020542	NCT00583115	Terminated	Phase 2	Unable to enroll subjects	CHEBI_45783	"282388"		"10037400"	"70995007"
chlorhexidine	DB00878	Pulmonary Hypertension	C0020542	NCT03787082	Withdrawn	Phase 1	Study was never able to start after the pandemic restrictions lifted	CHEBI_3614	"2358"		"10037400"	"70995007"
nitric oxide	DB00435	Pulmonary Hypertension	C0020542	NCT03135860	Terminated	Early Phase 1	This was an exploratory open-label study and has met its initial objectives	CHEBI_16480	"7442"		"10037400"	"70995007"
sildenafil	DB00203	Pulmonary Hypertension	C0020542	NCT03997097	Withdrawn	Phase 3	New sponsor	CHEBI_9139	"136411"		"10037400"	"70995007"
alprostadil	DB00770	Pulmonary Hypertension	C0020542	NCT01467076	Terminated	Phase 2	The study was halted due to futility concerns based on the unmet benchmarks as specified in the pilot study protocol.	CHEBI_15544	"598"		"10037400"	"70995007"
carvedilol	DB01136	Pulmonary Hypertension	C0020542	NCT02120339	Terminated	Phase 1	Low enrollment	CHEBI_3441	"20352"		"10037400"	"70995007"
sildenafil	DB00203	Pulmonary Hypertension	C0020542	NCT00492531	Terminated	Phase 2	Subjects on drug were more likely to have severe pain crises requiring hospitalization.	CHEBI_9139	"136411"		"10037400"	"70995007"
tadalafil	DB00820	Pulmonary Hypertension	C0020542		Approved			CHEBI_71940	"358263"		"10037400"	"70995007"
bosentan	DB00559	Pulmonary Hypertension	C0020542	NCT00926627	Terminated	Phase 2	Not enough patients with the specified criteria could not	CHEBI_51450	"75207|1468845"		"10037400"	"70995007"
hydroxycarbamide	DB01005	Pulmonary Hypertension	C0020542	NCT01950585	Withdrawn	Early Phase 1		CHEBI_44423	"151871|5552"		"10037400"	"70995007"
nitric oxide	DB00435	Pulmonary Hypertension	C0020542		Approved			CHEBI_16480	"7442"		"10037400"	"70995007"
nitric oxide	DB00435	Pulmonary Hypertension	C0020542	NCT00041574	Terminated	Phase 2	Closed for lack of enrollment	CHEBI_16480	"7442"		"10037400"	"70995007"
bosentan	DB00559	Pulmonary Hypertension	C0020542	NCT00313196	Terminated	Phase 3	Slow enrollment	CHEBI_51450	"75207|1468845"		"10037400"	"70995007"
sildenafil	DB00203	Pulmonary Hypertension	C0020542	NCT00796510	Terminated	Phase 3	Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury	CHEBI_9139	"136411"		"10037400"	"70995007"
bosentan	DB00559	Pulmonary Hypertension	C0020542	NCT00360087	Terminated	Phase 3	Slow enrollment	CHEBI_51450	"75207|1468845"		"10037400"	"70995007"
bosentan	DB00559	Pulmonary Hypertension	C0020542		Approved			CHEBI_51450	"75207|1468845"		"10037400"	"70995007"
bosentan	DB00559	Pulmonary Hypertension	C0020542	NCT00310830	Terminated	Phase 3	Slow enrollment	CHEBI_51450	"75207|1468845"		"10037400"	"70995007"
epoprostenol	DB01240	Pulmonary Hypertension	C0020542		Approved			CHEBI_15552	"8814"		"10037400"	"70995007"
hydroxycarbamide	DB01005	Pulmonary Hypertension	C0020542	NCT00350844	Terminated	Phase 1/Phase 2	Low subject accrual	CHEBI_44423	"151871|5552"		"10037400"	"70995007"
dexmedetomidine	DB00633	Pulmonary Hypertension	C0020542	NCT01072643	Terminated	Phase 2/Phase 3	Study was terminated due to increased PVR in one subject from T0-T1 reaching the level of a predetermined stopping rule	CHEBI_4466	"48937"		"10037400"	"70995007"
tadalafil	DB00820	Pulmonary Hypertension	C0020542	NCT01960153	Withdrawn	Phase 3	Award was ended by NIH for parent study	CHEBI_71940	"358263"		"10037400"	"70995007"
imatinib	DB00619	Pulmonary Hypertension	C0020542	NCT01568645	Withdrawn	Phase 1		CHEBI_45783	"282388"		"10037400"	"70995007"
	DB00559	Pulmonary Hypertension	C0020542	NCT00302211	Terminated	Phase 3	Terminated due to slow enrollment	CHEBI_51450	"75207|1468845"		"10037400"	"70995007"
	DB00203	Pulmonary Hypertension	C0020542	NCT00302211	Terminated	Phase 3	Terminated due to slow enrollment	CHEBI_9139	"136411"		"10037400"	"70995007"
iloprost	DB01088	Pulmonary Hypertension	C0020542	NCT00302211	Terminated	Phase 3	Terminated due to slow enrollment	CHEBI_63916	"40138"		"10037400"	"70995007"
methotrexate	DB00563	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_44185	"6851"	HP:0006721	"10000846"	"91857003"
vincristine	DB00541	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_28445	"11202"	HP:0006721	"10000846"	"91857003"
teniposide	DB00444	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_75988	"10362"	HP:0006721	"10000846"	"91857003"
pegaspargase	DB00059	Acute lymphocytic leukemia	C0023449		Approved				"34132"	HP:0006721	"10000846"	"91857003"
cortisone acetate	DB01380	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_3897	"21655"	HP:0006721	"10000846"	"91857003"
asparaginase	DB00023	Acute lymphocytic leukemia	C0023449		Approved				"1156"	HP:0006721	"10000846"	"91857003"
hydrocortisone	DB00741	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_17650	"5492"	HP:0006721	"10000846"	"91857003"
betamethasone	DB00443	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_3077	"1514"	HP:0006721	"10000846"	"91857003"
clofarabine	DB00631	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_681569	"44151"	HP:0006721	"10000846"	"91857003"
methylprednisolone	DB00959	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_6888	"6902"	HP:0006721	"10000846"	"91857003"
ecabet	DB05265	Peptic Ulcer	C0030920		Approved			CHEBI_135593		MONDO_0004247	"10034341"	"13200003"
betamethasone acetate	DB00443	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_3077	"1514"	HP:0006721	"10000846"	"91857003"
enocitabine	DB00741	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_17650	"5492"	HP:0006721	"10000846"	"91857003"
	DB02546	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_45716	"194337"	HP:0006721	"10000846"	"91857003"
	DB00188	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_52717	"358258"	HP:0006721	"10000846"	"91857003"
	DB01204	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_50729	"7005"	HP:0006721	"10000846"	"91857003"
hydrocortisone succinate	DB00741	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_17650	"5492"	HP:0006721	"10000846"	"91857003"
dexamethasone	DB01234	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_41879	"3264"	HP:0006721	"10000846"	"91857003"
vindesine	DB00309	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_36373	"11204"	HP:0006721	"10000846"	"91857003"
	DB00531	Acute lymphocytic leukemia	C0023449	NCT01749111	Terminated	Phase 3	Lack of accrual	CHEBI_4027	"1545988|3002"	HP:0006721	"10000846"	"91857003"
prednisolone	DB00860	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_8378	"8638"	HP:0006721	"10000846"	"91857003"
	DB00987	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_28680	"3041|968804"	HP:0006721	"10000846"	"91857003"
	DB00023	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.		"1156"	HP:0006721	"10000846"	"91857003"
methotrexate	DB00563	Acute lymphocytic leukemia	C0023449	NCT01749111	Terminated	Phase 3	Lack of accrual	CHEBI_44185	"6851"	HP:0006721	"10000846"	"91857003"
	DB00997	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_28748	"142433|3639"	HP:0006721	"10000846"	"91857003"
	DB01234	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_41879	"3264"	HP:0006721	"10000846"	"91857003"
doxorubicin	DB00997	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_28748	"142433|3639"	HP:0006721	"10000846"	"91857003"
hydrocortisone acetate	DB14539	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_17609	"27197"	HP:0006721	"10000846"	"91857003"
hydrocortisone succinate	DB14545	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_31677	"21651"	HP:0006721	"10000846"	"91857003"
	DB00563	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_44185	"6851"	HP:0006721	"10000846"	"91857003"
mercaptopurine	DB01033	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_50667	"103|1546028"	HP:0006721	"10000846"	"91857003"
hydrocortisone acetate	DB00741	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_17650	"5492"	HP:0006721	"10000846"	"91857003"
crisantaspase	DB08886	Acute lymphocytic leukemia	C0023449		Approved				"1431738|1232186|2561249"	HP:0006721	"10000846"	"91857003"
daunorubicin	DB00694	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_41977	"214468|3109"	HP:0006721	"10000846"	"91857003"
triamcinolone acetonide	DB00620	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_9667	"10759"	HP:0006721	"10000846"	"91857003"
prednisone	DB00635	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_8382	"8640"	HP:0006721	"10000846"	"91857003"
	DB01033	Acute lymphocytic leukemia	C0023449	NCT02419755	Terminated	Phase 2	Accrual goals were no longer feasible based on restrictions imposed by the DSMB.	CHEBI_50667	"103|1546028"	HP:0006721	"10000846"	"91857003"
cytarabine	DB00987	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_28680	"3041|968804"	HP:0006721	"10000846"	"91857003"
triamcinolone	DB00620	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_9667	"10759"	HP:0006721	"10000846"	"91857003"
triamcinolone diacetate	DB00620	Acute lymphocytic leukemia	C0023449		Approved			CHEBI_9667	"10759"	HP:0006721	"10000846"	"91857003"
mycophenolate mofetil	DB01024	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00589316	Terminated	Phase 1	Terminated due to loss of funding	CHEBI_168396	"7145|265323"	MONDO_0020311	"10009018"	"127225006"
	DB01008	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01773395	Terminated	Phase 2	Recommendation by the Data and Safety Monitoring Board due to efficacy concerns	CHEBI_28901	"1828"	MONDO_0020311	"10009018"	"127225006"
	DB01262	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03146871	Terminated	Phase 2	Lack of funding	CHEBI_50131	"15657"	MONDO_0020311	"10009018"	"127225006"
	DB01254	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01620216	Terminated	Phase 2	Unable to recruit enough eligible subjects	CHEBI_49375	"475342|1546019"	MONDO_0020311	"10009018"	"127225006"
azacitidine	DB00928	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03146871	Terminated	Phase 2	Lack of funding	CHEBI_2038	"1251"	MONDO_0020311	"10009018"	"127225006"
methotrexate	DB00563	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01749111	Terminated	Phase 3	Lack of accrual	CHEBI_44185	"6851"	MONDO_0020311	"10009018"	"127225006"
	DB00091	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03128034	Suspended	Phase 1/Phase 2	Administrative - FDA Comments	CHEBI_4031	"3008"	MONDO_0020311	"10009018"	"127225006"
methotrexate	DB00563	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_44185	"6851"	MONDO_0020311	"10009018"	"127225006"
	DB00864	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_61049	"42316|235991"	MONDO_0020311	"10009018"	"127225006"
	DB00531	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00589316	Terminated	Phase 1	Terminated due to loss of funding	CHEBI_4027	"1545988|3002"	MONDO_0020311	"10009018"	"127225006"
decitabine	DB01262	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00113321	Terminated	Phase 2	Low Accrual	CHEBI_50131	"15657"	MONDO_0020311	"10009018"	"127225006"
deferasirox	DB01609	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01159067	Terminated	Phase 2	Low enrollment	CHEBI_49005	"614373"	MONDO_0020311	"10009018"	"127225006"
	DB01268	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01620216	Terminated	Phase 2	Unable to recruit enough eligible subjects	CHEBI_38940	"357977"	MONDO_0020311	"10009018"	"127225006"
azacitidine	DB00928	Leukemia, Myelomonocytic, Chronic	C0023480		Approved			CHEBI_2038	"1251"	MONDO_0020311	"10009018"	"127225006"
	DB00091	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_4031	"3008"	MONDO_0020311	"10009018"	"127225006"
clofarabine	DB00631	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00852709	Terminated	Phase 1	Lack of accrual	CHEBI_681569	"44151"	MONDO_0020311	"10009018"	"127225006"
clofarabine	DB00631	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00708721	Terminated	Phase 1/Phase 2	Data analysis revealed sufficient data for safety and efficacy	CHEBI_681569	"44151"	MONDO_0020311	"10009018"	"127225006"
sunitinib	DB01268	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00387426	Terminated	Phase 2		CHEBI_38940	"357977"	MONDO_0020311	"10009018"	"127225006"
	DB00531	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00852709	Terminated	Phase 1	Lack of accrual	CHEBI_4027	"1545988|3002"	MONDO_0020311	"10009018"	"127225006"
mycophenolate mofetil	DB01024	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03128034	Suspended	Phase 1/Phase 2	Administrative - FDA Comments	CHEBI_168396	"7145|265323"	MONDO_0020311	"10009018"	"127225006"
methotrexate	DB00563	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01773395	Terminated	Phase 2	Recommendation by the Data and Safety Monitoring Board due to efficacy concerns	CHEBI_44185	"6851"	MONDO_0020311	"10009018"	"127225006"
	DB00091	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00119366	Terminated	Phase 2	Funding ended before target accrual was reached; participants are no longer being examined or receiving intervention.	CHEBI_4031	"3008"	MONDO_0020311	"10009018"	"127225006"
azacitidine	DB00928	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01908387	Terminated	Phase 1	Due to Slow Accrual study was terminated.	CHEBI_2038	"1251"	MONDO_0020311	"10009018"	"127225006"
decitabine	DB01262	Leukemia, Myelomonocytic, Chronic	C0023480	NCT02564536	Withdrawn	Phase 1	Lack of funding following full FDA clinical hold	CHEBI_50131	"15657"	MONDO_0020311	"10009018"	"127225006"
sorafenib	DB00398	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01620216	Terminated	Phase 2	Unable to recruit enough eligible subjects	CHEBI_50924	"495881"	MONDO_0020311	"10009018"	"127225006"
inqovi	DB15694	Leukemia, Myelomonocytic, Chronic	C0023480		Approved				"2384449"	MONDO_0020311	"10009018"	"127225006"
	DB00864	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00589316	Terminated	Phase 1	Terminated due to loss of funding	CHEBI_61049	"42316|235991"	MONDO_0020311	"10009018"	"127225006"
mycophenolate mofetil	DB01024	Leukemia, Myelomonocytic, Chronic	C0023480	NCT00119366	Terminated	Phase 2	Funding ended before target accrual was reached; participants are no longer being examined or receiving intervention.	CHEBI_168396	"7145|265323"	MONDO_0020311	"10009018"	"127225006"
vidarabine	DB00194	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03326921	Suspended	Phase 1	Pause in funding	CHEBI_45327	"11194"	MONDO_0020311	"10009018"	"127225006"
	DB00864	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01773395	Terminated	Phase 2	Recommendation by the Data and Safety Monitoring Board due to efficacy concerns	CHEBI_61049	"42316|235991"	MONDO_0020311	"10009018"	"127225006"
	DB00531	Leukemia, Myelomonocytic, Chronic	C0023480	NCT01749111	Terminated	Phase 3	Lack of accrual	CHEBI_4027	"1545988|3002"	MONDO_0020311	"10009018"	"127225006"
	DB01008	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_28901	"1828"	MONDO_0020311	"10009018"	"127225006"
	DB00531	Leukemia, Myelomonocytic, Chronic	C0023480	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_4027	"1545988|3002"	MONDO_0020311	"10009018"	"127225006"
chloroquine	DB00608	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_3638	"2393"		"10057929"	"238927000"
triamcinolone hexacetonide	DB00620	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_9667	"10759"		"10057929"	"238927000"
fluticasone propionate	DB13867	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_5134	"41126"		"10057929"	"238927000"
fluocinolone acetonide	DB12553	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_5108	"25126"		"10057929"	"238927000"
fludroxycortide	DB00846	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_5127	"4500"		"10057929"	"238927000"
hydrocortisone	DB00741	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_17650	"5492"		"10057929"	"238927000"
clocortolone pivalate	DB00838	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_59582	"21249"		"10057929"	"238927000"
betamethasone valerate	DB00443	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_3077	"1514"		"10057929"	"238927000"
triamcinolone	DB00620	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_9667	"10759"		"10057929"	"238927000"
fluocinonide	DB12553	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_5108	"25126"		"10057929"	"238927000"
betamethasone dipropionate	DB00443	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_3077	"1514"		"10057929"	"238927000"
betamethasone	DB00443	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_3077	"1514"		"10057929"	"238927000"
hydroxychloroquine	DB01611	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_5801	"5521"		"10057929"	"238927000"
prednisolone	DB00860	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_8378	"8638"		"10057929"	"238927000"
fluocinolone acetonide	DB00591	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_31623	"4461"		"10057929"	"238927000"
alclometasone dipropionate	DB00240	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_53776	"108088"		"10057929"	"238927000"
fluocinonide	DB01047	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_5109	"4462"		"10057929"	"238927000"
flumetasone	DB00663	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_34764	"4458"		"10057929"	"238927000"
triamcinolone diacetate	DB00620	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_9667	"10759"		"10057929"	"238927000"
cortisone acetate	DB01380	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_3897	"21655"		"10057929"	"238927000"
desoximetasone	DB00547	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_691037	"3255"		"10057929"	"238927000"
desonide	DB01260	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_204734	"3254"		"10057929"	"238927000"
prednicarbate	DB01130	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_135791	"34369"		"10057929"	"238927000"
prednicarbate	DB00860	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_8378	"8638"		"10057929"	"238927000"
methylprednisolone	DB00959	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_6888	"6902"		"10057929"	"238927000"
diflorasone diacetate	DB00223	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_59750	"91311"		"10057929"	"238927000"
ulobetasol propionate	DB00596	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_135782	"41208"		"10057929"	"238927000"
triamcinolone acetonide	DB00620	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_9667	"10759"		"10057929"	"238927000"
halcinonide	DB06786	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_31663	"5084"		"10057929"	"238927000"
mometasone furoate	DB00764	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_6970			"10057929"	"238927000"
dexamethasone	DB01234	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_41879	"3264"		"10057929"	"238927000"
fluticasone propionate	DB00588	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_31441	"50121"		"10057929"	"238927000"
betamethasone benzoate	DB00443	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_3077	"1514"		"10057929"	"238927000"
mometasone furoate	DB14512	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_47564	"30145"		"10057929"	"238927000"
amcinonide	DB00288	Chronic discoid lupus erythematosus	C0024138		Approved			CHEBI_31199	"17652"		"10057929"	"238927000"
prasterone	DB01708	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_28689	"3143"	HP:0002725	"10042945"	"55464009"
	DB00563	Lupus Erythematosus, Systemic	C0024141	NCT00230035	Withdrawn	Phase 2	Recommended by DSMB due to lack of accrual	CHEBI_44185	"6851"	HP:0002725	"10042945"	"55464009"
	DB08880	Lupus Erythematosus, Systemic	C0024141	NCT00230035	Withdrawn	Phase 2	Recommended by DSMB due to lack of accrual	CHEBI_68540	"1310520"	HP:0002725	"10042945"	"55464009"
leflunomide	DB01097	Lupus Erythematosus, Systemic	C0024141	NCT00230035	Withdrawn	Phase 2	Recommended by DSMB due to lack of accrual	CHEBI_6402	"27169"	HP:0002725	"10042945"	"55464009"
prednisone	DB00635	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_8382	"8640"	HP:0002725	"10042945"	"55464009"
	DB00993	Lupus Erythematosus, Systemic	C0024141	NCT00626197	Terminated	Phase 3	Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.	CHEBI_2948	"1256"	HP:0002725	"10042945"	"55464009"
methylprednisolone	DB00959	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_6888	"6902"	HP:0002725	"10042945"	"55464009"
cortisone acetate	DB01380	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_3897	"21655"	HP:0002725	"10042945"	"55464009"
betamethasone	DB00443	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_3077	"1514"	HP:0002725	"10042945"	"55464009"
caffeine	DB00201	Nasal congestion (finding)	C0027424		Approved			CHEBI_27732	"1886"	HP:0001742	"10028735"	"68235000"
	DB00531	Lupus Erythematosus, Systemic	C0024141	NCT00626197	Terminated	Phase 3	Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.	CHEBI_4027	"1545988|3002"	HP:0002725	"10042945"	"55464009"
	DB00087	Lupus Erythematosus, Systemic	C0024141	NCT00684255	Terminated	Phase 1	inactive		"117055"	HP:0002725	"10042945"	"55464009"
busulfan	DB01008	Lupus Erythematosus, Systemic	C0024141	NCT00684255	Terminated	Phase 1	inactive	CHEBI_28901	"1828"	HP:0002725	"10042945"	"55464009"
belimumab	DB08879	Lupus Erythematosus, Systemic	C0024141		Approved				"1092437"	HP:0002725	"10042945"	"55464009"
	DB00959	Lupus Erythematosus, Systemic	C0024141	NCT00230035	Withdrawn	Phase 2	Recommended by DSMB due to lack of accrual	CHEBI_6888	"6902"	HP:0002725	"10042945"	"55464009"
betamethasone acetate	DB00443	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_3077	"1514"	HP:0002725	"10042945"	"55464009"
hydroxychloroquine	DB01611	Lupus Erythematosus, Systemic	C0024141	NCT01946880	Terminated	Phase 2	Slow enrollment.	CHEBI_5801	"5521"	HP:0002725	"10042945"	"55464009"
	DB01024	Lupus Erythematosus, Systemic	C0024141	NCT01946880	Terminated	Phase 2	Slow enrollment.	CHEBI_168396	"7145|265323"	HP:0002725	"10042945"	"55464009"
	DB01281	Lupus Erythematosus, Systemic	C0024141	NCT00430677	Terminated	Phase 2/Phase 3	Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period		"614391"	HP:0002725	"10042945"	"55464009"
	DB00073	Lupus Erythematosus, Systemic	C0024141	NCT00230035	Withdrawn	Phase 2	Recommended by DSMB due to lack of accrual		"2273510|2472325|121191|2105824"	HP:0002725	"10042945"	"55464009"
	DB01024	Lupus Erythematosus, Systemic	C0024141	NCT00230035	Withdrawn	Phase 2	Recommended by DSMB due to lack of accrual	CHEBI_168396	"7145|265323"	HP:0002725	"10042945"	"55464009"
	DB00993	Lupus Erythematosus, Systemic	C0024141	NCT00230035	Withdrawn	Phase 2	Recommended by DSMB due to lack of accrual	CHEBI_2948	"1256"	HP:0002725	"10042945"	"55464009"
prednisolone	DB00860	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_8378	"8638"	HP:0002725	"10042945"	"55464009"
hydrocortisone acetate	DB14539	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_17609	"27197"	HP:0002725	"10042945"	"55464009"
hydrocortisone acetate	DB00741	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_17650	"5492"	HP:0002725	"10042945"	"55464009"
dexamethasone	DB01234	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_41879	"3264"	HP:0002725	"10042945"	"55464009"
hydroxychloroquine	DB01611	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_5801	"5521"	HP:0002725	"10042945"	"55464009"
bortezomib	DB00188	Lupus Erythematosus, Systemic	C0024141	NCT02102594	Terminated	Phase 2	recruitment difficulties	CHEBI_52717	"358258"	HP:0002725	"10042945"	"55464009"
hydrocortisone	DB00741	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_17650	"5492"	HP:0002725	"10042945"	"55464009"
nivolumab	DB09035	Lupus Erythematosus, Systemic	C0024141	NCT03656627	Terminated	Phase 1	low accrual		"1597876"	HP:0002725	"10042945"	"55464009"
	DB00993	Lupus Erythematosus, Systemic	C0024141	NCT00539838	Terminated	Phase 3	The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.	CHEBI_2948	"1256"	HP:0002725	"10042945"	"55464009"
	DB00635	Lupus Erythematosus, Systemic	C0024141	NCT00539838	Terminated	Phase 3	The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.	CHEBI_8382	"8640"	HP:0002725	"10042945"	"55464009"
	DB01024	Lupus Erythematosus, Systemic	C0024141	NCT00539838	Terminated	Phase 3	The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.	CHEBI_168396	"7145|265323"	HP:0002725	"10042945"	"55464009"
	DB00959	Lupus Erythematosus, Systemic	C0024141	NCT00539838	Terminated	Phase 3	The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.	CHEBI_6888	"6902"	HP:0002725	"10042945"	"55464009"
methotrexate	DB00563	Lupus Erythematosus, Systemic	C0024141	NCT00539838	Terminated	Phase 3	The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.	CHEBI_44185	"6851"	HP:0002725	"10042945"	"55464009"
colecalciferol	DB00169	Lupus Erythematosus, Systemic	C0024141	NCT01709474	Terminated	Phase 2	Due to slow enrollment	CHEBI_28940	"2418"	HP:0002725	"10042945"	"55464009"
triamcinolone diacetate	DB00620	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_9667	"10759"	HP:0002725	"10042945"	"55464009"
mycophenolate mofetil	DB01024	Lupus Erythematosus, Systemic	C0024141	NCT00430677	Terminated	Phase 2/Phase 3	Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period	CHEBI_168396	"7145|265323"	HP:0002725	"10042945"	"55464009"
triamcinolone acetonide	DB00620	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_9667	"10759"	HP:0002725	"10042945"	"55464009"
chloroquine	DB00608	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_3638	"2393"	HP:0002725	"10042945"	"55464009"
nelfinavir	DB00220	Lupus Erythematosus, Systemic	C0024141	NCT02066311	Terminated	Phase 2	Stage 1 terminated 6/1/18 prior to completion of Stage 1 due to low enrollment and efficacy	CHEBI_7496	"134527"	HP:0002725	"10042945"	"55464009"
	DB00860	Lupus Erythematosus, Systemic	C0024141	NCT00430677	Terminated	Phase 2/Phase 3	Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period	CHEBI_8378	"8638"	HP:0002725	"10042945"	"55464009"
	DB00635	Lupus Erythematosus, Systemic	C0024141	NCT00430677	Terminated	Phase 2/Phase 3	Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period	CHEBI_8382	"8640"	HP:0002725	"10042945"	"55464009"
medroxyprogesterone	DB00603	Lupus Erythematosus, Systemic	C0024141	NCT00000419	Terminated	Phase 3		CHEBI_6716	"1000112"	HP:0002725	"10042945"	"55464009"
hydrocortisone succinate	DB14545	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_31677	"21651"	HP:0002725	"10042945"	"55464009"
azathioprine	DB00993	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_2948	"1256"	HP:0002725	"10042945"	"55464009"
triamcinolone	DB00620	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_9667	"10759"	HP:0002725	"10042945"	"55464009"
hydrocortisone succinate	DB00741	Lupus Erythematosus, Systemic	C0024141		Approved			CHEBI_17650	"5492"	HP:0002725	"10042945"	"55464009"
	DB00993	Lupus Erythematosus, Systemic	C0024141	NCT00504244	Terminated	Phase 3	Insufficient recruitment	CHEBI_2948	"1256"	HP:0002725	"10042945"	"55464009"
Polymyxin B	DB00781	Urinary tract infection	C0042029		Approved				"8536"		"10046571"	"68566005"
mycophenolate mofetil	DB01024	Lupus Erythematosus, Systemic	C0024141	NCT00504244	Terminated	Phase 3	Insufficient recruitment	CHEBI_168396	"7145|265323"	HP:0002725	"10042945"	"55464009"
	DB00608	Lupus Erythematosus, Systemic	C0024141	NCT01946880	Terminated	Phase 2	Slow enrollment.	CHEBI_3638	"2393"	HP:0002725	"10042945"	"55464009"
	DB00635	Lupus Erythematosus, Systemic	C0024141	NCT01946880	Terminated	Phase 2	Slow enrollment.	CHEBI_8382	"8640"	HP:0002725	"10042945"	"55464009"
mycophenolate mofetil	DB01024	Lupus Erythematosus, Systemic	C0024141	NCT00626197	Terminated	Phase 3	Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.	CHEBI_168396	"7145|265323"	HP:0002725	"10042945"	"55464009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT01714817	Terminated	Phase 3	Inability to meet protocol objectives.	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
	DB00860	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	CHEBI_8378	"8638"	MONDO_0005556	"10025140"	"68815009"
	DB00993	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	CHEBI_2948	"1256"	MONDO_0005556	"10025140"	"68815009"
	DB00531	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	CHEBI_4027	"1545988|3002"	MONDO_0005556	"10025140"	"68815009"
tacrolimus	DB00864	Lupus Nephritis	C0024143	NCT01288664	Withdrawn	Phase 3	sponsor withdraw from this study	CHEBI_61049	"42316|235991"	MONDO_0005556	"10025140"	"68815009"
rituximab	DB00073	Lupus Nephritis	C0024143	NCT00404157	Withdrawn	Phase 3			"2273510|2472325|121191|2105824"	MONDO_0005556	"10025140"	"68815009"
	DB00864	Lupus Nephritis	C0024143	NCT01342016	Terminated	Phase 3	Due to safety concern of active control drug	CHEBI_61049	"42316|235991"	MONDO_0005556	"10025140"	"68815009"
	DB00635	Lupus Nephritis	C0024143	NCT01342016	Terminated	Phase 3	Due to safety concern of active control drug	CHEBI_8382	"8640"	MONDO_0005556	"10025140"	"68815009"
	DB08880	Lupus Nephritis	C0024143	NCT01342016	Terminated	Phase 3	Due to safety concern of active control drug	CHEBI_68540	"1310520"	MONDO_0005556	"10025140"	"68815009"
leflunomide	DB01097	Lupus Nephritis	C0024143	NCT01342016	Terminated	Phase 3	Due to safety concern of active control drug	CHEBI_6402	"27169"	MONDO_0005556	"10025140"	"68815009"
infliximab	DB00065	Lupus Nephritis	C0024143	NCT00368264	Terminated	Phase 2/Phase 3	Failure to recruit patients with membranous lupus nephritis not previously treated with azathioprine .		"1790539|1927283|191831|2266523|2103476"	MONDO_0005556	"10025140"	"68815009"
voclosporin	DB11693	Lupus Nephritis	C0024143		Approved			CHEBI_135957	"2475166"	MONDO_0005556	"10025140"	"68815009"
	DB00531	Lupus Nephritis	C0024143	NCT00626197	Terminated	Phase 3	Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.	CHEBI_4027	"1545988|3002"	MONDO_0005556	"10025140"	"68815009"
	DB00993	Lupus Nephritis	C0024143	NCT00626197	Terminated	Phase 3	Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.	CHEBI_2948	"1256"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT00626197	Terminated	Phase 3	Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
etanercept	DB00005	Lupus Nephritis	C0024143	NCT00447265	Terminated	Phase 2	The perceived risk-benefit ratio for individuals with early active RA	CHEBI_4875	"214555|2103480|2462511"	MONDO_0005556	"10025140"	"68815009"
prednicarbate	DB00860	Lupus Nephritis	C0024143	NCT00539799	Withdrawn	Phase 3	Local pharmacy unwilling to comply with study protocol	CHEBI_8378	"8638"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT00573157	Terminated	Phase 2/Phase 3	The study was terminated due to unanticipated safety issues	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT01930890	Terminated	Phase 2	Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate sufficient efficacy to warrant continuation of the study	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
	DB00091	Lupus Nephritis	C0024143	NCT01299922	Withdrawn	Phase 3	IT was impossible to find patients	CHEBI_4031	"3008"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT01299922	Withdrawn	Phase 3	IT was impossible to find patients	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
	DB00531	Lupus Nephritis	C0024143	NCT01015456	Terminated	Phase 3	Data Safety Monitoring Board concerning of the participants' safety	CHEBI_4027	"1545988|3002"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT01015456	Terminated	Phase 3	Data Safety Monitoring Board concerning of the participants' safety	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT02081183	Terminated	Phase 3		CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
	DB00635	Lupus Nephritis	C0024143	NCT02081183	Terminated	Phase 3		CHEBI_8382	"8640"	MONDO_0005556	"10025140"	"68815009"
	DB00531	Lupus Nephritis	C0024143	NCT02081183	Terminated	Phase 3		CHEBI_4027	"1545988|3002"	MONDO_0005556	"10025140"	"68815009"
	DB01281	Lupus Nephritis	C0024143	NCT01714817	Terminated	Phase 3	Inability to meet protocol objectives.		"614391"	MONDO_0005556	"10025140"	"68815009"
	DB00635	Lupus Nephritis	C0024143	NCT01714817	Terminated	Phase 3	Inability to meet protocol objectives.	CHEBI_8382	"8640"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT03943147	Terminated	Phase 2	Insufficient enrollment	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT00425438	Terminated	Phase 3	Study was terminated early for administrative reasons.	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Lupus Nephritis	C0024143	NCT01499355	Terminated	Phase 2	Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.	CHEBI_168396	"7145|265323"	MONDO_0005556	"10025140"	"68815009"
mycophenolate mofetil	DB01024	Waldenstrom Macroglobulinemia	C0024419	NCT01652014	Withdrawn	Phase 2	Funding unavailable	CHEBI_168396	"7145|265323"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
prednisone	DB00635	Waldenstrom Macroglobulinemia	C0024419	NCT00088881	Terminated	Phase 2		CHEBI_8382	"8640"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
rituximab	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT01812005	Terminated	Phase 2	Slow patient enrollment and study discontinued after 14 patients enrolled		"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00541	Waldenstrom Macroglobulinemia	C0024419	NCT00088881	Terminated	Phase 2		CHEBI_28445	"11202"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
ibrutinib	DB09053	Waldenstrom Macroglobulinemia	C0024419		Approved			CHEBI_76612	"1442981"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
bortezomib	DB00188	Waldenstrom Macroglobulinemia	C0024419	NCT00103272	Terminated	Phase 1		CHEBI_52717	"358258"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT00088881	Terminated	Phase 2			"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
mycophenolate mofetil	DB01024	Waldenstrom Macroglobulinemia	C0024419	NCT01044745	Terminated	Phase 2	Study was closed to accrual for safety related to the frequency of BK infections.	CHEBI_168396	"7145|265323"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
bortezomib	DB00188	Waldenstrom Macroglobulinemia	C0024419	NCT01536067	Terminated	Phase 2	funding was withdrawn	CHEBI_52717	"358258"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
rituximab	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT00288067	Terminated	Phase 1/Phase 2	NCI stopped supplying fenretinide in November of 2012.		"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00864	Waldenstrom Macroglobulinemia	C0024419	NCT01044745	Terminated	Phase 2	Study was closed to accrual for safety related to the frequency of BK infections.	CHEBI_61049	"42316|235991"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT01419795	Terminated	Phase 2	Low accrual		"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
rituximab	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT01805037	Terminated	Phase 1/Phase 2	Lack of funding		"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
lenalidomide	DB00480	Waldenstrom Macroglobulinemia	C0024419	NCT01419795	Terminated	Phase 2	Low accrual	CHEBI_63791	"342369"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB01008	Waldenstrom Macroglobulinemia	C0024419	NCT01044745	Terminated	Phase 2	Study was closed to accrual for safety related to the frequency of BK infections.	CHEBI_28901	"1828"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT01044745	Terminated	Phase 2	Study was closed to accrual for safety related to the frequency of BK infections.		"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00531	Waldenstrom Macroglobulinemia	C0024419	NCT01044745	Terminated	Phase 2	Study was closed to accrual for safety related to the frequency of BK infections.	CHEBI_4027	"1545988|3002"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
zanubrutinib	DB15035	Waldenstrom Macroglobulinemia	C0024419		Approved				"2262435"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00531	Waldenstrom Macroglobulinemia	C0024419	NCT00088881	Terminated	Phase 2		CHEBI_4027	"1545988|3002"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
tirabrutinib hydrochloride	DB15227	Waldenstrom Macroglobulinemia	C0024419		Approved					MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
lenalidomide	DB00480	Waldenstrom Macroglobulinemia	C0024419	NCT02281279	Withdrawn	Phase 1/Phase 2		CHEBI_63791	"342369"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT02281279	Withdrawn	Phase 1/Phase 2			"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00997	Waldenstrom Macroglobulinemia	C0024419	NCT00088881	Terminated	Phase 2		CHEBI_28748	"142433|3639"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00073	Waldenstrom Macroglobulinemia	C0024419	NCT02168907	Terminated	Phase 1	Slow Accruals		"2273510|2472325|121191|2105824"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
bortezomib	DB00188	Waldenstrom Macroglobulinemia	C0024419	NCT00096005	Terminated	Phase 1		CHEBI_52717	"358258"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00166	Waldenstrom Macroglobulinemia	C0024419	NCT02168907	Terminated	Phase 1	Slow Accruals	CHEBI_30314	"6417"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00864	Waldenstrom Macroglobulinemia	C0024419	NCT01652014	Withdrawn	Phase 2	Funding unavailable	CHEBI_61049	"42316|235991"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
bendamustine	DB06769	Waldenstrom Macroglobulinemia	C0024419	NCT02168907	Terminated	Phase 1	Slow Accruals	CHEBI_135515	"134547"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB00531	Waldenstrom Macroglobulinemia	C0024419	NCT01652014	Withdrawn	Phase 2	Funding unavailable	CHEBI_4027	"1545988|3002"	MONDO_0005190|MONDO_0100280	"10047801"	"190818004"
	DB09274	Malaria	C0024530	NCT01082718	Withdrawn	Phase 2/Phase 3	Logistical difficulties	CHEBI_63918	"18346"	MONDO_0005136	"10025487"	"248437004"
	DB00855	Malaria	C0024530	NCT04020653	Withdrawn	Phase 2	Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.	CHEBI_356416	"683"	MONDO_0005136	"10025487"	"248437004"
tafenoquine	DB06608	Malaria	C0024530		Approved			CHEBI_141487	"2054023"	MONDO_0005136	"10025487"	"248437004"
pyrimethamine	DB00205	Malaria	C0024530	NCT00361114	Terminated	Phase 3	SP arms were stopped due to high levels of treatment failure.CD not available.	CHEBI_8673	"9010"	MONDO_0005136	"10025487"	"248437004"
lumefantrine	DB06708	Malaria	C0024530	NCT04020653	Withdrawn	Phase 2	Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.	CHEBI_156095	"847728"	MONDO_0005136	"10025487"	"248437004"
	DB00207	Malaria	C0024530	NCT03278808	Withdrawn	Phase 2	The IND has been withdrawn from FDA	CHEBI_2955	"18631"	MONDO_0005136	"10025487"	"248437004"
rosiglitazone	DB00412	Malaria	C0024530	NCT00811356	Terminated	Phase 1	safety issues (toxicity)	CHEBI_50122	"84108"	MONDO_0005136	"10025487"	"248437004"
	DB01098	Malaria	C0024530	NCT00811356	Terminated	Phase 1	safety issues (toxicity)	CHEBI_38545	"301542"	MONDO_0005136	"10025487"	"248437004"
primaquine	DB01087	Malaria	C0024530	NCT02654730	Terminated	Phase 2/Phase 3	Enrollment took longer than anticipated; it was financially and logistically impossible to recruit the final cohort (G6PDd 0.4mg/kg PQ).	CHEBI_8405	"8687"	MONDO_0005136	"10025487"	"248437004"
	DB00608	Malaria	C0024530	NCT01785979	Withdrawn	Phase 3	Lack of funding	CHEBI_3638	"2393"	MONDO_0005136	"10025487"	"248437004"
	DB01041	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
	DB00608	Malaria	C0024530	NCT01290601	Terminated	Phase 2	Failure to meet pre-specified endpoint for the day 28 cure rate	CHEBI_3638	"2393"	MONDO_0005136	"10025487"	"248437004"
prednisone	DB00635	Malaria	C0024530	NCT01785979	Withdrawn	Phase 3	Lack of funding	CHEBI_8382	"8640"	MONDO_0005136	"10025487"	"248437004"
pyrimethamine	DB00205	Malaria	C0024530		Approved			CHEBI_8673	"9010"	MONDO_0005136	"10025487"	"248437004"
	DB06697	Malaria	C0024530	NCT03199755	Withdrawn	Phase 2	Withdrawn in 2018 because clinicians did not follow protocols, issues with communication and also with tablet processing, nearby Ebola outbreak in 2018 (in the N Kivu area) confounded efforts.	CHEBI_195280	"18343"	MONDO_0005136	"10025487"	"248437004"
mefloquine	DB00358	Malaria	C0024530	NCT01082718	Withdrawn	Phase 2/Phase 3	Logistical difficulties	CHEBI_63681	"6694"	MONDO_0005136	"10025487"	"248437004"
lumefantrine	DB06708	Malaria	C0024530	NCT03199755	Withdrawn	Phase 2	Withdrawn in 2018 because clinicians did not follow protocols, issues with communication and also with tablet processing, nearby Ebola outbreak in 2018 (in the N Kivu area) confounded efforts.	CHEBI_156095	"847728"	MONDO_0005136	"10025487"	"248437004"
proguanil	DB01131	Malaria	C0024530	NCT03278808	Withdrawn	Phase 2	The IND has been withdrawn from FDA	CHEBI_8455	"2382"	MONDO_0005136	"10025487"	"248437004"
	DB00250	Malaria	C0024530	NCT00361114	Terminated	Phase 3	SP arms were stopped due to high levels of treatment failure.CD not available.	CHEBI_4325	"3108"	MONDO_0005136	"10025487"	"248437004"
dapsone	DB00250	Malaria	C0024530	NCT00126971	Suspended	Phase 1		CHEBI_4325	"3108"	MONDO_0005136	"10025487"	"248437004"
	DB04272	Malaria	C0024530	NCT04020653	Withdrawn	Phase 2	Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.	CHEBI_30769	"21183|221946"	MONDO_0005136	"10025487"	"248437004"
	DB01117	Malaria	C0024530	NCT03278808	Withdrawn	Phase 2	The IND has been withdrawn from FDA	CHEBI_575568	"60212"	MONDO_0005136	"10025487"	"248437004"
artenimol	DB11638	Malaria	C0024530		Approved			CHEBI_207229		MONDO_0005136	"10025487"	"248437004"
lumefantrine	DB06708	Malaria	C0024530	NCT01445938	Terminated	Phase 2	Data Monitoring Committee recommendation	CHEBI_156095	"847728"	MONDO_0005136	"10025487"	"248437004"
	DB01299	Malaria	C0024530	NCT00361114	Terminated	Phase 3	SP arms were stopped due to high levels of treatment failure.CD not available.	CHEBI_9329	"10173"	MONDO_0005136	"10025487"	"248437004"
	DB09154	Malaria	C0024530	NCT04020653	Withdrawn	Phase 2	Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.	CHEBI_53258	"253204|56466|1310549"	MONDO_0005136	"10025487"	"248437004"
piperaquine	DB13941	Malaria	C0024530		Approved			CHEBI_91231		MONDO_0005136	"10025487"	"248437004"
	DB06697	Malaria	C0024530	NCT04020653	Withdrawn	Phase 2	Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.	CHEBI_195280	"18343"	MONDO_0005136	"10025487"	"248437004"
prasterone sulfate	DB00608	Malaria	C0024530	NCT00442403	Suspended	Phase 3	At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.	CHEBI_3638	"2393"	MONDO_0005136	"10025487"	"248437004"
quinidine	DB00908	Malaria	C0024530		Approved			CHEBI_28593	"9068"	MONDO_0005136	"10025487"	"248437004"
	DB01708	Malaria	C0024530	NCT00442403	Suspended	Phase 3	At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.	CHEBI_28689	"3143"	MONDO_0005136	"10025487"	"248437004"
primaquine	DB01087	Malaria	C0024530	NCT01290601	Terminated	Phase 2	Failure to meet pre-specified endpoint for the day 28 cure rate	CHEBI_8405	"8687"	MONDO_0005136	"10025487"	"248437004"
	DB00608	Malaria	C0024530	NCT03278808	Withdrawn	Phase 2	The IND has been withdrawn from FDA	CHEBI_3638	"2393"	MONDO_0005136	"10025487"	"248437004"
	DB00608	Malaria	C0024530	NCT04368910	Terminated	Phase 3	Due to slow recruitment the study was terminated prematurely by the Sponsor after 30 subjects had been included	CHEBI_3638	"2393"	MONDO_0005136	"10025487"	"248437004"
artesunate	DB09274	Malaria	C0024530	NCT04368910	Terminated	Phase 3	Due to slow recruitment the study was terminated prematurely by the Sponsor after 30 subjects had been included	CHEBI_63918	"18346"	MONDO_0005136	"10025487"	"248437004"
cyclophosphamide	DB00531	Multiple Myeloma	C0026764	NCT04025216	Terminated	Phase 1	The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
cyclophosphamide	DB00531	Multiple Myeloma	C0026764	NCT00963872	Terminated	Phase 1/Phase 2	Lack of efficacy after interim analysis	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB09258	Multiple Myeloma	C0026764	NCT00790842	Terminated	Phase 1/Phase 2	Slow enrollment		"280611"	MONDO_0009693	"10035226"	"109989006"
	DB06822	Multiple Myeloma	C0026764	NCT00790842	Terminated	Phase 1/Phase 2	Slow enrollment		"69646|104466"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB00002	Multiple Myeloma	C0026764	NCT00368121	Terminated	Phase 2	Lack of recruitable patients	CHEBI_68637	"318341"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00368121	Terminated	Phase 2	Lack of recruitable patients	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00790842	Terminated	Phase 1/Phase 2	Slow enrollment	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00984828	Terminated	Phase 2/Phase 3	Very slow recruitment	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02661022	Terminated	Phase 1/Phase 2		CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00718640	Terminated	Phase 2	Study stopped due to lagging enrolment.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT04243109	Terminated	Phase 2	Low recruitment rate. Lack of interest of the sponsor.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00718640	Terminated	Phase 2	Study stopped due to lagging enrolment.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
cyclophosphamide	DB00531	Multiple Myeloma	C0026764	NCT03399448	Terminated	Phase 1	Sponsor has terminated trial to pursue other targets.	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00573391	Terminated	Phase 3	low accrual	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764	NCT03608501	Withdrawn	Phase 2	Business decision (no safety or efficacy concerns)	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03608501	Withdrawn	Phase 2	Business decision (no safety or efficacy concerns)	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00573391	Terminated	Phase 3	low accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB00531	Multiple Myeloma	C0026764	NCT04243109	Terminated	Phase 2	Low recruitment rate. Lack of interest of the sponsor.	CHEBI_68637	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB01041	Multiple Myeloma	C0026764	NCT00573391	Terminated	Phase 3	low accrual	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00573391	Terminated	Phase 3	low accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
dasatinib	DB01254	Multiple Myeloma	C0026764	NCT01643603	Terminated	Phase 1	Study terminated due to slow accrual.	CHEBI_49375	"475342|1546019"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02807454	Terminated	Phase 2	Health Authority request due to class effect	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT02716805	Terminated	Phase 1	FDA placed on partial hold due to additional data	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02372240	Terminated	Phase 1/Phase 2	Dose limiting tox is observed. Study put on full clinical hold.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT02043860	Terminated	Phase 1	low accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02077959	Terminated	Phase 1	Pharmaceutical Companies decision	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00577668	Withdrawn	Phase 2	Poor accrual	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02576977	Terminated	Phase 3	The study was terminated early due to business reasons	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00577668	Withdrawn	Phase 2	Poor accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00843310	Terminated	Phase 2	Due to slow accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT00843310	Terminated	Phase 2	Due to slow accrual	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00843310	Terminated	Phase 2	Due to slow accrual	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01041	Multiple Myeloma	C0026764	NCT00577668	Withdrawn	Phase 2	Poor accrual	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00577668	Withdrawn	Phase 2	Poor accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB00087	Multiple Myeloma	C0026764	NCT00698685	Terminated	Phase 2	Pentostatin/alemtuzumab regimen had greater risk of graft failure.		"117055"	MONDO_0009693	"10035226"	"109989006"
pentostatin	DB00552	Multiple Myeloma	C0026764	NCT00698685	Terminated	Phase 2	Pentostatin/alemtuzumab regimen had greater risk of graft failure.	CHEBI_27834	"8011"	MONDO_0009693	"10035226"	"109989006"
bendamustine	DB06769	Multiple Myeloma	C0026764	NCT01177683	Terminated	Phase 1/Phase 2	Lack of accrual	CHEBI_135515	"134547"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01177683	Terminated	Phase 1/Phase 2	Lack of accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
panobinostat	DB06603	Multiple Myeloma	C0026764	NCT00445068	Terminated	Phase 2		CHEBI_85990	"1603350"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT01177683	Terminated	Phase 1/Phase 2	Lack of accrual	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00560352	Terminated	Phase 1		CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01254	Multiple Myeloma	C0026764	NCT00560352	Terminated	Phase 1		CHEBI_49375	"475342|1546019"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00560352	Terminated	Phase 1		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764		Approved			CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03871829	Terminated	Phase 2	The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
bendamustine	DB06769	Multiple Myeloma	C0026764	NCT02315157	Withdrawn	Phase 1	Withdrawn by PI	CHEBI_135515	"134547"	MONDO_0009693	"10035226"	"109989006"
leuprorelin	DB00007	Multiple Myeloma	C0026764	NCT00275262	Terminated	Phase 2		CHEBI_6427	"42375"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT01492881	Withdrawn	Phase 2	Doxil is currently unavailable	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
	DB02546	Multiple Myeloma	C0026764	NCT01492881	Withdrawn	Phase 2	Doxil is currently unavailable	CHEBI_45716	"194337"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01492881	Withdrawn	Phase 2	Doxil is currently unavailable	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT00516191	Withdrawn	Phase 1/Phase 2	low accrual	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00516191	Withdrawn	Phase 1/Phase 2	low accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00516191	Withdrawn	Phase 1/Phase 2	low accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00005834	Terminated	Phase 3	poor accrual	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT00005834	Terminated	Phase 3	poor accrual	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB01041	Multiple Myeloma	C0026764	NCT00005834	Terminated	Phase 3	poor accrual	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
etoposide	DB00773	Multiple Myeloma	C0026764	NCT00005834	Terminated	Phase 3	poor accrual	CHEBI_4911	"4179"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00920556	Terminated	Phase 2	Study terminated.24 subjects enrolled;provided adequate data for decision making.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT02658396	Withdrawn	Phase 1	Study was never open due to lack of funding	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00765102	Terminated	Phase 2	There was a change in the Sponsor's research strategy; safety concerns were not a factor.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB09035	Multiple Myeloma	C0026764	NCT03227432	Withdrawn	Phase 2	Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs.	CHEBI_68637	"1597876"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03227432	Withdrawn	Phase 2	Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02802163	Withdrawn	Phase 1/Phase 2	study drug unavailable	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
dasatinib	DB01254	Multiple Myeloma	C0026764	NCT01609816	Terminated	Phase 1	Low accrual. No Analyses were performed	CHEBI_49375	"475342|1546019"	MONDO_0009693	"10035226"	"109989006"
pomalidomide	DB08910	Multiple Myeloma	C0026764		Approved			CHEBI_72690	"1369713"	MONDO_0009693	"10035226"	"109989006"
	DB06603	Multiple Myeloma	C0026764	NCT02802163	Withdrawn	Phase 1/Phase 2	study drug unavailable	CHEBI_85990	"1603350"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02802163	Withdrawn	Phase 1/Phase 2	study drug unavailable	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02951117	Withdrawn	Phase 1	No participants enrolled	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00995059	Withdrawn	Phase 1/Phase 2		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00864	Multiple Myeloma	C0026764	NCT00995059	Withdrawn	Phase 1/Phase 2		CHEBI_61049	"42316|235991"	MONDO_0009693	"10035226"	"109989006"
	DB01248	Multiple Myeloma	C0026764	NCT02393248	Terminated	Phase 1/Phase 2		CHEBI_4672	"72962|1299922"	MONDO_0009693	"10035226"	"109989006"
trastuzumab	DB00072	Multiple Myeloma	C0026764	NCT02393248	Terminated	Phase 1/Phase 2			"2289225|2103478|2174802|2280730|2107051|224905"	MONDO_0009693	"10035226"	"109989006"
	DB00877	Multiple Myeloma	C0026764	NCT00995059	Withdrawn	Phase 1/Phase 2		CHEBI_9168	"35302"	MONDO_0009693	"10035226"	"109989006"
	DB09099	Multiple Myeloma	C0026764	NCT01234974	Withdrawn	Phase 2	Study never undertaken	CHEBI_64628	"9939"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00995059	Withdrawn	Phase 1/Phase 2		CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT01742793	Terminated	Phase 1	The study was terminated due to withdrawal of institutional support, Phase II never began.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
panobinostat	DB06603	Multiple Myeloma	C0026764		Approved			CHEBI_85990	"1603350"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02897830	Terminated	Phase 2	negatives results	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02897830	Terminated	Phase 2	negatives results	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
nivolumab	DB09035	Multiple Myeloma	C0026764	NCT03634800	Terminated	Phase 2	Lack of patient accruals.		"1597876"	MONDO_0009693	"10035226"	"109989006"
everolimus	DB01590	Multiple Myeloma	C0026764	NCT01234974	Withdrawn	Phase 2	Study never undertaken	CHEBI_68478	"141704"	MONDO_0009693	"10035226"	"109989006"
tacrolimus	DB00864	Multiple Myeloma	C0026764	NCT00579111	Terminated	Phase 1/Phase 2	slow accrual	CHEBI_61049	"42316|235991"	MONDO_0009693	"10035226"	"109989006"
	DB01008	Multiple Myeloma	C0026764	NCT00579111	Terminated	Phase 1/Phase 2	slow accrual	CHEBI_28901	"1828"	MONDO_0009693	"10035226"	"109989006"
busulfan	DB01008	Multiple Myeloma	C0026764	NCT00113919	Terminated	Phase 1/Phase 2	Due to poor accrual	CHEBI_28901	"1828"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT03003728	Withdrawn	Phase 2	Withdrawal of study support	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
doxorubicin	DB00997	Multiple Myeloma	C0026764	NCT01101594	Terminated	Phase 1/Phase 2	Study was terminated due to lack of efficacy	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
	DB00087	Multiple Myeloma	C0026764	NCT00579111	Terminated	Phase 1/Phase 2	slow accrual		"117055"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT01464034	Terminated	Phase 1/Phase 2	Lack of enrollment	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00124579	Terminated	Phase 2	poor accrual	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00124579	Terminated	Phase 2	poor accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764	NCT00124579	Terminated	Phase 2	poor accrual	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
zoledronic acid	DB00399	Multiple Myeloma	C0026764	NCT00216151	Terminated	Phase 2	Study terminated due to low patient enrollment.	CHEBI_46557	"1546014|77655"	MONDO_0009693	"10035226"	"109989006"
vorinostat	DB02546	Multiple Myeloma	C0026764	NCT00857324	Terminated	Phase 1/Phase 2	The Phase I of the study was completed, but Phase 2 has not been activated	CHEBI_45716	"194337"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00983346	Terminated	Phase 2	Lab Staff that was required left the institution, therefore accrual closed prematurely	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03657420	Withdrawn	Phase 1	Funding withdrawn by sponsor	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02155634	Withdrawn	Phase 3	The study was terminated due to poor feasibility and lack of interest at the participating sites.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
nivolumab	DB09035	Multiple Myeloma	C0026764	NCT03782064	Terminated	Phase 2	Funding		"1597876"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT01979276	Terminated	Phase 1/Phase 2	this study was terminated due to losing financial support, and enrollment challenges	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03201250	Terminated	Phase 1/Phase 2	Phase I response to treatment was not as expected and the myeloma field in treatment has changed since initiating the study, so investigators felt the study should not be pursued into Phase II.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
cyclophosphamide	DB00531	Multiple Myeloma	C0026764		Approved			CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
fenofibrate	DB01039	Multiple Myeloma	C0026764	NCT01965834	Terminated	Phase 2	Lack of adequate accrual.	CHEBI_5001	"8703"	MONDO_0009693	"10035226"	"109989006"
enocitabine	DB00773	Multiple Myeloma	C0026764	NCT01653418	Terminated	Phase 2	Due to the high rate of morbidity and mortality	CHEBI_4911	"4179"	MONDO_0009693	"10035226"	"109989006"
	DB01042	Multiple Myeloma	C0026764	NCT01653418	Terminated	Phase 2	Due to the high rate of morbidity and mortality	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01653418	Terminated	Phase 2	Due to the high rate of morbidity and mortality	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00262	Multiple Myeloma	C0026764	NCT01653418	Terminated	Phase 2	Due to the high rate of morbidity and mortality	CHEBI_3423	"2105"	MONDO_0009693	"10035226"	"109989006"
	DB00987	Multiple Myeloma	C0026764	NCT01653418	Terminated	Phase 2	Due to the high rate of morbidity and mortality	CHEBI_28680	"3041|968804"	MONDO_0009693	"10035226"	"109989006"
prednicarbate	DB00860	Multiple Myeloma	C0026764	NCT01179490	Terminated	Phase 2		CHEBI_8378	"8638"	MONDO_0009693	"10035226"	"109989006"
etodolac	DB00749	Multiple Myeloma	C0026764	NCT00293111	Terminated	Phase 2		CHEBI_4909	"24605"	MONDO_0009693	"10035226"	"109989006"
vincristine	DB00541	Multiple Myeloma	C0026764	NCT00441168	Terminated	Phase 2	TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved	CHEBI_28445	"11202"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03168100	Withdrawn	Phase 2	No study population. No subjects enrolled.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT03168100	Withdrawn	Phase 2	No study population. No subjects enrolled.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT03168100	Withdrawn	Phase 2	No study population. No subjects enrolled.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01680796	Withdrawn	Phase 1	The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily treated multiple myeloma.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02145598	Terminated	Phase 2/Phase 3	Insufficient recruitment	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01680796	Withdrawn	Phase 1	The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily treated multiple myeloma.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
cyclophosphamide	DB00531	Multiple Myeloma	C0026764	NCT00167180	Terminated	Phase 2	Accrual Goal Met	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02720510	Terminated	Phase 2	A study was terminated due to low enrollment.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB06603	Multiple Myeloma	C0026764	NCT02720510	Terminated	Phase 2	A study was terminated due to low enrollment.	CHEBI_85990	"1603350"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT02720510	Terminated	Phase 2	A study was terminated due to low enrollment.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02720510	Terminated	Phase 2	A study was terminated due to low enrollment.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00441168	Terminated	Phase 2	TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02548962	Terminated	Phase 1/Phase 2	After completing Phase 1, the Sponsor elected not to move forward with Phase 2.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02516696	Terminated	Phase 3	low enrollment	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01211	Multiple Myeloma	C0026764	NCT02516696	Terminated	Phase 3	low enrollment	CHEBI_3732	"21212"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02516696	Terminated	Phase 3	low enrollment	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
azacitidine	DB00928	Multiple Myeloma	C0026764	NCT00412919	Terminated	Phase 2	Lack of efficacy	CHEBI_2038	"1251"	MONDO_0009693	"10035226"	"109989006"
clofarabine	DB00631	Multiple Myeloma	C0026764	NCT00241371	Terminated	Phase 2	No response seen in patients	CHEBI_681569	"44151"	MONDO_0009693	"10035226"	"109989006"
leuprorelin	DB00007	Multiple Myeloma	C0026764	NCT01343368	Terminated	Phase 2		CHEBI_6427	"42375"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00337506	Terminated	Phase 2		CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00337506	Terminated	Phase 2		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00441168	Terminated	Phase 2	TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT01832727	Terminated	Phase 1/Phase 2	Enrollment halted during phase 2 to reformulate the investigational product	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03567616	Terminated	Phase 2	Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT00441168	Terminated	Phase 2	TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01720043	Terminated	Phase 2	Slow Accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01042	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01672736	Terminated	Phase 1/Phase 2	The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01672736	Terminated	Phase 1/Phase 2	The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00091	Multiple Myeloma	C0026764	NCT00303719	Terminated	Phase 2	IRB Study Closure	CHEBI_4031	"3008"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01374217	Terminated	Phase 2	early stopping rule	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01211	Multiple Myeloma	C0026764	NCT01374217	Terminated	Phase 2	early stopping rule	CHEBI_3732	"21212"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT01374217	Terminated	Phase 2	early stopping rule	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT00303719	Terminated	Phase 2	IRB Study Closure	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
mycophenolate mofetil	DB01024	Multiple Myeloma	C0026764	NCT00303719	Terminated	Phase 2	IRB Study Closure	CHEBI_168396	"7145|265323"	MONDO_0009693	"10035226"	"109989006"
hyaluronidase	DB14740	Multiple Myeloma	C0026764		Approved				"2382595|578350|2375132"	MONDO_0009693	"10035226"	"109989006"
tadalafil	DB00820	Multiple Myeloma	C0026764	NCT01374217	Terminated	Phase 2	early stopping rule	CHEBI_71940	"358263"	MONDO_0009693	"10035226"	"109989006"
hyaluronidase	DB06205	Multiple Myeloma	C0026764		Approved				"1300478"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01266811	Withdrawn	Phase 3	Study canceled based on results of different study with similar hypothesis, investigational agent, & patient	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01266811	Withdrawn	Phase 3	Study canceled based on results of different study with similar hypothesis, investigational agent, & patient	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB00531	Multiple Myeloma	C0026764	NCT03440411	Terminated	Phase 3	Low enrollment	CHEBI_68637	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03440411	Terminated	Phase 3	Low enrollment	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03492138	Terminated	Phase 1/Phase 2	Low enrollment	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01555281	Terminated	Phase 1/Phase 2	In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine whether a continuation of the trial would still add value to the data analysis, or whether they do not and could therefore be prematurely terminated.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT01617213	Terminated	Phase 2	Study is no longer needed as recent data have answered the primary hypotheses for this study.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT01617213	Terminated	Phase 2	Study is no longer needed as recent data have answered the primary hypotheses for this study.	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT01555281	Terminated	Phase 1/Phase 2	In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine whether a continuation of the trial would still add value to the data analysis, or whether they do not and could therefore be prematurely terminated.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
nelfinavir	DB00220	Multiple Myeloma	C0026764	NCT01555281	Terminated	Phase 1/Phase 2	In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine whether a continuation of the trial would still add value to the data analysis, or whether they do not and could therefore be prematurely terminated.	CHEBI_7496	"134527"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764		Approved			CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00891033	Terminated	Phase 1	This study was terminated because the drug company stopped making the study drug	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB06603	Multiple Myeloma	C0026764	NCT00891033	Terminated	Phase 1	This study was terminated because the drug company stopped making the study drug	CHEBI_85990	"1603350"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00985907	Terminated	Phase 1/Phase 2	Low Accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
carfilzomib	DB08889	Multiple Myeloma	C0026764		Approved			CHEBI_65347	"1302966"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00075608	Terminated	Phase 2	poor accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT01999335	Terminated	Phase 1	A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ007 was halted during dose-expansion.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00985907	Terminated	Phase 1/Phase 2	Low Accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT00790842	Terminated	Phase 1/Phase 2	Slow enrollment	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
vorinostat	DB02546	Multiple Myeloma	C0026764	NCT00109109	Terminated	Phase 1		CHEBI_45716	"194337"	MONDO_0009693	"10035226"	"109989006"
daratumumab	DB09331	Multiple Myeloma	C0026764		Approved				"1721947"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764		Approved			CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT02112045	Terminated	Phase 2	Terminated due to results of interim analysis	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
ixazomib	DB09570	Multiple Myeloma	C0026764		Approved			CHEBI_90942	"1723735"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT01303965	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
etoposide	DB00773	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	CHEBI_4911	"4179"	MONDO_0009693	"10035226"	"109989006"
elotuzumab	DB06317	Multiple Myeloma	C0026764		Approved				"1726104"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT01438177	Terminated	Phase 2	PI left institution.	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB00608	Multiple Myeloma	C0026764	NCT01438177	Terminated	Phase 2	PI left institution.	CHEBI_3638	"2393"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01438177	Terminated	Phase 2	PI left institution.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
bendamustine	DB06769	Multiple Myeloma	C0026764	NCT01438177	Terminated	Phase 2	PI left institution.	CHEBI_135515	"134547"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02402725	Withdrawn	Phase 2	poor accrual	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT01548573	Terminated	Phase 2	Met study stopping rules	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
hyoscyamine	DB00424	Peptic Ulcer	C0030920		Approved			CHEBI_17486	"153970"	MONDO_0004247	"10034341"	"13200003"
	DB00188	Multiple Myeloma	C0026764	NCT00793650	Terminated	Phase 1/Phase 2		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00793650	Terminated	Phase 1/Phase 2		CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02389543	Withdrawn	Phase 1/Phase 2	Terminated this trial and added a Lenalidomide arm to KCP-330-017	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02389543	Withdrawn	Phase 1/Phase 2	Terminated this trial and added a Lenalidomide arm to KCP-330-017	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00128921	Terminated	Phase 2	study terminated due to low accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
colesevelam	DB00930	Multiple Myeloma	C0026764	NCT02619812	Terminated	Phase 2	Difficulty recruiting; pill burden and nausea were barriers	CHEBI_59594	"141626"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB00631	Multiple Myeloma	C0026764	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision	CHEBI_681569	"44151"	MONDO_0009693	"10035226"	"109989006"
alemtuzumab	DB00087	Multiple Myeloma	C0026764	NCT00626626	Terminated	Phase 1/Phase 2	Investigator decision		"117055"	MONDO_0009693	"10035226"	"109989006"
	DB00864	Multiple Myeloma	C0026764	NCT01303965	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_61049	"42316|235991"	MONDO_0009693	"10035226"	"109989006"
carmustine	DB00262	Multiple Myeloma	C0026764		Approved			CHEBI_3423	"2105"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT01660997	Withdrawn	Phase 2		CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT02928029	Terminated	Phase 1/Phase 2	Due to the changes of standard of care and the slow recruitment of participants.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02928029	Terminated	Phase 1/Phase 2	Due to the changes of standard of care and the slow recruitment of participants.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
sirolimus	DB00877	Multiple Myeloma	C0026764	NCT01303965	Terminated	Phase 1/Phase 2	Slow accrual	CHEBI_9168	"35302"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT01658904	Terminated	Phase 1/Phase 2	study closed prematurely because investigator left National Institutes of Health	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
dexamethasone	DB01234	Multiple Myeloma	C0026764		Approved			CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03465540	Terminated	Phase 1	Strategic decisions	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
azacitidine	DB00928	Multiple Myeloma	C0026764	NCT03465540	Terminated	Phase 1	Strategic decisions	CHEBI_2038	"1251"	MONDO_0009693	"10035226"	"109989006"
dexamethasone acetate	DB14649	Multiple Myeloma	C0026764		Approved			CHEBI_4463	"22690|2378841"	MONDO_0009693	"10035226"	"109989006"
dexamethasone acetate	DB01234	Multiple Myeloma	C0026764		Approved			CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT04895410	Terminated	Phase 1	Strategic considerations	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02952573	Terminated	Phase 2	Low patient accrual	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00361088	Terminated	Phase 1/Phase 2	Initial Principal Investigator left Moffitt	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01329289	Withdrawn	Phase 2	Clinical trial being transferred to Columbia University with the Investigator.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01329289	Withdrawn	Phase 2	Clinical trial being transferred to Columbia University with the Investigator.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03000634	Withdrawn	Phase 2	Study was not and will not be initiated due to lack of funding.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT03000634	Withdrawn	Phase 2	Study was not and will not be initiated due to lack of funding.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT03000634	Withdrawn	Phase 2	Study was not and will not be initiated due to lack of funding.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT01969565	Terminated	Phase 2	Logistical reasons	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
disulfiram	DB00822	Multiple Myeloma	C0026764	NCT04521335	Terminated	Phase 1	Closed at PI's Request	CHEBI_4659	"3554"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764		Approved			CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB09035	Multiple Myeloma	C0026764	NCT03023527	Terminated	Phase 1	Safety	CHEBI_68637	"1597876"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03023527	Terminated	Phase 1	Safety	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT02447055	Withdrawn	Early Phase 1		CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
sirolimus	DB00877	Multiple Myeloma	C0026764	NCT00973804	Terminated	Phase 1		CHEBI_9168	"35302"	MONDO_0009693	"10035226"	"109989006"
	DB13144	Multiple Myeloma	C0026764	NCT02447055	Withdrawn	Early Phase 1			"70167"	MONDO_0009693	"10035226"	"109989006"
	DB00864	Multiple Myeloma	C0026764	NCT02447055	Withdrawn	Early Phase 1		CHEBI_61049	"42316|235991"	MONDO_0009693	"10035226"	"109989006"
	DB00864	Multiple Myeloma	C0026764	NCT00973804	Terminated	Phase 1		CHEBI_61049	"42316|235991"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01470131	Terminated	Phase 3	Sponsor decision based on portfolio prioritization	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01024	Multiple Myeloma	C0026764	NCT02447055	Withdrawn	Early Phase 1		CHEBI_168396	"7145|265323"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02578121	Withdrawn	Phase 2	Investigator decided to close study without enrollment	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB14483	Multiple Myeloma	C0026764	NCT00590603	Terminated	Phase 1	Poor accrual - terminated during Phase I; Phase II never started.		"1307765|142407"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03033316	Terminated	Phase 1/Phase 2	Patient enrolment issues	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB14482	Multiple Myeloma	C0026764	NCT00590603	Terminated	Phase 1	Poor accrual - terminated during Phase I; Phase II never started.	CHEBI_113451	"267366"	MONDO_0009693	"10035226"	"109989006"
	DB00126	Multiple Myeloma	C0026764	NCT00590603	Terminated	Phase 1	Poor accrual - terminated during Phase I; Phase II never started.	CHEBI_29073	"1151|1370460"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00590603	Terminated	Phase 1	Poor accrual - terminated during Phase I; Phase II never started.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
arsenic trioxide	DB01169	Multiple Myeloma	C0026764	NCT00590603	Terminated	Phase 1	Poor accrual - terminated during Phase I; Phase II never started.	CHEBI_49900	"18330"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT02447055	Withdrawn	Early Phase 1		CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00352742	Terminated	Phase 1/Phase 2		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00987	Multiple Myeloma	C0026764	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_28680	"3041|968804"	MONDO_0009693	"10035226"	"109989006"
clarithromycin	DB01211	Multiple Myeloma	C0026764	NCT02573935	Terminated	Phase 2	Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone)	CHEBI_3732	"21212"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02756663	Withdrawn	Phase 2		CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB06603	Multiple Myeloma	C0026764	NCT02756663	Withdrawn	Phase 2		CHEBI_68637	"1603350"	MONDO_0009693	"10035226"	"109989006"
	DB00631	Multiple Myeloma	C0026764	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_681569	"44151"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT03481556	Terminated	Phase 1/Phase 2	The sponsor decided to terminate the study following an FDA request of a partial clinical hold.	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB00262	Multiple Myeloma	C0026764	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_3423	"2105"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT03481556	Terminated	Phase 1/Phase 2	The sponsor decided to terminate the study following an FDA request of a partial clinical hold.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01470131	Terminated	Phase 3	Sponsor decision based on portfolio prioritization	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03481556	Terminated	Phase 1/Phase 2	The sponsor decided to terminate the study following an FDA request of a partial clinical hold.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01008	Multiple Myeloma	C0026764	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_28901	"1828"	MONDO_0009693	"10035226"	"109989006"
	DB01042	Multiple Myeloma	C0026764	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
enocitabine	DB00773	Multiple Myeloma	C0026764	NCT01500161	Terminated	Phase 2	Insufficient accruals	CHEBI_4911	"4179"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01501370	Withdrawn	Phase 2		CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB02546	Multiple Myeloma	C0026764	NCT01501370	Withdrawn	Phase 2		CHEBI_45716	"194337"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT01501370	Withdrawn	Phase 2		CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02605356	Withdrawn	Phase 1/Phase 2	Study restarted under new study number 18987	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT02605356	Withdrawn	Phase 1/Phase 2	Study restarted under new study number 18987	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00399	Multiple Myeloma	C0026764	NCT02739594	Terminated	Phase 3	Slow recruitment	CHEBI_46557	"1546014|77655"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT01750762	Terminated	Phase 1		CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
etoposide	DB00773	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_4911	"4179"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01881789	Terminated	Phase 1/Phase 2	A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
alimemazine	DB01246	Nasal congestion (finding)	C0027424		Approved			CHEBI_9725	"10825"	HP:0001742	"10028735"	"68235000"
	DB00531	Multiple Myeloma	C0026764	NCT01881789	Terminated	Phase 1/Phase 2	A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT01881789	Terminated	Phase 1/Phase 2	A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
ibandronic acid	DB00710	Multiple Myeloma	C0026764	NCT02739594	Terminated	Phase 3	Slow recruitment		"115265|115264"	MONDO_0009693	"10035226"	"109989006"
	DB01042	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03104270	Terminated	Phase 2	The study was terminated early by Funding Sponsor due to low enrollment.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
busulfan	DB01008	Multiple Myeloma	C0026764	NCT00615589	Terminated	Phase 2	Low accrual	CHEBI_28901	"1828"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03639610	Terminated	Phase 2	The sponsor decided to terminate the study following an FDA request of a partial clinical hold.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT03639610	Terminated	Phase 2	The sponsor decided to terminate the study following an FDA request of a partial clinical hold.	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
bendamustine	DB06769	Multiple Myeloma	C0026764	NCT01484626	Terminated	Phase 1/Phase 2	Celgene would no longer supply lenalidomide for the study	CHEBI_135515	"134547"	MONDO_0009693	"10035226"	"109989006"
	DB01041	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
plerixafor	DB06809	Multiple Myeloma	C0026764		Approved			CHEBI_125354	"733003"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02030483	Terminated	Phase 1	The company providing one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764	NCT00256776	Terminated	Phase 3		CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02030483	Terminated	Phase 1	The company providing one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT03785184	Withdrawn	Phase 2	Strategic considerations	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00515	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_27899	"2555"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT03683277	Terminated	Phase 2	Recruitment issue, 26 patients enrolled instead of 70 initially planned	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03785184	Withdrawn	Phase 2	Strategic considerations	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
natalizumab	DB00108	Multiple Myeloma	C0026764	NCT00675428	Terminated	Phase 1/Phase 2	Sponsor decision due to low enrollment and not safety concerns.		"354770"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00256776	Terminated	Phase 3		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00256776	Terminated	Phase 3		CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT04223661	Withdrawn	Phase 2	lack of funding	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00464178	Terminated	Phase 2	The study was closed early due to poor accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01002248	Terminated	Phase 3		CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT04223661	Withdrawn	Phase 2	lack of funding	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01002248	Terminated	Phase 3		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB13144	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.		"70167"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02289222	Terminated	Phase 1/Phase 2	Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the study.	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00609817	Terminated	Phase 1	Lack of funding	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00609817	Terminated	Phase 1	Lack of funding	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00681044	Terminated	Phase 2	Poor accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
doxorubicin	DB00997	Multiple Myeloma	C0026764		Approved			CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03117361	Terminated	Phase 2	PharmaMar has decided to end this study due to the slow recruitment rate of the trial	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
rituximab	DB00073	Multiple Myeloma	C0026764	NCT02356159	Suspended	Phase 1/Phase 2	One of the study drugs is temporarily not available from the manufacturer and unable to recruit new subjects at this time.		"2273510|2472325|121191|2105824"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03411031	Terminated	Phase 2	Sponsor no longer providing drug	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT03411031	Terminated	Phase 2	Sponsor no longer providing drug	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764	NCT03411031	Terminated	Phase 2	Sponsor no longer providing drug	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
bendamustine	DB06769	Multiple Myeloma	C0026764	NCT01315873	Terminated	Phase 2	PI left the institution before all data analysis was completed	CHEBI_135515	"134547"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT03117361	Terminated	Phase 2	PharmaMar has decided to end this study due to the slow recruitment rate of the trial	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
bevacizumab	DB00112	Multiple Myeloma	C0026764	NCT02079519	Terminated	Phase 2	The study was discontinued prematurely by the sponsor due to a lack of recruitment.		"253337|2046138"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
heparin	DB01109	Multiple Myeloma	C0026764	NCT00790842	Terminated	Phase 1/Phase 2	Slow enrollment	CHEBI_28304	"5224"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764	NCT00215943	Terminated	Phase 3	Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT01729338	Terminated	Phase 2		CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01729338	Terminated	Phase 2		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT01729338	Terminated	Phase 2		CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT03283046	Withdrawn	Phase 1	Similar to another study.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB06186	Multiple Myeloma	C0026764	NCT03283046	Withdrawn	Phase 1	Similar to another study.		"1094833"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02579863	Terminated	Phase 3	The study was terminated early due to business reasons	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB09035	Multiple Myeloma	C0026764	NCT03283046	Withdrawn	Phase 1	Similar to another study.		"1597876"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT03283046	Withdrawn	Phase 1	Similar to another study.	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00541	Multiple Myeloma	C0026764	NCT00215943	Terminated	Phase 3	Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.	CHEBI_28445	"11202"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01062230	Terminated	Phase 2	Slow accrual; PI left primary institution	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00987	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_28680	"3041|968804"	MONDO_0009693	"10035226"	"109989006"
	DB00399	Multiple Myeloma	C0026764	NCT00215943	Terminated	Phase 3	Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.	CHEBI_46557	"1546014|77655"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00215943	Terminated	Phase 3	Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT00215943	Terminated	Phase 3	Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
bexarotene	DB00307	Multiple Myeloma	C0026764	NCT01504490	Terminated	Phase 1	Drug no longer available	CHEBI_50859	"233272"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
etoposide	DB00773	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_4911	"4179"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB00262	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_3423	"2105"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02579863	Terminated	Phase 3	The study was terminated early due to business reasons	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
vemurafenib	DB08881	Multiple Myeloma	C0026764	NCT02115035	Withdrawn	Phase 1/Phase 2	Funding issues	CHEBI_63637	"1147220"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT00366106	Terminated	Phase 2	Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
	DB00515	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_27899	"2555"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01315873	Terminated	Phase 2	PI left the institution before all data analysis was completed	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01042	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB01041	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT00837200	Terminated	Phase 2	PI said to close accrual do to funding	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
asparaginase	DB00023	Multiple Myeloma	C0026764	NCT00837200	Terminated	Phase 2	PI said to close accrual do to funding		"1156"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00366106	Terminated	Phase 2	Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01041	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01042	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT01055301	Withdrawn	Phase 2	lack of accrual	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
enocitabine	DB00773	Multiple Myeloma	C0026764	NCT00574080	Terminated	Phase 3	low accrual	CHEBI_4911	"4179"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT04288765	Withdrawn	Phase 3	incomplete recruitment	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02462525	Terminated	Phase 1	No Go decision for ABBV-838	CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT04288765	Withdrawn	Phase 3	incomplete recruitment	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00366106	Terminated	Phase 2	Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
azacitidine	DB00928	Multiple Myeloma	C0026764	NCT01908387	Terminated	Phase 1	Due to Slow Accrual study was terminated.	CHEBI_2038	"1251"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT01675141	Terminated	Phase 2	Original investigator left the NIH and the primary outcome was not reached	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT02128230	Terminated	Phase 2	Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.	CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT01647165	Withdrawn	Phase 2		CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01647165	Withdrawn	Phase 2		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00657553	Terminated	Phase 3	Due to poor accrual	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
rituximab	DB00073	Multiple Myeloma	C0026764	NCT04045028	Terminated	Phase 1	Slow recruitment		"2273510|2472325|121191|2105824"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01647165	Withdrawn	Phase 2		CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT00538824	Terminated	Phase 2	low enrollment	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
dexamethasone phosphate	DB01234	Multiple Myeloma	C0026764	NCT02628704	Withdrawn	Phase 2		CHEBI_68637	"3264"	MONDO_0009693	"10035226"	"109989006"
ascorbic acid	DB00126	Multiple Myeloma	C0026764	NCT01125449	Suspended	Phase 2	Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche (Ireland).	CHEBI_29073	"1151|1370460"	MONDO_0009693	"10035226"	"109989006"
	DB14482	Multiple Myeloma	C0026764	NCT01125449	Suspended	Phase 2	Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche (Ireland).	CHEBI_113451	"267366"	MONDO_0009693	"10035226"	"109989006"
	DB14483	Multiple Myeloma	C0026764	NCT01125449	Suspended	Phase 2	Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche (Ireland).		"1307765|142407"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT00538824	Terminated	Phase 2	low enrollment	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764	NCT01537861	Terminated	Early Phase 1	Unexpected toxicity (2 early deaths)	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
	DB00997	Multiple Myeloma	C0026764	NCT00706953	Withdrawn	Phase 2		CHEBI_28748	"142433|3639"	MONDO_0009693	"10035226"	"109989006"
	DB00480	Multiple Myeloma	C0026764	NCT01537861	Terminated	Early Phase 1	Unexpected toxicity (2 early deaths)	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB00188	Multiple Myeloma	C0026764	NCT01537861	Terminated	Early Phase 1	Unexpected toxicity (2 early deaths)	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT00706953	Withdrawn	Phase 2		CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
thalidomide	DB01041	Multiple Myeloma	C0026764	NCT00538824	Terminated	Phase 2	low enrollment	CHEBI_74947	"10432"	MONDO_0009693	"10035226"	"109989006"
isatuximab	DB14811	Multiple Myeloma	C0026764		Approved				"2282018|2282019"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT02254551	Terminated	Phase 2	Safety lead-in data did not support continuation of study.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
lenalidomide	DB00480	Multiple Myeloma	C0026764	NCT02036502	Terminated	Phase 1	Business Reasons	CHEBI_63791	"342369"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT02036502	Terminated	Phase 1	Business Reasons	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
bortezomib	DB00188	Multiple Myeloma	C0026764	NCT01695330	Terminated	Phase 2	Terminated by Sponsor of this study.	CHEBI_52717	"358258"	MONDO_0009693	"10035226"	"109989006"
melphalan	DB01042	Multiple Myeloma	C0026764	NCT00968396	Withdrawn	Phase 2		CHEBI_28876	"6718"	MONDO_0009693	"10035226"	"109989006"
belantamab mafodotin	DB15719	Multiple Myeloma	C0026764		Approved				"2387834|2387833"	MONDO_0009693	"10035226"	"109989006"
	DB13144	Multiple Myeloma	C0026764	NCT01537861	Terminated	Early Phase 1	Unexpected toxicity (2 early deaths)		"70167"	MONDO_0009693	"10035226"	"109989006"
	DB01234	Multiple Myeloma	C0026764	NCT01537861	Terminated	Early Phase 1	Unexpected toxicity (2 early deaths)	CHEBI_41879	"3264"	MONDO_0009693	"10035226"	"109989006"
	DB00531	Multiple Myeloma	C0026764	NCT01537861	Terminated	Early Phase 1	Unexpected toxicity (2 early deaths)	CHEBI_4027	"1545988|3002"	MONDO_0009693	"10035226"	"109989006"
busulfan	DB01008	Multiple Myeloma	C0026764	NCT00934232	Terminated	Phase 1	PI left the institution	CHEBI_28901	"1828"	MONDO_0009693	"10035226"	"109989006"
	DB14644	Multiple Sclerosis	C0026769	NCT00947895	Terminated	Phase 2/Phase 3	Study reached halfway point in approximately one year time period and was halted to analyze data.	CHEBI_135765		MONDO_0005301	"10028245"	"24700007"
cortisone acetate	DB01380	Multiple Sclerosis	C0026769		Approved			CHEBI_3897	"21655"	MONDO_0005301	"10028245"	"24700007"
fingolimod	DB08868	Multiple Sclerosis	C0026769	NCT01647880	Terminated	Phase 2/Phase 3	delayed recruitment	CHEBI_63115	"1012892"	MONDO_0005301	"10028245"	"24700007"
testosterone	DB00624	Multiple Sclerosis	C0026769	NCT02317263	Withdrawn	Phase 2	NIH did not fund the study so it never started	CHEBI_17347	"10379"	MONDO_0005301	"10028245"	"24700007"
betamethasone acetate	DB00443	Multiple Sclerosis	C0026769		Approved			CHEBI_3077	"1514"	MONDO_0005301	"10028245"	"24700007"
fampridine	DB06637	Multiple Sclerosis	C0026769		Approved			CHEBI_34385	"897018"	MONDO_0005301	"10028245"	"24700007"
teriflunomide	DB08880	Multiple Sclerosis	C0026769		Approved			CHEBI_68540	"1310520"	MONDO_0005301	"10028245"	"24700007"
interferon beta-1b	DB00068	Multiple Sclerosis	C0026769	NCT00313976	Withdrawn	Phase 3		CHEBI_5938	"72257|72258"	MONDO_0005301	"10028245"	"24700007"
triamcinolone acetonide	DB00620	Multiple Sclerosis	C0026769		Approved			CHEBI_9667	"10759"	MONDO_0005301	"10028245"	"24700007"
hydroxycarbamide	DB01005	Multiple Sclerosis	C0026769	NCT01103583	Terminated	Phase 2/Phase 3	No efficacy (interim.analysis)	CHEBI_44423	"151871|5552"	MONDO_0005301	"10028245"	"24700007"
methylprednisolone	DB00959	Multiple Sclerosis	C0026769		Approved			CHEBI_6888	"6902"	MONDO_0005301	"10028245"	"24700007"
rituximab	DB00073	Multiple Sclerosis	C0026769	NCT01212094	Terminated	Phase 1/Phase 2	The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial		"2273510|2472325|121191|2105824"	MONDO_0005301	"10028245"	"24700007"
daclizumab	DB00111	Multiple Sclerosis	C0026769	NCT01797965	Terminated	Phase 3	Study terminated because of differences in the participant population under study compared with indicated Zinbryta use in most countries.		"190353"	MONDO_0005301	"10028245"	"24700007"
	DB09061	Multiple Sclerosis	C0026769	NCT03172741	Withdrawn	Phase 2/Phase 3	Did not pursue study	CHEBI_69478	"2045371"	MONDO_0005301	"10028245"	"24700007"
histamine	DB05381	Multiple Sclerosis	C0026769	NCT04764383	Withdrawn	Phase 2	Withdrawn as more data drug analysis is recommended before the study.	CHEBI_18295	"5333"	MONDO_0005301	"10028245"	"24700007"
acetazolamide	DB00819	Multiple Sclerosis	C0026769	NCT02466074	Terminated	Phase 2	Inadequate recruitment; termination of funding	CHEBI_27690	"167"	MONDO_0005301	"10028245"	"24700007"
triamcinolone	DB00620	Multiple Sclerosis	C0026769		Approved			CHEBI_9667	"10759"	MONDO_0005301	"10028245"	"24700007"
cyclophosphamide	DB00531	Multiple Sclerosis	C0026769	NCT00296205	Withdrawn	Phase 2	I am changing locations to Johns Hopkins Medical Center	CHEBI_4027	"1545988|3002"	MONDO_0005301	"10028245"	"24700007"
abatacept	DB01281	Multiple Sclerosis	C0026769	NCT00035529	Terminated	Phase 2			"614391"	MONDO_0005301	"10028245"	"24700007"
hydrocortisone succinate	DB14545	Multiple Sclerosis	C0026769		Approved			CHEBI_31677	"21651"	MONDO_0005301	"10028245"	"24700007"
	DB00531	Multiple Sclerosis	C0026769	NCT01679041	Terminated	Phase 2	Insufficient accruals; PI leaving site	CHEBI_4027	"1545988|3002"	MONDO_0005301	"10028245"	"24700007"
dexamethasone	DB01234	Multiple Sclerosis	C0026769		Approved			CHEBI_41879	"3264"	MONDO_0005301	"10028245"	"24700007"
hydrocortisone succinate	DB00741	Multiple Sclerosis	C0026769		Approved			CHEBI_17650	"5492"	MONDO_0005301	"10028245"	"24700007"
biotin	DB00121	Multiple Sclerosis	C0026769	NCT02936037	Terminated	Phase 3	Sponsor decision for business purposes	CHEBI_15956	"314583|1588"	MONDO_0005301	"10028245"	"24700007"
alemtuzumab	DB00087	Multiple Sclerosis	C0026769	NCT01679041	Terminated	Phase 2	Insufficient accruals; PI leaving site		"117055"	MONDO_0005301	"10028245"	"24700007"
donepezil	DB00843	Multiple Sclerosis	C0026769	NCT00062972	Withdrawn	Phase 3	Study terminated/withdrawn	CHEBI_145499	"135447"	MONDO_0005301	"10028245"	"24700007"
methylprednisolone	DB00959	Multiple Sclerosis	C0026769	NCT02048358	Terminated	Phase 1		CHEBI_6888	"6902"	MONDO_0005301	"10028245"	"24700007"
	DB14644	Multiple Sclerosis	C0026769	NCT02048358	Terminated	Phase 1		CHEBI_135765		MONDO_0005301	"10028245"	"24700007"
methylprednisolone	DB00959	Multiple Sclerosis	C0026769	NCT00418145	Terminated	Phase 3	low enrollment - data was not analyzed for this study	CHEBI_6888	"6902"	MONDO_0005301	"10028245"	"24700007"
prednisolone	DB00860	Multiple Sclerosis	C0026769		Approved			CHEBI_8378	"8638"	MONDO_0005301	"10028245"	"24700007"
prednisone	DB00635	Multiple Sclerosis	C0026769		Approved			CHEBI_8382	"8640"	MONDO_0005301	"10028245"	"24700007"
colecalciferol	DB00169	Multiple Sclerosis	C0026769	NCT01440062	Terminated	Phase 2		CHEBI_28940	"2418"	MONDO_0005301	"10028245"	"24700007"
testosterone	DB00624	Multiple Sclerosis	C0026769	NCT03000127	Withdrawn	Phase 2	Lack of funding	CHEBI_17347	"10379"	MONDO_0005301	"10028245"	"24700007"
minocycline	DB01017	Multiple Sclerosis	C0026769	NCT04291456	Terminated	Phase 3	Completion is not possible due to recruitment concerns	CHEBI_50694	"6980"	MONDO_0005301	"10028245"	"24700007"
nivolumab	DB09035	Multiple Sclerosis	C0026769	NCT03656627	Terminated	Phase 1	low accrual		"1597876"	MONDO_0005301	"10028245"	"24700007"
	DB14644	Multiple Sclerosis	C0026769	NCT00418145	Terminated	Phase 3	low enrollment - data was not analyzed for this study	CHEBI_135765		MONDO_0005301	"10028245"	"24700007"
dronabinol	DB00470	Multiple Sclerosis	C0026769	NCT00682929	Terminated	Phase 1/Phase 2	Unable to complete subject recruitment	CHEBI_66964	"10402"	MONDO_0005301	"10028245"	"24700007"
interferon beta-1a	DB00060	Multiple Sclerosis	C0026769	NCT00784836	Terminated	Phase 3	Terminated early by Sponsor for business reasons unrelated to safety.		"75917"	MONDO_0005301	"10028245"	"24700007"
	DB00860	Multiple Sclerosis	C0026769	NCT02048358	Terminated	Phase 1		CHEBI_8378	"8638"	MONDO_0005301	"10028245"	"24700007"
dimethyl fumarate	DB08908	Multiple Sclerosis	C0026769	NCT02428231	Terminated	Phase 3	Sponsor decision	CHEBI_76004	"1373478"	MONDO_0005301	"10028245"	"24700007"
	DB00860	Multiple Sclerosis	C0026769	NCT00418145	Terminated	Phase 3	low enrollment - data was not analyzed for this study	CHEBI_8378	"8638"	MONDO_0005301	"10028245"	"24700007"
	DB06710	Multiple Sclerosis	C0026769	NCT01516554	Terminated	Phase 2	Poor recruitment	CHEBI_27436	"6904"	MONDO_0005301	"10028245"	"24700007"
	DB00860	Multiple Sclerosis	C0026769	NCT00947895	Terminated	Phase 2/Phase 3	Study reached halfway point in approximately one year time period and was halted to analyze data.	CHEBI_8378	"8638"	MONDO_0005301	"10028245"	"24700007"
memantine	DB01043	Multiple Sclerosis	C0026769	NCT00638833	Terminated	Phase 2	Unexpected side-effects: reversible and mild to moderate neurological impairment	CHEBI_64312	"6719"	MONDO_0005301	"10028245"	"24700007"
methylprednisolone	DB00959	Multiple Sclerosis	C0026769	NCT00947895	Terminated	Phase 2/Phase 3	Study reached halfway point in approximately one year time period and was halted to analyze data.	CHEBI_6888	"6902"	MONDO_0005301	"10028245"	"24700007"
minocycline	DB01017	Multiple Sclerosis	C0026769	NCT01073813	Terminated	Phase 2	Lack of recruitment	CHEBI_50694	"6980"	MONDO_0005301	"10028245"	"24700007"
acetylsalicylic acid	DB00945	Multiple Sclerosis	C0026769	NCT00467584	Terminated	Phase 3	Interim analysis indicated treatment unlikely effective;slow recruitment	CHEBI_15365	"91101|1191"	MONDO_0005301	"10028245"	"24700007"
guanabenz	DB00629	Multiple Sclerosis	C0026769	NCT02423083	Terminated	Phase 1		CHEBI_5553	"5033"	MONDO_0005301	"10028245"	"24700007"
natalizumab	DB00108	Multiple Sclerosis	C0026769		Approved				"354770"	MONDO_0005301	"10028245"	"24700007"
hydrocortisone	DB00741	Multiple Sclerosis	C0026769		Approved			CHEBI_17650	"5492"	MONDO_0005301	"10028245"	"24700007"
zoledronic acid	DB00399	Multiple Sclerosis	C0026769	NCT01166178	Terminated	Phase 3		CHEBI_46557	"1546014|77655"	MONDO_0005301	"10028245"	"24700007"
alemtuzumab	DB00087	Multiple Sclerosis	C0026769	NCT01712945	Terminated	Phase 1/Phase 2	interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab		"117055"	MONDO_0005301	"10028245"	"24700007"
bisacodyl	DB09020	Multiple Sclerosis	C0026769	NCT02609607	Terminated	Phase 2	Poor enrollment; funding ending Dec 31, 2018.	CHEBI_3125	"1596"	MONDO_0005301	"10028245"	"24700007"
betamethasone	DB00443	Multiple Sclerosis	C0026769		Approved			CHEBI_3077	"1514"	MONDO_0005301	"10028245"	"24700007"
hydrocortisone acetate	DB00741	Multiple Sclerosis	C0026769		Approved			CHEBI_17650	"5492"	MONDO_0005301	"10028245"	"24700007"
dronabinol	DB00470	Multiple Sclerosis	C0026769	NCT03172741	Withdrawn	Phase 2/Phase 3	Did not pursue study	CHEBI_66964	"10402"	MONDO_0005301	"10028245"	"24700007"
ozanimod	DB12612	Multiple Sclerosis	C0026769		Approved				"2288236"	MONDO_0005301	"10028245"	"24700007"
triamcinolone diacetate	DB00620	Multiple Sclerosis	C0026769		Approved			CHEBI_9667	"10759"	MONDO_0005301	"10028245"	"24700007"
hydrocortisone acetate	DB14539	Multiple Sclerosis	C0026769		Approved			CHEBI_17609	"27197"	MONDO_0005301	"10028245"	"24700007"
testosterone	DB00624	Multiple Sclerosis	C0026769	NCT01516554	Terminated	Phase 2	Poor recruitment	CHEBI_17347	"10379"	MONDO_0005301	"10028245"	"24700007"
colecalciferol	DB00169	Multiple Sclerosis	C0026769	NCT02096133	Terminated	Phase 2	difficulties with inclusion	CHEBI_28940	"2418"	MONDO_0005301	"10028245"	"24700007"
posaconazole	DB01263	Mycoses	C0026946		Approved			CHEBI_64355	"282446"		"10017533"	"3218000"
dicoumarol	DB00266	Myocardial Infarction	C0027051		Approved			CHEBI_4513	"1598"	MONDO_0005068	"10028596"	"22298006"
tirofiban	DB00775	Myocardial Infarction	C0027051	NCT01245725	Withdrawn	Phase 3	Study was not initiated, change in clinical development	CHEBI_9605	"73137"	MONDO_0005068	"10028596"	"22298006"
metoprolol	DB00264	Myocardial Infarction	C0027051		Approved			CHEBI_6904	"6918"	MONDO_0005068	"10028596"	"22298006"
	DB00945	Myocardial Infarction	C0027051	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	CHEBI_15365	"91101|1191"	MONDO_0005068	"10028596"	"22298006"
eptifibatide	DB00063	Myocardial Infarction	C0027051	NCT00812435	Terminated	Phase 3		CHEBI_291902	"288688|75635"	MONDO_0005068	"10028596"	"22298006"
lisinopril	DB00722	Myocardial Infarction	C0027051		Approved			CHEBI_43755	"1546022|29046"	MONDO_0005068	"10028596"	"22298006"
atenolol	DB00335	Myocardial Infarction	C0027051		Approved			CHEBI_2904	"1202"	MONDO_0005068	"10028596"	"22298006"
fondaparinux	DB00569	Myocardial Infarction	C0027051	NCT00060554	Withdrawn	Phase 2	Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.	CHEBI_61033	"321208"	MONDO_0005068	"10028596"	"22298006"
	DB01109	Myocardial Infarction	C0027051	NCT00060554	Withdrawn	Phase 2	Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.	CHEBI_28304	"5224"	MONDO_0005068	"10028596"	"22298006"
Vitamin E	DB00163	Myocardial Infarction	C0027051	NCT00220831	Terminated	Phase 2/Phase 3	interim analysis showed significant differences between two treatment groups	CHEBI_18145	"11256|237099"	MONDO_0005068	"10028596"	"22298006"
	DB00758	Myocardial Infarction	C0027051	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	CHEBI_37941	"32968"	MONDO_0005068	"10028596"	"22298006"
	DB00627	Myocardial Infarction	C0027051	NCT00120289	Terminated	Phase 3	AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.	CHEBI_15940	"7393"	MONDO_0005068	"10028596"	"22298006"
acetylsalicylic acid	DB00945	Myocardial Infarction	C0027051		Approved			CHEBI_15365	"91101|1191"	MONDO_0005068	"10028596"	"22298006"
acetylsalicylic acid	DB00945	Myocardial Infarction	C0027051	NCT00501345	Terminated	Phase 3	Low accrual, study terminated.	CHEBI_15365	"91101|1191"	MONDO_0005068	"10028596"	"22298006"
esomeprazole	DB00338	Myocardial Infarction	C0027051	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	CHEBI_77260	"7646"	MONDO_0005068	"10028596"	"22298006"
etofibrate	DB00641	Myocardial Infarction	C0027051	NCT00120289	Terminated	Phase 3	AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.	CHEBI_9150	"36567"	MONDO_0005068	"10028596"	"22298006"
colchicine	DB01394	Myocardial Infarction	C0027051	NCT04218786	Withdrawn	Phase 2	Due to the pandemic, there were logistical issues in continuing the study.	CHEBI_27882	"2683"	MONDO_0005068	"10028596"	"22298006"
phenprocoumon	DB00946	Myocardial Infarction	C0027051		Approved			CHEBI_50438	"8150"	MONDO_0005068	"10028596"	"22298006"
sulfogaiacol	DB13735	Nasal congestion (finding)	C0027424		Approved			CHEBI_85537		HP:0001742	"10028735"	"68235000"
ammonium chloride	DB06767	Nasal congestion (finding)	C0027424		Approved			CHEBI_31206	"712"	HP:0001742	"10028735"	"68235000"
cyclizine	DB01176	Nasal congestion (finding)	C0027424		Approved			CHEBI_3994	"2977"	HP:0001742	"10028735"	"68235000"
sulfogaiacol	DB15992	Nasal congestion (finding)	C0027424		Approved			CHEBI_85537		HP:0001742	"10028735"	"68235000"
methscopolamine	DB11315	Nasal congestion (finding)	C0027424		Approved			CHEBI_135361	"89785"	HP:0001742	"10028735"	"68235000"
dextromethorphan	DB00514	Nasal congestion (finding)	C0027424		Approved			CHEBI_4470	"3289"	HP:0001742	"10028735"	"68235000"
oxedrine	DB09203	Nasal congestion (finding)	C0027424		Approved			CHEBI_29081		HP:0001742	"10028735"	"68235000"
hydrocodone	DB00956	Nasal congestion (finding)	C0027424		Approved			CHEBI_5779	"5489"	HP:0001742	"10028735"	"68235000"
bromazine	DB01237	Nasal congestion (finding)	C0027424		Approved			CHEBI_59177	"19759"	HP:0001742	"10028735"	"68235000"
antazoline	DB08799	Nasal congestion (finding)	C0027424		Approved			CHEBI_84115	"865"	HP:0001742	"10028735"	"68235000"
diphenylpyraline	DB01146	Nasal congestion (finding)	C0027424		Approved			CHEBI_59788	"23386"	HP:0001742	"10028735"	"68235000"
scopolamine	DB00747	Nasal congestion (finding)	C0027424		Approved			CHEBI_16794	"9601|9603"	HP:0001742	"10028735"	"68235000"
phenylephrine	DB00388	Nasal congestion (finding)	C0027424		Approved			CHEBI_8093	"8163"	HP:0001742	"10028735"	"68235000"
clemastine	DB00283	Nasal congestion (finding)	C0027424		Approved			CHEBI_3738	"2578"	HP:0001742	"10028735"	"68235000"
indanazoline	DB13827	Nasal congestion (finding)	C0027424		Approved			CHEBI_134863		HP:0001742	"10028735"	"68235000"
sodium citrate	DB09154	Nasal congestion (finding)	C0027424		Approved			CHEBI_53258	"253204|56466|1310549"	HP:0001742	"10028735"	"68235000"
pseudoephedrine	DB00852	Nasal congestion (finding)	C0027424		Approved			CHEBI_51209	"8896"	HP:0001742	"10028735"	"68235000"
potassium iodide	DB06715	Nasal congestion (finding)	C0027424		Approved			CHEBI_8346	"8597"	HP:0001742	"10028735"	"68235000"
loratadine	DB00455	Nasal congestion (finding)	C0027424		Approved			CHEBI_6538	"28889"	HP:0001742	"10028735"	"68235000"
glycine	DB00145	Nasal congestion (finding)	C0027424		Approved			CHEBI_15428	"4919"	HP:0001742	"10028735"	"68235000"
codeine	DB00318	Nasal congestion (finding)	C0027424		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0001742	"10028735"	"68235000"
doxylamine	DB00366	Nasal congestion (finding)	C0027424		Approved			CHEBI_51380	"3642"	HP:0001742	"10028735"	"68235000"
methscopolamine	DB00462	Nasal congestion (finding)	C0027424		Approved			CHEBI_61276	"56092"	HP:0001742	"10028735"	"68235000"
terfenadine	DB00342	Nasal congestion (finding)	C0027424		Approved			CHEBI_9453	"42330"	HP:0001742	"10028735"	"68235000"
azatadine	DB00719	Nasal congestion (finding)	C0027424		Approved			CHEBI_2946	"18600"	HP:0001742	"10028735"	"68235000"
tramazoline	DB13064	Nasal congestion (finding)	C0027424		Approved			CHEBI_134893	"38453"	HP:0001742	"10028735"	"68235000"
mepyramine	DB06691	Nasal congestion (finding)	C0027424		Approved			CHEBI_6762	"9009"	HP:0001742	"10028735"	"68235000"
desloratadine	DB00967	Nasal congestion (finding)	C0027424		Approved			CHEBI_291342	"275635"	HP:0001742	"10028735"	"68235000"
guaifenesin	DB00874	Nasal congestion (finding)	C0027424		Approved			CHEBI_5551	"5032"	HP:0001742	"10028735"	"68235000"
pyrithione	DB06815	Nasal congestion (finding)	C0027424		Approved			CHEBI_36584	"35100"	HP:0001742	"10028735"	"68235000"
xylometazoline	DB06694	Nasal congestion (finding)	C0027424		Approved			CHEBI_10082	"39841"	HP:0001742	"10028735"	"68235000"
methdilazine	DB00902	Nasal congestion (finding)	C0027424		Approved			CHEBI_6823	"29648"	HP:0001742	"10028735"	"68235000"
dihydrocodeine	DB01551	Nasal congestion (finding)	C0027424		Approved			CHEBI_135276	"23088"	HP:0001742	"10028735"	"68235000"
ephedrine	DB01364	Nasal congestion (finding)	C0027424		Approved			CHEBI_15407	"3966"	HP:0001742	"10028735"	"68235000"
phenindamine	DB01619	Nasal congestion (finding)	C0027424		Approved			CHEBI_8065	"33283"	HP:0001742	"10028735"	"68235000"
metizoline	DB13614	Nasal congestion (finding)	C0027424		Approved			CHEBI_136017		HP:0001742	"10028735"	"68235000"
phenylpropanolamine	DB00397	Nasal congestion (finding)	C0027424		Approved			CHEBI_80680	"8175"	HP:0001742	"10028735"	"68235000"
epoprostenol	DB01240	Nasal congestion (finding)	C0027424		Approved			CHEBI_15552	"8814"	HP:0001742	"10028735"	"68235000"
tetryzoline	DB06764	Nasal congestion (finding)	C0027424		Approved			CHEBI_28674	"37935"	HP:0001742	"10028735"	"68235000"
pheniramine	DB01620	Nasal congestion (finding)	C0027424		Approved			CHEBI_91591	"8132"	HP:0001742	"10028735"	"68235000"
chlorphenamine	DB01114	Nasal congestion (finding)	C0027424		Approved			CHEBI_52010	"221074|2400"	HP:0001742	"10028735"	"68235000"
pentoxyverine	DB11186	Nasal congestion (finding)	C0027424		Approved			CHEBI_94484	"20217"	HP:0001742	"10028735"	"68235000"
cetirizine	DB00341	Nasal congestion (finding)	C0027424		Approved			CHEBI_3561	"20610"	HP:0001742	"10028735"	"68235000"
oxymetazoline	DB00935	Nasal congestion (finding)	C0027424		Approved			CHEBI_7862	"7812"	HP:0001742	"10028735"	"68235000"
acrivastine	DB09488	Nasal congestion (finding)	C0027424		Approved			CHEBI_83168	"19959"	HP:0001742	"10028735"	"68235000"
promazine	DB00420	Nasal congestion (finding)	C0027424		Approved			CHEBI_8459	"8742"	HP:0001742	"10028735"	"68235000"
levmetamfetamine	DB09571	Nasal congestion (finding)	C0027424		Approved			CHEBI_136013	"1314416"	HP:0001742	"10028735"	"68235000"
methapyrilene	DB04819	Nasal congestion (finding)	C0027424		Approved			CHEBI_6820	"6822"	HP:0001742	"10028735"	"68235000"
tripelennamine	DB00792	Nasal congestion (finding)	C0027424		Approved			CHEBI_9741	"10847"	HP:0001742	"10028735"	"68235000"
guaiacol	DB11359	Nasal congestion (finding)	C0027424		Approved			CHEBI_28591	"5031"	HP:0001742	"10028735"	"68235000"
cyproheptadine	DB00434	Nasal congestion (finding)	C0027424		Approved			CHEBI_4046	"3013"	HP:0001742	"10028735"	"68235000"
chlorcyclizine	DB08936	Nasal congestion (finding)	C0027424		Approved			CHEBI_94402	"2354"	HP:0001742	"10028735"	"68235000"
clofedanol	DB04837	Nasal congestion (finding)	C0027424		Approved			CHEBI_135207	"21254"	HP:0001742	"10028735"	"68235000"
rabeprazole	DB01129	Multiple Endocrine Neoplasia	C0027662		Approved			CHEBI_8768	"183877|114979"	MONDO_0017169	"10051747"	"60549007"
pantoprazole	DB00213	Multiple Endocrine Neoplasia	C0027662		Approved			CHEBI_7915	"40790"	MONDO_0017169	"10051747"	"60549007"
cimetidine	DB00501	Multiple Endocrine Neoplasia	C0027662		Approved			CHEBI_3699	"2541"	MONDO_0017169	"10051747"	"60549007"
penthienate	DB13695	Peptic Ulcer	C0030920		Approved			CHEBI_135447		MONDO_0004247	"10034341"	"13200003"
	DB01181	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	CHEBI_5864	"5657"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00541	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_28445	"11202"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00958	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_31355	"40048"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00252	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	CHEBI_8107	"8183"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
melphalan	DB01042	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	CHEBI_28876	"6718"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
heparin	DB01109	Neuroblastoma	C0027819	NCT02164097	Terminated	Phase 1	low accrual	CHEBI_28304	"5224"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00762	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	CHEBI_80630	"51499"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00087	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual		"117055"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
naxitamab	DB15965	Neuroblastoma	C0027819		Approved				"2474235|2474039"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00853	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	CHEBI_72564	"37776"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
rituximab	DB00073	Neuroblastoma	C0027819	NCT00202930	Terminated	Phase 2	Closed early due to low accrual.		"2273510|2472325|121191|2105824"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00541	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	CHEBI_28445	"11202"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00755	Neuroblastoma	C0027819	NCT01048086	Withdrawn	Phase 2	No patients were enrolled because the company that pledged the drug does not yet have it available.	CHEBI_15367	"10753"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
isotretinoin	DB00982	Neuroblastoma	C0027819	NCT01048086	Withdrawn	Phase 2	No patients were enrolled because the company that pledged the drug does not yet have it available.	CHEBI_6067	"6064"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
octreotide	DB00104	Neuroblastoma	C0027819	NCT03013387	Withdrawn	Phase 2	This project has undergone a significant amount of updates and has been resubmitted under IRB# 201708778	CHEBI_7726	"7617"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00531	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	CHEBI_4027	"1545988|3002"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
busulfan	DB01008	Neuroblastoma	C0027819		Approved			CHEBI_28901	"1828"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00531	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	CHEBI_4027	"1545988|3002"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB01008	Neuroblastoma	C0027819	NCT00874315	Withdrawn	Phase 2	lack of accrual	CHEBI_28901	"1828"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB11596	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_63606	"877015"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00526	Neuroblastoma	C0027819	NCT02630043	Terminated	Phase 1	Lack of study enrollment	CHEBI_31941	"32592"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00997	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	CHEBI_28748	"142433|3639"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
isotretinoin	DB00982	Neuroblastoma	C0027819	NCT04909515	Withdrawn	Phase 2	Study terminated due to business priorities	CHEBI_6067	"6064"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00531	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_4027	"1545988|3002"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
cyclophosphamide	DB00531	Neuroblastoma	C0027819	NCT02439788	Withdrawn	Phase 1	Based on newly available preclinical data we changed the CAR construct to a more effective version and will now study that product on a different protocol.	CHEBI_4027	"1545988|3002"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
tolcapone	DB00323	Neuroblastoma	C0027819	NCT02630043	Terminated	Phase 1	Lack of study enrollment	CHEBI_63630	"72937"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
doxorubicin	DB00997	Neuroblastoma	C0027819		Approved			CHEBI_28748	"142433|3639"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
isotretinoin	DB00982	Neuroblastoma	C0027819	NCT00533169	Terminated	Phase 1	Lack of enrollment.	CHEBI_6067	"6064"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
doxorubicin	DB00997	Neuroblastoma	C0027819	NCT02557854	Withdrawn	Phase 1	Lack of enrollment	CHEBI_28748	"142433|3639"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
cyclophosphamide	DB00531	Neuroblastoma	C0027819	NCT00698009	Terminated	Phase 2	Slow accrual.	CHEBI_4027	"1545988|3002"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB13144	Neuroblastoma	C0027819	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual		"70167"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB01008	Neuroblastoma	C0027819	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_28901	"1828"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00755	Neuroblastoma	C0027819	NCT02641782	Terminated	Phase 2	Antibody supply was discontinued by United Therapeutics Corporation.	CHEBI_15367	"10753"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB04572	Neuroblastoma	C0027819	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_9570	"10473"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
isotretinoin	DB00982	Neuroblastoma	C0027819	NCT02641782	Terminated	Phase 2	Antibody supply was discontinued by United Therapeutics Corporation.	CHEBI_6067	"6064"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00997	Neuroblastoma	C0027819	NCT00808899	Terminated	Phase 2	Voluntarily closed and terminated by the PI due to lack of feasibility	CHEBI_28748	"142433|3639"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
deferasirox	DB01609	Neuroblastoma	C0027819	NCT00602446	Terminated	Phase 2	Due to slow accrual of patients	CHEBI_49005	"614373"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
cyclophosphamide	DB00531	Neuroblastoma	C0027819		Approved			CHEBI_4027	"1545988|3002"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB01042	Neuroblastoma	C0027819	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_28876	"6718"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00531	Neuroblastoma	C0027819	NCT00808899	Terminated	Phase 2	Voluntarily closed and terminated by the PI due to lack of feasibility	CHEBI_4027	"1545988|3002"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00755	Neuroblastoma	C0027819	NCT00808899	Terminated	Phase 2	Voluntarily closed and terminated by the PI due to lack of feasibility	CHEBI_15367	"10753"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
dinutuximab	DB09077	Neuroblastoma	C0027819		Approved				"1606274"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
ofloxacin	DB01165	Klebsiella cystitis	C0520775		Approved			CHEBI_7731	"7623"		"10011797"	"60867007"
amifostine	DB01143	Neuroblastoma	C0027819	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_2636	"1545987|4126"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
isotretinoin	DB00982	Neuroblastoma	C0027819	NCT01319838	Withdrawn	Phase 1	no patient enrollment	CHEBI_6067	"6064"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB01030	Neuroblastoma	C0027819	NCT00808899	Terminated	Phase 2	Voluntarily closed and terminated by the PI due to lack of feasibility	CHEBI_63632	"57308"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
moxifloxacin	DB00218	Neuroblastoma	C0027819	NCT00324324	Terminated	Phase 3		CHEBI_63611	"139462"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00313	Neuroblastoma	C0027819	NCT01204450	Terminated	Phase 1	Funding has become unavailable	CHEBI_39867	"11118|40254"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
sirolimus	DB00877	Neuroblastoma	C0027819	NCT01204450	Terminated	Phase 1	Funding has become unavailable	CHEBI_9168	"35302"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
zoledronic acid	DB00399	Neuroblastoma	C0027819	NCT01404702	Terminated	Phase 1	Accrual slower than anticipated	CHEBI_46557	"1546014|77655"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
octreotide	DB00104	Neuroblastoma	C0027819	NCT02177773	Terminated	Phase 1/Phase 2	FDA approved agent for this indication during enrollment	CHEBI_7726	"7617"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
vincristine	DB00541	Neuroblastoma	C0027819		Approved			CHEBI_28445	"11202"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00864	Neuroblastoma	C0027819	NCT00874315	Withdrawn	Phase 2	lack of accrual	CHEBI_61049	"42316|235991"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
erlotinib	DB00530	Neuroblastoma	C0027819	NCT00947167	Terminated	Phase 2	Extreme toxicity of Pertuzumab and Erlotinib combination	CHEBI_114785	"337525"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
ketoconazole	DB01026	Neuroblastoma	C0027819	NCT02163356	Terminated	Phase 1	drug supply	CHEBI_48339	"6135"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00755	Neuroblastoma	C0027819	NCT00533169	Terminated	Phase 1	Lack of enrollment.	CHEBI_15367	"10753"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
mycophenolate mofetil	DB01024	Neuroblastoma	C0027819	NCT00874315	Withdrawn	Phase 2	lack of accrual	CHEBI_168396	"7145|265323"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00541	Neuroblastoma	C0027819	NCT02163356	Terminated	Phase 1	drug supply	CHEBI_28445	"11202"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB01008	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	CHEBI_28901	"1828"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00091	Neuroblastoma	C0027819	NCT00874315	Withdrawn	Phase 2	lack of accrual	CHEBI_4031	"3008"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
etoposide	DB00773	Neuroblastoma	C0027819	NCT00539500	Terminated	Phase 2/Phase 3	Slow Accrual.	CHEBI_4911	"4179"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
etoposide	DB00773	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_4911	"4179"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB01042	Neuroblastoma	C0027819	NCT00539500	Terminated	Phase 2/Phase 3	Slow Accrual.	CHEBI_28876	"6718"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00958	Neuroblastoma	C0027819	NCT00539500	Terminated	Phase 2/Phase 3	Slow Accrual.	CHEBI_31355	"40048"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00650	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_15640	"6313"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
etoposide	DB00773	Neuroblastoma	C0027819	NCT00960063	Terminated	Phase 1	Study was terminated for business reasons.	CHEBI_4911	"4179"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00563	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_44185	"6851"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB04572	Neuroblastoma	C0027819	NCT00801931	Terminated	Phase 1/Phase 2	Poor accrual	CHEBI_9570	"10473"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
busulfan	DB01008	Neuroblastoma	C0027819	NCT00670410	Terminated	Phase 1	Poor accrual	CHEBI_28901	"1828"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00853	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_72564	"37776"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
topotecan	DB01030	Neuroblastoma	C0027819	NCT00389766	Withdrawn	Phase 2	Withdrawn because protocol has been discontinued. It was never opened.	CHEBI_63632	"57308"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB04572	Neuroblastoma	C0027819	NCT00003273	Withdrawn	Phase 2		CHEBI_9570	"10473"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00762	Neuroblastoma	C0027819	NCT00808899	Terminated	Phase 2	Voluntarily closed and terminated by the PI due to lack of feasibility	CHEBI_80630	"51499"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
etoposide	DB00773	Neuroblastoma	C0027819	NCT00808899	Terminated	Phase 2	Voluntarily closed and terminated by the PI due to lack of feasibility	CHEBI_4911	"4179"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
irinotecan	DB00762	Neuroblastoma	C0027819	NCT01505608	Terminated	Phase 1/Phase 2	Lack of Enrollment	CHEBI_80630	"51499"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00853	Neuroblastoma	C0027819	NCT01505608	Terminated	Phase 1/Phase 2	Lack of Enrollment	CHEBI_72564	"37776"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
	DB00982	Neuroblastoma	C0027819	NCT00808899	Terminated	Phase 2	Voluntarily closed and terminated by the PI due to lack of feasibility	CHEBI_6067	"6064"	MONDO_0005072|MONDO_0009741	"10029260"	"432328008"
varenicline	DB01273	Obesity	C0028754	NCT02412631	Terminated	Phase 2/Phase 3	Lorcaserin removed from market	CHEBI_84500	"591622"	MONDO_0011122	"10029883"	"414915002"
liraglutide	DB06655	Obesity	C0028754	NCT02417103	Terminated	Phase 3	Recruiting failure	CHEBI_71193	"475968"	MONDO_0011122	"10029883"	"414915002"
fenofibrate	DB01039	Obesity	C0028754	NCT00376285	Withdrawn	Phase 1		CHEBI_5001	"8703"	MONDO_0011122	"10029883"	"414915002"
	DB01083	Obesity	C0028754	NCT01351753	Terminated	Phase 2	Lack of funding	CHEBI_94686	"37925"	MONDO_0011122	"10029883"	"414915002"
phendimetrazine	DB01579	Obesity	C0028754		Approved			CHEBI_8059	"33272"	MONDO_0011122	"10029883"	"414915002"
phenmetrazine	DB00830	Obesity	C0028754		Approved			CHEBI_8067	"8133"	MONDO_0011122	"10029883"	"414915002"
cetilistat	DB06586	Obesity	C0028754		Approved			CHEBI_134721		MONDO_0011122	"10029883"	"414915002"
hydrocortamate	DB00741	Obesity	C0028754	NCT01422707	Withdrawn	Early Phase 1	The study team decided not to pursue this study.	CHEBI_17650	"5492"	MONDO_0011122	"10029883"	"414915002"
naltrexone	DB00704	Obesity	C0028754	NCT03132571	Terminated	Phase 2	Study discontinued due to funding.	CHEBI_7465	"7243"	MONDO_0011122	"10029883"	"414915002"
	DB01156	Obesity	C0028754	NCT03132571	Terminated	Phase 2	Study discontinued due to funding.	CHEBI_3219	"42347"	MONDO_0011122	"10029883"	"414915002"
hydrochlorothiazide	DB00999	Obesity	C0028754	NCT01983462	Terminated	Phase 2	Funding expired	CHEBI_5778	"5487"	MONDO_0011122	"10029883"	"414915002"
	DB00575	Obesity	C0028754	NCT01983462	Terminated	Phase 2	Funding expired	CHEBI_46632	"2599"	MONDO_0011122	"10029883"	"414915002"
insulin glargine	DB01307	Obesity	C0028754	NCT00656422	Terminated	Phase 3			"139825"	MONDO_0011122	"10029883"	"414915002"
	DB00030	Obesity	C0028754	NCT00656422	Terminated	Phase 3		CHEBI_5931	"253182|631657"	MONDO_0011122	"10029883"	"414915002"
mefenorex	DB13852	Obesity	C0028754		Approved			CHEBI_134883		MONDO_0011122	"10029883"	"414915002"
bupropion	DB01156	Obesity	C0028754		Approved			CHEBI_3219	"42347"	MONDO_0011122	"10029883"	"414915002"
topiramate	DB00273	Obesity	C0028754	NCT00231634	Terminated	Phase 3	Program discontinued	CHEBI_63631	"38404"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00228176	Terminated	Phase 3	Company decision taken in light of demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
melatonin	DB01065	Obesity	C0028754	NCT02631148	Terminated	Phase 2	International shortage of the chemical para-aminohippuric acid (PAH) due to manufacturing changes, led to inability to perform key measurements to meet trial objectives	CHEBI_16796	"6711"	MONDO_0011122	"10029883"	"414915002"
lorcaserin	DB04871	Obesity	C0028754		Approved			CHEBI_65353	"1300701"	MONDO_0011122	"10029883"	"414915002"
phentermine	DB00191	Obesity	C0028754		Approved			CHEBI_8080	"221138|8152"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00678483	Terminated	Phase 3	Company decision taken in light of demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
fenfluramine	DB00574	Obesity	C0028754		Approved			CHEBI_5000	"4328"	MONDO_0011122	"10029883"	"414915002"
colecalciferol	DB00169	Obesity	C0028754	NCT01728987	Withdrawn	Phase 2	study stopped due to Financial problems	CHEBI_28940	"2418"	MONDO_0011122	"10029883"	"414915002"
metformin	DB00331	Obesity	C0028754	NCT03349775	Terminated	Early Phase 1	After discussion with the Data Safety Monitoring Board and NIH, the randomized clinical trial involving metformin vs. placebo is terminated due to slow enrollment in the setting of the COVID-19 pandemic.	CHEBI_6801	"6809"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00408148	Terminated	Phase 3	Company decision has been taken in light of recent demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
etofibrate	DB02701	Obesity	C0028754	NCT01237041	Terminated	Phase 1/Phase 2	Study Medication unavailable	CHEBI_17154	"7405"	MONDO_0011122	"10029883"	"414915002"
exenatide	DB01276	Obesity	C0028754	NCT03419624	Terminated	Phase 3	Delay in patient enrolment	CHEBI_64073	"60548"	MONDO_0011122	"10029883"	"414915002"
	DB00331	Obesity	C0028754	NCT03419624	Terminated	Phase 3	Delay in patient enrolment	CHEBI_6801	"6809"	MONDO_0011122	"10029883"	"414915002"
amfetamine	DB00182	Obesity	C0028754		Approved			CHEBI_132233	"3288|725"	MONDO_0011122	"10029883"	"414915002"
sitagliptin	DB01261	Obesity	C0028754	NCT02697253	Withdrawn	Phase 2		CHEBI_40237	"593411"	MONDO_0011122	"10029883"	"414915002"
insulin glargine	DB00030	Obesity	C0028754	NCT02642523	Withdrawn	Early Phase 1	Preliminary data run on rat samples showed that this study question and design would not produce conclusive results. The PI decided not to carry out the study.	CHEBI_5931	"253182|631657"	MONDO_0011122	"10029883"	"414915002"
orlistat	DB01083	Obesity	C0028754		Approved			CHEBI_94686	"37925"	MONDO_0011122	"10029883"	"414915002"
metformin	DB00331	Obesity	C0028754	NCT04839237	Withdrawn	Phase 2	The sponsor decides withdrawn this study.	CHEBI_6801	"6809"	MONDO_0011122	"10029883"	"414915002"
	DB06655	Obesity	C0028754	NCT04839237	Withdrawn	Phase 2	The sponsor decides withdrawn this study.	CHEBI_71193	"475968"	MONDO_0011122	"10029883"	"414915002"
methamphetamine	DB01577	Obesity	C0028754		Approved			CHEBI_6809	"6816"	MONDO_0011122	"10029883"	"414915002"
hydrocortamate	DB00741	Obesity	C0028754	NCT01422733	Withdrawn	Early Phase 1	The study team decided not to pursue this study.	CHEBI_17650	"5492"	MONDO_0011122	"10029883"	"414915002"
	DB00273	Obesity	C0028754	NCT01351753	Terminated	Phase 2	Lack of funding	CHEBI_63631	"38404"	MONDO_0011122	"10029883"	"414915002"
mazindol	DB00579	Obesity	C0028754		Approved			CHEBI_6702	"6664"	MONDO_0011122	"10029883"	"414915002"
sibutramine	DB01105	Obesity	C0028754		Approved			CHEBI_9137	"36514"	MONDO_0011122	"10029883"	"414915002"
	DB01284	Obesity	C0028754	NCT01422733	Withdrawn	Early Phase 1	The study team decided not to pursue this study.	CHEBI_3901	"2890"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754		Approved			CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
	DB01234	Obesity	C0028754	NCT01422733	Withdrawn	Early Phase 1	The study team decided not to pursue this study.	CHEBI_41879	"3264"	MONDO_0011122	"10029883"	"414915002"
metformin	DB00331	Obesity	C0028754	NCT01351753	Terminated	Phase 2	Lack of funding	CHEBI_6801	"6809"	MONDO_0011122	"10029883"	"414915002"
	DB13860	Obesity	C0028754	NCT00837590	Terminated	Phase 1	Preliminary results indicated no measurable benefit.			MONDO_0011122	"10029883"	"414915002"
phosphorylcholine	DB00122	Obesity	C0028754	NCT01807910	Withdrawn	Early Phase 1	The study was not funded	CHEBI_15354	"2449"	MONDO_0011122	"10029883"	"414915002"
insulin glargine	DB00030	Obesity	C0028754	NCT01581736	Terminated	Phase 1	PI job change	CHEBI_5931	"253182|631657"	MONDO_0011122	"10029883"	"414915002"
naltrexone	DB00704	Obesity	C0028754		Approved			CHEBI_7465	"7243"	MONDO_0011122	"10029883"	"414915002"
topiramate	DB00273	Obesity	C0028754	NCT00231621	Terminated	Phase 3	The study was terminated prior to completion to focus on the development of a controlled release formulation.	CHEBI_63631	"38404"	MONDO_0011122	"10029883"	"414915002"
leuprorelin	DB00007	Obesity	C0028754	NCT01422096	Withdrawn	Early Phase 1	The study team decided not to pursue this study.	CHEBI_6427	"42375"	MONDO_0011122	"10029883"	"414915002"
dexfenfluramine	DB01191	Obesity	C0028754		Approved			CHEBI_439329	"3268"	MONDO_0011122	"10029883"	"414915002"
etofibrate	DB00627	Obesity	C0028754	NCT03867500	Suspended	Early Phase 1	Study halted prematurely but potentially will resume.	CHEBI_15940	"7393"	MONDO_0011122	"10029883"	"414915002"
dexfenfluramine	DB00574	Obesity	C0028754		Approved			CHEBI_5000	"4328"	MONDO_0011122	"10029883"	"414915002"
chlorphentermine	DB01556	Obesity	C0028754		Approved			CHEBI_3646		MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00478972	Terminated	Phase 3	Company decision taken in light of demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00412698	Terminated	Phase 3	Company decision has been taken in light of recent demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
varenicline	DB01273	Obesity	C0028754	NCT02683161	Terminated	Phase 2	Inability to adequately recruit participants during pre-post operative period.	CHEBI_84500	"591622"	MONDO_0011122	"10029883"	"414915002"
benzphetamine	DB00865	Obesity	C0028754		Approved			CHEBI_3044	"1422"	MONDO_0011122	"10029883"	"414915002"
metoprolol	DB00264	Obesity	C0028754	NCT00993421	Terminated	Phase 2	Clinical trial terminated due to results from recent nonclinical studies	CHEBI_6904	"6918"	MONDO_0011122	"10029883"	"414915002"
salicylic acid	DB00936	Obesity	C0028754	NCT00837590	Terminated	Phase 1	Preliminary results indicated no measurable benefit.	CHEBI_16914	"9525"	MONDO_0011122	"10029883"	"414915002"
	DB00627	Obesity	C0028754	NCT01237041	Terminated	Phase 1/Phase 2	Study Medication unavailable	CHEBI_15940	"7393"	MONDO_0011122	"10029883"	"414915002"
	DB14006	Obesity	C0028754	NCT00837590	Terminated	Phase 1	Preliminary results indicated no measurable benefit.	CHEBI_3668	"20974"	MONDO_0011122	"10029883"	"414915002"
pirenzepine	DB00670	Peptic Ulcer	C0030920		Approved			CHEBI_8247	"8352"	MONDO_0004247	"10034341"	"13200003"
rimonabant	DB06155	Obesity	C0028754	NCT00547118	Terminated	Phase 2	Withdrawn due to medication withdrawal from the EMEA	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
fenproporex	DB01550	Obesity	C0028754		Approved			CHEBI_134837	"24867"	MONDO_0011122	"10029883"	"414915002"
setmelanotide	DB11700	Obesity	C0028754		Approved				"2469247"	MONDO_0011122	"10029883"	"414915002"
perindopril	DB00790	Obesity	C0028754	NCT02777489	Terminated	Phase 2	Unproven hypothesis	CHEBI_8024	"54552"	MONDO_0011122	"10029883"	"414915002"
	DB14213	Obesity	C0028754	NCT02777489	Terminated	Phase 2	Unproven hypothesis	CHEBI_132041		MONDO_0011122	"10029883"	"414915002"
pioglitazone	DB01132	Obesity	C0028754	NCT00787644	Terminated	Phase 2	new safety concerns which emerged about pioglitazone during the trial	CHEBI_8228	"33738"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00478595	Terminated	Phase 3	Company decision taken in light of demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
lidocaine	DB00281	Obesity	C0028754	NCT02607488	Suspended	Phase 1/Phase 2	No fund no enough recruiting centers	CHEBI_6456	"6387"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00405808	Terminated	Phase 3	EMEA recommendation to suspend Acomplia marketing authorisation	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
oxytocin	DB00107	Obesity	C0028754	NCT03497988	Withdrawn	Phase 2	Grant proposal not funded, study has been withdrawn with IRB	CHEBI_7872	"7824"	MONDO_0011122	"10029883"	"414915002"
diethylpropion	DB00937	Obesity	C0028754		Approved			CHEBI_4530	"3389"	MONDO_0011122	"10029883"	"414915002"
anastrozole	DB01217	Obesity	C0028754	NCT00440180	Terminated	Phase 3	Not able meet target enrollment.	CHEBI_2704	"84857"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00458081	Terminated	Phase 3	Company decision has been taken in light of recent demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
fenofibrate	DB01039	Obesity	C0028754	NCT00816829	Terminated	Phase 2	The study was prematurely terminated because of slow recruitment	CHEBI_5001	"8703"	MONDO_0011122	"10029883"	"414915002"
rimonabant	DB06155	Obesity	C0028754	NCT00434096	Terminated	Phase 3	Company decision taken in light of demands by certain national health authorities	CHEBI_34967		MONDO_0011122	"10029883"	"414915002"
isosorbide	DB09401	Ocular Hypertension	C0028840		Approved			CHEBI_6060	"6057"	MONDO_0006875	"10030043"	"4210003"
metipranolol	DB01214	Ocular Hypertension	C0028840		Approved			CHEBI_6897	"10824"	MONDO_0006875	"10030043"	"4210003"
levobunolol	DB01210	Ocular Hypertension	C0028840		Approved			CHEBI_6438	"1813"	MONDO_0006875	"10030043"	"4210003"
ofloxacin	DB01165	Ocular Hypertension	C0028840	NCT04005079	Withdrawn	Phase 3	not performing Trabectomes	CHEBI_7731	"7623"	MONDO_0006875	"10030043"	"4210003"
	DB01085	Ocular Hypertension	C0028840	NCT04005079	Withdrawn	Phase 3	not performing Trabectomes	CHEBI_8207	"8328"	MONDO_0006875	"10030043"	"4210003"
	DB00860	Ocular Hypertension	C0028840	NCT04005079	Withdrawn	Phase 3	not performing Trabectomes	CHEBI_8378	"8638"	MONDO_0006875	"10030043"	"4210003"
latanoprost	DB00654	Ocular Hypertension	C0028840	NCT00143429	Withdrawn	Phase 2		CHEBI_6384	"43611"	MONDO_0006875	"10030043"	"4210003"
omidenepag isopropyl	DB15071	Ocular Hypertension	C0028840		Approved				"2612690"	MONDO_0006875	"10030043"	"4210003"
latanoprost	DB00654	Ocular Hypertension	C0028840	NCT00283764	Withdrawn	Phase 3		CHEBI_6384	"43611"	MONDO_0006875	"10030043"	"4210003"
dorzolamide	DB00869	Ocular Hypertension	C0028840		Approved			CHEBI_4702	"60207"	MONDO_0006875	"10030043"	"4210003"
netarsudil	DB13931	Ocular Hypertension	C0028840		Approved				"1992864"	MONDO_0006875	"10030043"	"4210003"
latanoprostene bunod	DB11660	Ocular Hypertension	C0028840		Approved			CHEBI_177703	"1988390"	MONDO_0006875	"10030043"	"4210003"
mannitol	DB00742	Ocular Hypertension	C0028840		Approved			CHEBI_16899	"6628"	MONDO_0006875	"10030043"	"4210003"
travoprost	DB00287	Ocular Hypertension	C0028840	NCT00767481	Terminated	Phase 3	Project Cancelled	CHEBI_746859	"283809"	MONDO_0006875	"10030043"	"4210003"
hydrocortamate	DB00741	Ocular Hypertension	C0028840	NCT00788541	Terminated	Phase 2	Project cancellation	CHEBI_17650	"5492"	MONDO_0006875	"10030043"	"4210003"
betaxolol	DB00195	Ocular Hypertension	C0028840		Approved			CHEBI_3082	"1520"	MONDO_0006875	"10030043"	"4210003"
carteolol	DB00521	Ocular Hypertension	C0028840		Approved			CHEBI_3437	"2116"	MONDO_0006875	"10030043"	"4210003"
bimatoprost	DB00905	Ocular Hypertension	C0028840		Approved			CHEBI_51230	"283810"	MONDO_0006875	"10030043"	"4210003"
befunolol	DB09013	Ocular Hypertension	C0028840		Approved			CHEBI_135212		MONDO_0006875	"10030043"	"4210003"
latanoprost	DB00654	Ocular Hypertension	C0028840		Approved			CHEBI_6384	"43611"	MONDO_0006875	"10030043"	"4210003"
travoprost	DB00287	Ocular Hypertension	C0028840	NCT01312454	Terminated	Phase 2	Management decision	CHEBI_746859	"283809"	MONDO_0006875	"10030043"	"4210003"
brimonidine	DB00484	Ocular Hypertension	C0028840		Approved			CHEBI_3175	"134615"	MONDO_0006875	"10030043"	"4210003"
brinzolamide	DB01194	Ocular Hypertension	C0028840		Approved			CHEBI_3176	"194881"	MONDO_0006875	"10030043"	"4210003"
travoprost	DB00287	Ocular Hypertension	C0028840	NCT01452009	Withdrawn	Phase 3	Management Decision	CHEBI_746859	"283809"	MONDO_0006875	"10030043"	"4210003"
timolol	DB00373	Ocular Hypertension	C0028840		Approved			CHEBI_9599	"1546004|10600"	MONDO_0006875	"10030043"	"4210003"
timolol	DB00373	Ocular Hypertension	C0028840	NCT00862472	Withdrawn	Phase 3	Management decision not to conduct an additional efficacy study.	CHEBI_9599	"1546004|10600"	MONDO_0006875	"10030043"	"4210003"
	DB11507	Ocular Hypertension	C0028840	NCT00862472	Withdrawn	Phase 3	Management decision not to conduct an additional efficacy study.			MONDO_0006875	"10030043"	"4210003"
brimonidine	DB00484	Ocular Hypertension	C0028840	NCT00961649	Terminated	Phase 2		CHEBI_3175	"134615"	MONDO_0006875	"10030043"	"4210003"
tafluprost	DB08819	Ocular Hypertension	C0028840		Approved			CHEBI_66899	"1244607"	MONDO_0006875	"10030043"	"4210003"
latanoprost	DB00654	Ocular Hypertension	C0028840	NCT00855517	Withdrawn	Phase 2	Sponsor's decision	CHEBI_6384	"43611"	MONDO_0006875	"10030043"	"4210003"
latanoprost	DB00654	Ocular Hypertension	C0028840	NCT01721707	Withdrawn	Phase 3	withdrawn by industry	CHEBI_6384	"43611"	MONDO_0006875	"10030043"	"4210003"
paclitaxel	DB01229	Ocular Hypertension	C0028840		Approved			CHEBI_45863	"56946"	MONDO_0006875	"10030043"	"4210003"
levobetaxolol	DB09351	Ocular Hypertension	C0028840		Approved			CHEBI_59254	"353497"	MONDO_0006875	"10030043"	"4210003"
ripasudil	DB13165	Ocular Hypertension	C0028840		Approved			CHEBI_136046		MONDO_0006875	"10030043"	"4210003"
pilocarpine	DB01085	Ocular Hypertension	C0028840		Approved			CHEBI_8207	"8328"	MONDO_0006875	"10030043"	"4210003"
bimatoprost	DB00905	Ocular Hypertension	C0028840	NCT03927443	Withdrawn	Phase 3	[Sponsors decision]	CHEBI_51230	"283810"	MONDO_0006875	"10030043"	"4210003"
	DB00373	Ocular Hypertension	C0028840	NCT01284166	Withdrawn	Phase 3	Study was never initiated due to company decision. No study subjects were ever enrolled or treated.	CHEBI_9599	"1546004|10600"	MONDO_0006875	"10030043"	"4210003"
brimonidine	DB00484	Ocular Hypertension	C0028840	NCT01284166	Withdrawn	Phase 3	Study was never initiated due to company decision. No study subjects were ever enrolled or treated.	CHEBI_3175	"134615"	MONDO_0006875	"10030043"	"4210003"
latanoprost	DB00654	Ocular Hypertension	C0028840	NCT02801617	Terminated	Phase 3	expiration time limit of recruitment	CHEBI_6384	"43611"	MONDO_0006875	"10030043"	"4210003"
travoprost	DB00287	Ocular Hypertension	C0028840		Approved			CHEBI_746859	"283809"	MONDO_0006875	"10030043"	"4210003"
travoprost	DB00287	Ocular Hypertension	C0028840	NCT00767494	Terminated	Phase 3	Project Cancelled	CHEBI_746859	"283809"	MONDO_0006875	"10030043"	"4210003"
lithium carbonate	DB14509	Degenerative polyarthritis	C0029408		Approved			CHEBI_6504	"42351"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
meloxicam	DB00814	Degenerative polyarthritis	C0029408		Approved			CHEBI_6741	"41493"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
proglumetacin	DB13527	Degenerative polyarthritis	C0029408		Approved			CHEBI_76263		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
salicylic acid	DB14006	Degenerative polyarthritis	C0029408		Approved			CHEBI_16914	"20974"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
diclofenac	DB00586	Degenerative polyarthritis	C0029408		Approved			CHEBI_47381	"3355"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
oxycodone	DB00497	Degenerative polyarthritis	C0029408	NCT00312221	Terminated	Phase 3	terminated early for administrative reasons unrelated to safety or efficacy	CHEBI_7852	"7804"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
	DB00921	Degenerative polyarthritis	C0029408	NCT00312221	Terminated	Phase 3	terminated early for administrative reasons unrelated to safety or efficacy	CHEBI_3216	"1819"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
tramadol	DB00193	Degenerative polyarthritis	C0029408		Approved			CHEBI_75722	"10689"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
lacosamide	DB06218	Degenerative polyarthritis	C0029408	NCT00485472	Terminated	Phase 2	Based on the outcome of the planned first interim analysis, it was decided not to continue the trial. No safety concerns were identified.	CHEBI_135939	"623400"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
oxycodone	DB00497	Degenerative polyarthritis	C0029408	NCT00483977	Terminated	Phase 2	Met criteria for study futility at interim analysis	CHEBI_7852	"7804"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
ibuprofen	DB01050	Degenerative polyarthritis	C0029408		Approved			CHEBI_5855	"5640"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
sodium thiosalicylate	DB14026	Degenerative polyarthritis	C0029408		Approved			CHEBI_59124		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
meloxicam	DB00814	Degenerative polyarthritis	C0029408	NCT02405793	Withdrawn	Phase 2	Internal business decision not to move forward with study	CHEBI_6741	"41493"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
oxaceprol	DB13363	Degenerative polyarthritis	C0029408		Approved					MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
meclofenamic acid	DB00939	Degenerative polyarthritis	C0029408		Approved			CHEBI_6710	"6678|588003"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
azapropazone	DB07402	Degenerative polyarthritis	C0029408		Approved			CHEBI_38010	"1029"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
rofecoxib	DB00533	Degenerative polyarthritis	C0029408		Approved			CHEBI_8887	"232158"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
piroxicam	DB00554	Degenerative polyarthritis	C0029408		Approved			CHEBI_8249	"8356|68115"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
oxaprozin	DB00991	Degenerative polyarthritis	C0029408		Approved			CHEBI_7822	"32613"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
naltrexone	DB00704	Degenerative polyarthritis	C0029408	NCT04115020	Withdrawn	Phase 2	A pilot study was negative.	CHEBI_7465	"7243"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
salsalate	DB00936	Degenerative polyarthritis	C0029408		Approved			CHEBI_16914	"9525"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
buprenorphine	DB00921	Degenerative polyarthritis	C0029408	NCT00315458	Terminated	Phase 3	Administrative reasons.	CHEBI_3216	"1819"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
diclofenac	DB00586	Degenerative polyarthritis	C0029408	NCT00864097	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_47381	"3355"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
etofenamate	DB08984	Degenerative polyarthritis	C0029408		Approved			CHEBI_94731		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
salsalate	DB01399	Degenerative polyarthritis	C0029408		Approved			CHEBI_9014	"36108"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
dexibuprofen	DB09213	Degenerative polyarthritis	C0029408		Approved			CHEBI_43415		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
esflurbiprofen	DB16159	Degenerative polyarthritis	C0029408		Approved			CHEBI_42446		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
ketoprofen	DB01009	Degenerative polyarthritis	C0029408	NCT00532038	Terminated	Phase 3	Corporate decision	CHEBI_6128	"6142"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
ketoprofen	DB01009	Degenerative polyarthritis	C0029408		Approved			CHEBI_6128	"6142"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
tiaprofenic acid	DB01600	Degenerative polyarthritis	C0029408		Approved			CHEBI_32221	"38253"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
celecoxib	DB00482	Degenerative polyarthritis	C0029408		Approved			CHEBI_41423	"140587"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
buprenorphine	DB00921	Degenerative polyarthritis	C0029408	NCT00320801	Terminated	Phase 3	This study was terminated early due to administrative reasons.	CHEBI_3216	"1819"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
diflunisal	DB00861	Degenerative polyarthritis	C0029408		Approved			CHEBI_39669	"3393"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
salicylic acid	DB00936	Degenerative polyarthritis	C0029408		Approved			CHEBI_16914	"9525"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
celecoxib	DB00482	Degenerative polyarthritis	C0029408	NCT00163241	Terminated	Phase 3	Please see detailed description for termination reason.	CHEBI_41423	"140587"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
magnesium salicylate	DB01397	Degenerative polyarthritis	C0029408		Approved			CHEBI_6640		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
naproxen	DB00788	Degenerative polyarthritis	C0029408		Approved			CHEBI_7476	"7258"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
oxycodone	DB00497	Degenerative polyarthritis	C0029408	NCT00985621	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_7852	"7804"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
indomethacin	DB00328	Degenerative polyarthritis	C0029408		Approved			CHEBI_49662	"5781"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
oxycodone	DB00497	Degenerative polyarthritis	C0029408	NCT01094262	Terminated	Phase 2	Logistic reasons associated with the FDA-imposed clinical hold.	CHEBI_7852	"7804"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
lacosamide	DB06218	Degenerative polyarthritis	C0029408	NCT02342977	Withdrawn	Phase 2	We were unable to enroll any patients into the study.	CHEBI_135939	"623400"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
acetylsalicylic acid	DB00945	Degenerative polyarthritis	C0029408		Approved			CHEBI_15365	"91101|1191"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
felbinac	DB07477	Degenerative polyarthritis	C0029408		Approved			CHEBI_31597		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
etodolac	DB00749	Degenerative polyarthritis	C0029408		Approved			CHEBI_4909	"24605"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
salicylic acid	DB13860	Degenerative polyarthritis	C0029408		Approved			CHEBI_16914		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
tolmetin	DB00500	Degenerative polyarthritis	C0029408		Approved			CHEBI_71941	"10636"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
nabumetone	DB00461	Degenerative polyarthritis	C0029408		Approved			CHEBI_7443	"31448"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
buprenorphine	DB00921	Degenerative polyarthritis	C0029408	NCT01135524	Terminated	Phase 3	This study was terminated early for administrative reasons.	CHEBI_3216	"1819"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
histamine	DB05381	Degenerative polyarthritis	C0029408		Approved			CHEBI_18295	"5333"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
sulindac	DB00605	Degenerative polyarthritis	C0029408		Approved			CHEBI_9352	"10237"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
polmacoxib	DB12399	Degenerative polyarthritis	C0029408		Approved					MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
naproxen	DB00788	Degenerative polyarthritis	C0029408	NCT00418782	Terminated	Phase 2	Results of interim analysis indicate lack of efficacy when compared to placebo.	CHEBI_7476	"7258"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
imrecoxib	DB12354	Degenerative polyarthritis	C0029408		Approved					MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
flurbiprofen	DB00712	Degenerative polyarthritis	C0029408		Approved			CHEBI_5130	"4502"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
choline magnesium trisalicylate	DB01401	Degenerative polyarthritis	C0029408		Approved				"215799"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
bupivacaine	DB00297	Degenerative polyarthritis	C0029408	NCT02341079	Withdrawn	Phase 2/Phase 3	Principal no longer interested in conducting study	CHEBI_77431	"1815"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
fenoprofen	DB00573	Degenerative polyarthritis	C0029408		Approved			CHEBI_5004	"4331"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
choline magnesium trisalicylate	DB00122	Degenerative polyarthritis	C0029408		Approved			CHEBI_15354	"2449"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
choline magnesium trisalicylate	DB00936	Degenerative polyarthritis	C0029408		Approved			CHEBI_16914	"9525"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
tapentadol	DB06204	Degenerative polyarthritis	C0029408	NCT00982280	Terminated	Phase 3	Slow Recruitment and supply of Investigational Medicinal Product Issues	CHEBI_135935	"787390"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
lumiracoxib	DB01283	Degenerative polyarthritis	C0029408		Approved			CHEBI_73044		MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
ibuprofen	DB01050	Degenerative polyarthritis	C0029408	NCT01420666	Withdrawn	Phase 3	The study was withdrawn for administrative reason	CHEBI_5855	"5640"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
aceclofenac	DB06736	Degenerative polyarthritis	C0029408		Approved			CHEBI_31159	"16689"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
	DB00316	Degenerative polyarthritis	C0029408	NCT01420666	Withdrawn	Phase 3	The study was withdrawn for administrative reason	CHEBI_46195	"161"	MONDO_0005178|MONDO_0008143	"10031161"	"396275006"
	DB00601	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_63607	"190376"	MONDO_0005246	"10031252"	"60168000"
	DB00595	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_133011	"7821|1545999"	MONDO_0005246	"10031252"	"60168000"
	DB06795	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6633	"6572"	MONDO_0005246	"10031252"	"60168000"
cefepime	DB01413	Klebsiella cystitis	C0520775		Approved			CHEBI_478164	"20481"		"10011797"	"60867007"
	DB00760	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_43968	"1546029|29561"	MONDO_0005246	"10031252"	"60168000"
	DB00931	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6805	"6812"	MONDO_0005246	"10031252"	"60168000"
	DB01603	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6827	"2181306"	MONDO_0005246	"10031252"	"60168000"
	DB00916	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6909	"6922"	MONDO_0005246	"10031252"	"60168000"
	DB00512	Osteomyelitis	C0029443	NCT02344511	Withdrawn	Phase 3		CHEBI_28001	"11124"	MONDO_0005246	"10031252"	"60168000"
	DB01327	Osteomyelitis	C0029443	NCT02344511	Withdrawn	Phase 3		CHEBI_474053	"2180"	MONDO_0005246	"10031252"	"60168000"
	DB00713	Osteomyelitis	C0029443	NCT02344511	Withdrawn	Phase 3		CHEBI_7809	"7773"	MONDO_0005246	"10031252"	"60168000"
nafcillin	DB00607	Osteomyelitis	C0029443	NCT02344511	Withdrawn	Phase 3		CHEBI_7447	"7233"	MONDO_0005246	"10031252"	"60168000"
linezolid	DB00601	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_63607	"190376"	MONDO_0005246	"10031252"	"60168000"
	DB00760	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_43968	"1546029|29561"	MONDO_0005246	"10031252"	"60168000"
	DB00916	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_6909	"6922"	MONDO_0005246	"10031252"	"60168000"
	DB15759	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_50688		MONDO_0005246	"10031252"	"60168000"
	DB15759	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_50688		MONDO_0005246	"10031252"	"60168000"
	DB00218	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_63611	"139462"	MONDO_0005246	"10031252"	"60168000"
	DB00319	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_8232	"1546000|8339"	MONDO_0005246	"10031252"	"60168000"
	DB01015	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_9332	"10180"	MONDO_0005246	"10031252"	"60168000"
	DB01606	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_9421	"37617"	MONDO_0005246	"10031252"	"60168000"
	DB00440	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_45924	"10829"	MONDO_0005246	"10031252"	"60168000"
poldine	DB13507	Peptic Ulcer	C0030920		Approved			CHEBI_135443		MONDO_0004247	"10034341"	"13200003"
	DB00355	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_161680	"1272"	MONDO_0005246	"10031252"	"60168000"
	DB00512	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_28001	"11124"	MONDO_0005246	"10031252"	"60168000"
	DB01413	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_478164	"20481"	MONDO_0005246	"10031252"	"60168000"
	DB00948	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6919	"6927"	MONDO_0005246	"10031252"	"60168000"
	DB00537	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_192484	"2551"	MONDO_0005246	"10031252"	"60168000"
	DB01190	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_3745	"2582"	MONDO_0005246	"10031252"	"60168000"
	DB00080	Osteomyelitis	C0029443	NCT02168816	Terminated	Phase 2	The study was stopped for feasibility (i.e., low recruitment)	CHEBI_600103	"22299"	MONDO_0005246	"10031252"	"60168000"
	DB01017	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_50694	"6980"	MONDO_0005246	"10031252"	"60168000"
amikacin	DB00479	Osteomyelitis	C0029443		Approved			CHEBI_2637	"641"	MONDO_0005246	"10031252"	"60168000"
	DB00218	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_63611	"139462"	MONDO_0005246	"10031252"	"60168000"
	DB00410	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_7025	"42372"	MONDO_0005246	"10031252"	"60168000"
	DB00607	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_7447	"7233"	MONDO_0005246	"10031252"	"60168000"
	DB00779	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_100147	"7240"	MONDO_0005246	"10031252"	"60168000"
	DB00254	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_50845	"1545992|3640"	MONDO_0005246	"10031252"	"60168000"
	DB00485	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_4511	"3356"	MONDO_0005246	"10031252"	"60168000"
	DB00618	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_4392	"3154"	MONDO_0005246	"10031252"	"60168000"
	DB00260	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_40009	"3007"	MONDO_0005246	"10031252"	"60168000"
	DB01147	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_49566	"2625"	MONDO_0005246	"10031252"	"60168000"
	DB01190	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3745	"2582"	MONDO_0005246	"10031252"	"60168000"
	DB00766	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_48947	"48203|21216"	MONDO_0005246	"10031252"	"60168000"
	DB01211	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3732	"21212"	MONDO_0005246	"10031252"	"60168000"
neridronic acid	DB11620	Osteoporosis	C0029456		Approved			CHEBI_135145		HP:0000939	"10031282"	"64859006"
	DB00537	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_192484	"2551"	MONDO_0005246	"10031252"	"60168000"
	DB00955	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_7528	"7337"	MONDO_0005246	"10031252"	"60168000"
	DB00827	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3716	"2550"	MONDO_0005246	"10031252"	"60168000"
	DB01060	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_2676	"1297882|723"	MONDO_0005246	"10031252"	"60168000"
	DB01597	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3697	"2540"	MONDO_0005246	"10031252"	"60168000"
	DB09093	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_27644	"2408"	MONDO_0005246	"10031252"	"60168000"
	DB00698	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_71415	"235559|7454"	MONDO_0005246	"10031252"	"60168000"
	DB00446	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_17698	"2348"	MONDO_0005246	"10031252"	"60168000"
	DB01112	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3515	"2194"	MONDO_0005246	"10031252"	"60168000"
	DB01212	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_29007	"2193"	MONDO_0005246	"10031252"	"60168000"
	DB01332	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_553473	"2192"	MONDO_0005246	"10031252"	"60168000"
	DB01415	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3510	"20492"	MONDO_0005246	"10031252"	"60168000"
	DB00438	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3508	"2191|1545984"	MONDO_0005246	"10031252"	"60168000"
	DB01331	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_209807	"2189"	MONDO_0005246	"10031252"	"60168000"
	DB01330	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3499	"2187"	MONDO_0005246	"10031252"	"60168000"
	DB00493	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_204928	"2186"	MONDO_0005246	"10031252"	"60168000"
	DB01329	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3493	"2184"	MONDO_0005246	"10031252"	"60168000"
	DB01328	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3491	"2183"	MONDO_0005246	"10031252"	"60168000"
	DB00274	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3489	"2182"	MONDO_0005246	"10031252"	"60168000"
	DB00671	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_472657	"25033|1546021"	MONDO_0005246	"10031252"	"60168000"
	DB01413	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_478164	"20481"	MONDO_0005246	"10031252"	"60168000"
	DB00535	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3485	"25037"	MONDO_0005246	"10031252"	"60168000"
	DB01326	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3480	"2178"	MONDO_0005246	"10031252"	"60168000"
	DB00833	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3478	"1450910|2176"	MONDO_0005246	"10031252"	"60168000"
	DB00578	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3393	"2015"	MONDO_0005246	"10031252"	"60168000"
	DB09320	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_52154	"7983"	MONDO_0005246	"10031252"	"60168000"
	DB00803	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing		"2709"	MONDO_0005246	"10031252"	"60168000"
	DB00336	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing		"7455"	MONDO_0005246	"10031252"	"60168000"
	DB00994	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_7507	"7299"	MONDO_0005246	"10031252"	"60168000"
	DB01053	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_18208	"7980"	MONDO_0005246	"10031252"	"60168000"
	DB00781	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing		"8536"	MONDO_0005246	"10031252"	"60168000"
	DB05245	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9142	"9793"	MONDO_0005246	"10031252"	"60168000"
	DB11476	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing			MONDO_0005246	"10031252"	"60168000"
	DB06799	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6824	"6832"	MONDO_0005246	"10031252"	"60168000"
	DB09096	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_82405	"1418"	MONDO_0005246	"10031252"	"60168000"
	DB00314	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_3371	"78903"	MONDO_0005246	"10031252"	"60168000"
	DB00626	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_184381	"1291|1986366"	MONDO_0005246	"10031252"	"60168000"
	DB01421	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_7934	"7934"	MONDO_0005246	"10031252"	"60168000"
	DB00512	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_28001	"11124"	MONDO_0005246	"10031252"	"60168000"
fentiazac	DB13217	Pain	C0030193		Approved			CHEBI_94523		HP:0012531	"10033371"	"22253000"
	DB00355	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_161680	"1272"	MONDO_0005246	"10031252"	"60168000"
	DB00207	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_2955	"18631"	MONDO_0005246	"10031252"	"60168000"
	DB00440	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_45924	"10829"	MONDO_0005246	"10031252"	"60168000"
	DB00684	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_28864	"10627"	MONDO_0005246	"10031252"	"60168000"
	DB01607	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9587	"10591"	MONDO_0005246	"10031252"	"60168000"
	DB09550	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing		"2105975"	MONDO_0005246	"10031252"	"60168000"
	DB00759	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_27902	"10395"	MONDO_0005246	"10031252"	"60168000"
	DB01606	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9421	"37617"	MONDO_0005246	"10031252"	"60168000"
	DB01059	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_100246	"7517"	MONDO_0005246	"10031252"	"60168000"
	DB00263	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_102484	"10207"	MONDO_0005246	"10031252"	"60168000"
	DB00244	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6775	"52582"	MONDO_0005246	"10031252"	"60168000"
	DB00795	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9334	"9524"	MONDO_0005246	"10031252"	"60168000"
	DB01015	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9332	"10180"	MONDO_0005246	"10031252"	"60168000"
	DB00576	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9331	"10179"	MONDO_0005246	"10031252"	"60168000"
	DB00359	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9328	"10171"	MONDO_0005246	"10031252"	"60168000"
	DB00634	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_63845	"10169"	MONDO_0005246	"10031252"	"60168000"
	DB09324	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9321	"10167"	MONDO_0005246	"10031252"	"60168000"
	DB01082	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_17076	"10109"	MONDO_0005246	"10031252"	"60168000"
	DB00919	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_9215	"270"	MONDO_0005246	"10031252"	"60168000"
	DB01045	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_71365	"9384"	MONDO_0005246	"10031252"	"60168000"
	DB00615	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_45367	"55672"	MONDO_0005246	"10031252"	"60168000"
	DB00339	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_45285	"8987"	MONDO_0005246	"10031252"	"60168000"
	DB00721	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_8430	"8701"	MONDO_0005246	"10031252"	"60168000"
enoxacin	DB00467	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_157175	"3925"	MONDO_0005246	"10031252"	"60168000"
	DB00199	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_42355	"4053"	MONDO_0005246	"10031252"	"60168000"
	DB00609	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_4885	"4127"	MONDO_0005246	"10031252"	"60168000"
	DB00828	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_28915	"4550"	MONDO_0005246	"10031252"	"60168000"
	DB01044	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_5280	"228476|1546025"	MONDO_0005246	"10031252"	"60168000"
	DB01598	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_471744	"5690|1545986"	MONDO_0005246	"10031252"	"60168000"
	DB00319	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_8232	"1546000|8339"	MONDO_0005246	"10031252"	"60168000"
	DB00951	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6030	"6038"	MONDO_0005246	"10031252"	"60168000"
	DB00417	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_27446	"7984"	MONDO_0005246	"10031252"	"60168000"
	DB01172	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_17630	"6099|1727573"	MONDO_0005246	"10031252"	"60168000"
	DB01137	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_63598	"1546009|82122"	MONDO_0005246	"10031252"	"60168000"
	DB00479	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_2637	"641"	MONDO_0005246	"10031252"	"60168000"
	DB01051	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_28368	"7538"	MONDO_0005246	"10031252"	"60168000"
	DB00415	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_28971	"733|221058"	MONDO_0005246	"10031252"	"60168000"
	DB01627	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_6472	"6398"	MONDO_0005246	"10031252"	"60168000"
	DB01165	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_7731	"7623"	MONDO_0005246	"10031252"	"60168000"
	DB00713	Osteomyelitis	C0029443	NCT02099240	Terminated	Early Phase 1	Not enough patient enrollment and lack of staffing	CHEBI_7809	"7773"	MONDO_0005246	"10031252"	"60168000"
phytomenadione	DB01022	Osteoporosis	C0029456		Approved			CHEBI_18067	"11258|8308"	HP:0000939	"10031282"	"64859006"
calcium gluconate	DB11126	Osteoporosis	C0029456		Approved			CHEBI_3309	"1908"	HP:0000939	"10031282"	"64859006"
calcium citrate	DB11093	Osteoporosis	C0029456		Approved			CHEBI_190513	"47613"	HP:0000939	"10031282"	"64859006"
alendronic acid	DB00630	Osteoporosis	C0029456	NCT00822029	Terminated	Phase 3	only 2 patients inclued and Study Principal Investigator has left the hospital	CHEBI_2567	"46041|236083"	HP:0000939	"10031282"	"64859006"
alendronic acid	DB00630	Osteoporosis	C0029456	NCT01512446	Terminated	Phase 3	low recruitment rate	CHEBI_2567	"46041|236083"	HP:0000939	"10031282"	"64859006"
risedronic acid	DB00884	Osteoporosis	C0029456		Approved			CHEBI_8869	"73056|55685"	HP:0000939	"10031282"	"64859006"
calcium phosphate	DB11348	Osteoporosis	C0029456		Approved			CHEBI_9679	"1919"	HP:0000939	"10031282"	"64859006"
denosumab	DB06643	Osteoporosis	C0029456	NCT03457818	Terminated	Phase 2	Due to enrollment difficulties compounded by the COVID pandemic.		"993449"	HP:0000939	"10031282"	"64859006"
teriparatide	DB06285	Osteoporosis	C0029456	NCT00624481	Withdrawn	Phase 2		CHEBI_135983	"32915"	HP:0000939	"10031282"	"64859006"
calcium lactate	DB13231	Osteoporosis	C0029456		Approved				"47622"	HP:0000939	"10031282"	"64859006"
parathyroid hormone	DB05829	Osteoporosis	C0029456	NCT01333267	Withdrawn	Phase 1			"1427222"	HP:0000939	"10031282"	"64859006"
zoledronic acid	DB00399	Osteoporosis	C0029456	NCT01166178	Terminated	Phase 3		CHEBI_46557	"1546014|77655"	HP:0000939	"10031282"	"64859006"
magnesium oxide	DB01377	Osteoporosis	C0029456		Approved			CHEBI_31794	"6582"	HP:0000939	"10031282"	"64859006"
denosumab	DB06643	Osteoporosis	C0029456		Approved				"993449"	HP:0000939	"10031282"	"64859006"
	DB06724	Osteoporosis	C0029456	NCT01552122	Withdrawn	Phase 3		CHEBI_3311	"349908|1897"	HP:0000939	"10031282"	"64859006"
	DB00169	Osteoporosis	C0029456	NCT01552122	Withdrawn	Phase 3		CHEBI_28940	"2418"	HP:0000939	"10031282"	"64859006"
alendronic acid	DB00630	Osteoporosis	C0029456	NCT01552122	Withdrawn	Phase 3		CHEBI_2567	"46041|236083"	HP:0000939	"10031282"	"64859006"
denosumab	DB06643	Osteoporosis	C0029456	NCT02418273	Withdrawn	Phase 1/Phase 2	was not funded		"993449"	HP:0000939	"10031282"	"64859006"
zoledronic acid	DB00399	Osteoporosis	C0029456	NCT01426555	Terminated	Phase 2/Phase 3	Incomplete data set & analysis	CHEBI_46557	"1546014|77655"	HP:0000939	"10031282"	"64859006"
eldecalcitol	DB05295	Osteoporosis	C0029456		Approved			CHEBI_73927		HP:0000939	"10031282"	"64859006"
magnesium citrate	DB11110	Osteoporosis	C0029456		Approved			CHEBI_131391	"52356"	HP:0000939	"10031282"	"64859006"
pamidronic acid	DB00282	Osteoporosis	C0029456	NCT00022841	Terminated	Phase 1/Phase 2	Inadequate eligible subjects to expect sufficient numbers to analyse outcomes.	CHEBI_7903	"11473|1546406"	HP:0000939	"10031282"	"64859006"
ergocalciferol	DB00153	Osteoporosis	C0029456		Approved			CHEBI_28934	"4018"	HP:0000939	"10031282"	"64859006"
ergocalciferol	DB11094	Osteoporosis	C0029456		Approved			CHEBI_28934	"11253"	HP:0000939	"10031282"	"64859006"
incadronic acid	DB06255	Osteoporosis	C0029456		Approved			CHEBI_135189		HP:0000939	"10031282"	"64859006"
colecalciferol	DB00169	Osteoporosis	C0029456		Approved			CHEBI_28940	"2418"	HP:0000939	"10031282"	"64859006"
	DB06285	Osteoporosis	C0029456	NCT00471237	Terminated	Phase 2	Terminated for futility by sponsor after a pre-planned interim review of data		"32915"	HP:0000939	"10031282"	"64859006"
alendronic acid	DB00630	Osteoporosis	C0029456	NCT00471237	Terminated	Phase 2	Terminated for futility by sponsor after a pre-planned interim review of data	CHEBI_2567	"46041|236083"	HP:0000939	"10031282"	"64859006"
zoledronic acid	DB00399	Osteoporosis	C0029456		Approved			CHEBI_46557	"1546014|77655"	HP:0000939	"10031282"	"64859006"
denosumab	DB06643	Osteoporosis	C0029456	NCT04231682	Withdrawn	Phase 2	Grant support was withdrawn from Amgen Pharmaceuticals		"993449"	HP:0000939	"10031282"	"64859006"
	DB06724	Osteoporosis	C0029456	NCT00960934	Terminated	Phase 2		CHEBI_3311	"349908|1897"	HP:0000939	"10031282"	"64859006"
colecalciferol	DB00169	Osteoporosis	C0029456	NCT00960934	Terminated	Phase 2		CHEBI_28940	"2418"	HP:0000939	"10031282"	"64859006"
denosumab	DB06643	Osteoporosis	C0029456	NCT03960554	Terminated	Phase 2	Study lost funding		"993449"	HP:0000939	"10031282"	"64859006"
risedronic acid	DB00884	Osteoporosis	C0029456	NCT00324714	Withdrawn	Phase 3		CHEBI_8869	"73056|55685"	HP:0000939	"10031282"	"64859006"
zoledronic acid	DB00399	Osteoporosis	C0029456	NCT02632903	Withdrawn	Phase 2	While the clinical need for and the scientific merit remain valid, this regulated drug trial was not feasible logistically due to limited funds.	CHEBI_46557	"1546014|77655"	HP:0000939	"10031282"	"64859006"
butedronic acid	DB16004	Osteoporosis	C0029456		Approved			CHEBI_135216		HP:0000939	"10031282"	"64859006"
colecalciferol	DB00169	Osteoporosis	C0029456	NCT00058188	Terminated	Phase 3	Closed by the research committee	CHEBI_28940	"2418"	HP:0000939	"10031282"	"64859006"
	DB00399	Osteoporosis	C0029456	NCT00058188	Terminated	Phase 3	Closed by the research committee	CHEBI_46557	"1546014|77655"	HP:0000939	"10031282"	"64859006"
parathyroid hormone	DB05829	Osteoporosis	C0029456	NCT00177411	Withdrawn	Phase 1	Protocol design was changed so it no longer fit the description of this study.		"1427222"	HP:0000939	"10031282"	"64859006"
zoledronic acid	DB00399	Osteoporosis	C0029456	NCT03040765	Terminated	Phase 3	failed to recruit eligible subjects	CHEBI_46557	"1546014|77655"	HP:0000939	"10031282"	"64859006"
	DB06643	Osteoporosis	C0029456	NCT03040765	Terminated	Phase 3	failed to recruit eligible subjects		"993449"	HP:0000939	"10031282"	"64859006"
estradiol	DB00783	Osteoporosis	C0029456	NCT01928082	Terminated	Phase 2	The fellow conducting the recruitment and screening left the institution	CHEBI_16469	"4083"	HP:0000939	"10031282"	"64859006"
	DB00005	Osteoporosis	C0029456	NCT01294397	Terminated	Phase 1	Lack of enrollment.		"214555|2103480|2462511"	HP:0000939	"10031282"	"64859006"
denosumab	DB06643	Osteoporosis	C0029456	NCT01294397	Terminated	Phase 1	Lack of enrollment.		"993449"	HP:0000939	"10031282"	"64859006"
alendronic acid	DB00630	Osteoporosis	C0029456	NCT01460654	Terminated	Phase 2		CHEBI_2567	"46041|236083"	HP:0000939	"10031282"	"64859006"
	DB00624	Osteoporosis	C0029456	NCT01460654	Terminated	Phase 2		CHEBI_17347	"10379"	HP:0000939	"10031282"	"64859006"
	DB06710	Osteoporosis	C0029456	NCT01460654	Terminated	Phase 2		CHEBI_27436	"6904"	HP:0000939	"10031282"	"64859006"
alendronic acid	DB00630	Osteoporosis	C0029456	NCT00236002	Terminated	Phase 3	Slow accrual than anticipated.	CHEBI_2567	"46041|236083"	HP:0000939	"10031282"	"64859006"
minodronic acid	DB06548	Osteoporosis	C0029456		Approved					HP:0000939	"10031282"	"64859006"
alendronic acid	DB00630	Osteoporosis	C0029456	NCT00000430	Terminated	Phase 3		CHEBI_2567	"46041|236083"	HP:0000939	"10031282"	"64859006"
romosozumab	DB11866	Osteoporosis, Postmenopausal	C0029458		Approved				"2123180|2123126"	MONDO_0008159	"10031285"	"102447009"
ibandronic acid	DB00710	Osteoporosis, Postmenopausal	C0029458		Approved				"115265|115264"	MONDO_0008159	"10031285"	"102447009"
phytomenadione	DB01022	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_18067	"11258|8308"	MONDO_0008159	"10031285"	"102447009"
zoledronic acid	DB00399	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_46557	"1546014|77655"	MONDO_0008159	"10031285"	"102447009"
progesterone	DB00396	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_17026	"8727"	MONDO_0008159	"10031285"	"102447009"
calcitonin (salmon synthetic)	DB00017	Osteoporosis, Postmenopausal	C0029458		Approved				"36118"	MONDO_0008159	"10031285"	"102447009"
ethinylestradiol	DB00977	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_4903	"4124"	MONDO_0008159	"10031285"	"102447009"
risedronic acid	DB00884	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_8869	"73056|55685"	MONDO_0008159	"10031285"	"102447009"
denosumab	DB06643	Osteoporosis, Postmenopausal	C0029458		Approved				"993449"	MONDO_0008159	"10031285"	"102447009"
calcium citrate	DB11093	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_190513	"47613"	MONDO_0008159	"10031285"	"102447009"
	DB06724	Osteoporosis, Postmenopausal	C0029458	NCT01552122	Withdrawn	Phase 3		CHEBI_3311	"349908|1897"	MONDO_0008159	"10031285"	"102447009"
medroxyprogesterone	DB00603	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_6716	"1000112"	MONDO_0008159	"10031285"	"102447009"
bazedoxifene	DB06401	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_135947	"1441386"	MONDO_0008159	"10031285"	"102447009"
tibolone	DB09070	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_32223	"38260"	MONDO_0008159	"10031285"	"102447009"
lasofoxifene	DB06202	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_135938		MONDO_0008159	"10031285"	"102447009"
levonorgestrel	DB09389	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_7630	"7518"	MONDO_0008159	"10031285"	"102447009"
levonorgestrel	DB00367	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_6443	"6373"	MONDO_0008159	"10031285"	"102447009"
	DB00169	Osteoporosis, Postmenopausal	C0029458	NCT01552122	Withdrawn	Phase 3		CHEBI_28940	"2418"	MONDO_0008159	"10031285"	"102447009"
norethisterone	DB00717	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_7627	"7514"	MONDO_0008159	"10031285"	"102447009"
ipriflavone	DB13618	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_31719		MONDO_0008159	"10031285"	"102447009"
norgestimate	DB00957	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_50815	"31994"	MONDO_0008159	"10031285"	"102447009"
magnesium oxide	DB01377	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_31794	"6582"	MONDO_0008159	"10031285"	"102447009"
alendronic acid	DB00630	Osteoporosis, Postmenopausal	C0029458	NCT01552122	Withdrawn	Phase 3		CHEBI_2567	"46041|236083"	MONDO_0008159	"10031285"	"102447009"
teriparatide	DB06285	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_135983	"32915"	MONDO_0008159	"10031285"	"102447009"
calcium phosphate	DB11348	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_9679	"1919"	MONDO_0008159	"10031285"	"102447009"
calcium lactate	DB13231	Osteoporosis, Postmenopausal	C0029458		Approved				"47622"	MONDO_0008159	"10031285"	"102447009"
strontium ranelate	DB09267	Osteoporosis, Postmenopausal	C0029458		Approved					MONDO_0008159	"10031285"	"102447009"
magnesium citrate	DB11110	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_131391	"52356"	MONDO_0008159	"10031285"	"102447009"
	DB06724	Osteoporosis, Postmenopausal	C0029458	NCT00529373	Terminated	Phase 3		CHEBI_3311	"349908|1897"	MONDO_0008159	"10031285"	"102447009"
colecalciferol	DB00169	Osteoporosis, Postmenopausal	C0029458	NCT00529373	Terminated	Phase 3		CHEBI_28940	"2418"	MONDO_0008159	"10031285"	"102447009"
estradiol	DB00783	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_16469	"4083"	MONDO_0008159	"10031285"	"102447009"
ergocalciferol	DB00153	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_28934	"4018"	MONDO_0008159	"10031285"	"102447009"
ergocalciferol	DB11094	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_28934	"11253"	MONDO_0008159	"10031285"	"102447009"
alendronic acid	DB00630	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_2567	"46041|236083"	MONDO_0008159	"10031285"	"102447009"
raloxifene	DB00481	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_8772	"72143"	MONDO_0008159	"10031285"	"102447009"
colecalciferol	DB00169	Osteoporosis, Postmenopausal	C0029458		Approved			CHEBI_28940	"2418"	MONDO_0008159	"10031285"	"102447009"
mepivacaine	DB00961	Pain	C0030193	NCT01522534	Terminated	Phase 3	not enough inclusions	CHEBI_6759	"6759"	HP:0012531	"10033371"	"22253000"
morphine	DB00295	Pain	C0030193	NCT00362219	Withdrawn	Phase 3	no patients were recrueted	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
bupivacaine	DB00297	Pain	C0030193	NCT03827213	Terminated	Phase 2	Ran out of medication	CHEBI_77431	"1815"	HP:0012531	"10033371"	"22253000"
ibuprofen	DB01050	Pain	C0030193		Approved			CHEBI_5855	"5640"	HP:0012531	"10033371"	"22253000"
ropivacaine	DB00296	Pain	C0030193	NCT01866917	Terminated	Phase 1/Phase 2	Pharmacy stopped dispensing study medication	CHEBI_8890	"35780"	HP:0012531	"10033371"	"22253000"
	DB00497	Pain	C0030193	NCT01014559	Terminated	Phase 3	Lack of recruitment	CHEBI_7852	"7804"	HP:0012531	"10033371"	"22253000"
bromfenac	DB00963	Pain	C0030193		Approved			CHEBI_240107	"19737"	HP:0012531	"10033371"	"22253000"
reboxetine	DB00234	Pain	C0030193	NCT00353808	Terminated	Phase 2	This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.	CHEBI_135342	"60842"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193	NCT00126789	Terminated	Phase 3	Based on PK data, product did not meet requirement for further development.	CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
paracetamol	DB00316	Pain	C0030193	NCT01520298	Withdrawn	Phase 3	Difficulty in recruiting subjects for the trial.	CHEBI_46195	"161"	HP:0012531	"10033371"	"22253000"
	DB00296	Pain	C0030193	NCT01318161	Terminated	Phase 3	Difficulty in recruiting	CHEBI_8890	"35780"	HP:0012531	"10033371"	"22253000"
morphine	DB00295	Pain	C0030193	NCT01318161	Terminated	Phase 3	Difficulty in recruiting	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
morphine	DB00295	Pain	C0030193		Approved			CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
tapentadol	DB06204	Pain	C0030193	NCT00986258	Terminated	Phase 3	This clinical trial was terminated early, due to slow recruitment and study drug shortages.	CHEBI_135935	"787390"	HP:0012531	"10033371"	"22253000"
tapentadol	DB06204	Pain	C0030193	NCT01264887	Terminated	Phase 3	Administrative reasons	CHEBI_135935	"787390"	HP:0012531	"10033371"	"22253000"
hydromorphone	DB00327	Pain	C0030193		Approved			CHEBI_5790	"3423"	HP:0012531	"10033371"	"22253000"
salicylamide	DB08797	Pain	C0030193		Approved			CHEBI_32114	"9518"	HP:0012531	"10033371"	"22253000"
diclofenac	DB00586	Pain	C0030193		Approved			CHEBI_47381	"3355"	HP:0012531	"10033371"	"22253000"
hydrocodone	DB00956	Pain	C0030193		Approved			CHEBI_5779	"5489"	HP:0012531	"10033371"	"22253000"
methadone	DB00333	Pain	C0030193	NCT00930332	Terminated	Phase 1	Poor accrual	CHEBI_167309	"6813"	HP:0012531	"10033371"	"22253000"
	DB00201	Pain	C0030193	NCT01426971	Withdrawn	Phase 3		CHEBI_27732	"1886"	HP:0012531	"10033371"	"22253000"
naproxen	DB00788	Pain	C0030193		Approved			CHEBI_7476	"7258"	HP:0012531	"10033371"	"22253000"
dezocine	DB01209	Pain	C0030193		Approved			CHEBI_4474	"22713"	HP:0012531	"10033371"	"22253000"
dextropropoxyphene	DB00647	Pain	C0030193		Approved			CHEBI_51173	"8785"	HP:0012531	"10033371"	"22253000"
etoricoxib	DB01628	Pain	C0030193	NCT00746720	Terminated	Phase 2	Patient recruitment difficulties	CHEBI_6339	"307296"	HP:0012531	"10033371"	"22253000"
methadone	DB00333	Pain	C0030193	NCT00351715	Terminated	Phase 2	Study stopped due to low accrual	CHEBI_167309	"6813"	HP:0012531	"10033371"	"22253000"
	DB00234	Pain	C0030193	NCT00334685	Terminated	Phase 2	The Data Monitoring Committee terminated the study on the basis of futility (insufficient clinical response).	CHEBI_135342	"60842"	HP:0012531	"10033371"	"22253000"
flufenamic acid	DB02266	Pain	C0030193		Approved			CHEBI_42638	"4453"	HP:0012531	"10033371"	"22253000"
ibuprofen	DB01050	Pain	C0030193	NCT01842633	Terminated	Phase 3		CHEBI_5855	"5640"	HP:0012531	"10033371"	"22253000"
capsaicin	DB06774	Pain	C0030193	NCT00089557	Terminated	Phase 2		CHEBI_3374	"1992"	HP:0012531	"10033371"	"22253000"
	DB00201	Pain	C0030193	NCT01842633	Terminated	Phase 3		CHEBI_27732	"1886"	HP:0012531	"10033371"	"22253000"
tiaprofenic acid	DB01600	Pain	C0030193		Approved			CHEBI_32221	"38253"	HP:0012531	"10033371"	"22253000"
dexibuprofen	DB09213	Pain	C0030193		Approved			CHEBI_43415		HP:0012531	"10033371"	"22253000"
	DB00316	Pain	C0030193	NCT01842633	Terminated	Phase 3		CHEBI_46195	"161"	HP:0012531	"10033371"	"22253000"
caffeine	DB00201	Pain	C0030193		Approved			CHEBI_27732	"1886"	HP:0012531	"10033371"	"22253000"
	DB00316	Pain	C0030193	NCT03792295	Withdrawn	Phase 2	no enrollment, reallocation of resources	CHEBI_46195	"161"	HP:0012531	"10033371"	"22253000"
	DB00497	Pain	C0030193	NCT03792295	Withdrawn	Phase 2	no enrollment, reallocation of resources	CHEBI_7852	"7804"	HP:0012531	"10033371"	"22253000"
epinephrine	DB00668	Pain	C0030193	NCT00813111	Terminated	Phase 3	Sponsor decision, unrelated to safety	CHEBI_28918	"3992"	HP:0012531	"10033371"	"22253000"
etodolac	DB00749	Pain	C0030193		Approved			CHEBI_4909	"24605"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193	NCT00959400	Withdrawn	Phase 3		CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
ibandronic acid	DB00710	Pain	C0030193	NCT00301886	Withdrawn	Phase 3	withdrawn support for study		"115265|115264"	HP:0012531	"10033371"	"22253000"
mefenamic acid	DB00784	Pain	C0030193		Approved			CHEBI_6717	"6693"	HP:0012531	"10033371"	"22253000"
	DB00297	Pain	C0030193	NCT00813111	Terminated	Phase 3	Sponsor decision, unrelated to safety	CHEBI_77431	"1815"	HP:0012531	"10033371"	"22253000"
	DB00399	Pain	C0030193	NCT00099177	Terminated	Phase 3		CHEBI_46557	"1546014|77655"	HP:0012531	"10033371"	"22253000"
ibandronic acid	DB00710	Pain	C0030193	NCT00099177	Terminated	Phase 3			"115265|115264"	HP:0012531	"10033371"	"22253000"
prednisone	DB00635	Pain	C0030193	NCT00503984	Terminated	Phase 1/Phase 2	Withdrawal of Funding	CHEBI_8382	"8640"	HP:0012531	"10033371"	"22253000"
	DB00928	Pain	C0030193	NCT00503984	Terminated	Phase 1/Phase 2	Withdrawal of Funding	CHEBI_2038	"1251"	HP:0012531	"10033371"	"22253000"
	DB01248	Pain	C0030193	NCT00503984	Terminated	Phase 1/Phase 2	Withdrawal of Funding	CHEBI_4672	"72962|1299922"	HP:0012531	"10033371"	"22253000"
	DB00575	Pain	C0030193	NCT01986751	Terminated	Phase 1/Phase 2	failure to enroll	CHEBI_46632	"2599"	HP:0012531	"10033371"	"22253000"
pregabalin	DB00230	Pain	C0030193	NCT00879021	Terminated	Phase 3	lack of funding and patients	CHEBI_64356	"187832"	HP:0012531	"10033371"	"22253000"
salicylic acid	DB14006	Pain	C0030193		Approved			CHEBI_16914	"20974"	HP:0012531	"10033371"	"22253000"
rofecoxib	DB00533	Pain	C0030193		Approved			CHEBI_8887	"232158"	HP:0012531	"10033371"	"22253000"
	DB06204	Pain	C0030193	NCT00505414	Terminated	Phase 3	Recall of rescue medication, alternative rescue medication availability issues.	CHEBI_135935	"787390"	HP:0012531	"10033371"	"22253000"
ketoprofen	DB01009	Pain	C0030193		Approved			CHEBI_6128	"6142"	HP:0012531	"10033371"	"22253000"
benzydamine	DB09084	Pain	C0030193		Approved			CHEBI_94563	"1425"	HP:0012531	"10033371"	"22253000"
	DB00295	Pain	C0030193	NCT00573937	Terminated	Phase 2	Slow accrual.	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
sufentanil	DB00708	Pain	C0030193	NCT01012999	Terminated	Phase 1/Phase 2	Difficulty enrolling patients	CHEBI_9316	"56795"	HP:0012531	"10033371"	"22253000"
acetylsalicylic acid	DB00945	Pain	C0030193		Approved			CHEBI_15365	"91101|1191"	HP:0012531	"10033371"	"22253000"
morphine	DB00295	Pain	C0030193	NCT00505414	Terminated	Phase 3	Recall of rescue medication, alternative rescue medication availability issues.	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
	DB00750	Pain	C0030193	NCT03508804	Withdrawn	Phase 3	Lack of funding.	CHEBI_8404	"8686"	HP:0012531	"10033371"	"22253000"
methadone	DB00333	Pain	C0030193	NCT00573937	Terminated	Phase 2	Slow accrual.	CHEBI_167309	"6813"	HP:0012531	"10033371"	"22253000"
lidocaine	DB00281	Pain	C0030193	NCT03508804	Withdrawn	Phase 3	Lack of funding.	CHEBI_6456	"6387"	HP:0012531	"10033371"	"22253000"
bupivacaine	DB00297	Pain	C0030193	NCT02847013	Withdrawn	Phase 2/Phase 3		CHEBI_77431	"1815"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193		Approved			CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193	NCT00187135	Terminated	Phase 3	The study was terminated due to slow accrual.	CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
	DB00295	Pain	C0030193	NCT01906073	Withdrawn	Phase 3		CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
magnesium sulfate	DB00653	Pain	C0030193	NCT00998738	Terminated	Phase 3	lack of accrual	CHEBI_32599	"6585|1311625"	HP:0012531	"10033371"	"22253000"
oxymorphone	DB01192	Pain	C0030193		Approved			CHEBI_7865	"7814"	HP:0012531	"10033371"	"22253000"
fenoprofen	DB00573	Pain	C0030193		Approved			CHEBI_5004	"4331"	HP:0012531	"10033371"	"22253000"
lithium carbonate	DB14509	Pain	C0030193		Approved			CHEBI_6504	"42351"	HP:0012531	"10033371"	"22253000"
ketamine	DB01221	Pain	C0030193	NCT00492388	Terminated	Phase 3	Business decision not to continue development	CHEBI_6121	"6130"	HP:0012531	"10033371"	"22253000"
capsaicin	DB06774	Pain	C0030193	NCT00085761	Terminated	Phase 3	Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes	CHEBI_3374	"1992"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193	NCT01906073	Withdrawn	Phase 3		CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
celecoxib	DB00482	Pain	C0030193	NCT00585156	Terminated	Early Phase 1	New clinical finding with Celebrex and cardiac concerns.	CHEBI_41423	"140587"	HP:0012531	"10033371"	"22253000"
levobupivacaine	DB01002	Pain	C0030193	NCT02728323	Terminated	Phase 3	Terminated	CHEBI_6149	"1815|259453"	HP:0012531	"10033371"	"22253000"
ketamine	DB01221	Pain	C0030193	NCT05671913	Withdrawn	Early Phase 1	Funding not acquired to run the study.	CHEBI_6121	"6130"	HP:0012531	"10033371"	"22253000"
tramadol	DB00193	Pain	C0030193	NCT02247648	Terminated	Phase 2		CHEBI_75722	"10689"	HP:0012531	"10033371"	"22253000"
tramadol	DB00193	Pain	C0030193		Approved			CHEBI_75722	"10689"	HP:0012531	"10033371"	"22253000"
lansoprazole	DB00448	Peptic Ulcer	C0030920		Approved			CHEBI_6375	"17128"	MONDO_0004247	"10034341"	"13200003"
diclofenac	DB00586	Pain	C0030193	NCT00140933	Terminated	Phase 3		CHEBI_47381	"3355"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193	NCT00126763	Terminated	Phase 3	PK results suggested product did not meet requirement for further development.	CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
lidocaine	DB00281	Pain	C0030193	NCT00924963	Withdrawn	Early Phase 1	Study ended due to lack of funding.	CHEBI_6456	"6387"	HP:0012531	"10033371"	"22253000"
ibuprofen	DB01050	Pain	C0030193	NCT02929589	Terminated	Phase 3	The use of robotic surgery made this study obsolete.	CHEBI_5855	"5640"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193	NCT00278824	Terminated	Phase 2	Difficulty identifying and enrolling eligible patients	CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
	DB00575	Pain	C0030193	NCT00287326	Terminated	Phase 3	terminated by PI	CHEBI_46632	"2599"	HP:0012531	"10033371"	"22253000"
	DB00297	Pain	C0030193	NCT00287326	Terminated	Phase 3	terminated by PI	CHEBI_77431	"1815"	HP:0012531	"10033371"	"22253000"
butorphanol	DB00611	Pain	C0030193		Approved			CHEBI_3242	"1841"	HP:0012531	"10033371"	"22253000"
levorphanol	DB00854	Pain	C0030193		Approved			CHEBI_6444	"6378"	HP:0012531	"10033371"	"22253000"
alclofenac	DB13167	Pain	C0030193		Approved			CHEBI_31183		HP:0012531	"10033371"	"22253000"
lidocaine	DB00281	Pain	C0030193	NCT03787147	Withdrawn	Phase 2	Never started the study cause of the lack of funding	CHEBI_6456	"6387"	HP:0012531	"10033371"	"22253000"
morphine	DB00295	Pain	C0030193	NCT00287326	Terminated	Phase 3	terminated by PI	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
	DB00297	Pain	C0030193	NCT03787147	Withdrawn	Phase 2	Never started the study cause of the lack of funding	CHEBI_77431	"1815"	HP:0012531	"10033371"	"22253000"
reboxetine	DB00234	Pain	C0030193	NCT00354094	Terminated	Phase 2	The study was stopped due to business/operational issues.	CHEBI_135342	"60842"	HP:0012531	"10033371"	"22253000"
ibuprofen	DB01050	Pain	C0030193	NCT03792295	Withdrawn	Phase 2	no enrollment, reallocation of resources	CHEBI_5855	"5640"	HP:0012531	"10033371"	"22253000"
pentazocine	DB00652	Pain	C0030193		Approved			CHEBI_182080	"8001"	HP:0012531	"10033371"	"22253000"
tilidine	DB13787	Pain	C0030193		Approved			CHEBI_77822		HP:0012531	"10033371"	"22253000"
ropivacaine	DB00296	Pain	C0030193	NCT00802048	Terminated	Phase 3		CHEBI_8890	"35780"	HP:0012531	"10033371"	"22253000"
tinoridine	DB13001	Pain	C0030193		Approved			CHEBI_135353		HP:0012531	"10033371"	"22253000"
felbinac	DB07477	Pain	C0030193		Approved			CHEBI_31597		HP:0012531	"10033371"	"22253000"
tapentadol	DB06204	Pain	C0030193	NCT01615510	Terminated	Phase 1		CHEBI_135935	"787390"	HP:0012531	"10033371"	"22253000"
codeine	DB00318	Pain	C0030193		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0012531	"10033371"	"22253000"
nitrous oxide	DB06690	Pain	C0030193	NCT00219713	Terminated	Phase 3		CHEBI_17045	"7486"	HP:0012531	"10033371"	"22253000"
morphine	DB00295	Pain	C0030193	NCT03035578	Withdrawn	Phase 1/Phase 2	research project has been abandoned primarily because of the excessive delays associated with past challenges in obtaining approval from Health Canada	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
lidocaine	DB00281	Pain	C0030193	NCT01930877	Withdrawn	Phase 2	Withdrawn by PI	CHEBI_6456	"6387"	HP:0012531	"10033371"	"22253000"
naloxone	DB01183	Pain	C0030193	NCT01014559	Terminated	Phase 3	Lack of recruitment	CHEBI_7459	"7242"	HP:0012531	"10033371"	"22253000"
ropivacaine	DB00296	Pain	C0030193	NCT02819544	Withdrawn	Phase 3	investigator choice	CHEBI_8890	"35780"	HP:0012531	"10033371"	"22253000"
salicylic acid	DB13860	Pain	C0030193		Approved			CHEBI_16914		HP:0012531	"10033371"	"22253000"
lidocaine	DB00281	Pain	C0030193	NCT03117166	Terminated	Phase 1/Phase 2	multidisciplinary participation could not be overcome.	CHEBI_6456	"6387"	HP:0012531	"10033371"	"22253000"
lornoxicam	DB06725	Pain	C0030193		Approved			CHEBI_31783	"20890"	HP:0012531	"10033371"	"22253000"
ibuprofen	DB01050	Pain	C0030193	NCT03722238	Terminated	Phase 3	Study was terminated on 18NOV2020 after an FDA meeting where it was determined no further actual use data was needed. There were no safety concerns.	CHEBI_5855	"5640"	HP:0012531	"10033371"	"22253000"
doxepin	DB01142	Pruritus	C0033774		Approved			CHEBI_4710	"3638"	HP:0000989	"10037087"	"424492005"
	DB00295	Pain	C0030193	NCT00558870	Terminated	Phase 2	Low Accrual.	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
methadone	DB00333	Pain	C0030193	NCT00558870	Terminated	Phase 2	Low Accrual.	CHEBI_167309	"6813"	HP:0012531	"10033371"	"22253000"
magnesium salicylate	DB01397	Pain	C0030193		Approved			CHEBI_6640		HP:0012531	"10033371"	"22253000"
hydromorphone	DB00327	Pain	C0030193	NCT00125801	Terminated	Phase 3	Lack of patients	CHEBI_5790	"3423"	HP:0012531	"10033371"	"22253000"
capsaicin	DB06774	Pain	C0030193	NCT03153813	Terminated	Phase 3		CHEBI_3374	"1992"	HP:0012531	"10033371"	"22253000"
cycloserine	DB00260	Pain	C0030193	NCT00301080	Terminated	Phase 3	Funding for the study fell through.	CHEBI_40009	"3007"	HP:0012531	"10033371"	"22253000"
fentanyl	DB00813	Pain	C0030193	NCT00387010	Terminated	Phase 3	The sponsor felt enough information was available for the exploratory assessment of the effect of treatment with FBT on pain anxiety	CHEBI_119915	"4337"	HP:0012531	"10033371"	"22253000"
ibandronic acid	DB00710	Pain	C0030193	NCT00099203	Terminated	Phase 3			"115265|115264"	HP:0012531	"10033371"	"22253000"
buprenorphine	DB00921	Pain	C0030193	NCT01431742	Withdrawn	Phase 3		CHEBI_3216	"1819"	HP:0012531	"10033371"	"22253000"
pethidine	DB00454	Pain	C0030193		Approved			CHEBI_6754	"6754"	HP:0012531	"10033371"	"22253000"
oxycodone	DB00497	Pain	C0030193	NCT01094262	Terminated	Phase 2	Logistic reasons associated with the FDA-imposed clinical hold.	CHEBI_7852	"7804"	HP:0012531	"10033371"	"22253000"
hydromorphone	DB00327	Pain	C0030193	NCT01986946	Terminated	Phase 3	Lack of recruitment.	CHEBI_5790	"3423"	HP:0012531	"10033371"	"22253000"
lidocaine	DB00281	Pain	C0030193	NCT01155986	Terminated	Phase 2	Trial was stopped due to difficult enrolment	CHEBI_6456	"6387"	HP:0012531	"10033371"	"22253000"
	DB00482	Pain	C0030193	NCT00305643	Terminated	Phase 3	Terminated due to low accrual. No data analyzed.	CHEBI_41423	"140587"	HP:0012531	"10033371"	"22253000"
	DB00399	Pain	C0030193	NCT00099203	Terminated	Phase 3		CHEBI_46557	"1546014|77655"	HP:0012531	"10033371"	"22253000"
levobupivacaine	DB01002	Pain	C0030193	NCT02728310	Terminated	Phase 3	Terminated	CHEBI_6149	"1815|259453"	HP:0012531	"10033371"	"22253000"
reboxetine	DB00234	Pain	C0030193	NCT00348894	Terminated	Phase 2	- Study was terminated due to insufficient clinical efficacy observed in previous studies conducted in postherpetic neuralgia.	CHEBI_135342	"60842"	HP:0012531	"10033371"	"22253000"
capecitabine	DB01101	Pain	C0030193	NCT00305643	Terminated	Phase 3	Terminated due to low accrual. No data analyzed.	CHEBI_31348	"194000"	HP:0012531	"10033371"	"22253000"
morphine	DB00295	Pain	C0030193	NCT01964378	Terminated	Phase 3	low accrual made the study no longer feasible/decision not related to safety and efficacy	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
mitoxantrone	DB01204	Pain	C0030193	NCT01522443	Terminated	Phase 3	Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.	CHEBI_50729	"7005"	HP:0012531	"10033371"	"22253000"
choline magnesium trisalicylate	DB01401	Pain	C0030193		Approved				"215799"	HP:0012531	"10033371"	"22253000"
	DB00316	Pain	C0030193	NCT02540512	Withdrawn	Early Phase 1	No participants enrolled	CHEBI_46195	"161"	HP:0012531	"10033371"	"22253000"
hydrocodone	DB00956	Pain	C0030193	NCT02540512	Withdrawn	Early Phase 1	No participants enrolled	CHEBI_5779	"5489"	HP:0012531	"10033371"	"22253000"
cannabidiol	DB09061	Pain	C0030193	NCT04613102	Withdrawn	Phase 2/Phase 3	The study protocol should to be updated (major updates), following the second Health Canada review /requests. The study has been withdrawn form the REB review and will not be performed at SickKids.	CHEBI_69478	"2045371"	HP:0012531	"10033371"	"22253000"
	DB00635	Pain	C0030193	NCT01522443	Terminated	Phase 3	Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.	CHEBI_8382	"8640"	HP:0012531	"10033371"	"22253000"
ketorolac	DB00465	Pain	C0030193	NCT00349401	Withdrawn	Phase 2	Study was not initiated. No subjects were screened or enrolled.	CHEBI_76223	"35827"	HP:0012531	"10033371"	"22253000"
	DB00295	Pain	C0030193	NCT00349401	Withdrawn	Phase 2	Study was not initiated. No subjects were screened or enrolled.	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
naloxone	DB01183	Pain	C0030193		Approved			CHEBI_7459	"7242"	HP:0012531	"10033371"	"22253000"
modafinil	DB00745	Pain	C0030193	NCT00267332	Terminated	Phase 3	Low accrual	CHEBI_77585	"30125"	HP:0012531	"10033371"	"22253000"
bupivacaine	DB00297	Pain	C0030193	NCT02933814	Withdrawn	Phase 3	Inadequate number of subjects meet study criteria	CHEBI_77431	"1815"	HP:0012531	"10033371"	"22253000"
choline magnesium trisalicylate	DB00122	Pain	C0030193		Approved			CHEBI_15354	"2449"	HP:0012531	"10033371"	"22253000"
nalbuphine	DB00844	Pain	C0030193		Approved			CHEBI_7454	"7238"	HP:0012531	"10033371"	"22253000"
voriconazole	DB00582	Pain	C0030193	NCT02689713	Withdrawn	Phase 2	Inability to recruit subjects at the study site.	CHEBI_10023	"121243"	HP:0012531	"10033371"	"22253000"
choline magnesium trisalicylate	DB00936	Pain	C0030193		Approved			CHEBI_16914	"9525"	HP:0012531	"10033371"	"22253000"
cisplatin	DB00515	Pain	C0030193	NCT00360971	Terminated	Phase 3	Due to positive preliminary results from other palifermin studies.	CHEBI_27899	"2555"	HP:0012531	"10033371"	"22253000"
citric acid	DB04272	Pain	C0030193		Approved			CHEBI_30769	"21183|221946"	HP:0012531	"10033371"	"22253000"
	DB00818	Pain	C0030193	NCT00187135	Terminated	Phase 3	The study was terminated due to slow accrual.	CHEBI_44915	"8782"	HP:0012531	"10033371"	"22253000"
hydrocodone	DB00956	Pain	C0030193	NCT02542098	Withdrawn	Phase 2	Study has been updated with a new protocol number	CHEBI_5779	"5489"	HP:0012531	"10033371"	"22253000"
ropivacaine	DB00296	Pain	C0030193	NCT02369523	Terminated	Early Phase 1	Adequate enrollment was not reached for this study.	CHEBI_8890	"35780"	HP:0012531	"10033371"	"22253000"
dihydrocodeine	DB01551	Pain	C0030193		Approved			CHEBI_135276	"23088"	HP:0012531	"10033371"	"22253000"
	DB00295	Pain	C0030193	NCT01522534	Terminated	Phase 3	not enough inclusions	CHEBI_17303	"7052|32926"	HP:0012531	"10033371"	"22253000"
	DB00297	Pain	C0030193	NCT02369523	Terminated	Early Phase 1	Adequate enrollment was not reached for this study.	CHEBI_77431	"1815"	HP:0012531	"10033371"	"22253000"
lenalidomide	DB00480	Pain	C0030193	NCT00684242	Terminated	Phase 2	Low accrual.	CHEBI_63791	"342369"	HP:0012531	"10033371"	"22253000"
diflunisal	DB00861	Pain	C0030193		Approved			CHEBI_39669	"3393"	HP:0012531	"10033371"	"22253000"
tapentadol	DB06204	Pain	C0030193		Approved			CHEBI_135935	"787390"	HP:0012531	"10033371"	"22253000"
salicylic acid	DB00936	Pain	C0030193		Approved			CHEBI_16914	"9525"	HP:0012531	"10033371"	"22253000"
pregabalin	DB00230	Pain	C0030193	NCT00334685	Terminated	Phase 2	The Data Monitoring Committee terminated the study on the basis of futility (insufficient clinical response).	CHEBI_64356	"187832"	HP:0012531	"10033371"	"22253000"
pregabalin	DB00230	Pain	C0030193	NCT03407430	Terminated	Phase 2	Low patient accrual	CHEBI_64356	"187832"	HP:0012531	"10033371"	"22253000"
	DB00399	Pain	C0030193	NCT00301886	Withdrawn	Phase 3	withdrawn support for study	CHEBI_46557	"1546014|77655"	HP:0012531	"10033371"	"22253000"
	DB00186	Pain	C0030193	NCT01067144	Terminated	Phase 3	Trial met futility stopping point	CHEBI_6539	"6470"	HP:0012531	"10033371"	"22253000"
codeine	DB00318	Pain	C0030193	NCT01676493	Terminated	Phase 3	Decision to stop study due to low recruitment.	CHEBI_16714	"2670|1545976|235412"	HP:0012531	"10033371"	"22253000"
gabapentin	DB00996	Pain	C0030193	NCT00735124	Terminated	Phase 2/Phase 3	Changes to surgical practices led to the loss of eligible patients	CHEBI_42797	"25480"	HP:0012531	"10033371"	"22253000"
ibandronic acid	DB00710	Pain	C0030193	NCT00478270	Withdrawn	Phase 2			"115265|115264"	HP:0012531	"10033371"	"22253000"
meclofenamic acid	DB00939	Pain	C0030193		Approved			CHEBI_6710	"6678|588003"	HP:0012531	"10033371"	"22253000"
oxycodone	DB00497	Pain	C0030193	NCT02240602	Withdrawn	Phase 3	Lack of internal resources	CHEBI_7852	"7804"	HP:0012531	"10033371"	"22253000"
midazolam	DB00683	Pain	C0030193	NCT00942539	Terminated	Phase 2		CHEBI_6931	"6960"	HP:0012531	"10033371"	"22253000"
paracetamol	DB00316	Pain	C0030193		Approved			CHEBI_46195	"161"	HP:0012531	"10033371"	"22253000"
methadone	DB00333	Pain	C0030193	NCT00351637	Terminated	Phase 2	Study suspended due to low accrual	CHEBI_167309	"6813"	HP:0012531	"10033371"	"22253000"
ibuprofen	DB01050	Pain	C0030193	NCT01426971	Withdrawn	Phase 3		CHEBI_5855	"5640"	HP:0012531	"10033371"	"22253000"
gabapentin	DB00996	Pain	C0030193	NCT01067144	Terminated	Phase 3	Trial met futility stopping point	CHEBI_42797	"25480"	HP:0012531	"10033371"	"22253000"
ropivacaine	DB00296	Pain	C0030193	NCT01986751	Terminated	Phase 1/Phase 2	failure to enroll	CHEBI_8890	"35780"	HP:0012531	"10033371"	"22253000"
ketorolac	DB00465	Pain	C0030193	NCT02297906	Terminated	Phase 1	Enrolment issues	CHEBI_76223	"35827"	HP:0012531	"10033371"	"22253000"
lidocaine	DB00281	Pain	C0030193	NCT00321347	Withdrawn	Phase 2	No patients enrolled and clinician no longer at institution.	CHEBI_6456	"6387"	HP:0012531	"10033371"	"22253000"
selegiline	DB01037	Parkinson Disease	C0030567		Approved			CHEBI_9086	"9639"	MONDO_0005180	"10061536"	"49049000"
ropinirole	DB00268	Parkinson Disease	C0030567		Approved			CHEBI_8888	"72302"	MONDO_0005180	"10061536"	"49049000"
quetiapine	DB01224	Parkinson Disease	C0030567	NCT04164758	Terminated	Phase 2	Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons	CHEBI_8707	"51272"	MONDO_0005180	"10061536"	"49049000"
tolcapone	DB00323	Parkinson Disease	C0030567		Approved			CHEBI_63630	"72937"	MONDO_0005180	"10061536"	"49049000"
cycrimine	DB00942	Parkinson Disease	C0030567		Approved			CHEBI_59692	"22037"	MONDO_0005180	"10061536"	"49049000"
pramipexole	DB00413	Parkinson Disease	C0030567		Approved			CHEBI_8356	"746741"	MONDO_0005180	"10061536"	"49049000"
levodopa	DB01235	Parkinson Disease	C0030567	NCT02782481	Withdrawn	Phase 3	Decision to change the study design	CHEBI_15765	"6375"	MONDO_0005180	"10061536"	"49049000"
opicapone	DB11632	Parkinson Disease	C0030567		Approved			CHEBI_134699	"2362167"	MONDO_0005180	"10061536"	"49049000"
pimavanserin	DB05316	Parkinson Disease	C0030567		Approved			CHEBI_133017	"1791685"	MONDO_0005180	"10061536"	"49049000"
modafinil	DB00745	Parkinson Disease	C0030567	NCT02857244	Withdrawn	Phase 2	Site did not obtain LIRB approval due to medication usage.	CHEBI_77585	"30125"	MONDO_0005180	"10061536"	"49049000"
buspirone	DB00490	Parkinson Disease	C0030567	NCT02589340	Terminated	Phase 1	Low enrollment	CHEBI_3223	"1827"	MONDO_0005180	"10061536"	"49049000"
	DB00843	Parkinson Disease	C0030567	NCT02857244	Withdrawn	Phase 2	Site did not obtain LIRB approval due to medication usage.	CHEBI_145499	"135447"	MONDO_0005180	"10061536"	"49049000"
	DB00476	Parkinson Disease	C0030567	NCT02857244	Withdrawn	Phase 2	Site did not obtain LIRB approval due to medication usage.	CHEBI_36795	"72625"	MONDO_0005180	"10061536"	"49049000"
	DB00425	Parkinson Disease	C0030567	NCT01351168	Withdrawn	Phase 2	study not funded	CHEBI_10125	"39993"	MONDO_0005180	"10061536"	"49049000"
benzatropine	DB00245	Parkinson Disease	C0030567		Approved			CHEBI_3048	"1424"	MONDO_0005180	"10061536"	"49049000"
amantadine	DB00915	Parkinson Disease	C0030567		Approved			CHEBI_2618	"620"	MONDO_0005180	"10061536"	"49049000"
sildenafil	DB00203	Parkinson Disease	C0030567	NCT02162979	Terminated	Phase 2	Not enough subjects.	CHEBI_9139	"136411"	MONDO_0005180	"10061536"	"49049000"
	DB00988	Parkinson Disease	C0030567	NCT01351168	Withdrawn	Phase 2	study not funded	CHEBI_18243	"3628"	MONDO_0005180	"10061536"	"49049000"
rotigotine	DB05271	Parkinson Disease	C0030567		Approved			CHEBI_135351	"616739"	MONDO_0005180	"10061536"	"49049000"
procyclidine	DB00387	Parkinson Disease	C0030567		Approved			CHEBI_8448	"8718"	MONDO_0005180	"10061536"	"49049000"
	DB00368	Parkinson Disease	C0030567	NCT01927055	Terminated	Phase 3	Due to potential competition with a post-marketing study requested by FDA	CHEBI_18357	"7512"	MONDO_0005180	"10061536"	"49049000"
	DB06262	Parkinson Disease	C0030567	NCT01927055	Terminated	Phase 3	Due to potential competition with a post-marketing study requested by FDA	CHEBI_31524	"1489913"	MONDO_0005180	"10061536"	"49049000"
norepinephrine	DB00742	Parkinson Disease	C0030567	NCT01927055	Terminated	Phase 3	Due to potential competition with a post-marketing study requested by FDA	CHEBI_16899	"6628"	MONDO_0005180	"10061536"	"49049000"
apomorphine	DB00714	Parkinson Disease	C0030567	NCT00758368	Withdrawn	Phase 2	Inadequate support to conduct the study	CHEBI_48538	"1043"	MONDO_0005180	"10061536"	"49049000"
dexmedetomidine	DB00633	Parkinson Disease	C0030567	NCT00608231	Withdrawn	Phase 2/Phase 3	Intraoperative recording could not be maintained for required period	CHEBI_4466	"48937"	MONDO_0005180	"10061536"	"49049000"
droxidopa	DB00368	Parkinson Disease	C0030567		Approved			CHEBI_18357	"7512"	MONDO_0005180	"10061536"	"49049000"
bromocriptine	DB01200	Parkinson Disease	C0030567		Approved			CHEBI_3181	"1760"	MONDO_0005180	"10061536"	"49049000"
droxidopa	DB06262	Parkinson Disease	C0030567		Approved			CHEBI_31524	"1489913"	MONDO_0005180	"10061536"	"49049000"
safinamide	DB06654	Parkinson Disease	C0030567		Approved			CHEBI_134718	"1922448"	MONDO_0005180	"10061536"	"49049000"
benzalkonium	DB11105	Pruritus	C0033774		Approved			CHEBI_188978	"1378"	HP:0000989	"10037087"	"424492005"
amantadine	DB00915	Parkinson Disease	C0030567	NCT01652534	Terminated	Phase 3	Due to lack of recruitment	CHEBI_2618	"620"	MONDO_0005180	"10061536"	"49049000"
apomorphine	DB00714	Parkinson Disease	C0030567		Approved			CHEBI_48538	"1043"	MONDO_0005180	"10061536"	"49049000"
levodopa	DB01235	Parkinson Disease	C0030567	NCT01351168	Withdrawn	Phase 2	study not funded	CHEBI_15765	"6375"	MONDO_0005180	"10061536"	"49049000"
domperidone	DB01184	Parkinson Disease	C0030567	NCT00305331	Terminated	Phase 2	lack of recruitment	CHEBI_31515	"3626"	MONDO_0005180	"10061536"	"49049000"
levodopa	DB01235	Parkinson Disease	C0030567		Approved			CHEBI_15765	"6375"	MONDO_0005180	"10061536"	"49049000"
isopropamide	DB01625	Peptic Ulcer	C0030920		Approved			CHEBI_6043	"89784"	MONDO_0004247	"10034341"	"13200003"
esomeprazole	DB01060	Parkinson Disease	C0030567	NCT00664209	Terminated	Phase 3	Prevalence of H Pylori in the study population was much lower than anticipated	CHEBI_2676	"1297882|723"	MONDO_0005180	"10061536"	"49049000"
	DB00338	Parkinson Disease	C0030567	NCT00664209	Terminated	Phase 3	Prevalence of H Pylori in the study population was much lower than anticipated	CHEBI_77260	"7646"	MONDO_0005180	"10061536"	"49049000"
levodopa	DB00988	Parkinson Disease	C0030567		Approved			CHEBI_18243	"3628"	MONDO_0005180	"10061536"	"49049000"
carbidopa	DB00190	Parkinson Disease	C0030567		Approved			CHEBI_39585	"2019|1545982"	MONDO_0005180	"10061536"	"49049000"
amantadine	DB00915	Parkinson Disease	C0030567	NCT02153632	Terminated	Phase 3		CHEBI_2618	"620"	MONDO_0005180	"10061536"	"49049000"
apomorphine	DB00714	Parkinson Disease	C0030567	NCT00472355	Withdrawn	Phase 2	Insufficient study materials	CHEBI_48538	"1043"	MONDO_0005180	"10061536"	"49049000"
rasagiline	DB01367	Parkinson Disease	C0030567		Approved			CHEBI_63620	"134748"	MONDO_0005180	"10061536"	"49049000"
trihexyphenidyl	DB00376	Parkinson Disease	C0030567		Approved			CHEBI_9720	"10811"	MONDO_0005180	"10061536"	"49049000"
biperiden	DB00810	Parkinson Disease	C0030567		Approved			CHEBI_3112	"1589"	MONDO_0005180	"10061536"	"49049000"
	DB00988	Parkinson Disease	C0030567	NCT02782481	Withdrawn	Phase 3	Decision to change the study design	CHEBI_18243	"3628"	MONDO_0005180	"10061536"	"49049000"
topiramate	DB00273	Parkinson Disease	C0030567	NCT00296959	Terminated	Phase 2	early termination due to slow recruitment	CHEBI_63631	"38404"	MONDO_0005180	"10061536"	"49049000"
entacapone	DB00494	Parkinson Disease	C0030567		Approved			CHEBI_4798	"60307"	MONDO_0005180	"10061536"	"49049000"
amantadine	DB00915	Parkinson Disease	C0030567	NCT02153645	Terminated	Phase 3		CHEBI_2618	"620"	MONDO_0005180	"10061536"	"49049000"
istradefylline	DB11757	Parkinson Disease	C0030567		Approved			CHEBI_134726	"2199015"	MONDO_0005180	"10061536"	"49049000"
donepezil	DB00843	Parkinson Disease	C0030567	NCT01014858	Terminated	Phase 3	Due to low recruitment	CHEBI_145499	"135447"	MONDO_0005180	"10061536"	"49049000"
	DB00190	Parkinson Disease	C0030567	NCT02782481	Withdrawn	Phase 3	Decision to change the study design	CHEBI_39585	"2019|1545982"	MONDO_0005180	"10061536"	"49049000"
gentamicin	DB00798	Paronychia Inflammation	C0030578		Approved			CHEBI_17833	"1596450"	MONDO_0005898	"10034016"	"71906005"
fusidic acid	DB02703	Paronychia Inflammation	C0030578		Approved			CHEBI_29013	"4608|113608"	MONDO_0005898	"10034016"	"71906005"
pantoprazole	DB00213	Peptic Ulcer	C0030920		Approved			CHEBI_7915	"40790"	MONDO_0004247	"10034341"	"13200003"
sodium citrate	DB09154	Peptic Ulcer	C0030920		Approved			CHEBI_53258	"253204|56466|1310549"	MONDO_0004247	"10034341"	"13200003"
mepenzolate	DB04843	Peptic Ulcer	C0030920		Approved			CHEBI_94411	"107770"	MONDO_0004247	"10034341"	"13200003"
dexrabeprazole	DB13762	Peptic Ulcer	C0030920		Approved			CHEBI_134729		MONDO_0004247	"10034341"	"13200003"
octatropine methylbromide	DB00517	Peptic Ulcer	C0030920		Approved			CHEBI_2739	"17945"	MONDO_0004247	"10034341"	"13200003"
oxyphencyclimine	DB00383	Peptic Ulcer	C0030920		Approved			CHEBI_7868	"32698"	MONDO_0004247	"10034341"	"13200003"
magnesium silicate	DB13249	Peptic Ulcer	C0030920		Approved				"1310566"	MONDO_0004247	"10034341"	"13200003"
nizatidine	DB00585	Peptic Ulcer	C0030920		Approved			CHEBI_7601	"42319"	MONDO_0004247	"10034341"	"13200003"
carbenoxolone	DB02329	Peptic Ulcer	C0030920		Approved			CHEBI_41462		MONDO_0004247	"10034341"	"13200003"
scopolamine	DB00747	Peptic Ulcer	C0030920		Approved			CHEBI_16794	"9601|9603"	MONDO_0004247	"10034341"	"13200003"
chlordiazepoxide	DB00475	Peptic Ulcer	C0030920		Approved			CHEBI_3611	"2356"	MONDO_0004247	"10034341"	"13200003"
methanthelinium	DB00940	Peptic Ulcer	C0030920		Approved			CHEBI_6817	"6821"	MONDO_0004247	"10034341"	"13200003"
propantheline	DB00782	Peptic Ulcer	C0030920		Approved			CHEBI_8481	"8761"	MONDO_0004247	"10034341"	"13200003"
ilaprazole	DB11964	Peptic Ulcer	C0030920		Approved			CHEBI_135544		MONDO_0004247	"10034341"	"13200003"
magnesium silicate	DB09281	Peptic Ulcer	C0030920		Approved				"29170"	MONDO_0004247	"10034341"	"13200003"
omeprazole	DB00338	Peptic Ulcer	C0030920		Approved			CHEBI_77260	"7646"	MONDO_0004247	"10034341"	"13200003"
potassium hydrogencarbonate	DB11098	Peptic Ulcer	C0030920		Approved			CHEBI_81862	"34296"	MONDO_0004247	"10034341"	"13200003"
carbaldrate	DB15825	Peptic Ulcer	C0030920		Approved					MONDO_0004247	"10034341"	"13200003"
rebamipide	DB11656	Peptic Ulcer	C0030920		Approved			CHEBI_93814		MONDO_0004247	"10034341"	"13200003"
polaprezinc	DB09221	Peptic Ulcer	C0030920		Approved			CHEBI_32024		MONDO_0004247	"10034341"	"13200003"
methylhomatropine	DB00725	Peptic Ulcer	C0030920		Approved			CHEBI_50373	"1546413|27085"	MONDO_0004247	"10034341"	"13200003"
homatropine	DB11181	Peptic Ulcer	C0030920		Approved			CHEBI_5747	"27084"	MONDO_0004247	"10034341"	"13200003"
almasilate	DB13595	Peptic Ulcer	C0030920		Approved				"17614"	MONDO_0004247	"10034341"	"13200003"
rabeprazole	DB01129	Peptic Ulcer	C0030920		Approved			CHEBI_8768	"183877|114979"	MONDO_0004247	"10034341"	"13200003"
alum	DB09087	Peptic Ulcer	C0030920		Approved			CHEBI_86463	"221456|54989"	MONDO_0004247	"10034341"	"13200003"
glycopyrronium bromide	DB00986	Peptic Ulcer	C0030920		Approved			CHEBI_94449	"1546438|4955"	MONDO_0004247	"10034341"	"13200003"
magnesium carbonate	DB09481	Peptic Ulcer	C0030920		Approved			CHEBI_31793	"29155"	MONDO_0004247	"10034341"	"13200003"
silicon dioxide	DB11132	Peptic Ulcer	C0030920		Approved			CHEBI_30563	"314826|1362874|9771"	MONDO_0004247	"10034341"	"13200003"
neomycin	DB00994	Urinary tract infection	C0042029		Approved			CHEBI_7507	"7299"		"10046571"	"68566005"
esomeprazole	DB00736	Peptic Ulcer	C0030920		Approved			CHEBI_50275	"283742"	MONDO_0004247	"10034341"	"13200003"
propranolol	DB00571	Peptic Ulcer	C0030920	NCT04140591	Terminated	Phase 2/Phase 3	"1. Most patients with liver cirrhosis already use PPI and NSBB 2. 90 % Peptic ulcer size is smaller than 5cm"	CHEBI_8499	"8787"	MONDO_0004247	"10034341"	"13200003"
algeldrate	DB06723	Peptic Ulcer	C0030920		Approved			CHEBI_33130	"612|81948"	MONDO_0004247	"10034341"	"13200003"
magnesium hydroxide	DB09104	Peptic Ulcer	C0030920		Approved			CHEBI_6637	"6581|243353"	MONDO_0004247	"10034341"	"13200003"
tridihexethyl	DB00505	Peptic Ulcer	C0030920		Approved			CHEBI_9701	"38617"	MONDO_0004247	"10034341"	"13200003"
dexlansoprazole	DB05351	Peptic Ulcer	C0030920		Approved			CHEBI_135931	"816346"	MONDO_0004247	"10034341"	"13200003"
esomeprazole	DB00338	Peptic Ulcer	C0030920		Approved			CHEBI_77260	"7646"	MONDO_0004247	"10034341"	"13200003"
	DB01109	Pneumonia	C0032285	NCT01532544	Terminated	Phase 2	Difficulty recruiting patients, company closed down	CHEBI_28304	"5224"	MONDO_0005249	"10035664"	"233604007"
loracarbef	DB00447	Pneumonia	C0032285		Approved			CHEBI_47544	"28981"	MONDO_0005249	"10035664"	"233604007"
ceftizoxime	DB01332	Pneumonia	C0032285		Approved			CHEBI_553473	"2192"	MONDO_0005249	"10035664"	"233604007"
cefaclor	DB00833	Pneumonia	C0032285		Approved			CHEBI_3478	"1450910|2176"	MONDO_0005249	"10035664"	"233604007"
cefradine	DB01333	Pneumonia	C0032285		Approved			CHEBI_3547	"2239"	MONDO_0005249	"10035664"	"233604007"
fusidic acid	DB02703	Pneumonia	C0032285		Approved			CHEBI_29013	"4608|113608"	MONDO_0005249	"10035664"	"233604007"
cefamandole	DB01326	Pneumonia	C0032285		Approved			CHEBI_3480	"2178"	MONDO_0005249	"10035664"	"233604007"
cefapirin	DB01139	Pneumonia	C0032285		Approved			CHEBI_554446	"2238"	MONDO_0005249	"10035664"	"233604007"
meclocycline	DB13092	Pneumonia	C0032285		Approved			CHEBI_135772	"29418"	MONDO_0005249	"10035664"	"233604007"
cefalotin	DB00456	Pneumonia	C0032285		Approved			CHEBI_124991	"2236"	MONDO_0005249	"10035664"	"233604007"
lidocaine	DB00281	Pneumonia	C0032285	NCT03829618	Terminated	Phase 3	COVID lack of cases/recruitment	CHEBI_6456	"6387"	MONDO_0005249	"10035664"	"233604007"
simvastatin	DB00641	Pneumonia	C0032285	NCT01057758	Terminated	Phase 3	stopped for futility	CHEBI_9150	"36567"	MONDO_0005249	"10035664"	"233604007"
nitric oxide	DB00435	Pneumonia	C0032285	NCT00016523	Terminated	Phase 3	Preliminary results showed increased intraventricular hemorrhage (IVH) in experimental arm	CHEBI_16480	"7442"	MONDO_0005249	"10035664"	"233604007"
colistin	DB00803	Pneumonia	C0032285	NCT01863719	Terminated	Phase 1	Completion of cohort 3, safety concerns	CHEBI_37943	"2709"	MONDO_0005249	"10035664"	"233604007"
oxytetracycline	DB00595	Pneumonia	C0032285		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005249	"10035664"	"233604007"
demeclocycline	DB00618	Pneumonia	C0032285		Approved			CHEBI_4392	"3154"	MONDO_0005249	"10035664"	"233604007"
ofloxacin	DB01165	Pneumonia	C0032285		Approved			CHEBI_7731	"7623"	MONDO_0005249	"10035664"	"233604007"
amphotericin B	DB00681	Pneumonia	C0032285		Approved			CHEBI_2682	"236594|732"	MONDO_0005249	"10035664"	"233604007"
norfloxacin	DB01059	Pneumonia	C0032285		Approved			CHEBI_100246	"7517"	MONDO_0005249	"10035664"	"233604007"
tetracycline	DB09550	Pneumonia	C0032285		Approved			CHEBI_27902	"2105975"	MONDO_0005249	"10035664"	"233604007"
cefmetazole	DB00274	Pneumonia	C0032285		Approved			CHEBI_3489	"2182"	MONDO_0005249	"10035664"	"233604007"
tetracycline	DB00759	Pneumonia	C0032285		Approved			CHEBI_27902	"10395"	MONDO_0005249	"10035664"	"233604007"
dirithromycin	DB00954	Pneumonia	C0032285		Approved			CHEBI_474014		MONDO_0005249	"10035664"	"233604007"
cefonicid	DB01328	Pneumonia	C0032285		Approved			CHEBI_3491	"2183"	MONDO_0005249	"10035664"	"233604007"
minocycline	DB01017	Pneumonia	C0032285		Approved			CHEBI_50694	"6980"	MONDO_0005249	"10035664"	"233604007"
eptifibatide	DB00063	Pneumonia	C0032285	NCT01532544	Terminated	Phase 2	Difficulty recruiting patients, company closed down	CHEBI_291902	"288688|75635"	MONDO_0005249	"10035664"	"233604007"
sparfloxacin	DB01208	Pneumonia	C0032285		Approved			CHEBI_9212	"18469"	MONDO_0005249	"10035664"	"233604007"
	DB09258	Pneumonia	C0032285	NCT01532544	Terminated	Phase 2	Difficulty recruiting patients, company closed down		"280611"	MONDO_0005249	"10035664"	"233604007"
	DB06822	Pneumonia	C0032285	NCT01532544	Terminated	Phase 2	Difficulty recruiting patients, company closed down		"69646|104466"	MONDO_0005249	"10035664"	"233604007"
clindamycin	DB01190	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3745	"2582"		"10035734"	"22754005"
cefapirin	DB01139	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_554446	"2238"		"10035734"	"22754005"
meticillin	DB01603	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_6827	"2181306"		"10035734"	"22754005"
ticarcillin	DB01607	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_9587	"10591"		"10035734"	"22754005"
ofloxacin	DB01165	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_7731	"7623"		"10035734"	"22754005"
cefmetazole	DB00274	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3489	"2182"		"10035734"	"22754005"
linezolid	DB00601	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_63607	"190376"		"10035734"	"22754005"
cefradine	DB01333	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3547	"2239"		"10035734"	"22754005"
cloxacillin	DB01147	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_49566	"2625"		"10035734"	"22754005"
vancomycin	DB00512	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_28001	"11124"		"10035734"	"22754005"
ampicillin	DB00415	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_28971	"733|221058"		"10035734"	"22754005"
cefotetan	DB01330	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3499	"2187"		"10035734"	"22754005"
cefotaxime	DB00493	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_204928	"2186"		"10035734"	"22754005"
norfloxacin	DB01059	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_100246	"7517"		"10035734"	"22754005"
alatrofloxacin	DB09335	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_135829	"141440"		"10035734"	"22754005"
nafcillin	DB00607	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_7447	"7233"		"10035734"	"22754005"
cefazolin	DB01327	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_474053	"2180"		"10035734"	"22754005"
cefuroxime	DB01112	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3515	"2194"		"10035734"	"22754005"
cefamandole	DB01326	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3480	"2178"		"10035734"	"22754005"
levofloxacin	DB01137	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_63598	"1546009|82122"		"10035734"	"22754005"
ceftriaxone	DB01212	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_29007	"2193"		"10035734"	"22754005"
moxifloxacin	DB00218	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_63611	"139462"		"10035734"	"22754005"
ceftazidime	DB00438	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3508	"2191|1545984"		"10035734"	"22754005"
amikacin	DB00479	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_2637	"641"		"10035734"	"22754005"
tobramycin	DB00684	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_28864	"10627"		"10035734"	"22754005"
gatifloxacin	DB01044	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_5280	"228476|1546025"		"10035734"	"22754005"
dicloxacillin	DB00485	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_4511	"3356"		"10035734"	"22754005"
cefoxitin	DB01331	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_209807	"2189"		"10035734"	"22754005"
clavulanic acid	DB00766	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_48947	"48203|21216"		"10035734"	"22754005"
clindamycin phosphate	DB01190	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_3745	"2582"		"10035734"	"22754005"
oxacillin	DB00713	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_7809	"7773"		"10035734"	"22754005"
trovafloxacin	DB00685	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_9763	"115552"		"10035734"	"22754005"
ceftizoxime	DB01332	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_553473	"2192"		"10035734"	"22754005"
fusidic acid	DB02703	Staphylococcal Pneumonia	C0032308		Approved			CHEBI_29013	"4608|113608"		"10035734"	"22754005"
tetracaine	DB09085	Pruritus	C0033774		Approved			CHEBI_9468	"91189|10391"	HP:0000989	"10037087"	"424492005"
zinc acetate	DB14487	Pruritus	C0033774		Approved			CHEBI_62984	"1299637|58295"	HP:0000989	"10037087"	"424492005"
carbinoxamine	DB00748	Pruritus	C0033774		Approved			CHEBI_3398	"20220"	HP:0000989	"10037087"	"424492005"
diphenylpyraline	DB01146	Pruritus	C0033774		Approved			CHEBI_59788	"23386"	HP:0000989	"10037087"	"424492005"
chlorphenamine	DB01114	Pruritus	C0033774		Approved			CHEBI_52010	"221074|2400"	HP:0000989	"10037087"	"424492005"
allantoin	DB11100	Pruritus	C0033774		Approved			CHEBI_15676	"508"	HP:0000989	"10037087"	"424492005"
phenol	DB03255	Pruritus	C0033774		Approved			CHEBI_15882	"33290"	HP:0000989	"10037087"	"424492005"
tripelennamine	DB00792	Pruritus	C0033774		Approved			CHEBI_9741	"10847"	HP:0000989	"10037087"	"424492005"
hydroxyzine	DB00557	Pruritus	C0033774		Approved			CHEBI_5818	"5553"	HP:0000989	"10037087"	"424492005"
alimemazine	DB01246	Pruritus	C0033774		Approved			CHEBI_9725	"10825"	HP:0000989	"10037087"	"424492005"
zinc oxide	DB09321	Pruritus	C0033774		Approved			CHEBI_36560	"11423"	HP:0000989	"10037087"	"424492005"
lactic acid	DB04398	Pruritus	C0033774		Approved			CHEBI_78320	"28393|1314409"	HP:0000989	"10037087"	"424492005"
azatadine	DB00719	Pruritus	C0033774		Approved			CHEBI_2946	"18600"	HP:0000989	"10037087"	"424492005"
lidocaine	DB00281	Pruritus	C0033774		Approved			CHEBI_6456	"6387"	HP:0000989	"10037087"	"424492005"
brompheniramine	DB00835	Pruritus	C0033774		Approved			CHEBI_3183	"1767"	HP:0000989	"10037087"	"424492005"
terbutaline	DB00871	Pruritus	C0033774		Approved			CHEBI_9449	"10368"	HP:0000989	"10037087"	"424492005"
phenindamine	DB01619	Pruritus	C0033774		Approved			CHEBI_8065	"33283"	HP:0000989	"10037087"	"424492005"
resorcinol	DB11085	Pruritus	C0033774		Approved			CHEBI_27810	"35382"	HP:0000989	"10037087"	"424492005"
pheniramine	DB01620	Pruritus	C0033774		Approved			CHEBI_91591	"8132"	HP:0000989	"10037087"	"424492005"
methapyrilene	DB04819	Pruritus	C0033774		Approved			CHEBI_6820	"6822"	HP:0000989	"10037087"	"424492005"
methdilazine	DB00902	Pruritus	C0033774		Approved			CHEBI_6823	"29648"	HP:0000989	"10037087"	"424492005"
mepyramine	DB06691	Pruritus	C0033774		Approved			CHEBI_6762	"9009"	HP:0000989	"10037087"	"424492005"
pramocaine	DB09345	Pruritus	C0033774		Approved			CHEBI_8357	"34347"	HP:0000989	"10037087"	"424492005"
phenyltoloxamine	DB11160	Pruritus	C0033774		Approved			CHEBI_135047	"33408"	HP:0000989	"10037087"	"424492005"
benzyl alcohol	DB06770	Pruritus	C0033774		Approved			CHEBI_17987	"1426"	HP:0000989	"10037087"	"424492005"
promazine	DB00420	Pruritus	C0033774		Approved			CHEBI_8459	"8742"	HP:0000989	"10037087"	"424492005"
antazoline	DB08799	Pruritus	C0033774		Approved			CHEBI_84115	"865"	HP:0000989	"10037087"	"424492005"
benzocaine	DB01086	Pruritus	C0033774		Approved			CHEBI_116735	"1399"	HP:0000989	"10037087"	"424492005"
butamben	DB11148	Pruritus	C0033774		Approved			CHEBI_3231	"19861"	HP:0000989	"10037087"	"424492005"
benzethonium	DB11125	Pruritus	C0033774		Approved			CHEBI_94725	"1390"	HP:0000989	"10037087"	"424492005"
benzalkonium	DB13282	Pruritus	C0033774		Approved			CHEBI_188978		HP:0000989	"10037087"	"424492005"
doxylamine	DB00366	Pruritus	C0033774		Approved			CHEBI_51380	"3642"	HP:0000989	"10037087"	"424492005"
dyclonine	DB00645	Pruritus	C0033774		Approved			CHEBI_4724	"23744"	HP:0000989	"10037087"	"424492005"
cinchocaine	DB00527	Pruritus	C0033774		Approved			CHEBI_247956	"3339"	HP:0000989	"10037087"	"424492005"
emedastine	DB01084	Pruritus	C0033774		Approved			CHEBI_4779	"28144"	HP:0000989	"10037087"	"424492005"
triprolidine	DB00427	Pruritus	C0033774		Approved			CHEBI_84116	"10849"	HP:0000989	"10037087"	"424492005"
dexbrompheniramine	DB00405	Pruritus	C0033774		Approved			CHEBI_59269	"22696|1767"	HP:0000989	"10037087"	"424492005"
cyproheptadine	DB00434	Pruritus	C0033774		Approved			CHEBI_4046	"3013"	HP:0000989	"10037087"	"424492005"
ammonium lactate	DB06768	Pruritus	C0033774		Approved				"215247"	HP:0000989	"10037087"	"424492005"
ferric oxide	DB11576	Pruritus	C0033774		Approved			CHEBI_50819		HP:0000989	"10037087"	"424492005"
levomenthol	DB00825	Pruritus	C0033774		Approved			CHEBI_15409	"236388|6750"	HP:0000989	"10037087"	"424492005"
crotamiton	DB00265	Pruritus	C0033774		Approved			CHEBI_31439	"21766"	HP:0000989	"10037087"	"424492005"
dexchlorpheniramine	DB09555	Pruritus	C0033774		Approved			CHEBI_4465	"54828"	HP:0000989	"10037087"	"424492005"
dexchlorpheniramine	DB13679	Pruritus	C0033774		Approved			CHEBI_4464	"22697"	HP:0000989	"10037087"	"424492005"
bupivacaine	DB00297	Pruritus	C0033774		Approved			CHEBI_77431	"1815"	HP:0000989	"10037087"	"424492005"
levomenthol	DB14123	Pruritus	C0033774		Approved			CHEBI_25187	"6750|1430390"	HP:0000989	"10037087"	"424492005"
clemastine	DB00283	Pruritus	C0033774		Approved			CHEBI_3738	"2578"	HP:0000989	"10037087"	"424492005"
betamethasone benzoate	DB00443	Pruritus Ani	C0033775		Approved			CHEBI_3077	"1514"		"10068172"	"90446007"
hydrocortisone	DB00741	Pruritus Ani	C0033775		Approved			CHEBI_17650	"5492"		"10068172"	"90446007"
desoximetasone	DB00547	Pruritus Ani	C0033775		Approved			CHEBI_691037	"3255"		"10068172"	"90446007"
triamcinolone	DB00620	Pruritus Ani	C0033775		Approved			CHEBI_9667	"10759"		"10068172"	"90446007"
fludroxycortide	DB00846	Pruritus Ani	C0033775		Approved			CHEBI_5127	"4500"		"10068172"	"90446007"
prednisolone	DB00860	Pruritus Ani	C0033775		Approved			CHEBI_8378	"8638"		"10068172"	"90446007"
amcinonide	DB00288	Pruritus Ani	C0033775		Approved			CHEBI_31199	"17652"		"10068172"	"90446007"
betamethasone dipropionate	DB00443	Pruritus Ani	C0033775		Approved			CHEBI_3077	"1514"		"10068172"	"90446007"
fluticasone propionate	DB00588	Pruritus Ani	C0033775		Approved			CHEBI_31441	"50121"		"10068172"	"90446007"
ammonium lactate	DB06768	Pruritus Ani	C0033775		Approved				"215247"		"10068172"	"90446007"
fluticasone propionate	DB13867	Pruritus Ani	C0033775		Approved			CHEBI_5134	"41126"		"10068172"	"90446007"
hydrocortisone acetate	DB00741	Pruritus Ani	C0033775		Approved			CHEBI_17650	"5492"		"10068172"	"90446007"
prednicarbate	DB01130	Pruritus Ani	C0033775		Approved			CHEBI_135791	"34369"		"10068172"	"90446007"
dexamethasone	DB01234	Pruritus Ani	C0033775		Approved			CHEBI_41879	"3264"		"10068172"	"90446007"
cortisone acetate	DB01380	Pruritus Ani	C0033775		Approved			CHEBI_3897	"21655"		"10068172"	"90446007"
flumetasone	DB00663	Pruritus Ani	C0033775		Approved			CHEBI_34764	"4458"		"10068172"	"90446007"
phenylephrine	DB00388	Pruritus Ani	C0033775		Approved			CHEBI_8093	"8163"		"10068172"	"90446007"
hydrocortisone acetate	DB14539	Pruritus Ani	C0033775		Approved			CHEBI_17609	"27197"		"10068172"	"90446007"
halcinonide	DB06786	Pruritus Ani	C0033775		Approved			CHEBI_31663	"5084"		"10068172"	"90446007"
fluocinolone acetonide	DB00591	Pruritus Ani	C0033775		Approved			CHEBI_31623	"4461"		"10068172"	"90446007"
clocortolone pivalate	DB00838	Pruritus Ani	C0033775		Approved			CHEBI_59582	"21249"		"10068172"	"90446007"
phenylmercuric nitrate	DB13388	Pruritus Ani	C0033775		Approved			CHEBI_136021			"10068172"	"90446007"
fluocinonide	DB01047	Pruritus Ani	C0033775		Approved			CHEBI_5109	"4462"		"10068172"	"90446007"
betamethasone	DB00443	Pruritus Ani	C0033775		Approved			CHEBI_3077	"1514"		"10068172"	"90446007"
fluocinonide	DB12553	Pruritus Ani	C0033775		Approved			CHEBI_5108	"25126"		"10068172"	"90446007"
betamethasone valerate	DB00443	Pruritus Ani	C0033775		Approved			CHEBI_3077	"1514"		"10068172"	"90446007"
methylprednisolone	DB00959	Pruritus Ani	C0033775		Approved			CHEBI_6888	"6902"		"10068172"	"90446007"
prednicarbate	DB00860	Pruritus Ani	C0033775		Approved			CHEBI_8378	"8638"		"10068172"	"90446007"
lidocaine	DB00281	Pruritus Ani	C0033775		Approved			CHEBI_6456	"6387"		"10068172"	"90446007"
benzoyl peroxide	DB09096	Pruritus Ani	C0033775		Approved			CHEBI_82405	"1418"		"10068172"	"90446007"
mometasone furoate	DB00764	Pruritus Ani	C0033775		Approved			CHEBI_6970			"10068172"	"90446007"
ulobetasol propionate	DB00596	Pruritus Ani	C0033775		Approved			CHEBI_135782	"41208"		"10068172"	"90446007"
mometasone furoate	DB14512	Pruritus Ani	C0033775		Approved			CHEBI_47564	"30145"		"10068172"	"90446007"
zinc oxide	DB09321	Pruritus Ani	C0033775		Approved			CHEBI_36560	"11423"		"10068172"	"90446007"
desonide	DB01260	Pruritus Ani	C0033775		Approved			CHEBI_204734	"3254"		"10068172"	"90446007"
alclometasone dipropionate	DB00240	Pruritus Ani	C0033775		Approved			CHEBI_53776	"108088"		"10068172"	"90446007"
diflorasone diacetate	DB00223	Pruritus Ani	C0033775		Approved			CHEBI_59750	"91311"		"10068172"	"90446007"
pramocaine	DB09345	Pruritus Ani	C0033775		Approved			CHEBI_8357	"34347"		"10068172"	"90446007"
triamcinolone acetonide	DB00620	Pruritus Ani	C0033775		Approved			CHEBI_9667	"10759"		"10068172"	"90446007"
fluocinolone acetonide	DB12553	Pruritus Ani	C0033775		Approved			CHEBI_5108	"25126"		"10068172"	"90446007"
desoximetasone	DB00547	Pruritus of genital organs	C0033777		Approved			CHEBI_691037	"3255"		"10037093"	"267802000"
triamcinolone	DB00620	Pruritus of genital organs	C0033777		Approved			CHEBI_9667	"10759"		"10037093"	"267802000"
alclometasone dipropionate	DB00240	Pruritus of genital organs	C0033777		Approved			CHEBI_53776	"108088"		"10037093"	"267802000"
prednisolone	DB00860	Pruritus of genital organs	C0033777		Approved			CHEBI_8378	"8638"		"10037093"	"267802000"
dexamethasone	DB01234	Pruritus of genital organs	C0033777		Approved			CHEBI_41879	"3264"		"10037093"	"267802000"
diflorasone diacetate	DB00223	Pruritus of genital organs	C0033777		Approved			CHEBI_59750	"91311"		"10037093"	"267802000"
betamethasone	DB00443	Pruritus of genital organs	C0033777		Approved			CHEBI_3077	"1514"		"10037093"	"267802000"
ulobetasol propionate	DB00596	Pruritus of genital organs	C0033777		Approved			CHEBI_135782	"41208"		"10037093"	"267802000"
hydrocortisone	DB00741	Pruritus of genital organs	C0033777		Approved			CHEBI_17650	"5492"		"10037093"	"267802000"
desonide	DB01260	Pruritus of genital organs	C0033777		Approved			CHEBI_204734	"3254"		"10037093"	"267802000"
betamethasone dipropionate	DB00443	Pruritus of genital organs	C0033777		Approved			CHEBI_3077	"1514"		"10037093"	"267802000"
halcinonide	DB06786	Pruritus of genital organs	C0033777		Approved			CHEBI_31663	"5084"		"10037093"	"267802000"
prednicarbate	DB00860	Pruritus of genital organs	C0033777		Approved			CHEBI_8378	"8638"		"10037093"	"267802000"
fluocinolone acetonide	DB00591	Pruritus of genital organs	C0033777		Approved			CHEBI_31623	"4461"		"10037093"	"267802000"
fluocinonide	DB12553	Pruritus of genital organs	C0033777		Approved			CHEBI_5108	"25126"		"10037093"	"267802000"
triamcinolone acetonide	DB00620	Pruritus of genital organs	C0033777		Approved			CHEBI_9667	"10759"		"10037093"	"267802000"
fluocinonide	DB01047	Pruritus of genital organs	C0033777		Approved			CHEBI_5109	"4462"		"10037093"	"267802000"
prednicarbate	DB01130	Pruritus of genital organs	C0033777		Approved			CHEBI_135791	"34369"		"10037093"	"267802000"
betamethasone valerate	DB00443	Pruritus of genital organs	C0033777		Approved			CHEBI_3077	"1514"		"10037093"	"267802000"
clocortolone pivalate	DB00838	Pruritus of genital organs	C0033777		Approved			CHEBI_59582	"21249"		"10037093"	"267802000"
fluocinolone acetonide	DB12553	Pruritus of genital organs	C0033777		Approved			CHEBI_5108	"25126"		"10037093"	"267802000"
ammonium lactate	DB06768	Pruritus of genital organs	C0033777		Approved				"215247"		"10037093"	"267802000"
flumetasone	DB00663	Pruritus of genital organs	C0033777		Approved			CHEBI_34764	"4458"		"10037093"	"267802000"
fludroxycortide	DB00846	Pruritus of genital organs	C0033777		Approved			CHEBI_5127	"4500"		"10037093"	"267802000"
cortisone acetate	DB01380	Pruritus of genital organs	C0033777		Approved			CHEBI_3897	"21655"		"10037093"	"267802000"
betamethasone benzoate	DB00443	Pruritus of genital organs	C0033777		Approved			CHEBI_3077	"1514"		"10037093"	"267802000"
methylprednisolone	DB00959	Pruritus of genital organs	C0033777		Approved			CHEBI_6888	"6902"		"10037093"	"267802000"
fluticasone propionate	DB13867	Pruritus of genital organs	C0033777		Approved			CHEBI_5134	"41126"		"10037093"	"267802000"
benzoyl peroxide	DB09096	Pruritus of genital organs	C0033777		Approved			CHEBI_82405	"1418"		"10037093"	"267802000"
mometasone furoate	DB00764	Pruritus of genital organs	C0033777		Approved			CHEBI_6970			"10037093"	"267802000"
amcinonide	DB00288	Pruritus of genital organs	C0033777		Approved			CHEBI_31199	"17652"		"10037093"	"267802000"
fluticasone propionate	DB00588	Pruritus of genital organs	C0033777		Approved			CHEBI_31441	"50121"		"10037093"	"267802000"
mometasone furoate	DB14512	Pruritus of genital organs	C0033777		Approved			CHEBI_47564	"30145"		"10037093"	"267802000"
	DB00051	Psoriasis	C0033860	NCT01704599	Terminated	Phase 1/Phase 2	side effect and poor clinical outcome		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0005083	"10037153"	"9014002"
hydrocortisone succinate	DB14545	Psoriasis	C0033860		Approved			CHEBI_31677	"21651"	MONDO_0005083	"10037153"	"9014002"
prednisone	DB00635	Psoriasis	C0033860		Approved			CHEBI_8382	"8640"	MONDO_0005083	"10037153"	"9014002"
methotrexate	DB00563	Psoriasis	C0033860	NCT00833053	Terminated	Phase 3	In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was discontinued due to low numbers of participants with suboptimal response.	CHEBI_44185	"6851"	MONDO_0005083	"10037153"	"9014002"
risankizumab	DB14762	Psoriasis	C0033860		Approved				"2166132|2166040"	MONDO_0005083	"10037153"	"9014002"
	DB00065	Psoriasis	C0033860	NCT00833053	Terminated	Phase 3	In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was discontinued due to low numbers of participants with suboptimal response.		"1790539|1927283|191831|2266523|2103476"	MONDO_0005083	"10037153"	"9014002"
hydrocortisone acetate	DB00741	Psoriasis	C0033860		Approved			CHEBI_17650	"5492"	MONDO_0005083	"10037153"	"9014002"
triamcinolone diacetate	DB00620	Psoriasis	C0033860		Approved			CHEBI_9667	"10759"	MONDO_0005083	"10037153"	"9014002"
ciclosporin	DB00091	Psoriasis	C0033860	NCT00377325	Withdrawn	Phase 2	Study terminated by the DSMB due to low recruitment	CHEBI_4031	"3008"	MONDO_0005083	"10037153"	"9014002"
triamcinolone acetonide	DB00620	Psoriasis	C0033860		Approved			CHEBI_9667	"10759"	MONDO_0005083	"10037153"	"9014002"
hydrocortisone succinate	DB00741	Psoriasis	C0033860		Approved			CHEBI_17650	"5492"	MONDO_0005083	"10037153"	"9014002"
dexamethasone phosphate	DB01234	Psoriasis	C0033860	NCT03979664	Withdrawn	Early Phase 1	FDA did not provide approval of the use of the drug for the study	CHEBI_68637	"3264"	MONDO_0005083	"10037153"	"9014002"
	DB00165	Psoriasis	C0033860	NCT01704599	Terminated	Phase 1/Phase 2	side effect and poor clinical outcome	CHEBI_16709	"42954|684879"	MONDO_0005083	"10037153"	"9014002"
triamcinolone	DB00620	Psoriasis	C0033860		Approved			CHEBI_9667	"10759"	MONDO_0005083	"10037153"	"9014002"
folic acid	DB00158	Psoriasis	C0033860	NCT01704599	Terminated	Phase 1/Phase 2	side effect and poor clinical outcome	CHEBI_27470	"62356|4511|202634"	MONDO_0005083	"10037153"	"9014002"
methotrexate	DB00563	Psoriasis	C0033860		Approved			CHEBI_44185	"6851"	MONDO_0005083	"10037153"	"9014002"
penamecillin	DB01053	Psoriasis	C0033860	NCT00427609	Terminated	Phase 2	Not enough enrollees to obtain a valid conclusion	CHEBI_18208	"7980"	MONDO_0005083	"10037153"	"9014002"
allantoin	DB11100	Psoriasis	C0033860		Approved			CHEBI_15676	"508"	MONDO_0005083	"10037153"	"9014002"
ammonia	DB11118	Psoriasis	C0033860		Approved			CHEBI_16134	"1299884"	MONDO_0005083	"10037153"	"9014002"
dexamethasone	DB01234	Psoriasis	C0033860		Approved			CHEBI_41879	"3264"	MONDO_0005083	"10037153"	"9014002"
liraglutide	DB06655	Psoriasis	C0033860	NCT02472717	Withdrawn	Phase 2		CHEBI_71193	"475968"	MONDO_0005083	"10037153"	"9014002"
hydrocortisone acetate	DB14539	Psoriasis	C0033860		Approved			CHEBI_17609	"27197"	MONDO_0005083	"10037153"	"9014002"
fluphenazine	DB00623	Psoriasis	C0033860	NCT00356200	Terminated	Phase 2	Enrollment criteria met	CHEBI_5123	"4496"	MONDO_0005083	"10037153"	"9014002"
betamethasone acetate	DB00443	Psoriasis	C0033860		Approved			CHEBI_3077	"1514"	MONDO_0005083	"10037153"	"9014002"
nivolumab	DB09035	Psoriasis	C0033860	NCT03656627	Terminated	Phase 1	low accrual		"1597876"	MONDO_0005083	"10037153"	"9014002"
tazarotene	DB00799	Psoriasis	C0033860		Approved			CHEBI_32184	"83947"	MONDO_0005083	"10037153"	"9014002"
erlotinib	DB00530	Psoriasis	C0033860	NCT01006096	Withdrawn	Phase 2	IND not obtained	CHEBI_114785	"337525"	MONDO_0005083	"10037153"	"9014002"
prednisolone	DB00860	Psoriasis	C0033860		Approved			CHEBI_8378	"8638"	MONDO_0005083	"10037153"	"9014002"
etofibrate	DB02701	Psoriasis	C0033860	NCT01368887	Suspended	Phase 2	Sponsor seeking additional financial support before starting the study	CHEBI_17154	"7405"	MONDO_0005083	"10037153"	"9014002"
	DB00627	Psoriasis	C0033860	NCT01368887	Suspended	Phase 2	Sponsor seeking additional financial support before starting the study	CHEBI_15940	"7393"	MONDO_0005083	"10037153"	"9014002"
cortisone acetate	DB01380	Psoriasis	C0033860		Approved			CHEBI_3897	"21655"	MONDO_0005083	"10037153"	"9014002"
hydrocortisone	DB00741	Psoriasis	C0033860		Approved			CHEBI_17650	"5492"	MONDO_0005083	"10037153"	"9014002"
methylprednisolone	DB00959	Psoriasis	C0033860		Approved			CHEBI_6888	"6902"	MONDO_0005083	"10037153"	"9014002"
atorvastatin	DB01076	Psoriasis	C0033860	NCT01527097	Withdrawn	Phase 3	We strongly feel that the ability to recruit the required number of patients is very low and thus decided to stop the study.	CHEBI_39548	"83367"	MONDO_0005083	"10037153"	"9014002"
fumaric acid	DB01677	Psoriasis	C0033860		Approved			CHEBI_18012	"25389"	MONDO_0005083	"10037153"	"9014002"
betamethasone	DB00443	Psoriasis	C0033860		Approved			CHEBI_3077	"1514"	MONDO_0005083	"10037153"	"9014002"
etretinate	DB00926	Psoriasis	C0033860		Approved			CHEBI_4913	"4182"	MONDO_0005083	"10037153"	"9014002"
etretinate	DB00459	Psoriasis	C0033860		Approved			CHEBI_50173	"16818"	MONDO_0005083	"10037153"	"9014002"
faropenem medoxil	DB05659	Respiratory Tract Infections	C0035243		Approved			CHEBI_134710		HP:0011947	"10062352"	"275498002"
anidulafungin	DB00362	Respiratory Tract Infections	C0035243	NCT00934934	Terminated	Phase 2	slow enrollment	CHEBI_55346	"341018"	HP:0011947	"10062352"	"275498002"
sitafloxacin	DB13261	Respiratory Tract Infections	C0035243		Approved			CHEBI_4304		HP:0011947	"10062352"	"275498002"
faropenem	DB12190	Respiratory Tract Infections	C0035243		Approved			CHEBI_51257		HP:0011947	"10062352"	"275498002"
azidocillin	DB08795	Respiratory Tract Infections	C0035243		Approved			CHEBI_51758		HP:0011947	"10062352"	"275498002"
azelastine	DB00972	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_2950	"18603"	MONDO_0006004	"10047145"	"8229003"
chlorphenamine	DB01114	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_52010	"221074|2400"	MONDO_0006004	"10047145"	"8229003"
cetirizine	DB00341	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_3561	"20610"	MONDO_0006004	"10047145"	"8229003"
ephedrine	DB01364	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_15407	"3966"	MONDO_0006004	"10047145"	"8229003"
methscopolamine	DB11315	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_135361	"89785"	MONDO_0006004	"10047145"	"8229003"
phenindamine	DB01619	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_8065	"33283"	MONDO_0006004	"10047145"	"8229003"
loratadine	DB00455	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_6538	"28889"	MONDO_0006004	"10047145"	"8229003"
doxylamine	DB00366	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_51380	"3642"	MONDO_0006004	"10047145"	"8229003"
tramazoline	DB13064	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_134893	"38453"	MONDO_0006004	"10047145"	"8229003"
pheniramine	DB01620	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_91591	"8132"	MONDO_0006004	"10047145"	"8229003"
phenylephrine	DB00388	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_8093	"8163"	MONDO_0006004	"10047145"	"8229003"
clemastine	DB00283	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_3738	"2578"	MONDO_0006004	"10047145"	"8229003"
phenylpropanolamine	DB00397	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_80680	"8175"	MONDO_0006004	"10047145"	"8229003"
dextromethorphan	DB00514	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_4470	"3289"	MONDO_0006004	"10047145"	"8229003"
beclometasone dipropionate	DB00394	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_3002	"1348"	MONDO_0006004	"10047145"	"8229003"
azatadine	DB00719	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_2946	"18600"	MONDO_0006004	"10047145"	"8229003"
phenyltoloxamine	DB11160	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_135047	"33408"	MONDO_0006004	"10047145"	"8229003"
acrivastine	DB09488	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_83168	"19959"	MONDO_0006004	"10047145"	"8229003"
dexchlorpheniramine	DB13679	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_4464	"22697"	MONDO_0006004	"10047145"	"8229003"
dexchlorpheniramine	DB09555	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_4465	"54828"	MONDO_0006004	"10047145"	"8229003"
diphenhydramine	DB01075	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_4636	"3498"	MONDO_0006004	"10047145"	"8229003"
diphenylpyraline	DB01146	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_59788	"23386"	MONDO_0006004	"10047145"	"8229003"
antazoline	DB08799	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_84115	"865"	MONDO_0006004	"10047145"	"8229003"
cyclizine	DB01176	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_3994	"2977"	MONDO_0006004	"10047145"	"8229003"
terfenadine	DB00342	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_9453	"42330"	MONDO_0006004	"10047145"	"8229003"
carbinoxamine	DB00748	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_3398	"20220"	MONDO_0006004	"10047145"	"8229003"
scopolamine	DB00747	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_16794	"9601|9603"	MONDO_0006004	"10047145"	"8229003"
pseudoephedrine	DB00852	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_51209	"8896"	MONDO_0006004	"10047145"	"8229003"
dexbrompheniramine	DB00405	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_59269	"22696|1767"	MONDO_0006004	"10047145"	"8229003"
brompheniramine	DB00835	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_3183	"1767"	MONDO_0006004	"10047145"	"8229003"
tripelennamine	DB00792	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_9741	"10847"	MONDO_0006004	"10047145"	"8229003"
promethazine	DB01069	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_8461	"8745"	MONDO_0006004	"10047145"	"8229003"
pentoxyverine	DB11186	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_94484	"20217"	MONDO_0006004	"10047145"	"8229003"
desloratadine	DB00967	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_291342	"275635"	MONDO_0006004	"10047145"	"8229003"
triprolidine	DB00427	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_84116	"10849"	MONDO_0006004	"10047145"	"8229003"
mepyramine	DB06691	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_6762	"9009"	MONDO_0006004	"10047145"	"8229003"
methscopolamine	DB00462	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_61276	"56092"	MONDO_0006004	"10047145"	"8229003"
chlorcyclizine	DB08936	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_94402	"2354"	MONDO_0006004	"10047145"	"8229003"
methapyrilene	DB04819	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_6820	"6822"	MONDO_0006004	"10047145"	"8229003"
pyrithione	DB06815	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_36584	"35100"	MONDO_0006004	"10047145"	"8229003"
clofedanol	DB04837	Rhinitis, Vasomotor	C0035460		Approved			CHEBI_135207	"21254"	MONDO_0006004	"10047145"	"8229003"
amphotericin B	DB00681	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_2682	"236594|732"	MONDO_0019359	"10039207"	"186772009"
minocycline	DB01017	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_50694	"6980"	MONDO_0019359	"10039207"	"186772009"
tetracycline	DB00759	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_27902	"10395"	MONDO_0019359	"10039207"	"186772009"
fusidic acid	DB02703	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_29013	"4608|113608"	MONDO_0019359	"10039207"	"186772009"
doxycycline	DB00254	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_50845	"1545992|3640"	MONDO_0019359	"10039207"	"186772009"
tetracycline	DB09550	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_27902	"2105975"	MONDO_0019359	"10039207"	"186772009"
oxytetracycline	DB00595	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_133011	"7821|1545999"	MONDO_0019359	"10039207"	"186772009"
meclocycline	DB13092	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_135772	"29418"	MONDO_0019359	"10039207"	"186772009"
demeclocycline	DB00618	Rocky Mountain Spotted Fever	C0035793		Approved			CHEBI_4392	"3154"	MONDO_0019359	"10039207"	"186772009"
benzathine benzylpenicillin	DB01053	Scarlet Fever	C0036285		Approved			CHEBI_18208	"7980"	MONDO_0005952	"10039587"	"30242009"
procaine benzylpenicillin	DB01053	Scarlet Fever	C0036285		Approved			CHEBI_18208	"7980"	MONDO_0005952	"10039587"	"30242009"
phenoxymethylpenicillin	DB00417	Scarlet Fever	C0036285		Approved			CHEBI_27446	"7984"	MONDO_0005952	"10039587"	"30242009"
benzylpenicillin	DB01053	Scarlet Fever	C0036285		Approved			CHEBI_18208	"7980"	MONDO_0005952	"10039587"	"30242009"
procaine benzylpenicillin	DB09320	Scarlet Fever	C0036285		Approved			CHEBI_52154	"7983"	MONDO_0005952	"10039587"	"30242009"
	DB01043	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_64312	"6719"	HP:0100753	"10039626"	"58214004"
molindone	DB01618	Schizophrenia	C0036341		Approved			CHEBI_6965	"7019"	HP:0100753	"10039626"	"58214004"
aripiprazole	DB01238	Schizophrenia	C0036341	NCT01509053	Terminated	Phase 3		CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
	DB00715	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_7936	"32937"	HP:0100753	"10039626"	"58214004"
	DB00230	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_64356	"187832"	HP:0100753	"10039626"	"58214004"
	DB06470	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_92875	"2372"	HP:0100753	"10039626"	"58214004"
	DB01069	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8461	"8745"	HP:0100753	"10039626"	"58214004"
	DB00726	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_9738	"10834"	HP:0100753	"10039626"	"58214004"
	DB00776	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_7824	"32624"	HP:0100753	"10039626"	"58214004"
	DB00842	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_7823	"7781"	HP:0100753	"10039626"	"58214004"
	DB00490	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_3223	"1827"	HP:0100753	"10039626"	"58214004"
	DB00734	Schizophrenia	C0036341	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
	DB01239	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_50931	"2406"	HP:0100753	"10039626"	"58214004"
fluphenazine enanthate	DB00623	Schizophrenia	C0036341		Approved			CHEBI_5123	"4496"	HP:0100753	"10039626"	"58214004"
zuclopenthixol	DB13841	Schizophrenia	C0036341		Approved			CHEBI_59115		HP:0100753	"10039626"	"58214004"
	DB01267	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_83804	"679314"	HP:0100753	"10039626"	"58214004"
	DB01174	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8069	"8134"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
	DB00564	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_3387	"2002"	HP:0100753	"10039626"	"58214004"
	DB01156	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_3219	"42347"	HP:0100753	"10039626"	"58214004"
iloperidone	DB04946	Schizophrenia	C0036341		Approved			CHEBI_65173	"73178"	HP:0100753	"10039626"	"58214004"
	DB12930	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_94614	"7674"	HP:0100753	"10039626"	"58214004"
	DB00334	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
	DB01224	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
	DB00215	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_77397	"2556"	HP:0100753	"10039626"	"58214004"
	DB01065	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_16796	"6711"	HP:0100753	"10039626"	"58214004"
	DB01403	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_6838	"6852"	HP:0100753	"10039626"	"58214004"
	DB00683	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_6931	"6960"	HP:0100753	"10039626"	"58214004"
risperidone	DB00734	Schizophrenia	C0036341	NCT01363349	Terminated	Phase 2/Phase 3	pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the trial would not meet the pre-specified primary efficacy endpoint.	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
	DB00234	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_135342	"60842"	HP:0100753	"10039626"	"58214004"
	DB06288	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_64045	"46303"	HP:0100753	"10039626"	"58214004"
	DB00540	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_7640	"7531"	HP:0100753	"10039626"	"58214004"
	DB06218	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_135939	"623400"	HP:0100753	"10039626"	"58214004"
	DB01558	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_31302	"1749"	HP:0100753	"10039626"	"58214004"
	DB00659	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_51041	"82819"	HP:0100753	"10039626"	"58214004"
ceftriaxone	DB01212	Schizophrenia	C0036341	NCT00591318	Terminated	Phase 1/Phase 2	Study was terminated after enrolling 12 patients due to poor enrollment rates	CHEBI_29007	"2193"	HP:0100753	"10039626"	"58214004"
fluphenazine decanoate	DB00623	Schizophrenia	C0036341		Approved			CHEBI_5123	"4496"	HP:0100753	"10039626"	"58214004"
	DB00850	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8028	"8076"	HP:0100753	"10039626"	"58214004"
	DB00810	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_3112	"1589"	HP:0100753	"10039626"	"58214004"
	DB00349	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_31413	"21241"	HP:0100753	"10039626"	"58214004"
naltrexone	DB00704	Schizophrenia	C0036341	NCT03132571	Terminated	Phase 2	Study discontinued due to funding.	CHEBI_7465	"7243"	HP:0100753	"10039626"	"58214004"
	DB00734	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
	DB12867	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_93403	"1373"	HP:0100753	"10039626"	"58214004"
tolcapone	DB00323	Schizophrenia	C0036341	NCT00044083	Terminated	Phase 2	Scientific Director request to use resources for other studies	CHEBI_63630	"72937"	HP:0100753	"10039626"	"58214004"
fluphenazine	DB00623	Schizophrenia	C0036341		Approved			CHEBI_5123	"4496"	HP:0100753	"10039626"	"58214004"
telmisartan	DB00966	Schizophrenia	C0036341	NCT03868839	Terminated	Phase 2	Lack of funding	CHEBI_9434	"73494"	HP:0100753	"10039626"	"58214004"
	DB01242	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_47780	"2597"	HP:0100753	"10039626"	"58214004"
	DB01068	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_3756	"2598"	HP:0100753	"10039626"	"58214004"
	DB00363	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_3766	"2626"	HP:0100753	"10039626"	"58214004"
	DB00829	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_49575	"3322"	HP:0100753	"10039626"	"58214004"
	DB01563	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_28142	"2344"	HP:0100753	"10039626"	"58214004"
	DB01075	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_4636	"3498"	HP:0100753	"10039626"	"58214004"
	DB00897	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_9674	"10767"	HP:0100753	"10039626"	"58214004"
	DB00425	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_10125	"39993"	HP:0100753	"10039626"	"58214004"
	DB00843	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_145499	"135447"	HP:0100753	"10039626"	"58214004"
	DB00934	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_6690	"6646"	HP:0100753	"10039626"	"58214004"
	DB06148	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_51137	"6929"	HP:0100753	"10039626"	"58214004"
	DB00656	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_9654	"10737"	HP:0100753	"10039626"	"58214004"
	DB00186	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_6539	"6470"	HP:0100753	"10039626"	"58214004"
	DB01142	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_4710	"3638"	HP:0100753	"10039626"	"58214004"
glycine	DB00145	Schizophrenia	C0036341	NCT00929370	Terminated	Phase 1	Study has now been terminated due to changes in project strategy. Current available data will be analysed and reported in a synoptic study report.	CHEBI_15428	"4919"	HP:0100753	"10039626"	"58214004"
	DB00476	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_36795	"72625"	HP:0100753	"10039626"	"58214004"
	DB00752	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_131512	"10734"	HP:0100753	"10039626"	"58214004"
zuclopenthixol	DB01624	Schizophrenia	C0036341		Approved			CHEBI_51364	"114176"	HP:0100753	"10039626"	"58214004"
	DB00285	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_9943	"39786"	HP:0100753	"10039626"	"58214004"
	DB01202	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_6437	"114477"	HP:0100753	"10039626"	"58214004"
aripiprazole	DB01238	Schizophrenia	C0036341	NCT01328093	Terminated	Phase 3	The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.	CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
	DB01238	Schizophrenia	C0036341	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341	NCT01129674	Terminated	Phase 2/Phase 3	The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.	CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
	DB01156	Schizophrenia	C0036341	NCT03132571	Terminated	Phase 2	Study discontinued due to funding.	CHEBI_3219	"42347"	HP:0100753	"10039626"	"58214004"
	DB01224	Schizophrenia	C0036341	NCT01129674	Terminated	Phase 2/Phase 3	The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341	NCT00988728	Withdrawn	Phase 2		CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
	DB00555	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_6367	"28439"	HP:0100753	"10039626"	"58214004"
	DB00734	Schizophrenia	C0036341	NCT01129674	Terminated	Phase 2/Phase 3	The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
	DB01238	Schizophrenia	C0036341	NCT01129674	Terminated	Phase 2/Phase 3	The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.	CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
aripiprazole	DB01238	Schizophrenia	C0036341	NCT00288353	Terminated	Phase 3	unable to secure additional funding	CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341		Approved			CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
lisdexamfetamine	DB01255	Schizophrenia	C0036341	NCT01738698	Terminated	Phase 3	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.	CHEBI_135925	"700810"	HP:0100753	"10039626"	"58214004"
	DB00363	Schizophrenia	C0036341	NCT00189995	Withdrawn	Phase 3		CHEBI_3766	"2626"	HP:0100753	"10039626"	"58214004"
	DB00458	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_47499	"5691"	HP:0100753	"10039626"	"58214004"
	DB01595	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_7581	"7440"	HP:0100753	"10039626"	"58214004"
ziprasidone	DB00246	Schizophrenia	C0036341		Approved			CHEBI_10119	"115698"	HP:0100753	"10039626"	"58214004"
haloperidol	DB00502	Schizophrenia	C0036341	NCT00189995	Withdrawn	Phase 3		CHEBI_5613	"5093"	HP:0100753	"10039626"	"58214004"
flupentixol	DB00875	Schizophrenia	C0036341		Approved			CHEBI_10454	"4495"	HP:0100753	"10039626"	"58214004"
	DB00313	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_39867	"11118|40254"	HP:0100753	"10039626"	"58214004"
sulpiride	DB00391	Schizophrenia	C0036341		Approved			CHEBI_32168	"10239"	HP:0100753	"10039626"	"58214004"
	DB00321	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_2666	"704"	HP:0100753	"10039626"	"58214004"
	DB00989	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8874	"183379"	HP:0100753	"10039626"	"58214004"
	DB00875	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_10454	"4495"	HP:0100753	"10039626"	"58214004"
	DB13841	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_59115		HP:0100753	"10039626"	"58214004"
perospirone	DB08922	Schizophrenia	C0036341		Approved			CHEBI_94777		HP:0100753	"10039626"	"58214004"
loxapine	DB00408	Schizophrenia	C0036341		Approved			CHEBI_50841	"6475"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341	NCT00734435	Terminated	Phase 2	Sponsor Decision- Financial Considerations	CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
colecalciferol	DB00169	Schizophrenia	C0036341	NCT02197286	Withdrawn	Phase 2	Personnel changes at study site.	CHEBI_28940	"2418"	HP:0100753	"10039626"	"58214004"
risperidone	DB00734	Schizophrenia	C0036341	NCT00645515	Terminated	Phase 3	This study was terminated on November 20, 2003 because of poor recruitment. This study was not terminated due to safety/efficacy.	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT00396214	Terminated	Phase 3	This trial discontinued on 2 May 2008 due to lack of enrolment	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
lisdexamfetamine	DB01255	Schizophrenia	C0036341	NCT01760993	Terminated	Phase 3	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.	CHEBI_135925	"700810"	HP:0100753	"10039626"	"58214004"
	DB00909	Schizophrenia	C0036341	NCT00734435	Terminated	Phase 2	Sponsor Decision- Financial Considerations	CHEBI_10127	"39998"	HP:0100753	"10039626"	"58214004"
risperidone	DB00734	Schizophrenia	C0036341	NCT00366704	Terminated	Phase 3		CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
	DB00391	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_32168	"10239"	HP:0100753	"10039626"	"58214004"
promazine	DB00420	Schizophrenia	C0036341		Approved			CHEBI_8459	"8742"	HP:0100753	"10039626"	"58214004"
nimodipine	DB00393	Schizophrenia	C0036341	NCT03671525	Suspended	Early Phase 1	Suspended because of COVID-19 pandemic.	CHEBI_7575	"7426"	HP:0100753	"10039626"	"58214004"
	DB00231	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_9435	"10355"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341		Approved			CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
	DB00690	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_5128	"4501"	HP:0100753	"10039626"	"58214004"
	DB00679	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_9566	"10502"	HP:0100753	"10039626"	"58214004"
perphenazine	DB00850	Schizophrenia	C0036341		Approved			CHEBI_8028	"8076"	HP:0100753	"10039626"	"58214004"
aripiprazole lauroxil	DB14185	Schizophrenia	C0036341		Approved			CHEBI_90930	"1673265"	HP:0100753	"10039626"	"58214004"
asenapine	DB06216	Schizophrenia	C0036341		Approved			CHEBI_71255	"784649"	HP:0100753	"10039626"	"58214004"
cariprazine	DB06016	Schizophrenia	C0036341		Approved			CHEBI_90933	"1667655"	HP:0100753	"10039626"	"58214004"
brexpiprazole	DB09128	Schizophrenia	C0036341		Approved			CHEBI_134716	"1658314"	HP:0100753	"10039626"	"58214004"
	DB00623	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_5123	"4496"	HP:0100753	"10039626"	"58214004"
	DB13025	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_94666	"10588"	HP:0100753	"10039626"	"58214004"
risperidone	DB00734	Schizophrenia	C0036341		Approved			CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
chlorpromazine	DB00477	Schizophrenia	C0036341		Approved			CHEBI_3647	"2403"	HP:0100753	"10039626"	"58214004"
	DB01267	Schizophrenia	C0036341	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_83804	"679314"	HP:0100753	"10039626"	"58214004"
pipotiazine palmitate	DB01621	Schizophrenia	C0036341		Approved			CHEBI_135769	"8348"	HP:0100753	"10039626"	"58214004"
samidorphan	DB12543	Schizophrenia	C0036341		Approved			CHEBI_177605	"2559612"	HP:0100753	"10039626"	"58214004"
prochlorperazine	DB00433	Schizophrenia	C0036341		Approved			CHEBI_8435	"8704"	HP:0100753	"10039626"	"58214004"
varenicline	DB01273	Schizophrenia	C0036341	NCT00743847	Withdrawn	Phase 2		CHEBI_84500	"591622"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT00457899	Terminated	Phase 3	Study terminated due to poor recruitment	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
perazine	DB12710	Schizophrenia	C0036341		Approved			CHEBI_59118	"8042"	HP:0100753	"10039626"	"58214004"
	DB00252	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8107	"8183"	HP:0100753	"10039626"	"58214004"
chlorprothixene	DB01239	Schizophrenia	C0036341		Approved			CHEBI_50931	"2406"	HP:0100753	"10039626"	"58214004"
	DB01238	Schizophrenia	C0036341	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
	DB00370	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_6950	"15996"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT00486798	Terminated	Phase 3	study was not ethically acceptable to continue and therefore it was finally stopped	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
	DB00734	Schizophrenia	C0036341	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
mosapramine	DB13676	Schizophrenia	C0036341		Approved			CHEBI_135775		HP:0100753	"10039626"	"58214004"
fluoxetine	DB00472	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_86990	"4493"	HP:0100753	"10039626"	"58214004"
	DB01224	Schizophrenia	C0036341	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
risperidone	DB00734	Schizophrenia	C0036341	NCT02538081	Withdrawn	Phase 1/Phase 2	Withdrawn	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
	DB00557	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_5818	"5553"	HP:0100753	"10039626"	"58214004"
lurasidone	DB08815	Schizophrenia	C0036341		Approved			CHEBI_70735	"1040028"	HP:0100753	"10039626"	"58214004"
	DB09210	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_32010	"8351"	HP:0100753	"10039626"	"58214004"
glycine	DB00145	Schizophrenia	C0036341	NCT00000372	Withdrawn	Phase 3	Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients with Schizophrenia, so the study was suspended.	CHEBI_15428	"4919"	HP:0100753	"10039626"	"58214004"
	DB00363	Schizophrenia	C0036341	NCT00000372	Withdrawn	Phase 3	Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients with Schizophrenia, so the study was suspended.	CHEBI_3766	"2626"	HP:0100753	"10039626"	"58214004"
aripiprazole	DB01238	Schizophrenia	C0036341	NCT02435836	Terminated	Phase 3	Study terminated when aripiprazole available commercially per protocol	CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
fluspirilene	DB04842	Schizophrenia	C0036341		Approved			CHEBI_93369	"4507"	HP:0100753	"10039626"	"58214004"
	DB00404	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_2611	"596"	HP:0100753	"10039626"	"58214004"
	DB00260	Schizophrenia	C0036341	NCT00000372	Withdrawn	Phase 3	Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients with Schizophrenia, so the study was suspended.	CHEBI_40009	"3007"	HP:0100753	"10039626"	"58214004"
memantine	DB01043	Schizophrenia	C0036341	NCT00148590	Terminated	Phase 3		CHEBI_64312	"6719"	HP:0100753	"10039626"	"58214004"
linagliptin	DB08882	Schizophrenia	C0036341	NCT01943019	Terminated	Phase 1	Inability to obtain patients	CHEBI_68610	"1100699"	HP:0100753	"10039626"	"58214004"
	DB00699	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_31902	"7398"	HP:0100753	"10039626"	"58214004"
oxypertine	DB13403	Schizophrenia	C0036341		Approved			CHEBI_31952		HP:0100753	"10039626"	"58214004"
modafinil	DB00745	Schizophrenia	C0036341	NCT00838227	Withdrawn	Phase 2	No source of funding to implement the study.	CHEBI_77585	"30125"	HP:0100753	"10039626"	"58214004"
lorazepam	DB00186	Schizophrenia	C0036341	NCT00364429	Terminated	Phase 1	terminated	CHEBI_6539	"6470"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341	NCT00440843	Withdrawn	Phase 3		CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
	DB00734	Schizophrenia	C0036341	NCT00364429	Terminated	Phase 1	terminated	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
lisdexamfetamine	DB01255	Schizophrenia	C0036341	NCT01760889	Terminated	Phase 3	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized	CHEBI_135925	"700810"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT00852631	Terminated	Phase 3	The study was prematurely terminated due to insufficient recruitment.	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
thiothixene	DB01623	Schizophrenia	C0036341		Approved			CHEBI_9571	"10510"	HP:0100753	"10039626"	"58214004"
papaverine	DB01113	Schizophrenia	C0036341	NCT01813955	Terminated	Early Phase 1	Patient recruitment insufficient	CHEBI_28241	"7895"	HP:0100753	"10039626"	"58214004"
	DB00502	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_5613	"5093"	HP:0100753	"10039626"	"58214004"
	DB00674	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_42944	"4637"	HP:0100753	"10039626"	"58214004"
oxytocin	DB00107	Schizophrenia	C0036341	NCT01712646	Terminated	Phase 1/Phase 2		CHEBI_7872	"7824"	HP:0100753	"10039626"	"58214004"
bexarotene	DB00307	Schizophrenia	C0036341	NCT00534898	Withdrawn	Phase 3	The study withdrawn due to lack financial support	CHEBI_50859	"233272"	HP:0100753	"10039626"	"58214004"
donepezil	DB00843	Schizophrenia	C0036341	NCT00206947	Terminated	Phase 2	No more funding	CHEBI_145499	"135447"	HP:0100753	"10039626"	"58214004"
	DB00996	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_42797	"25480"	HP:0100753	"10039626"	"58214004"
	DB01238	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
vorinostat	DB02546	Schizophrenia	C0036341	NCT03263533	Withdrawn	Early Phase 1	PIs were unable to recruit any participants	CHEBI_45716	"194337"	HP:0100753	"10039626"	"58214004"
dronabinol	DB00470	Schizophrenia	C0036341	NCT01832766	Terminated	Phase 1/Phase 2	Unable to find subjects with schizophrenia that were using only cannabis	CHEBI_66964	"10402"	HP:0100753	"10039626"	"58214004"
	DB01104	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_9123	"36437"	HP:0100753	"10039626"	"58214004"
paliperidone palmitate	DB01267	Schizophrenia	C0036341		Approved			CHEBI_83804	"679314"	HP:0100753	"10039626"	"58214004"
risperidone	DB00734	Schizophrenia	C0036341	NCT00768612	Withdrawn	Phase 2		CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
ondansetron	DB00904	Schizophrenia	C0036341	NCT02614586	Terminated	Phase 1		CHEBI_7773	"26225"	HP:0100753	"10039626"	"58214004"
	DB01043	Schizophrenia	C0036341	NCT02234752	Terminated	Phase 2	Funding no longer available and PI no longer working at the institution	CHEBI_64312	"6719"	HP:0100753	"10039626"	"58214004"
	DB00176	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_5138	"42355"	HP:0100753	"10039626"	"58214004"
	DB00273	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_63631	"38404"	HP:0100753	"10039626"	"58214004"
galantamine	DB00674	Schizophrenia	C0036341	NCT02234752	Terminated	Phase 2	Funding no longer available and PI no longer working at the institution	CHEBI_42944	"4637"	HP:0100753	"10039626"	"58214004"
blonanserin	DB09223	Schizophrenia	C0036341		Approved			CHEBI_31296		HP:0100753	"10039626"	"58214004"
rimonabant	DB06155	Schizophrenia	C0036341	NCT00547118	Terminated	Phase 2	Withdrawn due to medication withdrawal from the EMEA	CHEBI_34967		HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT00658645	Terminated	Phase 3	Interim analysis showed inadequate efficacy of bifeprunox	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
sertindole	DB06144	Schizophrenia	C0036341		Approved			CHEBI_9122	"41996"	HP:0100753	"10039626"	"58214004"
aripiprazole	DB01238	Schizophrenia	C0036341		Approved			CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
atomoxetine	DB00289	Schizophrenia	C0036341	NCT00216281	Terminated	Phase 3		CHEBI_127342	"38400"	HP:0100753	"10039626"	"58214004"
	DB00363	Schizophrenia	C0036341	NCT00216281	Terminated	Phase 3		CHEBI_3766	"2626"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341	NCT00211562	Terminated	Phase 3		CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
	DB00163	Schizophrenia	C0036341	NCT00211562	Terminated	Phase 3		CHEBI_18145	"11256|237099"	HP:0100753	"10039626"	"58214004"
	DB04842	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_93369	"4507"	HP:0100753	"10039626"	"58214004"
paliperidone	DB01267	Schizophrenia	C0036341		Approved			CHEBI_83804	"679314"	HP:0100753	"10039626"	"58214004"
	DB12710	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_59118	"8042"	HP:0100753	"10039626"	"58214004"
oxytocin	DB00107	Schizophrenia	C0036341	NCT02149823	Terminated	Phase 1	All study proceedings stopped prematurely due to Covid-19 restrictions for intranasal formulations	CHEBI_7872	"7824"	HP:0100753	"10039626"	"58214004"
trifluoperazine	DB00831	Schizophrenia	C0036341		Approved			CHEBI_45951	"10800"	HP:0100753	"10039626"	"58214004"
lumateperone	DB06077	Schizophrenia	C0036341		Approved				"2275602"	HP:0100753	"10039626"	"58214004"
risperidone	DB00734	Schizophrenia	C0036341	NCT02758067	Withdrawn	Phase 3	This study was withdrawn for administrative reasons. There were no safety concerns.	CHEBI_8871	"35636"	HP:0100753	"10039626"	"58214004"
haloperidol	DB00502	Schizophrenia	C0036341		Approved			CHEBI_5613	"5093"	HP:0100753	"10039626"	"58214004"
atomoxetine	DB00289	Schizophrenia	C0036341	NCT00548327	Terminated	Phase 2	The scientific director decided to terminate: low priority study with slow accrual	CHEBI_127342	"38400"	HP:0100753	"10039626"	"58214004"
	DB01100	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_8212	"8331"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT00704509	Terminated	Phase 3	Interim analysis showed inadequate efficacy of bifeprunox	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
aripiprazole	DB01238	Schizophrenia	C0036341	NCT01981811	Withdrawn	Phase 2	The trial was terminated because it was determined that the usability of the MIND1 System in the intended population was necessary before conducting this trial.	CHEBI_31236	"89013"	HP:0100753	"10039626"	"58214004"
olanzapine	DB00334	Schizophrenia	C0036341	NCT04518319	Suspended	Phase 2	The COVID-19 affects the recruitment of patients.	CHEBI_7735	"61381"	HP:0100753	"10039626"	"58214004"
mesoridazine	DB00933	Schizophrenia	C0036341		Approved			CHEBI_6780	"6779"	HP:0100753	"10039626"	"58214004"
quetiapine	DB01224	Schizophrenia	C0036341	NCT01071135	Terminated	Phase 3	Planned number of 30 subjects could not be recruited during recruitment phase.	CHEBI_8707	"51272"	HP:0100753	"10039626"	"58214004"
	DB01171	Schizophrenia	C0036341	NCT02374567	Terminated	Phase 3		CHEBI_83531	"30121"	HP:0100753	"10039626"	"58214004"
pyrithione	DB06815	Seborrheic dermatitis	C0036508		Approved			CHEBI_36584	"35100"	MONDO_0006608	"10039793"	"50563003"
prednicarbate	DB00860	Seborrheic dermatitis	C0036508		Approved			CHEBI_8378	"8638"	MONDO_0006608	"10039793"	"50563003"
prednicarbate	DB01130	Seborrheic dermatitis	C0036508		Approved			CHEBI_135791	"34369"	MONDO_0006608	"10039793"	"50563003"
diflorasone diacetate	DB00223	Seborrheic dermatitis	C0036508		Approved			CHEBI_59750	"91311"	MONDO_0006608	"10039793"	"50563003"
fluticasone propionate	DB13867	Seborrheic dermatitis	C0036508		Approved			CHEBI_5134	"41126"	MONDO_0006608	"10039793"	"50563003"
alclometasone dipropionate	DB00240	Seborrheic dermatitis	C0036508		Approved			CHEBI_53776	"108088"	MONDO_0006608	"10039793"	"50563003"
fluticasone propionate	DB00588	Seborrheic dermatitis	C0036508		Approved			CHEBI_31441	"50121"	MONDO_0006608	"10039793"	"50563003"
betamethasone valerate	DB00443	Seborrheic dermatitis	C0036508		Approved			CHEBI_3077	"1514"	MONDO_0006608	"10039793"	"50563003"
fluocinolone acetonide	DB12553	Seborrheic dermatitis	C0036508		Approved			CHEBI_5108	"25126"	MONDO_0006608	"10039793"	"50563003"
halcinonide	DB06786	Seborrheic dermatitis	C0036508		Approved			CHEBI_31663	"5084"	MONDO_0006608	"10039793"	"50563003"
betamethasone dipropionate	DB00443	Seborrheic dermatitis	C0036508		Approved			CHEBI_3077	"1514"	MONDO_0006608	"10039793"	"50563003"
salicylic acid	DB13860	Seborrheic dermatitis	C0036508		Approved			CHEBI_16914		MONDO_0006608	"10039793"	"50563003"
salicylic acid	DB14006	Seborrheic dermatitis	C0036508		Approved			CHEBI_16914	"20974"	MONDO_0006608	"10039793"	"50563003"
triamcinolone acetonide	DB00620	Seborrheic dermatitis	C0036508		Approved			CHEBI_9667	"10759"	MONDO_0006608	"10039793"	"50563003"
carbamide	DB03904	Seborrheic dermatitis	C0036508		Approved			CHEBI_16199	"11002"	MONDO_0006608	"10039793"	"50563003"
salicylic acid	DB00936	Seborrheic dermatitis	C0036508		Approved			CHEBI_16914	"9525"	MONDO_0006608	"10039793"	"50563003"
clobetasol propionate	DB11750	Seborrheic dermatitis	C0036508		Approved			CHEBI_205919	"2590"	MONDO_0006608	"10039793"	"50563003"
fluocinonide	DB01047	Seborrheic dermatitis	C0036508		Approved			CHEBI_5109	"4462"	MONDO_0006608	"10039793"	"50563003"
clobetasol propionate	DB01013	Seborrheic dermatitis	C0036508		Approved			CHEBI_31414	"21245"	MONDO_0006608	"10039793"	"50563003"
flumetasone	DB00663	Seborrheic dermatitis	C0036508		Approved			CHEBI_34764	"4458"	MONDO_0006608	"10039793"	"50563003"
ulobetasol propionate	DB00596	Seborrheic dermatitis	C0036508		Approved			CHEBI_135782	"41208"	MONDO_0006608	"10039793"	"50563003"
betamethasone	DB00443	Seborrheic dermatitis	C0036508		Approved			CHEBI_3077	"1514"	MONDO_0006608	"10039793"	"50563003"
fluocinonide	DB12553	Seborrheic dermatitis	C0036508		Approved			CHEBI_5108	"25126"	MONDO_0006608	"10039793"	"50563003"
desoximetasone	DB00547	Seborrheic dermatitis	C0036508		Approved			CHEBI_691037	"3255"	MONDO_0006608	"10039793"	"50563003"
hydrocortisone	DB00741	Seborrheic dermatitis	C0036508		Approved			CHEBI_17650	"5492"	MONDO_0006608	"10039793"	"50563003"
clocortolone pivalate	DB00838	Seborrheic dermatitis	C0036508		Approved			CHEBI_59582	"21249"	MONDO_0006608	"10039793"	"50563003"
climbazole	DB15580	Seborrheic dermatitis	C0036508		Approved			CHEBI_83719		MONDO_0006608	"10039793"	"50563003"
fluocinolone acetonide	DB00591	Seborrheic dermatitis	C0036508		Approved			CHEBI_31623	"4461"	MONDO_0006608	"10039793"	"50563003"
sulfacetamide	DB00634	Seborrheic dermatitis	C0036508		Approved			CHEBI_63845	"10169"	MONDO_0006608	"10039793"	"50563003"
ammonia	DB11118	Seborrheic dermatitis	C0036508		Approved			CHEBI_16134	"1299884"	MONDO_0006608	"10039793"	"50563003"
amcinonide	DB00288	Seborrheic dermatitis	C0036508		Approved			CHEBI_31199	"17652"	MONDO_0006608	"10039793"	"50563003"
ketoconazole	DB01026	Seborrheic dermatitis	C0036508		Approved			CHEBI_48339	"6135"	MONDO_0006608	"10039793"	"50563003"
ciclopirox	DB01188	Seborrheic dermatitis	C0036508		Approved			CHEBI_453011	"21090"	MONDO_0006608	"10039793"	"50563003"
benzoyl peroxide	DB09096	Seborrheic dermatitis	C0036508		Approved			CHEBI_82405	"1418"	MONDO_0006608	"10039793"	"50563003"
betamethasone benzoate	DB00443	Seborrheic dermatitis	C0036508		Approved			CHEBI_3077	"1514"	MONDO_0006608	"10039793"	"50563003"
desonide	DB01260	Seborrheic dermatitis	C0036508		Approved			CHEBI_204734	"3254"	MONDO_0006608	"10039793"	"50563003"
selenium sulfide	DB00971	Seborrheic dermatitis	C0036508		Approved			CHEBI_135934	"36345"	MONDO_0006608	"10039793"	"50563003"
dexamethasone	DB01234	Seborrheic dermatitis	C0036508		Approved			CHEBI_41879	"3264"	MONDO_0006608	"10039793"	"50563003"
methylprednisolone	DB00959	Seborrheic dermatitis	C0036508		Approved			CHEBI_6888	"6902"	MONDO_0006608	"10039793"	"50563003"
cortisone acetate	DB01380	Seborrheic dermatitis	C0036508		Approved			CHEBI_3897	"21655"	MONDO_0006608	"10039793"	"50563003"
prednisolone	DB00860	Seborrheic dermatitis	C0036508		Approved			CHEBI_8378	"8638"	MONDO_0006608	"10039793"	"50563003"
ammonium lactate	DB06768	Seborrheic dermatitis	C0036508		Approved				"215247"	MONDO_0006608	"10039793"	"50563003"
mometasone furoate	DB14512	Seborrheic dermatitis	C0036508		Approved			CHEBI_47564	"30145"	MONDO_0006608	"10039793"	"50563003"
levomenthol	DB14123	Seborrheic dermatitis	C0036508		Approved			CHEBI_25187	"6750|1430390"	MONDO_0006608	"10039793"	"50563003"
mometasone furoate	DB00764	Seborrheic dermatitis	C0036508		Approved			CHEBI_6970		MONDO_0006608	"10039793"	"50563003"
levomenthol	DB00825	Seborrheic dermatitis	C0036508		Approved			CHEBI_15409	"236388|6750"	MONDO_0006608	"10039793"	"50563003"
triamcinolone	DB00620	Seborrheic dermatitis	C0036508		Approved			CHEBI_9667	"10759"	MONDO_0006608	"10039793"	"50563003"
allantoin	DB11100	Seborrheic dermatitis	C0036508		Approved			CHEBI_15676	"508"	MONDO_0006608	"10039793"	"50563003"
chloroxine	DB01243	Seborrheic dermatitis	C0036508		Approved			CHEBI_59477	"20875"	MONDO_0006608	"10039793"	"50563003"
fludroxycortide	DB00846	Seborrheic dermatitis	C0036508		Approved			CHEBI_5127	"4500"	MONDO_0006608	"10039793"	"50563003"
fexofenadine	DB00950	Sneezing	C0037383		Approved			CHEBI_5050	"87636"	HP:0025095	"10041232"	"162367006"
phenindamine	DB01619	Sneezing	C0037383		Approved			CHEBI_8065	"33283"	HP:0025095	"10041232"	"162367006"
diphenylpyraline	DB01146	Sneezing	C0037383		Approved			CHEBI_59788	"23386"	HP:0025095	"10041232"	"162367006"
desloratadine	DB00967	Sneezing	C0037383		Approved			CHEBI_291342	"275635"	HP:0025095	"10041232"	"162367006"
mepyramine	DB06691	Sneezing	C0037383		Approved			CHEBI_6762	"9009"	HP:0025095	"10041232"	"162367006"
cyproheptadine	DB00434	Sneezing	C0037383		Approved			CHEBI_4046	"3013"	HP:0025095	"10041232"	"162367006"
cyclizine	DB01176	Sneezing	C0037383		Approved			CHEBI_3994	"2977"	HP:0025095	"10041232"	"162367006"
antazoline	DB08799	Sneezing	C0037383		Approved			CHEBI_84115	"865"	HP:0025095	"10041232"	"162367006"
pheniramine	DB01620	Sneezing	C0037383		Approved			CHEBI_91591	"8132"	HP:0025095	"10041232"	"162367006"
loratadine	DB00455	Sneezing	C0037383		Approved			CHEBI_6538	"28889"	HP:0025095	"10041232"	"162367006"
phenylephrine	DB00388	Sneezing	C0037383		Approved			CHEBI_8093	"8163"	HP:0025095	"10041232"	"162367006"
astemizole	DB00637	Sneezing	C0037383		Approved			CHEBI_2896	"42328"	HP:0025095	"10041232"	"162367006"
methdilazine	DB00902	Sneezing	C0037383		Approved			CHEBI_6823	"29648"	HP:0025095	"10041232"	"162367006"
cetirizine	DB00341	Sneezing	C0037383		Approved			CHEBI_3561	"20610"	HP:0025095	"10041232"	"162367006"
doxylamine	DB00366	Sneezing	C0037383		Approved			CHEBI_51380	"3642"	HP:0025095	"10041232"	"162367006"
tripelennamine	DB00792	Sneezing	C0037383		Approved			CHEBI_9741	"10847"	HP:0025095	"10041232"	"162367006"
codeine	DB00318	Sneezing	C0037383		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0025095	"10041232"	"162367006"
terfenadine	DB00342	Sneezing	C0037383		Approved			CHEBI_9453	"42330"	HP:0025095	"10041232"	"162367006"
tramazoline	DB13064	Sneezing	C0037383		Approved			CHEBI_134893	"38453"	HP:0025095	"10041232"	"162367006"
chlorcyclizine	DB08936	Sneezing	C0037383		Approved			CHEBI_94402	"2354"	HP:0025095	"10041232"	"162367006"
dextromethorphan	DB00514	Sneezing	C0037383		Approved			CHEBI_4470	"3289"	HP:0025095	"10041232"	"162367006"
chlorphenamine	DB01114	Sneezing	C0037383		Approved			CHEBI_52010	"221074|2400"	HP:0025095	"10041232"	"162367006"
azatadine	DB00719	Sneezing	C0037383		Approved			CHEBI_2946	"18600"	HP:0025095	"10041232"	"162367006"
clemastine	DB00283	Sneezing	C0037383		Approved			CHEBI_3738	"2578"	HP:0025095	"10041232"	"162367006"
alimemazine	DB01246	Sneezing	C0037383		Approved			CHEBI_9725	"10825"	HP:0025095	"10041232"	"162367006"
methapyrilene	DB04819	Sneezing	C0037383		Approved			CHEBI_6820	"6822"	HP:0025095	"10041232"	"162367006"
acrivastine	DB09488	Sneezing	C0037383		Approved			CHEBI_83168	"19959"	HP:0025095	"10041232"	"162367006"
promazine	DB00420	Sneezing	C0037383		Approved			CHEBI_8459	"8742"	HP:0025095	"10041232"	"162367006"
ephedrine	DB01364	Sneezing	C0037383		Approved			CHEBI_15407	"3966"	HP:0025095	"10041232"	"162367006"
quifenadine	DB13713	Sneezing	C0037383		Approved			CHEBI_134746		HP:0025095	"10041232"	"162367006"
phenylpropanolamine	DB00397	Sneezing	C0037383		Approved			CHEBI_80680	"8175"	HP:0025095	"10041232"	"162367006"
celecoxib	DB00482	Ankylosing spondylitis	C0038013		Approved			CHEBI_41423	"140587"		"10002556"	"9631008"
hydrocortisone succinate	DB00741	Ankylosing spondylitis	C0038013		Approved			CHEBI_17650	"5492"		"10002556"	"9631008"
sulindac	DB00605	Ankylosing spondylitis	C0038013		Approved			CHEBI_9352	"10237"		"10002556"	"9631008"
hydrocortisone succinate	DB14545	Ankylosing spondylitis	C0038013		Approved			CHEBI_31677	"21651"		"10002556"	"9631008"
betamethasone acetate	DB00443	Ankylosing spondylitis	C0038013		Approved			CHEBI_3077	"1514"		"10002556"	"9631008"
betamethasone	DB00443	Ankylosing spondylitis	C0038013		Approved			CHEBI_3077	"1514"		"10002556"	"9631008"
ixekizumab	DB11569	Ankylosing spondylitis	C0038013		Approved				"1745099"		"10002556"	"9631008"
hydrocortisone	DB00741	Ankylosing spondylitis	C0038013		Approved			CHEBI_17650	"5492"		"10002556"	"9631008"
indomethacin	DB00328	Ankylosing spondylitis	C0038013		Approved			CHEBI_49662	"5781"		"10002556"	"9631008"
azapropazone	DB07402	Ankylosing spondylitis	C0038013		Approved			CHEBI_38010	"1029"		"10002556"	"9631008"
dexamethasone	DB01234	Ankylosing spondylitis	C0038013		Approved			CHEBI_41879	"3264"		"10002556"	"9631008"
cortisone acetate	DB01380	Ankylosing spondylitis	C0038013		Approved			CHEBI_3897	"21655"		"10002556"	"9631008"
aceclofenac	DB06736	Ankylosing spondylitis	C0038013		Approved			CHEBI_31159	"16689"		"10002556"	"9631008"
etanercept	DB00005	Ankylosing spondylitis	C0038013		Approved			CHEBI_4875	"214555|2103480|2462511"		"10002556"	"9631008"
prednisone	DB00635	Ankylosing spondylitis	C0038013		Approved			CHEBI_8382	"8640"		"10002556"	"9631008"
infliximab	DB00065	Ankylosing spondylitis	C0038013		Approved				"1790539|1927283|191831|2266523|2103476"		"10002556"	"9631008"
certolizumab pegol	DB08904	Ankylosing spondylitis	C0038013		Approved				"709271"		"10002556"	"9631008"
golimumab	DB06674	Ankylosing spondylitis	C0038013		Approved				"819300"		"10002556"	"9631008"
methylprednisolone	DB00959	Ankylosing spondylitis	C0038013		Approved			CHEBI_6888	"6902"		"10002556"	"9631008"
acemetacin	DB13783	Ankylosing spondylitis	C0038013		Approved			CHEBI_31162	"16695"		"10002556"	"9631008"
hydrocortisone acetate	DB14539	Ankylosing spondylitis	C0038013		Approved			CHEBI_17609	"27197"		"10002556"	"9631008"
alclofenac	DB13167	Ankylosing spondylitis	C0038013		Approved			CHEBI_31183			"10002556"	"9631008"
secukinumab	DB09029	Ankylosing spondylitis	C0038013		Approved				"1599788"		"10002556"	"9631008"
naproxen	DB00788	Ankylosing spondylitis	C0038013		Approved			CHEBI_7476	"7258"		"10002556"	"9631008"
prednisolone	DB00860	Ankylosing spondylitis	C0038013		Approved			CHEBI_8378	"8638"		"10002556"	"9631008"
hydrocortisone acetate	DB00741	Ankylosing spondylitis	C0038013		Approved			CHEBI_17650	"5492"		"10002556"	"9631008"
triamcinolone	DB00620	Ankylosing spondylitis	C0038013		Approved			CHEBI_9667	"10759"		"10002556"	"9631008"
adalimumab	DB00051	Ankylosing spondylitis	C0038013		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"		"10002556"	"9631008"
diclofenac	DB00586	Ankylosing spondylitis	C0038013		Approved			CHEBI_47381	"3355"		"10002556"	"9631008"
triamcinolone acetonide	DB00620	Ankylosing spondylitis	C0038013		Approved			CHEBI_9667	"10759"		"10002556"	"9631008"
triamcinolone diacetate	DB00620	Ankylosing spondylitis	C0038013		Approved			CHEBI_9667	"10759"		"10002556"	"9631008"
sofalcone	DB05197	Gastric ulcer	C0038358		Approved			CHEBI_135732		MONDO_0001126	"10017822"	"397825006"
omeprazole	DB00338	Gastric ulcer	C0038358		Approved			CHEBI_77260	"7646"	MONDO_0001126	"10017822"	"397825006"
octatropine methylbromide	DB00517	Gastric ulcer	C0038358		Approved			CHEBI_2739	"17945"	MONDO_0001126	"10017822"	"397825006"
methanthelinium	DB00940	Gastric ulcer	C0038358		Approved			CHEBI_6817	"6821"	MONDO_0001126	"10017822"	"397825006"
chlorbenzoxamine	DB13788	Gastric ulcer	C0038358		Approved			CHEBI_135708		MONDO_0001126	"10017822"	"397825006"
mepenzolate	DB04843	Gastric ulcer	C0038358		Approved			CHEBI_94411	"107770"	MONDO_0001126	"10017822"	"397825006"
vonoprazan	DB11739	Gastric ulcer	C0038358		Approved			CHEBI_136048	"2604577"	MONDO_0001126	"10017822"	"397825006"
lansoprazole	DB00448	Gastric ulcer	C0038358		Approved			CHEBI_6375	"17128"	MONDO_0001126	"10017822"	"397825006"
revaprazan	DB16308	Gastric ulcer	C0038358		Approved			CHEBI_135529		MONDO_0001126	"10017822"	"397825006"
misoprostol	DB00929	Gastric ulcer	C0038358	NCT00594854	Terminated	Phase 3	POZEN agreed with FDA to stop study due to low and inadequate enrollment	CHEBI_63610	"42331"	MONDO_0001126	"10017822"	"397825006"
ranitidine	DB00863	Gastric ulcer	C0038358		Approved			CHEBI_92246	"9143"	MONDO_0001126	"10017822"	"397825006"
	DB00586	Gastric ulcer	C0038358	NCT00594854	Terminated	Phase 3	POZEN agreed with FDA to stop study due to low and inadequate enrollment	CHEBI_47381	"3355"	MONDO_0001126	"10017822"	"397825006"
roxatidine acetate	DB08806	Gastric ulcer	C0038358		Approved			CHEBI_94758		MONDO_0001126	"10017822"	"397825006"
tridihexethyl	DB00505	Gastric ulcer	C0038358		Approved			CHEBI_9701	"38617"	MONDO_0001126	"10017822"	"397825006"
cimetidine	DB00501	Gastric ulcer	C0038358		Approved			CHEBI_3699	"2541"	MONDO_0001126	"10017822"	"397825006"
famotidine	DB00927	Gastric ulcer	C0038358		Approved			CHEBI_4975	"4278"	MONDO_0001126	"10017822"	"397825006"
dexrabeprazole	DB13762	Gastric ulcer	C0038358		Approved			CHEBI_134729		MONDO_0001126	"10017822"	"397825006"
troxipide	DB13419	Gastric ulcer	C0038358		Approved			CHEBI_32271		MONDO_0001126	"10017822"	"397825006"
algeldrate	DB06723	Gastric ulcer	C0038358		Approved			CHEBI_33130	"612|81948"	MONDO_0001126	"10017822"	"397825006"
nizatidine	DB00585	Gastric ulcer	C0038358		Approved			CHEBI_7601	"42319"	MONDO_0001126	"10017822"	"397825006"
nimodipine	DB00393	Subarachnoid Hemorrhage	C0038525		Approved			CHEBI_7575	"7426"	MONDO_0005099	"10042316"	"21454007"
hydrocortisone	DB00741	Tendinitis	C0039503		Approved			CHEBI_17650	"5492"	MONDO_0004857	"10043255"	"34840004"
triamcinolone acetonide	DB00620	Tendinitis	C0039503		Approved			CHEBI_9667	"10759"	MONDO_0004857	"10043255"	"34840004"
indomethacin	DB00328	Tendinitis	C0039503		Approved			CHEBI_49662	"5781"	MONDO_0004857	"10043255"	"34840004"
triamcinolone	DB00620	Tendinitis	C0039503		Approved			CHEBI_9667	"10759"	MONDO_0004857	"10043255"	"34840004"
hydrocortisone acetate	DB00741	Tendinitis	C0039503		Approved			CHEBI_17650	"5492"	MONDO_0004857	"10043255"	"34840004"
sulindac	DB00605	Tendinitis	C0039503		Approved			CHEBI_9352	"10237"	MONDO_0004857	"10043255"	"34840004"
cortisone acetate	DB01380	Tendinitis	C0039503		Approved			CHEBI_3897	"21655"	MONDO_0004857	"10043255"	"34840004"
naproxen	DB00788	Tendinitis	C0039503		Approved			CHEBI_7476	"7258"	MONDO_0004857	"10043255"	"34840004"
betamethasone acetate	DB00443	Tendinitis	C0039503		Approved			CHEBI_3077	"1514"	MONDO_0004857	"10043255"	"34840004"
hydrocortisone succinate	DB14545	Tendinitis	C0039503		Approved			CHEBI_31677	"21651"	MONDO_0004857	"10043255"	"34840004"
hydrocortisone acetate	DB14539	Tendinitis	C0039503		Approved			CHEBI_17609	"27197"	MONDO_0004857	"10043255"	"34840004"
triamcinolone diacetate	DB00620	Tendinitis	C0039503		Approved			CHEBI_9667	"10759"	MONDO_0004857	"10043255"	"34840004"
betamethasone	DB00443	Tendinitis	C0039503		Approved			CHEBI_3077	"1514"	MONDO_0004857	"10043255"	"34840004"
hydrocortisone succinate	DB00741	Tendinitis	C0039503		Approved			CHEBI_17650	"5492"	MONDO_0004857	"10043255"	"34840004"
methylprednisolone	DB00959	Tendinitis	C0039503		Approved			CHEBI_6888	"6902"	MONDO_0004857	"10043255"	"34840004"
prednisolone	DB00860	Tendinitis	C0039503		Approved			CHEBI_8378	"8638"	MONDO_0004857	"10043255"	"34840004"
thiamine	DB00152	Thiamine Deficiency	C0039841	NCT02974257	Terminated	Phase 2	Study stopped early after consultation with DSMB	CHEBI_18385	"10454"	HP:0100503	"10047601"	"399357009"
thiamine	DB00152	Thiamine Deficiency	C0039841		Approved			CHEBI_18385	"10454"	HP:0100503	"10047601"	"399357009"
sulconazole	DB06820	Tinea Versicolor	C0040262		Approved			CHEBI_77776	"37319"	MONDO_0005915	"10056131"	"56454009"
clotrimazole	DB00257	Tinea Versicolor	C0040262		Approved			CHEBI_3764	"2623"	MONDO_0005915	"10056131"	"56454009"
carbamide	DB03904	Tinea Versicolor	C0040262		Approved			CHEBI_16199	"11002"	MONDO_0005915	"10056131"	"56454009"
pyrithione	DB06815	Tinea Versicolor	C0040262		Approved			CHEBI_36584	"35100"	MONDO_0005915	"10056131"	"56454009"
omoconazole	DB13684	Tinea Versicolor	C0040262		Approved			CHEBI_135685		MONDO_0005915	"10056131"	"56454009"
zinc oxide	DB09321	Tinea Versicolor	C0040262		Approved			CHEBI_36560	"11423"	MONDO_0005915	"10056131"	"56454009"
tolnaftate	DB00525	Tinea Versicolor	C0040262		Approved			CHEBI_9620	"10637"	MONDO_0005915	"10056131"	"56454009"
levomenthol	DB00825	Tinea Versicolor	C0040262		Approved			CHEBI_15409	"236388|6750"	MONDO_0005915	"10056131"	"56454009"
levomenthol	DB14123	Tinea Versicolor	C0040262		Approved			CHEBI_25187	"6750|1430390"	MONDO_0005915	"10056131"	"56454009"
miconazole	DB01110	Tinea Versicolor	C0040262		Approved			CHEBI_82892	"6932"	MONDO_0005915	"10056131"	"56454009"
selenium sulfide	DB00971	Tinea Versicolor	C0040262		Approved			CHEBI_135934	"36345"	MONDO_0005915	"10056131"	"56454009"
ketoconazole	DB01026	Tinea Versicolor	C0040262		Approved			CHEBI_48339	"6135"	MONDO_0005915	"10056131"	"56454009"
oxiconazole	DB00239	Tinea Versicolor	C0040262		Approved			CHEBI_7825	"32638"	MONDO_0005915	"10056131"	"56454009"
econazole	DB01127	Tinea Versicolor	C0040262		Approved			CHEBI_82873	"3743"	MONDO_0005915	"10056131"	"56454009"
butenafine	DB01091	Tinea Versicolor	C0040262		Approved			CHEBI_3238	"47461"	MONDO_0005915	"10056131"	"56454009"
ciclopirox	DB01188	Tinea Versicolor	C0040262		Approved			CHEBI_453011	"21090"	MONDO_0005915	"10056131"	"56454009"
terbinafine	DB00857	Tinea Versicolor	C0040262		Approved			CHEBI_9448	"37801"	MONDO_0005915	"10056131"	"56454009"
thiabendazole	DB00730	Toxocariasis	C0040553		Approved			CHEBI_45979	"10450"	MONDO_0005988	"10044269"	"406619001"
amoxicillin	DB01060	Urinary tract infection	C0042029		Approved			CHEBI_2676	"1297882|723"		"10046571"	"68566005"
erythromycin ethyl succinate	DB00199	Urinary tract infection	C0042029		Approved			CHEBI_42355	"4053"		"10046571"	"68566005"
fosfomycin	DB00828	Urinary tract infection	C0042029		Approved			CHEBI_28915	"4550"		"10046571"	"68566005"
cefaclor	DB00833	Urinary tract infection	C0042029		Approved			CHEBI_3478	"1450910|2176"		"10046571"	"68566005"
alatrofloxacin	DB09335	Urinary tract infection	C0042029		Approved			CHEBI_135829	"141440"		"10046571"	"68566005"
enoxacin	DB00467	Urinary tract infection	C0042029		Approved			CHEBI_157175	"3925"		"10046571"	"68566005"
fusidic acid	DB02703	Urinary tract infection	C0042029		Approved			CHEBI_29013	"4608|113608"		"10046571"	"68566005"
cefadroxil	DB01140	Urinary tract infection	C0042029		Approved			CHEBI_3479	"1545975|2177"		"10046571"	"68566005"
cefamandole	DB01326	Urinary tract infection	C0042029		Approved			CHEBI_3480	"2178"		"10046571"	"68566005"
plazomicin	DB12615	Urinary tract infection	C0042029		Approved				"2049549"		"10046571"	"68566005"
relebactam	DB12377	Urinary tract infection	C0042029		Approved				"2184137|2268500"		"10046571"	"68566005"
cefiderocol	DB14879	Urinary tract infection	C0042029		Approved			CHEBI_140376	"2265702"		"10046571"	"68566005"
cefixime	DB00671	Urinary tract infection	C0042029		Approved			CHEBI_472657	"25033|1546021"		"10046571"	"68566005"
cefmetazole	DB00274	Urinary tract infection	C0042029		Approved			CHEBI_3489	"2182"		"10046571"	"68566005"
cefonicid	DB01328	Urinary tract infection	C0042029		Approved			CHEBI_3491	"2183"		"10046571"	"68566005"
kanamycin	DB01172	Urinary tract infection	C0042029		Approved			CHEBI_17630	"6099|1727573"		"10046571"	"68566005"
lomefloxacin	DB00978	Urinary tract infection	C0042029		Approved			CHEBI_116278	"28872"		"10046571"	"68566005"
loracarbef	DB00447	Urinary tract infection	C0042029		Approved			CHEBI_47544	"28981"		"10046571"	"68566005"
mandelic acid	DB13218	Urinary tract infection	C0042029		Approved			CHEBI_35825	"29256"		"10046571"	"68566005"
mezlocillin	DB00948	Urinary tract infection	C0042029		Approved			CHEBI_6919	"6927"		"10046571"	"68566005"
minocycline	DB01017	Urinary tract infection	C0042029		Approved			CHEBI_50694	"6980"		"10046571"	"68566005"
nifurtoinol	DB13730	Urinary tract infection	C0042029		Approved			CHEBI_88255			"10046571"	"68566005"
norfloxacin	DB01059	Urinary tract infection	C0042029		Approved			CHEBI_100246	"7517"		"10046571"	"68566005"
ceftolozane	DB09050	Urinary tract infection	C0042029		Approved			CHEBI_134719	"1597609"		"10046571"	"68566005"
carbenicillin	DB00578	Urinary tract infection	C0042029		Approved			CHEBI_3393	"2015"		"10046571"	"68566005"
amphotericin B	DB00681	Urinary tract infection	C0042029		Approved			CHEBI_2682	"236594|732"		"10046571"	"68566005"
ampicillin	DB00415	Urinary tract infection	C0042029		Approved			CHEBI_28971	"733|221058"		"10046571"	"68566005"
ofloxacin	DB01165	Urinary tract infection	C0042029		Approved			CHEBI_7731	"7623"		"10046571"	"68566005"
oxytetracycline	DB00595	Urinary tract infection	C0042029		Approved			CHEBI_133011	"7821|1545999"		"10046571"	"68566005"
furazidin	DB13475	Urinary tract infection	C0042029		Approved			CHEBI_131714			"10046571"	"68566005"
piperacillin	DB00319	Urinary tract infection	C0042029		Approved			CHEBI_8232	"1546000|8339"		"10046571"	"68566005"
ceftizoxime	DB01332	Urinary tract infection	C0042029		Approved			CHEBI_553473	"2192"		"10046571"	"68566005"
demeclocycline	DB00618	Urinary tract infection	C0042029		Approved			CHEBI_4392	"3154"		"10046571"	"68566005"
sitafloxacin	DB13261	Urinary tract infection	C0042029		Approved			CHEBI_4304			"10046571"	"68566005"
sulfafurazole	DB00263	Urinary tract infection	C0042029		Approved			CHEBI_102484	"10207"		"10046571"	"68566005"
tetracycline	DB00759	Urinary tract infection	C0042029		Approved			CHEBI_27902	"10395"		"10046571"	"68566005"
tetracycline	DB09550	Urinary tract infection	C0042029		Approved			CHEBI_27902	"2105975"		"10046571"	"68566005"
ticarcillin	DB01607	Urinary tract infection	C0042029		Approved			CHEBI_9587	"10591"		"10046571"	"68566005"
sodium phosphate, monobasic	DB09449	Urinary tract infection	C0042029		Approved			CHEBI_37585	"36709|235496|314838|349753"		"10046571"	"68566005"
trimethoprim	DB00440	Urinary tract infection	C0042029		Approved			CHEBI_45924	"10829"		"10046571"	"68566005"
azlocillin	DB01061	Urinary tract infection	C0042029		Approved			CHEBI_2956	"1266"		"10046571"	"68566005"
trovafloxacin	DB00685	Urinary tract infection	C0042029		Approved			CHEBI_9763	"115552"		"10046571"	"68566005"
aztreonam	DB00355	Urinary tract infection	C0042029		Approved			CHEBI_161680	"1272"		"10046571"	"68566005"
bacampicillin	DB01602	Urinary tract infection	C0042029		Approved			CHEBI_2968	"18687"		"10046571"	"68566005"
clavulanic acid	DB00766	Urinary tract infection	C0042029		Approved			CHEBI_48947	"48203|21216"		"10046571"	"68566005"
cefalotin	DB00456	Urinary tract infection	C0042029		Approved			CHEBI_124991	"2236"		"10046571"	"68566005"
meclocycline	DB13092	Urinary tract infection	C0042029		Approved			CHEBI_135772	"29418"		"10046571"	"68566005"
methenamine	DB06799	Urinary tract infection	C0042029		Approved			CHEBI_6824	"6832"		"10046571"	"68566005"
cefapirin	DB01139	Urinary tract infection	C0042029		Approved			CHEBI_554446	"2238"		"10046571"	"68566005"
cinoxacin	DB00827	Urinary tract infection	C0042029		Approved			CHEBI_3716	"2550"		"10046571"	"68566005"
cefradine	DB01333	Urinary tract infection	C0042029		Approved			CHEBI_3547	"2239"		"10046571"	"68566005"
acetohydroxamic acid	DB00551	Urinary tract infection	C0042029		Approved			CHEBI_49029	"16728"		"10046571"	"68566005"
cyclacillin	DB01000	Urinary tract infection	C0042029		Approved			CHEBI_31444	"2968"		"10046571"	"68566005"
pheniramine	DB01620	Urticaria	C0042109		Approved			CHEBI_91591	"8132"	MONDO_0005492	"10046735"	"126485001"
promazine	DB00420	Urticaria	C0042109		Approved			CHEBI_8459	"8742"	MONDO_0005492	"10046735"	"126485001"
promethazine	DB01069	Urticaria	C0042109		Approved			CHEBI_8461	"8745"	MONDO_0005492	"10046735"	"126485001"
phenindamine	DB01619	Urticaria	C0042109		Approved			CHEBI_8065	"33283"	MONDO_0005492	"10046735"	"126485001"
methapyrilene	DB04819	Urticaria	C0042109		Approved			CHEBI_6820	"6822"	MONDO_0005492	"10046735"	"126485001"
bilastine	DB11591	Urticaria	C0042109		Approved			CHEBI_135954		MONDO_0005492	"10046735"	"126485001"
mepyramine	DB06691	Urticaria	C0042109		Approved			CHEBI_6762	"9009"	MONDO_0005492	"10046735"	"126485001"
emedastine	DB01084	Urticaria	C0042109		Approved			CHEBI_4779	"28144"	MONDO_0005492	"10046735"	"126485001"
dexchlorpheniramine	DB09555	Urticaria	C0042109		Approved			CHEBI_4465	"54828"	MONDO_0005492	"10046735"	"126485001"
carbinoxamine	DB00748	Urticaria	C0042109		Approved			CHEBI_3398	"20220"	MONDO_0005492	"10046735"	"126485001"
doxylamine	DB00366	Urticaria	C0042109		Approved			CHEBI_51380	"3642"	MONDO_0005492	"10046735"	"126485001"
azatadine	DB00719	Urticaria	C0042109		Approved			CHEBI_2946	"18600"	MONDO_0005492	"10046735"	"126485001"
bamipine	DB13489	Urticaria	C0042109		Approved			CHEBI_135165		MONDO_0005492	"10046735"	"126485001"
methotrexate	DB00563	Urticaria	C0042109	NCT00189878	Terminated	Phase 2	unable to recruit	CHEBI_44185	"6851"	MONDO_0005492	"10046735"	"126485001"
diphenylpyraline	DB01146	Urticaria	C0042109		Approved			CHEBI_59788	"23386"	MONDO_0005492	"10046735"	"126485001"
dexchlorpheniramine	DB13679	Urticaria	C0042109		Approved			CHEBI_4464	"22697"	MONDO_0005492	"10046735"	"126485001"
antazoline	DB08799	Urticaria	C0042109		Approved			CHEBI_84115	"865"	MONDO_0005492	"10046735"	"126485001"
alimemazine	DB01246	Urticaria	C0042109		Approved			CHEBI_9725	"10825"	MONDO_0005492	"10046735"	"126485001"
hydroxyzine	DB00557	Urticaria	C0042109		Approved			CHEBI_5818	"5553"	MONDO_0005492	"10046735"	"126485001"
tripelennamine	DB00792	Urticaria	C0042109		Approved			CHEBI_9741	"10847"	MONDO_0005492	"10046735"	"126485001"
brompheniramine	DB00835	Urticaria	C0042109		Approved			CHEBI_3183	"1767"	MONDO_0005492	"10046735"	"126485001"
triprolidine	DB00427	Urticaria	C0042109		Approved			CHEBI_84116	"10849"	MONDO_0005492	"10046735"	"126485001"
cyproheptadine	DB00434	Urticaria	C0042109		Approved			CHEBI_4046	"3013"	MONDO_0005492	"10046735"	"126485001"
clemastine	DB00283	Urticaria	C0042109		Approved			CHEBI_3738	"2578"	MONDO_0005492	"10046735"	"126485001"
rupatadine	DB11614	Urticaria	C0042109		Approved			CHEBI_135673		MONDO_0005492	"10046735"	"126485001"
phenyltoloxamine	DB11160	Urticaria	C0042109		Approved			CHEBI_135047	"33408"	MONDO_0005492	"10046735"	"126485001"
dexbrompheniramine	DB00405	Urticaria	C0042109		Approved			CHEBI_59269	"22696|1767"	MONDO_0005492	"10046735"	"126485001"
chlorphenamine	DB01114	Urticaria	C0042109		Approved			CHEBI_52010	"221074|2400"	MONDO_0005492	"10046735"	"126485001"
methdilazine	DB00902	Urticaria	C0042109		Approved			CHEBI_6823	"29648"	MONDO_0005492	"10046735"	"126485001"
rituximab	DB00073	Urticaria	C0042109	NCT00216762	Terminated	Phase 1/Phase 2	Full Clinical Hold		"2273510|2472325|121191|2105824"	MONDO_0005492	"10046735"	"126485001"
prednisolone	DB00860	Uveitis	C0042164		Approved			CHEBI_8378	"8638"	MONDO_0020283	"10046851"	"128473001"
triamcinolone	DB00620	Uveitis	C0042164		Approved			CHEBI_9667	"10759"	MONDO_0020283	"10046851"	"128473001"
ustekinumab	DB05679	Uveitis	C0042164	NCT01647152	Withdrawn	Phase 1/Phase 2			"847083"	MONDO_0020283	"10046851"	"128473001"
rimexolone	DB00896	Uveitis	C0042164		Approved			CHEBI_135566	"55681"	MONDO_0020283	"10046851"	"128473001"
scopolamine	DB00747	Uveitis	C0042164		Approved			CHEBI_16794	"9601|9603"	MONDO_0020283	"10046851"	"128473001"
prednisolone sodium phosphate	DB14631	Uveitis	C0042164		Approved			CHEBI_145705	"34374"	MONDO_0020283	"10046851"	"128473001"
triamcinolone	DB00620	Uveitis	C0042164	NCT01095809	Terminated	Phase 3	New intraocular steroid in the market. Recruitment no longer ethical.	CHEBI_9667	"10759"	MONDO_0020283	"10046851"	"128473001"
prednisolone sodium phosphate	DB00860	Uveitis	C0042164		Approved			CHEBI_8378	"8638"	MONDO_0020283	"10046851"	"128473001"
loteprednol etabonate	DB14596	Uveitis	C0042164		Approved			CHEBI_31784	"52177"	MONDO_0020283	"10046851"	"128473001"
loteprednol etabonate	DB00873	Uveitis	C0042164		Approved			CHEBI_50848	"237027"	MONDO_0020283	"10046851"	"128473001"
	DB00112	Uveitis	C0042164	NCT01095809	Terminated	Phase 3	New intraocular steroid in the market. Recruitment no longer ethical.		"253337|2046138"	MONDO_0020283	"10046851"	"128473001"
Polymyxin B	DB00781	Uveitis	C0042164		Approved				"8536"	MONDO_0020283	"10046851"	"128473001"
triamcinolone	DB00620	Uveitis	C0042164	NCT00846625	Withdrawn	Phase 2	Insufficient enrollment (no subjects were enrolled)	CHEBI_9667	"10759"	MONDO_0020283	"10046851"	"128473001"
neomycin	DB00994	Uveitis	C0042164		Approved			CHEBI_7507	"7299"	MONDO_0020283	"10046851"	"128473001"
	DB01270	Uveitis	C0042164	NCT00846625	Withdrawn	Phase 2	Insufficient enrollment (no subjects were enrolled)		"595060"	MONDO_0020283	"10046851"	"128473001"
medrysone	DB00253	Uveitis	C0042164		Approved			CHEBI_34829	"29439"	MONDO_0020283	"10046851"	"128473001"
fusidic acid	DB02703	Uveitis	C0042164		Approved			CHEBI_29013	"4608|113608"	MONDO_0020283	"10046851"	"128473001"
benzalkonium	DB13282	Uveitis	C0042164		Approved			CHEBI_188978		MONDO_0020283	"10046851"	"128473001"
benzalkonium	DB11105	Uveitis	C0042164		Approved			CHEBI_188978	"1378"	MONDO_0020283	"10046851"	"128473001"
sulfacetamide	DB00634	Uveitis	C0042164		Approved			CHEBI_63845	"10169"	MONDO_0020283	"10046851"	"128473001"
fluorometholone acetate	DB00324	Uveitis	C0042164		Approved			CHEBI_31625	"4491"	MONDO_0020283	"10046851"	"128473001"
prednisolone acetate	DB00860	Uveitis	C0042164		Approved			CHEBI_8378	"8638"	MONDO_0020283	"10046851"	"128473001"
tobramycin	DB00684	Uveitis	C0042164		Approved			CHEBI_28864	"10627"	MONDO_0020283	"10046851"	"128473001"
fluorometholone	DB00324	Uveitis	C0042164		Approved			CHEBI_31625	"4491"	MONDO_0020283	"10046851"	"128473001"
prednisolone acetate	DB15566	Uveitis	C0042164		Approved			CHEBI_8380	"34372"	MONDO_0020283	"10046851"	"128473001"
triamcinolone acetonide	DB00620	Uveitis	C0042164		Approved			CHEBI_9667	"10759"	MONDO_0020283	"10046851"	"128473001"
dexamethasone	DB01234	Uveitis	C0042164		Approved			CHEBI_41879	"3264"	MONDO_0020283	"10046851"	"128473001"
cortisone acetate	DB01380	Uveitis	C0042164		Approved			CHEBI_3897	"21655"	MONDO_0020283	"10046851"	"128473001"
homatropine	DB11181	Uveitis	C0042164		Approved			CHEBI_5747	"27084"	MONDO_0020283	"10046851"	"128473001"
hydrocortisone	DB00741	Uveitis	C0042164		Approved			CHEBI_17650	"5492"	MONDO_0020283	"10046851"	"128473001"
fondaparinux	DB00569	Venous Thrombosis	C0042487	NCT00539942	Terminated	Phase 3	Problems with accrual	CHEBI_61033	"321208"	HP:0004936	"10047249"	"111293003"
acenocoumarol	DB01418	Venous Thrombosis	C0042487		Approved			CHEBI_53766	"154"	HP:0004936	"10047249"	"111293003"
rosuvastatin	DB01098	Venous Thrombosis	C0042487	NCT01164540	Withdrawn	Phase 3	Due to discussion regarding the design of the study.	CHEBI_38545	"301542"	HP:0004936	"10047249"	"111293003"
pilocarpine	DB01085	Xerostomia	C0043352		Approved			CHEBI_8207	"8328"	HP:0000217	"10013781"	"56893005"
flumetasone	DB00663	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_34764	"4458"	HP:0012192	"10011677"	"400122007"
triamcinolone acetonide	DB00620	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_9667	"10759"	HP:0012192	"10011677"	"400122007"
fluocinonide	DB12553	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_5108	"25126"	HP:0012192	"10011677"	"400122007"
mometasone furoate	DB14512	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_47564	"30145"	HP:0012192	"10011677"	"400122007"
fludroxycortide	DB00846	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_5127	"4500"	HP:0012192	"10011677"	"400122007"
vorinostat	DB02546	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_45716	"194337"	HP:0012192	"10011677"	"400122007"
ulobetasol propionate	DB00596	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_135782	"41208"	HP:0012192	"10011677"	"400122007"
amcinonide	DB00288	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_31199	"17652"	HP:0012192	"10011677"	"400122007"
prednicarbate	DB00860	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_8378	"8638"	HP:0012192	"10011677"	"400122007"
fluticasone propionate	DB13867	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_5134	"41126"	HP:0012192	"10011677"	"400122007"
prednicarbate	DB01130	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_135791	"34369"	HP:0012192	"10011677"	"400122007"
desonide	DB01260	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_204734	"3254"	HP:0012192	"10011677"	"400122007"
fluocinonide	DB01047	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_5109	"4462"	HP:0012192	"10011677"	"400122007"
panobinostat	DB06603	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_85990	"1603350"	HP:0012192	"10011677"	"400122007"
denileukin diftitox	DB00004	Lymphoma, T-Cell, Cutaneous	C0079773		Approved				"214470"	HP:0012192	"10011677"	"400122007"
prednisolone	DB00860	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_8378	"8638"	HP:0012192	"10011677"	"400122007"
methoxsalen	DB00553	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_18358	"6854"	HP:0012192	"10011677"	"400122007"
methylprednisolone	DB00959	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_6888	"6902"	HP:0012192	"10011677"	"400122007"
clocortolone pivalate	DB00838	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_59582	"21249"	HP:0012192	"10011677"	"400122007"
mechlorethamine	DB00888	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_28925	"6674"	HP:0012192	"10011677"	"400122007"
fluticasone propionate	DB00588	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_31441	"50121"	HP:0012192	"10011677"	"400122007"
mometasone furoate	DB00764	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_6970		HP:0012192	"10011677"	"400122007"
cortisone acetate	DB01380	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_3897	"21655"	HP:0012192	"10011677"	"400122007"
prednisone	DB00635	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_8382	"8640"	HP:0012192	"10011677"	"400122007"
diflorasone diacetate	DB00223	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_59750	"91311"	HP:0012192	"10011677"	"400122007"
hydrocortisone	DB00741	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_17650	"5492"	HP:0012192	"10011677"	"400122007"
dexamethasone	DB01234	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_41879	"3264"	HP:0012192	"10011677"	"400122007"
bexarotene	DB00307	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_50859	"233272"	HP:0012192	"10011677"	"400122007"
betamethasone valerate	DB00443	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_3077	"1514"	HP:0012192	"10011677"	"400122007"
triamcinolone	DB00620	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_9667	"10759"	HP:0012192	"10011677"	"400122007"
romidepsin	DB06176	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_61080	"877510"	HP:0012192	"10011677"	"400122007"
halcinonide	DB06786	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_31663	"5084"	HP:0012192	"10011677"	"400122007"
mogamulizumab	DB12498	Lymphoma, T-Cell, Cutaneous	C0079773		Approved				"2054077|2054068"	HP:0012192	"10011677"	"400122007"
fluocinolone acetonide	DB12553	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_5108	"25126"	HP:0012192	"10011677"	"400122007"
betamethasone dipropionate	DB00443	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_3077	"1514"	HP:0012192	"10011677"	"400122007"
alclometasone dipropionate	DB00240	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_53776	"108088"	HP:0012192	"10011677"	"400122007"
fluocinolone acetonide	DB00591	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_31623	"4461"	HP:0012192	"10011677"	"400122007"
betamethasone	DB00443	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_3077	"1514"	HP:0012192	"10011677"	"400122007"
desoximetasone	DB00547	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_691037	"3255"	HP:0012192	"10011677"	"400122007"
betamethasone benzoate	DB00443	Lymphoma, T-Cell, Cutaneous	C0079773		Approved			CHEBI_3077	"1514"	HP:0012192	"10011677"	"400122007"
	DB00563	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_44185	"6851"		"10034623"	"1163404000"
enocitabine	DB00773	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_4911	"4179"		"10034623"	"1163404000"
lenalidomide	DB00480	Peripheral T-Cell Lymphoma	C0079774	NCT01036399	Terminated	Phase 2	The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and Supporter (Celgene)	CHEBI_63791	"342369"		"10034623"	"1163404000"
	DB00531	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Withdrawn	Phase 2	Funding unavailable	CHEBI_4027	"1545988|3002"		"10034623"	"1163404000"
	DB00864	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Withdrawn	Phase 2	Funding unavailable	CHEBI_61049	"42316|235991"		"10034623"	"1163404000"
mycophenolate mofetil	DB01024	Peripheral T-Cell Lymphoma	C0079774	NCT01652014	Withdrawn	Phase 2	Funding unavailable	CHEBI_168396	"7145|265323"		"10034623"	"1163404000"
lenalidomide	DB00480	Peripheral T-Cell Lymphoma	C0079774	NCT01419795	Terminated	Phase 2	Low accrual	CHEBI_63791	"342369"		"10034623"	"1163404000"
	DB00073	Peripheral T-Cell Lymphoma	C0079774	NCT01419795	Terminated	Phase 2	Low accrual		"2273510|2472325|121191|2105824"		"10034623"	"1163404000"
	DB00526	Peripheral T-Cell Lymphoma	C0079774	NCT00101205	Terminated	Phase 1		CHEBI_31941	"32592"		"10034623"	"1163404000"
etoposide	DB00773	Peripheral T-Cell Lymphoma	C0079774	NCT00101205	Terminated	Phase 1		CHEBI_4911	"4179"		"10034623"	"1163404000"
vincristine	DB00541	Peripheral T-Cell Lymphoma	C0079774	NCT00933985	Terminated	Phase 1		CHEBI_28445	"11202"		"10034623"	"1163404000"
	DB00380	Peripheral T-Cell Lymphoma	C0079774	NCT00933985	Terminated	Phase 1		CHEBI_50223	"42736"		"10034623"	"1163404000"
	DB00997	Peripheral T-Cell Lymphoma	C0079774	NCT00933985	Terminated	Phase 1		CHEBI_28748	"142433|3639"		"10034623"	"1163404000"
	DB02546	Peripheral T-Cell Lymphoma	C0079774	NCT01116154	Terminated	Phase 1	Sponsor withdrew support for the study	CHEBI_45716	"194337"		"10034623"	"1163404000"
lenalidomide	DB00480	Peripheral T-Cell Lymphoma	C0079774	NCT01116154	Terminated	Phase 1	Sponsor withdrew support for the study	CHEBI_63791	"342369"		"10034623"	"1163404000"
alemtuzumab	DB00087	Peripheral T-Cell Lymphoma	C0079774	NCT00441025	Terminated	Phase 2	a lack of a potential patient.		"117055"		"10034623"	"1163404000"
forodesine	DB06185	Peripheral T-Cell Lymphoma	C0079774		Approved			CHEBI_43362			"10034623"	"1163404000"
belinostat	DB05015	Peripheral T-Cell Lymphoma	C0079774		Approved			CHEBI_61076	"1543543"		"10034623"	"1163404000"
rituximab	DB00073	Peripheral T-Cell Lymphoma	C0079774	NCT01805037	Terminated	Phase 1/Phase 2	Lack of funding		"2273510|2472325|121191|2105824"		"10034623"	"1163404000"
aminopterin	DB08878	Peripheral T-Cell Lymphoma	C0079774	NCT01420679	Terminated	Phase 3		CHEBI_22526	"1440264"		"10034623"	"1163404000"
pralatrexate	DB06813	Peripheral T-Cell Lymphoma	C0079774		Approved			CHEBI_71223	"662019"		"10034623"	"1163404000"
romidepsin	DB06176	Peripheral T-Cell Lymphoma	C0079774		Approved			CHEBI_61080	"877510"		"10034623"	"1163404000"
mogamulizumab	DB12498	Peripheral T-Cell Lymphoma	C0079774		Approved				"2054077|2054068"		"10034623"	"1163404000"
tucidinostat	DB06334	Peripheral T-Cell Lymphoma	C0079774		Approved			CHEBI_135918			"10034623"	"1163404000"
	DB00997	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_28748	"142433|3639"		"10034623"	"1163404000"
	DB00987	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_28680	"3041|968804"		"10034623"	"1163404000"
	DB00531	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_4027	"1545988|3002"		"10034623"	"1163404000"
	DB13144	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil		"70167"		"10034623"	"1163404000"
	DB00262	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_3423	"2105"		"10034623"	"1163404000"
	DB00361	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_480999	"39541"		"10034623"	"1163404000"
	DB00541	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_28445	"11202"		"10034623"	"1163404000"
	DB00650	Peripheral T-Cell Lymphoma	C0079774	NCT00632827	Terminated	Phase 2	Manufacturing shortage of both Diftitox and Doxil	CHEBI_15640	"6313"		"10034623"	"1163404000"
halcinonide	DB06786	Granuloma Annulare	C0085074		Approved			CHEBI_31663	"5084"	MONDO_0006554	"10018692"	"65508009"
cortisone acetate	DB01380	Granuloma Annulare	C0085074		Approved			CHEBI_3897	"21655"	MONDO_0006554	"10018692"	"65508009"
flumetasone	DB00663	Granuloma Annulare	C0085074		Approved			CHEBI_34764	"4458"	MONDO_0006554	"10018692"	"65508009"
desoximetasone	DB00547	Granuloma Annulare	C0085074		Approved			CHEBI_691037	"3255"	MONDO_0006554	"10018692"	"65508009"
fluocinolone acetonide	DB12553	Granuloma Annulare	C0085074		Approved			CHEBI_5108	"25126"	MONDO_0006554	"10018692"	"65508009"
fluocinonide	DB12553	Granuloma Annulare	C0085074		Approved			CHEBI_5108	"25126"	MONDO_0006554	"10018692"	"65508009"
betamethasone	DB00443	Granuloma Annulare	C0085074		Approved			CHEBI_3077	"1514"	MONDO_0006554	"10018692"	"65508009"
amcinonide	DB00288	Granuloma Annulare	C0085074		Approved			CHEBI_31199	"17652"	MONDO_0006554	"10018692"	"65508009"
dexamethasone	DB01234	Granuloma Annulare	C0085074		Approved			CHEBI_41879	"3264"	MONDO_0006554	"10018692"	"65508009"
hydrocortisone	DB00741	Granuloma Annulare	C0085074		Approved			CHEBI_17650	"5492"	MONDO_0006554	"10018692"	"65508009"
betamethasone benzoate	DB00443	Granuloma Annulare	C0085074		Approved			CHEBI_3077	"1514"	MONDO_0006554	"10018692"	"65508009"
prednisolone	DB00860	Granuloma Annulare	C0085074		Approved			CHEBI_8378	"8638"	MONDO_0006554	"10018692"	"65508009"
fluocinolone acetonide	DB00591	Granuloma Annulare	C0085074		Approved			CHEBI_31623	"4461"	MONDO_0006554	"10018692"	"65508009"
triamcinolone	DB00620	Granuloma Annulare	C0085074		Approved			CHEBI_9667	"10759"	MONDO_0006554	"10018692"	"65508009"
fluocinonide	DB01047	Granuloma Annulare	C0085074		Approved			CHEBI_5109	"4462"	MONDO_0006554	"10018692"	"65508009"
prednicarbate	DB00860	Granuloma Annulare	C0085074		Approved			CHEBI_8378	"8638"	MONDO_0006554	"10018692"	"65508009"
fludroxycortide	DB00846	Granuloma Annulare	C0085074		Approved			CHEBI_5127	"4500"	MONDO_0006554	"10018692"	"65508009"
methylprednisolone	DB00959	Granuloma Annulare	C0085074		Approved			CHEBI_6888	"6902"	MONDO_0006554	"10018692"	"65508009"
mometasone furoate	DB00764	Granuloma Annulare	C0085074		Approved			CHEBI_6970		MONDO_0006554	"10018692"	"65508009"
mometasone furoate	DB14512	Granuloma Annulare	C0085074		Approved			CHEBI_47564	"30145"	MONDO_0006554	"10018692"	"65508009"
fluticasone propionate	DB13867	Granuloma Annulare	C0085074		Approved			CHEBI_5134	"41126"	MONDO_0006554	"10018692"	"65508009"
fluticasone propionate	DB00588	Granuloma Annulare	C0085074		Approved			CHEBI_31441	"50121"	MONDO_0006554	"10018692"	"65508009"
triamcinolone diacetate	DB00620	Granuloma Annulare	C0085074		Approved			CHEBI_9667	"10759"	MONDO_0006554	"10018692"	"65508009"
prednicarbate	DB01130	Granuloma Annulare	C0085074		Approved			CHEBI_135791	"34369"	MONDO_0006554	"10018692"	"65508009"
benzoyl peroxide	DB09096	Granuloma Annulare	C0085074		Approved			CHEBI_82405	"1418"	MONDO_0006554	"10018692"	"65508009"
betamethasone dipropionate	DB00443	Granuloma Annulare	C0085074		Approved			CHEBI_3077	"1514"	MONDO_0006554	"10018692"	"65508009"
betamethasone valerate	DB00443	Granuloma Annulare	C0085074		Approved			CHEBI_3077	"1514"	MONDO_0006554	"10018692"	"65508009"
triamcinolone acetonide	DB00620	Granuloma Annulare	C0085074		Approved			CHEBI_9667	"10759"	MONDO_0006554	"10018692"	"65508009"
ulobetasol propionate	DB00596	Granuloma Annulare	C0085074		Approved			CHEBI_135782	"41208"	MONDO_0006554	"10018692"	"65508009"
alclometasone dipropionate	DB00240	Granuloma Annulare	C0085074		Approved			CHEBI_53776	"108088"	MONDO_0006554	"10018692"	"65508009"
diflorasone diacetate	DB00223	Granuloma Annulare	C0085074		Approved			CHEBI_59750	"91311"	MONDO_0006554	"10018692"	"65508009"
clocortolone pivalate	DB00838	Granuloma Annulare	C0085074		Approved			CHEBI_59582	"21249"	MONDO_0006554	"10018692"	"65508009"
desonide	DB01260	Granuloma Annulare	C0085074		Approved			CHEBI_204734	"3254"	MONDO_0006554	"10018692"	"65508009"
ammonium lactate	DB06768	Granuloma Annulare	C0085074		Approved				"215247"	MONDO_0006554	"10018692"	"65508009"
bupropion	DB01156	Seasonal Affective Disorder	C0085159		Approved			CHEBI_3219	"42347"		"10039775"	"247803002"
hyoscyamine	DB00424	Sinus bradycardia	C0085610		Approved			CHEBI_17486	"153970"	HP:0001688	"10040741"	"49710005"
melatonin	DB01065	Migraine Disorders	C0149931	NCT03150797	Terminated	Phase 2	Insufficient Fund	CHEBI_16796	"6711"	HP:0002076	"10027599"	"37796009"
amitriptyline	DB00321	Migraine Disorders	C0149931	NCT01581281	Terminated	Phase 3	Interim assessment provided sufficient data to answer study questions	CHEBI_2666	"704"	HP:0002076	"10027599"	"37796009"
	DB00273	Migraine Disorders	C0149931	NCT01581281	Terminated	Phase 3	Interim assessment provided sufficient data to answer study questions	CHEBI_63631	"38404"	HP:0002076	"10027599"	"37796009"
almotriptan	DB00918	Migraine Disorders	C0149931		Approved			CHEBI_520985	"279645"	HP:0002076	"10027599"	"37796009"
galcanezumab	DB14042	Migraine Disorders	C0149931		Approved				"2058846|2058868"	HP:0002076	"10027599"	"37796009"
rofecoxib	DB00533	Migraine Disorders	C0149931		Approved			CHEBI_8887	"232158"	HP:0002076	"10027599"	"37796009"
frovatriptan	DB00998	Migraine Disorders	C0149931		Approved			CHEBI_134991	"228783"	HP:0002076	"10027599"	"37796009"
naproxen	DB00788	Migraine Disorders	C0149931		Approved			CHEBI_7476	"7258"	HP:0002076	"10027599"	"37796009"
eletriptan	DB00216	Migraine Disorders	C0149931		Approved			CHEBI_50922	"231049"	HP:0002076	"10027599"	"37796009"
naratriptan	DB00952	Migraine Disorders	C0149931		Approved			CHEBI_7478	"141366"	HP:0002076	"10027599"	"37796009"
lasmiditan	DB11732	Migraine Disorders	C0149931		Approved				"2256930"	HP:0002076	"10027599"	"37796009"
metoclopramide	DB01233	Migraine Disorders	C0149931	NCT02582996	Suspended	Phase 3	Strategic reasons of the company	CHEBI_107736	"6915"	HP:0002076	"10027599"	"37796009"
acetylsalicylic acid	DB00945	Migraine Disorders	C0149931		Approved			CHEBI_15365	"91101|1191"	HP:0002076	"10027599"	"37796009"
	DB00201	Migraine Disorders	C0149931	NCT02582996	Suspended	Phase 3	Strategic reasons of the company	CHEBI_27732	"1886"	HP:0002076	"10027599"	"37796009"
ketoprofen	DB01009	Migraine Disorders	C0149931	NCT00557544	Withdrawn	Phase 3		CHEBI_6128	"6142"	HP:0002076	"10027599"	"37796009"
naproxen	DB00788	Migraine Disorders	C0149931	NCT01390324	Withdrawn	Phase 3		CHEBI_7476	"7258"	HP:0002076	"10027599"	"37796009"
sumatriptan	DB00669	Migraine Disorders	C0149931		Approved			CHEBI_10650	"37418"	HP:0002076	"10027599"	"37796009"
oxetorone	DB13463	Migraine Disorders	C0149931		Approved			CHEBI_135364		HP:0002076	"10027599"	"37796009"
topiramate	DB00273	Migraine Disorders	C0149931	NCT03280342	Withdrawn	Phase 2	Sponsor terminated study	CHEBI_63631	"38404"	HP:0002076	"10027599"	"37796009"
lisuride	DB00589	Migraine Disorders	C0149931		Approved			CHEBI_51164	"6446"	HP:0002076	"10027599"	"37796009"
rizatriptan	DB00953	Migraine Disorders	C0149931		Approved			CHEBI_48273	"88014"	HP:0002076	"10027599"	"37796009"
meclocycline	DB13092	Klebsiella cystitis	C0520775		Approved			CHEBI_135772	"29418"		"10011797"	"60867007"
	DB00320	Migraine Disorders	C0149931	NCT02582996	Suspended	Phase 3	Strategic reasons of the company	CHEBI_4562	"3418"	HP:0002076	"10027599"	"37796009"
ubrogepant	DB15328	Migraine Disorders	C0149931		Approved				"2268216"	HP:0002076	"10027599"	"37796009"
caffeine	DB00201	Migraine Disorders	C0149931	NCT03022838	Terminated	Phase 2/Phase 3	The study was terminated prematurely due to poor recruitment.	CHEBI_27732	"1886"	HP:0002076	"10027599"	"37796009"
zolmitriptan	DB00315	Migraine Disorders	C0149931		Approved			CHEBI_10124	"135775"	HP:0002076	"10027599"	"37796009"
naproxen	DB00788	Migraine Disorders	C0149931	NCT01726920	Withdrawn	Phase 3	Due to budget limitations, the company decided to withdraw this study.	CHEBI_7476	"7258"	HP:0002076	"10027599"	"37796009"
	DB01233	Migraine Disorders	C0149931	NCT00557544	Withdrawn	Phase 3		CHEBI_107736	"6915"	HP:0002076	"10027599"	"37796009"
erenumab	DB14039	Migraine Disorders	C0149931		Approved				"2045613|2045614"	HP:0002076	"10027599"	"37796009"
caffeine	DB00201	Migraine Disorders	C0149931		Approved			CHEBI_27732	"1886"	HP:0002076	"10027599"	"37796009"
phenobarbital	DB01174	Migraine Disorders	C0149931		Approved			CHEBI_8069	"8134"	HP:0002076	"10027599"	"37796009"
dihydroergotamine	DB00320	Migraine Disorders	C0149931		Approved			CHEBI_4562	"3418"	HP:0002076	"10027599"	"37796009"
fremanezumab	DB14041	Migraine Disorders	C0149931		Approved				"2056691"	HP:0002076	"10027599"	"37796009"
	DB00316	Migraine Disorders	C0149931	NCT02582996	Suspended	Phase 3	Strategic reasons of the company	CHEBI_46195	"161"	HP:0002076	"10027599"	"37796009"
ergotamine	DB00696	Migraine Disorders	C0149931		Approved			CHEBI_64318	"4025"	HP:0002076	"10027599"	"37796009"
paracetamol	DB00316	Migraine Disorders	C0149931		Approved			CHEBI_46195	"161"	HP:0002076	"10027599"	"37796009"
eptinezumab	DB14040	Migraine Disorders	C0149931		Approved				"2282660"	HP:0002076	"10027599"	"37796009"
cetirizine	DB00341	Migraine Disorders	C0149931	NCT01981499	Terminated	Phase 1	The trial was prematurely terminated on 01April2014 due to safety concerns.	CHEBI_3561	"20610"	HP:0002076	"10027599"	"37796009"
ceftriaxone	DB01212	Staphylococcal meningitis	C0154640		Approved			CHEBI_29007	"2193"		"10027255"	"12166008"
cefuroxime	DB01112	Staphylococcal meningitis	C0154640		Approved			CHEBI_3515	"2194"		"10027255"	"12166008"
nafcillin	DB00607	Staphylococcal meningitis	C0154640		Approved			CHEBI_7447	"7233"		"10027255"	"12166008"
cloxacillin	DB01147	Staphylococcal meningitis	C0154640		Approved			CHEBI_49566	"2625"		"10027255"	"12166008"
oxacillin	DB00713	Staphylococcal meningitis	C0154640		Approved			CHEBI_7809	"7773"		"10027255"	"12166008"
amikacin	DB00479	Staphylococcal meningitis	C0154640		Approved			CHEBI_2637	"641"		"10027255"	"12166008"
sparfloxacin	DB01208	Streptococcal pneumonia	C0155862		Approved			CHEBI_9212	"18469"	MONDO_0005972	"10035728"	"233607000"
lefamulin	DB12825	Streptococcal pneumonia	C0155862		Approved				"2198944"	MONDO_0005972	"10035728"	"233607000"
cefotetan	DB01330	Streptococcal pneumonia	C0155862		Approved			CHEBI_3499	"2187"	MONDO_0005972	"10035728"	"233607000"
clindamycin phosphate	DB01190	Streptococcal pneumonia	C0155862		Approved			CHEBI_3745	"2582"	MONDO_0005972	"10035728"	"233607000"
ceftazidime	DB00438	Streptococcal pneumonia	C0155862		Approved			CHEBI_3508	"2191|1545984"	MONDO_0005972	"10035728"	"233607000"
cefapirin	DB01139	Streptococcal pneumonia	C0155862		Approved			CHEBI_554446	"2238"	MONDO_0005972	"10035728"	"233607000"
ceftriaxone	DB01212	Streptococcal pneumonia	C0155862		Approved			CHEBI_29007	"2193"	MONDO_0005972	"10035728"	"233607000"
clindamycin	DB01190	Streptococcal pneumonia	C0155862		Approved			CHEBI_3745	"2582"	MONDO_0005972	"10035728"	"233607000"
cefmetazole	DB00274	Streptococcal pneumonia	C0155862		Approved			CHEBI_3489	"2182"	MONDO_0005972	"10035728"	"233607000"
cefepime	DB01413	Streptococcal pneumonia	C0155862		Approved			CHEBI_478164	"20481"	MONDO_0005972	"10035728"	"233607000"
loracarbef	DB00447	Streptococcal pneumonia	C0155862		Approved			CHEBI_47544	"28981"	MONDO_0005972	"10035728"	"233607000"
cefpodoxime proxetil	DB01416	Streptococcal pneumonia	C0155862		Approved			CHEBI_3504	"20489"	MONDO_0005972	"10035728"	"233607000"
dirithromycin	DB00954	Streptococcal pneumonia	C0155862		Approved			CHEBI_474014		MONDO_0005972	"10035728"	"233607000"
linezolid	DB00601	Streptococcal pneumonia	C0155862		Approved			CHEBI_63607	"190376"	MONDO_0005972	"10035728"	"233607000"
ofloxacin	DB01165	Streptococcal pneumonia	C0155862		Approved			CHEBI_7731	"7623"	MONDO_0005972	"10035728"	"233607000"
cefotaxime	DB00493	Streptococcal pneumonia	C0155862		Approved			CHEBI_204928	"2186"	MONDO_0005972	"10035728"	"233607000"
cefoxitin	DB01331	Streptococcal pneumonia	C0155862		Approved			CHEBI_209807	"2189"	MONDO_0005972	"10035728"	"233607000"
imipenem	DB01598	Streptococcal pneumonia	C0155862		Approved			CHEBI_471744	"5690|1545986"	MONDO_0005972	"10035728"	"233607000"
cefuroxime	DB01112	Streptococcal pneumonia	C0155862		Approved			CHEBI_3515	"2194"	MONDO_0005972	"10035728"	"233607000"
benzylpenicillin	DB01053	Streptococcal pneumonia	C0155862		Approved			CHEBI_18208	"7980"	MONDO_0005972	"10035728"	"233607000"
ceftizoxime	DB01332	Streptococcal pneumonia	C0155862		Approved			CHEBI_553473	"2192"	MONDO_0005972	"10035728"	"233607000"
norfloxacin	DB01059	Streptococcal pneumonia	C0155862		Approved			CHEBI_100246	"7517"	MONDO_0005972	"10035728"	"233607000"
cefuroxime axetil	DB01112	Streptococcal pneumonia	C0155862		Approved			CHEBI_3515	"2194"	MONDO_0005972	"10035728"	"233607000"
cefdinir	DB00535	Streptococcal pneumonia	C0155862		Approved			CHEBI_3485	"25037"	MONDO_0005972	"10035728"	"233607000"
amoxicillin	DB01060	Streptococcal pneumonia	C0155862		Approved			CHEBI_2676	"1297882|723"	MONDO_0005972	"10035728"	"233607000"
trovafloxacin	DB00685	Streptococcal pneumonia	C0155862		Approved			CHEBI_9763	"115552"	MONDO_0005972	"10035728"	"233607000"
cefalexin	DB00567	Streptococcal pneumonia	C0155862		Approved			CHEBI_3534	"2231|1299782"	MONDO_0005972	"10035728"	"233607000"
cefaclor	DB00833	Streptococcal pneumonia	C0155862		Approved			CHEBI_3478	"1450910|2176"	MONDO_0005972	"10035728"	"233607000"
benzathine benzylpenicillin	DB01053	Streptococcal pneumonia	C0155862		Approved			CHEBI_18208	"7980"	MONDO_0005972	"10035728"	"233607000"
procaine benzylpenicillin	DB09320	Streptococcal pneumonia	C0155862		Approved			CHEBI_52154	"7983"	MONDO_0005972	"10035728"	"233607000"
moxifloxacin	DB00218	Streptococcal pneumonia	C0155862		Approved			CHEBI_63611	"139462"	MONDO_0005972	"10035728"	"233607000"
cefalotin	DB00456	Streptococcal pneumonia	C0155862		Approved			CHEBI_124991	"2236"	MONDO_0005972	"10035728"	"233607000"
cefonicid	DB01328	Streptococcal pneumonia	C0155862		Approved			CHEBI_3491	"2183"	MONDO_0005972	"10035728"	"233607000"
alatrofloxacin	DB09335	Streptococcal pneumonia	C0155862		Approved			CHEBI_135829	"141440"	MONDO_0005972	"10035728"	"233607000"
ampicillin	DB00415	Streptococcal pneumonia	C0155862		Approved			CHEBI_28971	"733|221058"	MONDO_0005972	"10035728"	"233607000"
procaine benzylpenicillin	DB01053	Streptococcal pneumonia	C0155862		Approved			CHEBI_18208	"7980"	MONDO_0005972	"10035728"	"233607000"
tigecycline	DB00560	Streptococcal pneumonia	C0155862		Approved			CHEBI_149836	"384455"	MONDO_0005972	"10035728"	"233607000"
ciprofloxacin	DB00537	Streptococcal pneumonia	C0155862		Approved			CHEBI_192484	"2551"	MONDO_0005972	"10035728"	"233607000"
gatifloxacin	DB01044	Streptococcal pneumonia	C0155862		Approved			CHEBI_5280	"228476|1546025"	MONDO_0005972	"10035728"	"233607000"
grepafloxacin	DB00365	Streptococcal pneumonia	C0155862		Approved			CHEBI_5543	"83719"	MONDO_0005972	"10035728"	"233607000"
cefradine	DB01333	Streptococcal pneumonia	C0155862		Approved			CHEBI_3547	"2239"	MONDO_0005972	"10035728"	"233607000"
cefazolin	DB01327	Streptococcal pneumonia	C0155862		Approved			CHEBI_474053	"2180"	MONDO_0005972	"10035728"	"233607000"
levofloxacin	DB01137	Streptococcal pneumonia	C0155862		Approved			CHEBI_63598	"1546009|82122"	MONDO_0005972	"10035728"	"233607000"
cilastatin	DB01597	Streptococcal pneumonia	C0155862		Approved			CHEBI_3697	"2540"	MONDO_0005972	"10035728"	"233607000"
cefamandole	DB01326	Streptococcal pneumonia	C0155862		Approved			CHEBI_3480	"2178"	MONDO_0005972	"10035728"	"233607000"
chlorpromazine	DB00477	Acute intermittent porphyria	C0162565		Approved			CHEBI_3647	"2403"	MONDO_0008294	"10036182"	"234422006"
promazine	DB00420	Acute intermittent porphyria	C0162565		Approved			CHEBI_8459	"8742"	MONDO_0008294	"10036182"	"234422006"
hemin	DB03404	Acute intermittent porphyria	C0162565		Approved			CHEBI_50385	"5175"	MONDO_0008294	"10036182"	"234422006"
trafermin	DB06244	Tympanic Membrane Perforation	C0206504		Approved						"10045210"	"60442001"
trafermin	DB14131	Tympanic Membrane Perforation	C0206504		Approved						"10045210"	"60442001"
pemafibrate	DB15212	Dyslipidemias	C0242339		Approved			CHEBI_228365		HP:0003119	"10058108"	"370992007"
lenvatinib	DB09078	Papillary thyroid carcinoma	C0238463		Approved			CHEBI_85994	"1603296"	MONDO_0005075	"10033701"	"255029007"
distigmine	DB13694	Difficulty passing urine	C0241705		Approved			CHEBI_80756			"10042170"	"16844001"
simvastatin	DB00641	Dyslipidemias	C0242339	NCT00267280	Terminated	Phase 3		CHEBI_9150	"36567"	HP:0003119	"10058108"	"370992007"
ezetimibe	DB00973	Dyslipidemias	C0242339	NCT00267267	Terminated	Phase 3		CHEBI_49040	"341248"	HP:0003119	"10058108"	"370992007"
fenofibrate	DB01039	Dyslipidemias	C0242339	NCT00361868	Terminated	Phase 3	The study was discontinued prematurely at the end of March 2007 due to slow enrolment.	CHEBI_5001	"8703"	HP:0003119	"10058108"	"370992007"
	DB00627	Dyslipidemias	C0242339	NCT01294683	Terminated	Phase 3		CHEBI_15940	"7393"	HP:0003119	"10058108"	"370992007"
	DB00331	Dyslipidemias	C0242339	NCT00361868	Terminated	Phase 3	The study was discontinued prematurely at the end of March 2007 due to slow enrolment.	CHEBI_6801	"6809"	HP:0003119	"10058108"	"370992007"
fenofibrate	DB01039	Dyslipidemias	C0242339	NCT00816829	Terminated	Phase 2	The study was prematurely terminated because of slow recruitment	CHEBI_5001	"8703"	HP:0003119	"10058108"	"370992007"
rimonabant	DB06155	Dyslipidemias	C0242339	NCT00458081	Terminated	Phase 3	Company decision has been taken in light of recent demands by certain national health authorities	CHEBI_34967		HP:0003119	"10058108"	"370992007"
	DB00177	Dyslipidemias	C0242339	NCT02662894	Withdrawn	Phase 3	Sponsor decision	CHEBI_9927	"69749"	HP:0003119	"10058108"	"370992007"
rosuvastatin	DB01098	Dyslipidemias	C0242339	NCT02662894	Withdrawn	Phase 3	Sponsor decision	CHEBI_38545	"301542"	HP:0003119	"10058108"	"370992007"
	DB01076	Dyslipidemias	C0242339	NCT01863225	Terminated	Phase 2		CHEBI_39548	"83367"	HP:0003119	"10058108"	"370992007"
	DB01076	Dyslipidemias	C0242339	NCT00267267	Terminated	Phase 3		CHEBI_39548	"83367"	HP:0003119	"10058108"	"370992007"
fenofibrate	DB01039	Dyslipidemias	C0242339	NCT00362765	Terminated	Phase 2/Phase 3	The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients who are not under statin therapy at inclusion.	CHEBI_5001	"8703"	HP:0003119	"10058108"	"370992007"
rosuvastatin	DB01098	Dyslipidemias	C0242339	NCT01863225	Terminated	Phase 2		CHEBI_38545	"301542"	HP:0003119	"10058108"	"370992007"
	DB00331	Dyslipidemias	C0242339	NCT00362765	Terminated	Phase 2/Phase 3	The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients who are not under statin therapy at inclusion.	CHEBI_6801	"6809"	HP:0003119	"10058108"	"370992007"
laropiprant	DB11629	Dyslipidemias	C0242339		Approved			CHEBI_135942		HP:0003119	"10058108"	"370992007"
	DB00412	Dyslipidemias	C0242339	NCT00361868	Terminated	Phase 3	The study was discontinued prematurely at the end of March 2007 due to slow enrolment.	CHEBI_50122	"84108"	HP:0003119	"10058108"	"370992007"
	DB00641	Dyslipidemias	C0242339	NCT01294683	Terminated	Phase 3		CHEBI_9150	"36567"	HP:0003119	"10058108"	"370992007"
etofibrate	DB02701	Dyslipidemias	C0242339	NCT01294683	Terminated	Phase 3		CHEBI_17154	"7405"	HP:0003119	"10058108"	"370992007"
	DB00641	Dyslipidemias	C0242339	NCT00267267	Terminated	Phase 3		CHEBI_9150	"36567"	HP:0003119	"10058108"	"370992007"
	DB01076	Dyslipidemias	C0242339	NCT00267280	Terminated	Phase 3		CHEBI_39548	"83367"	HP:0003119	"10058108"	"370992007"
etofibrate	DB00627	Dyslipidemias	C0242339	NCT00664287	Withdrawn	Phase 3		CHEBI_15940	"7393"	HP:0003119	"10058108"	"370992007"
trandolapril	DB00519	Chronic heart failure	C0264716		Approved			CHEBI_9649	"38454"	HP:0001635	"10007558"	"48447003"
captopril	DB01197	Chronic heart failure	C0264716		Approved			CHEBI_3380	"1998"	HP:0001635	"10007558"	"48447003"
fosinopril	DB00492	Chronic heart failure	C0264716		Approved			CHEBI_5163	"50166"	HP:0001635	"10007558"	"48447003"
trandolapril	DB14209	Chronic heart failure	C0264716		Approved			CHEBI_141521		HP:0001635	"10007558"	"48447003"
sacubitril	DB09292	Chronic heart failure	C0264716		Approved			CHEBI_134714	"1656328"	HP:0001635	"10007558"	"48447003"
metoprolol	DB00264	Chronic heart failure	C0264716		Approved			CHEBI_6904	"6918"	HP:0001635	"10007558"	"48447003"
lisinopril	DB00722	Chronic heart failure	C0264716		Approved			CHEBI_43755	"1546022|29046"	HP:0001635	"10007558"	"48447003"
vericiguat	DB15456	Chronic heart failure	C0264716		Approved			CHEBI_142432	"2475830"	HP:0001635	"10007558"	"48447003"
empagliflozin	DB09038	Chronic heart failure	C0264716		Approved			CHEBI_82720	"1545653"	HP:0001635	"10007558"	"48447003"
spironolactone	DB00421	Chronic heart failure	C0264716		Approved			CHEBI_9241	"9997"	HP:0001635	"10007558"	"48447003"
hydrochlorothiazide	DB00999	Chronic heart failure	C0264716		Approved			CHEBI_5778	"5487"	HP:0001635	"10007558"	"48447003"
chlorothiazide	DB00880	Chronic heart failure	C0264716		Approved			CHEBI_3640	"2396"	HP:0001635	"10007558"	"48447003"
hydralazine	DB01275	Chronic heart failure	C0264716		Approved			CHEBI_5775	"5470"	HP:0001635	"10007558"	"48447003"
fosinopril	DB14207	Chronic heart failure	C0264716		Approved			CHEBI_116962		HP:0001635	"10007558"	"48447003"
candesartan cilexetil	DB00796	Chronic heart failure	C0264716		Approved			CHEBI_3348	"135481"	HP:0001635	"10007558"	"48447003"
isosorbide dinitrate	DB00883	Chronic heart failure	C0264716		Approved			CHEBI_6061	"6058"	HP:0001635	"10007558"	"48447003"
valsartan	DB00177	Chronic heart failure	C0264716		Approved			CHEBI_9927	"69749"	HP:0001635	"10007558"	"48447003"
quinapril	DB00881	Chronic heart failure	C0264716		Approved			CHEBI_8713	"35208"	HP:0001635	"10007558"	"48447003"
dapagliflozin	DB06292	Chronic heart failure	C0264716		Approved			CHEBI_85078	"1488564"	HP:0001635	"10007558"	"48447003"
iron	DB01592	Chronic heart failure	C0264716	NCT00384657	Withdrawn	Phase 3	Lack of cooperation among centers, Financial reasons	CHEBI_18248	"90176|262150"	HP:0001635	"10007558"	"48447003"
quinapril	DB14217	Chronic heart failure	C0264716		Approved			CHEBI_140296		HP:0001635	"10007558"	"48447003"
carvedilol	DB01136	Chronic heart failure	C0264716		Approved			CHEBI_3441	"20352"	HP:0001635	"10007558"	"48447003"
digoxin	DB00390	Chronic heart failure	C0264716		Approved			CHEBI_4551	"3407"	HP:0001635	"10007558"	"48447003"
dipyridamole	DB00975	Chronic heart failure	C0264716		Approved			CHEBI_4653	"3521"	HP:0001635	"10007558"	"48447003"
olmesartan medoxomil	DB00275	Chronic heart failure	C0264716	NCT00679484	Terminated	Phase 3	Lack of subject recruitment	CHEBI_48416	"321064"	HP:0001635	"10007558"	"48447003"
ramipril	DB14208	Chronic heart failure	C0264716		Approved			CHEBI_77363		HP:0001635	"10007558"	"48447003"
amlodipine	DB00381	Chronic heart failure	C0264716	NCT00151619	Terminated	Phase 2		CHEBI_2668	"17767"	HP:0001635	"10007558"	"48447003"
ramipril	DB00178	Chronic heart failure	C0264716		Approved			CHEBI_8774	"35296"	HP:0001635	"10007558"	"48447003"
ivabradine	DB09083	Chronic heart failure	C0264716		Approved			CHEBI_85966	"1649480"	HP:0001635	"10007558"	"48447003"
candesartan cilexetil	DB13919	Chronic heart failure	C0264716		Approved			CHEBI_3347		HP:0001635	"10007558"	"48447003"
fosdenopterin	DB16628	Combined molybdoflavoprotein enzyme deficiency	C0268119		Approved			CHEBI_60210	"2531288"	HP:0003570	"10069687"	"29692004"
	DB01234	Acute otitis media	C0271429	NCT01908803	Terminated	Phase 2	Management decision	CHEBI_41879	"3264"	HP:0000371	"10033079"	"3110003"
trimethoprim	DB00440	Acute otitis media	C0271429		Approved			CHEBI_45924	"10829"	HP:0000371	"10033079"	"3110003"
sulfamethoxazole	DB01015	Acute otitis media	C0271429		Approved			CHEBI_9332	"10180"	HP:0000371	"10033079"	"3110003"
ceftibuten	DB01415	Acute otitis media	C0271429		Approved			CHEBI_3510	"20492"	HP:0000371	"10033079"	"3110003"
dexamethasone phosphate	DB00537	Acute otitis media	C0271429	NCT01908803	Terminated	Phase 2	Management decision	CHEBI_68637	"2551"	HP:0000371	"10033079"	"3110003"
cefuroxime axetil	DB01112	Acute otitis media	C0271429		Approved			CHEBI_3515	"2194"	HP:0000371	"10033079"	"3110003"
cefixime	DB00671	Acute otitis media	C0271429		Approved			CHEBI_472657	"25033|1546021"	HP:0000371	"10033079"	"3110003"
cefuroxime	DB01112	Acute otitis media	C0271429		Approved			CHEBI_3515	"2194"	HP:0000371	"10033079"	"3110003"
ampicillin	DB00415	Acute otitis media	C0271429		Approved			CHEBI_28971	"733|221058"	HP:0000371	"10033079"	"3110003"
benzylpenicillin	DB01053	Acute otitis media	C0271429		Approved			CHEBI_18208	"7980"	HP:0000371	"10033079"	"3110003"
amoxicillin	DB01060	Acute otitis media	C0271429		Approved			CHEBI_2676	"1297882|723"	HP:0000371	"10033079"	"3110003"
cefprozil	DB01150	Acute otitis media	C0271429		Approved			CHEBI_3506	"1546020|19552"	HP:0000371	"10033079"	"3110003"
cefradine	DB01333	Acute otitis media	C0271429		Approved			CHEBI_3547	"2239"	HP:0000371	"10033079"	"3110003"
moxifloxacin	DB00218	Acute otitis media	C0271429	NCT01071902	Terminated	Phase 3	Management decision	CHEBI_63611	"139462"	HP:0000371	"10033079"	"3110003"
cefpodoxime proxetil	DB01416	Acute otitis media	C0271429		Approved			CHEBI_3504	"20489"	HP:0000371	"10033079"	"3110003"
sulfamethizole	DB00576	Acute otitis media	C0271429		Approved			CHEBI_9331	"10179"	HP:0000371	"10033079"	"3110003"
erythromycin	DB00199	Acute otitis media	C0271429		Approved			CHEBI_42355	"4053"	HP:0000371	"10033079"	"3110003"
cefalexin	DB00567	Acute otitis media	C0271429		Approved			CHEBI_3534	"2231|1299782"	HP:0000371	"10033079"	"3110003"
benzocaine	DB01086	Acute otitis media	C0271429	NCT02074007	Terminated	Phase 3	primary outcome measure not met	CHEBI_116735	"1399"	HP:0000371	"10033079"	"3110003"
	DB00766	Acute otitis media	C0271429	NCT01511107	Terminated	Phase 2	The primary objective of the study was met.	CHEBI_48947	"48203|21216"	HP:0000371	"10033079"	"3110003"
procaine benzylpenicillin	DB09320	Acute otitis media	C0271429		Approved			CHEBI_52154	"7983"	HP:0000371	"10033079"	"3110003"
amoxicillin	DB01060	Acute otitis media	C0271429	NCT01511107	Terminated	Phase 2	The primary objective of the study was met.	CHEBI_2676	"1297882|723"	HP:0000371	"10033079"	"3110003"
sulfafurazole	DB00263	Acute otitis media	C0271429		Approved			CHEBI_102484	"10207"	HP:0000371	"10033079"	"3110003"
clarithromycin	DB01211	Acute otitis media	C0271429		Approved			CHEBI_3732	"21212"	HP:0000371	"10033079"	"3110003"
phenoxymethylpenicillin	DB00417	Acute otitis media	C0271429		Approved			CHEBI_27446	"7984"	HP:0000371	"10033079"	"3110003"
procaine benzylpenicillin	DB01053	Acute otitis media	C0271429		Approved			CHEBI_18208	"7980"	HP:0000371	"10033079"	"3110003"
doxorubicin	DB00997	AIDS with Kaposi's sarcoma	C0276535		Approved			CHEBI_28748	"142433|3639"		"10023286"	"420524008"
interferon alfa-2b	DB15131	AIDS with Kaposi's sarcoma	C0276535		Approved				"545290"		"10023286"	"420524008"
interferon alfa-2b	DB00105	AIDS with Kaposi's sarcoma	C0276535		Approved				"5880|545290"		"10023286"	"420524008"
amiodarone	DB01118	Hemorrhagic Fever, Ebola	C0282687	NCT02307591	Withdrawn	Phase 2/Phase 3	The Study could not be started due to an insufficient number of new EVD cases.	CHEBI_2663	"703"	MONDO_0005737	"10014071"	"37109004"
ansuvimab	DB16385	Hemorrhagic Fever, Ebola	C0282687		Approved				"2472151|2472152"	MONDO_0005737	"10014071"	"37109004"
odesivimab	DB15900	Hemorrhagic Fever, Ebola	C0282687		Approved				"2461340|2461434"	MONDO_0005737	"10014071"	"37109004"
natamycin	DB00826	Fungal conjunctivitis	C0339170		Approved			CHEBI_7488	"7268"		"10080825"	"231862003"
calcium pantothenate	DB01783	Pantothenic acid deficiency	C0342938		Approved			CHEBI_46905	"7891|62400"		"10033685"	"238128006"
darbepoetin alfa	DB00012	Anemia of renal disease	C0472713		Approved				"283838"		"10058116"	"234348004"
daprodustat	DB11682	Anemia of renal disease	C0472713		Approved			CHEBI_229223	"2628210"		"10058116"	"234348004"
vadadustat	DB12255	Anemia of renal disease	C0472713		Approved						"10058116"	"234348004"
enarodustat	DB14985	Anemia of renal disease	C0472713		Approved						"10058116"	"234348004"
	DB01043	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_64312	"6719"	HP:0000726	"10012267"	"52448006"
	DB01156	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_3219	"42347"	HP:0000726	"10012267"	"52448006"
	DB00273	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_63631	"38404"	HP:0000726	"10012267"	"52448006"
	DB06470	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_92875	"2372"	HP:0000726	"10012267"	"52448006"
	DB01239	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_50931	"2406"	HP:0000726	"10012267"	"52448006"
	DB12867	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_93403	"1373"	HP:0000726	"10012267"	"52448006"
	DB13025	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_94666	"10588"	HP:0000726	"10012267"	"52448006"
	DB01558	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_31302	"1749"	HP:0000726	"10012267"	"52448006"
	DB00679	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_9566	"10502"	HP:0000726	"10012267"	"52448006"
	DB00231	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_9435	"10355"	HP:0000726	"10012267"	"52448006"
	DB00490	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_3223	"1827"	HP:0000726	"10012267"	"52448006"
	DB00425	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_10125	"39993"	HP:0000726	"10012267"	"52448006"
	DB00850	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8028	"8076"	HP:0000726	"10012267"	"52448006"
	DB00285	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_9943	"39786"	HP:0000726	"10012267"	"52448006"
	DB01075	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_4636	"3498"	HP:0000726	"10012267"	"52448006"
	DB00843	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_145499	"135447"	HP:0000726	"10012267"	"52448006"
	DB09210	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_32010	"8351"	HP:0000726	"10012267"	"52448006"
	DB00313	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_39867	"11118|40254"	HP:0000726	"10012267"	"52448006"
	DB00726	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_9738	"10834"	HP:0000726	"10012267"	"52448006"
	DB00897	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_9674	"10767"	HP:0000726	"10012267"	"52448006"
	DB00391	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_32168	"10239"	HP:0000726	"10012267"	"52448006"
	DB06218	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_135939	"623400"	HP:0000726	"10012267"	"52448006"
	DB01068	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_3756	"2598"	HP:0000726	"10012267"	"52448006"
	DB13841	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_59115		HP:0000726	"10012267"	"52448006"
	DB01267	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_83804	"679314"	HP:0000726	"10012267"	"52448006"
quetiapine	DB01224	Dementia	C0497327	NCT00315900	Terminated	Phase 3	Investigator closed study and left VAMC.	CHEBI_8707	"51272"	HP:0000726	"10012267"	"52448006"
dexmedetomidine	DB00633	Dementia	C0497327	NCT05276830	Terminated	Phase 2	Study was terminated for business reasons; not due to safety or efficacy concerns	CHEBI_4466	"48937"	HP:0000726	"10012267"	"52448006"
	DB00252	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8107	"8183"	HP:0000726	"10012267"	"52448006"
	DB00989	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8874	"183379"	HP:0000726	"10012267"	"52448006"
	DB01242	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_47780	"2597"	HP:0000726	"10012267"	"52448006"
	DB00734	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8871	"35636"	HP:0000726	"10012267"	"52448006"
	DB00564	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_3387	"2002"	HP:0000726	"10012267"	"52448006"
	DB00313	Dementia	C0497327	NCT00315900	Terminated	Phase 3	Investigator closed study and left VAMC.	CHEBI_39867	"11118|40254"	HP:0000726	"10012267"	"52448006"
	DB01563	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_28142	"2344"	HP:0000726	"10012267"	"52448006"
	DB00715	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_7936	"32937"	HP:0000726	"10012267"	"52448006"
ergoloid mesylates	DB01049	Dementia	C0497327		Approved			CHEBI_34706	"4024"	HP:0000726	"10012267"	"52448006"
	DB00234	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_135342	"60842"	HP:0000726	"10012267"	"52448006"
	DB00776	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_7824	"32624"	HP:0000726	"10012267"	"52448006"
	DB00842	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_7823	"7781"	HP:0000726	"10012267"	"52448006"
	DB12930	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_94614	"7674"	HP:0000726	"10012267"	"52448006"
	DB00334	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_7735	"61381"	HP:0000726	"10012267"	"52448006"
	DB00540	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_7640	"7531"	HP:0000726	"10012267"	"52448006"
	DB00349	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_31413	"21241"	HP:0000726	"10012267"	"52448006"
	DB00215	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_77397	"2556"	HP:0000726	"10012267"	"52448006"
	DB01224	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8707	"51272"	HP:0000726	"10012267"	"52448006"
	DB01174	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8069	"8134"	HP:0000726	"10012267"	"52448006"
	DB01595	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_7581	"7440"	HP:0000726	"10012267"	"52448006"
	DB01069	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8461	"8745"	HP:0000726	"10012267"	"52448006"
	DB00230	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_64356	"187832"	HP:0000726	"10012267"	"52448006"
	DB00699	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_31902	"7398"	HP:0000726	"10012267"	"52448006"
	DB01171	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_83531	"30121"	HP:0000726	"10012267"	"52448006"
	DB00370	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_6950	"15996"	HP:0000726	"10012267"	"52448006"
fluoxetine	DB00472	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_86990	"4493"	HP:0000726	"10012267"	"52448006"
donepezil	DB00843	Dementia	C0497327	NCT00874939	Terminated	Phase 1		CHEBI_145499	"135447"	HP:0000726	"10012267"	"52448006"
	DB00683	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_6931	"6960"	HP:0000726	"10012267"	"52448006"
	DB00321	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_2666	"704"	HP:0000726	"10012267"	"52448006"
	DB00875	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_10454	"4495"	HP:0000726	"10012267"	"52448006"
	DB00623	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_5123	"4496"	HP:0000726	"10012267"	"52448006"
	DB00690	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_5128	"4501"	HP:0000726	"10012267"	"52448006"
	DB04842	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_93369	"4507"	HP:0000726	"10012267"	"52448006"
	DB00176	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_5138	"42355"	HP:0000726	"10012267"	"52448006"
	DB00996	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_42797	"25480"	HP:0000726	"10012267"	"52448006"
	DB00674	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_42944	"4637"	HP:0000726	"10012267"	"52448006"
	DB00502	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_5613	"5093"	HP:0000726	"10012267"	"52448006"
	DB00404	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_2611	"596"	HP:0000726	"10012267"	"52448006"
	DB00659	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_51041	"82819"	HP:0000726	"10012267"	"52448006"
risperidone	DB00734	Dementia	C0497327	NCT00287742	Terminated	Phase 3	A decision was made to discontinue the study due to a change in the strategic direction of the company.	CHEBI_8871	"35636"	HP:0000726	"10012267"	"52448006"
	DB00557	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_5818	"5553"	HP:0000726	"10012267"	"52448006"
	DB00458	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_47499	"5691"	HP:0000726	"10012267"	"52448006"
	DB00555	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_6367	"28439"	HP:0000726	"10012267"	"52448006"
	DB01202	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_6437	"114477"	HP:0000726	"10012267"	"52448006"
	DB00186	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_6539	"6470"	HP:0000726	"10012267"	"52448006"
	DB00934	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_6690	"6646"	HP:0000726	"10012267"	"52448006"
	DB00810	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_3112	"1589"	HP:0000726	"10012267"	"52448006"
	DB06148	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_51137	"6929"	HP:0000726	"10012267"	"52448006"
	DB06288	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_64045	"46303"	HP:0000726	"10012267"	"52448006"
vinpocetine	DB12131	Dementia	C0497327		Approved			CHEBI_32297	"24506"	HP:0000726	"10012267"	"52448006"
	DB01403	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_6838	"6852"	HP:0000726	"10012267"	"52448006"
	DB01065	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_16796	"6711"	HP:0000726	"10012267"	"52448006"
	DB01104	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_9123	"36437"	HP:0000726	"10012267"	"52448006"
	DB00656	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_9654	"10737"	HP:0000726	"10012267"	"52448006"
	DB00752	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_131512	"10734"	HP:0000726	"10012267"	"52448006"
	DB12710	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_59118	"8042"	HP:0000726	"10012267"	"52448006"
	DB01142	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_4710	"3638"	HP:0000726	"10012267"	"52448006"
	DB01100	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_8212	"8331"	HP:0000726	"10012267"	"52448006"
	DB00476	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_36795	"72625"	HP:0000726	"10012267"	"52448006"
flurbiprofen	DB00712	Dementia	C0497327	NCT00322036	Terminated	Phase 3	Myriad has discontinued the development of Flurizan.	CHEBI_5130	"4502"	HP:0000726	"10012267"	"52448006"
dihydroergocornine	DB11273	Dementia	C0497327		Approved			CHEBI_59909	"3415"	HP:0000726	"10012267"	"52448006"
	DB00829	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_49575	"3322"	HP:0000726	"10012267"	"52448006"
	DB01238	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_31236	"89013"	HP:0000726	"10012267"	"52448006"
megestrol acetate	DB00351	Dementia	C0497327	NCT00503516	Terminated	Phase 2/Phase 3	Difficulties to recruit the patients following the inclusion criteria	CHEBI_6723	"29451"	HP:0000726	"10012267"	"52448006"
	DB00363	Dementia	C0497327	NCT02374567	Terminated	Phase 3		CHEBI_3766	"2626"	HP:0000726	"10012267"	"52448006"
lomefloxacin	DB00978	Klebsiella cystitis	C0520775		Approved			CHEBI_116278	"28872"		"10011797"	"60867007"
ticarcillin	DB01607	Klebsiella cystitis	C0520775		Approved			CHEBI_9587	"10591"		"10011797"	"60867007"
betaine	DB06756	Klebsiella cystitis	C0520775		Approved			CHEBI_17750	"350374|1512"		"10011797"	"60867007"
cefapirin	DB01139	Klebsiella cystitis	C0520775		Approved			CHEBI_554446	"2238"		"10011797"	"60867007"
cefuroxime axetil	DB01112	Klebsiella cystitis	C0520775		Approved			CHEBI_3515	"2194"		"10011797"	"60867007"
cefotetan	DB01330	Klebsiella cystitis	C0520775		Approved			CHEBI_3499	"2187"		"10011797"	"60867007"
gatifloxacin	DB01044	Klebsiella cystitis	C0520775		Approved			CHEBI_5280	"228476|1546025"		"10011797"	"60867007"
ceftizoxime	DB01332	Klebsiella cystitis	C0520775		Approved			CHEBI_553473	"2192"		"10011797"	"60867007"
piperacillin	DB00319	Klebsiella cystitis	C0520775		Approved			CHEBI_8232	"1546000|8339"		"10011797"	"60867007"
cefonicid	DB01328	Klebsiella cystitis	C0520775		Approved			CHEBI_3491	"2183"		"10011797"	"60867007"
cefpodoxime proxetil	DB01416	Klebsiella cystitis	C0520775		Approved			CHEBI_3504	"20489"		"10011797"	"60867007"
cefalexin	DB00567	Klebsiella cystitis	C0520775		Approved			CHEBI_3534	"2231|1299782"		"10011797"	"60867007"
sulfamethoxazole	DB01015	Klebsiella cystitis	C0520775		Approved			CHEBI_9332	"10180"		"10011797"	"60867007"
cefuroxime	DB01112	Klebsiella cystitis	C0520775		Approved			CHEBI_3515	"2194"		"10011797"	"60867007"
sulfamethizole	DB00576	Klebsiella cystitis	C0520775		Approved			CHEBI_9331	"10179"		"10011797"	"60867007"
ciprofloxacin	DB00537	Klebsiella cystitis	C0520775		Approved			CHEBI_192484	"2551"		"10011797"	"60867007"
amoxicillin	DB01060	Klebsiella cystitis	C0520775		Approved			CHEBI_2676	"1297882|723"		"10011797"	"60867007"
ceftriaxone	DB01212	Klebsiella cystitis	C0520775		Approved			CHEBI_29007	"2193"		"10011797"	"60867007"
nitrofurantoin	DB00698	Klebsiella cystitis	C0520775		Approved			CHEBI_71415	"235559|7454"		"10011797"	"60867007"
demeclocycline	DB00618	Klebsiella cystitis	C0520775		Approved			CHEBI_4392	"3154"		"10011797"	"60867007"
clavulanic acid	DB00766	Klebsiella cystitis	C0520775		Approved			CHEBI_48947	"48203|21216"		"10011797"	"60867007"
nitrofurazone	DB00336	Klebsiella cystitis	C0520775		Approved			CHEBI_44368	"7455"		"10011797"	"60867007"
levofloxacin	DB01137	Klebsiella cystitis	C0520775		Approved			CHEBI_63598	"1546009|82122"		"10011797"	"60867007"
trimethoprim	DB00440	Klebsiella cystitis	C0520775		Approved			CHEBI_45924	"10829"		"10011797"	"60867007"
streptomycin	DB01082	Klebsiella cystitis	C0520775		Approved			CHEBI_17076	"10109"		"10011797"	"60867007"
ceftazidime	DB00438	Klebsiella cystitis	C0520775		Approved			CHEBI_3508	"2191|1545984"		"10011797"	"60867007"
cefadroxil	DB01140	Klebsiella cystitis	C0520775		Approved			CHEBI_3479	"1545975|2177"		"10011797"	"60867007"
cefamandole	DB01326	Klebsiella cystitis	C0520775		Approved			CHEBI_3480	"2178"		"10011797"	"60867007"
cefoxitin	DB01331	Klebsiella cystitis	C0520775		Approved			CHEBI_209807	"2189"		"10011797"	"60867007"
aztreonam	DB00355	Klebsiella cystitis	C0520775		Approved			CHEBI_161680	"1272"		"10011797"	"60867007"
norfloxacin	DB01059	Klebsiella cystitis	C0520775		Approved			CHEBI_100246	"7517"		"10011797"	"60867007"
cefradine	DB01333	Klebsiella cystitis	C0520775		Approved			CHEBI_3547	"2239"		"10011797"	"60867007"
cefotaxime	DB00493	Klebsiella cystitis	C0520775		Approved			CHEBI_204928	"2186"		"10011797"	"60867007"
	DB01394	Hepatitis C, Chronic	C0524910	NCT00840489	Terminated	Phase 2	Preliminary analysis	CHEBI_27882	"2683"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT01641666	Withdrawn	Phase 3		CHEBI_63580	"9344"		"10008912"	"128302006"
ombitasvir	DB09296	Hepatitis C, Chronic	C0524910		Approved			CHEBI_85183	"1597371"		"10008912"	"128302006"
	DB06756	Hepatitis C, Chronic	C0524910	NCT00882193	Terminated	Early Phase 1	new medications with improved response released, nonaccrual	CHEBI_17750	"350374|1512"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT01590225	Withdrawn	Phase 3		CHEBI_63580	"9344"		"10008912"	"128302006"
ritonavir	DB00503	Hepatitis C, Chronic	C0524910		Approved			CHEBI_45409	"85762"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT01095445	Terminated	Phase 3	Unlikely to recruit the adequate number of patients within a reasonable timeline	CHEBI_63580	"9344"		"10008912"	"128302006"
boceprevir	DB08873	Hepatitis C, Chronic	C0524910		Approved			CHEBI_68621	"1102129"		"10008912"	"128302006"
elbasvir	DB11574	Hepatitis C, Chronic	C0524910		Approved			CHEBI_132967	"1734628"		"10008912"	"128302006"
simeprevir	DB06290	Hepatitis C, Chronic	C0524910		Approved			CHEBI_134743	"1482790"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT01547312	Withdrawn	Phase 1		CHEBI_63580	"9344"		"10008912"	"128302006"
asunaprevir	DB11586	Hepatitis C, Chronic	C0524910		Approved			CHEBI_134723	"1652103"		"10008912"	"128302006"
peginterferon alfa-2b	DB00022	Hepatitis C, Chronic	C0524910		Approved				"253453"		"10008912"	"128302006"
pioglitazone	DB01132	Hepatitis C, Chronic	C0524910	NCT00927290	Terminated	Phase 3	Suspension of use of medicine containing Pioglitazone by French regulatory agency	CHEBI_8228	"33738"		"10008912"	"128302006"
telaprevir	DB05521	Hepatitis C, Chronic	C0524910		Approved			CHEBI_68595	"1102261"		"10008912"	"128302006"
grazoprevir	DB11575	Hepatitis C, Chronic	C0524910		Approved			CHEBI_132975	"1734630|1871173"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT00296972	Terminated	Phase 3	not funded	CHEBI_63580	"9344"		"10008912"	"128302006"
interferon alfa-2b	DB15131	Hepatitis C, Chronic	C0524910		Approved				"545290"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT02099604	Withdrawn	Phase 3	Study objectives were considered as obsolete regarding the new AAD arrival	CHEBI_63580	"9344"		"10008912"	"128302006"
paritaprevir	DB09297	Hepatitis C, Chronic	C0524910		Approved			CHEBI_85188	"1597373"		"10008912"	"128302006"
velpatasvir	DB11613	Hepatitis C, Chronic	C0524910		Approved			CHEBI_133009	"1799206"		"10008912"	"128302006"
peginterferon alfa-2a	DB00008	Hepatitis C, Chronic	C0524910		Approved				"120608"		"10008912"	"128302006"
voxilaprevir	DB12026	Hepatitis C, Chronic	C0524910		Approved				"1939323"		"10008912"	"128302006"
glecaprevir	DB13879	Hepatitis C, Chronic	C0524910		Approved				"1940635"		"10008912"	"128302006"
pibrentasvir	DB13878	Hepatitis C, Chronic	C0524910		Approved				"1940636"		"10008912"	"128302006"
ezetimibe	DB00973	Hepatitis C, Chronic	C0524910	NCT02971033	Terminated	Phase 2	Study Funding ended	CHEBI_49040	"341248"		"10008912"	"128302006"
dasabuvir	DB09183	Hepatitis C, Chronic	C0524910		Approved			CHEBI_85182	"1597381"		"10008912"	"128302006"
ledipasvir	DB09027	Hepatitis C, Chronic	C0524910		Approved			CHEBI_85089	"1591922"		"10008912"	"128302006"
ciclosporin	DB00091	Hepatitis C, Chronic	C0524910	NCT00375895	Terminated	Phase 3	Insufficient enrollment	CHEBI_4031	"3008"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT01890200	Withdrawn	Phase 3		CHEBI_63580	"9344"		"10008912"	"128302006"
sofosbuvir	DB08934	Hepatitis C, Chronic	C0524910		Approved			CHEBI_85083	"1484911"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT01517308	Withdrawn	Phase 3	Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week regimen in this setting. It seems non-ethical to start this trial	CHEBI_63580	"9344"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT01997203	Terminated	Phase 3	complete patients samples required	CHEBI_63580	"9344"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT00840489	Terminated	Phase 2	Preliminary analysis	CHEBI_63580	"9344"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT00662220	Terminated	Phase 3	Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study had to be terminated.	CHEBI_63580	"9344"		"10008912"	"128302006"
beclabuvir	DB12225	Hepatitis C, Chronic	C0524910		Approved						"10008912"	"128302006"
vaniprevir	DB11929	Hepatitis C, Chronic	C0524910		Approved			CHEBI_136047			"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910		Approved			CHEBI_63580	"9344"		"10008912"	"128302006"
daclatasvir	DB09102	Hepatitis C, Chronic	C0524910		Approved			CHEBI_82977	"1606218"		"10008912"	"128302006"
interferon alfa-2b	DB00105	Hepatitis C, Chronic	C0524910		Approved				"5880|545290"		"10008912"	"128302006"
ribavirin	DB00811	Hepatitis C, Chronic	C0524910	NCT00882193	Terminated	Early Phase 1	new medications with improved response released, nonaccrual	CHEBI_63580	"9344"		"10008912"	"128302006"
cefamandole	DB01326	Bacterial sepsis	C0684256		Approved			CHEBI_3480	"2178"		"10053840"	"10001005"
cefazolin	DB01327	Bacterial sepsis	C0684256		Approved			CHEBI_474053	"2180"		"10053840"	"10001005"
clindamycin phosphate	DB01190	Bacterial sepsis	C0684256		Approved			CHEBI_3745	"2582"		"10053840"	"10001005"
cefuroxime	DB01112	Bacterial sepsis	C0684256		Approved			CHEBI_3515	"2194"		"10053840"	"10001005"
metronidazole	DB00916	Bacterial sepsis	C0684256		Approved			CHEBI_6909	"6922"		"10053840"	"10001005"
amikacin	DB00479	Bacterial sepsis	C0684256		Approved			CHEBI_2637	"641"		"10053840"	"10001005"
metronidazole	DB15759	Bacterial sepsis	C0684256		Approved			CHEBI_50688			"10053840"	"10001005"
mezlocillin	DB00948	Bacterial sepsis	C0684256		Approved			CHEBI_6919	"6927"		"10053840"	"10001005"
ceftizoxime	DB01332	Bacterial sepsis	C0684256		Approved			CHEBI_553473	"2192"		"10053840"	"10001005"
ampicillin	DB00415	Bacterial sepsis	C0684256		Approved			CHEBI_28971	"733|221058"		"10053840"	"10001005"
kanamycin	DB01172	Bacterial sepsis	C0684256		Approved			CHEBI_17630	"6099|1727573"		"10053840"	"10001005"
cilastatin	DB01597	Bacterial sepsis	C0684256		Approved			CHEBI_3697	"2540"		"10053840"	"10001005"
ceftazidime	DB00438	Bacterial sepsis	C0684256		Approved			CHEBI_3508	"2191|1545984"		"10053840"	"10001005"
imipenem	DB01598	Bacterial sepsis	C0684256		Approved			CHEBI_471744	"5690|1545986"		"10053840"	"10001005"
clindamycin	DB01190	Bacterial sepsis	C0684256		Approved			CHEBI_3745	"2582"		"10053840"	"10001005"
fusidic acid	DB02703	Bacterial sepsis	C0684256		Approved			CHEBI_29013	"4608|113608"		"10053840"	"10001005"
ticarcillin	DB01607	Bacterial sepsis	C0684256		Approved			CHEBI_9587	"10591"		"10053840"	"10001005"
meticillin	DB01603	Bacterial sepsis	C0684256		Approved			CHEBI_6827	"2181306"		"10053840"	"10001005"
clavulanic acid	DB00766	Bacterial sepsis	C0684256		Approved			CHEBI_48947	"48203|21216"		"10053840"	"10001005"
cefoxitin	DB01331	Bacterial sepsis	C0684256		Approved			CHEBI_209807	"2189"		"10053840"	"10001005"
tobramycin	DB00684	Bacterial sepsis	C0684256		Approved			CHEBI_28864	"10627"		"10053840"	"10001005"
cefotetan	DB01330	Bacterial sepsis	C0684256		Approved			CHEBI_3499	"2187"		"10053840"	"10001005"
piperacillin	DB00319	Bacterial sepsis	C0684256		Approved			CHEBI_8232	"1546000|8339"		"10053840"	"10001005"
erythromycin ethyl succinate	DB00199	Bacterial sepsis	C0684256		Approved			CHEBI_42355	"4053"		"10053840"	"10001005"
cefotaxime	DB00493	Bacterial sepsis	C0684256		Approved			CHEBI_204928	"2186"		"10053840"	"10001005"
ceftriaxone	DB01212	Bacterial sepsis	C0684256		Approved			CHEBI_29007	"2193"		"10053840"	"10001005"
cefalotin	DB00456	Bacterial sepsis	C0684256		Approved			CHEBI_124991	"2236"		"10053840"	"10001005"
cefonicid	DB01328	Bacterial sepsis	C0684256		Approved			CHEBI_3491	"2183"		"10053840"	"10001005"
gentamicin	DB00798	Bacterial sepsis	C0684256		Approved			CHEBI_17833	"1596450"		"10053840"	"10001005"
Polymyxin B	DB00781	Bacterial sepsis	C0684256		Approved				"8536"		"10053840"	"10001005"
vancomycin	DB00512	Bacterial sepsis	C0684256		Approved			CHEBI_28001	"11124"		"10053840"	"10001005"
cefapirin	DB01139	Bacterial sepsis	C0684256		Approved			CHEBI_554446	"2238"		"10053840"	"10001005"
cefpodoxime proxetil	DB01416	Bacterial urinary infection	C0729524		Approved			CHEBI_3504	"20489"		"10054088"	"312124009"
clavulanic acid	DB00766	Bacterial urinary infection	C0729524		Approved			CHEBI_48947	"48203|21216"		"10054088"	"312124009"
ticarcillin	DB01607	Bacterial urinary infection	C0729524		Approved			CHEBI_9587	"10591"		"10054088"	"312124009"
cefalexin	DB00567	Bacterial urinary infection	C0729524		Approved			CHEBI_3534	"2231|1299782"		"10054088"	"312124009"
amoxicillin	DB01060	Bacterial urinary infection	C0729524		Approved			CHEBI_2676	"1297882|723"		"10054088"	"312124009"
cefamandole	DB01326	Bacterial urinary infection	C0729524		Approved			CHEBI_3480	"2178"		"10054088"	"312124009"
cycloserine	DB00260	Bacterial urinary infection	C0729524		Approved			CHEBI_40009	"3007"		"10054088"	"312124009"
cefuroxime	DB01112	Bacterial urinary infection	C0729524		Approved			CHEBI_3515	"2194"		"10054088"	"312124009"
gatifloxacin	DB01044	Bacterial urinary infection	C0729524		Approved			CHEBI_5280	"228476|1546025"		"10054088"	"312124009"
ceftriaxone	DB01212	Bacterial urinary infection	C0729524		Approved			CHEBI_29007	"2193"		"10054088"	"312124009"
serine	DB00133	Bacterial urinary infection	C0729524		Approved			CHEBI_17115	"9671"		"10054088"	"312124009"
tobramycin	DB00684	Bacterial urinary infection	C0729524		Approved			CHEBI_28864	"10627"		"10054088"	"312124009"
trimethoprim	DB00440	Bacterial urinary infection	C0729524		Approved			CHEBI_45924	"10829"		"10054088"	"312124009"
nalidixic acid	DB00779	Bacterial urinary infection	C0729524		Approved			CHEBI_100147	"7240"		"10054088"	"312124009"
avibactam	DB09060	Bacterial urinary infection	C0729524		Approved			CHEBI_85984	"1603834"		"10054088"	"312124009"
cefotaxime	DB00493	Bacterial urinary infection	C0729524		Approved			CHEBI_204928	"2186"		"10054088"	"312124009"
ceftazidime	DB00438	Bacterial urinary infection	C0729524		Approved			CHEBI_3508	"2191|1545984"		"10054088"	"312124009"
imipenem	DB01598	Bacterial urinary infection	C0729524		Approved			CHEBI_471744	"5690|1545986"		"10054088"	"312124009"
aztreonam	DB00355	Bacterial urinary infection	C0729524		Approved			CHEBI_161680	"1272"		"10054088"	"312124009"
ofloxacin	DB01165	Bacterial urinary infection	C0729524		Approved			CHEBI_7731	"7623"		"10054088"	"312124009"
sulfamethizole	DB00576	Bacterial urinary infection	C0729524		Approved			CHEBI_9331	"10179"		"10054088"	"312124009"
streptomycin	DB01082	Bacterial urinary infection	C0729524		Approved			CHEBI_17076	"10109"		"10054088"	"312124009"
cefepime	DB01413	Bacterial urinary infection	C0729524		Approved			CHEBI_478164	"20481"		"10054088"	"312124009"
cefiderocol	DB14879	Bacterial urinary infection	C0729524		Approved			CHEBI_140376	"2265702"		"10054088"	"312124009"
cefotetan	DB01330	Bacterial urinary infection	C0729524		Approved			CHEBI_3499	"2187"		"10054088"	"312124009"
norfloxacin	DB01059	Bacterial urinary infection	C0729524		Approved			CHEBI_100246	"7517"		"10054088"	"312124009"
cefoxitin	DB01331	Bacterial urinary infection	C0729524		Approved			CHEBI_209807	"2189"		"10054088"	"312124009"
sulfacytine	DB01298	Bacterial urinary infection	C0729524		Approved			CHEBI_135230	"78902"		"10054088"	"312124009"
cefazolin	DB01327	Bacterial urinary infection	C0729524		Approved			CHEBI_474053	"2180"		"10054088"	"312124009"
ampicillin	DB00415	Bacterial urinary infection	C0729524		Approved			CHEBI_28971	"733|221058"		"10054088"	"312124009"
sulfamethoxazole	DB01015	Bacterial urinary infection	C0729524		Approved			CHEBI_9332	"10180"		"10054088"	"312124009"
cilastatin	DB01597	Bacterial urinary infection	C0729524		Approved			CHEBI_3697	"2540"		"10054088"	"312124009"
carbenicillin	DB00578	Bacterial urinary infection	C0729524		Approved			CHEBI_3393	"2015"		"10054088"	"312124009"
fusidic acid	DB02703	Bacterial urinary infection	C0729524		Approved			CHEBI_29013	"4608|113608"		"10054088"	"312124009"
ceftizoxime	DB01332	Bacterial urinary infection	C0729524		Approved			CHEBI_553473	"2192"		"10054088"	"312124009"
betaine	DB06756	Bacterial urinary infection	C0729524		Approved			CHEBI_17750	"350374|1512"		"10054088"	"312124009"
carindacillin	DB00578	Bacterial urinary infection	C0729524		Approved			CHEBI_3393	"2015"		"10054088"	"312124009"
ciprofloxacin	DB00537	Bacterial urinary infection	C0729524		Approved			CHEBI_192484	"2551"		"10054088"	"312124009"
levofloxacin	DB01137	Bacterial urinary infection	C0729524		Approved			CHEBI_63598	"1546009|82122"		"10054088"	"312124009"
amikacin	DB00479	Bacterial urinary infection	C0729524		Approved			CHEBI_2637	"641"		"10054088"	"312124009"
carindacillin	DB09319	Bacterial urinary infection	C0729524		Approved			CHEBI_52015			"10054088"	"312124009"
cefuroxime axetil	DB01112	Bacterial urinary infection	C0729524		Approved			CHEBI_3515	"2194"		"10054088"	"312124009"
doxycycline	DB00254	Bacterial urinary infection	C0729524		Approved			CHEBI_50845	"1545992|3640"		"10054088"	"312124009"
eflapegrastim	DB15001	Febrile Neutropenia	C0746883		Approved				"2612526"		"10016288"	"409089005"
sapropterin	DB00360	Hyperphenylalaninemia, Non-Phenylketonuric	C0751436		Approved			CHEBI_59560	"753340"	MONDO_0016543	"10069116"	"68724006"
zonisamide	DB00909	Lewy Body Disease	C0752347		Approved			CHEBI_10127	"39998"	MONDO_0007488	"10067889"	"80098002"
ibrutinib	DB09053	Small Lymphocytic Lymphoma	C0855095		Approved			CHEBI_76612	"1442981"		"10003908"	"302841002"
venetoclax	DB11581	Small Lymphocytic Lymphoma	C0855095		Approved			CHEBI_133021	"1747556"		"10003908"	"302841002"
duvelisib	DB11952	Small Lymphocytic Lymphoma	C0855095		Approved			CHEBI_131169	"2058509"		"10003908"	"302841002"
idelalisib	DB09054	Small Lymphocytic Lymphoma	C0855095		Approved			CHEBI_82701	"1544460"		"10003908"	"302841002"
doxepin	DB01142	Sleeplessness	C0917801		Approved			CHEBI_4710	"3638"	HP:0100785	"10022437"	"193462001"
choline	DB00122	Sleeplessness	C0917801		Approved			CHEBI_15354	"2449"	HP:0100785	"10022437"	"193462001"
loprazolam	DB13643	Sleeplessness	C0917801		Approved			CHEBI_135754		HP:0100785	"10022437"	"193462001"
methyprylon	DB01107	Sleeplessness	C0917801		Approved			CHEBI_31837	"6910"	HP:0100785	"10022437"	"193462001"
talbutal	DB00306	Sleeplessness	C0917801		Approved			CHEBI_134923	"89810"	HP:0100785	"10022437"	"193462001"
metharbital	DB00463	Sleeplessness	C0917801		Approved			CHEBI_31827	"6825"	HP:0100785	"10022437"	"193462001"
amitriptyline	DB00321	Sleeplessness	C0917801	NCT02139098	Terminated	Phase 3	Recruiting problems because of the time expenditure required for participating and the strict criteria of inclusion and exclusion	CHEBI_2666	"704"	HP:0100785	"10022437"	"193462001"
	DB00425	Sleeplessness	C0917801	NCT02139098	Terminated	Phase 3	Recruiting problems because of the time expenditure required for participating and the strict criteria of inclusion and exclusion	CHEBI_10125	"39993"	HP:0100785	"10022437"	"193462001"
suvorexant	DB09034	Sleeplessness	C0917801		Approved			CHEBI_82698	"1547099"	HP:0100785	"10022437"	"193462001"
amobarbital	DB01351	Sleeplessness	C0917801		Approved			CHEBI_2673	"719"	HP:0100785	"10022437"	"193462001"
lemborexant	DB11951	Sleeplessness	C0917801		Approved				"2272403"	HP:0100785	"10022437"	"193462001"
	DB08997	Sleeplessness	C0917801	NCT00642694	Terminated	Phase 3	Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor	CHEBI_135531	"3267"	HP:0100785	"10022437"	"193462001"
citalopram	DB00215	Sleeplessness	C0917801	NCT00642694	Terminated	Phase 3	Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor	CHEBI_77397	"2556"	HP:0100785	"10022437"	"193462001"
methylpentynol	DB13733	Sleeplessness	C0917801		Approved			CHEBI_134752		HP:0100785	"10022437"	"193462001"
secobarbital	DB00418	Sleeplessness	C0917801		Approved			CHEBI_9073	"9624"	HP:0100785	"10022437"	"193462001"
temazepam	DB00231	Sleeplessness	C0917801		Approved			CHEBI_9435	"10355"	HP:0100785	"10022437"	"193462001"
eszopiclone	DB00402	Sleeplessness	C0917801		Approved			CHEBI_53760	"461016"	HP:0100785	"10022437"	"193462001"
nitrazepam	DB01595	Sleeplessness	C0917801		Approved			CHEBI_7581	"7440"	HP:0100785	"10022437"	"193462001"
ethchlorvynol	DB00189	Sleeplessness	C0917801		Approved			CHEBI_4882	"4118"	HP:0100785	"10022437"	"193462001"
ethinamate	DB01031	Sleeplessness	C0917801		Approved			CHEBI_4884	"24474"	HP:0100785	"10022437"	"193462001"
diphenhydramine	DB01075	Sleeplessness	C0917801		Approved			CHEBI_4636	"3498"	HP:0100785	"10022437"	"193462001"
triazolam	DB00897	Sleeplessness	C0917801		Approved			CHEBI_9674	"10767"	HP:0100785	"10022437"	"193462001"
doxefazepam	DB13837	Sleeplessness	C0917801		Approved			CHEBI_82460		HP:0100785	"10022437"	"193462001"
butobarbital	DB01353	Sleeplessness	C0917801		Approved			CHEBI_134884	"19874"	HP:0100785	"10022437"	"193462001"
sertraline	DB01104	Sleeplessness	C0917801	NCT00232167	Terminated	Phase 3	Please see Detailed Description below for termination reason.	CHEBI_9123	"36437"	HP:0100785	"10022437"	"193462001"
zolpidem	DB00425	Sleeplessness	C0917801		Approved			CHEBI_10125	"39993"	HP:0100785	"10022437"	"193462001"
zopiclone	DB01198	Sleeplessness	C0917801		Approved			CHEBI_32315	"40001"	HP:0100785	"10022437"	"193462001"
barbital	DB01483	Sleeplessness	C0917801		Approved			CHEBI_31252	"1325"	HP:0100785	"10022437"	"193462001"
secbutabarbital	DB00237	Sleeplessness	C0917801		Approved			CHEBI_3228	"477631"	HP:0100785	"10022437"	"193462001"
quazepam	DB01589	Sleeplessness	C0917801		Approved			CHEBI_8694	"35185"	HP:0100785	"10022437"	"193462001"
aceprometazine	DB01615	Sleeplessness	C0917801		Approved			CHEBI_53770		HP:0100785	"10022437"	"193462001"
aprobarbital	DB01352	Sleeplessness	C0917801		Approved			CHEBI_2791	"17381"	HP:0100785	"10022437"	"193462001"
mirtazapine	DB00370	Sleeplessness	C0917801	NCT00488072	Suspended	Phase 2	closed to accrual	CHEBI_6950	"15996"	HP:0100785	"10022437"	"193462001"
carbromal	DB13817	Sleeplessness	C0917801		Approved			CHEBI_134961		HP:0100785	"10022437"	"193462001"
glutethimide	DB01437	Sleeplessness	C0917801		Approved			CHEBI_5439	"4903"	HP:0100785	"10022437"	"193462001"
chloral hydrate	DB01563	Sleeplessness	C0917801		Approved			CHEBI_28142	"2344"	HP:0100785	"10022437"	"193462001"
daridorexant	DB15031	Sleeplessness	C0917801		Approved				"2591497"	HP:0100785	"10022437"	"193462001"
flurazepam	DB00690	Sleeplessness	C0917801		Approved			CHEBI_5128	"4501"	HP:0100785	"10022437"	"193462001"
prazepam	DB01588	Sleeplessness	C0917801		Approved			CHEBI_8362	"8627"	HP:0100785	"10022437"	"193462001"
pentobarbital	DB00312	Sleeplessness	C0917801		Approved			CHEBI_7983	"8004"	HP:0100785	"10022437"	"193462001"
clomethiazole	DB06470	Sleeplessness	C0917801		Approved			CHEBI_92875	"2372"	HP:0100785	"10022437"	"193462001"
pyridoxine	DB00165	Vitamin B 6 Deficiency	C0936215		Approved			CHEBI_16709	"42954|684879"	HP:0008326	"10047617"	"386080007"
sulbactam	DB09324	Abdominal Infection	C1112209		Approved			CHEBI_9321	"10167"		"10056519"	"128070006"
amphotericin B	DB00681	Abdominal Infection	C1112209		Approved			CHEBI_2682	"236594|732"		"10056519"	"128070006"
erythromycin ethyl succinate	DB00199	Abdominal Infection	C1112209		Approved			CHEBI_42355	"4053"		"10056519"	"128070006"
trovafloxacin	DB00685	Abdominal Infection	C1112209		Approved			CHEBI_9763	"115552"		"10056519"	"128070006"
ceftriaxone	DB01212	Abdominal Infection	C1112209		Approved			CHEBI_29007	"2193"		"10056519"	"128070006"
meropenem	DB00760	Abdominal Infection	C1112209		Approved			CHEBI_43968	"1546029|29561"		"10056519"	"128070006"
aztreonam	DB00355	Abdominal Infection	C1112209		Approved			CHEBI_161680	"1272"		"10056519"	"128070006"
ceftizoxime	DB01332	Abdominal Infection	C1112209		Approved			CHEBI_553473	"2192"		"10056519"	"128070006"
metronidazole	DB00916	Abdominal Infection	C1112209		Approved			CHEBI_6909	"6922"		"10056519"	"128070006"
cefamandole	DB01326	Abdominal Infection	C1112209		Approved			CHEBI_3480	"2178"		"10056519"	"128070006"
amikacin	DB00479	Abdominal Infection	C1112209		Approved			CHEBI_2637	"641"		"10056519"	"128070006"
metronidazole	DB15759	Abdominal Infection	C1112209		Approved			CHEBI_50688			"10056519"	"128070006"
ampicillin	DB00415	Abdominal Infection	C1112209		Approved			CHEBI_28971	"733|221058"		"10056519"	"128070006"
mezlocillin	DB00948	Abdominal Infection	C1112209		Approved			CHEBI_6919	"6927"		"10056519"	"128070006"
relebactam	DB12377	Abdominal Infection	C1112209		Approved				"2184137|2268500"		"10056519"	"128070006"
ofloxacin	DB01165	Abdominal Infection	C1112209		Approved			CHEBI_7731	"7623"		"10056519"	"128070006"
clindamycin phosphate	DB01190	Abdominal Infection	C1112209		Approved			CHEBI_3745	"2582"		"10056519"	"128070006"
kanamycin	DB01172	Abdominal Infection	C1112209		Approved			CHEBI_17630	"6099|1727573"		"10056519"	"128070006"
ceftazidime	DB00438	Abdominal Infection	C1112209		Approved			CHEBI_3508	"2191|1545984"		"10056519"	"128070006"
clindamycin	DB01190	Abdominal Infection	C1112209		Approved			CHEBI_3745	"2582"		"10056519"	"128070006"
norfloxacin	DB01059	Abdominal Infection	C1112209		Approved			CHEBI_100246	"7517"		"10056519"	"128070006"
ceftolozane	DB09050	Abdominal Infection	C1112209		Approved			CHEBI_134719	"1597609"		"10056519"	"128070006"
imipenem	DB01598	Abdominal Infection	C1112209		Approved			CHEBI_471744	"5690|1545986"		"10056519"	"128070006"
cefepime	DB01413	Abdominal Infection	C1112209		Approved			CHEBI_478164	"20481"		"10056519"	"128070006"
avibactam	DB09060	Abdominal Infection	C1112209		Approved			CHEBI_85984	"1603834"		"10056519"	"128070006"
ciprofloxacin	DB00537	Abdominal Infection	C1112209		Approved			CHEBI_192484	"2551"		"10056519"	"128070006"
doripenem	DB06211	Abdominal Infection	C1112209		Approved			CHEBI_135928	"119771"		"10056519"	"128070006"
cefmetazole	DB00274	Abdominal Infection	C1112209		Approved			CHEBI_3489	"2182"		"10056519"	"128070006"
alatrofloxacin	DB09335	Abdominal Infection	C1112209		Approved			CHEBI_135829	"141440"		"10056519"	"128070006"
cilastatin	DB01597	Abdominal Infection	C1112209		Approved			CHEBI_3697	"2540"		"10056519"	"128070006"
fusidic acid	DB02703	Abdominal Infection	C1112209		Approved			CHEBI_29013	"4608|113608"		"10056519"	"128070006"
gentamicin	DB00798	Abdominal Infection	C1112209		Approved			CHEBI_17833	"1596450"		"10056519"	"128070006"
moxifloxacin	DB00218	Abdominal Infection	C1112209		Approved			CHEBI_63611	"139462"		"10056519"	"128070006"
ticarcillin	DB01607	Abdominal Infection	C1112209		Approved			CHEBI_9587	"10591"		"10056519"	"128070006"
cefoxitin	DB01331	Abdominal Infection	C1112209		Approved			CHEBI_209807	"2189"		"10056519"	"128070006"
tigecycline	DB00560	Abdominal Infection	C1112209		Approved			CHEBI_149836	"384455"		"10056519"	"128070006"
eravacycline dihydrochloride	DB12329	Abdominal Infection	C1112209		Approved				"2055906"		"10056519"	"128070006"
piperacillin	DB00319	Abdominal Infection	C1112209		Approved			CHEBI_8232	"1546000|8339"		"10056519"	"128070006"
cefotaxime	DB00493	Abdominal Infection	C1112209		Approved			CHEBI_204928	"2186"		"10056519"	"128070006"
ertapenem	DB00303	Abdominal Infection	C1112209		Approved			CHEBI_404903	"325642"		"10056519"	"128070006"
cefotetan	DB01330	Abdominal Infection	C1112209		Approved			CHEBI_3499	"2187"		"10056519"	"128070006"
sulfogaiacol	DB15992	Rhinorrhea	C1260880		Approved			CHEBI_85537		HP:0031417	"10039101"	"267101005"
doxylamine	DB00366	Rhinorrhea	C1260880		Approved			CHEBI_51380	"3642"	HP:0031417	"10039101"	"267101005"
sodium citrate	DB09154	Rhinorrhea	C1260880		Approved			CHEBI_53258	"253204|56466|1310549"	HP:0031417	"10039101"	"267101005"
guaifenesin	DB00874	Rhinorrhea	C1260880		Approved			CHEBI_5551	"5032"	HP:0031417	"10039101"	"267101005"
pheniramine	DB01620	Rhinorrhea	C1260880		Approved			CHEBI_91591	"8132"	HP:0031417	"10039101"	"267101005"
guaiacol	DB11359	Rhinorrhea	C1260880		Approved			CHEBI_28591	"5031"	HP:0031417	"10039101"	"267101005"
brompheniramine	DB00835	Rhinorrhea	C1260880		Approved			CHEBI_3183	"1767"	HP:0031417	"10039101"	"267101005"
tramazoline	DB13064	Rhinorrhea	C1260880		Approved			CHEBI_134893	"38453"	HP:0031417	"10039101"	"267101005"
potassium iodide	DB06715	Rhinorrhea	C1260880		Approved			CHEBI_8346	"8597"	HP:0031417	"10039101"	"267101005"
desloratadine	DB00967	Rhinorrhea	C1260880		Approved			CHEBI_291342	"275635"	HP:0031417	"10039101"	"267101005"
scopolamine	DB00747	Rhinorrhea	C1260880		Approved			CHEBI_16794	"9601|9603"	HP:0031417	"10039101"	"267101005"
dihydrocodeine	DB01551	Rhinorrhea	C1260880		Approved			CHEBI_135276	"23088"	HP:0031417	"10039101"	"267101005"
caffeine	DB00201	Rhinorrhea	C1260880		Approved			CHEBI_27732	"1886"	HP:0031417	"10039101"	"267101005"
cyproheptadine	DB00434	Rhinorrhea	C1260880		Approved			CHEBI_4046	"3013"	HP:0031417	"10039101"	"267101005"
cyclizine	DB01176	Rhinorrhea	C1260880		Approved			CHEBI_3994	"2977"	HP:0031417	"10039101"	"267101005"
ipratropium	DB00332	Rhinorrhea	C1260880		Approved			CHEBI_46659	"1546373|203212|7213"	HP:0031417	"10039101"	"267101005"
methscopolamine	DB00462	Rhinorrhea	C1260880		Approved			CHEBI_61276	"56092"	HP:0031417	"10039101"	"267101005"
methscopolamine	DB11315	Rhinorrhea	C1260880		Approved			CHEBI_135361	"89785"	HP:0031417	"10039101"	"267101005"
methdilazine	DB00902	Rhinorrhea	C1260880		Approved			CHEBI_6823	"29648"	HP:0031417	"10039101"	"267101005"
methapyrilene	DB04819	Rhinorrhea	C1260880		Approved			CHEBI_6820	"6822"	HP:0031417	"10039101"	"267101005"
pentoxyverine	DB11186	Rhinorrhea	C1260880		Approved			CHEBI_94484	"20217"	HP:0031417	"10039101"	"267101005"
codeine	DB00318	Rhinorrhea	C1260880		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0031417	"10039101"	"267101005"
clemastine	DB00283	Rhinorrhea	C1260880		Approved			CHEBI_3738	"2578"	HP:0031417	"10039101"	"267101005"
loratadine	DB00455	Rhinorrhea	C1260880		Approved			CHEBI_6538	"28889"	HP:0031417	"10039101"	"267101005"
mepyramine	DB06691	Rhinorrhea	C1260880		Approved			CHEBI_6762	"9009"	HP:0031417	"10039101"	"267101005"
cetirizine	DB00341	Rhinorrhea	C1260880		Approved			CHEBI_3561	"20610"	HP:0031417	"10039101"	"267101005"
clofedanol	DB04837	Rhinorrhea	C1260880		Approved			CHEBI_135207	"21254"	HP:0031417	"10039101"	"267101005"
chlorcyclizine	DB08936	Rhinorrhea	C1260880		Approved			CHEBI_94402	"2354"	HP:0031417	"10039101"	"267101005"
carbinoxamine	DB00748	Rhinorrhea	C1260880		Approved			CHEBI_3398	"20220"	HP:0031417	"10039101"	"267101005"
phenindamine	DB01619	Rhinorrhea	C1260880		Approved			CHEBI_8065	"33283"	HP:0031417	"10039101"	"267101005"
diphenylpyraline	DB01146	Rhinorrhea	C1260880		Approved			CHEBI_59788	"23386"	HP:0031417	"10039101"	"267101005"
pseudoephedrine	DB00852	Rhinorrhea	C1260880		Approved			CHEBI_51209	"8896"	HP:0031417	"10039101"	"267101005"
phenylpropanolamine	DB00397	Rhinorrhea	C1260880		Approved			CHEBI_80680	"8175"	HP:0031417	"10039101"	"267101005"
promazine	DB00420	Rhinorrhea	C1260880		Approved			CHEBI_8459	"8742"	HP:0031417	"10039101"	"267101005"
hydrocodone	DB00956	Rhinorrhea	C1260880		Approved			CHEBI_5779	"5489"	HP:0031417	"10039101"	"267101005"
bromazine	DB01237	Rhinorrhea	C1260880		Approved			CHEBI_59177	"19759"	HP:0031417	"10039101"	"267101005"
ammonium chloride	DB06767	Rhinorrhea	C1260880		Approved			CHEBI_31206	"712"	HP:0031417	"10039101"	"267101005"
terfenadine	DB00342	Rhinorrhea	C1260880		Approved			CHEBI_9453	"42330"	HP:0031417	"10039101"	"267101005"
alimemazine	DB01246	Rhinorrhea	C1260880		Approved			CHEBI_9725	"10825"	HP:0031417	"10039101"	"267101005"
tripelennamine	DB00792	Rhinorrhea	C1260880		Approved			CHEBI_9741	"10847"	HP:0031417	"10039101"	"267101005"
dextromethorphan	DB00514	Rhinorrhea	C1260880		Approved			CHEBI_4470	"3289"	HP:0031417	"10039101"	"267101005"
epoprostenol	DB01240	Rhinorrhea	C1260880		Approved			CHEBI_15552	"8814"	HP:0031417	"10039101"	"267101005"
ephedrine	DB01364	Rhinorrhea	C1260880		Approved			CHEBI_15407	"3966"	HP:0031417	"10039101"	"267101005"
azatadine	DB00719	Rhinorrhea	C1260880		Approved			CHEBI_2946	"18600"	HP:0031417	"10039101"	"267101005"
chlorphenamine	DB01114	Rhinorrhea	C1260880		Approved			CHEBI_52010	"221074|2400"	HP:0031417	"10039101"	"267101005"
naproxen	DB00788	Rhinorrhea	C1260880		Approved			CHEBI_7476	"7258"	HP:0031417	"10039101"	"267101005"
phenylephrine	DB00388	Rhinorrhea	C1260880		Approved			CHEBI_8093	"8163"	HP:0031417	"10039101"	"267101005"
triprolidine	DB00427	Rhinorrhea	C1260880		Approved			CHEBI_84116	"10849"	HP:0031417	"10039101"	"267101005"
hydroxyzine	DB00557	Rhinorrhea	C1260880		Approved			CHEBI_5818	"5553"	HP:0031417	"10039101"	"267101005"
phenyltoloxamine	DB11160	Rhinorrhea	C1260880		Approved			CHEBI_135047	"33408"	HP:0031417	"10039101"	"267101005"
sulfogaiacol	DB13735	Rhinorrhea	C1260880		Approved			CHEBI_85537		HP:0031417	"10039101"	"267101005"
pyrithione	DB06815	Rhinorrhea	C1260880		Approved			CHEBI_36584	"35100"	HP:0031417	"10039101"	"267101005"
glycine	DB00145	Rhinorrhea	C1260880		Approved			CHEBI_15428	"4919"	HP:0031417	"10039101"	"267101005"
oxedrine	DB09203	Rhinorrhea	C1260880		Approved			CHEBI_29081		HP:0031417	"10039101"	"267101005"
tetryzoline	DB06764	Rhinorrhea	C1260880		Approved			CHEBI_28674	"37935"	HP:0031417	"10039101"	"267101005"
acrivastine	DB09488	Rhinorrhea	C1260880		Approved			CHEBI_83168	"19959"	HP:0031417	"10039101"	"267101005"
xylometazoline	DB06694	Rhinorrhea	C1260880		Approved			CHEBI_10082	"39841"	HP:0031417	"10039101"	"267101005"
oxymetazoline	DB00935	Rhinorrhea	C1260880		Approved			CHEBI_7862	"7812"	HP:0031417	"10039101"	"267101005"
antazoline	DB08799	Rhinorrhea	C1260880		Approved			CHEBI_84115	"865"	HP:0031417	"10039101"	"267101005"
difelikefalin	DB11938	Uremic pruritus	C1262019		Approved				"2569089"		"10060875"	"707151000"
mirtazapine	DB00370	Major Depressive Disorder	C1269683		Approved			CHEBI_6950	"15996"		"10057840"	"370143000"
ketamine	DB01221	Major Depressive Disorder	C1269683	NCT03889756	Terminated	Phase 2/Phase 3	No more funding available to continue since we could not recruit throughout the pandemic.	CHEBI_6121	"6130"		"10057840"	"370143000"
citalopram	DB00215	Major Depressive Disorder	C1269683	NCT00642694	Terminated	Phase 3	Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor	CHEBI_77397	"2556"		"10057840"	"370143000"
	DB01104	Major Depressive Disorder	C1269683	NCT01703039	Terminated	Phase 2	PI departure, slow recruitment	CHEBI_9123	"36437"		"10057840"	"370143000"
duloxetine	DB00476	Major Depressive Disorder	C1269683	NCT01288079	Terminated	Phase 2		CHEBI_36795	"72625"		"10057840"	"370143000"
isocarboxazid	DB01247	Major Depressive Disorder	C1269683		Approved			CHEBI_93635	"6011"		"10057840"	"370143000"
vortioxetine	DB09068	Major Depressive Disorder	C1269683		Approved			CHEBI_76016	"1455099"		"10057840"	"370143000"
dextromethorphan	DB00514	Major Depressive Disorder	C1269683		Approved			CHEBI_4470	"3289"		"10057840"	"370143000"
paroxetine	DB00715	Major Depressive Disorder	C1269683		Approved			CHEBI_7936	"32937"		"10057840"	"370143000"
levomilnacipran	DB08918	Major Depressive Disorder	C1269683		Approved			CHEBI_136040	"1433212"		"10057840"	"370143000"
citalopram	DB00215	Major Depressive Disorder	C1269683		Approved			CHEBI_77397	"2556"		"10057840"	"370143000"
agomelatine	DB06594	Major Depressive Disorder	C1269683		Approved			CHEBI_134990			"10057840"	"370143000"
reboxetine	DB00234	Major Depressive Disorder	C1269683		Approved			CHEBI_135342	"60842"		"10057840"	"370143000"
lurasidone	DB08815	Major Depressive Disorder	C1269683	NCT01423240	Withdrawn	Phase 3		CHEBI_70735	"1040028"		"10057840"	"370143000"
nefazodone	DB01149	Major Depressive Disorder	C1269683		Approved			CHEBI_7494	"31565"		"10057840"	"370143000"
venlafaxine	DB00285	Major Depressive Disorder	C1269683	NCT00766870	Terminated	Phase 2	Study was previously paused and is now terminated	CHEBI_9943	"39786"		"10057840"	"370143000"
duloxetine	DB00476	Major Depressive Disorder	C1269683		Approved			CHEBI_36795	"72625"		"10057840"	"370143000"
duloxetine	DB00476	Major Depressive Disorder	C1269683	NCT03068247	Withdrawn	Phase 3	Institution was unable to manufacture radiotracer that was central to the protocol. Study transferred to another institution.	CHEBI_36795	"72625"		"10057840"	"370143000"
fluoxetine	DB00472	Major Depressive Disorder	C1269683		Approved			CHEBI_86990	"4493"		"10057840"	"370143000"
ketamine	DB01221	Major Depressive Disorder	C1269683	NCT03051945	Withdrawn	Phase 3	Unable to perform brain imaging	CHEBI_6121	"6130"		"10057840"	"370143000"
modafinil	DB00745	Major Depressive Disorder	C1269683	NCT03620253	Terminated	Phase 3	Principal Investigator left study site	CHEBI_77585	"30125"		"10057840"	"370143000"
ketamine	DB01221	Major Depressive Disorder	C1269683	NCT03977675	Terminated	Phase 1	PI left the institution	CHEBI_6121	"6130"		"10057840"	"370143000"
duloxetine	DB00476	Major Depressive Disorder	C1269683	NCT01145755	Terminated	Phase 2		CHEBI_36795	"72625"		"10057840"	"370143000"
gepirone	DB12184	Major Depressive Disorder	C1269683		Approved			CHEBI_135990	"2672253"		"10057840"	"370143000"
riluzole	DB00740	Major Depressive Disorder	C1269683	NCT01703039	Terminated	Phase 2	PI departure, slow recruitment	CHEBI_8863	"35623"		"10057840"	"370143000"
escitalopram	DB01175	Major Depressive Disorder	C1269683		Approved			CHEBI_36791	"321988"		"10057840"	"370143000"
bupropion	DB01156	Major Depressive Disorder	C1269683		Approved			CHEBI_3219	"42347"		"10057840"	"370143000"
lisdexamfetamine	DB01255	Major Depressive Disorder	C1269683	NCT01436175	Terminated	Phase 3	SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.	CHEBI_135925	"700810"		"10057840"	"370143000"
desvenlafaxine	DB06700	Major Depressive Disorder	C1269683		Approved			CHEBI_83527	"734064"		"10057840"	"370143000"
trazodone	DB00656	Major Depressive Disorder	C1269683		Approved			CHEBI_9654	"10737"		"10057840"	"370143000"
vortioxetine	DB09068	Major Depressive Disorder	C1269683	NCT02454426	Withdrawn	Early Phase 1	PI left institution	CHEBI_76016	"1455099"		"10057840"	"370143000"
tranylcypromine	DB00752	Major Depressive Disorder	C1269683		Approved			CHEBI_131512	"10734"		"10057840"	"370143000"
modafinil	DB00745	Major Depressive Disorder	C1269683	NCT04317001	Withdrawn	Phase 3	Researcher leading the study moved institutions study not feasible	CHEBI_77585	"30125"		"10057840"	"370143000"
dosulepin	DB09167	Major Depressive Disorder	C1269683		Approved			CHEBI_36803	"3634"		"10057840"	"370143000"
quetiapine	DB01224	Major Depressive Disorder	C1269683	NCT00868374	Terminated	Phase 3	Study terminated due to low enrollment	CHEBI_8707	"51272"		"10057840"	"370143000"
vilazodone	DB06684	Major Depressive Disorder	C1269683		Approved			CHEBI_70707	"1086769"		"10057840"	"370143000"
	DB14509	Major Depressive Disorder	C1269683	NCT00400088	Terminated	Phase 3	Recruitment difficulties	CHEBI_6504	"42351"		"10057840"	"370143000"
olanzapine	DB00334	Major Depressive Disorder	C1269683		Approved			CHEBI_7735	"61381"		"10057840"	"370143000"
paroxetine	DB00715	Major Depressive Disorder	C1269683	NCT00400088	Terminated	Phase 3	Recruitment difficulties	CHEBI_7936	"32937"		"10057840"	"370143000"
selegiline	DB01037	Major Depressive Disorder	C1269683		Approved			CHEBI_9086	"9639"		"10057840"	"370143000"
ketamine	DB01221	Major Depressive Disorder	C1269683	NCT02882711	Terminated	Phase 2	Increasing off-label practice of IV ketamine administration for treatment-resistant depression.	CHEBI_6121	"6130"		"10057840"	"370143000"
mianserin	DB06148	Major Depressive Disorder	C1269683		Approved			CHEBI_51137	"6929"		"10057840"	"370143000"
quetiapine	DB01224	Major Depressive Disorder	C1269683	NCT01189318	Withdrawn	Phase 2		CHEBI_8707	"51272"		"10057840"	"370143000"
ketamine	DB01221	Major Depressive Disorder	C1269683	NCT01957410	Terminated	Phase 2	Clinical Team decision to terminate the study after the results from Cohort 1 did not support conducting Cohort 2.	CHEBI_6121	"6130"		"10057840"	"370143000"
	DB00683	Major Depressive Disorder	C1269683	NCT03889756	Terminated	Phase 2/Phase 3	No more funding available to continue since we could not recruit throughout the pandemic.	CHEBI_6931	"6960"		"10057840"	"370143000"
ketamine	DB01221	Major Depressive Disorder	C1269683	NCT05193318	Terminated	Phase 2	Primary Investigator leaving institution	CHEBI_6121	"6130"		"10057840"	"370143000"
brexpiprazole	DB09128	Major Depressive Disorder	C1269683		Approved			CHEBI_134716	"1658314"		"10057840"	"370143000"
venlafaxine	DB00285	Major Depressive Disorder	C1269683		Approved			CHEBI_9943	"39786"		"10057840"	"370143000"
	DB08997	Major Depressive Disorder	C1269683	NCT00642694	Terminated	Phase 3	Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor	CHEBI_135531	"3267"		"10057840"	"370143000"
ketamine	DB01221	Major Depressive Disorder	C1269683	NCT02661061	Terminated	Phase 1	Inadequate recruitment	CHEBI_6121	"6130"		"10057840"	"370143000"
	DB00683	Major Depressive Disorder	C1269683	NCT02661061	Terminated	Phase 1	Inadequate recruitment	CHEBI_6931	"6960"		"10057840"	"370143000"
sacrosidase	DB06760	Sucrase-isomaltase deficiency, congenital	C1283620		Approved				"214817"	MONDO_0009114	"10066387"	"360854006"
carvedilol	DB01136	Glioblastoma Multiforme	C1621958	NCT03861598	Terminated	Early Phase 1	Due to Covid	CHEBI_3441	"20352"	HP:0012174	"10018337"	"393563007"
	DB00958	Glioblastoma Multiforme	C1621958	NCT03149575	Terminated	Phase 3	Change in clinical development plan	CHEBI_31355	"40048"	HP:0012174	"10018337"	"393563007"
flucytosine	DB01099	Glioblastoma Multiforme	C1621958	NCT02414165	Terminated	Phase 2/Phase 3	Sponsor Decision	CHEBI_5100	"4451"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT01044966	Terminated	Phase 1/Phase 2	The study was terminated due to lack of adequate patient enrollment into trial.	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT00904852	Withdrawn	Phase 1			"253337|2046138"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT00904852	Withdrawn	Phase 1		CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
everolimus	DB01590	Glioblastoma Multiforme	C1621958	NCT00515086	Terminated	Phase 2	Early termination due to slow enrollment and protocol-defined stopping rule.	CHEBI_68478	"141704"	HP:0012174	"10018337"	"393563007"
cyclophosphamide	DB00531	Glioblastoma Multiforme	C1621958	NCT00990496	Terminated	Phase 1	Accrual goals not met	CHEBI_4027	"1545988|3002"	HP:0012174	"10018337"	"393563007"
	DB00853	Glioblastoma Multiforme	C1621958	NCT02414165	Terminated	Phase 2/Phase 3	Sponsor Decision	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT02510950	Terminated	Phase 1	Low accrual	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
aminolevulinic acid	DB00855	Glioblastoma Multiforme	C1621958	NCT01351519	Terminated	Phase 2	Limited staff available for enrollment and limited availability of drug	CHEBI_356416	"683"	HP:0012174	"10018337"	"393563007"
carboplatin	DB00958	Glioblastoma Multiforme	C1621958	NCT01317212	Withdrawn	Phase 1	Sufficient funding could not be secured for the study	CHEBI_31355	"40048"	HP:0012174	"10018337"	"393563007"
	DB01206	Glioblastoma Multiforme	C1621958	NCT02414165	Terminated	Phase 2/Phase 3	Sponsor Decision	CHEBI_6520	"6466"	HP:0012174	"10018337"	"393563007"
bevacizumab	DB00112	Glioblastoma Multiforme	C1621958	NCT01526837	Terminated	Phase 1	Investigators decision		"253337|2046138"	HP:0012174	"10018337"	"393563007"
paclitaxel	DB01229	Glioblastoma Multiforme	C1621958	NCT00479765	Terminated	Phase 1/Phase 2	Sponsor business decision, not based on safety or efficacy data	CHEBI_45863	"56946"	HP:0012174	"10018337"	"393563007"
	DB00262	Glioblastoma Multiforme	C1621958	NCT00548938	Terminated	Phase 2	Principal Investigator has left the institution	CHEBI_3423	"2105"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT01386710	Suspended	Phase 1/Phase 2	PI left previous institution study will reopen at new institution.		"253337|2046138"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT00508456	Terminated	Phase 1	Low Accrual	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
carvedilol	DB01136	Glioblastoma Multiforme	C1621958	NCT03980249	Withdrawn	Early Phase 1	No funding	CHEBI_3441	"20352"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT00615186	Terminated	Phase 3	Due to delay in site initiation and funding considerations	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT01186406	Terminated	Phase 2	Study ended early due to toxicity		"253337|2046138"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT01186406	Terminated	Phase 2	Study ended early due to toxicity	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
axitinib	DB06626	Glioblastoma Multiforme	C1621958	NCT01508117	Terminated	Phase 2	transferred study sponsor	CHEBI_66910	"1242999"	HP:0012174	"10018337"	"393563007"
lomustine	DB01206	Glioblastoma Multiforme	C1621958	NCT03149575	Terminated	Phase 3	Change in clinical development plan	CHEBI_6520	"6466"	HP:0012174	"10018337"	"393563007"
irinotecan	DB00762	Glioblastoma Multiforme	C1621958	NCT00984438	Withdrawn	Phase 1/Phase 2	No accrual	CHEBI_80630	"51499"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT00984438	Withdrawn	Phase 1/Phase 2	No accrual		"253337|2046138"	HP:0012174	"10018337"	"393563007"
	DB14483	Glioblastoma Multiforme	C1621958	NCT04900792	Suspended	Phase 1	Toxicity assessment per protocol		"1307765|142407"	HP:0012174	"10018337"	"393563007"
	DB00853	Glioblastoma Multiforme	C1621958	NCT03149575	Terminated	Phase 3	Change in clinical development plan	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
carboplatin	DB00958	Glioblastoma Multiforme	C1621958	NCT00650949	Terminated	Phase 1/Phase 2	Strategic	CHEBI_31355	"40048"	HP:0012174	"10018337"	"393563007"
sunitinib	DB01268	Glioblastoma Multiforme	C1621958	NCT00923117	Terminated	Phase 2	The study was terminated based on results of an interim analysis for futility.	CHEBI_38940	"357977"	HP:0012174	"10018337"	"393563007"
dexamethasone	DB01234	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_41879	"3264"	MONDO_0011786	"10039085"	"61582004"
erlotinib	DB00530	Glioblastoma Multiforme	C1621958	NCT01110876	Terminated	Phase 1/Phase 2	Unanticipated Toxicities	CHEBI_114785	"337525"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT00376103	Terminated	Phase 1/Phase 2	Loss of funding from sponsor	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
flucytosine	DB01099	Glioblastoma Multiforme	C1621958	NCT04327011	Terminated	Phase 1	Sponsor decision	CHEBI_5100	"4451"	HP:0012174	"10018337"	"393563007"
bevacizumab	DB00112	Glioblastoma Multiforme	C1621958	NCT01933815	Suspended	Phase 1/Phase 2	Business reasons		"253337|2046138"	HP:0012174	"10018337"	"393563007"
	DB00853	Glioblastoma Multiforme	C1621958	NCT01110876	Terminated	Phase 1/Phase 2	Unanticipated Toxicities	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
	DB14482	Glioblastoma Multiforme	C1621958	NCT04900792	Suspended	Phase 1	Toxicity assessment per protocol	CHEBI_113451	"267366"	HP:0012174	"10018337"	"393563007"
	DB02546	Glioblastoma Multiforme	C1621958	NCT01110876	Terminated	Phase 1/Phase 2	Unanticipated Toxicities	CHEBI_45716	"194337"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT00548938	Terminated	Phase 2	Principal Investigator has left the institution	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
lucanthone	DB04967	Glioblastoma Multiforme	C1621958	NCT01587144	Terminated	Phase 2	Sponsor's decision	CHEBI_51052		HP:0012174	"10018337"	"393563007"
	DB00126	Glioblastoma Multiforme	C1621958	NCT04900792	Suspended	Phase 1	Toxicity assessment per protocol	CHEBI_29073	"1151|1370460"	HP:0012174	"10018337"	"393563007"
	DB00988	Glioblastoma Multiforme	C1621958	NCT02176720	Terminated	Phase 1	PI left HMRI	CHEBI_18243	"3628"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT02864368	Terminated	Phase 1	Funding	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT04900792	Suspended	Phase 1	Toxicity assessment per protocol	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
	DB06186	Glioblastoma Multiforme	C1621958	NCT03707457	Terminated	Phase 1	Funding/material support withdrawn		"1094833"	HP:0012174	"10018337"	"393563007"
nivolumab	DB09035	Glioblastoma Multiforme	C1621958	NCT03707457	Terminated	Phase 1	Funding/material support withdrawn		"1597876"	HP:0012174	"10018337"	"393563007"
levodopa	DB01235	Glioblastoma Multiforme	C1621958	NCT02176720	Terminated	Phase 1	PI left HMRI	CHEBI_15765	"6375"	HP:0012174	"10018337"	"393563007"
	DB00262	Glioblastoma Multiforme	C1621958	NCT01186406	Terminated	Phase 2	Study ended early due to toxicity	CHEBI_3423	"2105"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT03419403	Terminated	Phase 3	The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
	DB00853	Glioblastoma Multiforme	C1621958	NCT01587144	Terminated	Phase 2	Sponsor's decision	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT02414165	Terminated	Phase 2/Phase 3	Sponsor Decision		"253337|2046138"	HP:0012174	"10018337"	"393563007"
irinotecan	DB00762	Glioblastoma Multiforme	C1621958	NCT02060955	Terminated	Phase 2	Substantial design modifications required.	CHEBI_80630	"51499"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT02060955	Terminated	Phase 2	Substantial design modifications required.		"253337|2046138"	HP:0012174	"10018337"	"393563007"
bevacizumab	DB00112	Glioblastoma Multiforme	C1621958		Approved				"253337|2046138"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT01884740	Terminated	Phase 1/Phase 2	The study was prematurely closed in December 2021 due to low accrual.		"253337|2046138"	HP:0012174	"10018337"	"393563007"
bevacizumab	DB00112	Glioblastoma Multiforme	C1621958	NCT02047214	Terminated	Phase 2	Due to lack of clinical benefit in the 17 subjects enrolled in the trial to date		"253337|2046138"	HP:0012174	"10018337"	"393563007"
bevacizumab	DB00112	Glioblastoma Multiforme	C1621958	NCT02663271	Terminated	Phase 2	stagnant enrollment		"253337|2046138"	HP:0012174	"10018337"	"393563007"
cetuximab	DB00002	Glioblastoma Multiforme	C1621958	NCT01884740	Terminated	Phase 1/Phase 2	The study was prematurely closed in December 2021 due to low accrual.		"318341"	HP:0012174	"10018337"	"393563007"
	DB00112	Glioblastoma Multiforme	C1621958	NCT00735436	Terminated	Phase 2	Study enrollment was halted due to slow accrual.		"253337|2046138"	HP:0012174	"10018337"	"393563007"
irinotecan	DB00762	Glioblastoma Multiforme	C1621958	NCT00735436	Terminated	Phase 2	Study enrollment was halted due to slow accrual.	CHEBI_80630	"51499"	HP:0012174	"10018337"	"393563007"
	DB00853	Glioblastoma Multiforme	C1621958	NCT03119064	Terminated	Phase 1/Phase 2	lack of response to study therapy	CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
carboplatin	DB00958	Glioblastoma Multiforme	C1621958	NCT01386710	Suspended	Phase 1/Phase 2	PI left previous institution study will reopen at new institution.	CHEBI_31355	"40048"	HP:0012174	"10018337"	"393563007"
irinotecan	DB00762	Glioblastoma Multiforme	C1621958	NCT03119064	Terminated	Phase 1/Phase 2	lack of response to study therapy	CHEBI_80630	"51499"	HP:0012174	"10018337"	"393563007"
temozolomide	DB00853	Glioblastoma Multiforme	C1621958	NCT02850744	Terminated	Phase 2		CHEBI_72564	"37776"	HP:0012174	"10018337"	"393563007"
meropenem	DB00760	Complicated appendicitis	C1632842		Approved			CHEBI_43968	"1546029|29561"		"10081534"	"418171008"
doripenem	DB06211	Complicated appendicitis	C1632842		Approved			CHEBI_135928	"119771"		"10081534"	"418171008"
tigecycline	DB00560	Complicated appendicitis	C1632842		Approved			CHEBI_149836	"384455"		"10081534"	"418171008"
codeine	DB00318	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_16714	"2670|1545976|235412"	MONDO_0011786	"10039085"	"61582004"
cortisone acetate	DB01380	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3897	"21655"	MONDO_0011786	"10039085"	"61582004"
cromoglicic acid	DB01003	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_59773	"2921|42612"	MONDO_0011786	"10039085"	"61582004"
cyclizine	DB01176	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3994	"2977"	MONDO_0011786	"10039085"	"61582004"
cyproheptadine	DB00434	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_4046	"3013"	MONDO_0011786	"10039085"	"61582004"
desloratadine	DB00967	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_291342	"275635"	MONDO_0011786	"10039085"	"61582004"
acrivastine	DB09488	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_83168	"19959"	MONDO_0011786	"10039085"	"61582004"
dexbrompheniramine	DB00405	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_59269	"22696|1767"	MONDO_0011786	"10039085"	"61582004"
dextromethorphan	DB00514	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_4470	"3289"	MONDO_0011786	"10039085"	"61582004"
dihydrocodeine	DB01551	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_135276	"23088"	MONDO_0011786	"10039085"	"61582004"
diphenylpyraline	DB01146	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_59788	"23386"	MONDO_0011786	"10039085"	"61582004"
clemastine	DB00283	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3738	"2578"	MONDO_0011786	"10039085"	"61582004"
doxylamine	DB00366	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_51380	"3642"	MONDO_0011786	"10039085"	"61582004"
ebastine	DB11742	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_31528	"23796"	MONDO_0011786	"10039085"	"61582004"
	DB00764	Allergic rhinitis (disorder)	C2607914	NCT02953379	Withdrawn	Phase 3	Sponsor decision	CHEBI_6970		MONDO_0011786	"10039085"	"61582004"
mometasone furoate	DB14512	Allergic rhinitis (disorder)	C2607914	NCT02953379	Withdrawn	Phase 3	Sponsor decision	CHEBI_47564	"30145"	MONDO_0011786	"10039085"	"61582004"
ephedrine	DB01364	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_15407	"3966"	MONDO_0011786	"10039085"	"61582004"
epoprostenol	DB01240	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_15552	"8814"	MONDO_0011786	"10039085"	"61582004"
fexofenadine	DB00950	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_5050	"87636"	MONDO_0011786	"10039085"	"61582004"
flunisolide	DB00180	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_5106	"1546428|25120"	MONDO_0011786	"10039085"	"61582004"
fluticasone propionate	DB00588	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_31441	"50121"	MONDO_0011786	"10039085"	"61582004"
paracetamol	DB00316	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_46195	"161"	MONDO_0011786	"10039085"	"61582004"
fluticasone propionate	DB13867	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_5134	"41126"	MONDO_0011786	"10039085"	"61582004"
glycine	DB00145	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_15428	"4919"	MONDO_0011786	"10039085"	"61582004"
guaifenesin	DB00874	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_5551	"5032"	MONDO_0011786	"10039085"	"61582004"
hydrocodone	DB00956	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_5779	"5489"	MONDO_0011786	"10039085"	"61582004"
hydrocortisone	DB00741	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_17650	"5492"	MONDO_0011786	"10039085"	"61582004"
hydroxyzine	DB00557	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_5818	"5553"	MONDO_0011786	"10039085"	"61582004"
ipratropium	DB00332	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_46659	"1546373|203212|7213"	MONDO_0011786	"10039085"	"61582004"
levocetirizine	DB06282	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_94559	"356887"	MONDO_0011786	"10039085"	"61582004"
carbinoxamine	DB00748	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3398	"20220"	MONDO_0011786	"10039085"	"61582004"
loratadine	DB00455	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_6538	"28889"	MONDO_0011786	"10039085"	"61582004"
mebhydrolin	DB13808	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_135144		MONDO_0011786	"10039085"	"61582004"
methapyrilene	DB04819	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_6820	"6822"	MONDO_0011786	"10039085"	"61582004"
methdilazine	DB00902	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_6823	"29648"	MONDO_0011786	"10039085"	"61582004"
methscopolamine	DB11315	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_135361	"89785"	MONDO_0011786	"10039085"	"61582004"
methscopolamine	DB00462	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_61276	"56092"	MONDO_0011786	"10039085"	"61582004"
isoflupredone acetate	DB11522	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_34511		MONDO_0011786	"10039085"	"61582004"
isoflupredone acetate	DB14640	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_34517		MONDO_0011786	"10039085"	"61582004"
methylprednisolone	DB00959	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_6888	"6902"	MONDO_0011786	"10039085"	"61582004"
mizolastine	DB12523	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_31857	"61455"	MONDO_0011786	"10039085"	"61582004"
mometasone furoate	DB14512	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_47564	"30145"	MONDO_0011786	"10039085"	"61582004"
pentoxyverine	DB11186	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_94484	"20217"	MONDO_0011786	"10039085"	"61582004"
mometasone furoate	DB00764	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_6970		MONDO_0011786	"10039085"	"61582004"
montelukast	DB00471	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_50730	"88249"	MONDO_0011786	"10039085"	"61582004"
olopatadine	DB00768	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_7769	"135391"	MONDO_0011786	"10039085"	"61582004"
pemirolast	DB00885	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_134936	"19551"	MONDO_0011786	"10039085"	"61582004"
phenindamine	DB01619	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_8065	"33283"	MONDO_0011786	"10039085"	"61582004"
pheniramine	DB01620	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_91591	"8132"	MONDO_0011786	"10039085"	"61582004"
phenylephrine	DB00388	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_8093	"8163"	MONDO_0011786	"10039085"	"61582004"
phenylpropanolamine	DB00397	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_80680	"8175"	MONDO_0011786	"10039085"	"61582004"
phenyltoloxamine	DB11160	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_135047	"33408"	MONDO_0011786	"10039085"	"61582004"
pranlukast	DB01411	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_94810		MONDO_0011786	"10039085"	"61582004"
antazoline	DB08799	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_84115	"865"	MONDO_0011786	"10039085"	"61582004"
quifenadine	DB13713	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_134746		MONDO_0011786	"10039085"	"61582004"
ephedrine	DB01364	Allergic rhinitis (disorder)	C2607914	NCT01055756	Withdrawn	Phase 3		CHEBI_15407	"3966"	MONDO_0011786	"10039085"	"61582004"
	DB00455	Allergic rhinitis (disorder)	C2607914	NCT01055756	Withdrawn	Phase 3		CHEBI_6538	"28889"	MONDO_0011786	"10039085"	"61582004"
	DB00852	Allergic rhinitis (disorder)	C2607914	NCT01055756	Withdrawn	Phase 3		CHEBI_51209	"8896"	MONDO_0011786	"10039085"	"61582004"
prednisolone	DB00860	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_8378	"8638"	MONDO_0011786	"10039085"	"61582004"
prednisone	DB00635	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_8382	"8640"	MONDO_0011786	"10039085"	"61582004"
promazine	DB00420	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_8459	"8742"	MONDO_0011786	"10039085"	"61582004"
pseudoephedrine	DB00852	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_51209	"8896"	MONDO_0011786	"10039085"	"61582004"
caffeine	DB00201	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_27732	"1886"	MONDO_0011786	"10039085"	"61582004"
mepyramine	DB06691	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_6762	"9009"	MONDO_0011786	"10039085"	"61582004"
ramatroban	DB13036	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_32087		MONDO_0011786	"10039085"	"61582004"
fluticasone furoate	DB13867	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_5134	"41126"	MONDO_0011786	"10039085"	"61582004"
fluticasone furoate	DB08906	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_74899	"705022"	MONDO_0011786	"10039085"	"61582004"
rupatadine	DB11614	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_135673		MONDO_0011786	"10039085"	"61582004"
salicylic acid	DB00936	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_16914	"9525"	MONDO_0011786	"10039085"	"61582004"
salicylic acid	DB14006	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_16914	"20974"	MONDO_0011786	"10039085"	"61582004"
salicylic acid	DB13860	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_16914		MONDO_0011786	"10039085"	"61582004"
scopolamine	DB00747	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_16794	"9601|9603"	MONDO_0011786	"10039085"	"61582004"
astemizole	DB00637	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_2896	"42328"	MONDO_0011786	"10039085"	"61582004"
hydrocortisone succinate	DB00741	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_17650	"5492"	MONDO_0011786	"10039085"	"61582004"
terfenadine	DB00342	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_9453	"42330"	MONDO_0011786	"10039085"	"61582004"
hydrocortisone succinate	DB14545	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_31677	"21651"	MONDO_0011786	"10039085"	"61582004"
dexchlorpheniramine	DB09555	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_4465	"54828"	MONDO_0011786	"10039085"	"61582004"
dexchlorpheniramine	DB13679	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_4464	"22697"	MONDO_0011786	"10039085"	"61582004"
bilastine	DB11591	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_135954		MONDO_0011786	"10039085"	"61582004"
potassium iodide	DB06715	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_8346	"8597"	MONDO_0011786	"10039085"	"61582004"
azatadine	DB00719	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_2946	"18600"	MONDO_0011786	"10039085"	"61582004"
	DB00764	Allergic rhinitis (disorder)	C2607914	NCT04670653	Withdrawn	Phase 3	Sponsor decision	CHEBI_6970		MONDO_0011786	"10039085"	"61582004"
mometasone furoate	DB14512	Allergic rhinitis (disorder)	C2607914	NCT04670653	Withdrawn	Phase 3	Sponsor decision	CHEBI_47564	"30145"	MONDO_0011786	"10039085"	"61582004"
azelastine	DB00972	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_2950	"18603"	MONDO_0011786	"10039085"	"61582004"
tranilast	DB07615	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_77572	"57330"	MONDO_0011786	"10039085"	"61582004"
triamcinolone	DB00620	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_9667	"10759"	MONDO_0011786	"10039085"	"61582004"
triamcinolone acetonide	DB00620	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_9667	"10759"	MONDO_0011786	"10039085"	"61582004"
triamcinolone diacetate	DB00620	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_9667	"10759"	MONDO_0011786	"10039085"	"61582004"
alimemazine	DB01246	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_9725	"10825"	MONDO_0011786	"10039085"	"61582004"
tripelennamine	DB00792	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_9741	"10847"	MONDO_0011786	"10039085"	"61582004"
triprolidine	DB00427	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_84116	"10849"	MONDO_0011786	"10039085"	"61582004"
hydrocortisone acetate	DB00741	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_17650	"5492"	MONDO_0011786	"10039085"	"61582004"
hydrocortisone acetate	DB14539	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_17609	"27197"	MONDO_0011786	"10039085"	"61582004"
	DB00764	Allergic rhinitis (disorder)	C2607914	NCT02953366	Withdrawn	Phase 3	Sponsor decision	CHEBI_6970		MONDO_0011786	"10039085"	"61582004"
mometasone furoate	DB14512	Allergic rhinitis (disorder)	C2607914	NCT02953366	Withdrawn	Phase 3	Sponsor decision	CHEBI_47564	"30145"	MONDO_0011786	"10039085"	"61582004"
	DB03255	Allergic rhinitis (disorder)	C2607914	NCT01989897	Withdrawn	Phase 1/Phase 2	Funding for the trial was lost so study was ended. No participants were enrolled.	CHEBI_15882	"33290"	MONDO_0011786	"10039085"	"61582004"
histamine	DB05381	Allergic rhinitis (disorder)	C2607914	NCT01989897	Withdrawn	Phase 1/Phase 2	Funding for the trial was lost so study was ended. No participants were enrolled.	CHEBI_18295	"5333"	MONDO_0011786	"10039085"	"61582004"
beclometasone dipropionate	DB00394	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3002	"1348"	MONDO_0011786	"10039085"	"61582004"
budesonide	DB01222	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3207	"19831"	MONDO_0011786	"10039085"	"61582004"
desonide	DB01260	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_204734	"3254"	MONDO_0011786	"10039085"	"61582004"
chlorcyclizine	DB08936	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_94402	"2354"	MONDO_0011786	"10039085"	"61582004"
betamethasone	DB00443	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3077	"1514"	MONDO_0011786	"10039085"	"61582004"
brompheniramine	DB00835	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3183	"1767"	MONDO_0011786	"10039085"	"61582004"
clofedanol	DB04837	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_135207	"21254"	MONDO_0011786	"10039085"	"61582004"
chlorphenamine	DB01114	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_52010	"221074|2400"	MONDO_0011786	"10039085"	"61582004"
cetirizine	DB00341	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3561	"20610"	MONDO_0011786	"10039085"	"61582004"
betamethasone acetate	DB00443	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_3077	"1514"	MONDO_0011786	"10039085"	"61582004"
ciclesonide	DB01410	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_31397	"274964"	MONDO_0011786	"10039085"	"61582004"
pyrithione	DB06815	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_36584	"35100"	MONDO_0011786	"10039085"	"61582004"
tramazoline	DB13064	Allergic rhinitis (disorder)	C2607914		Approved			CHEBI_134893	"38453"	MONDO_0011786	"10039085"	"61582004"
sitaxentan	DB06268	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_135736		MONDO_0015924	"10064911"	"11399002"
metformin	DB00331	Pulmonary arterial hypertension	C2973725	NCT01352026	Withdrawn	Phase 2	Several therapeutic have been developed making more difficult the eligibility of patients - Recruitment of new centers wasn't possible due to competing trials	CHEBI_6801	"6809"	MONDO_0015924	"10064911"	"11399002"
	DB00820	Pulmonary arterial hypertension	C2973725	NCT01244620	Terminated	Phase 1	Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.	CHEBI_71940	"358263"	MONDO_0015924	"10064911"	"11399002"
sildenafil	DB00203	Pulmonary arterial hypertension	C2973725	NCT01244620	Terminated	Phase 1	Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.	CHEBI_9139	"136411"	MONDO_0015924	"10064911"	"11399002"
riociguat	DB08931	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_76018	"1439816"	MONDO_0015924	"10064911"	"11399002"
macitentan	DB08932	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_76607	"1442132"	MONDO_0015924	"10064911"	"11399002"
iloprost	DB01088	Pulmonary arterial hypertension	C2973725	NCT00453414	Withdrawn	Phase 2	Withdrawn due to lack of enrollment	CHEBI_63916	"40138"	MONDO_0015924	"10064911"	"11399002"
imatinib	DB00619	Pulmonary arterial hypertension	C2973725	NCT01117987	Terminated	Phase 3	Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.	CHEBI_45783	"282388"	MONDO_0015924	"10064911"	"11399002"
sildenafil	DB00203	Pulmonary arterial hypertension	C2973725	NCT00796510	Terminated	Phase 3	Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury	CHEBI_9139	"136411"	MONDO_0015924	"10064911"	"11399002"
nitric oxide	DB00435	Pulmonary arterial hypertension	C2973725	NCT02436512	Withdrawn	Phase 3	Inability meet enrollment in study population.	CHEBI_16480	"7442"	MONDO_0015924	"10064911"	"11399002"
beraprost	DB05229	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_135633		MONDO_0015924	"10064911"	"11399002"
sildenafil	DB00203	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_9139	"136411"	MONDO_0015924	"10064911"	"11399002"
imatinib	DB00619	Pulmonary arterial hypertension	C2973725	NCT01392495	Terminated	Phase 3	Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.	CHEBI_45783	"282388"	MONDO_0015924	"10064911"	"11399002"
epoprostenol	DB01240	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_15552	"8814"	MONDO_0015924	"10064911"	"11399002"
rifampicin	DB01045	Pulmonary arterial hypertension	C2973725	NCT01251835	Withdrawn	Phase 1		CHEBI_71365	"9384"	MONDO_0015924	"10064911"	"11399002"
terguride	DB13399	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_32193		MONDO_0015924	"10064911"	"11399002"
imdevimab	DB15940	COVID19 (disease)	C5203670		Approved				"2465249"		"10084268"	"840539006"
sildenafil	DB00203	Pulmonary arterial hypertension	C2973725	NCT00796666	Terminated	Phase 3	Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.	CHEBI_9139	"136411"	MONDO_0015924	"10064911"	"11399002"
iloprost	DB01088	Pulmonary arterial hypertension	C2973725	NCT00723554	Terminated	Phase 3	sponsor's decision	CHEBI_63916	"40138"	MONDO_0015924	"10064911"	"11399002"
nitric oxide	DB00435	Pulmonary arterial hypertension	C2973725	NCT03602781	Withdrawn	Phase 3	Decision not to proceed with Study	CHEBI_16480	"7442"	MONDO_0015924	"10064911"	"11399002"
carvedilol	DB01136	Pulmonary arterial hypertension	C2973725	NCT02507011	Terminated	Phase 2	Recruitment	CHEBI_3441	"20352"	MONDO_0015924	"10064911"	"11399002"
ambrisentan	DB06403	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_135949	"358274"	MONDO_0015924	"10064911"	"11399002"
carvedilol	DB01136	Pulmonary arterial hypertension	C2973725	NCT01723371	Withdrawn	Phase 1/Phase 2	Due to lack of enrollment.	CHEBI_3441	"20352"	MONDO_0015924	"10064911"	"11399002"
salbutamol	DB01001	Pulmonary arterial hypertension	C2973725	NCT02782052	Withdrawn	Phase 3	Sponsor's decision	CHEBI_2549	"435"	MONDO_0015924	"10064911"	"11399002"
	DB00332	Pulmonary arterial hypertension	C2973725	NCT02782052	Withdrawn	Phase 3	Sponsor's decision	CHEBI_46659	"1546373|203212|7213"	MONDO_0015924	"10064911"	"11399002"
iloprost	DB01088	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_63916	"40138"	MONDO_0015924	"10064911"	"11399002"
bosentan	DB00559	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_51450	"75207|1468845"	MONDO_0015924	"10064911"	"11399002"
nitric oxide	DB00435	Pulmonary arterial hypertension	C2973725	NCT02725372	Terminated	Phase 3	Trial stopped for futility	CHEBI_16480	"7442"	MONDO_0015924	"10064911"	"11399002"
ritonavir	DB00503	Pulmonary arterial hypertension	C2973725	NCT01251848	Withdrawn	Phase 1		CHEBI_45409	"85762"	MONDO_0015924	"10064911"	"11399002"
treprostinil	DB00374	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_50861	"343048"	MONDO_0015924	"10064911"	"11399002"
selexipag	DB11362	Pulmonary arterial hypertension	C2973725		Approved			CHEBI_90844	"1729002"	MONDO_0015924	"10064911"	"11399002"
	DB00987	Refractory acute myeloid leukemia	C4528668	NCT04196010	Terminated	Phase 1	Terminated due to unfavorable risk-benefit ratio of investigational regimen.	CHEBI_28680	"3041|968804"		"10081513"	"12291000132102"
cyclophosphamide	DB00531	Refractory acute myeloid leukemia	C4528668	NCT04893915	Withdrawn	Phase 2	No funding support	CHEBI_4027	"1545988|3002"		"10081513"	"12291000132102"
azacitidine	DB00928	Refractory acute myeloid leukemia	C4528668	NCT02399917	Terminated	Phase 2	This study was terminated early due to response rates not meeting the anticipated minimum of 30%.	CHEBI_2038	"1251"		"10081513"	"12291000132102"
	DB00987	Refractory acute myeloid leukemia	C4528668	NCT04797767	Suspended	Phase 1	Pending protocol amendment	CHEBI_28680	"3041|968804"		"10081513"	"12291000132102"
	DB00242	Refractory acute myeloid leukemia	C4528668	NCT04797767	Suspended	Phase 1	Pending protocol amendment	CHEBI_567361	"44157"		"10081513"	"12291000132102"
decitabine	DB01262	Refractory acute myeloid leukemia	C4528668	NCT03752138	Withdrawn	Phase 1	The supporting pharamceutical company elected not to pursue this study at this time.	CHEBI_50131	"15657"		"10081513"	"12291000132102"
	DB01008	Refractory acute myeloid leukemia	C4528668	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_28901	"1828"		"10081513"	"12291000132102"
	DB13144	Refractory acute myeloid leukemia	C4528668	NCT04797767	Suspended	Phase 1	Pending protocol amendment		"70167"		"10081513"	"12291000132102"
enocitabine	DB01204	Refractory acute myeloid leukemia	C4528668	NCT04797767	Suspended	Phase 1	Pending protocol amendment	CHEBI_50729	"7005"		"10081513"	"12291000132102"
	DB00242	Refractory acute myeloid leukemia	C4528668	NCT04196010	Terminated	Phase 1	Terminated due to unfavorable risk-benefit ratio of investigational regimen.	CHEBI_567361	"44157"		"10081513"	"12291000132102"
	DB13144	Refractory acute myeloid leukemia	C4528668	NCT04196010	Terminated	Phase 1	Terminated due to unfavorable risk-benefit ratio of investigational regimen.		"70167"		"10081513"	"12291000132102"
	DB00091	Refractory acute myeloid leukemia	C4528668	NCT03128034	Suspended	Phase 1/Phase 2	Administrative - FDA Comments	CHEBI_4031	"3008"		"10081513"	"12291000132102"
enocitabine	DB00650	Refractory acute myeloid leukemia	C4528668	NCT05146739	Suspended	Phase 1	Other - Pending release of next amendment.	CHEBI_15640	"6313"		"10081513"	"12291000132102"
filgrastim	DB00099	Refractory acute myeloid leukemia	C4528668		Approved				"1605064|1433764|2057198|68442"		"10081513"	"12291000132102"
	DB00987	Refractory acute myeloid leukemia	C4528668	NCT05146739	Suspended	Phase 1	Other - Pending release of next amendment.	CHEBI_28680	"3041|968804"		"10081513"	"12291000132102"
azacitidine	DB00928	Refractory acute myeloid leukemia	C4528668	NCT02953561	Terminated	Phase 1/Phase 2	PDOL request	CHEBI_2038	"1251"		"10081513"	"12291000132102"
	DB01268	Refractory acute myeloid leukemia	C4528668	NCT01620216	Terminated	Phase 2	Unable to recruit enough eligible subjects	CHEBI_38940	"357977"		"10081513"	"12291000132102"
	DB00987	Refractory acute myeloid leukemia	C4528668	NCT03519984	Terminated	Phase 1	Study drug supply issue	CHEBI_28680	"3041|968804"		"10081513"	"12291000132102"
enocitabine	DB00541	Refractory acute myeloid leukemia	C4528668	NCT03519984	Terminated	Phase 1	Study drug supply issue	CHEBI_28445	"11202"		"10081513"	"12291000132102"
enocitabine	DB01204	Refractory acute myeloid leukemia	C4528668	NCT04196010	Terminated	Phase 1	Terminated due to unfavorable risk-benefit ratio of investigational regimen.	CHEBI_50729	"7005"		"10081513"	"12291000132102"
	DB00531	Refractory acute myeloid leukemia	C4528668	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_4027	"1545988|3002"		"10081513"	"12291000132102"
mycophenolate mofetil	DB01024	Refractory acute myeloid leukemia	C4528668	NCT03128034	Suspended	Phase 1/Phase 2	Administrative - FDA Comments	CHEBI_168396	"7145|265323"		"10081513"	"12291000132102"
azacitidine	DB00928	Refractory acute myeloid leukemia	C4528668	NCT03745352	Withdrawn	Phase 2	Inadequate accrual rate	CHEBI_2038	"1251"		"10081513"	"12291000132102"
decitabine	DB01262	Refractory acute myeloid leukemia	C4528668	NCT03041688	Suspended	Phase 1	Other - Pending amendment	CHEBI_50131	"15657"		"10081513"	"12291000132102"
	DB01254	Refractory acute myeloid leukemia	C4528668	NCT01620216	Terminated	Phase 2	Unable to recruit enough eligible subjects	CHEBI_49375	"475342|1546019"		"10081513"	"12291000132102"
	DB00091	Refractory acute myeloid leukemia	C4528668	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_4031	"3008"		"10081513"	"12291000132102"
enocitabine	DB00987	Refractory acute myeloid leukemia	C4528668	NCT04354025	Withdrawn	Phase 2	Principal investigator decided not to move forward with the study.	CHEBI_28680	"3041|968804"		"10081513"	"12291000132102"
lenograstim	DB13144	Refractory acute myeloid leukemia	C4528668		Approved				"70167"		"10081513"	"12291000132102"
decitabine	DB01262	Refractory acute myeloid leukemia	C4528668	NCT04493099	Withdrawn	Phase 1/Phase 2	The original sponsor was acquired by a new company and has elected to end funding for all Investigator Sponsored Trials (ISTs)	CHEBI_50131	"15657"		"10081513"	"12291000132102"
decitabine	DB01262	Refractory acute myeloid leukemia	C4528668	NCT04013880	Withdrawn	Phase 1/Phase 2	Loss of funding	CHEBI_50131	"15657"		"10081513"	"12291000132102"
sorafenib	DB00398	Refractory acute myeloid leukemia	C4528668	NCT01620216	Terminated	Phase 2	Unable to recruit enough eligible subjects	CHEBI_50924	"495881"		"10081513"	"12291000132102"
methotrexate	DB00563	Refractory acute myeloid leukemia	C4528668	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_44185	"6851"		"10081513"	"12291000132102"
enocitabine	DB00987	Refractory acute myeloid leukemia	C4528668	NCT02109627	Terminated	Phase 1	Low Accrual	CHEBI_28680	"3041|968804"		"10081513"	"12291000132102"
	DB00864	Refractory acute myeloid leukemia	C4528668	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_61049	"42316|235991"		"10081513"	"12291000132102"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04336332	Terminated	Phase 2	Ineffectiveness of treatment	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04336332	Terminated	Phase 2	Ineffectiveness of treatment	CHEBI_2955	"18631"		"10084268"	"840539006"
nitric oxide	DB00435	COVID19 (disease)	C5203670	NCT04398290	Withdrawn	Phase 2	IRB AND FDA REVIEWS DEFERRED	CHEBI_16480	"7442"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04329572	Suspended	Early Phase 1	Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.	CHEBI_2955	"18631"		"10084268"	"840539006"
chloroquine	DB00608	COVID19 (disease)	C5203670	NCT04344951	Terminated	Phase 2	No clinical efficacy against SARS-CoV-2 recorded	CHEBI_3638	"2393"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04329572	Suspended	Early Phase 1	Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.	CHEBI_5801	"5521"		"10084268"	"840539006"
fluvoxamine	DB00176	COVID19 (disease)	C5203670	NCT05216614	Withdrawn	Phase 2	Unable to obtain investigational product	CHEBI_5138	"42355"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04345692	Terminated	Phase 3	RECOVERY Trial results - no efficacy	CHEBI_5801	"5521"		"10084268"	"840539006"
rivaroxaban	DB06228	COVID19 (disease)	C5203670	NCT04504032	Terminated	Phase 2	Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.	CHEBI_68579	"1114195"		"10084268"	"840539006"
losartan	DB00678	COVID19 (disease)	C5203670	NCT04343001	Withdrawn	Phase 3	Grant not obtained	CHEBI_6541	"52175"		"10084268"	"840539006"
enoxaparin sodium	DB01225	COVID19 (disease)	C5203670	NCT04492254	Terminated	Phase 3	Average event rate (end point) was much lower than expected. A larger sample size would have been required to maintain same statistical power, which was not achievable in a feasible time scale. No safety concerns were identified with bleeding.		"67108"		"10084268"	"840539006"
	DB00860	COVID19 (disease)	C5203670	NCT04377503	Terminated	Phase 2	The number of critically ill patients wirh COVID-19 decrease abruptly	CHEBI_8378	"8638"		"10084268"	"840539006"
	DB14644	COVID19 (disease)	C5203670	NCT04377503	Terminated	Phase 2	The number of critically ill patients wirh COVID-19 decrease abruptly	CHEBI_135765			"10084268"	"840539006"
methylprednisolone	DB00959	COVID19 (disease)	C5203670	NCT04377503	Terminated	Phase 2	The number of critically ill patients wirh COVID-19 decrease abruptly	CHEBI_6888	"6902"		"10084268"	"840539006"
	DB00602	COVID19 (disease)	C5203670	NCT05283954	Withdrawn	Phase 2/Phase 3	Lack of funding		"6069"		"10084268"	"840539006"
	DB00860	COVID19 (disease)	C5203670	NCT05283954	Withdrawn	Phase 2/Phase 3	Lack of funding	CHEBI_8378	"8638"		"10084268"	"840539006"
	DB00472	COVID19 (disease)	C5203670	NCT05283954	Withdrawn	Phase 2/Phase 3	Lack of funding	CHEBI_86990	"4493"		"10084268"	"840539006"
albendazole	DB00518	COVID19 (disease)	C5203670	NCT05283954	Withdrawn	Phase 2/Phase 3	Lack of funding	CHEBI_16664	"430"		"10084268"	"840539006"
ivermectin	DB00602	COVID19 (disease)	C5203670	NCT05231603	Terminated	Phase 3	Poor response	CHEBI_6078	"6069"		"10084268"	"840539006"
ritonavir	DB00503	COVID19 (disease)	C5203670	NCT05011513	Terminated	Phase 3	Enrollment ceased due to a very low rate of hospitalization or death observed in the standard-risk patient population	CHEBI_45409	"85762"		"10084268"	"840539006"
maraviroc	DB04835	COVID19 (disease)	C5203670	NCT04475991	Terminated	Phase 2	No more patients complying the selection criteria were available for recruitment	CHEBI_63608	"620216"		"10084268"	"840539006"
aprepitant	DB00673	COVID19 (disease)	C5203670	NCT04470622	Terminated	Phase 2	Study was terminated early by Heron, and was not terminated for safety reasons.	CHEBI_499361	"358255"		"10084268"	"840539006"
nitric oxide	DB00435	COVID19 (disease)	C5203670	NCT04601077	Terminated	Phase 1/Phase 2	The study stopped due to futility.	CHEBI_16480	"7442"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04354441	Withdrawn	Phase 2	Not started	CHEBI_5801	"5521"		"10084268"	"840539006"
abatacept	DB01281	COVID19 (disease)	C5203670	NCT04477642	Withdrawn	Phase 1/Phase 2	Funding		"614391"		"10084268"	"840539006"
heparin	DB01109	COVID19 (disease)	C5203670	NCT04485429	Withdrawn	Phase 3	It was not possible to perform the study due to the availability and logistics of porcine heparin	CHEBI_28304	"5224"		"10084268"	"840539006"
	DB00959	COVID19 (disease)	C5203670	NCT04485429	Withdrawn	Phase 3	It was not possible to perform the study due to the availability and logistics of porcine heparin	CHEBI_6888	"6902"		"10084268"	"840539006"
dexamethasone phosphate	DB01234	COVID19 (disease)	C5203670	NCT04360876	Withdrawn	Phase 2	Funding not received	CHEBI_68637	"3264"		"10084268"	"840539006"
azithromycin	DB00207	COVID19 (disease)	C5203670	NCT04332107	Terminated	Phase 3	Futility	CHEBI_2955	"18631"		"10084268"	"840539006"
	DB14644	COVID19 (disease)	C5203670	NCT04485429	Withdrawn	Phase 3	It was not possible to perform the study due to the availability and logistics of porcine heparin	CHEBI_135765			"10084268"	"840539006"
	DB00860	COVID19 (disease)	C5203670	NCT04485429	Withdrawn	Phase 3	It was not possible to perform the study due to the availability and logistics of porcine heparin	CHEBI_8378	"8638"		"10084268"	"840539006"
folic acid	DB00158	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome	CHEBI_27470	"62356|4511|202634"		"10084268"	"840539006"
	DB01611	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB01601	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome	CHEBI_31781	"195088"		"10084268"	"840539006"
	DB00503	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome	CHEBI_45409	"85762"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome	CHEBI_2955	"18631"		"10084268"	"840539006"
	DB00126	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome	CHEBI_29073	"1151|1370460"		"10084268"	"840539006"
naproxen	DB00788	COVID19 (disease)	C5203670	NCT04325633	Terminated	Phase 3	Stop inclusions for insufficient recruitment	CHEBI_7476	"7258"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04389359	Withdrawn	Phase 2/Phase 3	Regulatory approvals not received	CHEBI_5801	"5521"		"10084268"	"840539006"
colecalciferol	DB00169	COVID19 (disease)	C5203670	NCT04400890	Terminated	Phase 2	Feasibility	CHEBI_28940	"2418"		"10084268"	"840539006"
	DB14482	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome	CHEBI_113451	"267366"		"10084268"	"840539006"
	DB14483	COVID19 (disease)	C5203670	NCT04354428	Terminated	Phase 2/Phase 3	Low number of events contributing to primary outcome		"1307765|142407"		"10084268"	"840539006"
prazosin	DB00457	COVID19 (disease)	C5203670	NCT04365257	Terminated	Phase 2	Lack of recruitment	CHEBI_8364	"8629"		"10084268"	"840539006"
	DB01234	COVID19 (disease)	C5203670	NCT04347980	Terminated	Phase 3	ANSM RECOMMANDATION	CHEBI_41879	"3264"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04347980	Terminated	Phase 3	ANSM RECOMMANDATION	CHEBI_5801	"5521"		"10084268"	"840539006"
diltiazem	DB00343	COVID19 (disease)	C5203670	NCT05563168	Withdrawn	Phase 2	the epidemiological situation has changed considerably.	CHEBI_101278	"3443"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04364815	Withdrawn	Phase 3	Investigators opted to change the design of the study.	CHEBI_5801	"5521"		"10084268"	"840539006"
tixagevimab	DB16394	COVID19 (disease)	C5203670		Approved				"2587300"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04363866	Withdrawn	Phase 2	discontinued in favor of more promising directions that may benefit patients	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00641	COVID19 (disease)	C5203670	NCT04343001	Withdrawn	Phase 3	Grant not obtained	CHEBI_9150	"36567"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04381988	Terminated	Phase 2	The study was terminated based results of other studies and use of the new vaccine.	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04348474	Suspended	Early Phase 1	Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.	CHEBI_2955	"18631"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04348474	Suspended	Early Phase 1	Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.	CHEBI_5801	"5521"		"10084268"	"840539006"
dexamethasone phosphate	DB01234	COVID19 (disease)	C5203670	NCT04395105	Terminated	Phase 3	Low rate of recruitment	CHEBI_68637	"3264"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04341441	Terminated	Phase 3	Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00608	COVID19 (disease)	C5203670	NCT04360759	Withdrawn	Phase 3	Equipoise for hydroxychloquine was lost	CHEBI_3638	"2393"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04369742	Terminated	Phase 2	Investigator decision	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04360759	Withdrawn	Phase 3	Equipoise for hydroxychloquine was lost	CHEBI_5801	"5521"		"10084268"	"840539006"
simvastatin	DB00641	COVID19 (disease)	C5203670	NCT05542095	Withdrawn	Phase 1	Study halted prematurely; IRB approval not obtained	CHEBI_9150	"36567"		"10084268"	"840539006"
melatonin	DB01065	COVID19 (disease)	C5203670	NCT04784754	Withdrawn	Phase 2	lack of subject enrollment	CHEBI_16796	"6711"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04339816	Terminated	Phase 3	Steering Committee decision in accordance with stopping rule 1: Emergence of new data	CHEBI_2955	"18631"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04339816	Terminated	Phase 3	Steering Committee decision in accordance with stopping rule 1: Emergence of new data	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04371406	Withdrawn	Phase 3	Regulatory approvals have not been obtained	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04371406	Withdrawn	Phase 3	Regulatory approvals have not been obtained	CHEBI_2955	"18631"		"10084268"	"840539006"
oxytocin	DB00107	COVID19 (disease)	C5203670	NCT04386447	Withdrawn	Phase 2	The study was not approved by the Italian Medicines Agency (AIFA).	CHEBI_7872	"7824"		"10084268"	"840539006"
enoxaparin sodium	DB01225	COVID19 (disease)	C5203670	NCT04400799	Terminated	Phase 3	due to results from interim analysis		"67108"		"10084268"	"840539006"
famotidine	DB00927	COVID19 (disease)	C5203670	NCT04621149	Terminated	Phase 2	Unable to recruit participants due to decline in COVID-19.	CHEBI_4975	"4278"		"10084268"	"840539006"
rivaroxaban	DB06228	COVID19 (disease)	C5203670	NCT04416048	Terminated	Phase 2	Due to lower COVID-19 cases and therefore difficulties with the recruitment.	CHEBI_68579	"1114195"		"10084268"	"840539006"
nitric oxide	DB00435	COVID19 (disease)	C5203670	NCT04388683	Terminated	Phase 2	Bellerophon requested study to be stopped.	CHEBI_16480	"7442"		"10084268"	"840539006"
tranexamic acid	DB00302	COVID19 (disease)	C5203670	NCT04390217	Withdrawn	Phase 2	Company focused on other clinical programs	CHEBI_48669	"10691"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04358068	Terminated	Phase 2	Slow enrollment and lack of community enthusiasm	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04358068	Terminated	Phase 2	Slow enrollment and lack of community enthusiasm	CHEBI_2955	"18631"		"10084268"	"840539006"
	DB00704	COVID19 (disease)	C5203670	NCT04365985	Terminated	Phase 2	Because of the decrease in COVID cases, enrollment is extremely low. Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality	CHEBI_7465	"7243"		"10084268"	"840539006"
ketamine	DB01221	COVID19 (disease)	C5203670	NCT04365985	Terminated	Phase 2	Because of the decrease in COVID cases, enrollment is extremely low. Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality	CHEBI_6121	"6130"		"10084268"	"840539006"
cilgavimab	DB16393	COVID19 (disease)	C5203670		Approved				"2587306"		"10084268"	"840539006"
melatonin	DB01065	COVID19 (disease)	C5203670	NCT04474483	Terminated	Phase 2	difficult recruitment and complete first visit in person during thne hight of tne pandemic and later not enough subjects	CHEBI_16796	"6711"		"10084268"	"840539006"
	DB00503	COVID19 (disease)	C5203670	NCT04328285	Terminated	Phase 3	French authority's decision	CHEBI_45409	"85762"		"10084268"	"840539006"
	DB01601	COVID19 (disease)	C5203670	NCT04328285	Terminated	Phase 3	French authority's decision	CHEBI_31781	"195088"		"10084268"	"840539006"
prednisone	DB00635	COVID19 (disease)	C5203670	NCT04344288	Terminated	Phase 2	Competent Authority's decision	CHEBI_8382	"8640"		"10084268"	"840539006"
dipyridamole	DB00975	COVID19 (disease)	C5203670	NCT05166876	Terminated	Phase 2	Low prevalence of COVID-19 in India led to lack of eligible subjects.	CHEBI_4653	"3521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04328285	Terminated	Phase 3	French authority's decision	CHEBI_5801	"5521"		"10084268"	"840539006"
maraviroc	DB04835	COVID19 (disease)	C5203670	NCT04441385	Terminated	Phase 2	lack of viability	CHEBI_63608	"620216"		"10084268"	"840539006"
colchicine	DB01394	COVID19 (disease)	C5203670	NCT04516941	Terminated	Phase 3	Insufficient rate of patient accrual and newly available scientific evidence	CHEBI_27882	"2683"		"10084268"	"840539006"
acetylsalicylic acid	DB00945	COVID19 (disease)	C5203670	NCT04498273	Terminated	Phase 3	an event rate lower than anticipated	CHEBI_15365	"91101|1191"		"10084268"	"840539006"
prednisone	DB00635	COVID19 (disease)	C5203670	NCT04451174	Terminated	Phase 3	Corticosteroid use approval	CHEBI_8382	"8640"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04363203	Suspended	Phase 3	concerns related to study drug	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04363203	Suspended	Phase 3	concerns related to study drug	CHEBI_2955	"18631"		"10084268"	"840539006"
dexamethasone	DB01234	Keloid	C0022548		Approved			CHEBI_41879	"3264"	HP:0010562	"10023330"	"33659008"
	DB00945	COVID19 (disease)	C5203670	NCT04343001	Withdrawn	Phase 3	Grant not obtained	CHEBI_15365	"91101|1191"		"10084268"	"840539006"
hydrocortamate	DB00741	COVID19 (disease)	C5203670	NCT04359511	Withdrawn	Phase 3	COMPETITOR TEST (RECOVERY)	CHEBI_17650	"5492"		"10084268"	"840539006"
	DB00635	COVID19 (disease)	C5203670	NCT04359511	Withdrawn	Phase 3	COMPETITOR TEST (RECOVERY)	CHEBI_8382	"8640"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04323631	Withdrawn	Early Phase 1	Trial not started due to accumulating evidence against HCQ for COVID	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04329923	Terminated	Phase 2	Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04329611	Terminated	Phase 3	Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04340544	Terminated	Phase 2	It appeared to be impossible for the study centres to recruit the targeted number of patients, due to reduced incidence and reduced acceptance to IMP	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04344444	Terminated	Phase 3	Lack of efficacy data from other studies	CHEBI_5801	"5521"		"10084268"	"840539006"
tranexamic acid	DB00302	COVID19 (disease)	C5203670	NCT04338074	Terminated	Phase 2	Lack of recruitment	CHEBI_48669	"10691"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04344444	Terminated	Phase 3	Lack of efficacy data from other studies	CHEBI_2955	"18631"		"10084268"	"840539006"
lopinavir	DB01601	COVID19 (disease)	C5203670	NCT04409483	Withdrawn	Phase 3	Epidemic dynamics	CHEBI_31781	"195088"		"10084268"	"840539006"
etoposide	DB00773	COVID19 (disease)	C5203670	NCT04356690	Terminated	Phase 2	Slow accrual, change in COVID prevalence, availability of effective vaccine	CHEBI_4911	"4179"		"10084268"	"840539006"
	DB00878	COVID19 (disease)	C5203670	NCT04344236	Withdrawn	Phase 2	This study was withdrawn by the institution to minimize risk to patients and staff with regard to COVID-19.	CHEBI_3614	"2358"		"10084268"	"840539006"
	DB11061	COVID19 (disease)	C5203670	NCT04344236	Withdrawn	Phase 2	This study was withdrawn by the institution to minimize risk to patients and staff with regard to COVID-19.		"8610"		"10084268"	"840539006"
povidone-iodine	DB06812	COVID19 (disease)	C5203670	NCT04344236	Withdrawn	Phase 2	This study was withdrawn by the institution to minimize risk to patients and staff with regard to COVID-19.	CHEBI_8347	"8611"		"10084268"	"840539006"
ritonavir	DB00503	COVID19 (disease)	C5203670		Approved			CHEBI_45409	"85762"		"10084268"	"840539006"
	DB01601	COVID19 (disease)	C5203670	NCT04307693	Terminated	Phase 2	Terminated early because no patients were further enrolled since mid-Apr 2020.	CHEBI_31781	"195088"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04385264	Suspended	Phase 2/Phase 3	Sufficient number of subjects would probably not reach	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04307693	Terminated	Phase 2	Terminated early because no patients were further enrolled since mid-Apr 2020.	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04347889	Withdrawn	Phase 2	Evidence that HCQ ineffective, loss of HCW interest,	CHEBI_5801	"5521"		"10084268"	"840539006"
regdanvimab	DB16405	COVID19 (disease)	C5203670		Approved						"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04372017	Terminated	Phase 3	Unlikelihood of benefit based on other studies.	CHEBI_5801	"5521"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04351516	Withdrawn	Phase 2/Phase 3	No Patients enrolled	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB00742	COVID19 (disease)	C5203670	NCT04385264	Suspended	Phase 2/Phase 3	Sufficient number of subjects would probably not reach	CHEBI_16899	"6628"		"10084268"	"840539006"
colchicine	DB01394	COVID19 (disease)	C5203670	NCT04375202	Terminated	Phase 2	Insufficient rate of patient accrual and newly available scientific evidence	CHEBI_27882	"2683"		"10084268"	"840539006"
	DB00503	COVID19 (disease)	C5203670	NCT04409483	Withdrawn	Phase 3	Epidemic dynamics	CHEBI_45409	"85762"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04350450	Withdrawn	Phase 2	PI withdrew the submission to the IRB	CHEBI_5801	"5521"		"10084268"	"840539006"
cannabidiol	DB09061	COVID19 (disease)	C5203670	NCT04615949	Terminated	Phase 2/Phase 3	The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame.	CHEBI_69478	"2045371"		"10084268"	"840539006"
	DB00482	COVID19 (disease)	C5203670	NCT05077969	Terminated	Phase 2	Low recruitment	CHEBI_41423	"140587"		"10084268"	"840539006"
famotidine	DB00927	COVID19 (disease)	C5203670	NCT05077969	Terminated	Phase 2	Low recruitment	CHEBI_4975	"4278"		"10084268"	"840539006"
molnupiravir	DB15661	COVID19 (disease)	C5203670		Approved			CHEBI_180653	"2587901"		"10084268"	"840539006"
molnupiravir	DB15660	COVID19 (disease)	C5203670		Approved			CHEBI_180653			"10084268"	"840539006"
bamlanivimab	DB15718	COVID19 (disease)	C5203670		Approved				"2463114"		"10084268"	"840539006"
etesevimab	DB15897	COVID19 (disease)	C5203670		Approved				"2477854"		"10084268"	"840539006"
casirivimab	DB15941	COVID19 (disease)	C5203670		Approved				"2465242"		"10084268"	"840539006"
sirolimus	DB00877	COVID19 (disease)	C5203670	NCT04371640	Withdrawn	Phase 1	Study population not regularly admitted to hospital and approaches have shifted away from repurposing old drugs.	CHEBI_9168	"35302"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04379492	Withdrawn	Phase 2	Emerging evidence does not support the use of HCQ for treatment or prevention of SARS -CoV2 infection. No pts have been enrolled.	CHEBI_5801	"5521"		"10084268"	"840539006"
telmisartan	DB00966	COVID19 (disease)	C5203670	NCT04360551	Terminated	Phase 2	Decrease in COVID-19 cases locally	CHEBI_9434	"73494"		"10084268"	"840539006"
tranexamic acid	DB00302	COVID19 (disease)	C5203670	NCT04550338	Withdrawn	Phase 3	With vaccination efforts ongoing, a feasibility survey indicated there would be inadequate recruitment	CHEBI_48669	"10691"		"10084268"	"840539006"
nirmatrelvir	DB16691	COVID19 (disease)	C5203670		Approved			CHEBI_170007	"2587892"		"10084268"	"840539006"
chloroquine	DB00608	COVID19 (disease)	C5203670	NCT04333628	Terminated	Phase 2/Phase 3	Teminated due to changes in treatment guidelines .	CHEBI_3638	"2393"		"10084268"	"840539006"
	DB00503	COVID19 (disease)	C5203670	NCT04307693	Terminated	Phase 2	Terminated early because no patients were further enrolled since mid-Apr 2020.	CHEBI_45409	"85762"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04435808	Terminated	Phase 1/Phase 2	Stopped for futility by DSMB	CHEBI_5801	"5521"		"10084268"	"840539006"
ritonavir	DB00503	COVID19 (disease)	C5203670	NCT04459286	Terminated	Phase 2	IDSMB recommendation	CHEBI_45409	"85762"		"10084268"	"840539006"
hydroxychloroquine	DB01611	COVID19 (disease)	C5203670	NCT04459702	Withdrawn	Phase 2	Was never started	CHEBI_5801	"5521"		"10084268"	"840539006"
	DB01601	COVID19 (disease)	C5203670	NCT04459702	Withdrawn	Phase 2	Was never started	CHEBI_31781	"195088"		"10084268"	"840539006"
	DB00503	COVID19 (disease)	C5203670	NCT04459702	Withdrawn	Phase 2	Was never started	CHEBI_45409	"85762"		"10084268"	"840539006"
	DB00207	COVID19 (disease)	C5203670	NCT04459702	Withdrawn	Phase 2	Was never started	CHEBI_2955	"18631"		"10084268"	"840539006"
	DB01072	COVID19 (disease)	C5203670	NCT04459286	Terminated	Phase 2	IDSMB recommendation	CHEBI_37924	"343047"		"10084268"	"840539006"
eltanolone	DB12308	COVID19 (disease)	C5203670	NCT04537806	Terminated	Phase 3	Internal company decision	CHEBI_1712			"10084268"	"840539006"
norethisterone	DB00717	Atrophic Vaginitis	C0221392		Approved			CHEBI_7627	"7514"			"52441000"
omoconazole	DB13684	Cutaneous Candidiasis	C0006846		Approved			CHEBI_135685		MONDO_0000879	"10054152"	"49883006"
progesterone	DB00396	Atrophic Vaginitis	C0221392		Approved			CHEBI_17026	"8727"			"52441000"
magnesium sulfate	DB00653	Eclampsia in pregnancy	C0156677		Approved			CHEBI_32599	"6585|1311625"			"198992004"
lansoprazole	DB00448	Diabetes Mellitus, Insulin-Dependent	C0011854	NCT00837759	Terminated	Phase 2	Changes to study personnel.	CHEBI_6375	"17128"	HP:0100651	"10067584"	"46635009"
dapagliflozin	DB06292	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			CHEBI_85078	"1488564"	HP:0100651	"10067584"	"46635009"
sotagliflozin	DB12713	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			CHEBI_229226	"2638675"	HP:0100651	"10067584"	"46635009"
insulin human	DB00030	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			CHEBI_5931	"253182|631657"	HP:0100651	"10067584"	"46635009"
insulin lispro	DB00030	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			CHEBI_5931	"253182|631657"	HP:0100651	"10067584"	"46635009"
	DB05351	Diabetes Mellitus, Insulin-Dependent	C0011854	NCT00837759	Terminated	Phase 2	Changes to study personnel.	CHEBI_135931	"816346"	HP:0100651	"10067584"	"46635009"
insulin glargine	DB00047	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved				"2563969|274783"	HP:0100651	"10067584"	"46635009"
teplizumab	DB06606	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved				"2621881|2621880"	HP:0100651	"10067584"	"46635009"
ipragliflozin	DB11698	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			CHEBI_134724		HP:0100651	"10067584"	"46635009"
	DB01261	Diabetes Mellitus, Insulin-Dependent	C0011854	NCT00837759	Terminated	Phase 2	Changes to study personnel.	CHEBI_40237	"593411"	HP:0100651	"10067584"	"46635009"
insulin lispro	DB00046	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved				"314684|2376838|86009"	HP:0100651	"10067584"	"46635009"
insulin glargine	DB00030	Diabetes Mellitus, Insulin-Dependent	C0011854		Approved			CHEBI_5931	"253182|631657"	HP:0100651	"10067584"	"46635009"
clidinium	DB00771	Enterocolitis	C0014356		Approved			CHEBI_3743	"21232|48212"	MONDO_0009172	"10014893"	"43752006"
methylprednisolone	DB00959	Disorder of eye	C0015397		Approved			CHEBI_6888	"6902"	HP:0000478	"10015916"	"371405004"
triamcinolone diacetate	DB00620	Disorder of eye	C0015397		Approved			CHEBI_9667	"10759"	HP:0000478	"10015916"	"371405004"
triamcinolone	DB00620	Disorder of eye	C0015397		Approved			CHEBI_9667	"10759"	HP:0000478	"10015916"	"371405004"
cortisone acetate	DB01380	Disorder of eye	C0015397		Approved			CHEBI_3897	"21655"	HP:0000478	"10015916"	"371405004"
triamcinolone acetonide	DB00620	Disorder of eye	C0015397		Approved			CHEBI_9667	"10759"	HP:0000478	"10015916"	"371405004"
betamethasone acetate	DB00443	Disorder of eye	C0015397		Approved			CHEBI_3077	"1514"	HP:0000478	"10015916"	"371405004"
hydrocortisone succinate	DB14545	Disorder of eye	C0015397		Approved			CHEBI_31677	"21651"	HP:0000478	"10015916"	"371405004"
prednisolone	DB00860	Disorder of eye	C0015397		Approved			CHEBI_8378	"8638"	HP:0000478	"10015916"	"371405004"
hydrocortisone succinate	DB00741	Disorder of eye	C0015397		Approved			CHEBI_17650	"5492"	HP:0000478	"10015916"	"371405004"
dexamethasone	DB01234	Disorder of eye	C0015397		Approved			CHEBI_41879	"3264"	HP:0000478	"10015916"	"371405004"
hydrocortisone acetate	DB14539	Disorder of eye	C0015397		Approved			CHEBI_17609	"27197"	HP:0000478	"10015916"	"371405004"
hydrocortisone	DB00741	Disorder of eye	C0015397		Approved			CHEBI_17650	"5492"	HP:0000478	"10015916"	"371405004"
betamethasone	DB00443	Disorder of eye	C0015397		Approved			CHEBI_3077	"1514"	HP:0000478	"10015916"	"371405004"
hydrocortisone acetate	DB00741	Disorder of eye	C0015397		Approved			CHEBI_17650	"5492"	HP:0000478	"10015916"	"371405004"
danazol	DB01406	Breast Fibrocystic Disease	C0016034		Approved			CHEBI_4315	"3102"	MONDO_0005219	"10016621"	"27431007"
silicon dioxide	DB11132	Flatulence	C0016204		Approved			CHEBI_30563	"314826|1362874|9771"	HP:0033589	"10016766"	"308698004"
calcium chloride	DB01164	Cardiac Arrest	C0018790		Approved			CHEBI_3312	"1901|1667640"	MONDO_0000745	"10007515"	"397829000"
calcium lactate	DB13231	Cardiac Arrest	C0018790		Approved				"47622"	MONDO_0000745	"10007515"	"397829000"
thiamine	DB00152	Cardiac Arrest	C0018790	NCT03450707	Terminated	Phase 2	DSMB recommendation based on differing mortality in a subgroup analysis	CHEBI_18385	"10454"	MONDO_0000745	"10007515"	"397829000"
	DB00264	Cardiac Arrest	C0018790	NCT00401882	Terminated	Phase 2	Difficult accrual	CHEBI_6904	"6918"	MONDO_0000745	"10007515"	"397829000"
	DB01183	Cardiac Arrest	C0018790	NCT03743805	Withdrawn	Early Phase 1	Insufficient patients	CHEBI_7459	"7242"	MONDO_0000745	"10007515"	"397829000"
calcium glucoheptonate	DB00326	Cardiac Arrest	C0018790		Approved			CHEBI_3314	"47618"	MONDO_0000745	"10007515"	"397829000"
calcium acetate	DB00258	Cardiac Arrest	C0018790		Approved			CHEBI_3310	"214342"	MONDO_0000745	"10007515"	"397829000"
thiamine	DB00152	Cardiac Arrest	C0018790	NCT02974257	Terminated	Phase 2	Study stopped early after consultation with DSMB	CHEBI_18385	"10454"	MONDO_0000745	"10007515"	"397829000"
epinephrine	DB00668	Cardiac Arrest	C0018790	NCT00401882	Terminated	Phase 2	Difficult accrual	CHEBI_28918	"3992"	MONDO_0000745	"10007515"	"397829000"
calcium glycerylphosphate	DB11264	Cardiac Arrest	C0018790		Approved			CHEBI_31336	"1909"	MONDO_0000745	"10007515"	"397829000"
flumazenil	DB01205	Cardiac Arrest	C0018790	NCT03743805	Withdrawn	Early Phase 1	Insufficient patients	CHEBI_5103	"4457"	MONDO_0000745	"10007515"	"397829000"
isoprenaline	DB01064	Cardiac Arrest	C0018790		Approved			CHEBI_64317	"6054"	MONDO_0000745	"10007515"	"397829000"
acyclovir	DB00787	Genital Herpes	C0019342		Approved			CHEBI_2453	"281"	MONDO_0005770	"10073931"	"33839006"
valaciclovir	DB00577	Genital Herpes	C0019342		Approved			CHEBI_35854	"73645"	MONDO_0005770	"10073931"	"33839006"
calcium chloride	DB01164	Hyperkalemia	C0020461		Approved			CHEBI_3312	"1901|1667640"	HP:0002153	"10020646"	"238142003"
calcium acetate	DB00258	Hyperkalemia	C0020461		Approved			CHEBI_3310	"214342"	HP:0002153	"10020646"	"238142003"
calcium glycerylphosphate	DB11264	Hyperkalemia	C0020461		Approved			CHEBI_31336	"1909"	HP:0002153	"10020646"	"238142003"
patiromer calcium	DB09263	Hyperkalemia	C0020461		Approved				"1716203"	HP:0002153	"10020646"	"238142003"
sodium polystyrene sulfonate	DB01344	Hyperkalemia	C0020461		Approved			CHEBI_53278	"1546437|1546436"	HP:0002153	"10020646"	"238142003"
calcium glucoheptonate	DB00326	Hyperkalemia	C0020461		Approved			CHEBI_3314	"47618"	HP:0002153	"10020646"	"238142003"
calcium lactate	DB13231	Hyperkalemia	C0020461		Approved				"47622"	HP:0002153	"10020646"	"238142003"
sodium zirconium cyclosilicate	DB14048	Hyperkalemia	C0020461		Approved				"2047628"	HP:0002153	"10020646"	"238142003"
calcium polystyrene sulfonate	DB01344	Hyperkalemia	C0020461		Approved			CHEBI_53278	"1546437|1546436"	HP:0002153	"10020646"	"238142003"
lefamulin	DB12825	Legionnaires' Disease	C0023241		Approved				"2198944"		"10035718"	"195889001"
onasemnogene abeparvovec	DB15528	Spinal Muscular Atrophy	C0026847		Approved				"2170225|2170226"	MONDO_0001516	"10041582"	"5262007"
risdiplam	DB15305	Spinal Muscular Atrophy	C0026847		Approved				"2390935"	MONDO_0001516	"10041582"	"5262007"
nusinersen	DB13161	Spinal Muscular Atrophy	C0026847		Approved				"1863556"	MONDO_0001516	"10041582"	"5262007"
triamcinolone diacetate	DB00620	Musculoskeletal Diseases	C0026857		Approved			CHEBI_9667	"10759"	MONDO_0002081	"10048592"	"928000"
methylprednisolone	DB00959	Musculoskeletal Diseases	C0026857		Approved			CHEBI_6888	"6902"	MONDO_0002081	"10048592"	"928000"
betamethasone	DB00443	Musculoskeletal Diseases	C0026857		Approved			CHEBI_3077	"1514"	MONDO_0002081	"10048592"	"928000"
cortisone acetate	DB01380	Musculoskeletal Diseases	C0026857		Approved			CHEBI_3897	"21655"	MONDO_0002081	"10048592"	"928000"
hydrocortisone	DB00741	Musculoskeletal Diseases	C0026857		Approved			CHEBI_17650	"5492"	MONDO_0002081	"10048592"	"928000"
prednisolone	DB00860	Musculoskeletal Diseases	C0026857		Approved			CHEBI_8378	"8638"	MONDO_0002081	"10048592"	"928000"
prednisone	DB00635	Musculoskeletal Diseases	C0026857		Approved			CHEBI_8382	"8640"	MONDO_0002081	"10048592"	"928000"
triamcinolone	DB00620	Musculoskeletal Diseases	C0026857		Approved			CHEBI_9667	"10759"	MONDO_0002081	"10048592"	"928000"
hydrocortisone succinate	DB00741	Musculoskeletal Diseases	C0026857		Approved			CHEBI_17650	"5492"	MONDO_0002081	"10048592"	"928000"
dexamethasone	DB01234	Musculoskeletal Diseases	C0026857		Approved			CHEBI_41879	"3264"	MONDO_0002081	"10048592"	"928000"
hydrocortisone succinate	DB14545	Musculoskeletal Diseases	C0026857		Approved			CHEBI_31677	"21651"	MONDO_0002081	"10048592"	"928000"
	DB00091	Myelofibrosis	C0026987	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_4031	"3008"	HP:0011974	"10028537"	"52967002"
mycophenolate mofetil	DB01024	Myelofibrosis	C0026987	NCT02728700	Terminated	Phase 1	Accrual factor	CHEBI_168396	"7145|265323"	HP:0011974	"10028537"	"52967002"
	DB00188	Myelofibrosis	C0026987	NCT02877082	Terminated	Phase 2		CHEBI_52717	"358258"	HP:0011974	"10028537"	"52967002"
azacitidine	DB00928	Myelofibrosis	C0026987	NCT04866056	Terminated	Phase 1/Phase 2	Corporate policy adjustments	CHEBI_2038	"1251"	HP:0011974	"10028537"	"52967002"
ruxolitinib	DB08877	Myelofibrosis	C0026987		Approved			CHEBI_66919	"1193326"	HP:0011974	"10028537"	"52967002"
	DB01008	Myelofibrosis	C0026987	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_28901	"1828"	HP:0011974	"10028537"	"52967002"
	DB00531	Myelofibrosis	C0026987	NCT00852709	Terminated	Phase 1	Lack of accrual	CHEBI_4027	"1545988|3002"	HP:0011974	"10028537"	"52967002"
decitabine	DB01262	Myelofibrosis	C0026987	NCT02564536	Withdrawn	Phase 1	Lack of funding following full FDA clinical hold	CHEBI_50131	"15657"	HP:0011974	"10028537"	"52967002"
pacritinib	DB11697	Myelofibrosis	C0026987		Approved				"2595243"	HP:0011974	"10028537"	"52967002"
clofarabine	DB00631	Myelofibrosis	C0026987	NCT00852709	Terminated	Phase 1	Lack of accrual	CHEBI_681569	"44151"	HP:0011974	"10028537"	"52967002"
teriparatide	DB06285	Myelofibrosis	C0026987	NCT00393380	Terminated	Phase 2	Study stopped because of toxicity concerns.	CHEBI_135983	"32915"	HP:0011974	"10028537"	"52967002"
	DB05829	Myelofibrosis	C0026987	NCT00393380	Terminated	Phase 2	Study stopped because of toxicity concerns.		"1427222"	HP:0011974	"10028537"	"52967002"
methotrexate	DB00563	Myelofibrosis	C0026987	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_44185	"6851"	HP:0011974	"10028537"	"52967002"
	DB00864	Myelofibrosis	C0026987	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_61049	"42316|235991"	HP:0011974	"10028537"	"52967002"
fedratinib	DB12500	Myelofibrosis	C0026987		Approved			CHEBI_91408	"2197490"	HP:0011974	"10028537"	"52967002"
	DB00877	Myelofibrosis	C0026987	NCT02728700	Terminated	Phase 1	Accrual factor	CHEBI_9168	"35302"	HP:0011974	"10028537"	"52967002"
decitabine	DB01262	Myelofibrosis	C0026987	NCT04283526	Withdrawn	Phase 1	This study was cancelled before enrolling any patients for business related reasons.	CHEBI_50131	"15657"	HP:0011974	"10028537"	"52967002"
bevacizumab	DB00112	Myelofibrosis	C0026987	NCT00667277	Terminated	Phase 2	lack of response activity in the setting of an unacceptable toxicity profile		"253337|2046138"	HP:0011974	"10028537"	"52967002"
griseofulvin	DB00400	Tinea cruris	C1384589		Approved			CHEBI_27779	"91077|5021"		"10043868"	"399029005"
tacrolimus	DB00864	Myelofibrosis	C0026987	NCT02877082	Terminated	Phase 2		CHEBI_61049	"42316|235991"	HP:0011974	"10028537"	"52967002"
	DB00531	Myelofibrosis	C0026987	NCT03602898	Withdrawn	Phase 2	Insufficient funding	CHEBI_4027	"1545988|3002"	HP:0011974	"10028537"	"52967002"
tetracycline	DB00759	Ophthalmia Neonatorum	C0029076		Approved			CHEBI_27902	"10395"	MONDO_0004854	"10030861"	"34298002"
chlortetracycline	DB09093	Ophthalmia Neonatorum	C0029076		Approved			CHEBI_27644	"2408"	MONDO_0004854	"10030861"	"34298002"
tetracycline	DB09550	Ophthalmia Neonatorum	C0029076		Approved			CHEBI_27902	"2105975"	MONDO_0004854	"10030861"	"34298002"
erythromycin	DB00199	Ophthalmia Neonatorum	C0029076		Approved			CHEBI_42355	"4053"	MONDO_0004854	"10030861"	"34298002"
cefotaxime	DB00493	Ophthalmia Neonatorum	C0029076		Approved			CHEBI_204928	"2186"	MONDO_0004854	"10030861"	"34298002"
guselkumab	DB11834	Pustulosis of Palms and Soles	C0030246		Approved				"1928588"	HP:0100847	"10050185"	"27520001"
pancrelipase	DB00085	Pancreatitis	C0030305	NCT02706236	Withdrawn	Phase 2	no funding was awarded		"1427034|235379|7880"	MONDO_0004982	"10033645"	"75694006"
ketamine	DB01221	Pancreatitis	C0030305	NCT02618668	Terminated	Phase 2		CHEBI_6121	"6130"	MONDO_0004982	"10033645"	"75694006"
diphenhydramine	DB01075	Pancreatitis	C0030305	NCT00240123	Withdrawn	Phase 1		CHEBI_4636	"3498"	MONDO_0004982	"10033645"	"75694006"
	DB00818	Pancreatitis	C0030305	NCT02618668	Terminated	Phase 2		CHEBI_44915	"8782"	MONDO_0004982	"10033645"	"75694006"
trepibutone	DB13311	Pancreatitis	C0030305		Approved			CHEBI_32255		MONDO_0004982	"10033645"	"75694006"
desmopressin	DB00035	Polyuria	C0032617		Approved			CHEBI_4450	"203658|3251"	HP:0000103	"10036142"	"28442001"
prilocaine	DB00750	Premature Ejaculation	C0033038		Approved			CHEBI_8404	"8686"	HP:0012876	"10036596"	"44001008"
tramadol	DB00193	Premature Ejaculation	C0033038	NCT00983736	Terminated	Phase 3	This study was terminated because of recruitment difficulties.	CHEBI_75722	"10689"	HP:0012876	"10036596"	"44001008"
dapoxetine	DB04884	Premature Ejaculation	C0033038		Approved			CHEBI_135962		HP:0012876	"10036596"	"44001008"
lidocaine	DB00281	Premature Ejaculation	C0033038		Approved			CHEBI_6456	"6387"	HP:0012876	"10036596"	"44001008"
tramadol	DB00193	Premature Ejaculation	C0033038	NCT00983151	Terminated	Phase 3		CHEBI_75722	"10689"	HP:0012876	"10036596"	"44001008"
flutamide	DB00499	Prostatic Neoplasms	C0033578		Approved			CHEBI_5132	"4508"	HP:0100787	"10029096"	"126906006"
estramustine	DB01196	Prostatic Neoplasms	C0033578		Approved			CHEBI_4868	"4089"	HP:0100787	"10029096"	"126906006"
histrelin	DB06788	Precocious Puberty	C0034013		Approved			CHEBI_63530	"50975"	MONDO_0000088	"10058084"	"400179000"
nafarelin	DB00666	Precocious Puberty	C0034013		Approved			CHEBI_7445	"28656"	MONDO_0000088	"10058084"	"400179000"
leuprorelin	DB00007	Precocious Puberty	C0034013		Approved			CHEBI_6427	"42375"	MONDO_0000088	"10058084"	"400179000"
betamethasone acetate	DB00443	Sarcoidosis	C0036202		Approved			CHEBI_3077	"1514"	MONDO_0019338	"10039486"	"31541009"
cortisone acetate	DB01380	Sarcoidosis	C0036202		Approved			CHEBI_3897	"21655"	MONDO_0019338	"10039486"	"31541009"
hydrocortisone	DB00741	Sarcoidosis	C0036202		Approved			CHEBI_17650	"5492"	MONDO_0019338	"10039486"	"31541009"
methylprednisolone	DB00959	Sarcoidosis	C0036202		Approved			CHEBI_6888	"6902"	MONDO_0019338	"10039486"	"31541009"
hydrocortisone succinate	DB00741	Sarcoidosis	C0036202		Approved			CHEBI_17650	"5492"	MONDO_0019338	"10039486"	"31541009"
dexamethasone	DB01234	Sarcoidosis	C0036202		Approved			CHEBI_41879	"3264"	MONDO_0019338	"10039486"	"31541009"
abatacept	DB01281	Sarcoidosis	C0036202	NCT00739960	Terminated	Phase 2	Funding has been pulled		"614391"	MONDO_0019338	"10039486"	"31541009"
adalimumab	DB00051	Sarcoidosis	C0036202	NCT00311246	Terminated	Phase 2	Difficulty in recruiting subjects		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0019338	"10039486"	"31541009"
betamethasone	DB00443	Sarcoidosis	C0036202		Approved			CHEBI_3077	"1514"	MONDO_0019338	"10039486"	"31541009"
bosentan	DB00559	Sarcoidosis	C0036202	NCT00926627	Terminated	Phase 2	Not enough patients with the specified criteria could not	CHEBI_51450	"75207|1468845"	MONDO_0019338	"10039486"	"31541009"
hydrocortisone succinate	DB14545	Sarcoidosis	C0036202		Approved			CHEBI_31677	"21651"	MONDO_0019338	"10039486"	"31541009"
hydrocortisone acetate	DB00741	Sarcoidosis	C0036202		Approved			CHEBI_17650	"5492"	MONDO_0019338	"10039486"	"31541009"
prednisolone	DB00860	Sarcoidosis	C0036202		Approved			CHEBI_8378	"8638"	MONDO_0019338	"10039486"	"31541009"
triamcinolone acetonide	DB00620	Sarcoidosis	C0036202		Approved			CHEBI_9667	"10759"	MONDO_0019338	"10039486"	"31541009"
prednisone	DB00635	Sarcoidosis	C0036202		Approved			CHEBI_8382	"8640"	MONDO_0019338	"10039486"	"31541009"
triamcinolone	DB00620	Sarcoidosis	C0036202		Approved			CHEBI_9667	"10759"	MONDO_0019338	"10039486"	"31541009"
triamcinolone diacetate	DB00620	Sarcoidosis	C0036202		Approved			CHEBI_9667	"10759"	MONDO_0019338	"10039486"	"31541009"
adalimumab	DB00051	Sarcoidosis	C0036202	NCT00690911	Withdrawn	Phase 2	Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the study started.		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0019338	"10039486"	"31541009"
adalimumab	DB00051	Sarcoidosis	C0036202	NCT00731757	Withdrawn	Phase 2			"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0019338	"10039486"	"31541009"
hydrocortisone acetate	DB14539	Sarcoidosis	C0036202		Approved			CHEBI_17609	"27197"	MONDO_0019338	"10039486"	"31541009"
dobutamine	DB00841	Shock, Cardiogenic	C0036980		Approved			CHEBI_4670	"3616"	MONDO_0800175	"10007625"	"89138009"
heparin	DB01109	Shock, Cardiogenic	C0036980	NCT00445211	Terminated	Phase 2	lack of enrollment	CHEBI_28304	"5224"	MONDO_0800175	"10007625"	"89138009"
tecovirimat	DB12020	Smallpox	C0037354		Approved				"2055104"	MONDO_0004651	"10041197"	"47452006"
tedizolid phosphate	DB14569	Staphylococcal Skin Infections	C0038166		Approved			CHEBI_82717	"1540825"		"10066409"	"402938009"
oritavancin	DB04911	Staphylococcal Skin Infections	C0038166		Approved			CHEBI_82699	"1547611"		"10066409"	"402938009"
ozenoxacin	DB12924	Staphylococcal Skin Infections	C0038166		Approved			CHEBI_136050	"1994739"		"10066409"	"402938009"
tedizolid phosphate	DB09042	Staphylococcal Skin Infections	C0038166		Approved			CHEBI_83326	"1540824"		"10066409"	"402938009"
sulconazole	DB06820	Tinea cruris	C1384589		Approved			CHEBI_77776	"37319"		"10043868"	"399029005"
dalbavancin	DB06219	Staphylococcal Skin Infections	C0038166		Approved			CHEBI_82721	"1539239"		"10066409"	"402938009"
corticotropin	DB01285	Stevens-Johnson Syndrome	C0038325		Approved			CHEBI_3892	"376"	MONDO_0018229	"10042033"	"73442001"
prednisolone	DB00860	Stevens-Johnson Syndrome	C0038325		Approved			CHEBI_8378	"8638"	MONDO_0018229	"10042033"	"73442001"
infliximab	DB00065	Stevens-Johnson Syndrome	C0038325	NCT02126020	Withdrawn	Phase 1/Phase 2	No patients met eligibility criteria. The study has been closed.		"1790539|1927283|191831|2266523|2103476"	MONDO_0018229	"10042033"	"73442001"
infliximab	DB00065	Stevens-Johnson Syndrome	C0038325	NCT01256489	Withdrawn	Phase 1/Phase 2	Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (~3 in 1 million). No eligible subjects have been identified.		"1790539|1927283|191831|2266523|2103476"	MONDO_0018229	"10042033"	"73442001"
doxycycline	DB00254	Endemic Flea-Borne Typhus	C0041472		Approved			CHEBI_50845	"1545992|3640"	MONDO_0000330	"10028282"	"25668000"
fusidic acid	DB02703	Endemic Flea-Borne Typhus	C0041472		Approved			CHEBI_29013	"4608|113608"	MONDO_0000330	"10028282"	"25668000"
cefradine	DB01333	Upper Respiratory Infections	C0041912		Approved			CHEBI_3547	"2239"		"10046306"	"54150009"
benzylpenicillin	DB01053	Upper Respiratory Infections	C0041912		Approved			CHEBI_18208	"7980"		"10046306"	"54150009"
cefprozil	DB01150	Upper Respiratory Infections	C0041912		Approved			CHEBI_3506	"1546020|19552"		"10046306"	"54150009"
phenoxymethylpenicillin	DB00417	Upper Respiratory Infections	C0041912		Approved			CHEBI_27446	"7984"		"10046306"	"54150009"
loracarbef	DB00447	Upper Respiratory Infections	C0041912		Approved			CHEBI_47544	"28981"		"10046306"	"54150009"
cefaclor	DB00833	Upper Respiratory Infections	C0041912		Approved			CHEBI_3478	"1450910|2176"		"10046306"	"54150009"
cefixime	DB00671	Upper Respiratory Infections	C0041912		Approved			CHEBI_472657	"25033|1546021"		"10046306"	"54150009"
erythromycin	DB00199	Pertussis	C0043167		Approved			CHEBI_42355	"4053"	MONDO_0005077	"10034738"	"27836007"
thalidomide	DB01041	POEMS Syndrome	C0085404		Approved			CHEBI_74947	"10432"	MONDO_0017364	"10053869"	"79268002"
fluconazole	DB00196	Meningitis, Cryptococcal	C0085436		Approved			CHEBI_46081	"202813|4450"	HP:0032160	"10027209"	"14232007"
enoxaparin sodium	DB01225	Deep Vein Thrombosis	C0149871		Approved				"67108"	HP:0002625	"10051055"	"128053003"
rivaroxaban	DB06228	Deep Vein Thrombosis	C0149871		Approved			CHEBI_68579	"1114195"	HP:0002625	"10051055"	"128053003"
warfarin	DB00682	Deep Vein Thrombosis	C0149871		Approved			CHEBI_87732	"11289"	HP:0002625	"10051055"	"128053003"
enoxaparin sodium	DB01225	Deep Vein Thrombosis	C0149871	NCT01573169	Terminated	Phase 3	The trial has been terminated prematurely after the randomization of 73 patients due to a lack of funding.		"67108"	HP:0002625	"10051055"	"128053003"
enoxaparin sodium	DB01225	Deep Vein Thrombosis	C0149871	NCT03003390	Terminated	Phase 2	Met protocol defined stopping rule for futility		"67108"	HP:0002625	"10051055"	"128053003"
nadroparin calcium	DB08813	Deep Vein Thrombosis	C0149871		Approved				"67031"	HP:0002625	"10051055"	"128053003"
fondaparinux	DB00569	Deep Vein Thrombosis	C0149871		Approved			CHEBI_61033	"321208"	HP:0002625	"10051055"	"128053003"
bemiparin	DB06822	Deep Vein Thrombosis	C0149871		Approved			CHEBI_28304	"69646|104466"	HP:0002625	"10051055"	"128053003"
bemiparin	DB09258	Deep Vein Thrombosis	C0149871		Approved			CHEBI_28304	"280611"	HP:0002625	"10051055"	"128053003"
heparin	DB01109	Deep Vein Thrombosis	C0149871		Approved			CHEBI_28304	"5224"	HP:0002625	"10051055"	"128053003"
enoxaparin sodium	DB01225	Deep Vein Thrombosis	C0149871	NCT02744833	Terminated	Phase 1/Phase 2	The trial was funded in part by a grant; the trial closed when the grant ended.		"67108"	HP:0002625	"10051055"	"128053003"
tranilast	DB07615	Cicatrix, Hypertrophic	C0162810		Approved			CHEBI_77572	"57330"		"10020879"	"19843006"
paclitaxel	DB01229	Fallopian Tube Carcinoma	C0238122		Approved			CHEBI_45863	"56946"	MONDO_0006206	"10016180"	"276870001"
liothyronine	DB00279	Myxedema coma	C0238298		Approved			CHEBI_533015	"10814"		"10060819"	"21263006"
hyaluronidase	DB14740	Primary amyloidosis	C0268381		Approved				"2382595|578350|2375132"	MONDO_0019438	"10036673"	"23132008"
cyclophosphamide	DB00531	Primary amyloidosis	C0268381		Approved			CHEBI_4027	"1545988|3002"	MONDO_0019438	"10036673"	"23132008"
hyaluronidase	DB06205	Primary amyloidosis	C0268381		Approved				"1300478"	MONDO_0019438	"10036673"	"23132008"
dexamethasone	DB01234	Primary amyloidosis	C0268381		Approved			CHEBI_41879	"3264"	MONDO_0019438	"10036673"	"23132008"
bortezomib	DB00188	Primary amyloidosis	C0268381		Approved			CHEBI_52717	"358258"	MONDO_0019438	"10036673"	"23132008"
daratumumab	DB09331	Primary amyloidosis	C0268381		Approved				"1721947"	MONDO_0019438	"10036673"	"23132008"
ranibizumab	DB01270	Exudative age-related macular degeneration	C0271084		Approved				"595060"		"10071129"	"414173003"
aflibercept	DB08885	Exudative age-related macular degeneration	C0271084		Approved				"1304475|1232150"		"10071129"	"414173003"
ranibizumab	DB01270	Exudative age-related macular degeneration	C0271084	NCT02348359	Terminated	Phase 2	Interim analysis found study had achieved primary objective		"595060"		"10071129"	"414173003"
faricimab	DB15303	Exudative age-related macular degeneration	C0271084		Approved				"2591519"		"10071129"	"414173003"
pegaptanib	DB04895	Exudative age-related macular degeneration	C0271084		Approved				"594119|498509"		"10071129"	"414173003"
brolucizumab	DB14864	Exudative age-related macular degeneration	C0271084		Approved				"2204915|2204916"		"10071129"	"414173003"
verteporfin	DB00460	Exudative age-related macular degeneration	C0271084		Approved			CHEBI_32293	"118886"		"10071129"	"414173003"
anecortave	DB05288	Exudative age-related macular degeneration	C0271084		Approved			CHEBI_177649			"10071129"	"414173003"
anecortave	DB12081	Exudative age-related macular degeneration	C0271084		Approved			CHEBI_177649			"10071129"	"414173003"
echothiophate	DB01057	Stargardt's disease	C0271093		Approved			CHEBI_4753	"89778"	MONDO_0019353	"10062766"	"47673003"
acyclovir	DB00787	Herpes encephalitis	C0276226		Approved			CHEBI_2453	"281"	HP:0012302	"10019953"	"428638009"
capmatinib	DB11791	Metastatic non-small cell lung cancer	C0278987		Approved				"2362165"		"10059515"	"457721000124104"
pralsetinib	DB15822	Metastatic non-small cell lung cancer	C0278987		Approved				"2394936"		"10059515"	"457721000124104"
selpercatinib	DB15685	Metastatic non-small cell lung cancer	C0278987		Approved				"2370147"		"10059515"	"457721000124104"
docetaxel	DB01248	Metastatic non-small cell lung cancer	C0278987	NCT04863248	Terminated	Phase 2	Treatment paradigm in second- and third-line NSCLC is shifting away from docetaxel, the backbone chemotherapy therapy used in this study.	CHEBI_4672	"72962|1299922"		"10059515"	"457721000124104"
nivolumab	DB09035	Metastatic non-small cell lung cancer	C0278987	NCT02639234	Withdrawn	Phase 2			"1597876"		"10059515"	"457721000124104"
thymalfasin	DB04900	Metastatic non-small cell lung cancer	C0278987	NCT02542930	Withdrawn	Phase 2	No recruitment.	CHEBI_135915	"38221"		"10059515"	"457721000124104"
atezolizumab	DB11595	Metastatic non-small cell lung cancer	C0278987		Approved				"1792776"		"10059515"	"457721000124104"
tepotinib	DB15133	Metastatic non-small cell lung cancer	C0278987		Approved				"2477103"		"10059515"	"457721000124104"
bleomycin	DB00290	Malignant Head and Neck Neoplasm	C0278996		Approved			CHEBI_22907	"1622"	MONDO_0005627	"10067821"	"255056009"
hydroxycarbamide	DB01005	Malignant Head and Neck Neoplasm	C0278996		Approved			CHEBI_44423	"151871|5552"	MONDO_0005627	"10067821"	"255056009"
pembrolizumab	DB09037	Malignant Head and Neck Neoplasm	C0278996		Approved				"1547545"	MONDO_0005627	"10067821"	"255056009"
docetaxel	DB01248	Malignant Head and Neck Neoplasm	C0278996		Approved			CHEBI_4672	"72962|1299922"	MONDO_0005627	"10067821"	"255056009"
methotrexate	DB00563	Malignant Head and Neck Neoplasm	C0278996		Approved			CHEBI_44185	"6851"	MONDO_0005627	"10067821"	"255056009"
amitriptyline	DB00321	Mixed anxiety and depressive disorder	C0338908		Approved			CHEBI_2666	"704"		"10080836"	"231504006"
perphenazine	DB00850	Mixed anxiety and depressive disorder	C0338908		Approved			CHEBI_8028	"8076"		"10080836"	"231504006"
maprotiline	DB00934	Mixed anxiety and depressive disorder	C0338908		Approved			CHEBI_6690	"6646"		"10080836"	"231504006"
chlordiazepoxide	DB00475	Mixed anxiety and depressive disorder	C0338908		Approved			CHEBI_3611	"2356"		"10080836"	"231504006"
alprazolam	DB00404	Mixed anxiety and depressive disorder	C0338908		Approved			CHEBI_2611	"596"		"10080836"	"231504006"
tolrestat	DB02383	Complications of Diabetes Mellitus	C0342257		Approved			CHEBI_48549	"38386"		"10061104"	"74627003"
testosterone cypionate	DB13943	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_9463	"835827"	HP:0008226	"10002261"	"38825009"
testosterone propionate	DB01420	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_9466	"10382"	HP:0008226	"10002261"	"38825009"
methyltestosterone	DB06710	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_27436	"6904"	HP:0008226	"10002261"	"38825009"
testosterone	DB00624	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_17347	"10379"	HP:0008226	"10002261"	"38825009"
testosterone enantate	DB00624	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_17347	"10379"	HP:0008226	"10002261"	"38825009"
testosterone propionate	DB00624	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_17347	"10379"	HP:0008226	"10002261"	"38825009"
testosterone enantate	DB13944	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_9464	"37859"	HP:0008226	"10002261"	"38825009"
testosterone cypionate	DB00624	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_17347	"10379"	HP:0008226	"10002261"	"38825009"
fluoxymesterone	DB01185	Deficiency of testosterone biosynthesis	C0342527		Approved			CHEBI_5120	"4494"	HP:0008226	"10002261"	"38825009"
tacrolimus	DB00864	Liver transplant rejection	C0400968		Approved			CHEBI_61049	"42316|235991"		"10024715"	"235911006"
arsenic trioxide	DB01169	Endometrial Carcinoma	C0476089	NCT01184053	Terminated	Phase 2	Accrual was very low. No subject had been enrolled in a year.	CHEBI_49900	"18330"	HP:0012114	"10014733"	"254878006"
progesterone	DB00396	Endometrial Carcinoma	C0476089		Approved			CHEBI_17026	"8727"	HP:0012114	"10014733"	"254878006"
medroxyprogesterone	DB00603	Endometrial Carcinoma	C0476089		Approved			CHEBI_6716	"1000112"	HP:0012114	"10014733"	"254878006"
megestrol acetate	DB00351	Endometrial Carcinoma	C0476089		Approved			CHEBI_6723	"29451"	HP:0012114	"10014733"	"254878006"
tobramycin	DB00684	Meibomianitis	C0549398		Approved			CHEBI_28864	"10627"		"10027137"	"309779001"
fusidic acid	DB02703	Meibomianitis	C0549398		Approved			CHEBI_29013	"4608|113608"		"10027137"	"309779001"
gentamicin	DB00798	Meibomianitis	C0549398		Approved			CHEBI_17833	"1596450"		"10027137"	"309779001"
prednisolone	DB00860	Meibomianitis	C0549398		Approved			CHEBI_8378	"8638"		"10027137"	"309779001"
testosterone undecanoate	DB13946	Primary hypogonadism	C0948896		Approved			CHEBI_135741	"37864"	HP:0000815	"10052649"	"370999003"
testosterone undecanoate	DB00624	Primary hypogonadism	C0948896		Approved			CHEBI_17347	"10379"	HP:0000815	"10052649"	"370999003"
methamphetamine	DB01577	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_6809	"6816"	HP:0007018	"10083622"	"406506008"
	DB00289	Attention deficit hyperactivity disorder	C1263846	NCT00562055	Withdrawn	Phase 2	This study was withdrawn due to business reasons.	CHEBI_127342	"38400"	HP:0007018	"10083622"	"406506008"
aripiprazole	DB01238	Attention deficit hyperactivity disorder	C1263846	NCT00279409	Terminated	Phase 2	Recruitment Rate too slow	CHEBI_31236	"89013"	HP:0007018	"10083622"	"406506008"
atomoxetine	DB00289	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_127342	"38400"	HP:0007018	"10083622"	"406506008"
methylphenidate	DB00422	Attention deficit hyperactivity disorder	C1263846	NCT02502799	Terminated	Phase 3		CHEBI_84276	"6901"	HP:0007018	"10083622"	"406506008"
lisdexamfetamine	DB01255	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_135925	"700810"	HP:0007018	"10083622"	"406506008"
amfetamine	DB00182	Attention deficit hyperactivity disorder	C1263846	NCT03242772	Terminated	Phase 2	The study stopped recruitment of new participants due to COVID. A substudy was developed with adaptations to the main design.	CHEBI_132233	"3288|725"	HP:0007018	"10083622"	"406506008"
viloxazine	DB09185	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_94405	"11196"	HP:0007018	"10083622"	"406506008"
pemoline	DB01230	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_7953	"7966"	HP:0007018	"10083622"	"406506008"
dexamfetamine	DB01576	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_4469	"3288"	HP:0007018	"10083622"	"406506008"
mebicar	DB13522	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_136038		HP:0007018	"10083622"	"406506008"
dexmethylphenidate	DB06701	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_51860	"352372"	HP:0007018	"10083622"	"406506008"
methylphenidate	DB00422	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_84276	"6901"	HP:0007018	"10083622"	"406506008"
reboxetine	DB00234	Attention deficit hyperactivity disorder	C1263846	NCT00562055	Withdrawn	Phase 2	This study was withdrawn due to business reasons.	CHEBI_135342	"60842"	HP:0007018	"10083622"	"406506008"
amfetamine	DB00182	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_132233	"3288|725"	HP:0007018	"10083622"	"406506008"
serdexmethylphenidate	DB16629	Attention deficit hyperactivity disorder	C1263846		Approved				"2562176"	HP:0007018	"10083622"	"406506008"
guanfacine	DB01018	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_5558	"40114"	HP:0007018	"10083622"	"406506008"
clonidine	DB00575	Attention deficit hyperactivity disorder	C1263846		Approved			CHEBI_46632	"2599"	HP:0007018	"10083622"	"406506008"
pexidartinib	DB12978	Fibrous histiocytoma of tendon sheath	C1318543		Approved			CHEBI_145373	"2183102"	MONDO_0002522	"10018255"	"310605004"
cetuximab	DB00002	Squamous cell carcinoma of pharynx	C1319317		Approved				"318341"	MONDO_0000536	"10066471"	"408649007"
ustekinumab	DB05679	Axial Spondyloarthritis	C3203547	NCT02437162	Terminated	Phase 3	Neither dose achieved the study's primary or major secondary endpoints. The safety profile was consistent with previous ustekinumab studies.		"847083"		"10071400"	"723116002"
ustekinumab	DB05679	Axial Spondyloarthritis	C3203547	NCT02438787	Terminated	Phase 3	This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.		"847083"		"10071400"	"723116002"
adalimumab	DB00051	Axial Spondyloarthritis	C3203547		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"		"10071400"	"723116002"
oxymorphone	DB01192	Severe pain	C0278140		Approved			CHEBI_7865	"7814"			"76948002"
magnesium citrate	DB11110	Incomplete passage of stool	C0426639		Approved			CHEBI_131391	"52356"			"249515001"
magnesium carbonate	DB09481	Incomplete passage of stool	C0426639		Approved			CHEBI_31793	"29155"			"249515001"
magnesium sulfate	DB00653	Incomplete passage of stool	C0426639		Approved			CHEBI_32599	"6585|1311625"			"249515001"
magnesium oxide	DB01377	Incomplete passage of stool	C0426639		Approved			CHEBI_31794	"6582"			"249515001"
diamorphine	DB01452	Severe pain	C0278140		Approved			CHEBI_27808	"3304"			"76948002"
diamorphine	DB00295	Severe pain	C0278140		Approved			CHEBI_17303	"7052|32926"			"76948002"
magnesium aspartate	DB13359	Incomplete passage of stool	C0426639		Approved							"249515001"
magnesium lactate	DB14515	Incomplete passage of stool	C0426639		Approved				"214688"			"249515001"
cefoxitin	DB01331	Sepsis caused by Bacteroides	C0276064		Approved			CHEBI_209807	"2189"			"1201760007"
antazoline	DB08799	Dermatographic urticaria	C0343065		Approved			CHEBI_84115	"865"	HP:0011971		"402410006"
mepyramine	DB06691	Dermatographic urticaria	C0343065		Approved			CHEBI_6762	"9009"	HP:0011971		"402410006"
chlorphenamine	DB01114	Dermatographic urticaria	C0343065		Approved			CHEBI_52010	"221074|2400"	HP:0011971		"402410006"
phenindamine	DB01619	Dermatographic urticaria	C0343065		Approved			CHEBI_8065	"33283"	HP:0011971		"402410006"
daptomycin	DB00080	MRSA - Methicillin resistant Staphylococcus aureus infection	C0343401		Approved			CHEBI_600103	"22299"	HP:0032326		"266096002"
sulbentine	DB13671	Dermatomycoses	C0011630		Approved			CHEBI_31477		MONDO_0002040	"10017543"	"14560005"
cannabidiol	DB09061	Epidermolysis Bullosa	C0014527	NCT04613102	Withdrawn	Phase 2/Phase 3	The study protocol should to be updated (major updates), following the second Health Canada review /requests. The study has been withdrawn form the REB review and will not be performed at SickKids.	CHEBI_69478	"2045371"		"10014989"	"61003004"
	DB00087	Epidermolysis Bullosa	C0014527	NCT00881556	Terminated	Early Phase 1			"117055"		"10014989"	"61003004"
	DB01008	Epidermolysis Bullosa	C0014527	NCT00881556	Terminated	Early Phase 1		CHEBI_28901	"1828"		"10014989"	"61003004"
	DB00864	Epidermolysis Bullosa	C0014527	NCT00881556	Terminated	Early Phase 1		CHEBI_61049	"42316|235991"		"10014989"	"61003004"
birch bark extract	DB16536	Epidermolysis Bullosa	C0014527		Approved				"1309815"		"10014989"	"61003004"
lorazepam	DB00186	Epidermolysis Bullosa	C0014527	NCT00881556	Terminated	Early Phase 1		CHEBI_6539	"6470"		"10014989"	"61003004"
grepafloxacin	DB00365	Gonorrhea	C0018081		Approved			CHEBI_5543	"83719"	MONDO_0004277	"10018612"	"15628003"
amphotericin B	DB00681	Gonorrhea	C0018081		Approved			CHEBI_2682	"236594|732"	MONDO_0004277	"10018612"	"15628003"
doxycycline	DB00254	Gonorrhea	C0018081		Approved			CHEBI_50845	"1545992|3640"	MONDO_0004277	"10018612"	"15628003"
ceftriaxone	DB01212	Gonorrhea	C0018081		Approved			CHEBI_29007	"2193"	MONDO_0004277	"10018612"	"15628003"
norfloxacin	DB01059	Gonorrhea	C0018081		Approved			CHEBI_100246	"7517"	MONDO_0004277	"10018612"	"15628003"
ceftizoxime	DB01332	Gonorrhea	C0018081		Approved			CHEBI_553473	"2192"	MONDO_0004277	"10018612"	"15628003"
piperacillin	DB00319	Gonorrhea	C0018081		Approved			CHEBI_8232	"1546000|8339"	MONDO_0004277	"10018612"	"15628003"
spectinomycin	DB00919	Gonorrhea	C0018081		Approved			CHEBI_9215	"270"	MONDO_0004277	"10018612"	"15628003"
enoxacin	DB00467	Gonorrhea	C0018081		Approved			CHEBI_157175	"3925"	MONDO_0004277	"10018612"	"15628003"
bacampicillin	DB01602	Gonorrhea	C0018081		Approved			CHEBI_2968	"18687"	MONDO_0004277	"10018612"	"15628003"
meclocycline	DB13092	Gonorrhea	C0018081		Approved			CHEBI_135772	"29418"	MONDO_0004277	"10018612"	"15628003"
fusidic acid	DB02703	Gonorrhea	C0018081		Approved			CHEBI_29013	"4608|113608"	MONDO_0004277	"10018612"	"15628003"
tetracycline	DB09550	Gonorrhea	C0018081		Approved			CHEBI_27902	"2105975"	MONDO_0004277	"10018612"	"15628003"
ceftriaxone	DB01212	Gonorrhea	C0018081	NCT02015637	Terminated	Phase 3		CHEBI_29007	"2193"	MONDO_0004277	"10018612"	"15628003"
demeclocycline	DB00618	Gonorrhea	C0018081		Approved			CHEBI_4392	"3154"	MONDO_0004277	"10018612"	"15628003"
cefoxitin	DB01331	Gonorrhea	C0018081		Approved			CHEBI_209807	"2189"	MONDO_0004277	"10018612"	"15628003"
tetracycline	DB00759	Gonorrhea	C0018081		Approved			CHEBI_27902	"10395"	MONDO_0004277	"10018612"	"15628003"
luliconazole	DB08933	Tinea cruris	C1384589		Approved			CHEBI_34825	"1482680"		"10043868"	"399029005"
cefixime	DB00671	Gonorrhea	C0018081		Approved			CHEBI_472657	"25033|1546021"	MONDO_0004277	"10018612"	"15628003"
mezlocillin	DB00948	Gonorrhea	C0018081		Approved			CHEBI_6919	"6927"	MONDO_0004277	"10018612"	"15628003"
ofloxacin	DB01165	Gonorrhea	C0018081		Approved			CHEBI_7731	"7623"	MONDO_0004277	"10018612"	"15628003"
cefuroxime axetil	DB01112	Gonorrhea	C0018081		Approved			CHEBI_3515	"2194"	MONDO_0004277	"10018612"	"15628003"
erythromycin	DB00199	Gonorrhea	C0018081		Approved			CHEBI_42355	"4053"	MONDO_0004277	"10018612"	"15628003"
cefuroxime	DB01112	Gonorrhea	C0018081		Approved			CHEBI_3515	"2194"	MONDO_0004277	"10018612"	"15628003"
cefpodoxime proxetil	DB01416	Gonorrhea	C0018081		Approved			CHEBI_3504	"20489"	MONDO_0004277	"10018612"	"15628003"
minocycline	DB01017	Gonorrhea	C0018081		Approved			CHEBI_50694	"6980"	MONDO_0004277	"10018612"	"15628003"
ampicillin	DB00415	Gonorrhea	C0018081		Approved			CHEBI_28971	"733|221058"	MONDO_0004277	"10018612"	"15628003"
menatetrenone	DB12148	Hemorrhagic Disease of Newborn	C0019088		Approved			CHEBI_16374	"29495"		"10019008"	"12546009"
menatetrenone	DB14936	Hemorrhagic Disease of Newborn	C0019088		Approved			CHEBI_16374	"42781|2607025"		"10019008"	"12546009"
succinimide	DB13376	Primary Hyperoxaluria	C0020501		Approved			CHEBI_9307		MONDO_0002474	"10084111"	"17901006"
	DB06262	Hypotension, Orthostatic	C0020651	NCT01370512	Suspended	Phase 2	Plan to increase enrollment due to preliminary data having lower statistical power than anticipated.	CHEBI_31524	"1489913"	HP:0001278	"10031127"	"28651003"
	DB00368	Hypotension, Orthostatic	C0020651	NCT01612078	Terminated	Phase 3		CHEBI_18357	"7512"	HP:0001278	"10031127"	"28651003"
	DB00368	Hypotension, Orthostatic	C0020651	NCT01370512	Suspended	Phase 2	Plan to increase enrollment due to preliminary data having lower statistical power than anticipated.	CHEBI_18357	"7512"	HP:0001278	"10031127"	"28651003"
norepinephrine	DB06262	Hypotension, Orthostatic	C0020651	NCT01612078	Terminated	Phase 3		CHEBI_31524	"1489913"	HP:0001278	"10031127"	"28651003"
droxidopa	DB06262	Hypotension, Orthostatic	C0020651		Approved			CHEBI_31524	"1489913"	HP:0001278	"10031127"	"28651003"
droxidopa	DB00368	Hypotension, Orthostatic	C0020651		Approved			CHEBI_18357	"7512"	HP:0001278	"10031127"	"28651003"
norepinephrine	DB00545	Hypotension, Orthostatic	C0020651	NCT01370512	Suspended	Phase 2	Plan to increase enrollment due to preliminary data having lower statistical power than anticipated.	CHEBI_8665	"9000"	HP:0001278	"10031127"	"28651003"
midodrine	DB00211	Hypotension, Orthostatic	C0020651		Approved			CHEBI_6933	"6963"	HP:0001278	"10031127"	"28651003"
	DB00368	Hypotension, Orthostatic	C0020651	NCT00977171	Terminated	Phase 2	Enrollment issues.	CHEBI_18357	"7512"	HP:0001278	"10031127"	"28651003"
norepinephrine	DB06262	Hypotension, Orthostatic	C0020651	NCT00977171	Terminated	Phase 2	Enrollment issues.	CHEBI_31524	"1489913"	HP:0001278	"10031127"	"28651003"
	DB00368	Hypotension, Orthostatic	C0020651	NCT00581477	Terminated	Phase 2/Phase 3	"1. enrollment slower than anticipated; 2. FDA approval of droxidopa so no longer need to treat patients on research basis; 3. personnel who were primarily responsible for the study are no longer at Vanderbilt."	CHEBI_18357	"7512"	HP:0001278	"10031127"	"28651003"
norepinephrine	DB06262	Hypotension, Orthostatic	C0020651	NCT00581477	Terminated	Phase 2/Phase 3	"1. enrollment slower than anticipated; 2. FDA approval of droxidopa so no longer need to treat patients on research basis; 3. personnel who were primarily responsible for the study are no longer at Vanderbilt."	CHEBI_31524	"1489913"	HP:0001278	"10031127"	"28651003"
	DB08918	Irritable Bowel Syndrome	C0022104	NCT01471379	Terminated	Phase 2	Due to recruitment difficulties the study is terminated.	CHEBI_136040	"1433212"	MONDO_0005052	"10023003"	"10743008"
methscopolamine	DB11315	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_135361	"89785"	MONDO_0005052	"10023003"	"10743008"
methylhomatropine	DB00725	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_50373	"1546413|27085"	MONDO_0005052	"10023003"	"10743008"
scopolamine	DB00747	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_16794	"9601|9603"	MONDO_0005052	"10023003"	"10743008"
dicycloverine	DB00804	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_4514	"3361"	MONDO_0005052	"10023003"	"10743008"
mebeverine	DB12554	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_91514	"29410"	MONDO_0005052	"10023003"	"10743008"
homatropine	DB11181	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_5747	"27084"	MONDO_0005052	"10023003"	"10743008"
milnacipran	DB04896	Irritable Bowel Syndrome	C0022104	NCT01471379	Terminated	Phase 2	Due to recruitment difficulties the study is terminated.	CHEBI_135005	"588250"	MONDO_0005052	"10023003"	"10743008"
rifaximin	DB01220	Irritable Bowel Syndrome	C0022104	NCT03462966	Terminated	Phase 2	recruitment challenges	CHEBI_75246	"35619"	MONDO_0005052	"10023003"	"10743008"
clidinium	DB00771	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_3743	"21232|48212"	MONDO_0005052	"10023003"	"10743008"
	DB09512	Irritable Bowel Syndrome	C0022104	NCT01269671	Withdrawn	Phase 1	PI has left institution		"9796"	MONDO_0005052	"10023003"	"10743008"
chlordiazepoxide	DB00475	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_3611	"2356"	MONDO_0005052	"10023003"	"10743008"
linaclotide	DB08890	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_68551	"1307404"	MONDO_0005052	"10023003"	"10743008"
	DB14005	Irritable Bowel Syndrome	C0022104	NCT01269671	Withdrawn	Phase 1	PI has left institution		"1299921"	MONDO_0005052	"10023003"	"10743008"
methscopolamine	DB00462	Irritable Bowel Syndrome	C0022104		Approved			CHEBI_61276	"56092"	MONDO_0005052	"10023003"	"10743008"
melatonin	DB01065	Irritable Bowel Syndrome	C0022104	NCT01269671	Withdrawn	Phase 1	PI has left institution	CHEBI_16796	"6711"	MONDO_0005052	"10023003"	"10743008"
lubiprostone	DB01046	Irritable Bowel Syndrome	C0022104	NCT02544152	Terminated	Phase 2		CHEBI_34945	"623033"	MONDO_0005052	"10023003"	"10743008"
	DB11074	Irritable Bowel Syndrome	C0022104	NCT01269671	Withdrawn	Phase 1	PI has left institution		"324072"	MONDO_0005052	"10023003"	"10743008"
triamcinolone	DB00620	Keloid	C0022548		Approved			CHEBI_9667	"10759"	HP:0010562	"10023330"	"33659008"
triamcinolone diacetate	DB00620	Keloid	C0022548		Approved			CHEBI_9667	"10759"	HP:0010562	"10023330"	"33659008"
triamcinolone hexacetonide	DB00620	Keloid	C0022548		Approved			CHEBI_9667	"10759"	HP:0010562	"10023330"	"33659008"
triamcinolone acetonide	DB00620	Keloid	C0022548		Approved			CHEBI_9667	"10759"	HP:0010562	"10023330"	"33659008"
tranilast	DB07615	Keloid	C0022548		Approved			CHEBI_77572	"57330"	HP:0010562	"10023330"	"33659008"
miltefosine	DB09031	Leishmaniasis, Visceral	C0023290		Approved			CHEBI_75283	"1494066"	MONDO_0005445	"10047505"	"186803007"
amphotericin B	DB00681	Leishmaniasis, Visceral	C0023290		Approved			CHEBI_2682	"236594|732"	MONDO_0005445	"10047505"	"186803007"
amphotericin B	DB00681	Leishmaniasis, Visceral	C0023290	NCT00832208	Terminated	Phase 2		CHEBI_2682	"236594|732"	MONDO_0005445	"10047505"	"186803007"
cladribine	DB00242	Hairy Cell Leukemia	C0023443		Approved			CHEBI_567361	"44157"	MONDO_0018935	"10019053"	"118613001"
interferon alfa-2b	DB00105	Hairy Cell Leukemia	C0023443		Approved				"5880|545290"	MONDO_0018935	"10019053"	"118613001"
interferon alfa-2b	DB15131	Hairy Cell Leukemia	C0023443		Approved				"545290"	MONDO_0018935	"10019053"	"118613001"
moxetumomab pasudotox	DB12688	Hairy Cell Leukemia	C0023443		Approved				"2099305|2099295"	MONDO_0018935	"10019053"	"118613001"
pentostatin	DB00552	Hairy Cell Leukemia	C0023443		Approved			CHEBI_27834	"8011"	MONDO_0018935	"10019053"	"118613001"
idarubicin	DB01177	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_42068	"5650"	MONDO_0018874	"10000880"	"1162928000"
fludarabine phosphate	DB01073	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_94701	"24698"	MONDO_0018874	"10000880"	"1162928000"
histamine	DB05381	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_18295	"5333"	MONDO_0018874	"10000880"	"1162928000"
doxorubicin	DB00997	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_28748	"142433|3639"	MONDO_0018874	"10000880"	"1162928000"
azacitidine	DB00928	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_2038	"1251"	MONDO_0018874	"10000880"	"1162928000"
mitoxantrone	DB01204	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_50729	"7005"	MONDO_0018874	"10000880"	"1162928000"
olutasidenib	DB16267	Leukemia, Myelocytic, Acute	C0023467		Approved				"2623641"	MONDO_0018874	"10000880"	"1162928000"
venetoclax	DB11581	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_133021	"1747556"	MONDO_0018874	"10000880"	"1162928000"
aldesleukin	DB00041	Leukemia, Myelocytic, Acute	C0023467		Approved				"70223"	MONDO_0018874	"10000880"	"1162928000"
thioguanine	DB00352	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_9555	"1546005|10485"	MONDO_0018874	"10000880"	"1162928000"
gemtuzumab ozogamicin	DB00056	Leukemia, Myelocytic, Acute	C0023467		Approved				"1294580"	MONDO_0018874	"10000880"	"1162928000"
midostaurin	DB06595	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_63452	"1919083"	MONDO_0018874	"10000880"	"1162928000"
cytarabine	DB00987	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_28680	"3041|968804"	MONDO_0018874	"10000880"	"1162928000"
enasidenib	DB13874	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_145374	"1940332"	MONDO_0018874	"10000880"	"1162928000"
daunorubicin	DB00694	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_41977	"214468|3109"	MONDO_0018874	"10000880"	"1162928000"
decitabine	DB01262	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_50131	"15657"	MONDO_0018874	"10000880"	"1162928000"
aclarubicin	DB11617	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_74619	"239"	MONDO_0018874	"10000880"	"1162928000"
ivosidenib	DB14568	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_145430	"2049873"	MONDO_0018874	"10000880"	"1162928000"
glasdegib	DB11978	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_145428	"2105845"	MONDO_0018874	"10000880"	"1162928000"
gilteritinib	DB12141	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_145372	"2105806"	MONDO_0018874	"10000880"	"1162928000"
quizartinib	DB12874	Leukemia, Myelocytic, Acute	C0023467		Approved			CHEBI_90217	"2643048"	MONDO_0018874	"10000880"	"1162928000"
tucidinostat	DB06334	Adult T-Cell Lymphoma/Leukemia	C0023493		Approved			CHEBI_135918		MONDO_0003540|MONDO_0019471	"10001413"	"77430005"
docetaxel	DB01248	liposarcoma	C0023827	NCT05116800	Withdrawn	Phase 2	IND withdrawn	CHEBI_4672	"72962|1299922"	MONDO_0005060	"10024627"	"254829001"
eribulin	DB08871	liposarcoma	C0023827		Approved			CHEBI_63587	"1045453"	MONDO_0005060	"10024627"	"254829001"
docetaxel	DB01248	liposarcoma	C0023827	NCT04906876	Withdrawn	Phase 2	IND withdrawn	CHEBI_4672	"72962|1299922"	MONDO_0005060	"10024627"	"254829001"
trabectedin	DB05109	liposarcoma	C0023827		Approved			CHEBI_84050	"1716278"	MONDO_0005060	"10024627"	"254829001"
trabectedin	DB05109	liposarcoma	C0023827	NCT03773510	Withdrawn	Phase 3	Not approved by the coordinating Ethical Committee	CHEBI_84050	"1716278"	MONDO_0005060	"10024627"	"254829001"
doxycycline	DB00254	Listeriosis	C0023860		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005828	"10024641"	"4241002"
erythromycin	DB00199	Listeriosis	C0023860		Approved			CHEBI_42355	"4053"	MONDO_0005828	"10024641"	"4241002"
minocycline	DB01017	Listeriosis	C0023860		Approved			CHEBI_50694	"6980"	MONDO_0005828	"10024641"	"4241002"
fusidic acid	DB02703	Listeriosis	C0023860		Approved			CHEBI_29013	"4608|113608"	MONDO_0005828	"10024641"	"4241002"
amphotericin B	DB00681	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_2682	"236594|732"	MONDO_0005834	"10025297"	"186946009"
minocycline	DB01017	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_50694	"6980"	MONDO_0005834	"10025297"	"186946009"
demeclocycline	DB00618	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_4392	"3154"	MONDO_0005834	"10025297"	"186946009"
oxytetracycline	DB00595	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005834	"10025297"	"186946009"
meclocycline	DB13092	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_135772	"29418"	MONDO_0005834	"10025297"	"186946009"
fusidic acid	DB02703	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_29013	"4608|113608"	MONDO_0005834	"10025297"	"186946009"
tetracycline	DB09550	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_27902	"2105975"	MONDO_0005834	"10025297"	"186946009"
doxycycline	DB00254	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005834	"10025297"	"186946009"
tetracycline	DB00759	Lymphogranuloma Venereum	C0024286		Approved			CHEBI_27902	"10395"	MONDO_0005834	"10025297"	"186946009"
valproic acid	DB00313	melanoma	C0025202	NCT00358319	Terminated	Phase 1/Phase 2	PI left Moffitt	CHEBI_39867	"11118|40254"	MONDO_0005105	"10025650"	"372244006"
cyclophosphamide	DB00531	melanoma	C0025202	NCT00924001	Terminated	Phase 1/Phase 2	study was stopped due to low accrual	CHEBI_4027	"1545988|3002"	MONDO_0005105	"10025650"	"372244006"
	DB00126	Thrombocythemia, Essential	C0040028	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_29073	"1151|1370460"	MONDO_0005029	"10015493"	"109994006"
ipilimumab	DB06186	melanoma	C0025202	NCT01557114	Terminated	Phase 1	New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab		"1094833"	MONDO_0005105	"10025650"	"372244006"
interferon alfa-2b	DB15131	melanoma	C0025202		Approved				"545290"	MONDO_0005105	"10025650"	"372244006"
interferon alfa-2b	DB00105	melanoma	C0025202		Approved				"5880|545290"	MONDO_0005105	"10025650"	"372244006"
vemurafenib	DB08881	melanoma	C0025202	NCT01519323	Terminated	Phase 1	Study was terminated due to low enrollment.	CHEBI_63637	"1147220"	MONDO_0005105	"10025650"	"372244006"
etretinate	DB08881	melanoma	C0025202	NCT02050321	Terminated	Phase 2	Pharmaceutical company pulled support for the trial.	CHEBI_63637	"1147220"	MONDO_0005105	"10025650"	"372244006"
talimogene laherparepvec	DB13896	melanoma	C0025202		Approved				"1721264"	MONDO_0005105	"10025650"	"372244006"
lapatinib	DB01259	melanoma	C0025202	NCT01264081	Terminated	Phase 2	Protocol would not be able to reach stated accrual.	CHEBI_49603	"480167"	MONDO_0005105	"10025650"	"372244006"
	DB00459	melanoma	C0025202	NCT02050321	Terminated	Phase 2	Pharmaceutical company pulled support for the trial.	CHEBI_50173	"16818"	MONDO_0005105	"10025650"	"372244006"
temozolomide	DB00853	melanoma	C0025202	NCT01543464	Terminated	Phase 2	Diminished rectruitment	CHEBI_72564	"37776"	MONDO_0005105	"10025650"	"372244006"
nivolumab	DB09035	melanoma	C0025202	NCT04223648	Withdrawn	Early Phase 1	Funding		"1597876"	MONDO_0005105	"10025650"	"372244006"
	DB06186	melanoma	C0025202	NCT04223648	Withdrawn	Early Phase 1	Funding		"1094833"	MONDO_0005105	"10025650"	"372244006"
vemurafenib	DB08881	melanoma	C0025202	NCT01586195	Terminated	Phase 2	Recruitment challenges	CHEBI_63637	"1147220"	MONDO_0005105	"10025650"	"372244006"
lovastatin	DB00227	melanoma	C0025202	NCT00963664	Withdrawn	Phase 2	Modifications will be necessary before full IRB approval will be secured.	CHEBI_40303	"6472"	MONDO_0005105	"10025650"	"372244006"
hydroxycarbamide	DB01005	melanoma	C0025202		Approved			CHEBI_44423	"151871|5552"	MONDO_0005105	"10025650"	"372244006"
vindesine	DB00309	melanoma	C0025202		Approved			CHEBI_36373	"11204"	MONDO_0005105	"10025650"	"372244006"
dexamethasone phosphate	DB01234	melanoma	C0025202	NCT02709889	Terminated	Phase 1/Phase 2	Strategic considerations	CHEBI_68637	"3264"	MONDO_0005105	"10025650"	"372244006"
vemurafenib	DB08881	melanoma	C0025202	NCT02303951	Terminated	Phase 2	The main reason for the early termination is the low recruitment rate.	CHEBI_63637	"1147220"	MONDO_0005105	"10025650"	"372244006"
chloramphenicol	DB00446	Meningococcal meningitis	C0025294		Approved			CHEBI_17698	"2348"	MONDO_0018059	"10027249"	"192644005"
sulfafurazole	DB00263	Meningococcal meningitis	C0025294		Approved			CHEBI_102484	"10207"	MONDO_0018059	"10027249"	"192644005"
ampicillin	DB00415	Meningococcal meningitis	C0025294		Approved			CHEBI_28971	"733|221058"	MONDO_0018059	"10027249"	"192644005"
benzylpenicillin	DB01053	Meningococcal meningitis	C0025294		Approved			CHEBI_18208	"7980"	MONDO_0018059	"10027249"	"192644005"
cefotaxime	DB00493	Meningococcal meningitis	C0025294		Approved			CHEBI_204928	"2186"	MONDO_0018059	"10027249"	"192644005"
meropenem	DB00760	Meningococcal meningitis	C0025294		Approved			CHEBI_43968	"1546029|29561"	MONDO_0018059	"10027249"	"192644005"
ceftazidime	DB00438	Meningococcal meningitis	C0025294		Approved			CHEBI_3508	"2191|1545984"	MONDO_0018059	"10027249"	"192644005"
ceftriaxone	DB01212	Meningococcal meningitis	C0025294		Approved			CHEBI_29007	"2193"	MONDO_0018059	"10027249"	"192644005"
estradiol	DB00783	Menopausal syndrome	C0025319		Approved			CHEBI_16469	"4083"		"10058825"	"123756000"
paroxetine	DB00715	Obsessive-Compulsive Disorder	C0028768		Approved			CHEBI_7936	"32937"		"10029898"	"191736004"
acetylcysteine	DB06151	Obsessive-Compulsive Disorder	C0028768	NCT00539513	Terminated	Phase 2	Researchers terminated study due to limited enrollment.	CHEBI_28939	"197"		"10029898"	"191736004"
	DB01104	Obsessive-Compulsive Disorder	C0028768	NCT00299611	Terminated	Phase 2/Phase 3	Sponsor decided to terminate the study due to budget consideration	CHEBI_9123	"36437"		"10029898"	"191736004"
	DB00683	Obsessive-Compulsive Disorder	C0028768	NCT02206776	Terminated	Phase 2	poor tolerability and low enrollment rate	CHEBI_6931	"6960"		"10029898"	"191736004"
fluoxetine	DB00472	Obsessive-Compulsive Disorder	C0028768		Approved			CHEBI_86990	"4493"		"10029898"	"191736004"
levetiracetam	DB01202	Obsessive-Compulsive Disorder	C0028768	NCT00299611	Terminated	Phase 2/Phase 3	Sponsor decided to terminate the study due to budget consideration	CHEBI_6437	"114477"		"10029898"	"191736004"
ketamine	DB01221	Obsessive-Compulsive Disorder	C0028768	NCT02206776	Terminated	Phase 2	poor tolerability and low enrollment rate	CHEBI_6121	"6130"		"10029898"	"191736004"
	DB00704	Obsessive-Compulsive Disorder	C0028768	NCT00758966	Terminated	Phase 2	Sponsor Decision- Financial Considerations	CHEBI_7465	"7243"		"10029898"	"191736004"
ketamine	DB01221	Obsessive-Compulsive Disorder	C0028768	NCT02234011	Terminated	Phase 2	Terminated due to difficulty in recruiting participants.	CHEBI_6121	"6130"		"10029898"	"191736004"
sertraline	DB01104	Obsessive-Compulsive Disorder	C0028768		Approved			CHEBI_9123	"36437"		"10029898"	"191736004"
fluoxetine	DB00472	Obsessive-Compulsive Disorder	C0028768	NCT00758966	Terminated	Phase 2	Sponsor Decision- Financial Considerations	CHEBI_86990	"4493"		"10029898"	"191736004"
clomipramine	DB01242	Obsessive-Compulsive Disorder	C0028768		Approved			CHEBI_47780	"2597"		"10029898"	"191736004"
ondansetron	DB00904	Obsessive-Compulsive Disorder	C0028768	NCT01275248	Terminated	Phase 2	lack of efficacy	CHEBI_7773	"26225"		"10029898"	"191736004"
fluvoxamine	DB00176	Obsessive-Compulsive Disorder	C0028768		Approved			CHEBI_5138	"42355"		"10029898"	"191736004"
sirolimus	DB00877	Massive Osteolyses	C0029438		Approved			CHEBI_9168	"35302"		"10071283"	"1515008"
doxycycline	DB00254	Rickettsia Infections	C0035585		Approved			CHEBI_50845	"1545992|3640"	MONDO_0006956	"10061495"	"416829003"
fusidic acid	DB02703	Rickettsia Infections	C0035585		Approved			CHEBI_29013	"4608|113608"	MONDO_0006956	"10061495"	"416829003"
chloramphenicol	DB00446	Rickettsia Infections	C0035585		Approved			CHEBI_17698	"2348"	MONDO_0006956	"10061495"	"416829003"
limaprost	DB09211	Thromboangiitis Obliterans	C0040021		Approved			CHEBI_135594		MONDO_0008889	"10043540"	"52403007"
	DB14483	Thrombocythemia, Essential	C0040028	NCT01014546	Terminated	Phase 1	low accrual		"1307765|142407"	MONDO_0005029	"10015493"	"109994006"
	DB14482	Thrombocythemia, Essential	C0040028	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_113451	"267366"	MONDO_0005029	"10015493"	"109994006"
anagrelide	DB00261	Thrombocythemia, Essential	C0040028		Approved			CHEBI_142290	"596724"	MONDO_0005029	"10015493"	"109994006"
arsenic trioxide	DB01169	Thrombocythemia, Essential	C0040028	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_49900	"18330"	MONDO_0005029	"10015493"	"109994006"
dexamethasone	DB01234	Thyroiditis	C0040147		Approved			CHEBI_41879	"3264"	MONDO_0004126	"10043778"	"82119001"
triamcinolone diacetate	DB00620	Thyroiditis	C0040147		Approved			CHEBI_9667	"10759"	MONDO_0004126	"10043778"	"82119001"
triamcinolone acetonide	DB00620	Thyroiditis	C0040147		Approved			CHEBI_9667	"10759"	MONDO_0004126	"10043778"	"82119001"
triamcinolone	DB00620	Thyroiditis	C0040147		Approved			CHEBI_9667	"10759"	MONDO_0004126	"10043778"	"82119001"
hydrocortisone acetate	DB00741	Thyroiditis	C0040147		Approved			CHEBI_17650	"5492"	MONDO_0004126	"10043778"	"82119001"
hydrocortisone acetate	DB14539	Thyroiditis	C0040147		Approved			CHEBI_17609	"27197"	MONDO_0004126	"10043778"	"82119001"
prednisolone	DB00860	Thyroiditis	C0040147		Approved			CHEBI_8378	"8638"	MONDO_0004126	"10043778"	"82119001"
hydrocortisone succinate	DB00741	Thyroiditis	C0040147		Approved			CHEBI_17650	"5492"	MONDO_0004126	"10043778"	"82119001"
methylprednisolone	DB00959	Thyroiditis	C0040147		Approved			CHEBI_6888	"6902"	MONDO_0004126	"10043778"	"82119001"
cortisone acetate	DB01380	Thyroiditis	C0040147		Approved			CHEBI_3897	"21655"	MONDO_0004126	"10043778"	"82119001"
prednisone	DB00635	Thyroiditis	C0040147		Approved			CHEBI_8382	"8640"	MONDO_0004126	"10043778"	"82119001"
betamethasone acetate	DB00443	Thyroiditis	C0040147		Approved			CHEBI_3077	"1514"	MONDO_0004126	"10043778"	"82119001"
hydrocortisone succinate	DB14545	Thyroiditis	C0040147		Approved			CHEBI_31677	"21651"	MONDO_0004126	"10043778"	"82119001"
betamethasone	DB00443	Thyroiditis	C0040147		Approved			CHEBI_3077	"1514"	MONDO_0004126	"10043778"	"82119001"
hydrocortisone	DB00741	Thyroiditis	C0040147		Approved			CHEBI_17650	"5492"	MONDO_0004126	"10043778"	"82119001"
griseofulvin	DB00400	Tinea Capitis	C0040250		Approved			CHEBI_27779	"91077|5021"		"10043866"	"5441008"
tolnaftate	DB00525	Tinea Capitis	C0040250		Approved			CHEBI_9620	"10637"		"10043866"	"5441008"
streptomycin	DB01082	Tularemia	C0041351		Approved			CHEBI_17076	"10109"	MONDO_0018077	"10045146"	"19265001"
minocycline	DB01017	Tularemia	C0041351		Approved			CHEBI_50694	"6980"	MONDO_0018077	"10045146"	"19265001"
doxycycline	DB00254	Tularemia	C0041351		Approved			CHEBI_50845	"1545992|3640"	MONDO_0018077	"10045146"	"19265001"
fusidic acid	DB02703	Tularemia	C0041351		Approved			CHEBI_29013	"4608|113608"	MONDO_0018077	"10045146"	"19265001"
botulinum toxin type A	DB00083	Increased frequency of micturition	C0042023		Approved				"1712|860168|1000104|860189"	HP:0100515	"10036018"	"300471006"
carbetocin	DB01282	Uterine Inertia	C0042135		Approved			CHEBI_59204			"10046763"	"26158002"
retinol	DB00162	Vitamin A Deficiency	C0042842		Approved			CHEBI_17336	"1367187|11246"	MONDO_0007016	"10047586"	"72000004"
desmopressin	DB00035	von Willebrand Disease	C0042974		Approved			CHEBI_4450	"203658|3251"	MONDO_0019565	"10047715"	"128105004"
vonicog alfa	DB12872	von Willebrand Disease	C0042974		Approved				"1812589"	MONDO_0019565	"10047715"	"128105004"
vonicog alfa	DB13133	von Willebrand Disease	C0042974		Approved				"826072"	MONDO_0019565	"10047715"	"128105004"
vasopressin	DB00067	von Willebrand Disease	C0042974		Approved			CHEBI_9937	"11149"	MONDO_0019565	"10047715"	"128105004"
pramocaine	DB09345	Injury wounds	C0043250		Approved			CHEBI_8357	"34347"		"10052428"	"13924000"
ferric oxide	DB11576	Injury wounds	C0043250		Approved			CHEBI_50819			"10052428"	"13924000"
zinc acetate	DB14487	Injury wounds	C0043250		Approved			CHEBI_62984	"1299637|58295"		"10052428"	"13924000"
zinc oxide	DB09321	Injury wounds	C0043250		Approved			CHEBI_36560	"11423"		"10052428"	"13924000"
fusidic acid	DB02703	Meningitis, Bacterial	C0085437		Approved			CHEBI_29013	"4608|113608"	MONDO_0006670	"10027202"	"95883001"
tobramycin	DB00684	Meningitis, Bacterial	C0085437		Approved			CHEBI_28864	"10627"	MONDO_0006670	"10027202"	"95883001"
cefuroxime	DB01112	Meningitis, Bacterial	C0085437		Approved			CHEBI_3515	"2194"	MONDO_0006670	"10027202"	"95883001"
ampicillin	DB00415	Meningitis, Bacterial	C0085437		Approved			CHEBI_28971	"733|221058"	MONDO_0006670	"10027202"	"95883001"
meropenem	DB00760	Meningitis, Bacterial	C0085437		Approved			CHEBI_43968	"1546029|29561"	MONDO_0006670	"10027202"	"95883001"
gentamicin	DB00798	Meningitis, Bacterial	C0085437		Approved			CHEBI_17833	"1596450"	MONDO_0006670	"10027202"	"95883001"
cefotaxime	DB00493	Meningitis, Bacterial	C0085437		Approved			CHEBI_204928	"2186"	MONDO_0006670	"10027202"	"95883001"
ceftriaxone	DB01212	Meningitis, Bacterial	C0085437		Approved			CHEBI_29007	"2193"	MONDO_0006670	"10027202"	"95883001"
amikacin	DB00479	Meningitis, Bacterial	C0085437		Approved			CHEBI_2637	"641"	MONDO_0006670	"10027202"	"95883001"
ceftazidime	DB00438	Meningitis, Bacterial	C0085437		Approved			CHEBI_3508	"2191|1545984"	MONDO_0006670	"10027202"	"95883001"
itopride	DB04924	Chronic gastritis	C0085695		Approved			CHEBI_94809		MONDO_0005001	"10008882"	"8493009"
dupilumab	DB12159	Chronic sinusitis	C0149516		Approved				"1876376"	MONDO_0006031	"10009137"	"40055000"
triamcinolone	DB00620	Chronic sinusitis	C0149516	NCT03729310	Withdrawn	Early Phase 1	No participants enrolled	CHEBI_9667	"10759"	MONDO_0006031	"10009137"	"40055000"
budesonide	DB01222	Chronic sinusitis	C0149516	NCT03519061	Withdrawn	Phase 2/Phase 3	Unable to obtain FDA exemption	CHEBI_3207	"19831"	MONDO_0006031	"10009137"	"40055000"
dalbavancin	DB06219	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_82721	"1539239"	HP:0100658	"10052891"	"128936008"
gentamicin	DB00798	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_17833	"1596450"	HP:0100658	"10052891"	"128936008"
omadacycline	DB12455	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_177758	"2059269"	HP:0100658	"10052891"	"128936008"
fusidic acid	DB02703	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_29013	"4608|113608"	HP:0100658	"10052891"	"128936008"
faropenem medoxil	DB05659	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_134710		HP:0100658	"10052891"	"128936008"
oritavancin	DB04911	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_82699	"1547611"	HP:0100658	"10052891"	"128936008"
faropenem	DB12190	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_51257		HP:0100658	"10052891"	"128936008"
chloramphenicol	DB00446	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_17698	"2348"	HP:0100658	"10052891"	"128936008"
tedizolid phosphate	DB09042	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_83326	"1540824"	HP:0100658	"10052891"	"128936008"
delafloxacin	DB11943	Skin Diseases, Bacterial	C0162627		Approved				"1927663"	HP:0100658	"10052891"	"128936008"
tedizolid phosphate	DB14569	Skin Diseases, Bacterial	C0162627		Approved			CHEBI_82717	"1540825"	HP:0100658	"10052891"	"128936008"
patisiran	DB14582	Amyloid Neuropathies, Familial	C0206245		Approved				"2053490"		"10019889"	"42295001"
leucovorin	DB00650	Neuroendocrine Tumors	C0206754	NCT00227617	Terminated	Phase 2/Phase 3	Low accrual	CHEBI_15640	"6313"	MONDO_0019496	"10052399"	"128928004"
octreotide	DB00104	Neuroendocrine Tumors	C0206754	NCT02177773	Terminated	Phase 1/Phase 2	FDA approved agent for this indication during enrollment	CHEBI_7726	"7617"	MONDO_0019496	"10052399"	"128928004"
	DB00544	Neuroendocrine Tumors	C0206754	NCT00227617	Terminated	Phase 2/Phase 3	Low accrual	CHEBI_46345	"4492"	MONDO_0019496	"10052399"	"128928004"
	DB00526	Neuroendocrine Tumors	C0206754	NCT00227617	Terminated	Phase 2/Phase 3	Low accrual	CHEBI_31941	"32592"	MONDO_0019496	"10052399"	"128928004"
isotretinoin	DB00982	Neuroendocrine Tumors	C0206754	NCT01048086	Withdrawn	Phase 2	No patients were enrolled because the company that pledged the drug does not yet have it available.	CHEBI_6067	"6064"	MONDO_0019496	"10052399"	"128928004"
	DB00755	Neuroendocrine Tumors	C0206754	NCT01048086	Withdrawn	Phase 2	No patients were enrolled because the company that pledged the drug does not yet have it available.	CHEBI_15367	"10753"	MONDO_0019496	"10052399"	"128928004"
lutetium (177Lu) oxodotreotide	DB13985	Neuroendocrine Tumors	C0206754		Approved				"1999335"	MONDO_0019496	"10052399"	"128928004"
	DB00112	Neuroendocrine Tumors	C0206754	NCT00227617	Terminated	Phase 2/Phase 3	Low accrual		"253337|2046138"	MONDO_0019496	"10052399"	"128928004"
rabeprazole	DB01129	Mastocytosis, Systemic	C0221013		Approved			CHEBI_8768	"183877|114979"	MONDO_0016586	"10042949"	"397016004"
cromoglicic acid	DB01003	Mastocytosis, Systemic	C0221013		Approved			CHEBI_59773	"2921|42612"	MONDO_0016586	"10042949"	"397016004"
imatinib	DB00619	Mastocytosis, Systemic	C0221013		Approved			CHEBI_45783	"282388"	MONDO_0016586	"10042949"	"397016004"
cimetidine	DB00501	Mastocytosis, Systemic	C0221013		Approved			CHEBI_3699	"2541"	MONDO_0016586	"10042949"	"397016004"
	DB01270	Age related macular degeneration	C0242383	NCT00457678	Withdrawn	Phase 2	Site did not enroll any patients to the study.		"595060"	MONDO_0005150	"10064930"	"267718000"
ranibizumab	DB01270	Age related macular degeneration	C0242383	NCT01025232	Terminated	Phase 1/Phase 2	The last remaining subject withdrew consent because the collaborator Genentech stopped supplying study drug.		"595060"	MONDO_0005150	"10064930"	"267718000"
ranibizumab	DB01270	Age related macular degeneration	C0242383		Approved				"595060"	MONDO_0005150	"10064930"	"267718000"
ranibizumab	DB01270	Age related macular degeneration	C0242383	NCT00726466	Withdrawn	Phase 1	Lack of recruitment		"595060"	MONDO_0005150	"10064930"	"267718000"
lutein	DB00137	Age related macular degeneration	C0242383		Approved			CHEBI_28838	"11359"	MONDO_0005150	"10064930"	"267718000"
	DB01234	Age related macular degeneration	C0242383	NCT00457678	Withdrawn	Phase 2	Site did not enroll any patients to the study.	CHEBI_41879	"3264"	MONDO_0005150	"10064930"	"267718000"
ranibizumab	DB01270	Age related macular degeneration	C0242383	NCT00557791	Withdrawn	Phase 3	Study never initiated		"595060"	MONDO_0005150	"10064930"	"267718000"
verteporfin	DB00460	Age related macular degeneration	C0242383	NCT00457678	Withdrawn	Phase 2	Site did not enroll any patients to the study.	CHEBI_32293	"118886"	MONDO_0005150	"10064930"	"267718000"
amphotericin B	DB00681	Mycotic endocarditis	C0276648		Approved			CHEBI_2682	"236594|732"	MONDO_0042433	"10017529"	"86348002"
cefepime	DB01413	Bacterial peritonitis	C0341503		Approved			CHEBI_478164	"20481"		"10062070"	"197171003"
sulbactam	DB09324	Bacterial peritonitis	C0341503		Approved			CHEBI_9321	"10167"		"10062070"	"197171003"
fusidic acid	DB02703	Bacterial peritonitis	C0341503		Approved			CHEBI_29013	"4608|113608"		"10062070"	"197171003"
ampicillin	DB00415	Bacterial peritonitis	C0341503		Approved			CHEBI_28971	"733|221058"		"10062070"	"197171003"
ceftolozane	DB09050	Bacterial peritonitis	C0341503		Approved			CHEBI_134719	"1597609"		"10062070"	"197171003"
ceftizoxime	DB01332	Bacterial peritonitis	C0341503		Approved			CHEBI_553473	"2192"		"10062070"	"197171003"
cefamandole	DB01326	Bacterial peritonitis	C0341503		Approved			CHEBI_3480	"2178"		"10062070"	"197171003"
aztreonam	DB00355	Bacterial peritonitis	C0341503		Approved			CHEBI_161680	"1272"		"10062070"	"197171003"
tobramycin	DB00684	Bacterial peritonitis	C0341503		Approved			CHEBI_28864	"10627"		"10062070"	"197171003"
benzylpenicillin	DB01053	Streptococcal toxic shock syndrome	C0343532		Approved			CHEBI_18208	"7980"	MONDO_0020544	"10044251"	"240451000"
tenofovir disoproxil	DB00300	Hepatitis B, Chronic	C0524909		Approved			CHEBI_63717	"300195"	MONDO_0005366	"10008910"	"61977001"
interferon alfa-2b	DB00105	Hepatitis B, Chronic	C0524909		Approved				"5880|545290"	MONDO_0005366	"10008910"	"61977001"
lamivudine	DB00709	Hepatitis B, Chronic	C0524909		Approved			CHEBI_63577	"68244"	MONDO_0005366	"10008910"	"61977001"
telbivudine	DB01265	Hepatitis B, Chronic	C0524909		Approved			CHEBI_63624	"474128"	MONDO_0005366	"10008910"	"61977001"
interferon alfa-2b	DB15131	Hepatitis B, Chronic	C0524909		Approved				"545290"	MONDO_0005366	"10008910"	"61977001"
adefovir dipivoxil	DB00718	Hepatitis B, Chronic	C0524909		Approved			CHEBI_31175	"141400"	MONDO_0005366	"10008910"	"61977001"
entecavir	DB00442	Hepatitis B, Chronic	C0524909		Approved			CHEBI_473990	"1546027|306266"	MONDO_0005366	"10008910"	"61977001"
peginterferon alfa-2a	DB00008	Hepatitis B, Chronic	C0524909		Approved				"120608"	MONDO_0005366	"10008910"	"61977001"
tenofovir	DB14126	Hepatitis B, Chronic	C0524909		Approved			CHEBI_63625	"1546017|117466"	MONDO_0005366	"10008910"	"61977001"
tenofovir disoproxil	DB14126	Hepatitis B, Chronic	C0524909		Approved			CHEBI_63625	"1546017|117466"	MONDO_0005366	"10008910"	"61977001"
clevudine	DB06683	Hepatitis B, Chronic	C0524909		Approved			CHEBI_135964		MONDO_0005366	"10008910"	"61977001"
adefovir dipivoxil	DB13868	Hepatitis B, Chronic	C0524909		Approved			CHEBI_2469	"16521"	MONDO_0005366	"10008910"	"61977001"
ocrelizumab	DB11988	Multiple Sclerosis, Primary Progressive	C0751964		Approved				"1876366"	MONDO_0000451	"10063401"	"428700003"
fingolimod	DB08868	Multiple Sclerosis, Primary Progressive	C0751964	NCT00731692	Terminated	Phase 3	The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression	CHEBI_63115	"1012892"	MONDO_0000451	"10063401"	"428700003"
cefazolin	DB01327	Biliary tract infection	C0920156		Approved			CHEBI_474053	"2180"		"10061695"	"846685008"
tocilizumab	DB06273	Cytokine Release Syndrome	C0948245		Approved				"612865"		"10052015"	"710027002"
canakinumab	DB06168	TNF receptor-associated periodic fever syndrome (TRAPS)	C1275126		Approved				"853491"		"10067774"	"403833009"
pramocaine	DB09345	Allergic otitis externa	C1320547		Approved			CHEBI_8357	"34347"		"10075072"	"405821001"
dexamethasone	DB01234	Allergic otitis externa	C1320547		Approved			CHEBI_41879	"3264"		"10075072"	"405821001"
benzalkonium	DB13282	Allergic otitis externa	C1320547		Approved			CHEBI_188978			"10075072"	"405821001"
benzalkonium	DB11105	Allergic otitis externa	C1320547		Approved			CHEBI_188978	"1378"		"10075072"	"405821001"
miltefosine	DB09031	Mucocutaneous leishmaniasis	C1328252		Approved			CHEBI_75283	"1494066"	MONDO_0005859	"10054165"	"721813000"
bendamustine	DB06769	Marginal Zone B-Cell Lymphoma	C1367654	NCT02623920	Withdrawn	Phase 2	Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study prior to enrollment of any patients.	CHEBI_135515	"134547"	MONDO_0017604	"10076596"	"447100004"
etoposide	DB00773	Marginal Zone B-Cell Lymphoma	C1367654	NCT04189952	Terminated	Phase 2	Investigator Decision	CHEBI_4911	"4179"	MONDO_0017604	"10076596"	"447100004"
rituximab	DB00073	Marginal Zone B-Cell Lymphoma	C1367654	NCT03269552	Terminated	Phase 2	Terminated due to low accrual.		"2273510|2472325|121191|2105824"	MONDO_0017604	"10076596"	"447100004"
prednisone	DB00635	Marginal Zone B-Cell Lymphoma	C1367654	NCT04745832	Terminated	Phase 3	Discontinuation of zandelisib program	CHEBI_8382	"8640"	MONDO_0017604	"10076596"	"447100004"
lenalidomide	DB00480	Marginal Zone B-Cell Lymphoma	C1367654		Approved			CHEBI_63791	"342369"	MONDO_0017604	"10076596"	"447100004"
vorinostat	DB02546	Marginal Zone B-Cell Lymphoma	C1367654	NCT01500538	Terminated	Phase 2	Poor recruitment rate	CHEBI_45716	"194337"	MONDO_0017604	"10076596"	"447100004"
	DB00480	Marginal Zone B-Cell Lymphoma	C1367654	NCT01121757	Terminated	Phase 2	The study closed temporarily in February 2012 pending analysis of samples collected. In October, 2012, Celgene requested closure of the study.	CHEBI_63791	"342369"	MONDO_0017604	"10076596"	"447100004"
	DB06769	Marginal Zone B-Cell Lymphoma	C1367654	NCT04745832	Terminated	Phase 3	Discontinuation of zandelisib program	CHEBI_135515	"134547"	MONDO_0017604	"10076596"	"447100004"
tacrolimus	DB00864	Marginal Zone B-Cell Lymphoma	C1367654	NCT02877082	Terminated	Phase 2		CHEBI_61049	"42316|235991"	MONDO_0017604	"10076596"	"447100004"
azacitidine	DB00928	Marginal Zone B-Cell Lymphoma	C1367654	NCT01121757	Terminated	Phase 2	The study closed temporarily in February 2012 pending analysis of samples collected. In October, 2012, Celgene requested closure of the study.	CHEBI_2038	"1251"	MONDO_0017604	"10076596"	"447100004"
	DB00188	Marginal Zone B-Cell Lymphoma	C1367654	NCT02877082	Terminated	Phase 2		CHEBI_52717	"358258"	MONDO_0017604	"10076596"	"447100004"
	DB00073	Marginal Zone B-Cell Lymphoma	C1367654	NCT02623920	Withdrawn	Phase 2	Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study prior to enrollment of any patients.		"2273510|2472325|121191|2105824"	MONDO_0017604	"10076596"	"447100004"
	DB01181	Marginal Zone B-Cell Lymphoma	C1367654	NCT04189952	Terminated	Phase 2	Investigator Decision	CHEBI_5864	"5657"	MONDO_0017604	"10076596"	"447100004"
bendamustine	DB06769	Marginal Zone B-Cell Lymphoma	C1367654	NCT02793583	Terminated	Phase 2/Phase 3	Strategic/Business Decision	CHEBI_135515	"134547"	MONDO_0017604	"10076596"	"447100004"
ibrutinib	DB09053	Marginal Zone B-Cell Lymphoma	C1367654		Approved			CHEBI_76612	"1442981"	MONDO_0017604	"10076596"	"447100004"
	DB00531	Marginal Zone B-Cell Lymphoma	C1367654	NCT04745832	Terminated	Phase 3	Discontinuation of zandelisib program	CHEBI_4027	"1545988|3002"	MONDO_0017604	"10076596"	"447100004"
bendamustine	DB06769	Marginal Zone B-Cell Lymphoma	C1367654	NCT02576275	Withdrawn	Phase 3	The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.	CHEBI_135515	"134547"	MONDO_0017604	"10076596"	"447100004"
	DB00073	Marginal Zone B-Cell Lymphoma	C1367654	NCT02576275	Withdrawn	Phase 3	The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.		"2273510|2472325|121191|2105824"	MONDO_0017604	"10076596"	"447100004"
	DB00541	Marginal Zone B-Cell Lymphoma	C1367654	NCT04745832	Terminated	Phase 3	Discontinuation of zandelisib program	CHEBI_28445	"11202"	MONDO_0017604	"10076596"	"447100004"
	DB00073	Marginal Zone B-Cell Lymphoma	C1367654	NCT01460602	Withdrawn	Phase 1/Phase 2	Investigator has relocated to MD Anderson		"2273510|2472325|121191|2105824"	MONDO_0017604	"10076596"	"447100004"
bortezomib	DB00188	Marginal Zone B-Cell Lymphoma	C1367654	NCT01460602	Withdrawn	Phase 1/Phase 2	Investigator has relocated to MD Anderson	CHEBI_52717	"358258"	MONDO_0017604	"10076596"	"447100004"
	DB00073	Marginal Zone B-Cell Lymphoma	C1367654	NCT04745832	Terminated	Phase 3	Discontinuation of zandelisib program		"2273510|2472325|121191|2105824"	MONDO_0017604	"10076596"	"447100004"
	DB00073	Marginal Zone B-Cell Lymphoma	C1367654	NCT04189952	Terminated	Phase 2	Investigator Decision		"2273510|2472325|121191|2105824"	MONDO_0017604	"10076596"	"447100004"
lenalidomide	DB00480	Marginal Zone B-Cell Lymphoma	C1367654	NCT01744912	Terminated	Phase 1	Sponsor's decision	CHEBI_63791	"342369"	MONDO_0017604	"10076596"	"447100004"
	DB00958	Marginal Zone B-Cell Lymphoma	C1367654	NCT04189952	Terminated	Phase 2	Investigator Decision	CHEBI_31355	"40048"	MONDO_0017604	"10076596"	"447100004"
pramocaine	DB09345	Tinea cruris	C1384589		Approved			CHEBI_8357	"34347"		"10043868"	"399029005"
haloprogin	DB00793	Tinea cruris	C1384589		Approved			CHEBI_5614	"26422"		"10043868"	"399029005"
clioquinol	DB04815	Tinea cruris	C1384589		Approved			CHEBI_74460	"5942"		"10043868"	"399029005"
terbinafine	DB00857	Tinea cruris	C1384589		Approved			CHEBI_9448	"37801"		"10043868"	"399029005"
naftifine	DB00735	Tinea cruris	C1384589		Approved			CHEBI_7451	"31476"		"10043868"	"399029005"
zinc oxide	DB09321	Tinea cruris	C1384589		Approved			CHEBI_36560	"11423"		"10043868"	"399029005"
betamethasone	DB00443	Tinea cruris	C1384589		Approved			CHEBI_3077	"1514"		"10043868"	"399029005"
cortisone acetate	DB01380	Tinea cruris	C1384589		Approved			CHEBI_3897	"21655"		"10043868"	"399029005"
ciclopirox	DB01188	Tinea cruris	C1384589		Approved			CHEBI_453011	"21090"		"10043868"	"399029005"
tolnaftate	DB00525	Tinea cruris	C1384589		Approved			CHEBI_9620	"10637"		"10043868"	"399029005"
econazole	DB01127	Tinea cruris	C1384589		Approved			CHEBI_82873	"3743"		"10043868"	"399029005"
clotrimazole	DB00257	Tinea cruris	C1384589		Approved			CHEBI_3764	"2623"		"10043868"	"399029005"
butenafine	DB01091	Tinea cruris	C1384589		Approved			CHEBI_3238	"47461"		"10043868"	"399029005"
betamethasone dipropionate	DB00443	Tinea cruris	C1384589		Approved			CHEBI_3077	"1514"		"10043868"	"399029005"
miconazole	DB01110	Tinea cruris	C1384589		Approved			CHEBI_82892	"6932"		"10043868"	"399029005"
hydrocortisone	DB00741	Tinea cruris	C1384589		Approved			CHEBI_17650	"5492"		"10043868"	"399029005"
oxiconazole	DB00239	Tinea cruris	C1384589		Approved			CHEBI_7825	"32638"		"10043868"	"399029005"
ketoconazole	DB01026	Tinea cruris	C1384589		Approved			CHEBI_48339	"6135"		"10043868"	"399029005"
benzoic acid	DB03793	Morphea	C1527383		Approved			CHEBI_30746	"18989"	HP:0012344	"10027982"	"201049004"
imiquimod	DB00724	Morphea	C1527383	NCT00230373	Withdrawn	Phase 3	Study never started.	CHEBI_36704	"59943"	HP:0012344	"10027982"	"201049004"
aminobenzoic acid	DB02362	Morphea	C1527383		Approved			CHEBI_30753	"74"	HP:0012344	"10027982"	"201049004"
setmelanotide	DB11700	Proopiomelanocortin Deficiency	C1857854		Approved				"2469247"	MONDO_0012335	"10083937"	"702949005"
trastuzumab	DB00072	HER2-positive carcinoma of breast	C1960398		Approved				"2289225|2103478|2174802|2280730|2107051|224905"	MONDO_0006244	"10065430"	"427685000"
trastuzumab emtansine	DB05773	HER2-positive carcinoma of breast	C1960398		Approved				"1371041"	MONDO_0006244	"10065430"	"427685000"
neratinib	DB11828	HER2-positive carcinoma of breast	C1960398		Approved			CHEBI_61397	"1940643"	MONDO_0006244	"10065430"	"427685000"
lapatinib	DB01259	HER2-positive carcinoma of breast	C1960398		Approved			CHEBI_49603	"480167"	MONDO_0006244	"10065430"	"427685000"
pertuzumab	DB06366	HER2-positive carcinoma of breast	C1960398		Approved				"1298944"	MONDO_0006244	"10065430"	"427685000"
ravulizumab	DB11580	Atypical Hemolytic Uremic Syndrome	C2931788		Approved				"2107316|2107301"	MONDO_0016244	"10079840"	"789660001"
aceclofenac	DB06736	Periarthritis of shoulder	C1306835		Approved			CHEBI_31159	"16689"			"399114005"
clobetasol propionate	DB11750	Inflammatory dermatosis	C3875321		Approved			CHEBI_205919	"2590"	MONDO_0002406		"703938007"
cefoxitin	DB01331	Arthropathy associated with infection	C0157749		Approved			CHEBI_209807	"2189"			"363162000"
cefalexin	DB00567	Arthropathy associated with infection	C0157749		Approved			CHEBI_3534	"2231|1299782"			"363162000"
cefalotin	DB00456	Arthropathy associated with infection	C0157749		Approved			CHEBI_124991	"2236"			"363162000"
cefapirin	DB01139	Arthropathy associated with infection	C0157749		Approved			CHEBI_554446	"2238"			"363162000"
cefradine	DB01333	Arthropathy associated with infection	C0157749		Approved			CHEBI_3547	"2239"			"363162000"
	DB01104	Infection by Cryptococcus neoformans	C0010414	NCT03002012	Terminated	Phase 3	SAEs with n=1 serotonin syndrome, n=2 SAEs after sertraline interruption.	CHEBI_9123	"36437"	MONDO_0005724	"10011490"	"42386007"
amphotericin B	DB00681	Infection by Cryptococcus neoformans	C0010414		Approved			CHEBI_2682	"236594|732"	MONDO_0005724	"10011490"	"42386007"
fluconazole	DB00196	Infection by Cryptococcus neoformans	C0010414	NCT03002012	Terminated	Phase 3	SAEs with n=1 serotonin syndrome, n=2 SAEs after sertraline interruption.	CHEBI_46081	"202813|4450"	MONDO_0005724	"10011490"	"42386007"
octreotide	DB00104	Diabetic Retinopathy	C0011884	NCT00248157	Terminated	Phase 3	Inconsistent treatment benefit	CHEBI_7726	"7617"	MONDO_0005266	"10012689"	"4855003"
infliximab	DB00065	Diabetic Retinopathy	C0011884	NCT00505947	Terminated	Phase 3	The number of the anticipated participants was not achieved		"1790539|1927283|191831|2266523|2103476"	MONDO_0005266	"10012689"	"4855003"
ranibizumab	DB01270	Diabetic Retinopathy	C0011884		Approved				"595060"	MONDO_0005266	"10012689"	"4855003"
octreotide	DB00104	Diabetic Retinopathy	C0011884	NCT00248131	Terminated	Phase 3		CHEBI_7726	"7617"	MONDO_0005266	"10012689"	"4855003"
ciprofloxacin	DB00537	Dysentery	C0013369		Approved			CHEBI_192484	"2551"	MONDO_0001517|MONDO_0001673	"10012742"	"19213003"
norfloxacin	DB01059	Dysentery	C0013369		Approved			CHEBI_100246	"7517"	MONDO_0001517|MONDO_0001673	"10012742"	"19213003"
ofloxacin	DB01165	Dysentery	C0013369		Approved			CHEBI_7731	"7623"	MONDO_0001517|MONDO_0001673	"10012742"	"19213003"
metronidazole	DB15759	Amebic colitis	C0013370		Approved			CHEBI_50688			"10001985"	"387754006"
metronidazole	DB00916	Amebic colitis	C0013370		Approved			CHEBI_6909	"6922"		"10001985"	"387754006"
metronidazole	DB15759	Giardiasis	C0017536		Approved			CHEBI_50688		MONDO_0001103	"10018262"	"58265007"
nitazoxanide	DB00507	Giardiasis	C0017536		Approved			CHEBI_94807	"31819"	MONDO_0001103	"10018262"	"58265007"
secnidazole	DB12834	Giardiasis	C0017536		Approved			CHEBI_94433	"36314"	MONDO_0001103	"10018262"	"58265007"
mepacrine	DB01103	Giardiasis	C0017536		Approved			CHEBI_8711	"9061"	MONDO_0001103	"10018262"	"58265007"
metronidazole	DB00916	Giardiasis	C0017536		Approved			CHEBI_6909	"6922"	MONDO_0001103	"10018262"	"58265007"
tinidazole	DB00911	Giardiasis	C0017536		Approved			CHEBI_63627	"10612"	MONDO_0001103	"10018262"	"58265007"
fusidic acid	DB02703	Granuloma Inguinale	C0018190		Approved			CHEBI_29013	"4608|113608"	MONDO_0005777	"10018693"	"28867007"
doxycycline	DB00254	Granuloma Inguinale	C0018190		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005777	"10018693"	"28867007"
minocycline	DB01017	Granuloma Inguinale	C0018190		Approved			CHEBI_50694	"6980"	MONDO_0005777	"10018693"	"28867007"
meclocycline	DB13092	Granuloma Inguinale	C0018190		Approved			CHEBI_135772	"29418"	MONDO_0005777	"10018693"	"28867007"
tetracycline	DB00759	Granuloma Inguinale	C0018190		Approved			CHEBI_27902	"10395"	MONDO_0005777	"10018693"	"28867007"
streptomycin	DB01082	Granuloma Inguinale	C0018190		Approved			CHEBI_17076	"10109"	MONDO_0005777	"10018693"	"28867007"
oxytetracycline	DB00595	Granuloma Inguinale	C0018190		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005777	"10018693"	"28867007"
amphotericin B	DB00681	Granuloma Inguinale	C0018190		Approved			CHEBI_2682	"236594|732"	MONDO_0005777	"10018693"	"28867007"
demeclocycline	DB00618	Granuloma Inguinale	C0018190		Approved			CHEBI_4392	"3154"	MONDO_0005777	"10018693"	"28867007"
tetracycline	DB09550	Granuloma Inguinale	C0018190		Approved			CHEBI_27902	"2105975"	MONDO_0005777	"10018693"	"28867007"
diazoxide	DB01119	Hyperinsulinism	C0020459		Approved			CHEBI_4495	"3327"	MONDO_0002177	"10061211"	"83469008"
sirolimus	DB00877	Hyperinsulinism	C0020459	NCT02524639	Withdrawn	Phase 1/Phase 2	Due to strict inclusion and exclusion criteria no subjects were enrolled	CHEBI_9168	"35302"	MONDO_0002177	"10061211"	"83469008"
carbamide peroxide	DB11129	Impacted cerumen	C0021092		Approved			CHEBI_75178	"47686"	HP:0030788	"10050337"	"18070006"
trolamine	DB13747	Impacted cerumen	C0021092		Approved			CHEBI_28621	"38623"	HP:0030788	"10050337"	"18070006"
carbamide	DB03904	Impacted cerumen	C0021092		Approved			CHEBI_16199	"11002"	HP:0030788	"10050337"	"18070006"
hydrocortisone succinate	DB00741	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_17650	"5492"	MONDO_0005265	"10021972"	"24526004"
dexamethasone	DB01234	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_41879	"3264"	MONDO_0005265	"10021972"	"24526004"
hydrocortisone acetate	DB14539	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_17609	"27197"	MONDO_0005265	"10021972"	"24526004"
betamethasone acetate	DB00443	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_3077	"1514"	MONDO_0005265	"10021972"	"24526004"
triamcinolone acetonide	DB00620	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_9667	"10759"	MONDO_0005265	"10021972"	"24526004"
betamethasone	DB00443	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_3077	"1514"	MONDO_0005265	"10021972"	"24526004"
triamcinolone diacetate	DB00620	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_9667	"10759"	MONDO_0005265	"10021972"	"24526004"
	DB00257	Inflammatory Bowel Diseases	C0021390	NCT00061282	Terminated	Phase 1/Phase 2	Funding Horizon	CHEBI_3764	"2623"	MONDO_0005265	"10021972"	"24526004"
miconazole	DB01110	Inflammatory Bowel Diseases	C0021390	NCT00061282	Terminated	Phase 1/Phase 2	Funding Horizon	CHEBI_82892	"6932"	MONDO_0005265	"10021972"	"24526004"
methylprednisolone	DB00959	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_6888	"6902"	MONDO_0005265	"10021972"	"24526004"
hydrocortisone	DB00741	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_17650	"5492"	MONDO_0005265	"10021972"	"24526004"
prednisolone	DB00860	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_8378	"8638"	MONDO_0005265	"10021972"	"24526004"
hydrocortisone acetate	DB00741	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_17650	"5492"	MONDO_0005265	"10021972"	"24526004"
naltrexone	DB00704	Inflammatory Bowel Diseases	C0021390	NCT01810185	Withdrawn	Phase 2	Low patient enrollment	CHEBI_7465	"7243"	MONDO_0005265	"10021972"	"24526004"
triamcinolone	DB00620	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_9667	"10759"	MONDO_0005265	"10021972"	"24526004"
cortisone acetate	DB01380	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_3897	"21655"	MONDO_0005265	"10021972"	"24526004"
infliximab	DB00065	Inflammatory Bowel Diseases	C0021390	NCT02771457	Withdrawn	Phase 3			"1790539|1927283|191831|2266523|2103476"	MONDO_0005265	"10021972"	"24526004"
	DB01222	Inflammatory Bowel Diseases	C0021390	NCT00805285	Terminated	Phase 2	Study terminated due to insufficient enrollment	CHEBI_3207	"19831"	MONDO_0005265	"10021972"	"24526004"
hydrocortamate	DB00741	Inflammatory Bowel Diseases	C0021390	NCT00805285	Terminated	Phase 2	Study terminated due to insufficient enrollment	CHEBI_17650	"5492"	MONDO_0005265	"10021972"	"24526004"
hydrocortisone succinate	DB14545	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_31677	"21651"	MONDO_0005265	"10021972"	"24526004"
prednisone	DB00635	Inflammatory Bowel Diseases	C0021390		Approved			CHEBI_8382	"8640"	MONDO_0005265	"10021972"	"24526004"
menadiol sodium diphosphate	DB09332	Jaundice, Obstructive	C0022354		Approved			CHEBI_134713	"52549"	MONDO_0006874	"10023129"	"59848001"
relebactam	DB12377	Klebsiella Infections	C0022729		Approved				"2184137|2268500"		"10061259"	"721756002"
cilastatin	DB01597	Klebsiella Infections	C0022729		Approved			CHEBI_3697	"2540"		"10061259"	"721756002"
docetaxel	DB01248	leiomyosarcoma	C0023269	NCT05116800	Withdrawn	Phase 2	IND withdrawn	CHEBI_4672	"72962|1299922"	MONDO_0005058	"10024189"	"443719001"
trabectedin	DB05109	leiomyosarcoma	C0023269	NCT03773510	Withdrawn	Phase 3	Not approved by the coordinating Ethical Committee	CHEBI_84050	"1716278"	MONDO_0005058	"10024189"	"443719001"
	DB00997	leiomyosarcoma	C0023269	NCT03437070	Withdrawn	Phase 1	Sponsor Decision	CHEBI_28748	"142433|3639"	MONDO_0005058	"10024189"	"443719001"
vorinostat	DB02546	leiomyosarcoma	C0023269	NCT03509207	Terminated	Phase 2	The early termination was NOT due to safety reasons, terminated because of the very slow recruitment and problematic access to the study medication in Europe	CHEBI_45716	"194337"	MONDO_0005058	"10024189"	"443719001"
trabectedin	DB05109	leiomyosarcoma	C0023269	NCT03437070	Withdrawn	Phase 1	Sponsor Decision	CHEBI_84050	"1716278"	MONDO_0005058	"10024189"	"443719001"
docetaxel	DB01248	leiomyosarcoma	C0023269	NCT04906876	Withdrawn	Phase 2	IND withdrawn	CHEBI_4672	"72962|1299922"	MONDO_0005058	"10024189"	"443719001"
letrozole	DB01006	leiomyosarcoma	C0023269	NCT00414076	Terminated	Phase 2	Low accrual	CHEBI_6413	"72965"	MONDO_0005058	"10024189"	"443719001"
trabectedin	DB05109	leiomyosarcoma	C0023269		Approved			CHEBI_84050	"1716278"	MONDO_0005058	"10024189"	"443719001"
docetaxel	DB01248	leiomyosarcoma	C0023269	NCT01418001	Terminated	Phase 1/Phase 2	Lack of accrual	CHEBI_4672	"72962|1299922"	MONDO_0005058	"10024189"	"443719001"
meglumine antimonate	DB13732	Leishmaniasis, Cutaneous	C0023283	NCT00682656	Terminated	Phase 2/Phase 3	Efficacy issues on test arm		"319866"	MONDO_0005446	"10011668"	"240637006"
paromomycin	DB01421	Leishmaniasis, Cutaneous	C0023283	NCT00657917	Terminated	Phase 2	No subjects were enrolled since the first subject completed the study 08Jun2007	CHEBI_7934	"7934"	MONDO_0005446	"10011668"	"240637006"
fluconazole	DB00196	Leishmaniasis, Cutaneous	C0023283	NCT01953744	Terminated	Phase 3	Low cure rate in the study (fluconazole) group	CHEBI_46081	"202813|4450"	MONDO_0005446	"10011668"	"240637006"
	DB13732	Leishmaniasis, Cutaneous	C0023283	NCT01953744	Terminated	Phase 3	Low cure rate in the study (fluconazole) group		"319866"	MONDO_0005446	"10011668"	"240637006"
meglumine antimonate	DB13732	Leishmaniasis, Cutaneous	C0023283	NCT00317629	Terminated	Phase 3	An interim analysis showed that nitric oxide patches are not enough effective		"319866"	MONDO_0005446	"10011668"	"240637006"
	DB00435	Leishmaniasis, Cutaneous	C0023283	NCT00317629	Terminated	Phase 3	An interim analysis showed that nitric oxide patches are not enough effective	CHEBI_16480	"7442"	MONDO_0005446	"10011668"	"240637006"
	DB00207	Leishmaniasis, Cutaneous	C0023283	NCT00682656	Terminated	Phase 2/Phase 3	Efficacy issues on test arm	CHEBI_2955	"18631"	MONDO_0005446	"10011668"	"240637006"
miltefosine	DB09031	Leishmaniasis, Cutaneous	C0023283		Approved			CHEBI_75283	"1494066"	MONDO_0005446	"10011668"	"240637006"
paromomycin	DB01421	Leishmaniasis, Cutaneous	C0023283	NCT01494350	Terminated	Phase 2	This study was closed prematurely due study team travel restrictions.	CHEBI_7934	"7934"	MONDO_0005446	"10011668"	"240637006"
laronidase	DB00090	Mucopolysaccharidosis I	C0023786		Approved				"392509"		"10056886"	"75610003"
eculizumab	DB01257	Paroxysmal nocturnal hemoglobinuria	C0024790		Approved				"591781"	MONDO_0100244	"10034042"	"1963002"
ravulizumab	DB11580	Paroxysmal nocturnal hemoglobinuria	C0024790		Approved				"2107316|2107301"	MONDO_0100244	"10034042"	"1963002"
pegcetacoplan	DB16694	Paroxysmal nocturnal hemoglobinuria	C0024790		Approved				"2557372"	MONDO_0100244	"10034042"	"1963002"
benzylpenicillin	DB01053	Meningitis, Listeria	C0025293		Approved			CHEBI_18208	"7980"	MONDO_0006836	"10027248"	"31568009"
tropicamide	DB00809	Mydriasis	C0026961		Approved			CHEBI_9757	"10869"	HP:0011499	"10028521"	"37125009"
hydroxyamfetamine	DB09352	Mydriasis	C0026961		Approved			CHEBI_103855	"7839"	HP:0011499	"10028521"	"37125009"
phenylephrine	DB00388	Mydriasis	C0026961		Approved			CHEBI_8093	"8163"	HP:0011499	"10028521"	"37125009"
cyclopentolate	DB00979	Mydriasis	C0026961		Approved			CHEBI_4024	"3001"	HP:0011499	"10028521"	"37125009"
scopolamine	DB00747	Mydriasis	C0026961		Approved			CHEBI_16794	"9601|9603"	HP:0011499	"10028521"	"37125009"
ruxolitinib	DB08877	Myeloproliferative disease	C0027022		Approved			CHEBI_66919	"1193326"	HP:0005547	"10077465"	"425333006"
liothyronine	DB00279	Myxedema	C0027145		Approved			CHEBI_533015	"10814"	MONDO_0009718	"10028665"	"43153006"
levothyroxine	DB00451	Myxedema	C0027145		Approved			CHEBI_58448	"10582"	MONDO_0009718	"10028665"	"43153006"
garenoxacin	DB06160	Peritonsillar Abscess	C0031157		Approved			CHEBI_131716		MONDO_0005906	"10034686"	"15033003"
hydrocortisone	DB00741	Proctitis	C0033246		Approved			CHEBI_17650	"5492"	MONDO_0005538	"10036774"	"3951002"
mesalazine	DB00244	Proctitis	C0033246	NCT01172444	Terminated	Phase 3	Enrollment difficulties	CHEBI_6775	"52582"	MONDO_0005538	"10036774"	"3951002"
pramocaine	DB09345	Proctitis	C0033246		Approved			CHEBI_8357	"34347"	MONDO_0005538	"10036774"	"3951002"
phenylmercuric nitrate	DB13388	Proctitis	C0033246		Approved			CHEBI_136021		MONDO_0005538	"10036774"	"3951002"
ferric oxide	DB11576	Proctitis	C0033246		Approved			CHEBI_50819		MONDO_0005538	"10036774"	"3951002"
zinc acetate	DB14487	Proctitis	C0033246		Approved			CHEBI_62984	"1299637|58295"	MONDO_0005538	"10036774"	"3951002"
budesonide	DB01222	Proctitis	C0033246	NCT01349673	Terminated	Phase 3	Terminated for non-safety reasons when Sponsor felt that sufficient long-term safety data was obtained.	CHEBI_3207	"19831"	MONDO_0005538	"10036774"	"3951002"
zinc oxide	DB09321	Proctitis	C0033246		Approved			CHEBI_36560	"11423"	MONDO_0005538	"10036774"	"3951002"
phenylephrine	DB00388	Proctitis	C0033246		Approved			CHEBI_8093	"8163"	MONDO_0005538	"10036774"	"3951002"
cortisone acetate	DB01380	Proctitis	C0033246		Approved			CHEBI_3897	"21655"	MONDO_0005538	"10036774"	"3951002"
ciprofloxacin	DB00537	prostatitis	C0033581		Approved			CHEBI_192484	"2551"	MONDO_0005280	"10036978"	"9713002"
ofloxacin	DB01165	prostatitis	C0033581		Approved			CHEBI_7731	"7623"	MONDO_0005280	"10036978"	"9713002"
carbenicillin	DB00578	prostatitis	C0033581		Approved			CHEBI_3393	"2015"	MONDO_0005280	"10036978"	"9713002"
norfloxacin	DB01059	prostatitis	C0033581		Approved			CHEBI_100246	"7517"	MONDO_0005280	"10036978"	"9713002"
cefradine	DB01333	prostatitis	C0033581		Approved			CHEBI_3547	"2239"	MONDO_0005280	"10036978"	"9713002"
cefalexin	DB00567	prostatitis	C0033581		Approved			CHEBI_3534	"2231|1299782"	MONDO_0005280	"10036978"	"9713002"
tetracycline	DB00759	Q Fever	C0034362		Approved			CHEBI_27902	"10395"	MONDO_0019186	"10037688"	"186788009"
tetracycline	DB09550	Q Fever	C0034362		Approved			CHEBI_27902	"2105975"	MONDO_0019186	"10037688"	"186788009"
demeclocycline	DB00618	Q Fever	C0034362		Approved			CHEBI_4392	"3154"	MONDO_0019186	"10037688"	"186788009"
fusidic acid	DB02703	Q Fever	C0034362		Approved			CHEBI_29013	"4608|113608"	MONDO_0019186	"10037688"	"186788009"
doxycycline	DB00254	Q Fever	C0034362		Approved			CHEBI_50845	"1545992|3640"	MONDO_0019186	"10037688"	"186788009"
oxytetracycline	DB00595	Q Fever	C0034362		Approved			CHEBI_133011	"7821|1545999"	MONDO_0019186	"10037688"	"186788009"
meclocycline	DB13092	Q Fever	C0034362		Approved			CHEBI_135772	"29418"	MONDO_0019186	"10037688"	"186788009"
minocycline	DB01017	Q Fever	C0034362		Approved			CHEBI_50694	"6980"	MONDO_0019186	"10037688"	"186788009"
amphotericin B	DB00681	Q Fever	C0034362		Approved			CHEBI_2682	"236594|732"	MONDO_0019186	"10037688"	"186788009"
chloramphenicol succinate	DB07565	Salmonella infections	C0036117		Approved			CHEBI_3606	"20769"	MONDO_0000827	"10039447"	"302231008"
chloramphenicol succinate	DB00446	Salmonella infections	C0036117		Approved			CHEBI_17698	"2348"	MONDO_0000827	"10039447"	"302231008"
sulfadiazine	DB00359	Toxoplasmosis	C0040558		Approved			CHEBI_9328	"10171"	MONDO_0005989	"10044272"	"187192000"
pyrimethamine	DB00205	Toxoplasmosis	C0040558		Approved			CHEBI_8673	"9010"	MONDO_0005989	"10044272"	"187192000"
sulfamethoxazole	DB01015	Toxoplasmosis	C0040558		Approved			CHEBI_9332	"10180"	MONDO_0005989	"10044272"	"187192000"
metronidazole	DB15759	Trichomonas Infections	C0040921		Approved			CHEBI_50688		MONDO_0002154	"10044620"	"105648001"
secnidazole	DB12834	Trichomonas Infections	C0040921		Approved			CHEBI_94433	"36314"	MONDO_0002154	"10044620"	"105648001"
tinidazole	DB00911	Trichomonas Infections	C0040921		Approved			CHEBI_63627	"10612"	MONDO_0002154	"10044620"	"105648001"
tenonitrozole	DB13659	Trichomonas Infections	C0040921		Approved			CHEBI_135042		MONDO_0002154	"10044620"	"105648001"
metronidazole	DB00916	Trichomonas Infections	C0040921		Approved			CHEBI_6909	"6922"	MONDO_0002154	"10044620"	"105648001"
hachimycin	DB13302	Trichomonas Infections	C0040921		Approved			CHEBI_35022		MONDO_0002154	"10044620"	"105648001"
pyrazinamide	DB00339	Tuberculosis, Meningeal	C0041318		Approved			CHEBI_45285	"8987"	MONDO_0006042	"10027259"	"58437007"
everolimus	DB01590	Tuberous Sclerosis	C0041341		Approved			CHEBI_68478	"141704"		"10080584"	"7199000"
sirolimus	DB00877	Tuberous Sclerosis	C0041341		Approved			CHEBI_9168	"35302"		"10080584"	"7199000"
bleomycin	DB00290	Diffuse Large B-Cell Lymphoma	C0079744		Approved			CHEBI_22907	"1622"	MONDO_0018905	"10012818"	"109969005"
doxorubicin	DB00997	Diffuse Large B-Cell Lymphoma	C0079744		Approved			CHEBI_28748	"142433|3639"	MONDO_0018905	"10012818"	"109969005"
prednisone	DB00635	Diffuse Large B-Cell Lymphoma	C0079744		Approved			CHEBI_8382	"8640"	MONDO_0018905	"10012818"	"109969005"
carmustine	DB00262	Diffuse Large B-Cell Lymphoma	C0079744		Approved			CHEBI_3423	"2105"	MONDO_0018905	"10012818"	"109969005"
dexamethasone	DB01234	Diffuse Large B-Cell Lymphoma	C0079744		Approved			CHEBI_41879	"3264"	MONDO_0018905	"10012818"	"109969005"
vincristine	DB00541	Diffuse Large B-Cell Lymphoma	C0079744		Approved			CHEBI_28445	"11202"	MONDO_0018905	"10012818"	"109969005"
bunazosin	DB12230	Essential Hypertension	C0085580		Approved			CHEBI_135576	"19850"	MONDO_0001134	"10015488"	"59621000"
tripamide	DB15959	Essential Hypertension	C0085580		Approved			CHEBI_32264		MONDO_0001134	"10015488"	"59621000"
alacepril	DB01197	Essential Hypertension	C0085580		Approved			CHEBI_3380	"1998"	MONDO_0001134	"10015488"	"59621000"
moxonidine	DB09242	Essential Hypertension	C0085580		Approved			CHEBI_7009	"30257"	MONDO_0001134	"10015488"	"59621000"
midazolam	DB00683	Agitation	C0085631		Approved			CHEBI_6931	"6960"	HP:0000713	"10001497"	"24199005"
erythromycin	DB00199	Gastroparesis	C0152020	NCT01323582	Terminated	Phase 2	Original investigator left this institution, replacement investigator retired.	CHEBI_42355	"4053"	MONDO_0006769	"10017753"	"235675006"
	DB00207	Gastroparesis	C0152020	NCT01323582	Terminated	Phase 2	Original investigator left this institution, replacement investigator retired.	CHEBI_2955	"18631"	MONDO_0006769	"10017753"	"235675006"
erythromycin	DB00199	Gastroparesis	C0152020	NCT01117376	Terminated	Phase 2	The study was prematurely terminated because of unavailibility of Methylnaltrexone in the region	CHEBI_42355	"4053"	MONDO_0006769	"10017753"	"235675006"
metoclopramide	DB01233	Gastroparesis	C0152020	NCT01934192	Terminated	Phase 2		CHEBI_107736	"6915"	MONDO_0006769	"10017753"	"235675006"
granisetron	DB00889	Gastroparesis	C0152020	NCT04501211	Withdrawn	Phase 2	Abandoned due to limited resources	CHEBI_5537	"26237"	MONDO_0006769	"10017753"	"235675006"
domperidone	DB01184	Gastroparesis	C0152020	NCT00760461	Terminated	Phase 2	Enrolled subjects were unable to receive drug from dispensing pharmacy.	CHEBI_31515	"3626"	MONDO_0006769	"10017753"	"235675006"
dexpanthenol	DB09357	Gastroparesis	C0152020		Approved			CHEBI_27373	"22701"	MONDO_0006769	"10017753"	"235675006"
domperidone	DB01184	Gastroparesis	C0152020	NCT01378884	Withdrawn	Phase 3		CHEBI_31515	"3626"	MONDO_0006769	"10017753"	"235675006"
ceftriaxone	DB01212	Gonococcal endocarditis	C0153227		Approved			CHEBI_29007	"2193"		"10014674"	"61048000"
vinblastine	DB00570	Malignant neoplasm of testis	C0153594		Approved			CHEBI_27375	"11198"	HP:0010788	"10057644"	"363449006"
etoposide phosphate	DB00773	Malignant neoplasm of testis	C0153594		Approved			CHEBI_4911	"4179"	HP:0010788	"10057644"	"363449006"
plicamycin	DB06810	Malignant neoplasm of testis	C0153594		Approved			CHEBI_31856	"6995"	HP:0010788	"10057644"	"363449006"
dactinomycin	DB00970	Malignant neoplasm of testis	C0153594		Approved			CHEBI_27666	"3100"	HP:0010788	"10057644"	"363449006"
etoposide	DB00773	Malignant neoplasm of testis	C0153594		Approved			CHEBI_4911	"4179"	HP:0010788	"10057644"	"363449006"
progesterone	DB00396	Metastatic malignant neoplasm to kidney	C0153685		Approved			CHEBI_17026	"8727"		"10027455"	"94360002"
medroxyprogesterone	DB00603	Metastatic malignant neoplasm to kidney	C0153685		Approved			CHEBI_6716	"1000112"		"10027455"	"94360002"
dibotermin alfa	DB11639	Intervertebral Disc Degeneration	C0158266		Approved					MONDO_0011385	"10061246"	"77547008"
infigratinib	DB11886	Cholangiocarcinoma	C0206698		Approved			CHEBI_63451	"2550729"	MONDO_0019087	"10008593"	"312104005"
benperidol	DB12867	Antisocial behavior	C0233523		Approved			CHEBI_93403	"1373"		"10002820"	"60814007"
	DB00327	Hemoglobin SS disease with crisis	C0238425	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	CHEBI_5790	"3423"		"10040642"	"417425009"
	DB00295	Hemoglobin SS disease with crisis	C0238425	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	CHEBI_17303	"7052|32926"		"10040642"	"417425009"
	DB00054	Hemoglobin SS disease with crisis	C0238425	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment		"83929"		"10040642"	"417425009"
	DB01050	Hemoglobin SS disease with crisis	C0238425	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	CHEBI_5855	"5640"		"10040642"	"417425009"
hydroxycarbamide	DB01005	Hemoglobin SS disease with crisis	C0238425		Approved			CHEBI_44423	"151871|5552"		"10040642"	"417425009"
fentanyl	DB00813	Hemoglobin SS disease with crisis	C0238425	NCT01932554	Withdrawn	Phase 2	Insufficient recruitment	CHEBI_119915	"4337"		"10040642"	"417425009"
methylprednisolone	DB00959	Acute Lung Injury	C0242488	NCT01757899	Withdrawn	Phase 2	Technical problems	CHEBI_6888	"6902"		"10069351"	"315345002"
rosuvastatin	DB01098	Acute Lung Injury	C0242488	NCT00979121	Terminated	Phase 3	stopped for futility	CHEBI_38545	"301542"		"10069351"	"315345002"
	DB14644	Acute Lung Injury	C0242488	NCT01757899	Withdrawn	Phase 2	Technical problems	CHEBI_135765			"10069351"	"315345002"
sivelestat	DB12863	Acute Lung Injury	C0242488		Approved			CHEBI_135704			"10069351"	"315345002"
	DB00860	Acute Lung Injury	C0242488	NCT01757899	Withdrawn	Phase 2	Technical problems	CHEBI_8378	"8638"		"10069351"	"315345002"
heparin	DB01109	Acute Lung Injury	C0242488	NCT04389840	Terminated	Phase 2/Phase 3	Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual.	CHEBI_28304	"5224"		"10069351"	"315345002"
phenylbutanoic acid	DB06819	Ornithine carbamoyltransferase deficiency	C0268542		Approved			CHEBI_41500	"1546447|81647"	MONDO_0010703	"10052450"	"80908008"
amphotericin B	DB00681	Pulmonary cryptococcosis	C0276688		Approved			CHEBI_2682	"236594|732"		"10067565"	"20953001"
bevacizumab	DB00112	Cervix carcinoma	C0302592		Approved				"253337|2046138"	MONDO_0005131|MONDO_0016274	"10008342"	"285432005"
loteprednol etabonate	DB14596	Corneal Perforation	C0339293		Approved			CHEBI_31784	"52177"	HP:0100583	"10011039"	"74895004"
fusidic acid	DB02703	Corneal Perforation	C0339293		Approved			CHEBI_29013	"4608|113608"	HP:0100583	"10011039"	"74895004"
loteprednol etabonate	DB00873	Corneal Perforation	C0339293		Approved			CHEBI_50848	"237027"	HP:0100583	"10011039"	"74895004"
tobramycin	DB00684	Corneal Perforation	C0339293		Approved			CHEBI_28864	"10627"	HP:0100583	"10011039"	"74895004"
dexamethasone	DB01234	Corneal Perforation	C0339293		Approved			CHEBI_41879	"3264"	HP:0100583	"10011039"	"74895004"
bezlotoxumab	DB13140	Clostridium difficile infection	C0343386		Approved				"1855048"		"10054236"	"186431008"
fidaxomicin	DB08874	Clostridium difficile infection	C0343386		Approved			CHEBI_68590	"1111103"		"10054236"	"186431008"
fidaxomicin	DB08874	Clostridium difficile infection	C0343386	NCT02395848	Terminated	Phase 3	Insufficient resource to complete the study	CHEBI_68590	"1111103"		"10054236"	"186431008"
vancomycin	DB00512	Clostridium difficile infection	C0343386	NCT03105479	Terminated	Phase 2/Phase 3	Study suspended in October 2017 and terminated April 17, 2018 after decision to discontinue the study drug development	CHEBI_28001	"11124"		"10054236"	"186431008"
	DB15759	Clostridium difficile infection	C0343386	NCT02301000	Terminated	Phase 2/Phase 3	Slow recruitment in pilot phase. A follow-up trial is launched (NCT03796650).	CHEBI_50688			"10054236"	"186431008"
metronidazole	DB00916	Clostridium difficile infection	C0343386	NCT02301000	Terminated	Phase 2/Phase 3	Slow recruitment in pilot phase. A follow-up trial is launched (NCT03796650).	CHEBI_6909	"6922"		"10054236"	"186431008"
cefotaxime	DB00493	Sepsis of the newborn	C0456103		Approved			CHEBI_204928	"2186"	HP:0040187	"10040049"	"206376005"
benzylpenicillin	DB01053	Sepsis of the newborn	C0456103		Approved			CHEBI_18208	"7980"	HP:0040187	"10040049"	"206376005"
gentamicin	DB00798	Sepsis of the newborn	C0456103		Approved			CHEBI_17833	"1596450"	HP:0040187	"10040049"	"206376005"
amikacin	DB00479	Sepsis of the newborn	C0456103		Approved			CHEBI_2637	"641"	HP:0040187	"10040049"	"206376005"
tobramycin	DB00684	Sepsis of the newborn	C0456103		Approved			CHEBI_28864	"10627"	HP:0040187	"10040049"	"206376005"
vancomycin	DB00512	Sepsis of the newborn	C0456103		Approved			CHEBI_28001	"11124"	HP:0040187	"10040049"	"206376005"
fusidic acid	DB02703	Sepsis of the newborn	C0456103		Approved			CHEBI_29013	"4608|113608"	HP:0040187	"10040049"	"206376005"
	DB00380	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	CHEBI_50223	"42736"	MONDO_0012817	"10015560"	"76909002"
	DB00531	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2	Study did not reach primary objective; study did not accrue enough patients.	CHEBI_4027	"1545988|3002"	MONDO_0012817	"10015560"	"76909002"
	DB00853	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2	Study did not reach primary objective; study did not accrue enough patients.	CHEBI_72564	"37776"	MONDO_0012817	"10015560"	"76909002"
temozolomide	DB00853	Ewings sarcoma	C0553580		Approved			CHEBI_72564	"37776"	MONDO_0012817	"10015560"	"76909002"
dactinomycin	DB00970	Ewings sarcoma	C0553580		Approved			CHEBI_27666	"3100"	MONDO_0012817	"10015560"	"76909002"
	DB00531	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	CHEBI_4027	"1545988|3002"	MONDO_0012817	"10015560"	"76909002"
	DB00997	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	CHEBI_28748	"142433|3639"	MONDO_0012817	"10015560"	"76909002"
erlotinib	DB00530	Ewings sarcoma	C0553580	NCT02689336	Withdrawn	Phase 2	Could not recruit any participants	CHEBI_114785	"337525"	MONDO_0012817	"10015560"	"76909002"
vincristine	DB00541	Ewings sarcoma	C0553580	NCT00038142	Terminated	Phase 2	Low Accrual	CHEBI_28445	"11202"	MONDO_0012817	"10015560"	"76909002"
	DB00541	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2	Study did not reach primary objective; study did not accrue enough patients.	CHEBI_28445	"11202"	MONDO_0012817	"10015560"	"76909002"
irinotecan	DB00762	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2	Study did not reach primary objective; study did not accrue enough patients.	CHEBI_80630	"51499"	MONDO_0012817	"10015560"	"76909002"
	DB00997	Ewings sarcoma	C0553580	NCT01313884	Terminated	Phase 2	Study did not reach primary objective; study did not accrue enough patients.	CHEBI_28748	"142433|3639"	MONDO_0012817	"10015560"	"76909002"
	DB00853	Ewings sarcoma	C0553580	NCT02689336	Withdrawn	Phase 2	Could not recruit any participants	CHEBI_72564	"37776"	MONDO_0012817	"10015560"	"76909002"
carmustine	DB00262	Malignant Glioma	C0555198		Approved			CHEBI_3423	"2105"	MONDO_0100342	"10065443"	"74532006"
erythromycin	DB00199	Chlamydial urethritis	C1278807		Approved			CHEBI_42355	"4053"		"10046482"	"236683007"
norfloxacin	DB01059	Chlamydial urethritis	C1278807		Approved			CHEBI_100246	"7517"		"10046482"	"236683007"
grepafloxacin	DB00365	Chlamydial urethritis	C1278807		Approved			CHEBI_5543	"83719"		"10046482"	"236683007"
sulfafurazole	DB00263	Chlamydial urethritis	C1278807		Approved			CHEBI_102484	"10207"		"10046482"	"236683007"
azithromycin	DB00207	Chlamydial urethritis	C1278807		Approved			CHEBI_2955	"18631"		"10046482"	"236683007"
ofloxacin	DB01165	Chlamydial urethritis	C1278807		Approved			CHEBI_7731	"7623"		"10046482"	"236683007"
losartan	DB00678	Idiopathic Pulmonary Fibrosis	C1800706	NCT00981747	Terminated	Phase 2/Phase 3	Funding was withdrawn.	CHEBI_6541	"52175"		"10021240"	"700250006"
doxycycline	DB00254	Idiopathic Pulmonary Fibrosis	C1800706	NCT02759120	Terminated	Phase 3	Terminated for futility after review of first planned interim analysis.	CHEBI_50845	"1545992|3640"		"10021240"	"700250006"
cromoglicic acid	DB01003	Idiopathic Pulmonary Fibrosis	C1800706	NCT01841307	Terminated	Phase 1	Difficulty recruiting; Funding ended; interim analysis provided sufficient data for interpretation.	CHEBI_59773	"2921|42612"		"10021240"	"700250006"
rituximab	DB00073	Idiopathic Pulmonary Fibrosis	C1800706	NCT01524068	Withdrawn	Phase 2			"2273510|2472325|121191|2105824"		"10021240"	"700250006"
warfarin	DB00682	Idiopathic Pulmonary Fibrosis	C1800706	NCT00957242	Terminated	Phase 3	Excess of mortality in the treatment group created safety concerns.	CHEBI_87732	"11289"		"10021240"	"700250006"
nintedanib	DB09079	Idiopathic Pulmonary Fibrosis	C1800706		Approved			CHEBI_85164	"1592737"		"10021240"	"700250006"
	DB00203	Idiopathic Pulmonary Fibrosis	C1800706	NCT00981747	Terminated	Phase 2/Phase 3	Funding was withdrawn.	CHEBI_9139	"136411"		"10021240"	"700250006"
pirfenidone	DB04951	Idiopathic Pulmonary Fibrosis	C1800706		Approved			CHEBI_32016	"1592254"		"10021240"	"700250006"
phytomenadione	DB01022	Factor II deficiency	C3203356		Approved			CHEBI_18067	"11258|8308"		"10021085"	"73975000"
ganaxolone	DB05087	Cyclin-dependent kinase-like 5 deficiency	C4750718		Approved			CHEBI_177658	"2604689"		"10083005"	"773230003"
oxymetholone	DB06412	Anemia, Diamond-Blackfan	C1260899		Approved			CHEBI_7864	"7813"	MONDO_0015253		"88854002"
phentolamine	DB00692	Paroxysmal hypertension	C0221154		Approved			CHEBI_8081	"8153"			"23130000"
promazine	DB00420	Disruptive Behavior Disorder	C0012734		Approved			CHEBI_8459	"8742"			"54319003"
propafenone	DB01182	Paroxysmal atrial flutter	C0741292		Approved			CHEBI_63619	"8754"			"427665004"
hydrocortisone succinate	DB14545	Arthritis, Psoriatic	C0003872		Approved			CHEBI_31677	"21651"	MONDO_0011849	"10037162"	"156370009"
hydrocortisone succinate	DB14545	Acquired thrombocytopenia	C0154301		Approved			CHEBI_31677	"21651"	MONDO_0001198		"154826009"
sodium oxybate	DB09072	Narcolepsy-Cataplexy Syndrome	C0751362		Approved				"9899"			"193042000"
sodium oxybate	DB01440	Narcolepsy-Cataplexy Syndrome	C0751362		Approved			CHEBI_30830	"1546380|2387302"			"193042000"
linaclotide	DB08890	Irritable bowel syndrome characterized by constipation	C1868889		Approved			CHEBI_68551	"1307404"			"440630006"
tremelimumab	DB11771	Epidermal growth factor receptor negative non-small cell lung cancer	C1960396		Approved				"2619313"			"427038005"
medrysone	DB00253	Cyclitis	C0010543		Approved			CHEBI_34829	"29439"		"10011715"	"17657000"
dexamethasone	DB01234	Cyclitis	C0010543		Approved			CHEBI_41879	"3264"		"10011715"	"17657000"
cortisone acetate	DB01380	Cyclitis	C0010543		Approved			CHEBI_3897	"21655"		"10011715"	"17657000"
fluorometholone acetate	DB00324	Cyclitis	C0010543		Approved			CHEBI_31625	"4491"		"10011715"	"17657000"
hydrocortisone	DB00741	Cyclitis	C0010543		Approved			CHEBI_17650	"5492"		"10011715"	"17657000"
prednisolone	DB00860	Cyclitis	C0010543		Approved			CHEBI_8378	"8638"		"10011715"	"17657000"
fluorometholone	DB00324	Cyclitis	C0010543		Approved			CHEBI_31625	"4491"		"10011715"	"17657000"
losartan	DB00678	Diabetic Nephropathy	C0011881		Approved			CHEBI_6541	"52175"		"10061835"	"127013003"
captopril	DB01197	Diabetic Nephropathy	C0011881		Approved			CHEBI_3380	"1998"		"10061835"	"127013003"
irbesartan	DB01029	Diabetic Nephropathy	C0011881		Approved			CHEBI_5959	"83818"		"10061835"	"127013003"
budesonide	DB01222	Diarrhea	C0011991	NCT02991768	Terminated	Phase 2	Enrollment not continued	CHEBI_3207	"19831"	HP:0002014	"10012735"	"267060006"
	DB06724	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.	CHEBI_3311	"349908|1897"	HP:0002014	"10012735"	"267060006"
diphenoxylate	DB01081	Diarrhea	C0011991		Approved			CHEBI_4639	"3500"	HP:0002014	"10012735"	"267060006"
bismuth subsalicylate	DB01294	Diarrhea	C0011991		Approved			CHEBI_261649	"19478"	HP:0002014	"10012735"	"267060006"
telotristat ethyl	DB12095	Diarrhea	C0011991		Approved				"1872441"	HP:0002014	"10012735"	"267060006"
irinotecan	DB00762	Diarrhea	C0011991	NCT00006269	Terminated	Phase 3		CHEBI_80630	"51499"	HP:0002014	"10012735"	"267060006"
	DB00495	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.	CHEBI_10110	"11413"	HP:0002014	"10012735"	"267060006"
difenoxin	DB01501	Diarrhea	C0011991		Approved			CHEBI_4534	"23024"	HP:0002014	"10012735"	"267060006"
lamivudine	DB00709	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.	CHEBI_63577	"68244"	HP:0002014	"10012735"	"267060006"
	DB00762	Diarrhea	C0011991	NCT00040391	Terminated	Phase 2		CHEBI_80630	"51499"	HP:0002014	"10012735"	"267060006"
morphine	DB00295	Diarrhea	C0011991		Approved			CHEBI_17303	"7052|32926"	HP:0002014	"10012735"	"267060006"
	DB00104	Diarrhea	C0011991	NCT00006269	Terminated	Phase 3			"7617"	HP:0002014	"10012735"	"267060006"
	DB00544	Diarrhea	C0011991	NCT00040391	Terminated	Phase 2		CHEBI_46345	"4492"	HP:0002014	"10012735"	"267060006"
loperamide	DB00836	Diarrhea	C0011991		Approved			CHEBI_6532	"6468"	HP:0002014	"10012735"	"267060006"
	DB00635	Diarrhea	C0011991	NCT01469338	Terminated	Phase 2	lack of funding	CHEBI_8382	"8640"	HP:0002014	"10012735"	"267060006"
leucovorin	DB00650	Diarrhea	C0011991	NCT00040391	Terminated	Phase 2		CHEBI_15640	"6313"	HP:0002014	"10012735"	"267060006"
octreotide	DB00104	Diarrhea	C0011991	NCT01469338	Terminated	Phase 2	lack of funding	CHEBI_7726	"7617"	HP:0002014	"10012735"	"267060006"
budesonide	DB01222	Diarrhea	C0011991	NCT00217022	Terminated	Phase 2/Phase 3	Study closed early, because of low enrollment.	CHEBI_3207	"19831"	HP:0002014	"10012735"	"267060006"
loperamide	DB00836	Diarrhea	C0011991	NCT00444093	Terminated	Phase 3	bad recruitment	CHEBI_6532	"6468"	HP:0002014	"10012735"	"267060006"
	DB00220	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.	CHEBI_7496	"134527"	HP:0002014	"10012735"	"267060006"
	DB00836	Diarrhea	C0011991	NCT00650637	Terminated	Phase 3	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.	CHEBI_6532	"6468"	HP:0002014	"10012735"	"267060006"
deflazacort	DB11921	Muscular Dystrophy, Duchenne	C0013264		Approved			CHEBI_135720	"22396"	MONDO_0010679	"10013801"	"76670001"
eteplirsen	DB06014	Muscular Dystrophy, Duchenne	C0013264		Approved				"1810569"	MONDO_0010679	"10013801"	"76670001"
casimersen	DB14984	Muscular Dystrophy, Duchenne	C0013264		Approved				"2480096"	MONDO_0010679	"10013801"	"76670001"
viltolarsen	DB15005	Muscular Dystrophy, Duchenne	C0013264		Approved				"2389840"	MONDO_0010679	"10013801"	"76670001"
golodirsen	DB15593	Muscular Dystrophy, Duchenne	C0013264		Approved				"2267207"	MONDO_0010679	"10013801"	"76670001"
prednisone	DB00635	Muscular Dystrophy, Duchenne	C0013264	NCT00308113	Terminated	Phase 3	New enrollment has been suspended, currently following previously enrolled participants	CHEBI_8382	"8640"	MONDO_0010679	"10013801"	"76670001"
ataluren	DB05016	Muscular Dystrophy, Duchenne	C0013264		Approved			CHEBI_94805		MONDO_0010679	"10013801"	"76670001"
sildenafil	DB00203	Muscular Dystrophy, Duchenne	C0013264	NCT01168908	Terminated	Phase 2	As recommended by the DSMB.	CHEBI_9139	"136411"	MONDO_0010679	"10013801"	"76670001"
goserelin	DB00014	Endometriosis	C0014175		Approved			CHEBI_5523	"50610"	HP:0030127	"10014778"	"129103003"
danazol	DB01406	Endometriosis	C0014175		Approved			CHEBI_4315	"3102"	HP:0030127	"10014778"	"129103003"
medroxyprogesterone	DB00603	Endometriosis	C0014175		Approved			CHEBI_6716	"1000112"	HP:0030127	"10014778"	"129103003"
norethynodrel	DB09371	Endometriosis	C0014175		Approved			CHEBI_34895	"7515"	HP:0030127	"10014778"	"129103003"
naltrexone	DB00704	Endometriosis	C0014175	NCT03970330	Terminated	Phase 3	Original PI left institution, lack of funding to continue	CHEBI_7465	"7243"	HP:0030127	"10014778"	"129103003"
pioglitazone	DB01132	Endometriosis	C0014175	NCT01184144	Withdrawn	Phase 2/Phase 3		CHEBI_8228	"33738"	HP:0030127	"10014778"	"129103003"
levonorgestrel	DB00367	Endometriosis	C0014175	NCT02599077	Suspended	Phase 2/Phase 3		CHEBI_6443	"6373"	HP:0030127	"10014778"	"129103003"
ketamine	DB01221	Endometriosis	C0014175	NCT05229653	Suspended	Phase 1	IRB approval time has lapsed; continuation must be filed before resuming study activities.	CHEBI_6121	"6130"	HP:0030127	"10014778"	"129103003"
	DB09389	Endometriosis	C0014175	NCT02599077	Suspended	Phase 2/Phase 3		CHEBI_7630	"7518"	HP:0030127	"10014778"	"129103003"
	DB00717	Endometriosis	C0014175	NCT03343067	Terminated	Phase 3	The study was terminated early for business reasons, not for safety concerns.	CHEBI_7627	"7514"	HP:0030127	"10014778"	"129103003"
leuprorelin	DB00007	Endometriosis	C0014175		Approved			CHEBI_6427	"42375"	HP:0030127	"10014778"	"129103003"
elagolix	DB11979	Endometriosis	C0014175		Approved			CHEBI_177453	"2049846"	HP:0030127	"10014778"	"129103003"
norethindrone acetate	DB00717	Endometriosis	C0014175		Approved			CHEBI_7627	"7514"	HP:0030127	"10014778"	"129103003"
norethisterone	DB00717	Endometriosis	C0014175		Approved			CHEBI_7627	"7514"	HP:0030127	"10014778"	"129103003"
axitinib	DB06626	Endometriosis	C0014175	NCT03481842	Withdrawn	Phase 1/Phase 2	Change in study design and sponsor	CHEBI_66910	"1242999"	HP:0030127	"10014778"	"129103003"
mestranol	DB01357	Endometriosis	C0014175		Approved			CHEBI_6784	"6782"	HP:0030127	"10014778"	"129103003"
nafarelin	DB00666	Endometriosis	C0014175		Approved			CHEBI_7445	"28656"	HP:0030127	"10014778"	"129103003"
chlormadinone	DB13528	Endometriosis	C0014175		Approved					HP:0030127	"10014778"	"129103003"
estradiol	DB00783	Endometriosis	C0014175	NCT03343067	Terminated	Phase 3	The study was terminated early for business reasons, not for safety concerns.	CHEBI_16469	"4083"	HP:0030127	"10014778"	"129103003"
thalidomide	DB01041	Endometriosis	C0014175	NCT01028781	Terminated	Phase 1	Difficulty finding eligible participants and lack of funding.	CHEBI_74947	"10432"	HP:0030127	"10014778"	"129103003"
	DB00717	Endometriosis	C0014175	NCT03970330	Terminated	Phase 3	Original PI left institution, lack of funding to continue	CHEBI_7627	"7514"	HP:0030127	"10014778"	"129103003"
rosiglitazone	DB00412	Endometriosis	C0014175	NCT00115661	Terminated	Phase 2	Due to the meta-analysis about CV adverse effects of rosiglitazone.	CHEBI_50122	"84108"	HP:0030127	"10014778"	"129103003"
	DB08916	Endometriosis	C0014175	NCT03481842	Withdrawn	Phase 1/Phase 2	Change in study design and sponsor	CHEBI_61390	"1430438"	HP:0030127	"10014778"	"129103003"
progesterone	DB00396	Endometriosis	C0014175		Approved			CHEBI_17026	"8727"	HP:0030127	"10014778"	"129103003"
rosiglitazone	DB00412	Endometriosis	C0014175	NCT00121953	Withdrawn	Phase 2/Phase 3	Due to the recent meta-analysis about CV adverse effects.	CHEBI_50122	"84108"	HP:0030127	"10014778"	"129103003"
chlormadinone	DB15903	Endometriosis	C0014175		Approved			CHEBI_31394	"2369"	HP:0030127	"10014778"	"129103003"
tranexamic acid	DB00302	Endometriosis	C0014175		Approved			CHEBI_48669	"10691"	HP:0030127	"10014778"	"129103003"
ceftazidime	DB00438	Endometritis	C0014179		Approved			CHEBI_3508	"2191|1545984"	MONDO_0000918	"10014791"	"78623009"
cefotetan	DB01330	Endometritis	C0014179		Approved			CHEBI_3499	"2187"	MONDO_0000918	"10014791"	"78623009"
ertapenem	DB00303	Endometritis	C0014179	NCT01587495	Terminated	Phase 1	study terminated due to low subject accrual	CHEBI_404903	"325642"	MONDO_0000918	"10014791"	"78623009"
imipenem	DB01598	Endometritis	C0014179		Approved			CHEBI_471744	"5690|1545986"	MONDO_0000918	"10014791"	"78623009"
ceftriaxone	DB01212	Endometritis	C0014179		Approved			CHEBI_29007	"2193"	MONDO_0000918	"10014791"	"78623009"
cilastatin	DB01597	Endometritis	C0014179		Approved			CHEBI_3697	"2540"	MONDO_0000918	"10014791"	"78623009"
cefoxitin	DB01331	Endometritis	C0014179		Approved			CHEBI_209807	"2189"	MONDO_0000918	"10014791"	"78623009"
aztreonam	DB00355	Endometritis	C0014179		Approved			CHEBI_161680	"1272"	MONDO_0000918	"10014791"	"78623009"
metronidazole	DB15759	Endometritis	C0014179		Approved			CHEBI_50688		MONDO_0000918	"10014791"	"78623009"
metronidazole	DB00916	Endometritis	C0014179		Approved			CHEBI_6909	"6922"	MONDO_0000918	"10014791"	"78623009"
siltuximab	DB09036	Angiolymphoid hyperplasia	C0017531		Approved				"1535218"	MONDO_0015564	"10050251"	"207036003"
tocilizumab	DB06273	Angiolymphoid hyperplasia	C0017531		Approved				"612865"	MONDO_0015564	"10050251"	"207036003"
paromomycin	DB01421	Hepatic Coma	C0019147		Approved			CHEBI_7934	"7934"	MONDO_0001548	"10010075"	"72836002"
neomycin	DB00994	Hepatic Coma	C0019147		Approved			CHEBI_7507	"7299"	MONDO_0001548	"10010075"	"72836002"
erythromycin ethyl succinate	DB00199	Hepatic Coma	C0019147		Approved			CHEBI_42355	"4053"	MONDO_0001548	"10010075"	"72836002"
tetrabenazine	DB04844	Huntington Disease	C0020179		Approved			CHEBI_64028	"10390"	MONDO_0007739	"10070668"	"58756001"
deutetrabenazine	DB12161	Huntington Disease	C0020179		Approved				"1876905"	MONDO_0007739	"10070668"	"58756001"
cinacalcet	DB01012	Hyperparathyroidism	C0020502	NCT01277510	Terminated	Phase 3	Study was put on clinical hold on 30 Jan 2013 following a subject fatality. Study was never restarted and was closed.	CHEBI_48390	"407990"	MONDO_0001741	"10020705"	"66999008"
parathyroid hormone	DB05829	Hyperparathyroidism	C0020502	NCT01333267	Withdrawn	Phase 1			"1427222"	MONDO_0001741	"10020705"	"66999008"
alfacalcidol	DB01436	Hyperparathyroidism	C0020502		Approved			CHEBI_31186	"12062"	MONDO_0001741	"10020705"	"66999008"
cromoglicic acid	DB01003	Keratoconjunctivitis, Vernal	C0022577		Approved			CHEBI_59773	"2921|42612"	MONDO_0019085	"10081000"	"317349009"
lodoxamide	DB06794	Keratoconjunctivitis, Vernal	C0022577		Approved			CHEBI_135333	"52151"	MONDO_0019085	"10081000"	"317349009"
aminopterin	DB08878	leukemia	C0023418		Approved			CHEBI_22526	"1440264"	MONDO_0005059	"10024288"	"93143009"
arsenic trioxide	DB01169	Acute myelomonocytic leukemia	C0023479		Approved			CHEBI_49900	"18330"	MONDO_0018871|MONDO_0020316	"10000890"	"110005000"
rasburicase	DB00049	Hyperuricemia	C0740394		Approved				"283821"	MONDO_0002144	"10020903"	"35885006"
vilanterol	DB09082	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_75037	"1424884"	HP:0006510	"10009033"	"13645005"
arformoterol	DB01274	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_408174	"304962"	HP:0006510	"10009033"	"13645005"
fluticasone furoate	DB13867	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_5134	"41126"	HP:0006510	"10009033"	"13645005"
olodaterol	DB09080	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_82700	"1546059"	HP:0006510	"10009033"	"13645005"
fluticasone furoate	DB08906	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_74899	"705022"	HP:0006510	"10009033"	"13645005"
ipratropium	DB00332	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_46659	"1546373|203212|7213"	HP:0006510	"10009033"	"13645005"
almitrine	DB01430	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_53778	"528"	HP:0006510	"10009033"	"13645005"
revefenacin	DB11855	Chronic Obstructive Airway Disease	C0024117		Approved				"2102775"	HP:0006510	"10009033"	"13645005"
oxitropium	DB12086	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_135418	"32649"	HP:0006510	"10009033"	"13645005"
umeclidinium	DB09076	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_79041	"1487514"	HP:0006510	"10009033"	"13645005"
aclidinium bromide	DB08897	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_65346	"1303098"	HP:0006510	"10009033"	"13645005"
glycopyrronium bromide	DB00986	Chronic Obstructive Airway Disease	C0024117		Approved			CHEBI_94449	"1546438|4955"	HP:0006510	"10009033"	"13645005"
diazoxide	DB01119	Nesidioblastosis	C0027773		Approved			CHEBI_4495	"3327"	HP:0034346	"10080024"	"42681006"
flavoxate	DB01148	Nocturia	C0028734		Approved			CHEBI_5088	"4440"	HP:0000017	"10029446"	"139394000"
minocycline	DB01017	Psittacosis	C0029291		Approved			CHEBI_50694	"6980"	MONDO_0005888	"10037151"	"75116005"
amphotericin B	DB00681	Psittacosis	C0029291		Approved			CHEBI_2682	"236594|732"	MONDO_0005888	"10037151"	"75116005"
oxytetracycline	DB00595	Psittacosis	C0029291		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005888	"10037151"	"75116005"
fusidic acid	DB02703	Psittacosis	C0029291		Approved			CHEBI_29013	"4608|113608"	MONDO_0005888	"10037151"	"75116005"
tetracycline	DB09550	Psittacosis	C0029291		Approved			CHEBI_27902	"2105975"	MONDO_0005888	"10037151"	"75116005"
doxycycline	DB00254	Psittacosis	C0029291		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005888	"10037151"	"75116005"
meclocycline	DB13092	Psittacosis	C0029291		Approved			CHEBI_135772	"29418"	MONDO_0005888	"10037151"	"75116005"
tetracycline	DB00759	Psittacosis	C0029291		Approved			CHEBI_27902	"10395"	MONDO_0005888	"10037151"	"75116005"
demeclocycline	DB00618	Psittacosis	C0029291		Approved			CHEBI_4392	"3154"	MONDO_0005888	"10037151"	"75116005"
benzylpenicillin	DB01053	Pinta	C0031946		Approved			CHEBI_18208	"7980"	MONDO_0000979	"10035068"	"22064009"
procaine benzylpenicillin	DB09320	Pinta	C0031946		Approved			CHEBI_52154	"7983"	MONDO_0000979	"10035068"	"22064009"
procaine benzylpenicillin	DB01053	Pinta	C0031946		Approved			CHEBI_18208	"7980"	MONDO_0000979	"10035068"	"22064009"
pramocaine	DB09345	Rectal pain	C0034886		Approved			CHEBI_8357	"34347"		"10036772"	"77880009"
phenylmercuric nitrate	DB13388	Rectal pain	C0034886		Approved			CHEBI_136021			"10036772"	"77880009"
ferric oxide	DB11576	Rectal pain	C0034886		Approved			CHEBI_50819			"10036772"	"77880009"
zinc acetate	DB14487	Rectal pain	C0034886		Approved			CHEBI_62984	"1299637|58295"		"10036772"	"77880009"
phenylephrine	DB00388	Rectal pain	C0034886		Approved			CHEBI_8093	"8163"		"10036772"	"77880009"
zinc oxide	DB09321	Rectal pain	C0034886		Approved			CHEBI_36560	"11423"		"10036772"	"77880009"
sulfadiazine	DB00359	Skin Ulcer	C0037299		Approved			CHEBI_9328	"10171"	HP:0200042	"10040943"	"46742003"
becaplermin	DB00102	Skin Ulcer	C0037299	NCT00034788	Terminated	Phase 3	Slow recruitment; Study did not address safety concern raised by European Medicines Agency		"115238"	HP:0200042	"10040943"	"46742003"
sulfadiazine silver	DB05245	Skin Ulcer	C0037299		Approved			CHEBI_9142	"9793"	HP:0200042	"10040943"	"46742003"
	DB00297	Toothache	C0040460	NCT02862691	Terminated	Phase 2	Difficulty recruiting patients	CHEBI_77431	"1815"		"10044055"	"27355003"
naproxen	DB00788	Toothache	C0040460		Approved			CHEBI_7476	"7258"		"10044055"	"27355003"
	DB00316	Toothache	C0040460	NCT02862691	Terminated	Phase 2	Difficulty recruiting patients	CHEBI_46195	"161"		"10044055"	"27355003"
oxycodone	DB00497	Toothache	C0040460	NCT02862691	Terminated	Phase 2	Difficulty recruiting patients	CHEBI_7852	"7804"		"10044055"	"27355003"
acetylsalicylic acid	DB00945	Toothache	C0040460		Approved			CHEBI_15365	"91101|1191"		"10044055"	"27355003"
paracetamol	DB00316	Toothache	C0040460		Approved			CHEBI_46195	"161"		"10044055"	"27355003"
sulfadiazine	DB00359	Toxoplasmosis, Congenital	C0040560		Approved			CHEBI_9328	"10171"	MONDO_0005715	"10010652"	"73893000"
landiolol	DB12212	Ventricular Fibrillation	C0042510		Approved			CHEBI_135809		MONDO_0000190	"10047290"	"71908006"
bretylium	DB01158	Ventricular Fibrillation	C0042510		Approved			CHEBI_3172	"19685"	MONDO_0000190	"10047290"	"71908006"
amiodarone	DB01118	Ventricular Fibrillation	C0042510		Approved			CHEBI_2663	"703"	MONDO_0000190	"10047290"	"71908006"
epinephrine	DB00668	Ventricular Fibrillation	C0042510	NCT00401882	Terminated	Phase 2	Difficult accrual	CHEBI_28918	"3992"	MONDO_0000190	"10047290"	"71908006"
	DB00264	Ventricular Fibrillation	C0042510	NCT00401882	Terminated	Phase 2	Difficult accrual	CHEBI_6904	"6918"	MONDO_0000190	"10047290"	"71908006"
diphenidol	DB01231	Vertigo	C0042571		Approved			CHEBI_4638	"23370"	HP:0002321	"10047340"	"399153001"
dimenhydrinate	DB00985	Vertigo	C0042571		Approved			CHEBI_94848	"3444"	HP:0002321	"10047340"	"399153001"
tramadol	DB00193	Vertigo	C0042571	NCT02247648	Terminated	Phase 2		CHEBI_75722	"10689"	HP:0002321	"10047340"	"399153001"
cinnarizine	DB00568	Vertigo	C0042571		Approved			CHEBI_31403	"2549"	HP:0002321	"10047340"	"399153001"
meclozine	DB00737	Vertigo	C0042571		Approved			CHEBI_6709	"6676"	HP:0002321	"10047340"	"399153001"
calcium lactate	DB13231	Hypermagnesemia	C0151714		Approved				"47622"		"10020669"	"66978005"
calcium glycerylphosphate	DB11264	Hypermagnesemia	C0151714		Approved			CHEBI_31336	"1909"		"10020669"	"66978005"
calcium acetate	DB00258	Hypermagnesemia	C0151714		Approved			CHEBI_3310	"214342"		"10020669"	"66978005"
calcium glucoheptonate	DB00326	Hypermagnesemia	C0151714		Approved			CHEBI_3314	"47618"		"10020669"	"66978005"
calcium chloride	DB01164	Hypermagnesemia	C0151714		Approved			CHEBI_3312	"1901|1667640"		"10020669"	"66978005"
infliximab	DB00065	Pustular psoriasis	C0152081		Approved				"1790539|1927283|191831|2266523|2103476"	MONDO_0022205	"10037575"	"200973000"
bimekizumab	DB12917	Pustular psoriasis	C0152081		Approved				"2668041"	MONDO_0022205	"10037575"	"200973000"
ixekizumab	DB11569	Pustular psoriasis	C0152081		Approved				"1745099"	MONDO_0022205	"10037575"	"200973000"
adalimumab	DB00051	Pustular psoriasis	C0152081		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0022205	"10037575"	"200973000"
secukinumab	DB09029	Pustular psoriasis	C0152081		Approved				"1599788"	MONDO_0022205	"10037575"	"200973000"
methotrexate	DB00563	Pustular psoriasis	C0152081		Approved			CHEBI_44185	"6851"	MONDO_0022205	"10037575"	"200973000"
certolizumab pegol	DB08904	Pustular psoriasis	C0152081		Approved				"709271"	MONDO_0022205	"10037575"	"200973000"
maxacalcitol	DB06272	Pustular psoriasis	C0152081		Approved			CHEBI_31801		MONDO_0022205	"10037575"	"200973000"
risankizumab	DB14762	Pustular psoriasis	C0152081		Approved				"2166132|2166040"	MONDO_0022205	"10037575"	"200973000"
tolnaftate	DB00525	tinea manus	C0153246		Approved			CHEBI_9620	"10637"	MONDO_0001699	"10067197"	"48971001"
scopolamine	DB00747	Cycloplegia	C0235238		Approved			CHEBI_16794	"9601|9603"	MONDO_0005555	"10011719"	"68158006"
tropicamide	DB00809	Cycloplegia	C0235238		Approved			CHEBI_9757	"10869"	MONDO_0005555	"10011719"	"68158006"
homatropine	DB11181	Cycloplegia	C0235238		Approved			CHEBI_5747	"27084"	MONDO_0005555	"10011719"	"68158006"
cyclopentolate	DB00979	Cycloplegia	C0235238		Approved			CHEBI_4024	"3001"	MONDO_0005555	"10011719"	"68158006"
selpercatinib	DB15685	Medullary carcinoma of thyroid	C0238462		Approved				"2370147"	MONDO_0015277	"10027105"	"255032005"
cabozantinib	DB08875	Medullary carcinoma of thyroid	C0238462		Approved			CHEBI_72317	"1363268"	MONDO_0015277	"10027105"	"255032005"
bortezomib	DB00188	Medullary carcinoma of thyroid	C0238462	NCT00923247	Terminated	Phase 1/Phase 2	Terminated due to slow accrual,primary endpoint reached & investigator left NIH.	CHEBI_52717	"358258"	MONDO_0015277	"10027105"	"255032005"
pralsetinib	DB15822	Medullary carcinoma of thyroid	C0238462		Approved				"2394936"	MONDO_0015277	"10027105"	"255032005"
sorafenib	DB00398	Medullary carcinoma of thyroid	C0238462	NCT01736878	Withdrawn	Phase 2	Study was withdrawn due to unanticipated hassle in patient recruitment.	CHEBI_50924	"495881"	MONDO_0015277	"10027105"	"255032005"
alprostadil	DB00770	Tricuspid Atresia	C0243002		Approved			CHEBI_15544	"598"	MONDO_0011514	"10049767"	"63042009"
dexamethasone	DB01234	Punctate keratitis	C0259799		Approved			CHEBI_41879	"3264"		"10037508"	"42513006"
loteprednol etabonate	DB14596	Punctate keratitis	C0259799		Approved			CHEBI_31784	"52177"		"10037508"	"42513006"
loteprednol etabonate	DB00873	Punctate keratitis	C0259799		Approved			CHEBI_50848	"237027"		"10037508"	"42513006"
fusidic acid	DB02703	Punctate keratitis	C0259799		Approved			CHEBI_29013	"4608|113608"		"10037508"	"42513006"
tobramycin	DB00684	Punctate keratitis	C0259799		Approved			CHEBI_28864	"10627"		"10037508"	"42513006"
cefotetan	DB01330	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_3499	"2187"		"10035699"	"51530003"
amoxicillin	DB01060	Staphylococcal pharyngitis	C0275794		Approved			CHEBI_2676	"1297882|723"		"10061554"	"82228008"
alatrofloxacin	DB09335	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_135829	"141440"		"10035699"	"51530003"
imipenem	DB01598	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_471744	"5690|1545986"		"10035699"	"51530003"
cefoxitin	DB01331	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_209807	"2189"		"10035699"	"51530003"
cefuroxime	DB01112	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_3515	"2194"		"10035699"	"51530003"
azlocillin	DB01061	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_2956	"1266"		"10035699"	"51530003"
norfloxacin	DB01059	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_100246	"7517"		"10035699"	"51530003"
ceftaroline fosamil	DB06590	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_70718	"1040005|1040004"		"10035699"	"51530003"
amikacin	DB00479	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_2637	"641"		"10035699"	"51530003"
cefotaxime	DB00493	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_204928	"2186"		"10035699"	"51530003"
fusidic acid	DB02703	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_29013	"4608|113608"		"10035699"	"51530003"
ticarcillin	DB01607	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_9587	"10591"		"10035699"	"51530003"
ceftriaxone	DB01212	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_29007	"2193"		"10035699"	"51530003"
tobramycin	DB00684	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_28864	"10627"		"10035699"	"51530003"
cilastatin	DB01597	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_3697	"2540"		"10035699"	"51530003"
cefonicid	DB01328	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_3491	"2183"		"10035699"	"51530003"
ceftizoxime	DB01332	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_553473	"2192"		"10035699"	"51530003"
ciprofloxacin	DB00537	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_192484	"2551"		"10035699"	"51530003"
gentamicin	DB00798	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_17833	"1596450"		"10035699"	"51530003"
cefmetazole	DB00274	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_3489	"2182"		"10035699"	"51530003"
piperacillin	DB00319	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_8232	"1546000|8339"		"10035699"	"51530003"
mezlocillin	DB00948	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_6919	"6927"		"10035699"	"51530003"
ceftazidime	DB00438	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_3508	"2191|1545984"		"10035699"	"51530003"
aztreonam	DB00355	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_161680	"1272"		"10035699"	"51530003"
ofloxacin	DB01165	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_7731	"7623"		"10035699"	"51530003"
cefamandole	DB01326	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_3480	"2178"		"10035699"	"51530003"
trovafloxacin	DB00685	Pneumonia due to Escherichia coli	C0276089		Approved			CHEBI_9763	"115552"		"10035699"	"51530003"
alfacalcidol	DB01436	Neonatal hypocalcemia	C0342634		Approved			CHEBI_31186	"12062"		"10079306"	"268846006"
zolpidem	DB00425	Initial insomnia	C0393760		Approved			CHEBI_10125	"39993"	HP:0031354	"10022035"	"59050008"
melatonin	DB01065	Initial insomnia	C0393760	NCT02333149	Withdrawn	Phase 3	Issues surrounding the current COVID-19 pandemic.	CHEBI_16796	"6711"	HP:0031354	"10022035"	"59050008"
zaleplon	DB00962	Initial insomnia	C0393760		Approved			CHEBI_10102	"74667"	HP:0031354	"10022035"	"59050008"
ramelteon	DB00980	Initial insomnia	C0393760		Approved			CHEBI_109549	"596205"	HP:0031354	"10022035"	"59050008"
ziconotide	DB06283	Pain in spine	C0423673		Approved			CHEBI_142406	"68503"		"10072005"	"48926009"
urapidil	DB12661	Hypertensive emergency	C0745136		Approved			CHEBI_32278	"39230"		"10058179"	"132721000119104"
cefotetan	DB01330	Peptostreptococcus infection	C1096562		Approved			CHEBI_3499	"2187"	MONDO_0024412	"10054124"	"135341000119101"
metronidazole	DB15759	Peptostreptococcus infection	C1096562		Approved			CHEBI_50688		MONDO_0024412	"10054124"	"135341000119101"
ceftizoxime	DB01332	Peptostreptococcus infection	C1096562		Approved			CHEBI_553473	"2192"	MONDO_0024412	"10054124"	"135341000119101"
cefoxitin	DB01331	Peptostreptococcus infection	C1096562		Approved			CHEBI_209807	"2189"	MONDO_0024412	"10054124"	"135341000119101"
ceftriaxone	DB01212	Peptostreptococcus infection	C1096562		Approved			CHEBI_29007	"2193"	MONDO_0024412	"10054124"	"135341000119101"
metronidazole	DB00916	Peptostreptococcus infection	C1096562		Approved			CHEBI_6909	"6922"	MONDO_0024412	"10054124"	"135341000119101"
ertapenem	DB00303	Peptostreptococcus infection	C1096562		Approved			CHEBI_404903	"325642"	MONDO_0024412	"10054124"	"135341000119101"
levocarnitine	DB00583	Carnitine deficiency	C1142132		Approved			CHEBI_16347	"42955"	HP:0003234	"10058892"	"421784001"
lidocaine	DB00281	Infestation by Phthirus pubis	C0030759		Approved			CHEBI_6456	"6387"	MONDO_0001794		"71011005"
lidocaine	DB00281	Pediculus capitis infestation	C0030757		Approved			CHEBI_6456	"6387"	MONDO_0003471		"81000006"
lindane	DB00431	Pediculus capitis infestation	C0030757		Approved			CHEBI_32888	"1388"	MONDO_0003471		"81000006"
lindane	DB00431	Infestation by Phthirus pubis	C0030759		Approved			CHEBI_32888	"1388"	MONDO_0001794		"71011005"
glyceryl trinitrate	DB00727	Perioperative hypertension	C3661921		Approved			CHEBI_28787	"4917"			"434711000124103"
norfloxacin	DB01059	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_100246	"7517"			"195722003"
phenobarbital	DB01174	Bipolar disorder in remission	C0270425		Approved			CHEBI_8069	"8134"			"85248005"
primidone	DB00794	Bipolar disorder in remission	C0270425		Approved			CHEBI_8412	"8691"			"85248005"
magnesium sulfate	DB00653	Mild pre-eclampsia	C0269658		Approved			CHEBI_32599	"6585|1311625"			"41114007"
lithium citrate	DB14507	Bipolar disorder in remission	C0270425		Approved			CHEBI_64735	"52105"			"85248005"
lithium citrate	DB14509	Bipolar disorder in remission	C0270425		Approved			CHEBI_6504	"42351"			"85248005"
potassium citrate	DB09125	Renal tubular acidosis	C0001126		Approved			CHEBI_64733	"54993|1374802"	MONDO_0001909	"10038535"	"1776003"
methylnaltrexone	DB06800	Therapeutic opioid induced constipation	C3874358		Approved			CHEBI_136007	"29899"			"136801000119102"
spinosad	DB08823	Pediculus capitis infestation	C0030757		Approved			CHEBI_39211	"299081"	MONDO_0003471		"81000006"
naloxegol	DB01183	Therapeutic opioid induced constipation	C3874358		Approved			CHEBI_7459	"7242"			"136801000119102"
cefpodoxime proxetil	DB01416	Acute Moraxella catarrhalis bronchitis	C0339932		Approved			CHEBI_3504	"20489"			"195722003"
cefalotin	DB00456	Female genital tract infection	C1263758		Approved			CHEBI_124991	"2236"			"125585007"
rivaroxaban	DB06228	Embolism	C0013922		Approved			CHEBI_68579	"1114195"		"10061169"	"414086009"
cefapirin	DB01139	Bacterial Endocarditis	C0014121		Approved			CHEBI_554446	"2238"	MONDO_0006669	"10014666"	"301183007"
cefazolin	DB01327	Bacterial Endocarditis	C0014121		Approved			CHEBI_474053	"2180"	MONDO_0006669	"10014666"	"301183007"
cilastatin	DB01597	Bacterial Endocarditis	C0014121		Approved			CHEBI_3697	"2540"	MONDO_0006669	"10014666"	"301183007"
procaine benzylpenicillin	DB01053	Bacterial Endocarditis	C0014121		Approved			CHEBI_18208	"7980"	MONDO_0006669	"10014666"	"301183007"
vancomycin	DB00512	Bacterial Endocarditis	C0014121		Approved			CHEBI_28001	"11124"	MONDO_0006669	"10014666"	"301183007"
ampicillin	DB00415	Bacterial Endocarditis	C0014121		Approved			CHEBI_28971	"733|221058"	MONDO_0006669	"10014666"	"301183007"
imipenem	DB01598	Bacterial Endocarditis	C0014121		Approved			CHEBI_471744	"5690|1545986"	MONDO_0006669	"10014666"	"301183007"
benzylpenicillin	DB01053	Bacterial Endocarditis	C0014121		Approved			CHEBI_18208	"7980"	MONDO_0006669	"10014666"	"301183007"
metronidazole	DB00916	Bacterial Endocarditis	C0014121		Approved			CHEBI_6909	"6922"	MONDO_0006669	"10014666"	"301183007"
procaine benzylpenicillin	DB09320	Bacterial Endocarditis	C0014121		Approved			CHEBI_52154	"7983"	MONDO_0006669	"10014666"	"301183007"
metronidazole	DB15759	Bacterial Endocarditis	C0014121		Approved			CHEBI_50688		MONDO_0006669	"10014666"	"301183007"
milnacipran	DB04896	Fibromyalgia	C0016053	NCT01418651	Terminated	Phase 3	Lack of subjects	CHEBI_135005	"588250"	MONDO_0005546	"10048439"	"203082005"
reboxetine	DB00234	Fibromyalgia	C0016053	NCT00754221	Terminated	Phase 3	This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.	CHEBI_135342	"60842"	MONDO_0005546	"10048439"	"203082005"
pregabalin	DB00230	Fibromyalgia	C0016053	NCT00696787	Terminated	Phase 2		CHEBI_64356	"187832"	MONDO_0005546	"10048439"	"203082005"
	DB06700	Fibromyalgia	C0016053	NCT00696787	Terminated	Phase 2		CHEBI_83527	"734064"	MONDO_0005546	"10048439"	"203082005"
duloxetine	DB00476	Fibromyalgia	C0016053		Approved			CHEBI_36795	"72625"	MONDO_0005546	"10048439"	"203082005"
pregabalin	DB00230	Fibromyalgia	C0016053		Approved			CHEBI_64356	"187832"	MONDO_0005546	"10048439"	"203082005"
reboxetine	DB00234	Fibromyalgia	C0016053	NCT00607256	Terminated	Phase 3		CHEBI_135342	"60842"	MONDO_0005546	"10048439"	"203082005"
pramipexole	DB00413	Fibromyalgia	C0016053	NCT00689052	Terminated	Phase 2		CHEBI_8356	"746741"	MONDO_0005546	"10048439"	"203082005"
milnacipran	DB04896	Fibromyalgia	C0016053		Approved			CHEBI_135005	"588250"	MONDO_0005546	"10048439"	"203082005"
milnacipran	DB04896	Fibromyalgia	C0016053	NCT00793520	Terminated	Phase 3		CHEBI_135005	"588250"	MONDO_0005546	"10048439"	"203082005"
	DB08918	Fibromyalgia	C0016053	NCT00793520	Terminated	Phase 3		CHEBI_136040	"1433212"	MONDO_0005546	"10048439"	"203082005"
topiroxostat	DB01685	Gout	C0018099		Approved					MONDO_0005393	"10018627"	"90560007"
pegloticase	DB09208	Gout	C0018099		Approved				"1011650"	MONDO_0005393	"10018627"	"90560007"
colchicine	DB01394	Gout	C0018099		Approved			CHEBI_27882	"2683"	MONDO_0005393	"10018627"	"90560007"
allopurinol	DB00437	Gout	C0018099		Approved			CHEBI_40279	"519"	MONDO_0005393	"10018627"	"90560007"
azapropazone	DB07402	Gout	C0018099		Approved			CHEBI_38010	"1029"	MONDO_0005393	"10018627"	"90560007"
benzbromarone	DB12319	Gout	C0018099		Approved			CHEBI_3023	"1385"	MONDO_0005393	"10018627"	"90560007"
indomethacin	DB00328	Gout	C0018099		Approved			CHEBI_49662	"5781"	MONDO_0005393	"10018627"	"90560007"
cinchophen	DB13551	Gout	C0018099		Approved			CHEBI_114195		MONDO_0005393	"10018627"	"90560007"
naproxen	DB00788	Gout	C0018099		Approved			CHEBI_7476	"7258"	MONDO_0005393	"10018627"	"90560007"
dotinurad	DB16145	Gout	C0018099		Approved					MONDO_0005393	"10018627"	"90560007"
allopurinol	DB00437	Gout	C0018099	NCT01459796	Terminated	Phase 3		CHEBI_40279	"519"	MONDO_0005393	"10018627"	"90560007"
cinacalcet	DB01012	Hypercalcemia	C0020437	NCT00415584	Terminated	Phase 1/Phase 2	low enrollment	CHEBI_48390	"407990"	MONDO_0001566	"10020583"	"66931009"
ibandronic acid	DB00710	Hypercalcemia	C0020437		Approved				"115265|115264"	MONDO_0001566	"10020583"	"66931009"
edetic acid	DB00974	Hypercalcemia	C0020437		Approved			CHEBI_42191	"1370600|3755"	MONDO_0001566	"10020583"	"66931009"
asfotase alfa	DB05768	Hypophosphatasia	C0020630		Approved					MONDO_0018570	"10049933"	"190859005"
asfotase alfa	DB09105	Hypophosphatasia	C0020630		Approved				"1720259"	MONDO_0018570	"10049933"	"190859005"
levothyroxine	DB00451	Hypothyroidism	C0020676		Approved			CHEBI_58448	"10582"	HP:0000821	"10021114"	"40930008"
liothyronine	DB00279	Hypothyroidism	C0020676		Approved			CHEBI_533015	"10814"	HP:0000821	"10021114"	"40930008"
metronidazole	DB15759	Infectious enteritis	C0021342		Approved			CHEBI_50688			"10058839"	"55184003"
metronidazole	DB00916	Infectious enteritis	C0021342		Approved			CHEBI_6909	"6922"		"10058839"	"55184003"
everolimus	DB01590	insulinoma	C0021670	NCT02273752	Terminated	Phase 2	Slow accrual	CHEBI_68478	"141704"	HP:0012197	"10022498"	"302822000"
everolimus	DB01590	insulinoma	C0021670	NCT02031536	Terminated	Phase 2	Slow accrual	CHEBI_68478	"141704"	HP:0012197	"10022498"	"302822000"
diazoxide	DB01119	insulinoma	C0021670		Approved			CHEBI_4495	"3327"	HP:0012197	"10022498"	"302822000"
cilostazol	DB01166	Intermittent Claudication	C0021775		Approved			CHEBI_31401	"21107"	MONDO_0005295	"10022562"	"63491006"
cilostazol	DB01166	Intermittent Claudication	C0021775	NCT05191862	Terminated	Phase 1	Randomization Error	CHEBI_31401	"21107"	MONDO_0005295	"10022562"	"63491006"
hydrocortisone succinate	DB00741	Laryngeal Edema	C0023052		Approved			CHEBI_17650	"5492"	HP:0012027	"10023845"	"51599000"
prednisolone	DB00860	Laryngeal Edema	C0023052		Approved			CHEBI_8378	"8638"	HP:0012027	"10023845"	"51599000"
triamcinolone acetonide	DB00620	Laryngeal Edema	C0023052		Approved			CHEBI_9667	"10759"	HP:0012027	"10023845"	"51599000"
betamethasone acetate	DB00443	Laryngeal Edema	C0023052		Approved			CHEBI_3077	"1514"	HP:0012027	"10023845"	"51599000"
triamcinolone	DB00620	Laryngeal Edema	C0023052		Approved			CHEBI_9667	"10759"	HP:0012027	"10023845"	"51599000"
hydrocortisone	DB00741	Laryngeal Edema	C0023052		Approved			CHEBI_17650	"5492"	HP:0012027	"10023845"	"51599000"
hydrocortisone succinate	DB14545	Laryngeal Edema	C0023052		Approved			CHEBI_31677	"21651"	HP:0012027	"10023845"	"51599000"
hydrocortisone acetate	DB00741	Laryngeal Edema	C0023052		Approved			CHEBI_17650	"5492"	HP:0012027	"10023845"	"51599000"
dexamethasone	DB01234	Laryngeal Edema	C0023052		Approved			CHEBI_41879	"3264"	HP:0012027	"10023845"	"51599000"
triamcinolone diacetate	DB00620	Laryngeal Edema	C0023052		Approved			CHEBI_9667	"10759"	HP:0012027	"10023845"	"51599000"
hydrocortisone acetate	DB14539	Laryngeal Edema	C0023052		Approved			CHEBI_17609	"27197"	HP:0012027	"10023845"	"51599000"
prednisone	DB00635	Laryngeal Edema	C0023052		Approved			CHEBI_8382	"8640"	HP:0012027	"10023845"	"51599000"
methylprednisolone	DB00959	Laryngeal Edema	C0023052		Approved			CHEBI_6888	"6902"	HP:0012027	"10023845"	"51599000"
cortisone acetate	DB01380	Laryngeal Edema	C0023052		Approved			CHEBI_3897	"21655"	HP:0012027	"10023845"	"51599000"
betamethasone	DB00443	Laryngeal Edema	C0023052		Approved			CHEBI_3077	"1514"	HP:0012027	"10023845"	"51599000"
sirolimus	DB00877	Lymphangiectasis	C0024214		Approved			CHEBI_9168	"35302"	MONDO_0006840	"10025210"	"48087001"
paracetamol	DB00316	Tension Headache	C0033893		Approved			CHEBI_46195	"161"	HP:0012228	"10043269"	"398057008"
caffeine	DB00201	Tension Headache	C0033893		Approved			CHEBI_27732	"1886"	HP:0012228	"10043269"	"398057008"
butalbital	DB00241	Tension Headache	C0033893		Approved			CHEBI_102524	"19860"	HP:0012228	"10043269"	"398057008"
codeine	DB00318	Tension Headache	C0033893		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0012228	"10043269"	"398057008"
relebactam	DB12377	Pyelonephritis	C0034186		Approved				"2184137|2268500"	MONDO_0006939	"10037596"	"45816000"
	DB00440	Pyelonephritis	C0034186	NCT00752375	Withdrawn	Phase 3	No participants	CHEBI_45924	"10829"	MONDO_0006939	"10037596"	"45816000"
sulfamethoxazole	DB01015	Pyelonephritis	C0034186	NCT00752375	Withdrawn	Phase 3	No participants	CHEBI_9332	"10180"	MONDO_0006939	"10037596"	"45816000"
levofloxacin	DB01137	Pyelonephritis	C0034186		Approved			CHEBI_63598	"1546009|82122"	MONDO_0006939	"10037596"	"45816000"
avibactam	DB09060	Pyelonephritis	C0034186		Approved			CHEBI_85984	"1603834"	MONDO_0006939	"10037596"	"45816000"
doripenem	DB06211	Pyelonephritis	C0034186		Approved			CHEBI_135928	"119771"	MONDO_0006939	"10037596"	"45816000"
norfloxacin	DB01059	Pyelonephritis	C0034186		Approved			CHEBI_100246	"7517"	MONDO_0006939	"10037596"	"45816000"
ofloxacin	DB01165	Pyelonephritis	C0034186		Approved			CHEBI_7731	"7623"	MONDO_0006939	"10037596"	"45816000"
cefiderocol	DB14879	Pyelonephritis	C0034186		Approved			CHEBI_140376	"2265702"	MONDO_0006939	"10037596"	"45816000"
ceftibuten	DB01415	Pyelonephritis	C0034186	NCT00724256	Terminated	Phase 3	other upcoming studies; patients refusal of invasive follow up (DMSA)	CHEBI_3510	"20492"	MONDO_0006939	"10037596"	"45816000"
fusidic acid	DB02703	Scrub Typhus	C0036472		Approved			CHEBI_29013	"4608|113608"	MONDO_0019365	"10039766"	"271425001"
doxycycline	DB00254	Scrub Typhus	C0036472		Approved			CHEBI_50845	"1545992|3640"	MONDO_0019365	"10039766"	"271425001"
epinephrine	DB00668	Septic Shock	C0036983		Approved			CHEBI_28918	"3992"		"10040070"	"76571007"
glycopyrronium bromide	DB00986	Sialorrhea	C0037036		Approved			CHEBI_94449	"1546438|4955"	HP:0002307	"10039424"	"53827007"
hyoscyamine	DB00424	Sialorrhea	C0037036		Approved			CHEBI_17486	"153970"	HP:0002307	"10039424"	"53827007"
procaine benzylpenicillin	DB01053	Syphilis, Latent	C0039133		Approved			CHEBI_18208	"7980"	MONDO_0005822	"10070738"	"444150000"
procaine benzylpenicillin	DB09320	Syphilis, Latent	C0039133		Approved			CHEBI_52154	"7983"	MONDO_0005822	"10070738"	"444150000"
benzylpenicillin	DB01053	Syphilis, Latent	C0039133		Approved			CHEBI_18208	"7980"	MONDO_0005822	"10070738"	"444150000"
terbinafine	DB00857	Tinea Pedis	C0040259		Approved			CHEBI_9448	"37801"	MONDO_0005984	"10043873"	"6020002"
griseofulvin	DB00400	Tinea Pedis	C0040259		Approved			CHEBI_27779	"91077|5021"	MONDO_0005984	"10043873"	"6020002"
betamethasone	DB00443	Tinea Pedis	C0040259		Approved			CHEBI_3077	"1514"	MONDO_0005984	"10043873"	"6020002"
naftifine	DB00735	Tinea Pedis	C0040259		Approved			CHEBI_7451	"31476"	MONDO_0005984	"10043873"	"6020002"
luliconazole	DB08933	Tinea Pedis	C0040259		Approved			CHEBI_34825	"1482680"	MONDO_0005984	"10043873"	"6020002"
zinc oxide	DB09321	Tinea Pedis	C0040259		Approved			CHEBI_36560	"11423"	MONDO_0005984	"10043873"	"6020002"
oxiconazole	DB00239	Tinea Pedis	C0040259		Approved			CHEBI_7825	"32638"	MONDO_0005984	"10043873"	"6020002"
ciclopirox	DB01188	Tinea Pedis	C0040259		Approved			CHEBI_453011	"21090"	MONDO_0005984	"10043873"	"6020002"
miconazole	DB01110	Tinea Pedis	C0040259		Approved			CHEBI_82892	"6932"	MONDO_0005984	"10043873"	"6020002"
butenafine	DB01091	Tinea Pedis	C0040259		Approved			CHEBI_3238	"47461"	MONDO_0005984	"10043873"	"6020002"
sertaconazole	DB01153	Tinea Pedis	C0040259		Approved			CHEBI_83682	"36435"	MONDO_0005984	"10043873"	"6020002"
benzocaine	DB01086	Tinea Pedis	C0040259		Approved			CHEBI_116735	"1399"	MONDO_0005984	"10043873"	"6020002"
clotrimazole	DB00257	Tinea Pedis	C0040259		Approved			CHEBI_3764	"2623"	MONDO_0005984	"10043873"	"6020002"
hydrocortisone	DB00741	Tinea Pedis	C0040259		Approved			CHEBI_17650	"5492"	MONDO_0005984	"10043873"	"6020002"
salicylic acid	DB00936	Tinea Pedis	C0040259		Approved			CHEBI_16914	"9525"	MONDO_0005984	"10043873"	"6020002"
undecylenic acid	DB11117	Tinea Pedis	C0040259		Approved			CHEBI_35045	"10989|314881"	MONDO_0005984	"10043873"	"6020002"
clioquinol	DB04815	Tinea Pedis	C0040259		Approved			CHEBI_74460	"5942"	MONDO_0005984	"10043873"	"6020002"
ketoconazole	DB01026	Tinea Pedis	C0040259		Approved			CHEBI_48339	"6135"	MONDO_0005984	"10043873"	"6020002"
cortisone acetate	DB01380	Tinea Pedis	C0040259		Approved			CHEBI_3897	"21655"	MONDO_0005984	"10043873"	"6020002"
pramocaine	DB09345	Tinea Pedis	C0040259		Approved			CHEBI_8357	"34347"	MONDO_0005984	"10043873"	"6020002"
econazole	DB01127	Tinea Pedis	C0040259		Approved			CHEBI_82873	"3743"	MONDO_0005984	"10043873"	"6020002"
salicylic acid	DB13860	Tinea Pedis	C0040259		Approved			CHEBI_16914		MONDO_0005984	"10043873"	"6020002"
tolnaftate	DB00525	Tinea Pedis	C0040259		Approved			CHEBI_9620	"10637"	MONDO_0005984	"10043873"	"6020002"
betamethasone dipropionate	DB00443	Tinea Pedis	C0040259		Approved			CHEBI_3077	"1514"	MONDO_0005984	"10043873"	"6020002"
haloprogin	DB00793	Tinea Pedis	C0040259		Approved			CHEBI_5614	"26422"	MONDO_0005984	"10043873"	"6020002"
sulconazole	DB06820	Tinea Pedis	C0040259		Approved			CHEBI_77776	"37319"	MONDO_0005984	"10043873"	"6020002"
ketoconazole	DB01026	Tinea Pedis	C0040259	NCT02606383	Withdrawn	Phase 3		CHEBI_48339	"6135"	MONDO_0005984	"10043873"	"6020002"
salicylic acid	DB14006	Tinea Pedis	C0040259		Approved			CHEBI_16914	"20974"	MONDO_0005984	"10043873"	"6020002"
ketoconazole	DB01026	Tinea Pedis	C0040259	NCT01110330	Terminated	Phase 3	Unexpected discordant results between the KOH microscopy and mycological culture tests at three study sites in the UK.	CHEBI_48339	"6135"	MONDO_0005984	"10043873"	"6020002"
somatropin	DB00052	Turner Syndrome	C0041408		Approved				"61148|314845"	MONDO_0019499	"10045181"	"38804009"
chloramphenicol succinate	DB07565	Typhoid Fever	C0041466		Approved			CHEBI_3606	"20769"	MONDO_0005619	"10045275"	"4834000"
norfloxacin	DB01059	Typhoid Fever	C0041466		Approved			CHEBI_100246	"7517"	MONDO_0005619	"10045275"	"4834000"
ciprofloxacin	DB00537	Typhoid Fever	C0041466		Approved			CHEBI_192484	"2551"	MONDO_0005619	"10045275"	"4834000"
ofloxacin	DB01165	Typhoid Fever	C0041466		Approved			CHEBI_7731	"7623"	MONDO_0005619	"10045275"	"4834000"
chloramphenicol	DB00446	Typhoid Fever	C0041466		Approved			CHEBI_17698	"2348"	MONDO_0005619	"10045275"	"4834000"
chloramphenicol succinate	DB00446	Typhoid Fever	C0041466		Approved			CHEBI_17698	"2348"	MONDO_0005619	"10045275"	"4834000"
maralixibat hydrochloride	DB16226	Alagille Syndrome	C0085280		Approved				"2571074"	MONDO_0007318	"10053870"	"31742004"
loracarbef	DB00447	Chronic pyelonephritis	C0085697		Approved			CHEBI_47544	"28981"	MONDO_0001110	"10037601"	"63302006"
butacaine	DB11502	Urge Incontinence	C0150045		Approved			CHEBI_94820	"1829"		"10046494"	"87557004"
oxybutynin	DB01062	Urge Incontinence	C0150045		Approved			CHEBI_7856	"32675"		"10046494"	"87557004"
trospium	DB00209	Urge Incontinence	C0150045		Approved			CHEBI_145791	"236778"		"10046494"	"87557004"
darifenacin	DB00496	Urge Incontinence	C0150045		Approved			CHEBI_391960	"136198"		"10046494"	"87557004"
tolterodine	DB01036	Urge Incontinence	C0150045		Approved			CHEBI_9622	"119565"		"10046494"	"87557004"
solifenacin	DB01591	Urge Incontinence	C0150045		Approved			CHEBI_135530	"322167"		"10046494"	"87557004"
fesoterodine	DB06702	Urge Incontinence	C0150045		Approved			CHEBI_135920	"797195"		"10046494"	"87557004"
fesoterodine	DB15578	Urge Incontinence	C0150045		Approved			CHEBI_135920			"10046494"	"87557004"
carmustine	DB00262	Malignant neoplasm of brain	C0153633		Approved			CHEBI_3423	"2105"		"10006131"	"428061005"
cefuroxime	DB01112	Streptococcal meningitis	C0154639		Approved			CHEBI_3515	"2194"	MONDO_0001316	"10027256"	"4510004"
ceftriaxone	DB01212	Streptococcal meningitis	C0154639		Approved			CHEBI_29007	"2193"	MONDO_0001316	"10027256"	"4510004"
benzylpenicillin	DB01053	Streptococcal meningitis	C0154639		Approved			CHEBI_18208	"7980"	MONDO_0001316	"10027256"	"4510004"
ceftizoxime	DB01332	Streptococcal meningitis	C0154639		Approved			CHEBI_553473	"2192"	MONDO_0001316	"10027256"	"4510004"
chloramphenicol	DB00446	Streptococcal meningitis	C0154639		Approved			CHEBI_17698	"2348"	MONDO_0001316	"10027256"	"4510004"
meropenem	DB00760	Streptococcal meningitis	C0154639		Approved			CHEBI_43968	"1546029|29561"	MONDO_0001316	"10027256"	"4510004"
cefotaxime	DB00493	Streptococcal meningitis	C0154639		Approved			CHEBI_204928	"2186"	MONDO_0001316	"10027256"	"4510004"
carbamazepine	DB00564	Glossopharyngeal Neuralgia	C0154731		Approved			CHEBI_3387	"2002"	MONDO_0016372	"10018391"	"43763009"
dinoprostone	DB00917	Unspecified Abortion	C0156543		Approved			CHEBI_15551	"3478"		"10000210"	"363681007"
carboprost	DB00429	Unspecified Abortion	C0156543		Approved			CHEBI_3404	"20259"		"10000210"	"363681007"
mifepristone	DB00834	Unspecified Abortion	C0156543		Approved			CHEBI_50692	"6964"		"10000210"	"363681007"
dinoprost	DB01160	Unspecified Abortion	C0156543		Approved			CHEBI_31502	"23321"		"10000210"	"363681007"
dinoprost	DB12789	Unspecified Abortion	C0156543		Approved			CHEBI_15553	"3477"		"10000210"	"363681007"
oxytocin	DB00107	Unspecified Abortion	C0156543		Approved			CHEBI_7872	"7824"		"10000210"	"363681007"
sutimlimab	DB14996	Cold Hemagglutinin Disease	C0175816		Approved				"2591404"	MONDO_0016450	"10009868"	"398937006"
lonapegsomatropin	DB16220	Somatotropin deficiency	C0271561		Approved				"2569562|2569592"		"10056438"	"397827003"
amphotericin B	DB00681	Disseminated sporotrichosis	C0276725		Approved			CHEBI_2682	"236594|732"	MONDO_0042484	"10080491"	"91051003"
sirolimus	DB00877	Eosinophilic esophagitis	C0341106	NCT01814059	Terminated	Phase 1		CHEBI_9168	"35302"	MONDO_0005361	"10064212"	"235599003"
	DB00764	Eosinophilic esophagitis	C0341106	NCT02113267	Terminated	Phase 2	Combination slow recruitment, short shelf life for placebo and insufficient funding for further drug production (probably anyway sufficient number included).	CHEBI_6970		MONDO_0005361	"10064212"	"235599003"
mometasone furoate	DB14512	Eosinophilic esophagitis	C0341106	NCT02113267	Terminated	Phase 2	Combination slow recruitment, short shelf life for placebo and insufficient funding for further drug production (probably anyway sufficient number included).	CHEBI_47564	"30145"	MONDO_0005361	"10064212"	"235599003"
	DB00455	Eosinophilic esophagitis	C0341106	NCT04248712	Terminated	Phase 2	low enrollment	CHEBI_6538	"28889"	MONDO_0005361	"10064212"	"235599003"
lansoprazole	DB00448	Eosinophilic esophagitis	C0341106	NCT01479231	Withdrawn	Phase 1/Phase 2	Souces of funding have been terminated	CHEBI_6375	"17128"	MONDO_0005361	"10064212"	"235599003"
budesonide	DB01222	Eosinophilic esophagitis	C0341106	NCT01821898	Terminated	Phase 2	Recruitment was below expectation	CHEBI_3207	"19831"	MONDO_0005361	"10064212"	"235599003"
famotidine	DB00927	Eosinophilic esophagitis	C0341106	NCT04248712	Terminated	Phase 2	low enrollment	CHEBI_4975	"4278"	MONDO_0005361	"10064212"	"235599003"
budesonide	DB01222	Eosinophilic esophagitis	C0341106		Approved			CHEBI_3207	"19831"	MONDO_0005361	"10064212"	"235599003"
	DB05351	Eosinophilic esophagitis	C0341106	NCT01479231	Withdrawn	Phase 1/Phase 2	Souces of funding have been terminated	CHEBI_135931	"816346"	MONDO_0005361	"10064212"	"235599003"
gemifloxacin	DB01155	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			CHEBI_101853	"138099"	MONDO_0030602	"10035717"	"64479007"
moxifloxacin	DB00218	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			CHEBI_63611	"139462"	MONDO_0030602	"10035717"	"64479007"
clavulanic acid	DB00766	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			CHEBI_48947	"48203|21216"	MONDO_0030602	"10035717"	"64479007"
norfloxacin	DB01059	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			CHEBI_100246	"7517"	MONDO_0030602	"10035717"	"64479007"
amoxicillin	DB01060	Pneumonia due to Klebsiella pneumoniae	C0519030		Approved			CHEBI_2676	"1297882|723"	MONDO_0030602	"10035717"	"64479007"
solriamfetol	DB14754	Sleep Apnea, Obstructive	C0520679		Approved				"2121751"	MONDO_0007147	"10029983"	"78275009"
atorvastatin	DB01076	Sleep Apnea, Obstructive	C0520679	NCT00669695	Terminated	Phase 2	Interim analysis performed without efficient results	CHEBI_39548	"83367"	MONDO_0007147	"10029983"	"78275009"
thiabendazole	DB00730	Larva Migrans, Cutaneous	C0546999		Approved			CHEBI_45979	"10450"		"10059547"	"19362000"
pramipexole	DB00413	Binge eating disorder	C0596170	NCT01106053	Withdrawn	Phase 3	No participants were recruited and study has been closed.	CHEBI_8356	"746741"		"10004716"	"439960005"
lisdexamfetamine	DB01255	Binge eating disorder	C0596170		Approved			CHEBI_135925	"700810"		"10004716"	"439960005"
retinol	DB00162	Mineral deficiency	C0687148		Approved			CHEBI_17336	"1367187|11246"		"10061291"	"111379007"
thiamine	DB00152	Mineral deficiency	C0687148		Approved			CHEBI_18385	"10454"		"10061291"	"111379007"
riboflavin	DB00140	Mineral deficiency	C0687148		Approved			CHEBI_17015	"9346"		"10061291"	"111379007"
folic acid	DB00158	Mineral deficiency	C0687148		Approved			CHEBI_27470	"62356|4511|202634"		"10061291"	"111379007"
abiraterone acetate	DB05812	Hormone refractory prostate cancer	C1328504	NCT04879589	Withdrawn	Phase 1	Study abandoned, no participants enrolled	CHEBI_68642	"1100072"		"10062904"	"427492003"
cyclophosphamide	DB00531	Hormone refractory prostate cancer	C1328504	NCT04227275	Terminated	Phase 1	Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.	CHEBI_4027	"1545988|3002"		"10062904"	"427492003"
	DB05812	Hormone refractory prostate cancer	C1328504	NCT04556617	Terminated	Phase 1/Phase 2	study terminated due to business realignment	CHEBI_68642	"1100072"		"10062904"	"427492003"
abiraterone acetate	DB05812	Hormone refractory prostate cancer	C1328504		Approved			CHEBI_68642	"1100072"		"10062904"	"427492003"
prednisone	DB00635	Hormone refractory prostate cancer	C1328504	NCT04556617	Terminated	Phase 1/Phase 2	study terminated due to business realignment	CHEBI_8382	"8640"		"10062904"	"427492003"
melatonin	DB01065	Sleep Initiation and Maintenance Disorders	C0021603		Approved			CHEBI_16796	"6711"			"194437008"
mephenytoin	DB00532	Epilepsies, Partial	C0014547		Approved			CHEBI_6757	"6757"	MONDO_0005384		"230381009"
oxcarbazepine	DB00776	Epilepsies, Partial	C0014547		Approved			CHEBI_7824	"32624"	MONDO_0005384		"230381009"
phenytoin	DB00252	Epilepsies, Partial	C0014547		Approved			CHEBI_8107	"8183"	MONDO_0005384		"230381009"
primidone	DB00794	Epilepsies, Partial	C0014547		Approved			CHEBI_8412	"8691"	MONDO_0005384		"230381009"
probenecid	DB01032	Chronic gouty arthritis	C0268108		Approved			CHEBI_8426	"8698"			"68451005"
hydroxocobalamin	DB00200	Anemia, Pernicious	C0002892		Approved			CHEBI_27786	"5514"	MONDO_0008228	"10034695"	"84027009"
testosterone cypionate	DB13943	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_9463	"835827"			"417181009"
testosterone cypionate	DB00624	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_17347	"10379"			"417181009"
magnesium salicylate	DB01397	Bursitis	C0006444		Approved			CHEBI_6640		MONDO_0002471	"10006811"	"84017003"
cobalamin	DB14098	Anemia, Pernicious	C0002892		Approved			CHEBI_30411		MONDO_0008228	"10034695"	"84027009"
testosterone enantate	DB13944	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_9464	"37859"			"417181009"
testosterone enantate	DB00624	Hormone receptor positive malignant neoplasm of breast	C1562029		Approved			CHEBI_17347	"10379"			"417181009"
spironolactone	DB00421	Hyperaldosteronism	C0020428		Approved			CHEBI_9241	"9997"	MONDO_0003009	"10020571"	"88213004"
potassium acetate	DB14498	Hypokalemia	C0020621		Approved			CHEBI_32029	"54987"	HP:0002900	"10021015"	"43339004"
potassium gluconate	DB13620	Hypokalemia	C0020621		Approved			CHEBI_32032	"89903"	HP:0002900	"10021015"	"43339004"
potassium hydrogencarbonate	DB11098	Hypokalemia	C0020621		Approved			CHEBI_81862	"34296"	HP:0002900	"10021015"	"43339004"
potassium chloride	DB00761	Hypokalemia	C0020621		Approved			CHEBI_32588	"8591"	HP:0002900	"10021015"	"43339004"
aspartic acid	DB00128	Hypokalemia	C0020621		Approved			CHEBI_17053	"1169|42543"	HP:0002900	"10021015"	"43339004"
calcium chloride	DB01164	Hypokalemia	C0020621		Approved			CHEBI_3312	"1901|1667640"	HP:0002900	"10021015"	"43339004"
magnesium aspartate	DB13359	Hypokalemia	C0020621		Approved					HP:0002900	"10021015"	"43339004"
potassium citrate	DB09125	Hypokalemia	C0020621		Approved			CHEBI_64733	"54993|1374802"	HP:0002900	"10021015"	"43339004"
oseltamivir	DB00198	Influenza	C0021400	NCT00979667	Terminated	Phase 3	Decreased Influenza activity; thus decrease/no eligible patient to recruit	CHEBI_7798	"260101"		"10022000"	"6142004"
oseltamivir	DB00198	Influenza	C0021400	NCT01053663	Terminated	Phase 1	The study was terminated prematurely after three influenza seasons.	CHEBI_7798	"260101"		"10022000"	"6142004"
	DB02600	Influenza	C0021400	NCT00979667	Terminated	Phase 3	Decreased Influenza activity; thus decrease/no eligible patient to recruit	CHEBI_73139			"10022000"	"6142004"
moroxydine	DB13597	Influenza	C0021400		Approved			CHEBI_94665			"10022000"	"6142004"
peramivir	DB06614	Influenza	C0021400		Approved			CHEBI_85202	"619693|1598096"		"10022000"	"6142004"
	DB02600	Influenza	C0021400	NCT01053663	Terminated	Phase 1	The study was terminated prematurely after three influenza seasons.	CHEBI_73139			"10022000"	"6142004"
	DB02600	Influenza	C0021400	NCT01546935	Withdrawn	Phase 2/Phase 3	Study drugs (Oseltamivir suspension from Roche) were unavailable	CHEBI_73139			"10022000"	"6142004"
zanamivir	DB00558	Influenza	C0021400	NCT02014649	Terminated	Phase 1/Phase 2	Study was terminated as per BARDA decision to terminate contract.	CHEBI_50663	"69722"		"10022000"	"6142004"
oseltamivir	DB00198	Influenza	C0021400		Approved			CHEBI_7798	"260101"		"10022000"	"6142004"
oseltamivir	DB02600	Influenza	C0021400		Approved			CHEBI_73139			"10022000"	"6142004"
zanamivir	DB00558	Influenza	C0021400		Approved			CHEBI_50663	"69722"		"10022000"	"6142004"
	DB02600	Influenza	C0021400	NCT00873886	Withdrawn	Phase 1	We will focus on other Tamiflu research studies. No subjects were enrolled.	CHEBI_73139			"10022000"	"6142004"
laninamivir octanoate hydrate	DB11888	Influenza	C0021400		Approved			CHEBI_134741			"10022000"	"6142004"
formaldehyde	DB03843	Influenza	C0021400		Approved			CHEBI_16842	"4530|314636"		"10022000"	"6142004"
oseltamivir	DB00198	Influenza	C0021400	NCT03903718	Withdrawn	Phase 2	Terminated due to delay in site enrollment timelines	CHEBI_7798	"260101"		"10022000"	"6142004"
	DB00558	Influenza	C0021400	NCT00979667	Terminated	Phase 3	Decreased Influenza activity; thus decrease/no eligible patient to recruit	CHEBI_50663	"69722"		"10022000"	"6142004"
	DB02600	Influenza	C0021400	NCT03903718	Withdrawn	Phase 2	Terminated due to delay in site enrollment timelines	CHEBI_73139			"10022000"	"6142004"
laninamivir octanoate hydrate	DB12791	Influenza	C0021400		Approved			CHEBI_134741			"10022000"	"6142004"
oseltamivir	DB00198	Influenza	C0021400	NCT00873886	Withdrawn	Phase 1	We will focus on other Tamiflu research studies. No subjects were enrolled.	CHEBI_7798	"260101"		"10022000"	"6142004"
umifenovir	DB13609	Influenza	C0021400		Approved			CHEBI_134730			"10022000"	"6142004"
oseltamivir	DB00198	Influenza	C0021400	NCT01546935	Withdrawn	Phase 2/Phase 3	Study drugs (Oseltamivir suspension from Roche) were unavailable	CHEBI_7798	"260101"		"10022000"	"6142004"
	DB02600	Influenza	C0021400	NCT01037634	Withdrawn	Phase 2		CHEBI_73139			"10022000"	"6142004"
favipiravir	DB12466	Influenza	C0021400		Approved			CHEBI_134722			"10022000"	"6142004"
oseltamivir	DB00198	Influenza	C0021400	NCT01037634	Withdrawn	Phase 2		CHEBI_7798	"260101"		"10022000"	"6142004"
scopolamine	DB00747	Iridocyclitis	C0022073		Approved			CHEBI_16794	"9601|9603"	MONDO_0004773	"10022941"	"77971008"
loteprednol etabonate	DB00873	Iridocyclitis	C0022073		Approved			CHEBI_50848	"237027"	MONDO_0004773	"10022941"	"77971008"
prednisolone	DB00860	Iridocyclitis	C0022073		Approved			CHEBI_8378	"8638"	MONDO_0004773	"10022941"	"77971008"
sulfacetamide	DB00634	Iridocyclitis	C0022073		Approved			CHEBI_63845	"10169"	MONDO_0004773	"10022941"	"77971008"
medrysone	DB00253	Iridocyclitis	C0022073		Approved			CHEBI_34829	"29439"	MONDO_0004773	"10022941"	"77971008"
prednisolone sodium phosphate	DB14631	Iridocyclitis	C0022073		Approved			CHEBI_145705	"34374"	MONDO_0004773	"10022941"	"77971008"
cortisone acetate	DB01380	Iridocyclitis	C0022073		Approved			CHEBI_3897	"21655"	MONDO_0004773	"10022941"	"77971008"
fluorometholone	DB00324	Iridocyclitis	C0022073		Approved			CHEBI_31625	"4491"	MONDO_0004773	"10022941"	"77971008"
prednisolone sodium phosphate	DB00860	Iridocyclitis	C0022073		Approved			CHEBI_8378	"8638"	MONDO_0004773	"10022941"	"77971008"
loteprednol etabonate	DB14596	Iridocyclitis	C0022073		Approved			CHEBI_31784	"52177"	MONDO_0004773	"10022941"	"77971008"
prednisolone acetate	DB15566	Iridocyclitis	C0022073		Approved			CHEBI_8380	"34372"	MONDO_0004773	"10022941"	"77971008"
prednisolone acetate	DB00860	Iridocyclitis	C0022073		Approved			CHEBI_8378	"8638"	MONDO_0004773	"10022941"	"77971008"
hydrocortisone	DB00741	Iridocyclitis	C0022073		Approved			CHEBI_17650	"5492"	MONDO_0004773	"10022941"	"77971008"
dexamethasone	DB01234	Iridocyclitis	C0022073		Approved			CHEBI_41879	"3264"	MONDO_0004773	"10022941"	"77971008"
fluorometholone acetate	DB00324	Iridocyclitis	C0022073		Approved			CHEBI_31625	"4491"	MONDO_0004773	"10022941"	"77971008"
aminolevulinic acid	DB00855	Actinic keratosis	C0022602		Approved			CHEBI_356416	"683"	MONDO_0005173	"10000614"	"856006"
imiquimod	DB00724	Actinic keratosis	C0022602		Approved			CHEBI_36704	"59943"	MONDO_0005173	"10000614"	"856006"
masoprocol	DB00179	Actinic keratosis	C0022602		Approved			CHEBI_73468	"227239"	MONDO_0005173	"10000614"	"856006"
fluorouracil	DB00544	Actinic keratosis	C0022602	NCT01525329	Terminated	Phase 3	study drug no longer available in the United States	CHEBI_46345	"4492"	MONDO_0005173	"10000614"	"856006"
ingenol mebutate	DB05013	Actinic keratosis	C0022602		Approved			CHEBI_66913	"1242806"	MONDO_0005173	"10000614"	"856006"
fluorouracil	DB00544	Actinic keratosis	C0022602		Approved			CHEBI_46345	"4492"	MONDO_0005173	"10000614"	"856006"
tirbanibulin	DB06137	Actinic keratosis	C0022602		Approved				"2471078"	MONDO_0005173	"10000614"	"856006"
diclofenac	DB00586	Actinic keratosis	C0022602		Approved			CHEBI_47381	"3355"	MONDO_0005173	"10000614"	"856006"
aminolevulinic acid	DB00855	Actinic keratosis	C0022602	NCT03024060	Withdrawn	Phase 3	Study withdrawn due to corporate business decision	CHEBI_356416	"683"	MONDO_0005173	"10000614"	"856006"
pirbuterol	DB01291	Lung diseases	C0024115		Approved			CHEBI_8245	"33767"	HP:0002088	"10025082"	"19829001"
theophylline	DB01223	Lung diseases	C0024115		Approved			CHEBI_2659	"689"	HP:0002088	"10025082"	"19829001"
theophylline	DB00277	Lung diseases	C0024115		Approved			CHEBI_28177	"10438|91178"	HP:0002088	"10025082"	"19829001"
tegafur	DB09256	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_32188	"4582"	HP:0012126	"10017758"	"363349007"
trifluridine	DB00432	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_75179	"10803"	HP:0012126	"10017758"	"363349007"
nivolumab	DB09035	Malignant neoplasm of stomach	C0024623		Approved				"1597876"	HP:0012126	"10017758"	"363349007"
docetaxel	DB01248	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_4672	"72962|1299922"	HP:0012126	"10017758"	"363349007"
tipiracil	DB09343	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_90879	"1670304"	HP:0012126	"10017758"	"363349007"
gimeracil	DB09257	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_31652		HP:0012126	"10017758"	"363349007"
ramucirumab	DB05578	Malignant neoplasm of stomach	C0024623		Approved				"1535922"	HP:0012126	"10017758"	"363349007"
oteracil	DB03209	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_30863		HP:0012126	"10017758"	"363349007"
fluorouracil	DB00544	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_46345	"4492"	HP:0012126	"10017758"	"363349007"
capecitabine	DB01101	Malignant neoplasm of stomach	C0024623		Approved			CHEBI_31348	"194000"	HP:0012126	"10017758"	"363349007"
ampicillin	DB00415	Meningitis, Pneumococcal	C0025295		Approved			CHEBI_28971	"733|221058"	MONDO_0006913	"10027253"	"51169003"
ceftriaxone	DB01212	Meningitis, Pneumococcal	C0025295		Approved			CHEBI_29007	"2193"	MONDO_0006913	"10027253"	"51169003"
meropenem	DB00760	Meningitis, Pneumococcal	C0025295		Approved			CHEBI_43968	"1546029|29561"	MONDO_0006913	"10027253"	"51169003"
benzylpenicillin	DB01053	Meningitis, Pneumococcal	C0025295		Approved			CHEBI_18208	"7980"	MONDO_0006913	"10027253"	"51169003"
levonorgestrel	DB00367	Menorrhagia	C0025323		Approved			CHEBI_6443	"6373"	HP:0000132	"10085423"	"386692008"
medroxyprogesterone	DB00603	Menorrhagia	C0025323	NCT02449161	Terminated	Phase 3	Missing fund to continue	CHEBI_6716	"1000112"	HP:0000132	"10085423"	"386692008"
norethisterone	DB00717	Menorrhagia	C0025323		Approved			CHEBI_7627	"7514"	HP:0000132	"10085423"	"386692008"
mestranol	DB01357	Menorrhagia	C0025323		Approved			CHEBI_6784	"6782"	HP:0000132	"10085423"	"386692008"
misoprostol	DB00929	Menorrhagia	C0025323	NCT00953641	Withdrawn	Phase 3	Principle Investigator retired, Resident moved away	CHEBI_63610	"42331"	HP:0000132	"10085423"	"386692008"
meclofenamic acid	DB00939	Menorrhagia	C0025323		Approved			CHEBI_6710	"6678|588003"	HP:0000132	"10085423"	"386692008"
chlormadinone	DB13528	Menorrhagia	C0025323		Approved					HP:0000132	"10085423"	"386692008"
levonorgestrel	DB09389	Menorrhagia	C0025323		Approved			CHEBI_7630	"7518"	HP:0000132	"10085423"	"386692008"
chlormadinone	DB15903	Menorrhagia	C0025323		Approved			CHEBI_31394	"2369"	HP:0000132	"10085423"	"386692008"
relugolix	DB11853	Menorrhagia	C0025323		Approved				"2472778"	HP:0000132	"10085423"	"386692008"
norethynodrel	DB09371	Menorrhagia	C0025323		Approved			CHEBI_34895	"7515"	HP:0000132	"10085423"	"386692008"
tranexamic acid	DB00302	Menorrhagia	C0025323		Approved			CHEBI_48669	"10691"	HP:0000132	"10085423"	"386692008"
benzylpenicillin	DB01053	Neurosyphilis	C0027927		Approved			CHEBI_18208	"7980"	MONDO_0004944	"10029339"	"26039008"
procaine benzylpenicillin	DB01053	Neurosyphilis	C0027927		Approved			CHEBI_18208	"7980"	MONDO_0004944	"10029339"	"26039008"
procaine benzylpenicillin	DB09320	Neurosyphilis	C0027927		Approved			CHEBI_52154	"7983"	MONDO_0004944	"10029339"	"26039008"
tonzonium	DB09552	Otitis Externa	C0029878		Approved			CHEBI_94514	"237058"	HP:0410017	"10033072"	"3135009"
dexamethasone phosphate	DB00537	Otitis Externa	C0029878	NCT01910155	Terminated	Phase 3	FDA's draft guidance (March 2015) provided option of in-vitro or in-vivo studies for bioequivalence. Small study size resulted in negative culture rates.	CHEBI_68637	"2551"	HP:0410017	"10033072"	"3135009"
colistin	DB00803	Otitis Externa	C0029878		Approved			CHEBI_37943	"2709"	HP:0410017	"10033072"	"3135009"
Polymyxin B	DB00781	Otitis Externa	C0029878		Approved				"8536"	HP:0410017	"10033072"	"3135009"
benzalkonium	DB11105	Otitis Externa	C0029878		Approved			CHEBI_188978	"1378"	HP:0410017	"10033072"	"3135009"
norfloxacin	DB01059	Otitis Externa	C0029878		Approved			CHEBI_100246	"7517"	HP:0410017	"10033072"	"3135009"
diclofenac	DB00586	Otitis Externa	C0029878	NCT00523120	Terminated	Phase 2		CHEBI_47381	"3355"	HP:0410017	"10033072"	"3135009"
	DB01234	Otitis Externa	C0029878	NCT01910155	Terminated	Phase 3	FDA's draft guidance (March 2015) provided option of in-vitro or in-vivo studies for bioequivalence. Small study size resulted in negative culture rates.	CHEBI_41879	"3264"	HP:0410017	"10033072"	"3135009"
desonide	DB01260	Otitis Externa	C0029878		Approved			CHEBI_204734	"3254"	HP:0410017	"10033072"	"3135009"
ciprofloxacin	DB00537	Otitis Externa	C0029878		Approved			CHEBI_192484	"2551"	HP:0410017	"10033072"	"3135009"
chloramphenicol	DB00446	Otitis Externa	C0029878		Approved			CHEBI_17698	"2348"	HP:0410017	"10033072"	"3135009"
dexamethasone	DB01234	Otitis Externa	C0029878		Approved			CHEBI_41879	"3264"	HP:0410017	"10033072"	"3135009"
hydrocortisone	DB00741	Otitis Externa	C0029878		Approved			CHEBI_17650	"5492"	HP:0410017	"10033072"	"3135009"
ofloxacin	DB01165	Otitis Externa	C0029878		Approved			CHEBI_7731	"7623"	HP:0410017	"10033072"	"3135009"
pramocaine	DB09345	Otitis Externa	C0029878		Approved			CHEBI_8357	"34347"	HP:0410017	"10033072"	"3135009"
neomycin	DB00994	Otitis Externa	C0029878		Approved			CHEBI_7507	"7299"	HP:0410017	"10033072"	"3135009"
acetic acid	DB03166	Otitis Externa	C0029878		Approved			CHEBI_15366	"168|164"	HP:0410017	"10033072"	"3135009"
cortisone acetate	DB01380	Otitis Externa	C0029878		Approved			CHEBI_3897	"21655"	HP:0410017	"10033072"	"3135009"
benzalkonium	DB13282	Otitis Externa	C0029878		Approved			CHEBI_188978		HP:0410017	"10033072"	"3135009"
zinc acetate	DB14487	Otitis Externa	C0029878		Approved			CHEBI_62984	"1299637|58295"	HP:0410017	"10033072"	"3135009"
thiopental	DB00599	Pseudotumor Cerebri	C0033845		Approved			CHEBI_102166	"10493"	MONDO_0009468	"10078904"	"68267002"
mannitol	DB00742	Pseudotumor Cerebri	C0033845		Approved			CHEBI_16899	"6628"	MONDO_0009468	"10078904"	"68267002"
	DB01181	Rhabdomyosarcoma	C0035412	NCT00162695	Terminated	Phase 3		CHEBI_5864	"5657"	MONDO_0005212	"10039022"	"30924005"
	DB00541	Rhabdomyosarcoma	C0035412	NCT00162695	Terminated	Phase 3		CHEBI_28445	"11202"	MONDO_0005212	"10039022"	"30924005"
dactinomycin	DB00970	Rhabdomyosarcoma	C0035412		Approved			CHEBI_27666	"3100"	MONDO_0005212	"10039022"	"30924005"
docetaxel	DB01248	Rhabdomyosarcoma	C0035412	NCT04906876	Withdrawn	Phase 2	IND withdrawn	CHEBI_4672	"72962|1299922"	MONDO_0005212	"10039022"	"30924005"
docetaxel	DB01248	Rhabdomyosarcoma	C0035412	NCT05116800	Withdrawn	Phase 2	IND withdrawn	CHEBI_4672	"72962|1299922"	MONDO_0005212	"10039022"	"30924005"
epirubicin	DB00445	Rhabdomyosarcoma	C0035412	NCT00162695	Terminated	Phase 3		CHEBI_47898	"3995"	MONDO_0005212	"10039022"	"30924005"
vincristine	DB00541	Rhabdomyosarcoma	C0035412		Approved			CHEBI_28445	"11202"	MONDO_0005212	"10039022"	"30924005"
dasatinib	DB01254	Rhabdomyosarcoma	C0035412	NCT03041701	Terminated	Phase 1/Phase 2	The pharmaceutical company discontinued availability of the drug and we were forced to close the study before phase II was completed. Only one participant was enrolled on phase II.	CHEBI_49375	"475342|1546019"	MONDO_0005212	"10039022"	"30924005"
	DB00958	Rhabdomyosarcoma	C0035412	NCT00162695	Terminated	Phase 3		CHEBI_31355	"40048"	MONDO_0005212	"10039022"	"30924005"
doxorubicin	DB00997	Rhabdomyosarcoma	C0035412	NCT02557854	Withdrawn	Phase 1	Lack of enrollment	CHEBI_28748	"142433|3639"	MONDO_0005212	"10039022"	"30924005"
	DB00773	Rhabdomyosarcoma	C0035412	NCT00162695	Terminated	Phase 3		CHEBI_4911	"4179"	MONDO_0005212	"10039022"	"30924005"
	DB00853	Rhabdomyosarcoma	C0035412	NCT02689336	Withdrawn	Phase 2	Could not recruit any participants	CHEBI_72564	"37776"	MONDO_0005212	"10039022"	"30924005"
erlotinib	DB00530	Rhabdomyosarcoma	C0035412	NCT02689336	Withdrawn	Phase 2	Could not recruit any participants	CHEBI_114785	"337525"	MONDO_0005212	"10039022"	"30924005"
minocycline	DB01017	Rosacea	C0035854	NCT01134991	Terminated	Phase 2	Difficulty in recruitment	CHEBI_50694	"6980"	MONDO_0006604	"10039218"	"398909004"
cortisone acetate	DB01380	Rosacea	C0035854		Approved			CHEBI_3897	"21655"	MONDO_0006604	"10039218"	"398909004"
azelaic acid	DB00548	Rosacea	C0035854		Approved			CHEBI_48131	"18602"	MONDO_0006604	"10039218"	"398909004"
tobramycin	DB00684	Rosacea	C0035854		Approved			CHEBI_28864	"10627"	MONDO_0006604	"10039218"	"398909004"
loteprednol etabonate	DB00873	Rosacea	C0035854		Approved			CHEBI_50848	"237027"	MONDO_0006604	"10039218"	"398909004"
prednisolone	DB00860	Rosacea	C0035854		Approved			CHEBI_8378	"8638"	MONDO_0006604	"10039218"	"398909004"
fluorometholone	DB00324	Rosacea	C0035854		Approved			CHEBI_31625	"4491"	MONDO_0006604	"10039218"	"398909004"
brimonidine	DB00484	Rosacea	C0035854		Approved			CHEBI_3175	"134615"	MONDO_0006604	"10039218"	"398909004"
metronidazole	DB15759	Rosacea	C0035854		Approved			CHEBI_50688		MONDO_0006604	"10039218"	"398909004"
metronidazole	DB00916	Rosacea	C0035854		Approved			CHEBI_6909	"6922"	MONDO_0006604	"10039218"	"398909004"
hydrocortisone	DB00741	Rosacea	C0035854		Approved			CHEBI_17650	"5492"	MONDO_0006604	"10039218"	"398909004"
tretinoin tocoferil	DB00755	Rosacea	C0035854	NCT01125930	Terminated	Phase 3	Due to slow recruitment and sponsor request study ended early	CHEBI_15367	"10753"	MONDO_0006604	"10039218"	"398909004"
rifaximin	DB01220	Rosacea	C0035854	NCT01359228	Withdrawn	Phase 2		CHEBI_75246	"35619"	MONDO_0006604	"10039218"	"398909004"
dexamethasone	DB01234	Rosacea	C0035854		Approved			CHEBI_41879	"3264"	MONDO_0006604	"10039218"	"398909004"
fusidic acid	DB02703	Rosacea	C0035854		Approved			CHEBI_29013	"4608|113608"	MONDO_0006604	"10039218"	"398909004"
medrysone	DB00253	Rosacea	C0035854		Approved			CHEBI_34829	"29439"	MONDO_0006604	"10039218"	"398909004"
fluorometholone acetate	DB00324	Rosacea	C0035854		Approved			CHEBI_31625	"4491"	MONDO_0006604	"10039218"	"398909004"
loteprednol etabonate	DB14596	Rosacea	C0035854		Approved			CHEBI_31784	"52177"	MONDO_0006604	"10039218"	"398909004"
hydrocortisone acetate	DB00741	Serum Sickness	C0036830		Approved			CHEBI_17650	"5492"	MONDO_0043789	"10040400"	"213323001"
hydrocortisone succinate	DB14545	Serum Sickness	C0036830		Approved			CHEBI_31677	"21651"	MONDO_0043789	"10040400"	"213323001"
triamcinolone acetonide	DB00620	Serum Sickness	C0036830		Approved			CHEBI_9667	"10759"	MONDO_0043789	"10040400"	"213323001"
hydrocortisone	DB00741	Serum Sickness	C0036830		Approved			CHEBI_17650	"5492"	MONDO_0043789	"10040400"	"213323001"
cortisone acetate	DB01380	Serum Sickness	C0036830		Approved			CHEBI_3897	"21655"	MONDO_0043789	"10040400"	"213323001"
betamethasone	DB00443	Serum Sickness	C0036830		Approved			CHEBI_3077	"1514"	MONDO_0043789	"10040400"	"213323001"
prednisolone	DB00860	Serum Sickness	C0036830		Approved			CHEBI_8378	"8638"	MONDO_0043789	"10040400"	"213323001"
prednisone	DB00635	Serum Sickness	C0036830		Approved			CHEBI_8382	"8640"	MONDO_0043789	"10040400"	"213323001"
methylprednisolone acetate	DB00959	Serum Sickness	C0036830		Approved			CHEBI_6888	"6902"	MONDO_0043789	"10040400"	"213323001"
dexamethasone	DB01234	Serum Sickness	C0036830		Approved			CHEBI_41879	"3264"	MONDO_0043789	"10040400"	"213323001"
hydrocortisone acetate	DB14539	Serum Sickness	C0036830		Approved			CHEBI_17609	"27197"	MONDO_0043789	"10040400"	"213323001"
methylprednisolone	DB00959	Serum Sickness	C0036830		Approved			CHEBI_6888	"6902"	MONDO_0043789	"10040400"	"213323001"
hydrocortisone succinate	DB00741	Serum Sickness	C0036830		Approved			CHEBI_17650	"5492"	MONDO_0043789	"10040400"	"213323001"
betamethasone acetate	DB00443	Serum Sickness	C0036830		Approved			CHEBI_3077	"1514"	MONDO_0043789	"10040400"	"213323001"
triamcinolone	DB00620	Serum Sickness	C0036830		Approved			CHEBI_9667	"10759"	MONDO_0043789	"10040400"	"213323001"
triamcinolone diacetate	DB00620	Serum Sickness	C0036830		Approved			CHEBI_9667	"10759"	MONDO_0043789	"10040400"	"213323001"
benzylpenicillin	DB01053	Syphilis, Congenital	C0039131		Approved			CHEBI_18208	"7980"	MONDO_0005714	"10010641"	"35742006"
procaine benzylpenicillin	DB09320	Syphilis, Congenital	C0039131		Approved			CHEBI_52154	"7983"	MONDO_0005714	"10010641"	"35742006"
procaine benzylpenicillin	DB01053	Syphilis, Congenital	C0039131		Approved			CHEBI_18208	"7980"	MONDO_0005714	"10010641"	"35742006"
propylthiouracil	DB00550	Thyroid Crisis	C0040127		Approved			CHEBI_8502	"8794"	MONDO_0006996	"10043786"	"29028009"
melarsoprol	DB12864	African Trypanosomiasis	C0041228		Approved			CHEBI_6729		MONDO_0005459	"10001461"	"27031003"
eflornithine	DB06243	African Trypanosomiasis	C0041228		Approved			CHEBI_41948	"569"	MONDO_0005459	"10001461"	"27031003"
pentamidine	DB00738	African Trypanosomiasis	C0041228		Approved			CHEBI_45081	"7994"	MONDO_0005459	"10001461"	"27031003"
suramin	DB04786	African Trypanosomiasis	C0041228		Approved			CHEBI_45906	"10256"	MONDO_0005459	"10001461"	"27031003"
metronidazole	DB15759	Tubo-ovarian abscess	C0041343		Approved			CHEBI_50688		HP:0034493	"10054824"	"58949002"
metronidazole	DB00916	Tubo-ovarian abscess	C0041343		Approved			CHEBI_6909	"6922"	HP:0034493	"10054824"	"58949002"
lidocaine	DB00281	Urethritis	C0041976		Approved			CHEBI_6456	"6387"	HP:0500006	"10046480"	"31822004"
hydroxocobalamin	DB00200	Vitamin B 12 Deficiency	C0042847		Approved			CHEBI_27786	"5514"	MONDO_0020696	"10047609"	"190634004"
cobalamin	DB14098	Vitamin B 12 Deficiency	C0042847		Approved			CHEBI_30411		MONDO_0020696	"10047609"	"190634004"
thiamine	DB00152	Vitamin B 12 Deficiency	C0042847		Approved			CHEBI_18385	"10454"	MONDO_0020696	"10047609"	"190634004"
cyanocobalamin	DB00115	Vitamin B 12 Deficiency	C0042847		Approved			CHEBI_17439	"11248"	MONDO_0020696	"10047609"	"190634004"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT01170507	Withdrawn	Phase 1/Phase 2	No funding	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
penicillamine	DB00859	Vitamin D Deficiency	C0042870	NCT00552630	Withdrawn	Phase 2/Phase 3		CHEBI_7959	"7975"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT01170442	Terminated	Phase 3	In adequate enrollment	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
calcitriol	DB00136	Vitamin D Deficiency	C0042870	NCT00585442	Terminated	Early Phase 1	Lack of quality data	CHEBI_17823	"1894"	MONDO_0100471	"10047626"	"34713006"
acetylsalicylic acid	DB00945	Vitamin D Deficiency	C0042870	NCT04363840	Withdrawn	Phase 2	lack of funding	CHEBI_15365	"91101|1191"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT01183442	Terminated	Phase 3	unable to recruit	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT01046773	Terminated	Phase 1	Low enrollment	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT00279461	Withdrawn	Phase 2	Dr. Levy terminated from IU in December 2009. Indiana University has no record that this study was initiated prior to his termination.	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT04840238	Suspended	Phase 2	insufficient recruit activity	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
ergocalciferol	DB00153	Vitamin D Deficiency	C0042870		Approved			CHEBI_28934	"4018"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT04120064	Terminated	Phase 1	Covid19, not able to finish recruitment	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
ergocalciferol	DB11094	Vitamin D Deficiency	C0042870		Approved			CHEBI_28934	"11253"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT03270709	Terminated	Phase 1	Study terminated early due to lack of funding and the COVID-19 pandemic.	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870		Approved			CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
colecalciferol	DB00169	Vitamin D Deficiency	C0042870	NCT02868827	Terminated	Phase 2/Phase 3	The initial plan was 2 years but due to slow recruitment. We were able to screen 635 patients in 4 years and recruited only 127 patients.	CHEBI_28940	"2418"	MONDO_0100471	"10047626"	"34713006"
tocofersolan	DB11635	Vitamin E Deficiency	C0042875		Approved				"159151"		"10047631"	"54137008"
tocofersolan	DB00163	Vitamin E Deficiency	C0042875		Approved			CHEBI_18145	"11256|237099"		"10047631"	"54137008"
Vitamin E	DB00163	Vitamin E Deficiency	C0042875		Approved			CHEBI_18145	"11256|237099"		"10047631"	"54137008"
epinephrine	DB00668	Wheezing	C0043144		Approved			CHEBI_28918	"3992"	HP:0030828	"10047924"	"56018004"
doxycycline	DB00254	Gastrointestinal anthrax	C0152945		Approved			CHEBI_50845	"1545992|3640"	MONDO_0001701	"10017931"	"111798006"
benzylpenicillin	DB01053	Gastrointestinal anthrax	C0152945		Approved			CHEBI_18208	"7980"	MONDO_0001701	"10017931"	"111798006"
mezlocillin	DB00948	Serratia Infections	C0085394		Approved			CHEBI_6919	"6927"		"10061512"	"71120004"
fusidic acid	DB02703	Gastrointestinal anthrax	C0152945		Approved			CHEBI_29013	"4608|113608"	MONDO_0001701	"10017931"	"111798006"
olaparib	DB09074	Malignant tumor of peritoneum	C0153467		Approved			CHEBI_83766	"1597582"	MONDO_0002087	"10061269"	"363492001"
paclitaxel	DB01229	Malignant tumor of peritoneum	C0153467		Approved			CHEBI_45863	"56946"	MONDO_0002087	"10061269"	"363492001"
niraparib	DB11793	Malignant tumor of peritoneum	C0153467		Approved			CHEBI_176844	"1918231"	MONDO_0002087	"10061269"	"363492001"
bevacizumab	DB00112	Malignant tumor of peritoneum	C0153467		Approved				"253337|2046138"	MONDO_0002087	"10061269"	"363492001"
pentosan polysulfate	DB00686	Bladder pain	C0232849		Approved			CHEBI_184555	"155046"	HP:0032171	"10005063"	"15803009"
flavoxate	DB01148	Suprapubic pain	C0241310		Approved			CHEBI_5088	"4440"		"10050822"	"162053006"
acetazolamide	DB00819	Malignant glaucoma	C0271152		Approved			CHEBI_27690	"167"		"10079469"	"370504007"
testosterone	DB00624	Hypogonadotropic hypogonadism	C0271623		Approved			CHEBI_17347	"10379"	MONDO_0018555	"10059594"	"33927004"
testosterone undecanoate	DB00624	Hypogonadotropic hypogonadism	C0271623		Approved			CHEBI_17347	"10379"	MONDO_0018555	"10059594"	"33927004"
testosterone	DB00624	Hypogonadotropic hypogonadism	C0271623	NCT01155518	Terminated	Phase 2	lack of funding	CHEBI_17347	"10379"	MONDO_0018555	"10059594"	"33927004"
testosterone undecanoate	DB13946	Hypogonadotropic hypogonadism	C0271623		Approved			CHEBI_135741	"37864"	MONDO_0018555	"10059594"	"33927004"
anastrozole	DB01217	Hypogonadotropic hypogonadism	C0271623	NCT03118479	Terminated	Phase 1	Because the PI left the institution.	CHEBI_2704	"84857"	MONDO_0018555	"10059594"	"33927004"
	DB00624	Hypogonadotropic hypogonadism	C0271623	NCT03118479	Terminated	Phase 1	Because the PI left the institution.	CHEBI_17347	"10379"	MONDO_0018555	"10059594"	"33927004"
	DB00882	Hypogonadotropic hypogonadism	C0271623	NCT01155518	Terminated	Phase 2	lack of funding	CHEBI_3752	"2596"	MONDO_0018555	"10059594"	"33927004"
ofloxacin	DB01165	Enteric campylobacteriosis	C0275982		Approved			CHEBI_7731	"7623"		"10007048"	"18081009"
ciprofloxacin	DB00537	Enteric campylobacteriosis	C0275982		Approved			CHEBI_192484	"2551"		"10007048"	"18081009"
norfloxacin	DB01059	Enteric campylobacteriosis	C0275982		Approved			CHEBI_100246	"7517"		"10007048"	"18081009"
ramucirumab	DB05578	Gastric Adenocarcinoma	C0278701		Approved				"1535922"	MONDO_0005036	"10001150"	"408647009"
dasatinib	DB01254	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			CHEBI_49375	"475342|1546019"	HP:0005506	"10009013"	"92818009"
busulfan	DB01008	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			CHEBI_28901	"1828"	HP:0005506	"10009013"	"92818009"
nilotinib	DB04868	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			CHEBI_52172	"662281"	HP:0005506	"10009013"	"92818009"
imatinib	DB00619	Philadelphia chromosome positive chronic myelogenous leukemia	C0279543		Approved			CHEBI_45783	"282388"	HP:0005506	"10009013"	"92818009"
temozolomide	DB00853	Microglioma	C0280803	NCT02113007	Terminated	Phase 2	Closed early due to slow accrual.	CHEBI_72564	"37776"	HP:0030069	"10007953"	"307649006"
pemetrexed	DB00642	Microglioma	C0280803	NCT00712062	Withdrawn	Phase 2	Lack of accrual	CHEBI_63616	"68446"	HP:0030069	"10007953"	"307649006"
	DB00073	Microglioma	C0280803	NCT02113007	Terminated	Phase 2	Closed early due to slow accrual.		"2273510|2472325|121191|2105824"	HP:0030069	"10007953"	"307649006"
ezetimibe	DB00973	Sitosterolemia	C0342907		Approved			CHEBI_49040	"341248"	MONDO_0008863	"10063985"	"238104009"
floxuridine	DB00322	Malignant neoplasm of liver	C0345904		Approved			CHEBI_60761	"4488"	HP:0002896	"10073069"	"93870000"
loteprednol etabonate	DB00873	Ocular Rosacea	C0406486		Approved			CHEBI_50848	"237027"		"10072139"	"200933006"
prednisolone	DB00860	Ocular Rosacea	C0406486		Approved			CHEBI_8378	"8638"		"10072139"	"200933006"
loteprednol etabonate	DB14596	Ocular Rosacea	C0406486		Approved			CHEBI_31784	"52177"		"10072139"	"200933006"
isoprenaline	DB01064	Low Cardiac Output Syndrome	C0600177		Approved			CHEBI_64317	"6054"		"10024899"	"44088000"
dopamine	DB00988	Low Cardiac Output Syndrome	C0600177		Approved			CHEBI_18243	"3628"		"10024899"	"44088000"
gentian violet	DB00406	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_77181	"4778|1546369"	MONDO_0006014	"10047784"	"72605008"
nystatin	DB00646	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_473992	"7597"	MONDO_0006014	"10047784"	"72605008"
omoconazole	DB13684	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_135685		MONDO_0006014	"10047784"	"72605008"
terconazole	DB00251	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_82981	"37806"	MONDO_0006014	"10047784"	"72605008"
miconazole	DB01110	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_82892	"6932"	MONDO_0006014	"10047784"	"72605008"
fluconazole	DB00196	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_46081	"202813|4450"	MONDO_0006014	"10047784"	"72605008"
fenticonazole	DB13434	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_83602		MONDO_0006014	"10047784"	"72605008"
sulfanilamide	DB00259	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_45373	"10184"	MONDO_0006014	"10047784"	"72605008"
tioconazole	DB01007	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_77898	"38298"	MONDO_0006014	"10047784"	"72605008"
butoconazole	DB00639	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_3240	"19884"	MONDO_0006014	"10047784"	"72605008"
clotrimazole	DB00257	Candidiasis, Vulvovaginal	C0700345		Approved			CHEBI_3764	"2623"	MONDO_0006014	"10047784"	"72605008"
sulfinpyrazone	DB01138	Hyperuricemia	C0740394		Approved			CHEBI_9342	"10205"	MONDO_0002144	"10020903"	"35885006"
febuxostat	DB04854	Hyperuricemia	C0740394		Approved			CHEBI_31596	"73689"	MONDO_0002144	"10020903"	"35885006"
lesinurad	DB11560	Hyperuricemia	C0740394		Approved			CHEBI_90929	"1731031"	MONDO_0002144	"10020903"	"35885006"
allopurinol	DB00437	Hyperuricemia	C0740394	NCT03076684	Withdrawn	Early Phase 1	Preliminary data collected and diets developed. Funding has ended and data used to support a larger application to test the hypothesis.	CHEBI_40279	"519"	MONDO_0002144	"10020903"	"35885006"
allopurinol	DB00437	Hyperuricemia	C0740394	NCT03865407	Terminated	Phase 2	inability to achieve recruitment goals at a single center and given the current pandemic conditions	CHEBI_40279	"519"	MONDO_0002144	"10020903"	"35885006"
benzbromarone	DB12319	Hyperuricemia	C0740394		Approved			CHEBI_3023	"1385"	MONDO_0002144	"10020903"	"35885006"
probenecid	DB01032	Hyperuricemia	C0740394		Approved			CHEBI_8426	"8698"	MONDO_0002144	"10020903"	"35885006"
topiroxostat	DB01685	Hyperuricemia	C0740394		Approved					MONDO_0002144	"10020903"	"35885006"
dotinurad	DB16145	Hyperuricemia	C0740394		Approved					MONDO_0002144	"10020903"	"35885006"
allopurinol	DB00437	Hyperuricemia	C0740394	NCT00607152	Terminated	Phase 3	the patient enrollment is too difficult	CHEBI_40279	"519"	MONDO_0002144	"10020903"	"35885006"
allopurinol	DB00437	Hyperuricemia	C0740394		Approved			CHEBI_40279	"519"	MONDO_0002144	"10020903"	"35885006"
phenylbutanoic acid	DB06819	Carbamoyl-Phosphate Synthase I Deficiency Disease	C0751753		Approved			CHEBI_41500	"1546447|81647"		"10058297"	"765329008"
mitoxantrone	DB01204	Multiple Sclerosis, Secondary Progressive	C0751965	NCT00146159	Terminated	Phase 3		CHEBI_50729	"7005"	MONDO_0000450	"10063400"	"425500002"
natalizumab	DB00108	Multiple Sclerosis, Secondary Progressive	C0751965	NCT01416181	Terminated	Phase 3	The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.		"354770"	MONDO_0000450	"10063400"	"425500002"
ofatumumab	DB06650	Multiple Sclerosis, Secondary Progressive	C0751965		Approved				"712566"	MONDO_0000450	"10063400"	"425500002"
	DB14644	Chronic graft-versus-host disease	C0867389	NCT01028313	Withdrawn	Phase 2	A decision was made to not move forward with the study. No participants were enrolled or treated.	CHEBI_135765		MONDO_0020547	"10066261"	"402356004"
alefacept	DB00092	Chronic graft-versus-host disease	C0867389	NCT01226420	Terminated	Phase 2	Discontinuation of drug supply from Astellas.		"299635"	MONDO_0020547	"10066261"	"402356004"
	DB01024	Chronic graft-versus-host disease	C0867389	NCT01898377	Terminated	Phase 2	New treatment option introduced for patients with the study indication	CHEBI_168396	"7145|265323"	MONDO_0020547	"10066261"	"402356004"
	DB00860	Chronic graft-versus-host disease	C0867389	NCT01028313	Withdrawn	Phase 2	A decision was made to not move forward with the study. No participants were enrolled or treated.	CHEBI_8378	"8638"	MONDO_0020547	"10066261"	"402356004"
	DB06603	Chronic graft-versus-host disease	C0867389	NCT01028313	Withdrawn	Phase 2	A decision was made to not move forward with the study. No participants were enrolled or treated.	CHEBI_85990	"1603350"	MONDO_0020547	"10066261"	"402356004"
imatinib	DB00619	Chronic graft-versus-host disease	C0867389	NCT01898377	Terminated	Phase 2	New treatment option introduced for patients with the study indication	CHEBI_45783	"282388"	MONDO_0020547	"10066261"	"402356004"
methylprednisolone	DB00959	Chronic graft-versus-host disease	C0867389	NCT01028313	Withdrawn	Phase 2	A decision was made to not move forward with the study. No participants were enrolled or treated.	CHEBI_6888	"6902"	MONDO_0020547	"10066261"	"402356004"
ibrutinib	DB09053	Chronic graft-versus-host disease	C0867389		Approved			CHEBI_76612	"1442981"	MONDO_0020547	"10066261"	"402356004"
sirolimus	DB00877	Chronic graft-versus-host disease	C0867389	NCT01903473	Terminated	Phase 2	slow recruitment	CHEBI_9168	"35302"	MONDO_0020547	"10066261"	"402356004"
vemurafenib	DB08881	Erdheim-Chester Disease	C0878675		Approved			CHEBI_63637	"1147220"	MONDO_0018153	"10060801"	"699537002"
dimethyl sulfoxide	DB01093	Erdheim-Chester Disease	C0878675	NCT03794297	Withdrawn	Phase 2	Inadequate accrual rate	CHEBI_28262	"3455"	MONDO_0018153	"10060801"	"699537002"
sodium oxybate	DB09072	Hypersomnia	C0917799	NCT03626727	Withdrawn	Early Phase 1	Target study population was extremely difficult to recruit and planned study budget was exceeded		"9899"	MONDO_0005466	"10020765"	"77692006"
	DB01440	Hypersomnia	C0917799	NCT03626727	Withdrawn	Early Phase 1	Target study population was extremely difficult to recruit and planned study budget was exceeded	CHEBI_30830	"1546380|2387302"	MONDO_0005466	"10020765"	"77692006"
modafinil	DB00745	Hypersomnia	C0917799		Approved			CHEBI_77585	"30125"	MONDO_0005466	"10020765"	"77692006"
dactinomycin	DB00970	Gestational Trophoblastic Neoplasms	C1135868		Approved			CHEBI_27666	"3100"		"10061988"	"609519004"
vinblastine	DB00570	Gestational Trophoblastic Neoplasms	C1135868		Approved			CHEBI_27375	"11198"		"10061988"	"609519004"
bevacizumab	DB00112	Gestational Trophoblastic Neoplasms	C1135868	NCT02664961	Terminated	Phase 2	Rare tumor type, patients eligible via expanded access.		"253337|2046138"		"10061988"	"609519004"
methotrexate	DB00563	Gestational Trophoblastic Neoplasms	C1135868		Approved			CHEBI_44185	"6851"		"10061988"	"609519004"
mefloquine	DB00358	Malaria, Vivax	C0024537		Approved			CHEBI_63681	"6694"	MONDO_0005921		"27052006"
doconexent	DB03756	Breastfeeding (mother)	C1623040		Approved			CHEBI_28125	"1006469|144450"			"413712001"
glycopyrronium bromide	DB00986	Hyperhidrosis of axilla	C0580182		Approved			CHEBI_94449	"1546438|4955"			"303089000"
calcium phosphate	DB11348	Breastfeeding (mother)	C1623040		Approved			CHEBI_9679	"1919"			"413712001"
lefamulin	DB12825	Pneumonia due to Staphylococcus aureus	C2349530		Approved				"2198944"			"441658007"
oteseconazole	DB13055	Recurrent candidiasis of vagina	C3872606		Approved			CHEBI_188153	"2602577"			"708126004"
mercaptamine	DB00847	Nephropathic cystinosis	C2931187		Approved			CHEBI_17141	"3022"	MONDO_0100151		"62332007"
nitazoxanide	DB00507	Cryptosporidiosis	C0010418		Approved			CHEBI_94807	"31819"	MONDO_0015474	"10011502"	"240370009"
prednisone	DB00635	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_8382	"8640"	MONDO_0015614	"10012468"	"111196000"
dapsone	DB00250	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_4325	"3108"	MONDO_0015614	"10012468"	"111196000"
betamethasone	DB00443	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_3077	"1514"	MONDO_0015614	"10012468"	"111196000"
hydrocortisone	DB00741	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_17650	"5492"	MONDO_0015614	"10012468"	"111196000"
cortisone acetate	DB01380	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_3897	"21655"	MONDO_0015614	"10012468"	"111196000"
hydrocortisone succinate	DB14545	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_31677	"21651"	MONDO_0015614	"10012468"	"111196000"
sulfapyridine	DB00891	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_132842	"10188"	MONDO_0015614	"10012468"	"111196000"
dexamethasone	DB01234	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_41879	"3264"	MONDO_0015614	"10012468"	"111196000"
methylprednisolone	DB00959	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_6888	"6902"	MONDO_0015614	"10012468"	"111196000"
hydrocortisone acetate	DB14539	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_17609	"27197"	MONDO_0015614	"10012468"	"111196000"
encorafenib	DB11718	Malignant melanoma, metastatic	C0860594		Approved				"2049106"		"10027480"	"443493003"
triamcinolone	DB00620	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_9667	"10759"	MONDO_0015614	"10012468"	"111196000"
hydrocortisone succinate	DB00741	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_17650	"5492"	MONDO_0015614	"10012468"	"111196000"
prednisolone	DB00860	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_8378	"8638"	MONDO_0015614	"10012468"	"111196000"
methylprednisolone acetate	DB00959	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_6888	"6902"	MONDO_0015614	"10012468"	"111196000"
betamethasone acetate	DB00443	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_3077	"1514"	MONDO_0015614	"10012468"	"111196000"
triamcinolone acetonide	DB00620	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_9667	"10759"	MONDO_0015614	"10012468"	"111196000"
triamcinolone diacetate	DB00620	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_9667	"10759"	MONDO_0015614	"10012468"	"111196000"
hydrocortisone acetate	DB00741	Dermatitis Herpetiformis	C0011608		Approved			CHEBI_17650	"5492"	MONDO_0015614	"10012468"	"111196000"
dimethyl fumarate	DB08908	Scleroderma	C0011644	NCT02981082	Terminated	Phase 1	Low recruitment	CHEBI_76004	"1373478"	HP:0100324	"10039710"	"267874003"
valproic acid	DB00313	Scleroderma	C0011644	NCT02166229	Withdrawn	Phase 1/Phase 2	No subjects were enrolled.	CHEBI_39867	"11118|40254"	HP:0100324	"10039710"	"267874003"
cyclophosphamide	DB00531	Scleroderma	C0011644	NCT00040651	Terminated	Phase 1		CHEBI_4027	"1545988|3002"	HP:0100324	"10039710"	"267874003"
	DB00087	Scleroderma	C0011644	NCT00684255	Terminated	Phase 1	inactive		"117055"	HP:0100324	"10039710"	"267874003"
	DB00531	Scleroderma	C0011644	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_4027	"1545988|3002"	HP:0100324	"10039710"	"267874003"
methylprednisolone	DB00959	Scleroderma	C0011644	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_6888	"6902"	HP:0100324	"10039710"	"267874003"
aminobenzoic acid	DB02362	Scleroderma	C0011644		Approved			CHEBI_30753	"74"	HP:0100324	"10039710"	"267874003"
	DB00860	Scleroderma	C0011644	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_8378	"8638"	HP:0100324	"10039710"	"267874003"
iloprost	DB01088	Scleroderma	C0011644	NCT00622687	Terminated	Phase 2	sufficient number to reach the primary endpoint and as planned	CHEBI_63916	"40138"	HP:0100324	"10039710"	"267874003"
rituximab	DB00073	Scleroderma	C0011644		Approved				"2273510|2472325|121191|2105824"	HP:0100324	"10039710"	"267874003"
	DB14644	Scleroderma	C0011644	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_135765		HP:0100324	"10039710"	"267874003"
bosentan	DB00559	Scleroderma	C0011644		Approved			CHEBI_51450	"75207|1468845"	HP:0100324	"10039710"	"267874003"
	DB00073	Scleroderma	C0011644	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical		"2273510|2472325|121191|2105824"	HP:0100324	"10039710"	"267874003"
busulfan	DB01008	Scleroderma	C0011644	NCT00684255	Terminated	Phase 1	inactive	CHEBI_28901	"1828"	HP:0100324	"10039710"	"267874003"
hyoscyamine	DB00424	Dysuria	C0013428		Approved			CHEBI_17486	"153970"	HP:0100518	"10013990"	"49650001"
secbutabarbital	DB00237	Dysuria	C0013428		Approved			CHEBI_3228	"477631"	HP:0100518	"10013990"	"49650001"
flavoxate	DB01148	Dysuria	C0013428		Approved			CHEBI_5088	"4440"	HP:0100518	"10013990"	"49650001"
phenazopyridine	DB01438	Dysuria	C0013428		Approved			CHEBI_71416	"8120"	HP:0100518	"10013990"	"49650001"
arginine	DB00125	Exposure to radiation	C0015333		Approved			CHEBI_16467	"1091"		"10073306"	"218190002"
lysine	DB00123	Exposure to radiation	C0015333		Approved			CHEBI_18019	"6536"		"10073306"	"218190002"
leucovorin	DB00650	Folic Acid Deficiency	C0016412		Approved			CHEBI_15640	"6313"	HP:0100507	"10016880"	"190633005"
folic acid	DB00158	Folic Acid Deficiency	C0016412		Approved			CHEBI_27470	"62356|4511|202634"	HP:0100507	"10016880"	"190633005"
levofolinic acid	DB11596	Folic Acid Deficiency	C0016412		Approved			CHEBI_63606	"877015"	HP:0100507	"10016880"	"190633005"
dichlorophen	DB11396	Angle Closure Glaucoma	C0017605		Approved			CHEBI_34689		MONDO_0001744	"10002500"	"392291006"
dichlorphenamide	DB01144	Angle Closure Glaucoma	C0017605		Approved			CHEBI_101085	"3353"	MONDO_0001744	"10002500"	"392291006"
methazolamide	DB00703	Angle Closure Glaucoma	C0017605		Approved			CHEBI_6822	"6826"	MONDO_0001744	"10002500"	"392291006"
acetazolamide	DB00819	Angle Closure Glaucoma	C0017605		Approved			CHEBI_27690	"167"	MONDO_0001744	"10002500"	"392291006"
mycophenolate mofetil	DB00688	Graft-vs-Host Disease	C0018133		Approved			CHEBI_8764	"68149"	MONDO_0013730	"10018651"	"234646005"
mycophenolate mofetil	DB01024	Graft-vs-Host Disease	C0018133		Approved			CHEBI_168396	"7145|265323"	MONDO_0013730	"10018651"	"234646005"
isoprenaline	DB01064	Hypovolemic Shock	C0020683		Approved			CHEBI_64317	"6054"	HP:0031274	"10021138"	"39419009"
testosterone propionate	DB01420	Klinefelter Syndrome	C0022735		Approved			CHEBI_9466	"10382"	MONDO_0006823	"10023463"	"405769009"
testosterone propionate	DB00624	Klinefelter Syndrome	C0022735		Approved			CHEBI_17347	"10379"	MONDO_0006823	"10023463"	"405769009"
testosterone enantate	DB13944	Klinefelter Syndrome	C0022735		Approved			CHEBI_9464	"37859"	MONDO_0006823	"10023463"	"405769009"
testosterone cypionate	DB13943	Klinefelter Syndrome	C0022735		Approved			CHEBI_9463	"835827"	MONDO_0006823	"10023463"	"405769009"
testosterone cypionate	DB00624	Klinefelter Syndrome	C0022735		Approved			CHEBI_17347	"10379"	MONDO_0006823	"10023463"	"405769009"
testosterone enantate	DB00624	Klinefelter Syndrome	C0022735		Approved			CHEBI_17347	"10379"	MONDO_0006823	"10023463"	"405769009"
fluoxymesterone	DB01185	Klinefelter Syndrome	C0022735		Approved			CHEBI_5120	"4494"	MONDO_0006823	"10023463"	"405769009"
testosterone	DB00624	Klinefelter Syndrome	C0022735		Approved			CHEBI_17347	"10379"	MONDO_0006823	"10023463"	"405769009"
daunorubicin	DB00694	Acute Erythroblastic Leukemia	C0023440		Approved			CHEBI_41977	"214468|3109"	MONDO_0017858	"10000739"	"93451002"
ceftolozane	DB09050	Liver Abscess	C0023885		Approved			CHEBI_134719	"1597609"	HP:0100523	"10024652"	"27916005"
metronidazole	DB00916	Liver Abscess	C0023885		Approved			CHEBI_6909	"6922"	HP:0100523	"10024652"	"27916005"
tazobactam	DB01606	Liver Abscess	C0023885		Approved			CHEBI_9421	"37617"	HP:0100523	"10024652"	"27916005"
metronidazole	DB15759	Liver Abscess	C0023885		Approved			CHEBI_50688		HP:0100523	"10024652"	"27916005"
cefuroxime axetil	DB01112	Lyme Disease	C0024198		Approved			CHEBI_3515	"2194"	MONDO_0019632	"10025169"	"23502006"
cefuroxime	DB01112	Lyme Disease	C0024198		Approved			CHEBI_3515	"2194"	MONDO_0019632	"10025169"	"23502006"
nicotinyl alcohol	DB04145	Meniere Disease	C0025281		Approved			CHEBI_45213		MONDO_0007972	"10027183"	"13445001"
betahistine	DB06698	Meniere Disease	C0025281		Approved			CHEBI_35677	"1511"	MONDO_0007972	"10027183"	"13445001"
benzylpenicillin	DB01053	Meningococcemia	C0025306		Approved			CHEBI_18208	"7980"	MONDO_0042972	"10027280"	"4089001"
dexpanthenol	DB09357	Paralytic Ileus	C0030446		Approved			CHEBI_27373	"22701"	MONDO_0004568	"10021333"	"55525008"
ticarcillin	DB01607	Pelvic abscess	C0030785		Approved			CHEBI_9587	"10591"		"10034236"	"111367007"
bosentan	DB00559	Persistent Fetal Circulation Syndrome	C0031190	NCT01389856	Terminated	Phase 3	To be compliant with the timelines as agreed with Paediatric Committee (PC) within the Paediatric Investigational Plan	CHEBI_51450	"75207|1468845"	MONDO_0022430	"10034708"	"233815004"
tolazoline	DB00797	Persistent Fetal Circulation Syndrome	C0031190		Approved			CHEBI_28502	"10634"	MONDO_0022430	"10034708"	"233815004"
nitric oxide	DB00435	Persistent Fetal Circulation Syndrome	C0031190		Approved			CHEBI_16480	"7442"	MONDO_0022430	"10034708"	"233815004"
nitrogen	DB09152	Persistent Fetal Circulation Syndrome	C0031190		Approved			CHEBI_17997	"7456"	MONDO_0022430	"10034708"	"233815004"
sildenafil	DB00203	Persistent Fetal Circulation Syndrome	C0031190	NCT01360671	Withdrawn	Phase 2		CHEBI_9139	"136411"	MONDO_0022430	"10034708"	"233815004"
pregabalin	DB00230	Postherpetic neuralgia	C0032768	NCT01058642	Terminated	Phase 2		CHEBI_64356	"187832"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
pregabalin	DB00230	Postherpetic neuralgia	C0032768	NCT00352651	Terminated	Phase 2	"This study should be terminated as the study has been closed for years and the investigator has since retired. No records are available.

Thank you, Marlene"	CHEBI_64356	"187832"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
pregabalin	DB00230	Postherpetic neuralgia	C0032768		Approved			CHEBI_64356	"187832"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
gabapentin enacarbil	DB08872	Postherpetic neuralgia	C0032768		Approved			CHEBI_68840	"1101333"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
gabapentin enacarbil	DB00996	Postherpetic neuralgia	C0032768		Approved			CHEBI_42797	"25480"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
capsaicin	DB06774	Postherpetic neuralgia	C0032768		Approved			CHEBI_3374	"1992"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
lidocaine	DB00281	Postherpetic neuralgia	C0032768		Approved			CHEBI_6456	"6387"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
gabapentin	DB00996	Postherpetic neuralgia	C0032768		Approved			CHEBI_42797	"25480"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
mirogabalin	DB11825	Postherpetic neuralgia	C0032768		Approved					MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
etoricoxib	DB01628	Postherpetic neuralgia	C0032768	NCT01088256	Terminated	Phase 2		CHEBI_6339	"307296"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
valaciclovir	DB00577	Postherpetic neuralgia	C0032768	NCT02412917	Terminated	Phase 3		CHEBI_35854	"73645"	MONDO_0014151|MONDO_0041052	"10036376"	"2177002"
imatinib	DB00619	Pulmonary Edema	C0034063	NCT04794088	Terminated	Phase 2	Due to the decline of COVID-19 patients on Dutch ICUs. A sample size reestimation based on blinded study data of 66 patients was furthermore favorable, indicating sufficient power to detect a difference in primary endpoint between groups.	CHEBI_45783	"282388"	MONDO_0006932	"10037423"	"19242006"
trimetaphan	DB01116	Pulmonary Edema	C0034063		Approved			CHEBI_9728	"10828"	MONDO_0006932	"10037423"	"19242006"
ribavirin	DB00811	Respiratory Syncytial Virus Infections	C0035235		Approved			CHEBI_63580	"9344"	MONDO_0001577	"10061603"	"55735004"
palivizumab	DB00110	Respiratory Syncytial Virus Infections	C0035235		Approved				"194279"	MONDO_0001577	"10061603"	"55735004"
sodium thiosalicylate	DB14026	Rheumatic Fever	C0035436		Approved			CHEBI_59124		MONDO_0017767	"10039054"	"58718002"
calcifediol	DB00146	Rickets	C0035579		Approved			CHEBI_17933	"1855064|1889"	MONDO_0005520	"10039119"	"41345002"
dihydrotachysterol	DB01070	Rickets	C0035579		Approved			CHEBI_4591	"3429"	MONDO_0005520	"10039119"	"41345002"
calcitriol	DB00136	Rickets	C0035579	NCT00001151	Terminated	Phase 2	Terminated because of lack of drug supply	CHEBI_17823	"1894"	MONDO_0005520	"10039119"	"41345002"
ergocalciferol	DB11094	Rickets	C0035579		Approved			CHEBI_28934	"11253"	MONDO_0005520	"10039119"	"41345002"
ergocalciferol	DB00153	Rickets	C0035579		Approved			CHEBI_28934	"4018"	MONDO_0005520	"10039119"	"41345002"
colecalciferol	DB00169	Rickets	C0035579		Approved			CHEBI_28940	"2418"	MONDO_0005520	"10039119"	"41345002"
sorafenib	DB00398	Kaposi Sarcoma	C0036220	NCT00287495	Terminated	Phase 1		CHEBI_50924	"495881"	HP:0100726	"10023284"	"109385007"
doxorubicin	DB00997	Kaposi Sarcoma	C0036220		Approved			CHEBI_28748	"142433|3639"	HP:0100726	"10023284"	"109385007"
vinblastine	DB00570	Kaposi Sarcoma	C0036220		Approved			CHEBI_27375	"11198"	HP:0100726	"10023284"	"109385007"
daunorubicin	DB00694	Kaposi Sarcoma	C0036220		Approved			CHEBI_41977	"214468|3109"	HP:0100726	"10023284"	"109385007"
paclitaxel	DB01229	Kaposi Sarcoma	C0036220		Approved			CHEBI_45863	"56946"	HP:0100726	"10023284"	"109385007"
praziquantel	DB01058	Schistosomiasis	C0036323		Approved			CHEBI_91583	"8628"	MONDO_0015254	"10039603"	"10087007"
oxamniquine	DB01096	Schistosomiasis	C0036323		Approved			CHEBI_78416	"7778"	MONDO_0015254	"10039603"	"10087007"
stibophen	DB13236	Schistosomiasis	C0036323		Approved					MONDO_0015254	"10039603"	"10087007"
prednisone	DB00635	Dermatologic disorders	C0037274		Approved			CHEBI_8382	"8640"		"10040831"	"95320005"
triamcinolone	DB00620	Dermatologic disorders	C0037274		Approved			CHEBI_9667	"10759"		"10040831"	"95320005"
triamcinolone diacetate	DB00620	Dermatologic disorders	C0037274		Approved			CHEBI_9667	"10759"		"10040831"	"95320005"
dexpanthenol	DB09357	Dermatologic disorders	C0037274		Approved			CHEBI_27373	"22701"		"10040831"	"95320005"
prednisolone	DB00860	Dermatologic disorders	C0037274		Approved			CHEBI_8378	"8638"		"10040831"	"95320005"
methylprednisolone	DB00959	Dermatologic disorders	C0037274		Approved			CHEBI_6888	"6902"		"10040831"	"95320005"
betamethasone	DB00443	Dermatologic disorders	C0037274		Approved			CHEBI_3077	"1514"		"10040831"	"95320005"
cortisone acetate	DB01380	Dermatologic disorders	C0037274		Approved			CHEBI_3897	"21655"		"10040831"	"95320005"
dexamethasone	DB01234	Dermatologic disorders	C0037274		Approved			CHEBI_41879	"3264"		"10040831"	"95320005"
benzylpenicillin	DB01053	Tetanus	C0039614		Approved			CHEBI_18208	"7980"	MONDO_0005526	"10043376"	"76902006"
diazepam	DB00829	Tetanus	C0039614		Approved			CHEBI_49575	"3322"	MONDO_0005526	"10043376"	"76902006"
	DB06822	Thrombosis	C0040053	NCT01817257	Terminated	Phase 2	Early findings showed trial was not feasible		"69646|104466"		"10043607"	"118927008"
	DB09258	Thrombosis	C0040053	NCT01817257	Terminated	Phase 2	Early findings showed trial was not feasible		"280611"		"10043607"	"118927008"
	DB00682	Thrombosis	C0040053	NCT02872649	Terminated	Phase 2	safety reasons	CHEBI_87732	"11289"		"10043607"	"118927008"
acetylsalicylic acid	DB00945	Thrombosis	C0040053	NCT02807441	Withdrawn	Phase 3		CHEBI_15365	"91101|1191"		"10043607"	"118927008"
phenprocoumon	DB00946	Thrombosis	C0040053	NCT02872649	Terminated	Phase 2	safety reasons	CHEBI_50438	"8150"		"10043607"	"118927008"
phenprocoumon	DB00946	Thrombosis	C0040053		Approved			CHEBI_50438	"8150"		"10043607"	"118927008"
dicoumarol	DB00266	Thrombosis	C0040053		Approved			CHEBI_4513	"1598"		"10043607"	"118927008"
warfarin	DB00682	Thrombosis	C0040053		Approved			CHEBI_87732	"11289"		"10043607"	"118927008"
heparin	DB01109	Thrombosis	C0040053	NCT01817257	Terminated	Phase 2	Early findings showed trial was not feasible	CHEBI_28304	"5224"		"10043607"	"118927008"
	DB01225	Thrombosis	C0040053	NCT01817257	Terminated	Phase 2	Early findings showed trial was not feasible		"67108"		"10043607"	"118927008"
betamethasone acetate	DB00443	Trichinellosis	C0040896		Approved			CHEBI_3077	"1514"		"10044608"	"709018004"
hydrocortisone	DB00741	Trichinellosis	C0040896		Approved			CHEBI_17650	"5492"		"10044608"	"709018004"
triamcinolone diacetate	DB00620	Trichinellosis	C0040896		Approved			CHEBI_9667	"10759"		"10044608"	"709018004"
betamethasone	DB00443	Trichinellosis	C0040896		Approved			CHEBI_3077	"1514"		"10044608"	"709018004"
thiabendazole	DB00730	Trichinellosis	C0040896		Approved			CHEBI_45979	"10450"		"10044608"	"709018004"
cortisone acetate	DB01380	Trichinellosis	C0040896		Approved			CHEBI_3897	"21655"		"10044608"	"709018004"
dexamethasone	DB01234	Trichinellosis	C0040896		Approved			CHEBI_41879	"3264"		"10044608"	"709018004"
hydrocortisone succinate	DB14545	Trichinellosis	C0040896		Approved			CHEBI_31677	"21651"		"10044608"	"709018004"
prednisone	DB00635	Trichinellosis	C0040896		Approved			CHEBI_8382	"8640"		"10044608"	"709018004"
methylprednisolone	DB00959	Trichinellosis	C0040896		Approved			CHEBI_6888	"6902"		"10044608"	"709018004"
hydrocortisone acetate	DB14539	Trichinellosis	C0040896		Approved			CHEBI_17609	"27197"		"10044608"	"709018004"
hydrocortisone acetate	DB00741	Trichinellosis	C0040896		Approved			CHEBI_17650	"5492"		"10044608"	"709018004"
hydrocortisone succinate	DB00741	Trichinellosis	C0040896		Approved			CHEBI_17650	"5492"		"10044608"	"709018004"
triamcinolone acetonide	DB00620	Trichinellosis	C0040896		Approved			CHEBI_9667	"10759"		"10044608"	"709018004"
fusidic acid	DB02703	Typhus, Epidemic Louse-Borne	C0041473		Approved			CHEBI_29013	"4608|113608"		"10014979"	"39111003"
doxycycline	DB00254	Typhus, Epidemic Louse-Borne	C0041473		Approved			CHEBI_50845	"1545992|3640"		"10014979"	"39111003"
sodium bicarbonate	DB01390	Upper gastrointestinal hemorrhage	C0041909		Approved			CHEBI_32139	"36676"		"10046274"	"37372002"
omeprazole	DB00338	Upper gastrointestinal hemorrhage	C0041909		Approved			CHEBI_77260	"7646"		"10046274"	"37372002"
amphotericin B	DB00681	Vulvovaginitis	C0042998	NCT03167957	Withdrawn	Phase 2	No longer target indication	CHEBI_2682	"236594|732"	MONDO_0007019	"10047794"	"53277000"
sulfathiazole	DB06147	Vulvovaginitis	C0042998		Approved			CHEBI_9337	"10193"	MONDO_0007019	"10047794"	"53277000"
sulfabenzamide	DB09355	Vulvovaginitis	C0042998		Approved			CHEBI_94677	"37320"	MONDO_0007019	"10047794"	"53277000"
sulfacetamide	DB00634	Vulvovaginitis	C0042998		Approved			CHEBI_63845	"10169"	MONDO_0007019	"10047794"	"53277000"
sulfanilamide	DB00259	Vulvovaginitis	C0042998		Approved			CHEBI_45373	"10184"	MONDO_0007019	"10047794"	"53277000"
metronidazole	DB00916	Bacterial Vaginosis	C0085166	NCT03769688	Withdrawn	Phase 1	Replaced with different study at another site.	CHEBI_6909	"6922"	MONDO_0005316	"10004055"	"419760006"
metronidazole	DB00916	Bacterial Vaginosis	C0085166		Approved			CHEBI_6909	"6922"	MONDO_0005316	"10004055"	"419760006"
metronidazole	DB00916	Bacterial Vaginosis	C0085166	NCT00741845	Terminated	Phase 3	Terminated for site documentation and monitoring issues - not safety, study drug, or adverse event issues.	CHEBI_6909	"6922"	MONDO_0005316	"10004055"	"419760006"
	DB01220	Bacterial Vaginosis	C0085166	NCT02376972	Terminated	Phase 2	According to the Recommendation of the Indipendent Data Monitoring Committee	CHEBI_75246	"35619"	MONDO_0005316	"10004055"	"419760006"
	DB15759	Bacterial Vaginosis	C0085166	NCT02376972	Terminated	Phase 2	According to the Recommendation of the Indipendent Data Monitoring Committee	CHEBI_50688		MONDO_0005316	"10004055"	"419760006"
clindamycin	DB01190	Bacterial Vaginosis	C0085166		Approved			CHEBI_3745	"2582"	MONDO_0005316	"10004055"	"419760006"
	DB15759	Bacterial Vaginosis	C0085166	NCT00741845	Terminated	Phase 3	Terminated for site documentation and monitoring issues - not safety, study drug, or adverse event issues.	CHEBI_50688		MONDO_0005316	"10004055"	"419760006"
metronidazole	DB00916	Bacterial Vaginosis	C0085166	NCT02376972	Terminated	Phase 2	According to the Recommendation of the Indipendent Data Monitoring Committee	CHEBI_6909	"6922"	MONDO_0005316	"10004055"	"419760006"
metronidazole	DB00916	Bacterial Vaginosis	C0085166	NCT01762670	Terminated	Phase 1/Phase 2	Company decided to stop study for reasons other than safety	CHEBI_6909	"6922"	MONDO_0005316	"10004055"	"419760006"
secnidazole	DB12834	Bacterial Vaginosis	C0085166		Approved			CHEBI_94433	"36314"	MONDO_0005316	"10004055"	"419760006"
tinidazole	DB00911	Bacterial Vaginosis	C0085166		Approved			CHEBI_63627	"10612"	MONDO_0005316	"10004055"	"419760006"
metronidazole	DB15759	Bacterial Vaginosis	C0085166		Approved			CHEBI_50688		MONDO_0005316	"10004055"	"419760006"
	DB15759	Bacterial Vaginosis	C0085166	NCT03769688	Withdrawn	Phase 1	Replaced with different study at another site.	CHEBI_50688		MONDO_0005316	"10004055"	"419760006"
	DB15759	Bacterial Vaginosis	C0085166	NCT01762670	Terminated	Phase 1/Phase 2	Company decided to stop study for reasons other than safety	CHEBI_50688		MONDO_0005316	"10004055"	"419760006"
aztreonam	DB00355	Serratia Infections	C0085394		Approved			CHEBI_161680	"1272"		"10061512"	"71120004"
fusidic acid	DB02703	Serratia Infections	C0085394		Approved			CHEBI_29013	"4608|113608"		"10061512"	"71120004"
piperacillin	DB00319	Serratia Infections	C0085394		Approved			CHEBI_8232	"1546000|8339"		"10061512"	"71120004"
gentamicin	DB00798	Serratia Infections	C0085394		Approved			CHEBI_17833	"1596450"		"10061512"	"71120004"
cefotaxime	DB00493	Serratia Infections	C0085394		Approved			CHEBI_204928	"2186"		"10061512"	"71120004"
tobramycin	DB00684	Serratia Infections	C0085394		Approved			CHEBI_28864	"10627"		"10061512"	"71120004"
ceftizoxime	DB01332	Serratia Infections	C0085394		Approved			CHEBI_553473	"2192"		"10061512"	"71120004"
ticarcillin	DB01607	Serratia Infections	C0085394		Approved			CHEBI_9587	"10591"		"10061512"	"71120004"
ceftriaxone	DB01212	Serratia Infections	C0085394		Approved			CHEBI_29007	"2193"		"10061512"	"71120004"
amikacin	DB00479	Serratia Infections	C0085394		Approved			CHEBI_2637	"641"		"10061512"	"71120004"
azlocillin	DB01061	Serratia Infections	C0085394		Approved			CHEBI_2956	"1266"		"10061512"	"71120004"
amphotericin B	DB00681	Meningitis, Fungal	C0085438		Approved			CHEBI_2682	"236594|732"	MONDO_0006764	"10027236"	"24321005"
orazamide	DB06143	Liver Failure	C0085605		Approved			CHEBI_2030		HP:0001399	"10019663"	"59927004"
dexamethasone	DB01234	Addisonian crisis	C0151467		Approved			CHEBI_41879	"3264"	MONDO_0019801	"10001389"	"24867002"
methylprednisolone	DB00959	Addisonian crisis	C0151467		Approved			CHEBI_6888	"6902"	MONDO_0019801	"10001389"	"24867002"
triamcinolone diacetate	DB00620	Addisonian crisis	C0151467		Approved			CHEBI_9667	"10759"	MONDO_0019801	"10001389"	"24867002"
prednisolone	DB00860	Addisonian crisis	C0151467		Approved			CHEBI_8378	"8638"	MONDO_0019801	"10001389"	"24867002"
betamethasone	DB00443	Addisonian crisis	C0151467		Approved			CHEBI_3077	"1514"	MONDO_0019801	"10001389"	"24867002"
hydrocortisone succinate	DB14545	Addisonian crisis	C0151467		Approved			CHEBI_31677	"21651"	MONDO_0019801	"10001389"	"24867002"
cortisone acetate	DB01380	Addisonian crisis	C0151467		Approved			CHEBI_3897	"21655"	MONDO_0019801	"10001389"	"24867002"
hydrocortisone	DB00741	Addisonian crisis	C0151467		Approved			CHEBI_17650	"5492"	MONDO_0019801	"10001389"	"24867002"
triamcinolone acetonide	DB00620	Addisonian crisis	C0151467		Approved			CHEBI_9667	"10759"	MONDO_0019801	"10001389"	"24867002"
betamethasone acetate	DB00443	Addisonian crisis	C0151467		Approved			CHEBI_3077	"1514"	MONDO_0019801	"10001389"	"24867002"
hydrocortisone succinate	DB00741	Addisonian crisis	C0151467		Approved			CHEBI_17650	"5492"	MONDO_0019801	"10001389"	"24867002"
triamcinolone	DB00620	Addisonian crisis	C0151467		Approved			CHEBI_9667	"10759"	MONDO_0019801	"10001389"	"24867002"
hydrocortisone acetate	DB14539	Addisonian crisis	C0151467		Approved			CHEBI_17609	"27197"	MONDO_0019801	"10001389"	"24867002"
hydrocortisone acetate	DB00741	Addisonian crisis	C0151467		Approved			CHEBI_17650	"5492"	MONDO_0019801	"10001389"	"24867002"
alatrofloxacin	DB09335	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_135829	"141440"		"10035731"	"41381004"
ticarcillin	DB01607	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_9587	"10591"		"10035731"	"41381004"
tobramycin	DB00684	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_28864	"10627"		"10035731"	"41381004"
cefotaxime	DB00493	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_204928	"2186"		"10035731"	"41381004"
ofloxacin	DB01165	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_7731	"7623"		"10035731"	"41381004"
fusidic acid	DB02703	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_29013	"4608|113608"		"10035731"	"41381004"
gentamicin	DB00798	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_17833	"1596450"		"10035731"	"41381004"
amikacin	DB00479	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_2637	"641"		"10035731"	"41381004"
cefepime	DB01413	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_478164	"20481"		"10035731"	"41381004"
ceftazidime	DB00438	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_3508	"2191|1545984"		"10035731"	"41381004"
ciprofloxacin	DB00537	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_192484	"2551"		"10035731"	"41381004"
mezlocillin	DB00948	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_6919	"6927"		"10035731"	"41381004"
aztreonam	DB00355	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_161680	"1272"		"10035731"	"41381004"
piperacillin	DB00319	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_8232	"1546000|8339"		"10035731"	"41381004"
norfloxacin	DB01059	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_100246	"7517"		"10035731"	"41381004"
trovafloxacin	DB00685	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_9763	"115552"		"10035731"	"41381004"
azlocillin	DB01061	Pneumonia due to Pseudomonas	C0155860		Approved			CHEBI_2956	"1266"		"10035731"	"41381004"
obiltoxaximab	DB05336	Inhalational anthrax	C0155866		Approved				"1746906"	MONDO_0016595	"10035667"	"11389007"
doxycycline	DB00254	Inhalational anthrax	C0155866		Approved			CHEBI_50845	"1545992|3640"	MONDO_0016595	"10035667"	"11389007"
benzylpenicillin	DB01053	Inhalational anthrax	C0155866		Approved			CHEBI_18208	"7980"	MONDO_0016595	"10035667"	"11389007"
fusidic acid	DB02703	Inhalational anthrax	C0155866		Approved			CHEBI_29013	"4608|113608"	MONDO_0016595	"10035667"	"11389007"
raxibacumab	DB08902	Inhalational anthrax	C0155866		Approved				"1366567"	MONDO_0016595	"10035667"	"11389007"
trastuzumab	DB00072	Malignant neoplasm of salivary gland	C0220636		Approved				"2289225|2103478|2174802|2280730|2107051|224905"	HP:0100684	"10061934"	"255072001"
osilodrostat	DB11837	Pituitary-dependent Cushing's disease	C0221406		Approved				"2286252"	MONDO_0009050|MONDO_0020528	"10035109"	"190502001"
zinc acetate	DB14487	Zinc deficiency	C0235950		Approved			CHEBI_62984	"1299637|58295"		"10048259"	"238124008"
cortisone acetate	DB01380	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_3897	"21655"		"10024794"	"64936001"
betamethasone	DB00443	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_3077	"1514"		"10024794"	"64936001"
prednisolone	DB00860	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_8378	"8638"		"10024794"	"64936001"
hydrocortisone acetate	DB14539	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_17609	"27197"		"10024794"	"64936001"
prednisone	DB00635	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_8382	"8640"		"10024794"	"64936001"
methylprednisolone	DB00959	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_6888	"6902"		"10024794"	"64936001"
dexamethasone	DB01234	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_41879	"3264"		"10024794"	"64936001"
triamcinolone diacetate	DB00620	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_9667	"10759"		"10024794"	"64936001"
triamcinolone acetonide	DB00620	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_9667	"10759"		"10024794"	"64936001"
betamethasone acetate	DB00443	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_3077	"1514"		"10024794"	"64936001"
triamcinolone	DB00620	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_9667	"10759"		"10024794"	"64936001"
hydrocortisone acetate	DB00741	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_17650	"5492"		"10024794"	"64936001"
hydrocortisone succinate	DB14545	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_31677	"21651"		"10024794"	"64936001"
hydrocortisone	DB00741	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_17650	"5492"		"10024794"	"64936001"
hydrocortisone succinate	DB00741	Simple Pulmonary Eosinophilia	C0242459		Approved			CHEBI_17650	"5492"		"10024794"	"64936001"
cenegermin	DB13926	Neurotrophic keratitis	C0339296		Approved				"2104332|2104331"	MONDO_0015290	"10069732"	"128080005"
sparfloxacin	DB01208	Chlamydial pneumonia	C0339959		Approved			CHEBI_9212	"18469"	MONDO_0025598	"10035673"	"233609002"
trovafloxacin	DB00685	Chlamydial pneumonia	C0339959		Approved			CHEBI_9763	"115552"	MONDO_0025598	"10035673"	"233609002"
azithromycin	DB00207	Chlamydial pneumonia	C0339959		Approved			CHEBI_2955	"18631"	MONDO_0025598	"10035673"	"233609002"
norfloxacin	DB01059	Chlamydial pneumonia	C0339959		Approved			CHEBI_100246	"7517"	MONDO_0025598	"10035673"	"233609002"
erythromycin	DB00199	Chlamydial pneumonia	C0339959		Approved			CHEBI_42355	"4053"	MONDO_0025598	"10035673"	"233609002"
telithromycin	DB00976	Chlamydial pneumonia	C0339959		Approved			CHEBI_29688	"274786"	MONDO_0025598	"10035673"	"233609002"
gemifloxacin	DB01155	Chlamydial pneumonia	C0339959		Approved			CHEBI_101853	"138099"	MONDO_0025598	"10035673"	"233609002"
gatifloxacin	DB01044	Chlamydial pneumonia	C0339959		Approved			CHEBI_5280	"228476|1546025"	MONDO_0025598	"10035673"	"233609002"
ofloxacin	DB01165	Chlamydial pneumonia	C0339959		Approved			CHEBI_7731	"7623"	MONDO_0025598	"10035673"	"233609002"
moxifloxacin	DB00218	Chlamydial pneumonia	C0339959		Approved			CHEBI_63611	"139462"	MONDO_0025598	"10035673"	"233609002"
clarithromycin	DB01211	Chlamydial pneumonia	C0339959		Approved			CHEBI_3732	"21212"	MONDO_0025598	"10035673"	"233609002"
alatrofloxacin	DB09335	Chlamydial pneumonia	C0339959		Approved			CHEBI_135829	"141440"	MONDO_0025598	"10035673"	"233609002"
levofloxacin	DB01137	Chlamydial pneumonia	C0339959		Approved			CHEBI_63598	"1546009|82122"	MONDO_0025598	"10035673"	"233609002"
ampicillin	DB00415	Staphylococcal endocarditis	C0520767		Approved			CHEBI_28971	"733|221058"		"10014684"	"73028002"
vancomycin	DB00512	Staphylococcal endocarditis	C0520767		Approved			CHEBI_28001	"11124"		"10014684"	"73028002"
cefapirin	DB01139	Staphylococcal endocarditis	C0520767		Approved			CHEBI_554446	"2238"		"10014684"	"73028002"
nafcillin	DB00607	Staphylococcal endocarditis	C0520767		Approved			CHEBI_7447	"7233"		"10014684"	"73028002"
oxacillin	DB00713	Staphylococcal endocarditis	C0520767		Approved			CHEBI_7809	"7773"		"10014684"	"73028002"
bimekizumab	DB12917	Erythrodermic psoriasis	C0748052		Approved				"2668041"		"10015278"	"200977004"
methotrexate	DB00563	Erythrodermic psoriasis	C0748052		Approved			CHEBI_44185	"6851"		"10015278"	"200977004"
risankizumab	DB14762	Erythrodermic psoriasis	C0748052		Approved				"2166132|2166040"		"10015278"	"200977004"
infliximab	DB00065	Erythrodermic psoriasis	C0748052		Approved				"1790539|1927283|191831|2266523|2103476"		"10015278"	"200977004"
certolizumab pegol	DB08904	Erythrodermic psoriasis	C0748052		Approved				"709271"		"10015278"	"200977004"
ixekizumab	DB11569	Erythrodermic psoriasis	C0748052		Approved				"1745099"		"10015278"	"200977004"
	DB00571	Malignant melanoma, metastatic	C0860594	NCT01705392	Terminated	Phase 2	Lack of financing of the study drug. Not sufficient financial support.	CHEBI_8499	"8787"		"10027480"	"443493003"
trametinib	DB08911	Malignant melanoma, metastatic	C0860594		Approved			CHEBI_75998	"1425099"		"10027480"	"443493003"
dacarbazine	DB00851	Malignant melanoma, metastatic	C0860594		Approved			CHEBI_4305	"3098"		"10027480"	"443493003"
ipilimumab	DB06186	Malignant melanoma, metastatic	C0860594		Approved				"1094833"		"10027480"	"443493003"
	DB00851	Malignant melanoma, metastatic	C0860594	NCT01705392	Terminated	Phase 2	Lack of financing of the study drug. Not sufficient financial support.	CHEBI_4305	"3098"		"10027480"	"443493003"
	DB00112	Malignant melanoma, metastatic	C0860594	NCT01705392	Terminated	Phase 2	Lack of financing of the study drug. Not sufficient financial support.		"253337|2046138"		"10027480"	"443493003"
	DB09477	Malignant melanoma, metastatic	C0860594	NCT01705392	Terminated	Phase 2	Lack of financing of the study drug. Not sufficient financial support.	CHEBI_4786	"1545989|3829"		"10027480"	"443493003"
nivolumab	DB09035	Malignant melanoma, metastatic	C0860594		Approved				"1597876"		"10027480"	"443493003"
enalapril	DB00584	Malignant melanoma, metastatic	C0860594	NCT01705392	Terminated	Phase 2	Lack of financing of the study drug. Not sufficient financial support.	CHEBI_4784	"3827"		"10027480"	"443493003"
cobimetinib	DB05239	Malignant melanoma, metastatic	C0860594		Approved			CHEBI_90851	"1722365"		"10027480"	"443493003"
sunitinib	DB01268	Malignant melanoma, metastatic	C0860594	NCT00304200	Terminated	Phase 1/Phase 2	Funding was inadequate to continue; Companies requested closure.	CHEBI_38940	"357977"		"10027480"	"443493003"
	DB00853	Malignant melanoma, metastatic	C0860594	NCT00304200	Terminated	Phase 1/Phase 2	Funding was inadequate to continue; Companies requested closure.	CHEBI_72564	"37776"		"10027480"	"443493003"
dabrafenib	DB08912	Malignant melanoma, metastatic	C0860594		Approved			CHEBI_75045	"1424911"		"10027480"	"443493003"
binimetinib	DB11967	Malignant melanoma, metastatic	C0860594		Approved			CHEBI_145371	"2049122"		"10027480"	"443493003"
pembrolizumab	DB09037	Malignant melanoma, metastatic	C0860594		Approved				"1547545"		"10027480"	"443493003"
temozolomide	DB00853	Malignant melanoma, metastatic	C0860594	NCT00961844	Terminated	Phase 1/Phase 2	Logistical problems	CHEBI_72564	"37776"		"10027480"	"443493003"
aldesleukin	DB00041	Malignant melanoma, metastatic	C0860594		Approved				"70223"		"10027480"	"443493003"
lutein	DB00137	Meibomian gland dysfunction	C1275684		Approved			CHEBI_28838	"11359"	HP:0025610	"10065062"	"397549002"
azithromycin	DB00207	Meibomian gland dysfunction	C1275684	NCT01797107	Withdrawn	Phase 2	Lack of enrollment	CHEBI_2955	"18631"	HP:0025610	"10065062"	"397549002"
brimonidine	DB00484	Meibomian gland dysfunction	C1275684	NCT02975557	Terminated	Phase 1/Phase 2	Slow accrual of subjects. May take longer than expected to complete the trial.	CHEBI_3175	"134615"	HP:0025610	"10065062"	"397549002"
methylprednisolone	DB00959	Microscopic Polyarteritis	C2347126	NCT01408836	Terminated	Phase 2/Phase 3	Completed	CHEBI_6888	"6902"	MONDO_0019124	"10063344"	"1144805008"
	DB00860	Microscopic Polyarteritis	C2347126	NCT01408836	Terminated	Phase 2/Phase 3	Completed	CHEBI_8378	"8638"	MONDO_0019124	"10063344"	"1144805008"
avacopan	DB15011	Microscopic Polyarteritis	C2347126		Approved				"2572100"	MONDO_0019124	"10063344"	"1144805008"
rituximab	DB00073	Microscopic Polyarteritis	C2347126		Approved				"2273510|2472325|121191|2105824"	MONDO_0019124	"10063344"	"1144805008"
	DB14644	Microscopic Polyarteritis	C2347126	NCT01408836	Terminated	Phase 2/Phase 3	Completed	CHEBI_135765		MONDO_0019124	"10063344"	"1144805008"
etodolac	DB00749	Juvenile arthritis	C3495559		Approved			CHEBI_4909	"24605"	HP:0005681	"10059176"	"410502007"
methotrexate	DB00563	Juvenile arthritis	C3495559		Approved			CHEBI_44185	"6851"	HP:0005681	"10059176"	"410502007"
prednisone	DB00635	Juvenile arthritis	C3495559		Approved			CHEBI_8382	"8640"	HP:0005681	"10059176"	"410502007"
betamethasone	DB00443	Juvenile arthritis	C3495559		Approved			CHEBI_3077	"1514"	HP:0005681	"10059176"	"410502007"
naproxen	DB00788	Juvenile arthritis	C3495559		Approved			CHEBI_7476	"7258"	HP:0005681	"10059176"	"410502007"
ibuprofen	DB01050	Juvenile arthritis	C3495559		Approved			CHEBI_5855	"5640"	HP:0005681	"10059176"	"410502007"
methylprednisolone	DB00959	Juvenile arthritis	C3495559		Approved			CHEBI_6888	"6902"	HP:0005681	"10059176"	"410502007"
infliximab	DB00065	Juvenile arthritis	C3495559	NCT00029042	Terminated	Phase 2			"1790539|1927283|191831|2266523|2103476"	HP:0005681	"10059176"	"410502007"
triamcinolone	DB00620	Juvenile arthritis	C3495559		Approved			CHEBI_9667	"10759"	HP:0005681	"10059176"	"410502007"
tocilizumab	DB06273	Juvenile arthritis	C3495559		Approved				"612865"	HP:0005681	"10059176"	"410502007"
etanercept	DB00005	Juvenile arthritis	C3495559	NCT00078806	Terminated	Phase 3	the study was terminated because of slow enrollment	CHEBI_4875	"214555|2103480|2462511"	HP:0005681	"10059176"	"410502007"
sulfasalazine	DB00244	Juvenile arthritis	C3495559		Approved			CHEBI_6775	"52582"	HP:0005681	"10059176"	"410502007"
denosumab	DB06643	Juvenile arthritis	C3495559	NCT02418273	Withdrawn	Phase 1/Phase 2	was not funded		"993449"	HP:0005681	"10059176"	"410502007"
prednisolone	DB00860	Juvenile arthritis	C3495559		Approved			CHEBI_8378	"8638"	HP:0005681	"10059176"	"410502007"
celecoxib	DB00482	Juvenile arthritis	C3495559		Approved			CHEBI_41423	"140587"	HP:0005681	"10059176"	"410502007"
dexibuprofen	DB09213	Juvenile arthritis	C3495559		Approved			CHEBI_43415		HP:0005681	"10059176"	"410502007"
triamcinolone diacetate	DB00620	Juvenile arthritis	C3495559		Approved			CHEBI_9667	"10759"	HP:0005681	"10059176"	"410502007"
sodium aurothiomalate	DB09276	Juvenile arthritis	C3495559		Approved			CHEBI_35864	"4981"	HP:0005681	"10059176"	"410502007"
rofecoxib	DB00533	Juvenile arthritis	C3495559		Approved			CHEBI_8887	"232158"	HP:0005681	"10059176"	"410502007"
aurothioglucose	DB09121	Juvenile arthritis	C3495559		Approved			CHEBI_2930	"4980"	HP:0005681	"10059176"	"410502007"
meloxicam	DB00814	Juvenile arthritis	C3495559		Approved			CHEBI_6741	"41493"	HP:0005681	"10059176"	"410502007"
lithium carbonate	DB14509	Juvenile arthritis	C3495559		Approved			CHEBI_6504	"42351"	HP:0005681	"10059176"	"410502007"
cortisone acetate	DB01380	Juvenile arthritis	C3495559		Approved			CHEBI_3897	"21655"	HP:0005681	"10059176"	"410502007"
	DB00005	Juvenile arthritis	C3495559	NCT03781375	Terminated	Phase 3			"214555|2103480|2462511"	HP:0005681	"10059176"	"410502007"
oxaprozin	DB00991	Juvenile arthritis	C3495559		Approved			CHEBI_7822	"32613"	HP:0005681	"10059176"	"410502007"
tolmetin	DB00500	Juvenile arthritis	C3495559		Approved			CHEBI_71941	"10636"	HP:0005681	"10059176"	"410502007"
methotrexate	DB00563	Juvenile arthritis	C3495559	NCT03781375	Terminated	Phase 3		CHEBI_44185	"6851"	HP:0005681	"10059176"	"410502007"
sulfasalazine	DB00795	Juvenile arthritis	C3495559		Approved			CHEBI_9334	"9524"	HP:0005681	"10059176"	"410502007"
ethinylestradiol	DB00977	Atrophy of vulva	C0156393		Approved			CHEBI_4903	"4124"	MONDO_0001932		"248861000"
ketamine	DB01221	Anxiety	C0003467	NCT05086250	Suspended	Early Phase 1	Study Drug supply shortage	CHEBI_6121	"6130"	HP:0000739	"10002855"	"48694002"
oxaflozane	DB13457	Anxiety	C0003467		Approved			CHEBI_135128		HP:0000739	"10002855"	"48694002"
fluticasone propionate	DB00588	Intrinsic asthma	C0155880		Approved			CHEBI_31441	"50121"	MONDO_0004765		"266361008"
etizolam	DB09166	Anxiety	C0003467		Approved			CHEBI_31583		HP:0000739	"10002855"	"48694002"
ethyl loflazepate	DB01545	Anxiety	C0003467		Approved			CHEBI_31573	"24524"	HP:0000739	"10002855"	"48694002"
oxazepam	DB00842	Anxiety	C0003467		Approved			CHEBI_7823	"7781"	HP:0000739	"10002855"	"48694002"
prazosin	DB00457	Anxiety	C0003467	NCT03894345	Suspended	Phase 1	COVID-19	CHEBI_8364	"8629"	HP:0000739	"10002855"	"48694002"
fluticasone propionate	DB13867	Intrinsic asthma	C0155880		Approved			CHEBI_5134	"41126"	MONDO_0004765		"266361008"
perazine	DB12710	Anxiety	C0003467		Approved			CHEBI_59118	"8042"	HP:0000739	"10002855"	"48694002"
doxepin	DB01142	Anxiety	C0003467		Approved			CHEBI_4710	"3638"	HP:0000739	"10002855"	"48694002"
amikacin	DB00479	Pneumonia due to Gram negative bacteria	C0854248		Approved			CHEBI_2637	"641"	MONDO_0041850		"430395005"
norethisterone	DB00717	Atrophy of vulva	C0156393		Approved			CHEBI_7627	"7514"	MONDO_0001932		"248861000"
norfloxacin	DB01059	Acute bacterial bronchitis	C0339933		Approved			CHEBI_100246	"7517"			"233598009"
piperacillin	DB00319	Proteus urinary tract infection	C0577709		Approved			CHEBI_8232	"1546000|8339"			"301012009"
proguanil	DB01131	Malaria, Falciparum	C0024535		Approved			CHEBI_8455	"2382"	MONDO_0005920		"248441000"
butropium	DB15968	Gastritis	C0017152		Approved			CHEBI_145697		MONDO_0004966	"10017853"	"4556007"
triamcinolone diacetate	DB00620	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_9667	"10759"	MONDO_0000004		"386584007"
trimethoprim	DB00440	Proteus urinary tract infection	C0577709		Approved			CHEBI_45924	"10829"			"301012009"
leucovorin	DB00650	Merkel cell carcinoma	C0007129	NCT03167164	Withdrawn	Phase 1/Phase 2	Trial not initiated	CHEBI_15640	"6313"	MONDO_0019210	"10029266"	"5052009"
	DB01101	Merkel cell carcinoma	C0007129	NCT02831179	Withdrawn	Phase 1	Loss of funding support	CHEBI_31348	"194000"	MONDO_0019210	"10029266"	"5052009"
hydroxocobalamin	DB00200	Toxic effect of cyanide	C0238080		Approved			CHEBI_27786	"5514"			"66207005"
prednisolone sodium phosphate	DB14631	Infective blepharitis	C0729587		Approved			CHEBI_145705	"34374"			"312219000"
prednisolone sodium phosphate	DB00860	Infective blepharitis	C0729587		Approved			CHEBI_8378	"8638"			"312219000"
tetracosactide	DB01284	Adrenal cortical hypofunction	C0405580		Approved			CHEBI_3901	"2890"	MONDO_0000004		"386584007"
quinine	DB00468	Malaria, Falciparum	C0024535		Approved			CHEBI_15854	"9071"	MONDO_0005920		"248441000"
cobalamin	DB14098	Toxic effect of cyanide	C0238080		Approved			CHEBI_30411				"66207005"
metreleptin	DB09046	Acquired partial lipodystrophy	C0220989		Approved				"1491625"	MONDO_0012104		"75659004"
ceritinib	DB09063	Anaplastic lymphoma kinase fusion oncogene positive non-small cell lung cancer	C5394780		Approved			CHEBI_78432	"1535457"			"830151004"
lefamulin	DB12825	Bronchopneumonia due to Haemophilus influenzae	C4040491		Approved				"2198944"			"10625231000119106"
cefepime	DB01413	Proteus urinary tract infection	C0577709		Approved			CHEBI_478164	"20481"			"301012009"
cefoxitin	DB01331	Proteus urinary tract infection	C0577709		Approved			CHEBI_209807	"2189"			"301012009"
cefpodoxime proxetil	DB01416	Proteus urinary tract infection	C0577709		Approved			CHEBI_3504	"20489"			"301012009"
cefpodoxime proxetil	DB01416	Acute bacterial bronchitis	C0339933		Approved			CHEBI_3504	"20489"			"233598009"
cefprozil	DB01150	Acute bacterial bronchitis	C0339933		Approved			CHEBI_3506	"1546020|19552"			"233598009"
cefalexin	DB00567	Proteus urinary tract infection	C0577709		Approved			CHEBI_3534	"2231|1299782"			"301012009"
cefapirin	DB01139	Proteus urinary tract infection	C0577709		Approved			CHEBI_554446	"2238"			"301012009"
cefradine	DB01333	Proteus urinary tract infection	C0577709		Approved			CHEBI_3547	"2239"			"301012009"
dantrolene	DB01219	Malignant hyperpyrexia due to anesthesia	C0024591		Approved			CHEBI_4317	"3105"	MONDO_0018493		"213026003"
nafamostat	DB12598	Cystic Fibrosis	C0010674		Approved			CHEBI_135466		MONDO_0009061	"10011762"	"190905008"
sitagliptin	DB01261	Cystic Fibrosis	C0010674	NCT00967798	Terminated	Phase 3	Could not achieve target enrollment	CHEBI_40237	"593411"	MONDO_0009061	"10011762"	"190905008"
elexacaftor	DB15444	Cystic Fibrosis	C0010674		Approved				"2256951"	MONDO_0009061	"10011762"	"190905008"
aztreonam	DB00355	Cystic Fibrosis	C0010674	NCT02730793	Terminated	Phase 2	terminated due to an inability to recruit study subjects	CHEBI_161680	"1272"	MONDO_0009061	"10011762"	"190905008"
dornase alfa	DB09551	Cystic Fibrosis	C0010674		Approved				"3210"	MONDO_0009061	"10011762"	"190905008"
dornase alfa	DB00003	Cystic Fibrosis	C0010674		Approved				"337623"	MONDO_0009061	"10011762"	"190905008"
minocycline	DB01017	Cystic Fibrosis	C0010674	NCT01349192	Terminated	Phase 2	Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects	CHEBI_50694	"6980"	MONDO_0009061	"10011762"	"190905008"
tobramycin	DB00684	Cystic Fibrosis	C0010674	NCT02888730	Terminated	Phase 3	No suffisant recruitment	CHEBI_28864	"10627"	MONDO_0009061	"10011762"	"190905008"
	DB00410	Cystic Fibrosis	C0010674	NCT01349192	Terminated	Phase 2	Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects	CHEBI_7025	"42372"	MONDO_0009061	"10011762"	"190905008"
	DB01045	Cystic Fibrosis	C0010674	NCT01349192	Terminated	Phase 2	Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects	CHEBI_71365	"9384"	MONDO_0009061	"10011762"	"190905008"
	DB01015	Cystic Fibrosis	C0010674	NCT01349192	Terminated	Phase 2	Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects	CHEBI_9332	"10180"	MONDO_0009061	"10011762"	"190905008"
	DB00440	Cystic Fibrosis	C0010674	NCT01349192	Terminated	Phase 2	Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects	CHEBI_45924	"10829"	MONDO_0009061	"10011762"	"190905008"
losartan	DB00678	Cystic Fibrosis	C0010674	NCT03206788	Terminated	Phase 2	due to slow enrollment and approval of the Trikafta for CF patients	CHEBI_6541	"52175"	MONDO_0009061	"10011762"	"190905008"
sitagliptin	DB01261	Cystic Fibrosis	C0010674	NCT01257464	Terminated	Phase 2	Lack of recruitment	CHEBI_40237	"593411"	MONDO_0009061	"10011762"	"190905008"
	DB00878	Cystic Fibrosis	C0010674	NCT01349192	Terminated	Phase 2	Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects	CHEBI_3614	"2358"	MONDO_0009061	"10011762"	"190905008"
vardenafil	DB00862	Cystic Fibrosis	C0010674	NCT01002534	Terminated	Phase 2	not yet started	CHEBI_46295	"306674"	MONDO_0009061	"10011762"	"190905008"
simvastatin	DB00641	Cystic Fibrosis	C0010674	NCT01092572	Withdrawn	Phase 1/Phase 2	Lack of funding	CHEBI_9150	"36567"	MONDO_0009061	"10011762"	"190905008"
tobramycin	DB00684	Cystic Fibrosis	C0010674	NCT00125346	Terminated	Phase 3	per Data Monitoring Committee recommendation	CHEBI_28864	"10627"	MONDO_0009061	"10011762"	"190905008"
amikacin	DB00479	Cystic Fibrosis	C0010674	NCT01315691	Withdrawn	Phase 3		CHEBI_2637	"641"	MONDO_0009061	"10011762"	"190905008"
nitric oxide	DB00435	Cystic Fibrosis	C0010674	NCT02498535	Terminated	Phase 2	Terminated for the safety of cystic fibrosis clinical trial subjects due to Covid-19.	CHEBI_16480	"7442"	MONDO_0009061	"10011762"	"190905008"
glycerol	DB09462	Cystic Fibrosis	C0010674	NCT02323100	Terminated	Phase 1/Phase 2	funding ended	CHEBI_17754	"4910"	MONDO_0009061	"10011762"	"190905008"
mannitol	DB00742	Cystic Fibrosis	C0010674		Approved			CHEBI_16899	"6628"	MONDO_0009061	"10011762"	"190905008"
misoprostol	DB00929	Postpartum Hemorrhage	C0032797		Approved			CHEBI_63610	"42331"	HP:0011891	"10036417"	"47821001"
aztreonam	DB00355	Cystic Fibrosis	C0010674	NCT03219164	Terminated	Phase 3	Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.	CHEBI_161680	"1272"	MONDO_0009061	"10011762"	"190905008"
vancomycin	DB00512	Cystic Fibrosis	C0010674	NCT01509339	Withdrawn	Phase 1	Lab unable to measure vancomycin levels in Sputum	CHEBI_28001	"11124"	MONDO_0009061	"10011762"	"190905008"
penicillamine	DB00859	Cystinuria	C0010691		Approved			CHEBI_7959	"7975"	MONDO_0009067	"10011778"	"85020001"
tiopronin	DB06823	Cystinuria	C0010691		Approved			CHEBI_32229	"6765"	MONDO_0009067	"10011778"	"85020001"
letermovir	DB12070	Cytomegalovirus Infections	C0010823		Approved				"1988648"	MONDO_0005132	"10011831"	"28944009"
eptacog alfa (activated)	DB00036	Factor VII Deficiency	C0015503		Approved				"4256|253149|2386863"	MONDO_0002244	"10016079"	"37193007"
gentamicin	DB00798	Folliculitis	C0016436		Approved			CHEBI_17833	"1596450"	HP:0025084	"10016936"	"721130001"
miconazole	DB01110	Folliculitis	C0016436	NCT01244256	Suspended	Phase 2/Phase 3		CHEBI_82892	"6932"	HP:0025084	"10016936"	"721130001"
	DB00257	Folliculitis	C0016436	NCT01244256	Suspended	Phase 2/Phase 3		CHEBI_3764	"2623"	HP:0025084	"10016936"	"721130001"
fusidic acid	DB02703	Folliculitis	C0016436		Approved			CHEBI_29013	"4608|113608"	HP:0025084	"10016936"	"721130001"
lidocaine	DB00281	Hemorrhoids	C0019112		Approved			CHEBI_6456	"6387"	MONDO_0004872	"10019022"	"70153002"
zinc oxide	DB09321	Hemorrhoids	C0019112		Approved			CHEBI_36560	"11423"	MONDO_0004872	"10019022"	"70153002"
pramocaine	DB09345	Hemorrhoids	C0019112		Approved			CHEBI_8357	"34347"	MONDO_0004872	"10019022"	"70153002"
hydrocortisone	DB00741	Hemorrhoids	C0019112		Approved			CHEBI_17650	"5492"	MONDO_0004872	"10019022"	"70153002"
zinc acetate	DB14487	Hemorrhoids	C0019112		Approved			CHEBI_62984	"1299637|58295"	MONDO_0004872	"10019022"	"70153002"
ferric oxide	DB11576	Hemorrhoids	C0019112		Approved			CHEBI_50819		MONDO_0004872	"10019022"	"70153002"
phenylephrine	DB00388	Hemorrhoids	C0019112		Approved			CHEBI_8093	"8163"	MONDO_0004872	"10019022"	"70153002"
cortisone acetate	DB01380	Hemorrhoids	C0019112		Approved			CHEBI_3897	"21655"	MONDO_0004872	"10019022"	"70153002"
hydrocortisone acetate	DB14539	Hemorrhoids	C0019112		Approved			CHEBI_17609	"27197"	MONDO_0004872	"10019022"	"70153002"
hydrocortisone acetate	DB00741	Hemorrhoids	C0019112		Approved			CHEBI_17650	"5492"	MONDO_0004872	"10019022"	"70153002"
phenylmercuric nitrate	DB13388	Hemorrhoids	C0019112		Approved			CHEBI_136021		MONDO_0004872	"10019022"	"70153002"
choline fenofibrate	DB13873	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_83469	"24852"	HP:0008158	"10045263"	"299465007"
ciprofibrate	DB09064	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_50867	"21149"	HP:0008158	"10045263"	"299465007"
fenofibrate	DB01039	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_5001	"8703"	HP:0008158	"10045263"	"299465007"
ezetimibe	DB00973	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_49040	"341248"	HP:0008158	"10045263"	"299465007"
rosuvastatin	DB01098	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_38545	"301542"	HP:0008158	"10045263"	"299465007"
lovastatin	DB00227	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_40303	"6472"	HP:0008158	"10045263"	"299465007"
pitavastatin	DB08860	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_32020	"861634"	HP:0008158	"10045263"	"299465007"
cerivastatin	DB00439	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_3558	"596723"	HP:0008158	"10045263"	"299465007"
atorvastatin	DB01076	Hyperlipidemia, Familial Combined	C0020474	NCT00134238	Terminated	Phase 3		CHEBI_39548	"83367"	HP:0008158	"10045263"	"299465007"
simvastatin	DB00641	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_9150	"36567"	HP:0008158	"10045263"	"299465007"
inositol	DB13178	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_17268	"5833"	HP:0008158	"10045263"	"299465007"
fluvastatin	DB01095	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_38562	"41127"	HP:0008158	"10045263"	"299465007"
nicotinic acid	DB00627	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_15940	"7393"	HP:0008158	"10045263"	"299465007"
atorvastatin	DB01076	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_39548	"83367"	HP:0008158	"10045263"	"299465007"
pravastatin	DB00175	Hyperlipidemia, Familial Combined	C0020474		Approved			CHEBI_63618	"42463"	HP:0008158	"10045263"	"299465007"
metronidazole	DB15759	Liver Abscess, Amebic	C0023886		Approved			CHEBI_50688			"10063741"	"75119003"
tinidazole	DB00911	Liver Abscess, Amebic	C0023886		Approved			CHEBI_63627	"10612"		"10063741"	"75119003"
metronidazole	DB00916	Liver Abscess, Amebic	C0023886		Approved			CHEBI_6909	"6922"		"10063741"	"75119003"
sirolimus	DB00877	Lymphangioma	C0024221		Approved			CHEBI_9168	"35302"	MONDO_0002013	"10025219"	"400178008"
estetrol	DB12235	Oral contraception	C0029151		Approved			CHEBI_142773	"2539031"		"10030970"	"5935008"
azathioprine	DB00993	Polyarteritis Nodosa	C0031036		Approved			CHEBI_2948	"1256"	MONDO_0014306|MONDO_0019170	"10036024"	"155441006"
sertraline	DB01104	Phobia, Social	C0031572		Approved			CHEBI_9123	"36437"		"10041242"	"25501002"
venlafaxine	DB00285	Phobia, Social	C0031572		Approved			CHEBI_9943	"39786"		"10041242"	"25501002"
fluvoxamine	DB00176	Phobia, Social	C0031572		Approved			CHEBI_5138	"42355"		"10041242"	"25501002"
paroxetine	DB00715	Phobia, Social	C0031572		Approved			CHEBI_7936	"32937"		"10041242"	"25501002"
oxytocin	DB00107	Postpartum Hemorrhage	C0032797	NCT02503319	Suspended	Phase 3	Authorization denied	CHEBI_7872	"7824"	HP:0011891	"10036417"	"47821001"
oxytocin	DB00107	Postpartum Hemorrhage	C0032797	NCT02999100	Terminated	Phase 1	Inability to reliably measure plasma oxytocin levels during third stage labour, regardless of administration method (intramuscular or inhaled).	CHEBI_7872	"7824"	HP:0011891	"10036417"	"47821001"
tranexamic acid	DB00302	Postpartum Hemorrhage	C0032797	NCT02026297	Terminated	Phase 2	funding and manpower unavailable, completion within a reasonable timeframe not possible.	CHEBI_48669	"10691"	HP:0011891	"10036417"	"47821001"
methylergometrine	DB00353	Postpartum Hemorrhage	C0032797	NCT03303235	Withdrawn	Early Phase 1	Collaborators left the institution.	CHEBI_92607	"6883"	HP:0011891	"10036417"	"47821001"
	DB00107	Postpartum Hemorrhage	C0032797	NCT01710566	Withdrawn	Phase 3			"7824"	HP:0011891	"10036417"	"47821001"
carboprost	DB00429	Postpartum Hemorrhage	C0032797		Approved			CHEBI_3404	"20259"	HP:0011891	"10036417"	"47821001"
	DB00302	Postpartum Hemorrhage	C0032797	NCT02503319	Suspended	Phase 3	Authorization denied	CHEBI_48669	"10691"	HP:0011891	"10036417"	"47821001"
misoprostol	DB00929	Postpartum Hemorrhage	C0032797	NCT01710566	Withdrawn	Phase 3		CHEBI_63610	"42331"	HP:0011891	"10036417"	"47821001"
oxytocin	DB00107	Postpartum Hemorrhage	C0032797		Approved			CHEBI_7872	"7824"	HP:0011891	"10036417"	"47821001"
methylergometrine	DB00353	Postpartum Hemorrhage	C0032797		Approved			CHEBI_92607	"6883"	HP:0011891	"10036417"	"47821001"
ergometrine	DB01253	Postpartum Hemorrhage	C0032797		Approved			CHEBI_4822	"4021"	HP:0011891	"10036417"	"47821001"
cetyl alcohol	DB09494	Respiratory Distress Syndrome, Newborn	C0035220		Approved			CHEBI_16125	"20615"	MONDO_0100077	"10028974"	"46775006"
lucinactant	DB04897	Respiratory Distress Syndrome, Newborn	C0035220		Approved				"1293254"	MONDO_0100077	"10028974"	"46775006"
tyloxapol	DB06439	Respiratory Distress Syndrome, Newborn	C0035220		Approved			CHEBI_141517	"38998"	MONDO_0100077	"10028974"	"46775006"
colfosceril palmitate	DB09114	Respiratory Distress Syndrome, Newborn	C0035220		Approved			CHEBI_72999	"69782"	MONDO_0100077	"10028974"	"46775006"
calfactant	DB06415	Respiratory Distress Syndrome, Newborn	C0035220		Approved				"232539"	MONDO_0100077	"10028974"	"46775006"
beractant	DB06761	Respiratory Distress Syndrome, Newborn	C0035220		Approved				"46967"	MONDO_0100077	"10028974"	"46775006"
poractant alfa	DB09113	Respiratory Distress Syndrome, Newborn	C0035220		Approved				"236381"	MONDO_0100077	"10028974"	"46775006"
rimonabant	DB06155	Schizoaffective Disorder	C0036337	NCT00547118	Terminated	Phase 2	Withdrawn due to medication withdrawal from the EMEA	CHEBI_34967			"10039621"	"191567000"
ceftriaxone	DB01212	Schizoaffective Disorder	C0036337	NCT00591318	Terminated	Phase 1/Phase 2	Study was terminated after enrolling 12 patients due to poor enrollment rates	CHEBI_29007	"2193"		"10039621"	"191567000"
olanzapine	DB00334	Schizoaffective Disorder	C0036337	NCT00440843	Withdrawn	Phase 3		CHEBI_7735	"61381"		"10039621"	"191567000"
	DB01238	Schizoaffective Disorder	C0036337	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_31236	"89013"		"10039621"	"191567000"
	DB00734	Schizoaffective Disorder	C0036337	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_8871	"35636"		"10039621"	"191567000"
	DB01267	Schizoaffective Disorder	C0036337	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_83804	"679314"		"10039621"	"191567000"
quetiapine	DB01224	Schizoaffective Disorder	C0036337	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_8707	"51272"		"10039621"	"191567000"
aripiprazole	DB01238	Schizoaffective Disorder	C0036337	NCT00288353	Terminated	Phase 3	unable to secure additional funding	CHEBI_31236	"89013"		"10039621"	"191567000"
bexarotene	DB00307	Schizoaffective Disorder	C0036337	NCT00534898	Withdrawn	Phase 3	The study withdrawn due to lack financial support	CHEBI_50859	"233272"		"10039621"	"191567000"
olanzapine	DB00334	Schizoaffective Disorder	C0036337	NCT00734435	Terminated	Phase 2	Sponsor Decision- Financial Considerations	CHEBI_7735	"61381"		"10039621"	"191567000"
	DB00734	Schizoaffective Disorder	C0036337	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_8871	"35636"		"10039621"	"191567000"
	DB01238	Schizoaffective Disorder	C0036337	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_31236	"89013"		"10039621"	"191567000"
paliperidone	DB01267	Schizoaffective Disorder	C0036337		Approved			CHEBI_83804	"679314"		"10039621"	"191567000"
olanzapine	DB00334	Schizoaffective Disorder	C0036337	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_7735	"61381"		"10039621"	"191567000"
	DB01224	Schizoaffective Disorder	C0036337	NCT02462473	Terminated	Phase 2	Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.	CHEBI_8707	"51272"		"10039621"	"191567000"
	DB00909	Schizoaffective Disorder	C0036337	NCT00734435	Terminated	Phase 2	Sponsor Decision- Financial Considerations	CHEBI_10127	"39998"		"10039621"	"191567000"
colecalciferol	DB00169	Schizoaffective Disorder	C0036337	NCT02197286	Withdrawn	Phase 2	Personnel changes at study site.	CHEBI_28940	"2418"		"10039621"	"191567000"
oxytocin	DB00107	Schizoaffective Disorder	C0036337	NCT02149823	Terminated	Phase 1	All study proceedings stopped prematurely due to Covid-19 restrictions for intranasal formulations	CHEBI_7872	"7824"		"10039621"	"191567000"
galantamine	DB00674	Schizoaffective Disorder	C0036337	NCT02234752	Terminated	Phase 2	Funding no longer available and PI no longer working at the institution	CHEBI_42944	"4637"		"10039621"	"191567000"
	DB01043	Schizoaffective Disorder	C0036337	NCT02234752	Terminated	Phase 2	Funding no longer available and PI no longer working at the institution	CHEBI_64312	"6719"		"10039621"	"191567000"
lorazepam	DB00186	Status Epilepticus	C0038220		Approved			CHEBI_6539	"6470"	MONDO_0002125	"10041962"	"230456007"
midazolam	DB00683	Status Epilepticus	C0038220		Approved			CHEBI_6931	"6960"	MONDO_0002125	"10041962"	"230456007"
	DB01202	Status Epilepticus	C0038220	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_6437	"114477"	MONDO_0002125	"10041962"	"230456007"
	DB00599	Status Epilepticus	C0038220	NCT00265616	Terminated	Phase 3	Insufficient recruitment	CHEBI_102166	"10493"	MONDO_0002125	"10041962"	"230456007"
	DB00818	Status Epilepticus	C0038220	NCT00265616	Terminated	Phase 3	Insufficient recruitment	CHEBI_44915	"8782"	MONDO_0002125	"10041962"	"230456007"
pentobarbital	DB00312	Status Epilepticus	C0038220	NCT00265616	Terminated	Phase 3	Insufficient recruitment	CHEBI_7983	"8004"	MONDO_0002125	"10041962"	"230456007"
	DB01174	Status Epilepticus	C0038220	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_8069	"8134"	MONDO_0002125	"10041962"	"230456007"
fosphenytoin	DB01320	Status Epilepticus	C0038220		Approved			CHEBI_5165	"72236"	MONDO_0002125	"10041962"	"230456007"
diazepam	DB00829	Status Epilepticus	C0038220		Approved			CHEBI_49575	"3322"	MONDO_0002125	"10041962"	"230456007"
secobarbital	DB00418	Status Epilepticus	C0038220		Approved			CHEBI_9073	"9624"	MONDO_0002125	"10041962"	"230456007"
phenytoin	DB00252	Status Epilepticus	C0038220		Approved			CHEBI_8107	"8183"	MONDO_0002125	"10041962"	"230456007"
	DB06218	Status Epilepticus	C0038220	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_135939	"623400"	MONDO_0002125	"10041962"	"230456007"
amobarbital	DB01351	Status Epilepticus	C0038220		Approved			CHEBI_2673	"719"	MONDO_0002125	"10041962"	"230456007"
lorazepam	DB00186	Status Epilepticus	C0038220	NCT00343096	Terminated	Phase 3	The buccal arm of the study was 30% less effective in stopping seizures within 10 minutes compared with the IV dose. This met a stopping rule for the study	CHEBI_6539	"6470"	MONDO_0002125	"10041962"	"230456007"
ketamine	DB01221	Status Epilepticus	C0038220	NCT02431663	Terminated	Phase 3	Futility	CHEBI_6121	"6130"	MONDO_0002125	"10041962"	"230456007"
pentobarbital	DB00312	Status Epilepticus	C0038220		Approved			CHEBI_7983	"8004"	MONDO_0002125	"10041962"	"230456007"
ketamine	DB01221	Status Epilepticus	C0038220	NCT02726867	Withdrawn	Phase 3	No participants enrolled	CHEBI_6121	"6130"	MONDO_0002125	"10041962"	"230456007"
landiolol	DB12212	Sinus Tachycardia	C0039239		Approved			CHEBI_135809		HP:0011703	"10040752"	"11092001"
cortisone acetate	DB01380	Tenosynovitis	C0039520		Approved			CHEBI_3897	"21655"	MONDO_0004855	"10043261"	"67801009"
dexamethasone	DB01234	Tenosynovitis	C0039520		Approved			CHEBI_41879	"3264"	MONDO_0004855	"10043261"	"67801009"
hydrocortisone acetate	DB14539	Tenosynovitis	C0039520		Approved			CHEBI_17609	"27197"	MONDO_0004855	"10043261"	"67801009"
indomethacin	DB00328	Tenosynovitis	C0039520		Approved			CHEBI_49662	"5781"	MONDO_0004855	"10043261"	"67801009"
betamethasone acetate	DB00443	Tenosynovitis	C0039520		Approved			CHEBI_3077	"1514"	MONDO_0004855	"10043261"	"67801009"
hydrocortisone succinate	DB14545	Tenosynovitis	C0039520		Approved			CHEBI_31677	"21651"	MONDO_0004855	"10043261"	"67801009"
prednisolone	DB00860	Tenosynovitis	C0039520		Approved			CHEBI_8378	"8638"	MONDO_0004855	"10043261"	"67801009"
methylprednisolone	DB00959	Tenosynovitis	C0039520		Approved			CHEBI_6888	"6902"	MONDO_0004855	"10043261"	"67801009"
triamcinolone	DB00620	Tenosynovitis	C0039520		Approved			CHEBI_9667	"10759"	MONDO_0004855	"10043261"	"67801009"
betamethasone	DB00443	Tenosynovitis	C0039520		Approved			CHEBI_3077	"1514"	MONDO_0004855	"10043261"	"67801009"
	DB01234	Tenosynovitis	C0039520	NCT02266433	Terminated	Phase 3	due to PI's change to private practice	CHEBI_41879	"3264"	MONDO_0004855	"10043261"	"67801009"
hydrocortisone	DB00741	Tenosynovitis	C0039520		Approved			CHEBI_17650	"5492"	MONDO_0004855	"10043261"	"67801009"
triamcinolone diacetate	DB00620	Tenosynovitis	C0039520		Approved			CHEBI_9667	"10759"	MONDO_0004855	"10043261"	"67801009"
hydrocortisone acetate	DB00741	Tenosynovitis	C0039520		Approved			CHEBI_17650	"5492"	MONDO_0004855	"10043261"	"67801009"
ketorolac	DB00465	Tenosynovitis	C0039520	NCT02266433	Terminated	Phase 3	due to PI's change to private practice	CHEBI_76223	"35827"	MONDO_0004855	"10043261"	"67801009"
triamcinolone acetonide	DB00620	Tenosynovitis	C0039520		Approved			CHEBI_9667	"10759"	MONDO_0004855	"10043261"	"67801009"
hydrocortisone succinate	DB00741	Tenosynovitis	C0039520		Approved			CHEBI_17650	"5492"	MONDO_0004855	"10043261"	"67801009"
diclofenac	DB00586	Tenosynovitis	C0039520		Approved			CHEBI_47381	"3355"	MONDO_0004855	"10043261"	"67801009"
cefpodoxime proxetil	DB01416	Tonsillitis	C0040425		Approved			CHEBI_3504	"20489"		"10044008"	"90176007"
cefradine	DB01333	Tonsillitis	C0040425		Approved			CHEBI_3547	"2239"		"10044008"	"90176007"
cefaclor	DB00833	Tonsillitis	C0040425		Approved			CHEBI_3478	"1450910|2176"		"10044008"	"90176007"
loracarbef	DB00447	Tonsillitis	C0040425		Approved			CHEBI_47544	"28981"		"10044008"	"90176007"
cefadroxil	DB01140	Tonsillitis	C0040425		Approved			CHEBI_3479	"1545975|2177"		"10044008"	"90176007"
azithromycin	DB00207	Tonsillitis	C0040425	NCT01919996	Terminated	Phase 2	See Termination Statement in the Detailed Description below	CHEBI_2955	"18631"		"10044008"	"90176007"
dirithromycin	DB00954	Tonsillitis	C0040425		Approved			CHEBI_474014			"10044008"	"90176007"
cefprozil	DB01150	Tonsillitis	C0040425		Approved			CHEBI_3506	"1546020|19552"		"10044008"	"90176007"
ceftibuten	DB01415	Tonsillitis	C0040425		Approved			CHEBI_3510	"20492"		"10044008"	"90176007"
cefixime	DB00671	Tonsillitis	C0040425		Approved			CHEBI_472657	"25033|1546021"		"10044008"	"90176007"
haloperidol	DB00502	Gilles de la Tourette syndrome	C0040517		Approved			CHEBI_5613	"5093"		"10044126"	"5158005"
pimozide	DB01100	Gilles de la Tourette syndrome	C0040517		Approved			CHEBI_8212	"8331"		"10044126"	"5158005"
methylprednisolone acetate	DB00959	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_6888	"6902"	MONDO_0043455	"10020584"	"47709007"
triamcinolone acetonide	DB00620	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_9667	"10759"	MONDO_0043455	"10020584"	"47709007"
hydrocortisone acetate	DB00741	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_17650	"5492"	MONDO_0043455	"10020584"	"47709007"
betamethasone acetate	DB00443	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_3077	"1514"	MONDO_0043455	"10020584"	"47709007"
dexamethasone	DB01234	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_41879	"3264"	MONDO_0043455	"10020584"	"47709007"
hydrocortisone succinate	DB00741	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_17650	"5492"	MONDO_0043455	"10020584"	"47709007"
betamethasone	DB00443	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_3077	"1514"	MONDO_0043455	"10020584"	"47709007"
methylprednisolone	DB00959	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_6888	"6902"	MONDO_0043455	"10020584"	"47709007"
zoledronic acid	DB00399	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_46557	"1546014|77655"	MONDO_0043455	"10020584"	"47709007"
hydrocortisone acetate	DB14539	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_17609	"27197"	MONDO_0043455	"10020584"	"47709007"
hydrocortisone	DB00741	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_17650	"5492"	MONDO_0043455	"10020584"	"47709007"
triamcinolone diacetate	DB00620	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_9667	"10759"	MONDO_0043455	"10020584"	"47709007"
pamidronic acid	DB00282	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_7903	"11473|1546406"	MONDO_0043455	"10020584"	"47709007"
acetoxolone	DB13640	Gastritis	C0017152		Approved			CHEBI_81306		MONDO_0004966	"10017853"	"4556007"
etidronic acid	DB01077	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_4907	"42682|1356715"	MONDO_0043455	"10020584"	"47709007"
hydrocortisone succinate	DB14545	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_31677	"21651"	MONDO_0043455	"10020584"	"47709007"
prednisone	DB00635	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_8382	"8640"	MONDO_0043455	"10020584"	"47709007"
cortisone acetate	DB01380	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_3897	"21655"	MONDO_0043455	"10020584"	"47709007"
prednisolone	DB00860	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_8378	"8638"	MONDO_0043455	"10020584"	"47709007"
incadronic acid	DB06255	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_135189		MONDO_0043455	"10020584"	"47709007"
triamcinolone	DB00620	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_9667	"10759"	MONDO_0043455	"10020584"	"47709007"
neridronic acid	DB11620	Humoral hypercalcemia of malignancy (disorder)	C0149911		Approved			CHEBI_135145		MONDO_0043455	"10020584"	"47709007"
acebutolol	DB01193	Premature ventricular contractions	C0151636		Approved			CHEBI_2379	"149"	HP:0006682	"10047289"	"251175005"
encainide	DB01228	Premature ventricular contractions	C0151636		Approved			CHEBI_4788	"42368"	HP:0006682	"10047289"	"251175005"
somatrem	DB09098	Growth retardation	C0151686		Approved				"56570"	HP:0001510	"10053759"	"444896005"
somatropin	DB00052	Growth retardation	C0151686		Approved				"61148|314845"	HP:0001510	"10053759"	"444896005"
magnesium carbonate	DB09481	Hypomagnesemia	C0151723		Approved			CHEBI_31793	"29155"	HP:0002917	"10021027"	"190855004"
magnesium sulfate	DB00653	Hypomagnesemia	C0151723		Approved			CHEBI_32599	"6585|1311625"	HP:0002917	"10021027"	"190855004"
magnesium chloride	DB09407	Hypomagnesemia	C0151723		Approved			CHEBI_6636	"1311539|6579"	HP:0002917	"10021027"	"190855004"
magnesium gluconate	DB13749	Hypomagnesemia	C0151723		Approved				"52358"	HP:0002917	"10021027"	"190855004"
magnesium lactate	DB14515	Hypomagnesemia	C0151723		Approved				"214688"	HP:0002917	"10021027"	"190855004"
magnesium aspartate	DB13359	Hypomagnesemia	C0151723		Approved					HP:0002917	"10021027"	"190855004"
magnesium oxide	DB01377	Hypomagnesemia	C0151723		Approved			CHEBI_31794	"6582"	HP:0002917	"10021027"	"190855004"
bleomycin	DB00290	Malignant neoplasm of penis	C0153601		Approved			CHEBI_22907	"1622"	MONDO_0001325	"10034299"	"363516004"
melatonin	DB01065	Acute myocardial infarction	C0155626	NCT00640094	Terminated	Phase 2		CHEBI_16796	"6711"	MONDO_0004781	"10000891"	"57054005"
tenecteplase	DB00031	Acute myocardial infarction	C0155626		Approved				"259280"	MONDO_0004781	"10000891"	"57054005"
nitric oxide	DB00435	Acute myocardial infarction	C0155626	NCT00568061	Terminated	Phase 2	Slow Enrollment	CHEBI_16480	"7442"	MONDO_0004781	"10000891"	"57054005"
heparin	DB01109	Acute myocardial infarction	C0155626	NCT02565147	Terminated	Phase 3	Futility at the interim analysis.	CHEBI_28304	"5224"	MONDO_0004781	"10000891"	"57054005"
ciclosporin	DB00091	Acute myocardial infarction	C0155626	NCT01901471	Withdrawn	Phase 2		CHEBI_4031	"3008"	MONDO_0004781	"10000891"	"57054005"
alteplase	DB00009	Acute myocardial infarction	C0155626		Approved				"8410"	MONDO_0004781	"10000891"	"57054005"
abciximab	DB00054	Acute myocardial infarction	C0155626	NCT00894023	Terminated	Phase 3	the study was stopped because the sample size was very difficult to achieve.		"83929"	MONDO_0004781	"10000891"	"57054005"
reteplase	DB00015	Acute myocardial infarction	C0155626		Approved				"76895"	MONDO_0004781	"10000891"	"57054005"
phenylbutanoic acid	DB06819	Citrullinemia	C0175683		Approved			CHEBI_41500	"1546447|81647"	MONDO_0015991	"10058298"	"398680004"
tazemetostat	DB12887	Sarcoma, Epithelioid	C0205944		Approved				"2274378"	MONDO_0017387	"10015099"	"59238007"
pantoprazole	DB00213	Erosive esophagitis	C0267055		Approved			CHEBI_7915	"40790"		"10063655"	"40719004"
dexlansoprazole	DB05351	Erosive esophagitis	C0267055		Approved			CHEBI_135931	"816346"		"10063655"	"40719004"
ranitidine	DB00863	Erosive esophagitis	C0267055		Approved			CHEBI_92246	"9143"		"10063655"	"40719004"
omeprazole	DB00338	Erosive esophagitis	C0267055		Approved			CHEBI_77260	"7646"		"10063655"	"40719004"
lansoprazole	DB00448	Erosive esophagitis	C0267055	NCT02873702	Terminated	Phase 3	Compound is not expected to change the current treatment practice or fill significant clinical need for patients in China over currently available EE agents.	CHEBI_6375	"17128"		"10063655"	"40719004"
lansoprazole	DB00448	Erosive esophagitis	C0267055		Approved			CHEBI_6375	"17128"		"10063655"	"40719004"
dexrabeprazole	DB13762	Erosive esophagitis	C0267055		Approved			CHEBI_134729			"10063655"	"40719004"
famotidine	DB00927	Erosive esophagitis	C0267055		Approved			CHEBI_4975	"4278"		"10063655"	"40719004"
	DB05351	Erosive esophagitis	C0267055	NCT02873702	Terminated	Phase 3	Compound is not expected to change the current treatment practice or fill significant clinical need for patients in China over currently available EE agents.	CHEBI_135931	"816346"		"10063655"	"40719004"
esomeprazole	DB00338	Erosive esophagitis	C0267055		Approved			CHEBI_77260	"7646"		"10063655"	"40719004"
nizatidine	DB00585	Erosive esophagitis	C0267055		Approved			CHEBI_7601	"42319"		"10063655"	"40719004"
esomeprazole	DB00736	Erosive esophagitis	C0267055		Approved			CHEBI_50275	"283742"		"10063655"	"40719004"
promethazine	DB01069	Gastroparesis due to diabetes mellitus	C0267176	NCT02130622	Terminated	Phase 2	Lack of recruitment	CHEBI_8461	"8745"		"10051153"	"713704004"
metoclopramide	DB01233	Gastroparesis due to diabetes mellitus	C0267176		Approved			CHEBI_107736	"6915"		"10051153"	"713704004"
	DB01075	Gastroparesis due to diabetes mellitus	C0267176	NCT02130622	Terminated	Phase 2	Lack of recruitment	CHEBI_4636	"3498"		"10051153"	"713704004"
deferiprone	DB08826	Iron Overload	C0282193		Approved			CHEBI_68554	"11645"		"10065973"	"60737008"
deferasirox	DB01609	Iron Overload	C0282193	NCT01927913	Withdrawn	Phase 2	This study was withdrawn until the evaluation of the nonclinical rat findings is complete.	CHEBI_49005	"614373"		"10065973"	"60737008"
deferasirox	DB01609	Iron Overload	C0282193	NCT00602446	Terminated	Phase 2	Due to slow accrual of patients	CHEBI_49005	"614373"		"10065973"	"60737008"
deferasirox	DB01609	Iron Overload	C0282193	NCT01159067	Terminated	Phase 2	Low enrollment	CHEBI_49005	"614373"		"10065973"	"60737008"
pentosan polysulfate	DB00686	Interstitial Cystitis	C0282488		Approved			CHEBI_184555	"155046"	MONDO_0018301	"10011801"	"111409009"
dimethyl sulfoxide	DB01093	Interstitial Cystitis	C0282488		Approved			CHEBI_28262	"3455"	MONDO_0018301	"10011801"	"111409009"
cetuximab	DB00002	Squamous cell carcinoma of mouth	C0585362		Approved				"318341"	MONDO_0004958	"10041857"	"307502000"
estradiol	DB00783	Ovarian failure	C0747102		Approved			CHEBI_16469	"4083"		"10033165"	"111550004"
salicylic acid	DB14006	Hyperkeratosis	C0870082		Approved			CHEBI_16914	"20974"	HP:0000962	"10020649"	"26996000"
salicylic acid	DB00936	Hyperkeratosis	C0870082		Approved			CHEBI_16914	"9525"	HP:0000962	"10020649"	"26996000"
salicylic acid	DB13860	Hyperkeratosis	C0870082		Approved			CHEBI_16914		HP:0000962	"10020649"	"26996000"
tretinoin	DB00755	Hyperkeratosis	C0870082		Approved			CHEBI_15367	"10753"	HP:0000962	"10020649"	"26996000"
prednisolone	DB00860	Sjogren's Syndrome	C1527336		Approved			CHEBI_8378	"8638"		"10040767"	"83901003"
dexamethasone phosphate	DB01234	Sjogren's Syndrome	C1527336	NCT01316770	Terminated	Phase 2	Slow enrollment	CHEBI_68637	"3264"		"10040767"	"83901003"
cortisone acetate	DB01380	Aspiration pneumonitis	C1761609		Approved			CHEBI_3897	"21655"		"10035744"	"155597006"
hydrocortisone	DB00741	Aspiration pneumonitis	C1761609		Approved			CHEBI_17650	"5492"		"10035744"	"155597006"
triamcinolone	DB00620	Aspiration pneumonitis	C1761609		Approved			CHEBI_9667	"10759"		"10035744"	"155597006"
betamethasone acetate	DB00443	Aspiration pneumonitis	C1761609		Approved			CHEBI_3077	"1514"		"10035744"	"155597006"
triamcinolone acetonide	DB00620	Aspiration pneumonitis	C1761609		Approved			CHEBI_9667	"10759"		"10035744"	"155597006"
triamcinolone diacetate	DB00620	Aspiration pneumonitis	C1761609		Approved			CHEBI_9667	"10759"		"10035744"	"155597006"
hydrocortisone succinate	DB14545	Aspiration pneumonitis	C1761609		Approved			CHEBI_31677	"21651"		"10035744"	"155597006"
hydrocortisone succinate	DB00741	Aspiration pneumonitis	C1761609		Approved			CHEBI_17650	"5492"		"10035744"	"155597006"
hydrocortisone acetate	DB00741	Aspiration pneumonitis	C1761609		Approved			CHEBI_17650	"5492"		"10035744"	"155597006"
methylprednisolone	DB00959	Aspiration pneumonitis	C1761609		Approved			CHEBI_6888	"6902"		"10035744"	"155597006"
prednisolone	DB00860	Aspiration pneumonitis	C1761609		Approved			CHEBI_8378	"8638"		"10035744"	"155597006"
betamethasone	DB00443	Aspiration pneumonitis	C1761609		Approved			CHEBI_3077	"1514"		"10035744"	"155597006"
hydrocortisone acetate	DB14539	Aspiration pneumonitis	C1761609		Approved			CHEBI_17609	"27197"		"10035744"	"155597006"
pembrolizumab	DB09037	Triple Negative Breast Neoplasms	C3539878		Approved				"1547545"		"10075566"	"706970001"
paclitaxel	DB01229	Triple Negative Breast Neoplasms	C3539878	NCT02685306	Withdrawn	Phase 2		CHEBI_45863	"56946"		"10075566"	"706970001"
dasatinib	DB01254	Triple Negative Breast Neoplasms	C3539878	NCT02720185	Terminated	Phase 2	Study terminated early due to COVID-19 related slow enrollment and funding	CHEBI_49375	"475342|1546019"		"10075566"	"706970001"
sacituzumab govitecan	DB12893	Triple Negative Breast Neoplasms	C3539878		Approved				"2360232|2360530"		"10075566"	"706970001"
	DB01248	Triple Negative Breast Neoplasms	C3539878	NCT02124902	Terminated	Phase 2	Insufficient funding/staff	CHEBI_4672	"72962|1299922"		"10075566"	"706970001"
carboplatin	DB00958	Triple Negative Breast Neoplasms	C3539878	NCT02124902	Terminated	Phase 2	Insufficient funding/staff	CHEBI_31355	"40048"		"10075566"	"706970001"
everolimus	DB01590	Neuroendocrine tumor of pancreas	C4305467		Approved			CHEBI_68478	"141704"		"10067517"	"126864006"
streptozocin	DB00428	Neuroendocrine tumor of pancreas	C4305467		Approved			CHEBI_9288	"10114"		"10067517"	"126864006"
sunitinib	DB01268	Neuroendocrine tumor of pancreas	C4305467		Approved			CHEBI_38940	"357977"		"10067517"	"126864006"
meropenem	DB00760	Ascites	C0003962	NCT01455246	Terminated	Phase 2/Phase 3	Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.	CHEBI_43968	"1546029|29561"	HP:0001541	"10003445"	"389026000"
norfloxacin	DB01059	Miscarriage with sepsis	C0269398		Approved			CHEBI_100246	"7517"			"67465009"
norfloxacin	DB01059	Hospital acquired pneumonia	C0949083		Approved			CHEBI_100246	"7517"			"425464007"
oxybutynin	DB01062	Neurogenic Urinary Bladder	C0005697		Approved			CHEBI_7856	"32675"	MONDO_0001445	"10029279"	"398064005"
oxacillin	DB00713	Sepsis due to Staphylococcus aureus	C2887088		Approved			CHEBI_7809	"7773"			"448417001"
piperacillin	DB00319	Acute gonococcal endometritis	C0153196		Approved			CHEBI_8232	"1546000|8339"	MONDO_0004264		"65295003"
piperacillin	DB00319	Hospital acquired pneumonia	C0949083		Approved			CHEBI_8232	"1546000|8339"			"425464007"
proglumetacin	DB13527	Arthritis	C0003864		Approved			CHEBI_76263		MONDO_0005578	"10003246"	"3723001"
promazine	DB00420	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_8459	"8742"			"191618007"
quinfamide	DB12780	Amebiasis	C0002438		Approved			CHEBI_135493	"35216"	MONDO_0005644	"10001980"	"111910009"
quetiapine	DB01224	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_8707	"51272"			"191618007"
edaravone	DB12243	Amyotrophic Lateral Sclerosis	C0002736		Approved			CHEBI_31530	"1921877"	MONDO_0004976	"10002026"	"86044005"
lithium citrate	DB14507	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_64735	"52105"			"191618007"
lithium citrate	DB14509	Bipolar affective disorder, current episode manic	C0338873		Approved			CHEBI_6504	"42351"			"191618007"
roxadustat	DB04847	Anemia in chronic kidney disease	C1561828		Approved			CHEBI_132774				"707323002"
taurursodiol	DB08834	Amyotrophic Lateral Sclerosis	C0002736		Approved			CHEBI_80774	"2613950"	MONDO_0004976	"10002026"	"86044005"
cefuroxime axetil	DB01112	Acute gonococcal endometritis	C0153196		Approved			CHEBI_3515	"2194"	MONDO_0004264		"65295003"
riluzole	DB00740	Amyotrophic Lateral Sclerosis	C0002736	NCT00818389	Terminated	Phase 2/Phase 3	NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.	CHEBI_8863	"35623"	MONDO_0004976	"10002026"	"86044005"
	DB14509	Amyotrophic Lateral Sclerosis	C0002736	NCT00818389	Terminated	Phase 2/Phase 3	NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.	CHEBI_6504	"42351"	MONDO_0004976	"10002026"	"86044005"
rebamipide	DB11656	Gastritis	C0017152		Approved			CHEBI_93814		MONDO_0004966	"10017853"	"4556007"
	DB00104	Hepatorenal Syndrome	C0019212	NCT01587222	Withdrawn	Phase 2	the sponsor did not provide the treatment		"7617"	MONDO_0001382	"10019846"	"51292008"
midodrine	DB00211	Hepatorenal Syndrome	C0019212	NCT00742339	Terminated	Phase 2/Phase 3	Decision of independent monitoring committee: Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.	CHEBI_6933	"6963"	MONDO_0001382	"10019846"	"51292008"
	DB02638	Hepatorenal Syndrome	C0019212	NCT00742339	Terminated	Phase 2/Phase 3	Decision of independent monitoring committee: Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.	CHEBI_135905	"57048"	MONDO_0001382	"10019846"	"51292008"
	DB00104	Hepatorenal Syndrome	C0019212	NCT00742339	Terminated	Phase 2/Phase 3	Decision of independent monitoring committee: Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.		"7617"	MONDO_0001382	"10019846"	"51292008"
terlipressin	DB02638	Hepatorenal Syndrome	C0019212		Approved			CHEBI_135905	"57048"	MONDO_0001382	"10019846"	"51292008"
midodrine	DB00211	Hepatorenal Syndrome	C0019212	NCT01587222	Withdrawn	Phase 2	the sponsor did not provide the treatment	CHEBI_6933	"6963"	MONDO_0001382	"10019846"	"51292008"
amphotericin B	DB00681	Histoplasmosis	C0019655		Approved			CHEBI_2682	"236594|732"	MONDO_0018312	"10020141"	"12962009"
itraconazole	DB01167	Histoplasmosis	C0019655		Approved			CHEBI_6076	"28031"	MONDO_0018312	"10020141"	"12962009"
ketoconazole	DB01026	Histoplasmosis	C0019655		Approved			CHEBI_48339	"6135"	MONDO_0018312	"10020141"	"12962009"
fluorometholone acetate	DB00324	Iritis	C0022081		Approved			CHEBI_31625	"4491"	MONDO_0006814	"10022955"	"65074000"
dexamethasone	DB01234	Iritis	C0022081		Approved			CHEBI_41879	"3264"	MONDO_0006814	"10022955"	"65074000"
fluorometholone	DB00324	Iritis	C0022081		Approved			CHEBI_31625	"4491"	MONDO_0006814	"10022955"	"65074000"
cortisone acetate	DB01380	Iritis	C0022081		Approved			CHEBI_3897	"21655"	MONDO_0006814	"10022955"	"65074000"
loteprednol etabonate	DB00873	Iritis	C0022081		Approved			CHEBI_50848	"237027"	MONDO_0006814	"10022955"	"65074000"
loteprednol etabonate	DB14596	Iritis	C0022081		Approved			CHEBI_31784	"52177"	MONDO_0006814	"10022955"	"65074000"
hydrocortisone	DB00741	Iritis	C0022081		Approved			CHEBI_17650	"5492"	MONDO_0006814	"10022955"	"65074000"
medrysone	DB00253	Iritis	C0022081		Approved			CHEBI_34829	"29439"	MONDO_0006814	"10022955"	"65074000"
prednisolone	DB00860	Iritis	C0022081		Approved			CHEBI_8378	"8638"	MONDO_0006814	"10022955"	"65074000"
ritodrine	DB00867	Premature Obstetric Labor	C0022876		Approved			CHEBI_156577	"9392"		"10036600"	"6383007"
triamcinolone hexacetonide	DB00620	Lichen Planus	C0023646		Approved			CHEBI_9667	"10759"	MONDO_0006572	"10024429"	"4776004"
etanercept	DB00005	Lichen Planus	C0023646	NCT00285779	Terminated	Phase 2	Slow recruitment	CHEBI_4875	"214555|2103480|2462511"	MONDO_0006572	"10024429"	"4776004"
triamcinolone acetonide	DB00620	Lichen Planus	C0023646		Approved			CHEBI_9667	"10759"	MONDO_0006572	"10024429"	"4776004"
triamcinolone diacetate	DB00620	Lichen Planus	C0023646		Approved			CHEBI_9667	"10759"	MONDO_0006572	"10024429"	"4776004"
triamcinolone	DB00620	Lichen Planus	C0023646		Approved			CHEBI_9667	"10759"	MONDO_0006572	"10024429"	"4776004"
alefacept	DB00092	Lichen Planus	C0023646	NCT00135733	Terminated	Phase 2	Pharmaceutical sponsor withdrew financial support.		"299635"	MONDO_0006572	"10024429"	"4776004"
lenograstim	DB13144	Lymphoma	C0024299	NCT01016795	Terminated	Phase 2	Study closed Nov 2000 by Amgen, who stopped drug delivery		"70167"	MONDO_0005062	"10025310"	"118600007"
tirabrutinib hydrochloride	DB15227	Lymphoma	C0024299		Approved					MONDO_0005062	"10025310"	"118600007"
cyclophosphamide	DB00531	Lymphoma	C0024299		Approved			CHEBI_4027	"1545988|3002"	MONDO_0005062	"10025310"	"118600007"
thiotepa	DB04572	Lymphoma	C0024299		Approved			CHEBI_9570	"10473"	MONDO_0005062	"10025310"	"118600007"
busulfan	DB01008	Lymphoma	C0024299		Approved			CHEBI_28901	"1828"	MONDO_0005062	"10025310"	"118600007"
scopolamine	DB00747	Motion Sickness	C0026603	NCT04219982	Terminated	Phase 2/Phase 3	Failure to meet enrollment	CHEBI_16794	"9601|9603"	MONDO_0008015	"10027990"	"37031009"
buclizine	DB00354	Motion Sickness	C0026603		Approved			CHEBI_3205	"59636"	MONDO_0008015	"10027990"	"37031009"
scopolamine	DB00747	Motion Sickness	C0026603	NCT02155309	Terminated	Phase 2/Phase 3	Business reason	CHEBI_16794	"9601|9603"	MONDO_0008015	"10027990"	"37031009"
cinnarizine	DB00568	Motion Sickness	C0026603		Approved			CHEBI_31403	"2549"	MONDO_0008015	"10027990"	"37031009"
meclozine	DB00737	Motion Sickness	C0026603		Approved			CHEBI_6709	"6676"	MONDO_0008015	"10027990"	"37031009"
dimenhydrinate	DB00985	Motion Sickness	C0026603		Approved			CHEBI_94848	"3444"	MONDO_0008015	"10027990"	"37031009"
cyclizine	DB01176	Motion Sickness	C0026603		Approved			CHEBI_3994	"2977"	MONDO_0008015	"10027990"	"37031009"
scopolamine	DB00747	Motion Sickness	C0026603		Approved			CHEBI_16794	"9601|9603"	MONDO_0008015	"10027990"	"37031009"
parathiazine	DB15978	Motion Sickness	C0026603		Approved			CHEBI_135253		MONDO_0008015	"10027990"	"37031009"
cyclobenzaprine	DB00924	Muscle Spasticity	C0026838		Approved			CHEBI_3996	"21949"	HP:0001257	"10028335"	"397790002"
diazepam	DB00829	Muscle Spasticity	C0026838		Approved			CHEBI_49575	"3322"	HP:0001257	"10028335"	"397790002"
chlorphenesin carbamate	DB14656	Muscle Spasticity	C0026838		Approved			CHEBI_3643	"20880"	HP:0001257	"10028335"	"397790002"
tizanidine	DB00697	Muscle Spasticity	C0026838		Approved			CHEBI_63629	"57258"	HP:0001257	"10028335"	"397790002"
chlorphenesin carbamate	DB00856	Muscle Spasticity	C0026838		Approved			CHEBI_3642	"2399"	HP:0001257	"10028335"	"397790002"
thiocolchicoside	DB11582	Muscle Spasticity	C0026838		Approved			CHEBI_94557		HP:0001257	"10028335"	"397790002"
dantrolene	DB01219	Muscle Spasticity	C0026838		Approved			CHEBI_4317	"3105"	HP:0001257	"10028335"	"397790002"
caffeine	DB00201	Muscle Spasticity	C0026838		Approved			CHEBI_27732	"1886"	HP:0001257	"10028335"	"397790002"
tolperisone	DB06264	Muscle Spasticity	C0026838		Approved			CHEBI_93835	"10639"	HP:0001257	"10028335"	"397790002"
methocarbamol	DB00423	Muscle Spasticity	C0026838		Approved			CHEBI_77498	"6845"	HP:0001257	"10028335"	"397790002"
chlorzoxazone	DB00356	Muscle Spasticity	C0026838		Approved			CHEBI_3655	"2410"	HP:0001257	"10028335"	"397790002"
carisoprodol	DB00395	Muscle Spasticity	C0026838		Approved			CHEBI_3419	"2101"	HP:0001257	"10028335"	"397790002"
orphenadrine	DB01173	Muscle Spasticity	C0026838		Approved			CHEBI_7789	"7715"	HP:0001257	"10028335"	"397790002"
metaxalone	DB00660	Muscle Spasticity	C0026838		Approved			CHEBI_6797	"59078"	HP:0001257	"10028335"	"397790002"
baclofen	DB00181	Muscle Spasticity	C0026838	NCT00280280	Terminated	Phase 1	low patient accrual	CHEBI_2972	"1292"	HP:0001257	"10028335"	"397790002"
sodium oxybate	DB01440	Narcolepsy	C0027404		Approved			CHEBI_30830	"1546380|2387302"	MONDO_0021107	"10028713"	"60380001"
sodium oxybate	DB09072	Narcolepsy	C0027404		Approved				"9899"	MONDO_0021107	"10028713"	"60380001"
methylphenidate	DB00422	Narcolepsy	C0027404		Approved			CHEBI_84276	"6901"	MONDO_0021107	"10028713"	"60380001"
sodium oxybate	DB09072	Narcolepsy	C0027404	NCT03626727	Withdrawn	Early Phase 1	Target study population was extremely difficult to recruit and planned study budget was exceeded		"9899"	MONDO_0021107	"10028713"	"60380001"
modafinil	DB00745	Narcolepsy	C0027404		Approved			CHEBI_77585	"30125"	MONDO_0021107	"10028713"	"60380001"
	DB01440	Narcolepsy	C0027404	NCT03626727	Withdrawn	Early Phase 1	Target study population was extremely difficult to recruit and planned study budget was exceeded	CHEBI_30830	"1546380|2387302"	MONDO_0021107	"10028713"	"60380001"
armodafinil	DB06413	Narcolepsy	C0027404		Approved			CHEBI_77590	"641465|30125"	MONDO_0021107	"10028713"	"60380001"
dexamfetamine	DB01576	Narcolepsy	C0027404		Approved			CHEBI_4469	"3288"	MONDO_0021107	"10028713"	"60380001"
amfetamine	DB00182	Narcolepsy	C0027404		Approved			CHEBI_132233	"3288|725"	MONDO_0021107	"10028713"	"60380001"
pitolisant	DB11642	Narcolepsy	C0027404		Approved			CHEBI_134709	"2197878"	MONDO_0021107	"10028713"	"60380001"
solriamfetol	DB14754	Narcolepsy	C0027404		Approved				"2121751"	MONDO_0021107	"10028713"	"60380001"
ketoconazole	DB01026	Paracoccidioidomycosis	C0030409		Approved			CHEBI_48339	"6135"	MONDO_0005894	"10061906"	"59925007"
colchicine	DB01394	Familial Mediterranean Fever	C0031069		Approved			CHEBI_27882	"2683"	MONDO_0018088	"10016207"	"12579009"
canakinumab	DB06168	Familial Mediterranean Fever	C0031069		Approved				"853491"	MONDO_0018088	"10016207"	"12579009"
	DB00297	Periodontitis	C0031099	NCT01878864	Terminated	Phase 2	Too slow patient inclusion and superior effect of the injection	CHEBI_77431	"1815"	MONDO_0005076	"10034539"	"41565005"
minocycline	DB01017	Periodontitis	C0031099		Approved			CHEBI_50694	"6980"	MONDO_0005076	"10034539"	"41565005"
lidocaine	DB00281	Periodontitis	C0031099	NCT01878864	Terminated	Phase 2	Too slow patient inclusion and superior effect of the injection	CHEBI_6456	"6387"	MONDO_0005076	"10034539"	"41565005"
sulbentine	DB13671	Pityriasis	C0032024		Approved			CHEBI_31477			"10035110"	"34630004"
cannabidiol	DB09061	Prader-Willi Syndrome	C0032897	NCT02844933	Terminated	Phase 2	Insys Therapeutics filed Chapter 11 and terminated all studies.	CHEBI_69478	"2045371"	MONDO_0008300	"10036476"	"89392001"
cannabidiol	DB09061	Prader-Willi Syndrome	C0032897	NCT03458416	Terminated	Phase 2	Insys Therapeutics filed Chapter 11 and terminated all studies.	CHEBI_69478	"2045371"	MONDO_0008300	"10036476"	"89392001"
somatropin	DB00052	Prader-Willi Syndrome	C0032897		Approved				"61148|314845"	MONDO_0008300	"10036476"	"89392001"
metoprolol	DB00264	Prader-Willi Syndrome	C0032897	NCT05198362	Withdrawn	Phase 2	Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients	CHEBI_6904	"6918"	MONDO_0008300	"10036476"	"89392001"
topiramate	DB00273	Prader-Willi Syndrome	C0032897	NCT02810483	Terminated	Phase 3		CHEBI_63631	"38404"	MONDO_0008300	"10036476"	"89392001"
octreotide	DB00104	Prader-Willi Syndrome	C0032897	NCT00175305	Terminated	Phase 3		CHEBI_7726	"7617"	MONDO_0008300	"10036476"	"89392001"
carbetocin	DB01282	Prader-Willi Syndrome	C0032897		Approved			CHEBI_59204		MONDO_0008300	"10036476"	"89392001"
rimonabant	DB06155	Prader-Willi Syndrome	C0032897	NCT00603109	Terminated	Phase 3	Drug side effects leading to premature stop	CHEBI_34967		MONDO_0008300	"10036476"	"89392001"
glutamine	DB00130	Short Bowel Syndrome	C0036992		Approved			CHEBI_18050	"4885"	MONDO_0015183	"10049416"	"235724004"
glucagon	DB00040	Short Bowel Syndrome	C0036992	NCT01573286	Terminated	Phase 1/Phase 2	GLP-2 Drug product stability concerns	CHEBI_5391	"4832|261716"	MONDO_0015183	"10049416"	"235724004"
ethanol	DB00898	Short Bowel Syndrome	C0036992	NCT01263574	Withdrawn	Phase 2	No participants. IND denied by FDA.	CHEBI_16236	"1310469|448|216449"	MONDO_0015183	"10049416"	"235724004"
liraglutide	DB06655	Short Bowel Syndrome	C0036992	NCT03371862	Withdrawn	Phase 2	No participants recruited. Not able to recruit due to COVID 19.	CHEBI_71193	"475968"	MONDO_0015183	"10049416"	"235724004"
teduglutide	DB08900	Short Bowel Syndrome	C0036992		Approved			CHEBI_72305	"1364468"	MONDO_0015183	"10049416"	"235724004"
loperamide	DB00836	Short Bowel Syndrome	C0036992	NCT02266849	Terminated	Phase 3	Insuficcient recruiting	CHEBI_6532	"6468"	MONDO_0015183	"10049416"	"235724004"
pyrazinamide	DB00339	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_45285	"8987"	MONDO_0006052	"10037440"	"700272008"
cycloserine	DB00260	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_40009	"3007"	MONDO_0006052	"10037440"	"700272008"
ethionamide	DB00609	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_4885	"4127"	MONDO_0006052	"10037440"	"700272008"
tiocarlide	DB13608	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_135637		MONDO_0006052	"10037440"	"700272008"
enviomycin	DB08993	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_135872		MONDO_0006052	"10037440"	"700272008"
capreomycin	DB00314	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_3371	"78903"	MONDO_0006052	"10037440"	"700272008"
streptomycin	DB01082	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_17076	"10109"	MONDO_0006052	"10037440"	"700272008"
bedaquiline	DB08903	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_72292	"1364504"	MONDO_0006052	"10037440"	"700272008"
ethambutol	DB00330	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_4877	"4110"	MONDO_0006052	"10037440"	"700272008"
aminosalicylic acid	DB00233	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_27565	"7833"	MONDO_0006052	"10037440"	"700272008"
thioacetazone	DB12829	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_134958		MONDO_0006052	"10037440"	"700272008"
succinic acid	DB00139	Iron deficiency anemia	C0162316		Approved			CHEBI_15741	"37255"	MONDO_0001356	"10022972"	"87522002"
isoniazid	DB00951	Tuberculosis, Pulmonary	C0041327	NCT00571753	Terminated	Phase 3	Enrolling participants has halted prematurely due to a low recruitment rate.	CHEBI_6030	"6038"	MONDO_0006052	"10037440"	"700272008"
rifampicin	DB01045	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_71365	"9384"	MONDO_0006052	"10037440"	"700272008"
isoniazid	DB00951	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_6030	"6038"	MONDO_0006052	"10037440"	"700272008"
serine	DB00133	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_17115	"9671"	MONDO_0006052	"10037440"	"700272008"
rifapentine	DB01201	Tuberculosis, Pulmonary	C0041327		Approved			CHEBI_45304	"35617"	MONDO_0006052	"10037440"	"700272008"
sodium tetradecyl sulfate	DB11328	Varicosity	C0042345		Approved			CHEBI_75275	"1370424"	MONDO_0008638	"10046996"	"12856003"
sodium tetradecyl sulfate	DB00464	Varicosity	C0042345		Approved			CHEBI_75273	"9913"	MONDO_0008638	"10046996"	"12856003"
polidocanol	DB06811	Varicosity	C0042345		Approved			CHEBI_46859	"968170"	MONDO_0008638	"10046996"	"12856003"
phenobarbital	DB01174	Vascular Headaches	C0042376		Approved			CHEBI_8069	"8134"	MONDO_0040797	"10047077"	"128187005"
dihydroergotamine	DB00320	Vascular Headaches	C0042376		Approved			CHEBI_4562	"3418"	MONDO_0040797	"10047077"	"128187005"
caffeine	DB00201	Vascular Headaches	C0042376		Approved			CHEBI_27732	"1886"	MONDO_0040797	"10047077"	"128187005"
ergotamine	DB00696	Vascular Headaches	C0042376		Approved			CHEBI_64318	"4025"	MONDO_0040797	"10047077"	"128187005"
vestronidase alfa	DB12366	Mucopolysaccharidosis VII	C0085132		Approved				"1989818|1989819"	MONDO_0009662	"10056893"	"124470009"
cyanocobalamin	DB00115	Megaloblastic anemia due to folate deficiency	C0151482		Approved			CHEBI_17439	"11248"	MONDO_0001860	"10002043"	"85649008"
iron	DB01592	Megaloblastic anemia due to folate deficiency	C0151482		Approved			CHEBI_18248	"90176|262150"	MONDO_0001860	"10002043"	"85649008"
ferrous fumarate	DB14491	Megaloblastic anemia due to folate deficiency	C0151482		Approved			CHEBI_31607	"24941"	MONDO_0001860	"10002043"	"85649008"
folic acid	DB00158	Megaloblastic anemia due to folate deficiency	C0151482		Approved			CHEBI_27470	"62356|4511|202634"	MONDO_0001860	"10002043"	"85649008"
hematin	DB13387	Megaloblastic anemia due to folate deficiency	C0151482		Approved			CHEBI_36161		MONDO_0001860	"10002043"	"85649008"
docusate sodium	DB11089	Megaloblastic anemia due to folate deficiency	C0151482		Approved			CHEBI_534	"82003"	MONDO_0001860	"10002043"	"85649008"
carbenoxolone	DB02329	Ulcer of esophagus	C0151970		Approved			CHEBI_41462		HP:0004791	"10030201"	"30811009"
tetracaine	DB09085	Skin irritation	C0152030		Approved			CHEBI_9468	"91189|10391"		"10040880"	"367466007"
levomenthol	DB14123	Skin irritation	C0152030		Approved			CHEBI_25187	"6750|1430390"		"10040880"	"367466007"
levomenthol	DB00825	Skin irritation	C0152030		Approved			CHEBI_15409	"236388|6750"		"10040880"	"367466007"
allantoin	DB11100	Skin irritation	C0152030		Approved			CHEBI_15676	"508"		"10040880"	"367466007"
zinc acetate	DB14487	Skin irritation	C0152030		Approved			CHEBI_62984	"1299637|58295"		"10040880"	"367466007"
terbutaline	DB00871	Skin irritation	C0152030		Approved			CHEBI_9449	"10368"		"10040880"	"367466007"
phenol	DB03255	Skin irritation	C0152030		Approved			CHEBI_15882	"33290"		"10040880"	"367466007"
butamben	DB11148	Skin irritation	C0152030		Approved			CHEBI_3231	"19861"		"10040880"	"367466007"
dyclonine	DB00645	Skin irritation	C0152030		Approved			CHEBI_4724	"23744"		"10040880"	"367466007"
benzethonium	DB11125	Skin irritation	C0152030		Approved			CHEBI_94725	"1390"		"10040880"	"367466007"
lidocaine	DB00281	Skin irritation	C0152030		Approved			CHEBI_6456	"6387"		"10040880"	"367466007"
benzalkonium	DB13282	Skin irritation	C0152030		Approved			CHEBI_188978			"10040880"	"367466007"
zinc oxide	DB09321	Skin irritation	C0152030		Approved			CHEBI_36560	"11423"		"10040880"	"367466007"
benzyl alcohol	DB06770	Skin irritation	C0152030		Approved			CHEBI_17987	"1426"		"10040880"	"367466007"
benzalkonium	DB11105	Skin irritation	C0152030		Approved			CHEBI_188978	"1378"		"10040880"	"367466007"
cinchocaine	DB00527	Skin irritation	C0152030		Approved			CHEBI_247956	"3339"		"10040880"	"367466007"
pramocaine	DB09345	Skin irritation	C0152030		Approved			CHEBI_8357	"34347"		"10040880"	"367466007"
bupivacaine	DB00297	Skin irritation	C0152030		Approved			CHEBI_77431	"1815"		"10040880"	"367466007"
benzocaine	DB01086	Skin irritation	C0152030		Approved			CHEBI_116735	"1399"		"10040880"	"367466007"
aluminum acetate	DB14518	Skin irritation	C0152030		Approved				"17609"		"10040880"	"367466007"
resorcinol	DB11085	Skin irritation	C0152030		Approved			CHEBI_27810	"35382"		"10040880"	"367466007"
moxifloxacin	DB00218	Septicemic Plague	C0152936		Approved			CHEBI_63611	"139462"	MONDO_0005956	"10058889"	"9012003"
ferric maltol	DB15598	Iron deficiency anemia	C0162316		Approved				"2539932"	MONDO_0001356	"10022972"	"87522002"
ferrous gluconate	DB09517	Iron deficiency anemia	C0162316		Approved			CHEBI_31608	"261435"	MONDO_0001356	"10022972"	"87522002"
ferric derisomaltose	DB15617	Iron deficiency anemia	C0162316		Approved				"2274394"	MONDO_0001356	"10022972"	"87522002"
ferumoxytol	DB06215	Iron deficiency anemia	C0162316		Approved			CHEBI_50821	"473387"	MONDO_0001356	"10022972"	"87522002"
ferric carboxymaltose	DB08917	Iron deficiency anemia	C0162316		Approved				"1433693"	MONDO_0001356	"10022972"	"87522002"
ferrous gluconate	DB14488	Iron deficiency anemia	C0162316		Approved			CHEBI_31608	"24942"	MONDO_0001356	"10022972"	"87522002"
iron	DB01592	Iron deficiency anemia	C0162316		Approved			CHEBI_18248	"90176|262150"	MONDO_0001356	"10022972"	"87522002"
ferric citrate	DB14520	Iron deficiency anemia	C0162316		Approved			CHEBI_144421	"1594675"	MONDO_0001356	"10022972"	"87522002"
hematin	DB13387	Iron deficiency anemia	C0162316		Approved			CHEBI_36161		MONDO_0001356	"10022972"	"87522002"
folic acid	DB00158	Iron deficiency anemia	C0162316		Approved			CHEBI_27470	"62356|4511|202634"	MONDO_0001356	"10022972"	"87522002"
ferric oxide	DB11576	Iron deficiency anemia	C0162316		Approved			CHEBI_50819		MONDO_0001356	"10022972"	"87522002"
docusate sodium	DB11089	Iron deficiency anemia	C0162316		Approved			CHEBI_534	"82003"	MONDO_0001356	"10022972"	"87522002"
cyanocobalamin	DB00115	Iron deficiency anemia	C0162316		Approved			CHEBI_17439	"11248"	MONDO_0001356	"10022972"	"87522002"
ferrous fumarate	DB14491	Iron deficiency anemia	C0162316		Approved			CHEBI_31607	"24941"	MONDO_0001356	"10022972"	"87522002"
pramiracetam	DB13247	Memory impairment	C0233794		Approved			CHEBI_135110		HP:0002354	"10027175"	"386807006"
caspofungin	DB00520	Candidiasis of the esophagus	C0239295		Approved			CHEBI_474180	"140108"	MONDO_0001648	"10030154"	"20639004"
amphotericin B	DB00681	Candidiasis of the esophagus	C0239295		Approved			CHEBI_2682	"236594|732"	MONDO_0001648	"10030154"	"20639004"
fluconazole	DB00196	Candidiasis of the esophagus	C0239295		Approved			CHEBI_46081	"202813|4450"	MONDO_0001648	"10030154"	"20639004"
anidulafungin	DB00362	Candidiasis of the esophagus	C0239295		Approved			CHEBI_55346	"341018"	MONDO_0001648	"10030154"	"20639004"
itraconazole	DB01167	Candidiasis of the esophagus	C0239295		Approved			CHEBI_6076	"28031"	MONDO_0001648	"10030154"	"20639004"
voriconazole	DB00582	Candidiasis of the esophagus	C0239295		Approved			CHEBI_10023	"121243"	MONDO_0001648	"10030154"	"20639004"
micafungin	DB01141	Candidiasis of the esophagus	C0239295		Approved			CHEBI_600520	"325887"	MONDO_0001648	"10030154"	"20639004"
alprostadil	DB00770	Erectile dysfunction	C0242350		Approved			CHEBI_15544	"598"	HP:0100639	"10061461"	"860914002"
sildenafil	DB00203	Erectile dysfunction	C0242350		Approved			CHEBI_9139	"136411"	HP:0100639	"10061461"	"860914002"
mirodenafil	DB11792	Erectile dysfunction	C0242350		Approved			CHEBI_136049		HP:0100639	"10061461"	"860914002"
udenafil	DB06267	Erectile dysfunction	C0242350		Approved			CHEBI_135926		HP:0100639	"10061461"	"860914002"
moxisylyte	DB09205	Erectile dysfunction	C0242350		Approved			CHEBI_94754	"10561"	HP:0100639	"10061461"	"860914002"
avanafil	DB06237	Erectile dysfunction	C0242350		Approved			CHEBI_66876	"1291301"	HP:0100639	"10061461"	"860914002"
tadalafil	DB00820	Erectile dysfunction	C0242350		Approved			CHEBI_71940	"358263"	HP:0100639	"10061461"	"860914002"
vardenafil	DB00862	Erectile dysfunction	C0242350		Approved			CHEBI_46295	"306674"	HP:0100639	"10061461"	"860914002"
benzylpenicillin	DB01053	Pneumonia, Necrotizing	C0264515		Approved			CHEBI_18208	"7980"		"10055672"	"7063008"
odevixibat	DB16261	Progressive intrahepatic cholestasis (disorder)	C0268312		Approved				"2563966"	MONDO_0015762	"10076033"	"74162007"
venlafaxine	DB00285	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_9943	"39786"		"10018075"	"21897009"
paroxetine	DB00715	Generalized Anxiety Disorder	C0270549	NCT00658762	Terminated	Phase 3	Please see Detailed Description for termination reason.	CHEBI_7936	"32937"		"10018075"	"21897009"
paroxetine	DB00715	Generalized Anxiety Disorder	C0270549	NCT00658008	Terminated	Phase 3	Please see Detailed Description for termination reason.	CHEBI_7936	"32937"		"10018075"	"21897009"
quetiapine	DB01224	Generalized Anxiety Disorder	C0270549	NCT00868374	Terminated	Phase 3	Study terminated due to low enrollment	CHEBI_8707	"51272"		"10018075"	"21897009"
cimetidine	DB00501	Generalized Anxiety Disorder	C0270549	NCT00800280	Terminated	Phase 1	Please see Detailed Description for termination reason.	CHEBI_3699	"2541"		"10018075"	"21897009"
paroxetine	DB00715	Generalized Anxiety Disorder	C0270549	NCT00658372	Terminated	Phase 3	Please see Detailed Description for termination reason.	CHEBI_7936	"32937"		"10018075"	"21897009"
duloxetine	DB00476	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_36795	"72625"		"10018075"	"21897009"
escitalopram	DB01175	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_36791	"321988"		"10018075"	"21897009"
citalopram	DB00215	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_77397	"2556"		"10018075"	"21897009"
buspirone	DB00490	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_3223	"1827"		"10018075"	"21897009"
metformin	DB00331	Generalized Anxiety Disorder	C0270549	NCT00809536	Terminated	Phase 1	Please Detailed Description for termination reason.	CHEBI_6801	"6809"		"10018075"	"21897009"
paroxetine	DB00715	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_7936	"32937"		"10018075"	"21897009"
alprazolam	DB00404	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_2611	"596"		"10018075"	"21897009"
pregabalin	DB00230	Generalized Anxiety Disorder	C0270549		Approved			CHEBI_64356	"187832"		"10018075"	"21897009"
mecasermin	DB01277	Laron Syndrome	C0271568		Approved				"274403"	MONDO_0009877	"10075492"	"38196001"
mecasermin rinfabate	DB14751	Laron Syndrome	C0271568		Approved				"616877"	MONDO_0009877	"10075492"	"38196001"
benzylpenicillin	DB01053	Pulmonary actinomycosis	C0275566		Approved			CHEBI_18208	"7980"		"10000628"	"21846001"
gentamicin	DB00798	Neonatal pneumonia	C0339968		Approved			CHEBI_17833	"1596450"		"10053584"	"233619008"
benzylpenicillin	DB01053	Neonatal pneumonia	C0339968		Approved			CHEBI_18208	"7980"		"10053584"	"233619008"
vancomycin	DB00512	Neonatal pneumonia	C0339968		Approved			CHEBI_28001	"11124"		"10053584"	"233619008"
cefotaxime	DB00493	Neonatal pneumonia	C0339968		Approved			CHEBI_204928	"2186"		"10053584"	"233619008"
erythromycin	DB00199	Neonatal pneumonia	C0339968		Approved			CHEBI_42355	"4053"		"10053584"	"233619008"
fusidic acid	DB02703	Neonatal pneumonia	C0339968		Approved			CHEBI_29013	"4608|113608"		"10053584"	"233619008"
amikacin	DB00479	Neonatal pneumonia	C0339968		Approved			CHEBI_2637	"641"		"10053584"	"233619008"
deferasirox	DB01609	Chronic eosinophilic leukemia	C0346421	NCT01159067	Terminated	Phase 2	Low enrollment	CHEBI_49005	"614373"	MONDO_0015687	"10065854"	"413836008"
imatinib	DB00619	Chronic eosinophilic leukemia	C0346421		Approved			CHEBI_45783	"282388"	MONDO_0015687	"10065854"	"413836008"
alvimopan	DB06274	Postoperative ileus	C0400877		Approved			CHEBI_135686	"1516803|480639"		"10054048"	"235833007"
testosterone	DB00624	Hot flushes	C0600142		Approved			CHEBI_17347	"10379"	HP:0031217	"10060800"	"427368007"
conjugated estrogens	DB00286	Hot flushes	C0600142		Approved			CHEBI_8389	"4099"	HP:0031217	"10060800"	"427368007"
estradiol cypionate	DB00783	Hot flushes	C0600142		Approved			CHEBI_16469	"4083"	HP:0031217	"10060800"	"427368007"
testosterone cypionate	DB13943	Hot flushes	C0600142		Approved			CHEBI_9463	"835827"	HP:0031217	"10060800"	"427368007"
paroxetine	DB00715	Hot flushes	C0600142		Approved			CHEBI_7936	"32937"	HP:0031217	"10060800"	"427368007"
bazedoxifene	DB06401	Hot flushes	C0600142		Approved			CHEBI_135947	"1441386"	HP:0031217	"10060800"	"427368007"
testosterone enantate	DB00624	Hot flushes	C0600142		Approved			CHEBI_17347	"10379"	HP:0031217	"10060800"	"427368007"
testosterone enantate	DB13944	Hot flushes	C0600142		Approved			CHEBI_9464	"37859"	HP:0031217	"10060800"	"427368007"
norethisterone	DB00717	Hot flushes	C0600142		Approved			CHEBI_7627	"7514"	HP:0031217	"10060800"	"427368007"
quinestrol	DB04575	Hot flushes	C0600142		Approved			CHEBI_8716	"9066"	HP:0031217	"10060800"	"427368007"
drospirenone	DB01395	Hot flushes	C0600142		Approved			CHEBI_50838	"11636"	HP:0031217	"10060800"	"427368007"
methyltestosterone	DB06710	Hot flushes	C0600142		Approved			CHEBI_27436	"6904"	HP:0031217	"10060800"	"427368007"
levonorgestrel	DB00367	Hot flushes	C0600142		Approved			CHEBI_6443	"6373"	HP:0031217	"10060800"	"427368007"
estradiol cypionate	DB13954	Hot flushes	C0600142		Approved			CHEBI_34745	"1000146"	HP:0031217	"10060800"	"427368007"
norgestimate	DB00957	Hot flushes	C0600142		Approved			CHEBI_50815	"31994"	HP:0031217	"10060800"	"427368007"
medroxyprogesterone	DB00603	Hot flushes	C0600142		Approved			CHEBI_6716	"1000112"	HP:0031217	"10060800"	"427368007"
levonorgestrel	DB09389	Hot flushes	C0600142		Approved			CHEBI_7630	"7518"	HP:0031217	"10060800"	"427368007"
testosterone cypionate	DB00624	Hot flushes	C0600142		Approved			CHEBI_17347	"10379"	HP:0031217	"10060800"	"427368007"
estradiol valerate	DB13956	Hot flushes	C0600142		Approved			CHEBI_31561	"24395"	HP:0031217	"10060800"	"427368007"
estradiol valerate	DB00783	Hot flushes	C0600142		Approved			CHEBI_16469	"4083"	HP:0031217	"10060800"	"427368007"
ethinylestradiol	DB00977	Hot flushes	C0600142		Approved			CHEBI_4903	"4124"	HP:0031217	"10060800"	"427368007"
estradiol	DB00783	Hot flushes	C0600142		Approved			CHEBI_16469	"4083"	HP:0031217	"10060800"	"427368007"
progesterone	DB00396	Hot flushes	C0600142		Approved			CHEBI_17026	"8727"	HP:0031217	"10060800"	"427368007"
	DB06710	Dyspareunia	C1384606	NCT01122342	Suspended	Phase 1/Phase 2	Evaluating outcomes of current subjects pre further enrollment/dose reduction.	CHEBI_27436	"6904"	HP:0030016	"10013941"	"71315007"
prasterone	DB01708	Dyspareunia	C1384606		Approved			CHEBI_28689	"3143"	HP:0030016	"10013941"	"71315007"
dienestrol	DB00890	Dyspareunia	C1384606		Approved			CHEBI_4518	"3368"	HP:0030016	"10013941"	"71315007"
testosterone	DB00624	Dyspareunia	C1384606	NCT01122342	Suspended	Phase 1/Phase 2	Evaluating outcomes of current subjects pre further enrollment/dose reduction.	CHEBI_17347	"10379"	HP:0030016	"10013941"	"71315007"
ospemifene	DB04938	Dyspareunia	C1384606		Approved			CHEBI_73275	"1370971"	HP:0030016	"10013941"	"71315007"
conjugated estrogens	DB00286	Dyspareunia	C1384606		Approved			CHEBI_8389	"4099"	HP:0030016	"10013941"	"71315007"
benralizumab	DB12023	Eosinophilic Pneumonia	C1527407		Approved				"1989100"	MONDO_0005749	"10014962"	"367542003"
reslizumab	DB06602	Eosinophilic Pneumonia	C1527407		Approved				"1746889"	MONDO_0005749	"10014962"	"367542003"
prednisolone	DB00860	Eosinophilic Pneumonia	C1527407		Approved			CHEBI_8378	"8638"	MONDO_0005749	"10014962"	"367542003"
mepolizumab	DB06612	Eosinophilic Pneumonia	C1527407		Approved				"1720597"	MONDO_0005749	"10014962"	"367542003"
diethylcarbamazine	DB00711	Eosinophilic Pneumonia	C1527407		Approved			CHEBI_4527	"3384"	MONDO_0005749	"10014962"	"367542003"
velaglucerase alfa	DB06720	Gaucher Disease, Type 1	C1961835		Approved				"901805"		"10075697"	"62201009"
taliglucerase alfa	DB08876	Gaucher Disease, Type 1	C1961835		Approved				"1291609"		"10075697"	"62201009"
alglucerase	DB00088	Gaucher Disease, Type 1	C1961835		Approved				"46049"		"10075697"	"62201009"
amikacin	DB00479	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_2637	"641"			"369001000119100"
medrysone	DB00253	Corneal Ulcer	C0010043		Approved			CHEBI_34829	"29439"	MONDO_0004577		"91514001"
megestrol acetate	DB00351	Nutritional deficiency with AIDS (acquired immunodeficiency syndrome)	C0276587		Approved			CHEBI_6723	"29451"			"420691000"
norfloxacin	DB01059	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_100246	"7517"			"369001000119100"
norfloxacin	DB01059	Acute maxillary sinusitis	C0155804		Approved			CHEBI_100246	"7517"	MONDO_0002186		"68272006"
norfloxacin	DB01059	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_100246	"7517"			"128945009"
norfloxacin	DB01059	Acute gonococcal urethritis	C0275652		Approved			CHEBI_100246	"7517"			"29864006"
oxazepam	DB00842	Alcohol Withdrawal Delirium	C0001957		Approved			CHEBI_7823	"7781"		"10012225"	"8635005"
oxycodone	DB00497	Postoperative Pain, Acute	C2215257		Approved			CHEBI_7852	"7804"			"107401000119105"
azithromycin	DB00207	Acute gonococcal urethritis	C0275652		Approved			CHEBI_2955	"18631"			"29864006"
aztreonam	DB00355	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_161680	"1272"			"128945009"
clobetasol propionate	DB01013	Scalp Dermatoses	C0036271		Approved			CHEBI_31414	"21245"	MONDO_0006605		"402694007"
clobetasol propionate	DB11750	Scalp Dermatoses	C0036271		Approved			CHEBI_205919	"2590"	MONDO_0006605		"402694007"
prednisolone sodium phosphate	DB00860	Bacterial conjunctivitis	C0009768		Approved			CHEBI_8378	"8638"	MONDO_0006668	"10061784"	"243321006"
relebactam	DB12377	Urinary tract infection caused by Klebsiella	C4076057		Approved				"2184137|2268500"			"369001000119100"
cefepime	DB01413	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_478164	"20481"			"369001000119100"
cefiderocol	DB14879	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_140376	"2265702"			"369001000119100"
cefixime	DB00671	Acute gonococcal urethritis	C0275652		Approved			CHEBI_472657	"25033|1546021"			"29864006"
bempedoic acid	DB11936	Atherosclerotic occlusive disease	C0543822		Approved			CHEBI_149601	"2282403"			"129573006"
cefpodoxime proxetil	DB01416	Acute maxillary sinusitis	C0155804		Approved			CHEBI_3504	"20489"	MONDO_0002186		"68272006"
cefpodoxime proxetil	DB01416	Acute gonococcal urethritis	C0275652		Approved			CHEBI_3504	"20489"			"29864006"
ceftazidime	DB00438	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_3508	"2191|1545984"			"369001000119100"
ceftazidime	DB00438	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_3508	"2191|1545984"			"128945009"
ceftriaxone	DB01212	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_29007	"2193"			"128945009"
cefuroxime	DB01112	Acute maxillary sinusitis	C0155804		Approved			CHEBI_3515	"2194"	MONDO_0002186		"68272006"
cefuroxime	DB01112	Enterobacteriaceae Infections	C0014347		Approved			CHEBI_3515	"2194"			"128945009"
cefuroxime	DB01112	Acute gonococcal urethritis	C0275652		Approved			CHEBI_3515	"2194"			"29864006"
cefuroxime axetil	DB01112	Acute maxillary sinusitis	C0155804		Approved			CHEBI_3515	"2194"	MONDO_0002186		"68272006"
cefuroxime axetil	DB01112	Acute gonococcal urethritis	C0275652		Approved			CHEBI_3515	"2194"			"29864006"
celecoxib	DB00482	Postoperative Pain, Acute	C2215257		Approved			CHEBI_41423	"140587"			"107401000119105"
racecadotril	DB11696	Acute diarrhea	C0740441		Approved			CHEBI_91508	"16738"	MONDO_0000257		"409966000"
racecadotril	DB08626	Acute diarrhea	C0740441		Approved					MONDO_0000257		"409966000"
ciprofloxacin	DB00537	Acute maxillary sinusitis	C0155804		Approved			CHEBI_192484	"2551"	MONDO_0002186		"68272006"
ciprofloxacin	DB00537	Urinary tract infection caused by Klebsiella	C4076057		Approved			CHEBI_192484	"2551"			"369001000119100"
	DB00635	Dermatomyositis	C0011633	NCT00035958	Terminated	Phase 2/Phase 3	Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make the project budget over the limit for this funding mechanism.	CHEBI_8382	"8640"	MONDO_0016367	"10012503"	"396230008"
abatacept	DB01281	Dermatomyositis	C0011633	NCT02971683	Terminated	Phase 3	Inability to meet protocol objectives		"614391"	MONDO_0016367	"10012503"	"396230008"
ustekinumab	DB05679	Dermatomyositis	C0011633	NCT03981744	Terminated	Phase 3	The study did not meet the primary endpoint.		"847083"	MONDO_0016367	"10012503"	"396230008"
denosumab	DB06643	Dermatomyositis	C0011633	NCT02418273	Withdrawn	Phase 1/Phase 2	was not funded		"993449"	MONDO_0016367	"10012503"	"396230008"
azathioprine	DB00993	Dermatomyositis	C0011633		Approved			CHEBI_2948	"1256"	MONDO_0016367	"10012503"	"396230008"
methotrexate	DB00563	Dermatomyositis	C0011633	NCT00035958	Terminated	Phase 2/Phase 3	Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make the project budget over the limit for this funding mechanism.	CHEBI_44185	"6851"	MONDO_0016367	"10012503"	"396230008"
	DB00005	Dermatomyositis	C0011633	NCT00035958	Terminated	Phase 2/Phase 3	Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make the project budget over the limit for this funding mechanism.		"214555|2103480|2462511"	MONDO_0016367	"10012503"	"396230008"
aminobenzoic acid	DB02362	Dermatomyositis	C0011633		Approved			CHEBI_30753	"74"	MONDO_0016367	"10012503"	"396230008"
benzoic acid	DB03793	Dermatomyositis	C0011633		Approved			CHEBI_30746	"18989"	MONDO_0016367	"10012503"	"396230008"
procaine benzylpenicillin	DB09320	Primary genital syphilis	C0017418		Approved			CHEBI_52154	"7983"		"10042880"	"186847001"
benzylpenicillin	DB01053	Primary genital syphilis	C0017418		Approved			CHEBI_18208	"7980"		"10042880"	"186847001"
procaine benzylpenicillin	DB01053	Primary genital syphilis	C0017418		Approved			CHEBI_18208	"7980"		"10042880"	"186847001"
	DB06822	Hemorrhage	C0019080	NCT02094157	Terminated	Phase 3	Change of practice made further recruitment impossible		"69646|104466"		"10055798"	"131148009"
menadiol sodium diphosphate	DB09332	Hemorrhage	C0019080		Approved			CHEBI_134713	"52549"		"10055798"	"131148009"
aprotinin	DB06692	Hemorrhage	C0019080		Approved				"1056|353110"		"10055798"	"131148009"
acetylsalicylic acid	DB00945	Hemorrhage	C0019080	NCT02807441	Withdrawn	Phase 3		CHEBI_15365	"91101|1191"		"10055798"	"131148009"
	DB00682	Hemorrhage	C0019080	NCT02094157	Terminated	Phase 3	Change of practice made further recruitment impossible	CHEBI_87732	"11289"		"10055798"	"131148009"
	DB09258	Hemorrhage	C0019080	NCT02094157	Terminated	Phase 3	Change of practice made further recruitment impossible		"280611"		"10055798"	"131148009"
heparin	DB01109	Hemorrhage	C0019080	NCT02094157	Terminated	Phase 3	Change of practice made further recruitment impossible	CHEBI_28304	"5224"		"10055798"	"131148009"
defibrotide	DB04932	Hepatic Veno-Occlusive Disease	C0019156		Approved				"1311089"	MONDO_0019514	"10047216"	"65617004"
belzutifan	DB15463	Von Hippel-Lindau Syndrome	C0019562		Approved				"2567226"	MONDO_0008667	"10047716"	"46659004"
aluminium chlorohydrate	DB11573	Hyperhidrosis disorder	C0020458		Approved				"17610"	HP:0000975	"10020642"	"312230002"
aluminium chloride	DB11081	Hyperhidrosis disorder	C0020458		Approved			CHEBI_30114	"46241"	HP:0000975	"10020642"	"312230002"
venetoclax	DB11581	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_133021	"1747556"	MONDO_0004948	"10008958"	"51092000"
ofatumumab	DB06650	Chronic Lymphocytic Leukemia	C0023434		Approved				"712566"	MONDO_0004948	"10008958"	"51092000"
fludarabine phosphate	DB01073	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_94701	"24698"	MONDO_0004948	"10008958"	"51092000"
duvelisib	DB11952	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_131169	"2058509"	MONDO_0004948	"10008958"	"51092000"
prednisone	DB00635	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_8382	"8640"	MONDO_0004948	"10008958"	"51092000"
rituximab	DB00073	Chronic Lymphocytic Leukemia	C0023434		Approved				"2273510|2472325|121191|2105824"	MONDO_0004948	"10008958"	"51092000"
ibrutinib	DB09053	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_76612	"1442981"	MONDO_0004948	"10008958"	"51092000"
obinutuzumab	DB08935	Chronic Lymphocytic Leukemia	C0023434		Approved				"974779"	MONDO_0004948	"10008958"	"51092000"
mechlorethamine	DB00888	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_28925	"6674"	MONDO_0004948	"10008958"	"51092000"
idelalisib	DB09054	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_82701	"1544460"	MONDO_0004948	"10008958"	"51092000"
chlorambucil	DB00291	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_28830	"2346"	MONDO_0004948	"10008958"	"51092000"
bendamustine	DB06769	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_135515	"134547"	MONDO_0004948	"10008958"	"51092000"
uracil mustard	DB00791	Chronic Lymphocytic Leukemia	C0023434		Approved			CHEBI_9884	"10996"	MONDO_0004948	"10008958"	"51092000"
idarubicin	DB01177	Acute Promyelocytic Leukemia	C0023487		Approved			CHEBI_42068	"5650"	MONDO_0012883	"10001019"	"110004001"
tamibarotene	DB04942	Acute Promyelocytic Leukemia	C0023487		Approved			CHEBI_32181		MONDO_0012883	"10001019"	"110004001"
daunorubicin	DB00694	Acute Promyelocytic Leukemia	C0023487		Approved			CHEBI_41977	"214468|3109"	MONDO_0012883	"10001019"	"110004001"
arsenic trioxide	DB01169	Acute Promyelocytic Leukemia	C0023487		Approved			CHEBI_49900	"18330"	MONDO_0012883	"10001019"	"110004001"
tretinoin	DB00755	Acute Promyelocytic Leukemia	C0023487		Approved			CHEBI_15367	"10753"	MONDO_0012883	"10001019"	"110004001"
mercaptopurine	DB01033	Acute Promyelocytic Leukemia	C0023487		Approved			CHEBI_50667	"103|1546028"	MONDO_0012883	"10001019"	"110004001"
cytarabine	DB00987	Acute Promyelocytic Leukemia	C0023487		Approved			CHEBI_28680	"3041|968804"	MONDO_0012883	"10001019"	"110004001"
azathioprine	DB00993	Myasthenia Gravis	C0026896		Approved			CHEBI_2948	"1256"	MONDO_0009688	"10028417"	"91637004"
bortezomib	DB00188	Myasthenia Gravis	C0026896	NCT02102594	Terminated	Phase 2	recruitment difficulties	CHEBI_52717	"358258"	MONDO_0009688	"10028417"	"91637004"
	DB00860	Myasthenia Gravis	C0026896	NCT00424489	Terminated	Phase 1	No participants enrolled for more than two years. No plan to continue study.	CHEBI_8378	"8638"	MONDO_0009688	"10028417"	"91637004"
	DB14644	Myasthenia Gravis	C0026896	NCT00424489	Terminated	Phase 1	No participants enrolled for more than two years. No plan to continue study.	CHEBI_135765		MONDO_0009688	"10028417"	"91637004"
methylprednisolone	DB00959	Myasthenia Gravis	C0026896	NCT00424489	Terminated	Phase 1	No participants enrolled for more than two years. No plan to continue study.	CHEBI_6888	"6902"	MONDO_0009688	"10028417"	"91637004"
	DB00531	Myasthenia Gravis	C0026896	NCT00424489	Terminated	Phase 1	No participants enrolled for more than two years. No plan to continue study.	CHEBI_4027	"1545988|3002"	MONDO_0009688	"10028417"	"91637004"
ambenonium	DB01122	Myasthenia Gravis	C0026896		Approved			CHEBI_2627	"623"	MONDO_0009688	"10028417"	"91637004"
abatacept	DB01281	Myasthenia Gravis	C0026896	NCT03059888	Terminated	Early Phase 1	Mutual decision of sponsor and investigator due to logistical challenges		"614391"	MONDO_0009688	"10028417"	"91637004"
efgartigimod alfa	DB15270	Myasthenia Gravis	C0026896		Approved				"2587717"	MONDO_0009688	"10028417"	"91637004"
ravulizumab	DB11580	Myasthenia Gravis	C0026896		Approved				"2107316|2107301"	MONDO_0009688	"10028417"	"91637004"
distigmine	DB13694	Myasthenia Gravis	C0026896		Approved			CHEBI_80756		MONDO_0009688	"10028417"	"91637004"
pyridostigmine	DB00545	Myasthenia Gravis	C0026896		Approved			CHEBI_8665	"9000"	MONDO_0009688	"10028417"	"91637004"
neostigmine	DB01400	Myasthenia Gravis	C0026896		Approved			CHEBI_7514	"7315"	MONDO_0009688	"10028417"	"91637004"
doxorubicin	DB00997	Nephroblastoma	C0027708		Approved			CHEBI_28748	"142433|3639"	MONDO_0006058	"10029145"	"302849000"
vincristine	DB00541	Nephroblastoma	C0027708		Approved			CHEBI_28445	"11202"	MONDO_0006058	"10029145"	"302849000"
dactinomycin	DB00970	Nephroblastoma	C0027708		Approved			CHEBI_27666	"3100"	MONDO_0006058	"10029145"	"302849000"
streptomycin	DB01082	Plague	C0032064		Approved			CHEBI_17076	"10109"	MONDO_0019095	"10035148"	"58750007"
minocycline	DB01017	Plague	C0032064		Approved			CHEBI_50694	"6980"	MONDO_0019095	"10035148"	"58750007"
mezlocillin	DB00948	Aspiration Pneumonia	C0032290		Approved			CHEBI_6919	"6927"	MONDO_0000265|MONDO_0002572	"10035669"	"422588002"
benzylpenicillin	DB01053	Aspiration Pneumonia	C0032290		Approved			CHEBI_18208	"7980"	MONDO_0000265|MONDO_0002572	"10035669"	"422588002"
clindamycin phosphate	DB01190	Aspiration Pneumonia	C0032290		Approved			CHEBI_3745	"2582"	MONDO_0000265|MONDO_0002572	"10035669"	"422588002"
ticarcillin	DB01607	Aspiration Pneumonia	C0032290		Approved			CHEBI_9587	"10591"	MONDO_0000265|MONDO_0002572	"10035669"	"422588002"
azlocillin	DB01061	Aspiration Pneumonia	C0032290		Approved			CHEBI_2956	"1266"	MONDO_0000265|MONDO_0002572	"10035669"	"422588002"
clindamycin	DB01190	Aspiration Pneumonia	C0032290		Approved			CHEBI_3745	"2582"	MONDO_0000265|MONDO_0002572	"10035669"	"422588002"
rituximab	DB00073	Purpura, Thrombotic Thrombocytopenic	C0034155		Approved				"2273510|2472325|121191|2105824"	MONDO_0018896	"10043648"	"78129009"
danazol	DB01406	Purpura, Thrombotic Thrombocytopenic	C0034155	NCT00953771	Terminated	Phase 2	low enrollment	CHEBI_4315	"3102"	MONDO_0018896	"10043648"	"78129009"
rituximab	DB00073	Purpura, Thrombotic Thrombocytopenic	C0034155	NCT00251277	Withdrawn	Phase 1/Phase 2			"2273510|2472325|121191|2105824"	MONDO_0018896	"10043648"	"78129009"
rituximab	DB00073	Purpura, Thrombotic Thrombocytopenic	C0034155	NCT00799773	Terminated	Phase 3	Low enrollment rate		"2273510|2472325|121191|2105824"	MONDO_0018896	"10043648"	"78129009"
caplacizumab	DB06081	Purpura, Thrombotic Thrombocytopenic	C0034155		Approved				"2110605|2110604"	MONDO_0018896	"10043648"	"78129009"
bevacizumab	DB00112	Retinopathy of Prematurity	C0035344	NCT00702819	Terminated	Phase 1	Low enrollment due to the stringent enrollment criteria. Unable to answer study questions		"253337|2046138"	MONDO_0006952|MONDO_0007589	"10038933"	"415297005"
bevacizumab	DB00112	Retinopathy of Prematurity	C0035344	NCT01232777	Withdrawn	Phase 2	Lack of funding		"253337|2046138"	MONDO_0006952|MONDO_0007589	"10038933"	"415297005"
ranibizumab	DB01270	Retinopathy of Prematurity	C0035344		Approved				"595060"	MONDO_0006952|MONDO_0007589	"10038933"	"415297005"
betamethasone acetate	DB00443	Rheumatic Heart Disease	C0035439		Approved			CHEBI_3077	"1514"		"10062110"	"23685000"
	DB06228	Rheumatic Heart Disease	C0035439	NCT03926156	Terminated	Phase 3	COVID-19 has impacted our study recruitment	CHEBI_68579	"1114195"		"10062110"	"23685000"
warfarin	DB00682	Rheumatic Heart Disease	C0035439	NCT03926156	Terminated	Phase 3	COVID-19 has impacted our study recruitment	CHEBI_87732	"11289"		"10062110"	"23685000"
hydrocortisone succinate	DB00741	Rheumatic Heart Disease	C0035439		Approved			CHEBI_17650	"5492"		"10062110"	"23685000"
methylprednisolone	DB00959	Rheumatic Heart Disease	C0035439		Approved			CHEBI_6888	"6902"		"10062110"	"23685000"
hydrocortisone	DB00741	Rheumatic Heart Disease	C0035439		Approved			CHEBI_17650	"5492"		"10062110"	"23685000"
	DB00945	Rheumatic Heart Disease	C0035439	NCT02832531	Withdrawn	Phase 3	Focus on recruitment for non-inferiority trial	CHEBI_15365	"91101|1191"		"10062110"	"23685000"
rivaroxaban	DB06228	Rheumatic Heart Disease	C0035439	NCT02832531	Withdrawn	Phase 3	Focus on recruitment for non-inferiority trial	CHEBI_68579	"1114195"		"10062110"	"23685000"
hydrocortisone succinate	DB14545	Rheumatic Heart Disease	C0035439		Approved			CHEBI_31677	"21651"		"10062110"	"23685000"
cortisone acetate	DB01380	Rheumatic Heart Disease	C0035439		Approved			CHEBI_3897	"21655"		"10062110"	"23685000"
triamcinolone	DB00620	Rheumatic Heart Disease	C0035439		Approved			CHEBI_9667	"10759"		"10062110"	"23685000"
triamcinolone acetonide	DB00620	Rheumatic Heart Disease	C0035439		Approved			CHEBI_9667	"10759"		"10062110"	"23685000"
triamcinolone diacetate	DB00620	Rheumatic Heart Disease	C0035439		Approved			CHEBI_9667	"10759"		"10062110"	"23685000"
hydrocortisone acetate	DB00741	Rheumatic Heart Disease	C0035439		Approved			CHEBI_17650	"5492"		"10062110"	"23685000"
hydrocortisone acetate	DB14539	Rheumatic Heart Disease	C0035439		Approved			CHEBI_17609	"27197"		"10062110"	"23685000"
betamethasone	DB00443	Rheumatic Heart Disease	C0035439		Approved			CHEBI_3077	"1514"		"10062110"	"23685000"
prednisolone	DB00860	Rheumatic Heart Disease	C0035439		Approved			CHEBI_8378	"8638"		"10062110"	"23685000"
dexamethasone	DB01234	Rheumatic Heart Disease	C0035439		Approved			CHEBI_41879	"3264"		"10062110"	"23685000"
prednisone	DB00635	Rheumatic Heart Disease	C0035439		Approved			CHEBI_8382	"8640"		"10062110"	"23685000"
vigabatrin	DB01080	West Syndrome	C0037769		Approved			CHEBI_63638	"14851"	MONDO_0018097|MONDO_0100062	"10021750"	"28055006"
corticotropin	DB01285	West Syndrome	C0037769		Approved			CHEBI_3892	"376"	MONDO_0018097|MONDO_0100062	"10021750"	"28055006"
vancomycin	DB00512	Staphylococcal Infections	C0038160		Approved			CHEBI_28001	"11124"		"10058080"	"56038003"
lincomycin	DB01627	Staphylococcal Infections	C0038160		Approved			CHEBI_6472	"6398"		"10058080"	"56038003"
oxacillin	DB00713	Staphylococcal Infections	C0038160		Approved			CHEBI_7809	"7773"		"10058080"	"56038003"
fusidic acid	DB02703	Staphylococcal Infections	C0038160		Approved			CHEBI_29013	"4608|113608"		"10058080"	"56038003"
teicoplanin	DB06149	Staphylococcal Infections	C0038160		Approved			CHEBI_29687	"57021"		"10058080"	"56038003"
nafcillin	DB00607	Staphylococcal Infections	C0038160		Approved			CHEBI_7447	"7233"		"10058080"	"56038003"
cortisone acetate	DB01380	Aphthous Stomatitis	C0038363		Approved			CHEBI_3897	"21655"	HP:0032154	"10002959"	"426965005"
amlexanox	DB01025	Aphthous Stomatitis	C0038363		Approved			CHEBI_31205	"46307"	HP:0032154	"10002959"	"426965005"
triamcinolone	DB00620	Aphthous Stomatitis	C0038363		Approved			CHEBI_9667	"10759"	HP:0032154	"10002959"	"426965005"
triamcinolone acetonide	DB00620	Aphthous Stomatitis	C0038363		Approved			CHEBI_9667	"10759"	HP:0032154	"10002959"	"426965005"
hydrocortisone	DB00741	Aphthous Stomatitis	C0038363		Approved			CHEBI_17650	"5492"	HP:0032154	"10002959"	"426965005"
salicylic acid	DB00936	Synovitis	C0039103		Approved			CHEBI_16914	"9525"	HP:0100769	"10042868"	"416209007"
betamethasone acetate	DB00443	Synovitis	C0039103		Approved			CHEBI_3077	"1514"	HP:0100769	"10042868"	"416209007"
salicylic acid	DB14006	Synovitis	C0039103		Approved			CHEBI_16914	"20974"	HP:0100769	"10042868"	"416209007"
bevacizumab	DB00112	Synovitis	C0039103	NCT02060305	Terminated	Phase 1	Very slow enrollment		"253337|2046138"	HP:0100769	"10042868"	"416209007"
hydrocortisone acetate	DB14539	Synovitis	C0039103		Approved			CHEBI_17609	"27197"	HP:0100769	"10042868"	"416209007"
salicylic acid	DB13860	Synovitis	C0039103		Approved			CHEBI_16914		HP:0100769	"10042868"	"416209007"
indomethacin	DB00328	Synovitis	C0039103		Approved			CHEBI_49662	"5781"	HP:0100769	"10042868"	"416209007"
hydrocortisone acetate	DB00741	Synovitis	C0039103		Approved			CHEBI_17650	"5492"	HP:0100769	"10042868"	"416209007"
prednisolone	DB00860	Synovitis	C0039103		Approved			CHEBI_8378	"8638"	HP:0100769	"10042868"	"416209007"
triamcinolone diacetate	DB00620	Synovitis	C0039103		Approved			CHEBI_9667	"10759"	HP:0100769	"10042868"	"416209007"
betamethasone	DB00443	Synovitis	C0039103		Approved			CHEBI_3077	"1514"	HP:0100769	"10042868"	"416209007"
triamcinolone acetonide	DB00620	Synovitis	C0039103		Approved			CHEBI_9667	"10759"	HP:0100769	"10042868"	"416209007"
cortisone acetate	DB01380	Synovitis	C0039103		Approved			CHEBI_3897	"21655"	HP:0100769	"10042868"	"416209007"
hydrocortisone succinate	DB14545	Synovitis	C0039103		Approved			CHEBI_31677	"21651"	HP:0100769	"10042868"	"416209007"
methylprednisolone	DB00959	Synovitis	C0039103		Approved			CHEBI_6888	"6902"	HP:0100769	"10042868"	"416209007"
hydrocortisone succinate	DB00741	Synovitis	C0039103		Approved			CHEBI_17650	"5492"	HP:0100769	"10042868"	"416209007"
hydrocortisone	DB00741	Synovitis	C0039103		Approved			CHEBI_17650	"5492"	HP:0100769	"10042868"	"416209007"
triamcinolone	DB00620	Synovitis	C0039103		Approved			CHEBI_9667	"10759"	HP:0100769	"10042868"	"416209007"
magnesium salicylate	DB01397	Synovitis	C0039103		Approved			CHEBI_6640		HP:0100769	"10042868"	"416209007"
prednisone	DB00635	Giant Cell Arteritis	C0039483	NCT03600805	Terminated	Phase 3	Protracted recruitment timeline exacerbated by COVID-19 pandemic	CHEBI_8382	"8640"		"10018250"	"400130008"
abatacept	DB01281	Giant Cell Arteritis	C0039483	NCT03192969	Withdrawn	Phase 3	Business objectives have changed		"614391"		"10018250"	"400130008"
infliximab	DB00065	Giant Cell Arteritis	C0039483	NCT00076726	Terminated	Phase 2	Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative glucocorticosteroid dosage		"1790539|1927283|191831|2266523|2103476"		"10018250"	"400130008"
prednisone	DB00635	Giant Cell Arteritis	C0039483	NCT02531633	Terminated	Phase 3	GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in giant cell arteritis.	CHEBI_8382	"8640"		"10018250"	"400130008"
	DB05679	Giant Cell Arteritis	C0039483	NCT02955147	Terminated	Phase 1/Phase 2	Inefficacy		"847083"		"10018250"	"400130008"
prednisolone	DB00860	Giant Cell Arteritis	C0039483		Approved			CHEBI_8378	"8638"		"10018250"	"400130008"
tocilizumab	DB06273	Giant Cell Arteritis	C0039483		Approved				"612865"		"10018250"	"400130008"
triamcinolone	DB00620	Giant Cell Arteritis	C0039483		Approved			CHEBI_9667	"10759"		"10018250"	"400130008"
triamcinolone acetonide	DB00620	Giant Cell Arteritis	C0039483		Approved			CHEBI_9667	"10759"		"10018250"	"400130008"
prednisone	DB00635	Giant Cell Arteritis	C0039483	NCT02955147	Terminated	Phase 1/Phase 2	Inefficacy	CHEBI_8382	"8640"		"10018250"	"400130008"
nivolumab	DB09035	Giant Cell Arteritis	C0039483	NCT03656627	Terminated	Phase 1	low accrual		"1597876"		"10018250"	"400130008"
dibotermin alfa	DB11639	Tibial Fractures	C0040185		Approved					HP:0041143	"10043827"	"31978002"
econazole	DB01127	Tinea corporis (disorder)	C0040252		Approved			CHEBI_82873	"3743"	MONDO_0001461	"10005913"	"84849002"
naftifine	DB00735	Tinea corporis (disorder)	C0040252		Approved			CHEBI_7451	"31476"	MONDO_0001461	"10005913"	"84849002"
pramocaine	DB09345	Tinea corporis (disorder)	C0040252		Approved			CHEBI_8357	"34347"	MONDO_0001461	"10005913"	"84849002"
salicylic acid	DB13860	Tinea corporis (disorder)	C0040252		Approved			CHEBI_16914		MONDO_0001461	"10005913"	"84849002"
betamethasone dipropionate	DB00443	Tinea corporis (disorder)	C0040252		Approved			CHEBI_3077	"1514"	MONDO_0001461	"10005913"	"84849002"
benzocaine	DB01086	Tinea corporis (disorder)	C0040252		Approved			CHEBI_116735	"1399"	MONDO_0001461	"10005913"	"84849002"
salicylic acid	DB14006	Tinea corporis (disorder)	C0040252		Approved			CHEBI_16914	"20974"	MONDO_0001461	"10005913"	"84849002"
cortisone acetate	DB01380	Tinea corporis (disorder)	C0040252		Approved			CHEBI_3897	"21655"	MONDO_0001461	"10005913"	"84849002"
salicylic acid	DB00936	Tinea corporis (disorder)	C0040252		Approved			CHEBI_16914	"9525"	MONDO_0001461	"10005913"	"84849002"
tolnaftate	DB00525	Tinea corporis (disorder)	C0040252		Approved			CHEBI_9620	"10637"	MONDO_0001461	"10005913"	"84849002"
clioquinol	DB04815	Tinea corporis (disorder)	C0040252		Approved			CHEBI_74460	"5942"	MONDO_0001461	"10005913"	"84849002"
ketoconazole	DB01026	Tinea corporis (disorder)	C0040252		Approved			CHEBI_48339	"6135"	MONDO_0001461	"10005913"	"84849002"
oxiconazole	DB00239	Tinea corporis (disorder)	C0040252		Approved			CHEBI_7825	"32638"	MONDO_0001461	"10005913"	"84849002"
terbinafine	DB00857	Tinea corporis (disorder)	C0040252		Approved			CHEBI_9448	"37801"	MONDO_0001461	"10005913"	"84849002"
butenafine	DB01091	Tinea corporis (disorder)	C0040252		Approved			CHEBI_3238	"47461"	MONDO_0001461	"10005913"	"84849002"
undecylenic acid	DB11117	Tinea corporis (disorder)	C0040252		Approved			CHEBI_35045	"10989|314881"	MONDO_0001461	"10005913"	"84849002"
betamethasone	DB00443	Tinea corporis (disorder)	C0040252		Approved			CHEBI_3077	"1514"	MONDO_0001461	"10005913"	"84849002"
zinc oxide	DB09321	Tinea corporis (disorder)	C0040252		Approved			CHEBI_36560	"11423"	MONDO_0001461	"10005913"	"84849002"
griseofulvin	DB00400	Tinea corporis (disorder)	C0040252		Approved			CHEBI_27779	"91077|5021"	MONDO_0001461	"10005913"	"84849002"
luliconazole	DB08933	Tinea corporis (disorder)	C0040252		Approved			CHEBI_34825	"1482680"	MONDO_0001461	"10005913"	"84849002"
clotrimazole	DB00257	Tinea corporis (disorder)	C0040252		Approved			CHEBI_3764	"2623"	MONDO_0001461	"10005913"	"84849002"
ciclopirox	DB01188	Tinea corporis (disorder)	C0040252		Approved			CHEBI_453011	"21090"	MONDO_0001461	"10005913"	"84849002"
hydrocortisone	DB00741	Tinea corporis (disorder)	C0040252		Approved			CHEBI_17650	"5492"	MONDO_0001461	"10005913"	"84849002"
haloprogin	DB00793	Tinea corporis (disorder)	C0040252		Approved			CHEBI_5614	"26422"	MONDO_0001461	"10005913"	"84849002"
sulconazole	DB06820	Tinea corporis (disorder)	C0040252		Approved			CHEBI_77776	"37319"	MONDO_0001461	"10005913"	"84849002"
miconazole	DB01110	Tinea corporis (disorder)	C0040252		Approved			CHEBI_82892	"6932"	MONDO_0001461	"10005913"	"84849002"
ciclopirox	DB01188	Onychomycosis	C0040261		Approved			CHEBI_453011	"21090"	MONDO_0001628	"10030338"	"414941008"
tavaborole	DB09041	Onychomycosis	C0040261		Approved			CHEBI_77942	"1543173"	MONDO_0001628	"10030338"	"414941008"
efinaconazole	DB09040	Onychomycosis	C0040261		Approved			CHEBI_82718	"1539753"	MONDO_0001628	"10030338"	"414941008"
miconazole	DB01110	Onychomycosis	C0040261		Approved			CHEBI_82892	"6932"	MONDO_0001628	"10030338"	"414941008"
griseofulvin	DB00400	Onychomycosis	C0040261		Approved			CHEBI_27779	"91077|5021"	MONDO_0001628	"10030338"	"414941008"
terbinafine	DB00857	Onychomycosis	C0040261		Approved			CHEBI_9448	"37801"	MONDO_0001628	"10030338"	"414941008"
domperidone	DB01184	Peripheral edema	C0085649	NCT00305331	Terminated	Phase 2	lack of recruitment	CHEBI_31515	"3626"	HP:0012398	"10030124"	"424372002"
acetazolamide	DB00819	Peripheral edema	C0085649		Approved			CHEBI_27690	"167"	HP:0012398	"10030124"	"424372002"
sevelamer	DB00658	Hyperphosphatemia (disorder)	C0085681	NCT00833768	Terminated	Phase 3	After an extensive review,the ASPIRE in CKD study was terminated because it was not possible to complete the study in an appropriate time frame.		"214824"	MONDO_0000328	"10020711"	"20165001"
colestilan	DB11634	Hyperphosphatemia (disorder)	C0085681		Approved			CHEBI_31428		MONDO_0000328	"10020711"	"20165001"
sucroferric oxyhydroxide	DB14695	Hyperphosphatemia (disorder)	C0085681		Approved					MONDO_0000328	"10020711"	"20165001"
sucroferric oxyhydroxide	DB09146	Hyperphosphatemia (disorder)	C0085681		Approved				"1484283|24909"	MONDO_0000328	"10020711"	"20165001"
ferric citrate	DB14520	Hyperphosphatemia (disorder)	C0085681		Approved			CHEBI_144421	"1594675"	MONDO_0000328	"10020711"	"20165001"
sodium phosphate, monobasic	DB09449	Hypophosphatemia	C0085682		Approved			CHEBI_37585	"36709|235496|314838|349753"	MONDO_0000313	"10021058"	"4996001"
calcifediol	DB00146	Hypophosphatemia	C0085682		Approved			CHEBI_17933	"1855064|1889"	MONDO_0000313	"10021058"	"4996001"
calcitriol	DB00136	Hypophosphatemia	C0085682		Approved			CHEBI_17823	"1894"	MONDO_0000313	"10021058"	"4996001"
sodium glycerophosphate	DB09561	Hypophosphatemia	C0085682		Approved				"1423802|1595589"	MONDO_0000313	"10021058"	"4996001"
dihydrotachysterol	DB01070	Hypophosphatemia	C0085682		Approved			CHEBI_4591	"3429"	MONDO_0000313	"10021058"	"4996001"
durvalumab	DB11714	Small cell carcinoma of lung	C0149925		Approved				"1919503"	MONDO_0008433	"10041067"	"254632001"
etoposide	DB00773	Small cell carcinoma of lung	C0149925		Approved			CHEBI_4911	"4179"	MONDO_0008433	"10041067"	"254632001"
doxorubicin	DB00997	Small cell carcinoma of lung	C0149925		Approved			CHEBI_28748	"142433|3639"	MONDO_0008433	"10041067"	"254632001"
topotecan	DB01030	Small cell carcinoma of lung	C0149925		Approved			CHEBI_63632	"57308"	MONDO_0008433	"10041067"	"254632001"
etoposide phosphate	DB00773	Small cell carcinoma of lung	C0149925		Approved			CHEBI_4911	"4179"	MONDO_0008433	"10041067"	"254632001"
lurbinectedin	DB12674	Small cell carcinoma of lung	C0149925		Approved				"2374729"	MONDO_0008433	"10041067"	"254632001"
procaine benzylpenicillin	DB09320	Syphilis, secondary	C0149985		Approved			CHEBI_52154	"7983"	MONDO_0002897	"10056883"	"240557004"
benzylpenicillin	DB01053	Syphilis, secondary	C0149985		Approved			CHEBI_18208	"7980"	MONDO_0002897	"10056883"	"240557004"
procaine benzylpenicillin	DB01053	Syphilis, secondary	C0149985		Approved			CHEBI_18208	"7980"	MONDO_0002897	"10056883"	"240557004"
micafungin	DB01141	Systemic candidiasis	C0153252		Approved			CHEBI_600520	"325887"		"10042938"	"70572005"
itraconazole	DB01167	Systemic candidiasis	C0153252		Approved			CHEBI_6076	"28031"		"10042938"	"70572005"
ketoconazole	DB01026	Systemic candidiasis	C0153252		Approved			CHEBI_48339	"6135"		"10042938"	"70572005"
amphotericin B	DB00681	Systemic candidiasis	C0153252		Approved			CHEBI_2682	"236594|732"		"10042938"	"70572005"
fluconazole	DB00196	Systemic candidiasis	C0153252		Approved			CHEBI_46081	"202813|4450"		"10042938"	"70572005"
voriconazole	DB00582	Systemic candidiasis	C0153252		Approved			CHEBI_10023	"121243"		"10042938"	"70572005"
amphotericin B	DB00681	Candidal endocarditis	C0153254		Approved			CHEBI_2682	"236594|732"		"10014669"	"63553008"
amphotericin B	DB00681	Candidal meningitis	C0153256		Approved			CHEBI_2682	"236594|732"		"10027205"	"45021001"
clomethiazole	DB06470	Alcohol withdrawal syndrome	C0236663		Approved			CHEBI_92875	"2372"	MONDO_0005433	"10053164"	"191480000"
baclofen	DB00181	Alcohol withdrawal syndrome	C0236663	NCT02052440	Terminated	Phase 3	Insufficient funding to complete with low enrollment rate	CHEBI_2972	"1292"	MONDO_0005433	"10053164"	"191480000"
diazepam	DB00829	Alcohol withdrawal syndrome	C0236663		Approved			CHEBI_49575	"3322"	MONDO_0005433	"10053164"	"191480000"
clorazepate	DB00628	Alcohol withdrawal syndrome	C0236663		Approved			CHEBI_3761	"2353|235408"	MONDO_0005433	"10053164"	"191480000"
chlordiazepoxide	DB00475	Alcohol withdrawal syndrome	C0236663		Approved			CHEBI_3611	"2356"	MONDO_0005433	"10053164"	"191480000"
pergolide	DB01186	Parkinsonian Disorders	C0242422		Approved			CHEBI_63617	"8047"	HP:0001300	"10034010"	"32798002"
metixene	DB00340	Parkinsonian Disorders	C0242422		Approved			CHEBI_51024	"29682"	HP:0001300	"10034010"	"32798002"
levodopa	DB01235	Parkinsonian Disorders	C0242422		Approved			CHEBI_15765	"6375"	HP:0001300	"10034010"	"32798002"
amantadine	DB00915	Parkinsonian Disorders	C0242422		Approved			CHEBI_2618	"620"	HP:0001300	"10034010"	"32798002"
biperiden	DB00810	Parkinsonian Disorders	C0242422		Approved			CHEBI_3112	"1589"	HP:0001300	"10034010"	"32798002"
trihexyphenidyl	DB00376	Parkinsonian Disorders	C0242422		Approved			CHEBI_9720	"10811"	HP:0001300	"10034010"	"32798002"
orphenadrine	DB01173	Parkinsonian Disorders	C0242422		Approved			CHEBI_7789	"7715"	HP:0001300	"10034010"	"32798002"
piribedil	DB12478	Parkinsonian Disorders	C0242422		Approved			CHEBI_92833	"8353"	HP:0001300	"10034010"	"32798002"
benzatropine	DB00245	Parkinsonian Disorders	C0242422		Approved			CHEBI_3048	"1424"	HP:0001300	"10034010"	"32798002"
levodopa	DB00988	Parkinsonian Disorders	C0242422		Approved			CHEBI_18243	"3628"	HP:0001300	"10034010"	"32798002"
procyclidine	DB00387	Parkinsonian Disorders	C0242422		Approved			CHEBI_8448	"8718"	HP:0001300	"10034010"	"32798002"
carbidopa	DB00190	Parkinsonian Disorders	C0242422		Approved			CHEBI_39585	"2019|1545982"	HP:0001300	"10034010"	"32798002"
melevodopa	DB13313	Parkinsonian Disorders	C0242422		Approved			CHEBI_134880		HP:0001300	"10034010"	"32798002"
alprostadil	DB00770	Congenital atresia of pulmonary valve	C0242855		Approved			CHEBI_15544	"598"	HP:0010882	"10052644"	"719955006"
cefuroxime	DB01112	Gonorrhea of rectum	C0275665		Approved			CHEBI_3515	"2194"		"10036777"	"42746002"
amphotericin B	DB00681	Gonorrhea of rectum	C0275665		Approved			CHEBI_2682	"236594|732"		"10036777"	"42746002"
demeclocycline	DB00618	Gonorrhea of rectum	C0275665		Approved			CHEBI_4392	"3154"		"10036777"	"42746002"
ofloxacin	DB01165	Gonorrhea of rectum	C0275665		Approved			CHEBI_7731	"7623"		"10036777"	"42746002"
fusidic acid	DB02703	Gonorrhea of rectum	C0275665		Approved			CHEBI_29013	"4608|113608"		"10036777"	"42746002"
cefpodoxime proxetil	DB01416	Gonorrhea of rectum	C0275665		Approved			CHEBI_3504	"20489"		"10036777"	"42746002"
alatrofloxacin	DB09335	Gonorrhea of rectum	C0275665		Approved			CHEBI_135829	"141440"		"10036777"	"42746002"
doxycycline	DB00254	Gonorrhea of rectum	C0275665		Approved			CHEBI_50845	"1545992|3640"		"10036777"	"42746002"
minocycline	DB01017	Gonorrhea of rectum	C0275665		Approved			CHEBI_50694	"6980"		"10036777"	"42746002"
tetracycline	DB09550	Gonorrhea of rectum	C0275665		Approved			CHEBI_27902	"2105975"		"10036777"	"42746002"
cefuroxime axetil	DB01112	Gonorrhea of rectum	C0275665		Approved			CHEBI_3515	"2194"		"10036777"	"42746002"
spectinomycin	DB00919	Gonorrhea of rectum	C0275665		Approved			CHEBI_9215	"270"		"10036777"	"42746002"
oxytetracycline	DB00595	Gonorrhea of rectum	C0275665		Approved			CHEBI_133011	"7821|1545999"		"10036777"	"42746002"
norfloxacin	DB01059	Gonorrhea of rectum	C0275665		Approved			CHEBI_100246	"7517"		"10036777"	"42746002"
ceftizoxime	DB01332	Gonorrhea of rectum	C0275665		Approved			CHEBI_553473	"2192"		"10036777"	"42746002"
erythromycin	DB00199	Gonorrhea of rectum	C0275665		Approved			CHEBI_42355	"4053"		"10036777"	"42746002"
gatifloxacin	DB01044	Gonorrhea of rectum	C0275665		Approved			CHEBI_5280	"228476|1546025"		"10036777"	"42746002"
ampicillin	DB00415	Gonorrhea of rectum	C0275665		Approved			CHEBI_28971	"733|221058"		"10036777"	"42746002"
meclocycline	DB13092	Gonorrhea of rectum	C0275665		Approved			CHEBI_135772	"29418"		"10036777"	"42746002"
ceftriaxone	DB01212	Gonorrhea of rectum	C0275665		Approved			CHEBI_29007	"2193"		"10036777"	"42746002"
enoxacin	DB00467	Gonorrhea of rectum	C0275665		Approved			CHEBI_157175	"3925"		"10036777"	"42746002"
tetracycline	DB00759	Gonorrhea of rectum	C0275665		Approved			CHEBI_27902	"10395"		"10036777"	"42746002"
trovafloxacin	DB00685	Gonorrhea of rectum	C0275665		Approved			CHEBI_9763	"115552"		"10036777"	"42746002"
cetuximab	DB00002	Laryngeal Squamous Cell Carcinoma	C0280324		Approved				"318341"	MONDO_0005595	"10023856"	"405822008"
	DB00762	Adenocarcinoma of pancreas	C0281361	NCT01359007	Terminated	Phase 2	The principal investigator terminated the study due to inactivity and low enrollment	CHEBI_80630	"51499"	MONDO_0006047	"10052747"	"700423003"
erlotinib	DB00530	Adenocarcinoma of pancreas	C0281361		Approved			CHEBI_114785	"337525"	MONDO_0006047	"10052747"	"700423003"
irinotecan	DB00762	Adenocarcinoma of pancreas	C0281361		Approved			CHEBI_80630	"51499"	MONDO_0006047	"10052747"	"700423003"
	DB00526	Adenocarcinoma of pancreas	C0281361	NCT01359007	Terminated	Phase 2	The principal investigator terminated the study due to inactivity and low enrollment	CHEBI_31941	"32592"	MONDO_0006047	"10052747"	"700423003"
leucovorin	DB00650	Adenocarcinoma of pancreas	C0281361	NCT01359007	Terminated	Phase 2	The principal investigator terminated the study due to inactivity and low enrollment	CHEBI_15640	"6313"	MONDO_0006047	"10052747"	"700423003"
gemcitabine	DB00441	Adenocarcinoma of pancreas	C0281361		Approved			CHEBI_175901	"12574"	MONDO_0006047	"10052747"	"700423003"
mitomycin	DB00305	Adenocarcinoma of pancreas	C0281361		Approved			CHEBI_27504	"632"	MONDO_0006047	"10052747"	"700423003"
fluorouracil	DB00544	Adenocarcinoma of pancreas	C0281361		Approved			CHEBI_46345	"4492"	MONDO_0006047	"10052747"	"700423003"
temozolomide	DB00853	Anaplastic astrocytoma	C0334579		Approved			CHEBI_72564	"37776"	MONDO_0016684	"10060971"	"55353007"
gentamicin	DB00798	Neonatal meningitis	C0456107		Approved			CHEBI_17833	"1596450"		"10058780"	"276674008"
tobramycin	DB00684	Neonatal meningitis	C0456107		Approved			CHEBI_28864	"10627"		"10058780"	"276674008"
amikacin	DB00479	Neonatal meningitis	C0456107		Approved			CHEBI_2637	"641"		"10058780"	"276674008"
fusidic acid	DB02703	Neonatal meningitis	C0456107		Approved			CHEBI_29013	"4608|113608"		"10058780"	"276674008"
cefotaxime	DB00493	Neonatal meningitis	C0456107		Approved			CHEBI_204928	"2186"		"10058780"	"276674008"
benzylpenicillin	DB01053	Neonatal meningitis	C0456107		Approved			CHEBI_18208	"7980"		"10058780"	"276674008"
ceftazidime	DB00438	Neonatal meningitis	C0456107		Approved			CHEBI_3508	"2191|1545984"		"10058780"	"276674008"
ofloxacin	DB01165	Chlamydial pelvic inflammatory disease	C0520777		Approved			CHEBI_7731	"7623"		"10008565"	"188463006"
norfloxacin	DB01059	Chlamydial pelvic inflammatory disease	C0520777		Approved			CHEBI_100246	"7517"		"10008565"	"188463006"
alatrofloxacin	DB09335	Chlamydial pelvic inflammatory disease	C0520777		Approved			CHEBI_135829	"141440"		"10008565"	"188463006"
azithromycin	DB00207	Chlamydial pelvic inflammatory disease	C0520777		Approved			CHEBI_2955	"18631"		"10008565"	"188463006"
trovafloxacin	DB00685	Chlamydial pelvic inflammatory disease	C0520777		Approved			CHEBI_9763	"115552"		"10008565"	"188463006"
hydrochlorothiazide	DB00999	Hypertensive urgency	C0745138		Approved			CHEBI_5778	"5487"		"10058181"	"443482000"
chlorothiazide	DB00880	Hypertensive urgency	C0745138		Approved			CHEBI_3640	"2396"		"10058181"	"443482000"
nitroprusside	DB00325	Hypertensive urgency	C0745138		Approved			CHEBI_7596	"7476"		"10058181"	"443482000"
diazoxide	DB01119	Hypertensive urgency	C0745138		Approved			CHEBI_4495	"3327"		"10058181"	"443482000"
fenoldopam	DB00800	Hypertensive urgency	C0745138		Approved			CHEBI_5002	"24853"		"10058181"	"443482000"
losartan	DB00678	Hypertensive urgency	C0745138		Approved			CHEBI_6541	"52175"		"10058181"	"443482000"
	DB00734	Bipolar I disorder	C0853193	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_8871	"35636"		"10004939"	"371596008"
	DB01238	Bipolar I disorder	C0853193	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_31236	"89013"		"10004939"	"371596008"
quetiapine	DB01224	Bipolar I disorder	C0853193	NCT00857818	Terminated	Phase 3	Slow Accrual	CHEBI_8707	"51272"		"10004939"	"371596008"
samidorphan	DB12543	Bipolar I disorder	C0853193		Approved			CHEBI_177605	"2559612"		"10004939"	"371596008"
relebactam	DB12377	Infection caused by Citrobacter	C0948204		Approved				"2184137|2268500"		"10051904"	"1137353009"
imipenem	DB01598	Infection caused by Citrobacter	C0948204		Approved			CHEBI_471744	"5690|1545986"		"10051904"	"1137353009"
cilastatin	DB01597	Infection caused by Citrobacter	C0948204		Approved			CHEBI_3697	"2540"		"10051904"	"1137353009"
procaine benzylpenicillin	DB09320	Infection due to Erysipelothrix rhusiopathiae (disorder)	C1276801		Approved			CHEBI_52154	"7983"	MONDO_0006752	"10015146"	"400105005"
benzylpenicillin	DB01053	Infection due to Erysipelothrix rhusiopathiae (disorder)	C1276801		Approved			CHEBI_18208	"7980"	MONDO_0006752	"10015146"	"400105005"
procaine benzylpenicillin	DB01053	Infection due to Erysipelothrix rhusiopathiae (disorder)	C1276801		Approved			CHEBI_18208	"7980"	MONDO_0006752	"10015146"	"400105005"
cefotaxime	DB00493	Arthritis, Bacterial	C1692886		Approved			CHEBI_204928	"2186"		"10053555"	"48245008"
ceftriaxone	DB01212	Arthritis, Bacterial	C1692886		Approved			CHEBI_29007	"2193"		"10053555"	"48245008"
foscarnet	DB00529	Human Herpesvirus 6 encephalitis	C1955629		Approved			CHEBI_127780	"33562"		"10081897"	"441512004"
trafermin	DB06244	Alveolar Bone Loss	C0002382		Approved					HP:0006308	"10074846"	"109706009"
fluticasone propionate	DB00588	Allergic asthma	C0155877		Approved			CHEBI_31441	"50121"	MONDO_0004784		"389145006"
fluticasone propionate	DB13867	Allergic asthma	C0155877		Approved			CHEBI_5134	"41126"	MONDO_0004784		"389145006"
amikacin	DB00479	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_2637	"641"			"448813005"
methylphenobarbital	DB00849	apprehension	C0233485		Approved			CHEBI_6758	"6758"			"49971008"
norfloxacin	DB01059	Female pelvic cellulitis	C0349734		Approved			CHEBI_100246	"7517"			"280486004"
trovafloxacin	DB00685	Female pelvic cellulitis	C0349734		Approved			CHEBI_9763	"115552"			"280486004"
aztreonam	DB00355	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_161680	"1272"			"448813005"
roxadustat	DB04847	Refractory anemia, without ringed sideroblasts, without excess blasts	C2981142		Approved			CHEBI_132774				"1260268001"
cefoxitin	DB01331	Female pelvic cellulitis	C0349734		Approved			CHEBI_209807	"2189"			"280486004"
ceftazidime	DB00438	Sepsis due to Pseudomonas	C2887096		Approved			CHEBI_3508	"2191|1545984"			"448813005"
acetylcarnitine	DB00583	Senile dementia	C0011268		Approved			CHEBI_16347	"42955"		"10039966"	"15662003"
pramiracetam	DB13247	Senile dementia	C0011268		Approved			CHEBI_135110			"10039966"	"15662003"
epicriptine	DB11275	Senile dementia	C0011268		Approved			CHEBI_135927	"91171|1546422"		"10039966"	"15662003"
acetylcarnitine	DB08842	Senile dementia	C0011268		Approved			CHEBI_57589	"193"		"10039966"	"15662003"
acetylsalicylic acid	DB00945	Disseminated Intravascular Coagulation	C0012739	NCT04363840	Withdrawn	Phase 2	lack of funding	CHEBI_15365	"91101|1191"	MONDO_0001243	"10013442"	"67406007"
heparin	DB01109	Disseminated Intravascular Coagulation	C0012739		Approved			CHEBI_28304	"5224"	MONDO_0001243	"10013442"	"67406007"
diethylcarbamazine	DB00711	Elephantiasis	C0013882		Approved			CHEBI_4527	"3384"	MONDO_0005424	"10014472"	"240820001"
erythromycin	DB00199	Erythrasma	C0014752		Approved			CHEBI_42355	"4053"	MONDO_0002885	"10015248"	"238418005"
eptotermin alfa	DB11631	Fractures, Ununited	C0016665		Approved						"10017088"	"302941001"
carbimazole	DB00389	Graves Disease	C0018213		Approved			CHEBI_617099	"2020"	HP:0100647	"10018706"	"353295004"
idoxuridine	DB00249	Keratitis, Herpetic	C0019357		Approved			CHEBI_147675	"5653"	MONDO_0015288	"10062004"	"9389005"
trifluridine	DB00432	Keratitis, Herpetic	C0019357		Approved			CHEBI_75179	"10803"	MONDO_0015288	"10062004"	"9389005"
vidarabine	DB00194	Keratitis, Herpetic	C0019357		Approved			CHEBI_45327	"11194"	MONDO_0015288	"10062004"	"9389005"
bromocriptine	DB01200	Hyperprolactinemia	C0020514		Approved			CHEBI_3181	"1760"	MONDO_0005804|MONDO_0014250	"10020737"	"237662005"
cabergoline	DB00248	Hyperprolactinemia	C0020514		Approved			CHEBI_3286	"47579"	MONDO_0005804|MONDO_0014250	"10020737"	"237662005"
dibromotyrosine	DB07637	Hyperthyroidism	C0020550		Approved			CHEBI_28335		HP:0000836	"10020850"	"34486009"
propylthiouracil	DB00550	Hyperthyroidism	C0020550		Approved			CHEBI_8502	"8794"	HP:0000836	"10020850"	"34486009"
thiamazole	DB00763	Hyperthyroidism	C0020550		Approved			CHEBI_50673	"6835"	HP:0000836	"10020850"	"34486009"
carbimazole	DB00389	Hyperthyroidism	C0020550		Approved			CHEBI_617099	"2020"	HP:0000836	"10020850"	"34486009"
calcium glucoheptonate	DB00326	Hypocalcemia	C0020598		Approved			CHEBI_3314	"47618"	HP:0002901	"10020947"	"5291005"
calcifediol	DB00146	Hypocalcemia	C0020598		Approved			CHEBI_17933	"1855064|1889"	HP:0002901	"10020947"	"5291005"
calcium chloride	DB01164	Hypocalcemia	C0020598		Approved			CHEBI_3312	"1901|1667640"	HP:0002901	"10020947"	"5291005"
calcium glycerylphosphate	DB11264	Hypocalcemia	C0020598		Approved			CHEBI_31336	"1909"	HP:0002901	"10020947"	"5291005"
magnesium citrate	DB11110	Hypocalcemia	C0020598		Approved			CHEBI_131391	"52356"	HP:0002901	"10020947"	"5291005"
colecalciferol	DB00169	Hypocalcemia	C0020598		Approved			CHEBI_28940	"2418"	HP:0002901	"10020947"	"5291005"
calcium phosphate	DB11348	Hypocalcemia	C0020598		Approved			CHEBI_9679	"1919"	HP:0002901	"10020947"	"5291005"
calcium citrate	DB11093	Hypocalcemia	C0020598		Approved			CHEBI_190513	"47613"	HP:0002901	"10020947"	"5291005"
calcium gluconate	DB11126	Hypocalcemia	C0020598		Approved			CHEBI_3309	"1908"	HP:0002901	"10020947"	"5291005"
calcium lactate	DB13231	Hypocalcemia	C0020598		Approved				"47622"	HP:0002901	"10020947"	"5291005"
dihydrotachysterol	DB01070	Hypocalcemia	C0020598		Approved			CHEBI_4591	"3429"	HP:0002901	"10020947"	"5291005"
calcitriol	DB00136	Hypocalcemia	C0020598		Approved			CHEBI_17823	"1894"	HP:0002901	"10020947"	"5291005"
phytomenadione	DB01022	Hypocalcemia	C0020598		Approved			CHEBI_18067	"11258|8308"	HP:0002901	"10020947"	"5291005"
ergocalciferol	DB11094	Hypocalcemia	C0020598		Approved			CHEBI_28934	"11253"	HP:0002901	"10020947"	"5291005"
ergocalciferol	DB00153	Hypocalcemia	C0020598		Approved			CHEBI_28934	"4018"	HP:0002901	"10020947"	"5291005"
teriparatide	DB06285	Hypocalcemia	C0020598	NCT00623974	Terminated	Phase 2	Terminated due to slow accrual.	CHEBI_135983	"32915"	HP:0002901	"10020947"	"5291005"
calcium carbonate	DB06724	Hypocalcemia	C0020598		Approved			CHEBI_3311	"349908|1897"	HP:0002901	"10020947"	"5291005"
calcium acetate	DB00258	Hypocalcemia	C0020598		Approved			CHEBI_3310	"214342"	HP:0002901	"10020947"	"5291005"
calcium lactate gluconate	DB13365	Hypocalcemia	C0020598		Approved					HP:0002901	"10020947"	"5291005"
calcitriol	DB00136	Hypocalcemia	C0020598	NCT00001151	Terminated	Phase 2	Terminated because of lack of drug supply	CHEBI_17823	"1894"	HP:0002901	"10020947"	"5291005"
calcium levulinate	DB13800	Hypocalcemia	C0020598		Approved			CHEBI_81717	"47624"	HP:0002901	"10020947"	"5291005"
magnesium oxide	DB01377	Hypocalcemia	C0020598		Approved			CHEBI_31794	"6582"	HP:0002901	"10020947"	"5291005"
	DB00136	Hypocalcemia	C0020598	NCT00623974	Terminated	Phase 2	Terminated due to slow accrual.	CHEBI_17823	"1894"	HP:0002901	"10020947"	"5291005"
	DB05829	Hypocalcemia	C0020598	NCT00623974	Terminated	Phase 2	Terminated due to slow accrual.		"1427222"	HP:0002901	"10020947"	"5291005"
alfacalcidol	DB01436	Hypoparathyroidism	C0020626		Approved			CHEBI_31186	"12062"	HP:0000829	"10021041"	"36976004"
ergocalciferol	DB00153	Hypoparathyroidism	C0020626		Approved			CHEBI_28934	"4018"	HP:0000829	"10021041"	"36976004"
ergocalciferol	DB11094	Hypoparathyroidism	C0020626		Approved			CHEBI_28934	"11253"	HP:0000829	"10021041"	"36976004"
dihydrotachysterol	DB01070	Hypoparathyroidism	C0020626		Approved			CHEBI_4591	"3429"	HP:0000829	"10021041"	"36976004"
colecalciferol	DB00169	Hypoparathyroidism	C0020626		Approved			CHEBI_28940	"2418"	HP:0000829	"10021041"	"36976004"
parathyroid hormone	DB05829	Hypoparathyroidism	C0020626		Approved				"1427222"	HP:0000829	"10021041"	"36976004"
calcitriol	DB00136	Hypoparathyroidism	C0020626		Approved			CHEBI_17823	"1894"	HP:0000829	"10021041"	"36976004"
mupirocin	DB00410	Impetigo	C0021099		Approved			CHEBI_7025	"42372"	MONDO_0004592	"10021531"	"48277006"
cefuroxime	DB01112	Impetigo	C0021099		Approved			CHEBI_3515	"2194"	MONDO_0004592	"10021531"	"48277006"
cefuroxime axetil	DB01112	Impetigo	C0021099		Approved			CHEBI_3515	"2194"	MONDO_0004592	"10021531"	"48277006"
retapamulin	DB01256	Impetigo	C0021099		Approved			CHEBI_166679	"642274"	MONDO_0004592	"10021531"	"48277006"
sodium stibogluconate	DB05630	Leishmaniasis	C0023281		Approved			CHEBI_28148	"8010"	MONDO_0011989	"10024198"	"80612004"
amphotericin B	DB00681	Leishmaniasis	C0023281		Approved			CHEBI_2682	"236594|732"	MONDO_0011989	"10024198"	"80612004"
panitumumab	DB01269	Malignant Carcinoid Syndrome	C0024586	NCT01172717	Withdrawn	Phase 2	Study never began		"263034"		"10007270"	"35868009"
octreotide	DB00104	Malignant Carcinoid Syndrome	C0024586	NCT00884715	Terminated	Phase 1/Phase 2	Program was terminated for business reasons	CHEBI_7726	"7617"		"10007270"	"35868009"
octreotide	DB00104	Malignant Carcinoid Syndrome	C0024586		Approved			CHEBI_7726	"7617"		"10007270"	"35868009"
methylthioninium chloride	DB09241	Methemoglobinemia	C0025637		Approved			CHEBI_6872	"6878|2198975"	MONDO_0001117	"10027496"	"38959009"
norethisterone	DB00717	Metrorrhagia	C0025874		Approved			CHEBI_7627	"7514"	HP:0100608	"10022559"	"64996003"
medroxyprogesterone	DB00603	Metrorrhagia	C0025874		Approved			CHEBI_6716	"1000112"	HP:0100608	"10022559"	"64996003"
progesterone	DB00396	Metrorrhagia	C0025874		Approved			CHEBI_17026	"8727"	HP:0100608	"10022559"	"64996003"
norethindrone acetate	DB00717	Metrorrhagia	C0025874		Approved			CHEBI_7627	"7514"	HP:0100608	"10022559"	"64996003"
idursulfase	DB01271	Mucopolysaccharidosis II	C0026705		Approved				"644101"	MONDO_0010674	"10056889"	"70737009"
tiludronic acid	DB01133	Osteitis Deformans	C0029401		Approved			CHEBI_9598	"11476|57230"	MONDO_0005382	"10031151"	"2089002"
	DB00904	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_7773	"26225"	HP:0002018	"10028813"	"422587007"
promazine	DB00420	Nausea	C0027497		Approved			CHEBI_8459	"8742"	HP:0002018	"10028813"	"422587007"
triflupromazine	DB00508	Nausea	C0027497		Approved			CHEBI_9711	"10805"	HP:0002018	"10028813"	"422587007"
midazolam	DB00683	Nausea	C0027497	NCT01687751	Withdrawn	Phase 2	Study design determined to be not likely feasible	CHEBI_6931	"6960"	HP:0002018	"10028813"	"422587007"
olanzapine	DB00334	Nausea	C0027497	NCT00124930	Terminated	Phase 3	Study suspended due to low enrollment	CHEBI_7735	"61381"	HP:0002018	"10028813"	"422587007"
esomeprazole	DB00736	Nausea	C0027497	NCT00206440	Terminated	Phase 3	Accrual was not optimized	CHEBI_50275	"283742"	HP:0002018	"10028813"	"422587007"
palonosetron	DB00377	Nausea	C0027497	NCT00982995	Terminated	Phase 2	site terminated due to lack of enrollment	CHEBI_85161	"70561"	HP:0002018	"10028813"	"422587007"
	DB00673	Nausea	C0027497	NCT01649258	Terminated	Phase 1	Lack of Efficacy	CHEBI_499361	"358255"	HP:0002018	"10028813"	"422587007"
haloperidol	DB00502	Nausea	C0027497	NCT01684969	Withdrawn	Early Phase 1	lack of accrual and funding is about to expire.	CHEBI_5613	"5093"	HP:0002018	"10028813"	"422587007"
tramadol	DB00193	Nausea	C0027497	NCT02247648	Terminated	Phase 2		CHEBI_75722	"10689"	HP:0002018	"10028813"	"422587007"
dimenhydrinate	DB00985	Nausea	C0027497		Approved			CHEBI_94848	"3444"	HP:0002018	"10028813"	"422587007"
lorazepam	DB00186	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_6539	"6470"	HP:0002018	"10028813"	"422587007"
aprepitant	DB00673	Nausea	C0027497	NCT01249001	Terminated	Phase 2	lack of eligible participants to enrol	CHEBI_499361	"358255"	HP:0002018	"10028813"	"422587007"
granisetron	DB00889	Nausea	C0027497	NCT01649258	Terminated	Phase 1	Lack of Efficacy	CHEBI_5537	"26237"	HP:0002018	"10028813"	"422587007"
	DB01234	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_41879	"3264"	HP:0002018	"10028813"	"422587007"
dronabinol	DB00470	Nausea	C0027497	NCT02608931	Withdrawn	Phase 2	Unable to begin study with drug provider	CHEBI_66964	"10402"	HP:0002018	"10028813"	"422587007"
	DB01075	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_4636	"3498"	HP:0002018	"10028813"	"422587007"
trimethobenzamide	DB00662	Nausea	C0027497		Approved			CHEBI_27796	"38685"	HP:0002018	"10028813"	"422587007"
perazine	DB12710	Nausea	C0027497		Approved			CHEBI_59118	"8042"	HP:0002018	"10028813"	"422587007"
	DB00633	Nausea	C0027497	NCT01687751	Withdrawn	Phase 2	Study design determined to be not likely feasible	CHEBI_4466	"48937"	HP:0002018	"10028813"	"422587007"
	DB00338	Nausea	C0027497	NCT00206440	Terminated	Phase 3	Accrual was not optimized	CHEBI_77260	"7646"	HP:0002018	"10028813"	"422587007"
aprepitant	DB00673	Nausea	C0027497	NCT01405924	Terminated	Phase 2	Low enrollment	CHEBI_499361	"358255"	HP:0002018	"10028813"	"422587007"
	DB00673	Nausea	C0027497	NCT01183481	Terminated	Phase 2	Study was stopped due to inadequate accrual.	CHEBI_499361	"358255"	HP:0002018	"10028813"	"422587007"
granisetron	DB00889	Nausea	C0027497	NCT01183481	Terminated	Phase 2	Study was stopped due to inadequate accrual.	CHEBI_5537	"26237"	HP:0002018	"10028813"	"422587007"
thiethylperazine	DB00372	Nausea	C0027497		Approved			CHEBI_9544	"10471"	HP:0002018	"10028813"	"422587007"
cinnarizine	DB00568	Nausea	C0027497		Approved			CHEBI_31403	"2549"	HP:0002018	"10028813"	"422587007"
	DB01069	Nausea	C0027497	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_8461	"8745"	HP:0002018	"10028813"	"422587007"
	DB01234	Nausea	C0027497	NCT01405924	Terminated	Phase 2	Low enrollment	CHEBI_41879	"3264"	HP:0002018	"10028813"	"422587007"
valproic acid	DB00313	Neuralgia	C0027796	NCT00221637	Terminated	Phase 2/Phase 3	slow recruitment and treatments beyond expiry date	CHEBI_39867	"11118|40254"	HP:0033345	"10029223"	"16269008"
capsaicin	DB06774	Neuralgia	C0027796	NCT00089557	Terminated	Phase 2		CHEBI_3374	"1992"	HP:0033345	"10029223"	"16269008"
pregabalin	DB00230	Neuralgia	C0027796	NCT01485094	Terminated	Phase 2	The trial was early terminated after it was concluded that there was no added benefit from exposing further participants after an unblinded interim analysis.	CHEBI_64356	"187832"	HP:0033345	"10029223"	"16269008"
lidocaine	DB00281	Neuralgia	C0027796		Approved			CHEBI_6456	"6387"	HP:0033345	"10029223"	"16269008"
capsaicin	DB06774	Neuralgia	C0027796		Approved			CHEBI_3374	"1992"	HP:0033345	"10029223"	"16269008"
methylprednisolone	DB00959	Neuromyelitis Optica	C0027873	NCT03829566	Withdrawn	Phase 2/Phase 3	Discontinued by Investigator	CHEBI_6888	"6902"	MONDO_0019100	"10077875"	"25044007"
	DB14644	Neuromyelitis Optica	C0027873	NCT02087813	Withdrawn	Phase 1		CHEBI_135765		MONDO_0019100	"10077875"	"25044007"
satralizumab	DB15762	Neuromyelitis Optica	C0027873		Approved				"2391541|2391551"	MONDO_0019100	"10077875"	"25044007"
inebilizumab	DB12530	Neuromyelitis Optica	C0027873		Approved				"2373951|2373950"	MONDO_0019100	"10077875"	"25044007"
methylprednisolone	DB00959	Neuromyelitis Optica	C0027873	NCT02398994	Terminated	Phase 3	Continued effort did not successfully increase recruitment into the study.	CHEBI_6888	"6902"	MONDO_0019100	"10077875"	"25044007"
	DB00531	Neuromyelitis Optica	C0027873	NCT03829566	Withdrawn	Phase 2/Phase 3	Discontinued by Investigator	CHEBI_4027	"1545988|3002"	MONDO_0019100	"10077875"	"25044007"
	DB00073	Neuromyelitis Optica	C0027873	NCT03829566	Withdrawn	Phase 2/Phase 3	Discontinued by Investigator		"2273510|2472325|121191|2105824"	MONDO_0019100	"10077875"	"25044007"
eculizumab	DB01257	Neuromyelitis Optica	C0027873		Approved				"591781"	MONDO_0019100	"10077875"	"25044007"
	DB00860	Neuromyelitis Optica	C0027873	NCT03829566	Withdrawn	Phase 2/Phase 3	Discontinued by Investigator	CHEBI_8378	"8638"	MONDO_0019100	"10077875"	"25044007"
	DB14644	Neuromyelitis Optica	C0027873	NCT03829566	Withdrawn	Phase 2/Phase 3	Discontinued by Investigator	CHEBI_135765		MONDO_0019100	"10077875"	"25044007"
rituximab	DB00073	Neuromyelitis Optica	C0027873		Approved				"2273510|2472325|121191|2105824"	MONDO_0019100	"10077875"	"25044007"
methylprednisolone	DB00959	Neuromyelitis Optica	C0027873	NCT02087813	Withdrawn	Phase 1		CHEBI_6888	"6902"	MONDO_0019100	"10077875"	"25044007"
risedronic acid	DB00884	Osteitis Deformans	C0029401		Approved			CHEBI_8869	"73056|55685"	MONDO_0005382	"10031151"	"2089002"
alendronic acid	DB00630	Osteitis Deformans	C0029401		Approved			CHEBI_2567	"46041|236083"	MONDO_0005382	"10031151"	"2089002"
etidronic acid	DB01077	Osteitis Deformans	C0029401		Approved			CHEBI_4907	"42682|1356715"	MONDO_0005382	"10031151"	"2089002"
zoledronic acid	DB00399	Osteitis Deformans	C0029401		Approved			CHEBI_46557	"1546014|77655"	MONDO_0005382	"10031151"	"2089002"
calcitonin (salmon synthetic)	DB00017	Osteitis Deformans	C0029401		Approved				"36118"	MONDO_0005382	"10031151"	"2089002"
pamidronic acid	DB00282	Osteitis Deformans	C0029401		Approved			CHEBI_7903	"11473|1546406"	MONDO_0005382	"10031151"	"2089002"
chloramphenicol	DB00446	Paratyphoid Fever	C0030528		Approved			CHEBI_17698	"2348"	MONDO_0018626	"10033971"	"85904008"
ampicillin	DB00415	Paratyphoid Fever	C0030528		Approved			CHEBI_28971	"733|221058"	MONDO_0018626	"10033971"	"85904008"
pirbuterol	DB01291	Pulmonary Emphysema	C0034067		Approved			CHEBI_8245	"33767"	HP:0002097	"10014561"	"87433001"
fluticasone propionate	DB13867	Pulmonary Emphysema	C0034067		Approved			CHEBI_5134	"41126"	HP:0002097	"10014561"	"87433001"
theophylline	DB00277	Pulmonary Emphysema	C0034067		Approved			CHEBI_28177	"10438|91178"	HP:0002097	"10014561"	"87433001"
norepinephrine	DB00368	Pulmonary Emphysema	C0034067		Approved			CHEBI_18357	"7512"	HP:0002097	"10014561"	"87433001"
tulobuterol	DB12248	Pulmonary Emphysema	C0034067		Approved			CHEBI_93856	"38967"	HP:0002097	"10014561"	"87433001"
orciprenaline	DB00816	Pulmonary Emphysema	C0034067		Approved			CHEBI_83329	"7688"	HP:0002097	"10014561"	"87433001"
ipratropium	DB00332	Pulmonary Emphysema	C0034067		Approved			CHEBI_46659	"1546373|203212|7213"	HP:0002097	"10014561"	"87433001"
tiotropium bromide	DB01409	Pulmonary Emphysema	C0034067		Approved			CHEBI_90960	"69120"	HP:0002097	"10014561"	"87433001"
vilanterol	DB09082	Pulmonary Emphysema	C0034067		Approved			CHEBI_75037	"1424884"	HP:0002097	"10014561"	"87433001"
terbutaline	DB00871	Pulmonary Emphysema	C0034067		Approved			CHEBI_9449	"10368"	HP:0002097	"10014561"	"87433001"
fluticasone furoate	DB08906	Pulmonary Emphysema	C0034067		Approved			CHEBI_74899	"705022"	HP:0002097	"10014561"	"87433001"
arformoterol	DB01274	Pulmonary Emphysema	C0034067		Approved			CHEBI_408174	"304962"	HP:0002097	"10014561"	"87433001"
theophylline	DB01223	Pulmonary Emphysema	C0034067		Approved			CHEBI_2659	"689"	HP:0002097	"10014561"	"87433001"
umeclidinium	DB09076	Pulmonary Emphysema	C0034067		Approved			CHEBI_79041	"1487514"	HP:0002097	"10014561"	"87433001"
diprophylline	DB00651	Pulmonary Emphysema	C0034067		Approved			CHEBI_4728	"3714"	HP:0002097	"10014561"	"87433001"
bitolterol	DB00901	Pulmonary Emphysema	C0034067		Approved			CHEBI_3133	"19499"	HP:0002097	"10014561"	"87433001"
fluticasone propionate	DB00588	Pulmonary Emphysema	C0034067		Approved			CHEBI_31441	"50121"	HP:0002097	"10014561"	"87433001"
fluticasone furoate	DB13867	Pulmonary Emphysema	C0034067		Approved			CHEBI_5134	"41126"	HP:0002097	"10014561"	"87433001"
epinephrine	DB00668	Pulmonary Emphysema	C0034067		Approved			CHEBI_28918	"3992"	HP:0002097	"10014561"	"87433001"
formoterol	DB00983	Pulmonary Emphysema	C0034067		Approved			CHEBI_63082	"25255"	HP:0002097	"10014561"	"87433001"
salmeterol	DB00938	Pulmonary Emphysema	C0034067		Approved			CHEBI_64064	"36117"	HP:0002097	"10014561"	"87433001"
cefuroxime	DB01112	Rhinoscleroma	C0035468		Approved			CHEBI_3515	"2194"	MONDO_0005945	"10039102"	"72409005"
ceftazidime	DB00438	Rhinoscleroma	C0035468		Approved			CHEBI_3508	"2191|1545984"	MONDO_0005945	"10039102"	"72409005"
ofloxacin	DB01165	Rhinoscleroma	C0035468		Approved			CHEBI_7731	"7623"	MONDO_0005945	"10039102"	"72409005"
clavulanic acid	DB00766	Rhinoscleroma	C0035468		Approved			CHEBI_48947	"48203|21216"	MONDO_0005945	"10039102"	"72409005"
cefoxitin	DB01331	Rhinoscleroma	C0035468		Approved			CHEBI_209807	"2189"	MONDO_0005945	"10039102"	"72409005"
ticarcillin	DB01607	Rhinoscleroma	C0035468		Approved			CHEBI_9587	"10591"	MONDO_0005945	"10039102"	"72409005"
ceftizoxime	DB01332	Rhinoscleroma	C0035468		Approved			CHEBI_553473	"2192"	MONDO_0005945	"10039102"	"72409005"
ampicillin	DB00415	Rhinoscleroma	C0035468		Approved			CHEBI_28971	"733|221058"	MONDO_0005945	"10039102"	"72409005"
sulbactam	DB09324	Rhinoscleroma	C0035468		Approved			CHEBI_9321	"10167"	MONDO_0005945	"10039102"	"72409005"
aztreonam	DB00355	Rhinoscleroma	C0035468		Approved			CHEBI_161680	"1272"	MONDO_0005945	"10039102"	"72409005"
ceftriaxone	DB01212	Rhinoscleroma	C0035468		Approved			CHEBI_29007	"2193"	MONDO_0005945	"10039102"	"72409005"
amikacin	DB00479	Rhinoscleroma	C0035468		Approved			CHEBI_2637	"641"	MONDO_0005945	"10039102"	"72409005"
gentamicin	DB00798	Rhinoscleroma	C0035468		Approved			CHEBI_17833	"1596450"	MONDO_0005945	"10039102"	"72409005"
norfloxacin	DB01059	Rhinoscleroma	C0035468		Approved			CHEBI_100246	"7517"	MONDO_0005945	"10039102"	"72409005"
fusidic acid	DB02703	Rhinoscleroma	C0035468		Approved			CHEBI_29013	"4608|113608"	MONDO_0005945	"10039102"	"72409005"
ceftaroline fosamil	DB06590	Rhinoscleroma	C0035468		Approved			CHEBI_70718	"1040005|1040004"	MONDO_0005945	"10039102"	"72409005"
cefapirin	DB01139	Rhinoscleroma	C0035468		Approved			CHEBI_554446	"2238"	MONDO_0005945	"10039102"	"72409005"
piperacillin	DB00319	Rhinoscleroma	C0035468		Approved			CHEBI_8232	"1546000|8339"	MONDO_0005945	"10039102"	"72409005"
amoxicillin	DB01060	Rhinoscleroma	C0035468		Approved			CHEBI_2676	"1297882|723"	MONDO_0005945	"10039102"	"72409005"
tobramycin	DB00684	Rhinoscleroma	C0035468		Approved			CHEBI_28864	"10627"	MONDO_0005945	"10039102"	"72409005"
moxifloxacin	DB00218	Rhinoscleroma	C0035468		Approved			CHEBI_63611	"139462"	MONDO_0005945	"10039102"	"72409005"
ciprofloxacin	DB00537	Rhinoscleroma	C0035468		Approved			CHEBI_192484	"2551"	MONDO_0005945	"10039102"	"72409005"
leuprorelin	DB00007	Uterine Fibroids	C0042133	NCT00683917	Terminated	Phase 2	Repros stopped the study for safety and FDA put the study on hold for safety.	CHEBI_6427	"42375"	MONDO_0007886	"10046798"	"95315005"
norethindrone acetate	DB00717	Uterine Fibroids	C0042133		Approved			CHEBI_7627	"7514"	MONDO_0007886	"10046798"	"95315005"
relugolix	DB11853	Uterine Fibroids	C0042133		Approved				"2472778"	MONDO_0007886	"10046798"	"95315005"
mifepristone	DB00834	Uterine Fibroids	C0042133	NCT01786226	Terminated	Phase 2/Phase 3		CHEBI_50692	"6964"	MONDO_0007886	"10046798"	"95315005"
	DB01234	Vomiting	C0042963	NCT01405924	Terminated	Phase 2	Low enrollment	CHEBI_41879	"3264"	HP:0002013	"10047700"	"249497008"
granisetron	DB00889	Vomiting	C0042963	NCT01183481	Terminated	Phase 2	Study was stopped due to inadequate accrual.	CHEBI_5537	"26237"	HP:0002013	"10047700"	"249497008"
trimethobenzamide	DB00662	Vomiting	C0042963		Approved			CHEBI_27796	"38685"	HP:0002013	"10047700"	"249497008"
triflupromazine	DB00508	Vomiting	C0042963		Approved			CHEBI_9711	"10805"	HP:0002013	"10047700"	"249497008"
dimenhydrinate	DB00985	Vomiting	C0042963		Approved			CHEBI_94848	"3444"	HP:0002013	"10047700"	"249497008"
ondansetron	DB00904	Vomiting	C0042963	NCT02028910	Terminated	Phase 3		CHEBI_7773	"26225"	HP:0002013	"10047700"	"249497008"
palonosetron	DB00377	Vomiting	C0042963	NCT00982995	Terminated	Phase 2	site terminated due to lack of enrollment	CHEBI_85161	"70561"	HP:0002013	"10047700"	"249497008"
	DB00673	Vomiting	C0042963	NCT01183481	Terminated	Phase 2	Study was stopped due to inadequate accrual.	CHEBI_499361	"358255"	HP:0002013	"10047700"	"249497008"
dronabinol	DB00470	Vomiting	C0042963	NCT02608931	Withdrawn	Phase 2	Unable to begin study with drug provider	CHEBI_66964	"10402"	HP:0002013	"10047700"	"249497008"
dexamethasone phosphate	DB01234	Vomiting	C0042963	NCT01975727	Terminated	Phase 2	Study was halted prematurely for futility after an intermediate analysis	CHEBI_68637	"3264"	HP:0002013	"10047700"	"249497008"
	DB01234	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_41879	"3264"	HP:0002013	"10047700"	"249497008"
	DB01075	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_4636	"3498"	HP:0002013	"10047700"	"249497008"
	DB01069	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_8461	"8745"	HP:0002013	"10047700"	"249497008"
promazine	DB00420	Vomiting	C0042963		Approved			CHEBI_8459	"8742"	HP:0002013	"10047700"	"249497008"
perazine	DB12710	Vomiting	C0042963		Approved			CHEBI_59118	"8042"	HP:0002013	"10047700"	"249497008"
	DB00904	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_7773	"26225"	HP:0002013	"10047700"	"249497008"
granisetron	DB00889	Vomiting	C0042963	NCT01649258	Terminated	Phase 1	Lack of Efficacy	CHEBI_5537	"26237"	HP:0002013	"10047700"	"249497008"
aprepitant	DB00673	Vomiting	C0042963	NCT01405924	Terminated	Phase 2	Low enrollment	CHEBI_499361	"358255"	HP:0002013	"10047700"	"249497008"
thiethylperazine	DB00372	Vomiting	C0042963		Approved			CHEBI_9544	"10471"	HP:0002013	"10047700"	"249497008"
	DB00673	Vomiting	C0042963	NCT01649258	Terminated	Phase 1	Lack of Efficacy	CHEBI_499361	"358255"	HP:0002013	"10047700"	"249497008"
lorazepam	DB00186	Vomiting	C0042963	NCT00429702	Terminated	Phase 2	Closed due to poor accrual and lack of feasibility to finish study per DSMB	CHEBI_6539	"6470"	HP:0002013	"10047700"	"249497008"
haloperidol	DB00502	Vomiting	C0042963	NCT01684969	Withdrawn	Early Phase 1	lack of accrual and funding is about to expire.	CHEBI_5613	"5093"	HP:0002013	"10047700"	"249497008"
aprepitant	DB00673	Vomiting	C0042963	NCT01249001	Terminated	Phase 2	lack of eligible participants to enrol	CHEBI_499361	"358255"	HP:0002013	"10047700"	"249497008"
dexamethasone phosphate	DB01234	Vomiting	C0042963	NCT01135550	Terminated	Phase 3	premature closure due to lack of accrual	CHEBI_68637	"3264"	HP:0002013	"10047700"	"249497008"
ceftriaxone	DB01212	Gonococcal joint infection	C0153216		Approved			CHEBI_29007	"2193"	MONDO_0041903	"10003256"	"44743006"
benzylpenicillin	DB01053	Gonococcal joint infection	C0153216		Approved			CHEBI_18208	"7980"	MONDO_0041903	"10003256"	"44743006"
furosemide	DB00695	Acute pulmonary edema	C0155919		Approved			CHEBI_47426	"4603"		"10001029"	"40541001"
lactulose	DB00581	Hyperammonemia (disorder)	C0220994		Approved			CHEBI_6359	"6218"		"10020575"	"9360008"
phenylacetic acid	DB09269	Hyperammonemia (disorder)	C0220994		Approved			CHEBI_30745	"33332"		"10020575"	"9360008"
benzoic acid	DB03793	Hyperammonemia (disorder)	C0220994		Approved			CHEBI_30746	"18989"		"10020575"	"9360008"
relugolix	DB11853	Lower abdominal pain	C0232495		Approved				"2472778"		"10000084"	"54586004"
methylphenobarbital	DB00849	Tension	C0233494		Approved			CHEBI_6758	"6758"		"10043268"	"53489000"
	DB01268	Gastrointestinal Stromal Tumors	C0238198	NCT00372567	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_38940	"357977"	MONDO_0011719	"10051066"	"420120006"
imatinib	DB00619	Gastrointestinal Stromal Tumors	C0238198		Approved			CHEBI_45783	"282388"	MONDO_0011719	"10051066"	"420120006"
sunitinib	DB01268	Gastrointestinal Stromal Tumors	C0238198		Approved			CHEBI_38940	"357977"	MONDO_0011719	"10051066"	"420120006"
imatinib	DB00619	Gastrointestinal Stromal Tumors	C0238198	NCT00573404	Terminated	Phase 1	slow accrual	CHEBI_45783	"282388"	MONDO_0011719	"10051066"	"420120006"
	DB01268	Gastrointestinal Stromal Tumors	C0238198	NCT00573404	Terminated	Phase 1	slow accrual	CHEBI_38940	"357977"	MONDO_0011719	"10051066"	"420120006"
imatinib	DB00619	Gastrointestinal Stromal Tumors	C0238198	NCT00324987	Terminated	Phase 3	The trial failed to accrue	CHEBI_45783	"282388"	MONDO_0011719	"10051066"	"420120006"
	DB00112	Gastrointestinal Stromal Tumors	C0238198	NCT00324987	Terminated	Phase 3	The trial failed to accrue		"253337|2046138"	MONDO_0011719	"10051066"	"420120006"
regorafenib	DB08896	Gastrointestinal Stromal Tumors	C0238198		Approved			CHEBI_68647	"1312397"	MONDO_0011719	"10051066"	"420120006"
imatinib	DB00619	Gastrointestinal Stromal Tumors	C0238198	NCT00956072	Terminated	Phase 3	low accrual	CHEBI_45783	"282388"	MONDO_0011719	"10051066"	"420120006"
avapritinib	DB15233	Gastrointestinal Stromal Tumors	C0238198		Approved				"2272107"	MONDO_0011719	"10051066"	"420120006"
imatinib	DB00619	Gastrointestinal Stromal Tumors	C0238198	NCT00091078	Terminated	Phase 2		CHEBI_45783	"282388"	MONDO_0011719	"10051066"	"420120006"
ripretinib	DB14840	Gastrointestinal Stromal Tumors	C0238198		Approved				"2369389"	MONDO_0011719	"10051066"	"420120006"
imatinib	DB00619	Gastrointestinal Stromal Tumors	C0238198	NCT00009906	Terminated	Phase 3		CHEBI_45783	"282388"	MONDO_0011719	"10051066"	"420120006"
pimitespib	DB14876	Gastrointestinal Stromal Tumors	C0238198		Approved					MONDO_0011719	"10051066"	"420120006"
imatinib	DB00619	Gastrointestinal Stromal Tumors	C0238198	NCT00372567	Terminated	Phase 3	See termination reason in detailed description.	CHEBI_45783	"282388"	MONDO_0011719	"10051066"	"420120006"
daclizumab	DB00111	Renal transplant rejection	C0238217		Approved				"190353"		"10076656"	"236570004"
muromonab-CD3	DB00075	Renal transplant rejection	C0238217		Approved				"42405"		"10076656"	"236570004"
imlifidase	DB15258	Renal transplant rejection	C0238217		Approved						"10076656"	"236570004"
belatacept	DB06681	Renal transplant rejection	C0238217		Approved				"1112973"		"10076656"	"236570004"
tacrolimus	DB00864	Renal transplant rejection	C0238217		Approved			CHEBI_61049	"42316|235991"		"10076656"	"236570004"
basiliximab	DB00074	Renal transplant rejection	C0238217		Approved				"196102"		"10076656"	"236570004"
	DB00864	Renal transplant rejection	C0238217	NCT05073822	Withdrawn	Phase 1/Phase 2	Funding not secured	CHEBI_61049	"42316|235991"		"10076656"	"236570004"
mycophenolate mofetil	DB01024	Renal transplant rejection	C0238217	NCT05073822	Withdrawn	Phase 1/Phase 2	Funding not secured	CHEBI_168396	"7145|265323"		"10076656"	"236570004"
spironolactone	DB00421	Acute heart failure	C0264714	NCT02299726	Withdrawn	Phase 2	Study was not funded	CHEBI_9241	"9997"		"10007556"	"56675007"
nitroprusside	DB00325	Acute heart failure	C0264714		Approved			CHEBI_7596	"7476"		"10007556"	"56675007"
estradiol cypionate	DB00783	Female hypogonadism syndrome	C0271578		Approved			CHEBI_16469	"4083"	HP:0000134	"10021010"	"16041008"
estradiol valerate	DB13956	Female hypogonadism syndrome	C0271578		Approved			CHEBI_31561	"24395"	HP:0000134	"10021010"	"16041008"
estradiol	DB00783	Female hypogonadism syndrome	C0271578		Approved			CHEBI_16469	"4083"	HP:0000134	"10021010"	"16041008"
tranexamic acid	DB00302	Female hypogonadism syndrome	C0271578		Approved			CHEBI_48669	"10691"	HP:0000134	"10021010"	"16041008"
quinestrol	DB04575	Female hypogonadism syndrome	C0271578		Approved			CHEBI_8716	"9066"	HP:0000134	"10021010"	"16041008"
estrone sulphate	DB04574	Female hypogonadism syndrome	C0271578		Approved			CHEBI_17474		HP:0000134	"10021010"	"16041008"
estradiol valerate	DB00783	Female hypogonadism syndrome	C0271578		Approved			CHEBI_16469	"4083"	HP:0000134	"10021010"	"16041008"
norethynodrel	DB09371	Female hypogonadism syndrome	C0271578		Approved			CHEBI_34895	"7515"	HP:0000134	"10021010"	"16041008"
estradiol cypionate	DB13954	Female hypogonadism syndrome	C0271578		Approved			CHEBI_34745	"1000146"	HP:0000134	"10021010"	"16041008"
mestranol	DB01357	Female hypogonadism syndrome	C0271578		Approved			CHEBI_6784	"6782"	HP:0000134	"10021010"	"16041008"
estrone sulphate	DB00655	Female hypogonadism syndrome	C0271578		Approved			CHEBI_17263	"4103"	HP:0000134	"10021010"	"16041008"
norethisterone	DB00717	Female hypogonadism syndrome	C0271578		Approved			CHEBI_7627	"7514"	HP:0000134	"10021010"	"16041008"
metreleptin	DB09046	Acquired generalized lipodystrophy	C0271693		Approved				"1491625"	MONDO_0019193	"10087376"	"86907008"
emapalumab	DB14724	Familial Hemophagocytic Lymphocytosis	C0272199		Approved				"2104604|2104603"	MONDO_0015541	"10070904"	"398250003"
fluorouracil	DB00544	Squamous cell carcinoma of esophagus	C0279626	NCT01248299	Terminated	Phase 2		CHEBI_46345	"4492"	MONDO_0005580	"10061534"	"276804009"
paclitaxel	DB01229	Squamous cell carcinoma of esophagus	C0279626	NCT02033538	Withdrawn	Phase 2	This clinical trial was closed due to slow recruitment of patients.	CHEBI_45863	"56946"	MONDO_0005580	"10061534"	"276804009"
pembrolizumab	DB09037	Squamous cell carcinoma of esophagus	C0279626		Approved				"1547545"	MONDO_0005580	"10061534"	"276804009"
	DB00515	Squamous cell carcinoma of esophagus	C0279626	NCT01248299	Terminated	Phase 2		CHEBI_27899	"2555"	MONDO_0005580	"10061534"	"276804009"
	DB00526	Squamous cell carcinoma of esophagus	C0279626	NCT01248299	Terminated	Phase 2		CHEBI_31941	"32592"	MONDO_0005580	"10061534"	"276804009"
	DB01248	Squamous cell carcinoma of esophagus	C0279626	NCT01248299	Terminated	Phase 2		CHEBI_4672	"72962|1299922"	MONDO_0005580	"10061534"	"276804009"
dinoprostone	DB00917	Hydatidiform mole, benign	C0549315		Approved			CHEBI_15551	"3478"		"10004272"	"417044008"
dinoprost	DB12789	Hydatidiform mole, benign	C0549315		Approved			CHEBI_15553	"3477"		"10004272"	"417044008"
dinoprost	DB01160	Hydatidiform mole, benign	C0549315		Approved			CHEBI_31502	"23321"		"10004272"	"417044008"
solifenacin	DB01591	Overactive Bladder	C0878773	NCT00821184	Terminated	Phase 3	Insufficient subject availability/findings for data analysis	CHEBI_135530	"322167"	HP:0000012	"10020853"	"786457000"
tolterodine	DB01036	Overactive Bladder	C0878773	NCT01500382	Terminated	Phase 1	This study was terminated early due to insufficient recruitment.	CHEBI_9622	"119565"	HP:0000012	"10020853"	"786457000"
dimethyl sulfoxide	DB01093	Overactive Bladder	C0878773	NCT00667095	Terminated	Phase 3	Study terminated early due to PI's extended medical leave.	CHEBI_28262	"3455"	HP:0000012	"10020853"	"786457000"
tolterodine	DB01036	Overactive Bladder	C0878773	NCT00439192	Terminated	Phase 2	side effect profile did not match expectations	CHEBI_9622	"119565"	HP:0000012	"10020853"	"786457000"
lidocaine	DB00281	Overactive Bladder	C0878773	NCT00427648	Terminated	Phase 3	funding ran out, poor accrual.	CHEBI_6456	"6387"	HP:0000012	"10020853"	"786457000"
botulinum toxin type A	DB00083	Overactive Bladder	C0878773		Approved				"1712|860168|1000104|860189"	HP:0000012	"10020853"	"786457000"
solifenacin	DB01591	Overactive Bladder	C0878773	NCT02805452	Terminated	Phase 3	Target of recruitment not reachable	CHEBI_135530	"322167"	HP:0000012	"10020853"	"786457000"
fusidic acid	DB02703	Proteus pneumonia	C1260917		Approved			CHEBI_29013	"4608|113608"		"10079867"	"195888009"
cefamandole	DB01326	Proteus pneumonia	C1260917		Approved			CHEBI_3480	"2178"		"10079867"	"195888009"
aztreonam	DB00355	Proteus pneumonia	C1260917		Approved			CHEBI_161680	"1272"		"10079867"	"195888009"
norfloxacin	DB01059	Proteus pneumonia	C1260917		Approved			CHEBI_100246	"7517"		"10079867"	"195888009"
ciprofloxacin	DB00537	Proteus pneumonia	C1260917		Approved			CHEBI_192484	"2551"		"10079867"	"195888009"
gentamicin	DB00798	Proteus pneumonia	C1260917		Approved			CHEBI_17833	"1596450"		"10079867"	"195888009"
cefotaxime	DB00493	Proteus pneumonia	C1260917		Approved			CHEBI_204928	"2186"		"10079867"	"195888009"
cefotetan	DB01330	Proteus pneumonia	C1260917		Approved			CHEBI_3499	"2187"		"10079867"	"195888009"
ticarcillin	DB01607	Proteus pneumonia	C1260917		Approved			CHEBI_9587	"10591"		"10079867"	"195888009"
ceftazidime	DB00438	Proteus pneumonia	C1260917		Approved			CHEBI_3508	"2191|1545984"		"10079867"	"195888009"
ceftizoxime	DB01332	Proteus pneumonia	C1260917		Approved			CHEBI_553473	"2192"		"10079867"	"195888009"
amikacin	DB00479	Proteus pneumonia	C1260917		Approved			CHEBI_2637	"641"		"10079867"	"195888009"
ceftriaxone	DB01212	Proteus pneumonia	C1260917		Approved			CHEBI_29007	"2193"		"10079867"	"195888009"
olaratumab	DB06043	Sarcoma	C1261473		Approved				"1855735"	HP:0100242	"10039491"	"424413001"
tasonermin	DB11626	Sarcoma	C1261473		Approved				"283746"	HP:0100242	"10039491"	"424413001"
pazopanib	DB06589	Sarcoma	C1261473		Approved			CHEBI_71219	"714438"	HP:0100242	"10039491"	"424413001"
cabozantinib	DB08875	Liver carcinoma	C2239176		Approved			CHEBI_72317	"1363268"	HP:0001402	"10073071"	"187769009"
regorafenib	DB08896	Liver carcinoma	C2239176		Approved			CHEBI_68647	"1312397"	HP:0001402	"10073071"	"187769009"
sorafenib	DB00398	Liver carcinoma	C2239176		Approved			CHEBI_50924	"495881"	HP:0001402	"10073071"	"187769009"
tremelimumab	DB11771	Liver carcinoma	C2239176		Approved				"2619313"	HP:0001402	"10073071"	"187769009"
sorafenib	DB00398	Liver carcinoma	C2239176	NCT02460991	Terminated	Phase 3	Slow enrollment	CHEBI_50924	"495881"	HP:0001402	"10073071"	"187769009"
bevacizumab	DB00112	Liver carcinoma	C2239176		Approved				"253337|2046138"	HP:0001402	"10073071"	"187769009"
atezolizumab	DB11595	Liver carcinoma	C2239176		Approved				"1792776"	HP:0001402	"10073071"	"187769009"
ramucirumab	DB05578	Liver carcinoma	C2239176		Approved				"1535922"	HP:0001402	"10073071"	"187769009"
rilonacept	DB06372	Cryopyrin-Associated Periodic Syndromes	C2316212		Approved				"763450"	MONDO_0016168	"10068850"	"430079001"
anakinra	DB00026	Cryopyrin-Associated Periodic Syndromes	C2316212		Approved				"72435"	MONDO_0016168	"10068850"	"430079001"
canakinumab	DB06168	Cryopyrin-Associated Periodic Syndromes	C2316212		Approved				"853491"	MONDO_0016168	"10068850"	"430079001"
tolnaftate	DB00525	Tinea barbae	C2349994		Approved			CHEBI_9620	"10637"	MONDO_0000242	"10057682"	"399329002"
griseofulvin	DB00400	Tinea barbae	C2349994		Approved			CHEBI_27779	"91077|5021"	MONDO_0000242	"10057682"	"399329002"
simoctocog alfa	DB09108	Factor VIII Deficiency	C3494187		Approved				"1729084"	HP:0003125	"10016080"	"234440005"
esomeprazole	DB00736	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_50275	"283742"	MONDO_0019610		"53132006"
esomeprazole	DB00338	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_77260	"7646"	MONDO_0019610		"53132006"
floxuridine	DB00322	Primary malignant neoplasm of gastrointestinal tract	C1306632		Approved			CHEBI_60761	"4488"			"363745004"
fluoxymesterone	DB01185	Generalized Myotonia of Thomsen	C2936781		Approved			CHEBI_5120	"4494"			"726051002"
fluvastatin	DB01095	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_38562	"41127"			"238079002"
mizolastine	DB12523	Rhinitis, Allergic, Perennial	C0035457		Approved			CHEBI_31857	"61455"	MONDO_0024332		"446096008"
ketoconazole	DB01026	Blastomycosis	C0005716		Approved			CHEBI_48339	"6135"	MONDO_0005672	"10005098"	"69996000"
amphotericin B	DB00681	Blastomycosis	C0005716		Approved			CHEBI_2682	"236594|732"	MONDO_0005672	"10005098"	"69996000"
itraconazole	DB01167	Blastomycosis	C0005716		Approved			CHEBI_6076	"28031"	MONDO_0005672	"10005098"	"69996000"
nilotinib	DB04868	Leukemia, Myeloid, Chronic-Phase	C0023474		Approved			CHEBI_52172	"662281"			"413847001"
glyceryl trinitrate	DB00727	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_28787	"4917"			"429589006"
omeprazole	DB00338	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_77260	"7646"	MONDO_0019610		"53132006"
amrinone	DB01427	Decompensated cardiac failure	C0581377		Approved			CHEBI_2686	"738"			"195111005"
pravastatin	DB00175	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_63618	"42463"			"238079002"
rabeprazole	DB01129	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_8768	"183877|114979"	MONDO_0019610		"53132006"
salicylic acid	DB14006	Plantar wart	C0042548		Approved			CHEBI_16914	"20974"	MONDO_0001795		"63440008"
salicylic acid	DB14006	Disorder of keratinization	C0475811		Approved			CHEBI_16914	"20974"	MONDO_0045011		"277905003"
bromocriptine	DB01200	Acromegaly	C0001206		Approved			CHEBI_3181	"1760"	MONDO_0019933	"10000599"	"74107003"
lubiprostone	DB01046	Chronic idiopathic constipation	C0267509		Approved			CHEBI_34945	"623033"			"82934008"
iron	DB01592	Anemia of prematurity	C0158996		Approved			CHEBI_18248	"90176|262150"	MONDO_0001239		"47100003"
magnesium sulfate	DB00653	Severe pre-eclampsia	C0341950		Approved			CHEBI_32599	"6585|1311625"			"46764007"
ferric oxide	DB11576	Anemia of prematurity	C0158996		Approved			CHEBI_50819		MONDO_0001239		"47100003"
ferrous gluconate	DB14488	Anemia of prematurity	C0158996		Approved			CHEBI_31608	"24942"	MONDO_0001239		"47100003"
ferrous gluconate	DB09517	Anemia of prematurity	C0158996		Approved			CHEBI_31608	"261435"	MONDO_0001239		"47100003"
choline fenofibrate	DB13873	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_83469	"24852"			"238079002"
linaclotide	DB08890	Chronic idiopathic constipation	C0267509		Approved			CHEBI_68551	"1307404"			"82934008"
ammonia	DB11118	Disorder of keratinization	C0475811		Approved			CHEBI_16134	"1299884"	MONDO_0045011		"277905003"
apremilast	DB05676	Behçet's disease affecting oral mucosa	C1321482		Approved			CHEBI_78540	"1492727"			"403443000"
captopril	DB01197	Left ventricular cardiac dysfunction	C1997351		Approved			CHEBI_3380	"1998"			"429589006"
somatropin	DB00052	Pituitary dwarfism	C0013338		Approved				"61148|314845"	MONDO_0000050|MONDO_0006909		"367460001"
dexrabeprazole	DB13762	Zollinger-Ellison syndrome	C0043515		Approved			CHEBI_134729		MONDO_0019610		"53132006"
ocriplasmin	DB08888	Vitreomacular traction syndrome	C0730274		Approved				"29998"			"312901001"
epoetin theta	DB00016	Anemia of chronic renal failure	C0271932		Approved				"2047589|105695|105694"			"49708008"
cefiderocol	DB14879	Gram-Negative Bacterial Infections	C0085423		Approved			CHEBI_140376	"2265702"			"371583007"
bempedoic acid	DB11936	Familial hypercholesterolemia - heterozygous	C0342882		Approved			CHEBI_149601	"2282403"			"238079002"
acetylcysteine	DB06151	Poisoning caused by acetaminophen	C0237963		Approved			CHEBI_28939	"197"			"70273001"
cysteine	DB00151	Poisoning caused by acetaminophen	C0237963		Approved			CHEBI_17561	"3024"			"70273001"
testosterone	DB00624	Cryptorchidism	C0010417		Approved			CHEBI_17347	"10379"	HP:0000028	"10011498"	"204878001"
testosterone propionate	DB00624	Cryptorchidism	C0010417		Approved			CHEBI_17347	"10379"	HP:0000028	"10011498"	"204878001"
testosterone enantate	DB00624	Cryptorchidism	C0010417		Approved			CHEBI_17347	"10379"	HP:0000028	"10011498"	"204878001"
fluoxymesterone	DB01185	Cryptorchidism	C0010417		Approved			CHEBI_5120	"4494"	HP:0000028	"10011498"	"204878001"
testosterone cypionate	DB13943	Cryptorchidism	C0010417		Approved			CHEBI_9463	"835827"	HP:0000028	"10011498"	"204878001"
testosterone propionate	DB01420	Cryptorchidism	C0010417		Approved			CHEBI_9466	"10382"	HP:0000028	"10011498"	"204878001"
testosterone enantate	DB13944	Cryptorchidism	C0010417		Approved			CHEBI_9464	"37859"	HP:0000028	"10011498"	"204878001"
tobramycin	DB00684	Dacryocystitis	C0010930		Approved			CHEBI_28864	"10627"	MONDO_0004926	"10011844"	"85777005"
prednisolone	DB00860	Dacryocystitis	C0010930		Approved			CHEBI_8378	"8638"	MONDO_0004926	"10011844"	"85777005"
fusidic acid	DB02703	Dacryocystitis	C0010930		Approved			CHEBI_29013	"4608|113608"	MONDO_0004926	"10011844"	"85777005"
azithromycin	DB00207	Dacryocystitis	C0010930		Approved			CHEBI_2955	"18631"	MONDO_0004926	"10011844"	"85777005"
gentamicin	DB00798	Dacryocystitis	C0010930		Approved			CHEBI_17833	"1596450"	MONDO_0004926	"10011844"	"85777005"
epalrestat	DB15293	Diabetic Neuropathies	C0011882		Approved			CHEBI_31539		MONDO_0006626	"10012680"	"230572002"
dimethicone	DB11074	Diaper Rash	C0011974		Approved			CHEBI_31498	"324072"		"10012444"	"91487003"
clotrimazole	DB00257	Diaper Rash	C0011974		Approved			CHEBI_3764	"2623"		"10012444"	"91487003"
amphotericin B	DB00681	Diaper Rash	C0011974		Approved			CHEBI_2682	"236594|732"		"10012444"	"91487003"
miconazole	DB01110	Diaper Rash	C0011974		Approved			CHEBI_82892	"6932"		"10012444"	"91487003"
zinc oxide	DB09321	Diaper Rash	C0011974		Approved			CHEBI_36560	"11423"		"10012444"	"91487003"
levomenthol	DB14123	Diaper Rash	C0011974		Approved			CHEBI_25187	"6750|1430390"		"10012444"	"91487003"
zinc acetate	DB14487	Diaper Rash	C0011974		Approved			CHEBI_62984	"1299637|58295"		"10012444"	"91487003"
dimethicone	DB09512	Diaper Rash	C0011974		Approved			CHEBI_31498	"9796"		"10012444"	"91487003"
dimethicone	DB14005	Diaper Rash	C0011974		Approved			CHEBI_31498	"1299921"		"10012444"	"91487003"
dexpanthenol	DB09357	Eczema	C0013595		Approved			CHEBI_27373	"22701"	HP:0000964	"10014184"	"43116000"
clobetasone butyrate	DB13158	Eczema	C0013595		Approved			CHEBI_31415	"108074"	HP:0000964	"10014184"	"43116000"
procaine benzylpenicillin	DB01053	Erysipelas	C0014733		Approved			CHEBI_18208	"7980"	MONDO_0001266	"10015145"	"44653001"
benzathine benzylpenicillin	DB01053	Erysipelas	C0014733		Approved			CHEBI_18208	"7980"	MONDO_0001266	"10015145"	"44653001"
procaine benzylpenicillin	DB09320	Erysipelas	C0014733		Approved			CHEBI_52154	"7983"	MONDO_0001266	"10015145"	"44653001"
benzylpenicillin	DB01053	Erysipelas	C0014733		Approved			CHEBI_18208	"7980"	MONDO_0001266	"10015145"	"44653001"
prednisone	DB00635	Erysipelas	C0014733	NCT00893048	Withdrawn	Phase 2	Study never enrolled any subjects before auto-terminated by the internal IRB.	CHEBI_8382	"8640"	MONDO_0001266	"10015145"	"44653001"
phenoxymethylpenicillin	DB00417	Erysipelas	C0014733		Approved			CHEBI_27446	"7984"	MONDO_0001266	"10015145"	"44653001"
triclabendazole	DB12245	Fascioliasis	C0015652		Approved			CHEBI_94759	"2118525"		"10016234"	"111922007"
choline magnesium trisalicylate	DB00122	Fever	C0015967		Approved			CHEBI_15354	"2449"	HP:0001945	"10005911"	"50177009"
pheniramine	DB01620	Fever	C0015967		Approved			CHEBI_91591	"8132"	HP:0001945	"10005911"	"50177009"
paracetamol	DB00316	Fever	C0015967	NCT01182974	Suspended	Phase 3	Difficulty in patient enrollment	CHEBI_46195	"161"	HP:0001945	"10005911"	"50177009"
lithium carbonate	DB14509	Fever	C0015967		Approved			CHEBI_6504	"42351"	HP:0001945	"10005911"	"50177009"
choline magnesium trisalicylate	DB01401	Fever	C0015967		Approved				"215799"	HP:0001945	"10005911"	"50177009"
	DB14644	Fever	C0015967	NCT02212210	Terminated	Early Phase 1	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed	CHEBI_135765		HP:0001945	"10005911"	"50177009"
salicylic acid	DB13860	Fever	C0015967		Approved			CHEBI_16914		HP:0001945	"10005911"	"50177009"
methylprednisolone	DB00959	Fever	C0015967	NCT02212210	Terminated	Early Phase 1	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed	CHEBI_6888	"6902"	HP:0001945	"10005911"	"50177009"
naproxen	DB00788	Fever	C0015967		Approved			CHEBI_7476	"7258"	HP:0001945	"10005911"	"50177009"
ibuprofen	DB01050	Fever	C0015967		Approved			CHEBI_5855	"5640"	HP:0001945	"10005911"	"50177009"
paracetamol	DB00316	Fever	C0015967		Approved			CHEBI_46195	"161"	HP:0001945	"10005911"	"50177009"
vancomycin	DB00512	Fever	C0015967	NCT00529282	Terminated	Phase 3	Study discontinued due to administrative reasons unrelated to safety	CHEBI_28001	"11124"	HP:0001945	"10005911"	"50177009"
guaifenesin	DB00874	Fever	C0015967		Approved			CHEBI_5551	"5032"	HP:0001945	"10005911"	"50177009"
codeine	DB00318	Fever	C0015967		Approved			CHEBI_16714	"2670|1545976|235412"	HP:0001945	"10005911"	"50177009"
amoxicillin	DB01060	Fever	C0015967	NCT00107081	Terminated	Phase 3	Accrual goal for interventional part not achievable	CHEBI_2676	"1297882|723"	HP:0001945	"10005911"	"50177009"
magnesium salicylate	DB01397	Fever	C0015967		Approved			CHEBI_6640		HP:0001945	"10005911"	"50177009"
	DB00537	Fever	C0015967	NCT00107081	Terminated	Phase 3	Accrual goal for interventional part not achievable	CHEBI_192484	"2551"	HP:0001945	"10005911"	"50177009"
salicylamide	DB08797	Fever	C0015967		Approved			CHEBI_32114	"9518"	HP:0001945	"10005911"	"50177009"
phenylephrine	DB00388	Fever	C0015967		Approved			CHEBI_8093	"8163"	HP:0001945	"10005911"	"50177009"
salicylic acid	DB00936	Fever	C0015967		Approved			CHEBI_16914	"9525"	HP:0001945	"10005911"	"50177009"
dexibuprofen	DB09213	Fever	C0015967		Approved			CHEBI_43415		HP:0001945	"10005911"	"50177009"
	DB01413	Fever	C0015967	NCT00529282	Terminated	Phase 3	Study discontinued due to administrative reasons unrelated to safety	CHEBI_478164	"20481"	HP:0001945	"10005911"	"50177009"
salicylic acid	DB14006	Fever	C0015967		Approved			CHEBI_16914	"20974"	HP:0001945	"10005911"	"50177009"
choline magnesium trisalicylate	DB00936	Fever	C0015967		Approved			CHEBI_16914	"9525"	HP:0001945	"10005911"	"50177009"
	DB00860	Fever	C0015967	NCT02212210	Terminated	Early Phase 1	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed	CHEBI_8378	"8638"	HP:0001945	"10005911"	"50177009"
dextromethorphan	DB00514	Fever	C0015967		Approved			CHEBI_4470	"3289"	HP:0001945	"10005911"	"50177009"
pregabalin	DB00230	Herpes zoster disease	C0019360	NCT00352651	Terminated	Phase 2	"This study should be terminated as the study has been closed for years and the investigator has since retired. No records are available.

Thank you, Marlene"	CHEBI_64356	"187832"	MONDO_0005609	"10019974"	"4740000"
capsaicin	DB06774	Herpes zoster disease	C0019360	NCT00089557	Terminated	Phase 2		CHEBI_3374	"1992"	MONDO_0005609	"10019974"	"4740000"
valaciclovir	DB00577	Herpes zoster disease	C0019360	NCT02412917	Terminated	Phase 3		CHEBI_35854	"73645"	MONDO_0005609	"10019974"	"4740000"
famciclovir	DB00426	Herpes zoster disease	C0019360		Approved			CHEBI_4974	"68099"	MONDO_0005609	"10019974"	"4740000"
acyclovir	DB00787	Herpes zoster disease	C0019360		Approved			CHEBI_2453	"281"	MONDO_0005609	"10019974"	"4740000"
amenamevir	DB11701	Herpes zoster disease	C0019360		Approved					MONDO_0005609	"10019974"	"4740000"
valaciclovir	DB00577	Herpes zoster disease	C0019360		Approved			CHEBI_35854	"73645"	MONDO_0005609	"10019974"	"4740000"
rosuvastatin	DB01098	Hyperlipoproteinemia Type III	C0020479		Approved			CHEBI_38545	"301542"	MONDO_0018473	"10060751"	"398796005"
simvastatin	DB00641	Hyperlipoproteinemia Type III	C0020479		Approved			CHEBI_9150	"36567"	MONDO_0018473	"10060751"	"398796005"
atorvastatin	DB01076	Hyperlipoproteinemia Type III	C0020479		Approved			CHEBI_39548	"83367"	MONDO_0018473	"10060751"	"398796005"
pravastatin	DB00175	Hyperlipoproteinemia Type III	C0020479		Approved			CHEBI_63618	"42463"	MONDO_0018473	"10060751"	"398796005"
phentermine	DB00191	Hypotension	C0020649		Approved			CHEBI_8080	"221138|8152"	HP:0002615	"10021097"	"45007003"
levodopa	DB00988	Hypotension	C0020649	NCT01482559	Terminated	Phase 3	Study ceased enrolling due to poor overall recruitment. Long-term follow up of enrolled participants ongoing.	CHEBI_18243	"3628"	HP:0002615	"10021097"	"45007003"
epinephrine	DB00668	Hypotension	C0020649		Approved			CHEBI_28918	"3992"	HP:0002615	"10021097"	"45007003"
dopamine	DB00988	Hypotension	C0020649		Approved			CHEBI_18243	"3628"	HP:0002615	"10021097"	"45007003"
metaraminol	DB00610	Hypotension	C0020649		Approved			CHEBI_6794	"6805"	HP:0002615	"10021097"	"45007003"
methoxamine	DB00723	Hypotension	C0020649		Approved			CHEBI_6839	"6853"	HP:0002615	"10021097"	"45007003"
mephentermine	DB01365	Hypotension	C0020649		Approved			CHEBI_6755	"6756"	HP:0002615	"10021097"	"45007003"
norepinephrine	DB00368	Hypotension	C0020649		Approved			CHEBI_18357	"7512"	HP:0002615	"10021097"	"45007003"
angiotensinamide	DB13517	Hypotension	C0020649		Approved			CHEBI_135950		HP:0002615	"10021097"	"45007003"
sunitinib	DB01268	Leukemia, Mast-Cell	C0023461	NCT00387426	Terminated	Phase 2		CHEBI_38940	"357977"	MONDO_0020334	"10056450"	"110002002"
midostaurin	DB06595	Leukemia, Mast-Cell	C0023461		Approved			CHEBI_63452	"1919083"	MONDO_0020334	"10056450"	"110002002"
triamcinolone	DB00620	Lymphoma, Follicular	C0024301		Approved			CHEBI_9667	"10759"	MONDO_0018906	"10085128"	"269476000"
duvelisib	DB11952	Lymphoma, Follicular	C0024301		Approved			CHEBI_131169	"2058509"	MONDO_0018906	"10085128"	"269476000"
methylprednisolone	DB00959	Lymphoma, Follicular	C0024301		Approved			CHEBI_6888	"6902"	MONDO_0018906	"10085128"	"269476000"
cortisone acetate	DB01380	Lymphoma, Follicular	C0024301		Approved			CHEBI_3897	"21655"	MONDO_0018906	"10085128"	"269476000"
idelalisib	DB09054	Lymphoma, Follicular	C0024301		Approved			CHEBI_82701	"1544460"	MONDO_0018906	"10085128"	"269476000"
betamethasone	DB00443	Lymphoma, Follicular	C0024301		Approved			CHEBI_3077	"1514"	MONDO_0018906	"10085128"	"269476000"
vincristine	DB00541	Lymphoma, Follicular	C0024301		Approved			CHEBI_28445	"11202"	MONDO_0018906	"10085128"	"269476000"
triamcinolone diacetate	DB00620	Lymphoma, Follicular	C0024301		Approved			CHEBI_9667	"10759"	MONDO_0018906	"10085128"	"269476000"
ibritumomab tiuxetan	DB00078	Lymphoma, Follicular	C0024301		Approved				"262323"	MONDO_0018906	"10085128"	"269476000"
doxorubicin	DB00997	Lymphoma, Follicular	C0024301		Approved			CHEBI_28748	"142433|3639"	MONDO_0018906	"10085128"	"269476000"
prednisone	DB00635	Lymphoma, Follicular	C0024301		Approved			CHEBI_8382	"8640"	MONDO_0018906	"10085128"	"269476000"
dexamethasone	DB01234	Lymphoma, Follicular	C0024301		Approved			CHEBI_41879	"3264"	MONDO_0018906	"10085128"	"269476000"
bleomycin	DB00290	Lymphoma, Follicular	C0024301		Approved			CHEBI_22907	"1622"	MONDO_0018906	"10085128"	"269476000"
bendamustine	DB06769	Lymphoma, Follicular	C0024301		Approved			CHEBI_135515	"134547"	MONDO_0018906	"10085128"	"269476000"
prednisolone	DB00860	Lymphoma, Follicular	C0024301		Approved			CHEBI_8378	"8638"	MONDO_0018906	"10085128"	"269476000"
chlorambucil	DB00291	Lymphoma, Follicular	C0024301		Approved			CHEBI_28830	"2346"	MONDO_0018906	"10085128"	"269476000"
	DB00087	Mucopolysaccharidosis VI	C0026709	NCT00668564	Terminated	Phase 2	Replaced by another study		"117055"	MONDO_0009661	"10056892"	"69463008"
	DB00531	Mucopolysaccharidosis VI	C0026709	NCT00668564	Terminated	Phase 2	Replaced by another study	CHEBI_4027	"1545988|3002"	MONDO_0009661	"10056892"	"69463008"
busulfan	DB01008	Mucopolysaccharidosis VI	C0026709	NCT00668564	Terminated	Phase 2	Replaced by another study	CHEBI_28901	"1828"	MONDO_0009661	"10056892"	"69463008"
galsulfase	DB01279	Mucopolysaccharidosis VI	C0026709		Approved				"578033"	MONDO_0009661	"10056892"	"69463008"
methylprednisolone succinate	DB14644	Nephrotic Syndrome	C0027726		Approved			CHEBI_135765		MONDO_0005377	"10029164"	"52254009"
hydrocortisone acetate	DB14539	Nephrotic Syndrome	C0027726		Approved			CHEBI_17609	"27197"	MONDO_0005377	"10029164"	"52254009"
betamethasone acetate	DB00443	Nephrotic Syndrome	C0027726		Approved			CHEBI_3077	"1514"	MONDO_0005377	"10029164"	"52254009"
triamcinolone	DB00620	Nephrotic Syndrome	C0027726		Approved			CHEBI_9667	"10759"	MONDO_0005377	"10029164"	"52254009"
triamcinolone diacetate	DB00620	Nephrotic Syndrome	C0027726		Approved			CHEBI_9667	"10759"	MONDO_0005377	"10029164"	"52254009"
hydrocortisone succinate	DB14545	Nephrotic Syndrome	C0027726		Approved			CHEBI_31677	"21651"	MONDO_0005377	"10029164"	"52254009"
atorvastatin	DB01076	Nephrotic Syndrome	C0027726	NCT00004466	Terminated	Phase 2	Very poor enrollment	CHEBI_39548	"83367"	MONDO_0005377	"10029164"	"52254009"
hydrocortisone succinate	DB00741	Nephrotic Syndrome	C0027726		Approved			CHEBI_17650	"5492"	MONDO_0005377	"10029164"	"52254009"
prednisone	DB00635	Nephrotic Syndrome	C0027726		Approved			CHEBI_8382	"8640"	MONDO_0005377	"10029164"	"52254009"
hydrocortisone acetate	DB00741	Nephrotic Syndrome	C0027726		Approved			CHEBI_17650	"5492"	MONDO_0005377	"10029164"	"52254009"
methylprednisolone succinate	DB00959	Nephrotic Syndrome	C0027726		Approved			CHEBI_6888	"6902"	MONDO_0005377	"10029164"	"52254009"
prednisolone	DB00860	Nephrotic Syndrome	C0027726		Approved			CHEBI_8378	"8638"	MONDO_0005377	"10029164"	"52254009"
betamethasone	DB00443	Nephrotic Syndrome	C0027726		Approved			CHEBI_3077	"1514"	MONDO_0005377	"10029164"	"52254009"
triamcinolone acetonide	DB00620	Nephrotic Syndrome	C0027726		Approved			CHEBI_9667	"10759"	MONDO_0005377	"10029164"	"52254009"
methylprednisolone	DB00959	Nephrotic Syndrome	C0027726		Approved			CHEBI_6888	"6902"	MONDO_0005377	"10029164"	"52254009"
atorvastatin	DB01076	Nephrotic Syndrome	C0027726	NCT03004001	Terminated	Phase 2	Difficult recruitment	CHEBI_39548	"83367"	MONDO_0005377	"10029164"	"52254009"
cortisone acetate	DB01380	Nephrotic Syndrome	C0027726		Approved			CHEBI_3897	"21655"	MONDO_0005377	"10029164"	"52254009"
enoxaparin sodium	DB01225	Nephrotic Syndrome	C0027726	NCT04558892	Terminated	Phase 2/Phase 3	The primary objectives were achieved.		"67108"	MONDO_0005377	"10029164"	"52254009"
dexamethasone	DB01234	Nephrotic Syndrome	C0027726		Approved			CHEBI_41879	"3264"	MONDO_0005377	"10029164"	"52254009"
hydrocortisone	DB00741	Nephrotic Syndrome	C0027726		Approved			CHEBI_17650	"5492"	MONDO_0005377	"10029164"	"52254009"
triamcinolone	DB00620	Ophthalmia, Sympathetic	C0029077		Approved			CHEBI_9667	"10759"	MONDO_0019198	"10042742"	"75315001"
prednisolone	DB00860	Ophthalmia, Sympathetic	C0029077		Approved			CHEBI_8378	"8638"	MONDO_0019198	"10042742"	"75315001"
triamcinolone acetonide	DB00620	Ophthalmia, Sympathetic	C0029077		Approved			CHEBI_9667	"10759"	MONDO_0019198	"10042742"	"75315001"
collagenase	DB00048	Peyronie Disease	C0030848		Approved				"898492|2475861|58939"	MONDO_0006361|MONDO_0008231	"10034765"	"1335005"
benzoic acid	DB03793	Peyronie Disease	C0030848		Approved			CHEBI_30746	"18989"	MONDO_0006361|MONDO_0008231	"10034765"	"1335005"
aminobenzoic acid	DB02362	Peyronie Disease	C0030848		Approved			CHEBI_30753	"74"	MONDO_0006361|MONDO_0008231	"10034765"	"1335005"
meropenem	DB00760	Peritonitis	C0031154	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_43968	"1546029|29561"	HP:0002586	"10034674"	"48661000"
cefoxitin	DB01331	Peritonitis	C0031154		Approved			CHEBI_209807	"2189"	HP:0002586	"10034674"	"48661000"
cilastatin	DB01597	Peritonitis	C0031154		Approved			CHEBI_3697	"2540"	HP:0002586	"10034674"	"48661000"
imipenem	DB01598	Peritonitis	C0031154		Approved			CHEBI_471744	"5690|1545986"	HP:0002586	"10034674"	"48661000"
tazobactam	DB01606	Peritonitis	C0031154		Approved			CHEBI_9421	"37617"	HP:0002586	"10034674"	"48661000"
piperacillin	DB00319	Peritonitis	C0031154		Approved			CHEBI_8232	"1546000|8339"	HP:0002586	"10034674"	"48661000"
gentamicin	DB00798	Peritonitis	C0031154		Approved			CHEBI_17833	"1596450"	HP:0002586	"10034674"	"48661000"
ceftazidime	DB00438	Peritonitis	C0031154		Approved			CHEBI_3508	"2191|1545984"	HP:0002586	"10034674"	"48661000"
norfloxacin	DB01059	Peritonitis	C0031154		Approved			CHEBI_100246	"7517"	HP:0002586	"10034674"	"48661000"
	DB01060	Peritonitis	C0031154	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_2676	"1297882|723"	HP:0002586	"10034674"	"48661000"
meropenem	DB00760	Peritonitis	C0031154		Approved			CHEBI_43968	"1546029|29561"	HP:0002586	"10034674"	"48661000"
	DB06211	Peritonitis	C0031154	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_135928	"119771"	HP:0002586	"10034674"	"48661000"
cefamandole	DB01326	Peritonitis	C0031154		Approved			CHEBI_3480	"2178"	HP:0002586	"10034674"	"48661000"
aztreonam	DB00355	Peritonitis	C0031154		Approved			CHEBI_161680	"1272"	HP:0002586	"10034674"	"48661000"
moxifloxacin	DB00218	Peritonitis	C0031154		Approved			CHEBI_63611	"139462"	HP:0002586	"10034674"	"48661000"
fusidic acid	DB02703	Peritonitis	C0031154		Approved			CHEBI_29013	"4608|113608"	HP:0002586	"10034674"	"48661000"
metronidazole	DB15759	Peritonitis	C0031154		Approved			CHEBI_50688		HP:0002586	"10034674"	"48661000"
cefotaxime	DB00493	Peritonitis	C0031154		Approved			CHEBI_204928	"2186"	HP:0002586	"10034674"	"48661000"
	DB00766	Peritonitis	C0031154	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_48947	"48203|21216"	HP:0002586	"10034674"	"48661000"
metronidazole	DB00916	Peritonitis	C0031154		Approved			CHEBI_6909	"6922"	HP:0002586	"10034674"	"48661000"
rivaroxaban	DB06228	Pulmonary Embolism	C0034065		Approved			CHEBI_68579	"1114195"	MONDO_0005279	"10037377"	"59282003"
ropinirole	DB00268	Restless Legs Syndrome	C0035258		Approved			CHEBI_8888	"72302"	MONDO_0005391	"10058920"	"32914008"
gabapentin enacarbil	DB08872	Restless Legs Syndrome	C0035258		Approved			CHEBI_68840	"1101333"	MONDO_0005391	"10058920"	"32914008"
gabapentin enacarbil	DB00996	Restless Legs Syndrome	C0035258		Approved			CHEBI_42797	"25480"	MONDO_0005391	"10058920"	"32914008"
gabapentin	DB00996	Restless Legs Syndrome	C0035258		Approved			CHEBI_42797	"25480"	MONDO_0005391	"10058920"	"32914008"
rotigotine	DB05271	Restless Legs Syndrome	C0035258		Approved			CHEBI_135351	"616739"	MONDO_0005391	"10058920"	"32914008"
pramipexole	DB00413	Restless Legs Syndrome	C0035258		Approved			CHEBI_8356	"746741"	MONDO_0005391	"10058920"	"32914008"
dextromethorphan	DB00514	Rhinitis	C0035455		Approved			CHEBI_4470	"3289"	MONDO_0003014	"10039083"	"70076002"
guaifenesin	DB00874	Rhinitis	C0035455		Approved			CHEBI_5551	"5032"	MONDO_0003014	"10039083"	"70076002"
sulfogaiacol	DB15992	Rhinitis	C0035455		Approved			CHEBI_85537		MONDO_0003014	"10039083"	"70076002"
glycine	DB00145	Rhinitis	C0035455		Approved			CHEBI_15428	"4919"	MONDO_0003014	"10039083"	"70076002"
sulfogaiacol	DB13735	Rhinitis	C0035455		Approved			CHEBI_85537		MONDO_0003014	"10039083"	"70076002"
	DB00852	Rhinitis	C0035455	NCT01177852	Withdrawn	Phase 3		CHEBI_51209	"8896"	MONDO_0003014	"10039083"	"70076002"
epoprostenol	DB01240	Rhinitis	C0035455		Approved			CHEBI_15552	"8814"	MONDO_0003014	"10039083"	"70076002"
pentoxyverine	DB11186	Rhinitis	C0035455		Approved			CHEBI_94484	"20217"	MONDO_0003014	"10039083"	"70076002"
sodium citrate	DB09154	Rhinitis	C0035455		Approved			CHEBI_53258	"253204|56466|1310549"	MONDO_0003014	"10039083"	"70076002"
beclometasone dipropionate	DB00394	Rhinitis	C0035455		Approved			CHEBI_3002	"1348"	MONDO_0003014	"10039083"	"70076002"
ephedrine	DB01364	Rhinitis	C0035455		Approved			CHEBI_15407	"3966"	MONDO_0003014	"10039083"	"70076002"
hydrocodone	DB00956	Rhinitis	C0035455		Approved			CHEBI_5779	"5489"	MONDO_0003014	"10039083"	"70076002"
phenylpropanolamine	DB00397	Rhinitis	C0035455		Approved			CHEBI_80680	"8175"	MONDO_0003014	"10039083"	"70076002"
guaiacol	DB11359	Rhinitis	C0035455		Approved			CHEBI_28591	"5031"	MONDO_0003014	"10039083"	"70076002"
dihydrocodeine	DB01551	Rhinitis	C0035455		Approved			CHEBI_135276	"23088"	MONDO_0003014	"10039083"	"70076002"
quinine	DB00468	Rhinitis	C0035455	NCT02630472	Terminated	Phase 1/Phase 2	Institutional decision	CHEBI_15854	"9071"	MONDO_0003014	"10039083"	"70076002"
codeine	DB00318	Rhinitis	C0035455		Approved			CHEBI_16714	"2670|1545976|235412"	MONDO_0003014	"10039083"	"70076002"
	DB01069	Rhinitis	C0035455	NCT01177852	Withdrawn	Phase 3		CHEBI_8461	"8745"	MONDO_0003014	"10039083"	"70076002"
phenylephrine	DB00388	Rhinitis	C0035455		Approved			CHEBI_8093	"8163"	MONDO_0003014	"10039083"	"70076002"
clofedanol	DB04837	Rhinitis	C0035455		Approved			CHEBI_135207	"21254"	MONDO_0003014	"10039083"	"70076002"
	DB01075	Rhinitis	C0035455	NCT01177852	Withdrawn	Phase 3		CHEBI_4636	"3498"	MONDO_0003014	"10039083"	"70076002"
ephedrine	DB01364	Rhinitis	C0035455	NCT01177852	Withdrawn	Phase 3		CHEBI_15407	"3966"	MONDO_0003014	"10039083"	"70076002"
triamcinolone	DB00620	Rhinitis	C0035455	NCT00344942	Terminated	Phase 3	patient's recruitment too difficult	CHEBI_9667	"10759"	MONDO_0003014	"10039083"	"70076002"
pseudoephedrine	DB00852	Rhinitis	C0035455		Approved			CHEBI_51209	"8896"	MONDO_0003014	"10039083"	"70076002"
	DB00835	Rhinitis	C0035455	NCT01177852	Withdrawn	Phase 3		CHEBI_3183	"1767"	MONDO_0003014	"10039083"	"70076002"
eperisone	DB08992	Spasm	C0037763		Approved			CHEBI_77070		HP:0003394	"10028334"	"45352006"
	DB00627	Cerebrovascular accident	C0038454	NCT00120289	Terminated	Phase 3	AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.	CHEBI_15940	"7393"	HP:0001297	"10008190"	"230690007"
etofibrate	DB00641	Cerebrovascular accident	C0038454	NCT00120289	Terminated	Phase 3	AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.	CHEBI_9150	"36567"	HP:0001297	"10008190"	"230690007"
ramipril	DB00178	Cerebrovascular accident	C0038454		Approved			CHEBI_8774	"35296"	HP:0001297	"10008190"	"230690007"
simvastatin	DB00641	Cerebrovascular accident	C0038454		Approved			CHEBI_9150	"36567"	HP:0001297	"10008190"	"230690007"
vorapaxar	DB09030	Cerebrovascular accident	C0038454		Approved			CHEBI_82702	"1537034"	HP:0001297	"10008190"	"230690007"
ramipril	DB14208	Cerebrovascular accident	C0038454		Approved			CHEBI_77363		HP:0001297	"10008190"	"230690007"
hydroxycarbamide	DB01005	Cerebrovascular accident	C0038454	NCT00122980	Terminated	Phase 3	The study has been stopped due to safety and futility concerns.	CHEBI_44423	"151871|5552"	HP:0001297	"10008190"	"230690007"
amlodipine	DB00381	Cerebrovascular accident	C0038454		Approved			CHEBI_2668	"17767"	HP:0001297	"10008190"	"230690007"
pravastatin	DB00175	Cerebrovascular accident	C0038454		Approved			CHEBI_63618	"42463"	HP:0001297	"10008190"	"230690007"
lidocaine	DB00281	Cerebrovascular accident	C0038454	NCT00907829	Withdrawn	Phase 2	Methods unexpectedly required additional refinement that precluded subject enrollment.	CHEBI_6456	"6387"	HP:0001297	"10008190"	"230690007"
rosuvastatin	DB01098	Cerebrovascular accident	C0038454		Approved			CHEBI_38545	"301542"	HP:0001297	"10008190"	"230690007"
atorvastatin	DB01076	Cerebrovascular accident	C0038454		Approved			CHEBI_39548	"83367"	HP:0001297	"10008190"	"230690007"
telmisartan	DB00966	Cerebrovascular accident	C0038454		Approved			CHEBI_9434	"73494"	HP:0001297	"10008190"	"230690007"
abciximab	DB00054	Cerebrovascular accident	C0038454	NCT00073372	Terminated	Phase 3	Based on the data and observed benefit-risk profile, the trial's independent oversight committee recommended that enrollment not resume.		"83929"	HP:0001297	"10008190"	"230690007"
meclocycline	DB13092	Syphilis	C0039128		Approved			CHEBI_135772	"29418"		"10062120"	"76272004"
doxycycline	DB00254	Syphilis	C0039128		Approved			CHEBI_50845	"1545992|3640"		"10062120"	"76272004"
oxytetracycline	DB00595	Syphilis	C0039128		Approved			CHEBI_133011	"7821|1545999"		"10062120"	"76272004"
procaine benzylpenicillin	DB01053	Syphilis	C0039128		Approved			CHEBI_18208	"7980"		"10062120"	"76272004"
benzylpenicillin	DB01053	Syphilis	C0039128		Approved			CHEBI_18208	"7980"		"10062120"	"76272004"
demeclocycline	DB00618	Syphilis	C0039128		Approved			CHEBI_4392	"3154"		"10062120"	"76272004"
amphotericin B	DB00681	Syphilis	C0039128		Approved			CHEBI_2682	"236594|732"		"10062120"	"76272004"
procaine benzylpenicillin	DB09320	Syphilis	C0039128		Approved			CHEBI_52154	"7983"		"10062120"	"76272004"
tetracycline	DB09550	Syphilis	C0039128		Approved			CHEBI_27902	"2105975"		"10062120"	"76272004"
tetracycline	DB00759	Syphilis	C0039128		Approved			CHEBI_27902	"10395"		"10062120"	"76272004"
erythromycin	DB00199	Syphilis	C0039128		Approved			CHEBI_42355	"4053"		"10062120"	"76272004"
minocycline	DB01017	Syphilis	C0039128		Approved			CHEBI_50694	"6980"		"10062120"	"76272004"
fusidic acid	DB02703	Syphilis	C0039128		Approved			CHEBI_29013	"4608|113608"		"10062120"	"76272004"
eptacog alfa (activated)	DB00036	Thrombasthenia	C0040015		Approved				"4256|253149|2386863"	HP:0001872	"10043529"	"32942005"
doxycycline	DB00254	Yaws	C0043388		Approved			CHEBI_50845	"1545992|3640"	MONDO_0006019	"10048234"	"70647001"
meclocycline	DB13092	Yaws	C0043388		Approved			CHEBI_135772	"29418"	MONDO_0006019	"10048234"	"70647001"
demeclocycline	DB00618	Yaws	C0043388		Approved			CHEBI_4392	"3154"	MONDO_0006019	"10048234"	"70647001"
procaine benzylpenicillin	DB01053	Yaws	C0043388		Approved			CHEBI_18208	"7980"	MONDO_0006019	"10048234"	"70647001"
tetracycline	DB09550	Yaws	C0043388		Approved			CHEBI_27902	"2105975"	MONDO_0006019	"10048234"	"70647001"
minocycline	DB01017	Yaws	C0043388		Approved			CHEBI_50694	"6980"	MONDO_0006019	"10048234"	"70647001"
procaine benzylpenicillin	DB09320	Yaws	C0043388		Approved			CHEBI_52154	"7983"	MONDO_0006019	"10048234"	"70647001"
amphotericin B	DB00681	Yaws	C0043388		Approved			CHEBI_2682	"236594|732"	MONDO_0006019	"10048234"	"70647001"
fusidic acid	DB02703	Yaws	C0043388		Approved			CHEBI_29013	"4608|113608"	MONDO_0006019	"10048234"	"70647001"
benzylpenicillin	DB01053	Yaws	C0043388		Approved			CHEBI_18208	"7980"	MONDO_0006019	"10048234"	"70647001"
tetracycline	DB00759	Yaws	C0043388		Approved			CHEBI_27902	"10395"	MONDO_0006019	"10048234"	"70647001"
oxytetracycline	DB00595	Yaws	C0043388		Approved			CHEBI_133011	"7821|1545999"	MONDO_0006019	"10048234"	"70647001"
pilsicainide	DB12712	Tachyarrhythmia	C0080203		Approved			CHEBI_135127			"10049447"	"6285003"
clofazimine	DB00845	Pyoderma Gangrenosum	C0085652		Approved			CHEBI_3749	"2592"	MONDO_0018824	"10037635"	"74578003"
adalimumab	DB00051	Pyoderma Gangrenosum	C0085652	NCT00730717	Withdrawn	Phase 2			"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0018824	"10037635"	"74578003"
adalimumab	DB00051	Pyoderma Gangrenosum	C0085652		Approved				"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0018824	"10037635"	"74578003"
adalimumab	DB00051	Pyoderma Gangrenosum	C0085652	NCT00690846	Withdrawn	Phase 2	Dr. Jorizzo has withdrawn from this study due to time it is taking to start		"2103479|2640402|2641642|2612153|2619155|2103477|327361"	MONDO_0018824	"10037635"	"74578003"
ceftazidime	DB00438	Gonococcal meningitis	C0153225		Approved			CHEBI_3508	"2191|1545984"		"10027239"	"151004"
ceftriaxone	DB01212	Gonococcal meningitis	C0153225		Approved			CHEBI_29007	"2193"		"10027239"	"151004"
taurine	DB01956	MELAS Syndrome	C0162671		Approved			CHEBI_507393	"10337"	MONDO_0010789	"10053872"	"39925003"
metreleptin	DB09046	Familial generalized lipodystrophy	C0221032		Approved				"1491625"	HP:0009059	"10053547"	"284449005"
mechlorethamine	DB00888	Malignant neoplasm of lung	C0242379		Approved			CHEBI_28925	"6674"	HP:0100526	"10058467"	"363358000"
vindesine	DB00309	Malignant neoplasm of lung	C0242379		Approved			CHEBI_36373	"11204"	HP:0100526	"10058467"	"363358000"
lonidamine	DB06266	Malignant neoplasm of lung	C0242379		Approved			CHEBI_50138		HP:0100526	"10058467"	"363358000"
doxorubicin	DB00997	Malignant neoplasm of lung	C0242379		Approved			CHEBI_28748	"142433|3639"	HP:0100526	"10058467"	"363358000"
talaporfin	DB11812	Malignant neoplasm of lung	C0242379		Approved			CHEBI_135875		HP:0100526	"10058467"	"363358000"
methotrexate	DB00563	Malignant neoplasm of lung	C0242379		Approved			CHEBI_44185	"6851"	HP:0100526	"10058467"	"363358000"
meropenem	DB00760	Abdominal Abscess	C0243001		Approved			CHEBI_43968	"1546029|29561"		"10060921"	"75100008"
metronidazole	DB00916	Abdominal Abscess	C0243001		Approved			CHEBI_6909	"6922"		"10060921"	"75100008"
tazobactam	DB01606	Abdominal Abscess	C0243001		Approved			CHEBI_9421	"37617"		"10060921"	"75100008"
	DB00766	Abdominal Abscess	C0243001	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_48947	"48203|21216"		"10060921"	"75100008"
doripenem	DB06211	Abdominal Abscess	C0243001		Approved			CHEBI_135928	"119771"		"10060921"	"75100008"
cefoxitin	DB01331	Abdominal Abscess	C0243001		Approved			CHEBI_209807	"2189"		"10060921"	"75100008"
moxifloxacin	DB00218	Abdominal Abscess	C0243001		Approved			CHEBI_63611	"139462"		"10060921"	"75100008"
meropenem	DB00760	Abdominal Abscess	C0243001	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_43968	"1546029|29561"		"10060921"	"75100008"
	DB06211	Abdominal Abscess	C0243001	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_135928	"119771"		"10060921"	"75100008"
tigecycline	DB00560	Abdominal Abscess	C0243001		Approved			CHEBI_149836	"384455"		"10060921"	"75100008"
piperacillin	DB00319	Abdominal Abscess	C0243001		Approved			CHEBI_8232	"1546000|8339"		"10060921"	"75100008"
ceftolozane	DB09050	Abdominal Abscess	C0243001		Approved			CHEBI_134719	"1597609"		"10060921"	"75100008"
imipenem	DB01598	Abdominal Abscess	C0243001		Approved			CHEBI_471744	"5690|1545986"		"10060921"	"75100008"
	DB01060	Abdominal Abscess	C0243001	NCT01110382	Terminated	Phase 3	Trial terminated early per business decision	CHEBI_2676	"1297882|723"		"10060921"	"75100008"
cilastatin	DB01597	Abdominal Abscess	C0243001		Approved			CHEBI_3697	"2540"		"10060921"	"75100008"
norfloxacin	DB01059	Abdominal Abscess	C0243001		Approved			CHEBI_100246	"7517"		"10060921"	"75100008"
ciprofloxacin	DB00537	Abdominal Abscess	C0243001		Approved			CHEBI_192484	"2551"		"10060921"	"75100008"
ofloxacin	DB01165	Abdominal Abscess	C0243001		Approved			CHEBI_7731	"7623"		"10060921"	"75100008"
ertapenem	DB00303	Abdominal Abscess	C0243001		Approved			CHEBI_404903	"325642"		"10060921"	"75100008"
metronidazole	DB15759	Abdominal Abscess	C0243001		Approved			CHEBI_50688			"10060921"	"75100008"
tafamidis	DB05352	Senile cardiac amyloidosis	C0268407		Approved			CHEBI_78538		HP:0030843	"10007509"	"16573007"
tafamidis	DB11644	Senile cardiac amyloidosis	C0268407		Approved			CHEBI_78538	"1545063"	HP:0030843	"10007509"	"16573007"
clarithromycin	DB01211	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3732	"21212"		"10044013"	"41582007"
cefprozil	DB01150	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3506	"1546020|19552"		"10044013"	"41582007"
phenoxymethylpenicillin	DB00417	Streptococcal tonsillitis	C0275804		Approved			CHEBI_27446	"7984"		"10044013"	"41582007"
procaine benzylpenicillin	DB09320	Streptococcal tonsillitis	C0275804		Approved			CHEBI_52154	"7983"		"10044013"	"41582007"
azithromycin	DB00207	Streptococcal tonsillitis	C0275804		Approved			CHEBI_2955	"18631"		"10044013"	"41582007"
cefadroxil	DB01140	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3479	"1545975|2177"		"10044013"	"41582007"
procaine benzylpenicillin	DB01053	Streptococcal tonsillitis	C0275804		Approved			CHEBI_18208	"7980"		"10044013"	"41582007"
benzylpenicillin	DB01053	Streptococcal tonsillitis	C0275804		Approved			CHEBI_18208	"7980"		"10044013"	"41582007"
cefalexin	DB00567	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3534	"2231|1299782"		"10044013"	"41582007"
cefradine	DB01333	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3547	"2239"		"10044013"	"41582007"
cefdinir	DB00535	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3485	"25037"		"10044013"	"41582007"
cefditoren pivoxil	DB01066	Streptococcal tonsillitis	C0275804		Approved			CHEBI_59343	"83682"		"10044013"	"41582007"
cefpodoxime proxetil	DB01416	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3504	"20489"		"10044013"	"41582007"
dirithromycin	DB00954	Streptococcal tonsillitis	C0275804		Approved			CHEBI_474014			"10044013"	"41582007"
cefuroxime axetil	DB01112	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3515	"2194"		"10044013"	"41582007"
ceftibuten	DB01415	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3510	"20492"		"10044013"	"41582007"
cefuroxime	DB01112	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3515	"2194"		"10044013"	"41582007"
cefixime	DB00671	Streptococcal tonsillitis	C0275804		Approved			CHEBI_472657	"25033|1546021"		"10044013"	"41582007"
ampicillin	DB00415	Streptococcal tonsillitis	C0275804		Approved			CHEBI_28971	"733|221058"		"10044013"	"41582007"
cefaclor	DB00833	Streptococcal tonsillitis	C0275804		Approved			CHEBI_3478	"1450910|2176"		"10044013"	"41582007"
amoxicillin	DB01060	Streptococcal tonsillitis	C0275804		Approved			CHEBI_2676	"1297882|723"		"10044013"	"41582007"
tecovirimat	DB12020	Monkeypox disease	C0276180		Approved				"2055104"	MONDO_0002594	"10069538"	"359814004"
voriconazole	DB00582	Fusariosis	C0276758		Approved			CHEBI_10023	"121243"		"10051919"	"64250002"
posaconazole	DB01263	Fusariosis	C0276758		Approved			CHEBI_64355	"282446"		"10051919"	"64250002"
itraconazole	DB01167	Fusariosis	C0276758		Approved			CHEBI_6076	"28031"		"10051919"	"64250002"
fusidic acid	DB02703	Q fever endocarditis	C0340354		Approved			CHEBI_29013	"4608|113608"		"10014682"	"95890006"
doxycycline	DB00254	Q fever endocarditis	C0340354		Approved			CHEBI_50845	"1545992|3640"		"10014682"	"95890006"
nystatin	DB00646	Gastrointestinal candidiasis	C0343886		Approved			CHEBI_473992	"7597"		"10017938"	"84679006"
relugolix	DB11853	Malignant neoplasm of prostate	C0376358		Approved				"2472778"	MONDO_0008315	"10060862"	"399068003"
docetaxel	DB01248	Malignant neoplasm of prostate	C0376358		Approved			CHEBI_4672	"72962|1299922"	MONDO_0008315	"10060862"	"399068003"
abiraterone acetate	DB05812	Malignant neoplasm of prostate	C0376358		Approved			CHEBI_68642	"1100072"	MONDO_0008315	"10060862"	"399068003"
apalutamide	DB11901	Malignant neoplasm of prostate	C0376358		Approved				"1999574"	MONDO_0008315	"10060862"	"399068003"
enzalutamide	DB08899	Malignant neoplasm of prostate	C0376358		Approved			CHEBI_68534	"1307298"	MONDO_0008315	"10060862"	"399068003"
radium Ra 223 dichloride	DB08913	Malignant neoplasm of prostate	C0376358		Approved			CHEBI_74895	"1424174"	MONDO_0008315	"10060862"	"399068003"
triamcinolone hexacetonide	DB00620	Necrobiosis Lipoidica Diabeticorum	C0392445		Approved			CHEBI_9667	"10759"		"10056969"	"56391002"
triamcinolone	DB00620	Necrobiosis Lipoidica Diabeticorum	C0392445		Approved			CHEBI_9667	"10759"		"10056969"	"56391002"
estradiol	DB00783	Urethral atrophy	C0520577		Approved			CHEBI_16469	"4083"		"10068313"	"52620003"
estradiol	DB00783	Premenstrual Dysphoric Disorder	C0520676	NCT00089414	Terminated	Phase 2	Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of protocol.	CHEBI_16469	"4083"		"10051537"	"596004"
drospirenone	DB01395	Premenstrual Dysphoric Disorder	C0520676		Approved			CHEBI_50838	"11636"		"10051537"	"596004"
sertraline	DB01104	Premenstrual Dysphoric Disorder	C0520676		Approved			CHEBI_9123	"36437"		"10051537"	"596004"
	DB00396	Premenstrual Dysphoric Disorder	C0520676	NCT00089414	Terminated	Phase 2	Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of protocol.	CHEBI_17026	"8727"		"10051537"	"596004"
fluoxetine	DB00472	Premenstrual Dysphoric Disorder	C0520676		Approved			CHEBI_86990	"4493"		"10051537"	"596004"
levomefolic acid	DB11256	Premenstrual Dysphoric Disorder	C0520676		Approved			CHEBI_136009	"1592257|1025342"		"10051537"	"596004"
estradiol	DB00783	Premenstrual Dysphoric Disorder	C0520676		Approved			CHEBI_16469	"4083"		"10051537"	"596004"
paroxetine	DB00715	Premenstrual Dysphoric Disorder	C0520676		Approved			CHEBI_7936	"32937"		"10051537"	"596004"
	DB00977	Premenstrual Dysphoric Disorder	C0520676	NCT00089414	Terminated	Phase 2	Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of protocol.	CHEBI_4903	"4124"		"10051537"	"596004"
ethinylestradiol	DB00977	Premenstrual Dysphoric Disorder	C0520676		Approved			CHEBI_4903	"4124"		"10051537"	"596004"
laquinimod	DB06685	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			CHEBI_134738		MONDO_0005314	"10063399"	"426373005"
interferon beta-1a	DB00060	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved				"75917"	MONDO_0005314	"10063399"	"426373005"
dimethyl fumarate	DB08908	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			CHEBI_76004	"1373478"	MONDO_0005314	"10063399"	"426373005"
interferon beta-1a	DB00060	Multiple Sclerosis, Relapsing-Remitting	C0751967	NCT01975298	Withdrawn	Phase 3	Business Decision		"75917"	MONDO_0005314	"10063399"	"426373005"
	DB00060	Multiple Sclerosis, Relapsing-Remitting	C0751967	NCT01058005	Terminated	Phase 3	Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.		"75917"	MONDO_0005314	"10063399"	"426373005"
fingolimod	DB08868	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			CHEBI_63115	"1012892"	MONDO_0005314	"10063399"	"426373005"
natalizumab	DB00108	Multiple Sclerosis, Relapsing-Remitting	C0751967	NCT01058005	Terminated	Phase 3	Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.		"354770"	MONDO_0005314	"10063399"	"426373005"
peginterferon beta-1a	DB09122	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved				"1546168"	MONDO_0005314	"10063399"	"426373005"
alemtuzumab	DB00087	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved				"117055"	MONDO_0005314	"10063399"	"426373005"
cyclophosphamide	DB00531	Multiple Sclerosis, Relapsing-Remitting	C0751967	NCT00939549	Withdrawn	Phase 2	Study revised to retrospective chart review	CHEBI_4027	"1545988|3002"	MONDO_0005314	"10063399"	"426373005"
teriflunomide	DB08880	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			CHEBI_68540	"1310520"	MONDO_0005314	"10063399"	"426373005"
interferon beta-1b	DB00068	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			CHEBI_5938	"72257|72258"	MONDO_0005314	"10063399"	"426373005"
mitoxantrone	DB01204	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			CHEBI_50729	"7005"	MONDO_0005314	"10063399"	"426373005"
interferon beta-1a	DB00060	Multiple Sclerosis, Relapsing-Remitting	C0751967	NCT01714089	Withdrawn	Phase 2			"75917"	MONDO_0005314	"10063399"	"426373005"
cefprozil	DB01150	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_3506	"1546020|19552"			"425748003"
interferon beta-1a	DB00060	Multiple Sclerosis, Relapsing-Remitting	C0751967	NCT01337427	Withdrawn	Phase 3	The study was not feasible to conduct in the US and abroad.		"75917"	MONDO_0005314	"10063399"	"426373005"
simvastatin	DB00641	Multiple Sclerosis, Relapsing-Remitting	C0751967	NCT00429442	Withdrawn	Phase 3		CHEBI_9150	"36567"	MONDO_0005314	"10063399"	"426373005"
daclizumab	DB00111	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved				"190353"	MONDO_0005314	"10063399"	"426373005"
siponimod	DB12371	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved				"2121085"	MONDO_0005314	"10063399"	"426373005"
cladribine	DB00242	Multiple Sclerosis, Relapsing-Remitting	C0751967		Approved			CHEBI_567361	"44157"	MONDO_0005314	"10063399"	"426373005"
phentolamine	DB00692	Cerebral Ischemia	C0917798		Approved			CHEBI_8081	"8153"	MONDO_0005299	"10008120"	"287731003"
papaverine	DB01113	Cerebral Ischemia	C0917798		Approved			CHEBI_28241	"7895"	MONDO_0005299	"10008120"	"287731003"
norepinephrine	DB00368	Cerebral Ischemia	C0917798	NCT00841633	Terminated	Phase 3	Our RCT recently started. The RCT is similar to the feasibility trial, so it was terminated to avoid 2 trials running simultaniously.	CHEBI_18357	"7512"	MONDO_0005299	"10008120"	"287731003"
fasudil	DB08162	Cerebral Ischemia	C0917798		Approved			CHEBI_43871		MONDO_0005299	"10008120"	"287731003"
pentobarbital	DB00312	Cerebral Ischemia	C0917798		Approved			CHEBI_7983	"8004"	MONDO_0005299	"10008120"	"287731003"
paclitaxel	DB01229	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_45863	"56946"	HP:0100615	"10033128"	"363443007"
doxorubicin	DB00997	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_28748	"142433|3639"	HP:0100615	"10033128"	"363443007"
trabectedin	DB05109	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_84050	"1716278"	HP:0100615	"10033128"	"363443007"
thiotepa	DB04572	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_9570	"10473"	HP:0100615	"10033128"	"363443007"
rucaparib	DB12332	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_134689	"1862579"	HP:0100615	"10033128"	"363443007"
topotecan	DB01030	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_63632	"57308"	HP:0100615	"10033128"	"363443007"
altretamine	DB00488	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_24564	"5296"	HP:0100615	"10033128"	"363443007"
carboplatin	DB00958	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_31355	"40048"	HP:0100615	"10033128"	"363443007"
olaparib	DB09074	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_83766	"1597582"	HP:0100615	"10033128"	"363443007"
cisplatin	DB00515	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_27899	"2555"	HP:0100615	"10033128"	"363443007"
hydroxycarbamide	DB01005	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_44423	"151871|5552"	HP:0100615	"10033128"	"363443007"
niraparib	DB11793	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_176844	"1918231"	HP:0100615	"10033128"	"363443007"
belotecan	DB12459	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_135702		HP:0100615	"10033128"	"363443007"
melphalan	DB01042	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_28876	"6718"	HP:0100615	"10033128"	"363443007"
gemcitabine	DB00441	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_175901	"12574"	HP:0100615	"10033128"	"363443007"
tretamine	DB14031	Malignant neoplasm of ovary	C1140680		Approved			CHEBI_27919		HP:0100615	"10033128"	"363443007"
medrysone	DB00253	Herpes zoster keratitis	C1275687		Approved			CHEBI_34829	"29439"		"10077496"	"397573005"
prednisolone	DB00860	Herpes zoster keratitis	C1275687		Approved			CHEBI_8378	"8638"		"10077496"	"397573005"
loteprednol etabonate	DB14596	Herpes zoster keratitis	C1275687		Approved			CHEBI_31784	"52177"		"10077496"	"397573005"
ganciclovir	DB01004	Herpes zoster keratitis	C1275687	NCT02382588	Terminated	Phase 2	There were difficulties meeting the enrollment goal within stipulated time frames.	CHEBI_465284	"4678"		"10077496"	"397573005"
fluorometholone acetate	DB00324	Herpes zoster keratitis	C1275687		Approved			CHEBI_31625	"4491"		"10077496"	"397573005"
cortisone acetate	DB01380	Herpes zoster keratitis	C1275687		Approved			CHEBI_3897	"21655"		"10077496"	"397573005"
hydrocortisone	DB00741	Herpes zoster keratitis	C1275687		Approved			CHEBI_17650	"5492"		"10077496"	"397573005"
dexamethasone	DB01234	Herpes zoster keratitis	C1275687		Approved			CHEBI_41879	"3264"		"10077496"	"397573005"
loteprednol etabonate	DB00873	Herpes zoster keratitis	C1275687		Approved			CHEBI_50848	"237027"		"10077496"	"397573005"
fluorometholone	DB00324	Herpes zoster keratitis	C1275687		Approved			CHEBI_31625	"4491"		"10077496"	"397573005"
tobramycin	DB00684	Herpes zoster keratitis	C1275687		Approved			CHEBI_28864	"10627"		"10077496"	"397573005"
fusidic acid	DB02703	Herpes zoster keratitis	C1275687		Approved			CHEBI_29013	"4608|113608"		"10077496"	"397573005"
darbepoetin alfa	DB00012	Chronic Kidney Diseases	C1561643	NCT00436748	Terminated	Phase 3	FDA and EMA agreed that the information that had been submitted to date was acceptable to meet the requirements of the post-marketing commitment.		"283838"	MONDO_0005300	"10064848"	"709044004"
darbepoetin alfa	DB00012	Chronic Kidney Diseases	C1561643	NCT00968617	Terminated	Phase 2			"283838"	MONDO_0005300	"10064848"	"709044004"
darbepoetin alfa	DB00012	Chronic Kidney Diseases	C1561643	NCT00364845	Terminated	Phase 3	The reason for the discontinuation of the study is difficulty with recruitment and timely enrolment and is not related to safety concerns		"283838"	MONDO_0005300	"10064848"	"709044004"
darbepoetin alfa	DB00012	Chronic Kidney Diseases	C1561643	NCT01428154	Withdrawn	Phase 1	Difficulty in recruitment. PDCO in the Day 30 summary report agrred to remove the PK study in children <1 year of age.		"283838"	MONDO_0005300	"10064848"	"709044004"
eplerenone	DB00700	Chronic Kidney Diseases	C1561643	NCT01100203	Terminated	Phase 3	It was not possible within the time frame to recruit the planned no. of patients.	CHEBI_31547	"298869"	MONDO_0005300	"10064848"	"709044004"
epoetin alfa	DB00016	Chronic Kidney Diseases	C1561643	NCT01695759	Terminated	Phase 3			"2047589|105695|105694"	MONDO_0005300	"10064848"	"709044004"
rosiglitazone	DB00412	Chronic Kidney Diseases	C1561643	NCT00169923	Withdrawn	Phase 2/Phase 3	it was not possible to recruit any patient in the study	CHEBI_50122	"84108"	MONDO_0005300	"10064848"	"709044004"
floxacillin	DB00301	Chronic Kidney Diseases	C1561643	NCT00433342	Terminated	Phase 1		CHEBI_5098	"4448"	MONDO_0005300	"10064848"	"709044004"
ceftazidime	DB00438	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3508	"2191|1545984"			"428783003"
cinacalcet	DB01012	Chronic Kidney Diseases	C1561643	NCT01439867	Terminated	Phase 2	Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.	CHEBI_48390	"407990"	MONDO_0005300	"10064848"	"709044004"
epoetin alfa	DB00016	Chronic Kidney Diseases	C1561643	NCT00924781	Terminated	Phase 2			"2047589|105695|105694"	MONDO_0005300	"10064848"	"709044004"
pioglitazone	DB01132	Chronic Kidney Diseases	C1561643	NCT00368017	Terminated	Phase 2	unable to replace Fellow conducting the study who left institution in 2007	CHEBI_8228	"33738"	MONDO_0005300	"10064848"	"709044004"
iron	DB01592	Chronic Kidney Diseases	C1561643	NCT00384657	Withdrawn	Phase 3	Lack of cooperation among centers, Financial reasons	CHEBI_18248	"90176|262150"	MONDO_0005300	"10064848"	"709044004"
epoetin alfa	DB00016	Chronic Kidney Diseases	C1561643	NCT00156962	Terminated	Phase 3	Regulatory decision not to proceed		"2047589|105695|105694"	MONDO_0005300	"10064848"	"709044004"
sevelamer	DB00658	Chronic Kidney Diseases	C1561643	NCT00833768	Terminated	Phase 3	After an extensive review,the ASPIRE in CKD study was terminated because it was not possible to complete the study in an appropriate time frame.		"214824"	MONDO_0005300	"10064848"	"709044004"
dapagliflozin	DB06292	Chronic Kidney Diseases	C1561643		Approved			CHEBI_85078	"1488564"	MONDO_0005300	"10064848"	"709044004"
cinacalcet	DB01012	Chronic Kidney Diseases	C1561643	NCT01277510	Terminated	Phase 3	Study was put on clinical hold on 30 Jan 2013 following a subject fatality. Study was never restarted and was closed.	CHEBI_48390	"407990"	MONDO_0005300	"10064848"	"709044004"
rosiglitazone	DB00412	Chronic Kidney Diseases	C1561643	NCT00452166	Terminated	Phase 3	it was not possible to recruit new patients anymore	CHEBI_50122	"84108"	MONDO_0005300	"10064848"	"709044004"
oxytocin	DB00107	Alcoholic Intoxication, Chronic	C0001973	NCT02711189	Withdrawn	Phase 1		CHEBI_7872	"7824"	HP:0030955	"10001639"	"7200002"
nalmefene	DB06230	Alcoholic Intoxication, Chronic	C0001973		Approved			CHEBI_7457	"31479"	HP:0030955	"10001639"	"7200002"
naltrexone	DB00704	Alcoholic Intoxication, Chronic	C0001973		Approved			CHEBI_7465	"7243"	HP:0030955	"10001639"	"7200002"
fasudil	DB08162	Cerebral Vasospasm	C0265110		Approved			CHEBI_43871				"73173006"
alfuzosin	DB00346	Prostatic Hypertrophy	C1739363		Approved			CHEBI_51141	"17300"			"266569009"
finasteride	DB01216	Prostatic Hypertrophy	C1739363		Approved			CHEBI_5062	"25025"			"266569009"
carisoprodol	DB00395	Back Pain	C0004604		Approved			CHEBI_3419	"2101"	HP:0003418	"10003988"	"161891005"
levomenthol	DB00825	Back Pain	C0004604		Approved			CHEBI_15409	"236388|6750"	HP:0003418	"10003988"	"161891005"
camphor	DB01744	Back Pain	C0004604		Approved			CHEBI_15396	"1297880|1298738|1952"	HP:0003418	"10003988"	"161891005"
capsaicin	DB06774	Back Pain	C0004604		Approved			CHEBI_3374	"1992"	HP:0003418	"10003988"	"161891005"
magnesium salicylate	DB01397	Back Pain	C0004604		Approved			CHEBI_6640		HP:0003418	"10003988"	"161891005"
methyl salicylate	DB09543	Back Pain	C0004604		Approved			CHEBI_31832	"29787"	HP:0003418	"10003988"	"161891005"
levomenthol	DB14123	Back Pain	C0004604		Approved			CHEBI_25187	"6750|1430390"	HP:0003418	"10003988"	"161891005"
aceclofenac	DB06736	Back Pain	C0004604		Approved			CHEBI_31159	"16689"	HP:0003418	"10003988"	"161891005"
caffeine	DB00201	Back Pain	C0004604		Approved			CHEBI_27732	"1886"	HP:0003418	"10003988"	"161891005"
lomustine	DB01206	Brain Neoplasms	C0006118		Approved			CHEBI_6520	"6466"	HP:0030692	"10061019"	"126952004"
amoxicillin	DB01060	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_2676	"1297882|723"			"425748003"
nitisinone	DB00348	Tyrosinemia, Type I	C0268490		Approved			CHEBI_50378	"61805"	MONDO_0010161		"410056006"
norfloxacin	DB01059	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_100246	"7517"			"425748003"
ofloxacin	DB01165	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_7731	"7623"			"425748003"
olanzapine	DB00334	Depression, Bipolar	C0005587		Approved			CHEBI_7735	"61381"			"191627008"
oxacillin	DB00713	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_7809	"7773"			"428783003"
oxymetazoline	DB00935	Persistent erythema of skin	C1720538		Approved			CHEBI_7862	"7812"			"420356000"
prulifloxacin	DB11892	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_32071				"425748003"
parathiazine	DB15978	Vomiting of pregnancy	C0269661		Approved			CHEBI_135253				"90325002"
quetiapine	DB01224	Depression, Bipolar	C0005587		Approved			CHEBI_8707	"51272"			"191627008"
azathioprine	DB00993	Autoimmune Chronic Hepatitis	C0241910		Approved			CHEBI_2948	"1256"			"16098491000119109"
trimethoprim	DB00440	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_45924	"10829"			"425748003"
azithromycin	DB00207	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_2955	"18631"			"425748003"
silodosin	DB06207	Prostatic Hypertrophy	C1739363		Approved			CHEBI_135929	"720825"			"266569009"
lurasidone	DB08815	Depression, Bipolar	C0005587		Approved			CHEBI_70735	"1040028"			"191627008"
zinc acetate	DB14487	Burn injury	C0006434		Approved			CHEBI_62984	"1299637|58295"			"125666000"
levofolinic acid	DB11596	Malignant tumor of small intestine	C0153425		Approved			CHEBI_63606	"877015"	MONDO_0000956		"363509000"
ferric oxide	DB11576	Burn injury	C0006434		Approved			CHEBI_50819				"125666000"
bedaquiline	DB08903	Tuberculosis, Drug-Resistant	C0206525		Approved			CHEBI_72292	"1364504"			"423709000"
prussian blue	DB06783	Thallium poisoning	C0238452		Approved			CHEBI_30069	"24902|539399"			"51040009"
relebactam	DB12377	Acinetobacter Infections	C0001139		Approved				"2184137|2268500"	MONDO_0006635	"10051894"	"840588006"
cefditoren pivoxil	DB01066	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_59343	"83682"			"425748003"
fedratinib	DB12500	Post-polycythemia vera myelofibrosis	C3805232		Approved			CHEBI_91408	"2197490"			"871540009"
cefixime	DB00671	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_472657	"25033|1546021"			"425748003"
cefoxitin	DB01331	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_209807	"2189"			"428783003"
tezepelumab	DB15090	Severe asthma	C0581126		Approved				"2587789"			"370221004"
cefpodoxime proxetil	DB01416	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_3504	"20489"			"425748003"
acetazolamide	DB00819	Absence Epilepsy	C0014553		Approved			CHEBI_27690	"167"		"10034759"	"79631006"
cefuroxime	DB01112	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3515	"2194"			"428783003"
cefuroxime	DB01112	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_3515	"2194"			"425748003"
cefuroxime axetil	DB01112	Acute exacerbation of chronic bronchitis	C0856695		Approved			CHEBI_3515	"2194"			"425748003"
cefalexin	DB00567	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3534	"2231|1299782"			"428783003"
cefapirin	DB01139	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_554446	"2238"			"428783003"
clavulanic acid	DB00766	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_48947	"48203|21216"			"428783003"
clindamycin	DB01190	Osteomyelitis due to Staphylococcus aureus	C1997728		Approved			CHEBI_3745	"2582"			"428783003"
dantrolene	DB01219	Muscle spasticity of spinal origin	C1562430		Approved			CHEBI_4317	"3105"			"416830008"
acyclovir	DB00787	Herpes Labialis	C0019345		Approved			CHEBI_2453	"281"	MONDO_0043653		"1475003"
sinecatechins	DB01266	Condylomata Acuminata	C0009663		Approved				"753346"	HP:0032301	"10059313"	"266113007"
interferon alfa-2b	DB15131	Condylomata Acuminata	C0009663		Approved				"545290"	HP:0032301	"10059313"	"266113007"
podophyllotoxin	DB01179	Condylomata Acuminata	C0009663		Approved			CHEBI_50305	"8463"	HP:0032301	"10059313"	"266113007"
cianidanol	DB14086	Condylomata Acuminata	C0009663		Approved			CHEBI_15600	"1367177"	HP:0032301	"10059313"	"266113007"
interferon alfa-2b	DB00105	Condylomata Acuminata	C0009663		Approved				"5880|545290"	HP:0032301	"10059313"	"266113007"
imiquimod	DB00724	Condylomata Acuminata	C0009663		Approved			CHEBI_36704	"59943"	HP:0032301	"10059313"	"266113007"
benzoin	DB14020	Condylomata Acuminata	C0009663		Approved			CHEBI_17682	"1406"	HP:0032301	"10059313"	"266113007"
tecovirimat	DB12020	Cowpox	C0010232		Approved				"2055104"	MONDO_0005720	"10011238"	"70090004"
almasilate	DB13595	Dyspepsia	C0013395		Approved				"17614"	HP:0410281	"10013946"	"162031009"
magnesium oxide	DB01377	Dyspepsia	C0013395		Approved			CHEBI_31794	"6582"	HP:0410281	"10013946"	"162031009"
ranitidine	DB00863	Dyspepsia	C0013395		Approved			CHEBI_92246	"9143"	HP:0410281	"10013946"	"162031009"
alum	DB09087	Dyspepsia	C0013395		Approved			CHEBI_86463	"221456|54989"	HP:0410281	"10013946"	"162031009"
sodium citrate	DB09154	Dyspepsia	C0013395		Approved			CHEBI_53258	"253204|56466|1310549"	HP:0410281	"10013946"	"162031009"
magnesium carbonate	DB09481	Dyspepsia	C0013395		Approved			CHEBI_31793	"29155"	HP:0410281	"10013946"	"162031009"
silicon dioxide	DB11132	Dyspepsia	C0013395		Approved			CHEBI_30563	"314826|1362874|9771"	HP:0410281	"10013946"	"162031009"
bismuth subsalicylate	DB01294	Dyspepsia	C0013395		Approved			CHEBI_261649	"19478"	HP:0410281	"10013946"	"162031009"
magnesium lactate	DB14515	Dyspepsia	C0013395		Approved				"214688"	HP:0410281	"10013946"	"162031009"
algeldrate	DB06723	Dyspepsia	C0013395		Approved			CHEBI_33130	"612|81948"	HP:0410281	"10013946"	"162031009"
nizatidine	DB00585	Dyspepsia	C0013395		Approved			CHEBI_7601	"42319"	HP:0410281	"10013946"	"162031009"
magnesium hydroxide	DB09104	Dyspepsia	C0013395		Approved			CHEBI_6637	"6581|243353"	HP:0410281	"10013946"	"162031009"
calcium carbonate	DB06724	Dyspepsia	C0013395		Approved			CHEBI_3311	"349908|1897"	HP:0410281	"10013946"	"162031009"
magnesium silicate	DB13249	Dyspepsia	C0013395		Approved				"1310566"	HP:0410281	"10013946"	"162031009"
magnesium silicate	DB09281	Dyspepsia	C0013395		Approved				"29170"	HP:0410281	"10013946"	"162031009"
magnesium gluconate	DB13749	Dyspepsia	C0013395		Approved				"52358"	HP:0410281	"10013946"	"162031009"
magnesium aspartate	DB13359	Dyspepsia	C0013395		Approved					HP:0410281	"10013946"	"162031009"
potassium hydrogencarbonate	DB11098	Dyspepsia	C0013395		Approved			CHEBI_81862	"34296"	HP:0410281	"10013946"	"162031009"
carbaldrate	DB15825	Dyspepsia	C0013395		Approved					HP:0410281	"10013946"	"162031009"
famotidine	DB00927	Dyspepsia	C0013395		Approved			CHEBI_4975	"4278"	HP:0410281	"10013946"	"162031009"
citric acid	DB04272	Dyspepsia	C0013395		Approved			CHEBI_30769	"21183|221946"	HP:0410281	"10013946"	"162031009"
cimetidine	DB00501	Dyspepsia	C0013395		Approved			CHEBI_3699	"2541"	HP:0410281	"10013946"	"162031009"
triamcinolone	DB00620	Epicondylitis	C0014488		Approved			CHEBI_9667	"10759"	MONDO_0001875	"10014971"	"73583000"
cortisone acetate	DB01380	Epicondylitis	C0014488		Approved			CHEBI_3897	"21655"	MONDO_0001875	"10014971"	"73583000"
triamcinolone acetonide	DB00620	Epicondylitis	C0014488		Approved			CHEBI_9667	"10759"	MONDO_0001875	"10014971"	"73583000"
prednisone	DB00635	Epicondylitis	C0014488		Approved			CHEBI_8382	"8640"	MONDO_0001875	"10014971"	"73583000"
methylprednisolone	DB00959	Epicondylitis	C0014488		Approved			CHEBI_6888	"6902"	MONDO_0001875	"10014971"	"73583000"
triamcinolone diacetate	DB00620	Epicondylitis	C0014488		Approved			CHEBI_9667	"10759"	MONDO_0001875	"10014971"	"73583000"
betamethasone	DB00443	Epicondylitis	C0014488		Approved			CHEBI_3077	"1514"	MONDO_0001875	"10014971"	"73583000"
prednisolone	DB00860	Epicondylitis	C0014488		Approved			CHEBI_8378	"8638"	MONDO_0001875	"10014971"	"73583000"
dexamethasone	DB01234	Epicondylitis	C0014488		Approved			CHEBI_41879	"3264"	MONDO_0001875	"10014971"	"73583000"
methsuximide	DB05246	Absence Epilepsy	C0014553		Approved			CHEBI_6846	"47858"		"10034759"	"79631006"
phensuximide	DB00832	Absence Epilepsy	C0014553		Approved			CHEBI_8079	"33309"		"10034759"	"79631006"
ethosuximide	DB00593	Absence Epilepsy	C0014553		Approved			CHEBI_4887	"4135"		"10034759"	"79631006"
valproic acid	DB00313	Absence Epilepsy	C0014553		Approved			CHEBI_39867	"11118|40254"		"10034759"	"79631006"
clonazepam	DB01068	Absence Epilepsy	C0014553		Approved			CHEBI_3756	"2598"		"10034759"	"79631006"
paramethadione	DB00617	Absence Epilepsy	C0014553		Approved			CHEBI_7921	"32894"		"10034759"	"79631006"
lorazepam	DB00186	Absence Epilepsy	C0014553		Approved			CHEBI_6539	"6470"		"10034759"	"79631006"
trimethadione	DB00347	Absence Epilepsy	C0014553		Approved			CHEBI_9727	"10827"		"10034759"	"79631006"
imiglucerase	DB00053	Gaucher Disease	C0017205		Approved				"84959"	MONDO_0018150	"10018048"	"180485001"
voglibose	DB04878	Gaucher Disease	C0017205		Approved			CHEBI_32300		MONDO_0018150	"10018048"	"180485001"
eliglustat	DB09039	Gaucher Disease	C0017205		Approved			CHEBI_82752	"1547220"	MONDO_0018150	"10018048"	"180485001"
miglustat	DB00419	Gaucher Disease	C0017205		Approved			CHEBI_50381	"402316"	MONDO_0018150	"10018048"	"180485001"
	DB00264	Heart failure	C0018801	NCT00589303	Terminated	Phase 3	Lack of funding	CHEBI_6904	"6918"	MONDO_0005252	"10007554"	"84114007"
tadalafil	DB00820	Heart failure	C0018801	NCT01910389	Terminated	Phase 3	terminated by funding agency	CHEBI_71940	"358263"	MONDO_0005252	"10007554"	"84114007"
melatonin	DB01065	Heart failure	C0018801	NCT00869869	Withdrawn	Phase 2	No subjects were enrolled in this study. Funding ran out.	CHEBI_16796	"6711"	MONDO_0005252	"10007554"	"84114007"
ibopamine	DB13316	Heart failure	C0018801		Approved			CHEBI_135306		MONDO_0005252	"10007554"	"84114007"
darbepoetin alfa	DB00012	Heart failure	C0018801	NCT00534456	Terminated	Phase 3	Study terminated		"283838"	MONDO_0005252	"10007554"	"84114007"
ranolazine	DB00243	Heart failure	C0018801	NCT01887353	Terminated	Phase 2	Difficultly in enrolling	CHEBI_87690	"35829"	MONDO_0005252	"10007554"	"84114007"
vericiguat	DB15456	Heart failure	C0018801		Approved			CHEBI_142432	"2475830"	MONDO_0005252	"10007554"	"84114007"
testosterone	DB00624	Heart failure	C0018801	NCT01469988	Terminated	Phase 2	Feasibility	CHEBI_17347	"10379"	MONDO_0005252	"10007554"	"84114007"
clenbuterol	DB01407	Heart failure	C0018801	NCT00585546	Terminated	Phase 1	No longer could obtain clenbuterol	CHEBI_174690	"2580"	MONDO_0005252	"10007554"	"84114007"
ibopamine	DB13917	Heart failure	C0018801		Approved			CHEBI_10554		MONDO_0005252	"10007554"	"84114007"
valsartan	DB00177	Heart failure	C0018801	NCT03415906	Withdrawn	Phase 2	Difficulties in recruiting patients	CHEBI_9927	"69749"	MONDO_0005252	"10007554"	"84114007"
spironolactone	DB00421	Heart failure	C0018801	NCT03682497	Terminated	Phase 1	Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study site visits has unacceptable study related patient safety risk.	CHEBI_9241	"9997"	MONDO_0005252	"10007554"	"84114007"
	DB00887	Heart failure	C0018801	NCT00372762	Withdrawn	Phase 3	Due to changes within the research program this study is not feasible at this time	CHEBI_3213	"1808"	MONDO_0005252	"10007554"	"84114007"
furosemide	DB00695	Heart failure	C0018801	NCT00372762	Withdrawn	Phase 3	Due to changes within the research program this study is not feasible at this time	CHEBI_47426	"4603"	MONDO_0005252	"10007554"	"84114007"
bisoprolol	DB00612	Heart failure	C0018801	NCT00702156	Terminated	Phase 2	Inadequate patient recruitment	CHEBI_3127	"19484"	MONDO_0005252	"10007554"	"84114007"
insulin glargine	DB00030	Heart failure	C0018801	NCT03665350	Terminated	Phase 2	Insulin-HF study was prematurely ended due principally to low recruitment rate.	CHEBI_5931	"253182|631657"	MONDO_0005252	"10007554"	"84114007"
adenosine	DB00640	Heart failure	C0018801	NCT00745316	Terminated	Phase 2	Company Decision	CHEBI_16335	"296"	MONDO_0005252	"10007554"	"84114007"
tadalafil	DB00820	Heart failure	C0018801	NCT01960153	Withdrawn	Phase 3	Award was ended by NIH for parent study	CHEBI_71940	"358263"	MONDO_0005252	"10007554"	"84114007"
	DB00214	Heart failure	C0018801	NCT01558674	Terminated	Phase 1	Lack of efficacy	CHEBI_9637	"38413"	MONDO_0005252	"10007554"	"84114007"
amiodarone	DB01118	Heart failure	C0018801	NCT00589303	Terminated	Phase 3	Lack of funding	CHEBI_2663	"703"	MONDO_0005252	"10007554"	"84114007"
furosemide	DB00695	Heart failure	C0018801	NCT01558674	Terminated	Phase 1	Lack of efficacy	CHEBI_47426	"4603"	MONDO_0005252	"10007554"	"84114007"
testosterone	DB00624	Heart failure	C0018801	NCT00957034	Terminated	Phase 2	Due to difficult patient enrollment.	CHEBI_17347	"10379"	MONDO_0005252	"10007554"	"84114007"
colchicine	DB01394	Heart failure	C0018801	NCT04857931	Terminated	Phase 2	Lack of funds to support opening of new sites to help patient recruitment, which was found to be more challenging than initially expected.	CHEBI_27882	"2683"	MONDO_0005252	"10007554"	"84114007"
	DB00819	Heart failure	C0018801	NCT00746954	Terminated	Phase 3	Patient recruitment and Funding inadequate to finish trial	CHEBI_27690	"167"	MONDO_0005252	"10007554"	"84114007"
buspirone	DB00490	Heart failure	C0018801	NCT00746954	Terminated	Phase 3	Patient recruitment and Funding inadequate to finish trial	CHEBI_3223	"1827"	MONDO_0005252	"10007554"	"84114007"
	DB00661	Heart failure	C0018801	NCT00589303	Terminated	Phase 3	Lack of funding	CHEBI_77733	"11170"	MONDO_0005252	"10007554"	"84114007"
	DB00635	Hemangioma	C0018916	NCT00555464	Terminated	Phase 2	The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas	CHEBI_8382	"8640"	MONDO_0006500	"10018814"	"400210000"
propranolol	DB00571	Hemangioma	C0018916		Approved			CHEBI_8499	"8787"	MONDO_0006500	"10018814"	"400210000"
timolol	DB00373	Hemangioma	C0018916	NCT01147601	Terminated	Early Phase 1		CHEBI_9599	"1546004|10600"	MONDO_0006500	"10018814"	"400210000"
	DB00571	Hemangioma	C0018916	NCT01074437	Terminated	Phase 2	Insufficient enrollment	CHEBI_8499	"8787"	MONDO_0006500	"10018814"	"400210000"
	DB00541	Hemangioma	C0018916	NCT00555464	Terminated	Phase 2	The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas	CHEBI_28445	"11202"	MONDO_0006500	"10018814"	"400210000"
methylprednisolone	DB00959	Hemangioma	C0018916	NCT00555464	Terminated	Phase 2	The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas	CHEBI_6888	"6902"	MONDO_0006500	"10018814"	"400210000"
	DB01193	Hemangioma	C0018916	NCT01743885	Terminated	Phase 3		CHEBI_2379	"149"	MONDO_0006500	"10018814"	"400210000"
	DB14644	Hemangioma	C0018916	NCT00555464	Terminated	Phase 2	The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas	CHEBI_135765		MONDO_0006500	"10018814"	"400210000"
prednicarbate	DB00860	Hemangioma	C0018916	NCT01074437	Terminated	Phase 2	Insufficient enrollment	CHEBI_8378	"8638"	MONDO_0006500	"10018814"	"400210000"
propranolol	DB00571	Hemangioma	C0018916	NCT01743885	Terminated	Phase 3		CHEBI_8499	"8787"	MONDO_0006500	"10018814"	"400210000"
	DB00860	Hemangioma	C0018916	NCT00555464	Terminated	Phase 2	The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas	CHEBI_8378	"8638"	MONDO_0006500	"10018814"	"400210000"
azithromycin	DB00207	Hordeolum	C0019917		Approved			CHEBI_2955	"18631"	MONDO_0005800	"10020377"	"397513003"
cinacalcet	DB01012	Hyperparathyroidism, Secondary	C0020503	NCT00415584	Terminated	Phase 1/Phase 2	low enrollment	CHEBI_48390	"407990"	MONDO_0006964	"10020708"	"91478007"
bacampicillin	DB01602	Pharyngitis	C0031350		Approved			CHEBI_2968	"18687"	MONDO_0002258	"10034835"	"405737000"
cinacalcet	DB01012	Hyperparathyroidism, Secondary	C0020503	NCT01277510	Terminated	Phase 3	Study was put on clinical hold on 30 Jan 2013 following a subject fatality. Study was never restarted and was closed.	CHEBI_48390	"407990"	MONDO_0006964	"10020708"	"91478007"
evocalcet	DB12388	Hyperparathyroidism, Secondary	C0020503		Approved					MONDO_0006964	"10020708"	"91478007"
etelcalcetide	DB12865	Hyperparathyroidism, Secondary	C0020503		Approved			CHEBI_134700	"1876119"	MONDO_0006964	"10020708"	"91478007"
glucagon	DB00040	Hypoglycemia	C0020615		Approved			CHEBI_5391	"4832|261716"	MONDO_0004946	"10020993"	"271327008"
conivaptan	DB00872	Hyponatremia	C0020625		Approved			CHEBI_681850	"302285"	HP:0002902	"10021036"	"89627008"
tolvaptan	DB06212	Hyponatremia	C0020625	NCT02012959	Terminated	Phase 3	Issues with participant recruitment & enrollment which made the trial impossible or highly impracticable. Trial termination was not due to safety reasons.	CHEBI_32246	"358257"	HP:0002902	"10021036"	"89627008"
tolvaptan	DB06212	Hyponatremia	C0020625	NCT02020278	Terminated	Phase 3	Issues with recruitment and enrollment made the trial impossible or highly impracticable. Termination of this trial was not due to safety reasons.	CHEBI_32246	"358257"	HP:0002902	"10021036"	"89627008"
tolvaptan	DB06212	Hyponatremia	C0020625	NCT01386372	Terminated	Phase 2	futility	CHEBI_32246	"358257"	HP:0002902	"10021036"	"89627008"
tolvaptan	DB06212	Hyponatremia	C0020625	NCT02442674	Withdrawn	Phase 3	Trial withdrawn due to inability to meet the trial objectives (Pilot).	CHEBI_32246	"358257"	HP:0002902	"10021036"	"89627008"
tolvaptan	DB06212	Hyponatremia	C0020625		Approved			CHEBI_32246	"358257"	HP:0002902	"10021036"	"89627008"
tolvaptan	DB06212	Hyponatremia	C0020625	NCT01227512	Terminated	Phase 3	Recruitment challenges and results of interim futility analysis, which showed less than likely to achieve primary endpoint goal-length of hospital stay.	CHEBI_32246	"358257"	HP:0002902	"10021036"	"89627008"
Polymyxin B	DB00781	Keratitis	C0022568		Approved				"8536"	MONDO_0003085	"10023332"	"5888003"
hydrocortisone acetate	DB14539	Keratitis	C0022568		Approved			CHEBI_17609	"27197"	MONDO_0003085	"10023332"	"5888003"
cortisone acetate	DB01380	Keratitis	C0022568		Approved			CHEBI_3897	"21655"	MONDO_0003085	"10023332"	"5888003"
hydrocortisone acetate	DB00741	Keratitis	C0022568		Approved			CHEBI_17650	"5492"	MONDO_0003085	"10023332"	"5888003"
neomycin	DB00994	Keratitis	C0022568		Approved			CHEBI_7507	"7299"	MONDO_0003085	"10023332"	"5888003"
dexamethasone	DB01234	Keratitis	C0022568		Approved			CHEBI_41879	"3264"	MONDO_0003085	"10023332"	"5888003"
loteprednol etabonate	DB14596	Keratitis	C0022568	NCT01721694	Withdrawn	Phase 3	withdrawn by industry	CHEBI_31784	"52177"	MONDO_0003085	"10023332"	"5888003"
	DB00873	Keratitis	C0022568	NCT01721694	Withdrawn	Phase 3	withdrawn by industry	CHEBI_50848	"237027"	MONDO_0003085	"10023332"	"5888003"
	DB00207	Keratitis	C0022568	NCT01721694	Withdrawn	Phase 3	withdrawn by industry	CHEBI_2955	"18631"	MONDO_0003085	"10023332"	"5888003"
prednisolone	DB00860	Keratitis	C0022568		Approved			CHEBI_8378	"8638"	MONDO_0003085	"10023332"	"5888003"
bacitracin	DB00626	Keratitis	C0022568		Approved			CHEBI_184381	"1291|1986366"	MONDO_0003085	"10023332"	"5888003"
hydrocortisone	DB00741	Keratitis	C0022568		Approved			CHEBI_17650	"5492"	MONDO_0003085	"10023332"	"5888003"
benzylpenicillin	DB01053	Lung Abscess	C0024110		Approved			CHEBI_18208	"7980"	MONDO_0000744	"10025028"	"73452002"
cefoxitin	DB01331	Lung Abscess	C0024110		Approved			CHEBI_209807	"2189"	MONDO_0000744	"10025028"	"73452002"
ticarcillin	DB01607	Lung Abscess	C0024110		Approved			CHEBI_9587	"10591"	MONDO_0000744	"10025028"	"73452002"
kanamycin	DB01172	Meningitis	C0025289		Approved			CHEBI_17630	"6099|1727573"	HP:0001287	"10027199"	"7180009"
ceftizoxime	DB01332	Meningitis	C0025289		Approved			CHEBI_553473	"2192"	HP:0001287	"10027199"	"7180009"
daptomycin	DB00080	Meningitis	C0025289	NCT01522105	Terminated	Phase 1	Insufficient patient recruitment	CHEBI_600103	"22299"	HP:0001287	"10027199"	"7180009"
erythromycin ethyl succinate	DB00199	Meningitis	C0025289		Approved			CHEBI_42355	"4053"	HP:0001287	"10027199"	"7180009"
doripenem	DB06211	Meningitis	C0025289	NCT01366651	Terminated	Phase 1	Trial terminated early per business decision.	CHEBI_135928	"119771"	HP:0001287	"10027199"	"7180009"
amphotericin B	DB00681	Mucormycosis	C0026718		Approved			CHEBI_2682	"236594|732"		"10028098"	"76627001"
posaconazole	DB01263	Mucormycosis	C0026718		Approved			CHEBI_64355	"282446"		"10028098"	"76627001"
isavuconazonium	DB06636	Mucormycosis	C0026718		Approved			CHEBI_85978	"1608322"		"10028098"	"76627001"
isavuconazonium	DB11633	Mucormycosis	C0026718		Approved			CHEBI_85979	"1720882"		"10028098"	"76627001"
fluoxymesterone	DB01185	Noonan Syndrome	C0028326		Approved			CHEBI_5120	"4494"	MONDO_0018997	"10029748"	"205824006"
diethylcarbamazine	DB00711	Onchocerciasis	C0029001		Approved			CHEBI_4527	"3384"	MONDO_0017137	"10030314"	"38539003"
moxidectin	DB11431	Onchocerciasis	C0029001		Approved			CHEBI_183811	"1047072"	MONDO_0017137	"10030314"	"38539003"
ivermectin	DB00602	Onchocerciasis	C0029001		Approved			CHEBI_6078	"6069"	MONDO_0017137	"10030314"	"38539003"
fluoxetine	DB00472	Panic Disorder	C0030319		Approved			CHEBI_86990	"4493"	MONDO_0005383	"10033666"	"371631005"
sertraline	DB01104	Panic Disorder	C0030319		Approved			CHEBI_9123	"36437"	MONDO_0005383	"10033666"	"371631005"
paroxetine	DB00715	Panic Disorder	C0030319		Approved			CHEBI_7936	"32937"	MONDO_0005383	"10033666"	"371631005"
paroxetine	DB00715	Panic Disorder	C0030319	NCT00206765	Terminated	Phase 2		CHEBI_7936	"32937"	MONDO_0005383	"10033666"	"371631005"
clonazepam	DB01068	Panic Disorder	C0030319		Approved			CHEBI_3756	"2598"	MONDO_0005383	"10033666"	"371631005"
lorazepam	DB00186	Panic Disorder	C0030319		Approved			CHEBI_6539	"6470"	MONDO_0005383	"10033666"	"371631005"
alprazolam	DB00404	Panic Disorder	C0030319		Approved			CHEBI_2611	"596"	MONDO_0005383	"10033666"	"371631005"
cycloserine	DB00260	Panic Disorder	C0030319	NCT01680107	Terminated	Phase 3		CHEBI_40009	"3007"	MONDO_0005383	"10033666"	"371631005"
venlafaxine	DB00285	Panic Disorder	C0030319		Approved			CHEBI_9943	"39786"	MONDO_0005383	"10033666"	"371631005"
	DB00734	Panic Disorder	C0030319	NCT00206765	Terminated	Phase 2		CHEBI_8871	"35636"	MONDO_0005383	"10033666"	"371631005"
oxacillin	DB00713	Pharyngitis	C0031350		Approved			CHEBI_7809	"7773"	MONDO_0002258	"10034835"	"405737000"
oxytetracycline	DB00595	Pharyngitis	C0031350		Approved			CHEBI_133011	"7821|1545999"	MONDO_0002258	"10034835"	"405737000"
cloxacillin	DB01147	Pharyngitis	C0031350		Approved			CHEBI_49566	"2625"	MONDO_0002258	"10034835"	"405737000"
benzylpenicillin	DB01053	Pharyngitis	C0031350		Approved			CHEBI_18208	"7980"	MONDO_0002258	"10034835"	"405737000"
phenoxymethylpenicillin	DB00417	Pharyngitis	C0031350		Approved			CHEBI_27446	"7984"	MONDO_0002258	"10034835"	"405737000"
azithromycin	DB00207	Pharyngitis	C0031350	NCT01919996	Terminated	Phase 2	See Termination Statement in the Detailed Description below	CHEBI_2955	"18631"	MONDO_0002258	"10034835"	"405737000"
cyclacillin	DB01000	Pharyngitis	C0031350		Approved			CHEBI_31444	"2968"	MONDO_0002258	"10034835"	"405737000"
doxycycline	DB00254	Pharyngitis	C0031350		Approved			CHEBI_50845	"1545992|3640"	MONDO_0002258	"10034835"	"405737000"
minocycline	DB01017	Pharyngitis	C0031350		Approved			CHEBI_50694	"6980"	MONDO_0002258	"10034835"	"405737000"
amoxicillin	DB01060	Pharyngitis	C0031350		Approved			CHEBI_2676	"1297882|723"	MONDO_0002258	"10034835"	"405737000"
cefradine	DB01333	Pharyngitis	C0031350		Approved			CHEBI_3547	"2239"	MONDO_0002258	"10034835"	"405737000"
fusidic acid	DB02703	Pharyngitis	C0031350		Approved			CHEBI_29013	"4608|113608"	MONDO_0002258	"10034835"	"405737000"
dirithromycin	DB00954	Pharyngitis	C0031350		Approved			CHEBI_474014		MONDO_0002258	"10034835"	"405737000"
meclocycline	DB13092	Pharyngitis	C0031350		Approved			CHEBI_135772	"29418"	MONDO_0002258	"10034835"	"405737000"
tetracycline	DB00759	Pharyngitis	C0031350		Approved			CHEBI_27902	"10395"	MONDO_0002258	"10034835"	"405737000"
demeclocycline	DB00618	Pharyngitis	C0031350		Approved			CHEBI_4392	"3154"	MONDO_0002258	"10034835"	"405737000"
tetracycline	DB09550	Pharyngitis	C0031350		Approved			CHEBI_27902	"2105975"	MONDO_0002258	"10034835"	"405737000"
amphotericin B	DB00681	Pharyngitis	C0031350		Approved			CHEBI_2682	"236594|732"	MONDO_0002258	"10034835"	"405737000"
ampicillin	DB00415	Pharyngitis	C0031350		Approved			CHEBI_28971	"733|221058"	MONDO_0002258	"10034835"	"405737000"
procaine benzylpenicillin	DB01053	Pharyngitis	C0031350		Approved			CHEBI_18208	"7980"	MONDO_0002258	"10034835"	"405737000"
cefpodoxime proxetil	DB01416	Pharyngitis	C0031350		Approved			CHEBI_3504	"20489"	MONDO_0002258	"10034835"	"405737000"
cefaclor	DB00833	Pharyngitis	C0031350		Approved			CHEBI_3478	"1450910|2176"	MONDO_0002258	"10034835"	"405737000"
cefixime	DB00671	Pharyngitis	C0031350		Approved			CHEBI_472657	"25033|1546021"	MONDO_0002258	"10034835"	"405737000"
procaine benzylpenicillin	DB09320	Pharyngitis	C0031350		Approved			CHEBI_52154	"7983"	MONDO_0002258	"10034835"	"405737000"
prednisone	DB00635	Polymyalgia Rheumatica	C0032533	NCT02702778	Terminated	Phase 2	lack of study recruitment	CHEBI_8382	"8640"	MONDO_0019735	"10036099"	"65323003"
prednisone	DB00635	Polymyalgia Rheumatica	C0032533	NCT02899026	Withdrawn	Phase 3	GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in polymyalgia rheumatica.	CHEBI_8382	"8640"	MONDO_0019735	"10036099"	"65323003"
prednisone	DB00635	Polymyalgia Rheumatica	C0032533	NCT01364389	Terminated	Phase 2	Data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period.	CHEBI_8382	"8640"	MONDO_0019735	"10036099"	"65323003"
prednisone	DB00635	Polymyalgia Rheumatica	C0032533	NCT03600818	Terminated	Phase 3	Protracted recruitment timeline exacerbated by COVID-19 pandemic	CHEBI_8382	"8640"	MONDO_0019735	"10036099"	"65323003"
prednisone	DB00635	Polymyalgia Rheumatica	C0032533	NCT01821040	Terminated	Phase 3		CHEBI_8382	"8640"	MONDO_0019735	"10036099"	"65323003"
prednisolone	DB00860	Polymyalgia Rheumatica	C0032533		Approved			CHEBI_8378	"8638"	MONDO_0019735	"10036099"	"65323003"
nivolumab	DB09035	Polymyalgia Rheumatica	C0032533	NCT03656627	Terminated	Phase 1	low accrual		"1597876"	MONDO_0019735	"10036099"	"65323003"
lonafarnib	DB06448	Progeria	C0033300		Approved			CHEBI_47097	"2467553"	MONDO_0008310	"10036794"	"238870004"
amphotericin B	DB00681	Rickettsialpox	C0035597		Approved			CHEBI_2682	"236594|732"	MONDO_0019360	"10039137"	"75096007"
minocycline	DB01017	Rickettsialpox	C0035597		Approved			CHEBI_50694	"6980"	MONDO_0019360	"10039137"	"75096007"
fusidic acid	DB02703	Rickettsialpox	C0035597		Approved			CHEBI_29013	"4608|113608"	MONDO_0019360	"10039137"	"75096007"
tetracycline	DB09550	Rickettsialpox	C0035597		Approved			CHEBI_27902	"2105975"	MONDO_0019360	"10039137"	"75096007"
demeclocycline	DB00618	Rickettsialpox	C0035597		Approved			CHEBI_4392	"3154"	MONDO_0019360	"10039137"	"75096007"
tetracycline	DB00759	Rickettsialpox	C0035597		Approved			CHEBI_27902	"10395"	MONDO_0019360	"10039137"	"75096007"
oxytetracycline	DB00595	Rickettsialpox	C0035597		Approved			CHEBI_133011	"7821|1545999"	MONDO_0019360	"10039137"	"75096007"
meclocycline	DB13092	Rickettsialpox	C0035597		Approved			CHEBI_135772	"29418"	MONDO_0019360	"10039137"	"75096007"
doxycycline	DB00254	Rickettsialpox	C0035597		Approved			CHEBI_50845	"1545992|3640"	MONDO_0019360	"10039137"	"75096007"
iloprost	DB01088	Systemic Scleroderma	C0036421	NCT00622687	Terminated	Phase 2	sufficient number to reach the primary endpoint and as planned	CHEBI_63916	"40138"	MONDO_0005100	"10078638"	"89155008"
	DB00073	Systemic Scleroderma	C0036421	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical		"2273510|2472325|121191|2105824"	MONDO_0005100	"10078638"	"89155008"
bosentan	DB00559	Systemic Scleroderma	C0036421		Approved			CHEBI_51450	"75207|1468845"	MONDO_0005100	"10078638"	"89155008"
	DB14644	Systemic Scleroderma	C0036421	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_135765		MONDO_0005100	"10078638"	"89155008"
	DB00531	Systemic Scleroderma	C0036421	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_4027	"1545988|3002"	MONDO_0005100	"10078638"	"89155008"
methylprednisolone	DB00959	Systemic Scleroderma	C0036421	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_6888	"6902"	MONDO_0005100	"10078638"	"89155008"
cyclophosphamide	DB00531	Systemic Scleroderma	C0036421	NCT00040651	Terminated	Phase 1		CHEBI_4027	"1545988|3002"	MONDO_0005100	"10078638"	"89155008"
busulfan	DB01008	Systemic Scleroderma	C0036421	NCT00684255	Terminated	Phase 1	inactive	CHEBI_28901	"1828"	MONDO_0005100	"10078638"	"89155008"
rituximab	DB00073	Systemic Scleroderma	C0036421		Approved				"2273510|2472325|121191|2105824"	MONDO_0005100	"10078638"	"89155008"
dimethyl fumarate	DB08908	Systemic Scleroderma	C0036421	NCT02981082	Terminated	Phase 1	Low recruitment	CHEBI_76004	"1373478"	MONDO_0005100	"10078638"	"89155008"
pseudoephedrine	DB00852	Sinus headache	C0037195		Approved			CHEBI_51209	"8896"		"10040744"	"4969004"
valproic acid	DB00313	Systemic Scleroderma	C0036421	NCT02166229	Withdrawn	Phase 1/Phase 2	No subjects were enrolled.	CHEBI_39867	"11118|40254"	MONDO_0005100	"10078638"	"89155008"
	DB00860	Systemic Scleroderma	C0036421	NCT03593902	Terminated	Phase 2/Phase 3	PI Sabbatical	CHEBI_8378	"8638"	MONDO_0005100	"10078638"	"89155008"
	DB00087	Systemic Scleroderma	C0036421	NCT00684255	Terminated	Phase 1	inactive		"117055"	MONDO_0005100	"10078638"	"89155008"
aminobenzoic acid	DB02362	Systemic Scleroderma	C0036421		Approved			CHEBI_30753	"74"	MONDO_0005100	"10078638"	"89155008"
benzoic acid	DB03793	Systemic Scleroderma	C0036421		Approved			CHEBI_30746	"18989"	MONDO_0005100	"10078638"	"89155008"
benzathine benzylpenicillin	DB01053	Streptococcal Infections	C0038395		Approved			CHEBI_18208	"7980"	MONDO_0021680	"10061372"	"85769006"
procaine benzylpenicillin	DB01053	Streptococcal Infections	C0038395		Approved			CHEBI_18208	"7980"	MONDO_0021680	"10061372"	"85769006"
benzylpenicillin	DB01053	Streptococcal Infections	C0038395		Approved			CHEBI_18208	"7980"	MONDO_0021680	"10061372"	"85769006"
lincomycin	DB01627	Streptococcal Infections	C0038395		Approved			CHEBI_6472	"6398"	MONDO_0021680	"10061372"	"85769006"
procaine benzylpenicillin	DB09320	Streptococcal Infections	C0038395		Approved			CHEBI_52154	"7983"	MONDO_0021680	"10061372"	"85769006"
fusidic acid	DB02703	Streptococcal Infections	C0038395		Approved			CHEBI_29013	"4608|113608"	MONDO_0021680	"10061372"	"85769006"
galantamine	DB00674	Post-Traumatic Stress Disorder	C0038436	NCT01416948	Terminated	Phase 2	The funding agency, DoD, determined that the study could not meet its enrollment numbers by the end of the grant.	CHEBI_42944	"4637"	HP:0033676	"10036316"	"47505003"
propranolol	DB00571	Post-Traumatic Stress Disorder	C0038436	NCT01239173	Terminated	Phase 3	Study stopped by promoter for lack of inclusion	CHEBI_8499	"8787"	HP:0033676	"10036316"	"47505003"
paroxetine	DB00715	Post-Traumatic Stress Disorder	C0038436		Approved			CHEBI_7936	"32937"	HP:0033676	"10036316"	"47505003"
ketamine	DB01221	Post-Traumatic Stress Disorder	C0038436	NCT02727998	Terminated	Phase 2	Study ran out of funding	CHEBI_6121	"6130"	HP:0033676	"10036316"	"47505003"
	DB00683	Post-Traumatic Stress Disorder	C0038436	NCT02727998	Terminated	Phase 2	Study ran out of funding	CHEBI_6931	"6960"	HP:0033676	"10036316"	"47505003"
sertraline	DB01104	Post-Traumatic Stress Disorder	C0038436		Approved			CHEBI_9123	"36437"	HP:0033676	"10036316"	"47505003"
acetylcysteine	DB06151	Post-Traumatic Stress Disorder	C0038436	NCT01664260	Withdrawn	Phase 2	The research project has been cancelled before any participants were enrolled.	CHEBI_28939	"197"	HP:0033676	"10036316"	"47505003"
	DB00422	Post-Traumatic Stress Disorder	C0038436	NCT01416948	Terminated	Phase 2	The funding agency, DoD, determined that the study could not meet its enrollment numbers by the end of the grant.	CHEBI_84276	"6901"	HP:0033676	"10036316"	"47505003"
esmolol	DB00187	Supraventricular tachycardia	C0039240		Approved			CHEBI_88206	"49737"	HP:0004755	"10042604"	"6456007"
landiolol	DB12212	Supraventricular tachycardia	C0039240		Approved			CHEBI_135809		HP:0004755	"10042604"	"6456007"
propranolol	DB00571	Supraventricular tachycardia	C0039240		Approved			CHEBI_8499	"8787"	HP:0004755	"10042604"	"6456007"
avatrombopag	DB11995	Thrombocytopenia	C0040034		Approved				"2045726"	MONDO_0002049	"10043554"	"302215000"
oprelvekin	DB00038	Thrombocytopenia	C0040034		Approved				"1311380|139994"	MONDO_0002049	"10043554"	"302215000"
lusutrombopag	DB13125	Thrombocytopenia	C0040034		Approved			CHEBI_136051	"2054984"	MONDO_0002049	"10043554"	"302215000"
methanthelinium	DB00940	Urinary Incontinence	C0042024		Approved			CHEBI_6817	"6821"	HP:0000020	"10046543"	"165232002"
estradiol	DB00783	Urinary Incontinence	C0042024	NCT05458375	Terminated	Early Phase 1	There is a lack of potential study participants at our study site that would meet inclusion criteria, therefore, the study is not feasible and is being terminated.	CHEBI_16469	"4083"	HP:0000020	"10046543"	"165232002"
testosterone	DB00624	Urinary Incontinence	C0042024	NCT04026880	Withdrawn	Phase 3	Lack of funds	CHEBI_17347	"10379"	HP:0000020	"10046543"	"165232002"
terodiline	DB13725	Urinary Incontinence	C0042024		Approved			CHEBI_135168		HP:0000020	"10046543"	"165232002"
dimethyl sulfoxide	DB01093	Urinary Incontinence	C0042024	NCT00667095	Terminated	Phase 3	Study terminated early due to PI's extended medical leave.	CHEBI_28262	"3455"	HP:0000020	"10046543"	"165232002"
	DB06710	Urinary Incontinence	C0042024	NCT04026880	Withdrawn	Phase 3	Lack of funds	CHEBI_27436	"6904"	HP:0000020	"10046543"	"165232002"
tolterodine	DB01036	Urinary Incontinence	C0042024	NCT00439192	Terminated	Phase 2	side effect profile did not match expectations	CHEBI_9622	"119565"	HP:0000020	"10046543"	"165232002"
flavoxate	DB01148	Urinary Incontinence	C0042024		Approved			CHEBI_5088	"4440"	HP:0000020	"10046543"	"165232002"
triamcinolone	DB00620	Vitiligo	C0042900	NCT02191748	Terminated	Phase 2/Phase 3	Principal investigator made the decision to close study and not submit a renewal. Lack of fixed research personnel to carry out the study effectively.	CHEBI_9667	"10759"	MONDO_0008661	"10047642"	"56727007"
tacrolimus	DB00864	Vitiligo	C0042900	NCT01841008	Terminated	Phase 2/Phase 3		CHEBI_61049	"42316|235991"	MONDO_0008661	"10047642"	"56727007"
trioxsalen	DB04571	Vitiligo	C0042900		Approved			CHEBI_28329	"10844"	MONDO_0008661	"10047642"	"56727007"
methoxsalen	DB00553	Vitiligo	C0042900		Approved			CHEBI_18358	"6854"	MONDO_0008661	"10047642"	"56727007"
loncastuximab tesirine	DB16222	B-Cell Lymphomas	C0079731		Approved				"2540965|2540964"	HP:0012191	"10003899"	"413616009"
flavoxate	DB01148	Urgency of micturition	C0085606		Approved			CHEBI_5088	"4440"	HP:0000012	"10027566"	"75088002"
fesoterodine	DB06702	Urgency of micturition	C0085606		Approved			CHEBI_135920	"797195"	HP:0000012	"10027566"	"75088002"
tolterodine	DB01036	Urgency of micturition	C0085606		Approved			CHEBI_9622	"119565"	HP:0000012	"10027566"	"75088002"
darifenacin	DB00496	Urgency of micturition	C0085606		Approved			CHEBI_391960	"136198"	HP:0000012	"10027566"	"75088002"
fesoterodine	DB15578	Urgency of micturition	C0085606		Approved			CHEBI_135920		HP:0000012	"10027566"	"75088002"
trospium	DB00209	Urgency of micturition	C0085606		Approved			CHEBI_145791	"236778"	HP:0000012	"10027566"	"75088002"
solifenacin	DB01591	Urgency of micturition	C0085606		Approved			CHEBI_135530	"322167"	HP:0000012	"10027566"	"75088002"
oxybutynin	DB01062	Urgency of micturition	C0085606		Approved			CHEBI_7856	"32675"	HP:0000012	"10027566"	"75088002"
butacaine	DB11502	Urgency of micturition	C0085606		Approved			CHEBI_94820	"1829"	HP:0000012	"10027566"	"75088002"
phenylbutanoic acid	DB06819	Urea Cycle Disorders, Inborn	C0154246		Approved			CHEBI_41500	"1546447|81647"	MONDO_0004739	"10080020"	"36444000"
glycerol phenylbutyrate	DB08909	Urea Cycle Disorders, Inborn	C0154246		Approved			CHEBI_134745	"1368451"	MONDO_0004739	"10080020"	"36444000"
oxymetholone	DB06412	Hypoplastic anemia	C0178416		Approved			CHEBI_7864	"7813"	HP:0012133	"10021074"	"167923006"
doxapram	DB00561	Respiratory Depression	C0235063		Approved			CHEBI_681848	"3637"	HP:0002791	"10038678"	"80954004"
cannabidiol	DB09061	Lennox-Gastaut syndrome	C0238111	NCT02815540	Terminated	Phase 1/Phase 2	Investigator no longer at institution, and difficult recruitment; study will not resume	CHEBI_69478	"2045371"	MONDO_0016532	"10048816"	"230418006"
clonazepam	DB01068	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_3756	"2598"	MONDO_0016532	"10048816"	"230418006"
felbamate	DB00949	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_4995	"24812"	MONDO_0016532	"10048816"	"230418006"
carbamazepine	DB00564	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_3387	"2002"	MONDO_0016532	"10048816"	"230418006"
lorazepam	DB00186	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_6539	"6470"	MONDO_0016532	"10048816"	"230418006"
topiramate	DB00273	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_63631	"38404"	MONDO_0016532	"10048816"	"230418006"
primidone	DB00794	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_8412	"8691"	MONDO_0016532	"10048816"	"230418006"
lamotrigine	DB00555	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_6367	"28439"	MONDO_0016532	"10048816"	"230418006"
phenytoin	DB00252	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_8107	"8183"	MONDO_0016532	"10048816"	"230418006"
clobazam	DB00349	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_31413	"21241"	MONDO_0016532	"10048816"	"230418006"
cannabidiol	DB09061	Lennox-Gastaut syndrome	C0238111	NCT02318537	Withdrawn	Phase 3	Sponsor elected not to continue with study.	CHEBI_69478	"2045371"	MONDO_0016532	"10048816"	"230418006"
phenobarbital	DB01174	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_8069	"8134"	MONDO_0016532	"10048816"	"230418006"
rufinamide	DB06201	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_134966	"69036"	MONDO_0016532	"10048816"	"230418006"
cannabidiol	DB09061	Lennox-Gastaut syndrome	C0238111		Approved			CHEBI_69478	"2045371"	MONDO_0016532	"10048816"	"230418006"
albendazole	DB00518	Neurocysticercosis	C0338437		Approved			CHEBI_16664	"430"		"10058443"	"230215006"
canakinumab	DB06168	Deficiency of mevalonate kinase	C0342731		Approved				"853491"		"10072221"	"124327008"
irinotecan	DB00762	Metastatic malignant neoplasm to pancreas	C0346976		Approved			CHEBI_80630	"51499"		"10049721"	"94459006"
paclitaxel	DB01229	Metastatic malignant neoplasm to pancreas	C0346976		Approved			CHEBI_45863	"56946"		"10049721"	"94459006"
adenosine phosphate	DB00640	Pulmonary Cystic Fibrosis	C0392164		Approved			CHEBI_16335	"296"		"10011763"	"86555001"
tezacaftor	DB11712	Pulmonary Cystic Fibrosis	C0392164		Approved				"1999382"		"10011763"	"86555001"
adenosine phosphate	DB00131	Pulmonary Cystic Fibrosis	C0392164		Approved			CHEBI_16027	"309"		"10011763"	"86555001"
acetylcysteine	DB06151	Pulmonary Cystic Fibrosis	C0392164		Approved			CHEBI_28939	"197"		"10011763"	"86555001"
ivacaftor	DB08820	Pulmonary Cystic Fibrosis	C0392164		Approved			CHEBI_66901	"1243041"		"10011763"	"86555001"
cysteine	DB00151	Pulmonary Cystic Fibrosis	C0392164		Approved			CHEBI_17561	"3024"		"10011763"	"86555001"
lumacaftor	DB09280	Pulmonary Cystic Fibrosis	C0392164		Approved			CHEBI_90951	"1655922"		"10011763"	"86555001"
methylprednisolone	DB00959	Labor Pain	C0474368	NCT02212210	Terminated	Early Phase 1	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed	CHEBI_6888	"6902"		"10059204"	"279055000"
	DB14644	Labor Pain	C0474368	NCT02212210	Terminated	Early Phase 1	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed	CHEBI_135765			"10059204"	"279055000"
butorphanol	DB00611	Labor Pain	C0474368		Approved			CHEBI_3242	"1841"		"10059204"	"279055000"
	DB00860	Labor Pain	C0474368	NCT02212210	Terminated	Early Phase 1	PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is closed	CHEBI_8378	"8638"		"10059204"	"279055000"
fentanyl	DB00813	Labor Pain	C0474368	NCT00871442	Withdrawn	Phase 3	would not substantially add to existing contributions in the literature	CHEBI_119915	"4337"		"10059204"	"279055000"
	DB00297	Labor Pain	C0474368	NCT00871442	Withdrawn	Phase 3	would not substantially add to existing contributions in the literature	CHEBI_77431	"1815"		"10059204"	"279055000"
pentazocine	DB00652	Labor Pain	C0474368		Approved			CHEBI_182080	"8001"		"10059204"	"279055000"
fentanyl	DB00813	Labor Pain	C0474368	NCT04011098	Terminated	Phase 1	Unable to meet recruitment numbers, lack of participation	CHEBI_119915	"4337"		"10059204"	"279055000"
remifentanil	DB00899	Labor Pain	C0474368	NCT04541719	Withdrawn	Phase 2	no participants enrolled	CHEBI_8802	"73032"		"10059204"	"279055000"
nalbuphine	DB00844	Labor Pain	C0474368		Approved			CHEBI_7454	"7238"		"10059204"	"279055000"
oxymorphone	DB01192	Labor Pain	C0474368		Approved			CHEBI_7865	"7814"		"10059204"	"279055000"
nitrous oxide	DB06690	Labor Pain	C0474368	NCT01738672	Terminated	Phase 2		CHEBI_17045	"7486"		"10059204"	"279055000"
pethidine	DB00454	Labor Pain	C0474368		Approved			CHEBI_6754	"6754"		"10059204"	"279055000"
stiripentol	DB09118	Infantile Severe Myoclonic Epilepsy	C0751122		Approved			CHEBI_228488	"2054968"	MONDO_0100135	"10073677"	"230437002"
cannabidiol	DB09061	Infantile Severe Myoclonic Epilepsy	C0751122		Approved			CHEBI_69478	"2045371"	MONDO_0100135	"10073677"	"230437002"
zinc acetate	DB14487	Itching of ear	C0849907		Approved			CHEBI_62984	"1299637|58295"		"10052138"	"699392007"
hydrocortisone	DB00741	Itching of ear	C0849907		Approved			CHEBI_17650	"5492"		"10052138"	"699392007"
benzalkonium	DB11105	Itching of ear	C0849907		Approved			CHEBI_188978	"1378"		"10052138"	"699392007"
benzalkonium	DB13282	Itching of ear	C0849907		Approved			CHEBI_188978			"10052138"	"699392007"
pramocaine	DB09345	Itching of ear	C0849907		Approved			CHEBI_8357	"34347"		"10052138"	"699392007"
cortisone acetate	DB01380	Itching of ear	C0849907		Approved			CHEBI_3897	"21655"		"10052138"	"699392007"
gramicidin	DB00027	Bacterial keratitis	C0854211		Approved			CHEBI_5530	"5011"		"10062028"	"314557000"
tetracycline	DB00759	Bacterial keratitis	C0854211		Approved			CHEBI_27902	"10395"		"10062028"	"314557000"
cortisone acetate	DB01380	Bacterial keratitis	C0854211		Approved			CHEBI_3897	"21655"		"10062028"	"314557000"
neomycin	DB00994	Bacterial keratitis	C0854211		Approved			CHEBI_7507	"7299"		"10062028"	"314557000"
hydrocortisone	DB00741	Bacterial keratitis	C0854211		Approved			CHEBI_17650	"5492"		"10062028"	"314557000"
gentamicin	DB00798	Bacterial keratitis	C0854211		Approved			CHEBI_17833	"1596450"		"10062028"	"314557000"
fusidic acid	DB02703	Bacterial keratitis	C0854211		Approved			CHEBI_29013	"4608|113608"		"10062028"	"314557000"
dexamethasone	DB01234	Bacterial keratitis	C0854211		Approved			CHEBI_41879	"3264"		"10062028"	"314557000"
bacitracin	DB00626	Bacterial keratitis	C0854211		Approved			CHEBI_184381	"1291|1986366"		"10062028"	"314557000"
oxytetracycline	DB00595	Bacterial keratitis	C0854211		Approved			CHEBI_133011	"7821|1545999"		"10062028"	"314557000"
prednisolone	DB00860	Bacterial keratitis	C0854211		Approved			CHEBI_8378	"8638"		"10062028"	"314557000"
hydrocortisone acetate	DB14539	Bacterial keratitis	C0854211		Approved			CHEBI_17609	"27197"		"10062028"	"314557000"
tetracycline	DB09550	Bacterial keratitis	C0854211		Approved			CHEBI_27902	"2105975"		"10062028"	"314557000"
hydrocortisone acetate	DB00741	Bacterial keratitis	C0854211		Approved			CHEBI_17650	"5492"		"10062028"	"314557000"
Polymyxin B	DB00781	Bacterial keratitis	C0854211		Approved				"8536"		"10062028"	"314557000"
tamoxifen	DB00675	Invasive Ductal Breast Carcinoma	C1134719		Approved			CHEBI_41774	"10324"		"10073095"	"408643008"
avacopan	DB15011	Granulomatosis with polyangiitis	C3495801		Approved				"2572100"	MONDO_0012105	"10072579"	"195353004"
rituximab	DB00073	Granulomatosis with polyangiitis	C3495801		Approved				"2273510|2472325|121191|2105824"	MONDO_0012105	"10072579"	"195353004"
baricitinib	DB11817	Pneumonia caused by SARS-CoV-2	C5244027		Approved			CHEBI_95341	"2047232"		"10084380"	"882784691000119100"
tocilizumab	DB06273	Pneumonia caused by SARS-CoV-2	C5244027		Approved				"612865"		"10084380"	"882784691000119100"
epinephrine	DB00668	Exacerbation of asthma	C0349790		Approved			CHEBI_28918	"3992"			"281239006"
ertapenem	DB00303	Acute bacterial peritonitis	C0275550		Approved			CHEBI_404903	"325642"			"31860008"
erythromycin	DB00199	Acute bacterial sinusitis	C0275556		Approved			CHEBI_42355	"4053"			"75498004"
mesalazine	DB00244	Chronic ulcerative proctitis	C2937222		Approved			CHEBI_6775	"52582"			"52231000"
amoxicillin	DB01060	Acute bacterial sinusitis	C0275556		Approved			CHEBI_2676	"1297882|723"			"75498004"
norfloxacin	DB01059	Acute bacterial peritonitis	C0275550		Approved			CHEBI_100246	"7517"			"31860008"
norfloxacin	DB01059	Acute bacterial sinusitis	C0275556		Approved			CHEBI_100246	"7517"			"75498004"
oxacillin	DB00713	Acute bacterial sinusitis	C0275556		Approved			CHEBI_7809	"7773"			"75498004"
aprobarbital	DB01352	Severe anxiety (panic)	C0231403		Approved			CHEBI_2791	"17381"			"80583007"
salicylic acid	DB00936	Scurfiness of scalp	C0423775		Approved			CHEBI_16914	"9525"			"200767005"
salicylic acid	DB14006	Scurfiness of scalp	C0423775		Approved			CHEBI_16914	"20974"			"200767005"
triamcinolone diacetate	DB00620	Autoimmune hemolytic anemia	C0002880		Approved			CHEBI_9667	"10759"	MONDO_0020108	"10073785"	"413603009"
azithromycin	DB00207	Acute bacterial sinusitis	C0275556		Approved			CHEBI_2955	"18631"			"75498004"
trovafloxacin	DB00685	Acute bacterial peritonitis	C0275550		Approved			CHEBI_9763	"115552"			"31860008"
trovafloxacin	DB00685	Acute bacterial sinusitis	C0275556		Approved			CHEBI_9763	"115552"			"75498004"
allantoin	DB11100	Scurfiness of scalp	C0423775		Approved			CHEBI_15676	"508"			"200767005"
selenium sulfide	DB00971	Scurfiness of scalp	C0423775		Approved			CHEBI_135934	"36345"			"200767005"
secbutabarbital	DB00237	Severe anxiety (panic)	C0231403		Approved			CHEBI_3228	"477631"			"80583007"
scopolamine butylbromide	DB09300	Gastric spasm (disorder)	C0581358		Approved			CHEBI_145701	"1085787"			"196754001"
ammonia	DB11118	Scurfiness of scalp	C0423775		Approved			CHEBI_16134	"1299884"			"200767005"
evolocumab	DB09303	Complex dyslipidemia	C3875286		Approved				"1665684"			"109041000119107"
relebactam	DB12377	Infection due to enterococcus	C1320183		Approved				"2184137|2268500"			"406574007"
pretomanid	DB05154	Extensively Drug-Resistant Tuberculosis	C1827301		Approved				"2198359"			"422481005"
trastuzumab deruxtecan	DB14962	Metastatic human epidermal growth factor 2 positive carcinoma of breast	C4721209		Approved				"2267582|2267574"			"459391000124109"
tucatinib	DB11652	Metastatic human epidermal growth factor 2 positive carcinoma of breast	C4721209		Approved				"2361285"			"459391000124109"
gefapixant	DB15097	Chronic refractory cough	C4552486		Approved							"2561000112106"
cefpodoxime proxetil	DB01416	Acute bacterial sinusitis	C0275556		Approved			CHEBI_3504	"20489"			"75498004"
cefprozil	DB01150	Acute bacterial sinusitis	C0275556		Approved			CHEBI_3506	"1546020|19552"			"75498004"
cefuroxime axetil	DB01112	Acute bacterial sinusitis	C0275556		Approved			CHEBI_3515	"2194"			"75498004"
chlordiazepoxide	DB00475	Severe anxiety (panic)	C0231403		Approved			CHEBI_3611	"2356"			"80583007"
chloroxine	DB01243	Scurfiness of scalp	C0423775		Approved			CHEBI_59477	"20875"			"200767005"
ciprofloxacin	DB00537	Acute bacterial peritonitis	C0275550		Approved			CHEBI_192484	"2551"			"31860008"
ciprofloxacin	DB00537	Acute bacterial sinusitis	C0275556		Approved			CHEBI_192484	"2551"			"75498004"
clarithromycin	DB01211	Acute bacterial sinusitis	C0275556		Approved			CHEBI_3732	"21212"			"75498004"
clavulanic acid	DB00766	Acute bacterial sinusitis	C0275556		Approved			CHEBI_48947	"48203|21216"			"75498004"
acyclovir	DB00787	Herpes simplex infection of skin	C0349719		Approved			CHEBI_2453	"281"			"240475000"
amikacin	DB00479	Cholangitis	C0008311		Approved			CHEBI_2637	"641"	MONDO_0004789	"10008604"	"82403002"
estradiol	DB00783	Hidradenitis Suppurativa	C0162836	NCT00722800	Terminated	Phase 2	Poor recruitment	CHEBI_16469	"4083"	MONDO_0006559		"59393003"
	DB00977	Hidradenitis Suppurativa	C0162836	NCT00722800	Terminated	Phase 2	Poor recruitment	CHEBI_4903	"4124"	MONDO_0006559		"59393003"
trioxsalen	DB04571	Photosensitivity of skin	C0349506		Approved			CHEBI_28329	"10844"	HP:0000992		"90128006"
mepyramine	DB06691	Sinus headache	C0037195		Approved			CHEBI_6762	"9009"		"10040744"	"4969004"
blinatumomab	DB09052	Pre B-cell acute lymphoblastic leukemia	C0349636		Approved				"1597258"	HP:0004812		"277572006"
inotuzumab ozogamicin	DB05889	Pre B-cell acute lymphoblastic leukemia	C0349636		Approved				"1942950"	HP:0004812		"277572006"
omoconazole	DB13684	Dermatophytosis	C0011636		Approved			CHEBI_135685		MONDO_0004678	"10012504"	"47382004"
trimethoprim	DB00440	Shigella Infections	C0013371		Approved			CHEBI_45924	"10829"		"10054178"	"36188001"
hydrocortisone acetate	DB14539	Erythema Multiforme	C0014742		Approved			CHEBI_17609	"27197"	MONDO_0006545	"10015218"	"36715001"
cortisone acetate	DB01380	Erythema Multiforme	C0014742		Approved			CHEBI_3897	"21655"	MONDO_0006545	"10015218"	"36715001"
dexamethasone	DB01234	Erythema Multiforme	C0014742		Approved			CHEBI_41879	"3264"	MONDO_0006545	"10015218"	"36715001"
prednisone	DB00635	Erythema Multiforme	C0014742		Approved			CHEBI_8382	"8640"	MONDO_0006545	"10015218"	"36715001"
prednisolone	DB00860	Erythema Multiforme	C0014742		Approved			CHEBI_8378	"8638"	MONDO_0006545	"10015218"	"36715001"
hydrocortisone	DB00741	Erythema Multiforme	C0014742		Approved			CHEBI_17650	"5492"	MONDO_0006545	"10015218"	"36715001"
triamcinolone	DB00620	Erythema Multiforme	C0014742		Approved			CHEBI_9667	"10759"	MONDO_0006545	"10015218"	"36715001"
triamcinolone acetonide	DB00620	Erythema Multiforme	C0014742		Approved			CHEBI_9667	"10759"	MONDO_0006545	"10015218"	"36715001"
triamcinolone diacetate	DB00620	Erythema Multiforme	C0014742		Approved			CHEBI_9667	"10759"	MONDO_0006545	"10015218"	"36715001"
hydrocortisone succinate	DB00741	Erythema Multiforme	C0014742		Approved			CHEBI_17650	"5492"	MONDO_0006545	"10015218"	"36715001"
hydrocortisone succinate	DB14545	Erythema Multiforme	C0014742		Approved			CHEBI_31677	"21651"	MONDO_0006545	"10015218"	"36715001"
betamethasone	DB00443	Erythema Multiforme	C0014742		Approved			CHEBI_3077	"1514"	MONDO_0006545	"10015218"	"36715001"
betamethasone acetate	DB00443	Erythema Multiforme	C0014742		Approved			CHEBI_3077	"1514"	MONDO_0006545	"10015218"	"36715001"
methylprednisolone acetate	DB00959	Erythema Multiforme	C0014742		Approved			CHEBI_6888	"6902"	MONDO_0006545	"10015218"	"36715001"
methylprednisolone	DB00959	Erythema Multiforme	C0014742		Approved			CHEBI_6888	"6902"	MONDO_0006545	"10015218"	"36715001"
hydrocortisone acetate	DB00741	Erythema Multiforme	C0014742		Approved			CHEBI_17650	"5492"	MONDO_0006545	"10015218"	"36715001"
chlorhexidine	DB00878	Gingivitis	C0017574		Approved			CHEBI_3614	"2358"	MONDO_0002508	"10018292"	"66383009"
trientine	DB06824	Hepatolenticular Degeneration	C0019202		Approved			CHEBI_39501	"10798"	MONDO_0010200	"10019819"	"190823004"
zinc acetate	DB14487	Hepatolenticular Degeneration	C0019202		Approved			CHEBI_62984	"1299637|58295"	MONDO_0010200	"10019819"	"190823004"
penicillamine	DB00859	Hepatolenticular Degeneration	C0019202		Approved			CHEBI_7959	"7975"	MONDO_0010200	"10019819"	"190823004"
tolvaptan	DB06212	Inappropriate ADH Syndrome	C0021141		Approved			CHEBI_32246	"358257"	MONDO_0006802	"10053198"	"55004003"
clofazimine	DB00845	Leprosy	C0023343		Approved			CHEBI_3749	"2592"	MONDO_0005124	"10024229"	"81004002"
dapsone	DB00250	Leprosy	C0023343		Approved			CHEBI_4325	"3108"	MONDO_0005124	"10024229"	"81004002"
daunorubicin	DB00694	Acute monocytic leukemia	C0023465		Approved			CHEBI_41977	"214468|3109"	MONDO_0007896	"10000871"	"22331004"
nicotine	DB00184	Nicotine Dependence	C0028043	NCT01480232	Terminated	Phase 2	Study has been put on clinical hold by FDA	CHEBI_17688	"7407|31765"	HP:0033543	"10057852"	"56294008"
varenicline	DB01273	Nicotine Dependence	C0028043	NCT01169610	Terminated	Phase 3		CHEBI_84500	"591622"	HP:0033543	"10057852"	"56294008"
	DB01273	Nicotine Dependence	C0028043	NCT01560507	Terminated	Phase 2/Phase 3	Low Recruitment	CHEBI_84500	"591622"	HP:0033543	"10057852"	"56294008"
pioglitazone	DB01132	Nicotine Dependence	C0028043	NCT01395797	Terminated	Phase 1/Phase 2	The funding period ended.	CHEBI_8228	"33738"	HP:0033543	"10057852"	"56294008"
mifepristone	DB00834	Nicotine Dependence	C0028043	NCT03248713	Terminated	Early Phase 1	Lack of recruitment	CHEBI_50692	"6964"	HP:0033543	"10057852"	"56294008"
nicotine	DB00184	Nicotine Dependence	C0028043	NCT02487953	Withdrawn	Phase 2	Study design changed significantly; was submitted as a different protocol.	CHEBI_17688	"7407|31765"	HP:0033543	"10057852"	"56294008"
prazosin	DB00457	Nicotine Dependence	C0028043	NCT01642433	Terminated	Phase 2		CHEBI_8364	"8629"	HP:0033543	"10057852"	"56294008"
	DB01156	Nicotine Dependence	C0028043	NCT01560507	Terminated	Phase 2/Phase 3	Low Recruitment	CHEBI_3219	"42347"	HP:0033543	"10057852"	"56294008"
nicotine	DB00184	Nicotine Dependence	C0028043	NCT02439944	Terminated	Phase 2/Phase 3	full RCT funded. no need to continue pilot data collection.	CHEBI_17688	"7407|31765"	HP:0033543	"10057852"	"56294008"
nicotine	DB00184	Nicotine Dependence	C0028043	NCT01842334	Terminated	Phase 1/Phase 2	left institution protocol closed	CHEBI_17688	"7407|31765"	HP:0033543	"10057852"	"56294008"
nicotine	DB00184	Nicotine Dependence	C0028043		Approved			CHEBI_17688	"7407|31765"	HP:0033543	"10057852"	"56294008"
nicotine	DB00184	Nicotine Dependence	C0028043	NCT01560507	Terminated	Phase 2/Phase 3	Low Recruitment	CHEBI_17688	"7407|31765"	HP:0033543	"10057852"	"56294008"
varenicline	DB01273	Nicotine Dependence	C0028043	NCT00571805	Withdrawn	Phase 1/Phase 2		CHEBI_84500	"591622"	HP:0033543	"10057852"	"56294008"
varenicline	DB01273	Nicotine Dependence	C0028043	NCT03069768	Withdrawn	Phase 1	Unable to obtain varenicline to provide to participants	CHEBI_84500	"591622"	HP:0033543	"10057852"	"56294008"
atomoxetine	DB00289	Nicotine Dependence	C0028043	NCT02046551	Withdrawn	Phase 1/Phase 2	funding lost	CHEBI_127342	"38400"	HP:0033543	"10057852"	"56294008"
bupropion	DB01156	Nicotine Dependence	C0028043		Approved			CHEBI_3219	"42347"	HP:0033543	"10057852"	"56294008"
baclofen	DB00181	Nicotine Dependence	C0028043	NCT01228994	Terminated	Phase 2	The study was terminated because of difficulties recruiting subjects.	CHEBI_2972	"1292"	HP:0033543	"10057852"	"56294008"
baclofen	DB00181	Nicotine Dependence	C0028043	NCT00257894	Terminated	Phase 2	Enrollment was completed with insufficient sample size for publishable results	CHEBI_2972	"1292"	HP:0033543	"10057852"	"56294008"
benzylpenicillin	DB01053	Pasteurella Infections	C0030636		Approved			CHEBI_18208	"7980"	MONDO_0005901	"10034106"	"83172007"
fusidic acid	DB02703	Pneumococcal Infections	C0032269		Approved			CHEBI_29013	"4608|113608"	MONDO_0005114	"10061353"	"16814004"
lincomycin	DB01627	Pneumococcal Infections	C0032269		Approved			CHEBI_6472	"6398"	MONDO_0005114	"10061353"	"16814004"
ruxolitinib	DB08877	Polycythemia Vera	C0032463		Approved			CHEBI_66919	"1193326"	MONDO_0009891	"10036057"	"128841001"
erlotinib	DB00530	Polycythemia Vera	C0032463	NCT01038856	Terminated	Phase 2	The study was terminated by the sponsor	CHEBI_114785	"337525"	MONDO_0009891	"10036057"	"128841001"
	DB00945	Polycythemia Vera	C0032463	NCT00940784	Withdrawn	Phase 2	Could not get drug	CHEBI_15365	"91101|1191"	MONDO_0009891	"10036057"	"128841001"
clopidogrel	DB00758	Polycythemia Vera	C0032463	NCT00940784	Withdrawn	Phase 2	Could not get drug	CHEBI_37941	"32968"	MONDO_0009891	"10036057"	"128841001"
uracil mustard	DB00791	Polycythemia Vera	C0032463		Approved			CHEBI_9884	"10996"	MONDO_0009891	"10036057"	"128841001"
dasatinib	DB01254	Polycythemia Vera	C0032463	NCT00538980	Terminated	Phase 2	This study was terminated due to lack of efficacy.	CHEBI_49375	"475342|1546019"	MONDO_0009891	"10036057"	"128841001"
arsenic trioxide	DB01169	Polycythemia Vera	C0032463	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_49900	"18330"	MONDO_0009891	"10036057"	"128841001"
	DB00126	Polycythemia Vera	C0032463	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_29073	"1151|1370460"	MONDO_0009891	"10036057"	"128841001"
	DB14482	Polycythemia Vera	C0032463	NCT01014546	Terminated	Phase 1	low accrual	CHEBI_113451	"267366"	MONDO_0009891	"10036057"	"128841001"
	DB14483	Polycythemia Vera	C0032463	NCT01014546	Terminated	Phase 1	low accrual		"1307765|142407"	MONDO_0009891	"10036057"	"128841001"
hydroxycarbamide	DB01005	Polycythemia Vera	C0032463	NCT01645124	Terminated	Phase 3	Low accrual rate not allowing planned sample size leads to a futility condition	CHEBI_44423	"151871|5552"	MONDO_0009891	"10036057"	"128841001"
mechlorethamine	DB00888	Polycythemia Vera	C0032463		Approved			CHEBI_28925	"6674"	MONDO_0009891	"10036057"	"128841001"
sodium phosphate (32P)	DB09370	Polycythemia Vera	C0032463		Approved				"91559"	MONDO_0009891	"10036057"	"128841001"
ropeginterferon alfa-2b	DB15119	Polycythemia Vera	C0032463		Approved				"2587059|2587060"	MONDO_0009891	"10036057"	"128841001"
testosterone propionate	DB00624	Delayed Puberty	C0034012		Approved			CHEBI_17347	"10379"	HP:0000823	"10012205"	"400003000"
testosterone	DB00624	Delayed Puberty	C0034012		Approved			CHEBI_17347	"10379"	HP:0000823	"10012205"	"400003000"
testosterone propionate	DB01420	Delayed Puberty	C0034012		Approved			CHEBI_9466	"10382"	HP:0000823	"10012205"	"400003000"
methyltestosterone	DB06710	Delayed Puberty	C0034012		Approved			CHEBI_27436	"6904"	HP:0000823	"10012205"	"400003000"
testosterone cypionate	DB00624	Delayed Puberty	C0034012		Approved			CHEBI_17347	"10379"	HP:0000823	"10012205"	"400003000"
testosterone cypionate	DB13943	Delayed Puberty	C0034012		Approved			CHEBI_9463	"835827"	HP:0000823	"10012205"	"400003000"
testosterone enantate	DB13944	Delayed Puberty	C0034012		Approved			CHEBI_9464	"37859"	HP:0000823	"10012205"	"400003000"
testosterone enantate	DB00624	Delayed Puberty	C0034012		Approved			CHEBI_17347	"10379"	HP:0000823	"10012205"	"400003000"
fluoxymesterone	DB01185	Delayed Puberty	C0034012		Approved			CHEBI_5120	"4494"	HP:0000823	"10012205"	"400003000"
thiabendazole	DB00730	Strongyloidiasis	C0038463		Approved			CHEBI_45979	"10450"	MONDO_0005974	"10042254"	"1214006"
ivermectin	DB00602	Strongyloidiasis	C0038463		Approved			CHEBI_6078	"6069"	MONDO_0005974	"10042254"	"1214006"
dobutamine	DB00841	Tetralogy of Fallot	C0039685	NCT00564993	Terminated	Phase 3		CHEBI_4670	"3616"	MONDO_0008542	"10016193"	"86299006"
alprostadil	DB00770	Tetralogy of Fallot	C0039685		Approved			CHEBI_15544	"598"	MONDO_0008542	"10016193"	"86299006"
carbamazepine	DB00564	Trigeminal Neuralgia	C0040997		Approved			CHEBI_3387	"2002"	MONDO_0008599	"10044652"	"31681005"
ketorolac	DB00465	Trigeminal Neuralgia	C0040997	NCT04353505	Withdrawn	Phase 1	PI closed the study before any enrollment	CHEBI_76223	"35827"	MONDO_0008599	"10044652"	"31681005"
amifostine	DB01143	Trigeminal Neuralgia	C0040997	NCT01364259	Terminated	Phase 3	Patterns of practice changed and this technique is no longer used.	CHEBI_2636	"1545987|4126"	MONDO_0008599	"10044652"	"31681005"
glycerol	DB09462	Trigeminal Neuralgia	C0040997	NCT02624661	Terminated	Phase 1/Phase 2	technical problems	CHEBI_17754	"4910"	MONDO_0008599	"10044652"	"31681005"
	DB01234	Trigeminal Neuralgia	C0040997	NCT04353505	Withdrawn	Phase 1	PI closed the study before any enrollment	CHEBI_41879	"3264"	MONDO_0008599	"10044652"	"31681005"
tolazoline	DB00797	Vascular Diseases	C0042373		Approved			CHEBI_28502	"10634"	MONDO_0005385	"10059245"	"27550009"
buphenine	DB06152	Vascular Diseases	C0042373		Approved			CHEBI_91656	"7595"	MONDO_0005385	"10059245"	"27550009"
isoxsuprine	DB08941	Vascular Diseases	C0042373		Approved				"6066"	MONDO_0005385	"10059245"	"27550009"
azapetine	DB13727	Peripheral Vascular Diseases	C0085096		Approved			CHEBI_134955		HP:0004950	"10034636"	"400047006"
bupivacaine	DB00297	Peripheral Vascular Diseases	C0085096	NCT02374320	Terminated	Phase 2/Phase 3	PI leaving institution	CHEBI_77431	"1815"	HP:0004950	"10034636"	"400047006"
ticagrelor	DB08816	Peripheral Vascular Diseases	C0085096		Approved			CHEBI_68558	"1116632"	HP:0004950	"10034636"	"400047006"
papaverine	DB01113	Peripheral Vascular Diseases	C0085096		Approved			CHEBI_28241	"7895"	HP:0004950	"10034636"	"400047006"
phentolamine	DB00692	Peripheral Vascular Diseases	C0085096		Approved			CHEBI_8081	"8153"	HP:0004950	"10034636"	"400047006"
pentoxifylline	DB00806	Peripheral Vascular Diseases	C0085096		Approved			CHEBI_7986	"8013"	HP:0004950	"10034636"	"400047006"
clobetasol propionate	DB11750	Nummular eczema	C0085656		Approved			CHEBI_205919	"2590"	HP:0033120	"10014201"	"81418003"
clobetasol propionate	DB01013	Nummular eczema	C0085656		Approved			CHEBI_31414	"21245"	HP:0033120	"10014201"	"81418003"
procaine benzylpenicillin	DB09320	Syphilis, tertiary	C0153188		Approved			CHEBI_52154	"7983"	MONDO_0004497	"10056873"	"72083004"
benzylpenicillin	DB01053	Syphilis, tertiary	C0153188		Approved			CHEBI_18208	"7980"	MONDO_0004497	"10056873"	"72083004"
procaine benzylpenicillin	DB01053	Syphilis, tertiary	C0153188		Approved			CHEBI_18208	"7980"	MONDO_0004497	"10056873"	"72083004"
ciprofloxacin	DB00537	Acute osteomyelitis	C0158371		Approved			CHEBI_192484	"2551"		"10031253"	"409780002"
norfloxacin	DB01059	Acute osteomyelitis	C0158371		Approved			CHEBI_100246	"7517"		"10031253"	"409780002"
ofloxacin	DB01165	Acute osteomyelitis	C0158371		Approved			CHEBI_7731	"7623"		"10031253"	"409780002"
nintedanib	DB09079	Lung Diseases, Interstitial	C0206062		Approved			CHEBI_85164	"1592737"		"10022611"	"233703007"
phenobarbital	DB01174	Simple Partial Seizures	C0234974		Approved			CHEBI_8069	"8134"	HP:0002349	"10040703"	"117891000119100"
topiramate	DB00273	Simple Partial Seizures	C0234974		Approved			CHEBI_63631	"38404"	HP:0002349	"10040703"	"117891000119100"
carbamazepine	DB00564	Simple Partial Seizures	C0234974		Approved			CHEBI_3387	"2002"	HP:0002349	"10040703"	"117891000119100"
felbamate	DB00949	Simple Partial Seizures	C0234974		Approved			CHEBI_4995	"24812"	HP:0002349	"10040703"	"117891000119100"
lamotrigine	DB00555	Simple Partial Seizures	C0234974		Approved			CHEBI_6367	"28439"	HP:0002349	"10040703"	"117891000119100"
phenytoin	DB00252	Simple Partial Seizures	C0234974		Approved			CHEBI_8107	"8183"	HP:0002349	"10040703"	"117891000119100"
primidone	DB00794	Simple Partial Seizures	C0234974		Approved			CHEBI_8412	"8691"	HP:0002349	"10040703"	"117891000119100"
tiagabine	DB00906	Simple Partial Seizures	C0234974		Approved			CHEBI_9586	"31914"	HP:0002349	"10040703"	"117891000119100"
oxcarbazepine	DB00776	Simple Partial Seizures	C0234974		Approved			CHEBI_7824	"32624"	HP:0002349	"10040703"	"117891000119100"
levetiracetam	DB01202	Simple Partial Seizures	C0234974		Approved			CHEBI_6437	"114477"	HP:0002349	"10040703"	"117891000119100"
susoctocog alfa	DB11606	Factor 8 deficiency, acquired	C0272325		Approved				"1592899"	MONDO_0035735	"10082745"	"14230004"
imatinib	DB00619	Dermatofibrosarcoma Protuberans	C0392784		Approved			CHEBI_45783	"282388"		"10057070"	"276799004"
phenobarbital	DB01174	Tonic - clonic seizures	C0494475		Approved			CHEBI_8069	"8134"	HP:0002069	"10018100"	"1217136003"
primidone	DB00794	Tonic - clonic seizures	C0494475		Approved			CHEBI_8412	"8691"	HP:0002069	"10018100"	"1217136003"
lamotrigine	DB00555	Tonic - clonic seizures	C0494475		Approved			CHEBI_6367	"28439"	HP:0002069	"10018100"	"1217136003"
phenytoin	DB00252	Tonic - clonic seizures	C0494475		Approved			CHEBI_8107	"8183"	HP:0002069	"10018100"	"1217136003"
carbamazepine	DB00564	Tonic - clonic seizures	C0494475		Approved			CHEBI_3387	"2002"	HP:0002069	"10018100"	"1217136003"
moxifloxacin	DB00218	Pneumonic Plague	C0524688		Approved			CHEBI_63611	"139462"	MONDO_0001024	"10053026"	"38976008"
tazobactam	DB01606	Bacterial cystitis	C0742964		Approved			CHEBI_9421	"37617"		"10065198"	"424551004"
ceftolozane	DB09050	Bacterial cystitis	C0742964		Approved			CHEBI_134719	"1597609"		"10065198"	"424551004"
pemetrexed	DB00642	Malignant Pleural Mesothelioma	C0812413		Approved			CHEBI_63616	"68446"	MONDO_0005112	"10059518"	"254645002"
gossypol	DB13044	Recurrent Chronic Lymphoid Leukemia	C0854802	NCT01003769	Terminated	Phase 1/Phase 2	Lack of funding	CHEBI_28584			"10008961"	"122961000119105"
lenalidomide	DB00480	Recurrent Chronic Lymphoid Leukemia	C0854802	NCT02225275	Terminated	Phase 2	Due to slow accrual	CHEBI_63791	"342369"		"10008961"	"122961000119105"
	DB00480	Recurrent Chronic Lymphoid Leukemia	C0854802	NCT01003769	Terminated	Phase 1/Phase 2	Lack of funding	CHEBI_63791	"342369"		"10008961"	"122961000119105"
	DB03166	Recurrent Chronic Lymphoid Leukemia	C0854802	NCT01003769	Terminated	Phase 1/Phase 2	Lack of funding	CHEBI_15366	"168|164"		"10008961"	"122961000119105"
cyclophosphamide	DB00531	Recurrent Chronic Lymphoid Leukemia	C0854802	NCT03579888	Terminated	Phase 1	Study halted prematurely	CHEBI_4027	"1545988|3002"		"10008961"	"122961000119105"
alemtuzumab	DB00087	Recurrent Chronic Lymphoid Leukemia	C0854802		Approved				"117055"		"10008961"	"122961000119105"
natamycin	DB00826	Fungal keratitis	C1262117		Approved			CHEBI_7488	"7268"		"10062353"	"314558005"
natamycin	DB00826	Fungal keratitis	C1262117	NCT00516399	Terminated	Phase 3	The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of povidone-iodine to Natamycin.	CHEBI_7488	"7268"		"10062353"	"314558005"
	DB11061	Fungal keratitis	C1262117	NCT00516399	Terminated	Phase 3	The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of povidone-iodine to Natamycin.		"8610"		"10062353"	"314558005"
	DB06812	Fungal keratitis	C1262117	NCT00516399	Terminated	Phase 3	The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of povidone-iodine to Natamycin.	CHEBI_8347	"8611"		"10062353"	"314558005"
theophylline	DB01223	Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome	C4038730		Approved			CHEBI_2659	"689"		"10077005"	"10692761000119107"
theophylline	DB00277	Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome	C4038730		Approved			CHEBI_28177	"10438|91178"		"10077005"	"10692761000119107"
diprophylline	DB00651	Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome	C4038730		Approved			CHEBI_4728	"3714"		"10077005"	"10692761000119107"
levodopa	DB00988	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_18243	"3628"	MONDO_0001945		"19972008"
amikacin	DB00479	Sepsis caused by Gram negative bacteria	C3163829		Approved			CHEBI_2637	"641"			"449082003"
liothyronine	DB00279	Endemic goiter	C0018022		Approved			CHEBI_533015	"10814"			"267369002"
meglumine antimonate	DB13732	Chemotherapy-induced nausea and vomiting	C0401160		Approved				"319866"			"18846006"
metronidazole	DB00916	Brain Abscess	C0006105		Approved			CHEBI_6909	"6922"	HP:0030049	"10006105"	"441806004"
metronidazole	DB15759	Brain Abscess	C0006105		Approved			CHEBI_50688		HP:0030049	"10006105"	"441806004"
nabilone	DB00486	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_135574	"31447"			"18846006"
ondansetron	DB00904	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_7773	"26225"			"18846006"
piperacillin	DB00319	Sepsis caused by Gram negative bacteria	C3163829		Approved			CHEBI_8232	"1546000|8339"			"449082003"
procyclidine	DB00387	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_8448	"8718"	MONDO_0001945		"19972008"
aprepitant	DB00673	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_499361	"358255"			"18846006"
trihexyphenidyl	DB00376	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_9720	"10811"	MONDO_0001945		"19972008"
tropisetron	DB11699	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_32269	"27392"			"18846006"
aztreonam	DB00355	Sepsis caused by Gram negative bacteria	C3163829		Approved			CHEBI_161680	"1272"			"449082003"
clindamycin phosphate	DB01190	Gas gangrene caused by clostridium perfringens	C0343500		Approved			CHEBI_3745	"2582"			"266093005"
bromocriptine	DB01200	Parkinson Disease, Postencephalitic	C0030568		Approved			CHEBI_3181	"1760"	MONDO_0001945		"19972008"
dronabinol	DB00470	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_66964	"10402"			"18846006"
apixaban	DB06605	Arterial embolus and thrombosis	C0155749		Approved			CHEBI_72296	"1364430"			"266262004"
deoxycholic acid	DB03619	Excess subcutaneous fat	C0424620		Approved			CHEBI_28834	"42627|3194"			"248302001"
deoxycholic acid	DB05780	Excess subcutaneous fat	C0424620		Approved			CHEBI_28834				"248302001"
rolapitant	DB09291	Chemotherapy-induced nausea and vomiting	C0401160		Approved			CHEBI_90908	"1665496"			"18846006"
durvalumab	DB11714	Extensive stage primary small cell carcinoma of lung	C4303663		Approved				"1919503"			"683991000119103"
lefamulin	DB12825	Pneumonia caused by Chlamydia pneumoniae	C4510691		Approved				"2198944"			"724498004"
brolucizumab	DB14864	Macular edema due to diabetes mellitus	C0730285		Approved				"2204915|2204916"	MONDO_0004728		"312912001"
faricimab	DB15303	Macular edema due to diabetes mellitus	C0730285		Approved				"2591519"	MONDO_0004728		"312912001"
acetazolamide	DB00819	Altitude Sickness	C0002351		Approved			CHEBI_27690	"167"			"87284002"
clindamycin	DB01190	Gas gangrene caused by clostridium perfringens	C0343500		Approved			CHEBI_3745	"2582"			"266093005"
ciprofloxacin	DB00537	Cystitis	C0010692		Approved			CHEBI_192484	"2551"	MONDO_0006032	"10011781"	"38822007"
norfloxacin	DB01059	Cystitis	C0010692	NCT01527019	Withdrawn	Phase 3	the company suspended the persecution of this combination	CHEBI_100246	"7517"	MONDO_0006032	"10011781"	"38822007"
norfloxacin	DB01059	Cystitis	C0010692		Approved			CHEBI_100246	"7517"	MONDO_0006032	"10011781"	"38822007"
ofloxacin	DB01165	Cystitis	C0010692		Approved			CHEBI_7731	"7623"	MONDO_0006032	"10011781"	"38822007"
betaine	DB06756	Cystitis	C0010692		Approved			CHEBI_17750	"350374|1512"	MONDO_0006032	"10011781"	"38822007"
dexibuprofen	DB09213	Dysmenorrhea	C0013390		Approved			CHEBI_43415		HP:0100607	"10013935"	"431416001"
caffeine	DB00201	Dysmenorrhea	C0013390		Approved			CHEBI_27732	"1886"	HP:0100607	"10013935"	"431416001"
mefenamic acid	DB00784	Dysmenorrhea	C0013390		Approved			CHEBI_6717	"6693"	HP:0100607	"10013935"	"431416001"
rofecoxib	DB00533	Dysmenorrhea	C0013390		Approved			CHEBI_8887	"232158"	HP:0100607	"10013935"	"431416001"
diclofenac	DB00586	Dysmenorrhea	C0013390		Approved			CHEBI_47381	"3355"	HP:0100607	"10013935"	"431416001"
dienogest	DB09123	Dysmenorrhea	C0013390		Approved			CHEBI_70708	"22968"	HP:0100607	"10013935"	"431416001"
naproxen	DB00788	Dysmenorrhea	C0013390		Approved			CHEBI_7476	"7258"	HP:0100607	"10013935"	"431416001"
ethinylestradiol	DB00977	Dysmenorrhea	C0013390		Approved			CHEBI_4903	"4124"	HP:0100607	"10013935"	"431416001"
drospirenone	DB01395	Dysmenorrhea	C0013390		Approved			CHEBI_50838	"11636"	HP:0100607	"10013935"	"431416001"
ibuprofen	DB01050	Dysmenorrhea	C0013390		Approved			CHEBI_5855	"5640"	HP:0100607	"10013935"	"431416001"
meclofenamic acid	DB00939	Dysmenorrhea	C0013390		Approved			CHEBI_6710	"6678|588003"	HP:0100607	"10013935"	"431416001"
mepyramine	DB06691	Dysmenorrhea	C0013390		Approved			CHEBI_6762	"9009"	HP:0100607	"10013935"	"431416001"
magnesium salicylate	DB01397	Dysmenorrhea	C0013390		Approved			CHEBI_6640		HP:0100607	"10013935"	"431416001"
ibuprofen	DB01050	Dysmenorrhea	C0013390	NCT02668822	Terminated	Phase 3	Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.	CHEBI_5855	"5640"	HP:0100607	"10013935"	"431416001"
levonorgestrel	DB09389	Dysmenorrhea	C0013390		Approved			CHEBI_7630	"7518"	HP:0100607	"10013935"	"431416001"
caffeine	DB00201	Dyspnea	C0013404	NCT02311088	Terminated	Phase 2	Too low enrolment rate	CHEBI_27732	"1886"	HP:0002094	"10013968"	"267036007"
	DB00633	Dyspnea	C0013404	NCT01687751	Withdrawn	Phase 2	Study design determined to be not likely feasible	CHEBI_4466	"48937"	HP:0002094	"10013968"	"267036007"
midazolam	DB00683	Dyspnea	C0013404	NCT01687751	Withdrawn	Phase 2	Study design determined to be not likely feasible	CHEBI_6931	"6960"	HP:0002094	"10013968"	"267036007"
morphine	DB00295	Dyspnea	C0013404	NCT02455362	Withdrawn	Phase 3	'Recruitment not possible given changes to trial criteria	CHEBI_17303	"7052|32926"	HP:0002094	"10013968"	"267036007"
epinephrine	DB00668	Dyspnea	C0013404		Approved			CHEBI_28918	"3992"	HP:0002094	"10013968"	"267036007"
nitric oxide	DB00435	Dyspnea	C0013404	NCT04290858	Withdrawn	Phase 2	New coordinating center has been defined (Massachusetts General Hospital)	CHEBI_16480	"7442"	HP:0002094	"10013968"	"267036007"
biperiden	DB00810	Extrapyramidal Disorders	C0015371		Approved			CHEBI_3112	"1589"	HP:0002071	"10015832"	"76349003"
trihexyphenidyl	DB00376	Extrapyramidal Disorders	C0015371		Approved			CHEBI_9720	"10811"	HP:0002071	"10015832"	"76349003"
benzatropine	DB00245	Extrapyramidal Disorders	C0015371		Approved			CHEBI_3048	"1424"	HP:0002071	"10015832"	"76349003"
amantadine	DB00915	Extrapyramidal Disorders	C0015371		Approved			CHEBI_2618	"620"	HP:0002071	"10015832"	"76349003"
procyclidine	DB00387	Extrapyramidal Disorders	C0015371		Approved			CHEBI_8448	"8718"	HP:0002071	"10015832"	"76349003"
	DB00820	Glaucoma	C0017601	NCT04052269	Suspended	Phase 3	suspended due to COVID	CHEBI_71940	"358263"	MONDO_0005041	"10018304"	"23986001"
bupranolol	DB08808	Glaucoma	C0017601		Approved			CHEBI_135123		MONDO_0005041	"10018304"	"23986001"
travoprost	DB00287	Glaucoma	C0017601	NCT00767481	Terminated	Phase 3	Project Cancelled	CHEBI_746859	"283809"	MONDO_0005041	"10018304"	"23986001"
sildenafil	DB00203	Glaucoma	C0017601	NCT04052269	Suspended	Phase 3	suspended due to COVID	CHEBI_9139	"136411"	MONDO_0005041	"10018304"	"23986001"
	DB00373	Glaucoma	C0017601	NCT01426113	Terminated	Phase 3	Study terminated due to corporate decision.	CHEBI_9599	"1546004|10600"	MONDO_0005041	"10018304"	"23986001"
travoprost	DB00287	Glaucoma	C0017601	NCT00767494	Terminated	Phase 3	Project Cancelled	CHEBI_746859	"283809"	MONDO_0005041	"10018304"	"23986001"
ripasudil	DB13165	Glaucoma	C0017601		Approved			CHEBI_136046		MONDO_0005041	"10018304"	"23986001"
	DB00373	Glaucoma	C0017601	NCT00579969	Terminated	Phase 2	Study stopped and data not analyzed	CHEBI_9599	"1546004|10600"	MONDO_0005041	"10018304"	"23986001"
echothiophate	DB01057	Glaucoma	C0017601		Approved			CHEBI_4753	"89778"	MONDO_0005041	"10018304"	"23986001"
latanoprost	DB00654	Glaucoma	C0017601	NCT00579969	Terminated	Phase 2	Study stopped and data not analyzed	CHEBI_6384	"43611"	MONDO_0005041	"10018304"	"23986001"
brimonidine	DB00484	Glaucoma	C0017601	NCT01284166	Withdrawn	Phase 3	Study was never initiated due to company decision. No study subjects were ever enrolled or treated.	CHEBI_3175	"134615"	MONDO_0005041	"10018304"	"23986001"
	DB00373	Glaucoma	C0017601	NCT01284166	Withdrawn	Phase 3	Study was never initiated due to company decision. No study subjects were ever enrolled or treated.	CHEBI_9599	"1546004|10600"	MONDO_0005041	"10018304"	"23986001"
acetylcholine	DB03128	Glaucoma	C0017601		Approved			CHEBI_15355	"194"	MONDO_0005041	"10018304"	"23986001"
latanoprost	DB00654	Glaucoma	C0017601	NCT00855517	Withdrawn	Phase 2	Sponsor's decision	CHEBI_6384	"43611"	MONDO_0005041	"10018304"	"23986001"
ranibizumab	DB01270	Glaucoma	C0017601	NCT00727038	Withdrawn	Phase 1/Phase 2	Company withdrew funding/sponsorship		"595060"	MONDO_0005041	"10018304"	"23986001"
omidenepag isopropyl	DB15071	Glaucoma	C0017601		Approved				"2612690"	MONDO_0005041	"10018304"	"23986001"
bimatoprost	DB00905	Glaucoma	C0017601	NCT01426113	Terminated	Phase 3	Study terminated due to corporate decision.	CHEBI_51230	"283810"	MONDO_0005041	"10018304"	"23986001"
sildenafil	DB00203	Congestive heart failure	C0018802	NCT00818701	Terminated	Phase 1	started a NIH study that is competing for same subjects	CHEBI_9139	"136411"	MONDO_0005009	"10007559"	"42343007"
acetyldigitoxin	DB00511	Congestive heart failure	C0018802		Approved			CHEBI_53773	"132871"	MONDO_0005009	"10007559"	"42343007"
levosimendan	DB00922	Congestive heart failure	C0018802		Approved			CHEBI_50567	"73107"	MONDO_0005009	"10007559"	"42343007"
azosemide	DB08961	Congestive heart failure	C0018802		Approved			CHEBI_31248	"18651"	MONDO_0005009	"10007559"	"42343007"
darbepoetin alfa	DB00012	Congestive heart failure	C0018802	NCT00534456	Terminated	Phase 3	Study terminated		"283838"	MONDO_0005009	"10007559"	"42343007"
enalapril	DB00584	Congestive heart failure	C0018802		Approved			CHEBI_4784	"3827"	MONDO_0005009	"10007559"	"42343007"
enalapril	DB09477	Congestive heart failure	C0018802		Approved			CHEBI_4786	"1545989|3829"	MONDO_0005009	"10007559"	"42343007"
enalaprilat	DB09477	Congestive heart failure	C0018802		Approved			CHEBI_4786	"1545989|3829"	MONDO_0005009	"10007559"	"42343007"
salbutamol	DB01001	Congestive heart failure	C0018802	NCT01375361	Withdrawn	Phase 2/Phase 3	Low enrollment.	CHEBI_2549	"435"	MONDO_0005009	"10007559"	"42343007"
ubidecarenone	DB09270	Congestive heart failure	C0018802		Approved			CHEBI_46245	"21406"	MONDO_0005009	"10007559"	"42343007"
icodextrin	DB00702	Congestive heart failure	C0018802	NCT01124227	Terminated	Phase 3	Due to very specific inclusion criteria the anticipated number of patients was not reached. Inclusion stopped at N=26, allowing for analyzing primary outcomes.		"140480"	MONDO_0005009	"10007559"	"42343007"
milrinone	DB00235	Congestive heart failure	C0018802	NCT00338455	Terminated	Phase 2	DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment	CHEBI_50693	"52769"	MONDO_0005009	"10007559"	"42343007"
	DB00841	Congestive heart failure	C0018802	NCT00338455	Terminated	Phase 2	DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment	CHEBI_4670	"3616"	MONDO_0005009	"10007559"	"42343007"
pantoprazole	DB00213	Congestive heart failure	C0018802	NCT00699361	Withdrawn	Phase 3	Study withdrawn for financial issues	CHEBI_7915	"40790"	MONDO_0005009	"10007559"	"42343007"
dronedarone	DB04855	Congestive heart failure	C0018802	NCT00696631	Terminated	Phase 3	Terminated as the active treatment was associated with an increased hazard	CHEBI_50659	"233698"	MONDO_0005009	"10007559"	"42343007"
icodextrin	DB00702	Congestive heart failure	C0018802	NCT00368641	Terminated	Phase 2	Enrollment		"140480"	MONDO_0005009	"10007559"	"42343007"
famciclovir	DB00426	Herpes simplex infection	C0019348		Approved			CHEBI_4974	"68099"	MONDO_0004609	"10019948"	"88594005"
valaciclovir	DB00577	Herpes simplex infection	C0019348	NCT00001054	Withdrawn	Phase 1		CHEBI_35854	"73645"	MONDO_0004609	"10019948"	"88594005"
acyclovir	DB00787	Herpes simplex infection	C0019348		Approved			CHEBI_2453	"281"	MONDO_0004609	"10019948"	"88594005"
acyclovir	DB00787	Herpes simplex infection	C0019348	NCT02349828	Withdrawn	Phase 2/Phase 3	PI decided to stop due to divisional reorganization. No pts enrolled.	CHEBI_2453	"281"	MONDO_0004609	"10019948"	"88594005"
betaine	DB06756	Homocystinuria	C0019880		Approved			CHEBI_17750	"350374|1512"	MONDO_0004737	"10020365"	"11282001"
topiramate	DB00273	Hypertriglyceridemia	C0020557	NCT00231621	Terminated	Phase 3	The study was terminated prior to completion to focus on the development of a controlled release formulation.	CHEBI_63631	"38404"		"10020869"	"302870006"
rosuvastatin	DB01098	Hypertriglyceridemia	C0020557		Approved			CHEBI_38545	"301542"		"10020869"	"302870006"
ciprofibrate	DB09064	Hypertriglyceridemia	C0020557		Approved			CHEBI_50867	"21149"		"10020869"	"302870006"
lovastatin	DB00227	Hypertriglyceridemia	C0020557		Approved			CHEBI_40303	"6472"		"10020869"	"302870006"
simvastatin	DB00641	Hypertriglyceridemia	C0020557		Approved			CHEBI_9150	"36567"		"10020869"	"302870006"
atorvastatin	DB01076	Hypertriglyceridemia	C0020557		Approved			CHEBI_39548	"83367"		"10020869"	"302870006"
fenofibrate	DB01039	Hypertriglyceridemia	C0020557		Approved			CHEBI_5001	"8703"		"10020869"	"302870006"
icosapent ethyl	DB08887	Hypertriglyceridemia	C0020557		Approved			CHEBI_84883	"1304974"		"10020869"	"302870006"
gemfibrozil	DB01241	Hypertriglyceridemia	C0020557		Approved			CHEBI_5296	"4719"		"10020869"	"302870006"
inositol	DB13178	Hypertriglyceridemia	C0020557		Approved			CHEBI_17268	"5833"		"10020869"	"302870006"
pravastatin	DB00175	Hypertriglyceridemia	C0020557		Approved			CHEBI_63618	"42463"		"10020869"	"302870006"
choline fenofibrate	DB13873	Hypertriglyceridemia	C0020557		Approved			CHEBI_83469	"24852"		"10020869"	"302870006"
	DB01119	Hypertriglyceridemia	C0020557	NCT00901823	Withdrawn	Phase 1	Did not support the planned development of DCCR in the new indication	CHEBI_4495	"3327"		"10020869"	"302870006"
phosphorylcholine	DB00122	Hypertriglyceridemia	C0020557	NCT00901823	Withdrawn	Phase 1	Did not support the planned development of DCCR in the new indication	CHEBI_15354	"2449"		"10020869"	"302870006"
nicotinic acid	DB00627	Hypertriglyceridemia	C0020557		Approved			CHEBI_15940	"7393"		"10020869"	"302870006"
	DB01076	Hypertriglyceridemia	C0020557	NCT00973271	Withdrawn	Phase 3	Did not continue with development of DCCR in Very High Triglycerides	CHEBI_39548	"83367"		"10020869"	"302870006"
fenofibrate	DB01039	Hypertriglyceridemia	C0020557	NCT00973271	Withdrawn	Phase 3	Did not continue with development of DCCR in Very High Triglycerides	CHEBI_5001	"8703"		"10020869"	"302870006"
omega-3-carboxylic acids	DB09568	Hypertriglyceridemia	C0020557		Approved				"1652071"		"10020869"	"302870006"
testosterone	DB00624	Hypopituitarism	C0020635		Approved			CHEBI_17347	"10379"	MONDO_0005152|MONDO_0015127	"10021067"	"74728003"
clomifene	DB00882	Female infertility	C0021361		Approved			CHEBI_3752	"2596"	MONDO_0021124	"10021928"	"6738008"
lactose	DB04465	Lactose Intolerance	C0022951		Approved			CHEBI_17716	"6211"	MONDO_0100345	"10023681"	"782415009"
fludarabine phosphate	DB01073	Lymphoma, Non-Hodgkin	C0024305		Approved			CHEBI_94701	"24698"	MONDO_0018908	"10029547"	"118601006"
metahexamide	DB13675	Chloasma	C0025218		Approved			CHEBI_135328		HP:0025272	"10008570"	"36209000"
dioxybenzone	DB11221	Chloasma	C0025218		Approved			CHEBI_34208	"23350"	HP:0025272	"10008570"	"36209000"
fluocinolone acetonide	DB00591	Chloasma	C0025218		Approved			CHEBI_31623	"4461"	HP:0025272	"10008570"	"36209000"
fluocinolone acetonide	DB12553	Chloasma	C0025218		Approved			CHEBI_5108	"25126"	HP:0025272	"10008570"	"36209000"
octinoxate	DB09496	Chloasma	C0025218		Approved			CHEBI_88667	"13369|283678"	HP:0025272	"10008570"	"36209000"
hydroquinone	DB09526	Chloasma	C0025218		Approved			CHEBI_17594	"5509"	HP:0025272	"10008570"	"36209000"
tretinoin	DB00755	Chloasma	C0025218		Approved			CHEBI_15367	"10753"	HP:0025272	"10008570"	"36209000"
sulfamethoxazole	DB01015	Nocardia Infections	C0028242		Approved			CHEBI_9332	"10180"		"10029444"	"29227009"
sulfafurazole	DB00263	Nocardia Infections	C0028242		Approved			CHEBI_102484	"10207"		"10029444"	"29227009"
praziquantel	DB01058	Opisthorchiasis	C0029106		Approved			CHEBI_91583	"8628"	MONDO_0005884	"10030897"	"1059007"
colecalciferol	DB00169	Osteomalacia	C0029442		Approved			CHEBI_28940	"2418"	HP:0002749	"10031250"	"4598005"
ergocalciferol	DB11094	Osteomalacia	C0029442		Approved			CHEBI_28934	"11253"	HP:0002749	"10031250"	"4598005"
burosumab	DB14012	Osteomalacia	C0029442		Approved				"2043854|2043855"	HP:0002749	"10031250"	"4598005"
ergocalciferol	DB00153	Osteomalacia	C0029442		Approved			CHEBI_28934	"4018"	HP:0002749	"10031250"	"4598005"
azathioprine	DB00993	Bullous pemphigoid	C0030805		Approved			CHEBI_2948	"1256"	MONDO_0019082	"10034277"	"86142006"
betamethasone	DB00443	Pemphigus	C0030807		Approved			CHEBI_3077	"1514"	MONDO_0006594	"10034280"	"65172003"
sirolimus	DB00877	Pemphigus	C0030807	NCT01313923	Terminated	Early Phase 1	Lack of funding	CHEBI_9168	"35302"	MONDO_0006594	"10034280"	"65172003"
betamethasone acetate	DB00443	Pemphigus	C0030807		Approved			CHEBI_3077	"1514"	MONDO_0006594	"10034280"	"65172003"
	DB00341	Pemphigus	C0030807	NCT02613910	Terminated	Phase 3	Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.	CHEBI_3561	"20610"	MONDO_0006594	"10034280"	"65172003"
	DB00316	Pemphigus	C0030807	NCT02613910	Terminated	Phase 3	Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.	CHEBI_46195	"161"	MONDO_0006594	"10034280"	"65172003"
	DB00635	Pemphigus	C0030807	NCT02613910	Terminated	Phase 3	Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.	CHEBI_8382	"8640"	MONDO_0006594	"10034280"	"65172003"
prednicarbate	DB00860	Pemphigus	C0030807	NCT02613910	Terminated	Phase 3	Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.	CHEBI_8378	"8638"	MONDO_0006594	"10034280"	"65172003"
hydrocortisone acetate	DB14539	Pemphigus	C0030807		Approved			CHEBI_17609	"27197"	MONDO_0006594	"10034280"	"65172003"
hydrocortisone acetate	DB00741	Pemphigus	C0030807		Approved			CHEBI_17650	"5492"	MONDO_0006594	"10034280"	"65172003"
triamcinolone diacetate	DB00620	Pemphigus	C0030807		Approved			CHEBI_9667	"10759"	MONDO_0006594	"10034280"	"65172003"
cortisone acetate	DB01380	Pemphigus	C0030807		Approved			CHEBI_3897	"21655"	MONDO_0006594	"10034280"	"65172003"
triamcinolone acetonide	DB00620	Pemphigus	C0030807		Approved			CHEBI_9667	"10759"	MONDO_0006594	"10034280"	"65172003"
triamcinolone	DB00620	Pemphigus	C0030807		Approved			CHEBI_9667	"10759"	MONDO_0006594	"10034280"	"65172003"
hydrocortisone succinate	DB14545	Pemphigus	C0030807		Approved			CHEBI_31677	"21651"	MONDO_0006594	"10034280"	"65172003"
hydrocortisone	DB00741	Pemphigus	C0030807		Approved			CHEBI_17650	"5492"	MONDO_0006594	"10034280"	"65172003"
hydrocortisone succinate	DB00741	Pemphigus	C0030807		Approved			CHEBI_17650	"5492"	MONDO_0006594	"10034280"	"65172003"
methylprednisolone	DB00959	Pemphigus	C0030807		Approved			CHEBI_6888	"6902"	MONDO_0006594	"10034280"	"65172003"
methylprednisolone acetate	DB00959	Pemphigus	C0030807		Approved			CHEBI_6888	"6902"	MONDO_0006594	"10034280"	"65172003"
aminobenzoic acid	DB02362	Pemphigus	C0030807		Approved			CHEBI_30753	"74"	MONDO_0006594	"10034280"	"65172003"
prednisolone	DB00860	Pemphigus	C0030807		Approved			CHEBI_8378	"8638"	MONDO_0006594	"10034280"	"65172003"
dexamethasone	DB01234	Pemphigus	C0030807		Approved			CHEBI_41879	"3264"	MONDO_0006594	"10034280"	"65172003"
benzoic acid	DB03793	Pemphigus	C0030807		Approved			CHEBI_30746	"18989"	MONDO_0006594	"10034280"	"65172003"
lanreotide	DB06791	Pituitary Neoplasms	C0032019		Approved			CHEBI_135901	"68092"	MONDO_0017611	"10035104"	"127024001"
ofloxacin	DB01165	Mycoplasma pneumonia	C0032302		Approved			CHEBI_7731	"7623"		"10035724"	"46970008"
alatrofloxacin	DB09335	Mycoplasma pneumonia	C0032302		Approved			CHEBI_135829	"141440"		"10035724"	"46970008"
grepafloxacin	DB00365	Mycoplasma pneumonia	C0032302		Approved			CHEBI_5543	"83719"		"10035724"	"46970008"
gatifloxacin	DB01044	Mycoplasma pneumonia	C0032302		Approved			CHEBI_5280	"228476|1546025"		"10035724"	"46970008"
dirithromycin	DB00954	Mycoplasma pneumonia	C0032302		Approved			CHEBI_474014			"10035724"	"46970008"
azithromycin	DB00207	Mycoplasma pneumonia	C0032302		Approved			CHEBI_2955	"18631"		"10035724"	"46970008"
gemifloxacin	DB01155	Mycoplasma pneumonia	C0032302		Approved			CHEBI_101853	"138099"		"10035724"	"46970008"
fusidic acid	DB02703	Mycoplasma pneumonia	C0032302		Approved			CHEBI_29013	"4608|113608"		"10035724"	"46970008"
lefamulin	DB12825	Mycoplasma pneumonia	C0032302		Approved				"2198944"		"10035724"	"46970008"
trovafloxacin	DB00685	Mycoplasma pneumonia	C0032302		Approved			CHEBI_9763	"115552"		"10035724"	"46970008"
telithromycin	DB00976	Mycoplasma pneumonia	C0032302		Approved			CHEBI_29688	"274786"		"10035724"	"46970008"
clarithromycin	DB01211	Mycoplasma pneumonia	C0032302		Approved			CHEBI_3732	"21212"		"10035724"	"46970008"
erythromycin	DB00199	Mycoplasma pneumonia	C0032302		Approved			CHEBI_42355	"4053"		"10035724"	"46970008"
sparfloxacin	DB01208	Mycoplasma pneumonia	C0032302		Approved			CHEBI_9212	"18469"		"10035724"	"46970008"
doxycycline	DB00254	Mycoplasma pneumonia	C0032302		Approved			CHEBI_50845	"1545992|3640"		"10035724"	"46970008"
norfloxacin	DB01059	Mycoplasma pneumonia	C0032302		Approved			CHEBI_100246	"7517"		"10035724"	"46970008"
levofloxacin	DB01137	Mycoplasma pneumonia	C0032302		Approved			CHEBI_63598	"1546009|82122"		"10035724"	"46970008"
moxifloxacin	DB00218	Mycoplasma pneumonia	C0032302		Approved			CHEBI_63611	"139462"		"10035724"	"46970008"
paliperidone	DB01267	Psychotic Disorders	C0033975		Approved			CHEBI_83804	"679314"	HP:0000709	"10061920"	"69322001"
fluphenazine enanthate	DB00623	Psychotic Disorders	C0033975		Approved			CHEBI_5123	"4496"	HP:0000709	"10061920"	"69322001"
acetophenazine	DB01063	Psychotic Disorders	C0033975		Approved			CHEBI_2401	"16735"	HP:0000709	"10061920"	"69322001"
reserpine	DB00206	Psychotic Disorders	C0033975		Approved			CHEBI_28487	"9260"	HP:0000709	"10061920"	"69322001"
haloperidol	DB00502	Psychotic Disorders	C0033975		Approved			CHEBI_5613	"5093"	HP:0000709	"10061920"	"69322001"
chlorpromazine	DB00477	Psychotic Disorders	C0033975		Approved			CHEBI_3647	"2403"	HP:0000709	"10061920"	"69322001"
clopenthixol	DB13841	Psychotic Disorders	C0033975		Approved			CHEBI_59115		HP:0000709	"10061920"	"69322001"
fluphenazine decanoate	DB00623	Psychotic Disorders	C0033975		Approved			CHEBI_5123	"4496"	HP:0000709	"10061920"	"69322001"
triflupromazine	DB00508	Psychotic Disorders	C0033975		Approved			CHEBI_9711	"10805"	HP:0000709	"10061920"	"69322001"
promazine	DB00420	Psychotic Disorders	C0033975		Approved			CHEBI_8459	"8742"	HP:0000709	"10061920"	"69322001"
fluphenazine	DB00623	Psychotic Disorders	C0033975		Approved			CHEBI_5123	"4496"	HP:0000709	"10061920"	"69322001"
prednisolone	DB00860	Pulmonary Fibrosis	C0034069		Approved			CHEBI_8378	"8638"	MONDO_0002771	"10037383"	"51615001"
	DB13144	Retinoblastoma	C0035335	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual		"70167"	MONDO_0008380	"10038916"	"370967009"
	DB01008	Retinoblastoma	C0035335	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_28901	"1828"	MONDO_0008380	"10038916"	"370967009"
	DB00541	Retinoblastoma	C0035335	NCT02116959	Terminated	Phase 1	Low accrual	CHEBI_28445	"11202"	MONDO_0008380	"10038916"	"370967009"
	DB04572	Retinoblastoma	C0035335	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_9570	"10473"	MONDO_0008380	"10038916"	"370967009"
	DB01042	Retinoblastoma	C0035335	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_28876	"6718"	MONDO_0008380	"10038916"	"370967009"
amifostine	DB01143	Retinoblastoma	C0035335	NCT00003926	Terminated	Phase 1	Withdrawn due to slow accrual	CHEBI_2636	"1545987|4126"	MONDO_0008380	"10038916"	"370967009"
	DB01042	Retinoblastoma	C0035335	NCT02116959	Terminated	Phase 1	Low accrual	CHEBI_28876	"6718"	MONDO_0008380	"10038916"	"370967009"
	DB00531	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_4027	"1545988|3002"	MONDO_0008380	"10038916"	"370967009"
melphalan	DB01042	Retinoblastoma	C0035335	NCT01293539	Terminated	Phase 2	IAC is now recognized as part of standard of care treatment options in the US.	CHEBI_28876	"6718"	MONDO_0008380	"10038916"	"370967009"
etoposide	DB00773	Retinoblastoma	C0035335	NCT02116959	Terminated	Phase 1	Low accrual	CHEBI_4911	"4179"	MONDO_0008380	"10038916"	"370967009"
	DB00563	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_44185	"6851"	MONDO_0008380	"10038916"	"370967009"
temozolomide	DB00853	Retinoblastoma	C0035335	NCT01857752	Terminated	Phase 2	accrual	CHEBI_72564	"37776"	MONDO_0008380	"10038916"	"370967009"
etoposide	DB00773	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	CHEBI_4911	"4179"	MONDO_0008380	"10038916"	"370967009"
melphalan	DB01042	Retinoblastoma	C0035335	NCT01393769	Terminated	Phase 2	Only 5 subjects could be enrolled. Sample of 25 pat. not be achieved (rare disease).	CHEBI_28876	"6718"	MONDO_0008380	"10038916"	"370967009"
	DB00853	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_72564	"37776"	MONDO_0008380	"10038916"	"370967009"
	DB01042	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	CHEBI_28876	"6718"	MONDO_0008380	"10038916"	"370967009"
topotecan	DB01030	Retinoblastoma	C0035335	NCT01466855	Terminated	Early Phase 1	Competing studies	CHEBI_63632	"57308"	MONDO_0008380	"10038916"	"370967009"
	DB11596	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_63606	"877015"	MONDO_0008380	"10038916"	"370967009"
	DB00958	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_31355	"40048"	MONDO_0008380	"10038916"	"370967009"
	DB01181	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	CHEBI_5864	"5657"	MONDO_0008380	"10038916"	"370967009"
	DB00541	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_28445	"11202"	MONDO_0008380	"10038916"	"370967009"
	DB01008	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	CHEBI_28901	"1828"	MONDO_0008380	"10038916"	"370967009"
	DB04572	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_9570	"10473"	MONDO_0008380	"10038916"	"370967009"
etoposide	DB00773	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_4911	"4179"	MONDO_0008380	"10038916"	"370967009"
	DB00650	Retinoblastoma	C0035335	NCT00003273	Withdrawn	Phase 2		CHEBI_15640	"6313"	MONDO_0008380	"10038916"	"370967009"
	DB04572	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	CHEBI_9570	"10473"	MONDO_0008380	"10038916"	"370967009"
cyclophosphamide	DB00531	Retinoblastoma	C0035335		Approved			CHEBI_4027	"1545988|3002"	MONDO_0008380	"10038916"	"370967009"
	DB09110	Retinoblastoma	C0035335	NCT00623077	Terminated	Phase 1	Replaced by another study	CHEBI_17905	"1546354"	MONDO_0008380	"10038916"	"370967009"
	DB00958	Retinoblastoma	C0035335	NCT02116959	Terminated	Phase 1	Low accrual	CHEBI_31355	"40048"	MONDO_0008380	"10038916"	"370967009"
ticarcillin	DB01607	Salpingitis	C0036130		Approved			CHEBI_9587	"10591"	MONDO_0003619	"10039453"	"88157006"
caffeine	DB00201	Sinus headache	C0037195		Approved			CHEBI_27732	"1886"		"10040744"	"4969004"
ibuprofen	DB01050	Sinus headache	C0037195		Approved			CHEBI_5855	"5640"		"10040744"	"4969004"
guaifenesin	DB00874	Sinus headache	C0037195		Approved			CHEBI_5551	"5032"		"10040744"	"4969004"
naproxen	DB00788	Sinus headache	C0037195		Approved			CHEBI_7476	"7258"		"10040744"	"4969004"
ephedrine	DB01364	Sinus headache	C0037195		Approved			CHEBI_15407	"3966"		"10040744"	"4969004"
phenylpropanolamine	DB00397	Sinus headache	C0037195		Approved			CHEBI_80680	"8175"		"10040744"	"4969004"
paracetamol	DB00316	Sinus headache	C0037195		Approved			CHEBI_46195	"161"		"10040744"	"4969004"
acetylsalicylic acid	DB00945	Sinus headache	C0037195		Approved			CHEBI_15365	"91101|1191"		"10040744"	"4969004"
pheniramine	DB01620	Sinus headache	C0037195		Approved			CHEBI_91591	"8132"		"10040744"	"4969004"
phenylephrine	DB00388	Sinus headache	C0037195		Approved			CHEBI_8093	"8163"		"10040744"	"4969004"
	DB00874	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		CHEBI_5551	"5032"	MONDO_0005961	"10040753"	"36971009"
doxycycline	DB00254	Sinusitis	C0037199		Approved			CHEBI_50845	"1545992|3640"	MONDO_0005961	"10040753"	"36971009"
quinine	DB00468	Sinusitis	C0037199	NCT02630472	Terminated	Phase 1/Phase 2	Institutional decision	CHEBI_15854	"9071"	MONDO_0005961	"10040753"	"36971009"
meclocycline	DB13092	Sinusitis	C0037199		Approved			CHEBI_135772	"29418"	MONDO_0005961	"10040753"	"36971009"
oxytetracycline	DB00595	Sinusitis	C0037199		Approved			CHEBI_133011	"7821|1545999"	MONDO_0005961	"10040753"	"36971009"
ephedrine	DB01364	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		CHEBI_15407	"3966"	MONDO_0005961	"10040753"	"36971009"
budesonide	DB01222	Sinusitis	C0037199	NCT01814618	Withdrawn	Phase 2	Difficulty recruiting	CHEBI_3207	"19831"	MONDO_0005961	"10040753"	"36971009"
	DB00397	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		CHEBI_80680	"8175"	MONDO_0005961	"10040753"	"36971009"
	DB00852	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		CHEBI_51209	"8896"	MONDO_0005961	"10040753"	"36971009"
	DB01112	Sinusitis	C0037199	NCT00000752	Withdrawn	Phase 2		CHEBI_3515	"2194"	MONDO_0005961	"10040753"	"36971009"
minocycline	DB01017	Sinusitis	C0037199		Approved			CHEBI_50694	"6980"	MONDO_0005961	"10040753"	"36971009"
bacampicillin	DB01602	Sinusitis	C0037199		Approved			CHEBI_2968	"18687"	MONDO_0005961	"10040753"	"36971009"
tetracycline	DB09550	Sinusitis	C0037199		Approved			CHEBI_27902	"2105975"	MONDO_0005961	"10040753"	"36971009"
ampicillin	DB00415	Sinusitis	C0037199		Approved			CHEBI_28971	"733|221058"	MONDO_0005961	"10040753"	"36971009"
amphotericin B	DB00681	Sinusitis	C0037199		Approved			CHEBI_2682	"236594|732"	MONDO_0005961	"10040753"	"36971009"
cloxacillin	DB01147	Sinusitis	C0037199		Approved			CHEBI_49566	"2625"	MONDO_0005961	"10040753"	"36971009"
garenoxacin	DB06160	Sinusitis	C0037199		Approved			CHEBI_131716		MONDO_0005961	"10040753"	"36971009"
tetracycline	DB00759	Sinusitis	C0037199		Approved			CHEBI_27902	"10395"	MONDO_0005961	"10040753"	"36971009"
oxacillin	DB00713	Sinusitis	C0037199		Approved			CHEBI_7809	"7773"	MONDO_0005961	"10040753"	"36971009"
meticillin	DB01603	Sinusitis	C0037199		Approved			CHEBI_6827	"2181306"	MONDO_0005961	"10040753"	"36971009"
fusidic acid	DB02703	Sinusitis	C0037199		Approved			CHEBI_29013	"4608|113608"	MONDO_0005961	"10040753"	"36971009"
demeclocycline	DB00618	Sinusitis	C0037199		Approved			CHEBI_4392	"3154"	MONDO_0005961	"10040753"	"36971009"
verapamil	DB00661	Sinusitis	C0037199	NCT03102190	Terminated	Phase 1	Phase II funding not available	CHEBI_77733	"11170"	MONDO_0005961	"10040753"	"36971009"
dihydrotachysterol	DB01070	Tetany	C0039621		Approved			CHEBI_4591	"3429"	HP:0001281	"10043380"	"10629009"
amphotericin B	DB00681	Trachoma	C0040592		Approved			CHEBI_2682	"236594|732"	MONDO_0001249	"10044325"	"2576002"
fusidic acid	DB02703	Trachoma	C0040592		Approved			CHEBI_29013	"4608|113608"	MONDO_0001249	"10044325"	"2576002"
chlortetracycline	DB09093	Trachoma	C0040592		Approved			CHEBI_27644	"2408"	MONDO_0001249	"10044325"	"2576002"
oxytetracycline	DB00595	Trachoma	C0040592		Approved			CHEBI_133011	"7821|1545999"	MONDO_0001249	"10044325"	"2576002"
tetracycline	DB09550	Trachoma	C0040592		Approved			CHEBI_27902	"2105975"	MONDO_0001249	"10044325"	"2576002"
tetracycline	DB00759	Trachoma	C0040592		Approved			CHEBI_27902	"10395"	MONDO_0001249	"10044325"	"2576002"
azithromycin	DB00207	Trachoma	C0040592	NCT02176057	Withdrawn	Phase 2/Phase 3	Nepal Ministry of Health implemented public drug treatment prior to the proposed start date	CHEBI_2955	"18631"	MONDO_0001249	"10044325"	"2576002"
sulfafurazole	DB00263	Trachoma	C0040592		Approved			CHEBI_102484	"10207"	MONDO_0001249	"10044325"	"2576002"
sulfacetamide	DB00634	Trachoma	C0040592		Approved			CHEBI_63845	"10169"	MONDO_0001249	"10044325"	"2576002"
minocycline	DB01017	Trachoma	C0040592		Approved			CHEBI_50694	"6980"	MONDO_0001249	"10044325"	"2576002"
meclocycline	DB13092	Trachoma	C0040592		Approved			CHEBI_135772	"29418"	MONDO_0001249	"10044325"	"2576002"
doxycycline	DB00254	Trachoma	C0040592		Approved			CHEBI_50845	"1545992|3640"	MONDO_0001249	"10044325"	"2576002"
demeclocycline	DB00618	Trachoma	C0040592		Approved			CHEBI_4392	"3154"	MONDO_0001249	"10044325"	"2576002"
nifurtimox	DB11820	Chagas Disease	C0041234		Approved			CHEBI_7566	"7421"	MONDO_0001444	"10001935"	"77506005"
benznidazole	DB11989	Chagas Disease	C0041234		Approved			CHEBI_133833	"18994"	MONDO_0001444	"10001935"	"77506005"
ethacizine	DB13645	Ventricular arrhythmia	C0085612		Approved			CHEBI_134732		HP:0004308	"10047281"	"44103008"
bretylium	DB01158	Ventricular arrhythmia	C0085612		Approved			CHEBI_3172	"19685"	HP:0004308	"10047281"	"44103008"
moracizine	DB00680	Ventricular arrhythmia	C0085612		Approved			CHEBI_6997	"40169"	HP:0004308	"10047281"	"44103008"
lidocaine	DB00281	Ventricular arrhythmia	C0085612		Approved			CHEBI_6456	"6387"	HP:0004308	"10047281"	"44103008"
oxprenolol	DB01580	Ventricular arrhythmia	C0085612		Approved			CHEBI_91704	"7801"	HP:0004308	"10047281"	"44103008"
aprindine	DB01429	Ventricular arrhythmia	C0085612		Approved			CHEBI_135370		HP:0004308	"10047281"	"44103008"
prajmalium	DB13555	Ventricular arrhythmia	C0085612		Approved			CHEBI_135560		HP:0004308	"10047281"	"44103008"
ajmaline	DB01426	Ventricular arrhythmia	C0085612		Approved			CHEBI_28462	"423"	HP:0004308	"10047281"	"44103008"
tocainide	DB01056	Ventricular arrhythmia	C0085612		Approved			CHEBI_9611	"42359"	HP:0004308	"10047281"	"44103008"
mexiletine	DB00379	Ventricular arrhythmia	C0085612		Approved			CHEBI_6916	"6926"	HP:0004308	"10047281"	"44103008"
disopyramide	DB00280	Ventricular arrhythmia	C0085612		Approved			CHEBI_4657	"3541"	HP:0004308	"10047281"	"44103008"
pyrantel	DB11156	Enterobiasis	C0086227		Approved			CHEBI_8654	"8984"	MONDO_0005746	"10014881"	"266162007"
piperazine	DB00592	Enterobiasis	C0086227		Approved			CHEBI_28568	"8340"	MONDO_0005746	"10014881"	"266162007"
mebendazole	DB00643	Enterobiasis	C0086227		Approved			CHEBI_6704	"6672"	MONDO_0005746	"10014881"	"266162007"
perazine	DB12710	Enterobiasis	C0086227		Approved			CHEBI_59118	"8042"	MONDO_0005746	"10014881"	"266162007"
thiabendazole	DB00730	Enterobiasis	C0086227		Approved			CHEBI_45979	"10450"	MONDO_0005746	"10014881"	"266162007"
cefapirin	DB01139	Lower respiratory tract infection	C0149725		Approved			CHEBI_554446	"2238"	HP:0002783	"10024968"	"50417007"
ceftriaxone	DB01212	Lower respiratory tract infection	C0149725		Approved			CHEBI_29007	"2193"	HP:0002783	"10024968"	"50417007"
cefalotin	DB00456	Lower respiratory tract infection	C0149725		Approved			CHEBI_124991	"2236"	HP:0002783	"10024968"	"50417007"
cefuroxime axetil	DB01112	Lower respiratory tract infection	C0149725		Approved			CHEBI_3515	"2194"	HP:0002783	"10024968"	"50417007"
norfloxacin	DB01059	Lower respiratory tract infection	C0149725		Approved			CHEBI_100246	"7517"	HP:0002783	"10024968"	"50417007"
cefuroxime	DB01112	Lower respiratory tract infection	C0149725		Approved			CHEBI_3515	"2194"	HP:0002783	"10024968"	"50417007"
ceftizoxime	DB01332	Lower respiratory tract infection	C0149725		Approved			CHEBI_553473	"2192"	HP:0002783	"10024968"	"50417007"
imipenem	DB01598	Lower respiratory tract infection	C0149725		Approved			CHEBI_471744	"5690|1545986"	HP:0002783	"10024968"	"50417007"
cloxacillin	DB01147	Lower respiratory tract infection	C0149725		Approved			CHEBI_49566	"2625"	HP:0002783	"10024968"	"50417007"
metronidazole	DB15759	Lower respiratory tract infection	C0149725		Approved			CHEBI_50688		HP:0002783	"10024968"	"50417007"
amoxicillin	DB01060	Lower respiratory tract infection	C0149725		Approved			CHEBI_2676	"1297882|723"	HP:0002783	"10024968"	"50417007"
cilastatin	DB01597	Lower respiratory tract infection	C0149725		Approved			CHEBI_3697	"2540"	HP:0002783	"10024968"	"50417007"
cefradine	DB01333	Lower respiratory tract infection	C0149725		Approved			CHEBI_3547	"2239"	HP:0002783	"10024968"	"50417007"
metronidazole	DB00916	Lower respiratory tract infection	C0149725		Approved			CHEBI_6909	"6922"	HP:0002783	"10024968"	"50417007"
ceftazidime	DB00438	Lower respiratory tract infection	C0149725		Approved			CHEBI_3508	"2191|1545984"	HP:0002783	"10024968"	"50417007"
cefmetazole	DB00274	Lower respiratory tract infection	C0149725		Approved			CHEBI_3489	"2182"	HP:0002783	"10024968"	"50417007"
ofloxacin	DB01165	Lower respiratory tract infection	C0149725		Approved			CHEBI_7731	"7623"	HP:0002783	"10024968"	"50417007"
cefamandole	DB01326	Lower respiratory tract infection	C0149725		Approved			CHEBI_3480	"2178"	HP:0002783	"10024968"	"50417007"
cefaclor	DB00833	Lower respiratory tract infection	C0149725		Approved			CHEBI_3478	"1450910|2176"	HP:0002783	"10024968"	"50417007"
cefonicid	DB01328	Lower respiratory tract infection	C0149725		Approved			CHEBI_3491	"2183"	HP:0002783	"10024968"	"50417007"
piperacillin	DB00319	Lower respiratory tract infection	C0149725		Approved			CHEBI_8232	"1546000|8339"	HP:0002783	"10024968"	"50417007"
oxacillin	DB00713	Lower respiratory tract infection	C0149725		Approved			CHEBI_7809	"7773"	HP:0002783	"10024968"	"50417007"
cefazolin	DB01327	Lower respiratory tract infection	C0149725		Approved			CHEBI_474053	"2180"	HP:0002783	"10024968"	"50417007"
cefotetan	DB01330	Lower respiratory tract infection	C0149725		Approved			CHEBI_3499	"2187"	HP:0002783	"10024968"	"50417007"
ciprofloxacin	DB00537	Lower respiratory tract infection	C0149725		Approved			CHEBI_192484	"2551"	HP:0002783	"10024968"	"50417007"
cefotaxime	DB00493	Lower respiratory tract infection	C0149725		Approved			CHEBI_204928	"2186"	HP:0002783	"10024968"	"50417007"
loracarbef	DB00447	Lower respiratory tract infection	C0149725		Approved			CHEBI_47544	"28981"	HP:0002783	"10024968"	"50417007"
aztreonam	DB00355	Lower respiratory tract infection	C0149725		Approved			CHEBI_161680	"1272"	HP:0002783	"10024968"	"50417007"
lomefloxacin	DB00978	Lower respiratory tract infection	C0149725		Approved			CHEBI_116278	"28872"	HP:0002783	"10024968"	"50417007"
nivolumab	DB09035	Squamous cell carcinoma of lung	C0149782		Approved				"1597876"	MONDO_0005097	"10041826"	"254634000"
testosterone propionate	DB00624	Testicular hypogonadism	C0151721		Approved			CHEBI_17347	"10379"	HP:0000026	"10021011"	"48723006"
testosterone cypionate	DB13943	Testicular hypogonadism	C0151721		Approved			CHEBI_9463	"835827"	HP:0000026	"10021011"	"48723006"
testosterone propionate	DB01420	Testicular hypogonadism	C0151721		Approved			CHEBI_9466	"10382"	HP:0000026	"10021011"	"48723006"
methyltestosterone	DB06710	Testicular hypogonadism	C0151721		Approved			CHEBI_27436	"6904"	HP:0000026	"10021011"	"48723006"
testosterone	DB00624	Testicular hypogonadism	C0151721		Approved			CHEBI_17347	"10379"	HP:0000026	"10021011"	"48723006"
fluoxymesterone	DB01185	Testicular hypogonadism	C0151721		Approved			CHEBI_5120	"4494"	HP:0000026	"10021011"	"48723006"
testosterone enantate	DB00624	Testicular hypogonadism	C0151721		Approved			CHEBI_17347	"10379"	HP:0000026	"10021011"	"48723006"
testosterone enantate	DB13944	Testicular hypogonadism	C0151721		Approved			CHEBI_9464	"37859"	HP:0000026	"10021011"	"48723006"
testosterone cypionate	DB00624	Testicular hypogonadism	C0151721		Approved			CHEBI_17347	"10379"	HP:0000026	"10021011"	"48723006"
fendiline	DB08980	Myocardial Ischemia	C0151744		Approved			CHEBI_94434	"4327"	MONDO_0005010|MONDO_0024644	"10028600"	"414795007"
metahexamide	DB13675	Discoloration of skin	C0151907		Approved			CHEBI_135328			"10040829"	"3253007"
octinoxate	DB09496	Discoloration of skin	C0151907		Approved			CHEBI_88667	"13369|283678"		"10040829"	"3253007"
hydroquinone	DB09526	Discoloration of skin	C0151907		Approved			CHEBI_17594	"5509"		"10040829"	"3253007"
dioxybenzone	DB11221	Discoloration of skin	C0151907		Approved			CHEBI_34208	"23350"		"10040829"	"3253007"
filgrastim	DB00099	Cyclic neutropenia	C0221023		Approved				"1605064|1433764|2057198|68442"	HP:0040289	"10053176"	"191347008"
naproxen	DB00788	Myalgia	C0231528		Approved			CHEBI_7476	"7258"	HP:0003326	"10028299"	"68962001"
thiamine	DB00152	Wernicke-Korsakoff Syndrome	C0349464		Approved			CHEBI_18385	"10454"		"10047913"	"69482004"
palifermin	DB00039	Mucositis following radiation therapy	C0392190		Approved				"196319"		"10042137"	"403725000"
anakinra	DB00026	Chronic Infantile Neurological, Cutaneous, and Articular Syndrome	C0409818		Approved				"72435"		"10064568"	"239826001"
ethacizine	DB13645	Supraventricular arrhythmia	C0428974		Approved			CHEBI_134732		HP:0005115	"10003130"	"72654001"
ajmaline	DB01426	Supraventricular arrhythmia	C0428974		Approved			CHEBI_28462	"423"	HP:0005115	"10003130"	"72654001"
adenosine triphosphate	DB00171	Supraventricular arrhythmia	C0428974		Approved			CHEBI_15422	"318"	HP:0005115	"10003130"	"72654001"
aprindine	DB01429	Supraventricular arrhythmia	C0428974		Approved			CHEBI_135370		HP:0005115	"10003130"	"72654001"
adenosine triphosphate	DB00640	Supraventricular arrhythmia	C0428974		Approved			CHEBI_16335	"296"	HP:0005115	"10003130"	"72654001"
desloratadine	DB00967	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_291342	"275635"	MONDO_0044212	"10072757"	"302162004"
astemizole	DB00637	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_2896	"42328"	MONDO_0044212	"10072757"	"302162004"
levocetirizine	DB06282	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_94559	"356887"	MONDO_0044212	"10072757"	"302162004"
cetirizine	DB00341	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_3561	"20610"	MONDO_0044212	"10072757"	"302162004"
etanercept	DB00005	Chronic Spontaneous Urticaria	C0578870	NCT01030120	Withdrawn	Phase 2/Phase 3	Unable to complete agreement with sponsor	CHEBI_4875	"214555|2103480|2462511"	MONDO_0044212	"10072757"	"302162004"
loratadine	DB00455	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_6538	"28889"	MONDO_0044212	"10072757"	"302162004"
ebastine	DB11742	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_31528	"23796"	MONDO_0044212	"10072757"	"302162004"
omalizumab	DB00043	Chronic Spontaneous Urticaria	C0578870		Approved				"302379"	MONDO_0044212	"10072757"	"302162004"
fexofenadine	DB00950	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_5050	"87636"	MONDO_0044212	"10072757"	"302162004"
terfenadine	DB00342	Chronic Spontaneous Urticaria	C0578870		Approved			CHEBI_9453	"42330"	MONDO_0044212	"10072757"	"302162004"
	DB00122	Ischemic stroke	C0948008	NCT02823106	Withdrawn	Phase 1	Study put on clinical hold by FDA. Sponsor decided to no pursue the study.	CHEBI_15354	"2449"	HP:0002140	"10061256"	"422504002"
glyceryl trinitrate	DB00727	Ischemic stroke	C0948008	NCT01811693	Terminated	Phase 2	The funding period for the study has ended.	CHEBI_28787	"4917"	HP:0002140	"10061256"	"422504002"
edaravone	DB12243	Ischemic stroke	C0948008		Approved			CHEBI_31530	"1921877"	HP:0002140	"10061256"	"422504002"
tenecteplase	DB00031	Ischemic stroke	C0948008	NCT02180204	Withdrawn	Phase 2/Phase 3			"259280"	HP:0002140	"10061256"	"422504002"
tirofiban	DB00775	Ischemic stroke	C0948008	NCT03357133	Terminated	Phase 2/Phase 3	The number and speed of enrollment were significantly less than expected.	CHEBI_9605	"73137"	HP:0002140	"10061256"	"422504002"
cromoglicic acid	DB01003	Ischemic stroke	C0948008	NCT03202147	Withdrawn	Phase 2	Study halted prematurely prior to initiation but potentially will resume in the future.	CHEBI_59773	"2921|42612"	HP:0002140	"10061256"	"422504002"
	DB00945	Ischemic stroke	C0948008	NCT00265408	Withdrawn	Phase 1		CHEBI_15365	"91101|1191"	HP:0002140	"10061256"	"422504002"
alteplase	DB00009	Ischemic stroke	C0948008		Approved				"8410"	HP:0002140	"10061256"	"422504002"
butylphthalide	DB12749	Ischemic stroke	C0948008		Approved			CHEBI_177504	"1484499"	HP:0002140	"10061256"	"422504002"
warfarin	DB00682	Ischemic stroke	C0948008	NCT00265408	Withdrawn	Phase 1		CHEBI_87732	"11289"	HP:0002140	"10061256"	"422504002"
clopidogrel	DB00758	Ischemic stroke	C0948008	NCT00816166	Terminated	Phase 2/Phase 3		CHEBI_37941	"32968"	HP:0002140	"10061256"	"422504002"
sildenafil	DB00203	Ischemic stroke	C0948008	NCT00452582	Terminated	Phase 1	Failure to recruit in expected time period.	CHEBI_9139	"136411"	HP:0002140	"10061256"	"422504002"
edoxaban	DB09075	Ischemic stroke	C0948008		Approved			CHEBI_85973	"1599538"	HP:0002140	"10061256"	"422504002"
tirofiban	DB00775	Ischemic stroke	C0948008	NCT04818944	Withdrawn	Phase 1/Phase 2	PI has left the Institution	CHEBI_9605	"73137"	HP:0002140	"10061256"	"422504002"
phosphorylcholine	DB00661	Ischemic stroke	C0948008	NCT02823106	Withdrawn	Phase 1	Study put on clinical hold by FDA. Sponsor decided to no pursue the study.	CHEBI_77733	"11170"	HP:0002140	"10061256"	"422504002"
	DB12153	Ischemic stroke	C0948008	NCT02823106	Withdrawn	Phase 1	Study put on clinical hold by FDA. Sponsor decided to no pursue the study.	CHEBI_16436	"997602"	HP:0002140	"10061256"	"422504002"
	DB00945	Ischemic stroke	C0948008	NCT00816166	Terminated	Phase 2/Phase 3		CHEBI_15365	"91101|1191"	HP:0002140	"10061256"	"422504002"
	DB00945	Acute Coronary Syndrome	C0948089	NCT02034292	Terminated	Phase 1	Sponsor Decision	CHEBI_15365	"91101|1191"	MONDO_0005542	"10051592"	"394659003"
prasugrel	DB06209	Acute Coronary Syndrome	C0948089		Approved			CHEBI_87723	"613391"	MONDO_0005542	"10051592"	"394659003"
ranolazine	DB00243	Acute Coronary Syndrome	C0948089	NCT01767987	Terminated	Phase 2	Sponsor terminated study due to lack of enrollment	CHEBI_87690	"35829"	MONDO_0005542	"10051592"	"394659003"
verapamil	DB00661	Acute Coronary Syndrome	C0948089		Approved			CHEBI_77733	"11170"	MONDO_0005542	"10051592"	"394659003"
	DB00945	Acute Coronary Syndrome	C0948089	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	CHEBI_15365	"91101|1191"	MONDO_0005542	"10051592"	"394659003"
	DB00758	Acute Coronary Syndrome	C0948089	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	CHEBI_37941	"32968"	MONDO_0005542	"10051592"	"394659003"
esomeprazole	DB00338	Acute Coronary Syndrome	C0948089	NCT00557921	Terminated	Phase 3	Terminated by Sponsor	CHEBI_77260	"7646"	MONDO_0005542	"10051592"	"394659003"
citalopram	DB00215	Acute Coronary Syndrome	C0948089	NCT01667744	Withdrawn	Phase 1/Phase 2	unfunded	CHEBI_77397	"2556"	MONDO_0005542	"10051592"	"394659003"
clopidogrel	DB00758	Acute Coronary Syndrome	C0948089	NCT02419820	Terminated	Phase 1	Sponsor Decision	CHEBI_37941	"32968"	MONDO_0005542	"10051592"	"394659003"
	DB00945	Acute Coronary Syndrome	C0948089	NCT02419820	Terminated	Phase 1	Sponsor Decision	CHEBI_15365	"91101|1191"	MONDO_0005542	"10051592"	"394659003"
metoprolol	DB00264	Acute Coronary Syndrome	C0948089		Approved			CHEBI_6904	"6918"	MONDO_0005542	"10051592"	"394659003"
	DB00945	Acute Coronary Syndrome	C0948089	NCT01755520	Terminated	Phase 3	DSMB Interim Analyses	CHEBI_15365	"91101|1191"	MONDO_0005542	"10051592"	"394659003"
eptifibatide	DB00063	Acute Coronary Syndrome	C0948089		Approved			CHEBI_291902	"288688|75635"	MONDO_0005542	"10051592"	"394659003"
tirofiban	DB00775	Acute Coronary Syndrome	C0948089		Approved			CHEBI_9605	"73137"	MONDO_0005542	"10051592"	"394659003"
atorvastatin	DB01076	Acute Coronary Syndrome	C0948089	NCT01187992	Terminated	Phase 3	Interim analysis showed significant effect in favour of full-dose atorvastatin.	CHEBI_39548	"83367"	MONDO_0005542	"10051592"	"394659003"
ticagrelor	DB08816	Acute Coronary Syndrome	C0948089	NCT01755520	Terminated	Phase 3	DSMB Interim Analyses	CHEBI_68558	"1116632"	MONDO_0005542	"10051592"	"394659003"
ticagrelor	DB08816	Acute Coronary Syndrome	C0948089		Approved			CHEBI_68558	"1116632"	MONDO_0005542	"10051592"	"394659003"
clopidogrel	DB00758	Acute Coronary Syndrome	C0948089		Approved			CHEBI_37941	"32968"	MONDO_0005542	"10051592"	"394659003"
clopidogrel	DB00758	Acute Coronary Syndrome	C0948089	NCT02034292	Terminated	Phase 1	Sponsor Decision	CHEBI_37941	"32968"	MONDO_0005542	"10051592"	"394659003"
nicotinic acid	DB00627	Vitamin Deficiency	C1510471		Approved			CHEBI_15940	"7393"		"10021135"	"85670002"
vitamin A palmitate	DB00162	Vitamin Deficiency	C1510471		Approved			CHEBI_17336	"1367187|11246"		"10021135"	"85670002"
folic acid	DB00158	Vitamin Deficiency	C1510471		Approved			CHEBI_27470	"62356|4511|202634"		"10021135"	"85670002"
thiamine	DB00152	Vitamin Deficiency	C1510471		Approved			CHEBI_18385	"10454"		"10021135"	"85670002"
ergocalciferol	DB00153	Vitamin Deficiency	C1510471		Approved			CHEBI_28934	"4018"		"10021135"	"85670002"
riboflavin	DB00140	Vitamin Deficiency	C1510471		Approved			CHEBI_17015	"9346"		"10021135"	"85670002"
retinol	DB00162	Vitamin Deficiency	C1510471		Approved			CHEBI_17336	"1367187|11246"		"10021135"	"85670002"
ergocalciferol	DB11094	Vitamin Deficiency	C1510471		Approved			CHEBI_28934	"11253"		"10021135"	"85670002"
colecalciferol	DB00169	Vitamin Deficiency	C1510471		Approved			CHEBI_28940	"2418"		"10021135"	"85670002"
sodium fluoride	DB09325	Vitamin Deficiency	C1510471		Approved			CHEBI_28741	"9873"		"10021135"	"85670002"
cyanocobalamin	DB00115	Vitamin Deficiency	C1510471		Approved			CHEBI_17439	"11248"		"10021135"	"85670002"
nelarabine	DB01280	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	C1961099		Approved			CHEBI_63612	"274771"	HP:0006727	"10042987"	"128824003"
	DB00977	Bulimia Nervosa	C2267227	NCT04278755	Terminated	Phase 2	Halted prematurely due to COVID-19-related enrollment challenges.	CHEBI_4903	"4124"		"10006550"	"78004001"
lisdexamfetamine	DB01255	Bulimia Nervosa	C2267227	NCT03397446	Terminated	Phase 2	Loss of resources due to COVID-19 resulted in insufficient funds to complete the trial as planned. However, sufficient data was collected to fulfill the aims of the trial. Discontinuation is not related to the drug, its use, or adverse events.	CHEBI_135925	"700810"		"10006550"	"78004001"
acetylcysteine	DB06151	Bulimia Nervosa	C2267227	NCT01033149	Terminated	Phase 3		CHEBI_28939	"197"		"10006550"	"78004001"
estradiol	DB00783	Bulimia Nervosa	C2267227	NCT04278755	Terminated	Phase 2	Halted prematurely due to COVID-19-related enrollment challenges.	CHEBI_16469	"4083"		"10006550"	"78004001"
fluoxetine	DB00472	Bulimia Nervosa	C2267227		Approved			CHEBI_86990	"4493"		"10006550"	"78004001"
